[
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 해발 4,500 m의 고산지대를 여행 중인 사람의 혈액과 적혈구에서 농도가 증가한 아래 물질이 헤모글로빈에 미치는 영향은?\n\n<Data (confidential)>\n\n① α-Subunit와 β-subunit의 분리를 촉진한다.\n② Heme에 결합하여 산소 친화도를 증가시킨다.\n③ β-Subunit 히스티딘 잔기의 이온화를 증가시킨다.\n④ T 형태를 안정화하여 산소 친화도를 감소시킨다.\n⑤ R 형태로의 전환을 촉진하여 산소 친화도를 증가시킨다.",
        "question_text": "Question: What is the effect on hemoglobin of the following substance, which has increased concentration in the blood and red blood cells of a person traveling in a high-altitude area at 4,500 m above sea level?\n\n<Data (confidential)>\n\n① It promotes the separation of α-subunits and β-subunits.\n② It binds to heme and increases oxygen affinity.\n③ It increases the ionization of histidine residues in β-subunits.\n④ It stabilizes the T state, decreasing oxygen affinity.\n⑤ It promotes the transition to the R state, increasing oxygen affinity.",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 골격근이 수축할 때, 근소포체에서 유리된 Ca2+이 결합하는 것은?\n\n① actin\n② troponin C\n③ troponin I\n④ troponin T\n⑤ tropomyosin",
        "question_text": "Question: When skeletal muscle contracts, which component does the Ca2+ released from the sarcoplasmic reticulum bind to?\n\n① actin\n② troponin C\n③ troponin I\n④ troponin T\n⑤ tropomyosin",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 기질과 구조가 유사하며, 효소의 활성부위에 가역적으로 결합하는 저해제가 효소촉매반응에 미치는 영향은?\n\n① K m 감소\n② K m 증가\n③ V max 감소\n④ V max 증가\n⑤ K m과 V max에 미치는 영향 없음",
        "question_text": "Question: What is the effect on enzyme-catalyzed reactions of an inhibitor that is structurally similar to the substrate and reversibly binds to the enzyme's active site?\n\n① Decrease in K m\n② Increase in K m\n③ Decrease in V max\n④ Increase in V max\n⑤ No effect on K m and V max",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 가수분해에 의한 표준 자유에너지(standard free-energy) 변화가 ATP보다 큰 인산 화합물(phosphate compound)은?\n\n① phosphoenolpyruvate\n② glycerol-3-phosphate\n③ glucose-1-phosphate\n④ glucose-6-phosphate\n⑤ fructose-6-phosphate",
        "question_text": "Question: Which phosphate compound has a greater standard free-energy change due to hydrolysis than ATP?\n\n① phosphoenolpyruvate\n② glycerol-3-phosphate\n③ glucose-1-phosphate\n④ glucose-6-phosphate\n⑤ fructose-6-phosphate",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 시트르산 회로에서 NADH를 생성하는 비가역반응을 촉매하는 효소는?\n\n① aconitase\n② citrate synthase\n③ malate dehydrogenase\n④ isocitrate dehydrogenase\n⑤ succinate dehydrogenase",
        "question_text": "Question: Which enzyme catalyzes the irreversible reaction that produces NADH in the citric acid cycle?\n\n① aconitase\n② citrate synthase\n③ malate dehydrogenase\n④ isocitrate dehydrogenase\n⑤ succinate dehydrogenase",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: Glycolysis 촉매 효소인 phosphofructokinase-1은 활성화하고, gluconeogenesis 촉매 효소인 fructose-1,6-bisphosphatase-1은 억제하는 것은?\n\n① AMP\n② ATP\n③ citrate\n④ 2,3-bisphosphoglycerate\n⑤ fructose-1,6-bisphosphate",
        "question_text": "Question: Which of the following activates phosphofructokinase-1, a catalytic enzyme in glycolysis, and inhibits fructose-1,6-bisphosphatase-1, a catalytic enzyme in gluconeogenesis?\n\n① AMP\n② ATP\n③ citrate\n④ 2,3-bisphosphoglycerate\n⑤ fructose-1,6-bisphosphate",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: DNA의 hormone response element(HRE)에 결합할 수 있는 수용체는?\n\n① 인슐린 수용체\n② 글루카곤 수용체\n③ 옥시토신 수용체\n④ 바소프레신 수용체\n⑤ 에스트로겐 수용체",
        "question_text": "Question: Which receptor can bind to the hormone response element (HRE) of DNA?\n\n① Insulin receptor\n② Glucagon receptor\n③ Oxytocin receptor\n④ Vasopressin receptor\n⑤ Estrogen receptor",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 전자전달계를 통한 전자이동을 억제하지 않으면서 양성자 기울기(proton gradient) 형성을 방해하는 것은?\n\n① amytal\n② rotenone\n③ antimycin A\n④ carbon monoxide\n⑤ 2,4-dinitrophenol",
        "question_text": "Question: Which of the following inhibits the formation of a proton gradient without inhibiting electron transfer through the electron transport chain?\n\n① amytal\n② rotenone\n③ antimycin A\n④ carbon monoxide\n⑤ 2,4-dinitrophenol",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 사람 세포에서 acetyl-CoA carboxylase를 활성화하여 지방산 생합성을 촉진하는 것은?\n\n① citrate\n② glucagon\n③ epinephrine\n④ palmitoyl-CoA\n⑤ propionyl-CoA",
        "question_text": "Question: Which of the following activates acetyl-CoA carboxylase in human cells, promoting fatty acid biosynthesis?\n\n① citrate\n② glucagon\n③ epinephrine\n④ palmitoyl-CoA\n⑤ propionyl-CoA",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: Ribonucleotide reductase가 촉매하는 반응은?\n\n① IMP → XMP\n② UTP → CTP\n③ AMP → dAMP\n④ ADP → dADP\n⑤ ATP → dATP",
        "question_text": "Question: Which reaction is catalyzed by ribonucleotide reductase?\n\n① IMP → XMP\n② UTP → CTP\n③ AMP → dAMP\n④ ADP → dADP\n⑤ ATP → dATP",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 대장균이 DNA를 복제할 때 ‘뒤처지는 가닥(lagging strand)’ 합성의 마지막 단계에서, 남아있는 틈(nick)을 채워 DNA 조각을 연결하는 효소는?\n\n① helicase\n② primase\n③ DNA ligase\n④ DNA polymerase II\n⑤ DNA polymerase III",
        "question_text": "Question: When E. coli replicates its DNA, which enzyme fills the remaining gap (nick) and connects DNA fragments in the final stage of 'lagging strand' synthesis?\n\n① helicase\n② primase\n③ DNA ligase\n④ DNA polymerase II\n⑤ DNA polymerase III",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 색소성건피증(xeroderma pigmentosum)의 주된 원인은?\n\n① RNA 가공(processing) 과정의 결함\n② 단백질 표적화(targeting) 과정의 결함\n③ 단백질 분해(degradation) 과정의 결함\n④ 손상받은 DNA의 mismatch repair 과정의 결함\n⑤ 손상받은 DNA의 nucleotide-excision repair 과정의 결함",
        "question_text": "Question: What is the main cause of xeroderma pigmentosum?\n\n① Defect in RNA processing\n② Defect in protein targeting\n③ Defect in protein degradation\n④ Defect in mismatch repair of damaged DNA\n⑤ Defect in nucleotide-excision repair of damaged DNA",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 진핵세포에서 mRNA 합성에 관여하는 것은?\n\n① telomerase\n② RNA polymerase I\n③ RNA polymerase II\n④ RNA polymerase III\n⑤ reverse transcriptase",
        "question_text": "Question: Which of the following is involved in mRNA synthesis in eukaryotic cells?\n\n① telomerase\n② RNA polymerase I\n③ RNA polymerase II\n④ RNA polymerase III\n⑤ reverse transcriptase",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: Eukaryotic elongation factor2(eEF2)에 ADP-ribosylation을 일으켜 단백질 합성을 억제하는 물질은?\n\n① puromycin\n② tetracycline\n③ actinomycin D\n④ cycloheximide\n⑤ diphtheria toxin",
        "question_text": "Question: Which substance inhibits protein synthesis by causing ADP-ribosylation of eukaryotic elongation factor 2 (eEF2)?\n\n① puromycin\n② tetracycline\n③ actinomycin D\n④ cycloheximide\n⑤ diphtheria toxin",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 작은 간섭 RNA(small interfering RNA, siRNA)가 직접 결합하여 분해를 촉진하는 것은?\n\n① DNA\n② mRNA\n③ rRNA\n④ tRNA\n⑤ 단백질",
        "question_text": "Question: Which of the following does small interfering RNA (siRNA) directly bind to and promote its degradation?\n\n① DNA\n② mRNA\n③ rRNA\n④ tRNA\n⑤ Protein",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 페닐케톤뇨증(phenylketonuria)에서 결함을 보이는 대사 과정은?\n\n① 시스테인 → 티로신\n② 티로신 → 시스테인\n③ 티로신 → 페닐알라닌\n④ 페닐알라닌 → 티로신\n⑤ 페닐알라닌 → 시스테인",
        "question_text": "Question: Which metabolic pathway is defective in phenylketonuria?\n\n① Cysteine → Tyrosine\n② Tyrosine → Cysteine\n③ Tyrosine → Phenylalanine\n④ Phenylalanine → Tyrosine\n⑤ Phenylalanine → Cysteine",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 혈액 중 퓨린 염기와 요산의 농도 증가, 강박성 자해 증상(compulsive self-destructive symptom) 등을 보이는 레슈-니한증후군(Lesch-Nyhan syndrome)에서 결핍되어 있는 효소는?\n\n① xanthine oxidase\n② thymidylate synthase\n③ adenosine deaminase\n④ ribonucleotide reductase\n⑤ hypoxanthine-guanine phosphoribosyltransferase",
        "question_text": "Question: Which enzyme is deficient in Lesch-Nyhan syndrome, characterized by increased concentrations of purine bases and uric acid in the blood, and compulsive self-destructive symptoms?\n\n① xanthine oxidase\n② thymidylate synthase\n③ adenosine deaminase\n④ ribonucleotide reductase\n⑤ hypoxanthine-guanine phosphoribosyltransferase",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: Acetyl-CoA carboxylase, propionyl-CoA carboxylase, pyruvate carboxylase의 촉매 반응에 관여하는 조효소는?\n\n① biotin\n② FADH2\n③ NADPH\n④ pyridoxal phosphate\n⑤ thiamine pyrophosphate",
        "question_text": "Question: Which coenzyme is involved in the catalytic reactions of acetyl-CoA carboxylase, propionyl-CoA carboxylase, and pyruvate carboxylase?\n\n① biotin\n② FADH2\n③ NADPH\n④ pyridoxal phosphate\n⑤ thiamine pyrophosphate",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n사람 세포에서 acetyl-CoA를 이용하는 대사가 다음과 같이 일어날 수 있다.\n<Data (confidential)>\n\nQuestion: A 대사과정을 억제하는 의약품이 사용되는 적응증은?\n\n① 통풍\n② 근무력증\n③ 파킨슨증\n④ 죽상경화증\n⑤ 하시모토병",
        "question_text": "In human cells, metabolism using acetyl-CoA can occur as follows:\n<Data (confidential)>\n\nQuestion: What is the indication for a drug that inhibits metabolic process A?\n\n① Gout\n② Myasthenia\n③ Parkinson's disease\n④ Atherosclerosis\n⑤ Hashimoto's disease",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n사람 세포에서 acetyl-CoA를 이용하는 대사가 다음과 같이 일어날 수 있다.\n<Data (confidential)>\n\nQuestion: B 대사반응이 일어나는 세포는?\n\n① 간세포\n② 뇌세포\n③ 적혈구\n④ 근육세포\n⑤ 지방세포",
        "question_text": "In human cells, metabolism using acetyl-CoA can occur as follows:\n<Data (confidential)>\n\nQuestion: In which cell does metabolic reaction B occur?\n\n① Liver cell\n② Brain cell\n③ Red blood cell\n④ Muscle cell\n⑤ Fat cell",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 사람T세포백혈병바이러스(human T cell leukemia virus)가 숙주세포에 침입하였을 때, 이 바이러스의 역전사효소에 의해 합성되는 것은?\n\n① mRNA\n② rRNA\n③ tRNA\n④ 상보적 DNA 가닥\n⑤ 상보적 RNA 가닥",
        "question_text": "Question: When the human T cell leukemia virus invades a host cell, what is synthesized by the virus's reverse transcriptase?\n\n① mRNA\n② rRNA\n③ tRNA\n④ Complementary DNA strand\n⑤ Complementary RNA strand",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 살아 있는 동물의 체내에서만 증식할 수 있는 것은?\n\n① Bacillus cereus\n② Rickettsia typhi\n③ Staphylococcus aureus\n④ Streptococcus pyogenes\n⑤ Mycobacterium tuberculosis",
        "question_text": "Question: Which of the following can only multiply inside a living animal?\n\n① Bacillus cereus\n② Rickettsia typhi\n③ Staphylococcus aureus\n④ Streptococcus pyogenes\n⑤ Mycobacterium tuberculosis",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 배뇨 시 동통을 호소하는 환자의 요도 분비물을 Modified Thayer-Martin 배지에 도말하고 5~10% 이산화탄소 존재하에서 배양하여 그람음성 쌍구균(diplococci)을 분리하였다. 이 균은?\n\n① Chlamydia trachomatis\n② Neisseria gonorrhoeae\n③ Treponema pallidum\n④ Trichomonas vaginalis\n⑤ Ureaplasma urealyticum",
        "question_text": "Question: A patient complains of pain during urination. The urethral discharge is smeared on Modified Thayer-Martin medium and cultured under 5-10% carbon dioxide, resulting in the isolation of Gram-negative diplococci. What is this organism?\n\n① Chlamydia trachomatis\n② Neisseria gonorrhoeae\n③ Treponema pallidum\n④ Trichomonas vaginalis\n⑤ Ureaplasma urealyticum",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 결핵치료약으로 사용되며, 원핵세포의 세포벽 구성분자와 구조가 유사하여 기질 경쟁적으로 작용함으로써 peptidoglycan 생합성 과정을 저해하는 것은?\n\n① 바시트라신(bacitracin)\n② 시클로세린(cycloserine)\n③ 포스포마이신(fosfomycin)\n④ 레보플록사신(levofloxacin)\n⑤ 스트렙토마이신(streptomycin)",
        "question_text": "Question: Which of the following is used as a tuberculosis treatment drug and inhibits the peptidoglycan biosynthesis process by acting as a substrate competitor due to its structural similarity to the cell wall components of prokaryotic cells?\n\n① Bacitracin\n② Cycloserine\n③ Fosfomycin\n④ Levofloxacin\n⑤ Streptomycin",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 반합성 카나마이신류 항생물질인 디베카신을 아실화한 것으로 methicillin-resistant Staphylococcus aureus(MRSA) 감염증에 사용하는 것은?\n\n① 아미카신(amikacin)\n② 아르베카신(arbekacin)\n③ 네틸마이신(netilmicin)\n④ 이세파마이신(isepamicin)\n⑤ 프리스티나마이신(pristinamycin)",
        "question_text": "Question: Which of the following is an acylated form of dibekacin, a semi-synthetic kanamycin-type antibiotic, used for methicillin-resistant Staphylococcus aureus (MRSA) infections?\n\n① Amikacin\n② Arbekacin\n③ Netilmicin\n④ Isepamicin\n⑤ Pristinamycin",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 15환 구조를 지닌 염기성 마크로라이드류 항생물질로, 클라미디아속, 나이세리아속 등 그람음성균에 강한 항균활성을 나타내는 것은?\n\n① 조사마이신(josamycin)\n② 스피라마이신(spiramycin)\n③ 미데카마이신(midecamycin)\n④ 아지트로마이신(azithromycin)\n⑤ 에리트로마이신(erythromycin)",
        "question_text": "Question: Which of the following is a basic macrolide antibiotic with a 15-membered ring structure that shows strong antimicrobial activity against Gram-negative bacteria such as Chlamydia and Neisseria species?\n\n① Josamycin\n② Spiramycin\n③ Midecamycin\n④ Azithromycin\n⑤ Erythromycin",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: Vancomycin-resistant enterococci(VRE) 감염증 치료에 사용하는 옥사졸리디논계 항미생물제는?\n\n① linezolid\n② imipenem\n③ daptomycin\n④ teichoplanin\n⑤ telithromycin",
        "question_text": "Question: Which oxazolidinone antimicrobial agent is used for the treatment of Vancomycin-resistant enterococci (VRE) infections?\n\n① linezolid\n② imipenem\n③ daptomycin\n④ teicoplanin\n⑤ telithromycin",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: Zanamivir와 oseltamivir의 공통된 작용기전은?\n\n① influenza virus A의 탈피 과정 억제\n② influenza virus B의 hemagglutinin 기능 억제\n③ influenza virus A와 B의 neuraminidase 기능 억제\n④ herpes simplex virus의 DNA polymerase 기능 억제\n⑤ human immunodeficiency virus의 reverse transcriptase 기능 억제",
        "question_text": "Question: What is the common mechanism of action for Zanamivir and Oseltamivir?\n\n① Inhibition of the uncoating process of influenza virus A\n② Inhibition of hemagglutinin function of influenza virus B\n③ Inhibition of neuraminidase function of influenza viruses A and B\n④ Inhibition of DNA polymerase function of herpes simplex virus\n⑤ Inhibition of reverse transcriptase function of human immunodeficiency virus",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 기생충에 감염되었을 때, 혈액에서 세포수가 급격히 증가하고 과립을 방출하여 기생충의 세포막을 손상시키는 것은?\n\n① B 세포\n② T 세포\n③ 호산구\n④ 대식세포\n⑤ 수지상세포",
        "question_text": "Question: When infected with parasites, which of the following rapidly increases in number in the blood and releases granules to damage the cell membrane of the parasite?\n\n① B cells\n② T cells\n③ Eosinophils\n④ Macrophages\n⑤ Dendritic cells",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 면역글로불린 G(immunoglobulin G)의 구조적 특징은?\n\n① 항원결합부위는 1개가 존재함\n② 중쇄는 kappa와 lambda로 구성됨\n③ 1개의 중쇄(heavy chain)와 1개의 경쇄(light chain)로 구성됨\n④ 파파인에 의해 중쇄(heavy chain)와 경쇄(light chain)로 분리됨\n⑤ 가변영역(variable region)과 불변영역(constant region)이 존재함",
        "question_text": "Question: What are the structural characteristics of immunoglobulin G (IgG)?\n\n① It has one antigen-binding site\n② The heavy chains are composed of kappa and lambda\n③ It consists of one heavy chain and one light chain\n④ It is separated into heavy chains and light chains by papain\n⑤ It has variable regions and constant regions",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 항원이 세포 표면의 수용체와 결합하면, 활성화되어 형질세포로 분화하는 것은?\n\n① B 세포\n② T 세포\n③ 호중구\n④ 대식세포\n⑤ 수지상세포",
        "question_text": "Question: When an antigen binds to a receptor on the cell surface, which of the following becomes activated and differentiates into plasma cells?\n\n① B cells\n② T cells\n③ Neutrophils\n④ Macrophages\n⑤ Dendritic cells",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: T 세포가, 항원제시세포가 제시하는 항원과 공동자극분자를 인지한 후, 다량으로 합성 분비한 물질로, T 세포 자신의 증식을 촉진하는 것은?\n\n① histamine\n② lymphotoxin(LT)\n③ interleukin-2(IL-2)\n④ interleukin-10(IL-10)\n⑤ tumor necrosis factor-α(TNF-α)",
        "question_text": "Question: After T cells recognize antigens and co-stimulatory molecules presented by antigen-presenting cells, which substance is synthesized and secreted in large quantities by T cells to promote their own proliferation?\n\n① histamine\n② lymphotoxin (LT)\n③ interleukin-2 (IL-2)\n④ interleukin-10 (IL-10)\n⑤ tumor necrosis factor-α (TNF-α)",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 바이러스에 감염된 세포가 바이러스 복제를 방해하는 효소 합성을 유도하기 위하여 분비하는 항바이러스 물질은?\n\n① interleukin-1(IL-1)\n② interferon-β(IFN-β)\n③ erythropoietin(EPO)\n④ platelet-activating factor(PAF)\n⑤ granulocyte-colony stimulating factor(G-CSF)",
        "question_text": "Question: What is the antiviral substance secreted by virus-infected cells to induce the synthesis of enzymes that interfere with virus replication?\n\n① interleukin-1 (IL-1)\n② interferon-β (IFN-β)\n③ erythropoietin (EPO)\n④ platelet-activating factor (PAF)\n⑤ granulocyte-colony stimulating factor (G-CSF)",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 폐렴구균(Streptococcus pneumoniae)에 의한 질병을 예방하기 위하여 사용하는 것은?\n\n① 생백신\n② 약독화 생백신\n③ 불활성화 사백신\n④ 재조합벡터 백신\n⑤ 협막 다당류를 사용한 백신",
        "question_text": "Question: Which of the following is used to prevent diseases caused by Streptococcus pneumoniae (pneumococcus)?\n\n① Live vaccine\n② Attenuated live vaccine\n③ Inactivated killed vaccine\n④ Recombinant vector vaccine\n⑤ Vaccine using capsular polysaccharides",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 미열, 두통, 마른기침 증상을 보이는 환자의 기도 세척액을 스테롤과 페니실린이 함유된 혈청배지에 도말, 배양하여 호기성 그람양성균을 분리하였다. 이 균은?\n\n① Klebsiella pneumoniae\n② Legionella pneumophila\n③ Mycobacterium avium\n④ Mycoplasma pneumoniae\n⑤ Streptococcus pneumoniae",
        "question_text": "Question: A patient shows symptoms of low-grade fever, headache, and dry cough. The patient's bronchial lavage fluid was cultured on serum media containing sterol and penicillin, and an aerobic gram-positive bacterium was isolated. Which bacterium is this?\n\n① Klebsiella pneumoniae\n② Legionella pneumophila\n③ Mycobacterium avium\n④ Mycoplasma pneumoniae\n⑤ Streptococcus pneumoniae",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 발적독(erythrogenic toxin)을 분비하여 성홍열을 일으키는 감염미생물은?\n\n① Bacillus anthracis\n② Clostridium tetani\n③ Staphylococcus aureus\n④ Streptococcus pyogenes\n⑤ Corynebacterium diphtheriae",
        "question_text": "Question: Which infectious microorganism secretes erythrogenic toxin and causes scarlet fever?\n\n① Bacillus anthracis\n② Clostridium tetani\n③ Staphylococcus aureus\n④ Streptococcus pyogenes\n⑤ Corynebacterium diphtheriae",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 신경절에 잠복감염 되었다가, 면역기능이 저하되면 활성화되어 통증을 동반한 수포성 발진을 일으키는 DNA 바이러스는?\n\n① parvovirus\n② adenovirus\n③ vaccinia virus\n④ papillomavirus\n⑤ varicella-zoster virus",
        "question_text": "Question: Which DNA virus lies dormant in nerve ganglia and, when the immune function is suppressed, becomes activated, causing painful vesicular rashes?\n\n① parvovirus\n② adenovirus\n③ vaccinia virus\n④ papillomavirus\n⑤ varicella-zoster virus",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 발열, 구역, 피로 등의 증상을 호소하는 50세 남자의 혈액검사 결과, alanine aminotransferase(ALT) 및 aspartate aminotransferase(AST) 수치가 증가되어 있고 D형 간염 바이러스의 델타 항원이 검출되었다. 이 환자에서 반드시 검출되는 간염 바이러스는?\n\n① A형\n② B형\n③ C형\n④ E형\n⑤ G형",
        "question_text": "Question: A 50-year-old man complaining of symptoms such as fever, nausea, and fatigue shows elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in his blood test results, and the delta antigen of hepatitis D virus is detected. Which hepatitis virus must be present in this patient?\n\n① Type A\n② Type B\n③ Type C\n④ Type E\n⑤ Type G",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n성매개질환 환자로부터 분리한 병원체를 암시야 현미경법으로 관찰한 결과, 운동성을 가진 나선형균으로 확인되었다. 또한, 이 환자의 혈청은 카디오리핀(cardiolipin) 항원을 침전시켰다.\n\nQuestion: 이 병원체는?\n\n① Chlamydia trachomatis\n② Haemophilus ducreyi\n③ Neisseria gonorrhoeae\n④ Treponema pallidum\n⑤ Ureaplasma urealyticum",
        "question_text": "A pathogen isolated from a patient with a sexually transmitted disease was observed using dark-field microscopy and identified as a motile spirochete. Additionally, the patient's serum precipitated cardiolipin antigen.\n\nQuestion: What is this pathogen?\n\n① Chlamydia trachomatis\n② Haemophilus ducreyi\n③ Neisseria gonorrhoeae\n④ Treponema pallidum\n⑤ Ureaplasma urealyticum",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n성매개질환 환자로부터 분리한 병원체를 암시야 현미경법으로 관찰한 결과, 운동성을 가진 나선형균으로 확인되었다. 또한, 이 환자의 혈청은 카디오리핀(cardiolipin) 항원을 침전시켰다.\n\nQuestion: 이 병원체와 유사한 형태학적 특징을 지니며, 진드기를 매개로 하는 라임병(Lyme disease)을 일으키는 것은?\n\n① Borrelia burgdorferi\n② Clostridium perfringens\n③ Neisseria meningitidis\n④ Orientia tsutsugamushi\n⑤ Rickettsia prowazekii",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA pathogen isolated from a patient with a sexually transmitted disease was observed using dark-field microscopy and identified as a motile spirochete. Additionally, the patient's serum precipitated cardiolipin antigen.\n\nQuestion: Which of the following has similar morphological characteristics to this pathogen and causes Lyme disease transmitted by ticks?\n\n① Borrelia burgdorferi\n② Clostridium perfringens\n③ Neisseria meningitidis\n④ Orientia tsutsugamushi\n⑤ Rickettsia prowazekii",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 아드레날린 β 수용체에 효능약이 지속적으로 작용할 때, G protein-coupled receptor kinase(GRK)에 의해 인산화된 수용체의 C-말단 꼬리에 결합하여 탈감작(desensitization)을 유발하는 단백질은?\n\n① β-arrestin\n② guanylyl cyclase\n③ Hsp90\n④ Janus-kinase(JAK)\n⑤ signal transducers and activators of transcription(STATs)",
        "question_text": "Question: When an agonist continuously acts on adrenergic β receptors, which protein binds to the C-terminal tail of the receptor phosphorylated by G protein-coupled receptor kinase (GRK) and causes desensitization?\n\n① β-arrestin\n② guanylyl cyclase\n③ Hsp90\n④ Janus-kinase (JAK)\n⑤ signal transducers and activators of transcription (STATs)",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: Buprenorphine(μ-아편수용체 부분효능약)과 morphine(μ-아편수용체 완전효능약)을 각각 최대효능을 나타내는 치료용량으로 병용투여 할 경우 나타나는 효과에 대한 설명으로 옳은 것은?\n\n① Morphine의 진통효과만 나타난다.\n② 두 약물의 진통효과가 상가(addition)된다.\n③ 두 약물의 진통효과가 나타나지 않는다.\n④ Morphine의 진통효과가 상승(synergism)된다.\n⑤ Morphine 단독투여보다 진통효과가 감소된다.",
        "question_text": "Question: When buprenorphine (a partial μ-opioid receptor agonist) and morphine (a full μ-opioid receptor agonist) are co-administered at their respective therapeutic doses that produce maximum efficacy, which of the following statements correctly describes the resulting effect?\n\n① Only the analgesic effect of morphine is observed.\n② The analgesic effects of both drugs are additive.\n③ The analgesic effects of both drugs are not observed.\n④ The analgesic effect of morphine is synergistically enhanced.\n⑤ The analgesic effect is reduced compared to morphine alone.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 약물-수용체 상호작용에서 평형해리상수(K d)의 역수가 의미하는 것은?\n\n① 친화력(affinity)\n② 생체이용률(bioavailability)\n③ 최대효능(maximal efficacy)\n④ 치료지수(therapeutic index)\n⑤ 내인성 효능(intrinsic efficacy)",
        "question_text": "Question: In drug-receptor interactions, what does the reciprocal of the equilibrium dissociation constant (K d) represent?\n\n① Affinity\n② Bioavailability\n③ Maximal efficacy\n④ Therapeutic index\n⑤ Intrinsic efficacy",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 아트로핀(atropine)을 점안하였을 때 나타나는 약리현상은?\n\n① 방수(aqueous humor) 분비 감소로 인한 안압 감소\n② 방수 배출 증가로 인한 안압 감소\n③ 동공 방사근(radial muscle) 수축에 의한 산동\n④ 홍채의 동공조임근(iris sphincter) 수축에 의한 축동\n⑤ 모양체근(ciliary muscle) 수축의 약화로 인한 원근조절 마비",
        "question_text": "Question: What is the pharmacological effect when atropine is administered as eye drops?\n\n① Decrease in intraocular pressure due to reduced aqueous humor secretion\n② Decrease in intraocular pressure due to increased aqueous humor outflow\n③ Mydriasis (pupil dilation) due to contraction of the radial muscle of the iris\n④ Miosis (pupil constriction) due to contraction of the iris sphincter\n⑤ Cycloplegia (paralysis of accommodation) due to weakened contraction of the ciliary muscle",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 전신마취 수술에서 마취 전에 투여하는 약물 – 기전 – 사용목적을 옳게 연결한 것은?\n\n① thiopental – 도파민 수용체 억제 – 마취 유도\n② midazolam – GABA_B 수용체 억제 – 통증 억제\n③ rocuronium – 니코틴 수용체 차단 – 골격근 이완\n④ ondansetron – 무스카린 수용체 억제 – 구토 방지\n⑤ dantrolene – GABA_A 수용체 차단 – 타액분비 억제",
        "question_text": "Question: Which of the following correctly matches the drug administered before general anesthesia, its mechanism of action, and its purpose of use?\n\n① thiopental – dopamine receptor inhibition – anesthesia induction\n② midazolam – GABA_B receptor inhibition – pain suppression\n③ rocuronium – nicotinic receptor blockade – skeletal muscle relaxation\n④ ondansetron – muscarinic receptor inhibition – antiemesis\n⑤ dantrolene – GABA_A receptor blockade – salivary secretion inhibition",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 조현병 치료약 중 다음 특성을 지니는 것은?\n\n• 조현병의 양성과 음성 증상 모두에 효과적임\n• 추체외로 증상(운동기능 이상)을 거의 나타내지 않음\n• 세로토닌 수용체, 히스타민 수용체, 도파민 수용체에 모두  작용함\n\n① 올란자핀(olanzapine)\n② 플루옥세틴(fluoxetine)\n③ 라모트리진(lamotrigine)\n④ 플루페나진(fluphenazine)\n⑤ 클로르프로마진(chlorpromazine)",
        "question_text": "Question: Which of the following medications for schizophrenia has these characteristics?\n\n• Effective for both positive and negative symptoms of schizophrenia\n• Rarely causes extrapyramidal symptoms (motor function abnormalities)\n• Acts on serotonin receptors, histamine receptors, and dopamine receptors\n\n① Olanzapine\n② Fluoxetine\n③ Lamotrigine\n④ Fluphenazine\n⑤ Chlorpromazine",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 레보도파(levodopa)를 처방받은 파킨슨증 환자에게 발생할 수 있는 유해작용(식욕부진, 구토, 빈맥)을 감소시키기 위하여 레보도파와 병용하는 약물은?\n\n① apomorphine\n② carbidopa\n③ haloperidol\n④ tetrabenazine\n⑤ thioridazine",
        "question_text": "Question: Which drug is used in combination with levodopa to reduce the adverse effects (anorexia, vomiting, tachycardia) that may occur in Parkinson's disease patients prescribed levodopa?\n\n① apomorphine\n② carbidopa\n③ haloperidol\n④ tetrabenazine\n⑤ thioridazine",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 아편 유사작용이 없는 순수 아편수용체 길항약은?\n\n① 펜타닐(fentanyl)\n② 날록손(naloxone)\n③ 날부핀(nalbuphine)\n④ 옥시코돈(oxycodone)\n⑤ 펜타조신(pentazocine)",
        "question_text": "Question: Which of the following is a pure opioid receptor antagonist without any opioid-like effects?\n\n① Fentanyl\n② Naloxone\n③ Nalbuphine\n④ Oxycodone\n⑤ Pentazocine",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 천식환자에게 흡입용 corticosteroid와 함께 투여하는 지속성 β2 수용체 효능약은?\n\n① albuterol\n② formoterol\n③ ipratropium\n④ montelukast\n⑤ theophylline",
        "question_text": "Question: Which long-acting β2 receptor agonist is administered together with inhaled corticosteroids for asthma patients?\n\n① albuterol\n② formoterol\n③ ipratropium\n④ montelukast\n⑤ theophylline",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 급성관상동맥증후군 환자에게 사용하는 혈소판 glycoprotein IIb/IIIa 수용체 차단약은?\n\n① abciximab\n② clopidogrel\n③ dipyridamole\n④ heparin\n⑤ warfarin",
        "question_text": "Question: Which platelet glycoprotein IIb/IIIa receptor blocker is used for patients with acute coronary syndrome?\n\n① abciximab\n② clopidogrel\n③ dipyridamole\n④ heparin\n⑤ warfarin",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 혈관평활근 세포막의 K+ 통로를 개방하는 고혈압치료제로서 모발성장 자극약으로도 사용할 수 있는 것은?\n\n① amiodarone\n② diazoxide\n③ enalapril\n④ minoxidil\n⑤ nateglinide",
        "question_text": "Question: Which antihypertensive drug that opens K+ channels in vascular smooth muscle cell membranes can also be used as a hair growth stimulant?\n\n① amiodarone\n② diazoxide\n③ enalapril\n④ minoxidil\n⑤ nateglinide",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 피질집합세관(cortical collecting tubule)에 있는 상피세포 Na+ 통로를 직접 차단하여 K+ 배설을 억제하는 이뇨약은?\n\n① 푸로세미드(furosemide)\n② 트리암테렌(triamterene)\n③ 스피로노락톤(spironolactone)\n④ 아세타졸아미드(acetazolamide)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: Which diuretic directly blocks the epithelial Na+ channels in the cortical collecting tubule, thereby inhibiting K+ excretion?\n\n① Furosemide\n② Triamterene\n③ Spironolactone\n④ Acetazolamide\n⑤ Hydrochlorothiazide",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: Tubulin과 결합하여 백혈구 이동을 저해함으로써 급성통풍을 치료하는 약물은?\n\n① allopurinol\n② colchicine\n③ febuxostat\n④ pegloticase\n⑤ probenecid",
        "question_text": "Question: Which drug treats acute gout by binding to tubulin and inhibiting leukocyte migration?\n\n① allopurinol\n② colchicine\n③ febuxostat\n④ pegloticase\n⑤ probenecid",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: Helicobacter pylori 에 감염된 급성 소화성궤양 환자를 치료하기 위한 삼제요법(triple therapy)에서 clarithromycin, amoxicillin과 함께 사용하는 약물은?\n\n① alosetron\n② metoclopramide\n③ misoprostol\n④ omeprazole\n⑤ sulfasalazine",
        "question_text": "Question: Which drug is used together with clarithromycin and amoxicillin in triple therapy for treating patients with acute peptic ulcer infected with Helicobacter pylori?\n\n① alosetron\n② metoclopramide\n③ misoprostol\n④ omeprazole\n⑤ sulfasalazine",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: Dihydrotestosterone의 생성을 억제하는 기능이 있어 전립샘비대 환자에게 사용하는 약물은?\n\n① clomiphene\n② finasteride\n③ oxybutynin\n④ tamoxifen\n⑤ tamsulosin",
        "question_text": "Question: Which drug is used in patients with benign prostatic hyperplasia due to its function of inhibiting the production of dihydrotestosterone?\n\n① clomiphene\n② finasteride\n③ oxybutynin\n④ tamoxifen\n⑤ tamsulosin",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: Glucagon-like polypeptide-1 수용체 효능약으로, 제2형 당뇨병에 사용하는 약물은?\n\n① acarbose\n② liraglutide\n③ metformin\n④ pioglitazone\n⑤ sitagliptin",
        "question_text": "Question: Which of the following is a Glucagon-like peptide-1 receptor agonist used for the treatment of Type 2 diabetes?\n\n① acarbose\n② liraglutide\n③ metformin\n④ pioglitazone\n⑤ sitagliptin",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: Ofloxacin의 약리기전은?\n\n① DNA gyrase 억제\n② squalene epoxidase 억제\n③ dihydrofolate reductase 억제\n④ 산성에서 분해되어 formaldehyde 유리\n⑤ 리보솜 소단위에 결합하여 단백질 합성 억제",
        "question_text": "Question: What is the pharmacological mechanism of Ofloxacin?\n\n① Inhibition of DNA gyrase\n② Inhibition of squalene epoxidase\n③ Inhibition of dihydrofolate reductase\n④ Degradation in acidic conditions to release formaldehyde\n⑤ Binding to ribosomal subunits to inhibit protein synthesis",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지니는 항암약은?\n\n• 진행성 신장세포암과 진행성 간세포암의 치료약으로 승인됨\n• 혈관내피성장인자 수용체, 혈소판유래성장인자 수용체 등 여러 receptor tyrosine kinase와 Raf kinase를 억제함\n\n① bevacizumab\n② bortezomib\n③ erlotinib\n④ imatinib\n⑤ sorafenib",
        "question_text": "Question: Which anticancer drug has the following characteristics?\n\n• Approved for the treatment of advanced renal cell carcinoma and advanced hepatocellular carcinoma\n• Inhibits multiple receptor tyrosine kinases including vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and Raf kinase\n\n① bevacizumab\n② bortezomib\n③ erlotinib\n④ imatinib\n⑤ sorafenib",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n눈꺼풀처짐(palpebral ptosis), 복시(diplopia), 삼킴곤란(dysphagia) 등의 증상을 호소하는 환자에게 진단 목적으로 약물 X를 정맥주사 한 결과, 이 증상들이 일시적으로 개선되었다.\n\nQuestion: 약물 X의 작용기전은?\n\n① 도파민 수용체 길항\n② 콜린에스테라제 억제\n③ 무스카린 수용체 길항\n④ 모노아민 산화효소 억제\n⑤ 아드레날린 α1 수용체 길항",
        "question_text": "A patient complaining of symptoms such as drooping eyelids (palpebral ptosis), double vision (diplopia), and difficulty swallowing (dysphagia) was given an intravenous injection of drug X for diagnostic purposes. As a result, these symptoms temporarily improved.\n\nQuestion: What is the mechanism of action of drug X?\n\n① Dopamine receptor antagonism\n② Cholinesterase inhibition\n③ Muscarinic receptor antagonism\n④ Monoamine oxidase inhibition\n⑤ Adrenergic α1 receptor antagonism",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n눈꺼풀처짐(palpebral ptosis), 복시(diplopia), 삼킴곤란(dysphagia) 등의 증상을 호소하는 환자에게 진단 목적으로 약물 X를 정맥주사 한 결과, 이 증상들이 일시적으로 개선되었다.\n\nQuestion: 위 증상이 나타나는 질병의 발생기전과 관련이 있는 수용체 – 치료약물을 옳게 연결한 것은?\n\n① 무스카린 수용체 – atropine\n② 무스카린 수용체 – cyclopentolate\n③ 니코틴 수용체 – pyridostigmine\n④ 니코틴 수용체 – mecamylamine\n⑤ 아드레날린 α1 수용체 – doxazosin",
        "question_text": "A patient complaining of symptoms such as drooping eyelids (palpebral ptosis), double vision (diplopia), and difficulty swallowing (dysphagia) was given an intravenous injection of drug X for diagnostic purposes. As a result, these symptoms temporarily improved.\n\nQuestion: Which of the following correctly matches the receptor associated with the mechanism of the disease causing the above symptoms with its therapeutic drug?\n\n① Muscarinic receptor – atropine\n② Muscarinic receptor – cyclopentolate\n③ Nicotinic receptor – pyridostigmine\n④ Nicotinic receptor – mecamylamine\n⑤ Adrenergic α1 receptor – doxazosin",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 어떤 질병을 진단하기 위해 양성 또는 음성으로만 결과가 도출되는 새로운 검사법을 개발하였다. 이의 타당도를 확인하고자 100명의 환자와 100명의 정상인을 대상으로 검사를 실시하였다. 그 결과, 환자 중 90명, 정상인 중 20명이 각각 양성으로 판정되었다면, 이 검사법의 민감도(sensitivity)는?\n\n① 10%\n② 20%\n③ 55%\n④ 80%\n⑤ 90%",
        "question_text": "Question: A new diagnostic test has been developed for a certain disease, which produces results only as positive or negative. To verify its validity, the test was conducted on 100 patients and 100 healthy individuals. As a result, 90 out of the patients and 20 out of the healthy individuals were diagnosed as positive. What is the sensitivity of this test?\n\n① 10%\n② 20%\n③ 55%\n④ 80%\n⑤ 90%",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 염소를 이용한 먹는물 살균 과정에서 생성되는 차아염소산(HClO)과 차아염소산이온(ClO-)을 비교한 설명으로 옳은 것은?\n\n① 살균력과 잔류성이 유사하다.\n② 살균력과 잔류성 모두 ClO-이 크다.\n③ 살균력과 잔류성 모두 HClO가 크다.\n④ 살균력은 ClO-이 크고, 잔류성은 HClO가 크다.\n⑤ 살균력은 HClO가 크고, 잔류성은 ClO-이 크다.",
        "question_text": "Question: Which of the following statements correctly compares hypochlorous acid (HClO) and hypochlorite ion (ClO-) produced during the chlorination process of drinking water?\n\n① Their disinfecting power and residual effect are similar.\n② ClO- has greater disinfecting power and residual effect.\n③ HClO has greater disinfecting power and residual effect.\n④ ClO- has greater disinfecting power, while HClO has greater residual effect.\n⑤ HClO has greater disinfecting power, while ClO- has greater residual effect.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 무색무취의 기체인 자연방사성 물질로서, 토양이나 건축자재로부터 유래하여 폐암을 유발할 수 있는 실내공기 오염물질은?\n\n① 라돈(Rn)\n② 라듐(Ra)\n③ 세슘(Cs)\n④ 우라늄(U)\n⑤ 스트론튬(Sr)",
        "question_text": "Question: Which colorless and odorless gaseous natural radioactive substance, originating from soil or building materials, can cause lung cancer as an indoor air pollutant?\n\n① Radon (Rn)\n② Radium (Ra)\n③ Cesium (Cs)\n④ Uranium (U)\n⑤ Strontium (Sr)",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: Primaquine, sulfapyridine 또는 nitrofurantoin을 복용할 때 용혈빈혈이 생기는 사람들에게 결핍되어 있을 가능성이 높은 효소는?\n\n① N-acetyltransferase\n② aldehyde dehydrogenase\n③ glucose-6-phosphate dehydrogenase\n④ glutathione-S-transferase\n⑤ vitamin K epoxide reductase",
        "question_text": "Question: Which enzyme is most likely to be deficient in people who develop hemolytic anemia when taking primaquine, sulfapyridine, or nitrofurantoin?\n\n① N-acetyltransferase\n② aldehyde dehydrogenase\n③ glucose-6-phosphate dehydrogenase\n④ glutathione-S-transferase\n⑤ vitamin K epoxide reductase",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 도료, 수지, 플라스틱 등의 용제로 사용되며, 만성적으로 노출되면 조혈기능 손상으로 인한 재생불량빈혈이나 백혈병을 유발하는 발암물질은?\n\n① benzene\n② dimethylnitrosamine\n③ melamine\n④ tetrabromobisphenol A\n⑤ toluene",
        "question_text": "Question: Which carcinogenic substance is used as a solvent in paints, resins, and plastics, and when chronically exposed, can cause aplastic anemia or leukemia due to damage to the hematopoietic function?\n\n① benzene\n② dimethylnitrosamine\n③ melamine\n④ tetrabromobisphenol A\n⑤ toluene",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 제초제인 paraquat가 폐에 선택적으로 독성을 나타내는 것은 폐포 상피세포의 어떠한 특성 때문인가?\n\n① CYP2D6의 선택적 발현\n② P-glycoprotein의 낮은 발현\n③ Na+,K+-ATPase의 높은 활성\n④ glutathione peroxidase의 높은 활성\n⑤ polyamine transporter의 특이적 분포",
        "question_text": "Question: Why does paraquat, a herbicide, show selective toxicity to the lungs? Which characteristic of alveolar epithelial cells is responsible for this?\n\n① Selective expression of CYP2D6\n② Low expression of P-glycoprotein\n③ High activity of Na+,K+-ATPase\n④ High activity of glutathione peroxidase\n⑤ Specific distribution of polyamine transporter",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 중독되면 혈액과 오줌의 δ-aminolevulinic acid 농도를 높이고 빈혈을 유발하며, 신경세포의 탈수초화와 축색돌기 퇴화로 운동신경 기능에 이상을 초래하는 금속은?\n\n① 납(Pb)\n② 비소(As)\n③ 크롬(Cr)\n④ 수은(Hg)\n⑤ 카드뮴(Cd)",
        "question_text": "Question: Which metal, when intoxicated, increases the concentration of δ-aminolevulinic acid in blood and urine, causes anemia, and leads to abnormalities in motor nerve function due to demyelination of nerve cells and degeneration of axons?\n\n① Lead (Pb)\n② Arsenic (As)\n③ Chromium (Cr)\n④ Mercury (Hg)\n⑤ Cadmium (Cd)",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 역학조사에서 한 폐광지역에 거주하는 주민들이 타 지역 거주자들에 비해 혈중 metallothionein 농도가 높고 오줌 중 저분자 단백질의 검출 빈도도 높았으며 골연화증 환자가 많았다. 이 폐광지역 주민들이 노출되었을 것으로 추정되는 물질은?\n\n① 납(Pb)\n② 비소(As)\n③ 크롬(Cr)\n④ 카드뮴(Cd)\n⑤ 코발트(Co)",
        "question_text": "Question: In an epidemiological study, residents living in a former mining area showed higher blood concentrations of metallothionein and a higher frequency of low molecular weight proteins in urine compared to residents in other areas. There were also many cases of osteomalacia. Which substance are these residents of the former mining area presumed to have been exposed to?\n\n① Lead (Pb)\n② Arsenic (As)\n③ Chromium (Cr)\n④ Cadmium (Cd)\n⑤ Cobalt (Co)",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 농약에 중독되어 구토, 설사, 축동, 기관지 수축, 경련, 호흡곤란과 같은 증상이 나타날 때 응급처치를 위해 사용할 수 있는 것은?\n\n① atropine\n② citric acid\n③ dimercaprol\n④ methylene blue\n⑤ penicillamine",
        "question_text": "Question: Which of the following can be used for emergency treatment when symptoms such as vomiting, diarrhea, miosis, bronchial constriction, convulsions, and difficulty breathing occur due to pesticide poisoning?\n\n① atropine\n② citric acid\n③ dimercaprol\n④ methylene blue\n⑤ penicillamine",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 식품 중의 단백질 영양가를 평가하는 데에 이용되는 단백질가(protein score)를 산출하기 위해 필요한 정보는?\n\n① 단백질 효율\n② 단백질 섭취량\n③ 체내 단백질 잔존량\n④ 달걀 중 제한 아미노산의 양\n⑤ 해당 식품 중 제한 아미노산의 양",
        "question_text": "Question: What information is needed to calculate the protein score used to evaluate the nutritional value of protein in food?\n\n① Protein efficiency\n② Protein intake\n③ Residual protein amount in the body\n④ Amount of limiting amino acids in eggs\n⑤ Amount of limiting amino acids in the food in question",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 신생아를 대상으로 한 선천성 대사이상 선별검사에서 혈중 메티오닌(methionine) 수치가 정상치보다 높았다. 이상이 있을 것으로 추정되는 대사 효소는?\n\n① branched-chain α-keto acid dehydrogenase\n② cystathionine β-synthase\n③ fumarylacetoacetate hydrolase\n④ phenylalanine hydroxylase\n⑤ tyrosine aminotransferase",
        "question_text": "Question: In a newborn screening test for congenital metabolic disorders, the blood methionine level was higher than normal. Which metabolic enzyme is likely to be abnormal?\n\n① branched-chain α-keto acid dehydrogenase\n② cystathionine β-synthase\n③ fumarylacetoacetate hydrolase\n④ phenylalanine hydroxylase\n⑤ tyrosine aminotransferase",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 영양소 결핍에 의해 잇몸이나 피하의 출혈, 치아나 뼈의 발육 이상, 상처 치유의 지연, 피로감과 같은 증상이 나타날 때 이를 개선하기 위해 권장할 수 있는 식품은?\n\n① 달걀, 우유\n② 콩, 옥수수\n③ 감귤, 시금치\n④ 꽁치, 고등어\n⑤ 닭고기, 소고기",
        "question_text": "Question: Which foods can be recommended to improve symptoms such as bleeding in the gums or subcutaneous tissue, abnormal development of teeth or bones, delayed wound healing, and fatigue, when these symptoms are caused by nutrient deficiency?\n\n① Eggs, milk\n② Beans, corn\n③ Citrus fruits, spinach\n④ Pacific saury, mackerel\n⑤ Chicken, beef",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 콜라겐 가교화를 매개하는 lysyl oxidase의 기능에 필수적이므로, 결핍되면 결합 조직이 약화되어 심장이나 혈관 장애를 유발하는 무기질은?\n\n① 철(Fe)\n② 아연(Zn)\n③ 구리(Cu)\n④ 망간(Mn)\n⑤ 셀레늄(Se)",
        "question_text": "Question: Which mineral is essential for the function of lysyl oxidase that mediates collagen cross-linking, and its deficiency weakens connective tissue, causing heart or vascular disorders?\n\n① Iron (Fe)\n② Zinc (Zn)\n③ Copper (Cu)\n④ Manganese (Mn)\n⑤ Selenium (Se)",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: Felodipine이나 simvastatin을 자몽주스와 함께 복용하지 않도록 하는 것은 자몽주스의 어떠한 작용 때문인가?\n\n① CYP3A4 억제\n② CYP1A2 유도\n③ 담즙분비 유도\n④ 위장관운동 촉진\n⑤ P-glycoprotein 유도",
        "question_text": "Question: Why is it advised not to take felodipine or simvastatin with grapefruit juice? Which action of grapefruit juice is responsible for this?\n\n① CYP3A4 inhibition\n② CYP1A2 induction\n③ Bile secretion induction\n④ Gastrointestinal motility promotion\n⑤ P-glycoprotein induction",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 단백질이 부패될 때에 리신(lysine)이 탈탄산되어 생성되는 분해산물은?\n\n① agmatine\n② cadaverine\n③ histamine\n④ putrescine\n⑤ tyramine",
        "question_text": "Question: What is the decomposition product formed when lysine is decarboxylated during protein putrefaction?\n\n① agmatine\n② cadaverine\n③ histamine\n④ putrescine\n⑤ tyramine",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 덜 익힌 소고기 햄버거를 섭취한 어린이가 용혈빈혈, 혈소판 감소, 급성 신장기능장애 등의 용혈요독증후군 증상을 보였다. 이 증상의 원인균은?\n\n① 포도알균\n② 살모넬라균\n③ 보툴리누스균\n④ 장염비브리오균\n⑤ 장출혈성대장균",
        "question_text": "Question: A child who consumed an undercooked beef hamburger showed symptoms of hemolytic uremic syndrome, including hemolytic anemia, thrombocytopenia, and acute renal dysfunction. What is the causative organism for these symptoms?\n\n① Staphylococcus\n② Salmonella\n③ Clostridium botulinum\n④ Vibrio parahaemolyticus\n⑤ Enterohemorrhagic E. coli",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 간경화를 앓고 있는 성인 남자가 여름철에 생선회와 초밥을 먹은 후에 구토와 설사를 하고 피부병변과 괴사성 근막염을 보이다가 패혈증과 쇼크로 사망하였다. 감염되었을 것으로 추정되는 균은?\n\n① Campylobacter jejuni\n② Clostridium botulinum\n③ Staphylococcus aureus\n④ Vibrio vulnificus\n⑤ Yersinia enterocolitica",
        "question_text": "Question: An adult male with cirrhosis ate raw fish and sushi in the summer, after which he experienced vomiting and diarrhea, showed skin lesions and necrotizing fasciitis, and eventually died from sepsis and shock. Which bacterium is most likely to have caused the infection?\n\n① Campylobacter jejuni\n② Clostridium botulinum\n③ Staphylococcus aureus\n④ Vibrio vulnificus\n⑤ Yersinia enterocolitica",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 식품 중에서 환원된 후 작용하는 식품첨가물로서, 과량 섭취 시 methemoglobin 혈증을 일으키고, 식품의 2급 아민과 반응하여 발암성 물질을 생성할 수 있는 것은?\n\n① 질산칼륨\n② 황산제일철\n③ 아황산나트륨\n④ 안식향산나트륨\n⑤ 아황산수소나트륨",
        "question_text": "Question: Which food additive, when reduced and active in food, can cause methemoglobinemia when consumed in excess and can react with secondary amines in food to produce carcinogenic substances?\n\n① Potassium nitrate\n② Ferrous sulfate\n③ Sodium sulfite\n④ Sodium benzoate\n⑤ Sodium bisulfite",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n인구 천만 명이 거주하는 한 도시의 모든 사람이 어떤 발암성 대기오염물질에 노출되었다. 인체위해성평가에서 이 대기오염물질의 개인초과발암위해도가 2×10^-6으로 산출되었다.\n\nQuestion: 위 사례에서 도시의 주민 모두가 이 화학물질에 현재의 수준으로 평생 노출된다면 이 물질에 의해 추가적으로 암이 발생할 수 있는 인구수는?\n\n① 2\n② 10\n③ 20\n④ 100\n⑤ 200",
        "question_text": "A city with a population of 10 million people has been exposed to a carcinogenic air pollutant. In a human health risk assessment, the individual excess cancer risk for this air pollutant was calculated to be 2×10^-6.\n\nQuestion: In the above case, if all residents of the city are exposed to this chemical at the current level for their lifetime, what is the number of additional cancer cases that could occur due to this substance?\n\n① 2\n② 10\n③ 20\n④ 100\n⑤ 200",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n인구 천만 명이 거주하는 한 도시의 모든 사람이 어떤 발암성 대기오염물질에 노출되었다. 인체위해성평가에서 이 대기오염물질의 개인초과발암위해도가 2×10^-6으로 산출되었다.\n\nQuestion: 위 사례에서 현오염도수준이 5 μg/L이었다면, 이 대기오염 물질의 단위위해도(unit risk)는? [단위: (μg/L)^-1]\n\n① 4×10^-5\n② 2.5×10^-5\n③ 4×10^-6\n④ 2.5×10^-6\n⑤ 4×10^-7",
        "question_text": "A city with a population of 10 million people has been exposed to a carcinogenic air pollutant. In a human health risk assessment, the individual excess cancer risk for this air pollutant was calculated to be 2×10^-6.\n\nQuestion: In the above case, if the current pollution level was 5 μg/L, what is the unit risk of this air pollutant? [Unit: (μg/L)^-1]\n\n① 4×10^-5\n② 2.5×10^-5\n③ 4×10^-6\n④ 2.5×10^-6\n⑤ 4×10^-7",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 허혈 ∙ 재관류에 의한 세포손상의 원인물질은?\n\n① 지방\n② 핵산\n③ 단백질\n④ 리포푸신\n⑤ 활성산소종",
        "question_text": "Question: What is the causative substance of cellular damage due to ischemia-reperfusion?\n\n① Lipids\n② Nucleic acids\n③ Proteins\n④ Lipofuscin\n⑤ Reactive oxygen species",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 모세혈관 주위에 많이 분포하며, 손상 부위에서 활성화되면 히스타민을 분비하고, 제1형 과민반응을 매개하는 세포는?\n\n① 혈소판\n② 호중구\n③ 비만세포\n④ 대식세포\n⑤ 섬유모세포",
        "question_text": "Question: Which cell is widely distributed around capillaries, releases histamine when activated at injury sites, and mediates Type I hypersensitivity reactions?\n\n① Platelets\n② Neutrophils\n③ Mast cells\n④ Macrophages\n⑤ Fibroblasts",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 재생불량빈혈 환자가 동종이형 골수를 이식받은 날로부터 6일 후 박리성 피부발진, 황달, 혈액이 섞인 설사 증세를 보이면서 간기능이 나빠졌다. 이러한 증상의 원인은?\n\n① 급성 거부반응\n② 만성 거부반응\n③ 면역억제약물 부작용\n④ 재생불량빈혈의 재발\n⑤ 급성 이식편대숙주반응",
        "question_text": "Question: A patient with aplastic anemia received an allogeneic bone marrow transplant. Six days after the transplantation, the patient developed exfoliative skin rash, jaundice, bloody diarrhea, and deteriorating liver function. What is the cause of these symptoms?\n\n① Acute rejection\n② Chronic rejection\n③ Side effects of immunosuppressive drugs\n④ Recurrence of aplastic anemia\n⑤ Acute graft-versus-host disease",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 10여 년 전에 사람면역결핍바이러스(human immunodeficiency virus) 감염 판정을 받은 환자가 결핵 증상 때문에 투베르쿨린 피부검사를 받았는데 결과는 음성이었고, 추가로 흉부 X-선 촬영 및 객담검사를 통해 결핵 확진을 받았다. 투베르쿨린 피부검사에서 음성이 나온 이유는?\n\n① 면역관용\n② 지연과민반응 소실\n③ 항체의존세포매개독성 소실\n④ 아루투스반응(Arthus reaction)\n⑤ 에피토프 확산(epitope spreading)",
        "question_text": "Question: A patient who was diagnosed with human immunodeficiency virus (HIV) infection about 10 years ago received a tuberculin skin test due to tuberculosis symptoms. The result was negative, but additional chest X-ray and sputum tests confirmed tuberculosis. What is the reason for the negative result in the tuberculin skin test?\n\n① Immune tolerance\n② Loss of delayed-type hypersensitivity\n③ Loss of antibody-dependent cell-mediated cytotoxicity\n④ Arthus reaction\n⑤ Epitope spreading",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 죽상동맥경화 진행의 초기병소인 지방반을 형성하는 주요 세포는?\n\n① 림프구\n② 지방세포\n③ 거품세포\n④ 평활근세포\n⑤ 혈관내피세포",
        "question_text": "Question: What is the main cell type that forms fatty streaks, the initial lesion in the progression of atherosclerosis?\n\n① Lymphocyte\n② Adipocyte\n③ Foam cell\n④ Smooth muscle cell\n⑤ Vascular endothelial cell",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 정맥류가 지속될 때 발생하는 합병증인 갈색경화성 정체피부염(stasis dermatitis)의 발생 기전은?\n\n① 알부민의 혈관 외 침착\n② 정맥류 부위의 세균 감염\n③ 혈관 외로 유출된 적혈구의 용해\n④ 혈관 외로 유출된 대식세포의 식작용 \n⑤ 혈관 외로 유출된 림프구의 면역반응",
        "question_text": "Question: What is the mechanism of stasis dermatitis, a complication that occurs when varicose veins persist?\n\n① Extravascular deposition of albumin\n② Bacterial infection at the site of varicose veins\n③ Lysis of red blood cells that have leaked outside the blood vessels\n④ Phagocytosis by macrophages that have leaked outside the blood vessels\n⑤ Immune response of lymphocytes that have leaked outside the blood vessels",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 상행 대동맥에서 흔히 발생하는 대동맥박리(aortic dissection)의 주요 원인은?\n\n① 고혈압(hypertension)\n② 심내막염(endocarditis)\n③ 죽상경화증(atherosclerosis)\n④ 측두동맥염(temporal arteritis)\n⑤ 폐쇄혈전혈관염(thromboangiitis obliterans)",
        "question_text": "Question: What is the main cause of aortic dissection that commonly occurs in the ascending aorta?\n\n① Hypertension\n② Endocarditis\n③ Atherosclerosis\n④ Temporal arteritis\n⑤ Thromboangiitis obliterans",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 다음의 환자 상태에서 다리 증상을 유발한 원인은?\n\n• 극심한 흉통으로 심근경색을 진단받음\n• 복부대동맥 동맥류와 심장벽혈전의 존재가 확인됨\n• 한쪽 다리에 수차례의 이상증상(아프고 차가워졌다가 다시 괜찮아짐)이 발생함\n\n① 혈관염(vasculitis)\n② 혈소판감소증(thrombocytopenia)\n③ 림프관폐쇄(lymphatic obstruction)\n④ 동맥혈전색전증(arterial thromboembolism)\n⑤ 파종혈관내응고(disseminated intravascular coagulation)",
        "question_text": "Question: What is the cause of the leg symptoms in the following patient condition?\n\n• Diagnosed with myocardial infarction due to severe chest pain\n• Presence of abdominal aortic aneurysm and intracardiac thrombus confirmed\n• Multiple episodes of abnormal symptoms (pain and coldness that resolve) occur in one leg\n\n① Vasculitis\n② Thrombocytopenia\n③ Lymphatic obstruction\n④ Arterial thromboembolism\n⑤ Disseminated intravascular coagulation",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "original_text": "Question: 기관지의 점액폐쇄가 있거나 복부수술 후 통증에 의해 호흡운동이 감소되는 경우에 발생하며, 확장된 폐조직의 붕괴가 특징인 질환은?\n\n① 규폐증(silicosis)\n② 무기폐(atelectasis)\n③ 기도감염증(airway infection)\n④ 기관지확장증(bronchiectasis)\n⑤ 세균성허파염(bacterial pneumonia)",
        "question_text": "Question: Which disease occurs when there is mucus obstruction in the bronchi or when respiratory movement is reduced due to pain after abdominal surgery, and is characterized by the collapse of expanded lung tissue?\n\n① Silicosis\n② Atelectasis\n③ Airway infection\n④ Bronchiectasis\n⑤ Bacterial pneumonia",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "original_text": "Question: 폐기종의 원인은?\n\n① 리파아제의 활성 감소\n② 아밀라아제 활성 감소\n③ 엘라스타아제 활성 감소\n④ 알파1 항트립신 활성 감소\n⑤ 콜라겐분해효소 활성 감소",
        "question_text": "Question: What is the cause of emphysema?\n\n① Decreased lipase activity\n② Decreased amylase activity\n③ Decreased elastase activity\n④ Decreased alpha-1 antitrypsin activity\n⑤ Decreased collagenase activity",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "original_text": "Question: 직장결장암의 다단계 발암 과정에서 다음 설명에 해당하는 유전자는?\n\n• APC 변이, DNA 메틸화 비정상화(abnormality) 단계 후에 돌연변이가 발생함\n• 돌연변이 시 표피성장인자수용체 차단약인 세툭시맙(cetuximab)에 대한 약물 반응성이 없음\n\n① DCC\n② KRAS\n③ MSH2\n④ TCF-4\n⑤ TP53",
        "question_text": "Question: In the multi-stage carcinogenesis process of colorectal cancer, which gene corresponds to the following description?\n\n• Mutation occurs after the APC mutation and DNA methylation abnormality stages\n• When mutated, there is no drug response to cetuximab, an epidermal growth factor receptor inhibitor\n\n① DCC\n② KRAS\n③ MSH2\n④ TCF-4\n⑤ TP53",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "original_text": "Question: 과음과 과식 후 극심한 상복부통증, 구역, 구토 증상을 보인 환자에서 혈청 아밀라아제와 리파아제 수치가 상승하였고, 이자관 근처에서 쓸개돌이 관찰되었다고 한다. 이러한 특징을 보이는 질환은?\n\n① 급성위염(acute gastritis)\n② 급성식도염(acute esophagitis)\n③ 급성쓸개염(acute cholecystitis)\n④ 급성이자염(acute pancreatitis)\n⑤ 쓸개암(gallbladder carcinoma)",
        "question_text": "Question: A patient shows severe upper abdominal pain, nausea, and vomiting symptoms after excessive drinking and eating. The serum amylase and lipase levels were elevated, and gallstones were observed near the pancreatic duct. What disease shows these characteristics?\n\n① Acute gastritis\n② Acute esophagitis\n③ Acute cholecystitis\n④ Acute pancreatitis\n⑤ Gallbladder carcinoma",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "original_text": "Question: 사람유두종바이러스 16형(human papillomavirus type 16) 감염으로 미세침습성 편평세포암종이 발생하는 과정에서 바이러스 단백질인 E6에 의해 불활성화되는 종양억제단백질은?\n\n① NF1\n② VHL\n③ p53\n④ PTEN\n⑤ PTCH1",
        "question_text": "Question: Which tumor suppressor protein is inactivated by the viral protein E6 in the process of developing microinvasive squamous cell carcinoma due to human papillomavirus type 16 infection?\n\n① NF1\n② VHL\n③ p53\n④ PTEN\n⑤ PTCH1",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "original_text": "Question: 다형핵 백혈구가 자궁내막에 비정상적으로 존재하는 질환으로, 자궁목관문이 분만 또는 의료기구에 의해 손상된 후에 발생하는 상행성 감염이 원인인 것은?\n\n① 자궁내막염(endometritis)\n② 자궁내막증(endometriosis)\n③ 자궁샘근증(adenomyosis uteri)\n④ 자궁내막용종(endometrial polyp)\n⑤ 자궁내막과다형성(endometrial hyperplasia)",
        "question_text": "Question: Which condition is characterized by the abnormal presence of polymorphonuclear leukocytes in the endometrium and is caused by an ascending infection that occurs after damage to the cervical barrier due to childbirth or medical instruments?\n\n① Endometritis\n② Endometriosis\n③ Adenomyosis uteri\n④ Endometrial polyp\n⑤ Endometrial hyperplasia",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "original_text": "Question: 다음 증상을 호소하는 37세의 여자에서 나타나는 내분비계 변화는?\n\n• 다습한 피부와 안구 돌출\n• 체온이 높고 땀 과다 분비\n• 빈맥과 과도한 가슴 두근거림\n• 수개월 동안의 신경쇠약과 현격한 체중 감소\n\n① 프로락틴의 분비 증가\n② 성장호르몬의 선천성 결함\n③ 부신피질자극호르몬의 분비 증가\n④ 혈청 갑상샘자극호르몬의 수치 증가\n⑤ 혈중 triiodothyronine(T3)의 수치 증가",
        "question_text": "Question: What endocrine system change is observed in a 37-year-old woman presenting with the following symptoms?\n\n• Moist skin and protruding eyes\n• High body temperature and excessive sweating\n• Tachycardia and excessive heart palpitations\n• Neurasthenia and significant weight loss over several months\n\n① Increased secretion of prolactin\n② Congenital defect in growth hormone\n③ Increased secretion of adrenocorticotropic hormone\n④ Increased serum thyroid-stimulating hormone levels\n⑤ Increased blood triiodothyronine (T3) levels",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "original_text": "Question: 크로이츠펠트-야콥 질환(Creutzfeldt-Jakob disease), 쿠루(kuru), 게르스트만-슈트로이슬러-샤잉커 증후군(Gerstmann-Sträussler- Scheinker syndrome)의 공통된 병인은?\n\n① 신경세포 내 루이체 축적\n② 신경세포 내 리포푸신 축적\n③ 신경세포 내 네그리소체 축적\n④ 신경세포 내 헤모시데린 축적\n⑤ 신경세포 내 불용성 프리온 축적",
        "question_text": "Question: What is the common pathogenesis of Creutzfeldt-Jakob disease, kuru, and Gerstmann-Sträussler-Scheinker syndrome?\n\n① Accumulation of Lewy bodies in neurons\n② Accumulation of lipofuscin in neurons\n③ Accumulation of Negri bodies in neurons\n④ Accumulation of hemosiderin in neurons\n⑤ Accumulation of insoluble prions in neurons",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "original_text": "Question: 젊은 남자에서 경계가 뚜렷한 홍반성 반점이 무릎과 팔꿈치에 나타나고 각질 증식과 은백색의 비늘판이 동반되었다. 이 질환의 발병 기전은?\n\n① 바닥막층 증식\n② 모반의 수 증가\n③ 피지샘세포의 수 감소\n④ 비만세포의 활성 억제\n⑤ T 림프구의 표피 침윤",
        "question_text": "Question: A young man presents with well-demarcated erythematous patches on his knees and elbows, accompanied by hyperkeratosis and silvery-white scales. What is the pathogenic mechanism of this condition?\n\n① Basement membrane proliferation\n② Increase in the number of nevi\n③ Decrease in the number of sebaceous gland cells\n④ Inhibition of mast cell activation\n⑤ T lymphocyte infiltration into the epidermis",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "original_text": "Question: 당뇨백내장 발생의 주된 기전은?\n\n① 망막의 혈관신생\n② 망막분리로 인한 출혈\n③ 망막동맥의 죽상경화증\n④ 수정체 내 소르비톨 증가\n⑤ 홍채 색소상피층의 글리코겐 증가",
        "question_text": "Question: What is the main mechanism for the development of diabetic cataract?\n\n① Neovascularization of the retina\n② Hemorrhage due to retinal detachment\n③ Atherosclerosis of retinal arteries\n④ Increase of sorbitol in the lens\n⑤ Increase of glycogen in the iris pigment epithelium",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n알코올성 간경화를 앓고 있는 환자가 불면증과 무기력에 이어 혼수상태가 되었고, 피를 토하였다. 검사 결과 식도하부 1/3 지점의 점막아래 정맥들이 여러 개 확장되어 있고 일부가 파열, 출혈된 것이 확인되었다고 한다.\n\nQuestion: 위 증상을 보이는 식도 질환은?\n\n① 이완불능증(achalasia)\n② 식도정맥류(esophageal varix)\n③ 바레트식도(Barrett esophagus)\n④ 식도게실(esophageal diverticulum)\n⑤ 호산구식도염(eosinophilic esophagitis)",
        "question_text": "A patient with alcoholic cirrhosis experienced insomnia and lethargy, followed by a comatose state and vomiting blood. Examination results revealed multiple dilated submucosal veins in the lower 1/3 of the esophagus, with some ruptured and bleeding.\n\nQuestion: What esophageal condition is indicated by the above symptoms?\n\n① Achalasia\n② Esophageal varix\n③ Barrett's esophagus\n④ Esophageal diverticulum\n⑤ Eosinophilic esophagitis",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n알코올성 간경화를 앓고 있는 환자가 불면증과 무기력에 이어 혼수상태가 되었고, 피를 토하였다. 검사 결과 식도하부 1/3 지점의 점막아래 정맥들이 여러 개 확장되어 있고 일부가 파열, 출혈된 것이 확인되었다고 한다.\n\nQuestion: 이 환자가 피를 토하기 전에 보인 혼수상태의 원인은?\n\n① 응고결손(coagulopathy)\n② 지라기능항진증(hypersplenism)\n③ 저알부민혈증(hypoalbuminemia)\n④ 간뇌병증(hepatic encephalopathy)\n⑤ 고에스트로겐혈증(hyperestrogenemia)",
        "question_text": "A patient with alcoholic cirrhosis experienced insomnia and lethargy, followed by a coma state, and then vomited blood. The examination results showed that multiple submucosal veins in the lower 1/3 of the esophagus were dilated, and some had ruptured and were bleeding.\n\nQuestion: What was the cause of the coma state that this patient exhibited before vomiting blood?\n\n① Coagulopathy\n② Hypersplenism\n③ Hypoalbuminemia\n④ Hepatic encephalopathy\n⑤ Hyperestrogenemia",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 벤젠이 상온, 상압에서 액체로 존재할 수 있도록 작용하는 분자 간의 결합양식은?\n\n① complexation\n② hydrogen bond\n③ ion-ion interaction\n④ ion-dipole interaction\n⑤ Keesom force",
        "question_text": "Question: What type of intermolecular bonding allows benzene to exist as a liquid at room temperature and standard pressure?\n\n① complexation\n② hydrogen bond\n③ ion-ion interaction\n④ ion-dipole interaction\n⑤ Keesom force",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 이산화탄소가 액체 상태로 존재할 수 있는 압력과 온도 조건은? (단, CO2의 임계압력은 73 기압이며 임계온도는 31℃이다.)\n\n① 60 기압, 35℃\n② 100 기압, 25℃\n③ 146 기압, 35℃\n④ 200 기압, 35℃\n⑤ 200 기압, 45℃",
        "question_text": "Question: Under which pressure and temperature conditions can carbon dioxide exist in a liquid state? (Note: The critical pressure of CO2 is 73 atm and the critical temperature is 31°C.)\n\n① 60 atm, 35°C\n② 100 atm, 25°C\n③ 146 atm, 35°C\n④ 200 atm, 35°C\n⑤ 200 atm, 45°C",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 부분섞임성이 있는 물과 n-butyl alcohol의 두 액체가 완전히 혼화된 하나의 상으로 존재할 때, 이 상에서의 자유도의 수(F)는? (단, 응축계로 취급함)\n\n① 0\n② 1\n③ 2\n④ 3\n⑤ 4",
        "question_text": "Question: When two liquids, water and n-butyl alcohol, which have partial miscibility, exist as a single completely miscible phase, what is the number of degrees of freedom (F) in this phase? (Assume it is a condensed system)\n\n① 0\n② 1\n③ 2\n④ 3\n⑤ 4",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 물 60%와 페놀 40%로 구성된 용액의 온도가 50℃에 이르렀을 때, 이 상태에서 아래층(하층)에 포함된 물의 함량(%)은? (단, 50℃일 때 물에 대한 페놀의 용해도는 11%이며, 페놀에 대한 물의 용해도는 37%이다.)\n\n① 11%\n② 37%\n③ 60%\n④ 63%\n⑤ 89%",
        "question_text": "Question: When a solution composed of 60% water and 40% phenol reaches a temperature of 50℃, what is the water content (%) in the lower layer at this state? (Note: At 50℃, the solubility of phenol in water is 11%, and the solubility of water in phenol is 37%.)\n\n① 11%\n② 37%\n③ 60%\n④ 63%\n⑤ 89%",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 난용성 약물인 voriconazole이 β-cyclodextrin과 내포화합물을 형성할 때의 주요 결합양식은?\n\n① 공유결합\n② 금속결합\n③ 배위결합\n④ 이온결합\n⑤ 소수성결합",
        "question_text": "Question: What is the primary binding mode when the poorly soluble drug voriconazole forms an inclusion complex with β-cyclodextrin?\n\n① Covalent bond\n② Metallic bond\n③ Coordinate bond\n④ Ionic bond\n⑤ Hydrophobic bond",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 작용 지속시간을 연장하기 위한 ‘근육주사용 약물저장고(depot) 요법’에 요변성(thixotropy) 특성을 보이는 부형제를 활용하는 이유는?\n\n① 보관 중 낮은 점도 유지\n② 주사 시 높은 점도 유지\n③ 주사 후 높은 점도 유지\n④ 주사 후 낮은 점도 유지\n⑤ 주사 시 높은 삼투압 유지",
        "question_text": "Question: What is the reason for using an excipient with thixotropic properties in the 'intramuscular depot therapy' to extend the duration of action?\n\n① Maintaining low viscosity during storage\n② Maintaining high viscosity during injection\n③ Maintaining high viscosity after injection\n④ Maintaining low viscosity after injection\n⑤ Maintaining high osmotic pressure during injection",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 이부프로펜 수용액의 ‘무한 희석 시의 당량전도도(Λ0)’에 대한 ‘어느 농도에서의 당량전도도(Λc)’의 비율(Λc/Λ0)에 해당되는 것은?\n\n① 해리도\n② 투과도\n③ 비전도도\n④ 이온강도\n⑤ 활성도계수",
        "question_text": "Question: Which of the following corresponds to the ratio (Λc/Λ0) of 'equivalent conductivity at a certain concentration (Λc)' to 'equivalent conductivity at infinite dilution (Λ0)' for an ibuprofen solution?\n\n① Degree of dissociation\n② Permeability\n③ Specific conductivity\n④ Ionic strength\n⑤ Activity coefficient",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 일정량의 증류수에 비전해질 약물 A(분자량 186 g/mol)를 2.0 g 녹인 용액의 어는점내림값이 0.5℃이었다. 같은 양의 증류수에 비전해질 약물 B를 4.0 g 녹인 용액의 어는점내림값이 2.0℃로 측정되었다면, 약물 B의 분자량(g/mol)은?\n\n① 46.5\n② 93\n③ 186\n④ 279\n⑤ 372",
        "question_text": "Question: A solution was prepared by dissolving 2.0 g of non-electrolyte drug A (molecular weight 186 g/mol) in a certain amount of distilled water. The freezing point depression of this solution was measured to be 0.5℃. When 4.0 g of non-electrolyte drug B was dissolved in the same amount of distilled water, the freezing point depression was measured to be 2.0℃. What is the molecular weight (g/mol) of drug B?\n\n① 46.5\n② 93\n③ 186\n④ 279\n⑤ 372",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 약산성 약물(pK a 4.7) 0.2 mole에 서로 다른 양의 NaOH를 첨가하여 1 L의 수용액 5가지를 다음과 같이 제조하였다. 다음 중 소량의 산 또는 염기의 추가에 의해 pH가 가장 많이 변화하는 것은?\n\n① pH 4.0\n② pH 4.5\n③ pH 5.0\n④ pH 5.5\n⑤ pH 6.0",
        "question_text": "Question: Five aqueous solutions of 1 L each were prepared by adding different amounts of NaOH to 0.2 mole of a weakly acidic drug (pK a 4.7). Which of the following pH values would show the greatest change when a small amount of acid or base is added?\n\n① pH 4.0\n② pH 4.5\n③ pH 5.0\n④ pH 5.5\n⑤ pH 6.0",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 약산성 약물의 진분배계수를 측정할 때 유상에서 일어날 가능성이 있어서 고려해야 할 현상은?\n\n① 해리\n② 회합\n③ 침전\n④ 결정화\n⑤ 무정형화",
        "question_text": "Question: When measuring the apparent partition coefficient of a weakly acidic drug, what phenomenon should be considered as it may occur in the oil phase?\n\n① Dissociation\n② Association\n③ Precipitation\n④ Crystallization\n⑤ Amorphization",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 약물이 흡수될 때, 생체막을 가로질러 형성되는 농도 기울기(gradient)가 일정한 상태임을 뜻하는 것은?\n\n① 정상상태\n② 제어상태\n③ 평형상태\n④ 지연상태\n⑤ 싱크상태",
        "question_text": "Question: When a drug is absorbed, what term describes the state where the concentration gradient across the biological membrane remains constant?\n\n① Steady state\n② Controlled state\n③ Equilibrium state\n④ Lag state\n⑤ Sink state",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 위장관의 pH에 영향을 받지 않고 약물을 일정한 속도로 방출할 수 있는 OROS 제형의 방출 구동력(driving force)은?\n\n① 온도차\n② 삼투압\n③ 표면장력\n④ 점막부착력\n⑤ 고분자 매트릭스의 분해",
        "question_text": "Question: What is the driving force for drug release in the OROS formulation, which can release the drug at a constant rate without being affected by the pH of the gastrointestinal tract?\n\n① Temperature difference\n② Osmotic pressure\n③ Surface tension\n④ Mucoadhesion\n⑤ Degradation of polymer matrix",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 유사0차반응으로 분해되는 약물 A의 현탁점안제(초기농도: 50 mg/mL)를 제조하고, 분해속도를 측정하여 1×10^-2 (mg/mL)/day의 속도상수를 얻었다. 이 제제를 동일 온도에서 보관할 때, 약물 A의 농도가 초기농도의 90%로 줄어드는 데 걸리는 기간(t90%)은?\n\n① 10일\n② 50일\n③ 100일\n④ 500일\n⑤ 1000일",
        "question_text": "Question: A suspension eye drop of drug A (initial concentration: 50 mg/mL), which decomposes by pseudo-zero-order reaction, was prepared. The decomposition rate was measured, and a rate constant of 1×10^-2 (mg/mL)/day was obtained. When this preparation is stored at the same temperature, how long (t90%) will it take for the concentration of drug A to decrease to 90% of its initial concentration?\n\n① 10 days\n② 50 days\n③ 100 days\n④ 500 days\n⑤ 1000 days",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 25℃의 보관 조건에서 유효기간이 14일인 항생제 용액을 5℃에서 냉장보관 할 때, 유효기간의 변화를 추정하는 데 유용한 인자는?\n\n① S(퍼짐계수)\n② Q10(큐텐값)\n③ Λc(당량전도도)\n④ εsol’n(용액의 유전상수)\n⑤ δwater(물의 용해도파라미터)",
        "question_text": "Question: When refrigerating an antibiotic solution at 5℃, which has a shelf life of 14 days at 25℃ storage conditions, what factor is useful in estimating the change in shelf life?\n\n① S (Spreading coefficient)\n② Q10 (Q10 value)\n③ Λc (Equivalent conductivity)\n④ εsol'n (Dielectric constant of solution)\n⑤ δwater (Solubility parameter of water)",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 3가지의 서로 다른 현탁제(S1, S2, S3)의, 입자 표면으로부터의 거리에 따른 퍼텐셜을 측정하여 비교한 다음 그림을 옳게 해석한 것은? (단, a-a′는 고체표면을 말한다.)\n\n<Data (confidential)>\n\n① 제타 퍼텐셜은 모두 양의 값이다.\n② S3의 네른스트 퍼텐셜은 양의 값이다.\n③ 고체의 표면은 음전하로 하전되어 있다.\n④ 전단면에서는 모두 전기적으로 중성이다.\n⑤ S2는 밀접 결합층에 양이온이 과다하게 존재한다.",
        "question_text": "Question: The following figure compares the potential measured at different distances from the particle surface for three different suspensions (S1, S2, S3). Which interpretation of the figure is correct? (Note: a-a′ represents the solid surface.)\n\n<Data (confidential)>\n\n① The zeta potentials are all positive values.\n② The Nernst potential of S3 is a positive value.\n③ The solid surface is negatively charged.\n④ All are electrically neutral at the shear plane.\n⑤ S2 has an excess of cations in the Stern layer.",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 시메티콘은 장내 이상발효에 의해 생성된 작은 기포들을 제거하는 기능이 있어서 아랫배가 더부룩할 때 장내 가스를 제거할 목적으로 사용하는 소포제이다. 시메티콘과 같은 효과를 가지는 약품을 개발하고자 할 때 가장 중요시해야 할 성질은?\n\n① 공극률\n② 투과계수\n③ 확산계수\n④ 퍼짐계수\n⑤ 친수-친유 평형비",
        "question_text": "Question: Simethicone has the function of removing small bubbles generated by abnormal fermentation in the intestines, and is used as an antifoaming agent to remove intestinal gas when the lower abdomen feels bloated. What is the most important property to consider when developing a drug with the same effect as simethicone?\n\n① Porosity\n② Permeability coefficient\n③ Diffusion coefficient\n④ Spreading coefficient\n⑤ Hydrophilic-lipophilic balance",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n페노바르비탈을 물에 녹이는 과정에서, 에탄올을 첨가했을 때의 효과를 나타낸 그래프이다. 25℃에서 페노바르비탈의 순수한 물에 대한 포화용해도는 약 0.1 g/100 mL이며, 페노바르비탈의 염화나트륨 당량은 0.24이다.\n<Data (confidential)>\n\nQuestion: 페노바르비탈의 용해도에 대한 에탄올의 역할은?\n\n① pH 증가\n② pK a 감소\n③ 용매의 극성 감소\n④ 용매분자의 열진동 증가\n⑤ 페노바르비탈의 활성도 감소",
        "question_text": "This graph shows the effect of adding ethanol when dissolving phenobarbital in water. At 25℃, the saturated solubility of phenobarbital in pure water is about 0.1 g/100 mL, and the sodium chloride equivalent of phenobarbital is 0.24.\n<Data (confidential)>\n\nQuestion: What is the role of ethanol in the solubility of phenobarbital?\n\n① Increase in pH\n② Decrease in pKa\n③ Decrease in solvent polarity\n④ Increase in thermal vibration of solvent molecules\n⑤ Decrease in the activity of phenobarbital",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n페노바르비탈을 물에 녹이는 과정에서, 에탄올을 첨가했을 때의 효과를 나타낸 그래프이다. 25℃에서 페노바르비탈의 순수한 물에 대한 포화용해도는 약 0.1 g/100 mL이며, 페노바르비탈의 염화나트륨 당량은 0.24이다.\n<Data (confidential)>\n\nQuestion: 25℃의 페노바르비탈 포화 수용액 100 mL를 등장으로 하기 위해 넣어야 하는 염화나트륨의 양(g)은?\n\n① 0.024\n② 0.240\n③ 0.660\n④ 0.760\n⑤ 0.876",
        "question_text": "This graph shows the effect of adding ethanol when dissolving phenobarbital in water. At 25℃, the saturated solubility of phenobarbital in pure water is about 0.1 g/100 mL, and the sodium chloride equivalent of phenobarbital is 0.24.\n<Data (confidential)>\n\nQuestion: How much sodium chloride (g) should be added to make 100 mL of saturated phenobarbital solution isotonic at 25℃?\n\n① 0.024\n② 0.240\n③ 0.660\n④ 0.760\n⑤ 0.876",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: Benzenesulfonic acid를 처리하여 염으로 만들 수 있는 약물은?\n\n① amlodipine\n② aspirin\n③ carisoprodol\n④ simvastatin\n⑤ thiopental",
        "question_text": "Question: Which drug can be converted into a salt by treating it with benzenesulfonic acid?\n\n① amlodipine\n② aspirin\n③ carisoprodol\n④ simvastatin\n⑤ thiopental",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: Tamoxifen의 중심 골격은?\n\n① 2-aminopyrimidine\n② anthraquinone\n③ enediyne\n④ quinoline\n⑤ triphenylethylene",
        "question_text": "Question: What is the core structure of Tamoxifen?\n\n① 2-aminopyrimidine\n② anthraquinone\n③ enediyne\n④ quinoline\n⑤ triphenylethylene",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: o-Phenylenediamine과 glyoxal을 원료로 하여 얻을 수 있는 약물은?\n\n① p-aminosalicylic acid\n② dapsone\n③ ethionamide\n④ isoniazid\n⑤ pyrazinamide",
        "question_text": "Question: Which drug can be obtained using o-phenylenediamine and glyoxal as raw materials?\n\n① p-aminosalicylic acid\n② dapsone\n③ ethionamide\n④ isoniazid\n⑤ pyrazinamide",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: Montelukast의 합성과정에서 출발물질 A로부터 얻어지는 주생성물 B는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: In the synthesis process of Montelukast, what is the main product B obtained from the starting material A?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: Sildenafil의 합성과정에서 중간체 A로부터 얻어지는 중간체 B와, 시약 C로 옳은 것은?\n\n<Data (confidential)>\n\nB | C\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: In the synthesis process of Sildenafil, which of the following are the correct intermediate B obtained from intermediate A, and reagent C?\n\n<Data (confidential)>\n\nB | C\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: L-DOPA의 합성과정 중 다음 반응에 사용하는 시약 A로 적절한 것은?\n\n<Data (confidential)>\n\n① AlCl3\n② Ac2O/NaOAc\n③ H2O2/NaOH\n④ NaBH4/Et3B\n⑤ POCl3/PCl5",
        "question_text": "Question: Which of the following is the appropriate reagent A used in the reaction during the synthesis of L-DOPA?\n\n<Data (confidential)>\n\n① AlCl3\n② Ac2O/NaOAc\n③ H2O2/NaOH\n④ NaBH4/Et3B\n⑤ POCl3/PCl5",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: Fischer indole synthesis 반응을 이용하여 핵심 골격을 합성할 수 있는 약물은?\n\n① fluoxetine\n② modafinil\n③ paroxetine\n④ quetiapine\n⑤ sumatriptan",
        "question_text": "Question: Which drug can have its core structure synthesized using the Fischer indole synthesis reaction?\n\n① fluoxetine\n② modafinil\n③ paroxetine\n④ quetiapine\n⑤ sumatriptan",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: Alfentanil의 합성과정에서 중간체 A의 구조는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the structure of intermediate A in the synthesis process of Alfentanil?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: Lamotrigine의 합성과정에서 중간체 A의 구조는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the structure of intermediate A in the synthesis process of Lamotrigine?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 다음 3단계 합성과정으로 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① fentanyl\n② methadone\n③ methylphenidate\n④ pentazocine\n⑤ ropinirole",
        "question_text": "Question: Which drug A is obtained through the following 3-step synthesis process?\n\n<Data (confidential)>\n\n① fentanyl\n② methadone\n③ methylphenidate\n④ pentazocine\n⑤ ropinirole",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 다음 합성과정으로 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① ambroxol\n② cilostazol\n③ fluconazole\n④ 5-fluorouracil\n⑤ metronidazole",
        "question_text": "Question: Which drug A is obtained through the following synthesis process?\n\n<Data (confidential)>\n\n① ambroxol\n② cilostazol\n③ fluconazole\n④ 5-fluorouracil\n⑤ metronidazole",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: Imidazo[1,2-a]pyridine이 중심 골격인 약물은?\n\n① aripiprazole\n② carvedilol\n③ diazepam\n④ sumatriptan\n⑤ zolpidem",
        "question_text": "Question: Which drug has Imidazo[1,2-a]pyridine as its core structure?\n\n① aripiprazole\n② carvedilol\n③ diazepam\n④ sumatriptan\n⑤ zolpidem",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: Benzodiazepine계 약물 중 다음 설명에 해당하는 것은?\n\n• 합성원료는 2-amino-5-chlorobenzophenone이다.\n• Triazole 구조를 포함한다.\n• 약물의 methyl기가 hydroxymethyl기로 대사된다.\n\n① alprazolam\n② chlordiazepoxide\n③ diazepam\n④ lorazepam\n⑤ oxazepam",
        "question_text": "Question: Which of the following benzodiazepine drugs matches the description below?\n\n• The synthetic starting material is 2-amino-5-chlorobenzophenone.\n• It contains a triazole structure.\n• The methyl group of the drug is metabolized to a hydroxymethyl group.\n\n① alprazolam\n② chlordiazepoxide\n③ diazepam\n④ lorazepam\n⑤ oxazepam",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: Cimetidine의 개발과정 중 guanidine기의 이온화를 감소시켜 H2 수용체와의 결합을 높일 수 있었다. 이러한 결과를 얻기 위해 cimetidine의 guanidine기에 도입된 치환기는?\n\n① -CH3\n② -CN\n③ -COOH\n④ -NH2\n⑤ -NO2",
        "question_text": "Question: During the development process of Cimetidine, the ionization of the guanidine group was reduced, which could increase its binding to H2 receptors. What substituent was introduced to the guanidine group of cimetidine to achieve this result?\n\n① -CH3\n② -CN\n③ -COOH\n④ -NH2\n⑤ -NO2",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: γ-Aminobutyric acid의 구조에 소수성 치환기를 도입하여 중추신경계로의 이동을 증가시킨 약물은?\n\n① baclofen\n② captopril\n③ naproxen\n④ procainamide\n⑤ sodium valproate",
        "question_text": "Question: Which drug has increased movement to the central nervous system by introducing a hydrophobic substituent to the structure of γ-Aminobutyric acid?\n\n① baclofen\n② captopril\n③ naproxen\n④ procainamide\n⑤ sodium valproate",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 키랄(chiral)탄소를 가지는 약물은?\n\n① celecoxib\n② cetirizine\n③ diclofenac\n④ indomethacin\n⑤ mefenamic acid",
        "question_text": "Question: Which of the following drugs contains a chiral carbon?\n\n① celecoxib\n② cetirizine\n③ diclofenac\n④ indomethacin\n⑤ mefenamic acid",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n• Clopidogrel은 CYP 효소에 의한 활성화 대사로 thiol 화합물로 변환되고, 수용체의 cysteine 곁사슬과 disulfide bond를 형성한다. \n• 약물 A는 산성 조건에서 활성 대사체로 변환되어 표적단백질과 disulfide bond를 형성한다.\n• 약물 A는 CYP 효소를 저해하는 작용이 있어 clopidogrel과 병용하는 것을 권장하지 않는다.\n\nQuestion: Clopidogrel의 활성화 대사반응에서 CYP 효소에 의해 산화가 일어나는 부위는?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "question_text": "• Clopidogrel is converted to a thiol compound through activation metabolism by CYP enzymes, and forms a disulfide bond with the cysteine side chain of the receptor.\n• Drug A is converted to an active metabolite under acidic conditions and forms a disulfide bond with the target protein.\n• Drug A has an inhibitory effect on CYP enzymes, so it is not recommended to be used in combination with clopidogrel.\n\nQuestion: In the activation metabolism reaction of clopidogrel, which site is oxidized by CYP enzymes?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n• Clopidogrel은 CYP 효소에 의한 활성화 대사로 thiol 화합물로 변환되고, 수용체의 cysteine 곁사슬과 disulfide bond를 형성한다. \n• 약물 A는 산성 조건에서 활성 대사체로 변환되어 표적단백질과 disulfide bond를 형성한다.\n• 약물 A는 CYP 효소를 저해하는 작용이 있어 clopidogrel과 병용하는 것을 권장하지 않는다.\n\nQuestion: 약물 A의 구조는?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "• Clopidogrel is converted to a thiol compound through activation metabolism by CYP enzymes, and forms a disulfide bond with the cysteine side chain of the receptor.\n• Drug A is converted to an active metabolite under acidic conditions and forms a disulfide bond with the target protein.\n• Drug A has an inhibitory effect on CYP enzymes, so it is not recommended to be used in combination with clopidogrel.\n\nQuestion: What is the structure of Drug A?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 0.1 mol/L NaOH 수용액의 수소이온 활동도(A H+)(mol/L)는? (단, 25℃에서 0.1 mol/L 용액의 활동도계수는 γH+=0.83이다.)\n\n① 0.1×0.83\n② 0.1×0.83^-1\n③ 10^-13×0.83\n④ 10^-13×0.83^-1\n⑤ 0.1×10^-13×0.83^-1",
        "question_text": "Question: What is the hydrogen ion activity (A H+) (mol/L) of a 0.1 mol/L NaOH solution? (Note: At 25℃, the activity coefficient of a 0.1 mol/L solution is γH+=0.83.)\n\n① 0.1×0.83\n② 0.1×0.83^-1\n③ 10^-13×0.83\n④ 10^-13×0.83^-1\n⑤ 0.1×10^-13×0.83^-1",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: pH 9.0의 수용액에 페놀이 녹아있을 때 총페놀 중 해리된 페놀의 몰분율은? (단, 페놀의 Ka=10^-10이다.)\n\n① 1/9\n② 1/11\n③ 9/10\n④ 9/11\n⑤ 10/11",
        "question_text": "Question: When phenol is dissolved in an aqueous solution with a pH of 9.0, what is the mole fraction of dissociated phenol among the total phenol? (Given that the Ka of phenol is 10^-10.)\n\n① 1/9\n② 1/11\n③ 9/10\n④ 9/11\n⑤ 10/11",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: 0.1 mol/L 에페드린 20 mL를 0.2 mol/L HCl 표준액으로 적정할 때 HCl 표준액 (A) mL를 가하면 당량점이 된다. 한편 HCl 표준액 4 mL를 적가한 적정용액의 pH는 (B)이다. A, B에 적합한 것은? (단, 에페드린의 pK a=9.4이다.)\n\nA | B\n① 4 | 9.4+log 1.5\n② 4 | 9.4+log 2\n③ 10 | 9.4+log 1.5\n④ 10 | 9.4+log 2\n⑤ 10 | 9.4+log 4",
        "question_text": "Question: When titrating 20 mL of 0.1 mol/L ephedrine with 0.2 mol/L HCl standard solution, the equivalence point is reached when (A) mL of HCl standard solution is added. Meanwhile, the pH of the titration solution after adding 4 mL of HCl standard solution is (B). Which of the following is appropriate for A and B? (Note: The pKa of ephedrine is 9.4.)\n\nA | B\n① 4 | 9.4+log 1.5\n② 4 | 9.4+log 2\n③ 10 | 9.4+log 1.5\n④ 10 | 9.4+log 2\n⑤ 10 | 9.4+log 4",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 아스피린을 중화적정법으로 정량할 때, 검액에 NaOH 표준액을 일정 과량 가한 후 가열해야 하는 이유는?\n\n① 가수분해 완결\n② 공기산화 억제\n③ 공침현상 방지\n④ 용해도적 증가\n⑤ 탄산오차 제거",
        "question_text": "Question: When quantifying aspirin using neutralization titration, what is the reason for adding an excess amount of NaOH standard solution to the test solution and then heating it?\n\n① Complete hydrolysis\n② Inhibition of air oxidation\n③ Prevention of coprecipitation\n④ Increase in solubility\n⑤ Elimination of carbonate error",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: EDTA를 표준액으로 하여 정량분석 할 수 있는 약물은?\n\n① 티오테파\n② 텔미사르탄\n③ 판토텐산칼슘\n④ 퀴닌황산염수화물\n⑤ 클로르페니라민말레산염",
        "question_text": "Question: Which drug can be quantitatively analyzed using EDTA as a standard solution?\n\n① Thiotepa\n② Telmisartan\n③ Calcium pantothenate\n④ Quinine sulfate hydrate\n⑤ Chlorpheniramine maleate",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 피리독신염산염을 비수적정법으로 정량할 때, 적정표준액 –용매를 옳게 연결한 것은?\n\n① NaOH – 메탄올\n② NaOCH3 – 메탄올\n③ NaOCH3 – 디메틸포름아미드\n④ HClO4 – 에틸렌디아민, 에탄올\n⑤ HClO4 – 아세트산무수물, 아세트산탈수물",
        "question_text": "Question: When quantifying pyridoxine hydrochloride using non-aqueous titration, which of the following correctly matches the titration standard solution with the solvent?\n\n① NaOH – Methanol\n② NaOCH3 – Methanol\n③ NaOCH3 – Dimethylformamide\n④ HClO4 – Ethylenediamine, Ethanol\n⑤ HClO4 – Acetic anhydride, Acetic anhydride",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 중금속의 원자흡수스펙트럼이 선스펙트럼(line spectrum)을 보이는 것과 달리 나프록센의 자외가시부흡수스펙트럼은 폭이 넓은 띠스펙트럼(band spectrum)으로 나타나는 이유는?\n\n① 원자는 진동전이가 크다.\n② 원자는 진동전이와 회전전이가 있다.\n③ 분자는 원자의 에너지 준위와 항상 동일하다.\n④ 분자는 전자전이 에너지가 회전전이 에너지보다 작다.\n⑤ 분자는 전자전이 이외에 진동전이와 회전전이가 있다.",
        "question_text": "Question: Unlike the atomic absorption spectrum of heavy metals which shows a line spectrum, why does the UV-visible absorption spectrum of naproxen appear as a broad band spectrum?\n\n① Atoms have large vibrational transitions.\n② Atoms have both vibrational and rotational transitions.\n③ The energy levels of molecules are always identical to those of atoms.\n④ In molecules, electronic transition energy is smaller than rotational transition energy.\n⑤ Molecules have vibrational and rotational transitions in addition to electronic transitions.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: d-캄파(camphor)의 비선광도 측정결과는 [α]^20_D=+41.0~+43.0°(5 g, 에탄올, 50 mL, 100 mm)와 같이 기록한다. 이에 대한 설명으로 옳은 것은?\n\n① 측정파장은 254 nm이다.\n② 측정 용액의 온도는 25℃이다.\n③ 시료를 5 g의 에탄올에 녹인다.\n④ 측정 셀의 길이는 100 mm이다.\n⑤ 50 mL 플라스틱 용기를 사용한다.",
        "question_text": "Question: The specific optical rotation measurement result for d-camphor is recorded as [α]^20_D=+41.0~+43.0° (5 g, ethanol, 50 mL, 100 mm). Which of the following statements about this is correct?\n\n① The measurement wavelength is 254 nm.\n② The temperature of the measured solution is 25℃.\n③ The sample is dissolved in 5 g of ethanol.\n④ The length of the measurement cell is 100 mm.\n⑤ A 50 mL plastic container is used.",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 적외부스펙트럼측정 시 1820~1660 cm^-1 영역에서 투광도(transmittance) 20% 정도의 강한 흡수대가 관찰되는 화합물은?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which compound shows a strong absorption band with approximately 20% transmittance in the 1820-1660 cm^-1 region when measuring infrared spectrum?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 달걀에 미량으로 잔류된, 유기염소계 살충제 성분인 피프로닐(fipronil)을 선택적으로 측정할 수 있는 기체크로마토그래피 검출기는?\n\n① 열이온검출기(TID)\n② 전자포획검출기(ECD)\n③ 열전도도검출기(TCD)\n④ 불꽃광도검출기(FPD)\n⑤ 불꽃이온화검출기(FID)",
        "question_text": "Question: Which gas chromatography detector can selectively measure fipronil, an organochlorine pesticide component that remains in trace amounts in eggs?\n\n① Thermionic Detector (TID)\n② Electron Capture Detector (ECD)\n③ Thermal Conductivity Detector (TCD)\n④ Flame Photometric Detector (FPD)\n⑤ Flame Ionization Detector (FID)",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 고성능액체크로마토그래프법에서 사용되는 검출기는?\n\n① 질소/인검출기\n② 열전도도검출기\n③ 전자포획검출기\n④ 질량분석검출기\n⑤ 불꽃이온화검출기",
        "question_text": "Question: Which detector is used in high-performance liquid chromatography?\n\n① Nitrogen/phosphorus detector\n② Thermal conductivity detector\n③ Electron capture detector\n④ Mass spectrometry detector\n⑤ Flame ionization detector",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 순상 액체크로마토그래피에 대한 설명으로 옳은 것은?\n\n① 비극성 고정상을 사용한다. \n② 이동상이 고정상에 비해 극성이 크다.\n③ 이동상은 이온세기가 큰 완충액을 사용한다.\n④ Octadecylsilyl기로 치환된 고정상을 사용한다.\n⑤ 순상 고정상은 역상 고정상에 비해 극성이 크다.",
        "question_text": "Question: Which of the following statements about normal-phase liquid chromatography is correct?\n\n① It uses a non-polar stationary phase.\n② The mobile phase is more polar than the stationary phase.\n③ The mobile phase uses a buffer solution with high ionic strength.\n④ It uses a stationary phase substituted with octadecylsilyl groups.\n⑤ The normal-phase stationary phase is more polar than the reversed-phase stationary phase.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 의약품 성분의 추출 효율이 일정하지 않아 크로마토그래프법에서 측정값이 변동할 우려가 있을 때 사용하기에 적절한 분석법은?\n\n① 내부표준법\n② 외부표준법\n③ 표준물첨가법\n④ 표준검량선법\n⑤ 면적백분율법",
        "question_text": "Question: When the extraction efficiency of pharmaceutical ingredients is inconsistent, potentially causing fluctuations in measurements in chromatography, which analytical method is appropriate to use?\n\n① Internal standard method\n② External standard method\n③ Standard addition method\n④ Standard calibration curve method\n⑤ Area normalization method",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 미셀 동전기 크로마토그래피에서 계면활성제 sodium dodecylsulfate(SDS)의 역할은?\n\n① 중성물질의 양이온화를 촉진한다.\n② 음이온성 물질을 중성물질화 한다.\n③ 양이온성 물질의 이온화를 억제한다.\n④ 중성물질을 소수성의 차이에 따라 분리한다.\n⑤ 음이온성 물질을 양이온성 물질로 변화시킨다.",
        "question_text": "Question: What is the role of the surfactant sodium dodecylsulfate (SDS) in micellar electrokinetic chromatography?\n\n① It promotes the cationization of neutral substances.\n② It neutralizes anionic substances.\n③ It inhibits the ionization of cationic substances.\n④ It separates neutral substances based on differences in hydrophobicity.\n⑤ It converts anionic substances into cationic substances.",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 측정치들의 결과를 이용하여 최적직선을 구하였을 때 직선에 측정치들이 밀집된 정도를 나타내는 것은?\n\n① 자유도\n② 상관계수\n③ 분석관리도\n④ 품질관리도\n⑤ 정규분포곡선",
        "question_text": "Question: When obtaining the best-fit line using measurement results, which of the following indicates the degree of concentration of measurements along the line?\n\n① Degrees of freedom\n② Correlation coefficient\n③ Analytical control chart\n④ Quality control chart\n⑤ Normal distribution curve",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 측정치의 기각 검정 시 사용되는 방법은?\n\n① Q test\n② blind test\n③ blank test\n④ control test\n⑤ recovery test",
        "question_text": "Question: Which method is used for rejection testing of measured values?\n\n① Q test\n② blind test\n③ blank test\n④ control test\n⑤ recovery test",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n국소마취제로 사용되는 프로카인의 구조적 특성을 적외부스펙트럼측정법과 핵자기공명스펙트럼측정법을 이용하여 분석하고 확인하였다.\n<Data (confidential)>\n\nQuestion: 적외부스펙트럼 측정에서 아민기에 의한 신축진동이 관찰되는 영역(cm^-1)은?\n\n① 850~700\n② 1150~1000\n③ 1750~1600\n④ 2350~2200\n⑤ 3550~3300",
        "question_text": "The structural characteristics of procaine, used as a local anesthetic, were analyzed and confirmed using infrared spectroscopy and nuclear magnetic resonance spectroscopy.\n<Data (confidential)>\n\nQuestion: In which region (cm^-1) is the stretching vibration due to the amine group observed in the infrared spectrum?\n\n① 850~700\n② 1150~1000\n③ 1750~1600\n④ 2350~2200\n⑤ 3550~3300",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n국소마취제로 사용되는 프로카인의 구조적 특성을 적외부스펙트럼측정법과 핵자기공명스펙트럼측정법을 이용하여 분석하고 확인하였다.\n<Data (confidential)>\n\nQuestion: 상온에서 완전한 수소짝풀림(proton decoupled) 상태로 13C-NMR 스펙트럼을 측정하면 몇 개의 피크가 관찰되는가?\n\n① 8\n② 9\n③ 10\n④ 12\n⑤ 13",
        "question_text": "The structural characteristics of procaine, used as a local anesthetic, were analyzed and confirmed using infrared spectroscopy and nuclear magnetic resonance spectroscopy.\n<Data (confidential)>\n\nQuestion: How many peaks are observed when measuring the 13C-NMR spectrum in a fully proton-decoupled state at room temperature?\n\n① 8\n② 9\n③ 10\n④ 12\n⑤ 13",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 용해 시 흡열반응으로 인해 입속에 넣었을 때 청량감을 주고 감미가 있어 추어블정(저작정)의 부형제로 많이 사용되는 것은?\n\n① 백당\n② 전분\n③ 유당\n④ 과당\n⑤ 만니톨",
        "question_text": "Question: Which of the following is often used as an excipient in chewable tablets due to its cooling effect in the mouth caused by an endothermic reaction when dissolved, and its sweet taste?\n\n① Sucrose\n② Starch\n③ Lactose\n④ Fructose\n⑤ Mannitol",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 혼합용기, 교반날개, 세단기로 구성된 장치를 사용하여 균일한 크기의 고밀도 과립을 재현성 있게 생산할 수 있는 과립 제조법은?\n\n① 분무건조법\n② 압출과립법\n③ 유동층조립법\n④ 고전단과립법\n⑤ 저전단과립법",
        "question_text": "Question: Which granulation method can consistently produce uniform, high-density granules using equipment consisting of a mixing vessel, stirring blades, and a chopper?\n\n① Spray drying method\n② Extrusion granulation method\n③ Fluidized bed granulation method\n④ High shear granulation method\n⑤ Low shear granulation method",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 입안에서 천천히 녹거나 붕해하도록 단단하게 만든 고형제제로서 주로 구강, 인두 등에 국소효과를 나타내는 것은?\n\n① 설하정\n② 발포정\n③ 용해정\n④ 주형정\n⑤ 트로키제",
        "question_text": "Question: Which of the following is a solid dosage form designed to dissolve or disintegrate slowly in the mouth, primarily used for local effects in the oral cavity and pharynx?\n\n① Sublingual tablet\n② Effervescent tablet\n③ Soluble tablet\n④ Molded tablet\n⑤ Troche",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 타정용 과립의 충전이 원활하지 못해, 제조된 정제의 질량편차가 크게 나타났다. 이러한 문제를 해결하는 방법은?\n\n① 습윤제를 가한다.\n② 과립을 분쇄한다.\n③ 미분말을 20% 이상 가한다.\n④ 과립체의 안식각을 크게 한다.\n⑤ 활택제를 첨가하여 내부마찰계수를 줄인다.",
        "question_text": "Question: The granules for tablet compression did not fill smoothly, resulting in large mass variations in the manufactured tablets. What is the method to solve this problem?\n\n① Add a wetting agent.\n② Grind the granules.\n③ Add more than 20% fine powder.\n④ Increase the angle of repose of the granules.\n⑤ Add a lubricant to reduce the internal friction coefficient.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 타정 시 결합제의 첨가량이 부족할 때 발생하는 주된 현상은?\n\n① 경도가 커진다.\n② 캡핑이 일어난다.\n③ 마손도가 감소한다.\n④ 용출시간이 길어진다.\n⑤ 붕해시간이 길어진다.",
        "question_text": "Question: What is the main phenomenon that occurs when there is insufficient binder added during tablet compression?\n\n① The hardness increases.\n② Capping occurs.\n③ Friability decreases.\n④ Dissolution time increases.\n⑤ Disintegration time increases.",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: Sudan III 분말을 가하면 전체적으로 붉게 착색되는 유제성 기제는?\n\n① 바셀린\n② 친수연고\n③ 흡수연고\n④ 바니싱크림\n⑤ 벤토나이트",
        "question_text": "Question: Which emulsion-type base turns entirely red when Sudan III powder is added?\n\n① Vaseline\n② Hydrophilic ointment\n③ Absorption ointment\n④ Vanishing cream\n⑤ Bentonite",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 안연고제 용기의 가스멸균에 사용하는 물질은?\n\n① n-부탄\n② 프로판\n③ 이소부탄\n④ 디메틸에테르\n⑤ 에틸렌옥사이드",
        "question_text": "Question: What substance is used for gas sterilization of eye ointment containers?\n\n① n-butane\n② propane\n③ isobutane\n④ dimethyl ether\n⑤ ethylene oxide",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: O/W형 유제에서 외상의 점도를 높여 유제를 안정화하기 위해 사용할 수 있는 수용성 첨가제는?\n\n① 파라핀\n② 벤질알코올\n③ 폴리에틸렌\n④ 에틸셀룰로오스\n⑤ 카르복시메틸셀룰로오스나트륨",
        "question_text": "Question: Which water-soluble additive can be used to increase the viscosity of the external phase in an O/W emulsion to stabilize the emulsion?\n\n① Paraffin\n② Benzyl alcohol\n③ Polyethylene\n④ Ethyl cellulose\n⑤ Sodium carboxymethylcellulose",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 각 제형에서 원료 의약품의 입자경 감소가 미치는 영향을 옳게 설명한 것은?\n\n① 과립제 – 약물의 용출속도 증가\n② 현탁제 – 약물의 침강속도 증가\n③ 연고제 – 약물의 혼합 균일성 감소\n④ 흡입제 – 약물의 폐포 도달률 감소\n⑤ 침출제제 – 유효성분의 침출속도 감소",
        "question_text": "Question: Which of the following correctly describes the effect of reducing the particle size of the active pharmaceutical ingredient in each dosage form?\n\n① Granules – Increase in drug dissolution rate\n② Suspensions – Increase in drug sedimentation rate\n③ Ointments – Decrease in drug mixing uniformity\n④ Inhalations – Decrease in drug alveolar deposition rate\n⑤ Extracts – Decrease in extraction rate of active ingredients",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 의약품에 사용하는 첨가제의 용도와 그 예를 옳게 연결한 것은?\n\n① 흡착제 – 글리세린\n② 방부제 – 산화티탄\n③ 항산화제 – 카올린\n④ 보습제 – 프로필렌글리콜\n⑤ 현탁화제 – 아황산나트륨",
        "question_text": "Question: Which of the following correctly matches the purpose of an excipient used in pharmaceuticals with its example?\n\n① Adsorbent – Glycerin\n② Preservative – Titanium dioxide\n③ Antioxidant – Kaolin\n④ Humectant – Propylene glycol\n⑤ Suspending agent – Sodium sulfite",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 분자량에 따라 녹는점, 물리적 상태와 점도가 변화하는 수용성 연고기제는?\n\n① 백납\n② 실리콘\n③ 벤토나이트\n④ 정제라놀린\n⑤ 폴리에틸렌글리콜",
        "question_text": "Question: Which water-soluble ointment base changes its melting point, physical state, and viscosity according to its molecular weight?\n\n① White wax\n② Silicone\n③ Bentonite\n④ Purified lanolin\n⑤ Polyethylene glycol",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 초음파를 이용하여 피부 각질층에 공극을 일시적으로 만들어 펩티드나 단백질 등 고분자 약물의 경피투과를 촉진하는 기술은?\n\n① 마이크로니들(microneedle)\n② 소노포레시스(sonophoresis)\n③ 이온토포레시스(iontophoresis)\n④ 마이크로에멀션(microemulsion)\n⑤ 일렉트로포레이션(electroporation)",
        "question_text": "Question: What is the technology that uses ultrasound to temporarily create pores in the stratum corneum of the skin to enhance transdermal penetration of macromolecular drugs such as peptides and proteins?\n\n① Microneedle\n② Sonophoresis\n③ Iontophoresis\n④ Microemulsion\n⑤ Electroporation",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 능동수송을 통한 약물의 흡수기전에 대한 설명으로 옳은 것은?\n\n① 구조 특이성을 나타내지 않는다.\n② 투과 속도는 온도의 영향을 받지 않는다.\n③ 투과량은 담체(carrier)가 포화된 후에도 약물농도에 비례하여 증가한다.\n④ 생체막 양측에 있는 물질의 농도 기울기(gradient)가 추진력으로 작용한다.\n⑤ 세포 내에서 에너지를 생산하는 대사반응을 저해하는 물질에 의하여 투과가 저해된다.",
        "question_text": "Question: Which of the following statements about the absorption mechanism of drugs through active transport is correct?\n\n① It does not show structural specificity.\n② The rate of permeation is not affected by temperature.\n③ The amount of permeation continues to increase proportionally to drug concentration even after the carrier is saturated.\n④ The concentration gradient of substances on both sides of the biological membrane acts as the driving force.\n⑤ Permeation is inhibited by substances that inhibit energy-producing metabolic reactions in the cell.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 생물약제학적분류체계(BCS)에 대한 설명으로 옳은 것은?\n\n① 용해도는 낮지만 막투과도가 높은 약물은 제2군에 속한다.\n② 용해도는 높지만 막투과도가 낮은 약물은 제1군에 속한다.\n③ 재현성 있는 용출 양상 관측이 힘든 난용성 약물은 제3군에 속한다.\n④ 비교용출시험만으로 생물학적동등성시험을 대체하는 약물은 제2군에 속한다.\n⑤ 난용성 약물을 고체분산체로 만들면 용출이 흡수의 율속단계가 되어 제4군에 속하게 된다.",
        "question_text": "Question: Which of the following statements about the Biopharmaceutics Classification System (BCS) is correct?\n\n① Drugs with low solubility but high membrane permeability belong to Class II.\n② Drugs with high solubility but low membrane permeability belong to Class I.\n③ Poorly soluble drugs that are difficult to observe reproducible dissolution patterns belong to Class III.\n④ Drugs that can replace bioequivalence studies with comparative dissolution tests alone belong to Class II.\n⑤ When a poorly soluble drug is made into a solid dispersion, dissolution becomes the rate-limiting step for absorption, placing it in Class IV.",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 신장에서의 약물 배설에 대한 설명으로 옳은 것은?\n\n① 근위요세관에는 유기 음이온 수송체가 존재한다.\n② 약물의 사구체 여과는 능동수송에 의해 일어난다.\n③ 요의 pH가 높아지면 약산성 약물의 재흡수가 증가한다.\n④ 혈장단백 결합률이 높아질수록 사구체 여과속도는 증가한다.\n⑤ 약물의 수용성이 클수록 원위요세관에서의 재흡수가 증가한다.",
        "question_text": "Question: Which of the following statements about drug excretion in the kidneys is correct?\n\n① Organic anion transporters are present in the proximal tubules.\n② Glomerular filtration of drugs occurs through active transport.\n③ As urine pH increases, reabsorption of weakly acidic drugs increases.\n④ As plasma protein binding increases, the glomerular filtration rate increases.\n⑤ The more water-soluble a drug is, the more it is reabsorbed in the distal tubules.",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 선형 1-컴파트먼트 모델을 따르는 어떤 약물이 사람에서 다음과 같은 약물동력학 파라미터를 나타낸다고 한다.\n• CL (전신클리어런스)=20 L/h\n• CLr (신클리어런스)=10 L/h\n\n이 약물 200 mg을 사람에게 경구 투여한 후 소변으로 배설된 약물의 총량이 80 mg이라고 한다면, 이 약물의 경구 흡수율(%)은?\n\n① 20\n② 40\n③ 60\n④ 80\n⑤ 100",
        "question_text": "Question: A certain drug that follows a linear 1-compartment model is said to exhibit the following pharmacokinetic parameters in humans:\n• CL (systemic clearance) = 20 L/h\n• CLr (renal clearance) = 10 L/h\n\nIf 200 mg of this drug is administered orally to a person, and the total amount of drug excreted in urine is 80 mg, what is the oral absorption rate (%) of this drug?\n\n① 20\n② 40\n③ 60\n④ 80\n⑤ 100",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n감기에 걸려 열이 나는 어린이 환자가 삼키는 해열제를 복용하는 것이 어려워 경구 제형이 아닌 항문에 삽입하는 제제 A를 처방받았다.\n\nQuestion: 제제 A를 제조하는 데 사용할 수 있는 기제는?\n\n① 비검\n② 카카오지\n③ 벤토나이트\n④ 셀라세페이트\n⑤ 플라스티베이스",
        "question_text": "A child patient with a fever due to a cold has difficulty taking oral antipyretics. Therefore, a prescription was given for preparation A, which is inserted into the rectum instead of an oral dosage form.\n\nQuestion: Which of the following bases can be used to manufacture preparation A?\n\n① Mucilage\n② Cocoa butter\n③ Bentonite\n④ Cellacefate\n⑤ Plastibase",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n감기에 걸려 열이 나는 어린이 환자가 삼키는 해열제를 복용하는 것이 어려워 경구 제형이 아닌 항문에 삽입하는 제제 A를 처방받았다.\n\nQuestion: 제제 A를 투여하였을 때 나타날 수 있는 약물 체내동태에 대한 설명으로 옳은 것은?\n\n① 전신작용은 나타나지 않는다.\n② 약물의 수용성이 클수록 흡수는 증가한다.\n③ 약물의 입자경이 클수록 흡수는 증가한다.\n④ 약물의 흡수는 일반적으로 능동수송을 따른다.\n⑤ 직장 하부에서 흡수된 약물은 간초회통과효과를 피할 수 있다.",
        "question_text": "A child patient with a fever due to a cold was prescribed preparation A, which is inserted into the rectum instead of an oral dosage form, as the child had difficulty taking oral antipyretics.\n\nQuestion: Which of the following statements is correct regarding the pharmacokinetics that may occur when administering preparation A?\n\n① Systemic effects do not occur.\n② The absorption increases as the water solubility of the drug increases.\n③ The absorption increases as the particle size of the drug increases.\n④ Drug absorption generally follows active transport.\n⑤ Drugs absorbed in the lower rectum can bypass the first-pass effect of the liver.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: L-Tyrosine으로부터 생성된 (R)-reticuline을 중간체로 하여 생합성되는 것은?\n\n① caffeine\n② (-)-ephedrine\n③ morphine\n④ nicotine\n⑤ physostigmine",
        "question_text": "Question: Which of the following is biosynthesized using (R)-reticuline, generated from L-Tyrosine, as an intermediate?\n\n① caffeine\n② (-)-ephedrine\n③ morphine\n④ nicotine\n⑤ physostigmine",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: 개똥쑥에서 얻어진 항말라리아 효과가 있는 endoperoxide sesquiterpene 성분은?\n\n① artemisinin\n② cephaeline \n③ emetine\n④ quinidine\n⑤ quinine",
        "question_text": "Question: What is the endoperoxide sesquiterpene component with antimalarial effects obtained from Artemisia annua (sweet wormwood)?\n\n① artemisinin\n② cephaeline \n③ emetine\n④ quinidine\n⑤ quinine",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: Secologanin과 L-tryptophan을 전구체로 하여 생합성되며 혈압강하와 진정작용을 나타내는 것은?\n\n① berberine\n② nicotine\n③ papaverine\n④ reserpine\n⑤ scopolamine",
        "question_text": "Question: Which of the following is biosynthesized using secologanin and L-tryptophan as precursors and exhibits blood pressure-lowering and sedative effects?\n\n① berberine\n② nicotine\n③ papaverine\n④ reserpine\n⑤ scopolamine",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: Campanulaceae에 속하는 생약으로 거담효과가 있으며 이눌린이 함유된 것은?\n\n① 길경\n② 천마\n③ 행인\n④ 후추\n⑤ 세네가",
        "question_text": "Question: Which medicinal herb belonging to Campanulaceae has an expectorant effect and contains inulin?\n\n① Platycodon Root\n② Gastrodia Rhizome\n③ Apricot Kernel\n④ Black Pepper\n⑤ Senega",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 방추사의 중합에 의한 미세소관의 형성을 촉진하고, 형성된 미세소관이 tubulin으로 해체되는 과정을 억제하는 성분이 함유된 식물은?\n\n① Akebia quinata\n② Brassica juncea\n③ Illicium verum\n④ Lobelia inflata\n⑤ Taxus cuspidata",
        "question_text": "Question: Which plant contains a component that promotes the formation of microtubules through the polymerization of spindle fibers and inhibits the process of disassembly of formed microtubules into tubulin?\n\n① Akebia quinata\n② Brassica juncea\n③ Illicium verum\n④ Lobelia inflata\n⑤ Taxus cuspidata",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: Salvia miltiorrhiza에서 얻어진 성분으로 관상동맥 확장작용을 나타내는 것은?\n\n① cimicifugin\n② decursin\n③ ophiopogonin A\n④ tanshinone I\n⑤ wogonin",
        "question_text": "Question: Which component obtained from Salvia miltiorrhiza exhibits coronary artery dilation effects?\n\n① cimicifugin\n② decursin\n③ ophiopogonin A\n④ tanshinone I\n⑤ wogonin",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: 아린 맛이 있고, 생강이나 백반으로 법제하면 자극성이 없어지며 진토제로 사용하는 생약은?\n\n① Allii Bulbus\n② Corydalis Tuber\n③ Lilii Bulbus\n④ Liriopis seu Ophiopogonis Tuber\n⑤ Pinelliae Tuber",
        "question_text": "Question: Which medicinal herb has a pungent taste, loses its irritating properties when processed with ginger or alum, and is used as an antiemetic?\n\n① Allii Bulbus\n② Corydalis Tuber\n③ Lilii Bulbus\n④ Liriopis seu Ophiopogonis Tuber\n⑤ Pinelliae Tuber",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: Acid amide 계열의 신미성분을 함유하는 생약은?\n\n① Corni Fructus\n② Foeniculi Fructus\n③ Ponciri Fructus Immaturus\n④ Schisandrae Fructus\n⑤ Zanthoxyli Pericarpium",
        "question_text": "Question: Which medicinal herb contains pungent components of the acid amide group?\n\n① Corni Fructus\n② Foeniculi Fructus\n③ Ponciri Fructus Immaturus\n④ Schisandrae Fructus\n⑤ Zanthoxyli Pericarpium",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 호지킨병(Hodgkin’s disease), 백혈병 치료에 쓰이는 bisindole alkaloid를 함유하는 생약은?\n\n① Cocae Folium\n② Coptidis Rhizoma\n③ Ergota\n④ Ipecacuanhae Radix et Rhizoma\n⑤ Vincae Herba",
        "question_text": "Question: Which crude drug containing bisindole alkaloid is used in the treatment of Hodgkin's disease and leukemia?\n\n① Cocae Folium\n② Coptidis Rhizoma\n③ Ergota\n④ Ipecacuanhae Radix et Rhizoma\n⑤ Vincae Herba",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 식물의 미숙과수 및 잎에서 얻어지는 성분으로 환각작용을 나타내는 것은?\n\n① bufotenine\n② emodin\n③ icariin\n④ naringin\n⑤ Δ9-tetrahydrocannabinol",
        "question_text": "Question: Which of the following substances, obtained from unripe fruits and leaves of plants, exhibits hallucinogenic effects?\n\n① bufotenine\n② emodin\n③ icariin\n④ naringin\n⑤ Δ9-tetrahydrocannabinol",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 물레나물과에 속하는 생약으로 항우울, 광감작작용을 나타내는 것은?\n\n① Bupleuri Radix\n② Colchici Semen\n③ Hydrastidis Rhizoma \n④ Hyperici Herba\n⑤ Jaborandi Folium",
        "question_text": "Question: Which of the following medicinal herbs, belonging to the Hypericaceae family, exhibits antidepressant and photosensitizing effects?\n\n① Bupleuri Radix\n② Colchici Semen\n③ Hydrastidis Rhizoma \n④ Hyperici Herba\n⑤ Jaborandi Folium",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 국화과에 속하는 식물의 꽃에 함유된 matricin이 분해되어 생성되는 화합물로 항염증작용을 나타내는 것은?\n\n① arecoline\n② chamazulene\n③ magnolol\n④ (+)-matrine\n⑤ pachyman",
        "question_text": "Question: Which compound, formed by the breakdown of matricin contained in the flowers of plants belonging to the Asteraceae family, exhibits anti-inflammatory properties?\n\n① arecoline\n② chamazulene\n③ magnolol\n④ (+)-matrine\n⑤ pachyman",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 중초(中焦)에 있으며 운화(運化)를 주관하고 정기(精氣)를 상승시키고 혈액을 통섭(統攝)하는 기능을 가진 것은?\n\n① 간(肝)\n② 비(脾)\n③ 신(腎)\n④ 심(心)\n⑤ 폐(肺)",
        "question_text": "Question: Which organ is located in the middle burner (中焦), governs transportation and transformation (運化), promotes the ascent of essence and qi (精氣), and controls the blood (統攝)?\n\n① Liver (肝)\n② Spleen (脾)\n③ Kidney (腎)\n④ Heart (心)\n⑤ Lung (肺)",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 건비보중(健脾補中), 영심안신(寧心安神) 효능이 있는 이수삼습약(利水滲濕藥)은?\n\n① 고삼(苦蔘)\n② 방기(防己)\n③ 복령(茯苓)\n④ 치자(梔子)\n⑤ 황백(黃柏)",
        "question_text": "Question: Which of the following diuretic and moisture-draining herbs (利水滲濕藥) has the effects of strengthening the spleen and replenishing the middle (健脾補中), as well as calming the mind and tranquilizing the spirit (寧心安神)?\n\n① Sophora flavescens (苦蔘)\n② Stephania tetrandra (防己)\n③ Poria cocos (茯苓)\n④ Gardenia jasminoides (梔子)\n⑤ Phellodendron amurense (黃柏)",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 신량투표(辛凉透表), 청열해독(淸熱解毒)의 효능이 있어 온병초기의 발열, 두통, 인후통 등의 증상 치료에 사용하는 것은?\n\n① 안중산(安中散)\n② 은교산(銀翹散)\n③ 고본환정환(固本還睛丸)\n④ 반하후박탕(半夏厚朴湯)\n⑤ 보중익기탕(補中益氣湯)",
        "question_text": "Question: Which of the following is used to treat symptoms such as fever, headache, and sore throat in the early stages of warm diseases, with the effects of dispersing heat from the exterior (辛凉透表) and clearing heat and detoxifying (淸熱解毒)?\n\n① Anjung-san (安中散)\n② Eungyo-san (銀翹散)\n③ Gobon-hwanjeong-hwan (固本還睛丸)\n④ Banha-hubak-tang (半夏厚朴湯)\n⑤ Bojungikgi-tang (補中益氣湯)",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 익위생진(益胃生津), 강역하기(降逆下氣)의 효능이 있어 만성기관지염, 만성인후염 등의 치료에 사용하는 것은?\n\n① 오령산(五苓散)\n② 맥문동탕(麥門冬湯)\n③ 소시호탕(小柴胡湯)\n④ 당귀작약산(當歸芍藥散)\n⑤ 삼황사심탕(三黃瀉心湯)",
        "question_text": "Question: Which of the following is used to treat chronic bronchitis, chronic pharyngitis, etc., due to its effects of nourishing the stomach and generating fluids (益胃生津), and descending adverse qi and relieving flatulence (降逆下氣)?\n\n① Oryeong-san (五苓散)\n② Maegmundong-tang (麥門冬湯)\n③ Sosiho-tang (小柴胡湯)\n④ Danggwi-jakyak-san (當歸芍藥散)\n⑤ Samhwang-sasim-tang (三黃瀉心湯)",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n콩과(Leguminosae)에 속하는 생약으로부터 분리된 이 화합물은 단맛이 나고 Liebermann-Burchard 반응에서 양성을 나타냈다. 구조분석 결과 이 화합물은 oleanane 배당체로 확인되었고, 부신피질호르몬 유사작용을 나타냈다.\n\nQuestion: 이 화합물은?\n\n① catalpol\n② curcumin\n③ glycyrrhizin\n④ puerarin\n⑤ saikosaponin a",
        "question_text": "A compound isolated from a medicinal herb belonging to the Leguminosae family has a sweet taste and showed a positive result in the Liebermann-Burchard reaction. Structural analysis confirmed that this compound is an oleanane glycoside, and it exhibited adrenocortical hormone-like activity.\n\nQuestion: What is this compound?\n\n① catalpol\n② curcumin\n③ glycyrrhizin\n④ puerarin\n⑤ saikosaponin a",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n콩과(Leguminosae)에 속하는 생약으로부터 분리된 이 화합물은 단맛이 나고 Liebermann-Burchard 반응에서 양성을 나타냈다. 구조분석 결과 이 화합물은 oleanane 배당체로 확인되었고, 부신피질호르몬 유사작용을 나타냈다.\n\nQuestion: 이 화합물을 산가수분해 하면 생성되는 당은?\n\n① D-galactose\n② D-glucose\n③ D-glucuronic acid\n④ D-xylose\n⑤ L-rhamnose",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThis compound, isolated from a medicinal herb belonging to the Leguminosae family, has a sweet taste and showed a positive result in the Liebermann-Burchard reaction. Structural analysis confirmed that this compound is an oleanane glycoside, and it exhibited adrenocortical hormone-like activity.\n\nQuestion: Which sugar is produced when this compound undergoes acid hydrolysis?\n\n① D-galactose\n② D-glucose\n③ D-glucuronic acid\n④ D-xylose\n⑤ L-rhamnose",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 항고혈압제를 복용하는 48세 남자에게 최근 급성통풍발작이 있었다. 원인약물은?\n\n① 로사르탄(losartan)\n② 아테놀롤(atenolol)\n③ 니페디핀(nifedipine)\n④ 독사조신(doxazosin)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: A 48-year-old man taking antihypertensive medication recently experienced an acute gout attack. Which drug is the likely cause?\n\n① Losartan\n② Atenolol\n③ Nifedipine\n④ Doxazosin\n⑤ Hydrochlorothiazide",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 고혈압, 심부전, 이상지질혈증이 있는 65세 남자가 다음과 같은 약물을 복용 중에 부정맥이 발생하였다. 원인약물은?\n\n[복용약물]\n디곡신(digoxin) 0.125 mg 1일 1회\n에날라프릴(enalapril) 10 mg 1일 1회\n푸로세미드(furosemide) 80 mg 1일 2회\n로수바스타틴/에제티미브(rosuvastatin/ezetimibe) 10/10 mg 1일 1회\n비타민B 복합정 1일 1회\n\n[임상검사 결과] Na 137 mEq/L, K 3.0 mEq/L, 디곡신 혈중농도: 0.8 ng/mL\n\n① 에날라프릴\n② 푸로세미드\n③ 에제티미브\n④ 로수바스타틴\n⑤ 비타민B 복합정",
        "question_text": "Question: A 65-year-old man with hypertension, heart failure, and dyslipidemia developed arrhythmia while taking the following medications. What is the likely causative drug?\n\n[Medications]\nDigoxin 0.125 mg once daily\nEnalapril 10 mg once daily\nFurosemide 80 mg twice daily\nRosuvastatin/Ezetimibe 10/10 mg once daily\nVitamin B complex tablet once daily\n\n[Clinical test results] Na 137 mEq/L, K 3.0 mEq/L, Serum digoxin level: 0.8 ng/mL\n\n① Enalapril\n② Furosemide\n③ Ezetimibe\n④ Rosuvastatin\n⑤ Vitamin B complex",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 안정형협심증, 당뇨병, 고혈압이 있는 56세 남자가 다음과 같은 약물을 복용하고 있다. 추가해야 할 약물은?\n\n[복용약물]\n아스피린(aspirin)\n라미프릴(ramipril)\n메토프롤롤(metoprolol)\n메트포르민(metformin)\n니트로글리세린(nitroglycerin) 설하정\n\n[임상검사 결과]\n혈압 128/81 mmHg, 심박수 65회/분, 호흡수 22회/분, TC 219 mg/dL, LDL-C 158 mg/dL, HDL-C 39 mg/dL\n\n① 아픽사반(apixaban)\n② 독사조신(doxazosin)\n③ 에제티미브(ezetimibe)\n④ 아토르바스타틴(atorvastatin)\n⑤ 스피로노락톤(spironolactone)",
        "question_text": "Question: A 56-year-old man with stable angina, diabetes, and hypertension is taking the following medications. Which drug should be added?\n\n[Current medications]\nAspirin\nRamipril\nMetoprolol\nMetformin\nNitroglycerin sublingual tablet\n\n[Clinical test results]\nBlood pressure 128/81 mmHg, Heart rate 65 beats/min, Respiratory rate 22 breaths/min, TC 219 mg/dL, LDL-C 158 mg/dL, HDL-C 39 mg/dL\n\n① Apixaban\n② Doxazosin\n③ Ezetimibe\n④ Atorvastatin\n⑤ Spironolactone",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 심근경색 치료 중 폰다파리눅스(fondaparinux)를 투여받는 환자에서 모니터링이 필요한 검사항목은?\n\n① 요산\n② 빌리루빈\n③ 중성지방\n④ 당화혈색소\n⑤ 혈청 크레아티닌",
        "question_text": "Question: Which test item needs to be monitored in patients receiving fondaparinux during the treatment of myocardial infarction?\n\n① Uric acid\n② Bilirubin\n③ Triglycerides\n④ Glycated hemoglobin\n⑤ Serum creatinine",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 고혈압, 심부전, 중등도 승모판협착증이 있는 66세 여자가 심방세동으로 진단받았다. 뇌졸중 예방을 위한 적절한 약물은?\n\n① 와파린(warfarin)\n② 아스피린(aspirin)\n③ 티카그렐러(ticagrelor)\n④ 리바록사반(rivaroxaban)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "Question: A 66-year-old woman with hypertension, heart failure, and moderate mitral stenosis has been diagnosed with atrial fibrillation. What is the appropriate medication for stroke prevention?\n\n① Warfarin\n② Aspirin\n③ Ticagrelor\n④ Rivaroxaban\n⑤ Clopidogrel",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 심방세동 병력이 있는 56세 여자가 다비가트란(dabigatran) 150 mg을 1일 2회 복용하고 있다. 병용투여하는 경우 다비가트란의 감량이 필요한 약물은?\n\n① 페니토인(phenytoin)\n② 리팜피신(rifampicin)\n③ 베라파밀(verapamil)\n④ 판토프라졸(pantoprazole)\n⑤ 카르바마제핀(carbamazepine)",
        "question_text": "Question: A 56-year-old woman with a history of atrial fibrillation is taking dabigatran 150 mg twice daily. Which drug, when co-administered, requires a dose reduction of dabigatran?\n\n① Phenytoin\n② Rifampicin\n③ Verapamil\n④ Pantoprazole\n⑤ Carbamazepine",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 67세 남자의 뇌졸중 예방을 위한 적절한 약물(요법)은?\n\n[병력] 고혈압, 심방세동\n[복용약물] 암로디핀(amlodipine) 히드로클로로티아지드(hydrochlorothiazide)\n[임상검사 결과] CrCl 72 mL/min, INR 1.0\n\n① 아스피린(aspirin)\n② 아픽사반(apixaban)\n③ 티카그렐러(ticagrelor)\n④ 아가트로반(argatroban)\n⑤ 아스피린(aspirin)+실로스타졸(cilostazol)",
        "question_text": "Question: What is the appropriate medication (therapy) for stroke prevention in a 67-year-old male?\n\n[Medical history] Hypertension, atrial fibrillation\n[Current medications] Amlodipine, hydrochlorothiazide\n[Clinical test results] CrCl 72 mL/min, INR 1.0\n\n① Aspirin\n② Apixaban\n③ Ticagrelor\n④ Argatroban\n⑤ Aspirin + Cilostazol",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 62세 남자가 이상지질혈증 치료를 위해 복용할 적절한 약물은?\n\n[병력] 고혈압, 당뇨병, 일과성허혈발작(TIA)\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 1회\n\n[임상검사 결과] 혈압 145/90 mmHg, 공복혈당 128 mg/dL, AST 25 IU/L, ALT 27 IU/L, TC 210 mg/dL, LDL-C 165 mg/dL, HDL-C 35 mg/dL\n\n① 로바스타틴(lovastatin) 20 mg\n② 심바스타틴(simvastatin) 20 mg\n③ 플루바스타틴(fluvastatin) 20 mg\n④ 프라바스타틴(pravastatin) 20 mg\n⑤ 로수바스타틴(rosuvastatin) 20 mg",
        "question_text": "Question: What is the appropriate medication for treating dyslipidemia in a 62-year-old male?\n\n[Medical history] Hypertension, Diabetes, Transient Ischemic Attack (TIA)\n\n[Current medications]\nAspirin 100 mg once daily\nAmlodipine 10 mg once daily\nMetformin 1,000 mg once daily\n\n[Clinical test results] Blood pressure 145/90 mmHg, Fasting blood glucose 128 mg/dL, AST 25 IU/L, ALT 27 IU/L, TC 210 mg/dL, LDL-C 165 mg/dL, HDL-C 35 mg/dL\n\n① Lovastatin 20 mg\n② Simvastatin 20 mg\n③ Fluvastatin 20 mg\n④ Pravastatin 20 mg\n⑤ Rosuvastatin 20 mg",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 60세 여자가 3개월 전부터 이상지질혈증 치료를 위해 약물을 복용하고 있다. 예전과 달리 최근에 다리에 힘이 없고 근육에 통증을 느낀다고 하였다. 약물이상반응과 관련하여 필요한 검사항목은?\n\n[복용약물] 아토르바스타틴(atorvastatin) 40 mg 1일 1회\n[임상검사 결과] TC 205 mg/dL, LDL-C 135 mg/dL, SCr 2.0 mg/dL\n\n① 혈당\n② 혈압\n③ 요산\n④ 헤모글로빈\n⑤ 크레아틴키나아제",
        "question_text": "Question: A 60-year-old woman has been taking medication for dyslipidemia for 3 months. Unlike before, she recently reported feeling weakness in her legs and muscle pain. What test item is necessary in relation to adverse drug reactions?\n\n[Medication] Atorvastatin 40 mg once daily\n[Clinical test results] TC 205 mg/dL, LDL-C 135 mg/dL, SCr 2.0 mg/dL\n\n① Blood glucose\n② Blood pressure\n③ Uric acid\n④ Hemoglobin\n⑤ Creatine kinase",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 47세 남자가 이틀 전부터 오른쪽 다리가 붓고 열감과 통증이 있다. 정맥혈전증으로 진단되어 치료하기 위해 헤파린을 주사하는 초기에 병용투여하는 약물은?\n\n① 와파린(warfarin)\n② 프로타민(protamine)\n③ 티카그렐러(ticagrelor)\n④ 프라수그렐(prasugrel)\n⑤ 폰다파리눅스(fondaparinux)",
        "question_text": "Question: A 47-year-old man has experienced swelling, heat, and pain in his right leg for the past two days. He is diagnosed with venous thrombosis. Which drug should be administered concurrently during the initial treatment with heparin injection?\n\n① Warfarin\n② Protamine\n③ Ticagrelor\n④ Prasugrel\n⑤ Fondaparinux",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 64세 남자가 와파린(warfarin)을 4 mg 1일 1회로 한 달 동안 복용하고 있다. 국제표준화비율(INR)이 5.5이고 출혈 증상은 없는 경우, INR을 재확인하기 전 와파린 약물요법에 대한 적절한 방안은?\n\n① 용량 감소\n② 용량 유지\n③ 용량 유지 후 비타민K 정맥투여\n④ 복용 중단 후 비타민K 경구투여\n⑤ 복용 중단 후 신선냉동혈장 투여",
        "question_text": "Question: A 64-year-old man has been taking warfarin 4 mg once daily for a month. His International Normalized Ratio (INR) is 5.5, and there are no bleeding symptoms. What is the appropriate approach for warfarin therapy before rechecking the INR?\n\n① Decrease the dose\n② Maintain the current dose\n③ Maintain the current dose and administer vitamin K intravenously\n④ Discontinue warfarin and administer vitamin K orally\n⑤ Discontinue warfarin and administer fresh frozen plasma",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n71세 여자가 오전 10시경 갑자기 말이 어눌해지고, 왼쪽 팔다리에 힘이 빠지며 어지러워, 딸과 함께 오전 11시경 병원에 왔다.\n\n[병력] 고혈압, 당뇨병\n\n[복용약물]\n리나글립틴(linagliptin) 5 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 12.5 mg 1일 1회\n\n[복약 이행도]\n평소 약을 잘 복용하였으나, 최근에 여행으로 3일간 약을 복용하지 못함\n\n[활력징후(내원 시)] 혈압 198/113 mmHg, 심박수 98회/분\n\n[뇌단층촬영] 뇌출혈 없음\n\n[심전도] 정상동리듬(normal sinus rhythm)\n\n[식도경유심초음파] 이상소견 없음\n\nQuestion: 허혈성뇌졸중으로 진단되어 혈전용해제 투여를 위해 혈압을 조절할 때, 적절한 약은?\n\n① 독사조신(doxazosin) 경구제\n② 암로디핀(amlodipine) 경구제\n③ 카르베딜롤(carvedilol) 경구제\n④ 라베탈롤(labetalol) 주사제\n⑤ 니트로프루시드(nitroprusside) 주사제",
        "question_text": "A 71-year-old woman suddenly developed slurred speech, weakness in her left arm and leg, and dizziness at around 10 AM. She came to the hospital with her daughter at around 11 AM.\n\n[Medical history] Hypertension, Diabetes\n\n[Medications]\nLinagliptin 5 mg once daily\nMetformin 1,000 mg once daily\nAmlodipine 10 mg once daily\nHydrochlorothiazide 12.5 mg once daily\n\n[Medication adherence]\nUsually took medications well, but recently missed 3 days of medication due to travel\n\n[Vital signs (at admission)] Blood pressure 198/113 mmHg, Heart rate 98 beats/min\n\n[Brain CT scan] No cerebral hemorrhage\n\n[ECG] Normal sinus rhythm\n\n[Transesophageal echocardiography] No abnormal findings\n\nQuestion: When controlling blood pressure for thrombolytic therapy after being diagnosed with ischemic stroke, which is the appropriate medication?\n\n① Doxazosin (oral)\n② Amlodipine (oral)\n③ Carvedilol (oral)\n④ Labetalol (injection)\n⑤ Nitroprusside (injection)",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n71세 여자가 오전 10시경 갑자기 말이 어눌해지고, 왼쪽 팔다리에 힘이 빠지며 어지러워, 딸과 함께 오전 11시경 병원에 왔다.\n\n[병력] 고혈압, 당뇨병\n\n[복용약물]\n리나글립틴(linagliptin) 5 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 12.5 mg 1일 1회\n\n[복약 이행도]\n평소 약을 잘 복용하였으나, 최근에 여행으로 3일간 약을 복용하지 못함\n\n[활력징후(내원 시)] 혈압 198/113 mmHg, 심박수 98회/분\n\n[뇌단층촬영] 뇌출혈 없음\n\n[심전도] 정상동리듬(normal sinus rhythm)\n\n[식도경유심초음파] 이상소견 없음\n\nQuestion: 허혈성뇌졸중 재발을 방지하기 위해 적절한 약물은?\n\n① 헤파린(heparin)\n② 와파린(warfarin)\n③ 에독사반(edoxaban)\n④ 압식시맙(abciximab)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "A 71-year-old woman suddenly developed slurred speech, weakness in her left arm and leg, and dizziness at around 10 AM. She came to the hospital with her daughter at around 11 AM.\n\n[Medical history] Hypertension, Diabetes mellitus\n\n[Current medications]\nLinagliptin 5 mg once daily\nMetformin 1,000 mg once daily\nAmlodipine 10 mg once daily\nHydrochlorothiazide 12.5 mg once daily\n\n[Medication adherence]\nUsually took medications well, but recently missed 3 days of medication due to travel\n\n[Vital signs (at admission)] Blood pressure 198/113 mmHg, Heart rate 98 beats/min\n\n[Brain CT scan] No cerebral hemorrhage\n\n[ECG] Normal sinus rhythm\n\n[Transesophageal echocardiography] No abnormal findings\n\nQuestion: Which medication is appropriate to prevent recurrence of ischemic stroke?\n\n① Heparin\n② Warfarin\n③ Edoxaban\n④ Abciximab\n⑤ Clopidogrel",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n67세 남자가 흉통, 오심, 호흡곤란이 발생하여 응급실로 이송되었다. 심전도, 심근효소검사 후 ST분절상승 심근경색\n으로 진단되어 경피경관관상동맥성형술(PTCA 또는 PCI)이 계획되었다.\n\n[병력] 이상지질혈증\n\n[복용약물]\n프라바스타틴(pravastatin) 40 mg 1일 1회\n\n[활력징후(내원 시)]\n혈압 157/102 mmHg, 심박수 88회/분, 호흡수 22회/분\n\n[임상검사 결과]\nNa 136 mEq/L, K 4.2 mEq/L, Cl 106 mEq/L, CO2 20 mEq/L\nBUN 16 mg/dL, SCr 1.1 mg/dL, Mg 2.4 mg/dL, Ca 8.7 mg/dL\nWBC 5,800/mm3, Hgb 13.6 g/dL, Hct 46.0%, PLT 200,000/mm3\nTC 196 mg/dL, LDL-C 133 mg/dL, TG 130 mg/dL\n\n[심전도] ST분절상승\n\n[심장초음파] 심장박출률(EF) 52%\n\nQuestion: 이 환자에게 경피경관관상동맥성형술 중에 투여할 약물은?\n\n① 와파린(warfarin)\n② 압식시맙(abciximab)\n③ 알테플라제(alteplase)\n④ 다비가트란(dabigatran)\n⑤ 리바록사반(rivaroxaban)",
        "question_text": "A 67-year-old male was transported to the emergency room with chest pain, nausea, and shortness of breath. After an ECG and cardiac enzyme tests, he was diagnosed with ST-segment elevation myocardial infarction (STEMI), and percutaneous transluminal coronary angioplasty (PTCA or PCI) was planned.\n\n[Medical history] Dyslipidemia\n\n[Current medication]\nPravastatin 40 mg once daily\n\n[Vital signs (at admission)]\nBlood pressure 157/102 mmHg, Heart rate 88 bpm, Respiratory rate 22 breaths/min\n\n[Laboratory results]\nNa 136 mEq/L, K 4.2 mEq/L, Cl 106 mEq/L, CO2 20 mEq/L\nBUN 16 mg/dL, SCr 1.1 mg/dL, Mg 2.4 mg/dL, Ca 8.7 mg/dL\nWBC 5,800/mm3, Hgb 13.6 g/dL, Hct 46.0%, PLT 200,000/mm3\nTC 196 mg/dL, LDL-C 133 mg/dL, TG 130 mg/dL\n\n[ECG] ST-segment elevation\n\n[Echocardiography] Ejection Fraction (EF) 52%\n\nQuestion: Which drug should be administered to this patient during percutaneous transluminal coronary angioplasty?\n\n① Warfarin\n② Abciximab\n③ Alteplase\n④ Dabigatran\n⑤ Rivaroxaban",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n67세 남자가 흉통, 오심, 호흡곤란이 발생하여 응급실로 이송되었다. 심전도, 심근효소검사 후 ST분절상승 심근경색\n으로 진단되어 경피경관관상동맥성형술(PTCA 또는 PCI)이 계획되었다.\n\n[병력] 이상지질혈증\n\n[복용약물]\n프라바스타틴(pravastatin) 40 mg 1일 1회\n\n[활력징후(내원 시)]\n혈압 157/102 mmHg, 심박수 88회/분, 호흡수 22회/분\n\n[임상검사 결과]\nNa 136 mEq/L, K 4.2 mEq/L, Cl 106 mEq/L, CO2 20 mEq/L\nBUN 16 mg/dL, SCr 1.1 mg/dL, Mg 2.4 mg/dL, Ca 8.7 mg/dL\nWBC 5,800/mm3, Hgb 13.6 g/dL, Hct 46.0%, PLT 200,000/mm3\nTC 196 mg/dL, LDL-C 133 mg/dL, TG 130 mg/dL\n\n[심전도] ST분절상승\n\n[심장초음파] 심장박출률(EF) 52%\n\nQuestion: 6개월 후 추적검사에서 심장박출률은 정상이었으나, 좌심실비대가 확인되었다. 현재 복용하는 약물은 아스피린(aspirin), 클로피도그렐(clopidogrel), 카르베딜롤(carvedilol), 프라바스타틴이다. 추가할 약물은?\n\n① 디곡신(digoxin)\n② 라미프릴(ramipril)\n③ 암로디핀(amlodipine)\n④ 이바브라딘(ivabradine)\n⑤ 히드랄라진(hydralazine)",
        "question_text": "A 67-year-old male was transported to the emergency room with chest pain, nausea, and shortness of breath. After an ECG and cardiac enzyme tests, he was diagnosed with ST-segment elevation myocardial infarction (STEMI) and percutaneous transluminal coronary angioplasty (PTCA or PCI) was planned.\n\n[Medical history] Dyslipidemia\n\n[Current medication]\nPravastatin 40 mg once daily\n\n[Vital signs (at admission)]\nBlood pressure 157/102 mmHg, Heart rate 88 beats/min, Respiratory rate 22 breaths/min\n\n[Clinical laboratory results]\nNa 136 mEq/L, K 4.2 mEq/L, Cl 106 mEq/L, CO2 20 mEq/L\nBUN 16 mg/dL, SCr 1.1 mg/dL, Mg 2.4 mg/dL, Ca 8.7 mg/dL\nWBC 5,800/mm3, Hgb 13.6 g/dL, Hct 46.0%, PLT 200,000/mm3\nTC 196 mg/dL, LDL-C 133 mg/dL, TG 130 mg/dL\n\n[ECG] ST-segment elevation\n\n[Echocardiography] Ejection fraction (EF) 52%\n\nQuestion: At a 6-month follow-up, the ejection fraction was normal, but left ventricular hypertrophy was confirmed. The patient is currently taking aspirin, clopidogrel, carvedilol, and pravastatin. Which medication should be added?\n\n① Digoxin\n② Ramipril\n③ Amlodipine\n④ Ivabradine\n⑤ Hydralazine",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 천식으로 고용량의 플루티카손/살메테롤(fluticasone/salmeterol)을 사용하는 14세 여자에게 오말리주맙(omalizumab)이 추가되었다. 용량 검토 시 확인이 필요한 검사항목은?\n\n① 혈액요소질소\n② 혈청 마그네슘\n③ 혈청 빌리루빈\n④ 알라닌아미노전이효소\n⑤ 총혈청 면역글로불린E",
        "question_text": "Question: A 14-year-old girl using high-dose fluticasone/salmeterol for asthma has been prescribed additional omalizumab. Which test item needs to be checked during dose review?\n\n① Blood Urea Nitrogen\n② Serum Magnesium\n③ Serum Bilirubin\n④ Alanine Aminotransferase\n⑤ Total Serum Immunoglobulin E",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 천식으로 진단받은 15세 여자에게 흡입용 스테로이드제 치료가 계획되었다. 평소 학교와 학원 일정으로 시간이 없어 흡입기 사용 후 구강 세척을 하기 어렵다고 할 때, 적절한 약물은?\n\n① 모메타손(mometasone)\n② 플루티카손(fluticasone)\n③ 부데소니드(budesonide)\n④ 시클레소니드(ciclesonide)\n⑤ 이프라트로퓸(ipratropium)",
        "question_text": "Question: A 15-year-old girl diagnosed with asthma is planned to be treated with an inhaled steroid. She says it's difficult for her to rinse her mouth after using the inhaler due to her busy schedule with school and academy. Which of the following is the most appropriate medication?\n\n① Mometasone\n② Fluticasone\n③ Budesonide\n④ Ciclesonide\n⑤ Ipratropium",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 71세 여자가 만성폐쇄폐질환으로 살부타몰(salbutamol)을 사용하고 있다. 지난 1년 동안 급성악화는 없었으나, 최근 검사에서 mMRC 호흡곤란점수는 2점, 1초간노력성호기량(FEV1)은 70%이었다. 적절한 추가약물(요법)은?\n\n① 부데소니드(budesonide)\n② 티오트로퓸(tiotropium)\n③ 플루티카손/살메테롤(fluticasone/salmeterol)\n④ 베클로메타손/포르모테롤(beclomethasone/formoterol)\n⑤ 티오트로퓸+플루티카손/살메테롤",
        "question_text": "Question: A 71-year-old woman is using salbutamol for chronic obstructive pulmonary disease (COPD). She has not experienced any acute exacerbations in the past year, but recent tests show an mMRC dyspnea score of 2 and a forced expiratory volume in 1 second (FEV1) of 70%. What is the appropriate additional medication (therapy)?\n\n① Budesonide\n② Tiotropium\n③ Fluticasone/salmeterol\n④ Beclomethasone/formoterol\n⑤ Tiotropium + Fluticasone/salmeterol",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 20년 동안 담배를 매일 한 갑씩 피운 66세 남자가 만성폐쇄폐질환의 증상이 잘 조절되던 중 호흡기감염으로 입원하였다. 입원기간에 투여할 약물은 살부타몰(salbutamol), 이프라트로퓸(ipratropium), 프레드니솔론(prednisolone), 세푸록심(cefuroxime), 인다카테롤(indacaterol), 테오필린(theophylline)이다. 입원 중 담배를 못 피우므로 용량조절이 필요한 약물은?\n\n① 살부타몰\n② 세푸록심\n③ 테오필린\n④ 이프라트로퓸\n⑤ 프레드니솔론",
        "question_text": "Question: A 66-year-old man who has smoked one pack of cigarettes daily for 20 years was admitted to the hospital with a respiratory infection while his chronic obstructive pulmonary disease symptoms were well-controlled. The medications to be administered during hospitalization are salbutamol, ipratropium, prednisolone, cefuroxime, indacaterol, and theophylline. Which medication requires dose adjustment since the patient cannot smoke during hospitalization?\n\n① Salbutamol\n② Cefuroxime\n③ Theophylline\n④ Ipratropium\n⑤ Prednisolone",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 28세 남자가 로라타딘(loratadine)을 복용해도 지속성 경증의 알레르기비염 증상이 조절되지 않는다. 적절한 추가약은?\n\n① 아클리디늄(aclidinium) 흡입제\n② 포르모테롤(formoterol) 흡입제\n③ 플루티카손(fluticasone) 비강분무제\n④ 케토티펜(ketotifen) 경구제\n⑤ 프레드니솔론(prednisolone) 경구제",
        "question_text": "Question: A 28-year-old man's persistent mild allergic rhinitis symptoms are not controlled despite taking loratadine. What is the appropriate additional medication?\n\n① Aclidinium inhaler\n② Formoterol inhaler\n③ Fluticasone nasal spray\n④ Ketotifen oral medication\n⑤ Prednisolone oral medication",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 소화성궤양을 가진 남자가 클래리트로마이신(clarithromycin) 내성이 있는 Helicobacter pylori 에 감염된 경우, 란소프라졸(lansoprazole)과 함께 사용할 수 있는 1차 약물요법은?\n\n① 세푸록심(cefuroxime)+리파부틴(rifabutin)\n② 아목시실린(amoxicillin)+비스무트(bismuth)\n③ 세푸록심(cefuroxime)+메트로니다졸(metronidazole)\n④ 비스무트+메트로니다졸+테트라사이클린(tetracycline)\n⑤ 아지트로마이신(azithromycin)+메트로니다졸+겐타마이신(gentamicin)",
        "question_text": "Question: For a man with peptic ulcer who is infected with clarithromycin-resistant Helicobacter pylori, what is the first-line drug therapy that can be used along with lansoprazole?\n\n① Cefuroxime + Rifabutin\n② Amoxicillin + Bismuth\n③ Cefuroxime + Metronidazole\n④ Bismuth + Metronidazole + Tetracycline\n⑤ Azithromycin + Metronidazole + Gentamicin",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 37세 남자가 최근 속쓰림과 위액 역류 증상이 있을 때, 제산제를 복용하면 증상이 일시적으로 개선된다. 내시경검사 결과 미란성 식도염이 있을 때 적절한 치료약물은?\n\n① 바클로펜(baclofen)\n② 파모티딘(famotidine)\n③ 모사프리드(mosapride)\n④ 라베프라졸(rabeprazole)\n⑤ 수크랄페이트(sucralfate)",
        "question_text": "Question: A 37-year-old man experiences recent symptoms of heartburn and acid reflux, which temporarily improve when he takes antacids. When an endoscopy reveals erosive esophagitis, what is the appropriate medication for treatment?\n\n① Baclofen\n② Famotidine\n③ Mosapride\n④ Rabeprazole\n⑤ Sucralfate",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 간경화증이 있는 65세 여자가 최근 집중력이 저하되고, 지남력 상실 증상이 나타났다. 증상 완화를 위한 적절한 약물은?\n\n① 락툴로오스(lactulose)\n② 알프라졸람(alprazolam)\n③ 푸로세미드(furosemide)\n④ 프로프라놀롤(propranolol)\n⑤ 스피로노락톤(spironolactone)",
        "question_text": "Question: A 65-year-old woman with liver cirrhosis has recently experienced decreased concentration and disorientation. What is the appropriate medication to alleviate these symptoms?\n\n① Lactulose\n② Alprazolam\n③ Furosemide\n④ Propranolol\n⑤ Spironolactone",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 과민성대장증후군이 있는 33세 여자가 최근 직장승진시험 이후 통증을 동반한 묽은 변(1일 3회 이상)을 보고, 잔변감이 있어 식이요법을 하였으나, 복부팽만, 변실금으로 일상활동에 제한을 받고 있다. 적절한 치료약물은?\n\n① 락티톨(lactitol)\n② 비사코딜(bisacodyl)\n③ 설트랄린(sertraline)\n④ 락툴로오스(lactulose)\n⑤ 라모세트론(ramosetron)",
        "question_text": "Question: A 33-year-old woman with irritable bowel syndrome has been experiencing loose stools with pain (more than 3 times a day) and a feeling of incomplete evacuation since her recent job promotion exam. Despite trying dietary changes, she is experiencing limitations in daily activities due to abdominal bloating and fecal incontinence. What is the appropriate medication for treatment?\n\n① Lactitol\n② Bisacodyl\n③ Sertraline\n④ Lactulose\n⑤ Ramosetron",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 49세 남자의 복용약물과 임상검사 결과가 다음과 같을 때 적절한 약물은?\n\n[병력] 비대상성 간경화증, 만성 B형간염\n\n[복용약물]\n푸로세미드(furosemide) 40 mg 1일 2회\n스피로노락톤(spironolactone) 200 mg 1일 1회\n프로프라놀롤(propranolol) 20 mg 1일 2회\n락툴로오스(lactulose) 무른 변이 1일 2~3회 초과하지 않도록 용량 조절\n\n[임상검사 결과] HBsAg 양성, HBeAg 양성, anti-HBe 음성, HBV DNA 25,000 IU/mL, AST 146 IU/L, ALT 170 IU/L\n\n① 아데포비어(adefovir)\n② 라미부딘(lamivudine)\n③ 엔테카비르(entecavir)\n④ 소포스부비르(sofosbuvir)\n⑤ 다클라타스비르(daclatasvir)",
        "question_text": "Question: For a 49-year-old male with the following medication regimen and clinical test results, which drug is most appropriate?\n\n[Medical history] Decompensated liver cirrhosis, chronic hepatitis B\n\n[Current medications]\nFurosemide 40 mg twice daily\nSpironolactone 200 mg once daily\nPropranolol 20 mg twice daily\nLactulose dose adjusted to not exceed 2-3 soft stools per day\n\n[Clinical test results] HBsAg positive, HBeAg positive, anti-HBe negative, HBV DNA 25,000 IU/mL, AST 146 IU/L, ALT 170 IU/L\n\n① Adefovir\n② Lamivudine\n③ Entecavir\n④ Sofosbuvir\n⑤ Daclatasvir",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 설파제 알레르기가 있는 38세 여자가 복통과 잦은 혈변(4회/일)을 보여 검사한 결과 직장 부위에 국한된 경증 궤양성대장염이 확인되었다. 적절한 치료약은?\n\n① 비사코딜(bisacodyl) 좌제\n② 메살라민(mesalamine) 좌제\n③ 인플릭시맵(infliximab) 주사제\n④ 설파살라진(sulfasalazine) 경구제\n⑤ 6-메르캅토푸린(6-mercaptopurine) 경구제",
        "question_text": "Question: A 38-year-old woman with a sulfa drug allergy presents with abdominal pain and frequent bloody stools (4 times/day). Upon examination, mild ulcerative colitis limited to the rectal area is confirmed. What is the appropriate treatment?\n\n① Bisacodyl suppository\n② Mesalamine suppository\n③ Infliximab injection\n④ Sulfasalazine oral medication\n⑤ 6-Mercaptopurine oral medication",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 활동기 크론병을 앓는 38세 여자가 프레드니솔론(prednisolone) 60 mg 경구 치료에도 적절한 관해를 보이지 않았다. 인플릭시맵(infliximab)으로 변경하는 경우, 치료 시작 전 확인이 필요한 것은?\n\n① 조증 병력\n② 위염 병력\n③ 결핵감염 여부\n④ 경구피임제 복용력\n⑤ 폴산(folic acid) 복용력",
        "question_text": "Question: A 38-year-old woman with active Crohn's disease did not show adequate remission despite oral treatment with prednisolone 60 mg. If switching to infliximab, what needs to be checked before starting treatment?\n\n① History of mania\n② History of gastritis\n③ Presence of tuberculosis infection\n④ History of oral contraceptive use\n⑤ History of folic acid intake",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n2개월 전 교통사고로 수혈을 받은 적이 있는 44세 남자가 평소보다 피로감을 더 느껴 병원에서 임상검사를 받았고, 그 결과는 다음과 같다.\n\n[임상검사 결과]\nAnti-HCV 양성, HCV RNA 1,000,000 IU/mL, HCV 유전자형 2형\nAST 470 IU/L, ALT 559 IU/L\n\nQuestion: 이 환자의 C형 간염을 치료하기 위해 사용되는 1차 약물요법은?\n\n① 엔테카비르(entecavir)+리바비린(ribavirin)\n② 인터페론알파(interferon alpha)+라미부딘(lamivudine)\n③ 인터페론알파+아데포비어(adefovir)\n④ 다클라타스비르(daclatasvir)+소포스부비르(sofosbuvir)\n⑤ 페그인터페론(pegylated interferon)+테노포비르(tenofovir)",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 44-year-old man who received a blood transfusion due to a traffic accident 2 months ago felt more fatigued than usual and underwent clinical tests at a hospital. The results are as follows:\n\n[Clinical Test Results]\nAnti-HCV positive, HCV RNA 1,000,000 IU/mL, HCV genotype 2\nAST 470 IU/L, ALT 559 IU/L\n\nQuestion: What is the first-line drug therapy used to treat this patient's hepatitis C?\n\n① Entecavir + Ribavirin\n② Interferon alpha + Lamivudine\n③ Interferon alpha + Adefovir\n④ Daclatasvir + Sofosbuvir\n⑤ Pegylated interferon + Tenofovir",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n2개월 전 교통사고로 수혈을 받은 적이 있는 44세 남자가 평소보다 피로감을 더 느껴 병원에서 임상검사를 받았고, 그 결과는 다음과 같다.\n\n[임상검사 결과]\nAnti-HCV 양성, HCV RNA 1,000,000 IU/mL, HCV 유전자형 2형\nAST 470 IU/L, ALT 559 IU/L\n\nQuestion: 지속적바이러스반응(SVR)을 확인하기 위해 모니터링할 검사항목은?\n\n① IgG anti-HCV\n② IgM anti-HCV\n③ HCV RNA\n④ HCV 유전자형\n⑤ HCV 내성관련 변이",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 44-year-old man who received a blood transfusion due to a traffic accident 2 months ago felt more fatigued than usual. He underwent clinical tests at a hospital, and the results are as follows:\n\n[Clinical Test Results]\nAnti-HCV positive, HCV RNA 1,000,000 IU/mL, HCV genotype 2\nAST 470 IU/L, ALT 559 IU/L\n\nQuestion: Which test item should be monitored to confirm Sustained Virologic Response (SVR)?\n\n① IgG anti-HCV\n② IgM anti-HCV\n③ HCV RNA\n④ HCV genotype\n⑤ HCV resistance-associated variants",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 62세 남자가 제2형 당뇨병과 만성신장병으로 치료받고 있다. 검사 결과는 다음과 같으며, 특이한 증상은 없다. 칼륨의 배설을 촉진시키기 위해 사용할 수 있는 적절한 약물은?\n\n[임상검사 결과]\nNa 142 mEq/L, K 5.7 mEq/L, Cl 105 mEq/L\nBUN 63 mg/dL, SCr 2.9 mg/dL\n동맥혈가스분석: pH 7.4, PaCO2 40 mmHg, HCO3- 24 mEq/L\n심전도: 이상소견 없음\n\n① 사이클로스포린(cyclosporine)\n② 스피로노락톤(spironolactone)\n③ 글루콘산칼슘(calcium gluconate)\n④ 탄산수소나트륨(sodium bicarbonate)\n⑤ 폴리스티렌설폰산칼슘(calcium polystyrene sulfonate)",
        "question_text": "Question: A 62-year-old man is being treated for type 2 diabetes and chronic kidney disease. The test results are as follows, and there are no specific symptoms. Which of the following drugs is appropriate to use to promote potassium excretion?\n\n[Clinical Test Results]\nNa 142 mEq/L, K 5.7 mEq/L, Cl 105 mEq/L\nBUN 63 mg/dL, SCr 2.9 mg/dL\nArterial Blood Gas Analysis: pH 7.4, PaCO2 40 mmHg, HCO3- 24 mEq/L\nECG: No abnormal findings\n\n① Cyclosporine\n② Spironolactone\n③ Calcium gluconate\n④ Sodium bicarbonate\n⑤ Calcium polystyrene sulfonate",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 54세 여자가 만성신장병, 고혈압, 이상지질혈증으로 에날라프릴(enalapril), 암로디핀(amlodipine), 아토르바스타틴(atorvastatin), 세벨라머(sevelamer), 에포에틴알파(epoetin alfa)를 사용하고 있다. 약물의 효과를 최대화하기 위해 식사와 함께 투여해야 하는 약물은?\n\n① 에날라프릴\n② 암로디핀\n③ 아토르바스타틴\n④ 세벨라머\n⑤ 에포에틴알파",
        "question_text": "Question: A 54-year-old woman is using enalapril, amlodipine, atorvastatin, sevelamer, and epoetin alfa for chronic kidney disease, hypertension, and dyslipidemia. Which medication should be administered with meals to maximize its effect?\n\n① Enalapril\n② Amlodipine\n③ Atorvastatin\n④ Sevelamer\n⑤ Epoetin alfa",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 68세 여자(키 160 cm, 체중 45 kg)가 시스플라틴(cisplatin)이 포함된 항암화학요법을 받을 예정이다. 급성신손상을 예방하기 위해 필요한 것은?\n\n① 메스나(mesna)\n② 아미카신(amikacin)\n③ 암로디핀(amlodipine)\n④ 생리식염수(0.9% sodium chloride)\n⑤ N-아세틸시스테인(N-acetylcysteine)",
        "question_text": "Question: A 68-year-old woman (height 160 cm, weight 45 kg) is scheduled to receive chemotherapy that includes cisplatin. What is needed to prevent acute kidney injury?\n\n① Mesna\n② Amikacin\n③ Amlodipine\n④ Normal saline (0.9% sodium chloride)\n⑤ N-acetylcysteine",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 고혈압, 당뇨병, 소화성궤양이 있는 63세 남자에게 만성신장병으로 인한 빈혈을 치료하기 위해 에포에틴알파(epoetin alfa)를 투여할 예정이다. 이 환자에서 헤모글로빈 수치를 12 g/dL 이상으로 유지할 경우 사망률 증가와 관련 있는 질환은?\n\n① 관절질환\n② 위장질환\n③ 내분비질환\n④ 비뇨기질환\n⑤ 심혈관질환",
        "question_text": "Question: A 63-year-old man with hypertension, diabetes, and peptic ulcer is scheduled to receive epoetin alfa to treat anemia due to chronic kidney disease. In this patient, which condition is associated with increased mortality if the hemoglobin level is maintained above 12 g/dL?\n\n① Joint disease\n② Gastrointestinal disease\n③ Endocrine disease\n④ Urinary tract disease\n⑤ Cardiovascular disease",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n60세 여자가 건강검진 결과 제2형 당뇨병과 만성신장병으로 진단되었고, 검사 결과는 다음과 같다.\n\n[임상검사 결과]\nBUN 45 mg/dL, SCr 2.5 mg/dL\neGFR 28 mL/min/1.73 m^2\n소변검사: 요단백 양성\n\nQuestion: 이 환자에서 메트포르민(metformin) 사용이 금기인 이유와 관련한 산-염기 장애는?\n\n① 호흡성 산증\n② 호흡성 알칼리증\n③ 대사성 알칼리증\n④ 음이온차이(anion gap)가 정상인 대사성 산증\n⑤ 음이온차이가 증가한 대사성 산증",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 60-year-old woman was diagnosed with type 2 diabetes mellitus and chronic kidney disease during a health checkup. Her test results are as follows:\n\n[Clinical Test Results]\nBUN 45 mg/dL, SCr 2.5 mg/dL\neGFR 28 mL/min/1.73 m^2\nUrinalysis: Proteinuria positive\n\nQuestion: What acid-base disorder is related to the reason why metformin use is contraindicated in this patient?\n\n① Respiratory acidosis\n② Respiratory alkalosis\n③ Metabolic alkalosis\n④ Metabolic acidosis with normal anion gap\n⑤ Metabolic acidosis with increased anion gap",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n60세 여자가 건강검진 결과 제2형 당뇨병과 만성신장병으로 진단되었고, 검사 결과는 다음과 같다.\n\n[임상검사 결과]\nBUN 45 mg/dL, SCr 2.5 mg/dL\neGFR 28 mL/min/1.73 m^2\n소변검사: 요단백 양성\n\nQuestion: 환자는 로사르탄(losartan)을 복용할 예정이다. 혈중 농도를 모니터링해야 하는 항목은?\n\n① 아연\n② 칼륨\n③ 레티놀\n④ 알부민\n⑤ 갑상샘글로불린",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 60-year-old woman was diagnosed with type 2 diabetes and chronic kidney disease during a health checkup. Her test results are as follows:\n\n[Clinical Test Results]\nBUN 45 mg/dL, SCr 2.5 mg/dL\neGFR 28 mL/min/1.73 m^2\nUrinalysis: Proteinuria positive\n\nQuestion: The patient is scheduled to take losartan. Which of the following should be monitored for blood concentration?\n\n① Zinc\n② Potassium\n③ Retinol\n④ Albumin\n⑤ Thyroglobulin",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 53세 여자가 소변이 자주 마렵고, 배뇨 시 통증이 있으며, 잔뇨감이 있어서 검사한 결과 요로감염으로 진단되었을 때, 원인이 될 수 있는 약물은?\n\n[병력] 제2형 당뇨병, 이상지질혈증, 고혈압\n\n[복용약물]\n메트포르민(metformin) 1,000 mg 1일 2회\n다파글리플로진(dapagliflozin) 10 mg 1일 1회\n로수바스타틴(rosuvastatin) 10 mg 1일 1회\n라미프릴(ramipril) 10 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n\n① 메트포르민\n② 다파글리플로진\n③ 로수바스타틴\n④ 라미프릴\n⑤ 암로디핀",
        "question_text": "Question: A 53-year-old woman was diagnosed with a urinary tract infection after experiencing frequent urination, pain during urination, and a feeling of incomplete bladder emptying. Which of the following medications could be the cause?\n\n[Medical history] Type 2 diabetes, dyslipidemia, hypertension\n\n[Current medications]\nMetformin 1,000 mg twice daily\nDapagliflozin 10 mg once daily\nRosuvastatin 10 mg once daily\nRamipril 10 mg once daily\nAmlodipine 10 mg once daily\n\n① Metformin\n② Dapagliflozin\n③ Rosuvastatin\n④ Ramipril\n⑤ Amlodipine",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 제1형 당뇨병으로 인슐린을 투여받는 48세 남자가 의식 저하 상태이며 혈당검사 결과가 45 mg/dL일 때, 적절한 약물은?\n\n① 아테놀롤(atenolol)\n② 글루카곤(glucagon)\n③ 살부타몰(salbutamol)\n④ 글리피지드(glipizide)\n⑤ 에피네프린(epinephrine)",
        "question_text": "Question: A 48-year-old man with Type 1 diabetes who is receiving insulin treatment is in a state of decreased consciousness, and his blood glucose test result is 45 mg/dL. What is the appropriate medication?\n\n① Atenolol\n② Glucagon\n③ Salbutamol\n④ Glipizide\n⑤ Epinephrine",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 78세 여자가 갑상선저하증 치료를 위해 레보티록신(levothyroxine)을 처방받았다. 용량을 검토할 때 확인이 필요한 병력은?\n\n[병력] 빈혈, 천식, 녹내장, 협심증, 골관절염\n\n① 빈혈\n② 천식\n③ 녹내장\n④ 협심증\n⑤ 골관절염",
        "question_text": "Question: A 78-year-old woman was prescribed levothyroxine for the treatment of hypothyroidism. Which medical history needs to be checked when reviewing the dosage?\n\n[Medical history] Anemia, Asthma, Glaucoma, Angina, Osteoarthritis\n\n① Anemia\n② Asthma\n③ Glaucoma\n④ Angina\n⑤ Osteoarthritis",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n제2형 당뇨병이 있는 55세 여자가 식이요법과 운동요법을 하고 있다.\n체중 73 kg, 키 158 cm, BMI 29 kg/m2\n\n[병력] 제2형 당뇨병, 고혈압, 이상지질혈증\n\n[활력징후] 혈압 136/80mmHg, 심박수 86회/분, 호흡수 24회/분\n\n[임상검사 결과]\n당화혈색소 7.9%, 공복혈당 155mg/dL, 식후 2시간 혈당 185mg/dL\nTC 210 mg/dL, LDL-C 125 mg/dL, TG 160 mg/dL\nSCr 1.2 mg/dL\n\n[복용약물]\n메트포르민(metformin) 1,000 mg 1일 2회\n글리피지드(glipizide) 5 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n아토르바스타틴(atorvastatin) 20 mg 1일 1회\n아스피린(aspirin) 100 mg 1일 1회\n\nQuestion: 환자의 체중조절을 위해 글리피지드를 대체할 약물로 적절한 것은?\n\n① 리라글루티드(liraglutide)\n② 글리메피리드(glimepiride)\n③ 레파글리니드(repaglinide)\n④ 피오글리타존(pioglitazone)\n⑤ 인슐린 리스프로(insulin lispro)",
        "question_text": "A 55-year-old woman with type 2 diabetes is on diet and exercise therapy.\nWeight 73 kg, Height 158 cm, BMI 29 kg/m2\n\n[Medical history] Type 2 diabetes, hypertension, dyslipidemia\n\n[Vital signs] Blood pressure 136/80mmHg, Heart rate 86/min, Respiratory rate 24/min\n\n[Clinical test results]\nHbA1c 7.9%, Fasting blood glucose 155mg/dL, 2-hour postprandial blood glucose 185mg/dL\nTC 210 mg/dL, LDL-C 125 mg/dL, TG 160 mg/dL\nSCr 1.2 mg/dL\n\n[Current medications]\nMetformin 1,000 mg twice daily\nGlipizide 5 mg once daily\nAmlodipine 10 mg once daily\nLisinopril 10 mg once daily\nAtorvastatin 20 mg once daily\nAspirin 100 mg once daily\n\nQuestion: Which of the following drugs is appropriate to replace glipizide for the patient's weight control?\n\n① Liraglutide\n② Glimepiride\n③ Repaglinide\n④ Pioglitazone\n⑤ Insulin lispro",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n제2형 당뇨병이 있는 55세 여자가 식이요법과 운동요법을 하고 있다.\n체중 73 kg, 키 158 cm, BMI 29 kg/m2\n\n[병력] 제2형 당뇨병, 고혈압, 이상지질혈증\n\n[활력징후] 혈압 136/80mmHg, 심박수 86회/분, 호흡수 24회/분\n\n[임상검사 결과]\n당화혈색소 7.9%, 공복혈당 155mg/dL, 식후 2시간 혈당 185mg/dL\nTC 210 mg/dL, LDL-C 125 mg/dL, TG 160 mg/dL\nSCr 1.2 mg/dL\n\n[복용약물]\n메트포르민(metformin) 1,000 mg 1일 2회\n글리피지드(glipizide) 5 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n아토르바스타틴(atorvastatin) 20 mg 1일 1회\n아스피린(aspirin) 100 mg 1일 1회\n\nQuestion: 환자의 비타민B12 수치에 영향을 줄 수 있는 약물은?\n\n① 메트포르민\n② 글리피지드\n③ 암로디핀\n④ 리시노프릴\n⑤ 아토르바스타틴",
        "question_text": "A 55-year-old woman with type 2 diabetes is on diet and exercise therapy.\nWeight 73 kg, Height 158 cm, BMI 29 kg/m2\n\n[Medical history] Type 2 diabetes, hypertension, dyslipidemia\n\n[Vital signs] Blood pressure 136/80mmHg, Heart rate 86/min, Respiratory rate 24/min\n\n[Clinical test results]\nHbA1c 7.9%, Fasting blood glucose 155mg/dL, 2-hour postprandial blood glucose 185mg/dL\nTC 210 mg/dL, LDL-C 125 mg/dL, TG 160 mg/dL\nSCr 1.2 mg/dL\n\n[Medications]\nMetformin 1,000 mg twice daily\nGlipizide 5 mg once daily\nAmlodipine 10 mg once daily\nLisinopril 10 mg once daily\nAtorvastatin 20 mg once daily\nAspirin 100 mg once daily\n\nQuestion: Which medication can affect the patient's vitamin B12 levels?\n\n① Metformin\n② Glipizide\n③ Amlodipine\n④ Lisinopril\n⑤ Atorvastatin",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n33세 여자가 3개월 전부터 심장이 빨리 뛰는 것 같고, 이유 없이 가슴이 두근거리면서 불안감이 들고, 더위를 참기 힘들다고 한다.\n\n[혈액검사 결과]\n유리 T4 12 ng/dL (참고치 0.8~1.5 ng/dL)\nTSH <0.01 μIU/mL (참고치 0.2~4.8 μIU/mL)\nAST 35 IU/L, ALT 32 IU/L\n\nQuestion: 환자의 갑상선질환 치료에 적절한 약물은?\n\n① 메티마졸(methimazole)\n② 리오티로닌(liothyronine)\n③ 레보티록신(levothyroxine)\n④ 요오드화칼륨(potassium iodide)\n⑤ 방사성 요오드(radioactive iodine)",
        "question_text": "A 33-year-old woman has been experiencing rapid heartbeat, unexplained palpitations with anxiety, and difficulty tolerating heat for the past 3 months.\n\n[Blood Test Results]\nFree T4: 12 ng/dL (Reference range: 0.8-1.5 ng/dL)\nTSH: <0.01 μIU/mL (Reference range: 0.2-4.8 μIU/mL)\nAST: 35 IU/L, ALT: 32 IU/L\n\nQuestion: Which drug is appropriate for treating the patient's thyroid condition?\n\n① Methimazole\n② Liothyronine\n③ Levothyroxine\n④ Potassium iodide\n⑤ Radioactive iodine",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n33세 여자가 3개월 전부터 심장이 빨리 뛰는 것 같고, 이유 없이 가슴이 두근거리면서 불안감이 들고, 더위를 참기 힘들다고 한다.\n\n[혈액검사 결과]\n유리 T4 12 ng/dL (참고치 0.8~1.5 ng/dL)\nTSH <0.01 μIU/mL (참고치 0.2~4.8 μIU/mL)\nAST 35 IU/L, ALT 32 IU/L\n\nQuestion: 환자의 증상을 신속하게 완화하기 위한 약물은?\n\n① 아스피린(aspirin)\n② 아카르보스(acarbose)\n③ 아미오다론(amiodarone)\n④ 프로프라놀롤(propranolol)\n⑤ 아세트아미노펜(acetaminophen)",
        "question_text": "A 33-year-old woman has been experiencing rapid heartbeat, unexplained palpitations with anxiety, and difficulty tolerating heat for the past 3 months.\n\n[Blood Test Results]\nFree T4: 12 ng/dL (Reference range: 0.8-1.5 ng/dL)\nTSH: <0.01 μIU/mL (Reference range: 0.2-4.8 μIU/mL)\nAST: 35 IU/L, ALT: 32 IU/L\n\nQuestion: Which drug is appropriate for rapidly alleviating the patient's symptoms?\n\n① Aspirin\n② Acarbose\n③ Amiodarone\n④ Propranolol\n⑤ Acetaminophen",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 62세 남자의 Pseudomonas aeruginosa로 인한 폐렴을 치료하기 위해 세페핌(cefepime)을 투여하고 있다. 동일 용량으로 정맥 내 점적주입 시간을 30분에서 3시간으로 연장한다면 예상되는 효과는?\n\n① 간독성 부작용 감소\n② 신독성 부작용 감소\n③ 아나필락시스 부작용 감소\n④ 농도 의존적 살균작용 증가\n⑤ 시간 의존적 살균작용 증가",
        "question_text": "Question: A 62-year-old man is being treated with cefepime for pneumonia caused by Pseudomonas aeruginosa. What is the expected effect if the intravenous infusion time is extended from 30 minutes to 3 hours at the same dose?\n\n① Decreased hepatotoxic side effects\n② Decreased nephrotoxic side effects\n③ Decreased anaphylactic side effects\n④ Increased concentration-dependent bactericidal action\n⑤ Increased time-dependent bactericidal action",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 2일 전부터 귀를 잡아당기고 칭얼거리는 증상이 나타난 18개월 남아가 급성중이염으로 진단받았다. 환아는 3주 전에도 동일한 증상으로 아목시실린(amoxicillin) 치료를 받고 회복된 적이 있다. 적절한 치료약물은?\n\n[임상검사 결과]\n체온 38.7℃\n이경검사(otoscopy): 고막부종\n\n① 세팔렉신(cefalexin)\n② 겐타마이신(gentamicin)\n③ 반코마이신(vancomycin)\n④ 목시플록사신(moxifloxacin)\n⑤ 아목시실린/클라불란산(amoxicillin/clavulanate)",
        "question_text": "Question: An 18-month-old male infant has been diagnosed with acute otitis media after showing symptoms of pulling at his ear and whining for the past 2 days. The patient had recovered from the same symptoms 3 weeks ago after receiving amoxicillin treatment. What is the appropriate treatment drug?\n\n[Clinical Test Results]\nBody temperature: 38.7℃\nOtoscopy: Tympanic membrane swelling\n\n① Cefalexin\n② Gentamicin\n③ Vancomycin\n④ Moxifloxacin\n⑤ Amoxicillin/clavulanate",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 7일 전 교통사고로 입원한 67세 남자에게 병원획득성 폐렴이 발생하였을 때, 적절한 경험적 항생제(요법)는?\n\n[병력] 당뇨병, 뇌수막염(한 달 전 입원하여 항생제 정맥주사 치료 후 퇴원함)\n\n[임상검사 결과]\n체온 39℃, WBC 23,000/mm^3\n흉부 방사선 촬영 검사: 폐침윤\n\n① 암피실린/설박탐(ampicillin/sulbactam)\n② 세포탁심(cefotaxime)+반코마이신(vancomycin)\n③ 세프트리악손(ceftriaxone)+리네졸리드(linezolid)\n④ 에르타페넴(ertapenem)+목시플록사신(moxifloxacin)+반코마이신\n⑤ 피페라실린/타조박탐(piperacillin/tazobactam)+토브라마이신(tobramycin)+리네졸리드",
        "question_text": "Question: A 67-year-old male who was hospitalized 7 days ago due to a traffic accident has developed hospital-acquired pneumonia. What is the appropriate empirical antibiotic (therapy)?\n\n[Medical history] Diabetes, meningitis (hospitalized a month ago and discharged after intravenous antibiotic treatment)\n\n[Clinical test results]\nBody temperature 39°C, WBC 23,000/mm^3\nChest X-ray: Pulmonary infiltration\n\n① Ampicillin/sulbactam\n② Cefotaxime + vancomycin\n③ Ceftriaxone + linezolid\n④ Ertapenem + moxifloxacin + vancomycin\n⑤ Piperacillin/tazobactam + tobramycin + linezolid",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 호흡곤란, 화농성 가래, 기침 증상이 나타나 일반병동에 입원한 73세 여자가 지역사회획득성 폐렴으로 진단받았다. 적절한 경험적 항생제(요법)는?\n\n[활력징후] 체온 38.8℃, 혈압 118/72 mmHg, 심박수 78회/분, 호흡수 32회/분\n\n① 세프타지딤(ceftazidime)\n② 클린다마이신(clindamycin)\n③ 시프로플록사신(ciprofloxacin)\n④ 세프트리악손(ceftriaxone)+아지트로마이신(azithromycin)\n⑤ 피페라실린/타조박탐(piperacillin/tazobactam)+리네졸리드(linezolid)",
        "question_text": "Question: A 73-year-old woman admitted to the general ward with symptoms of dyspnea, purulent sputum, and cough was diagnosed with community-acquired pneumonia. What is the appropriate empirical antibiotic (therapy)?\n\n[Vital signs] Temperature 38.8°C, Blood pressure 118/72 mmHg, Heart rate 78 beats/min, Respiratory rate 32 breaths/min\n\n① Ceftazidime\n② Clindamycin\n③ Ciprofloxacin\n④ Ceftriaxone + Azithromycin\n⑤ Piperacillin/Tazobactam + Linezolid",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 후천성면역결핍증(AIDS) 치료를 받고 있는 42세 남자의 잠복결핵 치료에 적절한 약물은?\n\n① 에탐부톨(ethambutol)\n② 이소니아지드(isoniazid)\n③ 레보플록사신(levofloxacin)\n④ 피라진아미드(pyrazinamide)\n⑤ 스트렙토마이신(streptomycin)",
        "question_text": "Question: Which drug is appropriate for treating latent tuberculosis in a 42-year-old man receiving treatment for Acquired Immune Deficiency Syndrome (AIDS)?\n\n① Ethambutol\n② Isoniazid\n③ Levofloxacin\n④ Pyrazinamide\n⑤ Streptomycin",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 추락사고로 신경외과 수술을 받은 후, 발열(38.8℃)과 심한 두통, 목이 경직되는 증상이 나타난 53세 환자의 뇌수막염 치료에 정맥으로 주사하는 적절한 경험적 항생제(요법)는?\n\n[뇌척수액 검사 결과] WBC 1,000/mm3, glucose 44 mg/dL, protein 220 mg/dL\n[뇌척수액 배양 검사] 검사 중\n\n① 설파메톡사졸/트리메토프림(sulfamethoxazole/trimethoprim)\n② 반코마이신(vancomycin)+세파졸린(cefazolin)\n③ 반코마이신+세페핌(cefepime)\n④ 암피실린(ampicillin)+메트로니다졸(metronidazole)\n⑤ 암피실린+세푸록심(cefuroxime)",
        "question_text": "Question: A 53-year-old patient who underwent neurosurgery after a fall accident is showing symptoms of fever (38.8℃), severe headache, and neck stiffness. What is the appropriate empirical antibiotic (therapy) to be administered intravenously for the treatment of meningitis in this patient?\n\n[Cerebrospinal fluid test results] WBC 1,000/mm3, glucose 44 mg/dL, protein 220 mg/dL\n[Cerebrospinal fluid culture test] In progress\n\n① Sulfamethoxazole/trimethoprim\n② Vancomycin + Cefazolin\n③ Vancomycin + Cefepime\n④ Ampicillin + Metronidazole\n⑤ Ampicillin + Cefuroxime",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 당뇨병이 있는 63세 남자에서 경미한 구강인두칸디다증이 처음 발생하였다. 평소 혈당이 잘 조절되지 않았다. 오늘 측정한 혈압, 체온 등 임상검사와 혈액검사 결과는 정상이다. 적절한 1차 치료약은?\n\n① 테르비나핀(terbinafine) 경구제\n② 플루코나졸(fluconazole) 경구제\n③ 보리코나졸(voriconazole) 주사제\n④ 카스포펀진(caspofungin) 주사제\n⑤ 암포테리신B(amphotericin B) 주사제",
        "question_text": "Question: A 63-year-old man with diabetes has developed mild oropharyngeal candidiasis for the first time. His blood sugar has not been well controlled. Today's clinical tests including blood pressure, body temperature, and blood tests are normal. What is the appropriate first-line treatment?\n\n① Oral terbinafine\n② Oral fluconazole\n③ Injectable voriconazole\n④ Injectable caspofungin\n⑤ Injectable amphotericin B",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 당뇨신장병과 소화성궤양이 있는 55세 남자가 발톱진균증 치료를 위해 이트라코나졸(itraconazole) 캡슐을 처방받았다. 기존에 복용하던 약물 중 이트라코나졸의 효과를 감소시킬 수 있는 것은?\n\n[복용약물]\n라니티딘(ranitidine) 150 mg 1일 2회\n메트포르민(metformin) 1,000 mg 1일 2회\n시타글립틴(sitagliptin) 100 mg 1일 1회\n에날라프릴(enalapril) 5 mg 1일 1회\n비타민B, C 복합제 1정, 1일 2회\n\n① 라니티딘\n② 메트포르민\n③ 시타글립틴\n④ 에날라프릴\n⑤ 비타민B, C 복합제",
        "question_text": "Question: A 55-year-old man with diabetic nephropathy and peptic ulcer was prescribed itraconazole capsules for the treatment of onychomycosis. Among the medications he was already taking, which one could potentially decrease the effectiveness of itraconazole?\n\n[Current medications]\nRanitidine 150 mg twice daily\nMetformin 1,000 mg twice daily\nSitagliptin 100 mg once daily\nEnalapril 5 mg once daily\nVitamin B and C complex, 1 tablet twice daily\n\n① Ranitidine\n② Metformin\n③ Sitagliptin\n④ Enalapril\n⑤ Vitamin B and C complex",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 72세 여자가 클린다마이신(clindamycin)을 3일간 복용하였는데, 발열, 복통, 심한 설사 증상이 나타났다. Clostridium difficile 독소 검사에서 양성으로 나타났을 때, 적절한 치료약은?\n\n① 로페라미드(loperamide) 경구제\n② 반코마이신(vancomycin) 경구제\n③ 아트로핀(atropine) 정맥주사제\n④ 암피실린(ampicillin) 정맥주사제\n⑤ 메로페넴(meropenem) 정맥주사제",
        "question_text": "Question: A 72-year-old woman took clindamycin for 3 days and developed symptoms of fever, abdominal pain, and severe diarrhea. When the Clostridium difficile toxin test came back positive, what is the appropriate treatment?\n\n① Oral loperamide\n② Oral vancomycin\n③ Intravenous atropine\n④ Intravenous ampicillin\n⑤ Intravenous meropenem",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n3일 전부터 발열, 허리통증, 구토가 나타난 58세 여자가 입원하여 중증 급성신우신염으로 진단받았다. 환자는 지난 24시간 동안 1일 5회 이상의 심한 구토로 인해 아무것도 먹지 못하였다.\n\n[알레르기력] 설파메톡사졸/트리메토프림(sulfamethoxazole/trimethoprim): 복용 후 두드러기 발생\n\n[임상검사 결과]\n소변 및 혈액 배양 검사: 검사 중\nBUN 35 mg/dL, SCr 1.3 mg/dL, CrCl 67 mL/min\n\nQuestion: 치료에 적절한 경험적 항생제는?\n\n① 세프포독심(cefpodoxime) 경구제\n② 포스포마이신(fosfomycin) 경구제\n③ 목시플록사신(moxifloxacin) 경구제\n④ 반코마이신(vancomycin) 정맥주사제\n⑤ 세프트리악손(ceftriaxone) 정맥주사제",
        "question_text": "A 58-year-old woman who has been experiencing fever, lower back pain, and vomiting for the past 3 days was admitted to the hospital and diagnosed with severe acute pyelonephritis. Due to severe vomiting more than 5 times a day for the past 24 hours, the patient has not been able to eat anything.\n\n[Allergy history] Sulfamethoxazole/trimethoprim: Urticaria after ingestion\n\n[Clinical test results]\nUrine and blood culture tests: In progress\nBUN 35 mg/dL, SCr 1.3 mg/dL, CrCl 67 mL/min\n\nQuestion: What is the appropriate empirical antibiotic for treatment?\n\n① Cefpodoxime (oral)\n② Fosfomycin (oral)\n③ Moxifloxacin (oral)\n④ Vancomycin (intravenous)\n⑤ Ceftriaxone (intravenous)",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n3일 전부터 발열, 허리통증, 구토가 나타난 58세 여자가 입원하여 중증 급성신우신염으로 진단받았다. 환자는 지난 24시간 동안 1일 5회 이상의 심한 구토로 인해 아무것도 먹지 못하였다.\n\n[알레르기력] 설파메톡사졸/트리메토프림(sulfamethoxazole/trimethoprim): 복용 후 두드러기 발생\n\n[임상검사 결과]\n소변 및 혈액 배양 검사: 검사 중\nBUN 35 mg/dL, SCr 1.3 mg/dL, CrCl 67 mL/min\n\nQuestion: 경험적 치료를 시작하고 4일 후, 증상이 호전된 환자가 퇴원하려고 한다. 퇴원 후에 복용해야 할 적절한 항생제는?\n\n① 리네졸리드(linezolid) 경구제\n② 독시사이클린(doxycycline) 경구제\n③ 레보플록사신(levofloxacin) 경구제\n④ 클린다마이신(clindamycin) 경구제\n⑤ 아지트로마이신(azithromycin) 경구제",
        "question_text": "A 58-year-old woman who has been experiencing fever, back pain, and vomiting for the past 3 days was admitted to the hospital and diagnosed with severe acute pyelonephritis. Due to severe vomiting more than 5 times a day for the past 24 hours, the patient has not been able to eat anything.\n\n[Allergy history] Sulfamethoxazole/trimethoprim: Urticaria after ingestion\n\n[Clinical test results]\nUrine and blood culture tests: In progress\nBUN 35 mg/dL, SCr 1.3 mg/dL, CrCl 67 mL/min\n\nQuestion: Four days after starting empirical treatment, the patient's symptoms have improved and she is preparing to be discharged. What is the appropriate antibiotic for the patient to take after discharge?\n\n① Oral linezolid\n② Oral doxycycline\n③ Oral levofloxacin\n④ Oral clindamycin\n⑤ Oral azithromycin",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 30세 여자가 간헐적인 편두통 치료를 위해 이부프로펜(ibuprofen)을 복용하고 있었으나, 최근 두통의 발생 빈도가 증가하였다. 적절한 대체 치료약물은?\n\n① 리자트립탄(rizatriptan)\n② 부토르파놀(butorphanol)\n③ 토피라메이트(topiramate)\n④ 프로프라놀롤(propranolol)\n⑤ 아세트아미노펜(acetaminophen)",
        "question_text": "Question: A 30-year-old woman has been taking ibuprofen for intermittent migraine treatment, but recently the frequency of headaches has increased. What is the appropriate alternative medication?\n\n① Rizatriptan\n② Butorphanol\n③ Topiramate\n④ Propranolol\n⑤ Acetaminophen",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 만성신장병이 있는 73세 남자가 알츠하이머병으로 기억력이 감소하고 정확한 용어 선택과 단어 사용에 어려움이 있다. 적절한 치료약물은?\n\n[임상검사 결과]\n간이정신상태(MMSE): 20점(경도)\nCrCl 35 mL/min\n\n① 메만틴(memantine)\n② 도네페질(donepezil)\n③ 올란자핀(olanzapine)\n④ 노르트립틸린(nortriptyline)\n⑤ 카르바마제핀(carbamazepine)",
        "question_text": "Question: A 73-year-old man with chronic kidney disease has decreased memory due to Alzheimer's disease and difficulty in choosing accurate terms and using words. What is the appropriate treatment medication?\n\n[Clinical Test Results]\nMini-Mental State Examination (MMSE): 20 points (mild)\nCrCl 35 mL/min\n\n① Memantine\n② Donepezil\n③ Olanzapine\n④ Nortriptyline\n⑤ Carbamazepine",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 파킨슨병으로 카르비도파/레보도파(carbidopa/levodopa)를 복용하던 78세 환자에게 잠을 깬 후 몸을 일으키기 어려운 증상과 진전이 심하게 나타나기 시작하였다. 적절한 추가약물은?\n\n① 도파민(dopamine)\n② 엔타카폰(entacapone)\n③ 돔페리돈(domperidone)\n④ 아미트립틸린(amitriptyline)\n⑤ 트리헥시페니딜(trihexyphenidyl)",
        "question_text": "Question: A 78-year-old patient taking carbidopa/levodopa for Parkinson's disease has begun to experience difficulty getting up after waking and severe tremors. What is the appropriate additional medication?\n\n① Dopamine\n② Entacapone\n③ Domperidone\n④ Amitriptyline\n⑤ Trihexyphenidyl",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 복합부분발작을 치료하기 위해 발프로산(valproic acid) 1,000 mg을 1일 2회 복용하고 있는 38세 남자가 라모트리진(lamotrigine)을 추가로 복용하게 되었다. 다른 병용약물이나 공존질환은 없다. 의사에게 적절한 용량변경으로 추천할 수 있는 것은?\n\n[라모트리진 허가사항]\n용법 및 용량: 시작용량 25 mg 1일 1회, 유지용량 50 mg 1일 1회\n\n① 발프로산 1일 용량의 50%를 감량\n② 발프로산 1일 용량의 50%를 증량\n③ 라모트리진 1일 용량의 50%를 감량하여 시작\n④ 라모트리진 1일 용량의 50%를 증량하여 시작\n⑤ 라모트리진 1일 용량의 75%를 증량하여 시작",
        "question_text": "Question: A 38-year-old man taking valproic acid 1,000 mg twice daily for the treatment of complex partial seizures is prescribed lamotrigine as an additional medication. There are no other concomitant medications or comorbidities. What is the appropriate dose adjustment to recommend to the doctor?\n\n[Lamotrigine Prescribing Information]\nDosage and Administration: Starting dose 25 mg once daily, maintenance dose 50 mg once daily\n\n① Reduce the daily dose of valproic acid by 50%\n② Increase the daily dose of valproic acid by 50%\n③ Start with a 50% reduction in the daily dose of lamotrigine\n④ Start with a 50% increase in the daily dose of lamotrigine\n⑤ Start with a 75% increase in the daily dose of lamotrigine",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 38세 남자가 우울증 치료를 위해 플루옥세틴(fluoxetine) 복용을 시작한 후 불면증이 나타났다. 적절한 추가약물은?\n\n① 설트랄린(sertraline)\n② 트라조돈(trazodone)\n③ 둘록세틴(duloxetine)\n④ 벤라팍신(venlafaxine)\n⑤ 부프로피온(bupropion)",
        "question_text": "Question: A 38-year-old man experienced insomnia after starting fluoxetine for depression treatment. What is the appropriate additional medication?\n\n① Sertraline\n② Trazodone\n③ Duloxetine\n④ Venlafaxine\n⑤ Bupropion",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 조현병 치료를 위해 리스페리돈(risperidone)을 복용하던 37세 여자에서 유즙분비가 나타나고, 체중이 최근 3개월간 5 kg 증가하는 부작용이 발생하였다. 적절한 대체약물은?\n\n① 클로자핀(clozapine)\n② 올란자핀(olanzapine)\n③ 할로페리돌(haloperidol)\n④ 팔리페리돈(paliperidone)\n⑤ 아리피프라졸(aripiprazole)",
        "question_text": "Question: A 37-year-old woman taking risperidone for the treatment of schizophrenia experienced side effects including lactation and a weight gain of 5 kg over the past 3 months. What is the appropriate alternative medication?\n\n① Clozapine\n② Olanzapine\n③ Haloperidol\n④ Paliperidone\n⑤ Aripiprazole",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n10세 남아가 주의력결핍과다행동장애(ADHD) 치료를 위하여 메틸페니데이트(methylphenidate) 정 5 mg을 오전 9시와 오후 5시에 1정씩 복용하고 있다.\n\nQuestion: 약물복용 시작 후 나타난 불면증 증상을 감소시키기 위해 적절한 것은?\n\n① 서방정으로 변경하여 복용\n② 오후 5시 복용약의 용량 증가\n③ 1일 1회 2정을 취침 전에 복용\n④ 1회 1정을 오전 9시와 취침 전에 복용\n⑤ 1회 1정을 오전 9시와 오후 2시에 복용",
        "question_text": "A 10-year-old boy is taking methylphenidate 5 mg tablets for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), one tablet at 9 AM and one tablet at 5 PM.\n\nQuestion: Which of the following is appropriate to reduce insomnia symptoms that appeared after starting the medication?\n\n① Change to an extended-release formulation\n② Increase the dose of the 5 PM medication\n③ Take 2 tablets once daily before bedtime\n④ Take 1 tablet at 9 AM and 1 tablet before bedtime\n⑤ Take 1 tablet at 9 AM and 1 tablet at 2 PM",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n10세 남아가 주의력결핍과다행동장애(ADHD) 치료를 위하여 메틸페니데이트(methylphenidate) 정 5 mg을 오전 9시와 오후 5시에 1정씩 복용하고 있다.\n\nQuestion: 약물복용 중 정기적으로 모니터링해야 하는 것은?\n\n① 안압\n② 혈당\n③ 골밀도\n④ 식사량\n⑤ 폐활량",
        "question_text": "A 10-year-old boy is taking methylphenidate 5 mg tablets, one tablet at 9 AM and one tablet at 5 PM, for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).\n\nQuestion: Which of the following should be regularly monitored during medication use?\n\n① Intraocular pressure\n② Blood glucose\n③ Bone density\n④ Food intake\n⑤ Lung capacity",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 우울증, 신경병증이 있는 56세 여자가 골관절염으로 이부프로펜(ibuprofen)을 복용하고 있다. 통증이 개선되지 않을 때 적절한 추가약물은?\n\n① 둘록세틴(duloxetine)\n② 데노수맙(denosumab)\n③ 아달리무맙(adalimumab)\n④ 테리파라타이드(teriparatide)\n⑤ 메토트렉세이트(methotrexate)",
        "question_text": "Question: A 56-year-old woman with depression and neuropathy is taking ibuprofen for osteoarthritis. What is the appropriate additional medication when pain does not improve?\n\n① Duloxetine\n② Denosumab\n③ Adalimumab\n④ Teriparatide\n⑤ Methotrexate",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 유방암의 가족력이 있는 54세 폐경기 여자에게 적절한 골다공증 치료약물은?\n\n① 랄록시펜(raloxifene)\n② 에스트로겐(estrogen)\n③ 인플릭시맵(infliximab)\n④ 글루코사민(glucosamine)\n⑤ 덱사메타손(dexamethasone)",
        "question_text": "Question: What is the appropriate osteoporosis medication for a 54-year-old postmenopausal woman with a family history of breast cancer?\n\n① Raloxifene\n② Estrogen\n③ Infliximab\n④ Glucosamine\n⑤ Dexamethasone",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 오른쪽 엄지발가락에 심한 통증과 부종이 있는 52세 남자가 급성통풍으로 진단받았다. 통증과 부종을 완화하기 위한 약물은?\n\n① 나프록센(naproxen)\n② 알로푸리놀(allopurinol)\n③ 페북소스타트(febuxostat)\n④ 라스부리카제(rasburicase)\n⑤ 벤즈브로마론(benzbromarone)",
        "question_text": "Question: A 52-year-old man with severe pain and swelling in his right big toe has been diagnosed with acute gout. Which drug is used to relieve the pain and swelling?\n\n① Naproxen\n② Allopurinol\n③ Febuxostat\n④ Rasburicase\n⑤ Benzbromarone",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 기립저혈압이 있는 69세 남자가 양성전립선비대로 진단받았다. 전립선이 크고(무게 42 g), 혈중 전립선특이항원(PSA)이 4.8 ng/mL으로 높으며, 국제전립선증상점수(IPSS)가 18점(중등도)에 해당한다. 적절한 약물(요법)은?\n\n① 실데나필(sildenafil)\n② 독사조신(doxazosin)\n③ 데스모프레신(desmopressin)\n④ 옥시부티닌(oxybutynin)+테라조신(terazosin)\n⑤ 피나스테리드(finasteride)+탐스로신(tamsulosin)",
        "question_text": "Question: A 69-year-old man with orthostatic hypotension has been diagnosed with benign prostatic hyperplasia. His prostate is enlarged (weighing 42 g), his blood prostate-specific antigen (PSA) is elevated at 4.8 ng/mL, and his International Prostate Symptom Score (IPSS) is 18 points (moderate). What is the appropriate medication (therapy)?\n\n① Sildenafil\n② Doxazosin\n③ Desmopressin\n④ Oxybutynin + Terazosin\n⑤ Finasteride + Tamsulosin",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n38세 여자에게 10개 이상의 관절 부위에서 통증과 부종이 5주 정도 지속되었다. 류마티스관절염으로 진단되어 메토트렉세이트(methotrexate)를 복용할 예정이다.\n\nQuestion: 메토트렉세이트에 의한 이상반응을 예방하기 위해 병용투여가 추천되는 약물은?\n\n① 폴산(folic acid)\n② 황산철(ferrous sulfate)\n③ 아스코르브산(ascorbic acid)\n④ 이소트레티노인(isotretinoin)\n⑤ 황산마그네슘(magnesium sulfate)",
        "question_text": "A 38-year-old woman has experienced pain and swelling in more than 10 joint areas for about 5 weeks. She has been diagnosed with rheumatoid arthritis and is scheduled to take methotrexate.\n\nQuestion: Which drug is recommended to be co-administered to prevent adverse reactions caused by methotrexate?\n\n① Folic acid\n② Ferrous sulfate\n③ Ascorbic acid\n④ Isotretinoin\n⑤ Magnesium sulfate",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n38세 여자에게 10개 이상의 관절 부위에서 통증과 부종이 5주 정도 지속되었다. 류마티스관절염으로 진단되어 메토트렉세이트(methotrexate)를 복용할 예정이다.\n\nQuestion: 메토트렉세이트의 약효가 발현하기 전에 류마티스관절염의 증상을 경감하기 위해 사용하는 약물은?\n\n① 설파살라진(sulfasalazine)\n② 아자티오프린(azathioprine)\n③ 프레드니솔론(prednisolone)\n④ 아세트아미노펜(acetaminophen)\n⑤ 히드록시클로로퀸(hydroxychloroquine)",
        "question_text": "A 38-year-old woman has experienced pain and swelling in more than 10 joint areas for about 5 weeks. She has been diagnosed with rheumatoid arthritis and is scheduled to take methotrexate.\n\nQuestion: Which drug is used to alleviate the symptoms of rheumatoid arthritis before the onset of methotrexate's therapeutic effect?\n\n① Sulfasalazine\n② Azathioprine\n③ Prednisolone\n④ Acetaminophen\n⑤ Hydroxychloroquine",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 평소 건강하였던 42세 남자가 필라델피아염색체 양성의 가속기 만성골수세포백혈병(CML)으로 진단받았다. BCR-ABL 키나아제 도메인에 돌연변이는 없다. 1차 항암약물(요법)은?\n\n① 닐로티닙(nilotinib)\n② 소라페닙(sorafenib)\n③ 레고라페닙(regorafenib)\n④ 트레티노인(tretinoin)+이다루비신(idarubicin)\n⑤ 시타라빈(cytarabine)+다우노루비신(daunorubicin)",
        "question_text": "Question: A previously healthy 42-year-old man was diagnosed with Philadelphia chromosome-positive accelerated chronic myeloid leukemia (CML). There are no mutations in the BCR-ABL kinase domain. What is the first-line anticancer drug (therapy)?\n\n① Nilotinib\n② Sorafenib\n③ Regorafenib\n④ Tretinoin + Idarubicin\n⑤ Cytarabine + Daunorubicin",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 1년 전 심부정맥혈전증으로 치료받은 61세 여자가 2기 유방암으로 절제수술을 받았다. 현재 폐경 상태이고, 다른 병력은 없다. 수술 후 적절한 보조항암약물은?\n\n[검사 결과]\n호르몬수용체(HR): 양성\n사람표피성장인자수용체2(HER2): 음성\n\n① 라파티닙(lapatinib)\n② 카페시타빈(capecitabine)\n③ 베바시주맙(bevacizumab)\n④ 아나스트로졸(anastrozole)\n⑤ 트라스투주맙(trastuzumab)",
        "question_text": "Question: A 61-year-old woman who was treated for deep vein thrombosis a year ago underwent a mastectomy for stage II breast cancer. She is currently postmenopausal and has no other medical history. What is the appropriate adjuvant chemotherapy drug after surgery?\n\n[Test Results]\nHormone Receptor (HR): Positive\nHuman Epidermal Growth Factor Receptor 2 (HER2): Negative\n\n① Lapatinib\n② Capecitabine\n③ Bevacizumab\n④ Anastrozole\n⑤ Trastuzumab",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 64세 남자가 4기 비소세포폐암(선암)으로 진단받았다(ECOG 수행도 1). 적절한 1차 항암약물(요법)은?\n\n[검사 결과]\n역형성림프종인산화효소(ALK) 유전자 재배열: 음성\n표피성장인자수용체(EGFR) 돌연변이: 양성\n\n① 엘로티닙(erlotinib)\n② 토포테칸(topotecan)\n③ 니볼루맙(nivolumab)\n④ 카페시타빈(capecitabine)+옥살리플라틴(oxaliplatin)\n⑤ 카르보플라틴(carboplatin)+파클리탁셀(paclitaxel)+크리조티닙(crizotinib)",
        "question_text": "Question: A 64-year-old man was diagnosed with stage 4 non-small cell lung cancer (adenocarcinoma) (ECOG performance status 1). What is the appropriate first-line anticancer drug (therapy)?\n\n[Test Results]\nAnaplastic lymphoma kinase (ALK) gene rearrangement: Negative\nEpidermal growth factor receptor (EGFR) mutation: Positive\n\n① Erlotinib\n② Topotecan\n③ Nivolumab\n④ Capecitabine + Oxaliplatin\n⑤ Carboplatin + Paclitaxel + Crizotinib",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 전이성 대장암으로 진단받은 53세 남자가 플루오로우라실(fluorouracil)+로이코보린(leucovorin)+이리노테칸(irinotecan) 항암화학요법을 처음 받았다. 항암화학요법 종료 2일 후부터 매일 수차례의 심한 설사가 발생하였다. 설사 외에 다른 증상은 없다. 설사 완화를 위한 적절한 초기약은?\n\n① 락툴로오스(lactulose) 경구제\n② 로페라미드(loperamide) 경구제\n③ 아트로핀(atropine) 주사제\n④ 덱사메타손(dexamethasone) 주사제\n⑤ 시프로플록사신(ciprofloxacin) 주사제",
        "question_text": "Question: A 53-year-old man diagnosed with metastatic colorectal cancer received his first chemotherapy treatment with fluorouracil + leucovorin + irinotecan. Two days after completing the chemotherapy, he began experiencing severe diarrhea several times a day. He has no other symptoms besides diarrhea. What is the appropriate initial medication to alleviate the diarrhea?\n\n① Lactulose oral preparation\n② Loperamide oral preparation\n③ Atropine injection\n④ Dexamethasone injection\n⑤ Ciprofloxacin injection",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 뼈로 전이된 소세포폐암이 있는 72세 남자가 허리, 어깨 등에 지속적인 뼈통증이 있다. 옥시코돈(oxycodone)과 최대용량의 아세트아미노펜(acetaminophen)을 복용하고 있지만, 통증이 잘 조절되지 않는다. 적절한 진통보조제는?\n\n① 날록손(naloxone)\n② 페티딘(pethidine)\n③ 디아제팜(diazepam)\n④ 가바펜틴(gabapentin)\n⑤ 졸레드론산(zoledronic acid)",
        "question_text": "Question: A 72-year-old man with small cell lung cancer metastasized to the bones has persistent bone pain in his lower back and shoulders. He is taking oxycodone and the maximum dose of acetaminophen, but the pain is not well controlled. What is the appropriate adjuvant analgesic?\n\n① Naloxone\n② Pethidine\n③ Diazepam\n④ Gabapentin\n⑤ Zoledronic acid",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 여자가 2기 유방암으로 절제수술을 받았다. 검사 결과, 호르몬수용체(HR)와 사람표피성장인자수용체2(HER2)는 모두 음성이다. 수술 후 예정된 보조항암화학요법은 다음과 같다.\n독소루비신(doxorubicin) 60 mg/m2 제1일\n시클로포스파미드(cyclophosphamide) 600 mg/m2 제1일\n\nQuestion: 위 보조항암화학요법의 용량을 검토할 때 확인이 필요한 검사항목은?\n\n① 안압\n② 간기능\n③ 골밀도\n④ 폐기능\n⑤ 갑상선기능",
        "question_text": "A 58-year-old woman underwent a mastectomy for stage II breast cancer. Test results show that both hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) are negative. The planned adjuvant chemotherapy regimen after surgery is as follows:\nDoxorubicin 60 mg/m2 on Day 1\nCyclophosphamide 600 mg/m2 on Day 1\n\nQuestion: When reviewing the dosage of the above adjuvant chemotherapy, which test item needs to be checked?\n\n① Intraocular pressure\n② Liver function\n③ Bone density\n④ Lung function\n⑤ Thyroid function",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 여자가 2기 유방암으로 절제수술을 받았다. 검사 결과, 호르몬수용체(HR)와 사람표피성장인자수용체2(HER2)는 모두 음성이다. 수술 후 예정된 보조항암화학요법은 다음과 같다.\n독소루비신(doxorubicin) 60 mg/m2 제1일\n시클로포스파미드(cyclophosphamide) 600 mg/m2 제1일\n\nQuestion: 항암제 유발 급성구역구토를 예방하기 위하여 보조항암화학요법 전에 투여하는 적절한 약물요법은?\n\n① 덱사메타손(dexamethasone)+메토클로프라미드(metoclopramide)\n② 덱사메타손+온단세트론(ondansetron)\n③ 아프레피탄트(aprepitant)+온단세트론+덱사메타손\n④ 아프레피탄트+온단세트론+그라니세트론(granisetron)\n⑤ 온단세트론+메토클로프라미드+로라제팜(lorazepam)",
        "question_text": "A 58-year-old woman underwent a mastectomy for stage II breast cancer. Test results show that both hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) are negative. The planned adjuvant chemotherapy after surgery is as follows:\nDoxorubicin 60 mg/m2 on Day 1\nCyclophosphamide 600 mg/m2 on Day 1\n\nQuestion: What is the appropriate drug therapy to be administered before adjuvant chemotherapy to prevent chemotherapy-induced acute nausea and vomiting?\n\n① Dexamethasone + Metoclopramide\n② Dexamethasone + Ondansetron\n③ Aprepitant + Ondansetron + Dexamethasone\n④ Aprepitant + Ondansetron + Granisetron\n⑤ Ondansetron + Metoclopramide + Lorazepam",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 얼굴에 가려움증과 발진이 나타난 27세 여자가 아토피피부염으로 진단받았다. 피부에 진물이나 감염의 징후는 없다. 적절한 치료약은?\n\n① 무피로신(mupirocin) 연고\n② 타크롤리무스(tacrolimus) 0.1% 연고\n③ 히드로코르티손(hydrocortisone) 1% 크림\n④ 아자티오프린(azathioprine) 정제\n⑤ 메틸프레드니솔론(methylprednisolone) 정제뒷면 계속",
        "question_text": "Question: A 27-year-old woman presenting with facial itching and rash has been diagnosed with atopic dermatitis. There are no signs of oozing or infection on the skin. What is the appropriate treatment?\n\n① Mupirocin ointment\n② Tacrolimus 0.1% ointment\n③ Hydrocortisone 1% cream\n④ Azathioprine tablets\n⑤ Methylprednisolone tablets\n\n(Continued on the back)",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 55세 남자에게 최근 왼쪽 눈의 시력이 저하되고 뿌옇게 보이는 증상이 발생하였다. 병원에서 측정한 안압이 25 mmHg였고, 개방각녹내장으로 진단되었다. 적절한 치료약은?\n\n① 만니톨(mannitol) 주사제\n② 아세타졸아미드(acetazolamide) 정제\n③ 티몰롤(timolol) 점안제\n④ 아트로핀(atropine) 점안제\n⑤ 플루오로메톨론(fluorometholone) 점안제",
        "question_text": "Question: A 55-year-old man recently experienced decreased vision and blurred sight in his left eye. His intraocular pressure measured at the hospital was 25 mmHg, and he was diagnosed with open-angle glaucoma. What is the appropriate treatment medication?\n\n① Mannitol injection\n② Acetazolamide tablet\n③ Timolol eye drops\n④ Atropine eye drops\n⑤ Fluorometholone eye drops",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 68세 남자가 지난 10일 동안 장폐쇄로 금식하였다. 정맥으로 영양공급을 시작할 때 발생할 수 있는 재주입증후군(refeeding syndrome)을 확인하기 위해 혈중농도 모니터링이 필요한 것은?\n\n① 인\n② 요산\n③ 혈소판\n④ 트로포닌\n⑤ 호모시스테인",
        "question_text": "Question: A 68-year-old man has been fasting for the past 10 days due to intestinal obstruction. Which of the following blood concentrations should be monitored to check for refeeding syndrome when starting intravenous nutrition?\n\n① Phosphorus\n② Uric acid\n③ Platelets\n④ Troponin\n⑤ Homocysteine",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: ‘최적의 근거중심약료를 제공하여, 약사서비스를 이용하는 사람들의 요구를 충족하는 약무’를 의미하는 것은?\n\n① Good Supply Practice(GSP)\n② Good Clinical Practice(GCP)\n③ Good Pharmacy Practice(GPP)\n④ Good Laboratory Practice(GLP)\n⑤ Good Manufacturing Practice(GMP)",
        "question_text": "Question: Which of the following refers to 'pharmacy practice that meets the needs of people using pharmaceutical services by providing optimal evidence-based pharmaceutical care'?\n\n① Good Supply Practice (GSP)\n② Good Clinical Practice (GCP)\n③ Good Pharmacy Practice (GPP)\n④ Good Laboratory Practice (GLP)\n⑤ Good Manufacturing Practice (GMP)",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 약사가 환자상담 후 중재서비스를 FARM 형식으로 기록하고자 한다. 다음 내용이 들어갈 항목은?\n\n본태성고혈압 환자가 에날라프릴(enalapril) 정 10 mg을 1달간 복용하였음에도 불구하고 혈압이 160/100 mmHg으로서 조절되지 않은 것은, 기침 부작용으로 환자가 약을 제대로 복용하지 않았기 때문인 것으로 보임.\n\n① Findings\n② Assessment\n③ Resolution\n④ Recommendation\n⑤ Monitoring",
        "question_text": "Question: A pharmacist wants to record the intervention service after patient counseling in FARM format. Which of the following items should this content be included under?\n\nA patient with essential hypertension has been taking enalapril 10 mg tablets for one month, but their blood pressure remains uncontrolled at 160/100 mmHg. It appears that this is because the patient has not been taking the medication properly due to the side effect of coughing.\n\n① Findings\n② Assessment\n③ Resolution\n④ Recommendation\n⑤ Monitoring",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 암성통증이 있는 55세 환자가 아세트아미노펜(acetaminophen) 서방정 650 mg을 1정씩 1일 3회, 옥시코돈(oxycodone) CR정 20 mg을 1정씩 1일 2회 복용하고 3일 뒤, 심한 변비가 생겼다. ‘약물관련문제’ 중 어디에 해당하는가?\n\n① 용량 과다\n② 용량 부족\n③ 약물상호작용 발생\n④ 약물이상반응 발생\n⑤ 비효과적인 약물 사용",
        "question_text": "Question: A 55-year-old patient with cancer pain has been taking acetaminophen extended-release 650 mg, 1 tablet 3 times a day, and oxycodone CR 20 mg, 1 tablet twice a day. After 3 days, the patient developed severe constipation. Which of the following 'drug-related problems' does this correspond to?\n\n① Excessive dosage\n② Insufficient dosage\n③ Occurrence of drug interaction\n④ Occurrence of adverse drug reaction\n⑤ Ineffective use of medication",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n54세 남자가 본태성고혈압과 이상지질혈증의 치료와, 관상\n동맥질환의 예방을 목적으로, 최근 다음과 같은 처방약 복용을 시작하였다.\n\n| 처방의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 심바스타틴(simvastatin) 정 20 mg | 1 | 1 |\n| 아스피린(aspirin) 정 100 mg | 1 | 1 |\n| 암로디핀(amlodipine) 정 5 mg | 1 | 1 |\n| 카르베딜롤(carvedilol) 정 12.5 mg | 1 | 1 |\n| 히드로클로로티아지드(hydrochlorothiazide) 정 25 mg | 1 | 1 |\n\nQuestion: 부작용을 예방하기 위하여 오전에 복용하도록 해야 하는 약은?\n\n① 아스피린\n② 암로디핀\n③ 심바스타틴\n④ 카르베딜롤\n⑤ 히드로클로로티아지드",
        "question_text": "A 54-year-old male recently started taking the following prescription medications for the treatment of essential hypertension and dyslipidemia, and for the prevention of coronary artery disease.\n\n| Prescription medication name | Dose per administration | Frequency per day |\n|---|---|---|\n| Simvastatin tablet 20 mg | 1 | 1 |\n| Aspirin tablet 100 mg | 1 | 1 |\n| Amlodipine tablet 5 mg | 1 | 1 |\n| Carvedilol tablet 12.5 mg | 1 | 1 |\n| Hydrochlorothiazide tablet 25 mg | 1 | 1 |\n\nQuestion: Which medication should be taken in the morning to prevent side effects?\n\n① Aspirin\n② Amlodipine\n③ Simvastatin\n④ Carvedilol\n⑤ Hydrochlorothiazide",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n54세 남자가 본태성고혈압과 이상지질혈증의 치료와, 관상\n동맥질환의 예방을 목적으로, 최근 다음과 같은 처방약 복용을 시작하였다.\n\n| 처방의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 심바스타틴(simvastatin) 정 20 mg | 1 | 1 |\n| 아스피린(aspirin) 정 100 mg | 1 | 1 |\n| 암로디핀(amlodipine) 정 5 mg | 1 | 1 |\n| 카르베딜롤(carvedilol) 정 12.5 mg | 1 | 1 |\n| 히드로클로로티아지드(hydrochlorothiazide) 정 25 mg | 1 | 1 |\n\nQuestion: 의학정보실 약사가 이상지질혈증 치료와 관상동맥질환 예방의 상관성에 관한 임상시험 정보 제공을 의뢰받았다. 해당 연구결과에 관한 초록과 서지 정보를 검색하는 데 적절한 정보원은?\n\n① PubMed\n② AHFS Drug Information\n③ Physician’s Desk Reference\n④ Drug Facts & Comparisons\n⑤ Lexi-Comp Drug Information Handbook",
        "question_text": "A 54-year-old male recently started taking the following prescription medications for the treatment of essential hypertension and dyslipidemia, and for the prevention of coronary artery disease.\n\n| Prescription Drug Name | Dose per Administration | Frequency per Day |\n|---|---|---|\n| Simvastatin tablet 20 mg | 1 | 1 |\n| Aspirin tablet 100 mg | 1 | 1 |\n| Amlodipine tablet 5 mg | 1 | 1 |\n| Carvedilol tablet 12.5 mg | 1 | 1 |\n| Hydrochlorothiazide tablet 25 mg | 1 | 1 |\n\nQuestion: A pharmacist in the medical information department was asked to provide clinical trial information on the correlation between dyslipidemia treatment and coronary artery disease prevention. Which of the following is the most appropriate source for searching abstracts and bibliographic information on relevant research results?\n\n① PubMed\n② AHFS Drug Information\n③ Physician's Desk Reference\n④ Drug Facts & Comparisons\n⑤ Lexi-Comp Drug Information Handbook",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 처방전 양식에서 ‘의약품 조제 명세’에 기입하는 것은?\n\n① 질병분류기호\n② 약국 전화번호\n③ 조제 시 참고사항\n④ 조제 약사의 면허번호\n⑤ 처방약의 대체조제 내용",
        "question_text": "Question: What is entered in the 'Medication Dispensing Details' section of a prescription form?\n\n① Disease classification code\n② Pharmacy phone number\n③ Notes for dispensing\n④ Dispensing pharmacist's license number\n⑤ Details of substitute medication dispensing",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 처방전에 산제로 조제하라는 지시가 있더라도, 제형의 특성상 산제로 조제하지 말아야 하므로 의사에게 문의해야 하는 약은?\n\n① 디곡신(digoxin) 정\n② 메트포르민(metformin) 정\n③ 판토프라졸(pantoprazole) 정\n④ 피나스테리드(finasteride) 정\n⑤ 메트로니다졸(metronidazole) 정",
        "question_text": "Question: Even if the prescription instructs to prepare as a powder, which of the following medications should not be prepared as a powder due to its formulation characteristics, and thus requires consultation with the physician?\n\n① Digoxin tablet\n② Metformin tablet\n③ Pantoprazole tablet\n④ Finasteride tablet\n⑤ Metronidazole tablet",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 2015년 발표된 Beers의 기준에 근거하여 75세 노인 환자의 처방을 검토할 때, 부적절한 처방이므로 의사에게 문의해야 하는 약은?\n\n① 가바펜틴(gabapentine) 정\n② 글리메피리드(glimepiride) 정\n③ 니페디핀(nifedipine) OROS 정\n④ 아미트리프틸린(amitriptyline) 정\n⑤ 에스시탈로프람(escitalopram) 정",
        "question_text": "Question: Based on the Beers Criteria published in 2015, when reviewing the prescription for a 75-year-old elderly patient, which medication is considered inappropriate and should be inquired about with the doctor?\n\n① Gabapentin tablet\n② Glimepiride tablet\n③ Nifedipine OROS tablet\n④ Amitriptyline tablet\n⑤ Escitalopram tablet",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 10세 남아의 처방에서 조제 전 의약품안전사용서비스(DUR) 점검과 관련하여 의사에게 문의해야 하는 약은?\n\n| 처방의약품의 명칭 | 1회 투약량 | 1일 투여횟수 | 용법 |\n|---|---|---|---|\n| 미노사이클린(minocycline) 캡슐 50 mg | 1 | 2 | 경구 |\n| 세티리진(cetirizine) 정 10 mg | 1 | 1 | 경구 |\n| 아세트아미노펜(acetaminophen) 정 160 mg | 1 | 3 | 필요시 |\n| 정장제(Bacillus subtilis 등) 캡슐 125 mg | 1 | 2 | 경구 |\n| 피메크로리무스(pimecrolimus) 크림 1% | - | - | 외용 |\n\n① 정장제 캡슐\n② 세티리진 정\n③ 미노사이클린 캡슐\n④ 아세트아미노펜 정\n⑤ 피메크로리무스 크림",
        "question_text": "Question: In the prescription for a 10-year-old boy, which medication should be inquired about to the doctor regarding the Drug Utilization Review (DUR) check before dispensing?\n\n| Prescribed medication name | Single dose | Daily frequency | Administration method |\n|---|---|---|---|\n| Minocycline capsule 50 mg | 1 | 2 | Oral |\n| Cetirizine tablet 10 mg | 1 | 1 | Oral |\n| Acetaminophen tablet 160 mg | 1 | 3 | As needed |\n| Probiotics (Bacillus subtilis, etc.) capsule 125 mg | 1 | 2 | Oral |\n| Pimecrolimus cream 1% | - | - | Topical |\n\n① Probiotics capsule\n② Cetirizine tablet\n③ Minocycline capsule\n④ Acetaminophen tablet\n⑤ Pimecrolimus cream",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 처방 검토 시 약물 선택의 적절성에 관하여 의사에게 문의해야 하는 경우는?\n\n① 탈모 – 피나스테리드(finasteride) 1 mg 정\n② HIV 감염증 – 라미부딘(lamivudine) 150 mg 정\n③ 수술 시 근이완 – 베쿠로늄(vecuronium) 60 mg 주\n④ 피부 가려움증 – 히드록시유레아(hydroxyurea) 250 mg 캡슐\n⑤ 류마티스관절염 – 메토트렉세이트(methotrexate) 2.5 mg 정",
        "question_text": "Question: In which case should you consult the doctor about the appropriateness of drug selection during prescription review?\n\n① Hair loss – Finasteride 1 mg tablet\n② HIV infection – Lamivudine 150 mg tablet\n③ Muscle relaxation during surgery – Vecuronium 60 mg injection\n④ Skin itching – Hydroxyurea 250 mg capsule\n⑤ Rheumatoid arthritis – Methotrexate 2.5 mg tablet",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 폐암 환자에게 수술 후 다음과 같은 항암화학요법이 처방되었다.\n• 파클리탁셀(paclitaxel) 주 200 mg/m^2 제1일\n• 카보플라틴(carboplatin) 주 AUC 6 제1일\n• 21일마다 4주기 투여\n\nQuestion: 이 항암화학요법에서 고려해야 할 보조치료제는?\n\n① 메스나(mesna) 주\n② 로이코보린(leucovorin) 주\n③ 돔페리돈(domperidone) 정\n④ 아세트아미노펜(acetaminophen) 정\n⑤ 클로르페니라민(chlorpheniramine) 정",
        "question_text": "A 58-year-old lung cancer patient was prescribed the following chemotherapy regimen after surgery:\n• Paclitaxel 200 mg/m^2 IV on Day 1\n• Carboplatin AUC 6 IV on Day 1\n• Administered every 21 days for 4 cycles\n\nQuestion: Which supportive care medication should be considered for this chemotherapy regimen?\n\n① Mesna injection\n② Leucovorin injection\n③ Domperidone tablet\n④ Acetaminophen tablet\n⑤ Chlorpheniramine tablet",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 폐암 환자에게 수술 후 다음과 같은 항암화학요법이 처방되었다.\n• 파클리탁셀(paclitaxel) 주 200 mg/m^2 제1일\n• 카보플라틴(carboplatin) 주 AUC 6 제1일\n• 21일마다 4주기 투여\n\nQuestion: 이 환자의 카보플라틴 용량을 결정하기 위하여 필요한 정보는?\n\n① 체질량지수\n② 크레아티닌 청소율\n③ 헤모글로빈 혈중 농도\n④ 카보플라틴 혈중 농도\n⑤ 알라닌아미노전이효소(ALT) 혈중 농도",
        "question_text": "A 58-year-old lung cancer patient was prescribed the following chemotherapy regimen after surgery:\n• Paclitaxel 200 mg/m^2 IV on Day 1\n• Carboplatin AUC 6 IV on Day 1\n• Administered every 21 days for 4 cycles\n\nQuestion: What information is necessary to determine the carboplatin dose for this patient?\n\n① Body Mass Index\n② Creatinine Clearance\n③ Hemoglobin Blood Concentration\n④ Carboplatin Blood Concentration\n⑤ Alanine Aminotransferase (ALT) Blood Concentration",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: Unit dose system(UDS) 적용을 통해 얻을 수 있는 장점은?\n\n① 투약오류 감소\n② 약사 인력 감축\n③ 직접 간호시간 감소\n④ 환자정보 유출 방지\n⑤ 투여약별 단계적 이중감사 감소",
        "question_text": "Question: What is an advantage that can be gained through the application of the Unit Dose System (UDS)?\n\n① Reduction in medication errors\n② Reduction in pharmacist workforce\n③ Decrease in direct nursing time\n④ Prevention of patient information leakage\n⑤ Reduction in step-by-step double-checking for each administered medication",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 항암화학요법 주사약의 무균조제에 있어서 적절한 행위는?\n\n① 루어록(luer-lock) 주사기나 수액세트를 사용함\n② 투과성이 높은 섬유로 만든, 소매가 긴 보호복을 착용함\n③ 항암제가 피부에 묻었을 때 비누를 사용하지 않고 물로만 세척함\n④ Class 100 환경의 항암제 전용 수평형 무균조제대 내에서 조제함\n⑤ 무균조제대 전면의 작업대 가장자리로부터 5 cm 안쪽에서 조제함",
        "question_text": "Question: Which of the following is an appropriate practice in the aseptic preparation of injectable anticancer chemotherapy drugs?\n\n① Using luer-lock syringes or infusion sets\n② Wearing long-sleeved protective clothing made of highly permeable fibers\n③ Washing only with water, without using soap, when anticancer drugs come into contact with the skin\n④ Preparing in a Class 100 environment using a horizontal laminar flow hood dedicated to anticancer drugs\n⑤ Preparing 5 cm inside from the edge of the work surface at the front of the laminar flow hood",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 처방전에서 1회 투약량이 0.1정이기 때문에 부형제를 넣어 산제로 조제하려고 할 때, 유당(lactose)과의 배합이 금기인 약은?\n\n① 폴산(folic acid) 정\n② 디곡신(digoxin) 정\n③ 피리독신(pyridoxine) 정\n④ 이소니아지드(isoniazid) 정\n⑤ 피라진아미드(pyrazinamide) 정",
        "question_text": "Question: When preparing a powder formulation by adding an excipient because the single dose on the prescription is 0.1 tablet, which of the following drugs is contraindicated for mixing with lactose?\n\n① Folic acid tablet\n② Digoxin tablet\n③ Pyridoxine tablet\n④ Isoniazid tablet\n⑤ Pyrazinamide tablet",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 입원 환자의 정맥영양수액에 칼슘과 인을 혼합하여 조제할 때, 칼슘과 인의 침전을 최소화하기 위한 방법으로 적절한 것은?\n\n① 혼합액을 알칼리화함\n② 혼합액을 상온에 보관함\n③ 먼저 칼슘을 영양수액에 혼합하고, 인을 나중에 혼합함\n④ 칼슘과 인의 농도 합이 45 mEq/L를 초과하도록 혼합함\n⑤ 칼슘제제로 글루콘산칼슘(calcium gluconate) 주사약을 선택하여 혼합함",
        "question_text": "Question: When preparing intravenous nutrition fluids for hospitalized patients by mixing calcium and phosphorus, which of the following methods is appropriate to minimize the precipitation of calcium and phosphorus?\n\n① Alkalinize the mixture\n② Store the mixture at room temperature\n③ Mix calcium into the nutrition fluid first, then mix in phosphorus later\n④ Mix so that the combined concentration of calcium and phosphorus exceeds 45 mEq/L\n⑤ Choose calcium gluconate injection as the calcium preparation for mixing",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 나란호 알고리듬(Naranjo algorithm)에 따라 약물이상반응 인과성을 평가할 때, 인과성이 가장 높다고 판단되는 정보는?\n\n① 의심되는 약을 투여한 후에 이상반응이 발생함\n② 이상반응이 객관적인 검사에 의하여 확인되지 않음\n③ 의심되는 약을 중단한 후에도 이상반응이 호전되지 않음\n④ 이전에 동일한 약에 노출되었을 때 유사한 반응을 보이지 않음\n⑤ 의심되는 약이 이러한 이상반응을 잘 일으키는 것으로 보고된 바가 없음",
        "question_text": "Question: According to the Naranjo algorithm, which information is considered to have the highest causality when evaluating adverse drug reactions?\n\n① The adverse reaction occurred after the suspected drug was administered\n② The adverse reaction was not confirmed by objective tests\n③ The adverse reaction did not improve after discontinuing the suspected drug\n④ Similar reactions were not observed when previously exposed to the same drug\n⑤ The suspected drug has not been reported to commonly cause such adverse reactions",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 신경병증성 통증(neuropathic pain)과 뇌전증 치료에 사용하는 약임을 숙지하고 복약지도를 해야 하는 약은?\n\n① 발프로산(valproic acid) 정\n② 라모트리진(lamotrigine) 정\n③ 클로나제팜(clonazepam) 정\n④ 프레가발린(pregabalin) 캡슐\n⑤ 페노바르비탈(phenobarbital) 정",
        "question_text": "Question: Which medication should be kept in mind for patient counseling as it is used for the treatment of neuropathic pain and epilepsy?\n\n① Valproic acid tablet\n② Lamotrigine tablet\n③ Clonazepam tablet\n④ Pregabalin capsule\n⑤ Phenobarbital tablet",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 아세트아미노펜(acetaminophen), 이소메텝텐(isometheptene), 디크로랄페나존(dichloralphenazone) 복합제에 대한 복약지도를 할 내용으로 옳은 것은?\n\n① 불면증 유발\n② 편두통 유발\n③ 1일 최대용량 4캡슐\n④ 혈관 확장 부작용 유발\n⑤ 고혈압 환자 사용 금기",
        "question_text": "Question: Which of the following is correct information for patient counseling regarding the combination drug containing acetaminophen, isometheptene, and dichloralphenazone?\n\n① Causes insomnia\n② Triggers migraines\n③ Maximum daily dose is 4 capsules\n④ Causes blood vessel dilation side effect\n⑤ Contraindicated for hypertensive patients",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 가래가 감기의 주된 증상인 성인 환자에게 추천할 일반의약품의 성분은?\n\n① 락티톨(lactitol)\n② 스코폴라민(scopolamine)\n③ 폴리카르보필(polycarbophil)\n④ 디멘히드리네이트(dimenhydrinate)\n⑤ 엘-카르보시스테인(L-carbocysteine)",
        "question_text": "Question: What is the recommended ingredient in over-the-counter medication for an adult patient whose main symptom of a cold is phlegm?\n\n① Lactitol\n② Scopolamine\n③ Polycarbophil\n④ Dimenhydrinate\n⑤ L-carbocysteine",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 발 무좀 환자에게 단 1회 사용할 수 있는 외용 일반의약품의 성분은?\n\n① 시클로피록스(ciclopirox)\n② 테르비나핀(terbinafine)\n③ 케토코나졸(ketoconazole)\n④ 이트라코나졸(itraconazole)\n⑤ 클로트리마졸(clotrimazole)",
        "question_text": "Question: Which of the following is an active ingredient in an over-the-counter topical medication that can be used only once for patients with athlete's foot?\n\n① Ciclopirox\n② Terbinafine\n③ Ketoconazole\n④ Itraconazole\n⑤ Clotrimazole",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 장기간 사용할 때의 부작용이 폐섬유증, 갑상선이상, 간기능이상, 피부변색이라고 복약지도를 해야 하는 약은?\n\n① 디곡신(digoxin) 정\n② 메트포르민(metformin) 정\n③ 아미오다론(amiodarone) 정\n④ 아토르바스타틴(atorvastatin) 정\n⑤ 이소트레티노인(isotretinoin) 캡슐",
        "question_text": "Question: Which medication requires patient counseling about long-term side effects including pulmonary fibrosis, thyroid dysfunction, liver function abnormalities, and skin discoloration?\n\n① Digoxin tablets\n② Metformin tablets\n③ Amiodarone tablets\n④ Atorvastatin tablets\n⑤ Isotretinoin capsules",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 다음과 같은 결핵약 처방을 받은 27세 여자에게 복약지도를 해야 하는 내용은?\n\n| 처방의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 이소니아지드(isoniazid) 정 100 mg | 4 | 1 |\n| 리팜피신(rifampicin) 정 450 mg | 1 | 1 |\n| 에탐부톨(ethambutol) 정 400 mg | 2 | 1 |\n| 피리독신(pyridoxine) 정 50 mg | 1 | 1 |\n\n① 공복에 한꺼번에 복용한다.\n② 대변이 흑색으로 변색될 수 있다.\n③ 결핵 증상이 개선되면 복용을 중단한다.\n④ 피리독신은 빈혈 예방을 위하여 복용한다.\n⑤ 에탐부톨은 경구피임약의 효과를 감소시킨다.",
        "question_text": "Question: What medication guidance should be given to a 27-year-old woman who received the following tuberculosis prescription?\n\n| Prescription Drug Name | Dosage per Administration | Frequency per Day |\n|---|---|---|\n| Isoniazid tablet 100 mg | 4 | 1 |\n| Rifampicin tablet 450 mg | 1 | 1 |\n| Ethambutol tablet 400 mg | 2 | 1 |\n| Pyridoxine tablet 50 mg | 1 | 1 |\n\n① Take all medications together on an empty stomach.\n② Stool may turn black in color.\n③ Discontinue medication when tuberculosis symptoms improve.\n④ Pyridoxine is taken to prevent anemia.\n⑤ Ethambutol reduces the effectiveness of oral contraceptives.",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 그림과 같이 티오트로퓸(tiotropium)이 포함된 흡입제의 사용 방법으로 옳은 것은?\n\n<Data (confidential)>\n\n① 흡입하기 전 숨을 충분히 들이마신다.\n② 1일 1회, 1회 2번 분사하여 흡입한다.\n③ 개봉하고 1개월이 경과한 약은 폐기한다.\n④ 흡입할 때 가능하면 강하고 빠르게 들이마셔야 한다.\n⑤ 버튼을 누르면서 투명몸체를 딸깍 소리가 날 때까지 돌린다.",
        "question_text": "Question: Which of the following is the correct method for using an inhaler containing tiotropium, as shown in the figure?\n\n① Inhale deeply before using the inhaler.\n② Inhale once daily, with two puffs per use.\n③ Discard the medication one month after opening.\n④ When inhaling, breathe in as forcefully and quickly as possible.\n⑤ Press the button while turning the transparent body until it clicks.",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 만성비염으로 인한 코막힘 증상을 완화하고 부비동의 섬모운동을 정상화하는 한약제제는?\n\n① 삼소음(蔘蘇飮)\n② 당귀작약산(當歸芍藥散)\n③ 마행감석탕(麻杏甘石湯)\n④ 배농산급탕(排膿散及湯)\n⑤ 갈근탕가천궁신이(葛根湯加川芎辛夷)",
        "question_text": "Question: Which herbal medicine formulation alleviates nasal congestion caused by chronic rhinitis and normalizes ciliary movement in the paranasal sinuses?\n\n① Samsoeumm (蔘蘇飮)\n② Danggwijagyaksan (當歸芍藥散)\n③ Mahaenggamseok-tang (麻杏甘石湯)\n④ Baenongsan-geup-tang (排膿散及湯)\n⑤ Galgeun-tang-gacheongungs-inyi (葛根湯加川芎辛夷)",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압과 심근경색 병력이 있는 60세 남자가 지난 3년간 약을 다음과 같이 복용하였으며, 복약 이행도는 높다. 환자가 발기부전 치료 목적으로 ‘실데나필(sildenafil) 정 50 mg 필요시 복용’ 처방을 받아 약국을 방문하였다.\n\n| 처방의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 발사르탄(valsartan) 정 80mg | 1 | 2 |\n| 아스피린(aspirin) 정 100mg | 1 | 1 |\n| 아테놀올(atenolol) 정 100mg | 1 | 1 |\n| 클로피도그렐(clopidogrel) 정 75mg | 1 | 1 |\n| 이소소르비드일질산염(isosorbide mononitrate) 정 20mg | 1 | 2 |\n\nQuestion: 실데나필과 병용하는 것이 금기이므로 복약지도가 필요한 약은?\n\n① 발사르탄 정\n② 아스피린 정\n③ 아테놀올 정\n④ 클로피도그렐 정\n⑤ 이소소르비드일질산염 정",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 60-year-old man with a history of hypertension and myocardial infarction has been taking the following medications for the past 3 years, with high medication adherence. The patient visited a pharmacy with a prescription for \"sildenafil 50 mg tablet to be taken as needed\" for the treatment of erectile dysfunction.\n\n| Prescription medication name | Dose per administration | Frequency per day |\n|---|---|---|\n| Valsartan tablet 80mg | 1 | 2 |\n| Aspirin tablet 100mg | 1 | 1 |\n| Atenolol tablet 100mg | 1 | 1 |\n| Clopidogrel tablet 75mg | 1 | 1 |\n| Isosorbide mononitrate tablet 20mg | 1 | 2 |\n\nQuestion: Which medication requires patient counseling as it is contraindicated for use with sildenafil?\n\n① Valsartan tablet\n② Aspirin tablet\n③ Atenolol tablet\n④ Clopidogrel tablet\n⑤ Isosorbide mononitrate tablet",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압과 심근경색 병력이 있는 60세 남자가 지난 3년간 약을 다음과 같이 복용하였으며, 복약 이행도는 높다. 환자가 발기부전 치료 목적으로 ‘실데나필(sildenafil) 정 50 mg 필요시 복용’ 처방을 받아 약국을 방문하였다.\n\n| 처방의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 발사르탄(valsartan) 정 80mg | 1 | 2 |\n| 아스피린(aspirin) 정 100mg | 1 | 1 |\n| 아테놀올(atenolol) 정 100mg | 1 | 1 |\n| 클로피도그렐(clopidogrel) 정 75mg | 1 | 1 |\n| 이소소르비드일질산염(isosorbide mononitrate) 정 20mg | 1 | 2 |\n\nQuestion: 갑자기 복용을 중지할 경우 급성 빈맥, 고혈압, 허혈 증상이 발생할 수 있으므로 이에 대하여 복약지도가 필요한 약은?\n\n① 발사르탄 정\n② 아스피린 정\n③ 아테놀올 정\n④ 클로피도그렐 정\n⑤ 이소소르비드일질산염 정",
        "question_text": "A 60-year-old man with a history of hypertension and myocardial infarction has been taking the following medications for the past 3 years, with high medication adherence. The patient visited a pharmacy with a prescription for \"sildenafil 50 mg tablet to be taken as needed\" for the treatment of erectile dysfunction.\n\n| Prescription medication name | Dose per administration | Frequency per day |\n|---|---|---|\n| Valsartan tablet 80mg | 1 | 2 |\n| Aspirin tablet 100mg | 1 | 1 |\n| Atenolol tablet 100mg | 1 | 1 |\n| Clopidogrel tablet 75mg | 1 | 1 |\n| Isosorbide mononitrate tablet 20mg | 1 | 2 |\n\nQuestion: Which medication requires patient counseling regarding the risk of acute tachycardia, hypertension, and ischemic symptoms if suddenly discontinued?\n\n① Valsartan tablet\n② Aspirin tablet\n③ Atenolol tablet\n④ Clopidogrel tablet\n⑤ Isosorbide mononitrate tablet",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 의약품 제조용수공급시스템을 검증하고 문서화하는 것은?\n\n① 세척 밸리데이션\n② 공정 밸리데이션\n③ 시험방법 밸리데이션\n④ 제조지원설비 밸리데이션\n⑤ 컴퓨터시스템 밸리데이션",
        "question_text": "Question: What is the validation and documentation of the water supply system for pharmaceutical manufacturing?\n\n① Cleaning validation\n② Process validation\n③ Test method validation\n④ Manufacturing support facility validation\n⑤ Computer system validation",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 의약품 제조 및 품질관리 기준(KGMP)에서 정하는 제조관리기준서에 포함되는 내용은?\n\n① 안정성시험\n② 작업소의 청정도관리\n③ 표준품 및 시약의 관리\n④ 제조시설의 세척 및 평가\n⑤ 제품 출하 시의 선입선출방법",
        "question_text": "Question: Which of the following is included in the Manufacturing Control Standards as specified in the Korean Good Manufacturing Practice (KGMP) for pharmaceuticals?\n\n① Stability testing\n② Cleanliness management of work areas\n③ Management of reference standards and reagents\n④ Cleaning and evaluation of manufacturing facilities\n⑤ First-in, first-out method for product release",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 주사제의 무균 충전과 미생물 시험을 수행하는 지역의 청정도 등급은?\n\n① A등급\n② B등급\n③ C등급\n④ D등급\n⑤ 관리대상 외",
        "question_text": "Question: What is the cleanliness grade of the area where aseptic filling of injections and microbial testing are performed?\n\n① Grade A\n② Grade B\n③ Grade C\n④ Grade D\n⑤ Not subject to control",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 멸균하고자 하는 제품의 초기 미생물 수가 103이고, 이 미생물의 해당 멸균법에 대한 D값은 1분이다. 10-6의 비멸균확률(B값)을 달성하기 위해서 요구되는 시간(F값)은?\n\n① 3분\n② 6분\n③ 9분\n④ 12분\n⑤ 15분",
        "question_text": "Question: The initial microbial count of a product to be sterilized is 103, and the D-value of this microorganism for the given sterilization method is 1 minute. What is the required time (F-value) to achieve a probability of non-sterility (B-value) of 10-6?\n\n① 3 minutes\n② 6 minutes\n③ 9 minutes\n④ 12 minutes\n⑤ 15 minutes",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 열에 안정한 대용량 수액제의 제조에서 조제액을 충전하고 밀봉한 후에 일반적으로 적용하는 멸균은?\n\n① 여과멸균\n② 방사선멸균\n③ 고압증기멸균\n④ 오븐식건열멸균\n⑤ 터널식건열멸균",
        "question_text": "Question: In the production of heat-stable large-volume parenteral solutions, what sterilization method is generally applied after filling and sealing the prepared solution?\n\n① Filtration sterilization\n② Radiation sterilization\n③ Autoclave sterilization\n④ Oven dry heat sterilization\n⑤ Tunnel dry heat sterilization",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 세척 밸리데이션에서 대표 오염제품의 복용량에 근거한 잔류허용한도를 설정하는 데 사용되는 후속 제품의 특성은?\n\n① 포장\n② 효능\n③ 보관조건\n④ 제조규모\n⑤ 제조단가",
        "question_text": "Question: In cleaning validation, which characteristic of the subsequent product is used to establish the residual limit based on the dosage of the representative contaminated product?\n\n① Packaging\n② Efficacy\n③ Storage conditions\n④ Manufacturing scale\n⑤ Manufacturing cost",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 팬형 코팅기를 사용한 정제의 코팅 공정에서 거칠어지거나 부서지는 정제가 다수 발생하였다. 이 문제를 개선하기 위해 타정 공정에서 취할 적절한 조치는?\n\n① 경도를 낮춘다.\n② 마손도를 낮춘다.\n③ 두께를 증가시킨다.\n④ 붕해시간을 줄인다.\n⑤ 정제질량을 감소시킨다.",
        "question_text": "Question: During the coating process of tablets using a pan coater, numerous tablets became rough or broken. What is the appropriate measure to take in the tableting process to improve this problem?\n\n① Lower the hardness.\n② Decrease the friability.\n③ Increase the thickness.\n④ Reduce the disintegration time.\n⑤ Decrease the tablet mass.",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 공신력 있는 공급업체로부터 출발원료물질을 25개 용기에 나누어 받았다. 세계보건기구(WHO)에서 권장하는 n-계획에 따라 시료를 채취할 때, 무작위로 선택하는 용기의 수는?\n\n① 2\n② 3\n③ 4\n④ 6\n⑤ 8",
        "question_text": "Question: You received starting materials from a reputable supplier, divided into 25 containers. When sampling according to the n-plan recommended by the World Health Organization (WHO), how many containers should be randomly selected?\n\n① 2\n② 3\n③ 4\n④ 6\n⑤ 8",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 제제균일성시험에서 질량편차시험이 가능한 정제의 1정당 주성분 함량 기준은?\n\n① 25% 미만\n② 25 mg 미만\n③ 25 mg 이상, 25% 이상\n④ 25 mg 이상, 25% 미만\n⑤ 25 mg 미만, 25% 이상",
        "question_text": "Question: What is the criterion for the content of the main ingredient per tablet that allows for mass variation testing in the uniformity of dosage units test?\n\n① Less than 25%\n② Less than 25 mg\n③ 25 mg or more, 25% or more\n④ 25 mg or more, less than 25%\n⑤ Less than 25 mg, 25% or more",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 의약품제조소의 완제의약품 출하승인에 대한 설명으로 옳은 것은?\n\n① 구두 출하승인을 할 수 있다.\n② 제조부서책임자가 출하승인을 한다.\n③ 출하승인서는 내부문건이므로 외부로 발행되지 않는다.\n④ 책임자가 아니어도 교육을 충분히 받으면 출하승인을 할 수 있다.\n⑤ 출하승인은 제품이 GMP에 의해 제조되었다는 것을 보증하는 것이다.",
        "question_text": "Question: Which of the following statements about the release approval of finished pharmaceutical products in a pharmaceutical manufacturing facility is correct?\n\n① Verbal release approval is acceptable.\n② The head of the manufacturing department approves the release.\n③ The release approval document is an internal document and is not issued externally.\n④ Even if not a responsible person, one can approve the release if sufficiently trained.\n⑤ Release approval guarantees that the product was manufactured according to GMP.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: Ministry of Food and Drug Safety 고시 \"Standards for Stability Testing of Drugs, etc.\"에 따라 장기보존시험을 수행할 때, 첫 1년간은 몇 개월마다 측정하는가?\n\n① 3개월\n② 4개월\n③ 5개월\n④ 6개월\n⑤ 9개월",
        "question_text": "Question: According to the Ministry of Food and Drug Safety notification \"Standards for Stability Testing of Drugs, etc.\", how often should measurements be taken during the first year when conducting long-term stability testing?\n\n① Every 3 months\n② Every 4 months\n③ Every 5 months\n④ Every 6 months\n⑤ Every 9 months",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에서 정의한 \"Container\" 중에서 외부환경으로부터 내용물을 보호하는 정도가 높은 것부터 순서대로 나열한 것은?\n\n① Hermetic Container – Sealed Container – Closed Container\n② Hermetic Container – Closed Container – Sealed Container\n③ Sealed Container – Hermetic Container – Closed Container\n④ Closed Container – Hermetic Container – Sealed Container\n⑤ Closed Container – Sealed Container – Hermetic Container",
        "question_text": "Question: According to the definition in the Korean Pharmacopoeia, which of the following lists \"Containers\" in order from the highest to lowest degree of protection from the external environment?\n\n① Hermetic Container – Sealed Container – Closed Container\n② Hermetic Container – Closed Container – Sealed Container\n③ Sealed Container – Hermetic Container – Closed Container\n④ Closed Container – Hermetic Container – Sealed Container\n⑤ Closed Container – Sealed Container – Hermetic Container",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia 의약품각조의 라니티딘염산염 정량법은 액체크로마토그래프법에 따라 시험한다. 이때 사용되는 검출기는?\n\n① 시차굴절계\n② 염광광도검출기\n③ 전자포획검출기\n④ 불꽃이온화검출기\n⑤ 자외부흡광광도계",
        "question_text": "Question: According to the Korean Pharmacopoeia, the assay method for Ranitidine Hydrochloride in the drug monographs is performed using liquid chromatography. Which detector is used in this method?\n\n① Differential refractometer\n② Flame photometric detector\n③ Electron capture detector\n④ Flame ionization detector\n⑤ UV spectrophotometer",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 지방소화력시험법에서 쓰는 표준 기질은?\n\n① 간유\n② 젤라틴\n③ 피마자유\n④ 올리브유\n⑤ 유동파라핀",
        "question_text": "Question: What is the standard substrate used in the fat digestibility test?\n\n① Cod liver oil\n② Gelatin\n③ Castor oil\n④ Olive oil\n⑤ Liquid paraffin",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 제조공정에서 공정능력지수를 향상하는 데 필요한 것은?\n\n① 규격상한을 낮춘다.\n② 규격하한을 높인다.\n③ 품질특성치의 산포를 줄인다.\n④ 품질특성치의 평균을 높인다.\n⑤ 품질특성치의 평균을 낮춘다.",
        "question_text": "Question: What is needed to improve the process capability index in the manufacturing process?\n\n① Lower the upper specification limit.\n② Raise the lower specification limit.\n③ Reduce the dispersion of quality characteristic values.\n④ Increase the average of quality characteristic values.\n⑤ Decrease the average of quality characteristic values.",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 동일한 정제를 두 종류의 타정기로 생산한 후, 표본에 의하여 두 모분산들의 동일성 여부를 판단할 수 있는 검정방법은?\n\n① F-검정\n② t-검정\n③ Q시험\n④ Z-검정\n⑤ 사후검정",
        "question_text": "Question: After producing the same tablet using two types of tablet presses, which test method can be used to determine whether the two population variances are equal based on samples?\n\n① F-test\n② t-test\n③ Q-test\n④ Z-test\n⑤ Post-hoc test",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nKorean Pharmacopoeia 의약품각조 중 d-클로르페니라민말레산염에 대한 내용의 일부이다.\n\n[확인시험]\n이 약 및 d-클로르페니라민말레산염표준품의 0.1 mol/L 염산시약용액(3 → 100000)을 가지고 자외가시부흡광도 측정법에 따라 측정할 때 같은 파장에서 같은 강도의 흡수를 나타낸다.\n\n[흡광도]\nE 1% 1 cm (265 nm): 210~220 (건조한 다음 5 mg, 0.25 mol/L 황산시액, 250 mL)\n\nQuestion: 확인시험에서 d-클로르페니라민말레산염 표준액을 제조하는 방법은?\n\n① 표준품 30 g을 용매에 녹여 전체량을 1 L로 한다.\n② 표준품 3 g을 용매에 녹여 전체량을 1 L로 한다.\n③ 표준품 300 mg을 용매에 녹여 전체량을 1 L로 한다.\n④ 표준품 30 mg을 용매에 녹여 전체량을 1 L로 한다.\n⑤ 표준품 3 mg을 용매에 녹여 전체량을 1 L로 한다.",
        "question_text": "This is a part of the monograph for d-Chlorpheniramine Maleate from the Korean Pharmacopoeia.\n\n[Identification]\nWhen the solution of this drug and d-Chlorpheniramine Maleate Reference Standard in 0.1 mol/L hydrochloric acid TS (3 in 100000) are examined as directed under Ultraviolet-visible Spectrophotometry, the spectra exhibit similar intensities of absorption at the same wavelengths.\n\n[Absorbance]\nE 1% 1 cm (265 nm): 210-220 (after drying, 5 mg, 0.25 mol/L sulfuric acid TS, 250 mL)\n\nQuestion: What is the method for preparing the standard solution of d-Chlorpheniramine Maleate in the identification test?\n\n① Dissolve 30 g of the reference standard in the solvent and make up to 1 L.\n② Dissolve 3 g of the reference standard in the solvent and make up to 1 L.\n③ Dissolve 300 mg of the reference standard in the solvent and make up to 1 L.\n④ Dissolve 30 mg of the reference standard in the solvent and make up to 1 L.\n⑤ Dissolve 3 mg of the reference standard in the solvent and make up to 1 L.",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nKorean Pharmacopoeia 의약품각조 중 d-클로르페니라민말레산염에 대한 내용의 일부이다.\n\n[확인시험]\n이 약 및 d-클로르페니라민말레산염표준품의 0.1 mol/L 염산시약용액(3 → 100000)을 가지고 자외가시부흡광도 측정법에 따라 측정할 때 같은 파장에서 같은 강도의 흡수를 나타낸다.\n\n[흡광도]\nE 1% 1 cm (265 nm): 210~220 (건조한 다음 5 mg, 0.25 mol/L 황산시액, 250 mL)\n\nQuestion: 흡광도 시험에서 검액 제조를 위해 이 약을 건조하는 온도 조건은?\n\n① 미온\n② 상온\n③ 실온\n④ 표준온도\n⑤ 건조감량항 온도",
        "question_text": "This is a part of the monograph for d-Chlorpheniramine Maleate from the Korean Pharmacopoeia.\n\n[Identification]\nWhen the solution of this drug and d-Chlorpheniramine Maleate Reference Standard in 0.1 mol/L hydrochloric acid TS (3 in 100,000) are examined as directed under Ultraviolet-visible Spectrophotometry, both solutions exhibit similar intensities of absorption at the same wavelengths.\n\n[Absorbance]\nE 1% 1 cm (265 nm): 210-220 (5 mg after drying, 0.25 mol/L sulfuric acid TS, 250 mL)\n\nQuestion: What is the temperature condition for drying this drug in preparation for the absorbance test?\n\n① Lukewarm\n② Room temperature\n③ Ambient temperature\n④ Standard temperature\n⑤ Temperature specified in the Loss on Drying section",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 약국 경영을 위한 마케팅 믹스 4P 중 장소(place)에 해당하는 것은?\n\n① 일반의약품의 판매가 할인\n② 의약품의 안전성 정보 제공\n③ 역세권 상가 1층에 약국개설\n④ 노인환자에 대한 복약지도 서비스 강화\n⑤ 인근 아파트의 엘리베이터 내 약국 광고",
        "question_text": "Question: Which of the following corresponds to \"place\" among the 4Ps of marketing mix for pharmacy management?\n\n① Discounting the price of over-the-counter medicines\n② Providing safety information for medicines\n③ Opening a pharmacy on the first floor of a commercial building near a subway station\n④ Strengthening medication counseling services for elderly patients\n⑤ Advertising the pharmacy in elevators of nearby apartment buildings",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: A 약사는 약국을 개업하면서 약국점포 구입대금 5억 원 중 2억 원은 현금으로, 3억 원은 은행에서 5년 장기대출을 받아 마련하였다. 또한, 현금으로 1억 원어치 의약품을 구매하였다. 약국 개업시점의 재무 상태에 대한 설명으로 옳은 것은?\n\n① 자본은 6억 원이다.\n② 자산은 6억 원이다.\n③ 유동자산은 5억 원이다.\n④ 유동부채는 5억 원이다.\n⑤ 비유동자산은 2억 원이다.",
        "question_text": "Question: A pharmacist opened a pharmacy, purchasing the store for 500 million won. Of this amount, 200 million won was paid in cash, and 300 million won was obtained through a 5-year long-term loan from a bank. Additionally, the pharmacist purchased 100 million won worth of medications in cash. Which of the following statements correctly describes the financial status at the time of opening the pharmacy?\n\n① The capital is 600 million won.\n② The assets are 600 million won.\n③ The current assets are 500 million won.\n④ The current liabilities are 500 million won.\n⑤ The non-current assets are 200 million won.",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 약국이 보유하고 있는 자동 정제포장기의 감가상각비에 대한 설명으로 옳은 것은?\n\n① 감가상각비는 매출원가에 해당된다.\n② 내용연수 종료 시점에 남아있는 가치를 총감가상각비라고 한다.\n③ 정률법을 사용하면 내용연수 동안 해마다 동일 금액이 감가상각 된다.\n④ 연수합계법을 사용하면 내용연수 초기의 감가상각비가 후기보다 크다.\n⑤ 감가상각비 계산을 위해 취득원가, 내용연수, 재고유지비용 자료가 필요하다.",
        "question_text": "Question: Which of the following statements about the depreciation expense of an automatic tablet packaging machine owned by a pharmacy is correct?\n\n① Depreciation expense is considered part of the cost of goods sold.\n② The remaining value at the end of the useful life is called total depreciation.\n③ When using the declining balance method, the same amount is depreciated each year during the useful life.\n④ When using the sum-of-the-years'-digits method, the depreciation expense is higher in the early years than in later years.\n⑤ To calculate depreciation expense, data on acquisition cost, useful life, and inventory holding costs are needed.",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: A 약국의 2018년도 재무현황이 다음과 같을 때 총자산이익률은?\n\n| 항목 | 매출액 | 매출원가 영업비용 | 자본 | 부채 |\n|---|---|---|---|---|\n| 비용 | 10억 원 | 8억 원 | 1억 원 | 3억 원 | 2억 원 |\n\n① (10억 원 - 8억 원) / 3억 원\n② (10억 원 - 9억 원) / 3억 원\n③ (10억 원 - 8억 원) / (3억 원+2억 원)\n④ (10억 원 - 9억 원) / (3억 원+2억 원)\n⑤ (10억 원 - 8억 원) / 10억 원",
        "question_text": "Question: Given the following financial status of Pharmacy A in 2018, what is the Return on Assets (ROA)?\n\n| Item | Sales | Cost of Goods Sold & Operating Expenses | Capital | Liabilities |\n|---|---|---|---|---|\n| Amount | 1 billion won | 800 million won | 100 million won | 300 million won | 200 million won |\n\n① (1 billion won - 800 million won) / 300 million won\n② (1 billion won - 900 million won) / 300 million won\n③ (1 billion won - 800 million won) / (300 million won + 200 million won)\n④ (1 billion won - 900 million won) / (300 million won + 200 million won)\n⑤ (1 billion won - 800 million won) / 1 billion won",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 약국에서 총재고관리비용을 최소화하기 위한 경제적 주문량을 계산하는 방법은?\n\n① 연간 재고부족비용=연간 주문비용\n② 연간 재고부족비용 < 연간 주문비용\n③ 연간 재고유지비용=연간 주문비용\n④ 연간 재고유지비용 < 연간 주문비용\n⑤ 연간 재고유지비용 > 연간 주문비용",
        "question_text": "Question: What is the method to calculate the economic order quantity to minimize the total inventory management cost in a pharmacy?\n\n① Annual stockout cost = Annual ordering cost\n② Annual stockout cost < Annual ordering cost\n③ Annual holding cost = Annual ordering cost\n④ Annual holding cost < Annual ordering cost\n⑤ Annual holding cost > Annual ordering cost",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 우리나라 국민건강보험의 특징으로 옳은 것은?\n\n① 보험료 납부액은 질병의 중증도를 기준으로 책정한다.\n② 지불한 보험료 액수와 상관없이 동일한 의료서비스를 받는다.\n③ 보험료 납부액은 보장 수준에 따라 가입자가 선택할 수 있다.\n④ 의료기관은 희망에 따라 국민건강보험 요양기관이 될 수 있다.\n⑤ 대한민국 국민은 본인의 희망에 따라 국민건강보험을 탈퇴할 수 있다.",
        "question_text": "Question: Which of the following is correct regarding the characteristics of South Korea's National Health Insurance?\n\n① Insurance premiums are determined based on the severity of illness.\n② Regardless of the amount of insurance premium paid, everyone receives the same medical services.\n③ Subscribers can choose their insurance premium amount according to the level of coverage.\n④ Medical institutions can become National Health Insurance providers at their discretion.\n⑤ South Korean citizens can opt out of the National Health Insurance system if they wish.",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 국민건강보험제도에서 나타나는 도덕적 해이에 대한 설명으로 옳은 것은?\n\n① 고가 약제의 사용이 감소한다.\n② 의료서비스 이용량이 감소한다.\n③ 보장률이 낮은 경우 도덕적 해이가 발생할 가능성이 크다.\n④ 도덕적 해이를 줄이기 위해서는 본인부담금을 줄여야 한다.\n⑤ 소비자와 공급자 양측 모두 도덕적 해이가 발생할 수 있다.",
        "question_text": "Question: Which of the following statements about moral hazard in the National Health Insurance system is correct?\n\n① The use of expensive medications decreases.\n② The utilization of medical services decreases.\n③ There is a higher possibility of moral hazard when the coverage rate is low.\n④ To reduce moral hazard, out-of-pocket expenses should be decreased.\n⑤ Moral hazard can occur on both the consumer and provider sides.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 진료비 지불방식의 기대효과에 대한 설명으로 옳은 것은?\n\n① 인두제는 행위별수가제에 비해 의료비용 절감효과가 작다.\n② 인두제는 행위별수가제에 비해 고가서비스 접근성이 높다.\n③ 인두제는 행위별수가제에 비해 의료서비스가 과다제공 된다.\n④ 총액예산제는 행위별수가제에 비해 의료비용 절감효과가 크다.\n⑤ 총액예산제는 행위별수가제에 비해 의료서비스가 과다제공 된다.",
        "question_text": "Question: Which of the following statements about the expected effects of medical payment methods is correct?\n\n① The capitation system has a smaller cost-saving effect compared to the fee-for-service system.\n② The capitation system provides better access to high-cost services compared to the fee-for-service system.\n③ The capitation system leads to more excessive provision of medical services compared to the fee-for-service system.\n④ The global budget system has a greater cost-saving effect compared to the fee-for-service system.\n⑤ The global budget system leads to more excessive provision of medical services compared to the fee-for-service system.",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 우리나라 약국의 약사서비스에 대한 국민건강보험 지불보상에 대한 설명으로 옳은 것은?\n\n① 공휴일 조제 및 야간 조제에 대해 가산료가 없다.\n② 비급여 일반의약품은 해당 약국에서 구매한 금액으로 보상한다.\n③ 약사의 1일 조제건수가 적정건수보다 적을 경우 조제료를 차감하여 지급한다.\n④ 처방약 조제에 대한 보상은 조제료, 조제기본료, 복약지도료, 의약품관리료, 약국관리료로 구성된다.\n⑤ 생물학적 동등성이 인정되는 저가 품목으로 대체조제할 경우 약가 차액을 의사에게 인센티브로 제공한다.",
        "question_text": "Question: Which of the following statements is correct regarding the National Health Insurance reimbursement for pharmacist services in Korean pharmacies?\n\n① There are no additional fees for dispensing on public holidays or during night hours.\n② Non-reimbursable over-the-counter medications are compensated based on the purchase price at the respective pharmacy.\n③ If a pharmacist's daily prescription dispensing count is below the appropriate number, the dispensing fee is deducted from the payment.\n④ Compensation for prescription drug dispensing consists of dispensing fee, basic dispensing fee, medication counseling fee, drug management fee, and pharmacy management fee.\n⑤ When substituting with a lower-priced bioequivalent product, the price difference is provided to the physician as an incentive.",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 다음과 관련된 약사 윤리원칙은?\n\n의료자원이 제한적인 상황에서 치료비가 매우 고가인 난치성 질환자 1명을 치료할 수 있는 약제비로 다른 질환을 앓고 있는 환자 10,000명에게 효과적인 약물치료를 하여 사회적 이익을 최대화하자고 주장한다.\n\n① 선행의 원칙\n② 정의의 원칙\n③ 충실성의 원칙\n④ 피해 회피의 원칙\n⑤ 사생활 존중의 원칙",
        "question_text": "Question: Which ethical principle of pharmacy is related to the following?\n\nIn a situation where medical resources are limited, it is argued that the cost of medication to treat one patient with an intractable disease, which is very expensive, should instead be used to provide effective drug treatment to 10,000 patients with other diseases, thereby maximizing social benefits.\n\n① Principle of beneficence\n② Principle of justice\n③ Principle of fidelity\n④ Principle of non-maleficence\n⑤ Principle of respect for privacy",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 다음과 같은 경우 2018년도 고혈압 발생률 계산으로 옳은 것은?\n\n2017년 12월 31일 당시 조사대상자 1,100명 중 100명은 이미 고혈압으로 진단된 상태였다. 고혈압으로 진단되지 않은 1,000명 중 2018년 1월 1일부터 1년간 새로 고혈압 진단을 받은 환자는 100명이었으며, 이 고혈압 환자들의 2018년도 평균 추적관찰기간은 0.5년이었다. 고혈압 환자가 아닌 900명은 모두 2018년 1년간 추적관찰 되었다.\n\n1년 누적발생률 (명/명) | 발생률 (명/인년(person-years))\n① 100/1,000 | 100/900\n② 100/1,000 | 100/950\n③ 100/1,000 | 100/1,000\n④ 100/1,100 | 100/950\n⑤ 100/1,100 | 100/1,000",
        "question_text": "Question: Which of the following is the correct calculation of the hypertension incidence rate for 2018 in the given scenario?\n\nAs of December 31, 2017, out of 1,100 subjects, 100 were already diagnosed with hypertension. Among the 1,000 individuals not diagnosed with hypertension, 100 were newly diagnosed with hypertension during the one-year period from January 1, 2018. The average follow-up period for these hypertension patients in 2018 was 0.5 years. The 900 individuals without hypertension were all followed up for the entire year of 2018.\n\n1-year Cumulative Incidence (per person) | Incidence Rate (per person-year)\n① 100/1,000 | 100/900\n② 100/1,000 | 100/950\n③ 100/1,000 | 100/1,000\n④ 100/1,100 | 100/950\n⑤ 100/1,100 | 100/1,000",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 다음 약물감시제도에 대한 설명으로 옳은 것은?\n\n시판 중인 A 약을 복용한 환자에게 심한 피부발진이 나타나서, 약사가 이 내용을 Korea Institute of Drug Safety & Risk Management에 ‘의약품등 이상사례 ∙ 약물이상반응 보고서’ 양식을 사용하여 보고하였다.\n\n① 약물이상반응의 발생률을 구할 수 있다.\n② 의약품 이상사례의 인과성을 분명히 파악할 수 있다.\n③ 의약품 허가 후 초기 1년의 기간에 한정하여 보고한다.\n④ 신약등의 재심사제도보다 더 적극적인 약물감시 방법이다.\n⑤ 약물이상반응에 대한 실마리정보를 발견하는 데 활용할 수 있다.",
        "question_text": "Question: Which of the following statements about the pharmacovigilance system is correct?\n\nA patient who took drug A, which is currently on the market, developed severe skin rash. The pharmacist reported this incident to the Korea Institute of Drug Safety & Risk Management using the 'Adverse Event/Adverse Drug Reaction Report Form for Medicinal Products'.\n\n① The incidence rate of adverse drug reactions can be calculated.\n② The causality of adverse events related to medicinal products can be clearly identified.\n③ Reporting is limited to the initial 1-year period after drug approval.\n④ It is a more proactive pharmacovigilance method than the re-examination system for new drugs.\n⑤ It can be used to detect signal information about adverse drug reactions.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 보험상한가가 1,000원인 약을 A 약국은 1,000원, B 약국은 800원에 구매하였다. 실거래가상환제도 하에서 약국이 National Health Insurance Service으로부터 상환받는 약가는?\n\nA 약국 | B 약국\n① 800원 | 800원\n② 900원 | 900원\n③ 1,000원 | 1,000원\n④ 800원 | 1,000원\n⑤ 1,000원 | 800원",
        "question_text": "Question: A drug with an insurance price cap of 1,000 won was purchased by Pharmacy A for 1,000 won and by Pharmacy B for 800 won. Under the actual transaction price reimbursement system, what is the drug price reimbursed to the pharmacies by the National Health Insurance Service?\n\nPharmacy A | Pharmacy B\n① 800 won | 800 won\n② 900 won | 900 won\n③ 1,000 won | 1,000 won\n④ 800 won | 1,000 won\n⑤ 1,000 won | 800 won",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 질병 A를 치료하기 위한 투약비용은 2019년에 50만원, 2020년에 70만원, 2021년에 100만원이라고 한다. 2019년~2021년 3년간 총투약비용을 2019년 현재가치로 환산한 것은? (가정: 비용은 연초에 발생됨. 연간 할인율은 5%임.)\n\n① 50만원+(70만원×0.95)+(100만원×0.95^2)\n② 50만원+(70만원÷0.95)+(100만원÷0.95^2)\n③ 50만원+(70만원×1.025)+(100만원×1.025^2)\n④ 50만원+(70만원×1.05)+(100만원×1.05^2)\n⑤ 50만원+(70만원÷1.05)+(100만원÷1.05^2)",
        "question_text": "Question: The medication cost for treating disease A is said to be 500,000 won in 2019, 700,000 won in 2020, and 1,000,000 won in 2021. What is the total medication cost for the three years from 2019 to 2021 when converted to present value in 2019? (Assumption: Costs occur at the beginning of the year. The annual discount rate is 5%.)\n\n① 500,000 won + (700,000 won × 0.95) + (1,000,000 won × 0.95^2)\n② 500,000 won + (700,000 won ÷ 0.95) + (1,000,000 won ÷ 0.95^2)\n③ 500,000 won + (700,000 won × 1.025) + (1,000,000 won × 1.025^2)\n④ 500,000 won + (700,000 won × 1.05) + (1,000,000 won × 1.05^2)\n⑤ 500,000 won + (700,000 won ÷ 1.05) + (1,000,000 won ÷ 1.05^2)",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 우리나라 의료급여제도에 대한 설명으로 옳은 것은?\n\n① Health Insurance Review & Assessment Service에 의한 진료비 심사가 없다.\n② 의료급여 수급권자는 1종, 2종, 3종으로 구분된다.\n③ 의료급여 수급권자는 국민건강보험료를 납부하지 않는다.\n④ 의료급여 수급권자의 자격선정은 Health Insurance Review & Assessment Service에서 한다.\n⑤ 약국 조제서비스의 본인부담금은 급여비용 총액의 30%이다.",
        "question_text": "Question: Which of the following statements about the Medical Aid System in our country is correct?\n\n① There is no review of medical expenses by the Health Insurance Review & Assessment Service.\n② Medical Aid beneficiaries are classified into Type 1, Type 2, and Type 3.\n③ Medical Aid beneficiaries do not pay National Health Insurance premiums.\n④ The eligibility determination for Medical Aid beneficiaries is done by the Health Insurance Review & Assessment Service.\n⑤ The out-of-pocket payment for pharmacy dispensing services is 30% of the total benefit cost.",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 우리나라 노인장기요양보험에서 제공하는 장기요양급여에 포함되는 것은?\n\n① 약물 사용 상담\n② 독감 예방 접종\n③ 임플란트 시술\n④ 가정방문 목욕제공 서비스\n⑤ 약국에서 구매한 일반의약품",
        "question_text": "Question: Which of the following is included in the long-term care benefits provided by the Long-Term Care Insurance for the Elderly in Korea?\n\n① Medication use counseling\n② Influenza vaccination\n③ Dental implant procedure\n④ Home-visit bathing service\n⑤ Over-the-counter medications purchased at a pharmacy",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n기존 항암제 A와 비교한 신약 항암제 B의 비용-효용분석을 하고자 한다. 두 약물 모두 무진행생존(progression-free survival) 기간에 효용가중치는 0.8(완전한 건강의 80% 수준)이며, 암이 진행(progression)되면 효용가중치는 0.4로 낮아진다.\n점증적 비용-효용비(incremental cost-utility ratio) 임계값은 4,000만원/QALY이며, 관련 정보는 다음 표와 같다.\n(연간 할인율은 0%로 가정함. QALY=quality-adjusted life year)\n\n| 항목 | 기존 항암제 A | 신약 항암제 B |\n|---|---|---|\n| 무진행 생존: 기간(치료 시작~암 진행 시작) | 1년 | 2년 |\n| 무진행 생존: 효용가중치 | 0.8 | 0.8 |\n| 진행: 기간(암 진행 시작~사망) | 0.5년 | 1년 |\n| 진행: 효용가중치 | 0.4 | 0.4 |\n| 총비용 | 1,000만원 | 3,000만원 |\n\nQuestion: 기존 항암제 A와 비교한 신약 항암제 B의 치료효과를 질보정수명(QALY) 증가분으로 바르게 계산한 것은?\n\n① 0.2 QALY\n② 0.6 QALY\n③ 0.8 QALY\n④ 1.0 QALY\n⑤ 1.8 QALY",
        "question_text": "A cost-utility analysis of a new anticancer drug B is to be conducted in comparison with an existing anticancer drug A. For both drugs, the utility weight during progression-free survival is 0.8 (80% of perfect health), and when cancer progresses, the utility weight decreases to 0.4.\nThe threshold for the incremental cost-utility ratio is 40 million won/QALY, and the relevant information is shown in the following table.\n(Assume an annual discount rate of 0%. QALY = quality-adjusted life year)\n\n| Item | Existing anticancer drug A | New anticancer drug B |\n|---|---|---|\n| Progression-free survival: Duration (treatment start to progression start) | 1 year | 2 years |\n| Progression-free survival: Utility weight | 0.8 | 0.8 |\n| Progression: Duration (progression start to death) | 0.5 years | 1 year |\n| Progression: Utility weight | 0.4 | 0.4 |\n| Total cost | 10 million won | 30 million won |\n\nQuestion: Which of the following correctly calculates the increase in quality-adjusted life years (QALY) for the new anticancer drug B compared to the existing anticancer drug A?\n\n① 0.2 QALY\n② 0.6 QALY\n③ 0.8 QALY\n④ 1.0 QALY\n⑤ 1.8 QALY",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n기존 항암제 A와 비교한 신약 항암제 B의 비용-효용분석을 하고자 한다. 두 약물 모두 무진행생존(progression-free survival) 기간에 효용가중치는 0.8(완전한 건강의 80% 수준)이며, 암이 진행(progression)되면 효용가중치는 0.4로 낮아진다.\n점증적 비용-효용비(incremental cost-utility ratio) 임계값은 4,000만원/QALY이며, 관련 정보는 다음 표와 같다.\n(연간 할인율은 0%로 가정함. QALY=quality-adjusted life year)\n\n| 항목 | 기존 항암제 A | 신약 항암제 B |\n|---|---|---|\n| 무진행 생존: 기간(치료 시작~암 진행 시작) | 1년 | 2년 |\n| 무진행 생존: 효용가중치 | 0.8 | 0.8 |\n| 진행: 기간(암 진행 시작~사망) | 0.5년 | 1년 |\n| 진행: 효용가중치 | 0.4 | 0.4 |\n| 총비용 | 1,000만원 | 3,000만원 |\n\nQuestion: 기존 항암제 A와 비교한 신약 항암제 B의 점증적 비용-효용비를 비용-효과 평면(cost-effectiveness plane)에 표시한 것으로 옳은 것은?\n\n<Data (confidential)>\n\n① 가\n② 나\n③ 다\n④ 라\n⑤ 마",
        "question_text": "A cost-utility analysis of a new anticancer drug B is to be conducted in comparison with an existing anticancer drug A. For both drugs, the utility weight during progression-free survival is 0.8 (80% of perfect health), and when cancer progresses, the utility weight decreases to 0.4.\nThe threshold for the incremental cost-utility ratio is 40 million won/QALY, and the relevant information is shown in the following table.\n(Assume an annual discount rate of 0%. QALY = quality-adjusted life year)\n\n| Item | Existing anticancer drug A | New anticancer drug B |\n|---|---|---|\n| Progression-free survival: Duration (treatment start to progression start) | 1 year | 2 years |\n| Progression-free survival: Utility weight | 0.8 | 0.8 |\n| Progression: Duration (progression start to death) | 0.5 years | 1 year |\n| Progression: Utility weight | 0.4 | 0.4 |\n| Total cost | 10 million won | 30 million won |\n\nQuestion: Which of the following correctly represents the incremental cost-utility ratio of the new anticancer drug B compared to the existing anticancer drug A on the cost-effectiveness plane?\n\n<Data (confidential)>\n\n① a\n② b\n③ c\n④ d\n⑤ e",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 “약사(藥事)”의 범위에 해당하는 것은?\n\n① 반창고의 제조\n② 수은 혈압계의 보관\n③ 임신 진단시약의 수출\n④ 백수오 기능성 식품의 감정\n⑤ 줄기세포배양액 화장품의 판매",
        "question_text": "Question: Which of the following falls within the scope of \"pharmaceutical affairs (藥事)\" according to the \"Pharmaceutical Affairs Act\"?\n\n① Manufacturing of adhesive bandages\n② Storage of mercury sphygmomanometers\n③ Export of pregnancy test reagents\n④ Appraisal of Cynanchum wilfordii functional foods\n⑤ Sale of stem cell culture fluid cosmetics",
        "answer": 1
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국 개설등록에 대한 설명으로 옳은 것은?\n\n① 의료기관의 구내에 약국을 개설할 수 있다.\n② 약국개설자는 개설등록이 취소된 날부터 3개월이 되면 등록을 할 수 있다.\n③ 개설등록을 하려는 자는 약국에 저온 보관 및 빛가림을 위한 시설을 갖추어야 한다.\n④ 개설하려는 자가 약국을 관리하는 약사를 두는 경우에는 두 개 이상의 약국을 개설할 수 있다.\n⑤ Mayor/Do Governor는 의료기관 부지의 일부를 개수하여 약국을 개설하는 경우 개설등록을 받지 아니한다.",
        "question_text": "Question: Which of the following statements about pharmacy establishment registration under the \"Pharmaceutical Affairs Act\" is correct?\n\n① A pharmacy can be established within the premises of a medical institution.\n② A pharmacy owner can register again 3 months after the date of registration cancellation.\n③ Those seeking to register a pharmacy must equip it with facilities for low-temperature storage and light protection.\n④ If the person intending to establish a pharmacy employs a pharmacist to manage it, they can establish more than one pharmacy.\n⑤ The Mayor/Do Governor does not accept registration for a pharmacy established by renovating part of a medical institution's property.",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자와 의료기관 개설자 간의 담합 행위 또는 유사담합행위가 아닌 것은?\n\n① 의료기관의 종사자가 약국개설자의 의약품 구매사무를 지원하는 행위\n② 약국개설자가 의료기관 개설자에게 처방전 알선의 대가로 사례비를 지급하는 행위\n③ 약사가 의료기관과 다중 이용 시설이 존재하는 건물의 같은 층에 약국을 개설하는 행위\n④ 의료기관 개설자가 사실상 그의 지휘 ∙ 감독을 받는 약사로 하여금 약국을 개설하도록 하는 행위\n⑤ 의료기관 개설자가 처방전 소지자의 요구가 없음에도 불구하고 특정 약국에서 조제하도록 처방전을 모사전송하는 행위",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT considered collusion or similar collusive behavior between pharmacy owners and medical institution owners?\n\n① An employee of a medical institution supporting the drug purchasing affairs of a pharmacy owner\n② A pharmacy owner paying a referral fee to a medical institution owner in exchange for prescriptions\n③ A pharmacist opening a pharmacy on the same floor of a building where a medical institution and multi-use facilities exist\n④ A medical institution owner having a pharmacist under their de facto direction and supervision open a pharmacy\n⑤ A medical institution owner faxing prescriptions to a specific pharmacy for dispensing without the prescription holder's request",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사의 조제행위에 대한 설명으로 옳은 것은?\n\n① 약학을 전공하는 대학의 학생은 의사의 지시 ∙ 감독을 받아 조제행위를 할 수 있다.\n② 의료기관의 조제실 약사는 처방전이 교부된 환자를 위하여 의약품을 조제할 수 있다.\n③ 약사가 Minister of Health and Welfare의 승인을 받은 경우에는 약국 조제실이 아닌 곳에서 조제할 수 있다.\n④ 약사는 처방전에 적힌 의약품을 대체조제한 경우에는 그 처방전을 지닌 자에게 즉시 대체조제한 내용을 알려야 한다.\n⑤ 약사는 미리 처방전을 발행한 의사의 동의를 받아 대체조제한 경우에는 그 의사에게 대체조제한 내용을 7일 이내에 통보하여야 한다.",
        "question_text": "Question: Which of the following statements about a pharmacist's dispensing actions is correct according to the \"Pharmaceutical Affairs Act\"?\n\n① A student majoring in pharmacy can dispense medications under the instruction and supervision of a doctor.\n② A pharmacist in a medical institution's dispensary can dispense medications for patients who have been issued prescriptions.\n③ A pharmacist can dispense medications outside of a pharmacy's dispensary if they receive approval from the Minister of Health and Welfare.\n④ When a pharmacist substitutes a medication prescribed on a prescription, they must immediately inform the person holding the prescription about the substitution.\n⑤ When a pharmacist substitutes a medication with prior consent from the prescribing doctor, they must notify the doctor of the substitution within 7 days.",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사가 의사 또는 치과의사의 처방전 없이 조제하거나 판매할 수 있는 경우가 아닌 것은?\n\n① 사회봉사 활동을 위하여 조제하는 경우\n② 의료기관이 없는 지역에서 조제하는 경우\n③ 재해가 발생하여 사실상 의료기관이 없게 되어 재해 구호를 위하여 조제하는 경우\n④ 응급환자 및 조현병으로 타인을 해칠 우려가 있는 정신질환자에 대하여 조제하는 경우\n⑤ 감염병이 집단으로 발생할 우려가 있다고 Minister of Health and Welfare이 인정하여 경구용 감염병 예방접종약을 판매하는 경우",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a case where a pharmacist can dispense or sell medication without a prescription from a doctor or dentist?\n\n① When dispensing for social service activities\n② When dispensing in areas without medical institutions\n③ When dispensing for disaster relief in areas where medical institutions have effectively ceased to exist due to a disaster\n④ When dispensing for emergency patients and mental health patients with schizophrenia who may harm others\n⑤ When selling oral vaccines for infectious diseases as recognized by the Minister of Health and Welfare due to the risk of a mass outbreak of an infectious disease",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사가 조제기록부에 적어야 할 사항이 아닌 것은?\n\n① 조제 내용\n② 조제 연월일\n③ 복약지도 내용\n④ 처방약품명과 일수\n⑤ 처방전 발행 의사의 면허번호",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT required to be recorded by a pharmacist in the prescription record book?\n\n① Contents of the prescription\n② Date of dispensing\n③ Contents of medication counseling\n④ Name of prescribed medication and duration\n⑤ License number of the prescribing physician",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품의 판매와 복약지도에 대한 설명으로 옳지 않은 것은?\n\n① 매약상이 판매할 수 있는 의약품은 일반의약품으로 한다.\n② 약국개설자는 의사 또는 치과의사의 처방전 없이 일반의약품을 판매할 수 있다.\n③ 약국개설자는 일반의약품을 판매할 때에 필요하다고 판단되면 복약지도를 할 수 있다.\n④ 약국개설자는 head of a Si/Gun/Gu의 승인을 받은 경우 그 약국 또는 점포 이외의 장소에서 의약품을 판매할 수 있다.\n⑤ 약국개설자는 의사 또는 치과의사의 처방전에 따라 조제하는 경우 외에는 동물병원 개설자에게 전문의약품을 판매하여서는 아니 된다.",
        "question_text": "Question: Which of the following statements about the sale of pharmaceuticals and medication counseling according to the \"Pharmaceutical Affairs Act\" is incorrect?\n\n① The medicines that can be sold by drug sellers are limited to over-the-counter drugs.\n② Pharmacy owners can sell over-the-counter drugs without a prescription from a doctor or dentist.\n③ When selling over-the-counter drugs, pharmacy owners can provide medication counseling if they deem it necessary.\n④ Pharmacy owners can sell pharmaceuticals outside their pharmacy or store with the approval of the head of a Si/Gun/Gu.\n⑤ Pharmacy owners must not sell prescription drugs to veterinary hospital owners except when dispensing according to a prescription from a doctor or dentist.",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자가 수의사 또는 수산질병관리사의 처방전이 있어야만 판매할 수 있는 동물용 의약품은?\n\n① 심장사상충 예방을 위하여 Minister of Oceans and Fisheries이 정한 이버멕틴 저작정\n② 외상 감염 치료를 위하여 Minister of Agriculture, Food and Rural Affairs이 정한 아목시실린주\n③ 제형과 약리작용상 장애를 일으킬 우려가 있다고 인정되는 덱사메타손정\n④ 수의사 또는 수산질병관리사의 전문지식을 필요로 하는 사이클로스포린주\n⑤ 오용 ∙ 남용으로 사람 및 동물의 건강에 위해를 끼칠 우려가 있는 에스트라디올주",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following veterinary medicines can a pharmacy owner sell only with a prescription from a veterinarian or an aquatic animal disease manager?\n\n① Ivermectin chewable tablets for heartworm prevention, as specified by the Minister of Oceans and Fisheries\n② Amoxicillin injection for treating wound infections, as specified by the Minister of Agriculture, Food and Rural Affairs\n③ Dexamethasone tablets, which are recognized as potentially causing disorders due to their formulation and pharmacological action\n④ Cyclosporine injection, which requires the specialized knowledge of a veterinarian or an aquatic animal disease manager\n⑤ Estradiol injection, which may pose a risk to human and animal health if misused or abused",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 재심사기간이 제조판매 ∙ 수입 품목허가를 받은 날부터 4년인 품목은?\n\n① 신약\n② 이미 허가된 의약품과 배합비율이 다른 전문의약품\n③ 이미 허가된 의약품과 유효성분의 종류가 다른 전문의약품\n④ 이미 허가된 의약품과 유효성분은 동일하나 투여경로가 다른 전문의약품\n⑤ 이미 허가된 의약품과 유효성분 및 투여경로는 동일하나 명백하게 다른 효능 ∙ 효과를 추가한 전문의약품",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which item has a re-examination period of 4 years from the date of receiving manufacturing, sales, or import approval?\n\n① New drug\n② Prescription drug with different mixing ratio from already approved drugs\n③ Prescription drug with different types of active ingredients from already approved drugs\n④ Prescription drug with the same active ingredient but different administration route from already approved drugs\n⑤ Prescription drug with the same active ingredient and administration route as already approved drugs, but with clearly different efficacy and effects added",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 생물학적 제제를 제조하는 제조업자가 제조관리자를 두려고 할 때 제조 업무를 관리할 수 없는 자는?\n\n① 약사\n② 한약사\n③ 4년제 대학의 생화학과를 졸업한 자\n④ Minister of Food and Drug Safety의 승인을 받은 의사\n⑤ 2년제 대학을 졸업한 자로서 2년 이상 관련 제조업무에 종사한 자",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following individuals cannot be appointed as a manufacturing manager by a manufacturer producing biological products?\n\n① Pharmacist\n② Oriental medicine pharmacist\n③ A person who graduated from a 4-year university with a degree in biochemistry\n④ A medical doctor approved by the Minister of Food and Drug Safety\n⑤ A person who graduated from a 2-year college and has worked in related manufacturing for more than 2 years",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 품목허가를 받은 자가 의사의 처방에 따라 조제에 사용되는 의약품이 아닌 것을 약국개설자에게 판매할 경우, 안전용기 ∙ 포장을 사용하여야 할 품목에 해당하지 않는 것은?\n\n① 소아용의약품 중 내용액제\n② 아스피린 성분을 함유한 정제\n③ 1회 복용량에 30밀리그램 이상의 철 성분을 함유한 과립제\n④ 1정당 10밀리그램의 세티리진염산염 성분을 함유한 정제의 10정 단위 포장\n⑤ 1정당 250밀리그램의 아세트아미노펜 성분을 함유한 정제의",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" when a person who has received product approval for a pharmaceutical sells to a pharmacy owner a drug that is not used for dispensing according to a doctor's prescription, which of the following items does NOT require the use of safety containers or packaging?\n\n① Liquid formulations among pediatric medicines\n② Tablets containing aspirin\n③ Granules containing 30 milligrams or more of iron per single dose\n④ 10-tablet package of tablets containing 10 milligrams of cetirizine hydrochloride per tablet\n⑤ Tablets containing 250 milligrams of acetaminophen per tablet",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사회장이 약사회의 윤리위원회 심의 ∙ 의결을 거쳐 Minister of Health and Welfare에게 약사면허 취소 처분을 요구할 수 있는 경우는?\n\n① 거짓 또는 과대 광고행위를 한 경우\n② 향정신성의약품 중독자에 해당하는 경우\n③ 학문적으로 인정되지 아니하는 약사(藥事) 행위를 한 경우\n④ 무자격자에게 의약품을 조제 ∙ 판매하도록 하는 행위를 한 경우\n⑤ 본인부담금의 일부를 면제하는 방법으로 의사의 처방전을 가진 자를 자신의 약국으로 유인하는 행위를 한 경우",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" in which case can the president of the Pharmacists Association request the Minister of Health and Welfare to cancel a pharmacist's license after deliberation and resolution by the ethics committee of the Pharmacists Association?\n\n① In case of false or exaggerated advertising\n② In case of being addicted to psychotropic drugs\n③ In case of performing pharmaceutical practices that are not academically recognized\n④ In case of allowing unqualified persons to dispense or sell medicines\n⑤ In case of attracting patients with doctor's prescriptions to one's own pharmacy by exempting part of the patient's co-payment",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 “마약류”에 해당하는 것은?\n\n① 대마초의 종자\n② 성숙한 대마초의 줄기\n③ 아편에서 추출되는 알칼로이드\n④ 양귀비의 액즙이 응결된 것을 의약품으로 가공한 것\n⑤ 엑고닌 ∙ 코카인 및 엑고닌 알칼로이드 성분이 모두 제거된 코카 잎",
        "question_text": "Question: According to the \"Narcotics Control Act,\" which of the following is considered a \"narcotic\"?\n\n① Cannabis seeds\n② Mature cannabis stems\n③ Alkaloids extracted from opium\n④ Processed medicinal products made from coagulated poppy sap\n⑤ Coca leaves with all ecgonine, cocaine, and ecgonine alkaloid components removed",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류취급자가 봉함을 하지 아니한 마약류를 수수하지 못하는 경우는?\n\n① 사용중단의 사유로 소유하던 마약을 원소유자인 마약류취급자에게 반품하려는 경우\n② 품목허가가 취소되어 소지 ∙ 소유 또는 관리하는 마약을 다른 마약류취급자에게 양도하려는 경우\n③ 마약류취급학술연구자가 학술연구를 위하여 수수하려는 사유로 Minister of Food and Drug Safety의 승인을 받은 경우\n④ 공무상 필요에 따라 연구 및 시험용으로 제품으로 수수하려는 사유로 Minister of Food and Drug Safety의 승인을 받은 경우\n⑤ 마약류제조업자 자격을 상실하여 보유하고 있는 마약류를 허가관청의 승인을 받아 마약류취급자에게 양도하려는 경우",
        "question_text": "Question: According to the \"Narcotics Control Act,\" in which case is a narcotics handler not allowed to receive narcotics that are not sealed?\n\n① When returning narcotics to the original owner who is a narcotics handler due to discontinuation of use\n② When transferring narcotics to another narcotics handler due to cancellation of product approval\n③ When a narcotics handling academic researcher receives approval from the Minister of Food and Drug Safety to receive narcotics for academic research purposes\n④ When receiving approval from the Minister of Food and Drug Safety to receive products for research and testing purposes due to official needs\n⑤ When a narcotics manufacturer who has lost their qualification seeks to transfer their narcotics to a narcotics handler with the approval of the licensing authority",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류 중독자의 증상을 고려하여 특히 필요하다고 인정하는 경우 Minister of Health and Welfare 또는 Mayor/Do Governor의 허가를 받아 마약을 투약할 수 있는 자는?\n\n① 대학병원에서 의료에 종사하는 의사\n② 국립의료원에서 의료에 종사하는 의사\n③ 국립재활병원에서 의료에 종사하는 의사\n④ 상급종합병원에서 의료에 종사하는 의사\n⑤ 치료보호기관에서 의료에 종사하는 의사",
        "question_text": "Question: According to the \"Narcotics Control Act,\" who can administer narcotics with the permission of the Minister of Health and Welfare or the Mayor/Do Governor when it is deemed particularly necessary considering the symptoms of a narcotics addict?\n\n① A doctor practicing medicine in a university hospital\n② A doctor practicing medicine in the National Medical Center\n③ A doctor practicing medicine in the National Rehabilitation Center\n④ A doctor practicing medicine in a tertiary hospital\n⑤ A doctor practicing medicine in a treatment and protection institution",
        "answer": 5
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: \"National Health Promotion Act\"상 “국민건강증진사업”의 정의에 포함되어 있지 않은 것은?\n\n① 건강관리\n② 보건교육\n③ 식품위생\n④ 영양개선\n⑤ 질병예방",
        "question_text": "Question: Which of the following is NOT included in the definition of \"National Health Promotion Project\" according to the \"National Health Promotion Act\"?\n\n① Health management\n② Health education\n③ Food hygiene\n④ Nutrition improvement\n⑤ Disease prevention",
        "answer": 3
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: \"Framework Act on Health and Medical Services\"상 보건의료인의 책임에 대한 설명으로 옳지 않은 것은?\n\n① 보건의료서비스의 제공을 요구받으면 정당한 이유 없이 이를 거부하지 못한다.\n② 식품, 의약품, 의료기기 및 화장품 등 건강 관련 물품으로부터 발생할 수 있는 위해(危害)를 방지하여야 한다.\n③ 자신의 학식과 경험, 양심에 따라 환자에게 양질의 적정한 보건의료서비스를 제공하기 위하여 노력하여야 한다.\n④ 적절한 보건의료서비스를 제공하기 위하여 필요하면 보건의료서비스를 받는 자를 다른 보건의료기관에 소개하여야 한다.\n⑤ 국가나 지방자치단체가 관리하여야 할 질병에 걸린 것으로 의심되는 대상자를 발견한 때에는 신고하는 등 필요한 조치를 하여야 한다.",
        "question_text": "Question: Which of the following statements about the responsibilities of healthcare professionals under the \"Framework Act on Health and Medical Services\" is incorrect?\n\n① They cannot refuse to provide healthcare services without a valid reason when requested.\n② They must prevent harm that may arise from health-related items such as food, pharmaceuticals, medical devices, and cosmetics.\n③ They must strive to provide quality and appropriate healthcare services to patients according to their knowledge, experience, and conscience.\n④ They should refer patients to other healthcare institutions when necessary to provide appropriate healthcare services.\n⑤ When they discover a person suspected of having a disease that should be managed by the state or local government, they must take necessary measures such as reporting it.",
        "answer": 2
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 “사용자”에 해당하지 않는 자는?\n\n① 국회사무총장\n② 중앙행정기관의 장\n③ 근로자가 소속되어 있는 사업장의 사업주\n④ 근로의 대가로 보수를 받아 생활하는 사람\n⑤ 교직원이 소속되어 있는 사립학교를 설립 ∙ 운영하는 자",
        "question_text": "Question: According to the \"National Health Insurance Act,\" which of the following is NOT considered an \"employer\"?\n\n① Secretary General of the National Assembly\n② Head of a central administrative agency\n③ Business owner of a workplace where workers are employed\n④ A person who receives compensation for work to make a living\n⑤ A person who establishes and operates a private school where teaching staff are employed",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 상대가치점수가 적용되지 않고 구입금액이 상한금액 이하인 경우, 약제 및 치료재료에 대한 요양급여비용의 산정 방법으로 옳은 것은?\n\n① 한약제 – 구입금액\n② 항생제 – 상한금액\n③ 치료재료 – 상한금액\n④ 처방의약품 – 구입금액\n⑤ 희귀의약품 – 상한금액",
        "question_text": "Question: According to the \"National Health Insurance Act,\" what is the correct method for calculating the health care benefit costs for pharmaceuticals and therapeutic materials when the relative value score is not applied and the purchase price is below the maximum limit?\n\n① Herbal medicine – Purchase price\n② Antibiotics – Maximum limit\n③ Therapeutic materials – Maximum limit\n④ Prescription drugs – Purchase price\n⑤ Rare disease drugs – Maximum limit",
        "answer": 4
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: \"Regional Public Health Act\"상 보건소에서 약사(藥事)에 관련하여 수행하는 업무는?\n\n① 의약품 제조업 허가\n② 보험급여 비용의 지급\n③ 요양급여의 적정성 평가\n④ 약국개설자의 관리자 변경 명령\n⑤ 의약품 부작용의 인과관계 조사",
        "question_text": "Question: According to the \"Regional Public Health Act,\" which of the following tasks related to pharmaceutical affairs is performed by public health centers?\n\n① Licensing of pharmaceutical manufacturing\n② Payment of insurance benefits\n③ Evaluation of the appropriateness of medical care benefits\n④ Ordering changes in the management of pharmacy owners\n⑤ Investigation of causal relationships in drug side effects",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: Proteoglycan과 함께 세포바깥바탕질(extracellular matrix)의 그물구조를 형성하는 단백질은?\n\n① actin\n② fibronectin\n③ α-keratin\n④ lamin\n⑤ tubulin",
        "question_text": "Question: Which protein forms the network structure of the extracellular matrix along with proteoglycan?\n\n① actin\n② fibronectin\n③ α-keratin\n④ lamin\n⑤ tubulin",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: Aminotransferase의 활성자리에서 아미노기의 중간 운반체로 작용하는 조효소는?\n\n① biotin\n② FADH2\n③ NADH\n④ pyridoxal phosphate\n⑤ thiamine pyrophosphate",
        "question_text": "Question: Which coenzyme acts as an intermediate carrier of the amino group at the active site of aminotransferase?\n\n① biotin\n② FADH2\n③ NADH\n④ pyridoxal phosphate\n⑤ thiamine pyrophosphate",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: Ceramide의 머리 부분에 1개의 단당류가 결합된 glycosphingolipid는?\n\n① cerebroside\n② ganglioside GM2\n③ lecithin\n④ plasmalogen\n⑤ sphingomyelin",
        "question_text": "Question: Which glycosphingolipid has one monosaccharide attached to the head portion of ceramide?\n\n① cerebroside\n② ganglioside GM2\n③ lecithin\n④ plasmalogen\n⑤ sphingomyelin",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 포도당신합성 과정에서 pyruvate로부터 oxaloacetate로의 변환이 일어나는 세포내 소기관은?\n\n① endoplasmic reticulum\n② Golgi apparatus\n③ lysosome\n④ mitochondria\n⑤ nucleus",
        "question_text": "Question: Which cellular organelle is responsible for the conversion of pyruvate to oxaloacetate in the process of gluconeogenesis?\n\n① endoplasmic reticulum\n② Golgi apparatus\n③ lysosome\n④ mitochondria\n⑤ nucleus",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 글리코겐 생성효소(glycogen synthase)가 촉매하는 반응에서 포도당의 직접적인 제공자는?\n\n① glucose 1,6-bisphosphate\n② glucose 1-phosphate\n③ glucose 6-phosphate\n④ UDP-galactose\n⑤ UDP-glucose",
        "question_text": "Question: In the reaction catalyzed by glycogen synthase, what is the direct donor of glucose?\n\n① glucose 1,6-bisphosphate\n② glucose 1-phosphate\n③ glucose 6-phosphate\n④ UDP-galactose\n⑤ UDP-glucose",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 혈중 포도당 농도가 낮은 기아 상태에서 뇌세포가 사용하는 주된 에너지원은?\n\n① citrate\n② D-β-hydroxybutyrate\n③ malate\n④ oxaloacetate\n⑤ pyruvate",
        "question_text": "Question: What is the main energy source used by brain cells during a fasting state when blood glucose concentration is low?\n\n① citrate\n② D-β-hydroxybutyrate\n③ malate\n④ oxaloacetate\n⑤ pyruvate",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 요소회로(urea cycle)에서 ornithine과 carbamoyl phosphate로부터 citrulline을 생성하는 효소는?\n\n① arginase\n② argininosuccinase\n③ argininosuccinate synthetase\n④ carbamoyl phosphate synthetase I\n⑤ ornithine transcarbamoylase",
        "question_text": "Question: In the urea cycle, which enzyme produces citrulline from ornithine and carbamoyl phosphate?\n\n① arginase\n② argininosuccinase\n③ argininosuccinate synthetase\n④ carbamoyl phosphate synthetase I\n⑤ ornithine transcarbamoylase",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 시트르산회로(citric acid cycle)에서 FADH2를 생성하여 미토콘드리아 내막의 ubiquinone으로 전자를 전달하는 효소는?\n\n① cytochrome oxidase\n② L-malate dehydrogenase\n③ NADH dehydrogenase\n④ succinate dehydrogenase\n⑤ ubiquinone : cytochrome c oxidoreductase",
        "question_text": "Question: In the citric acid cycle, which enzyme produces FADH2 and transfers electrons to ubiquinone in the inner mitochondrial membrane?\n\n① cytochrome oxidase\n② L-malate dehydrogenase\n③ NADH dehydrogenase\n④ succinate dehydrogenase\n⑤ ubiquinone : cytochrome c oxidoreductase",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 지방산 합성 과정에서 malonyl-CoA를 생성하며, palmitoyl-CoA에 의해 되먹임억제(feedback inhibition)되는 효소는?\n\n① acetyl-CoA carboxylase\n② acyl-CoA dehydrogenase\n③ enoyl-CoA hydratase\n④ β-hydroxyacyl-CoA dehydrogenase\n⑤ methylmalonyl-CoA epimerase",
        "question_text": "Question: Which enzyme produces malonyl-CoA in the fatty acid synthesis process and is subject to feedback inhibition by palmitoyl-CoA?\n\n① acetyl-CoA carboxylase\n② acyl-CoA dehydrogenase\n③ enoyl-CoA hydratase\n④ β-hydroxyacyl-CoA dehydrogenase\n⑤ methylmalonyl-CoA epimerase",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 지방조직에서 thiazolidinedione 계열의 약물에 의해 peroxisome proliferator-activated receptor-γ(PPAR-γ)가 활성화되었을 때 그 발현이 증가하는 효소는?\n\n① hexokinase\n② glycerol 3-phosphate acyltransferase\n③ glycerol 3-phosphate dehydrogenase\n④ lactate dehydrogenase\n⑤ phosphoenolpyruvate carboxykinase",
        "question_text": "Question: Which enzyme's expression increases when peroxisome proliferator-activated receptor-γ (PPAR-γ) is activated by thiazolidinedione class drugs in adipose tissue?\n\n① hexokinase\n② glycerol 3-phosphate acyltransferase\n③ glycerol 3-phosphate dehydrogenase\n④ lactate dehydrogenase\n⑤ phosphoenolpyruvate carboxykinase",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 생합성 과정에서 N 5-methyltetrahydrofolate가 필요한 아미노산은?\n\n① alanine\n② asparagine\n③ leucine\n④ lysine\n⑤ methionine",
        "question_text": "Question: Which amino acid requires N5-methyltetrahydrofolate in its biosynthesis process?\n\n① alanine\n② asparagine\n③ leucine\n④ lysine\n⑤ methionine",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 진핵세포의 유전자 발현 과정에서 전사 활성자(transcription activator)가 인식하여 결합하는 DNA 부위는?\n\n① DNA unwinding element\n② enhancer\n③ initiator\n④ TATA box\n⑤ telomere",
        "question_text": "Question: In the gene expression process of eukaryotic cells, which DNA region does the transcription activator recognize and bind to?\n\n① DNA unwinding element\n② enhancer\n③ initiator\n④ TATA box\n⑤ telomere",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 시클로부탄 피리미딘 이합체(cyclobutane pyrimidine dimer)의 생성으로 DNA가 손상되었다. 이를 복구하는 효소는?\n\n① Dam methylase\n② excinuclease\n③ MutH protein\n④ primase\n⑤ topoisomerase",
        "question_text": "Question: DNA was damaged by the formation of cyclobutane pyrimidine dimers. Which enzyme repairs this damage?\n\n① Dam methylase\n② excinuclease\n③ MutH protein\n④ primase\n⑤ topoisomerase",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 뉴클레오솜의 히스톤 H3과 H4의 아미노 말단에 위치한 lysine 잔기들이 아세틸화될 경우 나타나는 현상은?\n\n① 염색체의 응축\n② mRNA splicing 촉진\n③ 전사체의 번역활성 증가\n④ 유전자의 전사활성 증가\n⑤ 히스톤 octamer 구조의 분리",
        "question_text": "Question: What phenomenon occurs when lysine residues located at the amino terminals of histones H3 and H4 in nucleosomes are acetylated?\n\n① Chromosome condensation\n② Promotion of mRNA splicing\n③ Increased translation activity of transcripts\n④ Increased transcriptional activity of genes\n⑤ Separation of histone octamer structure",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 다음 A 단계에서 작용하는 효소의 결함과 관련된 유전질환은?\n\n<Data (confidential)>\n\n① alkaptonuria\n② maple syrup urine disease\n③ pernicious anemia\n④ phenylketonuria\n⑤ Zellweger syndrome",
        "question_text": "Question: Which genetic disorder is associated with a deficiency of the enzyme acting in step A?\n\n<Data (confidential)>\n\n① alkaptonuria\n② maple syrup urine disease\n③ pernicious anemia\n④ phenylketonuria\n⑤ Zellweger syndrome",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 혈관 내피세포에 존재하는 단백질로서 백혈구 표면의 당단백질을 인식하여 염증 부위에 백혈구를 부착시키는 것은?\n\n① actin\n② fibronectin\n③ hemagglutinin\n④ hyaluronan\n⑤ selectin",
        "question_text": "Question: Which protein present in vascular endothelial cells recognizes glycoproteins on the surface of leukocytes and facilitates the adhesion of leukocytes to inflammatory sites?\n\n① actin\n② fibronectin\n③ hemagglutinin\n④ hyaluronan\n⑤ selectin",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 저용량의 아스피린이 혈전 생성을 억제하는 기전은?\n\n① arachidonate 합성 저해\n② leukotriene A4 합성 저해\n③ prostacyclin 합성 증가\n④ prostaglandin H2 합성 증가\n⑤ thromboxane A2 합성 저해",
        "question_text": "Question: What is the mechanism by which low-dose aspirin inhibits thrombus formation?\n\n① Inhibition of arachidonate synthesis\n② Inhibition of leukotriene A4 synthesis\n③ Increase in prostacyclin synthesis\n④ Increase in prostaglandin H2 synthesis\n⑤ Inhibition of thromboxane A2 synthesis",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: Sphingomyelinase의 결핍으로 인하여 sphingomyelin이 뇌에 축적되어 지능발달이 지체되는 유전질환은?\n\n① cystic fibrosis\n② Lesch-Nyhan syndrome\n③ Niemann-Pick disease\n④ Tay-Sachs disease\n⑤ xeroderma pigmentosum",
        "question_text": "Question: Which genetic disorder is characterized by the accumulation of sphingomyelin in the brain due to sphingomyelinase deficiency, resulting in delayed intellectual development?\n\n① cystic fibrosis\n② Lesch-Nyhan syndrome\n③ Niemann-Pick disease\n④ Tay-Sachs disease\n⑤ xeroderma pigmentosum",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고등 진핵생물에서 microRNA(miRNA)가 성숙되는 단계는 다음과 같다.\n<Data (confidential)>\n\nQuestion: Dicer가 작용하는 단계는?\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "question_text": "In higher eukaryotes, the stages of microRNA (miRNA) maturation are as follows:\n<Data (confidential)>\n\nQuestion: At which stage does Dicer act?\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고등 진핵생물에서 microRNA(miRNA)가 성숙되는 단계는 다음과 같다.\n<Data (confidential)>\n\nQuestion: RNA-induced silencing complex(RISC)와 결합하는 miRNA의 형태는?\n\n① ⓐ\n② ⓑ\n③ ⓒ\n④ ⓓ\n⑤ ⓔ",
        "question_text": "In higher eukaryotes, the stages of microRNA (miRNA) maturation are as follows:\n<Data (confidential)>\n\nQuestion: Which form of miRNA binds to the RNA-induced silencing complex (RISC)?\n\n① ⓐ\n② ⓑ\n③ ⓒ\n④ ⓓ\n⑤ ⓔ",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: Leuconostoc mesenteroides의 발효 산물로서 혈장대용제로 사용되는 것은?\n\n① albumin\n② alginate\n③ dextran\n④ gelatin\n⑤ glucan",
        "question_text": "Question: Which fermentation product of Leuconostoc mesenteroides is used as a plasma substitute?\n\n① albumin\n② alginate\n③ dextran\n④ gelatin\n⑤ glucan",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 신약후보물질의 변이원성을 검사하기 위해 Salmonella Typhimurium의 영양요구균주를 이용하는 시험법은?\n\n① Ames test\n② D-test\n③ IMViC test\n④ Kirby-Bauer test\n⑤ Schick test",
        "question_text": "Question: Which test method uses nutritionally deficient strains of Salmonella Typhimurium to examine the mutagenicity of new drug candidate substances?\n\n① Ames test\n② D-test\n③ IMViC test\n④ Kirby-Bauer test\n⑤ Schick test",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 사람 단클론항체(human monoclonal antibody)를 제조하기 위해 특정 단백질을 발현하는 파지를 선별하는 기법은?\n\n① 접합(conjugation)\n② 형질도입(transduction)\n③ 파지전시(phage display)\n④ 유전체 교정(genome editing)\n⑤ 면역침강(immunoprecipitation)",
        "question_text": "Question: What technique is used to select phages expressing specific proteins for the production of human monoclonal antibodies?\n\n① Conjugation\n② Transduction\n③ Phage display\n④ Genome editing\n⑤ Immunoprecipitation",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 다음과 같은 특성을 가지는 그람음성균의 감염증에 사용하는 항생제는?\n\n• Extended spectrum β-lactamase(ESBL)를 생성함\n• 3세대 세팔로스포린류 약물에 내성을 가짐\n\n① amoxicillin\n② aztreonam\n③ cefaclor\n④ cefazolin\n⑤ imipenem",
        "question_text": "Question: Which antibiotic is used for infections caused by gram-negative bacteria with the following characteristics?\n\n• Produces Extended spectrum β-lactamase (ESBL)\n• Resistant to 3rd generation cephalosporins\n\n① amoxicillin\n② aztreonam\n③ cefaclor\n④ cefazolin\n⑤ imipenem",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 그람음성균에 유효한 항생제로, 다제내성 Pseudomonas 속 세균에 의한 중증 감염증을 치료하기 위해 사용하는 것은?\n\n① ampicillin\n② bacitracin\n③ clindamycin\n④ colistin\n⑤ tetracycline",
        "question_text": "Question: Which antibiotic effective against Gram-negative bacteria is used to treat severe infections caused by multidrug-resistant Pseudomonas species?\n\n① ampicillin\n② bacitracin\n③ clindamycin\n④ colistin\n⑤ tetracycline",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 호흡기로의 투과율이 높은 약물로서 다제내성결핵(multidrug-resistant tuberculosis)의 치료에 사용되는 것은?\n\n① bleomycin\n② cephalexin\n③ doxycycline\n④ levofloxacin\n⑤ methicillin",
        "question_text": "Question: Which of the following drugs, known for its high permeability in the respiratory system, is used in the treatment of multidrug-resistant tuberculosis?\n\n① bleomycin\n② cephalexin\n③ doxycycline\n④ levofloxacin\n⑤ methicillin",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: Itraconazole에 의해 합성이 저해되는 것은?\n\n① chitin\n② ergosterol\n③ glucan\n④ microtubule\n⑤ squalene",
        "question_text": "Question: Which of the following is inhibited in its synthesis by Itraconazole?\n\n① chitin\n② ergosterol\n③ glucan\n④ microtubule\n⑤ squalene",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: B형 간염 바이러스의 역전사효소를 저해하는 항바이러스제는?\n\n① acyclovir\n② entecavir\n③ raltegravir\n④ ribavirin\n⑤ sofosbuvir",
        "question_text": "Question: Which antiviral drug inhibits the reverse transcriptase of hepatitis B virus?\n\n① acyclovir\n② entecavir\n③ raltegravir\n④ ribavirin\n⑤ sofosbuvir",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 병원균의 세포벽 성분에 의한 보체 활성화 경로에서 C3 전환효소(convertase)를 안정화시키는 혈청 단백질은?\n\n① C1q\n② C4b \n③ immunoglobulin M\n④ mannose-binding lectin\n⑤ properdin",
        "question_text": "Question: Which serum protein stabilizes the C3 convertase in the complement activation pathway initiated by cell wall components of pathogens?\n\n① C1q\n② C4b\n③ immunoglobulin M\n④ mannose-binding lectin\n⑤ properdin",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 수지상세포가 항원펩티드를 제시할 때, T세포 표면에서 발현되는 공동자극수용체(costimulatory receptor)는?\n\n① CD4\n② CD8\n③ CD25\n④ CD28\n⑤ CD40",
        "question_text": "Question: When dendritic cells present antigen peptides, which costimulatory receptor is expressed on the surface of T cells?\n\n① CD4\n② CD8\n③ CD25\n④ CD28\n⑤ CD40",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 흑색종 환자의 T세포를 활성화시키는 단클론항체 의약품의 표적 항원이며, T세포 표면의 면역체크포인트(immune checkpoint) 분자는?\n\n① B7\n② CD3\n③ CD19\n④ CD20\n⑤ PD-1",
        "question_text": "Question: Which of the following is the target antigen for monoclonal antibody drugs that activate T cells in melanoma patients, and is also an immune checkpoint molecule on the surface of T cells?\n\n① B7\n② CD3\n③ CD19\n④ CD20\n⑤ PD-1",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 면역복합체 생성에 의한 과민반응으로 발생하는 질환은?\n\n① 천식(asthma)\n② 결핵(tuberculosis)\n③ 아토피피부염(atopic dermatitis)\n④ 태아적혈모구증(erythroblastosis fetalis)\n⑤ 전신홍반루푸스(systemic lupus erythematosus)",
        "question_text": "Question: Which disease is caused by hypersensitivity reaction due to immune complex formation?\n\n① Asthma\n② Tuberculosis\n③ Atopic dermatitis\n④ Erythroblastosis fetalis\n⑤ Systemic lupus erythematosus",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: HER2 양성 유방암의 치료에 사용하는 단클론항체 의약품은?\n\n① adalimumab\n② bevacizumab\n③ infliximab\n④ rituximab\n⑤ trastuzumab",
        "question_text": "Question: Which monoclonal antibody medication is used in the treatment of HER2-positive breast cancer?\n\n① adalimumab\n② bevacizumab\n③ infliximab\n④ rituximab\n⑤ trastuzumab",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: DTaP 백신의 제조에서 디프테리아의 예방을 위해 사용하는 원료는?\n\n① 핵산(DNA)\n② 변독소(toxoid)\n③ 사균(killed bacteria)\n④ 약독화 생균(attenuated bacteria)\n⑤ 재조합단백질(recombinant protein)",
        "question_text": "Question: In the production of the DTaP vaccine, what ingredient is used for the prevention of diphtheria?\n\n① Nucleic acid (DNA)\n② Toxoid\n③ Killed bacteria\n④ Attenuated bacteria\n⑤ Recombinant protein",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: Haemophilus influenzae type b 백신을 제조하는 데 사용하는 원료는?\n\n① 선모(pilus)\n② 캡슐(capsule)\n③ 세포벽(cell wall)\n④ 외막(outer membrane)\n⑤ 세포막(cell membrane)",
        "question_text": "Question: What is the raw material used in manufacturing the Haemophilus influenzae type b vaccine?\n\n① Pilus\n② Capsule\n③ Cell wall\n④ Outer membrane\n⑤ Cell membrane",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 사람의 상기도에 상주하는 그람양성균으로서 폐렴, 중이염, 수막염 등의 원인이 되는 병원균은?\n\n① Klebsiella pneumoniae\n② Legionella pneumophila\n③ Neisseria meningitidis\n④ Staphylococcus epidermidis\n⑤ Streptococcus pneumoniae",
        "question_text": "Question: Which gram-positive bacterium, residing in the upper respiratory tract of humans, is a pathogen that causes pneumonia, otitis media, meningitis, and other infections?\n\n① Klebsiella pneumoniae\n② Legionella pneumophila\n③ Neisseria meningitidis\n④ Staphylococcus epidermidis\n⑤ Streptococcus pneumoniae",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 물이나 음식 또는 감염된 사람과의 접촉을 통해 전파되며, 영유아 및 성인에게 심한 설사를 동반한 위장관 질환을 유발하는 바이러스는?\n\n① Coxsackie virus\n② Ebola virus\n③ norovirus\n④ poliovirus\n⑤ rhinovirus",
        "question_text": "Question: Which virus is transmitted through water, food, or contact with infected individuals, and causes severe diarrhea and gastrointestinal illness in infants and adults?\n\n① Coxsackie virus\n② Ebola virus\n③ norovirus\n④ poliovirus\n⑤ rhinovirus",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: Herpesviridae에 속하며, 전염성 단핵구증, 림프증식성 질환 등의 원인이 되는 바이러스는?\n\n① 엡스타인바 바이러스(Epstein-Barr virus)\n② 사람유두종 바이러스(human papillomavirus)\n③ 수두대상포진 바이러스(varicella-zoster virus)\n④ 사람거대세포 바이러스(human cytomegalovirus) \n⑤ 호흡기세포융합 바이러스(respiratory syncytial virus)",
        "question_text": "Question: Which virus belongs to the Herpesviridae family and is the cause of infectious mononucleosis, lymphoproliferative disorders, and other conditions?\n\n① Epstein-Barr virus\n② Human papillomavirus\n③ Varicella-zoster virus\n④ Human cytomegalovirus\n⑤ Respiratory syncytial virus",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n발진을 동반한 인두염 증상을 보인 6세 소아의 병소로부터 균을 분리하였다. 이 균은 그람양성으로 염색되었고 혈액한천배지에서 베타 용혈현상을 보였다.\n\nQuestion: 이 환자에게 나타날 수 있는 합병증은?\n\n① 위염\n② 장염\n③ 백일해\n④ 성홍열\n⑤ 파상풍",
        "question_text": "A bacterium was isolated from the lesion of a 6-year-old child showing symptoms of pharyngitis accompanied by a rash. This bacterium stained Gram-positive and showed beta-hemolysis on blood agar plates.\n\nQuestion: What complication might this patient develop?\n\n① Gastritis\n② Enteritis\n③ Whooping cough\n④ Scarlet fever\n⑤ Tetanus",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n발진을 동반한 인두염 증상을 보인 6세 소아의 병소로부터 균을 분리하였다. 이 균은 그람양성으로 염색되었고 혈액한천배지에서 베타 용혈현상을 보였다.\n\nQuestion: 이 환자의 혈액에서 streptolysin O에 대한 항체가 검출되었다면, 예측할 수 있는 질환은?\n\n① 결핵\n② 고환염\n③ 결막염\n④ 수막염\n⑤ 급성사구체신염",
        "question_text": "A 6-year-old child presented with symptoms of pharyngitis accompanied by a rash. Bacteria were isolated from the lesion. The bacteria stained Gram-positive and showed beta-hemolysis on blood agar plates.\n\nQuestion: If antibodies against streptolysin O were detected in this patient's blood, what disease can be predicted?\n\n① Tuberculosis\n② Orchitis\n③ Conjunctivitis\n④ Meningitis\n⑤ Acute glomerulonephritis",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: Dihydrofolate reductase 억제를 주 작용기전으로 하여 치료효과를 나타내는 항암제는?\n\n① gemcitabine\n② irinotecan\n③ methotrexate\n④ sulfamethoxazole\n⑤ trimethoprim",
        "question_text": "Question: Which anticancer drug exhibits its therapeutic effect primarily through the inhibition of dihydrofolate reductase?\n\n① gemcitabine\n② irinotecan\n③ methotrexate\n④ sulfamethoxazole\n⑤ trimethoprim",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 이온통로 형태의 수용체(ionotropic receptor)와 그 수용체를 통해 이동할 수 있는 이온의 조합으로 옳은 것은?\n\n① D2 수용체 – Ca2+\n② 5-HT3 수용체 – Na+\n③ NMDA 수용체 – Cl-\n④ GABA_B 수용체 – Cl-\n⑤ GABA_A 수용체 – Na+",
        "question_text": "Question: Which of the following is the correct combination of an ionotropic receptor and the ion that can pass through it?\n\n① D2 receptor – Ca2+\n② 5-HT3 receptor – Na+\n③ NMDA receptor – Cl-\n④ GABA_B receptor – Cl-\n⑤ GABA_A receptor – Na+",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 유전적으로 N-acetyltransferase 효소 활성이 낮은 사람에게 장기간 투여했을 때 말초신경염 유발 위험이 높은 약물은?\n\n① debrisoquine\n② dexamethasone\n③ isoniazid\n④ succinylcholine\n⑤ theophylline",
        "question_text": "Question: Which drug has a higher risk of causing peripheral neuropathy when administered long-term to individuals with genetically low N-acetyltransferase enzyme activity?\n\n① debrisoquine\n② dexamethasone\n③ isoniazid\n④ succinylcholine\n⑤ theophylline",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: Acetylcholine(X)의 기관지 평활근 수축효과를 나타낸 용량-반응곡선(dose-effect curve)이다. 약물 A 또는 B의 존재 시 측정한 X의 용량-반응곡선이 다음 그림과 같을 때, 약물 B에 해당하는 것은?\n\n<Data (confidential)>\n\n① bethanechol\n② doxazosin\n③ ipratropium\n④ phenoxybenzamine\n⑤ propranolol",
        "question_text": "Question: This is a dose-effect curve showing the bronchial smooth muscle contraction effect of Acetylcholine (X). When the dose-response curve of X measured in the presence of drug A or B is as shown in the following figure, which of the following corresponds to drug B?\n\n<Data (confidential)>\n\n① bethanechol\n② doxazosin\n③ ipratropium\n④ phenoxybenzamine\n⑤ propranolol",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 다음 특성을 가진 비정형 항정신병약물은?\n\n• D2 수용체보다 5-HT2A 수용체에 더 높은 친화력을 지님\n• 조현병의 음성 증상 개선 효과가 우수함\n• 체중증가, 혈당증가, 무과립구증 유발 위험이 있음\n\n① aripiprazole\n② chlorpromazine\n③ clozapine\n④ haloperidol\n⑤ lithium",
        "question_text": "Question: Which of the following atypical antipsychotic drugs has these characteristics?\n\n• Has higher affinity for 5-HT2A receptors than D2 receptors\n• Shows excellent improvement in negative symptoms of schizophrenia\n• Carries risks of weight gain, increased blood glucose, and agranulocytosis\n\n① aripiprazole\n② chlorpromazine\n③ clozapine\n④ haloperidol\n⑤ lithium",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 구강건조와 기립성저혈압, 졸음 등과 같은 자율신경계 부작용 위험이 낮은 항우울약으로, 신경성 폭식증 등 섭식장애의 치료에도 사용이 허가된 약물은?\n\n① alprazolam\n② amitriptyline\n③ fluoxetine\n④ trazodone\n⑤ venlafaxine",
        "question_text": "Question: Which antidepressant has a lower risk of autonomic nervous system side effects such as dry mouth, orthostatic hypotension, and drowsiness, and is also approved for the treatment of eating disorders like bulimia nervosa?\n\n① alprazolam\n② amitriptyline\n③ fluoxetine\n④ trazodone\n⑤ venlafaxine",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: Valproic acid와 병용 시 피부발진 위험이 증가하는 약물은?\n\n① gabapentin\n② hydroxyzine\n③ lamotrigine\n④ levetiracetam\n⑤ pregabalin",
        "question_text": "Question: Which drug increases the risk of skin rash when used concomitantly with valproic acid?\n\n① gabapentin\n② hydroxyzine\n③ lamotrigine\n④ levetiracetam\n⑤ pregabalin",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: Serotonin 및 norepinephrine 재흡수 차단작용이 있으며, μ-opioid 수용체에도 친화력이 있는 중추성 진통약은?\n\n① baclofen\n② cetirizine\n③ dextromethorphan\n④ ketorolac\n⑤ tramadol",
        "question_text": "Question: Which central analgesic has serotonin and norepinephrine reuptake inhibition effects, and also has affinity for μ-opioid receptors?\n\n① baclofen\n② cetirizine\n③ dextromethorphan\n④ ketorolac\n⑤ tramadol",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: Cysteinyl leukotriene(CysLT) 수용체 길항약으로, 천식 증상을 개선시키는 것은?\n\n① cromolyn\n② montelukast\n③ salmeterol\n④ theophylline\n⑤ zileuton",
        "question_text": "Question: Which of the following is a cysteinyl leukotriene (CysLT) receptor antagonist that improves asthma symptoms?\n\n① cromolyn\n② montelukast\n③ salmeterol\n④ theophylline\n⑤ zileuton",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 혈청 homocysteine 농도 증가와 신경학적 이상 증상을 보이는 거대적혈모구빈혈(megaloblastic anemia) 환자에게 결핍된 것은?\n\n① cyanocobalamin\n② erythropoietin\n③ folic acid\n④ iron\n⑤ vitamin B6",
        "question_text": "Question: Which of the following is deficient in a patient with megaloblastic anemia showing increased serum homocysteine concentration and neurological abnormalities?\n\n① cyanocobalamin\n② erythropoietin\n③ folic acid\n④ iron\n⑤ vitamin B6",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 레닌-안지오텐신-알도스테론 시스템에 작용하는 항고혈압약으로, bradykinin 대사를 억제하여 기침, 혈관부종 등의 부작용을 유발할 위험이 높은 약물은?\n\n① carvedilol\n② clonidine\n③ enalapril\n④ nifedipine\n⑤ nitroprusside",
        "question_text": "Question: Which antihypertensive drug that acts on the renin-angiotensin-aldosterone system has a higher risk of causing side effects such as cough and angioedema by inhibiting bradykinin metabolism?\n\n① carvedilol\n② clonidine\n③ enalapril\n④ nifedipine\n⑤ nitroprusside",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 이상지질혈증 치료약물과 주 작용기전을 옳게 연결한 것은?\n\n① ezetimibe – VLDL 분비 억제\n② gemfibrozil – 담즙산 재흡수 억제\n③ cholestyramine – 지방산 산화 증가\n④ atorvastatin – 콜레스테롤 생합성 억제\n⑤ niacin(nicotinic acid) – 콜레스테롤 장흡수 억제",
        "question_text": "Question: Which of the following correctly matches the drug used to treat dyslipidemia with its main mechanism of action?\n\n① ezetimibe – Inhibition of VLDL secretion\n② gemfibrozil – Inhibition of bile acid reabsorption\n③ cholestyramine – Increase in fatty acid oxidation\n④ atorvastatin – Inhibition of cholesterol biosynthesis\n⑤ niacin(nicotinic acid) – Inhibition of cholesterol intestinal absorption",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 이뇨약과 주 작용 부위를 옳게 연결한 것은?\n\n① amiloride – 원위세뇨관\n② acetazolamide – 집합관\n③ furosemide – 헨레고리 상행각\n④ hydrochlorothiazide – 근위세뇨관\n⑤ spironolactone – 헨레고리 하행각",
        "question_text": "Question: Which of the following correctly matches the diuretic drug with its primary site of action?\n\n① amiloride – distal tubule\n② acetazolamide – collecting duct\n③ furosemide – ascending limb of the loop of Henle\n④ hydrochlorothiazide – proximal tubule\n⑤ spironolactone – descending limb of the loop of Henle",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 벽세포소관(parietal cell canaliculus)에서 활성형 sulfenamide 양이온으로 변환된 후 H+/K+-ATPase와 비가역적 공유결합을 형성하여 위산 분비를 억제하는 약물은?\n\n① bismuth subsalicylate\n② cimetidine\n③ misoprostol\n④ omeprazole\n⑤ sucralfate",
        "question_text": "Question: Which drug inhibits gastric acid secretion by transforming into an active sulfenamide cation in the parietal cell canaliculus and then forming an irreversible covalent bond with H+/K+-ATPase?\n\n① bismuth subsalicylate\n② cimetidine\n③ misoprostol\n④ omeprazole\n⑤ sucralfate",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: Acarbose가 혈당을 강하시키는 주 작용기전은?\n\n① α-glucosidase 억제\n② dipeptidyl peptidase 4(DPP-4) 억제\n③ glucagon-like peptide 1(GLP-1) 수용체 길항\n④ ATP-sensitive K+ channel(KATP channel) 활성화\n⑤ peroxisome proliferator-activated receptor-γ(PPAR-γ) 활성화",
        "question_text": "Question: What is the main mechanism of action by which Acarbose lowers blood glucose?\n\n① Inhibition of α-glucosidase\n② Inhibition of dipeptidyl peptidase 4 (DPP-4)\n③ Antagonism of glucagon-like peptide 1 (GLP-1) receptor\n④ Activation of ATP-sensitive K+ channel (KATP channel)\n⑤ Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ)",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 뼈흡수를 억제하여 골다공증 치료효과를 나타내는 pyrophosphate 유도체는?\n\n① alendronate\n② calcitriol\n③ denosumab\n④ raloxifene\n⑤ teriparatide",
        "question_text": "Question: Which pyrophosphate derivative inhibits bone resorption and shows therapeutic effects for osteoporosis?\n\n① alendronate\n② calcitriol\n③ denosumab\n④ raloxifene\n⑤ teriparatide",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 녹농균 감염이 의심되는 환자에게 경험적 항균요법을 실시하고자 할 때, 상승효과를 나타낼 수 있는 조합은?\n\n① cefaclor – tetracycline\n② ticarcillin – tobramycin\n③ erythromycin – neomycin\n④ chloramphenicol – cefazolin\n⑤ kanamycin – sulfamethoxazole",
        "question_text": "Question: When initiating empirical antimicrobial therapy for a patient suspected of having a Pseudomonas aeruginosa infection, which combination can demonstrate a synergistic effect?\n\n① cefaclor – tetracycline\n② ticarcillin – tobramycin\n③ erythromycin – neomycin\n④ chloramphenicol – cefazolin\n⑤ kanamycin – sulfamethoxazole",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 다음 특성을 가진 면역억제약물은?\n\n• FK506-binding protein(FKBP)과 활성형 복합체 형성\n• mammalian target of rapamycin(mTOR) 억제\n• B세포와 T세포 증식 억제\n\n① azathioprine\n② cyclosporine\n③ infliximab\n④ mycophenolate mofetil\n⑤ sirolimus",
        "question_text": "Question: Which immunosuppressive drug has the following characteristics?\n\n• Forms an active complex with FK506-binding protein (FKBP)\n• Inhibits mammalian target of rapamycin (mTOR)\n• Inhibits B cell and T cell proliferation\n\n① azathioprine\n② cyclosporine\n③ infliximab\n④ mycophenolate mofetil\n⑤ sirolimus",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 동물실험 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n• A 그룹: 혈압과 심박동수를 모니터링하면서 phenylephrine을 정맥주사하였을 때, 주사 전보다 혈압은 상승하였고 심박동수는 감소하였다.\n• B 그룹: Trimethaphan 전처리로 자율신경절을 차단한 후 혈압과 심박동수를 모니터링하면서 phenylephrine을 정맥주사하였다.\n\nQuestion: 이 실험에서 사용한 phenylephrine의 혈압에 대한 작용을 매개하는 수용체는?\n\n① α1 수용체\n② α2 수용체\n③ β1 수용체\n④ β2 수용체\n⑤ 무스카린 수용체",
        "question_text": "• Group A: When phenylephrine was administered intravenously while monitoring blood pressure and heart rate, blood pressure increased and heart rate decreased compared to before the injection.\n• Group B: After pretreating with trimethaphan to block autonomic ganglia, phenylephrine was administered intravenously while monitoring blood pressure and heart rate.\n\nQuestion: Which receptor mediates the effect of phenylephrine on blood pressure in this experiment?\n\n① α1 receptor\n② α2 receptor\n③ β1 receptor\n④ β2 receptor\n⑤ Muscarinic receptor",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 동물실험 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n• A 그룹: 혈압과 심박동수를 모니터링하면서 phenylephrine을 정맥주사하였을 때, 주사 전보다 혈압은 상승하였고 심박동수는 감소하였다.\n• B 그룹: Trimethaphan 전처리로 자율신경절을 차단한 후 혈압과 심박동수를 모니터링하면서 phenylephrine을 정맥주사하였다.\n\nQuestion: B 그룹에서, phenylephrine 주사로 인한 혈압과 심박동수의 변화로 옳은 것은?\n\n< 혈압 > | < 심박동수 >\n① 상승 | 감소\n② 상승 | 유의한 변화 없음\n③ 유의한 변화 없음 | 증가\n④ 유의한 변화 없음 | 감소\n⑤ 유의한 변화 없음 | 유의한 변화 없음",
        "question_text": "• Group A: When phenylephrine was administered intravenously while monitoring blood pressure and heart rate, blood pressure increased and heart rate decreased compared to pre-injection levels.\n• Group B: After blocking autonomic ganglia with trimethaphan pretreatment, phenylephrine was administered intravenously while monitoring blood pressure and heart rate.\n\nQuestion: In Group B, which of the following correctly describes the changes in blood pressure and heart rate due to phenylephrine injection?\n\n< Blood Pressure > | < Heart Rate >\n① Increase | Decrease\n② Increase | No significant change\n③ No significant change | Increase\n④ No significant change | Decrease\n⑤ No significant change | No significant change",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 질병 발생의 원인을 설명하는 역학적 삼각형(epidemiologic triangle) 모델의 구성 요소는?\n\n① 병인, 숙주, 장소\n② 병인, 숙주, 환경\n③ 병인, 시간, 환경\n④ 숙주, 시간, 장소\n⑤ 시간, 장소, 환경",
        "question_text": "Question: What are the components of the epidemiologic triangle model that explains the causes of disease occurrence?\n\n① Agent, Host, Place\n② Agent, Host, Environment\n③ Agent, Time, Environment\n④ Host, Time, Place\n⑤ Time, Place, Environment",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 수용성이 비교적 낮아 세기관지나 폐포까지 도달하여, 폐포벽의 점막에 국소적으로 염증성 손상을 유발하고 산소교환에 영향을 주며 광화학 옥시단트(photochemical oxidant) 생성의 원인이 되는 가스상 물질은?\n\n① 벤젠증기\n② 수은증기\n③ 이산화황\n④ 이산화질소\n⑤ 일산화탄소",
        "question_text": "Question: Which gaseous substance has relatively low water solubility, reaches the small bronchi and alveoli, causes localized inflammatory damage to the alveolar wall mucosa, affects oxygen exchange, and is a cause of photochemical oxidant formation?\n\n① Benzene vapor\n② Mercury vapor\n③ Sulfur dioxide\n④ Nitrogen dioxide\n⑤ Carbon monoxide",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 정상인이 식품이나 환경 매체를 통하여 어떤 물질에 평생 노출되었을 경우 유해한 영향이 나타나지 않을 것으로 기대되는 1일 노출허용량을 의미하는 용어는?\n\n① 최소영향관찰용량(LOAEL)\n② 기준용량(benchmark dose)\n③ 독성참고치(reference dose)\n④ 최대무영향관찰용량(NOAEL)\n⑤ 노출한계(margin of exposure)",
        "question_text": "Question: What is the term that refers to the daily exposure amount that is expected to have no harmful effects when a normal person is exposed to a certain substance through food or environmental media for a lifetime?\n\n① Lowest Observed Adverse Effect Level (LOAEL)\n② Benchmark dose\n③ Reference dose\n④ No Observed Adverse Effect Level (NOAEL)\n⑤ Margin of exposure",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 발암 과정에서 장내미생물에 의한 대사가 필수적인 물질은?\n\n① aflatoxin B1\n② benzene\n③ 2,6-dinitrotoluene\n④ 2,3,7,8-tetrachlorodibenzo-p-dioxin\n⑤ vinyl chloride",
        "question_text": "Question: Which substance requires metabolism by intestinal microorganisms as an essential step in the carcinogenic process?\n\n① aflatoxin B1\n② benzene\n③ 2,6-dinitrotoluene\n④ 2,3,7,8-tetrachlorodibenzo-p-dioxin\n⑤ vinyl chloride",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: Acetaminophen의 간독성에 대한 설명으로 옳은 것은?\n\n① 간소엽의 zone 1에 특이적으로 독성을 유발한다.\n② Glucuronic acid 포합에 의해 독성이 더 강해진다.\n③ 대사 과정 없이 DNA와 결합하여 독성을 유발한다.\n④ Phase I 대사 과정 없이 glutathione 포합이 일어난다.\n⑤ Prostaglandin H synthase에 의해 독성대사체가 생성된다.",
        "question_text": "Question: Which of the following statements about the hepatotoxicity of Acetaminophen is correct?\n\n① It specifically induces toxicity in zone 1 of the liver lobule.\n② Its toxicity is enhanced by glucuronic acid conjugation.\n③ It causes toxicity by binding to DNA without metabolic processes.\n④ Glutathione conjugation occurs without Phase I metabolism.\n⑤ Toxic metabolites are produced by prostaglandin H synthase.",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 독성물질과 그 기원을 옳게 연결한 것은?\n\n① cycasin – 고사리 뿌리에 있는 고유성분\n② Trp-P-1 – 생선구이 과정 중 아미노산의 열분해\n③ benzo[a]pyrene – 식품 중의 아질산과 아민류의 반응\n④ acrylamide – 먹는물 염소 처리 중 소독 부산물로 생성\n⑤ dimethylnitrosamine – 육류의 숯불구이 과정 중 지질의 분해",
        "question_text": "Question: Which of the following correctly matches the toxic substance with its origin?\n\n① cycasin – a unique component found in fern roots\n② Trp-P-1 – thermal decomposition of amino acids during fish grilling\n③ benzo[a]pyrene – reaction between nitrites and amines in food\n④ acrylamide – formed as a disinfection by-product during chlorination of drinking water\n⑤ dimethylnitrosamine – decomposition of lipids during charcoal grilling of meat",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 화학물질에 의한 염색체 손상 시 수복되지 않은 염색체 단편이 세포분열 후에 잔존하는 현상을 관찰하는 유전독성 시험법은?\n\n① 소핵 시험\n② Draize 시험\n③ Hershberger 시험\n④ 복귀돌연변이 시험\n⑤ 마우스 lymphoma thymidine kinase 시험",
        "question_text": "Question: Which genotoxicity test method observes the phenomenon where unrepaired chromosome fragments remain after cell division due to chemical-induced chromosome damage?\n\n① Micronucleus test\n② Draize test\n③ Hershberger assay\n④ Reverse mutation test\n⑤ Mouse lymphoma thymidine kinase assay",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: Methomyl이나 propoxur의 중독에 사용할 수 있는 해독제는?\n\n① N-acetylcysteine\n② atropine\n③ EDTA\n④ methylene blue\n⑤ penicillamine",
        "question_text": "Question: What is the antidote that can be used for methomyl or propoxur poisoning?\n\n① N-acetylcysteine\n② atropine\n③ EDTA\n④ methylene blue\n⑤ penicillamine",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 음용수를 통한 만성 노출 시 과색소침착, 손바닥 각질화, 말초순환장애 등을 유발할 수 있으며, International Agency for Research on Cancer(IARC)에서 인체발암물질 Group 1로 분류한 것은?\n\n① 납(Pb)\n② 비소(As)\n③ 카드뮴(Cd)\n④ 6가 크롬(Cr6+)\n⑤ 메틸수은(CH3Hg)",
        "question_text": "Question: Which substance, when chronically exposed through drinking water, can cause hyperpigmentation, palmar keratosis, and peripheral circulatory disorders, and has been classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC)?\n\n① Lead (Pb)\n② Arsenic (As)\n③ Cadmium (Cd)\n④ Hexavalent Chromium (Cr6+)\n⑤ Methylmercury (CH3Hg)",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 점성이 큰 수용성 식이섬유로서 섭취 후 위에 음식물을 오래 머물게 하여 덤핑증후군에 사용될 수 있는 것은?\n\n① cellulose\n② chitin\n③ hemicellulose\n④ lignin\n⑤ pectic substance",
        "question_text": "Question: Which of the following is a highly viscous water-soluble dietary fiber that can be used for dumping syndrome by prolonging the retention of food in the stomach after ingestion?\n\n① cellulose\n② chitin\n③ hemicellulose\n④ lignin\n⑤ pectic substance",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: α-Linolenic acid로부터 합성되어, 혈중 중성지방을 감소시키고 혈소판 응집을 억제하는 기능을 가진 지방산은?\n\n① arachidonic acid\n② eicosapentaenoic acid\n③ linoleic acid\n④ γ-linolenic acid\n⑤ oleic acid",
        "question_text": "Question: Which fatty acid is synthesized from α-Linolenic acid and has the function of reducing blood triglycerides and inhibiting platelet aggregation?\n\n① arachidonic acid\n② eicosapentaenoic acid\n③ linoleic acid\n④ γ-linolenic acid\n⑤ oleic acid",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 단백질 식이 부족으로 부종, 설사, 피부질환, 면역기능 저하 등이 나타나고 저알부민혈증과 지방간비대를 특징으로 하는 영양 부족 질환은?\n\n① 소모증(marasmus)\n② 카시와커(kwashiorkor)\n③ 메니에르증후군(Ménière’s syndrome)\n④ 길랑바레증후군(Guillain-Barré syndrome)\n⑤ 베르니케 뇌병증(Wernicke encephalopathy)",
        "question_text": "Question: What is the nutritional deficiency disorder characterized by edema, diarrhea, skin disorders, decreased immune function, hypoalbuminemia, and fatty liver enlargement due to protein dietary deficiency?\n\n① Marasmus\n② Kwashiorkor\n③ Ménière's syndrome\n④ Guillain-Barré syndrome\n⑤ Wernicke encephalopathy",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 알코올탈수소효소의 활성에 필수적이며, 결핍 시 생식기 발달 저해와 미각이상이 나타날 수 있는 무기질은?\n\n① 아연(Zn)\n② 망간(Mn)\n③ 셀레늄(Se)\n④ 코발트(Co)\n⑤ 몰리브덴(Mo)",
        "question_text": "Question: Which mineral is essential for the activity of alcohol dehydrogenase, and its deficiency can lead to impaired reproductive organ development and taste disorders?\n\n① Zinc (Zn)\n② Manganese (Mn)\n③ Selenium (Se)\n④ Cobalt (Co)\n⑤ Molybdenum (Mo)",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: Isoniazid를 장기간 복용할 때 결핍될 수 있는 비타민은?\n\n① folic acid\n② vitamin B6\n③ vitamin B12\n④ vitamin E\n⑤ vitamin K",
        "question_text": "Question: Which vitamin may become deficient when taking Isoniazid for a long period?\n\n① folic acid\n② vitamin B6\n③ vitamin B12\n④ vitamin E\n⑤ vitamin K",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 식품성분 중 histidine을 histamine으로 대사시켜 알레르기성 식중독을 유발하는 원인균은?\n\n① Bacillus anthracis\n② Morganella morganii\n③ Listeria monocytogenes\n④ Campylobacter jejuni\n⑤ Staphylococcus aureus",
        "question_text": "Question: Which bacteria metabolizes histidine in food components into histamine, causing allergic food poisoning?\n\n① Bacillus anthracis\n② Morganella morganii\n③ Listeria monocytogenes\n④ Campylobacter jejuni\n⑤ Staphylococcus aureus",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 신경세포막의 sodium channel에 작용하여 Na+의 세포막 투과를 선택적으로 억제하는 독소는?\n\n① α-amanitin\n② fumonisin B\n③ grayanotoxin\n④ saxitoxin\n⑤ zearalenone",
        "question_text": "Question: Which toxin acts on the sodium channels of neuronal cell membranes to selectively inhibit Na+ permeability across the cell membrane?\n\n① α-amanitin\n② fumonisin B\n③ grayanotoxin\n④ saxitoxin\n⑤ zearalenone",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 환원작용에 의하여 색소를 파괴하는 표백제로서 공기 중에서 산화되어 유효농도 이하가 되면 표백작용이 소실되는 식품첨가물은?\n\n① 질산칼륨(potassium nitrate)\n② 과산화수소(hydrogen peroxide)\n③ 아황산수소나트륨(sodium bisulfite)\n④ 과황산암모늄(ammonium persulfate)\n⑤ 희석과산화벤조일(diluted benzoyl peroxide)",
        "question_text": "Question: Which food additive is a bleaching agent that destroys pigments through reduction, and loses its bleaching effect when oxidized in air, reducing its concentration below the effective level?\n\n① Potassium nitrate\n② Hydrogen peroxide\n③ Sodium bisulfite\n④ Ammonium persulfate\n⑤ Diluted benzoyl peroxide",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 건강기능식품 소재와 그 기능성을 옳게 연결한 것은?\n\n① 홍국 – 관절 건강\n② 정어리 펩타이드 – 혈압 개선\n③ 글루코사민 – 혈중 콜레스테롤 개선\n④ 쏘팔메토 열매 추출물 – 체지방 감소\n⑤ 가르시니아 캄보지아 추출물 – 전립선 건강유지",
        "question_text": "Question: Which of the following correctly matches the health functional food ingredient with its functionality?\n\n① Red yeast rice – Joint health\n② Sardine peptide – Blood pressure improvement\n③ Glucosamine – Blood cholesterol improvement\n④ Saw palmetto fruit extract – Body fat reduction\n⑤ Garcinia cambogia extract – Prostate health maintenance",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n불연속점을 지나도록 염소소독을 한 수도물을 마신 A 지역 주민들 다수에게서 설사, 복통, 발열, 구토 증상이 나타난 후 1~2주 내에 자연적으로 치유되었다. 오염원에 대한 조사 결과, 인근 축사의 가축 배설물이 폭우로 인하여 상수원으로 유입된 것으로 추정되었고, 소독한 물에서 4개의 자포자(sporozoite)로 이루어진 낭포체가 다수 검출되었다.\n\nQuestion: 염소소독에도 불구하고 수계 감염병이 나타난 것을 고려할 때, 추정되는 원인 병원체는?\n\n① Cryptosporidium parvum\n② Escherichia coli O157 : H7\n③ Helicobacter pylori\n④ Leptospira interrogans\n⑤ Shigella dysenteriae",
        "question_text": "Residents of area A who drank chlorine-disinfected water that passed through a discontinuity point experienced symptoms such as diarrhea, abdominal pain, fever, and vomiting, which naturally resolved within 1-2 weeks. Investigation of the source of contamination suggested that livestock excrement from a nearby farm had flowed into the water source due to heavy rain. Numerous oocysts consisting of 4 sporozoites were detected in the disinfected water.\n\nQuestion: Considering the occurrence of a waterborne disease despite chlorine disinfection, what is the most likely causative pathogen?\n\n① Cryptosporidium parvum\n② Escherichia coli O157 : H7\n③ Helicobacter pylori\n④ Leptospira interrogans\n⑤ Shigella dysenteriae",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n불연속점을 지나도록 염소소독을 한 수도물을 마신 A 지역 주민들 다수에게서 설사, 복통, 발열, 구토 증상이 나타난 후 1~2주 내에 자연적으로 치유되었다. 오염원에 대한 조사 결과, 인근 축사의 가축 배설물이 폭우로 인하여 상수원으로 유입된 것으로 추정되었고, 소독한 물에서 4개의 자포자(sporozoite)로 이루어진 낭포체가 다수 검출되었다.\n\nQuestion: 위 원인 병원체의 감염을 예방할 수 있는 먹는물 소독 방법은?\n\n① 불소처리\n② 연화처리\n③ 오존처리\n④ 폭기처리\n⑤ 황산동처리",
        "question_text": "Residents of area A who drank chlorine-disinfected tap water that passed through a discontinuity point experienced symptoms such as diarrhea, abdominal pain, fever, and vomiting, which naturally resolved within 1-2 weeks. Investigation of the contamination source suggested that livestock excrement from nearby farms had flowed into the water source due to heavy rain. Numerous oocysts consisting of 4 sporozoites were detected in the disinfected water.\n\nQuestion: Which drinking water disinfection method can prevent infection by the causative pathogen mentioned above?\n\n① Fluoridation\n② Softening treatment\n③ Ozone treatment\n④ Aeration treatment\n⑤ Copper sulfate treatment",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 다음의 특성을 가진 시토카인을 분비하는 세포는?\n\n• 상처조직으로의 백혈구 이동 촉진\n• 콜라겐 합성 자극\n• 혈관 형성 촉진\n\n① 호산구\n② 호중구\n③ 대식세포\n④ 형질세포\n⑤ 자연살해세포",
        "question_text": "Question: Which cell secretes cytokines with the following characteristics?\n\n• Promotes leukocyte migration to wound tissue\n• Stimulates collagen synthesis\n• Promotes angiogenesis\n\n① Eosinophil\n② Neutrophil\n③ Macrophage\n④ Plasma cell\n⑤ Natural killer cell",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 만성 알코올중독 환자에게서 결핍 되었을 때, 진행성 치매, 운동실조, 안근마비 증상을 유발하는 비타민은?\n\n① 니아신\n② 티아민\n③ 피리독신\n④ 리보플라빈\n⑤ 아스코르빈산",
        "question_text": "Question: Which vitamin, when deficient in chronic alcoholic patients, causes progressive dementia, ataxia, and ophthalmoplegia?\n\n① Niacin\n② Thiamine\n③ Pyridoxine\n④ Riboflavin\n⑤ Ascorbic acid",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 50세 남자가 최근 발열, 피로, 체중감소, 설사가 지속되어 혈액검사를 한 결과, CD4+ T세포 수가 현저히 감소된 것을 확인하였다. 이 환자에게서 추가적으로 나타날 수 있는 임상소견은?\n\n① 지방간\n② 파제트병\n③ 레이노현상\n④ 아토피피부염\n⑤ 구강 칸디다증",
        "question_text": "Question: A 50-year-old man recently experienced persistent fever, fatigue, weight loss, and diarrhea. Blood tests revealed a significant decrease in CD4+ T cell count. Which of the following clinical findings could additionally appear in this patient?\n\n① Fatty liver\n② Paget's disease\n③ Raynaud's phenomenon\n④ Atopic dermatitis\n⑤ Oral candidiasis",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 보툴리눔 식중독 환자에게 호흡곤란이 발생하는 병태생리 기전은?\n\n① 아세틸콜린 분비 차단\n② 기도세포 점액분비 촉진\n③ 호흡상피세포 손상 유발\n④ 호흡근육의 경련성 수축 유발\n⑤ 감마아미노부티르산 분비 차단",
        "question_text": "Question: What is the pathophysiological mechanism causing respiratory distress in patients with botulinum food poisoning?\n\n① Blockage of acetylcholine release\n② Stimulation of mucus secretion in airway cells\n③ Induction of respiratory epithelial cell damage\n④ Causing spasmodic contraction of respiratory muscles\n⑤ Inhibition of gamma-aminobutyric acid (GABA) release",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 안트라사이클린계 약물은 총 누적 사용 용량이 제한되고 있다. 그 이유가 되는 약물의 부작용은?\n\n① 방광염\n② 쓸개염\n③ 사구체신염\n④ 기관지확장증\n⑤ 심장근육병증",
        "question_text": "Question: The total cumulative dose of anthracycline drugs is limited. What is the side effect of the drug that is the reason for this?\n\n① Cystitis\n② Cholecystitis\n③ Glomerulonephritis\n④ Bronchiectasis\n⑤ Cardiomyopathy",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 12시간 동안 이코노미 등급의 좌석에 앉아 항공여행을 한 60세 비만 여자에게 4일 후부터 다음과 같은 상황이 발생하였다. 그 원인은?\n\n• 다리가 붓고 통증이 발생함\n• 발열이나 기침 증상 없이 호흡곤란 증세를 보임\n• 얼굴색이 창백해지다가 힘없이 쓰러짐\n\n① 폐렴\n② 폐기종\n③ 혈전색전\n④ 혈액응고결손\n⑤ 특발성폐섬유증",
        "question_text": "Question: A 60-year-old obese woman who traveled by air for 12 hours in an economy class seat experienced the following situation 4 days later. What is the cause?\n\n• Swelling and pain in the legs\n• Shortness of breath without fever or cough symptoms\n• Pale complexion followed by collapse due to weakness\n\n① Pneumonia\n② Emphysema\n③ Thromboembolism\n④ Blood coagulation deficiency\n⑤ Idiopathic pulmonary fibrosis",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 폐기종이나 폐고혈압을 주원인으로 하며, 우심실의 압력 과부하에 의해 초래되는 우심실비대가 특징인 질환은?\n\n① 흉막염(pleurisy)\n② 심근염(myocarditis)\n③ 심막염(pericarditis)\n④ 폐농양(lung abscess)\n⑤ 폐심장(cor pulmonale)",
        "question_text": "Question: Which disease is primarily caused by emphysema or pulmonary hypertension and is characterized by right ventricular hypertrophy resulting from right ventricular pressure overload?\n\n① Pleurisy\n② Myocarditis\n③ Pericarditis\n④ Lung abscess\n⑤ Cor pulmonale",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 외부 항원에 대한 과도한 Th2 반응과 IgE 매개 과민반응을 특징으로 하며 기관지수축과 점액분비가 증가되어, 천명, 호흡곤란, 기침발작의 증상을 보이는 질환은?\n\n① 천식\n② 진폐증\n③ 폐기종\n④ 과민성폐렴\n⑤ 만성기관지염",
        "question_text": "Question: Which disease is characterized by excessive Th2 response to external antigens and IgE-mediated hypersensitivity, with increased bronchial constriction and mucus secretion, resulting in symptoms of wheezing, shortness of breath, and coughing fits?\n\n① Asthma\n② Pneumoconiosis\n③ Emphysema\n④ Hypersensitivity pneumonitis\n⑤ Chronic bronchitis",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "original_text": "Question: Helicobacter pylori, 비스테로이드항염증제(NSAID), 흡연 등이 원인이 되며 위산 분비 증가 또는 중탄산 분비 저하에 의해서 유발되는 질환은?\n\n① 크론병\n② 휘플병\n③ 소화성궤양\n④ 바레트식도\n⑤ 과민성대장증후군",
        "question_text": "Question: Which disease is caused by factors such as Helicobacter pylori, non-steroidal anti-inflammatory drugs (NSAIDs), and smoking, and is triggered by increased gastric acid secretion or decreased bicarbonate secretion?\n\n① Crohn's disease\n② Whipple's disease\n③ Peptic ulcer\n④ Barrett's esophagus\n⑤ Irritable bowel syndrome",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "original_text": "Question: 궤양성대장염(ulcerative colitis)과 구별되는 크론병(Crohn disease)의 주된 임상소견은?\n\n① 점막층에 국한된 염증\n② 거짓폴립(pseudopolyps)\n③ 건너뛴 병변(skip lesions)\n④ 대장(colon)에 국한된 병변\n⑤ 넓은바닥궤양(broad-based ulcer)",
        "question_text": "Question: What is the main clinical finding that distinguishes Crohn's disease from ulcerative colitis?\n\n① Inflammation limited to the mucosal layer\n② Pseudopolyps\n③ Skip lesions\n④ Lesions confined to the colon\n⑤ Broad-based ulcer",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "original_text": "Question: 만성간염과 간경화를 일으키는 DNA 바이러스는?\n\n① A형 간염바이러스\n② B형 간염바이러스\n③ C형 간염바이러스\n④ E형 간염바이러스\n⑤ G형 간염바이러스",
        "question_text": "Question: Which DNA virus causes chronic hepatitis and cirrhosis?\n\n① Hepatitis A virus\n② Hepatitis B virus\n③ Hepatitis C virus\n④ Hepatitis E virus\n⑤ Hepatitis G virus",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "original_text": "Question: 급성이자염 발병 후 첫 72시간 동안 현저하게 증가하며 이자염 진단에 활용되는 것은?\n\n① 리파아제(lipase)\n② 빌리루빈(bilirubin)\n③ 칼시토닌(calcitonin)\n④ 알파태아단백질(α-fetoprotein)\n⑤ 크레아틴키나아제(creatine kinase)",
        "question_text": "Question: Which of the following significantly increases during the first 72 hours after the onset of acute pancreatitis and is used in the diagnosis of pancreatitis?\n\n① Lipase\n② Bilirubin\n③ Calcitonin\n④ α-fetoprotein\n⑤ Creatine kinase",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "original_text": "Question: 양성전립샘과다형성(benign prostatic hyperplasia)을 유발하며 제2형 5-알파 환원효소(5α-reductase type 2)에 의해 생성되는 호르몬은?\n\n① 코티손\n② 알도스테론\n③ 프로게스테론\n④ 부신피질자극호르몬\n⑤ 디히드로테스토스테론",
        "question_text": "Question: Which hormone is produced by 5α-reductase type 2 and causes benign prostatic hyperplasia?\n\n① Cortisone\n② Aldosterone\n③ Progesterone\n④ Adrenocorticotropic hormone\n⑤ Dihydrotestosterone",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "original_text": "Question: 당뇨병망막병증의 주원인은?\n\n① 세균감염\n② 혈관신생\n③ 말초신경 손상\n④ 조직 내 심한 탈수\n⑤ 수정체 내 소르비톨 축적",
        "question_text": "Question: What is the main cause of diabetic retinopathy?\n\n① Bacterial infection\n② Neovascularization\n③ Peripheral nerve damage\n④ Severe dehydration within tissues\n⑤ Accumulation of sorbitol in the lens",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "original_text": "Question: 내분비 호르몬과 그 분비기관을 옳게 연결한 것은?\n\n① calcitonin – 갑상샘\n② erythropoietin – 골수\n③ glucagon – 부갑상샘\n④ atrial natriuretic peptide – 콩팥\n⑤ antidiuretic hormone – 뇌하수체 전엽",
        "question_text": "Question: Which of the following correctly matches the endocrine hormone with its secreting organ?\n\n① calcitonin – thyroid gland\n② erythropoietin – bone marrow\n③ glucagon – parathyroid gland\n④ atrial natriuretic peptide – kidney\n⑤ antidiuretic hormone – anterior pituitary gland",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "original_text": "Question: 다음의 상태 또는 증상을 유발하는 원인은?\n\n• 정상보다 두꺼운 유골층\n• 근육 약화와 광범위한 뼈 통증\n• 뼈 두께 감소\n• 빈번한 대퇴부의 단순골절\n\n① 뼈와 골수의 세균 감염\n② 뼈의 불충분한 무기질화\n③ 요산(uric acid)의 과다생성\n④ 뼈파괴세포에 의한 뼈흡수 장애\n⑤ 판누스(pannus) 형성을 수반하는 활막염",
        "question_text": "Question: What is the cause of the following conditions or symptoms?\n\n• Thicker than normal osteoid layer\n• Muscle weakness and widespread bone pain\n• Decreased bone thickness\n• Frequent simple fractures of the femur\n\n① Bacterial infection of bone and bone marrow\n② Insufficient mineralization of bone\n③ Overproduction of uric acid\n④ Impaired bone resorption by osteoclasts\n⑤ Synovitis accompanied by pannus formation",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "original_text": "Question: 전신피로를 호소하는 60대 여자에게 바깥눈근육의 약화로 인한 눈꺼풀 처짐과 복시를 유발하는 자가항체의 표적 단백질은?\n\n① 데스민(desmin)\n② 트로포닌(troponin)\n③ 디스트로핀(dystrophin)\n④ 아세틸콜린수용체(acetylcholine receptor)\n⑤ 바탕질금속단백분해효소(matrix metalloproteinase)",
        "question_text": "Question: For a woman in her 60s complaining of general fatigue, what is the target protein of the autoantibody that causes eyelid drooping and diplopia due to weakness of the extraocular muscles?\n\n① Desmin\n② Troponin\n③ Dystrophin\n④ Acetylcholine receptor\n⑤ Matrix metalloproteinase",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "original_text": "Question: 흑색질의 도파민성 신경세포 내에 축적되어 신경세포의 소실을 야기하여 운동능력의 현저한 감소와 치매의 원인이 되는 단백질은?\n\n① 신트로핀(syntrophin)\n② 디스트로핀(dystrophin)\n③ 사르코글리칸(sarcoglycan)\n④ 디스트로글리칸(dystroglycan)\n⑤ 알파-시뉴클레인(α-synuclein)",
        "question_text": "Question: Which protein accumulates in dopaminergic neurons of the substantia nigra, causing neuronal loss and leading to significant reduction in motor ability and dementia?\n\n① Syntrophin\n② Dystrophin\n③ Sarcoglycan\n④ Dystroglycan\n⑤ α-synuclein",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n등산을 하거나 계단을 오르는 등 운동을 할 때에만 가슴을 쥐어 짜는 듯한 통증을 경험한 사람이 가슴 X-선 촬영 및 심장 초음파 검사를 하였다. 그 결과 특이적 소견은 관찰되지 않았으나 혈액검사에서는 중성지방과 LDL-C 수치가 높게 나왔다.\n\nQuestion: 이 환자의 흉통과 관련되는 질환은?\n\n① 폐렴\n② 협심증\n③ 가슴막염\n④ 역류식도염\n⑤ 급성심장막염",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA person experienced chest pain that felt like squeezing only during exercise, such as hiking or climbing stairs. They underwent a chest X-ray and echocardiogram. The results showed no specific findings, but blood tests revealed high levels of triglycerides and LDL-C.\n\nQuestion: Which disease is related to this patient's chest pain?\n\n① Pneumonia\n② Angina\n③ Pleurisy\n④ Reflux esophagitis\n⑤ Acute pericarditis",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n등산을 하거나 계단을 오르는 등 운동을 할 때에만 가슴을 쥐어 짜는 듯한 통증을 경험한 사람이 가슴 X-선 촬영 및 심장 초음파 검사를 하였다. 그 결과 특이적 소견은 관찰되지 않았으나 혈액검사에서는 중성지방과 LDL-C 수치가 높게 나왔다.\n\nQuestion: 이 환자에게 이러한 증상을 유발하는 직접적인 병태생리기전은?\n\n① 동맥류 발생\n② 육아종 형성\n③ 정맥내 울혈\n④ 죽상판 형성\n⑤ 면역복합체 침착에 의한 염증",
        "question_text": "A person who experienced chest pain, as if it were being squeezed, only during exercise such as hiking or climbing stairs, underwent a chest X-ray and echocardiogram. The results showed no specific findings, but blood tests revealed high levels of triglycerides and LDL-C.\n\nQuestion: What is the direct pathophysiological mechanism causing these symptoms in this patient?\n\n① Development of aneurysm\n② Formation of granuloma\n③ Venous congestion\n④ Formation of atherosclerotic plaque\n⑤ Inflammation due to immune complex deposition",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 펜토바르비탈(pentobarbital)을 펜토바르비탈나트륨(pentobarbital sodium)으로 변경시켰더니 물에 대한 용해도와 용출이 증가되었다. 이에 기여한 분자간 상호작용은?\n\n① 수소결합\n② 이온-쌍극자 상호작용\n③ 쌍극자-쌍극자 상호작용\n④ 쌍극자-유발쌍극자 상호작용\n⑤ 유발쌍극자-유발쌍극자 상호작용",
        "question_text": "Question: When pentobarbital was changed to pentobarbital sodium, its solubility in water and dissolution increased. Which intermolecular interaction contributed to this?\n\n① Hydrogen bonding\n② Ion-dipole interaction\n③ Dipole-dipole interaction\n④ Dipole-induced dipole interaction\n⑤ Induced dipole-induced dipole interaction",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 약물의 결정상태에 대한 내용으로 옳은 것은?\n\n① 결정형에 따라 안정성이 달라진다.\n② 결정형에 따라 화학구조가 달라진다.\n③ 결정형에 따라 용해도는 달라지지 않는다.\n④ 이온성 결정은 분자 결정에 비해 융점이 낮다.\n⑤ 결정형에 따라 치료효과는 영향을 받지 않는다.",
        "question_text": "Question: Which of the following statements about the crystalline state of drugs is correct?\n\n① Stability varies depending on the crystal form.\n② Chemical structure changes according to the crystal form.\n③ Solubility does not change according to the crystal form.\n④ Ionic crystals have lower melting points compared to molecular crystals.\n⑤ Therapeutic effects are not affected by the crystal form.",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 리도카인(lidocaine)과 프릴로카인(prilocaine)의 공융혼합물(공융점 18℃)에 대한 설명으로 옳은 것은?\n\n① 공융점에서는 액체상만 존재한다.\n② 공융혼합물 형성에 의해 피부흡수는 저해된다.\n③ 표준온도(20℃)에서 유제 또는 연고제로 제조하기가 쉽다.\n④ 공융점보다 온도가 낮아지면 하나의 액체상으로 존재한다.\n⑤ 공융점은 혼합물의 서로 다른 비율에서 가장 높은 녹는점을 나타낸다.",
        "question_text": "Question: Which of the following statements about the eutectic mixture of lidocaine and prilocaine (eutectic point 18°C) is correct?\n\n① At the eutectic point, only the liquid phase exists.\n② The formation of the eutectic mixture inhibits skin absorption.\n③ At standard temperature (20°C), it is easy to formulate as an emulsion or ointment.\n④ Below the eutectic point, it exists as a single liquid phase.\n⑤ The eutectic point represents the highest melting point at different ratios of the mixture.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 20℃, 1기압에서 자유도의 수(F)와 그 계를 구성하는 성분의 수(C) 및 계에 존재하는 상의 수(P) 사이의 관계식은?\n\n① F=P-C\n② F=C-P\n③ F=P-C+1\n④ F=C-P+1\n⑤ F=C-P+2",
        "question_text": "Question: At 20℃ and 1 atmosphere, what is the equation that relates the number of degrees of freedom (F), the number of components in the system (C), and the number of phases present in the system (P)?\n\n① F=P-C\n② F=C-P\n③ F=P-C+1\n④ F=C-P+1\n⑤ F=C-P+2",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 액상 바이오의약품을 개발하고자 할 때, 약물의 구조적 안정성과 용해도를 확보하기 위해 우선적으로 고려해야 하는 특성은?\n\n① pH\n② 삼투성\n③ 흡습성\n④ 방부 효과\n⑤ 점도 개선",
        "question_text": "Question: When developing a liquid biopharmaceutical, what characteristic should be primarily considered to ensure the structural stability and solubility of the drug?\n\n① pH\n② Osmolality\n③ Hygroscopicity\n④ Preservative effect\n⑤ Viscosity improvement",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: α, β, γ-시클로덱스트린(cyclodextrin, CD)에 대한 설명으로 옳은 것은?\n\n① 킬레이트화제이다.\n② α-CD와 β-CD의 공동(cavity) 크기는 같다.\n③ β-CD는 6개의 포도당으로 구성된 올리고당이다.\n④ γ-CD는 α, β, γ-CD 중 구성 포도당 수가 가장 적다.\n⑤ β-CD 일부의 OH그룹을 메틸화하면 친수성이 개선된다.",
        "question_text": "Question: Which of the following statements about α, β, γ-cyclodextrin (CD) is correct?\n\n① It is a chelating agent.\n② The cavity sizes of α-CD and β-CD are the same.\n③ β-CD is an oligosaccharide composed of 6 glucose units.\n④ Among α, β, and γ-CD, γ-CD has the least number of glucose units.\n⑤ Methylation of some OH groups in β-CD improves its hydrophilicity.",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 다음 레오그램(rheogram) 조건에서 전단시간의 증가에 따라 점조도가 증가하는 현상은?\n\n<Data (confidential)>\n\n① 박차(spurs)\n② 부풀림(bulge)\n③ 틱소트로피(thixotropy)\n④ 전단박화(shear thinning)\n⑤ 부틱소트로피(negative thixotropy)",
        "question_text": "Question: Which of the following phenomena shows an increase in viscosity with increasing shear time in rheogram conditions?\n\n<Data (confidential)>\n\n① Spurs\n② Bulge\n③ Thixotropy\n④ Shear thinning\n⑤ Negative thixotropy",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 어느 일정 온도에서 염화나트륨(NaCl), 염산(HCl), 프로피온산나트륨(sodium propionate)의 무한희석 시 당량전도도(Λ 0)가 각각 a, b, c일 때, 무한희석 시 프로피온산(propionic acid)의 당량전도도(Λ 0)는?\n\n① a-c\n② b-c\n③ a-b+c\n④ b-a+c\n⑤ b-a-c",
        "question_text": "Question: At a certain constant temperature, when the equivalent conductivity at infinite dilution (Λ 0) of sodium chloride (NaCl), hydrochloric acid (HCl), and sodium propionate are a, b, and c respectively, what is the equivalent conductivity at infinite dilution (Λ 0) of propionic acid?\n\n① a-c\n② b-c\n③ a-b+c\n④ b-a+c\n⑤ b-a-c",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 벤젠과 에탄올의 혼합용액은 라울의 법칙에서 정편차를 보인다. 벤젠과 에탄올이 몰분율 0.7 : 0.3으로 혼합된 용액에 대한 설명으로 옳은 것은? (단, 전체증기압(total vapor pressure)은 P T, 순수 벤젠과 에탄올의 증기압은 각각 P b o, P e o이고, 벤젠과 에탄올의 부분증기압은 각각 P b, P e이다.)\n\n① P b < 0.7P b o\n② P b = 0.7P b o\n③ P T = 0.3P b o + 0.7P e o\n④ P T > 0.7P b o + 0.3P e o\n⑤ P T < 0.7P b o + 0.3P e o",
        "question_text": "Question: A mixture of benzene and ethanol shows a positive deviation from Raoult's law. Which of the following statements is correct for a solution where benzene and ethanol are mixed in a mole fraction of 0.7 : 0.3? (Note: The total vapor pressure is P T, the vapor pressures of pure benzene and ethanol are P b o and P e o respectively, and the partial vapor pressures of benzene and ethanol are P b and P e respectively.)\n\n① P b < 0.7P b o\n② P b = 0.7P b o\n③ P T = 0.3P b o + 0.7P e o\n④ P T > 0.7P b o + 0.3P e o\n⑤ P T < 0.7P b o + 0.3P e o",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 단일 이온의 활성도계수와 용질의 평균이온활성도계수를 이론적으로 계산하는데 유용한 식은?\n\n① Stokes 식\n② Higuchi 식\n③ Van Slyke 식\n④ Debye-Hückel 식\n⑤ Henderson-Hasselbalch 식",
        "question_text": "Question: Which equation is useful for theoretically calculating the activity coefficient of a single ion and the mean ionic activity coefficient of a solute?\n\n① Stokes equation\n② Higuchi equation\n③ Van Slyke equation\n④ Debye-Hückel equation\n⑤ Henderson-Hasselbalch equation",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 디펜히드라민염산염의 염화나트륨당량은 0.2이고, 포도당의 염화나트륨당량은 0.16이다. 혈액과 동일한 어는점내림을 나타내는 1% 디펜히드라민염산염 용액 100 mL를 제조하기 위하여 가해야 하는 포도당의 양(g)은? (단, 소수점 둘째 자리에서 반올림)\n\n① 0.2\n② 0.7\n③ 2.2\n④ 4.4\n⑤ 6.0",
        "question_text": "Question: The sodium chloride equivalent of diphenhydramine hydrochloride is 0.2, and that of glucose is 0.16. How many grams of glucose should be added to prepare 100 mL of a 1% diphenhydramine hydrochloride solution that shows the same freezing point depression as blood? (Round to the first decimal place)\n\n① 0.2\n② 0.7\n③ 2.2\n④ 4.4\n⑤ 6.0",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 용해도가 낮고 막투과도가 높은 약물을 함유한 정제의 경구 투여 시 위장관 흡수 과정에서의 속도결정단계는?\n\n① 분배\n② 분해\n③ 삼투\n④ 용출\n⑤ 응결",
        "question_text": "Question: What is the rate-limiting step in the gastrointestinal absorption process when orally administering a tablet containing a drug with low solubility and high membrane permeability?\n\n① Distribution\n② Decomposition\n③ Osmosis\n④ Dissolution\n⑤ Coagulation",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 다음은 에틸아세테이트의 비누화 반응이다. 에틸아세테이트와 수산화나트륨의 초기농도가 각각 a로 같을 때, 반감기(t1/2)와 a와의 관계로 옳은 것은?\n\nCH3COOC2H5+NaOH → CH3COONa+C2H5OH\n\n① t1/2은 a와 관계없다.\n② t1/2은 a에 비례한다.\n③ t1/2은 a에 반비례한다.\n④ t1/2은 a^2에 비례한다.\n⑤ t1/2은 a^2에 반비례한다.",
        "question_text": "Question: The following is the saponification reaction of ethyl acetate. When the initial concentrations of ethyl acetate and sodium hydroxide are both equal to a, which of the following correctly describes the relationship between the half-life (t1/2) and a?\n\nCH3COOC2H5 + NaOH → CH3COONa + C2H5OH\n\n① t1/2 is independent of a.\n② t1/2 is proportional to a.\n③ t1/2 is inversely proportional to a.\n④ t1/2 is proportional to a^2.\n⑤ t1/2 is inversely proportional to a^2.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 표는 에스테르 구조를 가진 약물의 가수분해 반응에서 pH와 속도상수의 로그값(log k) 관계를 나타낸 것이다. pH 3 이하에서 나타나는 촉매반응은?\n\n| pH | 1 | 2 | 3 | 4 | 5 | 6 |\n|---|---|---|---|---|---|---|\n| log k | -4 | -5 | -6 | -5 | -4 | -3 |\n\n① 일반 산촉매반응(general acid catalysis)\n② 일반 염기촉매반응(general base catalysis)\n③ 특정 산촉매반응(specific acid catalysis)\n④ 특정 염기촉매반응(specific base catalysis)\n⑤ 금속촉매반응(metal catalysis)",
        "question_text": "Question: The table shows the relationship between pH and the logarithm of the rate constant (log k) in the hydrolysis reaction of drugs with ester structures. What type of catalytic reaction is observed at pH 3 or below?\n\n| pH | 1 | 2 | 3 | 4 | 5 | 6 |\n|---|---|---|---|---|---|---|\n| log k | -4 | -5 | -6 | -5 | -4 | -3 |\n\n① General acid catalysis\n② General base catalysis\n③ Specific acid catalysis\n④ Specific base catalysis\n⑤ Metal catalysis",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 필요 HLB(required hydrophilic-lipophilic balance, RHLB)값이 9.8인 O/W형 유제를 제조하고자 할 때, 선택해야 할 계면활성제의 조합은?\n\n① sorbitan tristearate (HLB : 2.1)와 Span 20 (HLB : 8.6)\n② Span 80 (HLB : 4.3)과 Span 20 (HLB : 8.6)\n③ Span 80 (HLB : 4.3)과 Tween 80 (HLB : 15.0)\n④ Tween 80 (HLB : 15.0)과 sodium oleate (HLB : 18.0)\n⑤ sodium oleate (HLB : 18.0)와 sodium lauryl sulfate (HLB : 40)",
        "question_text": "Question: When preparing an O/W type emulsion with a required HLB (hydrophilic-lipophilic balance, RHLB) value of 9.8, which combination of surfactants should be selected?\n\n① sorbitan tristearate (HLB: 2.1) and Span 20 (HLB: 8.6)\n② Span 80 (HLB: 4.3) and Span 20 (HLB: 8.6)\n③ Span 80 (HLB: 4.3) and Tween 80 (HLB: 15.0)\n④ Tween 80 (HLB: 15.0) and sodium oleate (HLB: 18.0)\n⑤ sodium oleate (HLB: 18.0) and sodium lauryl sulfate (HLB: 40)",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 분말이 액체에 의해 완전히 습윤되었을 때의 접촉각은?\n\n① 0°\n② 45°\n③ 90°\n④ 135°\n⑤ 180°",
        "question_text": "Question: What is the contact angle when a powder is completely wetted by a liquid?\n\n① 0°\n② 45°\n③ 90°\n④ 135°\n⑤ 180°",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n약산성 약물인 아스피린(pKa=3.5)과 약염기성 약물인 지프라시돈(pKa=6.5)을 동일한 용출속도가 되도록 제제화 하였다. 지름 2 mm의 균일한 구형 입자로 제제화된 아스피린 500 mg을 37℃, pH 1.5 용액 900 mL에서 싱크상태를 유지하면서 용출시험을 수행하였을 때, 1분간 3 mg의 아스피린이 용출되었다.\n\nQuestion: 아스피린 구형 입자의 지름을 0.2 mm로 변화시켜 동일 조건에서 용출시험을 수행한다면, 아스피린의 1분간 예상 방출량(mg)은? (단, 약물의 용출은 Noyes-Whitney 식을 따르며 확산계수 및 \n확산층의 두께는 같다.)\n\n① 3\n② 15\n③ 30\n④ 150\n⑤ 300",
        "question_text": "Aspirin, a weakly acidic drug (pKa=3.5), and ziprasidone, a weakly basic drug (pKa=6.5), were formulated to have the same dissolution rate. A dissolution test was performed on 500 mg of aspirin formulated into uniform spherical particles with a diameter of 2 mm, maintaining sink conditions in 900 mL of pH 1.5 solution at 37°C. During this test, 3 mg of aspirin dissolved in 1 minute.\n\nQuestion: If the diameter of the aspirin spherical particles is changed to 0.2 mm and the dissolution test is performed under the same conditions, what is the expected release amount (mg) of aspirin in 1 minute? (Assume that drug dissolution follows the Noyes-Whitney equation, and the diffusion coefficient and thickness of the diffusion layer remain the same.)\n\n① 3\n② 15\n③ 30\n④ 150\n⑤ 300",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n약산성 약물인 아스피린(pKa=3.5)과 약염기성 약물인 지프라시돈(pKa=6.5)을 동일한 용출속도가 되도록 제제화 하였다. 지름 2 mm의 균일한 구형 입자로 제제화된 아스피린 500 mg을 37℃, pH 1.5 용액 900 mL에서 싱크상태를 유지하면서 용출시험을 수행하였을 때, 1분간 3 mg의 아스피린이 용출되었다.\n\nQuestion: 위의 두 제제를 경구투여하였을 때, 아스피린이 위(stomach)에서 지프라시돈보다 더 많이 흡수되었다. 이 결과를 설명하는 이론은?\n\n① DLVO 이론\n② pH 분배 이론\n③ Lewis 전자 이론\n④ Debye-Hückel 이론\n⑤ Brönsted-Lowry 이론",
        "question_text": "Aspirin, a weakly acidic drug (pKa=3.5), and ziprasidone, a weakly basic drug (pKa=6.5), were formulated to have the same dissolution rate. A dissolution test was performed on 500 mg of aspirin formulated into uniform spherical particles with a diameter of 2 mm, maintaining sink conditions in 900 mL of pH 1.5 solution at 37℃. During the test, 3 mg of aspirin dissolved in 1 minute.\n\nQuestion: When these two formulations were administered orally, aspirin was absorbed more in the stomach than ziprasidone. Which theory explains this result?\n\n① DLVO theory\n② pH-partition theory\n③ Lewis electron theory\n④ Debye-Hückel theory\n⑤ Brönsted-Lowry theory",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 체내에서 에스테라제(esterase)에 의해 가수분해되어 활성화되는 전구약물은?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following is a prodrug that is activated by hydrolysis through esterase in the body?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: Terfenadine이 활성 대사체인 fexofenadine으로 전환될 때 대사되는 부위는?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "question_text": "Question: Which site is responsible for the metabolism of terfenadine when it is converted to its active metabolite, fexofenadine?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 약물과 수용체의 상호작용을 나타내는 중요한 파라미터 중의 하나이며, 치환기의 입체 효과를 정량화하기 위하여 Hammett의 전자 효과 계산법을 통해 얻는 값은?\n\n① π\n② σ\n③ ES\n④ MR\n⑤ logP",
        "question_text": "Question: Which of the following is an important parameter representing the interaction between drugs and receptors, and is obtained through Hammett's electronic effect calculation method to quantify the steric effect of substituents?\n\n① π\n② σ\n③ ES\n④ MR\n⑤ logP",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: Ethylbenzene을 출발물질로 하여 2단계 합성과정을 통하여 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① ketamine\n② zolpidem\n③ eperisone\n④ tolterodine\n⑤ anastrozole",
        "question_text": "Question: Which drug A is obtained through a two-step synthesis process starting from ethylbenzene?\n\n<Data (confidential)>\n\n① ketamine\n② zolpidem\n③ eperisone\n④ tolterodine\n⑤ anastrozole",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: Phenol을 출발물질로 하여 acetaminophen을 합성할 때, 반응순서로 옳은 것은?\n\n① acetylation – nitration – reduction\n② nitration – reduction – acetylation\n③ acetylation – oxidation – nitration – reduction\n④ acetylation – nitration – reduction – hydrolysis\n⑤ reduction – esterification – nitration – reduction",
        "question_text": "Question: When synthesizing acetaminophen using phenol as the starting material, which of the following is the correct order of reactions?\n\n① acetylation – nitration – reduction\n② nitration – reduction – acetylation\n③ acetylation – oxidation – nitration – reduction\n④ acetylation – nitration – reduction – hydrolysis\n⑤ reduction – esterification – nitration – reduction",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: Methamphetamine을 출발물질로 하여 2단계 반응을 거쳐서 합성되는 약물 A는?\n\n<Data (confidential)>\n\n① sulpiride\n② selegiline\n③ donepezil\n④ ropinirole\n⑤ lamotrigine",
        "question_text": "Question: Which drug A is synthesized through a two-step reaction process using methamphetamine as the starting material?\n\n<Data (confidential)>\n\n① sulpiride\n② selegiline\n③ donepezil\n④ ropinirole\n⑤ lamotrigine",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: Clopidogrel의 합성과정에서 각 단계의 반응명을 옳게 연결한 것은?\n\n<Data (confidential)>\n\n① Strecker reaction – aldol reaction\n② Mannich reaction – Strecker reaction\n③ Mannich reaction – Fischer esterification\n④ Knoevenagel condensation – Strecker reaction\n⑤ Knoevenagel condensation – Fischer esterification",
        "question_text": "Question: Which of the following correctly matches the reaction names for each step in the synthesis process of Clopidogrel?\n\n<Data (confidential)>\n\n① Strecker reaction – aldol reaction\n② Mannich reaction – Strecker reaction\n③ Mannich reaction – Fischer esterification\n④ Knoevenagel condensation – Strecker reaction\n⑤ Knoevenagel condensation – Fischer esterification",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: Ramipril의 합성과정에서 중간체 A의 구조로 옳은 것은?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following is the correct structure of intermediate A in the synthesis process of Ramipril?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: Etomidate의 합성과정에서 생성되는 중간체 A의 중심 골격 명칭은?\n\n<Data (confidential)>\n\n① oxazole\n② thiazole\n③ pyrazole\n④ imidazole\n⑤ isoxazole",
        "question_text": "Question: What is the name of the central skeleton of intermediate A produced during the synthesis of Etomidate?\n\n<Data (confidential)>\n\n① oxazole\n② thiazole\n③ pyrazole\n④ imidazole\n⑤ isoxazole",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 다음 반응으로 합성되는 약물 A는?\n\n<Data (confidential)>\n\n① carbidopa\n② donepezil\n③ alprazolam\n④ oxybutynin\n⑤ carbamazepine",
        "question_text": "Question: Which drug A is synthesized by the following reaction?\n\n<Data (confidential)>\n\n① carbidopa\n② donepezil\n③ alprazolam\n④ oxybutynin\n⑤ carbamazepine",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: Doxapram의 합성과정에서 생성되는 중간체 A의 구조는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the structure of intermediate A produced during the synthesis of Doxapram?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 다음 합성과정으로 생성되는 약물 A는?\n\n<Data (confidential)>\n\n① piperazine 계열의 cetirizine 염산염\n② imidazole 계열의 cimetidine 염산염\n③ phthalazinone 계열의 azelastine 염산염\n④ phenothiazine 계열의 promethazine 염산염\n⑤ ethanolamine 계열의 diphenhydramine 염산염",
        "question_text": "Question: Which drug A is produced by the following synthesis process?\n\n<Data (confidential)>\n\n① Cetirizine hydrochloride of the piperazine class\n② Cimetidine hydrochloride of the imidazole class\n③ Azelastine hydrochloride of the phthalazinone class\n④ Promethazine hydrochloride of the phenothiazine class\n⑤ Diphenhydramine hydrochloride of the ethanolamine class",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: Arylpropanoic acid 계열의 비스테로이드성 항염증제(NSAID)는?\n\n① celecoxib\n② ibuprofen\n③ piroxicam\n④ diclofenac\n⑤ mefenamic acid",
        "question_text": "Question: Which of the following is an arylpropionic acid class non-steroidal anti-inflammatory drug (NSAID)?\n\n① celecoxib\n② ibuprofen\n③ piroxicam\n④ diclofenac\n⑤ mefenamic acid",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: Pteridine 고리를 갖는 약물은?\n\n① acyclovir\n② tamoxifen\n③ methotrexate\n④ ketoconazole\n⑤ cyclophosphamide",
        "question_text": "Question: Which drug contains a pteridine ring?\n\n① acyclovir\n② tamoxifen\n③ methotrexate\n④ ketoconazole\n⑤ cyclophosphamide",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 신경안정제로 사용되는 diazepam의 R1과 R2 치환기 및 위치가 옳은 것은?\n\n<Data (confidential)>\n\n① R1=6-Cl, R2=Ph\n② R1=6-Cl, R2=Me\n③ R1=7-Cl, R2=Ph\n④ R1=7-Cl, R2=Me\n⑤ R1=8-Cl, R2=Ph",
        "question_text": "Question: Which of the following correctly represents the R1 and R2 substituents and their positions for diazepam, used as a tranquilizer?\n\n<Data (confidential)>\n\n① R1=6-Cl, R2=Ph\n② R1=6-Cl, R2=Me\n③ R1=7-Cl, R2=Ph\n④ R1=7-Cl, R2=Me\n⑤ R1=8-Cl, R2=Ph",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 다음 약물 구조의 질소에 isopropyl 그룹을 추가로 도입하여 4급 암모늄염을 갖는 약물은?\n\n<Data (confidential)>\n\n① fentanyl\n② lidocaine\n③ donepezil\n④ fluoxetine\n⑤ ipratropium",
        "question_text": "Question: Which of the following drugs forms a quaternary ammonium salt when an isopropyl group is additionally introduced to the nitrogen in its structure?\n\n<Data (confidential)>\n\n① fentanyl\n② lidocaine\n③ donepezil\n④ fluoxetine\n⑤ ipratropium",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 중간체 I를 거쳐 항암제인 imatinib을 합성하는 과정이다.\n<Data (confidential)>\n\nQuestion: Imatinib 구조 중 Abl kinase 활성자리에서 문지기(gatekeeper) Thr 잔기와 수소결합을 하는 부위는?\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "question_text": "The following is the process of synthesizing the anticancer drug imatinib through intermediate I.\n<Data (confidential)>\n\nQuestion: Which part of the imatinib structure forms a hydrogen bond with the gatekeeper Thr residue in the Abl kinase active site?\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 중간체 I를 거쳐 항암제인 imatinib을 합성하는 과정이다.\n<Data (confidential)>\n\nQuestion: 중간체 I에 포함되어 있는 중심 골격 명칭은?\n\n① purine\n② pyrrole\n③ pyrazine\n④ pyrazole\n⑤ pyrimidine",
        "question_text": "The following is the process of synthesizing the anticancer drug imatinib through intermediate I.\n<Data (confidential)>\n\nQuestion: What is the name of the central skeleton included in intermediate I?\n\n① purine\n② pyrrole\n③ pyrazine\n④ pyrazole\n⑤ pyrimidine",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 완충용량 효과가 가장 큰 Tris 완충용액은? (단, Tris ∙ H+의 pKa=8.1이다.)\n\n① 0.01 mol/L 완충용액 (pH 7.0)\n② 0.05 mol/L 완충용액 (pH 7.0)\n③ 0.01 mol/L 완충용액 (pH 8.0)\n④ 0.05 mol/L 완충용액 (pH 8.0)\n⑤ 0.01 mol/L 완충용액 (pH 9.0)",
        "question_text": "Question: Which Tris buffer solution has the greatest buffer capacity? (Note: The pKa of Tris ∙ H+ is 8.1.)\n\n① 0.01 mol/L buffer solution (pH 7.0)\n② 0.05 mol/L buffer solution (pH 7.0)\n③ 0.01 mol/L buffer solution (pH 8.0)\n④ 0.05 mol/L buffer solution (pH 8.0)\n⑤ 0.01 mol/L buffer solution (pH 9.0)",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 식품보존제로 사용되는 sorbic acid (pKa=4.8)의 항균작용이 용액 중의 비해리분자에 의해 나타날 때, sorbic acid의 항균력이 가장 큰 용액의 pH는?\n\n① 2.8\n② 3.8\n③ 4.8\n④ 5.8\n⑤ 6.8",
        "question_text": "Question: When the antimicrobial action of sorbic acid (pKa=4.8), used as a food preservative, is exhibited by undissociated molecules in solution, at which pH does sorbic acid show the strongest antimicrobial activity?\n\n① 2.8\n② 3.8\n③ 4.8\n④ 5.8\n⑤ 6.8",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: Lysine 분자 내에 2개의 NH2기와 1개의 COOH기가 있다. 이 분자의 등전점(pI)은? (단, lysine의 K1=1×10^-2, K2=1×10^-9, K3=1×10^-11이다.)\n\n① 2.0\n② 4.5\n③ 5.5\n④ 9.0\n⑤ 10.0",
        "question_text": "Question: Lysine has 2 NH2 groups and 1 COOH group within its molecule. What is the isoelectric point (pI) of this molecule? (Given: K1=1×10^-2, K2=1×10^-9, K3=1×10^-11 for lysine.)\n\n① 2.0\n② 4.5\n③ 5.5\n④ 9.0\n⑤ 10.0",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 붕산(H3BO3) 용액을 페놀프탈레인 지시약을 사용하여 NaOH 표준액으로 적정할 때 붕산의 해리도를 증가시키기 위하여 첨가하는 시약은?\n\n① NaCl\n② NH4Cl\n③ NaHCO3\n④ Nitramine\n⑤ D-Sorbitol",
        "question_text": "Question: When titrating a boric acid (H3BO3) solution with NaOH standard solution using phenolphthalein as an indicator, which reagent is added to increase the dissociation degree of boric acid?\n\n① NaCl\n② NH4Cl\n③ NaHCO3\n④ Nitramine\n⑤ D-Sorbitol",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 0.1 mol/L H2O2 용액 50 mL를 H2SO4 산성 조건에서 0.1 mol/L KMnO4 표준액으로 적정할 때 당량점에 도달하기 위해 필요한 표준액의 mL 수는?\n\n① 10\n② 20\n③ 40\n④ 50\n⑤ 100",
        "question_text": "Question: When titrating 50 mL of 0.1 mol/L H2O2 solution with 0.1 mol/L KMnO4 standard solution under H2SO4 acidic conditions, how many mL of the standard solution are needed to reach the equivalence point?\n\n① 10\n② 20\n③ 40\n④ 50\n⑤ 100",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 방향족 1급 아민을 함유하는 설파메티졸(sulfamethizole)을 염산 산성 용액에서 정량할 때 사용하는 표준액은?\n\n① 0.1 mol/L I2\n② 0.05 mol/L KIO3\n③ 0.1 mol/L KMnO4\n④ 0.1 mol/L NaNO2\n⑤ 0.1 mol/L Na2S2O3",
        "question_text": "Question: When quantifying sulfamethizole, which contains an aromatic primary amine, in a hydrochloric acid solution, which standard solution is used?\n\n① 0.1 mol/L I2\n② 0.05 mol/L KIO3\n③ 0.1 mol/L KMnO4\n④ 0.1 mol/L NaNO2\n⑤ 0.1 mol/L Na2S2O3",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 자외가시부흡광도측정법에서 검액과 표준액의 매트릭스 조성이 매우 다를 때, 검액에 대한 매트릭스 효과를 보정하기 위하여 사용할 수 있는 분석법은?\n\n① 맹시험법\n② 이중맹검법\n③ 평행시험법\n④ 회귀곡선법\n⑤ 표준물첨가법",
        "question_text": "Question: In UV-visible spectrophotometry, when the matrix composition of the sample solution and standard solution is very different, which analytical method can be used to correct for the matrix effect on the sample solution?\n\n① Blank test method\n② Double-blind method\n③ Parallel test method\n④ Regression curve method\n⑤ Standard addition method",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 메틸테스토스테론 원료의약품을 다음과 같이 자외가시부흡광광도법으로 분석하였을 때, 흡수극대파장(241 nm)에서의 몰흡광계수(ε)는? (단, 메틸테스토스테론의 분자량은 M이다.)\n\n이 약을 건조하여 10.0 mg을 정밀하게 달아 에탄올에 녹여 100 mL로 한 후, 이 액 5 mL를 취하여 에탄올을 넣어 50 mL로 한 것을 검액으로 한다. 이 검액을 층장 1 cm 셀로 측정한 흡수극대파장(241 nm)에서의 흡광도는 A이다.\n\n① A×M\n② A×M×10\n③ A×M×100\n④ A/M\n⑤ (A/M)×10",
        "question_text": "Question: When methyltestosterone raw material is analyzed using UV-visible spectrophotometry as follows, what is the molar absorption coefficient (ε) at the maximum absorption wavelength (241 nm)? (Note: The molecular weight of methyltestosterone is M.)\n\nAfter drying, accurately weigh 10.0 mg of this drug and dissolve it in ethanol to make 100 mL. Take 5 mL of this solution and add ethanol to make 50 mL, which is used as the test solution. The absorbance (A) of this test solution is measured at the maximum absorption wavelength (241 nm) using a 1 cm path length cell.\n\n① A×M\n② A×M×10\n③ A×M×100\n④ A/M\n⑤ (A/M)×10",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 리보플라빈 400 mg을 묽은수산화나트륨시액에 녹여 총 4 mL를 만든 후, 10 cm 편광계 셀과 Sodium-D line(589 nm)을 사용하여 온도 20℃에서 측정한 선광도 값을 환산한 비선광도 값이 -130°이다. 측정한 선광도(α) 값은?\n\n① -1.30°\n② -13.0°\n③ -26.0°\n④ -130°\n⑤ -260°",
        "question_text": "Question: 400 mg of riboflavin is dissolved in dilute sodium hydroxide solution to make a total of 4 mL. The specific optical rotation value, converted from the optical rotation measured using a 10 cm polarimeter cell and Sodium-D line (589 nm) at a temperature of 20℃, is -130°. What is the measured optical rotation (α) value?\n\n① -1.30°\n② -13.0°\n③ -26.0°\n④ -130°\n⑤ -260°",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 오플록사신을 물 ∙ 아세토니트릴 혼합액(6 : 1)에 녹여 만든 1 μg/mL 용액을 상온에서 형광광도법으로 측정하였다. 이 측정 조건을 변화시킴에 따라 소광현상(quenching)이 나타나는 경우는?\n\n① 10℃에서 측정한다.\n② 용존 산소 제거 후 측정한다.\n③ 1,000 μg/mL 농도로 측정한다.\n④ 입사광 세기를 2배로 하여 측정한다.\n⑤ 물 ∙ 아세토니트릴 혼합액(10 : 1)에 녹여 측정한다.",
        "question_text": "Question: A 1 μg/mL solution of ofloxacin dissolved in a water-acetonitrile mixture (6:1) was measured at room temperature using fluorescence spectrophotometry. In which of the following cases would quenching occur when changing the measurement conditions?\n\n① Measuring at 10℃\n② Measuring after removing dissolved oxygen\n③ Measuring at a concentration of 1,000 μg/mL\n④ Measuring with twice the intensity of incident light\n⑤ Measuring after dissolving in a water-acetonitrile mixture (10:1)",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 아세트아미노펜의 카르보닐 관능기의 존재 유무를 알 수 있는 분석법은?\n\n① 원자분광법\n② 기체크로마토그래프법\n③ 액체크로마토그래프법\n④ 적외부스펙트럼측정법\n⑤ 자외가시부흡광도측정법",
        "question_text": "Question: Which analytical method can be used to determine the presence or absence of the carbonyl functional group in acetaminophen?\n\n① Atomic spectroscopy\n② Gas chromatography\n③ Liquid chromatography\n④ Infrared spectroscopy\n⑤ UV-visible spectrophotometry",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 발사르탄(valsartan)에 미량으로 존재하는 발암성 불순물 N-nitrosodimethylamine(NDMA)을 유도체화 없이 액체크로마토그래프법으로 직접 분석하는데 적절한 검출기는?\n\n① 형광검출기\n② 전도도검출기\n③ 질소/인검출기\n④ 질량분석검출기\n⑤ 열전도도검출기",
        "question_text": "Question: Which detector is appropriate for direct analysis of the carcinogenic impurity N-nitrosodimethylamine (NDMA), present in trace amounts in valsartan, using liquid chromatography without derivatization?\n\n① Fluorescence detector\n② Conductivity detector\n③ Nitrogen/phosphorus detector\n④ Mass spectrometry detector\n⑤ Thermal conductivity detector",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 기체크로마토그래피 칼럼에 대한 설명으로 옳은 것은?\n\n① 칼럼의 길이가 길수록 분리능은 감소한다.\n② 분취용 칼럼으로 분리된 대량 시료를 얻을 수 있다.\n③ 칼럼의 성능은 이동상의 유속에 영향을 받지 않는다.\n④ 칼럼의 온도를 높이면 시료의 머무름 시간은 증가한다.\n⑤ 칼럼의 액체고정상은 시료 성분에 대해 화학적으로 반응할수록 좋다.",
        "question_text": "Question: Which of the following statements about gas chromatography columns is correct?\n\n① The longer the column, the lower the resolution.\n② Preparative columns can be used to obtain large amounts of separated samples.\n③ The performance of the column is not affected by the flow rate of the mobile phase.\n④ Increasing the column temperature increases the retention time of the sample.\n⑤ The liquid stationary phase of the column is better when it chemically reacts with the sample components.",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 기체크로마토그래프법에서 온도프로그래밍의 목적으로 옳은 것은?\n\n① 극성 증가\n② 분석시간 연장\n③ 분리효율 증가\n④ 피크 면적 증가\n⑤ 피크 대칭성 감소",
        "question_text": "Question: What is the correct purpose of temperature programming in gas chromatography?\n\n① Increase polarity\n② Extend analysis time\n③ Increase separation efficiency\n④ Increase peak area\n⑤ Decrease peak symmetry",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 측정치의 우연오차를 평가하기 위한 방법으로 사용하는 것은?\n\n① 공시험\n② 맹시험\n③ 조절시험\n④ 평행시험\n⑤ 회수시험",
        "question_text": "Question: Which method is used to evaluate random errors in measurements?\n\n① Blank test\n② Blind test\n③ Control test\n④ Parallel test\n⑤ Recovery test",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 약물 A(분자량: 234.56)의 1.000 M 용액 30.0 mL를 만들기 위하여 취해야 하는 약물 A의 양(mg)을 계산한 값의 유효자릿수는?\n\n① 3\n② 4\n③ 5\n④ 7\n⑤ 9",
        "question_text": "Question: How many significant figures are there in the calculated amount (mg) of drug A needed to prepare 30.0 mL of a 1.000 M solution of drug A (molecular weight: 234.56)?\n\n① 3\n② 4\n③ 5\n④ 7\n⑤ 9",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n아스피린 정을 고온 ∙ 다습 조건에서 장기간 보관했더니 자극적인 냄새가 났다. 이 약의 순도를 확인하기 위하여 액체크로마토그래프법에 따라 분석한 결과, 두 개의 피크가 검출되었다. 각 피크의 유지시간(tR)은 5.0 min, 10.0 min이었고, 이동상의 유지시간(t0)은 2.5 min이었다.\n\n[분석조건]\n검출기: 자외부흡광광도계(측정파장 UV 280 nm)\n칼럼: 안지름 약 4 mm, 길이 30 cm인 액체크로마토그래피용 옥타데실실리카겔을 충전한 스테인리스 칼럼\n이동상: 0.085% 인산 : 메탄올(60 : 40), (pH 3.0)\n유속: 1.0 mL/min\n\nQuestion: 앞에서 분리된 2개 피크에서 ‘기준선에서의 봉우리 나비(Wb)’가 각각 0.45 min, 0.55 min일 때 두 피크의 분리도(R)는?\n\n① 3\n② 4\n③ 5\n④ 10\n⑤ 15",
        "question_text": "Aspirin tablets were stored for a long period under high temperature and humidity conditions, resulting in an irritating odor. To verify the purity of this drug, it was analyzed according to liquid chromatography method, and two peaks were detected. The retention times (tR) of each peak were 5.0 min and 10.0 min, and the retention time of the mobile phase (t0) was 2.5 min.\n\n[Analysis Conditions]\nDetector: UV spectrophotometer (measurement wavelength UV 280 nm)\nColumn: Stainless steel column packed with octadecylsilica gel for liquid chromatography, with an inner diameter of about 4 mm and a length of 30 cm\nMobile phase: 0.085% phosphoric acid : methanol (60 : 40), (pH 3.0)\nFlow rate: 1.0 mL/min\n\nQuestion: When the 'peak width at baseline (Wb)' of the two separated peaks is 0.45 min and 0.55 min respectively, what is the resolution (R) between the two peaks?\n\n① 3\n② 4\n③ 5\n④ 10\n⑤ 15",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n아스피린 정을 고온 ∙ 다습 조건에서 장기간 보관했더니 자극적인 냄새가 났다. 이 약의 순도를 확인하기 위하여 액체크로마토그래프법에 따라 분석한 결과, 두 개의 피크가 검출되었다. 각 피크의 유지시간(tR)은 5.0 min, 10.0 min이었고, 이동상의 유지시간(t0)은 2.5 min이었다.\n\n[분석조건]\n검출기: 자외부흡광광도계(측정파장 UV 280 nm)\n칼럼: 안지름 약 4 mm, 길이 30 cm인 액체크로마토그래피용 옥타데실실리카겔을 충전한 스테인리스 칼럼\n이동상: 0.085% 인산 : 메탄올(60 : 40), (pH 3.0)\n유속: 1.0 mL/min\n\nQuestion: 불순물이 생기는 원인(가)과 상기 분석조건에서 5 min과 10 min에 각각 용리되는 화합물(나)로 옳게 연결한 것은?\n\n가 | 나 5 min | 나 10 min\n\n① hydrolysis | salicylic acid | acetic acid\n② hydrolysis | acetic acid | salicylic acid\n③ hydrolysis | aspirin | salicylic acid\n④ acetylation | aspirin | salicylic acid\n⑤ acetylation | acetic acid | aspirin",
        "question_text": "Aspirin tablets were stored for a long period under high temperature and humidity conditions, resulting in an irritating odor. To check the purity of this drug, it was analyzed according to liquid chromatography method, and two peaks were detected. The retention times (tR) of each peak were 5.0 min and 10.0 min, and the retention time of the mobile phase (t0) was 2.5 min.\n\n[Analysis conditions]\nDetector: UV spectrophotometer (measurement wavelength UV 280 nm)\nColumn: Stainless steel column packed with octadecylsilica gel for liquid chromatography with an inner diameter of about 4 mm and a length of 30 cm\nMobile phase: 0.085% phosphoric acid : methanol (60 : 40), (pH 3.0)\nFlow rate: 1.0 mL/min\n\nQuestion: Which of the following correctly matches the cause of impurity formation (a) and the compounds eluted at 5 min and 10 min under the above analysis conditions (b)?\n\na | b 5 min | b 10 min\n\n① hydrolysis | salicylic acid | acetic acid\n② hydrolysis | acetic acid | salicylic acid\n③ hydrolysis | aspirin | salicylic acid\n④ acetylation | aspirin | salicylic acid\n⑤ acetylation | acetic acid | aspirin",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 난용성 약물의 경구 제제화 과정에서 약물을 미분화하는 주된 목적은?\n\n① 분해 방지\n② 작용 지속화\n③ 흡습성 증가\n④ 나쁜 맛 차폐\n⑤ 용출속도 향상",
        "question_text": "Question: What is the main purpose of micronizing a poorly soluble drug during the process of oral formulation?\n\n① Prevention of degradation\n② Prolongation of action\n③ Increase in hygroscopicity\n④ Masking of unpleasant taste\n⑤ Enhancement of dissolution rate",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 회전형 혼합기를 사용하여 두 가지 이상의 분체를 혼합할 때 균일한 혼합물을 얻기에 적합한 것은?\n\n① 부착성이 큰 분체\n② 응집성이 큰 분체\n③ 조해성이 큰 분체\n④ 유동성이 낮은 분체\n⑤ 입자 크기가 균일한 분체",
        "question_text": "Question: When mixing two or more powders using a tumbling mixer, which of the following is most suitable for obtaining a uniform mixture?\n\n① Powders with high adhesiveness\n② Powders with high cohesiveness\n③ Powders with high hygroscopicity\n④ Powders with low flowability\n⑤ Powders with uniform particle size",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 수분에 불안정한 약물의 과립 제조에 적합한 방법은?\n\n① 롤러압축법\n② 저전단과립법\n③ 고전단과립법\n④ 유동층조립법\n⑤ 압출구형과립법",
        "question_text": "Question: Which method is suitable for granulation of moisture-sensitive drugs?\n\n① Roller compaction method\n② Low shear granulation method\n③ High shear granulation method\n④ Fluid bed granulation method\n⑤ Extrusion-spheronization method",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 과립을 건조할 때 항률건조 단계에 대한 설명으로 옳은 것은?\n\n① 단위시간당 건조량이 증가한다.\n② 수분의 표면증발량과 내부확산량이 같다.\n③ 건조속도는 시간이 지남에 따라 감소한다.\n④ 시료 내부 수분의 확산속도가 표면의 증발속도보다 늦어진다.\n⑤ 건조속도는 시료 내부의 수분이 표면으로 확산하는 속도에 의해 결정된다.",
        "question_text": "Question: Which of the following statements is correct regarding the constant rate drying stage when drying granules?\n\n① The amount of drying per unit time increases.\n② The surface evaporation rate of moisture is equal to the internal diffusion rate.\n③ The drying rate decreases over time.\n④ The diffusion rate of moisture inside the sample becomes slower than the evaporation rate at the surface.\n⑤ The drying rate is determined by the rate at which moisture diffuses from the interior of the sample to the surface.",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 현탁제에서 입자의 분산을 돕고 침강속도를 감소시킬 수 있는 방법은?\n\n① 분산매의 점도를 낮게 한다.\n② 무거운 분산입자를 사용한다.\n③ 분산입자의 크기를 증가시킨다.\n④ 밀도가 낮은 분산매를 사용한다.\n⑤ 분산입자의 밀도를 분산매의 밀도보다 약간 크게 한다.",
        "question_text": "Question: What method can help disperse particles and reduce sedimentation rate in a suspension?\n\n① Lower the viscosity of the dispersion medium.\n② Use heavy dispersed particles.\n③ Increase the size of dispersed particles.\n④ Use a dispersion medium with low density.\n⑤ Make the density of dispersed particles slightly higher than that of the dispersion medium.",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 안연고제 제조 시 사용되는 기제로서 눈에 대한 자극이 적고 온도에 따른 점도 변화가 적은 것은?\n\n① 백납\n② 실리콘\n③ 카라기난\n④ 플라스티베이스\n⑤ 폴리에틸렌글리콜",
        "question_text": "Question: Which of the following bases used in the manufacture of eye ointments has low eye irritation and minimal viscosity changes with temperature?\n\n① White wax\n② Silicone\n③ Carrageenan\n④ Plastibase\n⑤ Polyethylene glycol",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 포 또는 플라스틱제 필름 등에 주성분과 기제 또는 첨가제로 된 혼합물을 전연 또는 봉입하여 피부에 점착시켜 쓰는 국소에 작용하는 외용제는?\n\n① 첩부제\n② 크림제\n③ 연고제\n④ 리니멘트제\n⑤ 페이스트제",
        "question_text": "Question: What is the topical preparation that acts locally, which is made by spreading or enclosing a mixture of active ingredients and base or additives on cloth or plastic film, and is adhered to the skin?\n\n① Patch\n② Cream\n③ Ointment\n④ Liniment\n⑤ Paste",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 점안제를 눈물과 등장으로 제조하는 주된 목적은?\n\n① 점성 증가\n② 자극성 경감\n③ 작용시간 연장\n④ 보존기간 연장\n⑤ 생체이용률 향상",
        "question_text": "Question: What is the main purpose of manufacturing eye drops to be isotonic with tears?\n\n① Increase viscosity\n② Reduce irritation\n③ Extend duration of action\n④ Prolong shelf life\n⑤ Improve bioavailability",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 미세한 고체입자나 액적을 다양한 피막물질로 직접 둘러싸서 봉입하는 방법은?\n\n① 페길레이션\n② 고체분산기술\n③ 하이드로겔화\n④ 자가유화기술\n⑤ 마이크로캡슐화",
        "question_text": "Question: What is the method of directly encapsulating fine solid particles or droplets with various coating materials?\n\n① PEGylation\n② Solid dispersion technology\n③ Hydrogel formation\n④ Self-emulsification technology\n⑤ Microencapsulation",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 제제의 개발 과정에서 가속안정성시험을 이용하여 단기간 내에 제제의 유통기한을 예측하는 데 활용되는 주된 인자는?\n\n① pH\n② 습도\n③ 광선\n④ 온도\n⑤ 이온강도",
        "question_text": "Question: What is the main factor used to predict the shelf life of a preparation in a short period of time using accelerated stability testing during the development process of a formulation?\n\n① pH\n② Humidity\n③ Light\n④ Temperature\n⑤ Ionic strength",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 산화에 의해 변색되는 수성 제제의 안정성을 높이기 위해 사용하는 첨가제는?\n\n① 티메로살(thimerosal)\n② 벤질알코올(benzyl alcohol)\n③ 아황산나트륨(sodium sulfite)\n④ 폴리비닐알코올(polyvinyl alcohol)\n⑤ 파라옥시벤조산메틸(methylparaben)",
        "question_text": "Question: Which additive is used to increase the stability of aqueous preparations that discolor due to oxidation?\n\n① Thimerosal\n② Benzyl alcohol\n③ Sodium sulfite\n④ Polyvinyl alcohol\n⑤ Methylparaben",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 피부를 통한 약물의 전신흡수에 대한 설명으로 옳은 것은?\n\n① 각질층은 수용성이나 지용성 약물 모두가 쉽게 통과할 수 있다.\n② 유지성 연고기제는 강한 피부 침투력을 나타내어 전신작용을 기대할 수 있다.\n③ 피부를 통해 흡수된 약물은 간 초회통과효과를 받아 생체이용률이 저하된다.\n④ 밀봉포대법을 이용하면 피부 각질층의 각질화가 촉진되어 약물 투과가 용이해진다.\n⑤ 경피약물전달시스템은 적용부위의 피부 상태에 따라 약물의 투과도가 달라질 수 있다.",
        "question_text": "Question: Which of the following statements about systemic absorption of drugs through the skin is correct?\n\n① Both water-soluble and lipid-soluble drugs can easily pass through the stratum corneum.\n② Oil-based ointments show strong skin penetration, allowing for systemic effects.\n③ Drugs absorbed through the skin undergo first-pass hepatic metabolism, reducing their bioavailability.\n④ Using occlusive dressing technique promotes keratinization of the stratum corneum, facilitating drug permeation.\n⑤ In transdermal drug delivery systems, drug permeability can vary depending on the skin condition at the application site.",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 선형 1-컴파트먼트 모델을 따르는 어떤 약물의 혈중 반감기는 2시간이다. 이 약물의 혈중농도가 초기 혈중농도의 12.5%에 도달하는 데 소요되는 시간(h)은?\n\n① 2\n② 4\n③ 6\n④ 8\n⑤ 10",
        "question_text": "Question: The half-life of a drug that follows a linear one-compartment model is 2 hours. How long (in hours) does it take for the blood concentration of this drug to reach 12.5% of its initial blood concentration?\n\n① 2\n② 4\n③ 6\n④ 8\n⑤ 10",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 선형 1-컴파트먼트 모델을 따르는 약물을 환자에게 10 mg/h의 속도로 등속 정맥주입하였을 때, 정상상태에서의 혈중농도는 1.0 μg/mL이었다. 이 약물을 20 mg/h의 속도로 등속 정맥주입 한다면 정상상태에서의 혈중농도(μg/mL)는?\n\n① 0.5\n② 1.0\n③ 2.0\n④ 4.0\n⑤ 8.0",
        "question_text": "Question: When a drug following a linear one-compartment model was administered to a patient by constant intravenous infusion at a rate of 10 mg/h, the steady-state blood concentration was 1.0 μg/mL. If this drug is administered by constant intravenous infusion at a rate of 20 mg/h, what would be the steady-state blood concentration (μg/mL)?\n\n① 0.5\n② 1.0\n③ 2.0\n④ 4.0\n⑤ 8.0",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 약물의 신 클리어런스가 사구체 여과속도보다 작은 경우, 그 원인으로 추정할 수 있는 기전은?\n\n① 요세관에서 여과\n② 요세관에서 재흡수\n③ 요세관 분비에 의해서만 배설\n④ 사구체 여과에 의해서만 배설\n⑤ 요세관 분비 및 사구체 여과에 의해 배설",
        "question_text": "Question: When a drug's renal clearance is less than the glomerular filtration rate, which mechanism can be presumed as the cause?\n\n① Filtration in the renal tubules\n② Reabsorption in the renal tubules\n③ Excretion only by tubular secretion\n④ Excretion only by glomerular filtration\n⑤ Excretion by both tubular secretion and glomerular filtration",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 생체이용률에 대한 설명으로 옳은 것은?\n\n① 같은 약물의 경우 투여경로에 관계없이 생체이용률은 동일하다.\n② 생체이용률 평가의 양적 지표로 혈중약물농도-시간 곡선하 면적(AUC)을 사용한다.\n③ 두 경피흡수 제제 간의 생체이용률의 비로부터 간 초회통과효과를 예측한다.\n④ 상대생체이용률이란 정맥투여 시 생체이용률에 대한 기타 경로 투여 시 생체이용률의 비를 의미한다.\n⑤ 절대생체이용률이란 표준제제와 시험제제를 동일한 경로로 투여하였을 때 두 제제 간의 생체이용률의 비를 의미한다.",
        "question_text": "Question: Which of the following statements about bioavailability is correct?\n\n① For the same drug, bioavailability is identical regardless of the route of administration.\n② The area under the blood concentration-time curve (AUC) is used as a quantitative indicator for bioavailability assessment.\n③ The hepatic first-pass effect can be predicted from the ratio of bioavailability between two transdermal preparations.\n④ Relative bioavailability refers to the ratio of bioavailability via other routes of administration to that of intravenous administration.\n⑤ Absolute bioavailability refers to the ratio of bioavailability between a standard preparation and a test preparation when administered via the same route.",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n하루 여러 번 복용하는 약물은 환자의 복약순응도가 낮다. 이러한 경우, 약물을 서서히 방출시켜 1일 1회 복용으로 약효를 지속하는 경구용 제제 A를 개발하여 환자의 복약순응도를 높이고자 한다.\n\nQuestion: 제제 A의 제조에 적합한 친수성 매트릭스 기제는?\n\n① 쉘락(shellac)\n② 폴리락트산(polylactic acid)\n③ 크로스포비돈(crospovidone)\n④ 카르나우바납(carnauba wax)\n⑤ 히드록시프로필셀룰로오스(hydroxypropylcellulose)",
        "question_text": "Medications that need to be taken multiple times a day often result in low patient compliance. In this case, an oral preparation A is being developed to release the drug slowly, maintaining its effectiveness with once-daily dosing, in order to improve patient compliance.\n\nQuestion: Which hydrophilic matrix base is suitable for the manufacture of preparation A?\n\n① Shellac\n② Polylactic acid\n③ Crospovidone\n④ Carnauba wax\n⑤ Hydroxypropylcellulose",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n하루 여러 번 복용하는 약물은 환자의 복약순응도가 낮다. 이러한 경우, 약물을 서서히 방출시켜 1일 1회 복용으로 약효를 지속하는 경구용 제제 A를 개발하여 환자의 복약순응도를 높이고자 한다.\n\nQuestion: 제제 A로 개발하기에 적합한 약물은?\n\n① 치료계수가 좁은 약물\n② 1회 투여용량이 많은 약물\n③ 흡수속도와 배설속도가 매우 느린 약물\n④ 위장관에서 대사되어 매우 불안정한 약물\n⑤ 위장관의 특정부위가 아닌 전체에 걸쳐서 흡수가 일어나는 약물",
        "question_text": "Medications that need to be taken multiple times a day often result in low patient compliance. In this case, to improve patient compliance, an oral formulation A is being developed that slowly releases the drug, maintaining its effectiveness with once-daily dosing.\n\nQuestion: Which type of drug is most suitable for development as formulation A?\n\n① A drug with a narrow therapeutic index\n② A drug with a large single dose\n③ A drug with very slow absorption and elimination rates\n④ A drug that is highly unstable due to metabolism in the gastrointestinal tract\n⑤ A drug that is absorbed throughout the entire gastrointestinal tract, not just at specific sites",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: Polyketide 경로로 생합성되는 humulone, lupulone이 속하는 화합물군은?\n\n① stilbene\n② xanthone\n③ carotenoid\n④ phloroglucinol\n⑤ sesquiterpenoid",
        "question_text": "Question: Which group of compounds do humulone and lupulone, which are biosynthesized through the polyketide pathway, belong to?\n\n① stilbene\n② xanthone\n③ carotenoid\n④ phloroglucinol\n⑤ sesquiterpenoid",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: Shikimic acid를 전구체로 하여 생성된 페닐프로파노이드(C6-C3) 단위 2개의 산화적 축합으로 생성된 화합물군은?\n\n① lignan\n② alkaloid\n③ coumarin\n④ chromone\n⑤ polyacetylene",
        "question_text": "Question: Which group of compounds is formed by the oxidative condensation of two phenylpropanoid (C6-C3) units derived from shikimic acid as a precursor?\n\n① lignan\n② alkaloid\n③ coumarin\n④ chromone\n⑤ polyacetylene",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: Progesterone 등 반합성 스테로이드 호르몬 합성의 원료물질인 diosgenin의 기원식물은?\n\n① 마\n② 감초\n③ 대마\n④ 인삼\n⑤ 황기",
        "question_text": "Question: What is the source plant of diosgenin, which is the raw material for the synthesis of semi-synthetic steroid hormones such as progesterone?\n\n① Yam\n② Licorice\n③ Hemp\n④ Ginseng\n⑤ Astragalus",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 다음 설명에 해당되는 화합물군은?\n\n• 현초의 주성분임\n• 확인반응으로 FeCl3 시약을 사용함\n• 가수분해에 의해 gallic acid 또는 ellagic acid를 생성함\n• 단백질 및 알칼로이드 등과 결합하여 난용화 경향을 나타냄\n\n① tannin\n② iridoid\n③ coumarin\n④ diterpene\n⑤ anthraquinone",
        "question_text": "Question: Which group of compounds corresponds to the following description?\n\n• It is the main component of Geranium thunbergii\n• FeCl3 reagent is used for its identification reaction\n• It produces gallic acid or ellagic acid through hydrolysis\n• It tends to form insoluble complexes by binding with proteins and alkaloids\n\n① tannin\n② iridoid\n③ coumarin\n④ diterpene\n⑤ anthraquinone",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: Pyrethrin I을 함유하며 농업용, 가정용 살충제로 사용하는 생약은?\n\n① 괴화\n② 신이\n③ 정향\n④ 사프란\n⑤ 제충국",
        "question_text": "Question: Which medicinal herb contains Pyrethrin I and is used as an agricultural and household insecticide?\n\n① Sophora japonica (Japanese pagoda tree flowers)\n② Magnolia officinalis (Magnolia bark)\n③ Syzygium aromaticum (Clove)\n④ Crocus sativus (Saffron)\n⑤ Chrysanthemum cinerariaefolium (Pyrethrum)",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 디기탈리스 함유 성분 중 digitoxin에 포함된 2,6-dideoxy 당을 확인하는 반응은?\n\n① Vitali 반응\n② Halphen 반응\n③ Marquis 반응\n④ Keller-Killiani 반응\n⑤ Liebermann-Burchard 반응",
        "question_text": "Question: Which reaction is used to identify the 2,6-dideoxy sugar contained in digitoxin, one of the components found in digitalis?\n\n① Vitali reaction\n② Halphen reaction\n③ Marquis reaction\n④ Keller-Killiani reaction\n⑤ Liebermann-Burchard reaction",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: Diterpene 알칼로이드로 진통 작용을 나타내는 화합물은?\n\n① aconitine\n② reserpine\n③ higenamine\n④ tanshinone I\n⑤ pinoresinol di-O-β-D-glucopyranoside",
        "question_text": "Question: Which compound is a diterpene alkaloid that exhibits analgesic effects?\n\n① aconitine\n② reserpine\n③ higenamine\n④ tanshinone I\n⑤ pinoresinol di-O-β-D-glucopyranoside",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: 작약에 함유된 monoterpene 배당체로서 진경 작용을 나타내는 성분은?\n\n① crocin\n② menthol\n③ atractylon\n④ papaverine\n⑤ paeoniflorin",
        "question_text": "Question: Which monoterpene glycoside contained in peony exhibits antispasmodic action?\n\n① crocin\n② menthol\n③ atractylon\n④ papaverine\n⑤ paeoniflorin",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 행인에 함유된 성분인 amygdalin의 분해 산물은?\n\n① linamarin\n② quercetin\n③ (-)-tropic acid\n④ hydrogen cyanide\n⑤ allylisothiocyanate",
        "question_text": "Question: What is the decomposition product of amygdalin, a component found in apricot kernels?\n\n① linamarin\n② quercetin\n③ (-)-tropic acid\n④ hydrogen cyanide\n⑤ allylisothiocyanate",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 마리아엉겅퀴 열매에 함유된 간세포보호 작용을 나타내는 flavonolignan계 성분은?\n\n① silybin\n② baicalein\n③ hesperidin\n④ platycodin A\n⑤ (-)-epigallocatechin gallate",
        "question_text": "Question: Which flavonolignan compound found in milk thistle fruit exhibits hepatoprotective effects?\n\n① silybin\n② baicalein\n③ hesperidin\n④ platycodin A\n⑤ (-)-epigallocatechin gallate",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 혈액순환개선 작용을 나타내는 ginkgolides A, B, C 등을 함유하는 생약은?\n\n① 다엽\n② 코카\n③ 센나엽\n④ 은행엽\n⑤ 디기탈리스엽",
        "question_text": "Question: Which medicinal herb contains ginkgolides A, B, C, etc., which show blood circulation improvement effects?\n\n① Folium Sennae\n② Coca\n③ Senna leaf\n④ Ginkgo leaf\n⑤ Digitalis leaf",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 세균성 설사에 대한 지사약으로 사용되며 berberine을 함유한 근경류 생약의 기원식물은?\n\n① Coptis japonica\n② Curcuma longa\n③ Sophora japonica\n④ Bupleurum falcatum\n⑤ Rehmannia glutinosa",
        "question_text": "Question: Which of the following is the source plant of a rhizome-type medicinal herb containing berberine, used as an antidiarrheal for bacterial diarrhea?\n\n① Coptis japonica\n② Curcuma longa\n③ Sophora japonica\n④ Bupleurum falcatum\n⑤ Rehmannia glutinosa",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: D-lysergic acid계 화합물을 함유하며 진통 촉진, 지혈약으로 사용하는 생약은?\n\n① 맥각\n② 복령\n③ 산초\n④ 연교\n⑤ 원지",
        "question_text": "Question: Which medicinal herb contains D-lysergic acid compounds and is used as an analgesic enhancer and hemostatic agent?\n\n① Ergot\n② Poria\n③ Sichuan pepper\n④ Forsythia fruit\n⑤ Polygala root",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 외감병이 진행되는 과정에서 나타나는 각종 증후들을 음(陰)과 양(陽)으로 변별한 후 이를 삼음(三陰)과 삼양(三陽)으로 나누어 변증하는 방법은?\n\n① 병인변증(病因辨證)\n② 삼초변증(三焦辨證)\n③ 육경변증(六經辨證)\n④ 기혈진액변증(氣血津液辨證)\n⑤ 위기영혈변증(衛氣營血辨證)",
        "question_text": "Question: What is the method of differentiation that categorizes various symptoms appearing during the progression of externally contracted diseases into Yin and Yang, and then further divides them into Three Yin and Three Yang?\n\n① Pathogenic Factor Differentiation (病因辨證)\n② Triple Burner Differentiation (三焦辨證)\n③ Six Meridians Differentiation (六經辨證)\n④ Qi, Blood, and Body Fluid Differentiation (氣血津液辨證)\n⑤ Wei, Qi, Ying, and Blood Differentiation (衛氣營血辨證)",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 숙지황, 백작약, 당귀, 천궁의 약재로 구성되어 있고, 보혈활혈(補血活血), 조경(調經)의 효능을 나타내는 한약제제는?\n\n① 사물탕(四物湯)\n② 소풍산(消風散)\n③ 안중산(安中散)\n④ 연라환(連蘿丸)\n⑤ 패독산(敗毒散)",
        "question_text": "Question: Which herbal medicine preparation is composed of Rehmannia glutinosa (prepared), Paeonia lactiflora (white), Angelica sinensis, and Ligusticum chuanxiong, and has the effects of nourishing and activating blood (補血活血) and regulating menstruation (調經)?\n\n① Samul-tang (四物湯)\n② Sopung-san (消風散)\n③ Anjung-san (安中散)\n④ Yeollra-hwan (連蘿丸)\n⑤ Paedok-san (敗毒散)",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 양심안신(養心安神)의 효능이 있어 자율신경실조증, 불면증, 어지럼증, 가슴 두근거림, 건망증, 불안, 초조 등의 증상에 사용하는 한약제제는?\n\n① 당귀수산(當歸鬚散)\n② 산조인탕(酸棗仁湯)\n③ 소청룡탕(小靑龍湯)\n④ 맥문동탕(麥門冬湯)\n⑤ 배농산급탕(排膿散及湯)",
        "question_text": "Question: Which herbal medicine preparation, known for its effects of nourishing the heart and calming the mind (養心安神), is used for symptoms such as autonomic nervous system dysfunction, insomnia, dizziness, palpitations, forgetfulness, anxiety, and restlessness?\n\n① Dangguixusan (當歸鬚散)\n② Suanzaoren Tang (酸棗仁湯)\n③ Xiaoqinglong Tang (小靑龍湯)\n④ Maimendong Tang (麥門冬湯)\n⑤ Painongsanjie Tang (排膿散及湯)",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n30세 남자가 감기 증상으로 머리가 아프고, 어깨가 결리며 땀이 나지 않고, 근육통 및 코감기 증상 등을 호소하여 다음과 같은 한약제제를 추천하였다.\n구성생약: 갈근 9 g, 계지 ∙ 마황 ∙ 작약 ∙ 감초(자) ∙ 생강 각 6 g, 대추 5 g\n\nQuestion: 배합된 생약 중 발한해표(發汗解表), 선폐평천(宣肺平喘), 이수소종(利水消腫) 효능이 있는 것은?\n\n① 갈근\n② 계지\n③ 마황\n④ 작약\n⑤ 감초(자)",
        "question_text": "A 30-year-old man complained of cold symptoms including headache, stiff shoulders, lack of sweating, muscle pain, and nasal congestion. The following herbal medicine preparation was recommended:\n\nComposition: Pueraria root 9 g, Cinnamon twig ∙ Ephedra herb ∙ Peony root ∙ Licorice root ∙ Ginger 6 g each, Jujube 5 g\n\nQuestion: Which of the herbs in this mixture has the effects of inducing sweating and releasing the exterior (發汗解表), ventilating the lungs and relieving asthma (宣肺平喘), and promoting urination and reducing edema (利水消腫)?\n\n① Pueraria root\n② Cinnamon twig\n③ Ephedra herb\n④ Peony root\n⑤ Licorice root",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n30세 남자가 감기 증상으로 머리가 아프고, 어깨가 결리며 땀이 나지 않고, 근육통 및 코감기 증상 등을 호소하여 다음과 같은 한약제제를 추천하였다.\n구성생약: 갈근 9 g, 계지 ∙ 마황 ∙ 작약 ∙ 감초(자) ∙ 생강 각 6 g, 대추 5 g\n\nQuestion: 위 한약제제에 함유된 성분으로 치료량보다 다량으로 사용 시 대뇌피질과 피질하의 중추를 흥분시켜 불면, 불안, 떨림 등의 증상을 일으키는 성분은?\n\n① puerarin\n② ephedrine\n③ liquiritigenin\n④ jujuboside B\n⑤ betulinic acid",
        "question_text": "A 30-year-old man complained of cold symptoms including headache, stiff shoulders, lack of sweating, muscle pain, and nasal congestion. The following herbal medicine preparation was recommended:\n\nComposition of medicinal herbs: Pueraria root 9 g, Cinnamon twig ∙ Ephedra herb ∙ Peony root ∙ Licorice root ∙ Ginger 6 g each, Jujube 5 g\n\nQuestion: Which component in the above herbal medicine preparation, when used in doses higher than the therapeutic amount, can stimulate the cerebral cortex and subcortical centers, causing symptoms such as insomnia, anxiety, and tremors?\n\n① puerarin\n② ephedrine\n③ liquiritigenin\n④ jujuboside B\n⑤ betulinic acid",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 평소 복약이행도가 낮은 54세 남자가 극심한 두통과 어지러움으로 응급실에 왔다. 당시 혈압은 200/132 mmHg이었고, 망막출혈이 확인되었다. 고혈압성 응급상황(hypertensive emergency)으로 진단되었을 때 신속한 투여가 필요한 약물은?\n\n① 도파민(dopamine)\n② 라베타롤(labetalol)\n③ 니모디핀(nimodipine)\n④ 도부타민(dobutamine)\n⑤ 포시노프릴(fosinopril)",
        "question_text": "Question: A 54-year-old man with a history of poor medication adherence came to the emergency room with severe headache and dizziness. His blood pressure was 200/132 mmHg, and retinal hemorrhage was confirmed. When diagnosed with a hypertensive emergency, which drug needs to be administered promptly?\n\n① Dopamine\n② Labetalol\n③ Nimodipine\n④ Dobutamine\n⑤ Fosinopril",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 고혈압과 제2형 당뇨병을 가진 64세 남자가 다음의 처방약을 복용 중 발목이 심하게 붓는다고 할 때 그 원인으로 추정되는 약물은?\n\n[약물 알레르기] 특이사항 없음\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 12.5 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 2회\n레파글리니드(repaglinide) 0.1 mg 1일 3회\n\n[임상검사] eGFR 72 mL/min/1.73 m2\n\n① 아스피린\n② 암로디핀\n③ 메트포르민\n④ 레파글리니드\n⑤ 히드로클로로티아지드",
        "question_text": "Question: A 64-year-old man with hypertension and type 2 diabetes, who is taking the following prescription medications, complains of severe ankle swelling. Which drug is likely to be the cause?\n\n[Drug Allergies] No specific issues\n\n[Medications]\nAspirin 100 mg once daily\nAmlodipine 10 mg once daily\nHydrochlorothiazide 12.5 mg once daily\nMetformin 1,000 mg twice daily\nRepaglinide 0.1 mg three times daily\n\n[Clinical Test] eGFR 72 mL/min/1.73 m2\n\n① Aspirin\n② Amlodipine\n③ Metformin\n④ Repaglinide\n⑤ Hydrochlorothiazide",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 만성안정형협심증이 있는 43세 남자가 아테놀롤(atenolol) 복용 후 흉통은 조절되었으나 심한 피로감과 함께 성기능장애가 발생하였다. 환자 상황을 고려할 때 적절한 약물요법은?\n\n[활력징후]  혈압 128/82 mmHg, 심박수 58 회/분, 호흡수 20 회/분\n\n① 와파린(warfarin) 추가\n② 암로디핀(amlodipine) 추가\n③ 딜티아젬(diltiazem)으로 변경\n④ 메토프롤롤(metoprolol)로 변경\n⑤ 리바록사반(rivaroxaban)으로 변경",
        "question_text": "Question: A 43-year-old man with chronic stable angina experienced severe fatigue and sexual dysfunction after taking atenolol, although his chest pain was controlled. Considering the patient's situation, what is the appropriate drug therapy?\n\n[Vital signs] Blood pressure 128/82 mmHg, Heart rate 58 beats/min, Respiratory rate 20 breaths/min\n\n① Add warfarin\n② Add amlodipine\n③ Switch to diltiazem\n④ Switch to metoprolol\n⑤ Switch to rivaroxaban",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 만성신장병으로 혈액투석을 주기적으로 받고 있는 65세 남자에게 ST분절상승심근경색(STEMI)이 발생하였다. 초기 재관류요법 시행 시 사용할 보조적 항응고제는?\n\n① 와파린(warfarin)\n② 에독사반(edoxaban)\n③ 다비가트란(dabigatran)\n④ 폰다파리눅스(fondaparinux)\n⑤ 미분획 헤파린(unfractionated heparin)",
        "question_text": "Question: A 65-year-old man who regularly receives hemodialysis due to chronic kidney disease experiences ST-segment elevation myocardial infarction (STEMI). Which adjunctive anticoagulant should be used during initial reperfusion therapy?\n\n① Warfarin\n② Edoxaban\n③ Dabigatran\n④ Fondaparinux\n⑤ Unfractionated heparin",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 뇌졸중 병력이 있는 79세 남자가 ST분절비상승심근경색(NSTEMI)으로 경피적 관상동맥중재술을 받았다. 관상동맥중재술 이후에 아스피린과 함께 이중항혈소판요법(DAPT)에 사용할 수 있는 약물은?\n\n① 아픽사반(apixaban)\n② 티로피반(tirofiban)\n③ 티카그렐러(ticagrelor)\n④ 프라수그렐(prasugrel)\n⑤ 폰다파리눅스(fondaparinux)",
        "question_text": "Question: A 79-year-old male with a history of stroke underwent percutaneous coronary intervention (PCI) for non-ST-segment elevation myocardial infarction (NSTEMI). Which drug can be used for dual antiplatelet therapy (DAPT) along with aspirin after coronary intervention?\n\n① Apixaban\n② Tirofiban\n③ Ticagrelor\n④ Prasugrel\n⑤ Fondaparinux",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 심방세동이 있는 54세 남자에게 심박수 조절제를 사용한 후, 심박수가 적절히 조절되었으나, 심방세동 증상이 지속되어 동율동으로 전환하였다. 이 환자의 장기적인 동율동 유지를 위해 투여할 수 있는 약물은?\n\n[병력] 고혈압, 심부전, 심방세동\n[임상검사] AST/ALT 39/37 IU/L, 심장박출률(EF) 34%\n\n① 디곡신(digoxin)\n② 베라파밀(verapamil)\n③ 플레카이니드(flecainide)\n④ 아미오다론(amiodarone)\n⑤ 프로파페논(propafenone)",
        "question_text": "Question: A 54-year-old man with atrial fibrillation was treated with a rate control agent, which adequately controlled his heart rate. However, as atrial fibrillation symptoms persisted, he was converted to sinus rhythm. Which drug can be administered for long-term maintenance of sinus rhythm in this patient?\n\n[Medical history] Hypertension, heart failure, atrial fibrillation\n[Clinical tests] AST/ALT 39/37 IU/L, Ejection Fraction (EF) 34%\n\n① Digoxin\n② Verapamil\n③ Flecainide\n④ Amiodarone\n⑤ Propafenone",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 비판막성 심방세동을 진단받은 67세 여자에게 뇌졸중 1차 예방약으로 사용할 수 있는 것은?\n\n[병력] 고혈압, 당뇨병\n[복용약물] 라미프릴(ramipril), 암로디핀(amlodipine), 메트포르민(metformin)\n[임상검사] CrCl 61 mL/min, INR 1.0, HbA1c 6.7%\n\n① 아스피린(aspirin)\n② 에독사반(edoxaban)\n③ 압식시맙(abciximab)\n④ 실로스타졸(cilostazol)\n⑤ 프라수그렐(prasugrel)",
        "question_text": "Question: Which of the following can be used as a primary stroke prevention medication for a 67-year-old woman diagnosed with non-valvular atrial fibrillation?\n\n[Medical history] Hypertension, Diabetes mellitus\n[Current medications] Ramipril, Amlodipine, Metformin\n[Clinical tests] CrCl 61 mL/min, INR 1.0, HbA1c 6.7%\n\n① Aspirin\n② Edoxaban\n③ Abciximab\n④ Cilostazol\n⑤ Prasugrel",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 59세 여자가 갑작스런 의식소실로 응급실로 이송된 후 지주막하출혈을 진단받았다. 지연성 뇌경색으로 인한 신경손상 감소를 위해 특별한 금기사항이 없는 한 투여해야 하는 약물은?\n\n① 밀리논(milrinone)\n② 에스몰롤(esmolol)\n③ 딜티아젬(diltiazem)\n④ 니모디핀(nimodipine)\n⑤ 니트로프루시드(nitroprusside)",
        "question_text": "Question: A 59-year-old woman was transported to the emergency room due to sudden loss of consciousness and was diagnosed with subarachnoid hemorrhage. Which drug should be administered, unless specifically contraindicated, to reduce neurological damage from delayed cerebral infarction?\n\n① Milrinone\n② Esmolol\n③ Diltiazem\n④ Nimodipine\n⑤ Nitroprusside",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 평소 건강하던 57세 남자가 오전 8시경 갑자기 말이 어눌해지면서 왼쪽 다리를 움직일 수 없어 응급실로 이송되었다. 오전 11시 현재 허혈성 뇌졸중으로 진단받은 이 환자에게 즉시 투여해야 할 약물은?\n\n[임상검사] 혈압 152/96 mmHg, 혈소판 375×103/mm3, 혈당 135 mg/dL\n\n[단층촬영(CT)] \n뇌출혈 없음\n뇌허혈 부위는 한 구역 병변에 국한됨(전체의 20%)\n\n[National Institutes of Health Stroke Scale (NIHSS)] 21점\n\n① 아스피린(aspirin)\n② 압식시맙(abciximab)\n③ 티카그렐러(ticagrelor)\n④ 알테플라제(alteplase, tPA)\n⑤ 테넥테플라제(tenecteplase)",
        "question_text": "Question: A previously healthy 57-year-old man suddenly developed slurred speech and was unable to move his left leg at around 8 AM, and was transported to the emergency room. As of 11 AM, he has been diagnosed with ischemic stroke. Which drug should be administered immediately to this patient?\n\n[Clinical tests] Blood pressure 152/96 mmHg, Platelets 375×103/mm3, Blood glucose 135 mg/dL\n\n[Computed Tomography (CT)]\nNo cerebral hemorrhage\nIschemic area limited to one region (20% of total)\n\n[National Institutes of Health Stroke Scale (NIHSS)] 21 points\n\n① Aspirin\n② Abciximab\n③ Ticagrelor\n④ Alteplase (tPA)\n⑤ Tenecteplase",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 당뇨병과 이상지질혈증이 있는 58세 남자가 생활요법과 식이요법을 잘 이행 중이다. 환자의 검사결과가 다음과 같을 때 적절한 추가 약물은?\n\n[복용약물]\n메트포르민(metformin) 1,000 mg 1일 2회\n시타글립틴(sitagliptin) 50 mg 1일 1회\n아토르바스타틴(atorvastatin) 10 mg 1일 1회\n[임상검사] eGFR 78 mL/min/1.73 m^2, TC 235 mg/dL, LDL-C 79 mg/dL, HDL-C 49 mg/dL, TG 582 mg/dL\n\n① 에제티미브(ezetimibe)\n② 겜피브로질(gemfibrozil)\n③ 플루바스타틴(fluvastatin)\n④ 페노피브레이트(fenofibrate)\n⑤ 콜레스티라민(cholestyramine)",
        "question_text": "Question: A 58-year-old male with diabetes and dyslipidemia is adhering well to lifestyle and dietary modifications. Given the patient's test results, what is the appropriate additional medication?\n\n[Current Medications]\nMetformin 1,000 mg twice daily\nSitagliptin 50 mg once daily\nAtorvastatin 10 mg once daily\n\n[Clinical Tests]\neGFR 78 mL/min/1.73 m^2\nTC 235 mg/dL\nLDL-C 79 mg/dL\nHDL-C 49 mg/dL\nTG 582 mg/dL\n\n① Ezetimibe\n② Gemfibrozil\n③ Fluvastatin\n④ Fenofibrate\n⑤ Cholestyramine",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 68세 남자가 고혈압과 협심증 치료를 위해 다음 약물을 복용 중이다. 메토프롤롤(metoprolol)로 인한 약물이상반응이 발생하여 이 약을 베라파밀(verapamil)로 변경하려 한다. 베라파밀과의 약물상호작용을 고려하여 용량 조절이 필요한 약물은?\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 2회\n에날라프릴(enalapril) 10 mg 1일 2회\n이소소르비드질산염(isosorbide dinitrate) SR 40 mg 1일 2회\n심바스타틴(simvastatin) 40 mg 1일 1회\n니트로글리세린(nitroglycerin) 0.6 mg 설하정, 필요시\n\n[활력징후] 혈압 132/87 mmHg, 심박수 65회/분\n\n[임상검사] TC 152 mg/dL, LDL-C 74 mg/dL, HDL-C 51 mg/dL, TG 135 mg/dL\n\n① 아스피린\n② 심바스타틴\n③ 에날라프릴\n④ 니트로글리세린\n⑤ 이소소르비드질산염",
        "question_text": "Question: A 68-year-old man is taking the following medications for hypertension and angina treatment. Due to an adverse drug reaction to metoprolol, there is a plan to change this medication to verapamil. Considering drug interactions with verapamil, which medication requires dose adjustment?\n\n[Current medications]\nAspirin 100 mg once daily\nMetoprolol 100 mg twice daily\nEnalapril 10 mg twice daily\nIsosorbide dinitrate SR 40 mg twice daily\nSimvastatin 40 mg once daily\nNitroglycerin 0.6 mg sublingual tablet, as needed\n\n[Vital signs] Blood pressure 132/87 mmHg, Heart rate 65 beats/min\n\n[Clinical tests] TC 152 mg/dL, LDL-C 74 mg/dL, HDL-C 51 mg/dL, TG 135 mg/dL\n\n① Aspirin\n② Simvastatin\n③ Enalapril\n④ Nitroglycerin\n⑤ Isosorbide dinitrate",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n골관절염, 심부전, 알레르기비염이 있는 63세 여자가 다음 약물들을 저염식이와 함께 1년 전부터 복용 중이다. 1주 전, 텃밭에서 일한 후 알레르기비염과 골관절염이 심해져 약국에서 세티리진(cetirizine), 덱시부프로펜(dexibuprofen)을 구입해 복용하였다. 3일 전부터 갑작스런 체중증가(3 kg), 호흡곤란, 다리부종이 나타났고, 이 증상이 점점 악화되어 응급실을 방문하였다.\n\n[복용약물] \n라미프릴(ramipril) 5 mg 1일 2회\n비소프롤롤(bisoprolol) 10 mg 1일 1회\n아세트아미노펜(acetaminophen) 500 mg 1일 3회\n세티리진 10 mg 1일 1회(5일 전부터 복용)\n덱시부프로펜 300 mg 1일 3회(5일 전부터 복용)\n\n[활력징후] 혈압 136/84 mmHg, 심박수 67회/분\n\n[임상검사] \nSCr 1.3 mg/dL, Na 136 mEq/L, K 5.2 mEq/L\n\n[심장초음파] 심장박출률(EF) 33%\n\nQuestion: 이 환자의 증상 악화 원인으로 추정되어 즉시 중단이 필요한 약물은?\n\n① 라미프릴\n② 세티리진\n③ 비소프롤롤\n④ 덱시부프로펜\n⑤ 아세트아미노펜",
        "question_text": "A 63-year-old woman with osteoarthritis, heart failure, and allergic rhinitis has been taking the following medications along with a low-salt diet for the past year. One week ago, after working in her garden, her allergic rhinitis and osteoarthritis worsened, so she purchased and took cetirizine and dexibuprofen from a pharmacy. Three days ago, she experienced sudden weight gain (3 kg), shortness of breath, and leg edema. As these symptoms gradually worsened, she visited the emergency room.\n\n[Medications]\nRamipril 5 mg twice daily\nBisoprolol 10 mg once daily\nAcetaminophen 500 mg three times daily\nCetirizine 10 mg once daily (started 5 days ago)\nDexibuprofen 300 mg three times daily (started 5 days ago)\n\n[Vital Signs] Blood pressure 136/84 mmHg, Heart rate 67 beats/min\n\n[Clinical Tests]\nSCr 1.3 mg/dL, Na 136 mEq/L, K 5.2 mEq/L\n\n[Echocardiogram] Ejection Fraction (EF) 33%\n\nQuestion: Which medication is presumed to be the cause of the patient's worsening symptoms and needs to be discontinued immediately?\n\n① Ramipril\n② Cetirizine\n③ Bisoprolol\n④ Dexibuprofen\n⑤ Acetaminophen",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n골관절염, 심부전, 알레르기비염이 있는 63세 여자가 다음 약물들을 저염식이와 함께 1년 전부터 복용 중이다. 1주 전, 텃밭에서 일한 후 알레르기비염과 골관절염이 심해져 약국에서 세티리진(cetirizine), 덱시부프로펜(dexibuprofen)을 구입해 복용하였다. 3일 전부터 갑작스런 체중증가(3 kg), 호흡곤란, 다리부종이 나타났고, 이 증상이 점점 악화되어 응급실을 방문하였다.\n\n[복용약물] \n라미프릴(ramipril) 5 mg 1일 2회\n비소프롤롤(bisoprolol) 10 mg 1일 1회\n아세트아미노펜(acetaminophen) 500 mg 1일 3회\n세티리진 10 mg 1일 1회(5일 전부터 복용)\n덱시부프로펜 300 mg 1일 3회(5일 전부터 복용)\n\n[활력징후] 혈압 136/84 mmHg, 심박수 67회/분\n\n[임상검사] \nSCr 1.3 mg/dL, Na 136 mEq/L, K 5.2 mEq/L\n\n[심장초음파] 심장박출률(EF) 33%\n\nQuestion: 이 환자의 증상 완화를 위해 적절한 추가 약물은?\n\n① 이바브라딘(ivabradine)\n② 푸로세미드(furosemide)\n③ 스피로노락톤(spironolactone)\n④ 사쿠비트릴/발사르탄(sacubitril/valsartan)\n⑤ 히드랄라진/이소소르비드질산염(hydralazine/isosorbide dinitrate)",
        "question_text": "A 63-year-old woman with osteoarthritis, heart failure, and allergic rhinitis has been taking the following medications along with a low-salt diet for the past year. One week ago, after working in her garden, her allergic rhinitis and osteoarthritis worsened, so she purchased and took cetirizine and dexibuprofen from a pharmacy. Three days ago, she experienced sudden weight gain (3 kg), shortness of breath, and leg edema. As these symptoms gradually worsened, she visited the emergency room.\n\n[Medications]\nRamipril 5 mg twice daily\nBisoprolol 10 mg once daily\nAcetaminophen 500 mg three times daily\nCetirizine 10 mg once daily (started 5 days ago)\nDexibuprofen 300 mg three times daily (started 5 days ago)\n\n[Vital Signs] Blood pressure 136/84 mmHg, Heart rate 67 beats/min\n\n[Clinical Tests]\nSCr 1.3 mg/dL, Na 136 mEq/L, K 5.2 mEq/L\n\n[Echocardiogram] Ejection Fraction (EF) 33%\n\nQuestion: Which additional medication is appropriate to alleviate this patient's symptoms?\n\n① Ivabradine\n② Furosemide\n③ Spironolactone\n④ Sacubitril/valsartan\n⑤ Hydralazine/isosorbide dinitrate",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n38세 여자가 교통사고로 인한 대퇴부 골절로 장기간 입원 후 퇴원하였다. 퇴원 2일 후부터 왼쪽 종아리가 붓고 심한 통증이 발생하여, 도플러 초음파 검사를 시행한 결과 심부정맥혈전증으로 진단되었다. 다른 동반질환은 없다.\n\nQuestion: 이 환자가 병원에 방문하여 정기적인 임상검사를 받기 어렵다고 할 때 적절한 치료약물은?\n\n① 와파린(warfarin)\n② 아스피린(aspirin)\n③ 티카그렐러(ticagrelor)\n④ 리바록사반(rivaroxaban)\n⑤ 미분획 헤파린(unfractionated heparin)",
        "question_text": "A 38-year-old woman was discharged from the hospital after a long-term hospitalization due to a femur fracture caused by a traffic accident. Two days after discharge, her left calf became swollen and severely painful. A Doppler ultrasound examination was performed, and she was diagnosed with deep vein thrombosis. She has no other comorbidities.\n\nQuestion: If this patient finds it difficult to visit the hospital for regular clinical tests, what is the most appropriate medication for treatment?\n\n① Warfarin\n② Aspirin\n③ Ticagrelor\n④ Rivaroxaban\n⑤ Unfractionated heparin",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n38세 여자가 교통사고로 인한 대퇴부 골절로 장기간 입원 후 퇴원하였다. 퇴원 2일 후부터 왼쪽 종아리가 붓고 심한 통증이 발생하여, 도플러 초음파 검사를 시행한 결과 심부정맥혈전증으로 진단되었다. 다른 동반질환은 없다.\n\nQuestion: 2년 뒤 임신 31주차인 이 환자에게 심부정맥혈전증이 재발되었다. 적절한 치료약물은?\n\n① 와파린(warfarin)\n② 에독사반(edoxaban)\n③ 에녹사파린(enoxaparin)\n④ 클로피도그렐(clopidogrel)\n⑤ 아스피린/디피리다몰(aspirin/dipyridamole)",
        "question_text": "A 38-year-old woman was discharged after a long-term hospitalization due to a femur fracture from a traffic accident. Two days after discharge, her left calf became swollen and severely painful. A Doppler ultrasound examination was performed, and she was diagnosed with deep vein thrombosis. She has no other comorbidities.\n\nQuestion: Two years later, this patient, now at 31 weeks of pregnancy, experiences a recurrence of deep vein thrombosis. What is the appropriate treatment medication?\n\n① Warfarin\n② Edoxaban\n③ Enoxaparin\n④ Clopidogrel\n⑤ Aspirin/Dipyridamole",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 1년 전 천식 진단을 받은 21세 여자가 증상이 있을 때마다 살부타몰(salbutamol) 흡입제로 천식을 조절해왔다. 평소 주 1회 흡입제를 사용하였으나 최근 두 달 동안은 증상이 자주 나타나 주 3회 이상 사용하였다. 이 환자에게 추가해야 할 약은?\n\n① 테오필린(theophylline) 경구제\n② 티오트로퓸(tiotropium) 흡입제\n③ 부데소니드(budesonide) 흡입제\n④ 오말리주맙(omalizumab) 주사제\n⑤ 메틸프레드니솔론(methylprednisolone) 경구제",
        "question_text": "Question: A 21-year-old woman diagnosed with asthma a year ago has been controlling her asthma with a salbutamol inhaler whenever symptoms occur. She usually used the inhaler once a week, but in the past two months, symptoms have appeared frequently, requiring use more than three times a week. Which medication should be added for this patient?\n\n① Oral theophylline\n② Tiotropium inhaler\n③ Budesonide inhaler\n④ Omalizumab injection\n⑤ Oral methylprednisolone",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 2년 전 아스피린을 복용한 후 천식이 악화된 경험이 있는 23세 여자가 감기 증상으로 약국에서 일반의약품을 구입하고자 한다. 이 환자에게 피하도록 권고해야 할 약물은?\n\n① 암브록솔(ambroxol)\n② 로라타딘(loratadine)\n③ 리보플라빈(riboflavin)\n④ 이부프로펜(ibuprofen)\n⑤ 슈도에페드린(pseudoephedrine)",
        "question_text": "Question: A 23-year-old woman who experienced worsening of asthma after taking aspirin 2 years ago wants to purchase over-the-counter medication for cold symptoms at a pharmacy. Which drug should be advised to avoid for this patient?\n\n① Ambroxol\n② Loratadine\n③ Riboflavin\n④ Ibuprofen\n⑤ Pseudoephedrine",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 반동성 혈관 확장으로 인한 약물유발성 비염의 이상반응이 발생할 수 있어 수일 이상 연속해서 사용하는 것을 피해야 하는 약은?\n\n① 베포타스틴(bepotastine) 경구제\n② 몬테루카스트(montelukast) 경구제\n③ 모메타손(mometasone) 비강분무제\n④ 이프라트로퓸(ipratropium) 비강분무제\n⑤ 자일로메타졸린(xylometazoline) 비강분무제",
        "question_text": "Question: Which drug should be avoided for continuous use for more than a few days due to the potential side effect of drug-induced rhinitis caused by rebound vasodilation?\n\n① Bepotastine oral formulation\n② Montelukast oral formulation\n③ Mometasone nasal spray\n④ Ipratropium nasal spray\n⑤ Xylometazoline nasal spray",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n20년 동안 매일 담배를 한 갑씩 피우고 있는 56세 남자에게 기침과 가래 증상이 최근 심해지고 있다. 기관지확장제 흡입 후 폐기능 검사 결과, 1초간노력성호기량(FEV1)은 72%, 1초간 노력성호기량/노력성폐활량(FEV1/FVC) 비는 68%이었으며, 만성폐쇄성폐질환 평가검사(CAT) 점수는 8점이었다.\n\nQuestion: 이 환자에게 만성폐쇄성폐질환 치료를 시작하려고 할 때, 적절한 약물요법은?\n\n① 살부타몰(salbutamol) 흡입제\n② 부데소니드(budesonide) 흡입제\n③ 프레드니솔론(prednisolone) 정제\n④ 살메테롤/플루티카손(salmeterol/fluticasone) 흡입제\n⑤ 티오트로퓸(tiotropium) 흡입제+로플루밀라스트(roflumilast) 정제",
        "question_text": "A 56-year-old man who has been smoking one pack of cigarettes daily for 20 years has recently experienced worsening cough and sputum symptoms. After inhaling a bronchodilator, his pulmonary function test results showed a forced expiratory volume in one second (FEV1) of 72%, a forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio of 68%, and a COPD Assessment Test (CAT) score of 8 points.\n\nQuestion: When starting treatment for chronic obstructive pulmonary disease (COPD) in this patient, what is the appropriate drug therapy?\n\n① Salbutamol inhaler\n② Budesonide inhaler\n③ Prednisolone tablets\n④ Salmeterol/fluticasone inhaler\n⑤ Tiotropium inhaler + Roflumilast tablets",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n20년 동안 매일 담배를 한 갑씩 피우고 있는 56세 남자에게 기침과 가래 증상이 최근 심해지고 있다. 기관지확장제 흡입 후 폐기능 검사 결과, 1초간노력성호기량(FEV1)은 72%, 1초간 노력성호기량/노력성폐활량(FEV1/FVC) 비는 68%이었으며, 만성폐쇄성폐질환 평가검사(CAT) 점수는 8점이었다.\n\nQuestion: 이 환자에게 인플루엔자백신을 접종하려고 할 때, 적절한 예방접종 빈도는?\n\n① 매년 1회\n② 5년마다 1회\n③ 10년마다 1회\n④ 65세 이후 1회\n⑤ 65세가 되기 전 1회 + 65세 이후 1회",
        "question_text": "A 56-year-old man who has been smoking a pack of cigarettes daily for 20 years has recently experienced worsening cough and sputum symptoms. After inhaling a bronchodilator, his pulmonary function test results showed a forced expiratory volume in one second (FEV1) of 72%, a forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio of 68%, and a COPD Assessment Test (CAT) score of 8.\n\nQuestion: When considering administering an influenza vaccine to this patient, what is the appropriate frequency of vaccination?\n\n① Once a year\n② Once every 5 years\n③ Once every 10 years\n④ Once after age 65\n⑤ Once before age 65 + once after age 65",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 무릎관절염을 진단받은 68세 여자가 아세트아미노펜(acetaminophen) 복용에도 통증이 완화되지 않아서 나프록센(naproxen)으로 변경하고자 할 때, 소화성 궤양을 예방하기에 적절한 약물은?\n\n① 비스무트(bismuth)\n② 알긴산(alginic acid)\n③ 에스오메프라졸(esomeprazole)\n④ 에카베트나트륨(ecabet sodium)\n⑤ 수산화마그네슘(magnesium hydroxide)",
        "question_text": "Question: A 68-year-old woman diagnosed with knee osteoarthritis wants to switch from acetaminophen to naproxen as her pain is not relieved. Which of the following drugs is appropriate for preventing peptic ulcers?\n\n① Bismuth\n② Alginic acid\n③ Esomeprazole\n④ Ecabet sodium\n⑤ Magnesium hydroxide",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 위식도역류질환의 병력이 있는 58세 여자가 고혈압과 골감소증으로 다음의 약물을 복용 중이다. 이 중 하부식도괄약근압을 저하시켜 위식도역류질환의 재발 위험을 높일 수 있는 약물은?\n\n[복용약물]  비타민D 암로디핀(amlodipine) 메토프롤롤(metoprolol) 구연산칼슘(calcium citrate) 히드로클로로티아지드(hydrochlorothiazide)\n\n① 비타민D\n② 암로디핀\n③ 메토프롤롤\n④ 구연산칼슘\n⑤ 히드로클로로티아지드",
        "question_text": "Question: A 58-year-old woman with a history of gastroesophageal reflux disease (GERD) is taking the following medications for hypertension and osteopenia. Which of these medications can lower the lower esophageal sphincter pressure and increase the risk of GERD recurrence?\n\n[Medications] Vitamin D, Amlodipine, Metoprolol, Calcium citrate, Hydrochlorothiazide\n\n① Vitamin D\n② Amlodipine\n③ Metoprolol\n④ Calcium citrate\n⑤ Hydrochlorothiazide",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 35세 남자가 묽은 변(1일 3회 이상), 변실금을 보여 검사한 결과 과민성대장증후군으로 진단되었다. 다른 임상검사 결과는 모두 정상일 때 투여할 약물로 적절한 것은?\n\n① 도큐세이트(docusate)\n② 락툴로오스(lactulose)\n③ 로페라미드(loperamide)\n④ 루비프로스톤(lubiprostone)\n⑤ 프루칼로프라이드(prucalopride)",
        "question_text": "Question: A 35-year-old man showed loose stools (more than 3 times a day) and fecal incontinence. After examination, he was diagnosed with irritable bowel syndrome. When all other clinical test results are normal, which of the following drugs is appropriate to administer?\n\n① Docusate\n② Lactulose\n③ Loperamide\n④ Lubiprostone\n⑤ Prucalopride",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 38세 남자가 만성 C형간염(유전자형 1b형)을 진단받아 페그인터페론알파-2a (pegylated interferon α-2a)와 리바비린(ribavirin)으로 치료를 받았으나, 지속적바이러스반응(SVR)에는 도달하지 못했다. 간경변의 징후는 없다고 할 때 적절한 대체 약물요법은?\n\n① 텔비부딘(telbivudine) + 리바비린\n② 페그인터페론알파-2a + 라미부딘(lamivudine)\n③ 라미부딘 + 아수나프레비르(asunaprevir)\n④ 다클라타스비르(daclatasvir) + 테노포비르(tenofovir)\n⑤ 레디파스비르/소포스부비르(ledipasvir/sofosbuvir)",
        "question_text": "Question: A 38-year-old man was diagnosed with chronic hepatitis C (genotype 1b) and was treated with pegylated interferon α-2a and ribavirin, but did not achieve a sustained virologic response (SVR). Assuming there are no signs of cirrhosis, what is the appropriate alternative drug therapy?\n\n① Telbivudine + Ribavirin\n② Pegylated interferon α-2a + Lamivudine\n③ Lamivudine + Asunaprevir\n④ Daclatasvir + Tenofovir\n⑤ Ledipasvir/Sofosbuvir",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 31세 B형간염 보균자(HBsAg 양성)인 임부에게서 태어난 신생아에게 적절한 B형간염 예방요법은?\n\n① B형간염백신\n② 리바비린(ribavirin)\n③ 엔테카비어(entecavir)\n④ B형간염 면역글로불린 + B형간염백신\n⑤ 페그인터페론알파-2a (pegylated interferon α-2a)",
        "question_text": "Question: What is the appropriate hepatitis B prevention method for a newborn born to a 31-year-old pregnant woman who is a hepatitis B carrier (HBsAg positive)?\n\n① Hepatitis B vaccine\n② Ribavirin\n③ Entecavir\n④ Hepatitis B immunoglobulin + Hepatitis B vaccine\n⑤ Pegylated interferon α-2a",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 기저질환이 없는 40세 남자가 경증의 좌측대장염을 진단받아 메살라진(mesalazine) 정제를 2주 동안 복용했지만 혈변이 섞인 설사가 지속되었다. 활동기 궤양성대장염 치료에 적절한 약물요법은?\n\n① 간시클로버(ganciclovir) 주사제 추가\n② 프레드니솔론(prednisolone) 정제 추가\n③ 시클로스포린(cyclosporine) 캡슐제 추가\n④ 아달리무맙(adalimumab) 주사제로 변경\n⑤ 타크로리무스(tacrolimus) 캡슐제로 변경",
        "question_text": "Question: A 40-year-old man with no underlying diseases was diagnosed with mild left-sided colitis and took mesalazine tablets for 2 weeks, but diarrhea with blood continued. What is the appropriate drug therapy for treating active ulcerative colitis?\n\n① Add ganciclovir injection\n② Add prednisolone tablets\n③ Add cyclosporine capsules\n④ Switch to adalimumab injection\n⑤ Switch to tacrolimus capsules",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 37세 남자가 회장대장부위를 침범한 중등도의 크론병 치료를 위하여 고용량의 프레드니솔론(prednisolone)을 복용하였다. 관해에 도달한 이후, 프레드니솔론의 용량 감소와 크론병의 재발 방지를 위한 적절한 유지요법은?\n\n① 아자티오프린(azathioprine)\n② 시클로스포린(cyclosporine)\n③ 메트로니다졸(metronidazole)\n④ 시프로플록사신(ciprofloxacin)\n⑤ 히드로코르티손(hydrocortisone)",
        "question_text": "Question: A 37-year-old man took high-dose prednisolone for the treatment of moderate Crohn's disease affecting the ileocecal region. After reaching remission, what is the appropriate maintenance therapy to reduce the dose of prednisolone and prevent relapse of Crohn's disease?\n\n① Azathioprine\n② Cyclosporine\n③ Metronidazole\n④ Ciprofloxacin\n⑤ Hydrocortisone",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n57세의 남자가 토혈, 어지러움, 흑색변의 증상으로 응급실에 왔다. 만성B형간염 보균자이고 알코올남용의 병력이 있다. 신체검진 결과, 손바닥 홍반, 복부의 거미혈관종, 양쪽 다리부종이 관찰되었다. 위식도정맥류출혈이 확인되어 내시경치료와 수액공급을 시작하였다.\n\nQuestion: 이 환자의 위식도정맥류출혈 치료를 위해 추가할 수 있는 약은?\n\n① 니모디핀(nimodipine) 주사제\n② 테를리프레신(terlipressin) 주사제\n③ 메토프롤롤(metoprolol) 정제\n④ 판토프라졸(pantoprazole) 정제\n⑤ 이소소르비드일질산염(isosorbide mononitrate) 정제",
        "question_text": "A 57-year-old male came to the emergency room with symptoms of hematemesis, dizziness, and melena. He is a chronic hepatitis B carrier with a history of alcohol abuse. Physical examination revealed palmar erythema, spider angiomas on the abdomen, and edema in both legs. Esophageal variceal bleeding was confirmed, and endoscopic treatment and fluid resuscitation were initiated.\n\nQuestion: Which drug can be added for the treatment of esophageal variceal bleeding in this patient?\n\n① Nimodipine injection\n② Terlipressin injection\n③ Metoprolol tablet\n④ Pantoprazole tablet\n⑤ Isosorbide mononitrate tablet",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n57세의 남자가 토혈, 어지러움, 흑색변의 증상으로 응급실에 왔다. 만성B형간염 보균자이고 알코올남용의 병력이 있다. 신체검진 결과, 손바닥 홍반, 복부의 거미혈관종, 양쪽 다리부종이 관찰되었다. 위식도정맥류출혈이 확인되어 내시경치료와 수액공급을 시작하였다.\n\nQuestion: 이 환자에게 자발성 세균성복막염을 예방하기 위한 적절한 약물은?\n\n① 나프실린(nafcillin)\n② 반코마이신(vancomycin)\n③ 노르플록사신(norfloxacin)\n④ 메트로니다졸(metronidazole)\n⑤ 에리스로마이신(erythromycin)",
        "question_text": "A 57-year-old male came to the emergency room with symptoms of hematemesis, dizziness, and melena. He is a chronic hepatitis B carrier and has a history of alcohol abuse. Physical examination revealed palmar erythema, spider angiomas on the abdomen, and edema in both legs. Esophageal variceal bleeding was confirmed, and endoscopic treatment and fluid resuscitation were initiated.\n\nQuestion: What is the appropriate medication to prevent spontaneous bacterial peritonitis in this patient?\n\n① Nafcillin\n② Vancomycin\n③ Norfloxacin\n④ Metronidazole\n⑤ Erythromycin",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 고혈압과 당뇨병, 골관절염이 있는 59세 여자가 다음과 같은 약물을 복용 중에 전해질불균형이 발생하였다. 원인 약물은?\n\n[복용약물]\n암로디핀(amlodipine) 10 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 50 mg 1일 1회\n리나글립틴(linagliptin) 5 mg 1일 1회\n메트포르민(metformin) 500 mg 1일 2회\n아세트아미노펜(acetaminophen) 1,000 mg 1일 3회\n\n[임상검사]  Na 135 mEq/L, K 3.2 mEq/L, Cl 108 mEq/L, CO2 20 mEq/L\n\n① 암로디핀\n② 리나글립틴\n③ 메트포르민\n④ 아세트아미노펜\n⑤ 히드로클로로티아지드",
        "question_text": "Question: A 59-year-old woman with hypertension, diabetes, and osteoarthritis developed an electrolyte imbalance while taking the following medications. Which drug is the likely cause?\n\n[Medications]\nAmlodipine 10 mg once daily\nHydrochlorothiazide 50 mg once daily\nLinagliptin 5 mg once daily\nMetformin 500 mg twice daily\nAcetaminophen 1,000 mg three times daily\n\n[Clinical tests] Na 135 mEq/L, K 3.2 mEq/L, Cl 108 mEq/L, CO2 20 mEq/L\n\n① Amlodipine\n② Linagliptin\n③ Metformin\n④ Acetaminophen\n⑤ Hydrochlorothiazide",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 고혈압, 이상지질혈증, 제1형 당뇨병이 있는 40세 남자가 심한 복통과 함께 호흡이 가쁘고 정신이 혼미하여 응급실에 왔다. 평소 약을 잘 투약하였으나, 최근에 여행으로 3일간 약을 투약하지 못하였다고 한다. 검사결과가 다음과 같을 때 산염기불균형의 원인은?\n\n평소 주 1회(소주 0.5병/회) 술을 마시고 하루 평균 1갑(20년)의 담배를 피운다고 한다.\n[투여약물] 리시노프릴(lisinopril), 푸로세미드(furosemide), 로수바스타틴(rosuvastatin), 인슐린 디터머(insulin detemir), 인슐린 라이스프로(insulin lispro)\n[활력징후] 혈압 98/57 mmHg, 심박수 102회/분, 호흡수 22회/분\n[혈청검사] Na 142 mEq/L, K 3.3 mEq/L, Cl 107 mEq/L, CO2 11 mEq/L, 공복혈당 350 mg/dL\n[동맥혈가스분압검사]  pH 7.18, PaCO2 22 mmHg (참고치 35~45 mmHg), PaO2 88 mmHg (참고치 80~100 mmHg), HCO3- 9 mEq/L (참고치 22~26 mEq/L)\n[요검사] 케톤체 양성\n\n① 저혈압\n② 흡연력\n③ 음주력\n④ 인슐린 미투여\n⑤ 푸로세미드 미투여",
        "question_text": "Question: A 40-year-old man with hypertension, dyslipidemia, and type 1 diabetes came to the emergency room with severe abdominal pain, shortness of breath, and mental confusion. He had been taking his medications regularly, but recently couldn't take them for 3 days due to travel. Given the following test results, what is the cause of the acid-base imbalance?\n\nHe reportedly drinks alcohol once a week (0.5 bottle of soju per occasion) and smokes an average of 1 pack of cigarettes per day (for 20 years).\n[Medications] Lisinopril, Furosemide, Rosuvastatin, Insulin detemir, Insulin lispro\n[Vital signs] Blood pressure 98/57 mmHg, Heart rate 102 beats/min, Respiratory rate 22 breaths/min\n[Serum tests] Na 142 mEq/L, K 3.3 mEq/L, Cl 107 mEq/L, CO2 11 mEq/L, Fasting blood glucose 350 mg/dL\n[Arterial blood gas test] pH 7.18, PaCO2 22 mmHg (reference range 35-45 mmHg), PaO2 88 mmHg (reference range 80-100 mmHg), HCO3- 9 mEq/L (reference range 22-26 mEq/L)\n[Urine test] Ketones positive\n\n① Hypotension\n② Smoking history\n③ Drinking history\n④ Failure to administer insulin\n⑤ Failure to administer furosemide",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 69세 여자가 면역억제요법을 받은 지 3일째에 소변량 감소와 전신 부종 증상이 나타났고, 검사결과 약물유발 급성신손상으로 진단되었다. 원인 약물은?\n\n[투여약물]\n시클로스포린(cyclosporine) 400 mg 1일 2회\n아자티오프린(azathioprine) 150 mg 1일 1회\n프레드니솔론(prednisolone) 5 mg 1일 1회\n인슐린 데글루덱/인슐린 아스파트(insulin degludec/insulin aspart) 70/30 10 IU 1일 1회\n클로르헥시딘(chlorhexidine) 가글 1일 4회\n\n① 시클로스포린\n② 아자티오프린\n③ 프레드니솔론\n④ 클로르헥시딘\n⑤ 인슐린 데글루덱/인슐린 아스파트 70/30",
        "question_text": "Question: A 69-year-old woman developed decreased urine output and generalized edema on the third day of immunosuppressive therapy. Test results led to a diagnosis of drug-induced acute kidney injury. What is the causative drug?\n\n[Administered drugs]\nCyclosporine 400 mg twice daily\nAzathioprine 150 mg once daily\nPrednisolone 5 mg once daily\nInsulin degludec/insulin aspart 70/30 10 IU once daily\nChlorhexidine gargle 4 times daily\n\n① Cyclosporine\n② Azathioprine\n③ Prednisolone\n④ Chlorhexidine\n⑤ Insulin degludec/insulin aspart 70/30",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 고혈압이 있는 72세 남자가 만성신장병으로 진단받았다. 오늘 검사결과가 다음과 같을 때 적절한 약물요법은?\n\n[복용약물] 히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n[임상검사]\n혈압 135/89 mmHg, eGFR 45 mL/min/1.73 m2, K 4.0 mEq/L\n소변: 알부민 대 크레아티닌 비(ACR) 240 mg/g\n\n① 현 약물치료 지속\n② 라미프릴(ramipril) 추가\n③ 암로디핀(amlodipine) 추가\n④ 카르베딜롤(carvedilol) 추가\n⑤ 히드로클로로티아지드 용량 증가",
        "question_text": "Question: A 72-year-old man with hypertension has been diagnosed with chronic kidney disease. Given today's test results, what is the appropriate drug therapy?\n\n[Current medication] Hydrochlorothiazide 25 mg once daily\n[Clinical tests]\nBlood pressure 135/89 mmHg, eGFR 45 mL/min/1.73 m2, K 4.0 mEq/L\nUrine: Albumin-to-creatinine ratio (ACR) 240 mg/g\n\n① Continue current drug treatment\n② Add ramipril\n③ Add amlodipine\n④ Add carvedilol\n⑤ Increase hydrochlorothiazide dosage",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 남자가 고혈압, 이상지질혈증, 만성신장병으로 치료받는 중 오심, 구토, 가려움증과 같은 요독증 증상과 피곤함, 어지러움이 나타났다. 활동성 출혈 징후는 없으며 오늘 검사 결과는 다음과 같다.\n\n[임상검사] \nSCr 2.1 mg/dL, eGFR 36 mL/min/1.73 m^2\nHgb 10.1 g/dL (1개월 전 측정한 Hgb 9.4 g/dL)\nTsat 28% (목표치 >30%)\nferritin 210 ng/mL (목표치 >500 ng/mL)\n\nQuestion: 이 환자에게 요독증 증상 개선을 위한 약물로 적절한 것은?\n\n① 락티톨(lactitol)\n② 만니톨(mannitol)\n③ 토라세미드(torasemide)\n④ 구형 흡착탄(spherical adsorptive carbon, 크레메진Ⓡ 세립)\n⑤ 폴리스티렌설폰산칼슘(calcium polystyrene sulfonate)",
        "question_text": "A 58-year-old male, who is being treated for hypertension, dyslipidemia, and chronic kidney disease, has developed symptoms of uremia such as nausea, vomiting, and itching, along with fatigue and dizziness. There are no signs of active bleeding, and today's test results are as follows:\n\n[Clinical Tests]\nSCr 2.1 mg/dL, eGFR 36 mL/min/1.73 m^2\nHgb 10.1 g/dL (Hgb measured 1 month ago was 9.4 g/dL)\nTsat 28% (target >30%)\nferritin 210 ng/mL (target >500 ng/mL)\n\nQuestion: Which of the following drugs is appropriate for improving uremic symptoms in this patient?\n\n① Lactitol\n② Mannitol\n③ Torasemide\n④ Spherical adsorptive carbon (KremezinⓇ granules)\n⑤ Calcium polystyrene sulfonate",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 남자가 고혈압, 이상지질혈증, 만성신장병으로 치료받는 중 오심, 구토, 가려움증과 같은 요독증 증상과 피곤함, 어지러움이 나타났다. 활동성 출혈 징후는 없으며 오늘 검사 결과는 다음과 같다.\n\n[임상검사] \nSCr 2.1 mg/dL, eGFR 36 mL/min/1.73 m^2\nHgb 10.1 g/dL (1개월 전 측정한 Hgb 9.4 g/dL)\nTsat 28% (목표치 >30%)\nferritin 210 ng/mL (목표치 >500 ng/mL)\n\nQuestion: 이 환자는 1개월 전부터 다베포에틴 알파(darbepoetin alfa)를 사용하고 있다. 오늘 검사 결과를 고려할 때 조혈자극제 요법에 대한 적절한 대처 방안은?\n\n① 용량 감소\n② 용량 증가와 적혈구 수혈\n③ 용량 증가와 비타민C 추가\n④ 용량 증가와 레노그라스팀(lenograstim) 추가\n⑤ 용량 증가와 황산제일철(ferrous sulfate) 추가",
        "question_text": "A 58-year-old male, who is being treated for hypertension, dyslipidemia, and chronic kidney disease, has developed symptoms of uremia such as nausea, vomiting, and itching, along with fatigue and dizziness. There are no signs of active bleeding, and today's test results are as follows:\n\n[Clinical Tests]\nSCr 2.1 mg/dL, eGFR 36 mL/min/1.73 m^2\nHgb 10.1 g/dL (Hgb measured one month ago was 9.4 g/dL)\nTsat 28% (target >30%)\nferritin 210 ng/mL (target >500 ng/mL)\n\nQuestion: This patient has been using darbepoetin alfa for the past month. Considering today's test results, what is the appropriate course of action for the erythropoiesis-stimulating agent therapy?\n\n① Decrease the dose\n② Increase the dose and administer red blood cell transfusion\n③ Increase the dose and add vitamin C\n④ Increase the dose and add lenograstim\n⑤ Increase the dose and add ferrous sulfate",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 신기능이 감소한 환자(CrCl 28 mL/min)에게 신기능이 정상인 환자와 동일한 용량을 투여할 수 있는 혈당강하제는?\n\n① 알로글립틴(alogliptin)\n② 리나글립틴(linagliptin)\n③ 시타글립틴(sitagliptin)\n④ 메트포르민(metformin)\n⑤ 엠파글리플로진(empagliflozin)",
        "question_text": "Question: Which antidiabetic medication can be administered at the same dose to a patient with decreased renal function (CrCl 28 mL/min) as to a patient with normal renal function?\n\n① Alogliptin\n② Linagliptin\n③ Sitagliptin\n④ Metformin\n⑤ Empagliflozin",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 제2형 당뇨병으로 경구 혈당강하제를 복용하는 환자가 지난달부터 발바닥이 저리고 통증이 있어, 당뇨병성 말초신경병증으로 진단받았다. 증상 개선을 위해 추가할 약은?\n\n① 나프록센(naproxen) 정제\n② 둘록세틴(duloxetine) 캡슐제\n③ 피록시캄(piroxicam) 카타플라스마제\n④ 케토프로펜(ketoprofen) 카타플라스마제\n⑤ 메토클로프라미드(metoclopramide) 정제",
        "question_text": "Question: A patient taking oral hypoglycemic agents for type 2 diabetes was diagnosed with diabetic peripheral neuropathy last month due to numbness and pain in the soles of their feet. Which drug should be added to improve the symptoms?\n\n① Naproxen tablets\n② Duloxetine capsules\n③ Piroxicam cataplasma\n④ Ketoprofen cataplasma\n⑤ Metoclopramide tablets",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 제2형 당뇨병, 고혈압, 심부전, 이상지질혈증으로 약물치료를 받고 있는 64세 남자의 임상검사 결과와 복용약물은 다음과 같다. 이 환자에게 추가할 약물은?\n\n[활력징후] 혈압 136/84 mmHg, 심박수 68회/분, 호흡수 19회/분\n[임상검사]  HbA1c 7.8%, 공복혈당 155 mg/dL, 식후 2시간 혈당 195 mg/dL, TC 175 mg/dL, LDL-C 95 mg/dL, TG 150 mg/dL, eGFR 76 mL/min/1.73 m^2\n[복용약물]\n메트포르민(metformin) 1,000 mg 1일 2회\n리시노프릴(lisinopril) 10 mg 1일 1회\n카르베딜롤(carvedilol) 25 mg 1일 2회\n아토르바스타틴(atorvastatin) 20 mg 1일 1회\n아스피린(aspirin) 100 mg 1일 1회\n\n① 암로디핀(amlodipine)\n② 클로피도그렐(clopidogrel)\n③ 로수바스타틴(rosuvastatin)\n④ 피오글리타존(pioglitazone)\n⑤ 엠파글리플로진(empagliflozin)",
        "question_text": "Question: A 64-year-old man is receiving drug treatment for type 2 diabetes, hypertension, heart failure, and dyslipidemia. His clinical test results and current medications are as follows. Which drug should be added for this patient?\n\n[Vital Signs] Blood pressure 136/84 mmHg, Heart rate 68 beats/min, Respiratory rate 19 breaths/min\n[Clinical Tests] HbA1c 7.8%, Fasting blood glucose 155 mg/dL, 2-hour postprandial blood glucose 195 mg/dL, TC 175 mg/dL, LDL-C 95 mg/dL, TG 150 mg/dL, eGFR 76 mL/min/1.73 m^2\n[Current Medications]\nMetformin 1,000 mg twice daily\nLisinopril 10 mg once daily\nCarvedilol 25 mg twice daily\nAtorvastatin 20 mg once daily\nAspirin 100 mg once daily\n\n① Amlodipine\n② Clopidogrel\n③ Rosuvastatin\n④ Pioglitazone\n⑤ Empagliflozin",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: 갑상선항진증으로 프로필티오우라실(propylthiouracil) 100 mg 1일 3회로 복용하고 있는 32세 임부가 현재 임신 13주차에 접어들었다. 오늘 측정한 갑상선기능검사 결과는 정상이다. 이 환자에게 적절한 약물요법은?\n\n① 프로필티오우라실 용량 감소\n② 프로필티오우라실 용량 증가\n③ 메티마졸(methimazole) 추가\n④ 메티마졸(methimazole)으로 변경\n⑤ 요오드화칼륨(potassium iodide)으로 변경",
        "question_text": "Question: A 32-year-old pregnant woman with hyperthyroidism is taking propylthiouracil 100 mg three times daily. She is currently in her 13th week of pregnancy. Today's thyroid function test results are normal. What is the appropriate drug therapy for this patient?\n\n① Decrease the dose of propylthiouracil\n② Increase the dose of propylthiouracil\n③ Add methimazole\n④ Switch to methimazole\n⑤ Switch to potassium iodide",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 평소 건강하던 47세 여자가 오늘 갑상선저하증으로 진단받아 레보티록신(levothyroxine) 50 µg 1일 1회로 약물치료를 시작하고자 한다. 4주 후 약물효과를 평가하기 위해 확인해야 하는 검사 항목은?\n\n① TSH\n② 총 T3\n③ 갑상선글로불린(thyroglobulin)\n④ 방사성요오드섭취율(radioactive iodine uptake)\n⑤ 갑상선수용체항체(thyroid receptor antibody)",
        "question_text": "Question: A previously healthy 47-year-old woman is diagnosed with hypothyroidism today and is about to start medication with levothyroxine 50 µg once daily. Which test item should be checked after 4 weeks to evaluate the drug's effectiveness?\n\n① TSH\n② Total T3\n③ Thyroglobulin\n④ Radioactive iodine uptake\n⑤ Thyroid receptor antibody",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압과 제2형 당뇨병이 있는 58세 남자가 약을 잘 복용하였지만, 지난 한 달 동안 자가측정한 공복혈당은 평균 154 mg/dL였다. 환자는 주사제 사용에 대해 거부감이 있고, 체중 증가를 우려한다.\n\n[활력징후]\n혈압 134/82 mmHg, 심박수 68회/분, 호흡수 18회/분, 키 153 cm, 체중 68 kg\n\n[임상검사] \nHbA1c 7.2%, SCr 0.7 mg/dL, eGFR 78 mL/min/1.73 m^2, TC 204 mg/dL, LDL-C 126 mg/dL, HDL-C 42 mg/dL, TG 180 mg/dL\n\n[복용약물] \n메트포르민(metformin) 1,000 mg 1일 2회\n로사르탄(losartan) 50 mg 1일 1회\n아스피린(aspirin) 100 mg 1일 1회\n\nQuestion: 이 환자에게 혈당 조절을 위해 추가할 약물은?\n\n① 리라글루티드(liraglutide)\n② 글리메피리드(glimepiride)\n③ 피오글리타존(pioglitazone)\n④ 다파글리플로진(dapagliflozin)\n⑤ 인슐린 글라진(insulin glargine)",
        "question_text": "A 58-year-old man with hypertension and type 2 diabetes has been taking his medications well, but his average self-measured fasting blood glucose over the past month was 154 mg/dL. The patient is reluctant to use injectable medications and is concerned about weight gain.\n\n[Vital Signs]\nBlood pressure 134/82 mmHg, Heart rate 68 beats/min, Respiratory rate 18 breaths/min, Height 153 cm, Weight 68 kg\n\n[Clinical Tests]\nHbA1c 7.2%, SCr 0.7 mg/dL, eGFR 78 mL/min/1.73 m^2, TC 204 mg/dL, LDL-C 126 mg/dL, HDL-C 42 mg/dL, TG 180 mg/dL\n\n[Current Medications]\nMetformin 1,000 mg twice daily\nLosartan 50 mg once daily\nAspirin 100 mg once daily\n\nQuestion: Which medication should be added to control this patient's blood glucose?\n\n① Liraglutide\n② Glimepiride\n③ Pioglitazone\n④ Dapagliflozin\n⑤ Insulin glargine",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압과 제2형 당뇨병이 있는 58세 남자가 약을 잘 복용하였지만, 지난 한 달 동안 자가측정한 공복혈당은 평균 154 mg/dL였다. 환자는 주사제 사용에 대해 거부감이 있고, 체중 증가를 우려한다.\n\n[활력징후]\n혈압 134/82 mmHg, 심박수 68회/분, 호흡수 18회/분, 키 153 cm, 체중 68 kg\n\n[임상검사] \nHbA1c 7.2%, SCr 0.7 mg/dL, eGFR 78 mL/min/1.73 m^2, TC 204 mg/dL, LDL-C 126 mg/dL, HDL-C 42 mg/dL, TG 180 mg/dL\n\n[복용약물] \n메트포르민(metformin) 1,000 mg 1일 2회\n로사르탄(losartan) 50 mg 1일 1회\n아스피린(aspirin) 100 mg 1일 1회\n\nQuestion: 이 환자에게 심혈관 합병증 위험을 감소시키기 위해 추가할 약물은?\n\n① 리시노프릴(lisinopril)\n② 카르베딜롤(carvedilol)\n③ 에녹사파린(enoxaparin)\n④ 다비가트란(dabigatran)\n⑤ 아토르바스타틴(atorvastatin)",
        "question_text": "A 58-year-old man with hypertension and type 2 diabetes has been taking his medications well, but his average self-measured fasting blood glucose over the past month was 154 mg/dL. The patient is reluctant to use injectable medications and is concerned about weight gain.\n\n[Vital Signs]\nBlood pressure 134/82 mmHg, Heart rate 68 beats/min, Respiratory rate 18 breaths/min, Height 153 cm, Weight 68 kg\n\n[Clinical Tests]\nHbA1c 7.2%, SCr 0.7 mg/dL, eGFR 78 mL/min/1.73 m^2, TC 204 mg/dL, LDL-C 126 mg/dL, HDL-C 42 mg/dL, TG 180 mg/dL\n\n[Current Medications]\nMetformin 1,000 mg twice daily\nLosartan 50 mg once daily\nAspirin 100 mg once daily\n\nQuestion: Which medication should be added to reduce the risk of cardiovascular complications in this patient?\n\n① Lisinopril\n② Carvedilol\n③ Enoxaparin\n④ Dabigatran\n⑤ Atorvastatin",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 복막투석 중인 48세 남자가 복막염을 치료하기 위하여 겐타마이신(gentamicin)이 포함된 항생제요법을 시행하고 있다. 겐타마이신의 이상반응과 관련하여 모니터링이 필요한 검사항목은?\n\n① 혈당\n② 심전도\n③ 중성지방\n④ 갑상선기능\n⑤ 혈청크레아티닌",
        "question_text": "Question: A 48-year-old man undergoing peritoneal dialysis is receiving antibiotic therapy including gentamicin to treat peritonitis. Which test item needs to be monitored in relation to the side effects of gentamicin?\n\n① Blood glucose\n② Electrocardiogram\n③ Triglycerides\n④ Thyroid function\n⑤ Serum creatinine",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 과거 설파제를 복용한 후 전신 피부발진을 경험한 62세 남자에게 3일 전부터 배뇨 시 작열감, 통증, 빈뇨, 야간뇨, 절박뇨가 나타났고 전립선염으로 진단받았다. 적절한 1차 경험적 항생제는?\n\n① 나프실린(nafcillin)\n② 반코마이신(vancomycin)\n③ 시프로플록사신(ciprofloxacin)\n④ 스트렙토마이신(streptomycin)\n⑤ 설파메톡사졸/트리메토프림(sulfamethoxazole/trimethoprim)",
        "question_text": "Question: A 62-year-old man who previously experienced generalized skin rash after taking sulfa drugs has been diagnosed with prostatitis. For the past 3 days, he has been experiencing burning sensation during urination, pain, frequent urination, nocturia, and urinary urgency. What is the appropriate first-line empirical antibiotic?\n\n① Nafcillin\n② Vancomycin\n③ Ciprofloxacin\n④ Streptomycin\n⑤ Sulfamethoxazole/Trimethoprim",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 37세 남자에게 7일 전부터 코막힘, 콧물, 두통이 나타났으나 호전되는 양상을 보였다가 2일 전부터 화농성 콧물이 나며 증상이 악화되어 급성 세균성부비동염으로 진단되었다. 이 환자에게 적절한 항생제는?\n\n① 세페핌(cefepime)\n② 에르타페넴(ertapenem)\n③ 토브라마이신(tobramycin)\n④ 포스포마이신(fosfomycin)\n⑤ 아목시실린/클라불란산(amoxicillin/clavulanate)",
        "question_text": "Question: A 37-year-old man experienced nasal congestion, runny nose, and headache 7 days ago. The symptoms showed signs of improvement, but 2 days ago, purulent nasal discharge appeared and the symptoms worsened. He was diagnosed with acute bacterial sinusitis. Which antibiotic is appropriate for this patient?\n\n① Cefepime\n② Ertapenem\n③ Tobramycin\n④ Fosfomycin\n⑤ Amoxicillin/clavulanate",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 3세 환아가 급성중이염으로 항생제를 처방받았다. 보호자는 환아의 중이염으로 인한 귀 통증을 완화할 수 있는 약을 문의하였다. 적절한 약물은?\n\n① 케토티펜(ketotifen)\n② 이부프로펜(ibuprofen)\n③ 페닐레프린(phenylephrine)\n④ 슈도에페드린(pseudoephedrine)\n⑤ 클로르페니라민(chlorpheniramine)",
        "question_text": "Question: A 3-year-old child has been prescribed antibiotics for acute otitis media. The guardian inquired about medication to relieve ear pain caused by the child's otitis media. Which of the following is the appropriate medication?\n\n① Ketotifen\n② Ibuprofen\n③ Phenylephrine\n④ Pseudoephedrine\n⑤ Chlorpheniramine",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 7일 전 교통사고로 중환자실에 입원한 52세 남자에게 병원획득성 폐렴이 발생하였다. 적절한 경험적 항생제(요법)는?\n\n[병력] 당뇨병, 당뇨병성 족부감염[한 달 전 입원 시 메티실린저항성 황색포도상구균(MRSA)이 동정되어 항생제 치료 후 퇴원함]\n[임상검사]\n체온 38.8℃, WBC 20,400/mm^3\n흉부 방사선 촬영 검사: 폐침윤\n\n① 피페라실린/타조박탐(piperacillin/tazobactam)\n② 세페핌(cefepime) + 반코마이신(vancomycin)\n③ 세페핌 + 레보플록사신(levofloxacin) + 겐타마이신(gentamicin)\n④ 겐타마이신 + 클래리트로마이신(clarithromycin) + 반코마이신\n⑤ 세페핌 + 레보플록사신 + 반코마이신",
        "question_text": "Question: A 52-year-old man who was admitted to the ICU 7 days ago due to a traffic accident has developed hospital-acquired pneumonia. What is the appropriate empirical antibiotic (therapy)?\n\n[Medical history] Diabetes, diabetic foot infection [MRSA (Methicillin-resistant Staphylococcus aureus) was isolated during hospitalization a month ago, and he was discharged after antibiotic treatment]\n[Clinical tests]\nBody temperature 38.8°C, WBC 20,400/mm^3\nChest X-ray: Pulmonary infiltration\n\n① Piperacillin/tazobactam\n② Cefepime + Vancomycin\n③ Cefepime + Levofloxacin + Gentamicin\n④ Gentamicin + Clarithromycin + Vancomycin\n⑤ Cefepime + Levofloxacin + Vancomycin",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 당뇨병 병력이 있는 70세 남자가 지역사회획득성 폐렴으로 입원치료 후 퇴원할 예정이다. 이전에 폐렴구균백신을 접종한 적이 없다고 할 때, 백신 접종에 대한 권고 사항은?\n\n① 백신 접종은 필요하지 않음\n② 폐렴구균백신 13가를 12개월 간격으로 2회 접종함\n③ 폐렴구균백신 13가와 폐렴구균백신 23가 동시 접종함\n④ 폐렴구균백신 13가 접종 12개월 후 폐렴구균백신 23가 접종함\n⑤ 폐렴구균백신 23가 접종 12개월 후 폐렴구균백신 13가 접종함",
        "question_text": "Question: A 70-year-old man with a history of diabetes is about to be discharged after being hospitalized for community-acquired pneumonia. Assuming he has never received a pneumococcal vaccine before, what is the recommendation for vaccination?\n\n① Vaccination is not necessary\n② Administer pneumococcal vaccine 13-valent twice with a 12-month interval\n③ Administer pneumococcal vaccine 13-valent and pneumococcal vaccine 23-valent simultaneously\n④ Administer pneumococcal vaccine 13-valent, then pneumococcal vaccine 23-valent 12 months later\n⑤ Administer pneumococcal vaccine 23-valent, then pneumococcal vaccine 13-valent 12 months later",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 경구용 피임약을 복용 중인 29세 여자가 최근 결핵으로 이소니아지드(isoniazid), 리팜피신(rifampicin), 에탐부톨(ethambutol), 피라진아미드(pyrazinamide), 피리독신(pyridoxine) 복용을 시작하려 한다. 경구용 피임약의 효과를 감소시킬 수 있는 약물은?\n\n① 리팜피신\n② 에탐부톨\n③ 피리독신\n④ 이소니아지드\n⑤ 피라진아미드",
        "question_text": "Question: A 29-year-old woman taking oral contraceptives is about to start taking isoniazid, rifampicin, ethambutol, pyrazinamide, and pyridoxine for tuberculosis. Which drug can reduce the effectiveness of oral contraceptives?\n\n① Rifampicin\n② Ethambutol\n③ Pyridoxine\n④ Isoniazid\n⑤ Pyrazinamide",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 50세 여자가 항암화학요법을 마친 후 열이 나고 절대호중구수(ANC)가 150/mm3으로 감소하였다. 1주 이상 항생제 치료를 받았으나 열이 지속되고 있다. 경험적 칸디다혈증 치료를 시작하려고 할 때 적절한 항진균제는?\n\n① 플루시토신(flucytosine)\n② 시클로피록스(ciclopirox)\n③ 카스포펀진(caspofungin)\n④ 케토코나졸(ketoconazole)\n⑤ 클로트리마졸(clotrimazole)",
        "question_text": "Question: A 50-year-old woman developed a fever and her absolute neutrophil count (ANC) decreased to 150/mm3 after completing chemotherapy. She has been on antibiotic treatment for over a week, but the fever persists. When starting empirical treatment for candidemia, which antifungal agent is appropriate?\n\n① Flucytosine\n② Ciclopirox\n③ Caspofungin\n④ Ketoconazole\n⑤ Clotrimazole",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 최근 가족과 해외를 다녀온 6세 남아에게 구토, 복부 통증이 동반된 하루 4~5번의 심한 설사가 발생했다. 여행자 설사가 의심되어 항생제를 투여하려 할 때 적절한 약물은?\n\n① 반코마이신(vancomycin)\n② 세프타지딤(ceftazidime)\n③ 플루코나졸(fluconazole)\n④ 메트로니다졸(metronidazole)\n⑤ 아지트로마이신(azithromycin)",
        "question_text": "Question: A 6-year-old boy who recently traveled abroad with his family has developed severe diarrhea occurring 4-5 times a day, accompanied by vomiting and abdominal pain. When considering antibiotics for suspected traveler's diarrhea, which of the following is the appropriate medication?\n\n① Vancomycin\n② Ceftazidime\n③ Fluconazole\n④ Metronidazole\n⑤ Azithromycin",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n42세 남자가 갑작스러운 고열과 심한 두통으로 응급실에 왔다. 목이 뻣뻣해지며 빛에 과민하고 정신이 혼미한 증상을 나타내고 있다. 검사 결과는 다음과 같다.\n\n[임상검사] \nBUN 16 mg/dL, SCr 1.0 mg/dL, 혈당 80 mg/dL\n\n[뇌척수액 검사] \n혼탁 및 화농성\n백혈구 9,000/mm3, 호중구 79%\n단백질 300 mg/dL, 당(glucose) 27 mg/dL\n\n[뇌척수액 그람염색 검사] 그람양성균 검출\n\nQuestion: 세균성 뇌수막염으로 진단받은 이 환자에게 적절한 경험적 항생제요법은?\n\n① 반코마이신(vancomycin) + 세프트리악손(ceftriaxone)\n② 반코마이신 + 메트로니다졸(metronidazole)\n③ 겐타마이신(gentamicin) + 세파졸린(cefazolin)\n④ 리네졸리드(linezolid) + 아목시실린(amoxicillin)\n⑤ 아즈트레오남(aztreonam) + 시프로플록사신(ciprofloxacin)",
        "question_text": "A 42-year-old male came to the emergency room with sudden high fever and severe headache. He shows symptoms of neck stiffness, photosensitivity, and mental confusion. The test results are as follows:\n\n[Clinical tests]\nBUN 16 mg/dL, SCr 1.0 mg/dL, Blood glucose 80 mg/dL\n\n[Cerebrospinal fluid (CSF) test]\nTurbid and purulent\nWhite blood cells 9,000/mm3, Neutrophils 79%\nProtein 300 mg/dL, Glucose 27 mg/dL\n\n[CSF Gram stain] Gram-positive bacteria detected\n\nQuestion: What is the appropriate empirical antibiotic therapy for this patient diagnosed with bacterial meningitis?\n\n① Vancomycin + Ceftriaxone\n② Vancomycin + Metronidazole\n③ Gentamicin + Cefazolin\n④ Linezolid + Amoxicillin\n⑤ Aztreonam + Ciprofloxacin",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n42세 남자가 갑작스러운 고열과 심한 두통으로 응급실에 왔다. 목이 뻣뻣해지며 빛에 과민하고 정신이 혼미한 증상을 나타내고 있다. 검사 결과는 다음과 같다.\n\n[임상검사] \nBUN 16 mg/dL, SCr 1.0 mg/dL, 혈당 80 mg/dL\n\n[뇌척수액 검사] \n혼탁 및 화농성\n백혈구 9,000/mm3, 호중구 79%\n단백질 300 mg/dL, 당(glucose) 27 mg/dL\n\n[뇌척수액 그람염색 검사] 그람양성균 검출\n\nQuestion: 경험적 항생제 치료를 시작하고 3일 후 검사 결과는 다음과 같다. 약물요법을 변경하려 할 때, 적절한 확정적 항생제는?\n\n[뇌척수액 배양 검사] Streptococcus pneumoniae\n[항생제 감수성 검사]\n암피실린(ampicillin) MIC 4 μg/mL (R)*\n세푸록심(cefuroxime) MIC 2 μg/mL (R)*\n세포탁심(cefotaxime) MIC 0.25 μg/mL (S)*\n레보플록사신(levofloxacin) MIC 1 μg/mL (S)*\n\n* R, resistant; S, susceptible\n\n① 세팔렉신(cefalexin)\n② 암피실린(ampicillin)\n③ 겐타마이신(gentamicin)\n④ 세프트리악손(ceftriaxone)\n⑤ 아즈트레오남(aztreonam)",
        "question_text": "A 42-year-old male came to the emergency room with sudden high fever and severe headache. He shows symptoms of neck stiffness, photosensitivity, and mental confusion. The test results are as follows:\n\n[Clinical tests]\nBUN 16 mg/dL, SCr 1.0 mg/dL, Blood glucose 80 mg/dL\n\n[Cerebrospinal fluid (CSF) test]\nTurbid and purulent\nWhite blood cells 9,000/mm3, Neutrophils 79%\nProtein 300 mg/dL, Glucose 27 mg/dL\n\n[CSF Gram stain] Gram-positive bacteria detected\n\nQuestion: Empirical antibiotic treatment was started, and after 3 days, the test results are as follows. When considering changing the drug therapy, what is the appropriate definitive antibiotic?\n\n[CSF culture test] Streptococcus pneumoniae\n[Antibiotic susceptibility test]\nAmpicillin MIC 4 μg/mL (R)*\nCefuroxime MIC 2 μg/mL (R)*\nCefotaxime MIC 0.25 μg/mL (S)*\nLevofloxacin MIC 1 μg/mL (S)*\n\n* R, resistant; S, susceptible\n\n① Cephalexin\n② Ampicillin\n③ Gentamicin\n④ Ceftriaxone\n⑤ Aztreonam",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 30세 여자(체질량지수 30 kg/m2)가 편두통 치료를 위하여 수마트립탄(sumatriptan)을 복용 중이다. 이 환자에게 매달 2~3회 편두통이 발생하여 예방요법을 시작하고자 할 때 적절한 약물은?\n\n① 옥시코돈(oxycodone)\n② 발프로산(valproic acid)\n③ 에르고타민(ergotamine)\n④ 프로프라놀롤(propranolol)\n⑤ 모클로베미드(moclobemide)",
        "question_text": "Question: A 30-year-old woman (BMI 30 kg/m2) is taking sumatriptan for migraine treatment. When considering starting preventive therapy for this patient who experiences migraines 2-3 times a month, which of the following drugs is appropriate?\n\n① Oxycodone\n② Valproic acid\n③ Ergotamine\n④ Propranolol\n⑤ Moclobemide",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 73세 여자가 알츠하이머병의 치료를 위해 도네페질(donepezil)을 복용해 오던 중 우울증이 나타났다. 간이정신상태검사(MMSE)로 평가된 질병의 중증도에는 변화가 없을 때 우울증 개선을 위해 추가할 약물은?\n\n① 설트랄린(sertraline)\n② 이미프라민(imipramine)\n③ 황산제일철(ferrous sulfate)\n④ 리바스티그민(rivastigmine)\n⑤ 프레드니솔론(prednisolone)",
        "question_text": "Question: A 73-year-old woman who has been taking donepezil for the treatment of Alzheimer's disease developed depression. When there is no change in the severity of the disease as evaluated by the Mini-Mental State Examination (MMSE), which drug should be added to improve depression?\n\n① Sertraline\n② Imipramine\n③ Ferrous sulfate\n④ Rivastigmine\n⑤ Prednisolone",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 62세 남자가 파킨슨병 치료를 위해 레보도파/카르비도파(levodopa/carbidopa)를 복용 중 약물의 혈중농도가 최고에 도달할 시점에 불수의적 무도병 양상의 이상운동증(dyskinesia)을 보였다. 이상운동증을 개선하기 위해 추가할 약물은?\n\n① 바클로펜(baclofen)\n② 모다피닐(modafinil)\n③ 아만타딘(amantadine)\n④ 트리헥시페니딜(trihexyphenidyl)\n⑤ 클로스트리디움 보툴리눔 독소 A형(Clostridium botulinum toxin type A)",
        "question_text": "Question: A 62-year-old man taking levodopa/carbidopa for Parkinson's disease treatment showed choreiform dyskinesia at the peak plasma concentration of the drug. Which medication should be added to improve the dyskinesia?\n\n① Baclofen\n② Modafinil\n③ Amantadine\n④ Trihexyphenidyl\n⑤ Clostridium botulinum toxin type A",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 설파제 알레르기가 있는 20세 남자가 강직간대발작으로 진단받았다. 이 환자의 뇌전증 치료를 위해 적절한 1차 약물은?\n\n① 가바펜틴(gabapentin)\n② 조니사미드(zonisamide)\n③ 발프로산(valproic acid)\n④ 클로나제팜(clonazepam)\n⑤ 에토숙시미드(ethosuximide)",
        "question_text": "Question: A 20-year-old male with a sulfa drug allergy has been diagnosed with tonic-clonic seizures. What is the appropriate first-line medication for treating this patient's epilepsy?\n\n① Gabapentin\n② Zonisamide\n③ Valproic acid\n④ Clonazepam\n⑤ Ethosuximide",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 주요우울장애를 치료하기 위해 에스시탈로프람(escitalopram)을 복용 중인 45세 여자에게 편두통이 발생하여 나라트립탄(naratriptan)을 투여하고자 한다. 이때 주의하여야 할 약물이상반응은?\n\n① 통풍\n② 골다공증\n③ 세로토닌증후군\n④ 과립백혈구감소증\n⑤ 지연성이상운동증",
        "question_text": "Question: A 45-year-old woman taking escitalopram for major depressive disorder develops a migraine, and naratriptan is to be administered. What adverse drug reaction should be carefully monitored in this case?\n\n① Gout\n② Osteoporosis\n③ Serotonin syndrome\n④ Agranulocytosis\n⑤ Tardive dyskinesia",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 버스 운전기사인 50세 남자가 범불안장애 치료를 위하여 1주 전부터 벤라팍신(venlafaxine) 75 mg을 1일 1회 복용 중이다. 환자가 약물을 복용해 왔음에도 증상이 충분히 개선되지 않았다고 할 때 적절한 대처 방안은?\n\n① 벤라팍신(venlafaxine) 유지\n② 노르트립틸린(nortriptyline) 추가\n③ 부스피론(buspirone)으로 변경\n④ 알프라졸람(alprazolam)으로 변경\n⑤ 미르타자핀(mirtazapine)으로 변경",
        "question_text": "Question: A 50-year-old male bus driver has been taking venlafaxine 75 mg once daily for the past week to treat generalized anxiety disorder. If the patient reports that his symptoms have not sufficiently improved despite taking the medication, what is the appropriate course of action?\n\n① Maintain venlafaxine\n② Add nortriptyline\n③ Switch to buspirone\n④ Switch to alprazolam\n⑤ Switch to mirtazapine",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n조현병을 진단받고 할로페리돌(haloperidol)로 치료를 시작한 21세 남자에게 추체외로증후군 발생으로 근육긴장이상(dystonia)이 나타났다.\n\nQuestion: 이 환자에게 근육긴장이상을 처치하기 위한 적절한 약물은?\n\n① 클로니딘(clonidine)\n② 플루옥세틴(fluoxetine)\n③ 돔페리돈(domperidone)\n④ 벤즈트로핀(benztropine)\n⑤ 메토클로프라미드(metoclopramide)",
        "question_text": "A 21-year-old male diagnosed with schizophrenia started treatment with haloperidol. He developed dystonia as a result of extrapyramidal symptoms.\n\nQuestion: Which of the following drugs is appropriate for treating dystonia in this patient?\n\n① Clonidine\n② Fluoxetine\n③ Domperidone\n④ Benztropine\n⑤ Metoclopramide",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n조현병을 진단받고 할로페리돌(haloperidol)로 치료를 시작한 21세 남자에게 추체외로증후군 발생으로 근육긴장이상(dystonia)이 나타났다.\n\nQuestion: 이 환자에게 할로페리돌을 다른 약물로 변경하고자 할 때 적절한 것은?\n\n① 클로자핀(clozapine)\n② 파록세틴(paroxetine)\n③ 쿠에티아핀(quetiapine)\n④ 페르페나진(perphenazine)\n⑤ 클로르프로마진(chlorpromazine)",
        "question_text": "A 21-year-old male diagnosed with schizophrenia and started on haloperidol treatment developed dystonia due to extrapyramidal symptoms.\n\nQuestion: Which of the following would be an appropriate medication to switch to from haloperidol for this patient?\n\n① Clozapine\n② Paroxetine\n③ Quetiapine\n④ Perphenazine\n⑤ Chlorpromazine",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 지난 6개월간 2회의 급성통풍발작을 경험한 58세 남자에게 예방요법을 시작하려고 한다. 신장결석증 외에 다른 동반질환은 없을 때 적절한 약물요법은?\n\n① 이부프로펜(ibuprofen)\n② 라스부리카제(rasburicase)\n③ 벤즈브로마론(benzbromarone)\n④ 알로푸리놀(allopurinol) + 나프록센(naproxen)\n⑤ 세레콕시브(celecoxib) + 프레드니솔론(prednisolone)",
        "question_text": "Question: A 58-year-old man who has experienced two acute gout attacks in the past 6 months is about to start preventive therapy. When there are no other comorbidities except for kidney stones, what is the appropriate drug therapy?\n\n① Ibuprofen\n② Rasburicase\n③ Benzbromarone\n④ Allopurinol + Naproxen\n⑤ Celecoxib + Prednisolone",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 하루 평균 1갑(20개피)의 흡연을 하고 있는 37세 여자에게 경구용 복합호르몬피임제 복용이 금기인 이유는?\n\n[가족력] 유방암\n[병력] 방광염, 임신당뇨병, 6개월 전 출산\n\n① 방광염 병력\n② 유방암 가족력\n③ 6개월 전 출산\n④ 임신당뇨병 병력\n⑤ 하루 1갑(20개피) 흡연",
        "question_text": "Question: What is the reason for contraindication of oral combined hormonal contraceptives in a 37-year-old woman who smokes an average of 1 pack (20 cigarettes) per day?\n\n[Family history] Breast cancer\n[Medical history] Cystitis, Gestational diabetes, Childbirth 6 months ago\n\n① History of cystitis\n② Family history of breast cancer\n③ Childbirth 6 months ago\n④ History of gestational diabetes\n⑤ Smoking 1 pack (20 cigarettes) per day",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 현재 유방암 치료 중인 52세 환자에게 폐경기 혈관운동증상(vasomotor symptom)과 우울증상이 나타나 치료를 시작하려고 한다. 적절한 약물은?\n\n① 라록시펜(raloxifene)\n② 벤라팍신(venlafaxine)\n③ 메드록시프로게스테론(medroxyprogesterone)\n④ 바제독시펜/에스트로겐(bazedoxifene/conjugated equine estrogen)\n⑤ 에스트라디올/메드록시프로게스테론(estradiol/medroxyprogesterone)뒷면 계속",
        "question_text": "Question: A 52-year-old patient currently undergoing breast cancer treatment is experiencing menopausal vasomotor symptoms and depressive symptoms. You want to start treatment for these symptoms. Which of the following is the most appropriate medication?\n\n① Raloxifene\n② Venlafaxine\n③ Medroxyprogesterone\n④ Bazedoxifene/conjugated equine estrogen\n⑤ Estradiol/medroxyprogesterone\n\n(Continued on the back)",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 빈뇨, 잔뇨감, 요속 감소로 일상생활에 어려움이 있는 72세 남자에게 양성전립선비대 치료를 시작하려고 한다. 적절한 약물은?\n\n[임상검사]\n혈압 123/82 mmHg\n전립선 크기 30 mL (30 g)\n전립선특이항원(PSA) 1.2 ng/mL\n국제전립선증상점수(IPSS) 15점(중등도)\n\n① 타다라필(tadalafil)\n② 탐스로신(tamsulosin)\n③ 옥시부티닌(oxybutynin)\n④ 피나스테리드(finasteride)\n⑤ 데스모프레신(desmopressin)",
        "question_text": "Question: A 72-year-old man is experiencing difficulties in daily life due to frequent urination, residual urine sensation, and decreased urine flow. You are about to start treatment for benign prostatic hyperplasia. What is the appropriate medication?\n\n[Clinical Tests]\nBlood Pressure 123/82 mmHg\nProstate Size 30 mL (30 g)\nProstate-Specific Antigen (PSA) 1.2 ng/mL\nInternational Prostate Symptom Score (IPSS) 15 points (moderate)\n\n① Tadalafil\n② Tamsulosin\n③ Oxybutynin\n④ Finasteride\n⑤ Desmopressin",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n심부정맥혈전증 병력이 있는 68세 여자가 류마티스관절염과 골다공증 치료 중, 최근 관절의 부종과 통증이 심해져 에타너셉트(etanercept) 주사제를 추가하려고 한다.\n\n[복용약물] \n메토트렉세이트(methotrexate)\n폴산(folic acid)\n히드록시클로로퀸(hydroxychloroquine)\n리세드론산(risedronate)\n\nQuestion: 이 환자에게 에타너셉트 치료 시작 전 검사하여야 할 항목은?\n\n① 혈압, 혈당\n② 안저검사, 시야측정\n③ 심전도, 식도심장초음파\n④ 방광내시경, 위식도내시경\n⑤ 인터페론감마분비검사, 흉부X선",
        "question_text": "A 68-year-old woman with a history of deep vein thrombosis is currently being treated for rheumatoid arthritis and osteoporosis. Recently, her joint swelling and pain have worsened, and she is considering adding etanercept injections to her treatment regimen.\n\n[Current medications]\nMethotrexate\nFolic acid\nHydroxychloroquine\nRisedronate\n\nQuestion: Which of the following tests should be performed before starting etanercept treatment for this patient?\n\n① Blood pressure, blood glucose\n② Fundus examination, visual field test\n③ Electrocardiogram, transesophageal echocardiogram\n④ Cystoscopy, esophagogastroduodenoscopy\n⑤ Interferon-gamma release assay, chest X-ray",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n심부정맥혈전증 병력이 있는 68세 여자가 류마티스관절염과 골다공증 치료 중, 최근 관절의 부종과 통증이 심해져 에타너셉트(etanercept) 주사제를 추가하려고 한다.\n\n[복용약물] \n메토트렉세이트(methotrexate)\n폴산(folic acid)\n히드록시클로로퀸(hydroxychloroquine)\n리세드론산(risedronate)\n\nQuestion: 이 환자에게 약물로 조절되지 않는 위식도역류질환이 발생하여 골다공증 치료약을 변경하고자 한다. 적절한 약물은?\n\n① 라록시펜(raloxifene)\n② 알렌드론산(alendronate)\n③ 졸레드론산(zoledronic acid)\n④ 바제독시펜/에스트로겐(bazedoxifene/conjugated equine estrogen)\n⑤ 에스트라디올/메드록시프로게스테론(estradiol/medroxyprogesterone)",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 68-year-old woman with a history of deep vein thrombosis is being treated for rheumatoid arthritis and osteoporosis. Recently, her joint swelling and pain have worsened, and she is considering adding etanercept injections.\n\n[Current medications]\nMethotrexate\nFolic acid\nHydroxychloroquine\nRisedronate\n\nQuestion: The patient has developed gastroesophageal reflux disease that is not controlled by medication, and you want to change her osteoporosis treatment. Which of the following is the most appropriate medication?\n\n① Raloxifene\n② Alendronate\n③ Zoledronic acid\n④ Bazedoxifene/conjugated equine estrogen\n⑤ Estradiol/medroxyprogesterone",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 35세 여자가 급성골수성백혈병 치료를 위해 고용량 시타라빈(cytarabine) 포함 항암화학요법을 받을 예정이다. 다른 병력은 없다. 시타라빈의 이상반응을 예방하기 위해 투여가 필요한 약은?\n\n① 베탁솔롤(betaxolol) 점안제\n② 플루오로메톨론(fluorometholone) 점안제\n③ 페니토인(phenytoin) 경구제\n④ 로이코보린(leucovorin) 경구제\n⑤ 덱스라족산(dexrazoxane) 주사제",
        "question_text": "Question: A 35-year-old woman is scheduled to receive high-dose cytarabine-containing chemotherapy for the treatment of acute myeloid leukemia. She has no other medical history. Which drug should be administered to prevent the side effects of cytarabine?\n\n① Betaxolol eye drops\n② Fluorometholone eye drops\n③ Phenytoin oral medication\n④ Leucovorin oral medication\n⑤ Dexrazoxane injection",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 57세 남자가 급성골수성백혈병(AML M2)으로 진단받았다(ECOG 수행도 1). 다른 병력은 없고, 세포유전학적 검사 결과 치료경과가 양호한 유전자전위형이 확인되었다. 적절한 관해유도요법은?\n\n[세포유전학적 검사] t(8;21) 양성, t(15;17) 음성\n\n① 데시타빈(decitabine)\n② 고용량 시타라빈(cytarabine)\n③ 메르캅토푸린(6-mercaptopurine)\n④ 표준용량 시타라빈 + 이다루비신(idarubicin)\n⑤ 트레티노인(tretinoin) + 삼산화비소(arsenic trioxide)",
        "question_text": "Question: A 57-year-old man was diagnosed with acute myeloid leukemia (AML M2) (ECOG performance status 1). He has no other medical history, and cytogenetic testing revealed a genetic translocation associated with a favorable prognosis. What is the appropriate induction therapy?\n\n[Cytogenetic test results] t(8;21) positive, t(15;17) negative\n\n① Decitabine\n② High-dose cytarabine\n③ 6-Mercaptopurine\n④ Standard-dose cytarabine + idarubicin\n⑤ Tretinoin + arsenic trioxide",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 63세 여자가 만성기 만성골수성백혈병으로 진단받았다. 현재 부정맥 치료를 위해 아미오다론(amiodarone)을 복용 중이다. 적절한 초기 치료약물은?\n\n① 닐로티닙(nilotinib)\n② 수니티닙(sunitinib)\n③ 엘로티닙(erlotinib)\n④ 이매티닙(imatinib)\n⑤ 포나티닙(ponatinib)",
        "question_text": "Question: A 63-year-old woman has been diagnosed with chronic-phase chronic myeloid leukemia. She is currently taking amiodarone for the treatment of arrhythmia. What is the appropriate initial treatment drug?\n\n① Nilotinib\n② Sunitinib\n③ Erlotinib\n④ Imatinib\n⑤ Ponatinib",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 49세 남자가 확장병기 소세포폐암으로 진단받았다. 뇌 전이는 없으며, ECOG 수행도는 1이다. 다른 병력은 없다. 적절한 1차 항암화학요법은?\n\n① 아파티닙(afatinib)\n② 토포테칸(topotecan)\n③ 베바시주맙(bevacizumab)\n④ 시스플라틴(cisplatin) + 에토포시드(etoposide)\n⑤ 카르보플라틴(carboplatin) + 파클리탁셀(paclitaxel) + 크리조티닙(crizotinib)",
        "question_text": "Question: A 49-year-old man has been diagnosed with extensive-stage small cell lung cancer. There is no brain metastasis, and his ECOG performance status is 1. He has no other medical history. What is the appropriate first-line chemotherapy?\n\n① Afatinib\n② Topotecan\n③ Bevacizumab\n④ Cisplatin + Etoposide\n⑤ Carboplatin + Paclitaxel + Crizotinib",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 63세 남자가 간으로 전이된 대장암을 진단받아, 2주전 대장과 간 병변 절제술을 받았다. 조직검사 결과 KRAS 변이는 양성이었다. 고혈압 외에 다른 병력은 없고, ECOG 수행도는 1이다. 적절한 1차 보조항암화학요법은?\n\n① 레고라페닙(regorafenib)\n② 이리노테칸(irinotecan) + 애플리버셉트(ziv-aflibercept)\n③ 플루오로우라실(fluorouracil) + 로이코보린(leucovorin) + 옥살리플라틴(oxaliplatin)\n④ 플루오로우라실 + 로이코보린 + 니볼루맙(nivolumab)\n⑤ 플루오로우라실 + 로이코보린 + 이리노테칸 + 세툽시맙(cetuximab)",
        "question_text": "Question: A 63-year-old man was diagnosed with colon cancer metastasized to the liver and underwent resection of the colon and liver lesions 2 weeks ago. The biopsy result showed KRAS mutation positive. He has no other medical history except hypertension, and his ECOG performance status is 1. What is the appropriate first-line adjuvant chemotherapy?\n\n① Regorafenib\n② Irinotecan + Ziv-aflibercept\n③ Fluorouracil + Leucovorin + Oxaliplatin\n④ Fluorouracil + Leucovorin + Nivolumab\n⑤ Fluorouracil + Leucovorin + Irinotecan + Cetuximab",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n폐경 전인 40세 여자가 3기 유방암으로 진단받고, 유방전절제술을 받았다. 만성 변비 외에 다른 병력은 없다. 조직검사 결과 호르몬 수용체(hormone receptor, HR)는 양성, 사람표피성장인자 수용체 2(human epidermal growth factor receptor 2, HER2)는 음성이었다. 수술 후 치료로 보조항암화학요법, 방사선요법과 항호르몬요법을 받을 예정이다.\n\nQuestion: 이 환자에게 항호르몬요법을 위해 단독으로 투여를 시작할 수 있는 약물은?\n\n① 라파티닙(lapatinib)\n② 타목시펜(tamoxifen)\n③ 카페시타빈(capecitabine)\n④ 아나스트로졸(anastrozole)\n⑤ 트라스투주맙(trastuzumab)",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 40-year-old premenopausal woman was diagnosed with stage 3 breast cancer and underwent a mastectomy. She has no other medical history except for chronic constipation. The biopsy results showed hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative. Post-surgery treatment plan includes adjuvant chemotherapy, radiation therapy, and hormone therapy.\n\nQuestion: Which of the following drugs can be initiated as a single agent for hormone therapy in this patient?\n\n① Lapatinib\n② Tamoxifen\n③ Capecitabine\n④ Anastrozole\n⑤ Trastuzumab",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n폐경 전인 40세 여자가 3기 유방암으로 진단받고, 유방전절제술을 받았다. 만성 변비 외에 다른 병력은 없다. 조직검사 결과 호르몬 수용체(hormone receptor, HR)는 양성, 사람표피성장인자 수용체 2(human epidermal growth factor receptor 2, HER2)는 음성이었다. 수술 후 치료로 보조항암화학요법, 방사선요법과 항호르몬요법을 받을 예정이다.\n\nQuestion: 지속적인 통증을 조절하기 위해 모르핀(morphine) 경구제를 수일간 복용 중이다. 모르핀의 이상반응을 예방하기 위해 이 환자에게 투여가 필요한 약은?\n\n① 메살라진(mesalazine) 좌제\n② 옥트레오티드(octreotide) 주사제\n③ 차전자피(psyllium) 경구제\n④ 비사코딜(bisacodyl) 경구제\n⑤ 디옥타헤드랄스멕타이트(dioctahedral smectite) 경구제",
        "question_text": "A 40-year-old premenopausal woman was diagnosed with stage 3 breast cancer and underwent a mastectomy. She has no other medical history except for chronic constipation. The biopsy results showed hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative. Post-surgery treatment plan includes adjuvant chemotherapy, radiation therapy, and hormone therapy.\n\nQuestion: The patient has been taking oral morphine for several days to control persistent pain. Which drug should be administered to this patient to prevent side effects of morphine?\n\n① Mesalazine suppository\n② Octreotide injection\n③ Psyllium oral preparation\n④ Bisacodyl oral preparation\n⑤ Dioctahedral smectite oral preparation",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 아토피피부염이 있는 25세 여자가 외용 스테로이드연고를 얼굴과 팔 접힘병변에 사용 중이다. 지난 3개월간 피부건조 및 소양증이 악화되었고, 연고 도포 부위에 피부위축이 관찰되었다. 이 환자에게 적절한 약물요법은?\n\n① 리도카인(lidocaine) 크림 추가\n② 프라목신(pramoxine) 크림 추가\n③ 테르비나핀(terbinafine) 크림으로 변경\n④ 타크로리무스(tacrolimus) 0.1% 연고로 변경\n⑤ 덱사메타손(dexamethasone) 0.1% 연고로 변경",
        "question_text": "Question: A 25-year-old woman with atopic dermatitis has been using a topical steroid ointment on her face and arm fold lesions. Over the past 3 months, her skin dryness and pruritus have worsened, and skin atrophy has been observed at the sites where the ointment was applied. What is the appropriate drug therapy for this patient?\n\n① Add lidocaine cream\n② Add pramoxine cream\n③ Switch to terbinafine cream\n④ Switch to tacrolimus 0.1% ointment\n⑤ Switch to dexamethasone 0.1% ointment",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 42세 여자에게 녹내장 치료를 위해 안약을 투여하는 동안 속눈썹이 길어지고, 눈 주위가 검게 되는 색소침착이 나타났다. 이 환자가 사용한 것으로 추정되는 안약은?\n\n① 티몰롤(timolol)\n② 카르테올롤(carteolol)\n③ 필로카르핀(pilocarpine)\n④ 라타노프로스트(latanoprost)\n⑤ 플루오로메톨론(fluorometholone)",
        "question_text": "Question: A 42-year-old woman experienced eyelash growth and periocular hyperpigmentation while using eye drops for glaucoma treatment. Which eye drops are presumed to have been used by this patient?\n\n① Timolol\n② Carteolol\n③ Pilocarpine\n④ Latanoprost\n⑤ Fluorometholone",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 35세 여자에게 위절제술 후 중환자실에서 정맥영양요법을 시작할 예정이다. 수술 후 설사 증상이 있는 이 환자에게 결핍이 예상되어 보충을 고려하여야 하는 미량원소는?\n\n① 구리(Cu)\n② 망간(Mn)\n③ 아연(Zn)\n④ 크롬(Cr)\n⑤ 요오드(I)",
        "question_text": "Question: A 35-year-old woman is scheduled to start intravenous nutrition therapy in the intensive care unit after a gastrectomy. Which trace element should be considered for supplementation due to expected deficiency in this patient who has diarrhea symptoms after surgery?\n\n① Copper (Cu)\n② Manganese (Mn)\n③ Zinc (Zn)\n④ Chromium (Cr)\n⑤ Iodine (I)",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 병원에서 의료의 질향상을 위해 약사가 의약품사용과오와 약물이상반응에 관한 자료들을 수집 ∙ 확인 ∙ 분석하는 업무는?\n\n① 공중보건\n② 의약정보 제공\n③ 자가치료 상담\n④ 약물안전성조사\n⑤ 맞춤형 약물투여",
        "question_text": "Question: What is the task where a pharmacist collects, verifies, and analyzes data on medication errors and adverse drug reactions to improve the quality of medical care in a hospital?\n\n① Public health\n② Provision of medical information\n③ Self-treatment counseling\n④ Drug safety monitoring\n⑤ Personalized drug administration",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 흡연, 음주, 마약류 남용과 같은 환자정보를 파악할 수 있는 의무기록 항목은?\n\n① 주소(chief complaint)\n② 가족력(family history)\n③ 사회력(social history)\n④ 계통문진(review of system)\n⑤ 과거병력(past medical history)",
        "question_text": "Question: Which medical record section can identify patient information such as smoking, alcohol consumption, and drug abuse?\n\n① Chief complaint\n② Family history\n③ Social history\n④ Review of systems\n⑤ Past medical history",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 다음의 약사서비스 사례를 SOAP 노트 형식으로 기록하려고 한다. 계획(Plan) 항목에 기재하는 내용은?\n\n골관절염으로 나프록센(naproxen) 처방약을 복용하던 환자가 상복부 통증을 호소하여, 요소호기검사를 받은 후 H. pylori 제균을 위해 판토프라졸(pantoprazole)을 포함한 3제요법을 시작하였다. 1주일이 지난 현재 판토프라졸 복용만 유지하고 있다. 공복 시 통증은 완화되었으나 충분히 해소되지 않아 약사는 환자에게 매운 음식 등 자극적인 음식을 줄이도록 권고하였다.\n\n① 상복부 통증\n② 나프록센 처방\n③ 판토프라졸 처방\n④ 요소호기검사 결과\n⑤ 자극적인 음식 제한 권고",
        "question_text": "Question: You are going to record the following pharmacy service case in SOAP note format. What should be included in the Plan section?\n\nA patient who had been taking naproxen, a prescription medication for osteoarthritis, complained of upper abdominal pain. After undergoing a urea breath test, the patient started a triple therapy including pantoprazole for H. pylori eradication. Currently, after one week, the patient is only maintaining pantoprazole intake. While the pain during fasting has been alleviated, it has not been fully resolved, so the pharmacist advised the patient to reduce spicy and irritating foods.\n\n① Upper abdominal pain\n② Naproxen prescription\n③ Pantoprazole prescription\n④ Urea breath test results\n⑤ Recommendation to limit irritating foods",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 다약제를 복용하는 환자에게서 약물상호작용으로 의심되는 이상반응이 발생하였다. 인과성 파악을 위하여 3차 문헌을 활용하려고 할 때 적절한 정보원은?\n\n① MEDLINE\n② The Lancet\n③ Drug Interaction Facts\n④ New England Journal of Medicine\n⑤ American Journal of Health-System Pharmacy",
        "question_text": "Question: A patient taking multiple medications experienced an adverse reaction suspected to be due to drug interactions. Which of the following is an appropriate information source when using tertiary literature to determine causality?\n\n① MEDLINE\n② The Lancet\n③ Drug Interaction Facts\n④ New England Journal of Medicine\n⑤ American Journal of Health-System Pharmacy",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 니페디핀(nifedipine)을 복용하고 있는 83세 여자가 불안증 완화를 목적으로 디아제팜(diazepam)을 추가로 처방받았다. 이 환자가 주의해야 할 사항은?\n\n① 낙상\n② 설사\n③ 저혈당\n④ 말초신경염\n⑤ 위장관 출혈",
        "question_text": "Question: An 83-year-old woman taking nifedipine was additionally prescribed diazepam to alleviate anxiety. What should this patient be cautious about?\n\n① Falls\n② Diarrhea\n③ Hypoglycemia\n④ Peripheral neuropathy\n⑤ Gastrointestinal bleeding",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 10세 환자에게 연령금기인 약은?\n\n① 테오필린(theophylline) 건조시럽\n② 독시사이클린(doxycycline) 캡슐\n③ 몬테루카스트(montelukast) 츄정\n④ 아세트아미노펜(acetaminophen) 정\n⑤ 메토클로프라미드(metoclopramide) 정",
        "question_text": "Question: Which medication is contraindicated for a 10-year-old patient due to age restrictions?\n\n① Theophylline dry syrup\n② Doxycycline capsule\n③ Montelukast chewable tablet\n④ Acetaminophen tablet\n⑤ Metoclopramide tablet",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 임부에게 금기인 약은?\n\n① 피리독신(pyridoxine) 정\n② 시메티딘(cimetidine) 정\n③ 세팔렉신(cefalexin) 캡슐\n④ 아토르바스타틴(atorvastatin) 정\n⑤ 아목시실린/클라불란산(amoxicillin/clavulanate) 정",
        "question_text": "Question: Which medication is contraindicated for pregnant women?\n\n① Pyridoxine tablet\n② Cimetidine tablet\n③ Cefalexin capsule\n④ Atorvastatin tablet\n⑤ Amoxicillin/Clavulanate tablet",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 급성신손상이 있는 환자에게 투여할 때 신독성이 있어 피해야 하는 약은?\n\n① 나프록센(naproxen) 정\n② 독사조신(doxazosin) 정\n③ 레보티록신(levothyroxine) 정\n④ 아플로쿠알론(afloqualone) 정\n⑤ 아미트리프틸린(amitriptyline) 정",
        "question_text": "Question: Which medication should be avoided due to its nephrotoxicity when administered to a patient with acute kidney injury?\n\n① Naproxen tablet\n② Doxazosin tablet\n③ Levothyroxine tablet\n④ Afloqualone tablet\n⑤ Amitriptyline tablet",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 다음과 같이 반코마이신(vancomycin)을 투여받고 있는 환자에게서 신독성 발생이 우려되어, 약물투여 셋째 날 혈중약물농도를 측정하려고 한다. 적절한 채혈 시점은?\n\n반코마이신 1,000 mg IV q 12 h (오전 8시, 오후 8시)\n1시간 동안 점적 투여\n\n① 오전 7시 50분\n② 오전 9시\n③ 오전 9시 50분\n④ 오후 12시\n⑤ 오후 9시",
        "question_text": "Question: A patient is receiving vancomycin as follows, and there are concerns about the development of nephrotoxicity. You plan to measure the blood drug concentration on the third day of drug administration. What is the appropriate time for blood sampling?\n\nVancomycin 1,000 mg IV q 12 h (8 AM, 8 PM)\nAdministered as an infusion over 1 hour\n\n① 7:50 AM\n② 9:00 AM\n③ 9:50 AM\n④ 12:00 PM\n⑤ 9:00 PM",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 심부전, 조갑진균증이 있는 78세 여자가 다음 처방약을 복용한 후 복통, 구역, 구토, 심한 설사가 나타나서 응급실로 왔다. 서맥이 발견되어 디곡신 혈중농도를 측정하였다.\n\n| 처방 의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 비소프롤롤(bisoprolol) 2.5 mg 정 | 0.5정 | 2회 |\n| 디곡신(digoxin) 0.25 mg 정 | 0.5정 | 1회 |\n| 칸데사르탄(candesartan) 8 mg 정 | 1정 | 1회 |\n| 푸로세미드(furosemide) 40 mg 정 | 0.5정 | 1회 |\n| 아스피린(aspirin) 100 mg 정 | 1정 | 1회 |\n| 이트라코나졸(itraconazole) 200 mg 정 | 1정 | 1회 |\n\nQuestion: 이 환자의 치료에 적절한 디곡신 혈중농도(ng/mL)의 범위는?\n\n① 0.1~0.5\n② 0.5~1.0\n③ 1.0~1.5\n④ 1.5~2.0\n⑤ 2.0~2.5",
        "question_text": "A 78-year-old woman with hypertension, heart failure, and onychomycosis came to the emergency room with abdominal pain, nausea, vomiting, and severe diarrhea after taking the following prescription medications. Bradycardia was detected, and digoxin blood concentration was measured.\n\n| Prescription medication name | Single dose | Daily frequency |\n|---|---|---|\n| Bisoprolol 2.5 mg tablet | 0.5 tablet | 2 times |\n| Digoxin 0.25 mg tablet | 0.5 tablet | 1 time |\n| Candesartan 8 mg tablet | 1 tablet | 1 time |\n| Furosemide 40 mg tablet | 0.5 tablet | 1 time |\n| Aspirin 100 mg tablet | 1 tablet | 1 time |\n| Itraconazole 200 mg tablet | 1 tablet | 1 time |\n\nQuestion: What is the appropriate range of digoxin blood concentration (ng/mL) for this patient's treatment?\n\n① 0.1~0.5\n② 0.5~1.0\n③ 1.0~1.5\n④ 1.5~2.0\n⑤ 2.0~2.5",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 심부전, 조갑진균증이 있는 78세 여자가 다음 처방약을 복용한 후 복통, 구역, 구토, 심한 설사가 나타나서 응급실로 왔다. 서맥이 발견되어 디곡신 혈중농도를 측정하였다.\n\n| 처방 의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 비소프롤롤(bisoprolol) 2.5 mg 정 | 0.5정 | 2회 |\n| 디곡신(digoxin) 0.25 mg 정 | 0.5정 | 1회 |\n| 칸데사르탄(candesartan) 8 mg 정 | 1정 | 1회 |\n| 푸로세미드(furosemide) 40 mg 정 | 0.5정 | 1회 |\n| 아스피린(aspirin) 100 mg 정 | 1정 | 1회 |\n| 이트라코나졸(itraconazole) 200 mg 정 | 1정 | 1회 |\n\nQuestion: 이 환자의 디곡신 혈중농도를 검사한 결과, 혈중농도가 유효 혈중농도 범위를 상회하였다. 디곡신 혈중농도 상승에 영향을 미치는 것으로 추정되는 약물은?\n\n① 아스피린\n② 비소프롤롤\n③ 칸데사르탄\n④ 푸로세미드\n⑤ 이트라코나졸",
        "question_text": "A 78-year-old woman with hypertension, heart failure, and onychomycosis came to the emergency room with abdominal pain, nausea, vomiting, and severe diarrhea after taking the following prescription medications. Bradycardia was detected, and digoxin blood concentration was measured.\n\n| Prescription medication name | Single dose | Daily frequency |\n|---|---|---|\n| Bisoprolol 2.5 mg tablet | 0.5 tablet | 2 times |\n| Digoxin 0.25 mg tablet | 0.5 tablet | 1 time |\n| Candesartan 8 mg tablet | 1 tablet | 1 time |\n| Furosemide 40 mg tablet | 0.5 tablet | 1 time |\n| Aspirin 100 mg tablet | 1 tablet | 1 time |\n| Itraconazole 200 mg tablet | 1 tablet | 1 time |\n\nQuestion: The patient's digoxin blood concentration test results showed that the blood concentration exceeded the effective blood concentration range. Which drug is presumed to have influenced the increase in digoxin blood concentration?\n\n① Aspirin\n② Bisoprolol\n③ Candesartan\n④ Furosemide\n⑤ Itraconazole",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 페니실린 알레르기가 있는 5세 남아(체중 20 kg)의 중이염 처방과 처방약의 참고문헌 정보를 조사한 결과이다.\n\n| 가) 처방 의약품의 명칭 | 나) 1회 투약량 | 다) 1일 투여횟수 | 라) 총 투약일수 | 마) 용법 |\n|---|---|---|---|---|\n| 클래리트로마이신(clarithromycin) 건조시럽 125 mg / 5 mL | 12 mL | 2회 | 10일 | 12시간마다 |\n\n[참고문헌 정보] \n클래리트로마이신 건조시럽 용량 ∙ 용법\n소아: 중이염에는 1일 체중 kg당 15 mg을 2회 나누어 경구 복용한다.\n\nQuestion: 이 환자의 처방전에서 변경이 필요한 항목은?\n\n① 가)\n② 나)\n③ 다)\n④ 라)\n⑤ 마)",
        "question_text": "The following is a prescription for otitis media in a 5-year-old boy (weight 20 kg) with penicillin allergy, along with reference information for the prescribed medication.\n\n| a) Name of prescribed medication | b) Single dose | c) Daily frequency | d) Total days of medication | e) Instructions |\n|---|---|---|---|---|\n| Clarithromycin dry syrup 125 mg / 5 mL | 12 mL | 2 times | 10 days | Every 12 hours |\n\n[Reference Information]\nClarithromycin dry syrup dosage and administration\nPediatric: For otitis media, orally administer 15 mg per kg of body weight daily, divided into 2 doses.\n\nQuestion: Which item in this patient's prescription needs to be changed?\n\n① a)\n② b)\n③ c)\n④ d)\n⑤ e)",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 페니실린 알레르기가 있는 5세 남아(체중 20 kg)의 중이염 처방과 처방약의 참고문헌 정보를 조사한 결과이다.\n\n| 가) 처방 의약품의 명칭 | 나) 1회 투약량 | 다) 1일 투여횟수 | 라) 총 투약일수 | 마) 용법 |\n|---|---|---|---|---|\n| 클래리트로마이신(clarithromycin) 건조시럽 125 mg / 5 mL | 12 mL | 2회 | 10일 | 12시간마다 |\n\n[참고문헌 정보] \n클래리트로마이신 건조시럽 용량 ∙ 용법\n소아: 중이염에는 1일 체중 kg당 15 mg을 2회 나누어 경구 복용한다.\n\nQuestion: 이 처방에 따라 조제한 약에 부착된 보조라벨 중 조제감사과정에서 수정하여야 하는 내용은?\n\n① 냉장 보관하세요.\n② 차광 보관하세요.\n③ 흔들어서 복용하세요.\n④ 유효기간은 14일이에요.\n⑤ 어린이 손에 닿지 않게 하세요.",
        "question_text": "The following is a prescription for otitis media in a 5-year-old boy (weight 20 kg) with penicillin allergy, along with reference information for the prescribed medication.\n\n| a) Name of prescribed medication | b) Single dose | c) Daily frequency | d) Total days of medication | e) Instructions |\n|---|---|---|---|---|\n| Clarithromycin dry syrup 125 mg / 5 mL | 12 mL | 2 times | 10 days | Every 12 hours |\n\n[Reference Information]\nClarithromycin dry syrup dosage and administration\nChildren: For otitis media, orally administer 15 mg per kg of body weight daily, divided into 2 doses.\n\nQuestion: Which of the following auxiliary labels attached to the medication prepared according to this prescription should be modified during the prescription review process?\n\n① Store in refrigerator.\n② Protect from light.\n③ Shake well before use.\n④ Expiration date is 14 days.\n⑤ Keep out of reach of children.",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 다음 성분의 캡슐제 중 개봉하여 산제로 투약할 수 있는 약물은?\n\n① 트라조돈(trazodone)\n② 알파칼시돌(alfacalcidol)\n③ 시클로스포린(cyclosporine)\n④ 이소트레티노인(isotretinoin)\n⑤ 토코페롤아세테이트(tocopherol acetate)",
        "question_text": "Question: Among the following capsule formulations, which drug can be opened and administered as a powder?\n\n① Trazodone\n② Alfacalcidol\n③ Cyclosporine\n④ Isotretinoin\n⑤ Tocopherol acetate",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 처방전을 구분하여 발행 ∙ 조제하여야 하고, 조제실에서도 이중잠금장치가 있는 철제금고에 보관하면서 투약기록을 하여야 하는 약은?\n\n① 졸피뎀(zolpidem) CR 정\n② 알프라졸람(alprazolam) 정\n③ 옥시코돈(oxycodone) 서방정\n④ 클로티아제팜(clotiazepam) 정\n⑤ 페노바르비탈(phenobarbital) 정",
        "question_text": "Question: Which medication requires a separate prescription to be issued and dispensed, and must be stored in a double-locked steel safe in the dispensary while maintaining a record of administration?\n\n① Zolpidem CR tablets\n② Alprazolam tablets\n③ Oxycodone extended-release tablets\n④ Clotiazepam tablets\n⑤ Phenobarbital tablets",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 주사용 분말이 들어있는 바이알에 정해진 용매를 가해 분말을 녹이는 조제 방법은?\n\n① 희석(dilution)\n② 배산(trituration)\n③ 유화(emulsification)\n④ 논코어링(noncoring)\n⑤ 재구성(reconstitution)",
        "question_text": "Question: What is the preparation method for dissolving powder in a vial containing powder for injection by adding a specified solvent?\n\n① Dilution\n② Trituration\n③ Emulsification\n④ Noncoring\n⑤ Reconstitution",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 다음의 약물이상반응 사례에 대하여 WHO-UMC 방법으로 인과성을 평가하고자 한다. 평가 결과는?\n\n의약품 사용과 이상반응의 전후관계가 합당하나, 이상반응이 다른 병용 의약품으로도 설명되고, 해당 의약품의 투여중단에 관한 정보가 부족하다.\n\n① 확실함(certain)\n② 상당히 확실함(probable)\n③ 가능함(possible)\n④ 가능성 적음(unlikely)\n⑤ 평가 불가(unassessable)",
        "question_text": "Question: We want to evaluate the causality of the following adverse drug reaction case using the WHO-UMC method. What is the evaluation result?\n\nThe temporal relationship between drug use and adverse reaction is reasonable, but the adverse reaction can also be explained by other concomitant medications, and there is insufficient information about the discontinuation of the drug in question.\n\n① Certain\n② Probable\n③ Possible\n④ Unlikely\n⑤ Unassessable",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 골관절염으로 나프록센(naproxen) 정을 복용하는 환자가 위장관 통증을 호소하였다. 대체약으로 적절한 것은?\n\n① 바클로펜(baclofen) 정\n② 케토롤락(ketorolac) 정\n③ 디클로페낙(diclofenac) 정\n④ 세레콕시브(celecoxib) 캡슐\n⑤ 아세클로페낙(aceclofenac) 정",
        "question_text": "Question: A patient taking naproxen tablets for osteoarthritis complained of gastrointestinal pain. Which of the following is an appropriate alternative medication?\n\n① Baclofen tablets\n② Ketorolac tablets\n③ Diclofenac tablets\n④ Celecoxib capsules\n⑤ Aceclofenac tablets",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 디아제팜(diazepam)을 과량 복용한 환자가 응급실로 내원하였다. 이 환자에게 해독제로 적절한 것은?\n\n① 날록손(naloxone) 주\n② 로라제팜(lorazepam) 주\n③ 플루마제닐(flumazenil) 주\n④ 옥시코돈(oxycodone) 서방정\n⑤ 아세클로페낙(aceclofenac) 정",
        "question_text": "Question: A patient who overdosed on diazepam was brought to the emergency room. Which of the following is an appropriate antidote for this patient?\n\n① Naloxone injection\n② Lorazepam injection\n③ Flumazenil injection\n④ Oxycodone extended-release tablet\n⑤ Aceclofenac tablet",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 플루오로우라실(5-fluorouracil) 치료를 받아야 하는 환자가 주사제 대신 경구제 복용을 원한다. 플루오로우라실 대신 사용할 수 있는 약은?\n\n① 이매티닙(imatinib) 정\n② 레트로졸(letrozole) 정\n③ 카페시타빈(capecitabine) 정\n④ 메토트렉세이트(methotrexate) 정\n⑤ 시클로포스파미드(cyclophosphamide) 정",
        "question_text": "Question: A patient who needs to receive fluorouracil (5-fluorouracil) treatment wants to take an oral medication instead of an injection. Which drug can be used instead of fluorouracil?\n\n① Imatinib tablet\n② Letrozole tablet\n③ Capecitabine tablet\n④ Methotrexate tablet\n⑤ Cyclophosphamide tablet",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 철분의 흡수를 증가시키기 위하여 철분제와 같이 복용할 수 있는 것은?\n\n① 녹차\n② 홍차\n③ 유제품\n④ 제산제\n⑤ 비타민C",
        "question_text": "Question: Which of the following can be taken together with iron supplements to increase iron absorption?\n\n① Green tea\n② Black tea\n③ Dairy products\n④ Antacids\n⑤ Vitamin C",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 암로디핀(amlodipine)을 복용하는 환자가 병용할 경우 잇몸증식 부작용이 발생할 수 있어, 정기적인 치과 검진을 받아야 하는 약은?\n\n① 바클로펜(baclofen) 정\n② 케토롤락(ketorolac) 정\n③ 타목시펜(tamoxifen) 정\n④ 파록세틴(paroxetine) 정\n⑤ 시클로스포린(cyclosporine) 캡슐",
        "question_text": "Question: Which medication, when taken concurrently by a patient using amlodipine, may cause gingival hyperplasia as a side effect, necessitating regular dental check-ups?\n\n① Baclofen tablet\n② Ketorolac tablet\n③ Tamoxifen tablet\n④ Paroxetine tablet\n⑤ Cyclosporine capsule",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 불면증이 발생할 수 있어, 1일 1회 복용할 때 오전에 복용할 것을 권장하는 약은?\n\n① 졸피뎀(zolpidem) 서방정\n② 세티리진(cetirizine) 정\n③ 아미트리프틸린(amitriptyline) 정\n④ 메토클로프라미드(metoclopramide) 정\n⑤ 메틸페니데이트(methylphenidate) OROS 정",
        "question_text": "Question: Which medication is recommended to be taken in the morning when administered once daily, due to the potential for causing insomnia?\n\n① Zolpidem extended-release tablet\n② Cetirizine tablet\n③ Amitriptyline tablet\n④ Metoclopramide tablet\n⑤ Methylphenidate OROS tablet",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 6세 남아에게 플루티카손(fluticasone) 정량식흡입제(metered dose inhaler) 치료를 시작하려고 한다. 적절한 복약지도는?\n\n① 흡입기에 캡슐을 넣어 흡입한다.\n② 약물 장착 후 흔들지 않고 흡입한다.\n③ 스페이서(spacer)를 연결하여 흡입한다.\n④ 연무기(nebulizer)를 연결하여 흡입한다.\n⑤ 손잡이를 오른쪽 끝까지 돌린 후 흡입한다.",
        "question_text": "Question: You are about to start fluticasone metered dose inhaler treatment for a 6-year-old boy. What is the appropriate medication instruction?\n\n① Insert the capsule into the inhaler and inhale.\n② After loading the medication, inhale without shaking.\n③ Inhale using a spacer connected to the inhaler.\n④ Inhale using a nebulizer connected to the inhaler.\n⑤ Turn the handle all the way to the right before inhaling.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 원기가 없고 위장의 움직임이 쇠하여 피로하기 쉬운 사람의 허약체질, 피로권태, 식욕부진, 식은땀 등에 응용하는 한약제제는?\n\n① 삼소음(蔘蘇飮)\n② 맥문동탕(麥門冬湯)\n③ 고본환정환(固本還睛丸)\n④ 마행감석탕(麻杏甘石湯)\n⑤ 보중익기탕(補中益氣湯)",
        "question_text": "Question: Which herbal medicine preparation is used for people with weak constitution, fatigue, lack of appetite, and cold sweats, who are easily tired due to lack of energy and weakened stomach movement?\n\n① Samsoeum (蔘蘇飮)\n② Maekmoondong-tang (麥門冬湯)\n③ Gobon-hwanjeong-hwan (固本還睛丸)\n④ Mahaenggamseok-tang (麻杏甘石湯)\n⑤ Bojungikgi-tang (補中益氣湯)",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n59세 남자가 고혈압, 심근경색, 심방세동으로 다음의 약을 복용 중이다.\n\n| 처방 의약품의 명칭 | 1회 복용량 | 1일 복용횟수 | 용법 |\n|---|---|---|---|\n| 클로피도그렐(clopidogrel) 75 mg 정 | 1정 | 1회 | 경구 |\n| 디곡신(digoxin) 0.25 mg 정 | 0.5정 | 1회 | 경구 |\n| 로사르탄(losartan) 50 mg 정 | 1정 | 1회 | 경구 |\n| 프라바스타틴(pravastatin) 40 mg 정 | 1정 | 1회 | 경구 |\n| 스피로노락톤(spironolactone) 25 mg 정 | 1정 | 1회 | 경구 |\n| 와파린(warfarin) 5 mg 정 | 1정 | 1회 | 경구 |\n| 니트로글리세린(nitroglycerin) 0.6 mg 설하정 | 1정 | 필요시 | 설하 |\n\nQuestion: 이 처방약에 포함된 고혈압 치료약과 관련하여 주의하여야 하는 약물이상반응은?\n\n① 혈당 상승\n② 고칼륨혈증\n③ 저칼슘혈증\n④ 고요산혈증\n⑤ 고나트륨혈증",
        "question_text": "A 59-year-old male is taking the following medications for hypertension, myocardial infarction, and atrial fibrillation.\n\n| Prescription Drug Name | Single Dose | Daily Frequency | Administration Method |\n|---|---|---|---|\n| Clopidogrel 75 mg tablet | 1 tablet | Once | Oral |\n| Digoxin 0.25 mg tablet | 0.5 tablet | Once | Oral |\n| Losartan 50 mg tablet | 1 tablet | Once | Oral |\n| Pravastatin 40 mg tablet | 1 tablet | Once | Oral |\n| Spironolactone 25 mg tablet | 1 tablet | Once | Oral |\n| Warfarin 5 mg tablet | 1 tablet | Once | Oral |\n| Nitroglycerin 0.6 mg sublingual tablet | 1 tablet | As needed | Sublingual |\n\nQuestion: Which adverse drug reaction should be monitored carefully in relation to the antihypertensive medication included in this prescription?\n\n① Hyperglycemia\n② Hyperkalemia\n③ Hypocalcemia\n④ Hyperuricemia\n⑤ Hypernatremia",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n59세 남자가 고혈압, 심근경색, 심방세동으로 다음의 약을 복용 중이다.\n\n| 처방 의약품의 명칭 | 1회 복용량 | 1일 복용횟수 | 용법 |\n|---|---|---|---|\n| 클로피도그렐(clopidogrel) 75 mg 정 | 1정 | 1회 | 경구 |\n| 디곡신(digoxin) 0.25 mg 정 | 0.5정 | 1회 | 경구 |\n| 로사르탄(losartan) 50 mg 정 | 1정 | 1회 | 경구 |\n| 프라바스타틴(pravastatin) 40 mg 정 | 1정 | 1회 | 경구 |\n| 스피로노락톤(spironolactone) 25 mg 정 | 1정 | 1회 | 경구 |\n| 와파린(warfarin) 5 mg 정 | 1정 | 1회 | 경구 |\n| 니트로글리세린(nitroglycerin) 0.6 mg 설하정 | 1정 | 필요시 | 설하 |\n\nQuestion: 이 환자가 발기부전으로 실데나필(sildenafil)을 추가로 처방 받았는데, 이미 복용 중인 약과 병용금기이다. 병용금기의 사유는?\n\n① 뇌출혈 발생\n② 가성 뇌종양 발생\n③ 심각한 저혈압 유발\n④ 세로토닌 증후군 유발\n⑤ 다형 심실성 부정맥(torsade de pointes) 발생",
        "question_text": "A 59-year-old male is taking the following medications for hypertension, myocardial infarction, and atrial fibrillation.\n\n| Prescription Drug Name | Single Dose | Daily Frequency | Administration |\n|---|---|---|---|\n| Clopidogrel 75 mg tablet | 1 tablet | Once | Oral |\n| Digoxin 0.25 mg tablet | 0.5 tablet | Once | Oral |\n| Losartan 50 mg tablet | 1 tablet | Once | Oral |\n| Pravastatin 40 mg tablet | 1 tablet | Once | Oral |\n| Spironolactone 25 mg tablet | 1 tablet | Once | Oral |\n| Warfarin 5 mg tablet | 1 tablet | Once | Oral |\n| Nitroglycerin 0.6 mg sublingual tablet | 1 tablet | As needed | Sublingual |\n\nQuestion: This patient was additionally prescribed sildenafil for erectile dysfunction, but it is contraindicated with a medication he is already taking. What is the reason for this contraindication?\n\n① Risk of cerebral hemorrhage\n② Development of pseudotumor cerebri\n③ Induction of severe hypotension\n④ Induction of serotonin syndrome\n⑤ Development of torsade de pointes (polymorphic ventricular tachycardia)",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 공정밸리데이션 중 예측적 밸리데이션에 대한 설명으로 옳은 것은?\n\n① 판매용 의약품을 생산하면서 실시한다.\n② 제조단위 수의 절반 이상이 적합하여야 한다.\n③ 연간 생산 제조단위가 1개 이하일 때 실시한다.\n④ 연속으로 생산된 3개 이상의 제조단위를 대상으로 실시한다.\n⑤ 희귀의약품의 경우 과거 3개 제조단위에서 얻은 자료를 활용한다.",
        "question_text": "Question: Which of the following statements about predictive validation in process validation is correct?\n\n① It is conducted while producing drugs for sale.\n② More than half of the manufacturing units should be suitable.\n③ It is conducted when there is one or fewer manufacturing units produced annually.\n④ It is conducted on three or more consecutively produced manufacturing units.\n⑤ For rare drugs, data obtained from three previous manufacturing units is utilized.",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: GMP 시설기준에 따라 작업소로부터 방출된 공기에 대한 종말처리시설을 갖추어 생산해야 하는 제제는?\n\n① 백신제제\n② 바르비탈제제\n③ 성호르몬제제\n④ 페니실린제제\n⑤ 스테로이드제제",
        "question_text": "Question: According to GMP facility standards, which preparation requires production with terminal treatment facilities for air released from the work area?\n\n① Vaccine preparations\n② Barbital preparations\n③ Sex hormone preparations\n④ Penicillin preparations\n⑤ Steroid preparations",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 공기조화시스템에 대한 설명으로 옳은 것은?\n\n① 난기류는 공기의 질을 향상시킨다.\n② 공정에 한 번 사용된 공기는 재사용이 불가능하다.\n③ 중요공정을 수행하는 작업장에는 단일방향류를 공급한다.\n④ 공기는 청정도가 낮은 지역에서 높은 지역으로 흐르도록 설계한다.\n⑤ 주변환경에서의 공기유입을 차단하기 위하여 대상 지역을 음압으로 설정한다.",
        "question_text": "Question: Which of the following statements about air conditioning systems is correct?\n\n① Turbulent airflow improves air quality.\n② Air that has been used once in a process cannot be reused.\n③ Unidirectional airflow is supplied to workplaces performing critical processes.\n④ Air is designed to flow from areas of lower cleanliness to areas of higher cleanliness.\n⑤ The target area is set to negative pressure to prevent air inflow from the surrounding environment.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 결과에 영향을 미치는 공정과 변수의 관계를 나무의 잔가지 형태로 제시하는 공정요약 방법은?\n\n① 공정흐름도\n② 실험설계법\n③ 영향인자표\n④ 제품관리도\n⑤ 특성요인도",
        "question_text": "Question: What is the process summary method that presents the relationship between processes and variables affecting the result in the form of tree branches?\n\n① Process flow chart\n② Design of experiments\n③ Factor influence table\n④ Product control chart\n⑤ Cause and effect diagram",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 작업실의 청정도 등급을 나누는 기준으로 국제표준화기구가 제시한 평가 항목은?\n\n① 낙하균 수\n② 미생물 수\n③ 표면균 수\n④ 부유입자 수\n⑤ 엔도톡신 수",
        "question_text": "Question: What is the evaluation criterion presented by the International Organization for Standardization (ISO) for classifying the cleanliness grade of a work area?\n\n① Number of falling bacteria\n② Number of microorganisms\n③ Number of surface bacteria\n④ Number of airborne particles\n⑤ Number of endotoxins",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 고순도 정제수 생산에 사용되는 제조용수 시스템의 설비 및 구성 장비의 적격성평가에 대한 설명으로 옳은 것은?\n\n① 접착제를 사용하여 배관을 연결한다.\n② 냉수와 열수를 교차순환하여 시스템을 소독한다.\n③ CIP(cleaning-in-place) 시스템으로 배관을 세척한다.\n④ 고탄소 함유 스테인리스강으로 제조된 배관을 사용한다.\n⑤ 제조용수의 저장탱크에는 친수성 재질의 배기필터를 사용한다.",
        "question_text": "Question: Which of the following statements is correct regarding the qualification evaluation of equipment and components in the manufacturing water system used for producing high-purity purified water?\n\n① Pipes are connected using adhesives.\n② The system is disinfected by alternating circulation of cold and hot water.\n③ Pipes are cleaned using a CIP (cleaning-in-place) system.\n④ Pipes made of high-carbon content stainless steel are used.\n⑤ Hydrophilic vent filters are used in the storage tanks for manufacturing water.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 의약품등의 품목허가자료 중 흡광도, 선광도, 융점 등과 같은 원료의약품의 본질 및 순도에 관한 자료를 기재하는 항은?\n\n① 기원 항\n② 성상 항\n③ 시성치 항\n④ 순도시험 항\n⑤ 확인시험 항",
        "question_text": "Question: Which section in the drug product approval documentation is used to record data on the nature and purity of raw drug materials, such as absorbance, optical rotation, and melting point?\n\n① Origin section\n② Appearance section\n③ Physicochemical properties section\n④ Purity test section\n⑤ Identification test section",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에 엔도톡신시험을 하도록 규정된 제조용수는?\n\n① 상수\n② 정제수\n③ 주사용수\n④ 멸균정제수\n⑤ 이온교환수",
        "question_text": "Question: According to the Korean Pharmacopoeia, which type of water for pharmaceutical manufacturing is required to undergo endotoxin testing?\n\n① Tap water\n② Purified water\n③ Water for injection\n④ Sterile purified water\n⑤ Ion-exchanged water",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 제제균일성시험법 중 함량균일성시험을 적용하는 제제는?\n\n① 주성분이 30%인 나정\n② 주성분이 2 mg인 당의정\n③ 주성분이 50 mg인 경질캡슐\n④ 액상으로 충전한 연질캡슐\n⑤ 개별 용기에 들어 있는 액제",
        "question_text": "Question: Which of the following preparations is subject to the Content Uniformity Test in the Uniformity of Dosage Units test?\n\n① Uncoated tablets with 30% active ingredient\n② Sugar-coated tablets with 2 mg of active ingredient\n③ Hard capsules with 50 mg of active ingredient\n④ Soft capsules filled with liquid\n⑤ Liquid preparations in individual containers",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 니코틴산아미드 정제의 주성분에 대한 새로운 액체크로마토그래프법을 개발하였다. 개발된 분석법의 밸리데이션 과정에서 주성분이 정제의 첨가제 및 불순물로부터 충분히 분리되었는지를 확인하는 용어는?\n\n① 완건성(robustness)\n② 정밀성(precision)\n③ 정확성(accuracy)\n④ 직선성(linearity)\n⑤ 특이성(specificity)",
        "question_text": "Question: A new liquid chromatography method has been developed for the main component of nicotinamide tablets. In the validation process of the developed analytical method, what is the term used to confirm that the main component is sufficiently separated from the tablet's excipients and impurities?\n\n① Robustness\n② Precision\n③ Accuracy\n④ Linearity\n⑤ Specificity",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 메타인산용액(1 → 5)을 제조할 때 사용하는 용매는?\n\n① 메탄올\n② 아세톤\n③ 에탄올\n④ 정제수\n⑤ 인산완충액",
        "question_text": "Question: What solvent is used when preparing metaphosphoric acid solution (1 → 5)?\n\n① Methanol\n② Acetone\n③ Ethanol\n④ Purified water\n⑤ Phosphate buffer solution",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: 일상의 취급 또는 보통의 보존 상태에서 기체 또는 미생물의 침입을 방지하기 위해 사용하는 용기는?\n\n① 바이알\n② 유리병\n③ 약포지\n④ 나무상자\n⑤ 플라스틱병",
        "question_text": "Question: Which container is used to prevent the invasion of gases or microorganisms during routine handling or normal storage conditions?\n\n① Vial\n② Glass bottle\n③ Powder paper\n④ Wooden box\n⑤ Plastic bottle",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: d-클로르페니라민말레산염의 중금속 시험에 대한 내용은 다음과 같다. d-클로르페니라민말레산염에 대한 중금속(납으로서)의 한도(ppm)는?\n\n이 약 1.0 g을 달아 제4법에 따라 조작하여 시험한다. 비교액에는 납표준액 2.0 mL를 넣는다. 납표준액 1.0 mL는 납(Pb) 0.01 mg을 함유한다.\n\n① 1\n② 2\n③ 5\n④ 10\n⑤ 20",
        "question_text": "Question: The following describes the heavy metal test for d-chlorpheniramine maleate. What is the limit (ppm) for heavy metals (as lead) in d-chlorpheniramine maleate?\n\nWeigh 1.0 g of this drug and perform the test according to Method 4. Add 2.0 mL of lead standard solution to the control solution. 1.0 mL of lead standard solution contains 0.01 mg of lead (Pb).\n\n① 1\n② 2\n③ 5\n④ 10\n⑤ 20",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 다음 의약품에 대하여 Korean Pharmacopoeia에서 공통으로 규정하는 시험항목은?\n\n보글리보스, L-이소류신, dl-멘톨\n\n① 융점\n② 굴절률\n③ 강열감량\n④ 무균시험\n⑤ 비선광도",
        "question_text": "Question: Which of the following test items is commonly specified in the Korean Pharmacopoeia for these pharmaceutical products?\n\nVoglibose, L-Isoleucine, dl-Menthol\n\n① Melting point\n② Refractive index\n③ Loss on ignition\n④ Sterility test\n⑤ Specific optical rotation",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에 규정된 인슐린 중 아연함량 측정법은?\n\n① 형광광도법\n② 원자흡광광도법\n③ 기체크로마토그래프법\n④ 액체크로마토그래프법\n⑤ 자외가시부흡광도측정법",
        "question_text": "Question: What is the method for measuring zinc content in insulin as specified in the Korean Pharmacopoeia?\n\n① Fluorescence spectrophotometry\n② Atomic absorption spectrophotometry\n③ Gas chromatography\n④ Liquid chromatography\n⑤ UV-visible spectrophotometry",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 페노바르비탈 정에 대한 Korean Pharmacopoeia 규정 중 액체크로마토그래프법의 일부분이다. 이것으로 확인할 수 있는 것은?\n\n표준액 10 μL를 가지고 시험할 때 카페인(내부표준품) 및 페노바르비탈의 분리도는 1.2 이상이고 대칭계수는 2.0 이하이다.\n\n① 시스템의 성능\n② 시스템의 재현성\n③ 정량법의 정밀성\n④ 정량법의 정확성\n⑤ 정량법의 직선성",
        "question_text": "Question: This is a part of the liquid chromatography method in the Korean Pharmacopoeia regulations for phenobarbital tablets. What can be determined from this?\n\nWhen testing with 10 μL of the standard solution, the resolution between caffeine (internal standard) and phenobarbital is not less than 1.2, and the symmetry factor is not more than 2.0.\n\n① System suitability\n② System reproducibility\n③ Precision of the quantitative method\n④ Accuracy of the quantitative method\n⑤ Linearity of the quantitative method",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nA 사는 신규 고혈압 치료제 개발을 위하여 원료 혼합, 과립, 타정, 코팅 공정을 확립하였다. 설정된 정제 질량의 규격 하한은 95.0 mg이며, 규격상한은 105.0 mg이다. 실제 생산된 정제 질량의 평균은 100.0 mg, 표준편차는 ±2.0 mg이었다. 이 자료를 사용하여 공정능력지수를 산출하였다.\n\nQuestion: 산출된 공정능력지수로 판단할 때 정제 생산 공정에 대한 판정 내용과 그에 대한 조치로 옳은 것은?\n\n① 상태가 매우 만족할 만하며 현재 상태를 계속 유지한다.\n② 상태가 만족할 만하지만 관리에 주의한다.\n③ 상태가 불만족하며 공정의 개선이 필요하다.\n④ 상태가 매우 불만족하며 긴급한 조치가 필요하다.\n⑤ 응급 상태이므로 생산을 중단하고 문제를 해결해야 한다.",
        "question_text": "Company A has established processes for raw material mixing, granulation, tableting, and coating for the development of a new hypertension treatment. The lower specification limit for the set tablet mass is 95.0 mg, and the upper specification limit is 105.0 mg. The actual average mass of the produced tablets was 100.0 mg, with a standard deviation of ±2.0 mg. The process capability index was calculated using this data.\n\nQuestion: Based on the calculated process capability index, what is the correct assessment of the tablet production process and the appropriate action to take?\n\n① The state is very satisfactory, and the current state should be maintained.\n② The state is satisfactory, but caution is needed in management.\n③ The state is unsatisfactory, and process improvement is necessary.\n④ The state is very unsatisfactory, and urgent action is required.\n⑤ It is an emergency state, production should be stopped, and the problem must be resolved.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nA 사는 신규 고혈압 치료제 개발을 위하여 원료 혼합, 과립, 타정, 코팅 공정을 확립하였다. 설정된 정제 질량의 규격 하한은 95.0 mg이며, 규격상한은 105.0 mg이다. 실제 생산된 정제 질량의 평균은 100.0 mg, 표준편차는 ±2.0 mg이었다. 이 자료를 사용하여 공정능력지수를 산출하였다.\n\nQuestion: 공정능력지수를 향상시키기 위해 증가시켜야 할 공정요소는?\n\n① 과립의 유동성\n② 과립의 함습도\n③ 원료의 혼합도\n④ 정제의 마손도\n⑤ 정제의 타정압",
        "question_text": "Company A has established processes for raw material mixing, granulation, tableting, and coating for the development of a new hypertension treatment. The lower specification limit for the set tablet mass is 95.0 mg, and the upper specification limit is 105.0 mg. The actual average mass of the produced tablets was 100.0 mg, with a standard deviation of ±2.0 mg. The process capability index was calculated using this data.\n\nQuestion: Which process factor should be increased to improve the process capability index?\n\n① Flowability of granules\n② Moisture content of granules\n③ Mixing degree of raw materials\n④ Friability of tablets\n⑤ Compression pressure of tablets",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 약국경영을 위한 마케팅 믹스 4P 중 제품(product)에 해당하는 것은?\n\n① 약국 건물 옥외에 간판 달기\n② 만성질환 노인환자에게 복약지도 제공\n③ 건강기능식품의 대량구매 시 할인 제공\n④ 약국 홈페이지에 약국의 위치정보 게시\n⑤ 약국 내 일반의약품과 의약외품의 진열 위치 재배치",
        "question_text": "Question: Which of the following corresponds to the \"product\" among the 4Ps of marketing mix for pharmacy management?\n\n① Putting up a sign outside the pharmacy building\n② Providing medication counseling to elderly patients with chronic diseases\n③ Offering discounts for bulk purchases of health functional foods\n④ Posting the pharmacy's location information on the pharmacy website\n⑤ Rearranging the display locations of over-the-counter drugs and quasi-drugs within the pharmacy",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: A약국은 내용 연수 5년의 자동 산제포장기를 2018년 1월 1일에 700만 원에 구매하였다. 2022년 12월 31일 기준으로 이 기기의 잔존가치는 100만 원이 될 것으로 예상한다. 정액법을 이용한 이 기기의 2021년 당해 연도 감가상각비는?\n\n① 100만 원\n② 120만 원\n③ 240만 원\n④ 480만 원\n⑤ 600만 원",
        "question_text": "Question: Pharmacy A purchased an automatic powder packaging machine with a useful life of 5 years for 7 million won on January 1, 2018. As of December 31, 2022, the residual value of this machine is expected to be 1 million won. Using the straight-line method, what is the depreciation expense for this machine for the year 2021?\n\n① 1 million won\n② 1.2 million won\n③ 2.4 million won\n④ 4.8 million won\n⑤ 6 million won",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 약국경영을 위한 포괄손익계산서에 대한 설명으로 옳은 것은?\n\n① 감가상각비는 영업비용에 포함시키지 않는다.\n② 포괄손익계산서를 통해 당기순이익을 알 수 있다. \n③ 은행대출금의 이자는 당해 연도 비용에서 제외한다.\n④ 총매출액에서 총비용을 뺀 값이 의약품 매출원가이다.\n⑤ 유형자산의 취득원가는 연말 재고와 연초 재고의 차이를 말한다.",
        "question_text": "Question: Which of the following statements about the comprehensive income statement for pharmacy management is correct?\n\n① Depreciation expense is not included in operating expenses.\n② The comprehensive income statement shows the net income for the period.\n③ Interest on bank loans is excluded from the current year's expenses.\n④ The cost of goods sold for pharmaceuticals is the difference between total sales and total expenses.\n⑤ The acquisition cost of tangible assets refers to the difference between year-end inventory and beginning inventory.",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 보건의료서비스의 재원조달 방법 중 조세 방식과 사회보험료 방식을 비교했을 때, 사회보험료 방식의 특징으로 옳은 것은?\n\n① 관리운영이 단순하고 간편하다.\n② 개인이 자율적으로 가입할 수 있다.\n③ 국가의 재정 책임이 상대적으로 크다.\n④ 재원의 목적과 용도, 책임의 범위가 뚜렷하다.\n⑤ 재원조달 시 교육, 국방 등 다른 부문과 경쟁해야 한다.",
        "question_text": "Question: When comparing the tax-based method and the social insurance premium method among healthcare service financing methods, which of the following is a correct characteristic of the social insurance premium method?\n\n① Management and operation are simple and convenient.\n② Individuals can voluntarily enroll.\n③ The state's financial responsibility is relatively large.\n④ The purpose, use, and scope of responsibility for the funds are clear.\n⑤ When raising funds, it must compete with other sectors such as education and national defense.",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 우리나라 보건의료체계의 특성에 관한 설명으로 옳은 것은?\n\n① 신의료기술은 우선적으로 건강보험을 적용한다.\n② 주치의제도가 활성화되어 의료쇼핑 현상이 드물게 나타난다.\n③ 병원전체 평균재원일수는 OECD 국가들의 평균보다 적다.\n④ 인구 1천 명당 병상수는 OECD 국가들의 평균보다 많다.\n⑤ 공공의료기관이 대부분의 의료서비스를 제공한다.",
        "question_text": "Question: Which of the following statements about the characteristics of the healthcare system in our country is correct?\n\n① New medical technologies are given priority for health insurance coverage.\n② The primary care physician system is well-established, resulting in rare occurrences of medical shopping.\n③ The average length of hospital stay is shorter than the OECD countries' average.\n④ The number of hospital beds per 1,000 population is higher than the OECD countries' average.\n⑤ Public medical institutions provide most of the medical services.",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 민간보험시장에서 질병발생 위험이 낮은 사람은 보험에 가입하려 하지 않고, 위험이 높은 사람은 보험에 가입하려고 하는 현상은?\n\n① 역선택\n② 외부효과\n③ 무임승차\n④ 진입 장벽\n⑤ 위험군 선택",
        "question_text": "Question: In the private insurance market, what is the phenomenon where people with low risk of disease are reluctant to purchase insurance, while those with high risk are more likely to seek insurance?\n\n① Adverse selection\n② Externality\n③ Free-riding\n④ Entry barrier\n⑤ Risk group selection",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 국민건강보험 청구 자료를 활용하여 고혈압 환자의 복약이행도(medication adherence)를 측정하는 가장 적절한 방법은?\n\n① 알약 수 계수(pill count) 측정법\n② 환자의 자가보고(self-report) 측정법\n③ 혈중 생물학적 표지자(biological marker) 측정법\n④ 약물소지율(medication possession ratio) 측정법\n⑤ 전자투약모니터(electronic medication monitors) 측정법",
        "question_text": "Question: What is the most appropriate method to measure medication adherence of hypertensive patients using National Health Insurance claim data?\n\n① Pill count method\n② Patient self-report method\n③ Blood biological marker measurement method\n④ Medication possession ratio method\n⑤ Electronic medication monitors method",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 대학병원 약사위원회에서 신약의 병원의약품집 등재를 결정하기 위한 회의를 개최하였다. 이 약은 환자 1인당 연간 1억 원이 소요되는 고가약이다. 이 자리에서 다음과 같은 의견들이 오갔다. A 위원과 B 위원의 의견은 각각 어떠한 윤리원칙을 바탕으로 한 것인가?\n\nA 위원: 약값은 국민들이 낸 국민건강보험 재원에서 지출되기 때문에 무제한적인 것이 아닙니다. 자원이 한정된 상황에서는 특정 환자에게 자원을 사용한 만큼 다른 환자의 선택권이 제한되기 때문에 비용효과적인 자원 배분을 하도록 결정해야 합니다.\nB 위원: 우리는 환자의 질병 치료에 있어서 전체의 이익보다는 환자 개인에 초점을 맞추고, 환자에게 최선의 결과를 가져다 줄 수 있는 결정을 해야 합니다.\n\nA 위원 | B 위원\n① 충실성의 원칙 | 정직과 진실성의 원칙\n② 충실성의 원칙 | 자율성 존중의 원칙\n③ 정의의 원칙 | 자율성 존중의 원칙\n④ 정의의 원칙 | 선행의 원칙\n⑤ 선행의 원칙 | 충실성의 원칙",
        "question_text": "Question: The Pharmacy Committee of a university hospital held a meeting to decide on the inclusion of a new drug in the hospital formulary. This drug costs 100 million won per patient annually, making it a high-cost medication. The following opinions were exchanged during the meeting. What ethical principles are the opinions of Committee Member A and Committee Member B based on, respectively?\n\nCommittee Member A: The cost of medication is not unlimited as it comes from the National Health Insurance fund, which is funded by citizens. In a situation with limited resources, using resources for specific patients limits the choices for other patients, so we should make decisions that allocate resources cost-effectively.\n\nCommittee Member B: In treating patients' diseases, we should focus on individual patients rather than the overall benefit, and make decisions that can bring the best results for the patients.\n\nCommittee Member A | Committee Member B\n① Principle of fidelity | Principle of honesty and integrity\n② Principle of fidelity | Principle of respect for autonomy\n③ Principle of justice | Principle of respect for autonomy\n④ Principle of justice | Principle of beneficence\n⑤ Principle of beneficence | Principle of fidelity",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 유방암 검사에 있어서 초음파유방촬영술의 유용성을 알기 위해 81명의 환자에게 검사를 실시하였다. 이후, 수술을 통해 실제 악성 여부를 확진하였고, 검사법의 진단 결과가 다음과 같을 때, 옳은 설명은?\n\n| 검사 결과 | 초음파유방촬영술(명) |\n|---|---|\n| 진양성(true positive) | 52 |\n| 위음성(false negative) | 3 |\n| 위양성(false positive) | 9 |\n| 진음성(true negative) | 17 |\n| 전체(환자 수) | 81 |\n\n① 유방암 양성 진단을 받은 환자는 57명이다.\n② 유방암 음성 진단을 받은 환자는 12명이다.\n③ 실제 악성 유방암 환자는 52명이다.\n④ 음성예측도는 ‘3/17’이다.\n⑤ 민감도는 ‘52/(52+3)’이다.",
        "question_text": "Question: To determine the usefulness of breast ultrasound in breast cancer screening, 81 patients underwent the test. Subsequently, the actual malignancy was confirmed through surgery, and when the diagnostic results of the test method were as follows, which explanation is correct?\n\n| Test Result | Breast Ultrasound (number of patients) |\n|---|---|\n| True positive | 52 |\n| False negative | 3 |\n| False positive | 9 |\n| True negative | 17 |\n| Total (number of patients) | 81 |\n\n① 57 patients were diagnosed as positive for breast cancer.\n② 12 patients were diagnosed as negative for breast cancer.\n③ The actual number of malignant breast cancer patients is 52.\n④ The negative predictive value is '3/17'.\n⑤ The sensitivity is '52/(52+3)'.",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: A 지역에서 폐암으로 사망한 사람은 총 200명이다. A 지역의 연령별 인구수와 표준인구의 연령별 폐암사망률은 다음 표와 같다. A 지역에서 폐암의 연령표준화사망비는?\n\n| 연령 구간 | A 지역 인구수(명) | 표준인구의 폐암사망률 (명/10만 명) |\n|---|---|---|\n| 20~59세 | 500,000 | 2 |\n| 60세 이상 | 900,000 | 10 |\n| 계 | 1,400,000 | - |\n\n① 1\n② 1.5\n③ 2\n④ 7\n⑤ 14",
        "question_text": "Question: In region A, a total of 200 people died from lung cancer. The population by age group in region A and the age-specific lung cancer mortality rates of the standard population are shown in the following table. What is the age-standardized mortality ratio for lung cancer in region A?\n\n| Age Group | Population in Region A | Lung Cancer Mortality Rate in Standard Population (per 100,000) |\n|---|---|---|\n| 20-59 years | 500,000 | 2 |\n| 60 years and above | 900,000 | 10 |\n| Total | 1,400,000 | - |\n\n① 1\n② 1.5\n③ 2\n④ 7\n⑤ 14",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 우리나라의 의약품 사용량-약가 연동제도에 대한 설명으로 옳은 것은?\n\n① 요양기관의 약가 마진을 억제하기 위한 제도이다.\n② 약가와 사용량을 연계하여 약품비를 관리하기 위한 제도이다.\n③ 저가약으로 대체하여 약품비가 절감된 경우 장려금을 지급하는 제도이다.\n④ 치료효과와 경제적 가치가 우수한 의약품만을 선별적으로 보험등재하는 제도이다.\n⑤ 환자 1인당 사용 한도를 초과할 경우, 초과 금액의 일부를 제약회사가 환급하는 제도이다.",
        "question_text": "Question: Which of the following is the correct description of Korea's drug usage-price linkage system?\n\n① It is a system to suppress drug price margins of healthcare institutions.\n② It is a system to manage drug costs by linking drug prices and usage.\n③ It is a system that provides incentives when drug costs are reduced by substituting with lower-priced drugs.\n④ It is a system that selectively lists only drugs with superior therapeutic effects and economic value for insurance coverage.\n⑤ It is a system where pharmaceutical companies refund a portion of the excess amount when the usage limit per patient is exceeded.",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 우리나라 국민건강보험 약가제도에서 특허만료의약품과 제네릭의약품의 가격산정과 상환에 대한 설명으로 옳은 것은?\n\n① 제네릭의약품의 가격은 외국 약가와 비교하여 결정된다.\n② 최초 제네릭의약품 등재 시 약국에서 대체조제해야 한다.\n③ 제네릭의약품 등재 후 동일 성분의 특허만료의약품의 가격이 인하된다.\n④ 제네릭의약품의 가격은 제약회사와 건강보험공단과의 협상에 의해 결정된다.\n⑤ 제네릭의약품으로 대체조제받은 환자에게는 본인부담률을 낮추어 적용한다.",
        "question_text": "Question: Which of the following statements is correct regarding the pricing and reimbursement of off-patent drugs and generic drugs in South Korea's National Health Insurance drug pricing system?\n\n① The price of generic drugs is determined by comparing it with foreign drug prices.\n② When the first generic drug is listed, pharmacies must dispense it as a substitute.\n③ After generic drugs are listed, the price of off-patent drugs with the same active ingredient is reduced.\n④ The price of generic drugs is determined through negotiations between pharmaceutical companies and the National Health Insurance Service.\n⑤ Patients who receive generic drugs as substitutes are subject to a lower co-payment rate.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 다음 그림은 고혈압 치료제 A 약물의 비용-효용분석에 대한 민감도분석 결과이다. 이 그림에 대한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 점증적 비용-효용비 임계값을 알 수 있다.\n② A 약물이 비용-효과적일 확률을 알 수 있다.\n③ 기본분석의 점증적 비용-효용비를 알 수 없다.\n④ 비용-효용분석 결과는 기저혈압에 대해 가장 민감하다.\n⑤ 비용-효용분석 결과는 약물의 가격에 대해 가장 민감하다.",
        "question_text": "Question: The following figure shows the results of a sensitivity analysis for the cost-utility analysis of antihypertensive drug A. Which of the following statements about this figure is correct?\n\n<Data (confidential)>\n\n① The incremental cost-utility ratio threshold can be determined.\n② The probability of drug A being cost-effective can be determined.\n③ The incremental cost-utility ratio of the base case analysis cannot be determined.\n④ The cost-utility analysis results are most sensitive to baseline blood pressure.\n⑤ The cost-utility analysis results are most sensitive to the price of the drug.",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 다음은 1년간 약물치료에 대한 결정수형모형이다. 약물 B로 치료했을 때 예상되는 질 보정 수명을 바르게 계산한 것은?\n\n<Data (confidential)>\n\n① (0.5×0.3×0.2)+(1.0×0.8×0.3)\n② (0.5+1.0)×(0.3+0.8)×(0.2+0.3)\n③ (0.5×1.0)+(0.3×0.8)+(0.2×0.3)\n④ (0.5×50만 원)+(0.3×70만 원)+(0.2×100만 원)\n⑤ {(0.5×50만 원)+(0.3×70만 원)+(0.2×100만 원)}÷{(0.5×1.0)+(0.3×0.8)+(0.2×0.3)}",
        "question_text": "Question: The following is a decision tree model for drug treatment over one year. Which of the following correctly calculates the expected quality-adjusted life years (QALY) when treated with Drug B?\n\n<Data (confidential)>\n\n① (0.5×0.3×0.2)+(1.0×0.8×0.3)\n② (0.5+1.0)×(0.3+0.8)×(0.2+0.3)\n③ (0.5×1.0)+(0.3×0.8)+(0.2×0.3)\n④ (0.5×500,000 won)+(0.3×700,000 won)+(0.2×1,000,000 won)\n⑤ {(0.5×500,000 won)+(0.3×700,000 won)+(0.2×1,000,000 won)}÷{(0.5×1.0)+(0.3×0.8)+(0.2×0.3)}",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 우리나라 건강보험 지불보상제도 중 약국의 약사서비스 수가 결정에 대한 설명으로 옳은 것은?\n\n① 희귀의약품 조제 시 가산율이 적용된다.\n② 상대가치에 환산지수를 곱하여 산정한다.\n③ 난이도나 소요시간과 무관하게 산정된다.\n④ 환산지수는 소비자물가지수를 반영하여 Health Insurance Review & Assessment Service이 결정한다.\n⑤ 약사서비스의 상대가치는 건강보험공단과 대한약사회의 협상으로 결정한다.",
        "question_text": "Question: Which of the following statements is correct regarding the determination of pharmacist service fees in the payment compensation system of Korea's National Health Insurance?\n\n① A premium rate is applied when dispensing rare medicines.\n② It is calculated by multiplying the relative value by the conversion factor.\n③ It is determined regardless of difficulty or time required.\n④ The conversion factor is determined by the Health Insurance Review & Assessment Service, reflecting the consumer price index.\n⑤ The relative value of pharmacist services is determined through negotiations between the National Health Insurance Service and the Korean Pharmaceutical Association.",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 우리나라 병원약국의 약사서비스에 대한 건강보험 지불보상에 대한 설명으로 옳은 것은?\n\n① 휴일 및 야간 조제에 대해 30% 가산된 조제료를 지급한다.\n② 퇴원환자 조제에 대한 복약지도료는 조제일수에 따라 지급한다.\n③ 외래환자 조제에 대한 조제기본료는 방문당 보상금액으로 지급한다.\n④ 입원환자 조제에 대한 조제복약지도료는 조제일수에 따라 지급한다.\n⑤ 병원약국의 1일 조제건수가 적정 조제건수를 초과하는 경우 조제료 등을 차감하여 지급한다.",
        "question_text": "Question: Which of the following statements is correct regarding health insurance reimbursement for pharmacist services in hospital pharmacies in our country?\n\n① A 30% additional fee is paid for dispensing on holidays and during night hours.\n② Medication counseling fees for discharged patients are paid according to the number of days of medication dispensed.\n③ The basic dispensing fee for outpatients is paid as a per-visit reimbursement amount.\n④ The dispensing and medication counseling fee for inpatients is paid according to the number of days of medication dispensed.\n⑤ When the daily number of prescriptions dispensed in a hospital pharmacy exceeds the appropriate number, the dispensing fee and other fees are reduced.",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 A 약국의 2018년과 2019년의 재무상태이다.\n\n| | 2018년(단위: 억 원) | 2019년(단위: 억 원) |\n|---|---|---|\n| 총매출액 | 10 | 12 |\n| 매출원가 | 7 | 8 |\n| 총영업비용 | 2 | 2.5 |\n| 평균재고자산 | 2 | 2 |\n\nQuestion: A 약국의 순이익을 바르게 도출한 것은?\n\n2018년(단위: 억 원) | 2019년(단위: 억 원)\n① 0.5 | 0.5\n② 0.5 | 1\n③ 1 | 1\n④ 1 | 1.5\n⑤ 1 | 2",
        "question_text": "The following is the financial status of Pharmacy A for the years 2018 and 2019.\n\n| | 2018 (Unit: 100 million won) | 2019 (Unit: 100 million won) |\n|---|---|---|\n| Total Sales | 10 | 12 |\n| Cost of Goods Sold | 7 | 8 |\n| Total Operating Expenses | 2 | 2.5 |\n| Average Inventory | 2 | 2 |\n\nQuestion: Which of the following correctly shows the net profit of Pharmacy A?\n\n2018 (Unit: 100 million won) | 2019 (Unit: 100 million won)\n① 0.5 | 0.5\n② 0.5 | 1\n③ 1 | 1\n④ 1 | 1.5\n⑤ 1 | 2",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 A 약국의 2018년과 2019년의 재무상태이다.\n\n| | 2018년(단위: 억 원) | 2019년(단위: 억 원) |\n|---|---|---|\n| 총매출액 | 10 | 12 |\n| 매출원가 | 7 | 8 |\n| 총영업비용 | 2 | 2.5 |\n| 평균재고자산 | 2 | 2 |\n\nQuestion: A 약국의 경영성과를 바르게 평가한 것은?\n\n① 2018년의 재고자산회전율은 3.5회이다.\n② 2019년의 재고자산회전율은 6.0회이다.\n③ 2018년의 매출총이익률은 0.1이다\n④ 2019년의 매출총이익률은 0.125이다.\n⑤ 2018년의 매출순이익률은 0.3이다.",
        "question_text": "The following is the financial status of Pharmacy A for the years 2018 and 2019.\n\n| | 2018 (Unit: 100 million won) | 2019 (Unit: 100 million won) |\n|---|---|---|\n| Total Sales | 10 | 12 |\n| Cost of Goods Sold | 7 | 8 |\n| Total Operating Expenses | 2 | 2.5 |\n| Average Inventory | 2 | 2 |\n\nQuestion: Which of the following correctly evaluates the business performance of Pharmacy A?\n\n① The inventory turnover ratio in 2018 is 3.5 times.\n② The inventory turnover ratio in 2019 is 6.0 times.\n③ The gross profit margin in 2018 is 0.1.\n④ The gross profit margin in 2019 is 0.125.\n⑤ The net profit margin in 2018 is 0.3.",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 질병 치료를 위하여 의사의 전문지식이 없어도 사용할 수 있는 것으로서 Minister of Food and Drug Safety이 고시하는 기준에 해당하는 의약품은?\n\n① 희귀의약품\n② 일반의약품\n③ 방사성의약품\n④ 국가출하승인의약품\n⑤ 중독성 ∙ 습관성의약품",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is a type of medicine that can be used without a doctor's specialized knowledge for disease treatment and meets the standards announced by the Minister of Food and Drug Safety?\n\n① Orphan drugs\n② Over-the-counter drugs\n③ Radiopharmaceuticals\n④ National lot release approved drugs\n⑤ Addictive and habit-forming drugs",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국을 관리하는 약사가 준수하여야 할 사항이 아닌 것은?\n\n① “약사”의 명칭 및 성명이 함께 표시된 명찰을 달아야 한다.\n② 보건위생과 관련된 사고가 없도록 종업원을 철저히 감독하여야 한다.\n③ 전문의약품은 일반의약품과 구분하여 별도의 약장에 진열하여야 한다.\n④ 용기나 포장이 개봉된 상태의 의약품을 서로 섞어서 보관하지 않아야 한다.\n⑤ 의약품의 사용과 관련하여 부작용이 발생한 경우에는 필요한 안전대책을 강구하여야 한다.",
        "question_text": "Question: Which of the following is NOT a requirement that a pharmacist managing a pharmacy must comply with according to the \"Pharmaceutical Affairs Act\"?\n\n① They must wear a name tag displaying both the title \"Pharmacist\" and their name.\n② They must thoroughly supervise employees to prevent accidents related to public health and hygiene.\n③ Prescription drugs must be displayed in a separate cabinet, distinct from over-the-counter drugs.\n④ Medications with opened containers or packaging should not be mixed and stored together.\n⑤ In case of side effects related to the use of medications, necessary safety measures must be devised.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 서울특별시 종로구에 약국을 개설한 약사가 약국을 폐업하고자 할 때, 폐업신고서를 제출하여야 하는 대상은?\n\n① Mayor of Jongno District\n② 보건의료원장\n③ Mayor of Seoul\n④ Minister of Health and Welfare\n⑤ Minister of Food and Drug Safety",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" when a pharmacist who has established a pharmacy in Jongno-gu, Seoul, wishes to close the pharmacy, to whom should they submit the closure report?\n\n① Mayor of Jongno District\n② Director of Health Care Center\n③ Mayor of Seoul\n④ Minister of Health and Welfare\n⑤ Minister of Food and Drug Safety",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약학대학 학생이 Ordinance of the Ministry of Health and Welfare으로 정하는 범위에서 약사의 지시 ∙ 감독을 받아 할 수 있는 조제행위가 아닌 것은?\n\n① 전시 ∙ 사변 발생 시 국가의 요청에 따른 조제\n② 국가비상사태 시 지방자치단체의 요청에 따른 조제\n③ 하계방학기간에 노인요양시설의 봉사활동을 위한 조제\n④ 조울증으로 타인을 해칠 우려가 있는 정신질환자에 대한 조제\n⑤ 약학대학 학장의 요청에 따라 실무실습 및 연구를 위하여 하는 조제",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a dispensing activity that pharmacy students can perform under the instruction and supervision of a pharmacist within the scope determined by the Ordinance of the Ministry of Health and Welfare?\n\n① Dispensing at the request of the state during wartime or contingencies\n② Dispensing at the request of local governments during national emergencies\n③ Dispensing for volunteer activities at elderly care facilities during summer vacation\n④ Dispensing for mentally ill patients with bipolar disorder who may harm others\n⑤ Dispensing for practical training and research at the request of the Dean of the College of Pharmacy",
        "answer": 4
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사가 처방전을 발행한 의사에게 확인하지 않고 조제할 수 있는 경우는?\n\n① 의약품의 성분명을 확인할 수 없는 경우\n② 의약품의 제품명을 확인할 수 없는 경우\n③ Minister of Food and Drug Safety이 의약품의 안전성 문제로 품목 허가를 취소한 의약품이 기재된 경우\n④ Minister of Food and Drug Safety이 의약품의 유효성 문제로 품목 신고를 취소한 의약품이 기재된 경우\n⑤ Minister of Food and Drug Safety이 임부금기 성분으로 고시한 의약품을 처방한 의사가 정보시스템을 활용하여 사유를 기재한 경우",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" in which case can a pharmacist dispense medication without confirming with the prescribing physician?\n\n① When the ingredient name of the medication cannot be confirmed\n② When the product name of the medication cannot be confirmed\n③ When a medication whose product license has been revoked by the Minister of Food and Drug Safety due to safety issues is listed\n④ When a medication whose product registration has been canceled by the Minister of Food and Drug Safety due to efficacy issues is listed\n⑤ When a physician who prescribed a medication that the Minister of Food and Drug Safety has announced as contraindicated for pregnant women has provided a reason using the information system",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 복약지도에 대한 설명으로 옳지 않은 것은?\n\n① 약사는 의약품을 조제하면 환자에게 필요한 복약지도를 구두 또는 복약지도서로 하여야 한다.\n② 복약지도서에 포함되는 정보는 기호 또는 도안 등으로 이해하기 쉽게 요약하여 적을 수 있다.\n③ 약사는 약국에서 의약품을 조제하면 복약지도 내용을 조제기록부에 적어 2년 동안 보존하여야 한다.\n④ 약사는 일반의약품을 판매할 때 진단적 판단을 하지 아니하고 구매자가 필요한 의약품을 선택할 수 있도록 도와준다.\n⑤ Minister of Health and Welfare은 약사가 적정한 처방건수를 조제하게 하여 복약지도를 충실히 할 수 있도록 필요한 조치를 강구할 수 있다.",
        "question_text": "Question: Which of the following statements about medication counseling under the \"Pharmaceutical Affairs Act\" is incorrect?\n\n① Pharmacists must provide necessary medication counseling to patients either verbally or through a medication counseling document when dispensing medications.\n② Information included in the medication counseling document can be summarized in an easy-to-understand manner using symbols or diagrams.\n③ When dispensing medications at a pharmacy, pharmacists must record the content of the medication counseling in the dispensing record and preserve it for 2 years.\n④ When selling over-the-counter medications, pharmacists help buyers select the necessary medications without making diagnostic judgments.\n⑤ The Minister of Health and Welfare can take necessary measures to ensure that pharmacists dispense an appropriate number of prescriptions to provide thorough medication counseling.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사 또는 약국이 의약품공급자로부터 Ordinance of the Ministry of Health and Welfare으로 정하는 범위 안에서 제공받을 수 있는 경제적 이익이 아닌 것은?\n\n① 제품설명회에 참석하여 받은 5만 원 이하의 기념품\n② 의약품 거래를 담당하는 영업사원의 약국 전산업무 제공\n③ 의약품의 제형을 확인하는 데 필요한 최소 수량의 견본품\n④ 거래일로부터 2개월 이내에 의약품 거래금액을 결제하는 경우 1퍼센트 비용할인\n⑤ 발표자로 참가한 약학 관련 학술대회 주최자로부터 지원받는 식비 ∙ 숙박비 용도의 실제비용",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT an economic benefit that pharmacists or pharmacies can receive from pharmaceutical suppliers within the scope specified by the Ordinance of the Ministry of Health and Welfare?\n\n① A souvenir worth less than 50,000 won received for attending a product presentation\n② Provision of pharmacy computer services by sales representatives responsible for pharmaceutical transactions\n③ Minimum quantity of sample products necessary for verifying the formulation of pharmaceuticals\n④ 1 percent cost discount when settling pharmaceutical transaction amounts within 2 months from the transaction date\n⑤ Actual costs for meals and accommodation provided by the organizer of a pharmacy-related academic conference where the pharmacist participates as a presenter",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 봉함된 의약품의 용기나 포장을 개봉하여 판매할 수 없는 경우는?\n\n① 약국개설자가 동물병원 개설자에게 의약품을 판매하는 경우\n② 한약업사가 환자의 요구에 따라 한약을 개봉 판매하는 경우\n③ 매약상이 Minister of Health and Welfare이 따로 지정하는 의약품을 판매하는 경우\n④ 약국개설자가 의사의 처방전에 따라 의약품을 조제 ∙ 판매하는 경우\n⑤ 약국개설자가 의사가 처방한 의약품이 없어 긴급하게 구입하려는 다른 약국개설자에게 해당 의약품을 판매하는 경우",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" in which case is it not allowed to open and sell sealed pharmaceutical products?\n\n① When a pharmacy owner sells pharmaceuticals to a veterinary hospital owner\n② When an herbal medicine dealer opens and sells herbal medicine according to a patient's request\n③ When a drug seller sells pharmaceuticals specifically designated by the Minister of Health and Welfare\n④ When a pharmacy owner compounds and sells pharmaceuticals according to a doctor's prescription\n⑤ When a pharmacy owner sells pharmaceuticals to another pharmacy owner who urgently needs to purchase them due to lack of stock of prescribed medication",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 임상시험용 의약품을 Minister of Food and Drug Safety의 승인을 받은 경우에는 해당 의약품을 임상시험 이외의 다른 용도로 사용할 수 있다. 이 경우에 해당하지 않는 것은?\n\n① 중증천식 질환의 치료법 개발\n② 생명이 위급한 말기암환자 치료\n③ 대체치료수단이 없는 응급환자 치료\n④ 생명을 위협하는 후천성면역결핍증환자 치료\n⑤ 사람을 대상으로 하지 아니하는 해당 의약품의 연구",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" when a drug for clinical trials has been approved by the Minister of Food and Drug Safety, it can be used for purposes other than clinical trials. Which of the following does NOT fall under this case?\n\n① Development of treatment methods for severe asthma\n② Treatment of terminally ill cancer patients with life-threatening conditions\n③ Treatment of emergency patients with no alternative treatment options\n④ Treatment of patients with life-threatening AIDS\n⑤ Research on the drug that does not involve human subjects",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품의 부작용을 보고할 때 ‘총리령으로 정하는 중대한 질병 ∙ 장애 ∙ 사망 사례’에 해당하지 않는 것은?\n\n① 면역억제제 투여 후 생명을 위협하는 사례\n② 항부정맥제 투여 후 중대한 불구를 초래한 사례\n③ 스테로이드제제 사용 후 입원기간의 연장이 필요한 사례\n④ 마약성진통제 사용 후 의존성이 발생하여 치료가 필요한 사례\n⑤ 항응고제 사용 후 의도되지 않은 증상이 일시적으로 발생한 사례",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT considered a 'serious case of illness, disability, or death as specified by the Prime Minister's Decree' when reporting adverse drug reactions?\n\n① A life-threatening case after administration of immunosuppressants\n② A case of severe disability after administration of antiarrhythmic drugs\n③ A case requiring extended hospitalization after using steroid preparations\n④ A case requiring treatment due to dependency after using narcotic analgesics\n⑤ A case of temporary unintended symptoms after using anticoagulants",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 신문 ∙ 방송 매체를 이용하여 의약품의 명칭 ∙제조 방법 ∙ 효능에 관하여 광고할 수 있는 의약품은?\n\n① 반코마이신 주사제\n② 임상시험용 의약품\n③ B형간염 예방용 의약품\n④ 종합감기약에 사용되는 원료의약품\n⑤ 전문의약품과 제형, 투여 경로 및 1정당 주성분의 함량이 같은 일반의약품",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following medicines can be advertised in newspapers and broadcast media regarding their name, manufacturing method, and efficacy?\n\n① Vancomycin injection\n② Medicines for clinical trials\n③ Medicines for Hepatitis B prevention\n④ Raw materials used in combination cold medicines\n⑤ Over-the-counter drugs with the same formulation, route of administration, and main ingredient content per tablet as prescription drugs",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 행정처분 전에 청문을 하여야 하는 경우가 아닌 것은?\n\n① 약사 면허 취소\n② 약국개설자 업무정지\n③ 의약품 품목제조금지명령\n④ 임상시험실시기관 지정 취소\n⑤ 안전상비의약품 판매자 등록 취소",
        "question_text": "Question: Which of the following is NOT a case where a hearing must be held before an administrative disposition according to the \"Pharmaceutical Affairs Act\"?\n\n① Revocation of a pharmacist's license\n② Business suspension of a pharmacy owner\n③ Order to prohibit the manufacture of a pharmaceutical item\n④ Cancellation of designation as a clinical trial institution\n⑤ Cancellation of registration for over-the-counter medicine sellers",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류관리자가 될 수 있는 자는?\n\n① 약국개설자\n② 마약을 소분(小分)하는 자\n③ 의료기관에 종사하는 약사\n④ 의약품을 제조할 때 마약을 원료로 사용하는 자\n⑤ 학술연구를 위하여 대마를 수입하여 사용하는 자",
        "question_text": "Question: According to the \"Narcotics Control Act,\" who can become a narcotics manager?\n\n① Pharmacy owner\n② Person who subdivides narcotics\n③ Pharmacist working in a medical institution\n④ Person who uses narcotics as raw materials in manufacturing pharmaceuticals\n⑤ Person who imports and uses cannabis for academic research",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 Mayor/Do Governor의 허가를 받아야 하는 마약류취급자는?\n\n① 마약류도매업자\n② 마약류제조업자\n③ 마약류수출입업자\n④ 마약류원료사용자\n⑤ 마약류취급학술연구자",
        "question_text": "Question: According to the \"Narcotics Control Act,\" which of the following narcotic drug handlers requires permission from the Mayor/Do Governor?\n\n① Narcotic drug wholesaler\n② Narcotic drug manufacturer\n③ Narcotic drug importer/exporter\n④ Narcotic drug raw material user\n⑤ Narcotic drug handling academic researcher",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류 중독자의 치료보호에 대한 설명으로 옳은 것은?\n\n① 마약류 중독자의 치료보호 기간은 6개월 이내로 한다.\n② Minister of Food and Drug Safety은 치료보호기관을 지정할 수 있다.\n③ Mayor/Do Governor는 치료보호를 하려면 치료보호심사위원회의 심의를 거쳐야 한다.\n④ 마약류관리자는 마약류 사용자에 대해서 치료보호기관에서 판별검사를 받게 할 수 있다.\n⑤ 마약류취급의료업자는 의료기관에서 마약 중독자에게 중독 증상을 치료하기 위하여 마약을 투약할 수 있다.",
        "question_text": "Question: Which of the following statements about the treatment and protection of drug addicts under the \"Narcotics Control Act\" is correct?\n\n① The treatment and protection period for drug addicts is limited to 6 months.\n② The Minister of Food and Drug Safety can designate treatment and protection institutions.\n③ The Mayor/Do Governor must go through deliberation by the Treatment and Protection Review Committee to provide treatment and protection.\n④ The narcotics manager can have drug users undergo diagnostic tests at treatment and protection institutions.\n⑤ Medical practitioners handling narcotics can administer narcotics to drug addicts in medical institutions to treat addiction symptoms.",
        "answer": 3
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: \"National Health Promotion Act\"상 이 법의 목적이 아닌 것은?\n\n① 국민의 건강 증진\n② 국민보건 향상과 사회보장 증진\n③ 국민에게 건강에 관한 바른 지식 보급\n④ 국민에게 건강에 대한 가치와 책임의식 함양\n⑤ 국민에게 스스로 건강생활을 실천할 수 있는 여건 조성",
        "question_text": "Question: Which of the following is NOT a purpose of the \"National Health Promotion Act\"?\n\n① Promotion of national health\n② Improvement of public health and social security\n③ Dissemination of correct health knowledge to the public\n④ Cultivation of value and sense of responsibility for health among the public\n⑤ Creation of conditions for the public to practice healthy living on their own",
        "answer": 2
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: \"Framework Act on Health and Medical Services\"상 이 법에서 사용하는 용어의 뜻으로 옳지 않은 것은?\n\n① 보건의료서비스는 국민의 건강을 보호 ∙ 증진하기 위하여 보건의료인이 행하는 모든 활동이다.\n② 보건의료정보는 보건의료와 관련한 지식 또는 부호 ∙ 숫자∙ 문자 ∙ 음성 ∙ 음향 ∙ 영상 등으로 표현된 모든 종류의 자료이다.\n③ 보건의료는 국민의 건강을 보호 ∙ 증진하기 위하여 국가 ∙지방자치단체 ∙ 보건의료기관 또는 보건의료인 등이 행하는 모든 활동이다.\n④ 보건의료인은 보건의료 관계 법령에서 정하는 바에 따라 자격 ∙ 면허 등을 취득하거나 보건의료서비스에 종사하는 것이 허용된 자이다.\n⑤ 공공보건의료기관은 국민의 보건과 관련한 정보의 수집 ∙관리 ∙ 분석 ∙ 평가 및 제공 업무를 효율적이고 체계적으로 수행하기 위하여 설립한 기관이다.",
        "question_text": "Question: Which of the following is NOT correct regarding the definition of terms used in the \"Framework Act on Health and Medical Services\"?\n\n① Health and medical services are all activities performed by health and medical personnel to protect and promote the health of the people.\n② Health and medical information refers to all types of data expressed as knowledge, symbols, numbers, letters, voice, sound, or images related to health and medical care.\n③ Health and medical care refers to all activities performed by the state, local governments, health and medical institutions, or health and medical personnel to protect and promote the health of the people.\n④ Health and medical personnel are those who have obtained qualifications or licenses in accordance with health and medical-related laws or are permitted to engage in health and medical services.\n⑤ Public health and medical institutions are established to efficiently and systematically perform the collection, management, analysis, evaluation, and provision of information related to public health.",
        "answer": 5
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 건강보험사업을 맡아 주관하는 자는?\n\n① Minister of Health and Welfare\n② Minister of Food and Drug Safety\n③ President of Health Insurance Review & Assessment Service\n④ President of National Health Insurance Service\n⑤ Chairman of Health Insurance Policy Deliberation Committee",
        "question_text": "Question: According to the \"National Health Insurance Act,\" who is responsible for overseeing the health insurance business?\n\n① Minister of Health and Welfare\n② Minister of Food and Drug Safety\n③ President of Health Insurance Review & Assessment Service\n④ President of National Health Insurance Service\n⑤ Chairman of Health Insurance Policy Deliberation Committee",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 보험급여를 받을 수 있는 사람이 보험급여를 제한받는 경우가 아닌 것은?\n\n① 경미한 과실로 사고를 일으킨 경우\n② 고의로 인한 범죄행위에 그 원인이 있는 경우\n③ 공무로 생긴 부상으로 다른 법령에 따른 보험급여를 받게 되는 경우\n④ 업무로 생긴 질병으로 다른 법령에 따른 보상(報償)을 받게 되는 경우\n⑤ 중대한 과실로 요양기관의 요양에 관한 지시에 따르지 아니한 경우",
        "question_text": "Question: According to the \"National Health Insurance Act,\" which of the following is NOT a case where a person eligible for insurance benefits has their benefits restricted?\n\n① When an accident is caused by minor negligence\n② When the cause is due to an intentional criminal act\n③ When receiving insurance benefits under other laws for injuries sustained in the line of public duty\n④ When receiving compensation under other laws for occupational diseases\n⑤ When failing to follow medical instructions from a healthcare institution due to gross negligence",
        "answer": 1
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: \"Regional Public Health Act\"상 보건소에서 수행하는 마약류 관리 업무가 아닌 것은?\n\n① 대마 생산 현황 및 수량 보고\n② 마약류관리자의 마약류 취급 감시 및 단속\n③ 마약류소매업자에 대한 관리 및 업무 보고 명령\n④ 마약류취급의료업자의 마약류 폐기 및 조치 명령\n⑤ 마약류통합관리시스템의 구축 및 운영에 관한 사항",
        "question_text": "Question: According to the \"Regional Public Health Act,\" which of the following is NOT a task related to narcotic drug management performed by public health centers?\n\n① Reporting the production status and quantity of cannabis\n② Surveillance and crackdown on narcotic drug handlers' handling of narcotic drugs\n③ Management of narcotic drug retailers and issuing orders for business reports\n④ Ordering disposal and measures for narcotic drugs by medical practitioners handling narcotics\n⑤ Matters concerning the establishment and operation of an integrated narcotic drug management system",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: Michaelis-Menten 속도론을 따르는 단일 기질의 효소반응에서 경쟁적 억제제를 첨가할 경우 측정된 겉보기 값이 증가하는 것은?\n\n① equilibrium constant (K)\n② initial velocity (V 0)\n③ maximum velocity (V max)\n④ Michaelis constant (K m)\n⑤ turnover number (k cat)",
        "question_text": "Question: In an enzyme reaction with a single substrate following Michaelis-Menten kinetics, which measured apparent value increases when a competitive inhibitor is added?\n\n① equilibrium constant (K)\n② initial velocity (V₀)\n③ maximum velocity (Vmax)\n④ Michaelis constant (Km)\n⑤ turnover number (kcat)",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: Histone acetyltransferase에 의해 변형되는 histone 단백질의 아미노산 잔기는?\n\n① alanine\n② leucine\n③ lysine\n④ serine\n⑤ threonine",
        "question_text": "Question: Which amino acid residue of histone protein is modified by histone acetyltransferase?\n\n① alanine\n② leucine\n③ lysine\n④ serine\n⑤ threonine",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: Phosphocholine이나 phosphoethanolamine을 포함하고 있는 지질은?\n\n① ceramide\n② cerebroside\n③ ganglioside GM1\n④ globoside\n⑤ sphingomyelin",
        "question_text": "Question: Which lipid contains phosphocholine or phosphoethanolamine?\n\n① ceramide\n② cerebroside\n③ ganglioside GM1\n④ globoside\n⑤ sphingomyelin",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 사람 간에서 일어나는 당분해(glycolysis) 과정에서 ATP를 생성하며 가역적 반응을 촉매하는 효소는?\n\n① glyceraldehyde 3-phosphate dehydrogenase\n② hexokinase\n③ phosphofructokinase-1\n④ phosphoglycerate kinase\n⑤ pyruvate kinase",
        "question_text": "Question: Which enzyme catalyzes a reversible reaction and generates ATP during the glycolysis process in the human liver?\n\n① glyceraldehyde 3-phosphate dehydrogenase\n② hexokinase\n③ phosphofructokinase-1\n④ phosphoglycerate kinase\n⑤ pyruvate kinase",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 전력 질주를 하고 있는 사람의 근육 세포에서 다음 효소 반응에 참여하는 조효소 (A)와 (B)가 옳게 짝지어진 것은?\n\n<Data (confidential)>\n\n(A) | (B)\n① FADH2 | FAD\n② FMNH2 | FMN\n③ NADH | NAD+\n④ NADPH | NADP+\n⑤ ubiquinol(QH2) | ubiquinone(Q)",
        "question_text": "Question: Which of the following pairs of coenzymes (A) and (B) correctly participate in the enzyme reaction in muscle cells of a person sprinting at full speed?\n\n<Data (confidential)>\n\n(A) | (B)\n① FADH2 | FAD\n② FMNH2 | FMN\n③ NADH | NAD+\n④ NADPH | NADP+\n⑤ ubiquinol(QH2) | ubiquinone(Q)",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 다음에 해당하는 것은?\n\n• 시트르산 회로의 중간체\n• phosphofructokinase-1을 저해하여 당분해를 억제\n• acetyl-CoA carboxylase를 활성화하여 지방산 생합성을  촉진\n\n① α-ketoglutarate\n② citrate\n③ malate\n④ oxaloacetate\n⑤ succinate",
        "question_text": "Question: Which of the following applies?\n\n• An intermediate in the citric acid cycle\n• Inhibits glycolysis by inhibiting phosphofructokinase-1\n• Promotes fatty acid biosynthesis by activating acetyl-CoA carboxylase\n\n① α-ketoglutarate\n② citrate\n③ malate\n④ oxaloacetate\n⑤ succinate",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 사람 간세포의 glycogen phosphorylase 효소 반응에서 생성되는 물질은?\n\n① glucose\n② glucose 1-phosphate\n③ glucose 6-phosphate\n④ CDP-glucose\n⑤ UDP-glucose",
        "question_text": "Question: What is the substance produced in the glycogen phosphorylase enzyme reaction of human liver cells?\n\n① glucose\n② glucose 1-phosphate\n③ glucose 6-phosphate\n④ CDP-glucose\n⑤ UDP-glucose",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 다음 leukotriene A4 생합성 경로 (A)~(E) 중 사람에서는 효소가 없어서 일어나지 않으나 식물에서는 일어나는 것은?\n\n<Data (confidential)>\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "question_text": "Question: Among the following leukotriene A4 biosynthesis pathways (A)~(E), which one does not occur in humans due to the absence of the enzyme, but does occur in plants?\n\n<Data (confidential)>\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 사람 간세포에서 alanine transamination 반응의 생성물은?\n\n① α-ketoglutarate\n② oxaloacetate\n③ propionate\n④ pyruvate\n⑤ succinate",
        "question_text": "Question: What is the product of the alanine transamination reaction in human liver cells?\n\n① α-ketoglutarate\n② oxaloacetate\n③ propionate\n④ pyruvate\n⑤ succinate",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 대장균 DNA 복제과정에 필요한 효소 중 3’ → 5’ exonuclease 활성이 있어서 잘못 삽입된 nucleotide를 제거하는 교정(proofreading) 기능을 가진 효소는?\n\n① DNA ligase\n② DNA polymerase III\n③ DNA topoisomerase II\n④ helicase\n⑤ primase",
        "question_text": "Question: Among the enzymes required for E. coli DNA replication, which enzyme has a 3' → 5' exonuclease activity that provides a proofreading function by removing incorrectly inserted nucleotides?\n\n① DNA ligase\n② DNA polymerase III\n③ DNA topoisomerase II\n④ helicase\n⑤ primase",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 자외선에 의해 발생하는 유전자 손상 중 DNA 가닥의 뒤틀림(kink)을 유발하는 것은?\n\n① adenine의 deamination\n② cytosine의 methylation\n③ guanine의 alkylation\n④ guanine의 oxidation\n⑤ pyrimidine의 dimerization",
        "question_text": "Question: Which of the following genetic damages caused by ultraviolet radiation results in a kink in the DNA strand?\n\n① Deamination of adenine\n② Methylation of cytosine\n③ Alkylation of guanine\n④ Oxidation of guanine\n⑤ Dimerization of pyrimidine",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 단백질 생합성 시 특정 아미노산과 공유결합하여 아미노산을 활성화하는 RNA는?\n\n① messenger RNA (mRNA)\n② microRNA (miRNA)\n③ ribosomal RNA (rRNA)\n④ small nucleolar RNA (snoRNA)\n⑤ transfer RNA (tRNA)",
        "question_text": "Question: Which RNA forms a covalent bond with a specific amino acid during protein biosynthesis, activating the amino acid?\n\n① messenger RNA (mRNA)\n② microRNA (miRNA)\n③ ribosomal RNA (rRNA)\n④ small nucleolar RNA (snoRNA)\n⑤ transfer RNA (tRNA)",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: Ras 단백질이 세포막에 고정되도록 하는 번역 후 변형(posttranslational modification)은?\n\n① acetylation\n② carboxylation\n③ farnesylation\n④ phosphorylation\n⑤ ubiquitination",
        "question_text": "Question: What is the posttranslational modification that allows Ras protein to be anchored to the cell membrane?\n\n① acetylation\n② carboxylation\n③ farnesylation\n④ phosphorylation\n⑤ ubiquitination",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: Insulin receptor substrate-1 (IRS-1)의 인산화된 tyrosine 잔기를 포함하는 부위에 결합하는 growth factor receptor-bound protein 2 (Grb2)의 도메인(domain)은?\n\n① leucine rich\n② proline rich\n③ Src homology 2 (SH2)\n④ Src homology 3 (SH3)\n⑤ zinc finger",
        "question_text": "Question: Which domain of growth factor receptor-bound protein 2 (Grb2) binds to the region containing phosphorylated tyrosine residues of Insulin receptor substrate-1 (IRS-1)?\n\n① leucine rich\n② proline rich\n③ Src homology 2 (SH2)\n④ Src homology 3 (SH3)\n⑤ zinc finger",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 다음 각각의 반응을 촉매하는 효소 A와 효소 B에 공통으로 필요한 조효소는?\n\n<Data (confidential)>\n\n① coenzyme B12\n② FADH2\n③ lipoate\n④ NADH\n⑤ thiamine pyrophosphate",
        "question_text": "Question: Which coenzyme is commonly required for both enzyme A and enzyme B that catalyze the following reactions?\n\n<Data (confidential)>\n\n① coenzyme B12\n② FADH2\n③ lipoate\n④ NADH\n⑤ thiamine pyrophosphate",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 다음 효소 반응에 필요한 조효소는?\n\n<Data (confidential)>\n\n① biotin\n② FAD\n③ NADH\n④ pyridoxal phosphate\n⑤ tetrahydrofolate",
        "question_text": "Question: Which of the following is the coenzyme required for this enzyme reaction?\n\n<Data (confidential)>\n\n① biotin\n② FAD\n③ NADH\n④ pyridoxal phosphate\n⑤ tetrahydrofolate",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: DNA에서 발생한 thymine dimer를 복구하는 기전이며, 이 기전에 문제가 생겼을 때 햇빛에 과민반응을 보이고 xeroderma pigmentosum이라는 피부암이 유발될 수 있는 것은?\n\n① base-excision repair\n② direct repair\n③ mismatch repair\n④ nucleotide-excision repair\n⑤ recombination repair",
        "question_text": "Question: Which mechanism repairs thymine dimers in DNA, and when this mechanism is impaired, it can lead to hypersensitivity to sunlight and may cause a type of skin cancer called xeroderma pigmentosum?\n\n① base-excision repair\n② direct repair\n③ mismatch repair\n④ nucleotide-excision repair\n⑤ recombination repair",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 다음 thymidylate 생합성 과정 (A)~(E) 중 메토트렉세이트(methotrexate)가 억제하는 단계는?\n\n<Data (confidential)>\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "question_text": "Question: Which of the following steps (A)-(E) in the thymidylate biosynthesis process is inhibited by methotrexate?\n\n<Data (confidential)>\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n사람 간세포에서 palmitoyl-CoA가 β-산화 경로에 의해 분해되는 과정이다.\n<Data (confidential)>\n\nQuestion: Acetyl-CoA carboxylase에 의해 생성되며, (A) 단계를 억제하는 것은?\n\n① HMG-CoA\n② malonyl-CoA\n③ palmitoyl-CoA\n④ propionyl-CoA\n⑤ succinyl-CoA",
        "question_text": "This is the process of palmitoyl-CoA being broken down by the β-oxidation pathway in human liver cells.\n<Data (confidential)>\n\nQuestion: Which of the following is produced by Acetyl-CoA carboxylase and inhibits step (A)?\n\n① HMG-CoA\n② malonyl-CoA\n③ palmitoyl-CoA\n④ propionyl-CoA\n⑤ succinyl-CoA",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n사람 간세포에서 palmitoyl-CoA가 β-산화 경로에 의해 분해되는 과정이다.\n<Data (confidential)>\n\nQuestion: 전자전달계 Complex I에 전자를 제공하는 분자가 생성되는 단계는?\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "question_text": "This is the process of palmitoyl-CoA being broken down by the β-oxidation pathway in human liver cells.\n<Data (confidential)>\n\nQuestion: At which step is the molecule that provides electrons to the electron transport chain Complex I produced?\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 병원감염(nosocomial infection)을 매개하는 생물막(biofilm) 형성과 관련 있는 세균의 세포 외 다당질(exopolysaccharide) 구조는?\n\n① 협막(capsule)\n② 편모(flagella)\n③ 섬모(fimbriae)\n④ 성섬모(sex pili)\n⑤ 봉입체(inclusion body)",
        "question_text": "Question: Which extracellular polysaccharide (exopolysaccharide) structure of bacteria is associated with the formation of biofilms that mediate nosocomial infections?\n\n① Capsule\n② Flagella\n③ Fimbriae\n④ Sex pili\n⑤ Inclusion body",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 세균의 유전자 재조합 방법과 전달체의 조합으로 옳은 것은?\n\n① 형질전환(transformation) – 용균파지(lytic phage)\n② 형질주입(transfection) – 람다파지(lambda phage)\n③ 특수형질도입(specialized transduction) –도약유전자(jumping gene)\n④ 일반형질도입(generalized transduction) – 트랜스포존(transposon)\n⑤ 접합(conjugation) – Hfr(high frequency of recombination)균",
        "question_text": "Question: Which of the following is the correct combination of bacterial genetic recombination method and vector?\n\n① Transformation – Lytic phage\n② Transfection – Lambda phage\n③ Specialized transduction – Jumping gene\n④ Generalized transduction – Transposon\n⑤ Conjugation – Hfr (high frequency of recombination) strain",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 숙주세포의 신장인자 2(elongation factor 2)를 불활성화하여 단백질 합성을 억제하는 외독소를 생성하는 것은?\n\n① 콜레라균(Vibrio cholerae)\n② 백일해균(Bordetella pertussis)\n③ 보툴리눔균(Clostridium botulinum )\n④ 폐렴구균(Streptococcus pneumoniae)\n⑤ 디프테리아균(Corynebacterium diphtheriae)",
        "question_text": "Question: Which organism produces an exotoxin that inhibits protein synthesis by inactivating the host cell's elongation factor 2?\n\n① Vibrio cholerae (cholera bacterium)\n② Bordetella pertussis (whooping cough bacterium)\n③ Clostridium botulinum (botulism bacterium)\n④ Streptococcus pneumoniae (pneumococcus)\n⑤ Corynebacterium diphtheriae (diphtheria bacterium)",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 다음과 같은 특성을 지닌 세균은?\n\n• 편모운동을 하는 그람음성 간균\n• 식중독으로 인한 위장염, 장열(enteric fever), 패혈증 유발\n\n① 임균(Neisseria gonorrhoeae)\n② 살모넬라균(Salmonella Typhi)\n③ 가스괴저균(Clostridium perfringens)\n④ 클렙시엘라균(Klebsiella pneumoniae)\n⑤ 돼지단독균(Erysipelothrix rhusiopathiae)",
        "question_text": "Question: Which bacteria has the following characteristics?\n\n• Gram-negative bacillus with flagellar motility\n• Causes gastroenteritis due to food poisoning, enteric fever, and septicemia\n\n① Neisseria gonorrhoeae\n② Salmonella Typhi\n③ Clostridium perfringens\n④ Klebsiella pneumoniae\n⑤ Erysipelothrix rhusiopathiae",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 동물에 의해 매개되며 숙주세포의 아세틸콜린수용체에 결합하여 신경계 감염을 일으키는 것은?\n\n① 한타바이러스(hantavirus)\n② 광견병 바이러스(rabies virus)\n③ B형 간염 바이러스(hepatitis B virus)\n④ 단순헤르페스 바이러스(herpes simplex virus)\n⑤ 수두대상포진 바이러스(varicella-zoster virus)",
        "question_text": "Question: Which of the following is transmitted by animals and causes nervous system infection by binding to the acetylcholine receptors of host cells?\n\n① Hantavirus\n② Rabies virus\n③ Hepatitis B virus\n④ Herpes simplex virus\n⑤ Varicella-zoster virus",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 사람면역결핍바이러스(human immunodeficiency virus) 치료제인 랄테그라비르(raltegravir)의 주요 표적 단백질은?\n\n① integrase\n② neuraminidase\n③ protease\n④ reverse transcriptase\n⑤ thymidine kinase",
        "question_text": "Question: What is the main target protein of raltegravir, a treatment for human immunodeficiency virus (HIV)?\n\n① integrase\n② neuraminidase\n③ protease\n④ reverse transcriptase\n⑤ thymidine kinase",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 감염성 단백질 입자에 의해 발생하는 질환은?\n\n① 스포로트리쿰증(sporotrichosis)\n② 히스토플라스마증(histoplasmosis)\n③ 전염성단핵구증(infectious mononucleosis)\n④ 아프리카수면병(African sleeping sickness)\n⑤ 크로이츠펠트-야콥병(Creutzfeldt-Jakob disease)",
        "question_text": "Question: Which disease is caused by infectious protein particles?\n\n① Sporotrichosis\n② Histoplasmosis\n③ Infectious mononucleosis\n④ African sleeping sickness\n⑤ Creutzfeldt-Jakob disease",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 적혈구에서 분열소체(merozoite) 형태의 포자충류가 확인되고 주기적인 발열, 오한 증상을 호소하는 환자에게 일차적으로 사용되는 약물은?\n\n① 에메틴(emetine)\n② 푸마길린(fumagillin)\n③ 클로로퀸(chloroquine)\n④ 메벤다졸(mebendazole)\n⑤ 설파메타진(sulfamethazine)",
        "question_text": "Question: Which drug is primarily used for patients who have protozoa in the form of merozoites confirmed in their red blood cells and are complaining of periodic fever and chills?\n\n① Emetine\n② Fumagillin\n③ Chloroquine\n④ Mebendazole\n⑤ Sulfamethazine",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: Erythromycin과 clindamycin에 관한 그람양성 세균의 항생제 교차내성 기전은?\n\n① rRNA의 변화\n② 세포벽 합성의 변이\n③ DNA gyrase의 변이\n④ 세포막 구성 성분의 변이\n⑤ ribosome 구성 단백질의 변이",
        "question_text": "Question: What is the mechanism of antibiotic cross-resistance in Gram-positive bacteria for erythromycin and clindamycin?\n\n① Alteration of rRNA\n② Mutation in cell wall synthesis\n③ Mutation in DNA gyrase\n④ Mutation in cell membrane components\n⑤ Mutation in ribosomal proteins",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 악틴아민(actinamine) 구조를 지닌 아미노배당체 항생물질로서, 페니실린 내성 임균 감염의 치료에 사용되는 약물은?\n\n① 네틸마이신(netilmicin)\n② 겐타마이신(gentamicin)\n③ 토브라마이신(tobramycin)\n④ 스트렙토마이신(streptomycin)\n⑤ 스펙티노마이신(spectinomycin)",
        "question_text": "Question: Which aminoglycoside antibiotic with an actinamine structure is used for the treatment of penicillin-resistant gonococcal infections?\n\n① Netilmicin\n② Gentamicin\n③ Tobramycin\n④ Streptomycin\n⑤ Spectinomycin",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 뼈나 치아에 침착되며 소아에서 골격형성 장애의 부작용을 유발할 위험이 있는 약물은?\n\n① 니스타틴(nystatin)\n② 리팜피신(rifampicin)\n③ 카나마이신(kanamycin)\n④ 미노사이클린(minocycline)\n⑤ 클로람페니콜(chloramphenicol)",
        "question_text": "Question: Which drug can be deposited in bones or teeth and potentially cause skeletal formation disorders as a side effect in children?\n\n① Nystatin\n② Rifampicin\n③ Kanamycin\n④ Minocycline\n⑤ Chloramphenicol",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 헤르페스성 각막결막염(keratoconjunctivitis) 치료에 효과적인 것은?\n\n① 퀴닌(quinine)\n② 인디나빌(indinavir)\n③ 아미카신(amikacin)\n④ 아시클로버(acyclovir)\n⑤ 케토코나졸(ketoconazole)",
        "question_text": "Question: Which of the following is effective in treating herpetic keratoconjunctivitis?\n\n① Quinine\n② Indinavir\n③ Amikacin\n④ Acyclovir\n⑤ Ketoconazole",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 인플루엔자 바이러스 입자의 탈피(uncoating) 과정을 저해하는 항바이러스제는?\n\n① 지도부딘(zidovudine)\n② 아만타딘(amantadine)\n③ 자나미비르(zanamivir)\n④ 팜시클로비르(famciclovir)\n⑤ 오셀타미비르(oseltamivir)",
        "question_text": "Question: Which antiviral drug inhibits the uncoating process of influenza virus particles?\n\n① Zidovudine\n② Amantadine\n③ Zanamivir\n④ Famciclovir\n⑤ Oseltamivir",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 사람의 주조직적합성복합체(MHC) class II에 해당하는 유전자는?\n\n① H-2K\n② H-2D\n③ HLA-A\n④ HLA-B\n⑤ HLA-DQ",
        "question_text": "Question: Which gene corresponds to the Major Histocompatibility Complex (MHC) class II in humans?\n\n① H-2K\n② H-2D\n③ HLA-A\n④ HLA-B\n⑤ HLA-DQ",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 조절 T 세포(regulatory T cell)에 의해 생산되며 면역 억제 활성을 매개하는 시토카인은?\n\n① IL-6\n② IL-12\n③ IFN-γ\n④ TNF-α\n⑤ TGF-β",
        "question_text": "Question: Which cytokine is produced by regulatory T cells and mediates immunosuppressive activity?\n\n① IL-6\n② IL-12\n③ IFN-γ\n④ TNF-α\n⑤ TGF-β",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 흉선 발육 부진으로 인한 DiGeorge 증후군 환자에서 면역결핍 기회감염이 잘 일어나는 원인은?\n\n① 보체 활성화 반응 이상\n② 조절 T 세포의 생성 증가\n③ 프로페르딘(properdin)의 감소\n④ 자연살해(NK) 세포의 기능 이상\n⑤ T 세포 분화 결함과 B 세포 반응 이상",
        "question_text": "Question: What is the main cause of opportunistic infections due to immunodeficiency in patients with DiGeorge syndrome, which is characterized by thymic hypoplasia?\n\n① Abnormal complement activation reaction\n② Increased production of regulatory T cells\n③ Decrease in properdin\n④ Dysfunction of Natural Killer (NK) cells\n⑤ T cell differentiation defect and abnormal B cell response",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 종양괴사인자(TNF-α) 수용체에 IgG1의 Fc영역을 융합한 항체의약품으로 류마티스 관절염에 사용하는 약물은?\n\n① 리툭시맙(rituximab)\n② 세툭시맙(cetuximab)\n③ 에타너셉트(etanercept)\n④ 오말리주맙(omalizumab)\n⑤ 트라스투주맙(trastuzumab)",
        "question_text": "Question: Which drug, used for rheumatoid arthritis, is an antibody medication that fuses the Fc region of IgG1 to the tumor necrosis factor (TNF-α) receptor?\n\n① Rituximab\n② Cetuximab\n③ Etanercept\n④ Omalizumab\n⑤ Trastuzumab",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 호흡기 세포융합 바이러스(respiratory syncytial virus)에 감염될 가능성이 높은 소아환자의 중증 하기도질환 예방에 효과적인 단클론항체의약품은?\n\n① 오말리주맙(omalizumab)\n② 아달리무맙(adalimumab)\n③ 팔리비주맙(palivizumab)\n④ 베바시주맙(bevacizumab)\n⑤ 펨브롤리주맙(pembrolizumab)",
        "question_text": "Question: Which monoclonal antibody drug is effective in preventing severe lower respiratory tract disease in pediatric patients who are at high risk of respiratory syncytial virus (RSV) infection?\n\n① Omalizumab\n② Adalimumab\n③ Palivizumab\n④ Bevacizumab\n⑤ Pembrolizumab",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nRh 음성 산모가 첫 번째 임신으로 Rh 양성 태아를 출산한 경우, 두 번째 임신에서 태아적혈모구증(erythroblastosis fetalis)의 발생 가능성이 높아진다.\n\nQuestion: 태아적혈모구증이 발생되는 원인은?\n\n① 모체의 탐식세포 활성화\n② 출산 시 모체로 유입된 태아의 적혈구\n③ 모체의 T 세포에 의한 지연형 과민반응\n④ 모체에서 생성된 Rh 항원에 대한 IgM 항체\n⑤ 태아의 체내에서 생성된 Rh 항원에 대한 IgG 항체",
        "question_text": "An Rh-negative mother gives birth to an Rh-positive baby in her first pregnancy. In her second pregnancy, the risk of erythroblastosis fetalis increases.\n\nQuestion: What is the cause of erythroblastosis fetalis?\n\n① Activation of maternal phagocytes\n② Fetal red blood cells entering the maternal circulation during delivery\n③ Delayed-type hypersensitivity reaction by maternal T cells\n④ IgM antibodies against Rh antigen produced in the mother\n⑤ IgG antibodies against Rh antigen produced in the fetus",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nRh 음성 산모가 첫 번째 임신으로 Rh 양성 태아를 출산한 경우, 두 번째 임신에서 태아적혈모구증(erythroblastosis fetalis)의 발생 가능성이 높아진다.\n\nQuestion: 태아적혈모구증의 예방을 위해 첫 출산 후, 산모에게 투여하는 것은?\n\n① erythropoietin\n② isohemagglutinin\n③ rh immune globulin\n④ surface immunoglobulin\n⑤ keyhole limpet hemocyanin",
        "question_text": "A Rh-negative mother gives birth to a Rh-positive baby in her first pregnancy. This increases the risk of erythroblastosis fetalis in the second pregnancy.\n\nQuestion: What should be administered to the mother after the first delivery to prevent erythroblastosis fetalis?\n\n① erythropoietin\n② isohemagglutinin\n③ rh immune globulin\n④ surface immunoglobulin\n⑤ keyhole limpet hemocyanin",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 고혈압 치료를 위하여 아드레날린성 β-수용체 길항약을 장기간 복용하다 투약을 갑자기 중단할 경우, 혈압이 급격히 상승하는 금단증상이 발생하는 이유는?\n\n① 내성발현\n② 특이체질\n③ 수용체 탈감작\n④ 수용체 상향조절\n⑤ 수용체 하향조절",
        "question_text": "Question: What is the reason for the withdrawal symptom of a sudden increase in blood pressure when abruptly stopping long-term medication with adrenergic β-receptor antagonists for hypertension treatment?\n\n① Development of tolerance\n② Idiosyncrasy\n③ Receptor desensitization\n④ Receptor up-regulation\n⑤ Receptor down-regulation",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 다음 그림의 용량-반응곡선에서 각 약물들(A~D)의 용량과 반응의 상대적 관계에 관한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 약물 A가 약물 B보다 효력이 크다.\n② 약물 A가 약물 B보다 최대효능이 크다.\n③ 약물 C가 약물 D보다 최대효능이 크다.\n④ 약물 D가 약물 C보다 효력이 크다.\n⑤ 약물 A가 약물 C보다 최대효능이 크다.",
        "question_text": "Question: In the dose-response curve shown in the following figure, which statement is correct regarding the relative relationship between dose and response for each drug (A~D)?\n\n<Data (confidential)>\n\n① Drug A has greater potency than drug B.\n② Drug A has greater maximal efficacy than drug B.\n③ Drug C has greater maximal efficacy than drug D.\n④ Drug D has greater potency than drug C.\n⑤ Drug A has greater maximal efficacy than drug C.",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 약물을 경구투여 할 경우, 전신순환계에 도달하기 전에 주로 간에서 대사되어 생체이용률이 감소되는 이유는?\n\n① 초회통과효과\n② 약물대사효소 유도\n③ 수용액에 대한 낮은 용해도\n④ 낮은 지용성으로 인한 낮은 세포막투과도\n⑤ 장관 점막세포에서 multidrug resistance type 1 (MDR1) 수송체에 의한 약물흡수 억제",
        "question_text": "Question: When a drug is administered orally, what is the main reason for the decrease in bioavailability due to metabolism primarily in the liver before reaching the systemic circulation?\n\n① First-pass effect\n② Induction of drug-metabolizing enzymes\n③ Low solubility in aqueous solutions\n④ Low cell membrane permeability due to low lipophilicity\n⑤ Inhibition of drug absorption by multidrug resistance type 1 (MDR1) transporters in intestinal mucosal cells",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 무스카린 수용체 차단약으로서 전립샘절제술 후에 나타날 수 있는 방광 연축(spasm)을 완화하기 위해 사용하는 약물은?\n\n① 탐스로신(tamsulosin)\n② 베타네콜(bethanechol)\n③ 옥시부티닌(oxybutynin)\n④ 네오스티그민(neostigmine)\n⑤ 옥시메타졸린(oxymetazoline)",
        "question_text": "Question: Which drug is used as a muscarinic receptor antagonist to alleviate bladder spasms that may occur after prostatectomy?\n\n① Tamsulosin\n② Bethanechol\n③ Oxybutynin\n④ Neostigmine\n⑤ Oxymetazoline",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 아드레날린성 β-수용체를 억제하여 안방수 생성을 감소시킴으로써 개방각 녹내장에 사용하는 약물은?\n\n① 티몰롤(timolol)\n② 카바콜(carbachol)\n③ 브리모니딘(brimonidine)\n④ 라타노프로스트(latanoprost)\n⑤ 아세타졸아미드(acetazolamide)",
        "question_text": "Question: Which drug is used in open-angle glaucoma by inhibiting adrenergic β-receptors, thereby reducing aqueous humor production?\n\n① Timolol\n② Carbachol\n③ Brimonidine\n④ Latanoprost\n⑤ Acetazolamide",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 중추신경계에서 시냅스 흥분의 주요 매개체인 AMPA 수용체에 관한 비경쟁적 길항작용으로 국소발작에 사용하는 약물은?\n\n① 가바펜틴(gabapentin)\n② 페람파넬(perampanel)\n③ 에토숙시미드(ethosuximide)\n④ 레비티라세탐(levetiracetam)\n⑤ 카르바마제핀(carbamazepine)",
        "question_text": "Question: Which drug is used for focal seizures due to its non-competitive antagonistic action on AMPA receptors, which are the main mediators of synaptic excitation in the central nervous system?\n\n① Gabapentin\n② Perampanel\n③ Ethosuximide\n④ Levetiracetam\n⑤ Carbamazepine",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 레보도파(levodopa)의 작용시간을 연장시키거나 생체이용률을 증가시킬 목적으로 파킨슨병 치료에 레보도파와 함께 사용하는 catechol-O-methyltransferase (COMT) 억제약물은?\n\n① 셀레길린(selegiline)\n② 엔타카폰(entacapone)\n③ 카르비도파(carbidopa)\n④ 프라미펙솔(pramipexole)\n⑤ 트리헥시페니딜(trihexyphenidyl)",
        "question_text": "Question: Which catechol-O-methyltransferase (COMT) inhibitor is used in combination with levodopa in the treatment of Parkinson's disease to extend the duration of action or increase the bioavailability of levodopa?\n\n① Selegiline\n② Entacapone\n③ Carbidopa\n④ Pramipexole\n⑤ Trihexyphenidyl",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 지속적 사용에 의해서도 내성발현 정도가 낮은 모르핀(morphine)의 효과는?\n\n① 변비\n② 산동\n③ 진통\n④ 기침억제\n⑤ 호흡억제",
        "question_text": "Question: Which effect of morphine has a low degree of tolerance development even with continuous use?\n\n① Constipation\n② Pupil dilation\n③ Pain relief\n④ Cough suppression\n⑤ Respiratory depression",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 진정작용이 약한 알레르기비염 치료약물은?\n\n① 히드록시진(hydroxyzine)\n② 스코폴라민(scopolamine)\n③ 펙소페나딘(fexofenadine)\n④ 프로메타진(promethazine)\n⑤ 디펜히드라민(diphenhydramine)",
        "question_text": "Question: Which medication for allergic rhinitis has a weak sedative effect?\n\n① Hydroxyzine\n② Scopolamine\n③ Fexofenadine\n④ Promethazine\n⑤ Diphenhydramine",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 혈소판의 adenosine diphosphate (ADP) P2Y12 수용체를 차단하여 혈소판응집을 억제하는 약물은?\n\n① 실로스타졸(cilostazol)\n② 클로피도그렐(clopidogrel)\n③ 폰다파리눅스(fondaparinux)\n④ 엡티피바타이드(eptifibatide)\n⑤ 트라넥삼산(tranexamic acid)",
        "question_text": "Question: Which drug inhibits platelet aggregation by blocking the adenosine diphosphate (ADP) P2Y12 receptor on platelets?\n\n① Cilostazol\n② Clopidogrel\n③ Fondaparinux\n④ Eptifibatide\n⑤ Tranexamic acid",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: Angiotensin II type 1 (AT1) 수용체를 차단하는 작용기전으로 인해 마른기침, 혈관부종 유해작용이 약한 항고혈압약은?\n\n① 라미프릴(ramipril)\n② 라베탈롤(labetalol)\n③ 암로디핀(amlodipine)\n④ 텔미사르탄(telmisartan)\n⑤ 니트로프루시드나트륨(sodium nitroprusside)",
        "question_text": "Question: Which antihypertensive drug has a weak side effect of dry cough and angioedema due to its mechanism of action of blocking the Angiotensin II type 1 (AT1) receptor?\n\n① Ramipril\n② Labetalol\n③ Amlodipine\n④ Telmisartan\n⑤ Sodium nitroprusside",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 초저밀도 지질단백질(very-low-density lipoprotein, VLDL)의 증가가 두드러지는 고중성지방혈증 환자 치료에 효과적인 약물과 그 작용기전의 연결이 옳은 것은?\n\n① 콜레스티폴(colestipol) – 장내 담즙산 재흡수 억제\n② 에제티미브(ezetimibe) – 스테롤 수송체 NPC1L1 차단\n③ 로수바스타틴(rosuvastatin) – HMG-CoA reductase 억제\n④ 에볼로쿠맙(evolocumab) – proprotein convertase subtilisin/kexin type 9 (PCSK9)과 결합\n⑤ 페노피브레이트(fenofibrate) – peroxisome proliferator-activated receptor (PPAR)-α 활성화",
        "question_text": "Question: Which of the following is the correct match between an effective drug for treating patients with hypertriglyceridemia characterized by a significant increase in very-low-density lipoprotein (VLDL) and its mechanism of action?\n\n① Colestipol – Inhibition of bile acid reabsorption in the intestine\n② Ezetimibe – Blocking of sterol transporter NPC1L1\n③ Rosuvastatin – Inhibition of HMG-CoA reductase\n④ Evolocumab – Binding to proprotein convertase subtilisin/kexin type 9 (PCSK9)\n⑤ Fenofibrate – Activation of peroxisome proliferator-activated receptor (PPAR)-α",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 고칼슘혈증을 효과적으로 치료하기 위해 사용하는 이뇨약은?\n\n① 트리암테렌(triamterene)\n② 푸로세미드(furosemide)\n③ 아미로라이드(amiloride)\n④ 스피로노락톤(spironolactone)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: Which diuretic is used effectively to treat hypercalcemia?\n\n① Triamterene\n② Furosemide\n③ Amiloride\n④ Spironolactone\n⑤ Hydrochlorothiazide",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 설사가 동반된 과민대장증후군 환자 치료에 사용하는 알로세트론(alosetron)의 작용기전은?\n\n① H2 수용체 차단\n② 5-HT3 수용체 차단\n③ neurokinin 1 (NK1) 수용체 차단\n④ glucagon-like peptide 2 수용체 활성화\n⑤ cystic fibrosis transmembrane conductance regulator (CFTR) 활성화",
        "question_text": "Question: What is the mechanism of action of alosetron used in the treatment of irritable bowel syndrome with diarrhea?\n\n① H2 receptor blockade\n② 5-HT3 receptor blockade\n③ Neurokinin 1 (NK1) receptor blockade\n④ Glucagon-like peptide 2 receptor activation\n⑤ Cystic fibrosis transmembrane conductance regulator (CFTR) activation",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 배란장애 여자에게 배란유발 목적으로 사용하는 estrogen 수용체 부분효능약은?\n\n① 다나졸(danazol)\n② 클로미펜(clomiphene)\n③ 미소프로스톨(misoprostol)\n④ 미페프리스톤(mifepristone)\n⑤ 레보노르게스트렐(L-norgestrel)",
        "question_text": "Question: Which estrogen receptor partial agonist is used to induce ovulation in women with ovulatory disorders?\n\n① Danazol\n② Clomiphene\n③ Misoprostol\n④ Mifepristone\n⑤ Levonorgestrel",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 경구용 혈당강하약인 엠파글리플로진(empagliflozin)의 작용기전은?\n\n① dipeptidyl peptidase-4 (DPP-4) 억제\n② AMP-activated protein kinase (AMPK) 활성화\n③ glucagon-like polypeptide-1 (GLP-1) 수용체 활성화\n④ 근위세관의 sodium-glucose transporter 2 (SGLT2) 억제\n⑤ peroxisome proliferator-activated receptor (PPAR)-γ 활성화",
        "question_text": "Question: What is the mechanism of action of empagliflozin, an oral hypoglycemic agent?\n\n① Inhibition of dipeptidyl peptidase-4 (DPP-4)\n② Activation of AMP-activated protein kinase (AMPK)\n③ Activation of glucagon-like polypeptide-1 (GLP-1) receptor\n④ Inhibition of sodium-glucose transporter 2 (SGLT2) in the proximal tubule\n⑤ Activation of peroxisome proliferator-activated receptor (PPAR)-γ",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: HIV-1 외피 당단백질인 gp41 subunit에 결합함으로써, 바이러스가 숙주세포막에 융합하는 것을 차단하는 약물은?\n\n① 아바카비르(abacavir)\n② 리토나비르(ritonavir)\n③ 아시클로버(acyclovir)\n④ 델라비르딘(delavirdine)\n⑤ 엔푸버타이드(enfuvirtide)",
        "question_text": "Question: Which drug blocks the fusion of the virus with the host cell membrane by binding to the gp41 subunit, an HIV-1 envelope glycoprotein?\n\n① Abacavir\n② Ritonavir\n③ Acyclovir\n④ Delavirdine\n⑤ Enfuvirtide",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 혈관내피성장인자(vascular endothelial growth factor, VEGF)와 결합함으로써 VEGF가 수용체와 결합하는 것을 방해하여, 전이성 결장직장암과 전이성 비소세포폐암에 사용하는 약물은?\n\n① 이매티닙(imatinib)\n② 엘로티닙(erlotinib)\n③ 세툭시맙(cetuximab)\n④ 베바시주맙(bevacizumab)\n⑤ 파니투무맙(panitumumab)",
        "question_text": "Question: Which drug is used for metastatic colorectal cancer and metastatic non-small cell lung cancer by binding to vascular endothelial growth factor (VEGF), thereby interfering with VEGF binding to its receptor?\n\n① Imatinib\n② Erlotinib\n③ Cetuximab\n④ Bevacizumab\n⑤ Panitumumab",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음 그림은 아드레날린성 신경섬유 말단에서 신경전달물질인 norepinephrine (NE)의 유리, 작용, 작용종결 과정을 도식화 한 것이다.\n<Data (confidential)>\n\nQuestion: 위 그림에서 작동세포가 기도 평활근이라면, 테르부탈린(terbutaline)이 치료작용을 나타내는 작용점은?\n\n① (ㄱ)\n② (ㄴ)\n③ (ㄷ)\n④ (ㄹ)\n⑤ (ㅁ)",
        "question_text": "The following figure schematically illustrates the release, action, and termination process of the neurotransmitter norepinephrine (NE) at the adrenergic nerve fiber terminal.\n<Data (confidential)>\n\nQuestion: If the effector cell in the above figure is airway smooth muscle, at which point does terbutaline exert its therapeutic action?\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음 그림은 아드레날린성 신경섬유 말단에서 신경전달물질인 norepinephrine (NE)의 유리, 작용, 작용종결 과정을 도식화 한 것이다.\n<Data (confidential)>\n\nQuestion: 위 그림이 중추에서 정서반응에 관여하는 아드레날린성 신경이고,작동세포가신경절이후신경이라면,데시프라민(desipramine)이 항우울효과를 나타내는 작용점은?\n\n① (ㄴ)\n② (ㄷ)\n③ (ㄹ)\n④ (ㅁ)\n⑤ (ㅂ)",
        "question_text": "The following figure schematically illustrates the release, action, and termination process of the neurotransmitter norepinephrine (NE) at adrenergic nerve fiber terminals.\n<Data (confidential)>\n\nQuestion: If the above figure represents an adrenergic neuron involved in emotional responses in the central nervous system, and the effector cell is a post-ganglionic neuron, what is the site of action where desipramine exerts its antidepressant effect?\n\n① (B)\n② (C)\n③ (D)\n④ (E)\n⑤ (F)",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 분자역학에서 활용되는 생체지표(biomarker) 중 감수성지표(susceptibility biomarker)에 해당하는 것은?\n\n① 혈액 중 troponin I와 T\n② 화학물질과 DNA의 결합체(adduct)\n③ 소변이나 혈액 중의 화학물질 대사체\n④ 혈액 중 alanine aminotransferase (ALT)\n⑤ 화학물질 대사효소의 유전자 다형성(genetic polymorphism)",
        "question_text": "Question: Which of the following is a susceptibility biomarker used in molecular epidemiology?\n\n① Troponin I and T in blood\n② Chemical-DNA adducts\n③ Chemical metabolites in urine or blood\n④ Alanine aminotransferase (ALT) in blood\n⑤ Genetic polymorphism of chemical metabolizing enzymes",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 가축에서 유산이 일어나며, 병원체에 감염된 가축의 고기나 유즙을 섭취한 사람에서 파상열이 유발되는 인수공통감염병은?\n\n① 큐열\n② 브루셀라증\n③ 리스테리아증\n④ 중동호흡기증후군\n⑤ 지카바이러스감염증",
        "question_text": "Question: Which zoonotic disease causes abortions in livestock and undulant fever in humans who consume meat or milk from infected animals?\n\n① Q fever\n② Brucellosis\n③ Listeriosis\n④ Middle East Respiratory Syndrome (MERS)\n⑤ Zika virus infection",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 단열재, 내화재 등의 건축자재에서 유래하여 흡입을 통해 노출되며, 폐에서 산화적 스트레스를 유발하고 악성중피종과 폐암을 유발하는 실내공기 오염물질은?\n\n① 라듐\n② 벤젠\n③ 석면\n④ 톨루엔\n⑤ 포름알데히드",
        "question_text": "Question: Which indoor air pollutant originates from building materials such as insulation and fire-resistant materials, is exposed through inhalation, causes oxidative stress in the lungs, and induces malignant mesothelioma and lung cancer?\n\n① Radium\n② Benzene\n③ Asbestos\n④ Toluene\n⑤ Formaldehyde",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 정수 처리 과정의 일반적인 염소소독으로는 불활성화되기 어려운 수인성 감염병의 원인체로서, 우리나라 20~40대 젊은 층에서 항체양성률이 낮고 감염률이 높은 바이러스는?\n\n① coxsackie virus\n② hepatitis A virus\n③ poliovirus\n④ rotavirus\n⑤ varicella-zoster virus",
        "question_text": "Question: Which virus is difficult to inactivate through the general chlorine disinfection process in water treatment, and has a low antibody-positive rate but a high infection rate among young adults in their 20s to 40s in Korea?\n\n① coxsackie virus\n② hepatitis A virus\n③ poliovirus\n④ rotavirus\n⑤ varicella-zoster virus",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 부영양화된 호소나 하천에서 증식한 남세균(Cyanobacteria)이 생산하는 고리형 펩티드(cyclic peptide)로서, 단백질 인산분해효소(protein phosphatase)를 억제하거나 산화적 스트레스를 유발함으로써 간독성을 나타내는 물질은?\n\n① α-amanitin\n② geosmin\n③ humic acid\n④ microcystin LR\n⑤ phalloidin",
        "question_text": "Question: Which substance, produced by Cyanobacteria that proliferate in eutrophic lakes or rivers, is a cyclic peptide that exhibits hepatotoxicity by inhibiting protein phosphatase or inducing oxidative stress?\n\n① α-amanitin\n② geosmin\n③ humic acid\n④ microcystin LR\n⑤ phalloidin",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 전신적으로 작용하면 척추 손상 등 골격계 장애를, 국소적으로 작용하면 레이노 현상(Raynaud’s phenomenon)과 같은 말초순환장애를 유발하는 물리적 요인은?\n\n① 빛\n② 고온\n③ 소음\n④ 진동\n⑤ 방사선",
        "question_text": "Question: Which physical factor, when acting systemically, can cause skeletal disorders such as spinal injuries, and when acting locally, can cause peripheral circulatory disorders like Raynaud's phenomenon?\n\n① Light\n② High temperature\n③ Noise\n④ Vibration\n⑤ Radiation",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 대장암을 유발하는 이차발암물질로서, 대사활성화 과정에서 장내 세균의 β-glucuronidase 작용이 요구되는 것은?\n\n① 2-acetylaminofluorene\n② 2-aminonaphthalene\n③ 7,12-dimethylbenz[a]anthracene\n④ safrole\n⑤ sulfanilamide",
        "question_text": "Question: Which of the following is a secondary carcinogen that causes colon cancer and requires the action of β-glucuronidase from intestinal bacteria during its metabolic activation?\n\n① 2-acetylaminofluorene\n② 2-aminonaphthalene\n③ 7,12-dimethylbenz[a]anthracene\n④ safrole\n⑤ sulfanilamide",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: Phenylhydroxylamine이나 p -aminophenol로 대사되어 methemoglobin 혈증을 유발할 수 있는 화학물질은?\n\n① aniline\n② bromobenzene\n③ cyclohexane\n④ isoniazid\n⑤ primaquine",
        "question_text": "Question: Which chemical substance can be metabolized into phenylhydroxylamine or p-aminophenol, potentially causing methemoglobinemia?\n\n① aniline\n② bromobenzene\n③ cyclohexane\n④ isoniazid\n⑤ primaquine",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 과정을 통해 수행되는 독성시험법은?\n\n• 기니피그의 제모한 피부에 면역보조제와 시험물질을 피내주사 한다.\n• 1주 후 동일 부위에 시험물질이 함유된 패치를 48시간 부착한다.\n• 2주 후 다른 부위의 피부에 시험물질이 함유된 패치를 24시간 부착한다.\n• 패치 제거 24시간, 48시간 후에 피부반응을 평가한다.\n\n① 국소내성시험\n② 피부자극시험\n③ 피부감작성시험\n④ 아나필락시스 쇼크 반응시험\n⑤ 수동 피부 아나필락시스 반응시험",
        "question_text": "Question: Which toxicity test is performed through the process described below?\n\n• Intradermal injection of an immunoadjuvant and test substance into the shaved skin of a guinea pig.\n• One week later, a patch containing the test substance is applied to the same area for 48 hours.\n• Two weeks later, a patch containing the test substance is applied to a different skin area for 24 hours.\n• Skin reactions are evaluated 24 and 48 hours after patch removal.\n\n① Local tolerance test\n② Skin irritation test\n③ Skin sensitization test\n④ Anaphylactic shock reaction test\n⑤ Passive cutaneous anaphylaxis test",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 다음 중 카드뮴에 의해 억제되는 신장의 vitamin D 활성화 반응은?\n\n7-dehydrocholesterol (A)→ previtamin D3 (B)→ vitamin D3 (C)→ 25-hydroxyvitamin D3 (D)→ 1α,25-dihydroxyvitamin D3 (E)→ 1α,24,25-trihydroxyvitamin D3\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "question_text": "Question: Which of the following vitamin D activation reactions in the kidney is inhibited by cadmium?\n\n7-dehydrocholesterol (A)→ previtamin D3 (B)→ vitamin D3 (C)→ 25-hydroxyvitamin D3 (D)→ 1α,25-dihydroxyvitamin D3 (E)→ 1α,24,25-trihydroxyvitamin D3\n\n① (A)\n② (B)\n③ (C)\n④ (D)\n⑤ (E)",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 1 전자 환원(one-electron reduction)에 의해 자유라디칼(free radical)로 대사되고 redox cycle을 통해 활성산소를 생성함으로써 폐독성을 유발하는 제초제는?\n\n① benzene hexachloride\n② endrin\n③ glyphosate\n④ methomyl\n⑤ paraquat",
        "question_text": "Question: Which herbicide causes pulmonary toxicity by being metabolized into a free radical through one-electron reduction and generating reactive oxygen species through the redox cycle?\n\n① benzene hexachloride\n② endrin\n③ glyphosate\n④ methomyl\n⑤ paraquat",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 동물 유해성 자료를 근거로 독성참고치(reference dose)를 산출할 때, 종간 및 종내 감수성 차이, 시험 기간, 자료의 질적 수준, 최소영향관찰용량(lowest observed adverse effect level, LOAEL) 사용 여부 등을 고려하여 설정하는 값은?\n\n① 위해지수(hazard index)\n② 조정계수(modifying factor)\n③ 기준용량(benchmark dose)\n④ 노출한계(margin of exposure)\n⑤ 불확실성계수(uncertainty factor)",
        "question_text": "Question: When calculating the reference dose based on animal toxicity data, which value is established considering factors such as inter-species and intra-species sensitivity differences, test duration, quality of data, and whether the lowest observed adverse effect level (LOAEL) is used?\n\n① Hazard index\n② Modifying factor\n③ Benchmark dose\n④ Margin of exposure\n⑤ Uncertainty factor",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 글루탐산 잔기의 γ-carboxylation에 조효소로 작용함으로써 혈액응고나 골형성 관련 단백질의 기능에 필수적인 영양소는?\n\n① biotin\n② folic acid\n③ nicotinic acid\n④ pantothenic acid\n⑤ phylloquinone",
        "question_text": "Question: Which nutrient is essential for the function of blood coagulation and bone formation-related proteins by acting as a coenzyme in the γ-carboxylation of glutamic acid residues?\n\n① biotin\n② folic acid\n③ nicotinic acid\n④ pantothenic acid\n⑤ phylloquinone",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: 비타민 D 결핍, 시금치나 근대에 함유된 옥살산(oxalic acid), 곡물 껍질의 피트산(phytic acid), 과잉의 지방산에 의해 흡수가 저해되는 무기질은?\n\n① 인\n② 철\n③ 구리\n④ 칼슘\n⑤ 마그네슘",
        "question_text": "Question: Which mineral's absorption is inhibited by vitamin D deficiency, oxalic acid found in spinach and chard, phytic acid in grain husks, and excess fatty acids?\n\n① Phosphorus\n② Iron\n③ Copper\n④ Calcium\n⑤ Magnesium",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 식중독 원인균은?\n\n• 특성: 내열성 용혈독을 생성하는 통성혐기성 호염균\n• 주요 감염 경로: 여름철 어패류의 생식\n• 감염 증상: 상복부의 통증과 구토, 설사, 발열\n• 감염 예방 대책: 식재료의 담수 세척, 가열 조리\n\n① Clostridium botulinum\n② Escherichia coli O157:H7\n③ Listeria monocytogenes\n④ Staphylococcus aureus\n⑤ Vibrio parahaemolyticus",
        "question_text": "Question: Which food poisoning pathogen is described below?\n\n• Characteristics: Facultative anaerobic, halophilic bacteria that produces heat-stable hemolysin\n• Main route of infection: Consumption of raw seafood in summer\n• Infection symptoms: Upper abdominal pain, vomiting, diarrhea, fever\n• Prevention measures: Washing ingredients with fresh water, cooking with heat\n\n① Clostridium botulinum\n② Escherichia coli O157:H7\n③ Listeria monocytogenes\n④ Staphylococcus aureus\n⑤ Vibrio parahaemolyticus",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 땀버섯과 광대버섯 등의 독버섯에 함유되어 있으며, 중독 시 부교감 신경을 흥분시켜 분비기능의 항진, 발한, 축동, 호흡곤란, 경련, 혼수를 유발하는 알칼로이드는?\n\n① cicutoxin\n② hyoscyamine\n③ muscarine\n④ phaseolunatin\n⑤ scopolamine",
        "question_text": "Question: Which alkaloid is found in poisonous mushrooms such as Inocybe and Clitocybe species, and when ingested, stimulates the parasympathetic nervous system, causing increased secretory function, sweating, miosis, respiratory distress, convulsions, and coma?\n\n① cicutoxin\n② hyoscyamine\n③ muscarine\n④ phaseolunatin\n⑤ scopolamine",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 게나 가재와 같은 민물 갑각류의 생식을 통해 감염되고, 병원체가 복강, 흉강, 뇌, 안구, 폐에 기생할 수 있으며, 오한, 미열, 기침, 객혈, 흉통, 발작, 경련을 유발하는 기생충증은?\n\n① 요충증\n② 편충증\n③ 회충증\n④ 간흡충증\n⑤ 폐흡충증",
        "question_text": "Question: Which parasitic disease is transmitted through the consumption of freshwater crustaceans such as crayfish or freshwater crabs, where the pathogen can parasitize the peritoneal cavity, thoracic cavity, brain, eyes, and lungs, causing symptoms such as chills, low-grade fever, cough, hemoptysis, chest pain, seizures, and convulsions?\n\n① Enterobiasis\n② Trichuriasis\n③ Ascariasis\n④ Clonorchiasis\n⑤ Paragonimiasis",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 표백작용과 살균효과를 통해 제빵 효과를 증진하며, 제빵 과정 중에 안식향산으로 변환되는 밀가루 개량제는?\n\n① 에리토브산(erythorbic acid)\n② 소브산칼슘(calcium sorbate)\n③ 아황산나트륨(sodium sulfite)\n④ 사카린나트륨(sodium saccharin)\n⑤ 과산화벤조일(희석)(diluted benzoyl peroxide)",
        "question_text": "Question: Which flour improver enhances baking effects through bleaching action and sterilization, and is converted to benzoic acid during the baking process?\n\n① Erythorbic acid\n② Calcium sorbate\n③ Sodium sulfite\n④ Sodium saccharin\n⑤ Diluted benzoyl peroxide",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n신생아가 선별검사에서 혈액 중 류신(leucine), 이소류신(isoleucine), 발린(valine) 수치가 기준보다 높아 선천성 대사이상으로 진단되었다. 이후 추가검사를 통하여 대사이상의 정도는 가벼운 것으로 밝혀졌다.\n\nQuestion: 이 신생아에서 결핍되어 있을 것으로 추정되는 대사 효소는?\n\n① branched-chain α-keto acid dehydrogenase complex\n② cystathionine β-synthase\n③ fumarylacetoacetate hydrolase\n④ phenylalanine hydroxylase\n⑤ tyrosine aminotransferase",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA newborn was diagnosed with a congenital metabolic disorder in a screening test, showing higher than standard levels of leucine, isoleucine, and valine in the blood. Further tests revealed that the metabolic disorder was mild.\n\nQuestion: Which metabolic enzyme is likely to be deficient in this newborn?\n\n① branched-chain α-keto acid dehydrogenase complex\n② cystathionine β-synthase\n③ fumarylacetoacetate hydrolase\n④ phenylalanine hydroxylase\n⑤ tyrosine aminotransferase",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n신생아가 선별검사에서 혈액 중 류신(leucine), 이소류신(isoleucine), 발린(valine) 수치가 기준보다 높아 선천성 대사이상으로 진단되었다. 이후 추가검사를 통하여 대사이상의 정도는 가벼운 것으로 밝혀졌다.\n\nQuestion: 이 신생아에게 류신, 이소류신, 발린 제한 식이의 공급과 함께 투여를 고려할 수 있는 것은?\n\n① 비오틴(biotin)\n② 티아민(thiamine)\n③ 피리독신(pyridoxine)\n④ 페닐알라닌(phenylalanine)\n⑤ 코엔자임 Q10(coenzyme Q10)",
        "question_text": "A newborn was diagnosed with a congenital metabolic disorder after a screening test showed higher than normal levels of leucine, isoleucine, and valine in the blood. Further tests revealed that the metabolic disorder was mild.\n\nQuestion: In addition to providing a diet restricted in leucine, isoleucine, and valine, which of the following could be considered for administration to this newborn?\n\n① Biotin\n② Thiamine\n③ Pyridoxine\n④ Phenylalanine\n⑤ Coenzyme Q10",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 세포표면 또는 조직바탕질의 단백질 부위를 항원으로 인식하거나 외인성항원에 결합하여 조직손상을 야기하는 항체매개형 과민반응은?\n\n① 혈청병\n② 접촉피부염\n③ 염증성창자병\n④ 유행성 용혈요독증후군\n⑤ 자가면역혈소판감소자색반병",
        "question_text": "Question: Which antibody-mediated hypersensitivity reaction recognizes protein regions on cell surfaces or tissue matrices as antigens, or binds to exogenous antigens, causing tissue damage?\n\n① Serum sickness\n② Contact dermatitis\n③ Inflammatory bowel disease\n④ Epidemic hemolytic uremic syndrome\n⑤ Autoimmune thrombocytopenic purpura",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 콩팥 이식을 받은 환자에서 급성거부반응을 일으키는 기전은?\n\n① 수용자 항원제시세포의 B 세포 직접 활성화\n② 수용자 항원제시세포의 CD4+ T 세포 직접 활성화\n③ 수용자 항원제시세포의 CD8+ T 세포 직접 활성화\n④ 이식편 항원제시세포의 수용자 B 세포 직접 활성화\n⑤ 이식편 항원제시세포의 수용자 대식세포 직접 활성화",
        "question_text": "Question: What is the mechanism of acute rejection in patients who have received a kidney transplant?\n\n① Direct activation of B cells by recipient antigen-presenting cells\n② Direct activation of CD4+ T cells by recipient antigen-presenting cells\n③ Direct activation of CD8+ T cells by recipient antigen-presenting cells\n④ Direct activation of recipient B cells by graft antigen-presenting cells\n⑤ Direct activation of recipient macrophages by graft antigen-presenting cells",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 버킷림프종의 발암 기전에서 t(8;14) 염색체 전위의 직접적인 결과는?\n\n① DNA 메틸화(methylation)의 변화\n② 끝분절효소(telomerase)의 발현 증가\n③ 전암유전자(protooncogene)의 발현 증가\n④ 삼뉴클레오티드(trinucleotide)의 반복확장\n⑤ 종양억제유전자(tumor suppressor gene)의 불활성화",
        "question_text": "Question: What is the direct result of the t(8;14) chromosomal translocation in the carcinogenic mechanism of Burkitt's lymphoma?\n\n① Changes in DNA methylation\n② Increased expression of telomerase\n③ Increased expression of protooncogene\n④ Expansion of trinucleotide repeats\n⑤ Inactivation of tumor suppressor gene",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 일차 감염이 일어나고 수년 후 피부에 띠 모양의 반점상구진, 수포, 농포가 발생되면서 심한 통증을 동반하며, 이후 궤양이나 딱지가 생기는 질환은?\n\n① 풍진\n② 홍역\n③ 대상포진\n④ 성기헤르페스\n⑤ 거대세포바이러스단핵구증",
        "question_text": "Question: Which disease occurs years after the primary infection, presenting with band-shaped maculopapular rashes, vesicles, and pustules on the skin accompanied by severe pain, followed by ulcers or scabs?\n\n① Rubella\n② Measles\n③ Herpes zoster (Shingles)\n④ Genital herpes\n⑤ Cytomegalovirus mononucleosis",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 만성설사와 흡수장애가 있는 중증의 창자병증(enteropathy) 환자에서 발생하는 전신부종의 기전은?\n\n① 림프관 폐쇄\n② 정수압 증가\n③ 혈장삼투압 감소\n④ 염증성시토카인 분비\n⑤ 염류의 체내 보유량 증가",
        "question_text": "Question: What is the mechanism of generalized edema occurring in patients with severe enteropathy accompanied by chronic diarrhea and malabsorption?\n\n① Lymphatic obstruction\n② Increased hydrostatic pressure\n③ Decreased plasma osmotic pressure\n④ Secretion of inflammatory cytokines\n⑤ Increased retention of electrolytes in the body",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 인자 V 돌연변이(factor V Leiden)가 있는 사람이 장시간 비행기를 탄 후 가슴통증 없이 호흡곤란을 호소하며 전신이 축 늘어져 응급실로 이송되었다. 이 증상의 원인은?\n\n① 벽혈전증(mural thrombosis)\n② 심장눌림증(cardiac tamponade)\n③ 허파색전증(pulmonary embolism)\n④ 심근경색증(myocardial infarction)\n⑤ 대동맥류 파열(aortic aneurysm rupture)",
        "question_text": "Question: A person with factor V Leiden mutation complained of difficulty breathing without chest pain and general weakness after a long flight, and was transported to the emergency room. What is the cause of these symptoms?\n\n① Mural thrombosis\n② Cardiac tamponade\n③ Pulmonary embolism\n④ Myocardial infarction\n⑤ Aortic aneurysm rupture",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 야간 발한과 경부 림프절 비대로 내원한 환자의 림프절 조직 검사에서 리드-슈테른베르크 세포(Reed-Sternberg cell)가 관찰되었다. 이 질환은?\n\n① 소포림프종\n② 버킷림프종\n③ 호지킨림프종\n④ 소림프구림프종\n⑤ 역형성큰세포림프종",
        "question_text": "Question: A patient presented with night sweats and enlarged cervical lymph nodes. A lymph node biopsy revealed Reed-Sternberg cells. What is this disease?\n\n① Follicular lymphoma\n② Burkitt's lymphoma\n③ Hodgkin's lymphoma\n④ Small lymphocytic lymphoma\n⑤ Anaplastic large cell lymphoma",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 죽상경화증 환자에서 혈관 죽종의 섬유성 덮개 형성에 기여하는 세포는?\n\n① 림프구\n② 혈소판\n③ 내피세포\n④ 대식세포\n⑤ 평활근세포",
        "question_text": "Question: In patients with atherosclerosis, which cell contributes to the formation of the fibrous cap of the atherosclerotic plaque?\n\n① Lymphocyte\n② Platelet\n③ Endothelial cell\n④ Macrophage\n⑤ Smooth muscle cell",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "original_text": "Question: 본태성고혈압을 앓고 있는 60대 환자가 가슴 앞쪽의 심한 통증으로 응급실에 수송되어 검사받은 결과, 심전도검사와 관상동맥조영술에서는 이상이 나타나지 않았다. 이 환자의 가슴통증 원인은?\n\n① 대동맥박리\n② 심근경색증\n③ 확장심근증\n④ 승모판협착증\n⑤ 류마티스심장병",
        "question_text": "Question: A patient in their 60s with essential hypertension was transported to the emergency room due to severe pain in the anterior chest. After examination, the electrocardiogram and coronary angiography showed no abnormalities. What is the cause of this patient's chest pain?\n\n① Aortic dissection\n② Myocardial infarction\n③ Dilated cardiomyopathy\n④ Mitral stenosis\n⑤ Rheumatic heart disease",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "original_text": "Question: 일차성폐동맥고혈압의 발병기전은?\n\n① 폐혈관의 혈전색전증\n② 임신으로 인한 자간전증\n③ 좌심부전으로 인한 폐울혈\n④ 운동으로 인한 심박출량 증가\n⑤ 폐동맥벽 비후로 인한 혈관직경 감소",
        "question_text": "Question: What is the pathogenesis of primary pulmonary arterial hypertension?\n\n① Thromboembolism in pulmonary vessels\n② Preeclampsia due to pregnancy\n③ Pulmonary congestion due to left heart failure\n④ Increased cardiac output due to exercise\n⑤ Reduction in vascular diameter due to pulmonary arterial wall thickening",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "original_text": "Question: 황달 증세가 있는 환자에서 혈중 포합빌리루빈 농도가 증가하는 경우는?\n\n① 쓸개돌증(cholelithiasis)\n② 용혈성빈혈(hemolytic anemia)\n③ 급성바이러스성간염(acute viral hepatitis)\n④ 유전성공모양적혈구증(hereditary spherocytosis)\n⑤ 크리글러-나자르증후군(Crigler-Najjar syndrome)",
        "question_text": "Question: In patients with jaundice, which condition is associated with an increase in serum conjugated bilirubin concentration?\n\n① Cholelithiasis\n② Hemolytic anemia\n③ Acute viral hepatitis\n④ Hereditary spherocytosis\n⑤ Crigler-Najjar syndrome",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "original_text": "Question: 알코올중독자에서 다음의 증상과 검사소견을 나타내는 질환은?\n\n• 복통, 체중 감소와 설사\n• 복부 내부 장기의 석회화\n\n① 만성간염\n② 만성위염\n③ 만성이자염\n④ 인슐린종\n⑤ 글루카곤종",
        "question_text": "Question: In alcoholics, which disease presents the following symptoms and test findings?\n\n• Abdominal pain, weight loss, and diarrhea\n• Calcification of internal abdominal organs\n\n① Chronic hepatitis\n② Chronic gastritis\n③ Chronic pancreatitis\n④ Insulinoma\n⑤ Glucagonoma",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "original_text": "Question: 사슬알균(Streptococci ) 감염으로 인후통을 앓은 후에 발병한 막증식성토리콩팥염(membranoproliferative glomerulonephritis)의 병리소견은?\n\n① 토리에 면역복합체 침착\n② 아밀로이드 축적과 토리 파괴\n③ 토리사이질 부위에 IgA 다량 침착\n④ 항체의 침착이 없는 토리발돌기 소실\n⑤ 토리바닥막 비후와 토리모세혈관 파괴",
        "question_text": "Question: What is the pathological finding of membranoproliferative glomerulonephritis that developed after suffering from a sore throat due to Streptococci infection?\n\n① Immune complex deposition in the glomeruli\n② Amyloid accumulation and glomerular destruction\n③ Massive IgA deposition in the mesangial area\n④ Loss of podocytes without antibody deposition\n⑤ Thickening of the glomerular basement membrane and destruction of glomerular capillaries",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "original_text": "Question: 지속적인 월경불순과 골반통증이 있는 환자의 복강경검사 결과, 난소 및 나팔관 표면에 다수의 출혈성 병변과 섬유화 부위가 발견되었다. 해당 질환은?\n\n① 자궁내막증\n② 자궁샘근육증\n③ 급성자궁내막염\n④ 자궁내막과다형성\n⑤ 기능장애자궁출혈",
        "question_text": "Question: A patient with persistent menstrual irregularities and pelvic pain underwent a laparoscopic examination, which revealed multiple hemorrhagic lesions and areas of fibrosis on the surface of the ovaries and fallopian tubes. What is the corresponding condition?\n\n① Endometriosis\n② Adenomyosis\n③ Acute endometritis\n④ Endometrial hyperplasia\n⑤ Dysfunctional uterine bleeding",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "original_text": "Question: 쿠싱증후군 환자에서 발생할 수 있는 증상은?\n\n① 저혈압\n② 골다공증\n③ 성욕 증가\n④ 체중 감소\n⑤ 피부각화증뒷면 계속",
        "question_text": "Question: Which of the following symptoms can occur in patients with Cushing's syndrome?\n\n① Hypotension\n② Osteoporosis\n③ Increased libido\n④ Weight loss\n⑤ Hyperkeratosis\n\n(Continued on the back)",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "original_text": "Question: 70대 비만(BMI=34) 환자가 아침 기상 시 관절이 뻣뻣하고 활동을 하면 무릎과 손가락 관절의 통증이 심해지지만 휴식을 하면 가라앉는다고 하였다. 검사 결과 관절 내 염증지표인자는 확인되지 않았으며 손가락관절에서 헤베르덴결절(Heberden’s node)이 관찰되었다. 이 환자에서 관절의 기능저하와 통증을 유발하는 주된 원인은?\n\n① 림프성결절의 비대\n② 뼈성강직(bony ankylosis)\n③ 판누스에 의한 관절연골 파괴\n④ 관절연골의 진행성분해와 연골밑뼈 비후\n⑤ 항시트룰린화펩티드 항체 생성의 활성화",
        "question_text": "Question: A 70-year-old obese patient (BMI=34) reported feeling stiff joints upon waking in the morning, with pain in the knee and finger joints worsening with activity but subsiding with rest. Test results showed no inflammatory markers in the joints, and Heberden's nodes were observed in the finger joints. What is the main cause of joint dysfunction and pain in this patient?\n\n① Lymph node enlargement\n② Bony ankylosis\n③ Destruction of articular cartilage by pannus\n④ Progressive degradation of articular cartilage and subchondral bone thickening\n⑤ Activation of anti-citrullinated peptide antibody production",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "original_text": "Question: 디스트로핀 돌연변이가 있는 환자의 근육퇴행위축 기전은?\n\n① 말초신경의 축삭 손상\n② 근육 내 모세혈관 손상\n③ 신경근이음부의 기능 소실\n④ 독성단백질 축적에 의한 운동신경 손상\n⑤ 근섬유 내부의 세포골격과 세포바깥바탕질의 상호작용 저하",
        "question_text": "Question: What is the mechanism of muscle degeneration and atrophy in patients with dystrophin mutation?\n\n① Axonal damage of peripheral nerves\n② Damage to capillaries within muscles\n③ Loss of function at the neuromuscular junction\n④ Motor neuron damage due to accumulation of toxic proteins\n⑤ Reduced interaction between the cytoskeleton and extracellular matrix within muscle fibers",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "original_text": "Question: 윌리스고리 내 딸기형 동맥류가 있는 환자가 극심한 두통을 호소하다가 의식을 잃었으며, 요추천자검사 결과 뇌척수액에서 혈액이 검출되었다. 이 증상의 원인은?\n\n① 뇌부종(cerebral edema)\n② 경질막밑혈종(subdural hematoma)\n③ 경질막바깥혈종(epidural hematoma)\n④ 범대뇌허혈(global cerebral ischemia)\n⑤ 거미막밑출혈(subarachnoid hemorrhage)",
        "question_text": "Question: A patient with a berry aneurysm in the Circle of Willis complained of severe headache and then lost consciousness. A lumbar puncture test revealed blood in the cerebrospinal fluid. What is the cause of these symptoms?\n\n① Cerebral edema\n② Subdural hematoma\n③ Epidural hematoma\n④ Global cerebral ischemia\n⑤ Subarachnoid hemorrhage",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 토혈 증상으로 응급실에 이송된 62세 환자의 증상 및 검사결과이다.\n• 황달, 지라비대, 복수\n• 손바닥의 홍반, 광범위한 거미상혈관종\n• 혈청 내 빌리루빈 수치 증가\n\nQuestion: 이 환자에서 토혈의 원인 질환은?\n\n① 간경화\n② 간뇌병증\n③ 급성위염\n④ 역류성식도염\n⑤ 급성알코올성간염",
        "question_text": "The following are the symptoms and test results of a 62-year-old patient who was transported to the emergency room with hematemesis (vomiting blood):\n• Jaundice, splenomegaly, ascites\n• Palmar erythema, widespread spider angiomas\n• Increased serum bilirubin levels\n\nQuestion: What is the underlying cause of hematemesis in this patient?\n\n① Liver cirrhosis\n② Hepatic encephalopathy\n③ Acute gastritis\n④ Reflux esophagitis\n⑤ Acute alcoholic hepatitis",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 토혈 증상으로 응급실에 이송된 62세 환자의 증상 및 검사결과이다.\n• 황달, 지라비대, 복수\n• 손바닥의 홍반, 광범위한 거미상혈관종\n• 혈청 내 빌리루빈 수치 증가\n\nQuestion: 이 환자에서 복수의 원인은?\n\n① 고알부민혈증\n② 간문맥압의 증가\n③ 간림프액 유입 감소\n④ 혈관 내 삼투압 상승\n⑤ 혈관 내 혈액량 저하",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThe following are the symptoms and test results of a 62-year-old patient who was transported to the emergency room with hematemesis symptoms.\n• Jaundice, splenomegaly, ascites\n• Palmar erythema, widespread spider angiomas\n• Increased serum bilirubin levels\n\nQuestion: What is the cause of ascites in this patient?\n\n① Hyperalbuminemia\n② Increased portal pressure\n③ Decreased hepatic lymph inflow\n④ Increased intravascular osmotic pressure\n⑤ Decreased intravascular blood volume",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 나프록센(녹는점 155℃)과 인도메타신(녹는점 159℃)이 40 : 60 비율로 구성된 혼합물의 녹는점은 128℃이다. 이와 관련된 현상은?\n\n① 미셀(micelle) 형성\n② 용매화물(solvate) 형성\n③ 액정(liquid crystal) 형성\n④ 공유 결합(covalent bond) 형성\n⑤ 공융혼합물(eutectic mixture) 형성",
        "question_text": "Question: The melting point of a mixture composed of naproxen (melting point 155℃) and indomethacin (melting point 159℃) in a ratio of 40:60 is 128℃. What phenomenon is related to this?\n\n① Formation of micelle\n② Formation of solvate\n③ Formation of liquid crystal\n④ Formation of covalent bond\n⑤ Formation of eutectic mixture",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 1 기압에서 부분섞임성을 갖는 물과 페놀의 혼합물 상평형도를 얻었다. 1개의 액체상을 특정할 수 있는 세기변수(intensive variable)는?\n\n① 압력\n② 온도\n③ 페놀 농도\n④ 온도, 페놀 농도\n⑤ 압력, 페놀 농도",
        "question_text": "Question: A phase equilibrium diagram was obtained for a mixture of water and phenol with partial miscibility at 1 atmosphere. What is the intensive variable that can specify a single liquid phase?\n\n① Pressure\n② Temperature\n③ Phenol concentration\n④ Temperature, Phenol concentration\n⑤ Pressure, Phenol concentration",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 정제의 함량균일성에 영향을 주는 원료의약품의 물리화학적 성질은?\n\n① 선광도\n② 생분해성\n③ 유전상수\n④ 이온화상수\n⑤ 입자크기 분포",
        "question_text": "Question: What is the physicochemical property of the active pharmaceutical ingredient that affects the content uniformity of tablets?\n\n① Optical rotation\n② Biodegradability\n③ Dielectric constant\n④ Ionization constant\n⑤ Particle size distribution",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 25℃에서 농도가 0.236 M로 동일한 페노바르비탈의 수용액과 30% 에탄올 수용액의 pHp는 각각 9.1과 8.8이다. pHp가 에탄올에 의해 감소한 원인은? (단, pHp는 용액으로부터 약물이 침전되기 시작하는 pH이다.)\n\n① 용매 극성 증가\n② 약물 해리도 증가\n③ 용매 유전상수 증가\n④ 용액 이온강도 증가\n⑤ 비이온형 약물의 용해도 증가",
        "question_text": "Question: At 25℃, the pHp of a phenobarbital aqueous solution and a 30% ethanol aqueous solution, both with a concentration of 0.236 M, are 9.1 and 8.8 respectively. What is the reason for the decrease in pHp due to ethanol? (Note: pHp is the pH at which the drug begins to precipitate from the solution.)\n\n① Increase in solvent polarity\n② Increase in drug dissociation\n③ Increase in solvent dielectric constant\n④ Increase in solution ionic strength\n⑤ Increase in solubility of non-ionized drug",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 카르복시메틸셀룰로오스나트륨 겔처럼 레오그램에서 항복값이 나타나지 않으며 전단응력이 증가함에 따라 전단속도는 증가하고, 겉보기 점도는 감소하는 흐름은?\n\n① 박차흐름(spurs)\n② 소성흐름(plastic flow)\n③ 뉴턴계흐름(Newtonian flow)\n④ 딜레이턴트흐름(dilatant flow)\n⑤ 유사소성흐름(pseudoplastic flow)",
        "question_text": "Question: Which flow does not show a yield value in the rheogram like carboxymethylcellulose sodium gel, and as shear stress increases, shear rate increases and apparent viscosity decreases?\n\n① Spurs flow\n② Plastic flow\n③ Newtonian flow\n④ Dilatant flow\n⑤ Pseudoplastic flow",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 필로카르핀염산염 점안액에서 약물의 농도가 증가함에 따라 감소하는 물리화학적 성질은?\n\n① 점도\n② 어는점\n③ 끓는점\n④ 삼투압\n⑤ 용해도",
        "question_text": "Question: Which physicochemical property decreases as the concentration of the drug increases in pilocarpine hydrochloride eye drops?\n\n① Viscosity\n② Freezing point\n③ Boiling point\n④ Osmotic pressure\n⑤ Solubility",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 어느 일정 온도에서 클로로포름과 에탄올의 몰비율이 0.99 : 0.01로 혼합된 실제용액에서 에탄올의 부분 증기압을 계산하는 데 이용되는 것은?\n\n① Henry의 법칙\n② Gibbs의 상률\n③ Raoult의 법칙\n④ Fick의 확산법칙 \n⑤ Brodie의 pH분배가설",
        "question_text": "Question: Which of the following is used to calculate the partial vapor pressure of ethanol in a real solution where chloroform and ethanol are mixed at a molar ratio of 0.99 : 0.01 at a certain temperature?\n\n① Henry's law\n② Gibbs' phase rule\n③ Raoult's law\n④ Fick's law of diffusion\n⑤ Brodie's pH partition hypothesis",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 일정 온도에서 단백질 A가 녹아 있는 수용액의 삼투압을 측정하여 알 수 있는 이 물질의 물리화학적 특성은?\n\n① 비열\n② 분자량\n③ 편광성\n④ 결정형\n⑤ 유전상수",
        "question_text": "Question: At a constant temperature, what physicochemical property of protein A can be determined by measuring the osmotic pressure of its aqueous solution?\n\n① Specific heat\n② Molecular weight\n③ Optical rotation\n④ Crystal form\n⑤ Dielectric constant",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 1% 설파티아졸나트륨 수용액 100 mL의 어는점내림값이 0.13℃일 때, 이 수용액을 등장액으로 만들기 위해 넣어야 하는 NaCl의 양(g)은? (단, 0.9% NaCl등장액의 어는점내림값은 0.52℃이다.)\n\n① 9/40\n② 1/4\n③ 1/2\n④ 27/40\n⑤ 9/10",
        "question_text": "Question: When the freezing point depression of 100 mL of 1% sulfathiazole sodium solution is 0.13℃, what is the amount of NaCl (in grams) that should be added to make this solution isotonic? (Note: The freezing point depression of 0.9% NaCl isotonic solution is 0.52℃.)\n\n① 9/40\n② 1/4\n③ 1/2\n④ 27/40\n⑤ 9/10",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 25℃에서 벤조산 0.1 g을 함유하는 수용액 10 mL로부터 땅콩기름 4 mL를 사용하여 벤조산을 1회 추출할 때, 얻을 수 있는 벤조산의 양(g)은? (단, 온도는 일정하고, 물과 땅콩기름에서 벤조산의 분배계수(K=Co/Cw)는 10이고, 벤조산은 각각의 \n상에서 회합과 해리가 일어나지 않는다.)\n\n① 0.01\n② 0.02\n③ 0.04\n④ 0.08\n⑤ 0.09",
        "question_text": "Question: When extracting benzoic acid once using 4 mL of peanut oil from 10 mL of an aqueous solution containing 0.1 g of benzoic acid at 25℃, what is the amount (g) of benzoic acid that can be obtained? (Assume that the temperature remains constant, the partition coefficient (K=Co/Cw) of benzoic acid between water and peanut oil is 10, and benzoic acid does not associate or dissociate in either phase.)\n\n① 0.01\n② 0.02\n③ 0.04\n④ 0.08\n⑤ 0.09",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 다음 표는 막을 통한 확산시험에서 시간에 따른 투과된 약물의 양을 측정한 결과이다. 공여체의 농도를 100 mg/mL로 일정하게 유지하였을 때, 투과계수(cm/h)는? (단, 온도는 일정하고, 사용한 막의 면적은 2 cm2이며 막의 두께는 0.1 cm이다. 수용체 쪽 용액은 싱크상태가 유지된다.)\n\n| 시간(h) | 2 | 4 | 6 | 8 | 10 | 12 |\n| 투과된 양 (mg) | 1 | 3 | 6 | 10 | 14 | 18 |\n\n① 1/100\n② 1/200\n③ 1/400\n④ 3/400\n⑤ 1/1000",
        "question_text": "Question: The following table shows the results of measuring the amount of drug permeated over time in a membrane diffusion test. When the donor concentration is maintained constant at 100 mg/mL, what is the permeability coefficient (cm/h)? (Note: The temperature is constant, the area of the membrane used is 2 cm2, and the thickness of the membrane is 0.1 cm. The receptor side solution maintains sink conditions.)\n\n| Time (h) | 2 | 4 | 6 | 8 | 10 | 12 |\n| Amount permeated (mg) | 1 | 3 | 6 | 10 | 14 | 18 |\n\n① 1/100\n② 1/200\n③ 1/400\n④ 3/400\n⑤ 1/1000",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 일정 온도에서 단순 확산셀(simple diffusion cell)을 이용한 약물 수송 측정 실험을 할 때 약물의 확산을 증가시킬 수 있는 것은?\n\n① 공극률의 감소\n② 막 두께의 감소\n③ 분배계수의 감소\n④ 막세공 구경의 감소\n⑤ 약물의 농도구배(concentration gradient) 감소",
        "question_text": "Question: When conducting a drug transport measurement experiment using a simple diffusion cell at a constant temperature, which of the following can increase drug diffusion?\n\n① Decrease in porosity\n② Decrease in membrane thickness\n③ Decrease in partition coefficient\n④ Decrease in membrane pore size\n⑤ Decrease in drug concentration gradient",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 다음은 어떤 약물을 실온에서 보관할 때 시간에 따른 약물의 농도를 나타낸 표이다. 이 약물의 실온에서의 shelf life(t90, 개월)는?\n\n| 시간(월) | 0 | 0.5 | 1 | 2 | 3 |\n|---|---|---|---|---|---|\n| 농도(mg/mL) | 100 | 99 | 98 | 96 | 94 |\n\n① 5\n② 10\n③ 20\n④ 50\n⑤ 100",
        "question_text": "Question: The following table shows the concentration of a drug over time when stored at room temperature. What is the shelf life (t90, months) of this drug at room temperature?\n\n| Time (months) | 0 | 0.5 | 1 | 2 | 3 |\n|---|---|---|---|---|---|\n| Concentration (mg/mL) | 100 | 99 | 98 | 96 | 94 |\n\n① 5\n② 10\n③ 20\n④ 50\n⑤ 100",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 25℃에서 어떤 주사제의 분해반응 비반응속도상수 k는 2.3×10^-3 h^-1이다. 이 주사제의 초기농도가 5 mg/mL일 때, 농도가 0.5 mg/mL로 되는 데 걸리는 시간(h)은? (단, 온도는 일정하고, lnA=2.3 logA이다.)\n\n① 1.0×10^2\n② 2.0×10^2\n③ 6.9×10^2\n④ 1.0×10^3\n⑤ 1.0×10^4",
        "question_text": "Question: At 25℃, the first-order rate constant k for the decomposition reaction of an injectable drug is 2.3×10^-3 h^-1. If the initial concentration of this injectable drug is 5 mg/mL, how long (in hours) will it take for the concentration to decrease to 0.5 mg/mL? (Assume the temperature remains constant, and lnA=2.3 logA.)\n\n① 1.0×10^2\n② 2.0×10^2\n③ 6.9×10^2\n④ 1.0×10^3\n⑤ 1.0×10^4",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 친수-친유 평형값(HLB)이 가장 큰 계면활성제는?\n\n① Span 20\n② Span 80\n③ Tween 80\n④ sorbitan tristearate\n⑤ sodium lauryl sulfate",
        "question_text": "Question: Which surfactant has the highest Hydrophilic-Lipophilic Balance (HLB) value?\n\n① Span 20\n② Span 80\n③ Tween 80\n④ sorbitan tristearate\n⑤ sodium lauryl sulfate",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 콜로이드 분산계에서 콜로이드의 입자에 관한 설명으로 옳은 것은?\n\n① 확산되지 못한다.\n② 광산란을 나타내지 못한다.\n③ 반투막을 통과하지 못한다. \n④ 전자현미경으로 볼 수 없다.\n⑤ 일반 여과지를 통과하지 못한다.",
        "question_text": "Question: Which of the following statements about colloidal particles in a colloidal dispersion system is correct?\n\n① They cannot diffuse.\n② They do not exhibit light scattering.\n③ They cannot pass through a semipermeable membrane.\n④ They cannot be seen with an electron microscope.\n⑤ They cannot pass through ordinary filter paper.",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 25℃에서 단백질 의약품 A의 물리화학적 성질이다. 다량체는 단량체에 금속이온을 가하여 얻는다.\n\n| | 단량체 | 다량체 |\n|---|---|---|\n| 분자량(kDa) | 5 | 30 |\n| 등전점(isoelectric point) | 8 | |\n| 수용액상 확산계수(cm2/sec) | 2 | 1 |\n| 2차 구조 조성 | α-helix 70% | α-helix 65% β-sheet 10% |\n| 모양(shape) | 구형 | 구형 |\n| Melting temperature(℃) | 60 | |\n\nQuestion: 25℃에서 단백질 의약품 A의 단량체에 대한 설명으로 옳은 것은?\n\n① 단량체는 4차 구조를 가진다.\n② pH 5에서 단백질은 양전하를 띤다.\n③ 80℃와 25℃에서의 3차 구조는 같다.\n④ 2차 구조는 크기배제 액체크로마토그래프법으로 확인한다.\n⑤ 단량체 수용액에 고농도의 sodium dodecyl sulfate를 가해도",
        "question_text": "The following are the physicochemical properties of protein drug A at 25℃. The multimer is obtained by adding metal ions to the monomer.\n\n| | Monomer | Multimer |\n|---|---|---|\n| Molecular weight (kDa) | 5 | 30 |\n| Isoelectric point | 8 | |\n| Diffusion coefficient in aqueous solution (cm2/sec) | 2 | 1 |\n| Secondary structure composition | α-helix 70% | α-helix 65% β-sheet 10% |\n| Shape | Spherical | Spherical |\n| Melting temperature (℃) | 60 | |\n\nQuestion: Which of the following statements about the monomer of protein drug A at 25℃ is correct?\n\n① The monomer has a quaternary structure.\n② The protein carries a positive charge at pH 5.\n③ The tertiary structure is the same at 80℃ and 25℃.\n④ The secondary structure is confirmed by size exclusion liquid chromatography.\n⑤ Even if a high concentration of sodium dodecyl sulfate is added to the monomer solution,",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 25℃에서 단백질 의약품 A의 물리화학적 성질이다. 다량체는 단량체에 금속이온을 가하여 얻는다.\n\n| | 단량체 | 다량체 |\n|---|---|---|\n| 분자량(kDa) | 5 | 30 |\n| 등전점(isoelectric point) | 8 | |\n| 수용액상 확산계수(cm2/sec) | 2 | 1 |\n| 2차 구조 조성 | α-helix 70% | α-helix 65% β-sheet 10% |\n| 모양(shape) | 구형 | 구형 |\n| Melting temperature(℃) | 60 | |\n\nQuestion: 단량체와 다량체가 각각 Stokes-Einstein 식을 따를 때, 다량체 반지름(Stokes radius)은 단량체 반지름(Stokes radius)의 몇 배인가? (단, 온도와 점도는 일정하다.)\n\n① 1/6\n② 1/2\n③ 1\n④ 2\n⑤ 6",
        "question_text": "The following are the physicochemical properties of protein drug A at 25℃. The multimer is obtained by adding metal ions to the monomer.\n\n| | Monomer | Multimer |\n|---|---|---|\n| Molecular weight (kDa) | 5 | 30 |\n| Isoelectric point | 8 | |\n| Diffusion coefficient in aqueous solution (cm2/sec) | 2 | 1 |\n| Secondary structure composition | α-helix 70% | α-helix 65% β-sheet 10% |\n| Shape | Spherical | Spherical |\n| Melting temperature (℃) | 60 | |\n\nQuestion: When both the monomer and multimer follow the Stokes-Einstein equation, how many times larger is the radius (Stokes radius) of the multimer compared to the radius (Stokes radius) of the monomer? (Assume temperature and viscosity are constant.)\n\n① 1/6\n② 1/2\n③ 1\n④ 2\n⑤ 6",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 생체 내에서 CYP 효소에 의한 산화 반응과 베타-제거 반응(β-elimination)을 거쳐 타겟과의 공유 결합으로 약효를 나타내는 약물은?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which drug exhibits its pharmacological effect through covalent bonding with its target after undergoing oxidation reactions by CYP enzymes and β-elimination in the body?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 벤젠 환의 파라(para) 위치에 fluoro기가 치환되어 높은 대사안정성을 가지게 된 이상지질혈증 치료약물은?\n\n① 에제티미브(ezetimibe)\n② 실로스타졸(cilostazol)\n③ 심바스타틴(simvastatin)\n④ 레파글리니드(repaglinide)\n⑤ 베자피브레이트(bezafibrate)",
        "question_text": "Question: Which of the following drugs used for the treatment of dyslipidemia has high metabolic stability due to the substitution of a fluoro group at the para position of the benzene ring?\n\n① Ezetimibe\n② Cilostazol\n③ Simvastatin\n④ Repaglinide\n⑤ Bezafibrate",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 도파민 D2 수용체 차단 약물로서 4-arylpiperidine 구조를 갖는 것은?\n\n① 로라제팜(lorazepam)\n② 올란자핀(olanzapine)\n③ 리스페리돈(risperidone)\n④ 아미트리프틸린(amitriptyline)\n⑤ 클로르프로마진(chlorpromazine)",
        "question_text": "Question: Which of the following is a dopamine D2 receptor blocking drug with a 4-arylpiperidine structure?\n\n① Lorazepam\n② Olanzapine\n③ Risperidone\n④ Amitriptyline\n⑤ Chlorpromazine",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 에날라프릴라트(enalaprilat)는 캅토프릴(captopril)보다 ACE와의 추가 결합에 의해 더 강한 활성을 나타낸다. 추가 결합부위에서 작용한 분자 간 결합유형은?\n\n<Data (confidential)>\n\n① 공유 결합\n② 수소 결합\n③ 소수성 결합\n④ 이온-쌍극자 결합\n⑤ 쌍극자-쌍극자 결합",
        "question_text": "Question: Enalaprilat shows stronger activity than captopril due to additional binding with ACE. What type of intermolecular bonding occurs at the additional binding site?\n\n<Data (confidential)>\n\n① Covalent bond\n② Hydrogen bond\n③ Hydrophobic bond\n④ Ion-dipole bond\n⑤ Dipole-dipole bond",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 시메티딘(cimetidine)의 합성 과정 중 중간체 B를 합성하기 위해서 필요한 시약 A는?\n\n<Data (confidential)>\n\n① NH3\n② NH2OH\n③ NH2NH2\n④ NH2CHO\n⑤ NH2CONH2",
        "question_text": "Question: What is the reagent A needed to synthesize the intermediate B during the synthesis process of cimetidine?\n\n<Data (confidential)>\n\n① NH3\n② NH2OH\n③ NH2NH2\n④ NH2CHO\n⑤ NH2CONH2",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 다음 반응에서 얻어지는 주생성물 A의 헤테로고리 일반명은?\n\n<Data (confidential)>\n\n① oxazinone\n② piperazine\n③ pyrimidine\n④ quinazoline\n⑤ quinolone",
        "question_text": "Question: What is the general name of the heterocyclic main product A obtained from the following reaction?\n\n<Data (confidential)>\n\n① oxazinone\n② piperazine\n③ pyrimidine\n④ quinazoline\n⑤ quinolone",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 클로람페니콜(chloramphenicol) 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the intermediate A obtained in the following reaction during the synthesis process of chloramphenicol?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 졸피뎀(zolpidem) 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following is the intermediate A obtained during the synthesis process of zolpidem?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 옥시부티닌(oxybutynin) 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the intermediate A obtained in the following reaction during the synthesis process of oxybutynin?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 다음 반응에서 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① 밀리논(milrinone)\n② 딜티아젬(diltiazem)\n③ 니페디핀(nifedipine)\n④ 독사프람(doxapram)\n⑤ 베라파밀(verapamil)",
        "question_text": "Question: What is the drug A obtained from the following reaction?\n\n<Data (confidential)>\n\n① Milrinone\n② Diltiazem\n③ Nifedipine\n④ Doxapram\n⑤ Verapamil",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 다음 두 출발물질의 반응을 통해 얻어진 중간체 A를 거쳐 합성되는 약물 B는?\n\n<Data (confidential)>\n\n① 라니티딘(ranitidine)\n② 타목시펜(tamoxifen)\n③ 디클로페낙(diclofenac)\n④ 온단세트론(ondansetron)\n⑤ 글리메피리드(glimepiride)",
        "question_text": "Question: Which drug B is synthesized through intermediate A obtained by the reaction of the following two starting materials?\n\n<Data (confidential)>\n\n① Ranitidine\n② Tamoxifen\n③ Diclofenac\n④ Ondansetron\n⑤ Glimepiride",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 다음 반응으로 얻어지는 약물 A의 용도는?\n\n<Data (confidential)>\n\n① 구충제\n② 항균제\n③ 항암제\n④ 항진균제\n⑤ 항바이러스제",
        "question_text": "Question: What is the use of drug A obtained from the following reaction?\n\n<Data (confidential)>\n\n① Anthelmintic\n② Antibacterial\n③ Anticancer\n④ Antifungal\n⑤ Antiviral",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 오셀타미비르(oseltamivir) 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which intermediate A is obtained from the following reaction during the synthesis process of oseltamivir?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 다음 약물 A에 대한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 내산성균 질환 치료제이다.\n② Ca2+ 채널에 결합하여 작용한다.\n③ aminobenzoic acid 계열에 속한다.\n④ 3차 아민은 이온화된 형태로 수용체와 작용한다.\n⑤ 벤젠 환에 2,6-dimethyl기의 도입으로 amide의 가수분해가 촉진된다.",
        "question_text": "Question: Which of the following statements about drug A is correct?\n\n<Data (confidential)>\n\n① It is a treatment for acid-resistant bacterial diseases.\n② It acts by binding to Ca2+ channels.\n③ It belongs to the aminobenzoic acid family.\n④ The tertiary amine interacts with receptors in its ionized form.\n⑤ The introduction of 2,6-dimethyl groups to the benzene ring promotes hydrolysis of the amide.",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: Phenylethanolamine계 교감신경 효능제에서 벤젠 환의 치환기(R1)에 따른 아드레날린 수용체 선택성에 대한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 3번 위치에 OH기 도입 시 β2-수용체 선택성 증가\n② 4번 위치에 OH기 도입 시 α-수용체 선택성 증가\n③ 3번과 5번 위치에 각각 한 개의 OH기 도입 시 β2-수용체 선택성 증가\n④ 2번과 5번 위치에 각각 한 개의 OCH3기 도입 시 β2-수용체 선택성 증가\n⑤ 3번 위치에 CH2OH와 4번 위치에 OH 도입 시 α-수용체 선택성 증가",
        "question_text": "Question: Which of the following statements is correct regarding the adrenergic receptor selectivity based on the substituents (R1) on the benzene ring in phenylethanolamine sympathomimetics?\n\n<Data (confidential)>\n\n① Introduction of an OH group at position 3 increases β2-receptor selectivity\n② Introduction of an OH group at position 4 increases α-receptor selectivity\n③ Introduction of one OH group each at positions 3 and 5 increases β2-receptor selectivity\n④ Introduction of one OCH3 group each at positions 2 and 5 increases β2-receptor selectivity\n⑤ Introduction of CH2OH at position 3 and OH at position 4 increases α-receptor selectivity",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 당골격에 1,3-oxathiolane을 갖는 cytidine계 항바이러스 약물은?\n\n① 라미부딘(lamivudine)\n② 아데포비어(adefovir)\n③ 아시클로버(acyclovir)\n④ 젬시타빈(gemcitabine)\n⑤ 지도부딘(zidovudine)",
        "question_text": "Question: Which antiviral drug from the cytidine family has a 1,3-oxathiolane in its sugar skeleton?\n\n① Lamivudine\n② Adefovir\n③ Acyclovir\n④ Gemcitabine\n⑤ Zidovudine",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n메토클로프라미드(metoclopramide)로부터 구조 변형을 통해 설피리드(sulpiride)가 개발되었다.\n<Data (confidential)>\n\nQuestion: 구조 B로 옳은 것은?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Sulpiride was developed through structural modification from metoclopramide.\n<Data (confidential)>\n\nQuestion: Which of the following is the correct structure B?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n메토클로프라미드(metoclopramide)로부터 구조 변형을 통해 설피리드(sulpiride)가 개발되었다.\n<Data (confidential)>\n\nQuestion: 메토클로프라미드의 A로부터 설피리드의 B로의 구조 변형에 해당하는 것은?\n\n① 구조의 단순화\n② 구조의 강직화\n③ 사슬 길이의 연장\n④ 고리 구조의 축소\n⑤ 고리 구조의 확장",
        "question_text": "Sulpiride was developed through structural modification from metoclopramide.\n<Data (confidential)>\n\nQuestion: Which of the following best describes the structural modification from A of metoclopramide to B of sulpiride?\n\n① Simplification of structure\n② Rigidification of structure\n③ Extension of chain length\n④ Reduction of ring structure\n⑤ Expansion of ring structure",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 25℃에서 탄산칼슘(CaCO3, 분자량 100.0) 70 mg을 전부 녹이는 데에 필요한 물의 최소량(L)은? [단, 탄산칼슘의 용해도곱 상수(Ksp)=4.9×10^-9]\n\n① 0.001\n② 0.01\n③ 0.1\n④ 1\n⑤ 10",
        "question_text": "Question: What is the minimum volume of water (L) needed to completely dissolve 70 mg of calcium carbonate (CaCO3, molecular weight 100.0) at 25℃? [Given: The solubility product constant (Ksp) of calcium carbonate = 4.9×10^-9]\n\n① 0.001\n② 0.01\n③ 0.1\n④ 1\n⑤ 10",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 0.10 mol/L FeCl2 용액 100.0 mL를 0.10 mol/L Ce4+ 표준액으로 적정할 때 당량점에서의 전위(V)는? (단, E°Ce=1.61 V, E°Fe=0.77 V)\n\n① 0.77\n② 0.84\n③ 1.19\n④ 1.61\n⑤ 2.38",
        "question_text": "Question: What is the potential (V) at the equivalence point when titrating 100.0 mL of 0.10 mol/L FeCl2 solution with 0.10 mol/L Ce4+ standard solution? (Given: E°Ce=1.61 V, E°Fe=0.77 V)\n\n① 0.77\n② 0.84\n③ 1.19\n④ 1.61\n⑤ 2.38",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: 생리식염수 중의 염소이온을 침전으로 생성시켜 중량분석법으로 정량하고자 한다. 생성된 침전의 분리방법과 침전형을 칭량형으로 하는 방법을 바르게 연결한 것은?\n\n① 한외여과 – 강열\n② 여과지 여과 – 건조\n③ 고속원심분리 – 강열\n④ Gooch 도가니 여과 – 건조\n⑤ 유리여과기(glass filter) 여과 – 강열",
        "question_text": "Question: We want to quantify chloride ions in physiological saline by creating a precipitate and using gravimetric analysis. Which of the following correctly matches the precipitation separation method with the method of converting the precipitate to a weighing form?\n\n① Ultrafiltration – Ignition\n② Filter paper filtration – Drying\n③ High-speed centrifugation – Ignition\n④ Gooch crucible filtration – Drying\n⑤ Glass filter filtration – Ignition",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 페놀프탈레인을 지시약으로 하여 NaOH로 직접 적정하여 정량하는 약물은?\n\n① 페놀\n② 포도당\n③ 살리실산\n④ 이소니아지드\n⑤ 아세트아미노펜",
        "question_text": "Question: Which drug is directly titrated with NaOH using phenolphthalein as an indicator for quantitative analysis?\n\n① Phenol\n② Glucose\n③ Salicylic acid\n④ Isoniazid\n⑤ Acetaminophen",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 수분측정용 메탄올 25 mL를 플라스크에 넣은 후 칼피셔(KF) 시액을 종말점이 될 때까지 넣었다. 여기에 아스피린 원료 0.20 g을 넣어 녹인 후, 칼피셔(KF) 시액[f (mg/mL)=2.0]으로 다시 종말점이 될 때까지 적정하여 4.0 mL를 소비하였다. 아스피린 원료 중 수분 함량(%)은?\n\n① 2.0\n② 4.0\n③ 6.0\n④ 8.0\n⑤ 10.0",
        "question_text": "Question: 25 mL of methanol for moisture determination was placed in a flask, and Karl Fischer (KF) reagent was added until the endpoint was reached. Then, 0.20 g of aspirin raw material was added and dissolved, and titration was performed again with Karl Fischer (KF) reagent [f (mg/mL) = 2.0] until the endpoint was reached, consuming 4.0 mL. What is the moisture content (%) in the aspirin raw material?\n\n① 2.0\n② 4.0\n③ 6.0\n④ 8.0\n⑤ 10.0",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 1 cm 셀을 사용하여 237 nm에서 암로디핀베실산염 용액의 흡광도를 자외가시부흡광도측정법으로 측정하였더니 0.90이었다. 용액의 몰농도(mol/L)는? [단, 암로디핀베실산염의 몰흡광계수(237 nm): 900 L mol-1 cm^-1]\n\n① 1.0×10-4\n② 2.0×10-4\n③ 5.0×10-4\n④ 1.0×10-3\n⑤ 2.0×10-3",
        "question_text": "Question: Using a 1 cm cell, the absorbance of an amlodipine besylate solution was measured at 237 nm using UV-visible spectrophotometry and found to be 0.90. What is the molar concentration (mol/L) of the solution? [Given: Molar absorption coefficient of amlodipine besylate (237 nm): 900 L mol-1 cm^-1]\n\n① 1.0×10-4\n② 2.0×10-4\n③ 5.0×10-4\n④ 1.0×10-3\n⑤ 2.0×10-3",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 자외가시부흡광도측정법으로 흡수스펙트럼을 측정할 때 동일 용매 조건에서 최대흡수파장(λmax)이 가장 짧을 것으로 예측되는 약물은?\n\n① 돔페리돈  <Data (confidential)>\n② 레보티록신  <Data (confidential)>\n③ 아시클로버  <Data (confidential)>\n④ 클린다마이신  <Data (confidential)>\n⑤ 트리암시놀론  <Data (confidential)>",
        "question_text": "Question: When measuring the absorption spectrum using UV-visible spectrophotometry, which drug is expected to have the shortest maximum absorption wavelength (λmax) under the same solvent conditions?\n\n① Domperidone\n② Levothyroxine\n③ Acyclovir\n④ Clindamycin\n⑤ Triamcinolone",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 유도결합플라즈마발광광도법(ICP)을 이용하여 정량하는 약물은?\n\n① D-소르비톨 액\n② 포도당 주사액\n③ 셀레늄 가루\n④ 레티놀팔미테이트유\n⑤ 클로르페니라민말레산염 정",
        "question_text": "Question: Which of the following drugs is quantified using Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES)?\n\n① D-Sorbitol Solution\n② Glucose Injection\n③ Selenium Powder\n④ Retinol Palmitate Oil\n⑤ Chlorpheniramine Maleate Tablets",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 다음은 아세트아미노펜의 예측 수소핵자기공명스펙트럼(1H-NMR)이다. 피크 A, B, C의 면적비는?\n\n<Data (confidential)>\n\nA : B : C\n① 1 : 1 : 2\n② 1 : 1 : 3\n③ 1 : 1 : 4\n④ 2 : 2 : 1\n⑤ 2 : 2 : 3",
        "question_text": "Question: The following is the predicted proton nuclear magnetic resonance spectrum (1H-NMR) of acetaminophen. What is the area ratio of peaks A, B, and C?\n\n<Data (confidential)>\n\nA : B : C\n① 1 : 1 : 2\n② 1 : 1 : 3\n③ 1 : 1 : 4\n④ 2 : 2 : 1\n⑤ 2 : 2 : 3",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 전자충돌이온화-질량분석법(EI-MS)을 이용하여 얻은 암브록솔의 질량스펙트럼에서 M, M+2, M+4 피크의 대략적인 강도비는? (단, M: 분자이온의 m /z)\n\n <자료(비공개)\n\nM : M+2 : M+4\n① 1 : 1 : 1\n② 1 : 1 : 2\n③ 1 : 2 : 1\n④ 1 : 2 : 2\n⑤ 2 : 2 : 3",
        "question_text": "Question: What is the approximate intensity ratio of M, M+2, and M+4 peaks in the mass spectrum of ambroxol obtained using electron impact ionization-mass spectrometry (EI-MS)? (Note: M is the m/z of the molecular ion)\n\n<Data (not disclosed)>\n\nM : M+2 : M+4\n① 1 : 1 : 1\n② 1 : 1 : 2\n③ 1 : 2 : 1\n④ 1 : 2 : 2\n⑤ 2 : 2 : 3",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 크로마토그래피 고정상 소량을 충전한 소형 카트리지를 사용하여 소변에 들어있는 덱사메타손 대사체를 효율적으로 추출하고 간섭물질을 제거할 수 있는 전처리방법은?\n\n① 투석\n② 액상추출\n③ 한외여과\n④ 고체상추출\n⑤ 마이크로파추출",
        "question_text": "Question: Which pre-treatment method can efficiently extract dexamethasone metabolites from urine and remove interfering substances using a small cartridge filled with a small amount of chromatography stationary phase?\n\n① Dialysis\n② Liquid extraction\n③ Ultrafiltration\n④ Solid-phase extraction\n⑤ Microwave extraction",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 수입 구기자 중에 미량으로 존재하는 유기염소계 농약을 기체크로마토그래피를 이용하여 선택적으로 정량하기에 적합한 고감도 검출기는?\n\n① 전기화학검출기(electrochemical detector)\n② 전자포획검출기(electron capture detector)\n③ 불꽃이온화검출기(flame ionization detector)\n④ 질소인검출기(nitrogen phosphorous detector)\n⑤ 열전도도검출기(thermal conductivity detector)",
        "question_text": "Question: Which high-sensitivity detector is most suitable for selectively quantifying trace amounts of organochlorine pesticides present in imported goji berries using gas chromatography?\n\n① Electrochemical detector\n② Electron capture detector\n③ Flame ionization detector\n④ Nitrogen phosphorus detector\n⑤ Thermal conductivity detector",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 고성능액체크로마토그래피를 이용하여 다음 조건으로 로바스타틴 및 유연물질의 함량을 분석하였더니 분리도가 낮았다. 분석물질의 분리도를 향상하기 위한 방법은?\n\n칼럼: 안지름 4.6 mm, 길이 25 cm인 강관에 5 μm의 액체크로마토그래프용 옥타데실실릴실리카겔을 충전한 것\n이동상: 물 ∙ 아세토니트릴혼합액(1 : 2)\n유량: 1.5 mL/분\n\n① 칼럼의 길이 감소\n② 이동상의 강도 증가\n③ 이동상의 유량 증가\n④ 충전입자의 크기 감소\n⑤ 충전입자의 표면적 감소",
        "question_text": "Question: When analyzing the content of lovastatin and related substances using high-performance liquid chromatography under the following conditions, the resolution was low. What method can be used to improve the resolution of the analytes?\n\nColumn: A stainless steel column 4.6 mm in inner diameter and 25 cm in length packed with 5 μm octadecylsilyl silica gel for liquid chromatography\nMobile phase: Water · Acetonitrile mixture (1 : 2)\nFlow rate: 1.5 mL/min\n\n① Decrease column length\n② Increase mobile phase strength\n③ Increase mobile phase flow rate\n④ Decrease packing particle size\n⑤ Decrease packing particle surface area",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 혈청 중 아목시실린을 정량하기 위해서 전처리 과정으로 시료 용량의 두 배 부피에 해당하는 아세토니트릴을 가하고 원심분리 하였다. 이 전처리 과정의 주된 목적은 혈청 중의 무엇을 제거하기 위한 것인가?\n\n① 당 \n② 염류 \n③ 지질 \n④ 이온 \n⑤ 단백질",
        "question_text": "Question: To quantify amoxicillin in serum, a pretreatment process was performed by adding acetonitrile twice the volume of the sample and then centrifuging. What is the main purpose of this pretreatment process in terms of removing something from the serum?\n\n① Sugar\n② Salts\n③ Lipids\n④ Ions\n⑤ Proteins",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 코로나바이러스감염증-19 감염이 의심되어 병원을 방문한 여섯 명의 혈액검사 결과 중 헤모글로빈 수치는 다음과 같다. 중앙값(median)은(g/dL)?\n\n| 방문자 | A | B | C | D | E | F |\n|---|---|---|---|---|---|---|\n| 헤모글로빈 (g/dL) | 10.1 | 10.9 | 11.2 | 11.4 | 11.6 | 13.8 |\n\n① 10.9\n② 11.2\n③ 11.3\n④ 11.4\n⑤ 11.5",
        "question_text": "Question: The following are the hemoglobin levels from blood tests of six visitors who came to the hospital with suspected COVID-19 infection. What is the median value (g/dL)?\n\n| Visitor | A | B | C | D | E | F |\n|---|---|---|---|---|---|---|\n| Hemoglobin (g/dL) | 10.1 | 10.9 | 11.2 | 11.4 | 11.6 | 13.8 |\n\n① 10.9\n② 11.2\n③ 11.3\n④ 11.4\n⑤ 11.5",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 서로 다른 두 대의 타정기로 생산된 아토르바스타틴 정 20정씩의 질량 평균값은 각각 0.31 g과 0.32 g이다. 평균의 동일성을 Student t-검정법으로 판정할 때 필요한 것은? (단, 두 대의 타정기로 생산된 정제 질량의 분산은 동일하다.)\n\n① 4 d값\n② 범위\n③ 평균편차\n④ 상대평균편차\n⑤ 합동표준편차",
        "question_text": "Question: The average mass values of 20 tablets each of atorvastatin produced by two different tablet presses are 0.31 g and 0.32 g, respectively. What is needed when determining the equality of means using Student's t-test? (Note: The variance of tablet mass produced by the two tablet presses is the same.)\n\n① d value of 4\n② Range\n③ Mean deviation\n④ Relative mean deviation\n⑤ Pooled standard deviation",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n아스피린 정에 들어있는 아스피린을 고성능액체크로마토그래피를 이용하여 다음의 조건으로 분석하였다. (단, 아스피린의 pKa=3.5)\n검출기: 자외부가시부흡광광도계(측정파장 254 nm)\n칼럼: 안지름 4.6 mm, 길이 25 cm인 강관에 5 μm의 액체크로마토그래프용 옥타데실실릴실리카겔을 충전한 것\n이동상: 물 ∙ 메탄올혼합액(60 : 40)에 산을 가해 pH를 4.5로 조정\n유량: 1.2 mL/분\n\nQuestion: 아스피린이 고정상에 머무르는 평형의 기전은?\n\n① 분배\n② 친화\n③ 흡착\n④ 이온교환\n⑤ 크기배제",
        "question_text": "Aspirin in aspirin tablets was analyzed using high-performance liquid chromatography under the following conditions. (Note: pKa of aspirin = 3.5)\nDetector: UV-visible spectrophotometer (measurement wavelength 254 nm)\nColumn: Stainless steel tube with an inner diameter of 4.6 mm and length of 25 cm, packed with 5 μm octadecylsilyl silica gel for liquid chromatography\nMobile phase: Water-methanol mixture (60:40) adjusted to pH 4.5 by adding acid\nFlow rate: 1.2 mL/min\n\nQuestion: What is the mechanism of equilibrium for aspirin retention on the stationary phase?\n\n① Partition\n② Affinity\n③ Adsorption\n④ Ion exchange\n⑤ Size exclusion",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n아스피린 정에 들어있는 아스피린을 고성능액체크로마토그래피를 이용하여 다음의 조건으로 분석하였다. (단, 아스피린의 pKa=3.5)\n검출기: 자외부가시부흡광광도계(측정파장 254 nm)\n칼럼: 안지름 4.6 mm, 길이 25 cm인 강관에 5 μm의 액체크로마토그래프용 옥타데실실릴실리카겔을 충전한 것\n이동상: 물 ∙ 메탄올혼합액(60 : 40)에 산을 가해 pH를 4.5로 조정\n유량: 1.2 mL/분\n\nQuestion: 아스피린의 머무름 시간을 증가하기 위해 필요한 이동상의 개선방안은?\n\n① pH를 5.5로 조정한다.\n② pH를 3.0으로 조정한다.\n③ 조성을 물 ∙ 메탄올혼합액(50 : 50)으로 바꾼다.\n④ 조성을 물 ∙ 메탄올혼합액(40 : 60)으로 바꾼다.\n⑤ 조성을 물 ∙ 아세토니트릴혼합액(40 : 60)으로 바꾼다.",
        "question_text": "Aspirin in aspirin tablets was analyzed using high-performance liquid chromatography under the following conditions. (Note: pKa of aspirin = 3.5)\nDetector: UV-visible spectrophotometer (measurement wavelength 254 nm)\nColumn: Stainless steel tube with an inner diameter of 4.6 mm and length of 25 cm, packed with 5 μm octadecylsilyl silica gel for liquid chromatography\nMobile phase: Water-methanol mixture (60:40) adjusted to pH 4.5 by adding acid\nFlow rate: 1.2 mL/min\n\nQuestion: What improvement to the mobile phase is needed to increase the retention time of aspirin?\n\n① Adjust pH to 5.5\n② Adjust pH to 3.0\n③ Change composition to water-methanol mixture (50:50)\n④ Change composition to water-methanol mixture (40:60)\n⑤ Change composition to water-acetonitrile mixture (40:60)",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 구강에서 수 초 이내 붕해되어, 삼키거나 씹는 데 어려움을 겪는 소아 및 노인 등의 환자가 편리하게 복용할 수 있는 정제는?\n\n① 속용정\n② 저작정\n③ 장용정\n④ 박칼정\n⑤ 당의정",
        "question_text": "Question: Which tablet disintegrates within seconds in the oral cavity, allowing for convenient administration by patients such as children and the elderly who have difficulty swallowing or chewing?\n\n① Immediate-release tablet\n② Chewable tablet\n③ Enteric-coated tablet\n④ Buccal tablet\n⑤ Sugar-coated tablet",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 전신작용 목적으로 사용할 때 간초회통과 효과를 피할 수 있는 제제로서 모두 옳은 것은?\n\n① 과립제, 주사제\n② 시럽제, 점비제\n③ 캡슐제, 이식제\n④ 흡입제, 경피흡수제\n⑤ 엑스제, 에어로솔제",
        "question_text": "Question: Which of the following are all correct as preparations that can avoid the first-pass effect when used for systemic action?\n\n① Granules, Injections\n② Syrups, Nasal drops\n③ Capsules, Implants\n④ Inhalations, Transdermal absorptions\n⑤ Extracts, Aerosols",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 위장관에서 수분에 의해 팽윤되어 정제를 미세한 입자로 깨어지게 하는 첨가제는?\n\n① 쉘락\n② 아라비아고무\n③ 셀라세페이트\n④ 전분글리콜산나트륨\n⑤ 글리세린모노스테아레이트",
        "question_text": "Question: Which additive causes the tablet to break into fine particles by swelling due to water in the gastrointestinal tract?\n\n① Shellac\n② Gum arabic\n③ Cellacefate\n④ Sodium starch glycolate\n⑤ Glyceryl monostearate",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 과립의 과다 건조로 인하여 발생하는 타정 장애는?\n\n① capping\n② chipping\n③ die friction\n④ picking\n⑤ sticking",
        "question_text": "Question: What tableting problem occurs due to over-drying of granules?\n\n① capping\n② chipping\n③ die friction\n④ picking\n⑤ sticking",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 경질캡슐제에 대한 설명으로 옳은 것은?\n\n① 캡슐 크기는 3호가 2호보다 크다. \n② 피막 성형과 내용물 충전이 동시에 이루어진다.\n③ 젤라틴 피막에 함유된 가소제가 많을수록 딱딱해진다.\n④ 히프로멜로오스를 사용하여 캡슐 피막을 제조할 수 있다.\n⑤ 정제와 달리 압축과정이 없어 활택제를 첨가하지 않는다.",
        "question_text": "Question: Which of the following statements about hard capsules is correct?\n\n① Size 3 capsules are larger than size 2 capsules.\n② Shell formation and content filling occur simultaneously.\n③ The more plasticizer contained in the gelatin shell, the harder it becomes.\n④ Hypromellose can be used to manufacture capsule shells.\n⑤ Unlike tablets, lubricants are not added as there is no compression process.",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 마그네슘 알루미늄 실리케이트로서 약 10% 농도에서 틱소트로피 겔을 형성하는 것은?\n\n① 비검(Veegum)\n② 카올린(kaolin)\n③ 폴록사머(poloxamer)\n④ 잔탄검(xanthan gum)\n⑤ 벤토나이트(bentonite)",
        "question_text": "Question: Which of the following forms a thixotropic gel at about 10% concentration as magnesium aluminum silicate?\n\n① Veegum\n② Kaolin\n③ Poloxamer\n④ Xanthan gum\n⑤ Bentonite",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 액상제제에 대한 설명으로 옳은 것은?\n\n① 엘릭서제는 보통 산미 및 방향이 있는 액제이다.\n② 고농도 백당으로 구성된 시럽제에는 보존제를 첨가해야 한다.\n③ 콜로디온제는 에테르와 에탄올의 혼합물에 피록실린을 녹여 만든다.\n④ 방향수제에서 정유의 방향성 지속을 위해 미량의 중금속을 첨가한다.\n⑤ 주정제는 보통 비휘발성 의약품을 에탄올과 물의 혼합액에 녹여 만든다.",
        "question_text": "Question: Which of the following statements about liquid preparations is correct?\n\n① Elixirs are typically acidic and aromatic liquid preparations.\n② Preservatives must be added to syrups composed of high concentrations of sucrose.\n③ Collodions are made by dissolving pyroxylin in a mixture of ether and ethanol.\n④ In aromatic waters, trace amounts of heavy metals are added to maintain the fragrance of essential oils.\n⑤ Spirits are usually made by dissolving non-volatile drugs in a mixture of ethanol and water.",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 레보노르게스트렐(levonorgestrel)을 함유하여 장기간 피임효과를 기대할 수 있는 이식제의 제조에 사용하는 생체비분해성 고분자중합체는?\n\n① polyanhydrides\n② polyesteramides\n③ polycaprolactone\n④ polydimethylsiloxane\n⑤ poly(lactide-co-glycolide)",
        "question_text": "Question: Which non-biodegradable polymer is used in the manufacture of implants containing levonorgestrel that can provide long-term contraceptive effects?\n\n① polyanhydrides\n② polyesteramides\n③ polycaprolactone\n④ polydimethylsiloxane\n⑤ poly(lactide-co-glycolide)",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 점안제 제조에 사용하는 보존제로서, 에데트산나트륨 첨가에 의해 녹농균 및 기타 그람음성균에 대한 투과성이 증대되어 보존효과가 개선되는 것은?\n\n① benzalkonium chloride\n② butylated hydroxyanisole\n③ propyl gallate\n④ sodium bisulfite\n⑤ stearyl alcohol",
        "question_text": "Question: Which of the following preservatives used in the manufacture of eye drops has improved preservative effects due to increased permeability against Pseudomonas aeruginosa and other gram-negative bacteria when sodium edetate is added?\n\n① benzalkonium chloride\n② butylated hydroxyanisole\n③ propyl gallate\n④ sodium bisulfite\n⑤ stearyl alcohol",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 다음 그림은 push-pull 방식으로 작동하는 OROS 정제 시스템의 모식도이다. A~E에 대한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① A: 삼투압 유도 물질을 포함한 층\n② B: 위장관에서 물이 흡수되는 주된 통로\n③ C: 반투과성막\n④ D: 약물을 포함하는 층\n⑤ E: 약물은 통과할 수 없고 물은 통과할 수 있는 막",
        "question_text": "Question: The following figure is a schematic diagram of an OROS tablet system operating in a push-pull manner. Which of the following descriptions about A to E is correct?\n\n<Data (confidential)>\n\n① A: Layer containing osmotic pressure-inducing substance\n② B: Main pathway for water absorption in the gastrointestinal tract\n③ C: Semipermeable membrane\n④ D: Layer containing the drug\n⑤ E: Membrane that allows water to pass through but not the drug",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 경피흡수제에 대한 설명으로 옳은 것은?\n\n① 방출제어막은 생체분해성이어야 한다. \n② 분자량이 큰 단백질 약물의 전달에 효율적이다.\n③ 피부수화 정도가 약물의 경피흡수에 영향을 미친다.\n④ 혈중농도는 경피흡수제의 피부 부착 면적과는 무관하다.\n⑤ 피부에서 떼어 내면 전신순환혈중으로의 약물흡수는 즉시 중단된다.",
        "question_text": "Question: Which of the following statements about transdermal absorption systems is correct?\n\n① The release control membrane must be biodegradable.\n② They are efficient in delivering large molecular weight protein drugs.\n③ The degree of skin hydration affects the transdermal absorption of drugs.\n④ Blood concentration is unrelated to the skin contact area of the transdermal system.\n⑤ When removed from the skin, drug absorption into systemic circulation stops immediately.",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 선형 1-컴파트먼트 정맥투여 모델에서 약물의 겉보기 분포용적에 대한 설명으로 옳은 것은?\n\n① 단위 시간당 소실부피를 의미한다.\n② 체내 조직의 실제부피를 초과할 수 없다.\n③ 클리어런스와 반감기를 알면 구할 수 있다. \n④ 혈장단백결합이 높을수록 분포용적이 크다. \n⑤ 혈장 중 약물농도에 대한 조직 중 약물농도의 비율이다.",
        "question_text": "Question: Which of the following statements about the apparent volume of distribution of a drug in a linear one-compartment intravenous model is correct?\n\n① It represents the volume eliminated per unit time.\n② It cannot exceed the actual volume of body tissues.\n③ It can be calculated if clearance and half-life are known.\n④ The higher the plasma protein binding, the larger the volume of distribution.\n⑤ It is the ratio of drug concentration in tissues to drug concentration in plasma.",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 약물의 생체외-생체내 상관관계(IVIVC)에 대한 설명으로 옳은 것은?\n\n① 서방형 제형은 속방형 제형과는 달리 IVIVC가 성립하지 않는다.\n② 생물약제학적분류체계(BCS) 중 제4군이 IVIVC가 가장 잘 성립한다.\n③ 용해도가 낮은 약물은 막투과도와 상관없이 IVIVC가 잘 성립한다.\n④ 치료역이 좁은 약물이 IVIVC가 성립한다면 생물학적동등성시험을 면제한다.\n⑤ 약물의 용출속도가 약물흡수의 속도결정단계인 경우 IVIVC 성립 가능성이 높다.",
        "question_text": "Question: Which of the following statements about the in vitro-in vivo correlation (IVIVC) of drugs is correct?\n\n① Unlike immediate-release formulations, extended-release formulations do not establish IVIVC.\n② Class IV in the Biopharmaceutics Classification System (BCS) establishes IVIVC best.\n③ Drugs with low solubility establish IVIVC well, regardless of membrane permeability.\n④ If IVIVC is established for drugs with a narrow therapeutic index, bioequivalence studies can be waived.\n⑤ When the drug dissolution rate is the rate-limiting step for drug absorption, the possibility of establishing IVIVC is high.",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 다음 그림은 선형 1-컴파트먼트 모델을 따르는 약물을 정맥주사 또는 경구투여 하였을 때의 혈중농도-시간 그래프이다. 경구투여 그래프에서 기울기 a를 얻고 잔차법을 이용하여 기울기 b를 구하였을 때, 기울기 a에 의해 직접적으로 결정되는 약동학 파라미터는?\n\n<Data (confidential)>\n\n① 투여량\n② 분포용적\n③ 소실반감기\n④ 클리어런스\n⑤ 흡수속도상수",
        "question_text": "Question: The following figure shows the blood concentration-time graph when a drug following a linear 1-compartment model is administered intravenously or orally. When slope a is obtained from the oral administration graph and slope b is determined using the residual method, which pharmacokinetic parameter is directly determined by slope a?\n\n<Data (confidential)>\n\n① Dose\n② Volume of distribution\n③ Elimination half-life\n④ Clearance\n⑤ Absorption rate constant",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 선형 1-컴파트먼트 모델을 따르는 어떤 약물을 4시간 동안 정맥 등속주입하고 중단하였다. 그 후 4시간이 더 경과하였을 때 혈중농도는? (단, 약물의 혈중소실반감기는 4시간이고, 정상상태혈중농도는 Css이다.)\n\n① 0\n② 0.25Css\n③ 0.50Css\n④ 0.75Css\n⑤ Css",
        "question_text": "Question: A drug that follows a linear one-compartment model was administered by constant intravenous infusion for 4 hours and then discontinued. What is the blood concentration 4 hours after the infusion was stopped? (Note: The drug's elimination half-life in blood is 4 hours, and the steady-state blood concentration is Css.)\n\n① 0\n② 0.25Css\n③ 0.50Css\n④ 0.75Css\n⑤ Css",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 유전적 다형성으로 인하여 오메프라졸의 간 대사에 개인별 차이가 발생한다. 이의 원인이 되는 주된 대사효소(A)와 빠른 대사자에 비해 느린 대사자에서 감소하는 약동학 파라미터(B)를 옳게 짝지은 것은?\n\n(A) | (B)\n① CYP1A2 | 반감기\n② CYP3A4 | 생체이용률\n③ CYP2C19 | 클리어런스\n④ CYP2C9 | 최고혈중농도\n⑤ CYP2D6 | 소실속도상수",
        "question_text": "Question: Genetic polymorphism causes individual differences in the hepatic metabolism of omeprazole. Which of the following correctly pairs the main metabolizing enzyme (A) responsible for this and the pharmacokinetic parameter (B) that decreases in slow metabolizers compared to rapid metabolizers?\n\n(A) | (B)\n① CYP1A2 | Half-life\n② CYP3A4 | Bioavailability\n③ CYP2C19 | Clearance\n④ CYP2C9 | Peak plasma concentration\n⑤ CYP2D6 | Elimination rate constant",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n수술환자에 대한 신속한 열량보급 용도의 주사제 A를 아래의 처방을 사용하여 개발하고자 한다.\n정제대두유 10%\n정제난황인지질 1.2%\n글리세린 2.25%\n수산화나트륨 적량\n주사용수 적량\n\nQuestion: 위 처방에서 정제난황인지질의 주된 배합목적은?\n\n① 유화제\n② 보존제\n③ 등장화제\n④ 항산화제\n⑤ 현탁화제",
        "question_text": "A parenteral formulation A for rapid calorie supply to surgical patients is being developed using the following prescription:\nRefined soybean oil 10%\nRefined egg yolk phospholipids 1.2%\nGlycerin 2.25%\nSodium hydroxide q.s.\nWater for injection q.s.\n\nQuestion: What is the main purpose of including refined egg yolk phospholipids in the above prescription?\n\n① Emulsifier\n② Preservative\n③ Isotonicity agent\n④ Antioxidant\n⑤ Suspending agent",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n수술환자에 대한 신속한 열량보급 용도의 주사제 A를 아래의 처방을 사용하여 개발하고자 한다.\n정제대두유 10%\n정제난황인지질 1.2%\n글리세린 2.25%\n수산화나트륨 적량\n주사용수 적량\n\nQuestion: 주사제 A에 대한 설명으로 옳은 것은?\n\n① 척수강 내로 투여할 수 있다.\n② 보통 7 μm 이하의 입자크기로 제조한다.\n③ 신속한 생체이용을 위해 근육주사제로 제조한다.\n④ 동결건조를 통해 주사용 분말로 용이하게 제조된다.\n⑤ 대용량 정맥주사제로 제조 시 보존제를 첨가하여야 한다.",
        "question_text": "A parenteral preparation A for rapid calorie supply to surgical patients is to be developed using the following prescription:\nRefined soybean oil 10%\nRefined egg yolk phospholipids 1.2%\nGlycerin 2.25%\nSodium hydroxide q.s.\nWater for injection q.s.\n\nQuestion: Which of the following statements about parenteral preparation A is correct?\n\n① It can be administered intrathecally.\n② It is usually manufactured with particle sizes below 7 μm.\n③ It is manufactured as an intramuscular injection for rapid bioavailability.\n④ It can be easily manufactured as a powder for injection through freeze-drying.\n⑤ When manufactured as a large-volume intravenous injection, preservatives must be added.",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 미치광이풀의 주성분으로 ornithine을 전구체로 하여 생합성되는 화합물군은?\n\n① aporphine alkaloid\n② indole alkaloid\n③ protoberberine alkaloid\n④ quinoline alkaloid\n⑤ tropane alkaloid",
        "question_text": "Question: Which group of compounds, synthesized using ornithine as a precursor, is the main component of Datura stramonium (Jimsonweed)?\n\n① aporphine alkaloid\n② indole alkaloid\n③ protoberberine alkaloid\n④ quinoline alkaloid\n⑤ tropane alkaloid",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: 연수의 호흡중추를 흥분시키며, 전신 근육에 강직성 경련(tonic convulsion)을 일으키는 monoterpenoid indole alkaloid 성분은?\n\n① aconitine\n② matrine\n③ pilocarpine\n④ quinine\n⑤ strychnine",
        "question_text": "Question: Which monoterpenoid indole alkaloid component stimulates the respiratory center of the medulla oblongata and causes tonic convulsions in the entire body's muscles?\n\n① aconitine\n② matrine\n③ pilocarpine\n④ quinine\n⑤ strychnine",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 2개의 벤젠 환과 그 사이에 3개의 탄소로 이루어진 탄소골격(C6-C3-C6)에 isoprenyl기가 도입되어 생합성된 화합물은?\n\n① alliin\n② amygdalin\n③ emodin\n④ geraniin\n⑤ icariin",
        "question_text": "Question: Which compound is biosynthesized by introducing an isoprenyl group to a carbon skeleton (C6-C3-C6) consisting of two benzene rings connected by three carbon atoms?\n\n① alliin\n② amygdalin\n③ emodin\n④ geraniin\n⑤ icariin",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 생약을 아세트산탈수물로 추출하여 얻은 여액에 황산을 천천히 넣을 때 접계면의 정색반응으로 triterpenoid를 확인하는 방법은?\n\n① Bornträger 반응\n② Grahe 반응\n③ Halphen 반응\n④ Liebermann-Burchard 반응\n⑤ Vitali 반응",
        "question_text": "Question: Which method is used to identify triterpenoids through a color reaction at the interface when sulfuric acid is slowly added to the filtrate obtained by extracting crude drugs with acetic anhydride?\n\n① Bornträger reaction\n② Grahe reaction\n③ Halphen reaction\n④ Liebermann-Burchard reaction\n⑤ Vitali reaction",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 주성분이 triterpene계 saponin이며, 자극성거담약과 진해약으로 사용되는 생약의 기원식물은?\n\n① Angelica dahurica\n② Gentiana lutea \n③ Pinellia ternata \n④ Polygala tenuifolia\n⑤ Rheum palmatum",
        "question_text": "Question: Which of the following is the source plant of a crude drug whose main component is triterpene saponin and is used as an expectorant and antitussive?\n\n① Angelica dahurica\n② Gentiana lutea \n③ Pinellia ternata \n④ Polygala tenuifolia\n⑤ Rheum palmatum",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: Thalleioquin 반응으로 확인할 수 있는 Rubiaceae 생약은?\n\n① 계피\n② 길경\n③ 키나\n④ 길초근\n⑤ 제충국",
        "question_text": "Question: Which Rubiaceae medicinal herb can be confirmed by the Thalleioquin reaction?\n\n① Cinnamon bark\n② Platycodon root\n③ Cinchona\n④ Pueraria root\n⑤ Pyrethrum",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: Saikosaponin a를 함유하며, 간세포보호 및 해열 작용이 있는 Umbelliferae 근류 생약은?\n\n① 대황 \n② 시호\n③ 원지\n④ 지모\n⑤ 지황",
        "question_text": "Question: Which Umbelliferae root drug contains Saikosaponin a and has hepatoprotective and antipyretic effects?\n\n① Rhubarb\n② Bupleurum\n③ Polygala\n④ Anemarrhena\n⑤ Rehmannia",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: 이형유관속을 지니며, 주성분이 secoiridoid계 고미배당체인 생약의 기원식물은?\n\n① Bupleurum falcatum\n② Gentiana scabra \n③ Paeonia lactiflora\n④ Rauvolfia serpentina\n⑤ Scutellaria baicalensis",
        "question_text": "Question: Which medicinal plant has bicollateral vascular bundles and contains secoiridoid glycosides as its main component?\n\n① Bupleurum falcatum\n② Gentiana scabra \n③ Paeonia lactiflora\n④ Rauvolfia serpentina\n⑤ Scutellaria baicalensis",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 가수분해 되어 피부와 점막에 자극작용을 나타내는 개자(芥子)의 성분은?\n\n① capsaicin\n② gingerol\n③ sanshool\n④ shogaol \n⑤ sinigrin",
        "question_text": "Question: Which component of mustard seed (Sinapis alba) is hydrolyzed and shows irritant effects on skin and mucous membranes?\n\n① capsaicin\n② gingerol\n③ sanshool\n④ shogaol \n⑤ sinigrin",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 환각작용과 심계항진을 유발할 수 있는 phenylpropanoid 성분이 함유된 육두구과(科)의 생약은?\n\n① Armeniacae Semen\n② Brassicae Semen \n③ Colchici Semen\n④ Myristicae Semen\n⑤ Persicae Semen",
        "question_text": "Question: Which crude drug from the Myristicaceae family contains phenylpropanoid components that can cause hallucinations and palpitations?\n\n① Armeniacae Semen\n② Brassicae Semen \n③ Colchici Semen\n④ Myristicae Semen\n⑤ Persicae Semen",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: Iridoid와 carotenoid를 함유하며 이담작용을 나타내는 과실류 생약은?\n\n① 대황\n② 시호\n③ 울금\n④ 치자\n⑤ 인진호",
        "question_text": "Question: Which fruit-based medicinal herb contains iridoids and carotenoids and exhibits choleretic action?\n\n① Rhubarb\n② Bupleurum\n③ Turmeric\n④ Gardenia\n⑤ Artemisia capillaris",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 벼과(Gramineae) 식물에 기생하는 균핵을 약용으로 하는 생약은?\n\n① 맥각\n② 복령\n③ 영지\n④ 큐라레\n⑤ 동충하초",
        "question_text": "Question: Which medicinal herb is derived from the sclerotium that parasitizes plants of the grass family (Gramineae)?\n\n① Ergot\n② Poria\n③ Lingzhi\n④ Curare\n⑤ Cordyceps",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 몸 안의 액체형태의 물질이 유실되지 않게 하는 기(氣)의 생리기능은?\n\n① 고섭작용(固攝作用)\n② 기화작용(氣化作用)\n③ 방어작용(防禦作用)\n④ 온후작용(溫煦作用)\n⑤ 추동작용(推動作用)",
        "question_text": "Question: What is the physiological function of qi (vital energy) that prevents the loss of liquid substances in the body?\n\n① Consolidation and astringent action (固攝作用)\n② Qi transformation action (氣化作用)\n③ Defensive action (防禦作用)\n④ Warming action (溫煦作用)\n⑤ Propelling action (推動作用)",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 비(脾)와 폐(肺)로 귀경하며 보기승양(補氣升陽), 익위고표(益衛固表), 생진지갈(生津止渴)의 효능이 있는 보기약(補氣藥)은?\n\n① 갈근(葛根)\n② 계지(桂枝)\n③ 녹용(鹿茸)\n④ 천마(天麻)\n⑤ 황기(黃芪)",
        "question_text": "Question: Which of the following qi-tonifying herbs (補氣藥) enters the Spleen and Lung meridians and has the effects of tonifying qi and raising yang (補氣升陽), benefiting the defensive qi and securing the exterior (益衛固表), and generating fluids and stopping thirst (生津止渴)?\n\n① Pueraria root (Radix Puerariae, 葛根)\n② Cinnamon twig (Ramulus Cinnamomi, 桂枝)\n③ Deer antler (Cornu Cervi Pantotrichum, 鹿茸)\n④ Gastrodia tuber (Rhizoma Gastrodiae, 天麻)\n⑤ Astragalus root (Radix Astragali, 黃芪)",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 길경, 감초, 대추, 작약, 건강, 지실의 약재로 구성되어 있고, 청열해독(淸熱解毒)의 효능이 있어 국소적 화농성 염증에 사용하는 한약제제는?\n\n① 안중산(安中散)\n② 오적산(五積散)\n③ 소청룡탕(小靑龍湯)\n④ 배농산급탕(排膿散及湯)\n⑤ 천왕보심단(天王補心丹)",
        "question_text": "Question: Which herbal medicine preparation, composed of Platycodon Root, Licorice, Jujube, Peony Root, Dried Ginger, and Immature Citrus Fruit, has the effect of clearing heat and detoxifying (淸熱解毒) and is used for localized purulent inflammation?\n\n① Anjung-san (安中散)\n② Ojeok-san (五積散)\n③ Socheongryong-tang (小靑龍湯)\n④ Baenong-san-geup-tang (排膿散及湯)\n⑤ Cheonwangbosim-dan (天王補心丹)",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 청사간화(淸瀉肝火)와 청리습열(淸利濕熱)의 효능이 있어, 간담화왕(肝膽火旺)으로 인한 두통, 목적(目赤)과 하초습열(下焦濕熱)로 인한 배뇨통에 사용하는 한약제제는?\n\n① 반하후박탕(半夏厚朴湯)\n② 보중익기탕(補中益氣湯)\n③ 십전대보탕(十全大補湯)\n④ 용담사간탕(龍膽瀉肝湯)\n⑤ 인삼패독산(人蔘敗毒散)",
        "question_text": "Question: Which herbal medicine preparation has the effects of clearing liver fire (淸瀉肝火) and clearing damp-heat (淸利濕熱), and is used for headaches and red eyes caused by excessive liver and gallbladder fire (肝膽火旺), as well as painful urination caused by lower jiao damp-heat (下焦濕熱)?\n\n① Banhahoubak-tang (半夏厚朴湯)\n② Bojungikgi-tang (補中益氣湯)\n③ Sipjeondaebo-tang (十全大補湯)\n④ Yongdamsagan-tang (龍膽瀉肝湯)\n⑤ Insampaedok-san (人蔘敗毒散)",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n도핑검사를 받아야 하는 운동선수가 기침, 가래 증상으로 약국을 방문하여 의약품정보를 문의하였다. 약사는 초롱꽃과(科)의 생약과 마황과(科)의 생약을 비롯하여 이들 생약을 함유하는 생약제제들에 대하여 상담해 주었다.\n\nQuestion: 약사가 상담한 초롱꽃과(科)의 생약으로 진해거담작용을 나타내는 것은?\n\n① 길경\n② 반하\n③ 행인\n④ 상백피\n⑤ 하고초",
        "question_text": "An athlete who needs to undergo doping tests visited a pharmacy with symptoms of cough and phlegm, inquiring about medication information. The pharmacist provided counseling on crude drugs from the Campanulaceae family and the Ephedraceae family, as well as herbal preparations containing these crude drugs.\n\nQuestion: Which of the following crude drugs from the Campanulaceae family, mentioned by the pharmacist during counseling, exhibits antitussive and expectorant effects?\n\n① Platycodon Root (Platycodi Radix)\n② Pinellia Tuber (Pinelliae Rhizoma)\n③ Apricot Kernel (Armeniacae Semen)\n④ Mulberry Bark (Mori Cortex)\n⑤ Prunella Spike (Prunellae Spica)",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n도핑검사를 받아야 하는 운동선수가 기침, 가래 증상으로 약국을 방문하여 의약품정보를 문의하였다. 약사는 초롱꽃과(科)의 생약과 마황과(科)의 생약을 비롯하여 이들 생약을 함유하는 생약제제들에 대하여 상담해 주었다.\n\nQuestion: 위의 사례에서 마황과(科)의 생약에 함유된 성분으로 도핑검사와 관련되는 것은?\n\n① amygdalin\n② decursin \n③ ephedrine\n④ paeoniflorin\n⑤ tanshinone",
        "question_text": "An athlete who needs to undergo doping tests visited a pharmacy with symptoms of cough and phlegm, inquiring about medication information. The pharmacist provided counseling on crude drugs from the Campanulaceae family and the Ephedraceae family, as well as herbal preparations containing these crude drugs.\n\nQuestion: In the above case, which component contained in the crude drug from the Ephedraceae family is related to doping tests?\n\n① amygdalin\n② decursin \n③ ephedrine\n④ paeoniflorin\n⑤ tanshinone",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 67세 남자가 지난 몇 개월간 혈압조절을 위해 약물요법을 시행하였으나, 목표혈압에 도달하지 못했다. 이 환자에게 혈압조절을 위해 추가할 약으로 적절한 것은?\n\n[병력] 고혈압, 이상지질혈증\n[약물 알레르기] 로사르탄(losartan) – 혈관부종\n[복약이행도] 우수함, 생활요법/식이요법 – 적절함\n[활력징후] 혈압 151/89 mmHg, 심박수 61회/분, 호흡수 18회/분\n[임상검사] Na 140 mEq/L, K 4.2 mEq/L, Cl 99 mEq/L, BUN 18 mg/dL, SCr 1.1 mg/dL\n[복용약물]\n암로디핀(amlodipine) 10 mg 1일 1회\n카르베딜롤(carvedilol) 25 mg 1일 2회\n아토르바스타틴(atorvastatin) 20 mg 1일 1회\n\n① 딜티아젬(diltiazem)\n② 히드랄라진(hydralazine)\n③ 푸로세미드(furosemide)\n④ 이르베사르탄(irbesartan)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: A 67-year-old male has been on medication therapy for blood pressure control for the past few months but has not reached the target blood pressure. Which of the following drugs is appropriate to add for blood pressure control in this patient?\n\n[Medical history] Hypertension, dyslipidemia\n[Drug allergy] Losartan - angioedema\n[Medication adherence] Excellent, lifestyle/diet therapy - appropriate\n[Vital signs] Blood pressure 151/89 mmHg, heart rate 61 bpm, respiratory rate 18 breaths/min\n[Clinical tests] Na 140 mEq/L, K 4.2 mEq/L, Cl 99 mEq/L, BUN 18 mg/dL, SCr 1.1 mg/dL\n[Current medications]\nAmlodipine 10 mg once daily\nCarvedilol 25 mg twice daily\nAtorvastatin 20 mg once daily\n\n① Diltiazem\n② Hydralazine\n③ Furosemide\n④ Irbesartan\n⑤ Hydrochlorothiazide",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 75세 남자가 만성심부전으로 치료를 받고 있다. 현재 환자의 상태는 안정적이지만 증상은 지속되고 있다. 이 환자의 입원 가능성을 줄이기 위해 추가할 약물은?\n\n[활력징후] 혈압 128/76 mmHg, 심박수 86회/분(휴식 시), 호흡수 20회/분, 체질량지수 31 kg/m2\n[임상검사] 좌심실박출률(LVEF): 30% 심전도: 정상 동율동(normal sinus rhythm), Na 134 mEq/L, K 4.8 mEq/L, SCr 0.9 mg/dL, TC 160 mg/dL, LDL-C 80 mg/dL, TG 150 mg/dL HDL-C 50 mg/dL\n[복용약물]\n리시노프릴(lisinopril) 40 mg 1일 1회\n카르베딜롤(carvedilol) 25 mg 1일 2회\n푸로세미드(furosemide) 40 mg 1일 2회\n스피로노락톤(spironolactone) 25 mg 1일 1회\n\n① 발사르탄(valsartan)\n② 베라파밀(verapamil)\n③ 암로디핀(amlodipine)\n④ 이바브라딘(ivabradine)\n⑤ 아미오다론(amiodarone)",
        "question_text": "Question: A 75-year-old man is being treated for chronic heart failure. The patient's condition is currently stable, but symptoms persist. Which medication should be added to reduce the likelihood of hospitalization for this patient?\n\n[Vital Signs] Blood pressure 128/76 mmHg, Heart rate 86 beats/min (at rest), Respiratory rate 20 breaths/min, Body Mass Index 31 kg/m2\n[Clinical Tests] Left Ventricular Ejection Fraction (LVEF): 30%, ECG: Normal sinus rhythm, Na 134 mEq/L, K 4.8 mEq/L, SCr 0.9 mg/dL, TC 160 mg/dL, LDL-C 80 mg/dL, TG 150 mg/dL, HDL-C 50 mg/dL\n[Current Medications]\nLisinopril 40 mg once daily\nCarvedilol 25 mg twice daily\nFurosemide 40 mg twice daily\nSpironolactone 25 mg once daily\n\n① Valsartan\n② Verapamil\n③ Amlodipine\n④ Ivabradine\n⑤ Amiodarone",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 안정형 협심증이 있는 54세 남자에게 최근 흉통이 자주 발생하여, 니트로글리세린(nitroglycerin) 설하정의 사용 횟수가 증가하였다. 흉통을 조절하기 위해 추가할 약물은?\n\n[병력] 고혈압, 이상지질혈증, 안정형 협심증\n[활력징후] 혈압 132/84 mmHg, 심박수 57회/분\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 2회\n리시노프릴(lisinopril) 10 mg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n니트로글리세린 0.6 mg 설하정, 필요시\n\n① 아테놀롤(atenolol)\n② 발사르탄(valsartan)\n③ 딜티아젬(diltiazem)\n④ 펠로디핀(felodipine)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "Question: A 54-year-old man with stable angina has been experiencing frequent chest pain recently, leading to increased use of sublingual nitroglycerin tablets. Which drug should be added to control the chest pain?\n\n[Medical history] Hypertension, dyslipidemia, stable angina\n[Vital signs] Blood pressure 132/84 mmHg, heart rate 57 beats/min\n[Current medications]\nAspirin 100 mg once daily\nMetoprolol 100 mg twice daily\nLisinopril 10 mg once daily\nAtorvastatin 40 mg once daily\nNitroglycerin 0.6 mg sublingual tablet, as needed\n\n① Atenolol\n② Valsartan\n③ Diltiazem\n④ Felodipine\n⑤ Clopidogrel",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 심한 흉통으로 응급실로 이송된 55세 남자가 ST분절상승 심근경색을 진단받았다. 2시간 이내에 경피적 관상동맥중재술(percutaneous coronary intervention) 시행이 불가능하여 혈전용해제로 재관류 치료를 시행하고자 한다. 이때 이 환자에게 아스피린(aspirin)과 함께 투여해야 하는 항혈소판제는?\n\n[병력] 고혈압, 이상지질혈증\n[복용약물]\n에날라프릴(enalapril) 10 mg 1일 1회\n로수바스타틴(rosuvastatin) 10 mg 1일 1회\n\n① 티로피반(tirofiban)\n② 프라수그렐(prasugrel)\n③ 실로스타졸(cilostazol)\n④ 디피리다몰(dipyridamole)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "Question: A 55-year-old male was transported to the emergency room with severe chest pain and diagnosed with ST-segment elevation myocardial infarction. As percutaneous coronary intervention cannot be performed within 2 hours, reperfusion therapy with a thrombolytic agent is planned. Which antiplatelet agent should be administered along with aspirin to this patient?\n\n[Medical history] Hypertension, Dyslipidemia\n[Current medications]\nEnalapril 10 mg once daily\nRosuvastatin 10 mg once daily\n\n① Tirofiban\n② Prasugrel\n③ Cilostazol\n④ Dipyridamole\n⑤ Clopidogrel",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 비ST분절상승 급성관상동맥증후군(NSTE-ACS)을 진단받은 73세 여자가 허혈기반치료(ischemia-guided strategy)를 받고 있다. 이 환자에게 추가해야 하는 약물은?\n\n[병력] 이상지질혈증, 역류성 식도염\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n오메프라졸(omeprazole) 40 mg 1일 1회\n비소프롤롤(bisoprolol) 10 mg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n이소소르비드질산염(isosorbide dinitrate) 20 mg 1일 3회\n니트로글리세린(nitroglycerin) 0.6 mg 설하정, 필요시\n\n① 압식시맙(abciximab)\n② 티카그렐러(ticagrelor)\n③ 프라수그렐(prasugrel)\n④ 디피리다몰(dipyridamole)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "Question: A 73-year-old woman diagnosed with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is receiving ischemia-guided strategy. Which drug should be added for this patient?\n\n[Medical history] Dyslipidemia, Gastroesophageal reflux disease\n[Current medications]\nAspirin 100 mg once daily\nOmeprazole 40 mg once daily\nBisoprolol 10 mg once daily\nAtorvastatin 40 mg once daily\nIsosorbide dinitrate 20 mg three times daily\nNitroglycerin 0.6 mg sublingual tablet, as needed\n\n① Abciximab\n② Ticagrelor\n③ Prasugrel\n④ Dipyridamole\n⑤ Clopidogrel",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 최근 심방세동을 진단받은 66세 여자에게 항혈전요법을 계획하고 있다. 이 환자의 검사 결과와 복용약물이 다음과 같을 때, 출혈 위험을 평가하는 HAS-BLED 점수를 높이는 인자는?\n\n[병력] 고혈압, 당뇨병, 이상지질혈증\n[활력징후] 혈압 165/95 mmHg, 심박수 80회/분\n[임상검사] 당화혈색소 7.9%, LDL-C 110 mg/dL\n[복용약물]\n암로디핀(amlodipine) 10 mg 1일 1회\n텔미사르탄(telmisartan) 40 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 1회\n글리메피리드(glimepiride) 4 mg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n\n① 성별\n② LDL-C\n③ 복용약물\n④ 당화혈색소\n⑤ 수축기 혈압",
        "question_text": "Question: A 66-year-old woman recently diagnosed with atrial fibrillation is being planned for antithrombotic therapy. Given the following test results and medications for this patient, which factor increases the HAS-BLED score used to assess bleeding risk?\n\n[Medical history] Hypertension, Diabetes mellitus, Dyslipidemia\n[Vital signs] Blood pressure 165/95 mmHg, Heart rate 80 beats/min\n[Clinical tests] HbA1c 7.9%, LDL-C 110 mg/dL\n[Medications]\nAmlodipine 10 mg once daily\nTelmisartan 40 mg once daily\nMetoprolol 100 mg once daily\nGlimepiride 4 mg once daily\nAtorvastatin 40 mg once daily\n\n① Gender\n② LDL-C\n③ Medications\n④ HbA1c\n⑤ Systolic blood pressure",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 평소에 건강하던 65세 남자가 비심인성 허혈성뇌졸중으로 혈전용해제 치료를 받았다. 뇌졸중 재발을 예방하기 위해 장기 투여 항혈전요법으로 추천되는 것은?\n\n① 아스피린(aspirin) 100 mg 1일 1회\n② 에독사반(edoxaban) 60 mg 1일 1회\n③ 티카그렐러(ticagrelor) 90 mg 1일 2회\n④ 리바록사반(rivaroxaban) 15 mg 1일 1회\n⑤ 아스피린 100 mg+클로피도그렐(clopidogrel) 75 mg 1일 1회",
        "question_text": "Question: A previously healthy 65-year-old man received thrombolytic therapy for non-cardioembolic ischemic stroke. Which of the following is recommended as a long-term antithrombotic therapy to prevent stroke recurrence?\n\n① Aspirin 100 mg once daily\n② Edoxaban 60 mg once daily\n③ Ticagrelor 90 mg twice daily\n④ Rivaroxaban 15 mg once daily\n⑤ Aspirin 100 mg + Clopidogrel 75 mg once daily",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 평소에 건강하던 31세 남자가 건강검진 결과 이상지질혈증을 진단받았으며 다른 이상소견은 없다. 생활습관 개선과 함께 약물치료를 시작하려고 할 때 적절한 약물요법은?\n\n[임상검사] TC 340 mg/dL, LDL-C 250 mg/dL, TG 250 mg/dL, HDL-C 40 mg/dL\n\n① 로바스타틴(lovastatin) 20 mg 1일 1회\n② 심바스타틴(simvastatin) 20 mg 1일 1회\n③ 플루바스타틴(fluvastatin) 40 mg 1일 2회\n④ 프라바스타틴(pravastatin) 40 mg 1일 1회\n⑤ 아토르바스타틴(atorvastatin) 40 mg 1일 1회",
        "question_text": "Question: A previously healthy 31-year-old man was diagnosed with dyslipidemia during a health check-up, with no other abnormal findings. When starting drug therapy along with lifestyle modifications, what is the appropriate drug regimen?\n\n[Clinical test results] TC 340 mg/dL, LDL-C 250 mg/dL, TG 250 mg/dL, HDL-C 40 mg/dL\n\n① Lovastatin 20 mg once daily\n② Simvastatin 20 mg once daily\n③ Fluvastatin 40 mg twice daily\n④ Pravastatin 40 mg once daily\n⑤ Atorvastatin 40 mg once daily",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 64세 남자가 이상지질혈증 치료를 위해 약물을 복용하고 있음에도 불구하고 콜레스테롤 수치가 치료목표에 도달하지 못하였다. 적절한 약물요법은?\n\n[병력] 고혈압(10년), 심근경색(3년 전), 이상지질혈증(12년)\n[복약이행도] 우수함, 생활요법/식이요법 – 적절함\n[활력징후] 혈압 125/79 mmHg, 심박수 72회/분\n[임상검사] TC 236 mg/dL, LDL-C 150 mg/dL, TG 250 mg/dL HDL-C 36 mg/dL\n[복용약물] 아스피린(aspirin) 100 mg 1일 1회 리시노프릴(lisinopril) 20 mg 1일 1회 카르베딜롤(carvedilol) 12.5 mg 1일 2회 에제티미브(ezetimibe) 10 mg 1일 1회 아토르바스타틴(atorvastatin) 80 mg 1일 1회\n\n① 에제티미브 증량\n② 아토르바스타틴 증량\n③ 에볼로쿠맙(evolocumab) 추가\n④ 페노피브레이트(fenofibrate) 추가\n⑤ 오메가3산에틸에스테르(omega-3-acid ethyl esters) 추가",
        "question_text": "Question: A 64-year-old man is taking medication for dyslipidemia, but his cholesterol levels have not reached the treatment goal despite the treatment. What is the appropriate drug therapy?\n\n[Medical history] Hypertension (10 years), Myocardial infarction (3 years ago), Dyslipidemia (12 years)\n[Medication adherence] Excellent, Lifestyle/dietary therapy – Appropriate\n[Vital signs] Blood pressure 125/79 mmHg, Heart rate 72 beats/min\n[Clinical tests] TC 236 mg/dL, LDL-C 150 mg/dL, TG 250 mg/dL, HDL-C 36 mg/dL\n[Current medications] Aspirin 100 mg once daily\nLisinopril 20 mg once daily\nCarvedilol 12.5 mg twice daily\nEzetimibe 10 mg once daily\nAtorvastatin 80 mg once daily\n\n① Increase ezetimibe dose\n② Increase atorvastatin dose\n③ Add evolocumab\n④ Add fenofibrate\n⑤ Add omega-3-acid ethyl esters",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 76세 여자가 왼쪽 종아리에 발생한 심부정맥혈전증으로 입원하여 항혈전요법을 시작하려고 한다. 최소 5일간 비경구 항응고제 사용 후 투여해야 하며, 이 환자의 연령을 고려하여 용량을 선택하고, 1일 2회 투여해야 하는 경구 항혈전제는?\n\n① 와파린(warfarin)\n② 아픽사반(apixaban)\n③ 에독사반(edoxaban)\n④ 리바록사반(rivaroxaban)\n⑤ 다비가트란 에텍실레이트(dabigatran etexilate)",
        "question_text": "Question: A 76-year-old woman is admitted to the hospital with deep vein thrombosis in her left calf and is about to start antithrombotic therapy. Which oral antithrombotic agent should be administered twice daily, after using a parenteral anticoagulant for at least 5 days, considering the patient's age when selecting the dose?\n\n① Warfarin\n② Apixaban\n③ Edoxaban\n④ Rivaroxaban\n⑤ Dabigatran etexilate",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 65세 여자가 재발성 정맥혈전색전증으로 와파린(warfarin) 2.5 mg을 매일 복용하고 있으며, 지난 6개월 동안 INR이 2.1~2.7 범위를 유지하였다. 오늘 측정한 INR은 4.7이며 출혈 징후는 없다. 지난 5일간 시프로플록사신(ciprofloxacin)을 복용하였고, 오늘 중단할 예정이다. 이 환자의 INR 변화에 따른 조치로 적절한 것은?\n\n① 신선냉동혈장 수혈\n② 혈액응고제VII인자 투여\n③ 와파린을 3 mg으로 증량\n④ 비타민K 5 mg 경구 투여\n⑤ 와파린 복용 1회 중단 후 INR 재측정",
        "question_text": "Question: A 65-year-old woman has been taking warfarin 2.5 mg daily for recurrent venous thromboembolism, and her INR has been maintained in the range of 2.1-2.7 for the past 6 months. Today's measured INR is 4.7, and there are no signs of bleeding. She has been taking ciprofloxacin for the past 5 days and plans to discontinue it today. What is the appropriate action to take based on the change in this patient's INR?\n\n① Transfusion of fresh frozen plasma\n② Administration of coagulation factor VII\n③ Increase warfarin dose to 3 mg\n④ Oral administration of 5 mg vitamin K\n⑤ Skip one dose of warfarin and remeasure INR",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n55세 남자의 정기검사결과는 다음과 같고, 변비 이외에 별다른 임상소견은 없었다.\n\n[병력] 고혈압, 안정형 협심증, 알레르기 비염\n\n[복약이행도] 우수함\n\n[약물 알레르기] 특이사항 없음\n\n[활력징후] 혈압 142/87 mmHg, 심박수 63회/분, 호흡수 19회/분\n\n[임상검사]\nNa 141 mEq/L, K 4.2 mEq/L, SCr 1.1 mg/dL, eGFR 58 mL/min/1.73 m2\n소변: 알부민 대 크레아티닌 비(ACR) 120 mg/g\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n프라바스타틴(pravastatin) 40 mg 1일 1회\n베라파밀(verapamil) 서방정 240 mg 1일 1회\n아스코르브산(ascorbic acid) 500 mg 1일 1회\n니트로글리세린(nitroglycerin) 0.6 mg 설하정, 필요시\n모메타손(mometasone) 비강분무제 1일 1회 비강 분무\n\nQuestion: 이 환자에게서 변비의 원인이 될 수 있는 약물은?\n\n① 아스피린\n② 베라파밀\n③ 모메타손\n④ 아스코르브산\n⑤ 니트로글리세린",
        "question_text": "A 55-year-old male's regular check-up results are as follows, and there were no significant clinical findings other than constipation.\n\n[Medical history] Hypertension, stable angina, allergic rhinitis\n\n[Medication adherence] Excellent\n\n[Drug allergies] No specific issues\n\n[Vital signs] Blood pressure 142/87 mmHg, heart rate 63 beats/min, respiratory rate 19 breaths/min\n\n[Clinical tests]\nNa 141 mEq/L, K 4.2 mEq/L, SCr 1.1 mg/dL, eGFR 58 mL/min/1.73 m2\nUrine: Albumin to Creatinine Ratio (ACR) 120 mg/g\n\n[Current medications]\nAspirin 100 mg once daily\nPravastatin 40 mg once daily\nVerapamil extended-release 240 mg once daily\nAscorbic acid 500 mg once daily\nNitroglycerin 0.6 mg sublingual tablet, as needed\nMometasone nasal spray once daily\n\nQuestion: Which medication could be the cause of constipation in this patient?\n\n① Aspirin\n② Verapamil\n③ Mometasone\n④ Ascorbic acid\n⑤ Nitroglycerin",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n55세 남자의 정기검사결과는 다음과 같고, 변비 이외에 별다른 임상소견은 없었다.\n\n[병력] 고혈압, 안정형 협심증, 알레르기 비염\n\n[복약이행도] 우수함\n\n[약물 알레르기] 특이사항 없음\n\n[활력징후] 혈압 142/87 mmHg, 심박수 63회/분, 호흡수 19회/분\n\n[임상검사]\nNa 141 mEq/L, K 4.2 mEq/L, SCr 1.1 mg/dL, eGFR 58 mL/min/1.73 m2\n소변: 알부민 대 크레아티닌 비(ACR) 120 mg/g\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n프라바스타틴(pravastatin) 40 mg 1일 1회\n베라파밀(verapamil) 서방정 240 mg 1일 1회\n아스코르브산(ascorbic acid) 500 mg 1일 1회\n니트로글리세린(nitroglycerin) 0.6 mg 설하정, 필요시\n모메타손(mometasone) 비강분무제 1일 1회 비강 분무\n\nQuestion: 검사결과를 바탕으로 평가했을 때 추가가 필요한 약물은?\n\n① 라미프릴(ramipril)\n② 독사조신(doxazosin)\n③ 암로디핀(amlodipine)\n④ 스피로노락톤(spironolactone)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 55-year-old male's regular check-up results are as follows, and there were no significant clinical findings other than constipation.\n\n[Medical history] Hypertension, stable angina, allergic rhinitis\n\n[Medication adherence] Excellent\n\n[Drug allergies] No specific issues\n\n[Vital signs] Blood pressure 142/87 mmHg, Heart rate 63 beats/min, Respiratory rate 19 breaths/min\n\n[Clinical tests]\nNa 141 mEq/L, K 4.2 mEq/L, SCr 1.1 mg/dL, eGFR 58 mL/min/1.73 m2\nUrine: Albumin to Creatinine Ratio (ACR) 120 mg/g\n\n[Current medications]\nAspirin 100 mg once daily\nPravastatin 40 mg once daily\nVerapamil extended-release 240 mg once daily\nAscorbic acid 500 mg once daily\nNitroglycerin 0.6 mg sublingual tablet, as needed\nMometasone nasal spray once daily\n\nQuestion: Based on the test results, which medication needs to be added?\n\n① Ramipril\n② Doxazosin\n③ Amlodipine\n④ Spironolactone\n⑤ Hydrochlorothiazide",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 당뇨병, 만성심부전, 체부백선이 있는 75세 남자가 심부전 증상이 악화되어 입원하였다.\n\n[활력징후]\n키 175 cm, 체중 75 kg\n혈압 135/75 mmHg, 심박수 68회/분\n\n[임상검사]\n좌심실박출률(LVEF): 40%, NYHA class III\nNa 140 mEq/L, K 4.5 mEq/L, BUN 12 mg/dL, SCr 1.0 mg/dL\nAST 10 IU/L, ALT 25 IU/L\nTC 170 mg/dL, LDL-C 89 mg/dL, TG 180 mg/dL\nHDL-C 45 mg/dL\n\n[복용약물]\n리시노프릴(lisinopril) 40 mg 1일 1회\n카르베딜롤(carvedilol) 25 mg 1일 2회\n스피로노락톤(spironolactone) 25 mg 1일 1회\n메트포르민(metformin) 500 mg 1일 2회\n이트라코나졸(itraconazole) 100 mg 1일 1회\n피타바스타틴(pitavastatin) 2 mg 1일 1회\n\nQuestion: 이 환자의 심부전 증상을 악화시킨 원인이 될 수 있는 약물은?\n\n① 리시노프릴\n② 메트포르민\n③ 이트라코나졸\n④ 스피로노락톤\n⑤ 피타바스타틴",
        "question_text": "A 75-year-old male with hypertension, diabetes, chronic heart failure, and tinea corporis was admitted due to worsening heart failure symptoms.\n\n[Vital Signs]\nHeight 175 cm, Weight 75 kg\nBlood pressure 135/75 mmHg, Heart rate 68 beats/min\n\n[Clinical Tests]\nLeft Ventricular Ejection Fraction (LVEF): 40%, NYHA class III\nNa 140 mEq/L, K 4.5 mEq/L, BUN 12 mg/dL, SCr 1.0 mg/dL\nAST 10 IU/L, ALT 25 IU/L\nTC 170 mg/dL, LDL-C 89 mg/dL, TG 180 mg/dL\nHDL-C 45 mg/dL\n\n[Medications]\nLisinopril 40 mg once daily\nCarvedilol 25 mg twice daily\nSpironolactone 25 mg once daily\nMetformin 500 mg twice daily\nItraconazole 100 mg once daily\nPitavastatin 2 mg once daily\n\nQuestion: Which medication could be the cause of worsening heart failure symptoms in this patient?\n\n① Lisinopril\n② Metformin\n③ Itraconazole\n④ Spironolactone\n⑤ Pitavastatin",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 당뇨병, 만성심부전, 체부백선이 있는 75세 남자가 심부전 증상이 악화되어 입원하였다.\n\n[활력징후]\n키 175 cm, 체중 75 kg\n혈압 135/75 mmHg, 심박수 68회/분\n\n[임상검사]\n좌심실박출률(LVEF): 40%, NYHA class III\nNa 140 mEq/L, K 4.5 mEq/L, BUN 12 mg/dL, SCr 1.0 mg/dL\nAST 10 IU/L, ALT 25 IU/L\nTC 170 mg/dL, LDL-C 89 mg/dL, TG 180 mg/dL\nHDL-C 45 mg/dL\n\n[복용약물]\n리시노프릴(lisinopril) 40 mg 1일 1회\n카르베딜롤(carvedilol) 25 mg 1일 2회\n스피로노락톤(spironolactone) 25 mg 1일 1회\n메트포르민(metformin) 500 mg 1일 2회\n이트라코나졸(itraconazole) 100 mg 1일 1회\n피타바스타틴(pitavastatin) 2 mg 1일 1회\n\nQuestion: 이 환자는 적절한 입원치료로 상태가 안정되었다. 이 환자의 심부전으로 인한 사망위험을 낮추기 위해 고려할 수 있는 적절한 약물요법은?\n\n① 디곡신(digoxin) 추가\n② 로사르탄(losartan) 추가\n③ 카르베딜롤을 베라파밀(verapamil)로 변경\n④ 스피로노락톤을 푸로세미드(furosemide)로 변경\n⑤ 리시노프릴을 사쿠비트릴/발사르탄(sacubitril/valsartan)으로 변경",
        "question_text": "A 75-year-old male with hypertension, diabetes, chronic heart failure, and tinea corporis was admitted due to worsening heart failure symptoms.\n\n[Vital Signs]\nHeight 175 cm, Weight 75 kg\nBlood pressure 135/75 mmHg, Heart rate 68 beats/min\n\n[Clinical Tests]\nLeft Ventricular Ejection Fraction (LVEF): 40%, NYHA class III\nNa 140 mEq/L, K 4.5 mEq/L, BUN 12 mg/dL, SCr 1.0 mg/dL\nAST 10 IU/L, ALT 25 IU/L\nTC 170 mg/dL, LDL-C 89 mg/dL, TG 180 mg/dL\nHDL-C 45 mg/dL\n\n[Current Medications]\nLisinopril 40 mg once daily\nCarvedilol 25 mg twice daily\nSpironolactone 25 mg once daily\nMetformin 500 mg twice daily\nItraconazole 100 mg once daily\nPitavastatin 2 mg once daily\n\nQuestion: The patient's condition has stabilized with appropriate inpatient treatment. What is an appropriate pharmacotherapy to consider for reducing the risk of death from heart failure in this patient?\n\n① Add digoxin\n② Add losartan\n③ Change carvedilol to verapamil\n④ Change spironolactone to furosemide\n⑤ Change lisinopril to sacubitril/valsartan",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 호흡곤란, 천명, 기침 증상을 한 달에 한 번 정도 경험하던 47세 여자가 최근에 천식을 진단받았다. 최신 Global Initiative for Asthma (GINA) 가이드라인에 의거하여 천식 증상이 있을 때 사용할 수 있는 흡입제로 추천할 수 있는 약물은?\n\n① 살메테롤(salmeterol)\n② 티오트로퓸(tiotropium)\n③ 플루티카손(fluticasone)\n④ 부데소니드/포르모테롤(budesonide/formoterol)\n⑤ 살부타몰/이프라트로퓸(salbutamol/ipratropium)",
        "question_text": "Question: A 47-year-old woman who experienced symptoms of shortness of breath, wheezing, and coughing about once a month was recently diagnosed with asthma. According to the latest Global Initiative for Asthma (GINA) guidelines, which medication can be recommended as an inhaler for use when asthma symptoms occur?\n\n① Salmeterol\n② Tiotropium\n③ Fluticasone\n④ Budesonide/formoterol\n⑤ Salbutamol/ipratropium",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 23세 여자가 천식 치료를 위해 중간용량의 플루티카손/살메테롤(fluticasone/salmeterol) 흡입제를 규칙적으로 사용하고 있다. 최근 3개월 동안 천식 증상으로 증상완화제를 사용한 횟수가 한 달에 한 번 이하로 유지되었고, 수면장해나 활동제한이 없고, 폐기능도 정상이다. 이 환자에서 천식 치료단계를 낮추고자 할 때 추천되는 방법은?\n\n① 살메테롤 중단\n② 플루티카손 중단\n③ 살메테롤 감량, 플루티카손 유지\n④ 플루티카손 감량, 살메테롤 유지\n⑤ 플루티카손과 살메테롤 중단, 필요시 살부타몰(salbutamol) 흡입",
        "question_text": "Question: A 23-year-old woman is regularly using a medium-dose fluticasone/salmeterol inhaler for asthma treatment. Over the past 3 months, she has used a reliever medication for asthma symptoms less than once a month, has no sleep disturbances or activity limitations, and her lung function is normal. What is the recommended method to step down asthma treatment for this patient?\n\n① Discontinue salmeterol\n② Discontinue fluticasone\n③ Reduce salmeterol, maintain fluticasone\n④ Reduce fluticasone, maintain salmeterol\n⑤ Discontinue fluticasone and salmeterol, use salbutamol inhaler as needed",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 25세 여자가 거의 매일 콧물, 재채기, 코막힘 등의 알레르기 비염 증상으로 고생하고 있다. 이러한 증상은 지난 한 달 동안 지속되고 있으며, 직장 생활에 방해가 된다. 약국에서 로라타딘(loratadine)을 구입하여 복용해도 증상이 조절되지 않았다. 적절한 약은?\n\n① 클레마스틴(clemastine) 경구제\n② 프레드니솔론(prednisolone) 경구제\n③ 플루티카손(fluticasone) 비강분무제\n④ 이프라트로퓸(ipratropium) 비강분무제\n⑤ 슈도에페드린(pseudoephedrine) 경구제",
        "question_text": "Question: A 25-year-old woman has been suffering from allergic rhinitis symptoms such as runny nose, sneezing, and nasal congestion almost daily. These symptoms have persisted for the past month and are interfering with her work life. She purchased and took loratadine from a pharmacy, but it did not control her symptoms. What is the appropriate medication?\n\n① Oral clemastine\n② Oral prednisolone\n③ Fluticasone nasal spray\n④ Ipratropium nasal spray\n⑤ Oral pseudoephedrine",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n만성폐쇄성폐질환(COPD)으로 치료 중인 78세 남자가 휴식 시 호흡곤란 증상이 수일에 걸쳐 악화되어 응급실을 방문하였다. 검사결과와 사용약물은 다음과 같다.\n\n[폐기능검사] 1초간노력성호기량(FEV1) 45% 정상예측치\n\n[혈액검사] WBC 5,000/mm3, 호산구(eosinophil) 1%\n\n[흉부 방사선 촬영 검사] 특이 소견 없음\n\n[사용약물]\n살부타몰(salbutamol) 흡입제 2번 분무/회 필요시 병원 오기 전 수회 사용\n티오트로퓸(tiotropium) 흡입제 2번 분무/회 1일 1회\n\nQuestion: 산소공급과 병행하여 급성 악화에서 회복되는 기간과 재원기간을 줄이기 위해서 단기투여요법으로 고려할 수 있는 약은?\n\n① 포르모테롤(formoterol) 경구제\n② 아미노필린(aminophylline) 주사제\n③ 프레드니솔론(prednisolone) 경구제\n④ 플루티카손(fluticasone) 네뷸라이저\n⑤ 아지트로마이신(azithromycin) 주사제",
        "question_text": "A 78-year-old man being treated for chronic obstructive pulmonary disease (COPD) visited the emergency room due to worsening dyspnea at rest over several days. The test results and medications used are as follows:\n\n[Pulmonary Function Test] Forced Expiratory Volume in 1 second (FEV1) 45% of predicted normal value\n\n[Blood Test] WBC 5,000/mm3, eosinophil 1%\n\n[Chest X-ray] No significant findings\n\n[Medications Used]\nSalbutamol inhaler 2 puffs/time as needed, used several times before coming to the hospital\nTiotropium inhaler 2 puffs/time once daily\n\nQuestion: In addition to oxygen supply, which medication can be considered for short-term therapy to reduce the recovery period from acute exacerbation and hospital stay?\n\n① Oral formoterol\n② Intravenous aminophylline\n③ Oral prednisolone\n④ Fluticasone nebulizer\n⑤ Intravenous azithromycin",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n만성폐쇄성폐질환(COPD)으로 치료 중인 78세 남자가 휴식 시 호흡곤란 증상이 수일에 걸쳐 악화되어 응급실을 방문하였다. 검사결과와 사용약물은 다음과 같다.\n\n[폐기능검사] 1초간노력성호기량(FEV1) 45% 정상예측치\n\n[혈액검사] WBC 5,000/mm3, 호산구(eosinophil) 1%\n\n[흉부 방사선 촬영 검사] 특이 소견 없음\n\n[사용약물]\n살부타몰(salbutamol) 흡입제 2번 분무/회 필요시 병원 오기 전 수회 사용\n티오트로퓸(tiotropium) 흡입제 2번 분무/회 1일 1회\n\nQuestion: 호흡곤란 증상에서 회복되고, 폐기능검사 결과가 호전되어(FEV1, 53% 정상예측치) 퇴원이 결정되었다. 적절한 추가약은?\n\n① 인다카테롤(indacaterol) 흡입제\n② 부데소니드(budesonide) 흡입제\n③ 아클리디니움(aclidinium) 흡입제\n④ 로플루밀라스트(roflumilast) 경구제\n⑤ 서방형 테오필린(theophylline) 경구제",
        "question_text": "A 78-year-old man being treated for chronic obstructive pulmonary disease (COPD) visited the emergency room due to worsening dyspnea at rest over several days. The test results and medications used are as follows:\n\n[Pulmonary Function Test] Forced Expiratory Volume in 1 second (FEV1) 45% of predicted normal value\n\n[Blood Test] WBC 5,000/mm3, eosinophil 1%\n\n[Chest X-ray] No significant findings\n\n[Medications Used]\nSalbutamol inhaler 2 puffs/time as needed, used several times before coming to the hospital\nTiotropium inhaler 2 puffs/time once daily\n\nQuestion: The patient has recovered from dyspnea symptoms, and pulmonary function test results have improved (FEV1, 53% of predicted normal value), so discharge has been decided. What is the appropriate additional medication?\n\n① Indacaterol inhaler\n② Budesonide inhaler\n③ Aclidinium inhaler\n④ Roflumilast oral medication\n⑤ Extended-release theophylline oral medication",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 35세 여자에게 상복부불쾌감과 속쓰림 증상이 있다. 위내시경검사 결과는 Helicobacter pylori 양성인 십이지장궤양이다. 페니실린 알레르기가 있는 이 환자의 제균요법으로 비스무트(bismuth)제제 기반의 4제요법을 사용하고자 한다. 오메프라졸(omeprazole), 비스무트제제, 메트로니다졸(metronidazole) 외 4제요법에 포함되는 약물은?\n\n① 리파부틴(rifabutin)\n② 티니다졸(tinidazole)\n③ 레보플록사신(levofloxacin)\n④ 테트라사이클린(tetracycline)\n⑤ 클래리트로마이신(clarithromycin)",
        "question_text": "Question: A 35-year-old woman has symptoms of upper abdominal discomfort and heartburn. The endoscopy result shows Helicobacter pylori positive duodenal ulcer. For this patient with penicillin allergy, a bismuth-based quadruple therapy is considered for eradication. In addition to omeprazole, bismuth compound, and metronidazole, which drug should be included in the quadruple therapy?\n\n① Rifabutin\n② Tinidazole\n③ Levofloxacin\n④ Tetracycline\n⑤ Clarithromycin",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 뇌전증과 천식으로 약물치료 중인 38세 남자가 비미란성 위식도역류병으로 오메프라졸(omeprazole) 처방을 받았다. 환자가 사용하는 약 중에서 오메프라졸에 의해서 혈중농도가 증가할 것으로 예상되는 약물은?\n\n[사용약물]\n페니토인(phenytoin) 300 mg 1일 1회 복용\n레비티라세탐(levetiracetam) 500 mg 1일 2회 복용\n살부타몰(salbutamol) 필요시 흡입\n플루티카손/살메테롤(fluticasone/salmeterol) 흡입제 1일 2회 흡입\n\n① 페니토인\n② 살부타몰\n③ 살메테롤\n④ 플루티카손\n⑤ 레비티라세탐",
        "question_text": "Question: A 38-year-old man undergoing drug treatment for epilepsy and asthma was prescribed omeprazole for non-erosive gastroesophageal reflux disease. Which of the medications the patient is using is expected to have an increased blood concentration due to omeprazole?\n\n[Medications in use]\nPhenytoin 300 mg once daily\nLevetiracetam 500 mg twice daily\nSalbutamol inhaler as needed\nFluticasone/salmeterol inhaler twice daily\n\n① Phenytoin\n② Salbutamol\n③ Salmeterol\n④ Fluticasone\n⑤ Levetiracetam",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 토혈과 흑색변 증상이 있는 55세 간경변증 환자의 급성 정맥류 출혈을 치료하고자 한다. 수액 공급과 내시경 치료와 함께 투여하여야 할 약물(요법)은?\n\n① 옥트레오티드(octreotide)\n② 프로프라놀롤(propranolol)\n③ 아목시실린/클라불란산(amoxicillin/clavulanate)\n④ 나도롤(nadolol)+시프로플록사신(ciprofloxacin)\n⑤ 테를리프레신(terlipressin)+세프트리악손(ceftriaxone)",
        "question_text": "Question: A 55-year-old patient with liver cirrhosis presents with hematemesis and melena, indicating acute variceal bleeding. Which medication (therapy) should be administered along with fluid resuscitation and endoscopic treatment?\n\n① Octreotide\n② Propranolol\n③ Amoxicillin/clavulanate\n④ Nadolol + Ciprofloxacin\n⑤ Terlipressin + Ceftriaxone",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 28세 여자가 만성 변비를 치료하기 위하여 팽창성 완화제와 자극성 완화제를 6개월 이상 사용하였으나 증상이 완화되지 않았다. 이 환자의 변비 치료에 적절한 약물은?\n\n① 라모세트론(ramosetron)\n② 디시클로민(dicyclomine)\n③ 히오시아민(hyoscyamine)\n④ 니푸록사지드(nifuroxazide)\n⑤ 프루칼로프라이드(prucalopride)",
        "question_text": "Question: A 28-year-old woman has been using bulk-forming laxatives and stimulant laxatives for more than 6 months to treat chronic constipation, but her symptoms have not improved. Which of the following drugs is appropriate for treating this patient's constipation?\n\n① Ramosetron\n② Dicyclomine\n③ Hyoscyamine\n④ Nifuroxazide\n⑤ Prucalopride",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 42세 남자가 만성 B형 간염으로 엔테카비르(entecavir)를 1년 동안 복용 중이다. 3개월 전 검사에서 혈중 B형간염바이러스 DNA가 검출되지 않았으나, 오늘 검사 결과는 2,171 IU/mL이었다. ALT 수치는 정상이었으며, 약제내성 검사에서 엔테카비르와 라미부딘(lamivudine) 내성으로 나왔다. 적절한 약물요법은?\n\n① 리바비린(ribavirin) 추가\n② 클레부딘(clevudine) 추가\n③ 텔비부딘(telbivudine) 추가\n④ 엔테카비르를 아데포비어(adefovir)로 변경\n⑤ 엔테카비르를 테노포비르디소프록실(tenofovir disoproxil, TDF)로 변경",
        "question_text": "Question: A 42-year-old man has been taking entecavir for chronic hepatitis B for one year. Three months ago, his blood test showed no detectable hepatitis B virus DNA, but today's test result was 2,171 IU/mL. ALT levels were normal, and drug resistance testing showed resistance to entecavir and lamivudine. What is the appropriate drug therapy?\n\n① Add ribavirin\n② Add clevudine\n③ Add telbivudine\n④ Change entecavir to adefovir\n⑤ Change entecavir to tenofovir disoproxil (TDF)",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n46세 남자에게 심한 복통과 하루 6~7회의 혈변이 발생하였다. 지난 2개월간 체중이 6 kg 감소하였고, 종종 어지러워하였다. 환자는 중증의 활동기 궤양성대장염으로 진단받았고 입원치료를 받을 예정이다.\n\n[활력징후] 체온 38.3℃, 심박수 92회/분\n\n[임상검사] Hgb 9.4 g/dL\n\n[대장내시경 검사]\n직장, 하행결장, 횡행결장에 광범위한 표재성 염증\n\nQuestion: 이 환자에게 적절한 약은?\n\n① 메살라진(mesalazine) 좌제\n② 설파살라진(sulfasalazine) 정제\n③ 부데소니드(budesonide) 관장제\n④ 타크롤리무스(tacrolimus) 주사제\n⑤ 메틸프레드니솔론(methylprednisolone) 주사제",
        "question_text": "A 46-year-old man experienced severe abdominal pain and 6-7 episodes of bloody stools per day. He lost 6 kg over the past 2 months and occasionally felt dizzy. The patient was diagnosed with severe active ulcerative colitis and is scheduled for inpatient treatment.\n\n[Vital signs] Temperature 38.3°C, Heart rate 92 beats/min\n\n[Clinical test] Hgb 9.4 g/dL\n\n[Colonoscopy]\nExtensive superficial inflammation in the rectum, descending colon, and transverse colon\n\nQuestion: Which medication is appropriate for this patient?\n\n① Mesalazine suppository\n② Sulfasalazine tablet\n③ Budesonide enema\n④ Tacrolimus injection\n⑤ Methylprednisolone injection",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n46세 남자에게 심한 복통과 하루 6~7회의 혈변이 발생하였다. 지난 2개월간 체중이 6 kg 감소하였고, 종종 어지러워하였다. 환자는 중증의 활동기 궤양성대장염으로 진단받았고 입원치료를 받을 예정이다.\n\n[활력징후] 체온 38.3℃, 심박수 92회/분\n\n[임상검사] Hgb 9.4 g/dL\n\n[대장내시경 검사]\n직장, 하행결장, 횡행결장에 광범위한 표재성 염증\n\nQuestion: 치료 후 관해에 도달하여 아자티오프린(azathioprine)으로 유지요법을 시작하였다. 아자티오프린의 이상반응과 관련하여 모니터링이 필요한 검사 항목은?\n\n① 백혈구\n② 골밀도\n③ 심전도\n④ 당화혈색소\n⑤ 동맥혈가스분압",
        "question_text": "A 46-year-old man experienced severe abdominal pain and 6-7 episodes of bloody stools per day. He lost 6 kg over the past 2 months and occasionally felt dizzy. The patient was diagnosed with severe active ulcerative colitis and is scheduled for inpatient treatment.\n\n[Vital signs] Temperature 38.3°C, Heart rate 92 beats/min\n\n[Clinical test] Hgb 9.4 g/dL\n\n[Colonoscopy]\nExtensive superficial inflammation in the rectum, descending colon, and transverse colon\n\nQuestion: After treatment, remission was achieved and maintenance therapy with azathioprine was initiated. Which test item needs to be monitored in relation to the side effects of azathioprine?\n\n① White blood cells\n② Bone density\n③ Electrocardiogram\n④ Glycated hemoglobin\n⑤ Arterial blood gas",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 만성폐쇄성폐질환과 뇌전증이 있는 67세 남자에게 항이뇨호르몬부적절분비증후군(syndrome of inappropriate antidiuretic hormone, SIADH)에 의한 저나트륨혈증이 발생하였다. 원인약물은?\n\n[사용약물]\n살부타몰(salbutamol) 필요시 2번 흡입\n유메클리디늄/빌란테롤(umeclidinium/vilanterol) 1일 1회 한번 흡입\n알마게이트(almagate) 1.5 g 1일 3회 경구 투여\n프레드니솔론(prednisolone) 30 mg 1일 1회 경구 투여\n카르바마제핀(carbamazepine) 200 mg 1일 2회 경구 투여\n\n① 살부타몰\n② 알마게이트\n③ 프레드니솔론\n④ 카르바마제핀\n⑤ 유메클리디늄/빌란테롤",
        "question_text": "Question: A 67-year-old man with chronic obstructive pulmonary disease and epilepsy developed hyponatremia due to syndrome of inappropriate antidiuretic hormone (SIADH). Which drug is the likely cause?\n\n[Medications in use]\nSalbutamol (albuterol): 2 inhalations as needed\nUmeclidinium/vilanterol: 1 inhalation once daily\nAlmagate: 1.5 g orally three times daily\nPrednisolone: 30 mg orally once daily\nCarbamazepine: 200 mg orally twice daily\n\n① Salbutamol\n② Almagate\n③ Prednisolone\n④ Carbamazepine\n⑤ Umeclidinium/vilanterol",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 골관절염과 알레르기 비염이 있는 72세 남자가 2주 전 고혈압과 당뇨병을 진단받아 약물치료를 시작하였다. 3일 전부터 소변량이 감소하고 체중이 증가하는 등 급성신손상이 발생하였다. 이 환자에서 급성신손상의 원인약물은?\n\n[임상검사(2주 전)] SCr 0.8 mg/dL, BUN 19 mg/dL\n[임상검사(내원 시)]\nSCr 1.8 mg/dL, BUN 53 mg/dL, FENa 0.8%\n소변: Na 19 mEq/L, 요비중 1.020, RBC 불검출, WBC 불검출\n[복용약물]\n에날라프릴(enalapril) 20 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n메트포르민(metformin) 500 mg 1일 2회\n아세트아미노펜(acetaminophen) 1,000 mg 1일 3회\n로라타딘(loratadine) 10 mg, 필요시\n\n① 로라타딘\n② 암로디핀\n③ 메트포르민\n④ 에날라프릴\n⑤ 아세트아미노펜",
        "question_text": "Question: A 72-year-old man with osteoarthritis and allergic rhinitis was diagnosed with hypertension and diabetes 2 weeks ago and started medication. Three days ago, he developed acute kidney injury with decreased urine output and weight gain. What is the likely causative drug for acute kidney injury in this patient?\n\n[Clinical tests (2 weeks ago)] SCr 0.8 mg/dL, BUN 19 mg/dL\n[Clinical tests (at admission)]\nSCr 1.8 mg/dL, BUN 53 mg/dL, FENa 0.8%\nUrine: Na 19 mEq/L, Specific gravity 1.020, RBC not detected, WBC not detected\n[Medications]\nEnalapril 20 mg once daily\nAmlodipine 10 mg once daily\nMetformin 500 mg twice daily\nAcetaminophen 1,000 mg three times daily\nLoratadine 10 mg, as needed\n\n① Loratadine\n② Amlodipine\n③ Metformin\n④ Enalapril\n⑤ Acetaminophen",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 만성신장병과 심부전이 있는 63세 남자에게 두근거림과 근육경련이 발생하였다. 혈청 칼륨이 6.6 mEq/L이었고, 심전도 검사에서 T 파 상승과 QRS 간격 연장이 관찰되었다. 우선적으로 사용해야 하는 약은?\n\n① 살부타몰(salbutamol) 정제\n② 플레카이니드(flecainide) 정제\n③ 스피로노락톤(spironolactone) 정제\n④ 글루콘산칼슘(calcium gluconate) 주사제\n⑤ 탄산수소나트륨(sodium bicarbonate) 주사제",
        "question_text": "Question: A 63-year-old man with chronic kidney disease and heart failure developed palpitations and muscle cramps. His serum potassium was 6.6 mEq/L, and an ECG showed T wave elevation and prolonged QRS interval. Which drug should be used as the first priority?\n\n① Salbutamol tablet\n② Flecainide tablet\n③ Spironolactone tablet\n④ Calcium gluconate injection\n⑤ Sodium bicarbonate injection",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 말기신부전으로 주 2회 혈액투석을 받고 있는 64세 여자가 다베포에틴알파(darbepoetin alfa)를 투여받고 있다. 이 약의 이상반응과 관련하여 모니터링이 필요한 검사항목은?\n\n① 요산\n② 혈당\n③ 혈압\n④ LDL-C\n⑤ 절대호중구수",
        "question_text": "Question: A 64-year-old woman with end-stage renal failure receiving hemodialysis twice a week is being treated with darbepoetin alfa. Which of the following test parameters should be monitored for potential adverse reactions to this medication?\n\n① Uric acid\n② Blood glucose\n③ Blood pressure\n④ LDL-C\n⑤ Absolute neutrophil count",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n만성신장병으로 진단된 59세 여자가 정기적으로 진료를 받고 있다. 최근 입맛이 없고 사지에 힘이 없으며, 인두염으로 목이 부어 알약을 삼키기 힘들다고 한다. 오늘 검사 결과는 다음과 같다.\n\n[임상검사]\nSCr 2.0 mg/dL, eGFR 22 mL/min/1.73 m2\nNa 140 mEq/L, K 4.5 mEq/L, Ca 10.0 mg/dL\nP 6.0 mg/dL (참고치 2.5~4.5 mg/dL)\nHgb 11.1 g/dL, 알부민 2.0 g/dL\niPTH 300 pg/mL (목표치 70~110 pg/mL)\n\nQuestion: 이 환자의 고인산혈증을 조절하기 위한 약물로 적절한 것은?\n\n① 칼시토닌(calcitonin)\n② 칼시트리올(calcitriol)\n③ 탄산칼슘(calcium carbonate)\n④ 탄산란탄(lanthanum carbonate)\n⑤ 폴리스티렌설폰칼슘(calcium polystyrene sulfonate)",
        "question_text": "A 59-year-old woman diagnosed with chronic kidney disease is receiving regular medical care. Recently, she reports loss of appetite, weakness in her limbs, and difficulty swallowing pills due to swollen throat from pharyngitis. Today's test results are as follows:\n\n[Clinical Tests]\nSCr 2.0 mg/dL, eGFR 22 mL/min/1.73 m2\nNa 140 mEq/L, K 4.5 mEq/L, Ca 10.0 mg/dL\nP 6.0 mg/dL (reference range 2.5-4.5 mg/dL)\nHgb 11.1 g/dL, Albumin 2.0 g/dL\niPTH 300 pg/mL (target range 70-110 pg/mL)\n\nQuestion: Which of the following drugs is appropriate to control this patient's hyperphosphatemia?\n\n① Calcitonin\n② Calcitriol\n③ Calcium carbonate\n④ Lanthanum carbonate\n⑤ Calcium polystyrene sulfonate",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n만성신장병으로 진단된 59세 여자가 정기적으로 진료를 받고 있다. 최근 입맛이 없고 사지에 힘이 없으며, 인두염으로 목이 부어 알약을 삼키기 힘들다고 한다. 오늘 검사 결과는 다음과 같다.\n\n[임상검사]\nSCr 2.0 mg/dL, eGFR 22 mL/min/1.73 m2\nNa 140 mEq/L, K 4.5 mEq/L, Ca 10.0 mg/dL\nP 6.0 mg/dL (참고치 2.5~4.5 mg/dL)\nHgb 11.1 g/dL, 알부민 2.0 g/dL\niPTH 300 pg/mL (목표치 70~110 pg/mL)\n\nQuestion: 이 환자의 이차성 부갑상선항진증을 치료하기 위한 약물은?\n\n① 시나칼세트(cinacalcet)\n② 파리칼시톨(paricalcitol)\n③ 철수크로오즈(iron sucrose)\n④ 아세트산칼슘(calcium acetate)\n⑤ 에르고칼시페롤(ergocalciferol)",
        "question_text": "A 59-year-old woman diagnosed with chronic kidney disease is receiving regular medical care. Recently, she reports loss of appetite, weakness in her limbs, and difficulty swallowing pills due to swollen throat from pharyngitis. Today's test results are as follows:\n\n[Clinical Tests]\nSCr 2.0 mg/dL, eGFR 22 mL/min/1.73 m2\nNa 140 mEq/L, K 4.5 mEq/L, Ca 10.0 mg/dL\nP 6.0 mg/dL (reference range 2.5-4.5 mg/dL)\nHgb 11.1 g/dL, Albumin 2.0 g/dL\niPTH 300 pg/mL (target range 70-110 pg/mL)\n\nQuestion: Which drug is appropriate for treating this patient's secondary hyperparathyroidism?\n\n① Cinacalcet\n② Paricalcitol\n③ Iron sucrose\n④ Calcium acetate\n⑤ Ergocalciferol",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 63세 남자가 당뇨병을 진단받았다. 이 환자에게 투여할 경구혈당강하제로 적절한 것은?\n\n[병력] 만성심부전(NYHA class II), 만성신장병\n[임상검사] 당화혈색소 7.5%, SCr 2.5 mg/dL, eGFR 23 mL/min/1.73m2, 좌심실박출률(LVEF) 36%\n\n① 아카르보스(acarbose)\n② 리나글립틴(linagliptin)\n③ 메트포르민(metformin)\n④ 피오글리타존(pioglitazone)\n⑤ 이프라글리플로진(ipragliflozin)",
        "question_text": "Question: A 63-year-old man has been diagnosed with diabetes. Which of the following oral hypoglycemic agents is appropriate for this patient?\n\n[Medical history] Chronic heart failure (NYHA class II), Chronic kidney disease\n[Clinical tests] HbA1c 7.5%, SCr 2.5 mg/dL, eGFR 23 mL/min/1.73m2, Left ventricular ejection fraction (LVEF) 36%\n\n① Acarbose\n② Linagliptin\n③ Metformin\n④ Pioglitazone\n⑤ Ipragliflozin",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 76세 남자가 당뇨병, 고혈압, 이상지질혈증으로 다음과 같은 약물을 복용하고 있다. 최근 소변량이 증가하면서 가슴이 두근거리고, 혈압 감소, 심박수 증가 등의 탈수 증상이 나타났다. 이런 증상의 원인이 될 수 있는 약물은?\n\n[복용약물]\n펠로디핀(felodipine) 5 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 2회\n다파글리플로진(dapagliflozin) 5 mg 1일 1회\n아토르바스타틴(atorvastatin) 20 mg 1일 1회\n\n① 펠로디핀\n② 리시노프릴\n③ 메트포르민\n④ 다파글리플로진\n⑤ 아토르바스타틴",
        "question_text": "Question: A 76-year-old man is taking the following medications for diabetes, hypertension, and dyslipidemia. Recently, he has experienced increased urination, heart palpitations, decreased blood pressure, increased heart rate, and other symptoms of dehydration. Which of the following medications could be the cause of these symptoms?\n\n[Medications]\nFelodipine 5 mg once daily\nLisinopril 10 mg once daily\nMetformin 1,000 mg twice daily\nDapagliflozin 5 mg once daily\nAtorvastatin 20 mg once daily\n\n① Felodipine\n② Lisinopril\n③ Metformin\n④ Dapagliflozin\n⑤ Atorvastatin",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 56세 여자가 당뇨병을 진단받아 다음 약물을 복용하고 있다. 환자는 지난달 수차례 손떨림, 두근거림, 허기짐 등의 저혈당 증상이 나타났다. 이에 대한 해결 방안은?\n\n[임상검사] 공복혈당 104 mg/dL, 당화혈색소 6.4%\n[복용약물] 메트포르민(metformin) 1,000 mg 1일 2회, 글리메피리드(glimepiride) 2 mg 1일 1회\n\n① 리라글루티드(liraglutide) 추가\n② 메트포르민 중단, 글리메피리드 증량\n③ 메트포르민 중단, 글리피지드(glipizide) 추가\n④ 글리메피리드 중단, 시타글립틴(sitagliptin) 추가\n⑤ 글리메피리드 중단, 인슐린글라진(insulin glargine) 추가",
        "question_text": "Question: A 56-year-old woman has been diagnosed with diabetes and is taking the following medications. The patient experienced several episodes of hypoglycemic symptoms such as hand tremors, palpitations, and hunger last month. What is the solution for this?\n\n[Clinical tests] Fasting blood glucose 104 mg/dL, HbA1c 6.4%\n[Medications] Metformin 1,000 mg twice daily, Glimepiride 2 mg once daily\n\n① Add liraglutide\n② Discontinue metformin, increase glimepiride\n③ Discontinue metformin, add glipizide\n④ Discontinue glimepiride, add sitagliptin\n⑤ Discontinue glimepiride, add insulin glargine",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 갑상선항진증을 새로 진단받은 32세 여자가 지난 2개월간 메티마졸(methimazole)치료를 받았다. 오늘 진료 시 환자의 갑상선항진증과 관련된 임상증상은 모두 사라졌고, 검사 결과는 다음과 같다. 이후 환자의 갑상선항진증에 대한 약물치료로 적절한 것은?\n\n[임상검사]\n| | 2개월 전 | 오늘 |\n|---|---|---|\n| 유리 T4 (참고치 0.8~2.7 ng/dL) | 7.1 ng/dL | 1.5 ng/dL |\n| TSH (참고치 0.5~4.7 mIU/L) | 0.01 mIU/L | 2.1 mIU/L |\n| AST/ALT (IU/L) | 35/32 | 32/30 |\n\n[복용약물] 메티마졸 10 mg 1일 3회\n\n① 메티마졸 중단\n② 메티마졸 감량\n③ 프로필티오우라실(propylthiouracil) 추가\n④ 메티마졸을 프로필티오우라실로 변경\n⑤ 메티마졸을 레보티록신(levothyroxine)으로 변경",
        "question_text": "Question: A 32-year-old woman newly diagnosed with hyperthyroidism has been receiving methimazole treatment for the past 2 months. At today's consultation, all clinical symptoms related to her hyperthyroidism have disappeared, and the test results are as follows. What is the appropriate drug treatment for the patient's hyperthyroidism going forward?\n\n[Clinical Tests]\n| | 2 months ago | Today |\n|---|---|---|\n| Free T4 (reference range 0.8~2.7 ng/dL) | 7.1 ng/dL | 1.5 ng/dL |\n| TSH (reference range 0.5~4.7 mIU/L) | 0.01 mIU/L | 2.1 mIU/L |\n| AST/ALT (IU/L) | 35/32 | 32/30 |\n\n[Current Medication] Methimazole 10 mg 3 times a day\n\n① Discontinue methimazole\n② Reduce methimazole dose\n③ Add propylthiouracil\n④ Change methimazole to propylthiouracil\n⑤ Change methimazole to levothyroxine",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 55세 여자에게 심한 피로감, 무기력증과 체중증가가 발생하였다. 검사 결과 약물유발갑상선저하증이 의심되었다. 환자의 사용약물 중 원인이 될 수 있는 것은?\n\n① 리튬(lithium)\n② 와파린(warfarin)\n③ 피리독신(pyridoxine)\n④ 인슐린디터머(insulin detemir)\n⑤ 아세트아미노펜(acetaminophen)",
        "question_text": "Question: A 55-year-old woman experienced severe fatigue, lethargy, and weight gain. Test results suggested drug-induced hypothyroidism. Which of the following medications that the patient is using could be the cause?\n\n① Lithium\n② Warfarin\n③ Pyridoxine\n④ Insulin detemir\n⑤ Acetaminophen",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n57세 남자가 입원 중 시행한 검사 결과 혈중 비타민B12 수치가 낮게 나타났다. 10년 전부터 고혈압, 당뇨병, 이상지질\n혈증, 통풍으로 약물을 복용하고 있으며, 체중 조절을 위해 식이요법과 운동요법을 병행하고 있다.\n\n[활력징후]\n혈압 128/80 mmHg, 심박수 75회/분, 체질량지수 31 kg/m2\n\n[임상검사]\n공복혈당 135 mg/dL, 당화혈색소 7.5%\nTC 200 mg/dL, LDL-C 125 mg/dL, TG 175 mg/dL\nHDL-C 40 mg/dL, SCr 0.9 mg/dL\n비타민B12 160 pg/mL (참고치 180~1,000 pg/mL)\n\n[복용약물]\n암로디핀(amlodipine) 10 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n심바스타틴(simvastatin) 40 mg 1일 1회\n알로푸리놀(allopurinol) 100 mg 1일 2회\n메트포르민(metformin) 서방정 1,000 mg 1일 2회\n\nQuestion: 이 환자에서 혈중 비타민B12 수치가 낮은 원인이 될 수 있는 약물은?\n\n① 암로디핀\n② 리시노프릴\n③ 심바스타틴\n④ 알로푸리놀\n⑤ 메트포르민",
        "question_text": "A 57-year-old male patient's blood test during hospitalization showed low vitamin B12 levels. He has been taking medications for hypertension, diabetes, dyslipidemia, and gout for 10 years, and is combining diet and exercise therapy for weight control.\n\n[Vital Signs]\nBlood pressure 128/80 mmHg, Heart rate 75 beats/min, BMI 31 kg/m2\n\n[Clinical Tests]\nFasting blood glucose 135 mg/dL, HbA1c 7.5%\nTC 200 mg/dL, LDL-C 125 mg/dL, TG 175 mg/dL\nHDL-C 40 mg/dL, SCr 0.9 mg/dL\nVitamin B12 160 pg/mL (Reference range 180-1,000 pg/mL)\n\n[Medications]\nAmlodipine 10 mg once daily\nLisinopril 10 mg once daily\nSimvastatin 40 mg once daily\nAllopurinol 100 mg twice daily\nMetformin extended-release 1,000 mg twice daily\n\nQuestion: Which medication could be the cause of low blood vitamin B12 levels in this patient?\n\n① Amlodipine\n② Lisinopril\n③ Simvastatin\n④ Allopurinol\n⑤ Metformin",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n57세 남자가 입원 중 시행한 검사 결과 혈중 비타민B12 수치가 낮게 나타났다. 10년 전부터 고혈압, 당뇨병, 이상지질\n혈증, 통풍으로 약물을 복용하고 있으며, 체중 조절을 위해 식이요법과 운동요법을 병행하고 있다.\n\n[활력징후]\n혈압 128/80 mmHg, 심박수 75회/분, 체질량지수 31 kg/m2\n\n[임상검사]\n공복혈당 135 mg/dL, 당화혈색소 7.5%\nTC 200 mg/dL, LDL-C 125 mg/dL, TG 175 mg/dL\nHDL-C 40 mg/dL, SCr 0.9 mg/dL\n비타민B12 160 pg/mL (참고치 180~1,000 pg/mL)\n\n[복용약물]\n암로디핀(amlodipine) 10 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n심바스타틴(simvastatin) 40 mg 1일 1회\n알로푸리놀(allopurinol) 100 mg 1일 2회\n메트포르민(metformin) 서방정 1,000 mg 1일 2회\n\nQuestion: 환자는 비타민B12를 적절히 복용하여 혈중 비타민 B12 수치는 정상 범위로 회복되었다. 이 환자의 혈당조절을 위한 약물요법은?\n\n① 메트포르민 증량\n② 리라글루티드(liraglutide) 추가\n③ 인슐린글라진(insulin glargine) 추가\n④ 메트포르민을 시타글립틴(sitagliptin)으로 변경\n⑤ 메트포르민을 엠파글리플로진(empagliflozin)으로 변경",
        "question_text": "A 57-year-old male was found to have low serum vitamin B12 levels during hospitalization. He has been taking medications for hypertension, diabetes, dyslipidemia, and gout for 10 years, and is combining diet and exercise therapy for weight control.\n\n[Vital Signs]\nBlood pressure 128/80 mmHg, Heart rate 75 beats/min, BMI 31 kg/m2\n\n[Clinical Tests]\nFasting blood glucose 135 mg/dL, HbA1c 7.5%\nTC 200 mg/dL, LDL-C 125 mg/dL, TG 175 mg/dL\nHDL-C 40 mg/dL, SCr 0.9 mg/dL\nVitamin B12 160 pg/mL (reference range 180-1,000 pg/mL)\n\n[Current Medications]\nAmlodipine 10 mg once daily\nLisinopril 10 mg once daily\nSimvastatin 40 mg once daily\nAllopurinol 100 mg twice daily\nMetformin extended-release 1,000 mg twice daily\n\nQuestion: The patient has taken vitamin B12 appropriately, and his serum vitamin B12 level has returned to the normal range. What is the appropriate drug therapy for glycemic control in this patient?\n\n① Increase metformin dose\n② Add liraglutide\n③ Add insulin glargine\n④ Change metformin to sitagliptin\n⑤ Change metformin to empagliflozin",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 중환자실에서 두 달 동안 도뇨관(catheter)을 삽입하고 있는 58세 남자에게 요로감염이 재발하였고 검사결과는 다음과 같다. 도뇨관 교체와 함께 투여할 적절한 경험적 항생제(요법)은?\n\n[임상검사] 체온 39°C, WBC 15,000/mm3\n[소변 배양검사]\n4주 전: Pseudomonas aeruginosa 동정\n현재: 검사 중\n\n① 아목시실린/클라불란산(amoxicillin/clavulanate)\n② 반코마이신(vancomycin)+에르타페넴(ertapenem)\n③ 리네졸리드(linezolid)+세프트리악손(ceftriaxone)\n④ 세프타지딤(ceftazidime)+토브라마이신(tobramycin)\n⑤ 설파메톡사졸/트리메토프림(sulfamethoxazole/trimethoprim)",
        "question_text": "Question: A 58-year-old male patient in the intensive care unit, who has had a urinary catheter inserted for two months, has experienced a recurrence of urinary tract infection. The test results are as follows. What is the appropriate empirical antibiotic (therapy) to administer along with catheter replacement?\n\n[Clinical tests] Temperature 39°C, WBC 15,000/mm3\n[Urine culture test]\n4 weeks ago: Pseudomonas aeruginosa isolated\nCurrent: In progress\n\n① Amoxicillin/clavulanate\n② Vancomycin + ertapenem\n③ Linezolid + ceftriaxone\n④ Ceftazidime + tobramycin\n⑤ Sulfamethoxazole/trimethoprim",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 32세 임부의 소변 배양검사에서 Escherichia coli 가 106 CFU/mL 검출되었다. 요로감염과 관련한 증상은 없다고 한다. 적절한 치료는?\n\n① 항생제 투여 불필요\n② 티니다졸(tinidazole)\n③ 세프포독심(cefpodoxime)\n④ 테트라사이클린(tetracycline)\n⑤ 시프로플록사신(ciprofloxacin)",
        "question_text": "Question: A urine culture test of a 32-year-old pregnant woman showed Escherichia coli at 106 CFU/mL. She reports no symptoms related to urinary tract infection. What is the appropriate treatment?\n\n① No antibiotic treatment necessary\n② Tinidazole\n③ Cefpodoxime\n④ Tetracycline\n⑤ Ciprofloxacin",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 발열(37.6℃), 인두의 이물감, 목 안 염증과 통증이 있는 11세 여아에게 급성 인두염 치료를 시작하고자 한다. 적절한 항생제는?\n\n[약물 알레르기] 아목시실린(amoxicillin): 복용 후 아나필락시스 반응\n[임상검사] 신속 항원 검사: A군 베타 용혈연쇄구균 (group A beta-hemolytic Streptococcus) 양성\n\n① 세프포독심(cefpodoxime)\n② 시프로플록사신(ciprofloxacin)\n③ 아지트로마이신(azithromycin)\n④ 아목시실린/클라불란산(amoxicillin/clavulanate)\n⑤ 설파메톡사졸/트리메토프림(sulfamethoxazole/trimethoprim)",
        "question_text": "Question: An 11-year-old girl presents with fever (37.6°C), a foreign body sensation in the pharynx, and inflammation and pain in the throat. You want to start treatment for acute pharyngitis. What is the appropriate antibiotic?\n\n[Drug Allergy] Amoxicillin: Anaphylactic reaction after ingestion\n[Clinical Test] Rapid antigen test: Positive for group A beta-hemolytic Streptococcus\n\n① Cefpodoxime\n② Ciprofloxacin\n③ Azithromycin\n④ Amoxicillin/clavulanate\n⑤ Sulfamethoxazole/trimethoprim",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 뇌졸중 치료를 위하여 입원한 56세 여자에게 병원획득성 폐렴이 발생하였다. 환자가 입원한 병원에서 동정된 Staphylococcus aureus 중 메티실린(methicillin) 내성을 나타내는 비율은 매년 6~8%로 보고되고 있다. 환자는 지난 3개월간 항생제 치료를 받은 적은 없다. 적절한 경험적 항생제는?\n\n[활력징후] 혈압 136/87 mmHg, 심박수 78회/분, 체온 38.7℃, 호흡수 22회/분\n[임상검사]\n혈액검사: WBC 15,400/mm3\n흉부 방사선 촬영 검사: 폐침윤\n\n① 세포탁심(cefotaxime) 주사제\n② 에르타페넴(ertapenem) 주사제\n③ 반코마이신(vancomycin) 주사제\n④ 레보플록사신(levofloxacin) 주사제\n⑤ 타이제사이클린(tigecycline) 주사제",
        "question_text": "Question: A 56-year-old woman hospitalized for stroke treatment has developed hospital-acquired pneumonia. The hospital where the patient is admitted reports that the rate of methicillin-resistant Staphylococcus aureus among isolated S. aureus strains is 6-8% annually. The patient has not received antibiotic treatment in the past 3 months. What is the appropriate empirical antibiotic?\n\n[Vital signs] Blood pressure 136/87 mmHg, Heart rate 78 beats/min, Body temperature 38.7℃, Respiratory rate 22 breaths/min\n[Clinical tests]\nBlood test: WBC 15,400/mm3\nChest X-ray: Pulmonary infiltration\n\n① Cefotaxime injection\n② Ertapenem injection\n③ Vancomycin injection\n④ Levofloxacin injection\n⑤ Tigecycline injection",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 이틀 전부터 발열(39℃), 기침, 객담 증상이 나타난 52세 남자에게 지역사회획득성 폐렴이 진단되었다. 외래에서 항생제 치료를 시작하고자 할 때, 적절한 경험적 항생제는?\n\n① 리네졸리드(linezolid)\n② 클린다마이신(clindamycin)\n③ 시프로플록사신(ciprofloxacin)\n④ 클래리트로마이신(clarithromycin)\n⑤ 아목시실린/클라불란산(amoxicillin/clavulanate)",
        "question_text": "Question: A 52-year-old man has been diagnosed with community-acquired pneumonia after experiencing fever (39°C), cough, and sputum production for the past two days. When starting antibiotic treatment in an outpatient setting, which is the appropriate empirical antibiotic?\n\n① Linezolid\n② Clindamycin\n③ Ciprofloxacin\n④ Clarithromycin\n⑤ Amoxicillin/clavulanate",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 27세 여자에게 다제내성결핵치료를위하여 베다퀼린(bedaquiline), 리네졸리드(linezolid), 시클로세린(cycloserine), 클로파지민(clofazimine), 아미카신(amikacin) 투여를 시작하였다. 말초 및 중추신경계 약물이상반응을 예방하기 위하여 추가하여야 할 약물은?\n\n① 폴산(folic acid)\n② 피리독신(pyridoxine)\n③ 아스코르브산(ascorbic acid)\n④ 콜레칼시페롤(cholecalciferol)\n⑤ 시아노코발라민(cyanocobalamin)",
        "question_text": "Question: A 27-year-old woman was started on bedaquiline, linezolid, cycloserine, clofazimine, and amikacin for the treatment of multidrug-resistant tuberculosis. Which drug should be added to prevent peripheral and central nervous system adverse drug reactions?\n\n① Folic acid\n② Pyridoxine\n③ Ascorbic acid\n④ Cholecalciferol\n⑤ Cyanocobalamin",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 대학교 기숙사에 거주하는 23세 여자에게 뇌수막염이 발생하여 반코마이신(vancomycin)과 세프트리악손(ceftriaxone)으로 경험적 치료를 시작하였다. 경험적 치료 시작 3일 후 뇌척수액 미생물 검사 결과 페니실린(penicillin) 내성 Neisseria meningitidis가 동정되었을 때, 적절한 확정적 항생제 요법은?\n\n① 현재 항생제 요법 유지\n② 반코마이신 중단 후 세프트리악손 유지\n③ 세프트리악손 중단 후 반코마이신 유지\n④ 세프트리악손 중단 후 콜리스틴(colistin) 추가\n⑤ 반코마이신 중단 후 리네졸리드(linezolid) 추가",
        "question_text": "Question: A 23-year-old female living in a university dormitory developed meningitis, and empirical treatment was initiated with vancomycin and ceftriaxone. Three days after starting the empirical treatment, cerebrospinal fluid microbiology results identified penicillin-resistant Neisseria meningitidis. What is the appropriate definitive antibiotic therapy?\n\n① Maintain current antibiotic regimen\n② Discontinue vancomycin and continue ceftriaxone\n③ Discontinue ceftriaxone and continue vancomycin\n④ Discontinue ceftriaxone and add colistin\n⑤ Discontinue vancomycin and add linezolid",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 8세 남아가 이틀 전 햄버거를 먹은 후 경련성 복부통증, 복부팽창, 물설사가 있다가 어제부터 혈변 설사가 발생하였고 복통이 악화되었다. 검사 결과 장출혈대장균(enterohemorrhagic E. coli ) 감염으로 인한 용혈요독증후군으로 진단되었다. 적절한 치료요법은?\n\n① 유산균(lactobacillus)\n② 로페라미드(loperamide)\n③ 아지트로마이신(azithromycin)\n④ 시프로플록사신(ciprofloxacin)\n⑤ 항생제 비투여, 지지요법(supportive care)",
        "question_text": "Question: An 8-year-old boy developed spasmodic abdominal pain, abdominal distension, and watery diarrhea two days after eating a hamburger. Since yesterday, he has been experiencing bloody diarrhea and worsening abdominal pain. Test results diagnosed hemolytic uremic syndrome caused by enterohemorrhagic E. coli infection. What is the appropriate treatment?\n\n① Probiotics (lactobacillus)\n② Loperamide\n③ Azithromycin\n④ Ciprofloxacin\n⑤ No antibiotics, supportive care",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 고혈압, 위궤양, 골관절염으로 5년 동안 약물을 복용하고 있는 62세 남자에게서 3일 전부터 점액성 혈변 설사가 하루 5번 이상 매일 발생하였다. 검사 결과 Clostridium (Clostridioides) difficile 감염으로 진단되었을 때 관련 있는 약물은?\n\n[임상검사] 체온 38.8℃, WBC 18,000/mm3\n[대변 검사] C. difficile antigen 양성, C. difficile toxin A 양성, C. difficile toxin B 양성\n[복용약물]\n로사르탄(losartan) 50 mg 1일 1회\n알마게이트(almagate) 500 mg 1일 3회\n이부프로펜(ibuprofen) 400 mg 1일 3회\n란소프라졸(lansoprazole) 30 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 12.5 mg 1일 1회\n\n① 로사르탄\n② 알마게이트\n③ 이부프로펜\n④ 란소프라졸\n⑤ 히드로클로로티아지드",
        "question_text": "Question: A 62-year-old man who has been taking medication for hypertension, gastric ulcer, and osteoarthritis for 5 years has experienced mucoid bloody diarrhea more than 5 times a day for the past 3 days. When diagnosed with Clostridium (Clostridioides) difficile infection based on test results, which medication is likely to be associated?\n\n[Clinical tests] Body temperature 38.8°C, WBC 18,000/mm3\n[Stool test] C. difficile antigen positive, C. difficile toxin A positive, C. difficile toxin B positive\n[Medications]\nLosartan 50 mg once daily\nAlmagate 500 mg three times daily\nIbuprofen 400 mg three times daily\nLansoprazole 30 mg once daily\nHydrochlorothiazide 12.5 mg once daily\n\n① Losartan\n② Almagate\n③ Ibuprofen\n④ Lansoprazole\n⑤ Hydrochlorothiazide",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n평소에 건강하던 52세 남자가 3주 전 추락사고로 입원\n하여 수술 후 정맥영양공급 치료를 받고 있다. 10일 전 폐렴이 발생하여 반코마이신(vancomycin), 세페핌(cefepime), 시프로플록사신(ciprofloxacin)을 7일간 투여하였다. 항생제 치료 후 전반적인 상태가 호전 중이었으나 어제부터 발열, 오한 등의 증상이 나타나 검사결과 칸디다혈증이 진단되었다.\n\n[병력] 없음\n\n[입원 전 복용약물] 없음\n\n[활력징후]\n체온 38.9℃, 혈압 118/76 mmHg, 심박수 58회/분, 호흡수 18회/분\n\n[혈액검사]\nWBC 12,600/mm3, 절대호중구수(ANC) 8,820/mm3\n배양검사: Candida spp. (균종 및 감수성 검사 진행 중)\n\nQuestion: 적절한 경험적 치료제는?\n\n① 알벤다졸(albendazole)\n② 플루코나졸(fluconazole)\n③ 세프메타졸(cefmetazole)\n④ 케토코나졸(ketoconazole)\n⑤ 메트로니다졸(metronidazole)",
        "question_text": "A previously healthy 52-year-old man was hospitalized 3 weeks ago due to a fall accident and has been receiving intravenous nutritional support after surgery. 10 days ago, he developed pneumonia and was treated with vancomycin, cefepime, and ciprofloxacin for 7 days. After antibiotic treatment, his overall condition was improving, but since yesterday, symptoms such as fever and chills appeared. Test results diagnosed candidemia.\n\n[Medical history] None\n\n[Medications before hospitalization] None\n\n[Vital signs]\nTemperature 38.9°C, Blood pressure 118/76 mmHg, Heart rate 58 beats/min, Respiratory rate 18 breaths/min\n\n[Blood test]\nWBC 12,600/mm3, Absolute Neutrophil Count (ANC) 8,820/mm3\nCulture test: Candida spp. (Species identification and susceptibility testing in progress)\n\nQuestion: What is the appropriate empirical treatment?\n\n① Albendazole\n② Fluconazole\n③ Cefmetazole\n④ Ketoconazole\n⑤ Metronidazole",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n평소에 건강하던 52세 남자가 3주 전 추락사고로 입원\n하여 수술 후 정맥영양공급 치료를 받고 있다. 10일 전 폐렴이 발생하여 반코마이신(vancomycin), 세페핌(cefepime), 시프로플록사신(ciprofloxacin)을 7일간 투여하였다. 항생제 치료 후 전반적인 상태가 호전 중이었으나 어제부터 발열, 오한 등의 증상이 나타나 검사결과 칸디다혈증이 진단되었다.\n\n[병력] 없음\n\n[입원 전 복용약물] 없음\n\n[활력징후]\n체온 38.9℃, 혈압 118/76 mmHg, 심박수 58회/분, 호흡수 18회/분\n\n[혈액검사]\nWBC 12,600/mm3, 절대호중구수(ANC) 8,820/mm3\n배양검사: Candida spp. (균종 및 감수성 검사 진행 중)\n\nQuestion: 혈액배양검사 결과 Candida krusei 가 동정되었을 때, 적절한 항진균제는?\n\n① 테르비나핀(terbinafine)\n② 플루시토신(flucytosine)\n③ 그리세오풀빈(griseofulvin)\n④ 이트라코나졸(itraconazole)\n⑤ 아니둘라펀진(anidulafungin)",
        "question_text": "A previously healthy 52-year-old male was hospitalized 3 weeks ago due to a fall accident and has been receiving intravenous nutritional support after surgery. 10 days ago, he developed pneumonia and was treated with vancomycin, cefepime, and ciprofloxacin for 7 days. After antibiotic treatment, his overall condition was improving, but since yesterday, symptoms such as fever and chills appeared, and test results diagnosed candidemia.\n\n[Medical history] None\n\n[Medications before hospitalization] None\n\n[Vital signs]\nTemperature 38.9°C, Blood pressure 118/76 mmHg, Heart rate 58 beats/min, Respiratory rate 18 breaths/min\n\n[Blood test]\nWBC 12,600/mm3, Absolute Neutrophil Count (ANC) 8,820/mm3\nCulture test: Candida spp. (Species identification and susceptibility test in progress)\n\nQuestion: If Candida krusei is identified in the blood culture test, which antifungal agent is appropriate?\n\n① Terbinafine\n② Flucytosine\n③ Griseofulvin\n④ Itraconazole\n⑤ Anidulafungin",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 평소 아세트아미노펜(acetaminophen) 최대용량으로 편두통이 조절되지 않는 42세 남자에게 편두통 발작이 있었다. 이 환자의 편두통 부전치료(abortive therapy) 목적으로 사용할 수 있는 적절한 약물은?\n\n① 베라파밀(verapamil)\n② 가바펜틴(gabapentin)\n③ 플루옥세틴(fluoxetine)\n④ 프로바트립탄(frovatriptan)\n⑤ 프로프라놀롤(propranolol)",
        "question_text": "Question: A 42-year-old man who usually cannot control his migraine with the maximum dose of acetaminophen experienced a migraine attack. Which of the following drugs is appropriate for abortive therapy of this patient's migraine?\n\n① Verapamil\n② Gabapentin\n③ Fluoxetine\n④ Frovatriptan\n⑤ Propranolol",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 최근 중증 파킨슨병으로 진단받은 81세 여자가 근육 강직과 함께 표정이 없으며 진전과 운동기능 장애를 보이고 있다. 치료를 시작하려 할 때 적절한 약물은?\n\n① 셀레길린(selegiline)\n② 아만타딘(amantadine)\n③ 엔타카폰(entacapone)\n④ 프라미펙솔(pramipexole)\n⑤ 카르비도파/레보도파(carbidopa/levodopa)",
        "question_text": "Question: An 81-year-old woman recently diagnosed with severe Parkinson's disease shows muscle rigidity, lack of facial expression, tremor, and motor dysfunction. What is the appropriate medication to start treatment?\n\n① Selegiline\n② Amantadine\n③ Entacapone\n④ Pramipexole\n⑤ Carbidopa/Levodopa",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 26세 여자(체질량지수 30 kg/m2)가 부분발작(국소발작)으로 약물치료를 시작하려 한다. 체질량지수를 고려할 때 적절한 약물은?\n\n① 클로바잠(clobazam)\n② 프레가발린(pregabalin)\n③ 발프로산(valproic acid)\n④ 토피라메이트(topiramate)\n⑤ 에토숙시미드(ethosuximide)",
        "question_text": "Question: A 26-year-old woman (body mass index 30 kg/m2) is about to start drug treatment for partial seizures (focal seizures). Considering her body mass index, which drug is appropriate?\n\n① Clobazam\n② Pregabalin\n③ Valproic acid\n④ Topiramate\n⑤ Ethosuximide",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 42세 여자(키 155 cm, 체중 67 kg)가 조현병으로 두 달 전부터 올란자핀(olanzapine)을 복용하고 있다. 조현병 증상은 조절되었으나 체중이 5 kg 증가하여 올란자핀을 대체하려 할 때, 적절한 약물은?\n\n① 클로자핀(clozapine)\n② 리스페리돈(risperidone)\n③ 지프라시돈(ziprasidone)\n④ 팔리페리돈(paliperidone)\n⑤ 클로르프로마진(chlorpromazine)",
        "question_text": "Question: A 42-year-old woman (height 155 cm, weight 67 kg) has been taking olanzapine for schizophrenia for two months. While her schizophrenia symptoms are controlled, she has gained 5 kg. When considering replacing olanzapine, which of the following drugs is appropriate?\n\n① Clozapine\n② Risperidone\n③ Ziprasidone\n④ Paliperidone\n⑤ Chlorpromazine",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 38세 여자가 평소 숨이 차고 심장이 뛰며 죽을 것 같은 극도의 공포와 절박감을 나타냈고 공황장애로 진단받았다. 적절한 약물은?\n\n① 졸피뎀(zolpidem)\n② 트라조돈(trazodone)\n③ 파록세틴(paroxetine)\n④ 히드록시진(hydroxyzine)\n⑤ 아미트리프틸린(amitriptyline)",
        "question_text": "Question: A 38-year-old woman has been experiencing shortness of breath, heart palpitations, and extreme fear and desperation as if she were dying. She was diagnosed with panic disorder. What is the appropriate medication?\n\n① Zolpidem\n② Trazodone\n③ Paroxetine\n④ Hydroxyzine\n⑤ Amitriptyline",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 37세 남자가 불면증을 동반한 범불안장애로 에스시탈로프람(escitalopram)을 복용 중이다. 불안 증상은 호전되고 있으나 불면 증상이 개선되지 않았을 때 추가할 약물은?\n\n① 모다피닐(modafinil)\n② 플루옥세틴(fluoxetine)\n③ 부프로피온(bupropion)\n④ 알프라졸람(alprazolam)\n⑤ 아토목세틴(atomoxetine)",
        "question_text": "Question: A 37-year-old man is taking escitalopram for generalized anxiety disorder with insomnia. While his anxiety symptoms are improving, his insomnia symptoms have not improved. Which medication should be added?\n\n① modafinil\n② fluoxetine\n③ bupropion\n④ alprazolam\n⑤ atomoxetine",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 11세 남아가 가만히 있지 못하고 과도하게 돌아다니고 계속 말을 하는 등 주의력결핍과다활동장애가 있어 약물요법과 행동치료를 시작할 예정이다. 적절한 약물은?\n\n① 리튬(lithium)\n② 부프로피온(bupropion)\n③ 이미프라민(imipramine)\n④ 발프로산(valproic acid)\n⑤ 메틸페니데이트(methylphenidate)",
        "question_text": "Question: An 11-year-old boy is unable to sit still, excessively moves around, and constantly talks, showing symptoms of Attention Deficit Hyperactivity Disorder (ADHD). He is about to start medication therapy and behavioral treatment. What is the appropriate medication?\n\n① Lithium\n② Bupropion\n③ Imipramine\n④ Valproic acid\n⑤ Methylphenidate",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n알츠하이머병이 있는 72세 남자가 혼동, 망상, 격앙과 함께 괴상하고 공격적 행동을 보여 응급실에 왔다. 배우자는 이러한 증상이 2개월 전부터 있었다고 했다. 환자는 도네페질(donepezil) 10 mg을 1일 1회 복용하고 있다.\n\nQuestion: 이 환자의 정신증상을 치료하기 위해 적절한 약물은?\n\n① 벤라팍신(venlafaxine)\n② 플루옥세틴(fluoxetine)\n③ 아리피프라졸(aripiprazole)\n④ 아미트리프틸린(amitriptyline)\n⑤ 카르바마제핀(carbamazepine)",
        "question_text": "A 72-year-old man with Alzheimer's disease came to the emergency room showing confusion, delusions, agitation, and bizarre and aggressive behavior. His spouse reported that these symptoms had been present for 2 months. The patient is taking donepezil 10 mg once daily.\n\nQuestion: What is the appropriate medication to treat this patient's psychiatric symptoms?\n\n① Venlafaxine\n② Fluoxetine\n③ Aripiprazole\n④ Amitriptyline\n⑤ Carbamazepine",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n알츠하이머병이 있는 72세 남자가 혼동, 망상, 격앙과 함께 괴상하고 공격적 행동을 보여 응급실에 왔다. 배우자는 이러한 증상이 2개월 전부터 있었다고 했다. 환자는 도네페질(donepezil) 10 mg을 1일 1회 복용하고 있다.\n\nQuestion: 현재 이 환자의 간이정신상태검사(MMSE) 점수는 8점이다. 적절한 약물요법은?\n\n① 도네페질 감량\n② 메만틴(memantine) 추가\n③ 은행엽제제(ginkgo leaf) 추가\n④ 도네페질을 갈란타민(galantamine)으로 대체\n⑤ 도네페질을 리바스티그민(rivastigmine)으로 대체",
        "question_text": "A 72-year-old man with Alzheimer's disease came to the emergency room showing confusion, delusions, agitation, and bizarre and aggressive behavior. His spouse reported that these symptoms had been present for 2 months. The patient is currently taking donepezil 10 mg once daily.\n\nQuestion: The patient's current Mini-Mental State Examination (MMSE) score is 8 points. What is the appropriate drug therapy?\n\n① Reduce the dose of donepezil\n② Add memantine\n③ Add ginkgo leaf extract\n④ Replace donepezil with galantamine\n⑤ Replace donepezil with rivastigmine",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 성인의 류마티스관절염을 치료하기 위해 사용할 때 정기적인 안저검사와, 시각이상과 관련된 모니터링이 필요한 약물은?\n\n① 에타너셉트(etanercept)\n② 설파살라진(sulfasalazine)\n③ 사이클로스포린(cyclosporine)\n④ 메토트렉세이트(methotrexate)\n⑤ 히드록시클로로퀸(hydroxychloroquine)",
        "question_text": "Question: Which drug requires regular fundus examination and monitoring for visual disturbances when used to treat rheumatoid arthritis in adults?\n\n① Etanercept\n② Sulfasalazine\n③ Cyclosporine\n④ Methotrexate\n⑤ Hydroxychloroquine",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 만성신장병이 있는 58세 여자에게 골다공증 치료를 위하여 투여할 적절한 약물은?\n\n[임상검사]\nNa 142 mEq/L, K 4.5 mEq/L Ca 10.1 mg/dL, P 4.5 mg/dL (참고치 2.5~4.5 mg/dL), BUN 32 mg/dL, CrCl 28 mL/min, 알부민 2.6 g/dL\n골밀도 검사: T-score -3.0(요추), -2.3(고관절)\n\n① 데노수맙(denosumab)\n② 알렌드론산(alendronate)\n③ 이반드론산(ibandronate)\n④ 테리파라타이드(teriparatide)\n⑤ 탄산칼슘(calcium carbonate)",
        "question_text": "Question: What is the appropriate medication to administer for osteoporosis treatment in a 58-year-old woman with chronic kidney disease?\n\n[Clinical Tests]\nNa 142 mEq/L, K 4.5 mEq/L, Ca 10.1 mg/dL, P 4.5 mg/dL (reference range 2.5-4.5 mg/dL), BUN 32 mg/dL, CrCl 28 mL/min, Albumin 2.6 g/dL\nBone Density Test: T-score -3.0 (lumbar spine), -2.3 (hip)\n\n① Denosumab\n② Alendronate\n③ Ibandronate\n④ Teriparatide\n⑤ Calcium carbonate",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 27세 여자가 경구피임약을 생리 1일째부터 12일간 규칙적으로 복용하였으나, 이후 2일간 복용을 잊었다. 환자가 이 사실이 생각난 즉시 피임약을 1정 복용하였고, 이후 정해진 시간에 복용할 예정이다. 이 환자에서 추가피임법 시행이 필요한 최소기간은?\n\n[복용약물] 에티닐에스트라디올/데소게스트렐(ethinyl estradiol/desogestrel)  0.02/0.15 mg 정 1정 1일 1회, 21일간 복용 후 7일간 휴약\n\n① 불필요\n② 1일\n③ 3일\n④ 7일\n⑤ 14일",
        "question_text": "Question: A 27-year-old woman took oral contraceptives regularly from the first day of her menstrual cycle for 12 days, but then forgot to take them for 2 days. As soon as she remembered this fact, she took one pill and plans to continue taking them at the scheduled time thereafter. What is the minimum period for which additional contraceptive methods should be used for this patient?\n\n[Medication] Ethinyl estradiol/desogestrel 0.02/0.15 mg tablet, 1 tablet once daily for 21 days, followed by a 7-day break\n\n① Not necessary\n② 1 day\n③ 3 days\n④ 7 days\n⑤ 14 days",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 66세 남자가 1년 전부터 양성전립선비대 치료를 위하여 탐스로신(tamsulosin)과 피나스테리드(finasteride)를 복용 중이다. 치료 약물을 잘 복용하는데도 빈뇨, 절박뇨 등 방광자극 증상이 지속되어 약물을 추가하고자 할 때, 적절한 것은?\n\n① 타다라필(tadalafil)\n② 알푸조신(alfuzosin)\n③ 실로도신(silodosin)\n④ 둘록세틴(duloxetine)\n⑤ 톨터로딘(tolterodine)",
        "question_text": "Question: A 66-year-old man has been taking tamsulosin and finasteride for the treatment of benign prostatic hyperplasia for the past year. Despite adhering well to the treatment regimen, bladder irritation symptoms such as frequent urination and urinary urgency persist. When considering adding a medication, which of the following is appropriate?\n\n① Tadalafil\n② Alfuzosin\n③ Silodosin\n④ Duloxetine\n⑤ Tolterodine",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 소화성궤양, 만성허리통증이 있는 46세 남자의 임상검사결과와 복용약물은 다음과 같다. 환자는 3년 전에 급성 통풍 발작이 1회 있었고, 이후에는 통풍 발작이 없었으며, 요로결석증 과거병력이 없고, 통풍결절이나 통풍성 관절 손상이 없다.\n\n[임상검사]\n혈압 134/82 mmHg, 심박수 80회/분, 호흡수 18회/분\nNa 140 mEq/L, K 4.0 mEq/L, eGFR 100 mL/min/1.73 m2\n공복혈당 100mg/dL, 요산 7.9mg/dL (참고치 2.0~7.5 mg/dL)\n\n[복용약물]\n트라마돌(tramadol) 50 mg 1일 4회\n파모티딘(famotidine) 20 mg 1일 2회\n메토프롤롤(metoprolol) 100 mg 1일 1회\n아세트아미노펜(acetaminophen) 500 mg 1정 필요시\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n\nQuestion: 환자의 요산 수치가 높은 것과 관련이 큰 약물은?\n\n① 트라마돌(tramadol)\n② 파모티딘(famotidine)\n③ 메토프롤롤(metoprolol)\n④ 아세트아미노펜(acetaminophen)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "A 46-year-old male with hypertension, peptic ulcer, and chronic back pain has the following clinical test results and medications. The patient had one acute gout attack 3 years ago, with no gout attacks since then, no history of urolithiasis, and no gouty tophi or gouty joint damage.\n\n[Clinical Tests]\nBlood pressure 134/82 mmHg, Heart rate 80 beats/min, Respiratory rate 18 breaths/min\nNa 140 mEq/L, K 4.0 mEq/L, eGFR 100 mL/min/1.73 m2\nFasting blood glucose 100mg/dL, Uric acid 7.9mg/dL (reference range 2.0-7.5 mg/dL)\n\n[Medications]\nTramadol 50 mg 4 times daily\nFamotidine 20 mg twice daily\nMetoprolol 100 mg once daily\nAcetaminophen 500 mg 1 tablet as needed\nHydrochlorothiazide 25 mg once daily\n\nQuestion: Which medication is most likely related to the patient's elevated uric acid level?\n\n① Tramadol\n② Famotidine\n③ Metoprolol\n④ Acetaminophen\n⑤ Hydrochlorothiazide",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 소화성궤양, 만성허리통증이 있는 46세 남자의 임상검사결과와 복용약물은 다음과 같다. 환자는 3년 전에 급성 통풍 발작이 1회 있었고, 이후에는 통풍 발작이 없었으며, 요로결석증 과거병력이 없고, 통풍결절이나 통풍성 관절 손상이 없다.\n\n[임상검사]\n혈압 134/82 mmHg, 심박수 80회/분, 호흡수 18회/분\nNa 140 mEq/L, K 4.0 mEq/L, eGFR 100 mL/min/1.73 m2\n공복혈당 100mg/dL, 요산 7.9mg/dL (참고치 2.0~7.5 mg/dL)\n\n[복용약물]\n트라마돌(tramadol) 50 mg 1일 4회\n파모티딘(famotidine) 20 mg 1일 2회\n메토프롤롤(metoprolol) 100 mg 1일 1회\n아세트아미노펜(acetaminophen) 500 mg 1정 필요시\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n\nQuestion: 환자의 고요산혈증 유발 약물의 중지와 환자의 임상 관련 모니터링 이외에 환자에게 통풍과 관련하여 필요한 권고사항은?\n\n① 고단백 식이 추천\n② 콜키신(colchicine) 추가\n③ 퓨린(purine) 풍부 음식 제한\n④ 알로푸리놀(allopurinol) 추가\n⑤ 벤즈브로마론(benzbromarone) 추가",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 46-year-old male with hypertension, peptic ulcer, and chronic back pain has the following clinical test results and medications. The patient had one acute gout attack 3 years ago, with no gout attacks since then, no history of urolithiasis, and no gouty tophi or gouty joint damage.\n\n[Clinical Tests]\nBlood pressure 134/82 mmHg, Heart rate 80 beats/min, Respiratory rate 18 breaths/min\nNa 140 mEq/L, K 4.0 mEq/L, eGFR 100 mL/min/1.73 m2\nFasting blood glucose 100mg/dL, Uric acid 7.9mg/dL (reference range 2.0-7.5 mg/dL)\n\n[Medications]\nTramadol 50 mg 4 times daily\nFamotidine 20 mg twice daily\nMetoprolol 100 mg once daily\nAcetaminophen 500 mg 1 tablet as needed\nHydrochlorothiazide 25 mg once daily\n\nQuestion: Besides discontinuing the medication causing hyperuricemia and monitoring the patient's clinical condition, what recommendation should be given to the patient regarding gout?\n\n① Recommend high-protein diet\n② Add colchicine\n③ Restrict purine-rich foods\n④ Add allopurinol\n⑤ Add benzbromarone",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 급성골수성백혈병을 진단받은 56세 남자가 항암요법 시작 전에 심장초음파 검사를 받았다. 좌심실박출률(LVEF)이 35%일 때, 감량이나 중단이 필요한 약물은?\n\n[항암요법] 시타라빈(cytarabine) 200 mg/m2/일 정맥투여, 제1~7일 이다루비신(idarubicin) 12 mg/m2/일 정맥투여, 제1~3일 팔로노세트론(palonosetron) 0.25 mg 1회 정맥투여 포사코나졸(posaconazole) 장용정 300 mg 1일 2회 경구 투여, 이후 300 mg 1일 1회 경구투여 시프로플록사신(ciprofloxacin) 500 mg 1일 2회 경구투여\n\n① 시타라빈\n② 이다루비신\n③ 포사코나졸\n④ 팔로노세트론\n⑤ 시프로플록사신",
        "question_text": "Question: A 56-year-old man diagnosed with acute myeloid leukemia underwent an echocardiogram before starting chemotherapy. When the left ventricular ejection fraction (LVEF) is 35%, which drug requires dose reduction or discontinuation?\n\n[Chemotherapy regimen]\nCytarabine 200 mg/m2/day IV, Days 1-7\nIdarubicin 12 mg/m2/day IV, Days 1-3\nPalonosetron 0.25 mg IV single dose\nPosaconazole delayed-release tablet 300 mg PO twice daily, then 300 mg PO once daily\nCiprofloxacin 500 mg PO twice daily\n\n① Cytarabine\n② Idarubicin\n③ Posaconazole\n④ Palonosetron\n⑤ Ciprofloxacin",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 만성골수성백혈병을 진단받고 다사티닙(dasatinib)을 복용하고 있는 48세 여자에게 레보플록사신(levofloxacin)을 정맥투여 하고자 한다. 두 약물의 상호작용을 고려할 때 주의하여야 할 이상반응은?\n\n① 골다공증\n② 고요산혈증\n③ QT간격 연장\n④ 고마그네슘혈증\n⑤ 콜레스테롤 수치 상승",
        "question_text": "Question: A 48-year-old woman diagnosed with chronic myeloid leukemia and taking dasatinib is to be given levofloxacin intravenously. Considering the interaction between these two drugs, which adverse reaction should be monitored carefully?\n\n① Osteoporosis\n② Hyperuricemia\n③ QT interval prolongation\n④ Hypermagnesemia\n⑤ Elevated cholesterol levels",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 45세 여자가 3기 유방암을 진단받아 유방전절제술을 계획 중이다. 호르몬수용체는 음성, HER2는 양성이고, ECOG 수행도는 1이다. 적절한 수술 전 항암요법은?\n\n① 카페시타빈(capecitabine)+라파티닙(lapatinib)\n② 도세탁셀(docetaxel)+아나스트로졸(anastrozole)\n③ 퍼투주맙(pertuzumab)+트라스투주맙(trastuzumab)\n④ 도세탁셀+카르보플라틴(carboplatin)+트라스투주맙\n⑤ 도세탁셀+독소루비신(doxorubicin)+타목시펜(tamoxifen)",
        "question_text": "Question: A 45-year-old woman has been diagnosed with stage 3 breast cancer and is planning to undergo a mastectomy. Her hormone receptor status is negative, HER2 is positive, and her ECOG performance status is 1. What is the appropriate neoadjuvant chemotherapy?\n\n① Capecitabine + Lapatinib\n② Docetaxel + Anastrozole\n③ Pertuzumab + Trastuzumab\n④ Docetaxel + Carboplatin + Trastuzumab\n⑤ Docetaxel + Doxorubicin + Tamoxifen",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 62세 남자가 3B기 비소세포폐암(선암)으로 진단받고, 파클리탁셀(paclitaxel), 카르보플라틴(carboplatin)으로 구성된 항암화학요법을 투여받던 중 질병이 진행하였다. 중추신경계 전이는 없다. 베바시주맙(bevacizumab)을 추가하려고 할 때, 이 약의 이상반응을 고려하여 투여 전에 확인해야 하는 최근의 증상은?\n\n① 객혈\n② 골절\n③ 진전\n④ 우울증\n⑤ 체중증가",
        "question_text": "Question: A 62-year-old man was diagnosed with stage 3B non-small cell lung cancer (adenocarcinoma) and was receiving chemotherapy consisting of paclitaxel and carboplatin when the disease progressed. There is no central nervous system metastasis. When considering adding bevacizumab, what recent symptom should be checked before administration, considering the side effects of this drug?\n\n① Hemoptysis\n② Fracture\n③ Tremor\n④ Depression\n⑤ Weight gain",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 급성골수성백혈병으로 공고요법을 받은 38세 남자가 호중구감소성 발열을 예방하기 위해 필그라스팀(filgrastim)을 수일간 투여받고 있다. 모니터링이 필요한 약물이상반응은?\n\n① 발작\n② 서맥\n③ 혈변\n④ 뼈통증\n⑤ 미각이상",
        "question_text": "Question: A 38-year-old man who received consolidation therapy for acute myeloid leukemia has been administered filgrastim for several days to prevent neutropenic fever. Which adverse drug reaction needs to be monitored?\n\n① Seizures\n② Bradycardia\n③ Hematochezia\n④ Bone pain\n⑤ Dysgeusia",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 63세 남자가 전이성 비소세포폐암(선암)으로 진단받아 엘로티닙(erlotinib)을 복용 중이다. 최근 검사 결과, 질병이 진행되었고 표피성장인자수용체(EGFR) T790M 돌연변이가 양성으로 나타났다. 엘로티닙 중단 후 투여해야 할 약물은?\n\n① 세리티닙(ceritinib)\n② 게피티니브(gefitinib)\n③ 크리조티닙(crizotinib)\n④ 오시머티닙(osimertinib)\n⑤ 페메트렉시드(pemetrexed)",
        "question_text": "Question: A 63-year-old man has been diagnosed with metastatic non-small cell lung cancer (adenocarcinoma) and is taking erlotinib. Recent test results show disease progression and a positive epidermal growth factor receptor (EGFR) T790M mutation. Which drug should be administered after discontinuing erlotinib?\n\n① Ceritinib\n② Gefitinib\n③ Crizotinib\n④ Osimertinib\n⑤ Pemetrexed",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n55세 남자가 최근 전이성 대장암(좌측 결장암)으로 진단받고 플루오로우라실(fluorouracil), 로이코보린(leucovorin), 옥살리플라틴(oxaliplatin)으로 구성된 FOLFOX 항암화학요법을 받을 예정이다. 조직의 분자생물학적 검사 결과 EGFR이 양성이고 RAS와 BRAF 돌연변이는 없었다(야생형). 다른 병력은 없고, ECOG 수행도는 1이다.\n\nQuestion: 약물을 추가하려고 할 때 적절한 것은?\n\n① 알렉티닙(alectinib)\n② 세툭시맙(cetuximab)\n③ 레고라페닙(regorafenib)\n④ 아테졸리주맙(atezolizumab)\n⑤ 지브-애플리버셉트(ziv-aflibercept)",
        "question_text": "A 55-year-old man was recently diagnosed with metastatic colorectal cancer (left-sided colon cancer) and is scheduled to receive FOLFOX chemotherapy consisting of fluorouracil, leucovorin, and oxaliplatin. Molecular biological examination of the tissue showed EGFR positive and wild-type RAS and BRAF (no mutations). He has no other medical history, and his ECOG performance status is 1.\n\nQuestion: Which of the following drugs would be appropriate to add to the treatment?\n\n① Alectinib\n② Cetuximab\n③ Regorafenib\n④ Atezolizumab\n⑤ Ziv-aflibercept",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n55세 남자가 최근 전이성 대장암(좌측 결장암)으로 진단받고 플루오로우라실(fluorouracil), 로이코보린(leucovorin), 옥살리플라틴(oxaliplatin)으로 구성된 FOLFOX 항암화학요법을 받을 예정이다. 조직의 분자생물학적 검사 결과 EGFR이 양성이고 RAS와 BRAF 돌연변이는 없었다(야생형). 다른 병력은 없고, ECOG 수행도는 1이다.\n\nQuestion: 환자는 지속적인 통증을 조절하기 위해 옥시코돈(oxycodone) 경구제를 수일간 복용 중이다. 항암화학요법 7주기를 투여하던 중 환자는 손끝이 저리고, 젓가락질을 잘 하지 못해 힘들다고 한다. 이러한 증상 조절을 위해 약물을 추가하고자 할 때 적절한 1차 약물은?\n\n① 이부프로펜(ibuprofen)\n② 프레가발린(pregabalin)\n③ 졸레드론산(zoledronate)\n④ 팔리페리돈(paliperidone)\n⑤ 이소트레티노인(isotretinoin)",
        "question_text": "A 55-year-old man was recently diagnosed with metastatic colorectal cancer (left-sided colon cancer) and is scheduled to receive FOLFOX chemotherapy consisting of fluorouracil, leucovorin, and oxaliplatin. Molecular biological examination of the tissue showed EGFR positivity and wild-type RAS and BRAF (no mutations). He has no other medical history, and his ECOG performance status is 1.\n\nQuestion: The patient has been taking oral oxycodone for several days to control persistent pain. During the 7th cycle of chemotherapy, the patient complains of numbness in his fingertips and difficulty using chopsticks. What is the appropriate first-line medication to add for controlling these symptoms?\n\n① Ibuprofen\n② Pregabalin\n③ Zoledronate\n④ Paliperidone\n⑤ Isotretinoin",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 24세 여자가 2개월 전부터 팔, 다리 피부가 건조하고 가려운 증상이 있어 플루티카손 프로피오네이트(fluticasone propionate) 1% 크림을 1일 3회 바르고 있다. 지난주부터는 팔꿈치에 노란 삼출액이 있는 병변이 발생하였다. 플루티카손 프로피오네이트 1% 크림 대신 사용할 약은?\n\n① 퓨시드산(fusidic acid) 연고\n② 타크로리무스(tacrolimus) 0.03% 연고\n③ 피메크롤리무스(pimecrolimus) 1% 연고\n④ 히드로코르티손(hydrocortisone) 2.5% 로션\n⑤ 클로베타솔 프로피오네이트(clobetasol propionate) 0.05% 크림",
        "question_text": "Question: A 24-year-old woman has been applying fluticasone propionate 1% cream three times a day for dry and itchy skin on her arms and legs for the past two months. Since last week, she has developed lesions with yellow exudate on her elbows. Which medication should be used instead of fluticasone propionate 1% cream?\n\n① Fusidic acid ointment\n② Tacrolimus 0.03% ointment\n③ Pimecrolimus 1% ointment\n④ Hydrocortisone 2.5% lotion\n⑤ Clobetasol propionate 0.05% cream",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 방수 생성을 억제하고 방수 유출을 증가하여 안압을 감소시켜 개방각녹내장을 치료하는 약물은?\n\n① 티몰롤(timolol)\n② 카바콜(carbachol)\n③ 필로카르핀(pilocarpine)\n④ 브리모니딘(brimonidine)\n⑤ 라타노프로스트(latanoprost)",
        "question_text": "Question: Which drug treats open-angle glaucoma by reducing intraocular pressure through inhibiting aqueous humor production and increasing aqueous humor outflow?\n\n① Timolol\n② Carbachol\n③ Pilocarpine\n④ Brimonidine\n⑤ Latanoprost",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 8세 여자가 짧은창자증후군(short-bowel syndrome)으로 2개월 전부터 정맥영양을 투여받고 있다. 오늘 혈액 검사에서 직접 빌리루빈 농도가 2.6 mg/dL로 측정되었다. 정맥영양요법에서 적절한 조치는?\n\n① 글루타민 증량\n② 아미노산 증량\n③ 지방 유액 증량\n④ 아연 투여 중단\n⑤ 구리 투여 중단",
        "question_text": "Question: An 8-year-old girl has been receiving parenteral nutrition for 2 months due to short-bowel syndrome. Today's blood test shows a direct bilirubin concentration of 2.6 mg/dL. What is the appropriate measure in parenteral nutrition therapy?\n\n① Increase glutamine\n② Increase amino acids\n③ Increase lipid emulsion\n④ Discontinue zinc administration\n⑤ Discontinue copper administration",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 70세 여자가 아토르바스타틴(atorvastatin)과 이트라코나졸(itraconazole)을 함께 복용하던 중에 심한 근육통증이 발생하였다. 이와 관련하여 확인해야 하는 임상검사 수치는?\n\n① 공복혈당\n② 혈청 칼륨\n③ 혈청 빌리루빈\n④ 평균적혈구용적\n⑤ 크레아틴키나아제",
        "question_text": "Question: A 70-year-old woman experienced severe muscle pain while taking atorvastatin and itraconazole together. Which clinical laboratory value should be checked in relation to this?\n\n① Fasting blood glucose\n② Serum potassium\n③ Serum bilirubin\n④ Mean corpuscular volume\n⑤ Creatine kinase",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 65세 남자가 간성뇌증으로 인한 인지기능 저하가 있다. 이 환자는 페린도프릴(perindopril), 메트포르민(metformin), 시타글립틴(sitagliptin), 알프라졸람(alprazolam), 오플록사신(ofloxacin)을 복용하고 있다. 이 환자가 사용하는 약물 중에서 인지기능 저하를 악화시킬 수 있는 약물은?\n\n① 페린도프릴\n② 메트포르민\n③ 시타글립틴\n④ 알프라졸람\n⑤ 오플록사신",
        "question_text": "Question: A 65-year-old man has cognitive impairment due to hepatic encephalopathy. This patient is taking perindopril, metformin, sitagliptin, alprazolam, and ofloxacin. Which of the medications this patient is using could potentially worsen cognitive impairment?\n\n① Perindopril\n② Metformin\n③ Sitagliptin\n④ Alprazolam\n⑤ Ofloxacin",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 약사가 환자상담 후 중재서비스를 FARM 형식으로 기록하고자 한다. 항목 중 ‘R’ 부분에 들어갈 내용은?\n\n① 환자 가족력\n② 환자 호소 증상\n③ 식생활 개선 추천\n④ 환자 증상의 심각도\n⑤ 흉부 방사선 촬영 검사 결과",
        "question_text": "Question: A pharmacist wants to record an intervention service after patient counseling in FARM format. What content should be included in the 'R' part of the items?\n\n① Patient family history\n② Patient's reported symptoms\n③ Recommended dietary improvements\n④ Severity of patient's symptoms\n⑤ Chest X-ray examination results",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 정맥주사로 투여하는 약물은?\n\n① 인슐린글라진(insulin glargine)\n② 리스페리돈 콘스타(risperidone Consta)\n③ 벤자틴페니실린G(benzathine penicillin G)\n④ 트리암시놀론 아세토니드(triamcinolone acetonide)\n⑤ 메틸프레드니솔론 숙신산나트륨(methylprednisolone sodium succinate)",
        "question_text": "Question: Which of the following drugs is administered intravenously?\n\n① Insulin glargine\n② Risperidone Consta\n③ Benzathine penicillin G\n④ Triamcinolone acetonide\n⑤ Methylprednisolone sodium succinate",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: Ministry of Food and Drug Safety에서 고시한 DUR의 항목 중 임부금기 1등급에 해당하는 약물은?\n\n① 파록세틴(paroxetine)\n② 암로디핀(amlodipine)\n③ 아만타딘(amantadine)\n④ 리마프로스트(limaprost)\n⑤ 레보티록신(levothyroxine)",
        "question_text": "Question: Which of the following drugs is classified as Pregnancy Contraindication Category 1 according to the DUR (Drug Utilization Review) items announced by the Ministry of Food and Drug Safety?\n\n① Paroxetine\n② Amlodipine\n③ Amantadine\n④ Limaprost\n⑤ Levothyroxine",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 처방 검토 시 환자의 신장기능을 확인하여 용량 적절성을 평가하는 약물은?\n\n① 엔테카비르(entecavir)\n② 이소니아지드(isoniazid)\n③ 발프로산(valproic acid)\n④ 오메프라졸(omeprazole)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "Question: Which drug requires checking the patient's renal function during prescription review to evaluate the appropriateness of dosage?\n\n① Entecavir\n② Isoniazid\n③ Valproic acid\n④ Omeprazole\n⑤ Clopidogrel",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 골다공증 치료를 위한 이반드론산(ibandronate) 3 mg 주사제의 투여 간격은?\n\n① 1일\n② 1주\n③ 1개월\n④ 3개월\n⑤ 1년",
        "question_text": "Question: What is the administration interval for ibandronate 3 mg injection used in the treatment of osteoporosis?\n\n① 1 day\n② 1 week\n③ 1 month\n④ 3 months\n⑤ 1 year",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 동시 투여 시 흡수에 영향을 주는 상호작용이 있으므로 일정한 시간 간격을 두고 복용해야 하는 약물 조합은?\n\n① 디곡신(digoxin) – 아미오다론(amiodarone)\n② 리팜피신(rifampicin) – 타크롤리무스(tacrolimus)\n③ 리바록사반(rivaroxaban) – 보리코나졸(voriconazole)\n④ 아자티오프린(azathioprine) – 알로푸리놀(allopurinol)\n⑤ 레보플록사신(levofloxacin) – 탄산칼슘(calcium carbonate)",
        "question_text": "Question: Which combination of drugs should be taken with a certain time interval between them due to interactions that affect absorption when administered simultaneously?\n\n① Digoxin – Amiodarone\n② Rifampicin – Tacrolimus\n③ Rivaroxaban – Voriconazole\n④ Azathioprine – Allopurinol\n⑤ Levofloxacin – Calcium carbonate",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 조제 시 5% 포도당 용액에 희석해야 하는 항암제는?\n\n① 시스플라틴(cisplatin)\n② 미토마이신(mitomycin)\n③ 옥살리플라틴(oxaliplatin)\n④ 페메트렉시드(pemetrexed)\n⑤ 트라스투주맙(trastuzumab)",
        "question_text": "Question: Which anticancer drug should be diluted in 5% glucose solution during preparation?\n\n① Cisplatin\n② Mitomycin\n③ Oxaliplatin\n④ Pemetrexed\n⑤ Trastuzumab",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 뇌전증, 양성전립선비대가 있는 70세 남자가 가려움증과 만성 두통으로 다음과 같은 처방을 받았다.\n\n| 처방 의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 로사르탄(losartan) 50 mg | 1정 | 1회 |\n| 발프로산(valproic acid) 500 mg | 1정 | 2회 |\n| 알푸조신(alfuzosin) 10 mg | 1정 | 1회 |\n| 히드록시진(hydroxyzine) 10 mg 1정 | 3회 |\n| 아세트아미노펜(acetaminophen) 500 mg | 1정 | 3회 |\n\nQuestion: 이 환자의 치료에 적절한 발프로산의 총 혈장농도의 범위는?\n\n① 0.5~1.5 mg/L\n② 2~5 mg/L\n③ 20~30 mg/L\n④ 50~100 mg/L\n⑤ 200~300 mg/L",
        "question_text": "A 70-year-old man with hypertension, epilepsy, and benign prostatic hyperplasia received the following prescription for pruritus and chronic headache:\n\n| Prescribed medication | Dose per administration | Frequency per day |\n|---|---|---|\n| Losartan 50 mg | 1 tablet | Once |\n| Valproic acid 500 mg | 1 tablet | Twice |\n| Alfuzosin 10 mg | 1 tablet | Once |\n| Hydroxyzine 10 mg | 1 tablet | Three times |\n| Acetaminophen 500 mg | 1 tablet | Three times |\n\nQuestion: What is the appropriate range for the total plasma concentration of valproic acid for this patient's treatment?\n\n① 0.5-1.5 mg/L\n② 2-5 mg/L\n③ 20-30 mg/L\n④ 50-100 mg/L\n⑤ 200-300 mg/L",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 뇌전증, 양성전립선비대가 있는 70세 남자가 가려움증과 만성 두통으로 다음과 같은 처방을 받았다.\n\n| 처방 의약품의 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 로사르탄(losartan) 50 mg | 1정 | 1회 |\n| 발프로산(valproic acid) 500 mg | 1정 | 2회 |\n| 알푸조신(alfuzosin) 10 mg | 1정 | 1회 |\n| 히드록시진(hydroxyzine) 10 mg 1정 | 3회 |\n| 아세트아미노펜(acetaminophen) 500 mg | 1정 | 3회 |\n\nQuestion: Beers 기준에 근거하여 이 환자의 처방을 검토할 때, 약물 선택의 적절성에 관하여 의사에게 문의해야 하는 약물은?\n\n① 로사르탄\n② 발프로산\n③ 알푸조신\n④ 히드록시진\n⑤ 아세트아미노펜",
        "question_text": "A 70-year-old man with hypertension, epilepsy, and benign prostatic hyperplasia received the following prescription for pruritus and chronic headache:\n\n| Prescribed medication | Dosage per administration | Frequency per day |\n|---|---|---|\n| Losartan 50 mg | 1 tablet | Once |\n| Valproic acid 500 mg | 1 tablet | Twice |\n| Alfuzosin 10 mg | 1 tablet | Once |\n| Hydroxyzine 10 mg | 1 tablet | Three times |\n| Acetaminophen 500 mg | 1 tablet | Three times |\n\nQuestion: Based on the Beers Criteria, when reviewing this patient's prescription, which medication should be inquired about to the physician regarding the appropriateness of drug selection?\n\n① Losartan\n② Valproic acid\n③ Alfuzosin\n④ Hydroxyzine\n⑤ Acetaminophen",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 입원환자를 위한 UDS(unit dose distribution system)에 의한 조제란?\n\n① 한 병동에서 1일 사용할 분량을 조제\n② 제약회사에서 덕용포장 된 형태로 조제\n③ 병동에서 응급 환자에게 사용할 비품약을 조제\n④ 의사의 처방에 따라 수일간 사용할 분량을 조제\n⑤ 환자당 1회 투약할 단위별로 포장하여 24시간 내 사용할 분량을 조제",
        "question_text": "Question: What is dispensing by UDS (unit dose distribution system) for inpatients?\n\n① Dispensing the amount to be used for 1 day in one ward\n② Dispensing in the form of bulk packaging from pharmaceutical companies\n③ Dispensing stock medications to be used for emergency patients in the ward\n④ Dispensing the amount to be used for several days according to the doctor's prescription\n⑤ Dispensing the amount to be used within 24 hours, packaged in units for each patient's single dose",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 체중이 16 kg인 소아에게 아세트아미노펜 현탁액을 15 mg/kg, 4~6시간마다 복용하도록 처방되었다. 현탁액의 농도가 160mg/5 mL일 때, 1회 투약량은?\n\n① 2.5 mL\n② 7.5 mL\n③ 15 mL\n④ 20 mL\n⑤ 25 mL",
        "question_text": "Question: A child weighing 16 kg was prescribed acetaminophen suspension to be taken at 15 mg/kg every 4-6 hours. If the concentration of the suspension is 160mg/5 mL, what is the single dose?\n\n① 2.5 mL\n② 7.5 mL\n③ 15 mL\n④ 20 mL\n⑤ 25 mL",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 조제약 감사 시에 색상, 냄새, 점도를 확인하고 투약기구를 제공하는 약물은?\n\n① 도네페질(donepezil)\n② 파록세틴(paroxetine)\n③ 에탐부톨(ethambutol)\n④ 알프라졸람(alprazolam)\n⑤ 포수클로랄(chloral hydrate)",
        "question_text": "Question: Which medication requires checking color, odor, and viscosity during prescription review and providing a dispensing device?\n\n① Donepezil\n② Paroxetine\n③ Ethambutol\n④ Alprazolam\n⑤ Chloral hydrate",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 뇌전증으로 진단받은 환자가 라모트리진(lamotrigine) 복용을 시작한 후에 피부발진이 발생하였다. 라모트리진 복용을 중단한 후에 피부발진이 호전되었고, 재투여에 대한 정보는 없다. 피부발진의 발생은 다른 의약품이나 화학물질 또는 수반하는 질환에 따른 것으로 보이지 않는다. WHO-UMC 방법으로 약물이상반응의 인과성을 평가했을 때 결과는?\n\n① 상당히 확실함(probable)\n② 가능함(possible)\n③ 가능성 적음(unlikely)\n④ 평가 곤란(conditional)\n⑤ 평가 불가(unassessable)",
        "question_text": "Question: A patient diagnosed with epilepsy developed a skin rash after starting lamotrigine treatment. The skin rash improved after discontinuing lamotrigine, and there is no information about re-administration. The occurrence of the skin rash does not appear to be due to other medications, chemicals, or accompanying diseases. When evaluating the causality of the adverse drug reaction using the WHO-UMC method, what is the result?\n\n① Probable\n② Possible\n③ Unlikely\n④ Conditional\n⑤ Unassessable",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n22세 여자가 계절성 알레르기 비염으로 인한 콧물과 코막힘 증상 때문에 펙소페나딘(fexofenadine) 정 120 mg 1일 1회, 자일로메타졸린(xylometazoline) 0.1% 비강분무액 1일 3회 투여를 시작하였다. 약물사용으로 콧물과 코막힘 증상이 개선되다가 7일째부터 코막힘 증상이 악화되는 약물관련 문제(DRP)가 발생하였다.\n\nQuestion: 이 환자의 약물관련문제는?\n\n① 동일 성분 중복\n② 투여 횟수 부족\n③ 약물이상반응 발생\n④ 약물상호작용 발생\n⑤ 약물 적응증 부적절",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 22-year-old woman started taking fexofenadine 120 mg tablets once daily and xylometazoline 0.1% nasal spray three times daily for runny nose and nasal congestion due to seasonal allergic rhinitis. Her symptoms of runny nose and nasal congestion improved with medication use, but on the 7th day, a drug-related problem (DRP) occurred where her nasal congestion symptoms worsened.\n\nQuestion: What is this patient's drug-related problem?\n\n① Duplication of the same active ingredient\n② Insufficient dosing frequency\n③ Occurrence of adverse drug reaction\n④ Occurrence of drug interaction\n⑤ Inappropriate drug indication",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n22세 여자가 계절성 알레르기 비염으로 인한 콧물과 코막힘 증상 때문에 펙소페나딘(fexofenadine) 정 120 mg 1일 1회, 자일로메타졸린(xylometazoline) 0.1% 비강분무액 1일 3회 투여를 시작하였다. 약물사용으로 콧물과 코막힘 증상이 개선되다가 7일째부터 코막힘 증상이 악화되는 약물관련 문제(DRP)가 발생하였다.\n\nQuestion: 이 환자의 약물관련문제에 대한 해결방안은?\n\n① 펙소페나딘 감량\n② 자일로메타졸린 증량\n③ 올로파타딘(olopatadine) 점안액 추가\n④ 이프라트로퓸(ipratropium) 비액 추가\n⑤ 자일로메타졸린 서서히 감량 후 중단",
        "question_text": "A 22-year-old woman started taking fexofenadine 120 mg tablets once daily and xylometazoline 0.1% nasal spray three times daily for runny nose and nasal congestion due to seasonal allergic rhinitis. Her symptoms of runny nose and nasal congestion improved with medication use, but on the 7th day, a drug-related problem (DRP) occurred where her nasal congestion symptoms worsened.\n\nQuestion: What is the solution to this patient's drug-related problem?\n\n① Reduce the dose of fexofenadine\n② Increase the dose of xylometazoline\n③ Add olopatadine eye drops\n④ Add ipratropium nasal solution\n⑤ Gradually reduce and then discontinue xylometazoline",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 당뇨병, 불면증, 이상지질혈증이 있는 50세 남자가 다음과 같은 처방전을 가지고 약국에 왔다.\n\n| 처방 의약품 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 라미프릴(ramipril) 10 mg | 1정 | 1회 |\n| 암로디핀(amlodipine) 10 mg | 1정 | 2회 |\n| 메트포르민(metformin) 1 |000 mg | 1정 | 2회 |\n| 졸피뎀(zolpidem) 5 mg | 1정 | 1회 |\n| 로수바스타틴(rosuvastatin) 10 mg | 1정 | 1회 |\n\nQuestion: 이 환자의 처방전 검토 결과, 최대용량을 초과하므로 의사에게 용량에 대해 문의해야 하는 약물은?\n\n① 라미프릴\n② 암로디핀\n③ 메트포르민\n④ 졸피뎀\n⑤ 로수바스타틴",
        "question_text": "A 50-year-old man with hypertension, diabetes, insomnia, and dyslipidemia came to the pharmacy with the following prescription.\n\n| Prescribed Medication | Dosage per Administration | Frequency per Day |\n|---|---|---|\n| Ramipril 10 mg | 1 tablet | Once |\n| Amlodipine 10 mg | 1 tablet | Twice |\n| Metformin 1,000 mg | 1 tablet | Twice |\n| Zolpidem 5 mg | 1 tablet | Once |\n| Rosuvastatin 10 mg | 1 tablet | Once |\n\nQuestion: Upon reviewing this patient's prescription, which medication should be inquired about with the doctor regarding its dosage, as it exceeds the maximum dose?\n\n① Ramipril\n② Amlodipine\n③ Metformin\n④ Zolpidem\n⑤ Rosuvastatin",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 당뇨병, 불면증, 이상지질혈증이 있는 50세 남자가 다음과 같은 처방전을 가지고 약국에 왔다.\n\n| 처방 의약품 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 라미프릴(ramipril) 10 mg | 1정 | 1회 |\n| 암로디핀(amlodipine) 10 mg | 1정 | 2회 |\n| 메트포르민(metformin) 1 |000 mg | 1정 | 2회 |\n| 졸피뎀(zolpidem) 5 mg | 1정 | 1회 |\n| 로수바스타틴(rosuvastatin) 10 mg | 1정 | 1회 |\n\nQuestion: 이 환자는 영상검사를 위하여 요오드를 함유한 조영제를 투여받을 예정이다. 검사 전 복용 중단을 고려할 약물은?\n\n① 라미프릴\n② 암로디핀\n③ 메트포르민\n④ 졸피뎀\n⑤ 로수바스타틴",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 50-year-old man with hypertension, diabetes, insomnia, and dyslipidemia came to the pharmacy with the following prescription.\n\n| Prescribed medication | Dosage per administration | Frequency per day |\n|---|---|---|\n| Ramipril 10 mg | 1 tablet | Once |\n| Amlodipine 10 mg | 1 tablet | Twice |\n| Metformin 1,000 mg | 1 tablet | Twice |\n| Zolpidem 5 mg | 1 tablet | Once |\n| Rosuvastatin 10 mg | 1 tablet | Once |\n\nQuestion: This patient is scheduled to receive an iodine-containing contrast agent for an imaging test. Which medication should be considered for discontinuation before the test?\n\n① Ramipril\n② Amlodipine\n③ Metformin\n④ Zolpidem\n⑤ Rosuvastatin",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 위장관 내 가스로 복부팽만감이 심한 환자에게 적절한 일반의약품은?\n\n① 파모티딘(famotidine) 정\n② 시메티콘(simethicone) 액\n③ 온단세트론(ondansetron) 정\n④ 오메프라졸(omeprazole) 캡슐\n⑤ 수크랄페이트(sucralfate) 현탁액",
        "question_text": "Question: Which over-the-counter medication is appropriate for a patient with severe abdominal bloating due to gastrointestinal gas?\n\n① Famotidine tablet\n② Simethicone liquid\n③ Ondansetron tablet\n④ Omeprazole capsule\n⑤ Sucralfate suspension",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 세균성 피부 감염증에 외용으로 사용하는 일반의약품은?\n\n① 우레아(urea) 크림\n② 무피로신(mupirocin) 연고\n③ 살리실산(salicylic acid) 겔\n④ 클로트리마졸(clotrimazole) 크림\n⑤ 과산화벤조일(benzoyl peroxide) 로션",
        "question_text": "Question: Which of the following over-the-counter medications is used topically for bacterial skin infections?\n\n① Urea cream\n② Mupirocin ointment\n③ Salicylic acid gel\n④ Clotrimazole cream\n⑤ Benzoyl peroxide lotion",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 환부를 손발톱용 줄로 갈아낸 후 사용하는 일반의약품은?\n\n① 아모롤핀(amorolfine) 라카\n② 퓨시드산(fusidic acid) 연고\n③ 테르비나핀(terbinafine) 크림\n④ 플루벤다졸(flubendazole) 현탁액 \n⑤ 트리암시놀론(triamcinolone) 페이스트",
        "question_text": "Question: Which over-the-counter medication is used after filing down the affected area with a nail file?\n\n① Amorolfine lacquer\n② Fusidic acid ointment\n③ Terbinafine cream\n④ Flubendazole suspension\n⑤ Triamcinolone paste",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 7세 소아가 복숭아 알레르기로 몸에 두드러기가 났다. 약사가 아이의 증상 완화를 위해 추천할 수 있는 일반의약품은?\n\n① 에바스틴(ebastine) 정\n② 세티리진(cetirizine) 시럽\n③ 메퀴타진(mequitazine) 시럽\n④ 히드록시진(hydroxyzine) 시럽\n⑤ 디옥타헤드랄스멕타이트(dioctahedral smectite) 현탁액",
        "question_text": "Question: A 7-year-old child has developed hives due to a peach allergy. Which over-the-counter medication can a pharmacist recommend to alleviate the child's symptoms?\n\n① Ebastine tablets\n② Cetirizine syrup\n③ Mequitazine syrup\n④ Hydroxyzine syrup\n⑤ Dioctahedral smectite suspension",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 36세 여자가 편두통으로 수마트립탄(sumatriptan) 50 mg 정을 처방받았다. 이 환자에게 필요한 복약지도 내용은?\n\n① 24시간 동안 8정까지 복용할 수 있다.\n② 골다공증이 우려되므로 칼슘을 섭취한다.\n③ 임신한 경우에도 안전하게 사용할 수 있다.\n④ 졸릴 수 있으므로 복용 후 기계조작이나 운전 시에 주의한다.\n⑤ 에르고타민(ergotamine)이 포함된 편두통약과 동시에 복용할 수 있다.",
        "question_text": "Question: A 36-year-old woman was prescribed sumatriptan 50 mg tablets for migraine. What medication counseling should be provided to this patient?\n\n① Up to 8 tablets can be taken within 24 hours.\n② Calcium should be consumed due to concerns about osteoporosis.\n③ It can be safely used even during pregnancy.\n④ Caution should be exercised when operating machinery or driving after taking the medication, as it may cause drowsiness.\n⑤ It can be taken simultaneously with migraine medications containing ergotamine.",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 신장기능이 정상인 대상포진바이러스 감염 환자에게 1일 5회 복용하도록 설명해야 하는 약은?\n\n① 아시클로버(acyclovir) 정\n② 엔테카비르(entecavir) 정\n③ 팜시클로비르(famciclovir) 정\n④ 오셀타미비르(oseltamivir) 캡슐\n⑤ 테노포비르 디소프록실(tenofovir disoproxil) 정",
        "question_text": "Question: Which medication should be explained to be taken 5 times a day for a patient with herpes zoster virus infection and normal kidney function?\n\n① Acyclovir tablet\n② Entecavir tablet\n③ Famciclovir tablet\n④ Oseltamivir capsule\n⑤ Tenofovir disoproxil tablet",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 란소프라졸(lansoprazole) 엘에프디티정의 복약지도 내용으로 적절한 것은?\n\n① 씹어서 복용함\n② 구강 점막에 붙여 사용함\n③ 복용 후 1시간 이내에 눕지 않음\n④ 혀 위에 놓고 침으로 녹여 복용함\n⑤ 물에 녹여 입 안에 15초간 머금고 있은 후 뱉음",
        "question_text": "Question: Which of the following is an appropriate medication instruction for lansoprazole LFD tablets?\n\n① Chew before swallowing\n② Apply to the oral mucosa\n③ Do not lie down within 1 hour after taking\n④ Place on the tongue and allow to dissolve with saliva before swallowing\n⑤ Dissolve in water, hold in the mouth for 15 seconds, then spit out",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 갱년기 증상이 있는 55세 여자가 냉증과 피로감, 하복부통, 두중, 어지러움의 증상이 있어 약국에 방문하였다. 이 환자의 조혈기능을 활성화하여 정체된 수분을 배출하는 한약제제는?\n\n① 갈근탕(葛根湯)\n② 삼소음(蔘蘇飮)\n③ 산조인탕(酸棗仁湯)\n④ 소시호탕(小柴胡湯)\n⑤ 당귀작약산(當歸芍藥散)",
        "question_text": "Question: A 55-year-old woman with menopausal symptoms visited a pharmacy complaining of cold sensitivity, fatigue, lower abdominal pain, heaviness in the head, and dizziness. Which herbal medicine preparation activates hematopoietic function and expels stagnant fluids in this patient?\n\n① Galgeun-tang (Pueraria Decoction)\n② Samso-eum (Ginseng and Perilla Beverage)\n③ Sanjoin-tang (Sour Jujube Decoction)\n④ Sosiho-tang (Minor Bupleurum Decoction)\n⑤ Danggwi-jakyak-san (Angelica and Peony Powder)",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 의약품 제조 및 품질관리기준에서 정하는 제조지시서에 포함되는 사항은?\n\n① 제조단위\n② 안정성시험\n③ 시험시설의 점검\n④ 작업복장의 규격\n⑤ 제조시설의 세척방법",
        "question_text": "Question: What is included in the manufacturing instructions as specified in the Good Manufacturing Practice (GMP) for pharmaceuticals?\n\n① Manufacturing unit\n② Stability testing\n③ Inspection of testing facilities\n④ Specifications for work attire\n⑤ Cleaning methods for manufacturing facilities",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 원료의약품의 제조와 가공, 포장 및 보관에 사용되는 시설, 공정, 성분에 관하여 자세히 기술한 비공개 정보로서 Ministry of Food and Drug Safety에 제출하는 서류는?\n\n① COA (Certificate of Analysis) \n② DMF (Drug Master File)\n③ IND (Investigational New Drug)\n④ PQR (Product Quality Review)\n⑤ SOP (Standard Operation Procedure)",
        "question_text": "Question: What is the confidential document submitted to the Ministry of Food and Drug Safety that provides detailed information about the facilities, processes, and ingredients used in the manufacturing, processing, packaging, and storage of active pharmaceutical ingredients?\n\n① COA (Certificate of Analysis)\n② DMF (Drug Master File)\n③ IND (Investigational New Drug)\n④ PQR (Product Quality Review)\n⑤ SOP (Standard Operation Procedure)",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 작업소 내의 공기 청정도를 유지하기 위한 방법으로 옳은 것은?\n\n① 난기류의 지속적 공급\n② 양압의 차압 장치 도입\n③ 단일방향류의 간헐적 공급\n④ HEPA 필터의 교체 주기 연장\n⑤ 사전 여과 처리 필터(prefilter) 미사용",
        "question_text": "Question: Which of the following is the correct method for maintaining air cleanliness in a work area?\n\n① Continuous supply of turbulent airflow\n② Introduction of positive pressure differential devices\n③ Intermittent supply of unidirectional airflow\n④ Extended replacement cycle of HEPA filters\n⑤ Non-use of prefilters",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 세척밸리데이션을 실시해야 하는 대상으로 메트포르민 정제를 선정하였다. 이 제품 제조에 사용하는 과립기(G)를 공유하는 후속제품들과 제조규모를 다음의 표에 나타내었다. 메트포르민의 최대허용잔류한도를 설정하기 위해서 선택해야 하는 후속제품은? (단, 후속제품들의 1일 최대복용량은 500 mg으로 동일하다.)\n\n<과립기(G)를 사용하는 후속제품과 제조규모>\n| 후속제품 | 제조규모 (제품별 주성분 기준) |\n|---|---|\n| 가 | 70 kg |\n| 나 | 50 kg |\n| 다 | 20 kg |\n| 라 | 40 kg |\n| 마 | 60 kg |\n\n① 가\n② 나\n③ 다\n④ 라\n⑤ 마",
        "question_text": "Question: Metformin tablets were selected as the target for cleaning validation. The following table shows the subsequent products that share the granulator (G) used in the manufacturing of this product and their production scales. Which subsequent product should be chosen to set the maximum allowable residue limit for metformin? (Note: The maximum daily dose for all subsequent products is the same at 500 mg.)\n\n<Subsequent products using granulator (G) and their production scales>\n| Subsequent Product | Production Scale (based on the main ingredient per product) |\n|---|---|\n| A | 70 kg |\n| B | 50 kg |\n| C | 20 kg |\n| D | 40 kg |\n| E | 60 kg |\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 부득이한 사유로 예측적 밸리데이션을 실시하지 못하는 경우에 의약품을 제조 ∙ 판매하면서 실시하는 동시적 밸리데이션에 대한 설명으로 옳은 것은?\n\n① 품질보증의 수단이 될 수 없다. \n② 평가한 제조단위는 모두 적합하여야 한다.\n③ 기준에서 일탈한 제조단위는 결과에서 제외한다.\n④ 제조 ∙ 판매한 10~30개의 제조단위를 대상으로 실시한다.\n⑤ 실생산 규모보다 축소된 제조단위를 대상으로 실시한다.",
        "question_text": "Question: Which of the following statements is correct regarding concurrent validation, which is conducted while manufacturing and selling pharmaceutical products when predictive validation cannot be performed due to unavoidable reasons?\n\n① It cannot be a means of quality assurance.\n② All evaluated manufacturing batches must be compliant.\n③ Manufacturing batches that deviate from the standards are excluded from the results.\n④ It is conducted on 10-30 manufacturing batches that have been manufactured and sold.\n⑤ It is conducted on manufacturing batches that are scaled down from actual production size.",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 주사제의 증기멸균공정에서 목표로 하는 최소의 비무균확률(B값)을 얻기 위한 조치로 옳은 것은?\n\n① 상응시간 F값을 감소시킨다.\n② 초기 미생물 부하(A값)을 낮춘다.\n③ 멸균 설정온도를 121℃보다 낮게 한다. \n④ Z값이 큰 미생물이 채택되도록 한다.\n⑤ D값이 큰 미생물이 채택되도록 한다.",
        "question_text": "Question: Which of the following is the correct measure to achieve the target minimum sterility assurance level (SAL or B value) in the steam sterilization process for injectable products?\n\n① Decrease the F value (equivalent time).\n② Lower the initial bioburden (A value).\n③ Set the sterilization temperature lower than 121°C.\n④ Ensure that microorganisms with a higher Z value are adopted.\n⑤ Ensure that microorganisms with a higher D value are adopted.",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 증기멸균기의 적격성평가에서 열침투시험을 통해 확인하는 것은?\n\n① 열전대의 정밀도\n② 콜드스팟의 위치\n③ 콜드스팟의 F0값\n④ 생물학적 지표의 D값\n⑤ 생물학적 지표의 Z값",
        "question_text": "Question: What is confirmed through the heat penetration test in the qualification evaluation of a steam sterilizer?\n\n① Precision of the thermocouple\n② Location of the cold spot\n③ F0 value of the cold spot\n④ D value of the biological indicator\n⑤ Z value of the biological indicator",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 제약 생산 부문에서의 품질관리 체계를 세 영역(품질검사, 품질관리, 품질보증)으로 나누었을 때 품질보증 부문의 직무에 해당하는 것은?\n\n① 공정, 중간품의 검사\n② 공정 능력의 조사 및 확인\n③ 측정자 및 측정 조작의 확인\n④ 품질표준 및 각종 표준의 설정\n⑤ 소비자가 제기한 품질 불만 처리",
        "question_text": "Question: When dividing the quality control system in the pharmaceutical production sector into three areas (quality inspection, quality control, and quality assurance), which of the following is a responsibility of the quality assurance department?\n\n① Inspection of processes and intermediates\n② Investigation and verification of process capabilities\n③ Verification of measuring personnel and measurement operations\n④ Establishment of quality standards and various standards\n⑤ Handling quality complaints raised by consumers",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 의약품 제조 및 품질관리기준에 기재된 반품 및 재포장에 대한 내용으로 옳은 것은?\n\n① 재포장 작업은 품질관리부서 책임자의 승인이 있어야 한다.\n② 재포장할 수 없는 반품의 경우 실온에서 2년간 보관해야 한다.\n③ 재포장 제품의 유효기간은 6개월 단위로 내림하여 재표기한다.\n④ 직접용기가 파손되더라도 약품이 훼손되지 않았으면 재포장할 수 있다.\n⑤ 재포장한 제품에는 재포장한 것임을 나타내는 표시를 할 필요가 없다.",
        "question_text": "Question: Which of the following statements about returns and repackaging as stated in the Good Manufacturing Practice (GMP) guidelines is correct?\n\n① Repackaging operations must be approved by the head of the quality control department.\n② In case of returns that cannot be repackaged, they should be stored at room temperature for 2 years.\n③ The expiration date of repackaged products should be rounded down to 6-month intervals and relabeled.\n④ Even if the immediate container is damaged, the product can be repackaged if the medication itself is not damaged.\n⑤ It is not necessary to indicate that a product has been repackaged on its label.",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 의약품 제조소에서 검체 분석을 위한 이화학적 조작 및 추출, 정제실험을 수행하는 시설은?\n\n① 칭량실\n② 전처리시설\n③ 검체보관시설\n④ 시약보관시설\n⑤ 실험실 지원시설",
        "question_text": "Question: In a pharmaceutical manufacturing facility, which facility is used for physicochemical operations, extraction, and purification experiments for sample analysis?\n\n① Weighing room\n② Pre-treatment facility\n③ Sample storage facility\n④ Reagent storage facility\n⑤ Laboratory support facility",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에 규정된 플라스틱제의약품용기시험법 중 회화시험 항목에 해당하는 것은?\n\n① 강열잔분\n② 증발잔류물\n③ 미립자시험\n④ 투명성시험\n⑤ 과망간산칼륨환원성물질",
        "question_text": "Question: Which of the following corresponds to the incineration test item among the plastic pharmaceutical container test methods specified in the Korean Pharmacopoeia?\n\n① Ignition residue\n② Evaporation residue\n③ Particulate matter test\n④ Transparency test\n⑤ Potassium permanganate-reducing substances",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에 기재된 제조용수에 대한 내용으로 옳은 것은?\n\n① 정제수는 미생물관리가 불필요하다.\n② 주사용수는 무균시험의 적용대상이다.\n③ 멸균주사용수는 주사용수의 관리기준에 적합하다.\n④ 정제수와 정제수(Hermetic Container 내)의 전도율 관리기준은 같다.\n⑤ 멸균정제수와 멸균주사용수의 순도시험 관리기준은 같다.",
        "question_text": "Question: Which of the following statements about manufacturing water described in the Korean Pharmacopoeia is correct?\n\n① Purified water does not require microbial control.\n② Water for injection is subject to sterility testing.\n③ Sterile water for injection meets the management standards for water for injection.\n④ The conductivity management standards for purified water and purified water (in Hermetic Container) are the same.\n⑤ The purity test management standards for sterile purified water and sterile water for injection are the same.",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 의약품각조의 아스피린에 대한 건조감량시험에는 “0.5% 이하(3 g, 실리카겔, 5시간)”라고 규정되어 있다. 설명으로 옳지 않은 것은?\n\n① 실리카겔 데시케이터 속에서 5시간 건조한다.\n② 5시간 건조한 후 질량 변화가 0.5% 이하이다.\n③ 아스피린은 ±10% 범위에서 3 g을 정밀하게 달아서 검체로 한다.\n④ 칭량병은 105℃에서 미리 30분간 건조하여 질량을 정밀하게 단다.\n⑤ 검체가 큰 덩어리일 때에는 재빨리 갈아 지름 2 mm 이하로 하여 쓴다.",
        "question_text": "Question: The loss on drying test for Aspirin in the Pharmacopoeia states \"Not more than 0.5% (3 g, silica gel, 5 hours).\" Which of the following statements is NOT correct?\n\n① It is dried for 5 hours in a silica gel desiccator.\n② After 5 hours of drying, the mass change should be not more than 0.5%.\n③ Aspirin is accurately weighed to 3 g within a range of ±10% as the sample.\n④ The weighing bottle is dried at 105°C for 30 minutes in advance and accurately weighed.\n⑤ When the sample is in large lumps, it is quickly ground to a diameter of 2 mm or less before use.",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia 의약품각조의 L-이소류신에 대한 시험법이다. (가), (나), (다)에 해당하는 것은?\n\n(가) 이 약 0.5 g을 1 mol/L 염산시액 10 mL에 녹일 때 액은, 무색이며 맑다.\n(나) 이 약 및 표준품을 건조하여 적외부스펙트럼측정법의 브롬화칼륨정제법에 따라 측정할 때 같은 파수에서 같은 강도의 흡수를 나타낸다.\n(다) 이 약을 건조하여 약 0.13 g을 정밀하게 달아 포름산 3 mL에 녹이고 아세트산(100) 50 mL를 넣어 0.1 mol/L 과염소산으로 적정한다.\n\n(가) | (나) | (다)\n① 성상 | 순도시험 | 정량법\n② 순도시험 | 정량법 | 확인시험\n③ 순도시험 | 확인시험 | 정량법\n④ 확인시험 | 순도시험 | 정량법\n⑤ 확인시험 | 정량법 | 순도시험",
        "question_text": "Question: This is a test method for L-Isoleucine from the Korean Pharmacopoeia's drug monographs. What corresponds to (a), (b), and (c)?\n\n(a) When 0.5 g of this drug is dissolved in 10 mL of 1 mol/L hydrochloric acid solution, the liquid is colorless and clear.\n(b) When this drug and its reference standard are dried and measured according to the potassium bromide disk method of infrared spectrophotometry, they show absorptions of the same intensity at the same wave numbers.\n(c) About 0.13 g of this drug is accurately weighed after drying, dissolved in 3 mL of formic acid, 50 mL of acetic acid (100) is added, and then titrated with 0.1 mol/L perchloric acid.\n\n(a) | (b) | (c)\n① Description | Purity test | Assay\n② Purity test | Assay | Identification\n③ Purity test | Identification | Assay\n④ Identification | Purity test | Assay\n⑤ Identification | Assay | Purity test",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 실험 횟수를 늘리지 않고 실험 전체를 몇 개의 블록으로 나누어 배치함으로써 불필요한 교호작용을 구하지 않고 동일 환경 내의 실험 횟수를 적게 하도록 고안된 실험계획법은?\n\n① 교락법\n② 분할법\n③ 심플렉스법\n④ 반응표면계획법\n⑤ 혼합물 실험계획법",
        "question_text": "Question: Which experimental design method is designed to reduce the number of experiments within the same environment without increasing the total number of experiments by dividing the entire experiment into several blocks, thus avoiding unnecessary interaction effects?\n\n① Confounding method\n② Split-plot design\n③ Simplex method\n④ Response surface methodology\n⑤ Mixture experimental design",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 정제 무게에 대한 제조 규격의 상한값이 520 mg, 하한값이 490 mg이며, 표본으로 취한 정제들의 표준편차가 ±5.0 mg이었다. 공정능력지수(Cp)는?\n\n① 1.00\n② 1.33\n③ 2.00\n④ 4.00\n⑤ 6.00",
        "question_text": "Question: The upper limit of the manufacturing specification for tablet weight is 520 mg, and the lower limit is 490 mg. The standard deviation of the sampled tablets was ±5.0 mg. What is the Process Capability Index (Cp)?\n\n① 1.00\n② 1.33\n③ 2.00\n④ 4.00\n⑤ 6.00",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nKorean Pharmacopoeia에 수록된 덱스트란 40의 순도시험과 정량법이다.\n1. 중금속: 이 약 2.0 g을 달아 제1법에 따라 조작하여 시험한다. 비교액에는 납표준액 (A)mL을 넣는다(5 ppm 이하).\n2. 정량법: 건조한 약 3 g을 정밀하게 달아 물에 녹여 정확하게 50 mL로 한 액을 검액으로 하여 (B)에 따라 정량한다.\n\nQuestion: 납표준액의 납 농도가 0.01 mg/mL일 때 A는?\n\n① 0.5\n② 1.0\n③ 1.5\n④ 2.0\n⑤ 3.0",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThis is the purity test and assay method for Dextran 40 as listed in the Korean Pharmacopoeia.\n1. Heavy metals: Weigh 2.0 g of this drug and proceed according to Method 1. Add (A) mL of lead standard solution to the control solution (not more than 5 ppm).\n2. Assay: Accurately weigh about 3 g of the dried drug, dissolve it in water to make exactly 50 mL, and use this solution as the test solution. Perform the assay according to (B).\n\nQuestion: When the lead concentration in the lead standard solution is 0.01 mg/mL, what is A?\n\n① 0.5\n② 1.0\n③ 1.5\n④ 2.0\n⑤ 3.0",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nKorean Pharmacopoeia에 수록된 덱스트란 40의 순도시험과 정량법이다.\n1. 중금속: 이 약 2.0 g을 달아 제1법에 따라 조작하여 시험한다. 비교액에는 납표준액 (A)mL을 넣는다(5 ppm 이하).\n2. 정량법: 건조한 약 3 g을 정밀하게 달아 물에 녹여 정확하게 50 mL로 한 액을 검액으로 하여 (B)에 따라 정량한다.\n\nQuestion: 정량법 B는?\n\n① 선광도측정법\n② 분말X선 회절측정법\n③ 산소플라스크연소법\n④ 기체크로마토그래프법\n⑤ 자외가시부흡광도측정법",
        "question_text": "The following is the purity test and assay method for Dextran 40 as listed in the Korean Pharmacopoeia.\n1. Heavy metals: Weigh 2.0 g of this drug and proceed according to Method 1. Add (A) mL of lead standard solution to the control solution (not more than 5 ppm).\n2. Assay: Accurately weigh about 3 g of the dried drug, dissolve it in water to make exactly 50 mL, and use this solution as the test solution. Perform the assay according to method (B).\n\nQuestion: What is assay method B?\n\n① Optical rotation method\n② Powder X-ray diffraction method\n③ Oxygen flask combustion method\n④ Gas chromatography method\n⑤ UV-visible spectrophotometry method",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: A 약국은 취학 전 아동과 그 부모를 목표시장으로 결정한 후, ‘어린이 환자에게 정성을 쏟는 약국’이라는 이미지를 전달하기 위하여 실내 인테리어를 바꾸고 어린이 건강관리 요령을 담은 소책자를 제작하여 배포하기로 하였다. 이는 마케팅 전략과정 중 무엇인가?\n\n① 상황분석\n② 포지셔닝\n③ 전략대안 파악\n④ 통제방법 결정\n⑤ 마케팅 목표 수립",
        "question_text": "Question: Pharmacy A decided to target preschool children and their parents as their market. To convey the image of 'a pharmacy that devotes care to child patients,' they decided to change their interior design and produce and distribute booklets containing child health care tips. Which step of the marketing strategy process does this represent?\n\n① Situation analysis\n② Positioning\n③ Identifying strategic alternatives\n④ Determining control methods\n⑤ Establishing marketing objectives",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 약국의 재무상태표에 나타난 자산, 부채, 자본에 대한 설명으로 옳은 것은?\n\n① 매출채권은 유동부채이다.\n② 재고자산은 비유동자산이다.\n③ 감가상각누계액은 유동자산이다.\n④ 약국개설자가 약국에 투자한 현물자산은 자본이다.\n⑤ 당 회계기간 내에 만기가 도래하는 장기부채는 비유동부채이다.",
        "question_text": "Question: Which of the following statements about assets, liabilities, and equity shown on a pharmacy's balance sheet is correct?\n\n① Accounts receivable is a current liability.\n② Inventory is a non-current asset.\n③ Accumulated depreciation is a current asset.\n④ Tangible assets invested in the pharmacy by the pharmacy owner are equity.\n⑤ Long-term debt maturing within the current accounting period is a non-current liability.",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 약국의 손익분기점 분석에 포함하는 비용에 대한 설명으로 옳은 것은? (단, 매출 증가로 약국 확장까지 고려해야 하는 상황은 배제한다.)\n\n① 약국의 월 임차료는 변동비용이다.\n② 약국개설자의 인건비는 고정비용이다.\n③ 시럽제 포장용기 비용은 고정비용이다.\n④ 환자가 결제한 신용카드 수수료는 고정비용이다.\n⑤ 최신 자동화조제기기의 구입 할부금은 변동비용이다.",
        "question_text": "Question: Which of the following statements about costs included in a pharmacy's break-even analysis is correct? (Exclude situations where pharmacy expansion due to increased sales should be considered.)\n\n① The monthly rent of the pharmacy is a variable cost.\n② The labor cost of the pharmacy owner is a fixed cost.\n③ The cost of packaging containers for syrups is a fixed cost.\n④ The credit card fees paid by patients are fixed costs.\n⑤ The installment payments for purchasing the latest automated dispensing machine are variable costs.",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: A 약국의 2020년 재무현황이 다음과 같을 때 매출액 순이익률은?\n\n매출액 10억 원\n매출원가 6억 원\n영업비용 2억 원\n자본 2억 원\n부채 3억 원\n\n① 0.1\n② 0.2\n③ 0.3\n④ 0.4\n⑤ 0.5",
        "question_text": "Question: Given the following financial situation of Pharmacy A in 2020, what is the net profit margin?\n\nSales revenue: 1 billion won\nCost of goods sold: 600 million won\nOperating expenses: 200 million won\nCapital: 200 million won\nLiabilities: 300 million won\n\n① 0.1\n② 0.2\n③ 0.3\n④ 0.4\n⑤ 0.5",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: A 약국은 수액주사제를 연간 1,000병 사용한다. 수액주사제의 구입가격은 병당 10,000원이며, 병당 재고유지비용은 구입가격의 10%이다. 평균 재고량은 1회 주문량의 1/2, 1회 주문비용은 5,000원이라고 했을 때, 총재고관리비용을 최소화하는 1회 주문량은?\n\n① 50병\n② 100병\n③ 200병\n④ 500병\n⑤ 1,000병",
        "question_text": "Question: Pharmacy A uses 1,000 bottles of IV fluid annually. The purchase price of IV fluid is 10,000 won per bottle, and the inventory holding cost per bottle is 10% of the purchase price. The average inventory is 1/2 of the order quantity, and the cost per order is 5,000 won. What is the order quantity that minimizes the total inventory management cost?\n\n① 50 bottles\n② 100 bottles\n③ 200 bottles\n④ 500 bottles\n⑤ 1,000 bottles",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 현재 각국 정부는 코로나바이러스감염증-19 백신 접종을 통해 집단면역 효과를 얻기를 기대하고 있다. 집단면역이 형성되면 예방 접종을 하지 않은 사람들도 해당 질병에 걸릴 확률이 현저히 낮아지게 된다. 이와 관련 있는 보건의료 시장의 특성은?\n\n① 역선택\n② 유인수요\n③ 외부효과\n④ 위험군선택\n⑤ 정보의 비대칭",
        "question_text": "Question: Currently, governments around the world are hoping to achieve herd immunity through COVID-19 vaccine administration. When herd immunity is established, even unvaccinated individuals have a significantly lower chance of contracting the disease. Which characteristic of the healthcare market is related to this?\n\n① Adverse selection\n② Supplier-induced demand\n③ Externality\n④ Risk selection\n⑤ Information asymmetry",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: Minister of Health and Welfare이 고시한 경증질환 환자가 상급종합병원을 방문하여 외래처방전을 발급받으면 의원에서 발급받은 경우보다 약제비에 대한 본인부담률이 더 높다. 이러한 정책의 주된 목적은?\n\n① 약물 오남용 방지\n② 의료전달체계 확립\n③ 재난적 의료비 발생 방지 \n④ 의료소비자의 선택권 강화\n⑤ 의료기관의 경영 악화 방지",
        "question_text": "Question: When a patient with a minor illness, as designated by the Minister of Health and Welfare, visits a tertiary hospital and receives an outpatient prescription, the patient's co-payment rate for medication costs is higher than if they had received it from a clinic. What is the main purpose of this policy?\n\n① Prevention of drug misuse and abuse\n② Establishment of a healthcare delivery system\n③ Prevention of catastrophic medical expenses\n④ Strengthening medical consumers' right to choose\n⑤ Prevention of deterioration in healthcare institutions' management",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 개국 약국에 적용되는 요양급여기준에 대한 설명으로 옳은 것은?\n\n① 복약지도료는 조제일수에 따라 산정한다.\n② 약국관리료는 약국의 면적에 따라 산정한다.\n③ 약제비는 고시된 상한 금액을 기준으로 상환한다.\n④ 야간에 이루어진 조제서비스는 차등수가제 적용 대상이다.\n⑤ 의약품관리료는 조제일수와 관계없이 방문당 정액으로 산정한다.",
        "question_text": "Question: Which of the following statements about the health care benefit standards applied to community pharmacies is correct?\n\n① The medication counseling fee is calculated based on the number of days of prescription.\n② The pharmacy management fee is calculated based on the pharmacy's area.\n③ Drug costs are reimbursed based on the announced maximum price.\n④ Dispensing services provided at night are subject to differential pricing.\n⑤ The medication management fee is calculated as a fixed amount per visit, regardless of the number of days of prescription.",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 우리나라의 의약품 공급체계에 대한 설명으로 옳은 것은?\n\n① 도매상의 의약품 유통품질 관리기준 준수는 선택사항이다.\n② 약국개설자는 제조업자로부터 의약품을 직접 구입할 수 없다.\n③ Korea Orphan and Essential Drug Center에서는 희귀의약품 조제 업무를 한다.\n④ 도매상은 약국에 대금결제조건에 따른 비용할인을 제공할 수 없다.\n⑤ 국가비상상황에 대비하여 비축 ∙ 공급해야 하는 의약품은 퇴장방지의약품으로 지정한다.",
        "question_text": "Question: Which of the following statements about the pharmaceutical supply system in our country is correct?\n\n① Compliance with Good Distribution Practice (GDP) for wholesalers is optional.\n② Pharmacy owners cannot purchase medicines directly from manufacturers.\n③ The Korea Orphan and Essential Drug Center prepares orphan drugs.\n④ Wholesalers cannot offer cost discounts to pharmacies based on payment terms.\n⑤ Medicines that need to be stockpiled and supplied for national emergencies are designated as drugs subject to price maintenance.",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 우리나라에서 채택한 의약품 선별등재제도에 대한 설명으로 옳은 것은?\n\n① 저가 의약품을 입찰 구매하는 제도이다.\n② 신약에 대한 접근성을 개선하기 위하여 도입되었다.\n③ 임상적 가치와 경제적 가치를 기반으로 보험등재 여부를 결정한다.\n④ 진료상 필수약제는 약가협상 없이 Health Insurance Review & Assessment Service에서 보험약가를 결정한다.\n⑤ 비교약 대비 비열등성을 입증한 신약의 경우 비용-효과 분석 자료를 제출하여야 한다.",
        "question_text": "Question: Which of the following statements about the Positive List System for pharmaceuticals adopted in our country is correct?\n\n① It is a system for purchasing low-cost medicines through bidding.\n② It was introduced to improve access to new drugs.\n③ Insurance listing decisions are based on clinical value and economic value.\n④ For essential medicines, insurance prices are determined by the Health Insurance Review & Assessment Service without price negotiations.\n⑤ For new drugs that have proven non-inferiority compared to comparator drugs, cost-effectiveness analysis data must be submitted.",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 건강보험 약제비 관리를 위해 수요 측면에서 접근한 정책은?\n\n① 위험분담제도\n② 선별등재제도\n③ 실거래가 상환제도 \n④ 사용량-약가 연동제도\n⑤ 대체조제 장려금 제도",
        "question_text": "Question: Which policy approaches the management of health insurance pharmaceutical costs from the demand side?\n\n① Risk-sharing system\n② Selective listing system\n③ Actual transaction price reimbursement system\n④ Volume-price linkage system\n⑤ Generic substitution incentive system",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 약 A와 B의 헬리코박터 제균효과를 비교한 연구들을 메타분석 하여 다음과 같은 결과를 얻었다. 이에 대한 해석으로 옳은 것은?\n\n| 연구 | A 사용자 총환자수 (명) | A 사용자 제균성공사례 (명) | B 사용자 환자수 (명) | B 사용자 제균성공사례 (명) | 대응위험도(오즈비) [95% 신뢰구간] |\n|---|---|---|---|---|---|\n| (가) | 329 | 300 | 321 | 243 | 3.32 [2.10, 5.25] |\n| (나) | 72 | 69 | 69 | 48 | 10.06 [2.84, 35.64] |\n| (다) | 55 | 48 | 51 | 39 | 2.11 [0.76, 5.87] |\n| 합계 | 456 | 417 | 441 | 330 | 3.68 [1.87, 7.26] |\nHeterogeneity: Tau^2=0.17, Chi^2=3.69, df=2 (p=0.16): I^2=46%\nTest for overall effect: Z=3.77 (p=0.0002)\n\n① 이 표는 개별연구의 비뚤림 정보를 포함한다.\n② 메타분석을 할 때 가중치가 가장 큰 연구는 (나)이다.\n③ 메타분석에 의해 중재법의 효과에 대한 검정력은 감소한다.\n④ 메타분석 결과 5% 유의수준에서 A는 B보다 제균효과가 더 높다. \n⑤ 카이제곱검정 결과 10% 유의수준에서 개별 연구들 간에 이질성(heterogeneity)이 있다.",
        "question_text": "Question: A meta-analysis of studies comparing the Helicobacter pylori eradication effects of drugs A and B yielded the following results. Which interpretation of these results is correct?\n\n| Study | Total patients using A (n) | Successful eradication cases with A (n) | Patients using B (n) | Successful eradication cases with B (n) | Odds Ratio [95% Confidence Interval] |\n|---|---|---|---|---|---|\n| (a) | 329 | 300 | 321 | 243 | 3.32 [2.10, 5.25] |\n| (b) | 72 | 69 | 69 | 48 | 10.06 [2.84, 35.64] |\n| (c) | 55 | 48 | 51 | 39 | 2.11 [0.76, 5.87] |\n| Total | 456 | 417 | 441 | 330 | 3.68 [1.87, 7.26] |\nHeterogeneity: Tau^2=0.17, Chi^2=3.69, df=2 (p=0.16): I^2=46%\nTest for overall effect: Z=3.77 (p=0.0002)\n\n① This table includes bias information for individual studies.\n② In the meta-analysis, study (b) has the largest weight.\n③ Meta-analysis decreases the power to detect the effect of the intervention.\n④ The meta-analysis results show that A has a higher eradication effect than B at a 5% significance level.\n⑤ The chi-square test results indicate heterogeneity among individual studies at a 10% significance level.",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 경제성평가에서 비용추정에 대한 설명으로 옳은 것은?\n\n① 부작용 모니터링 비용은 간접비용에 포함된다.\n② 비용항목 선정 범위가 분석관점에 관계없이 동일하다.\n③ 보험자 관점에 따라 분석할 경우 비급여진료비를 포함한다.\n④ 보건의료체계 관점에 따라 분석할 경우 생산성 손실비용을 포함한다.\n⑤ 높은 할인율의 적용은 미래에 발생할 비용의 현재가치를 감소시킨다.",
        "question_text": "Question: Which of the following statements about cost estimation in economic evaluation is correct?\n\n① The cost of adverse event monitoring is included in indirect costs.\n② The scope of cost item selection is the same regardless of the perspective of analysis.\n③ When analyzing from the insurer's perspective, non-reimbursed medical expenses are included.\n④ When analyzing from the healthcare system perspective, productivity loss costs are included.\n⑤ Applying a high discount rate decreases the present value of future costs.",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 다음은 약 A와 B의 비용과 효과를 요약한 표이다. A와 B의 투약과 관련된 비용은 각각 4,000만 원과 1,000만 원이며, A를 복용한 환자는 0.6의 삶의 질로 10년을 살 수 있고, B를 복용한 환자는 0.5의 삶의 질로 6년을 살 수 있다. B와 비교한 A의 점증적 비용-효용비(만 원 / QALY)는? (단, 할인율은 0%로 가정함. QALY=quality adjusted life year)\n\n| 치료 대안 | 비용(만 원) | 생존기간(년) | 질가중치 |\n|---|---|---|---|\n| A | 4,000 | 10 | 0.6 |\n| B | 1,000 | 6 | 0.5 |\n\n① 900 \n② 3,000/4 \n③ 1,000 \n④ 3,000 \n⑤ 12,000",
        "question_text": "Question: The following table summarizes the costs and effects of drugs A and B. The costs associated with administering A and B are 40 million won and 10 million won, respectively. Patients taking A can live for 10 years with a quality of life of 0.6, while patients taking B can live for 6 years with a quality of life of 0.5. What is the incremental cost-utility ratio (10,000 won / QALY) of A compared to B? (Assume a discount rate of 0%. QALY = quality adjusted life year)\n\n| Treatment Option | Cost (10,000 won) | Survival Period (years) | Quality Weight |\n|---|---|---|---|\n| A | 4,000 | 10 | 0.6 |\n| B | 1,000 | 6 | 0.5 |\n\n① 900 \n② 3,000/4 \n③ 1,000 \n④ 3,000 \n⑤ 12,000",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: A 약사는 일일 상용량이 0.1 mg인 의약품이 처방전에 1.0 mg으로 기재된 것을 발견하였으나, 처방 의사에게 오류 여부를 확인하지 않고 처방전대로 조제하였다. 이는 약사의 윤리적 행동 원칙 중 무엇을 위반한 것인가?\n\n① 정의의 원칙\n② 피해회피의 원칙\n③ 자율성 존중의 원칙\n④ 정직과 진실성 원칙\n⑤ 사생활 존중과 보호 원칙",
        "question_text": "Question: A pharmacist noticed that a medication with a daily usual dose of 0.1 mg was prescribed as 1.0 mg on the prescription. However, the pharmacist dispensed the medication as prescribed without confirming the error with the prescribing physician. Which ethical principle of pharmacists' behavior does this violate?\n\n① Principle of justice\n② Principle of non-maleficence\n③ Principle of respect for autonomy\n④ Principle of honesty and integrity\n⑤ Principle of respect for and protection of privacy",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: A 약사가 제공하는 금연 프로그램에서는 환자의 상황을 금연 고려 전 – 고려 – 준비 – 행동 – 유지로 구분하여, 이에 따라 차별적인 환자교육 프로그램을 제공한다. 이 프로그램의 기반이 되는 건강행태모형은?\n\n① 사회인지이론\n② 건강신념모델\n③ 변화단계이론\n④ 앤더슨행동모델\n⑤ PRECEDE-PROCEED 모델",
        "question_text": "Question: In a smoking cessation program provided by a pharmacist, the patient's situation is categorized into pre-contemplation - contemplation - preparation - action - maintenance, and a differentiated patient education program is provided accordingly. What is the health behavior model that forms the basis of this program?\n\n① Social Cognitive Theory\n② Health Belief Model\n③ Transtheoretical Model (Stages of Change)\n④ Andersen Behavioral Model\n⑤ PRECEDE-PROCEED Model",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n약 A의 복용이 결핵 발생과 관련 있다는 보고가 있다. 이에 과거 10년 동안의 건강보험청구자료를 분석하여, A를 복용한 환자 1,000명과 A를 복용하지 않은 환자 1,000명에서 다음과 같은 결과를 확인하였다.\n\n| | 결핵 발생 | 결핵 발생하지 않음 | 합계 |\n|---|---|---|---|\n| A 복용(명) | 20 | 980 | 1,000 |\n| A 복용하지 않음(명) | 10 | 990 | 1,000 |\n| 합계 | 30 | 1,970 | 2,000 |\n\nQuestion: 위 사례에 적용된 연구설계 유형은?\n\n① 단면연구\n② 환자대조군 연구\n③ 전향적 코호트 연구\n④ 후향적 코호트 연구\n⑤ 무작위배정 임상연구",
        "question_text": "There have been reports suggesting a link between taking Drug A and the occurrence of tuberculosis. To investigate this, health insurance claim data from the past 10 years were analyzed, comparing 1,000 patients who took Drug A with 1,000 patients who did not take Drug A. The following results were obtained:\n\n| | Tuberculosis Occurred | Tuberculosis Did Not Occur | Total |\n|---|---|---|---|\n| Took Drug A (persons) | 20 | 980 | 1,000 |\n| Did Not Take Drug A (persons) | 10 | 990 | 1,000 |\n| Total | 30 | 1,970 | 2,000 |\n\nQuestion: What type of research design was applied in this case study?\n\n① Cross-sectional study\n② Case-control study\n③ Prospective cohort study\n④ Retrospective cohort study\n⑤ Randomized controlled trial",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n약 A의 복용이 결핵 발생과 관련 있다는 보고가 있다. 이에 과거 10년 동안의 건강보험청구자료를 분석하여, A를 복용한 환자 1,000명과 A를 복용하지 않은 환자 1,000명에서 다음과 같은 결과를 확인하였다.\n\n| | 결핵 발생 | 결핵 발생하지 않음 | 합계 |\n|---|---|---|---|\n| A 복용(명) | 20 | 980 | 1,000 |\n| A 복용하지 않음(명) | 10 | 990 | 1,000 |\n| 합계 | 30 | 1,970 | 2,000 |\n\nQuestion: 약 A와 결핵 발생의 연관성을 나타내는 지표와 그 결과 값으로 적절한 것은?\n\n지표 | 결과 값\n① 상대위험도 | (20/1000)/(10/1000)\n② 상대위험도 | (20×990)/(10×980)\n③ 대응위험도(오즈비) | (20/1000)/(10/1000)\n④ 대응위험도(오즈비) | (20/30)/(980/1970)\n⑤ 보고분율비 | (20×990)/(10×980)",
        "question_text": "There have been reports suggesting a link between taking Drug A and the occurrence of tuberculosis. To investigate this, health insurance claim data from the past 10 years were analyzed, comparing 1,000 patients who took Drug A with 1,000 patients who did not take Drug A. The following results were obtained:\n\n| | Tuberculosis Occurred | Tuberculosis Did Not Occur | Total |\n|---|---|---|---|\n| Took Drug A (persons) | 20 | 980 | 1,000 |\n| Did Not Take Drug A (persons) | 10 | 990 | 1,000 |\n| Total | 30 | 1,970 | 2,000 |\n\nQuestion: Which of the following indicators and its calculated value appropriately represents the association between Drug A and the occurrence of tuberculosis?\n\nIndicator | Calculated Value\n① Relative Risk | (20/1000)/(10/1000)\n② Relative Risk | (20×990)/(10×980)\n③ Odds Ratio | (20/1000)/(10/1000)\n④ Odds Ratio | (20/30)/(980/1970)\n⑤ Reporting Odds Ratio | (20×990)/(10×980)",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 적용 대상이 드문 의약품으로서 대체 가능한 의약품이 없거나 대체 가능한 의약품 보다 현저히 안전성 또는 유효성이 개선된 의약품은?\n\n① 일반의약품\n② 희귀의약품\n③ 생물학적 제제\n④ 국가필수의약품\n⑤ 국가출하승인의약품",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is a pharmaceutical product that is rarely applicable, has no substitutable alternatives, or shows significantly improved safety or efficacy compared to substitutable alternatives?\n\n① Over-the-counter drugs\n② Orphan drugs\n③ Biological products\n④ National essential medicines\n⑤ National lot release approved drugs",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 복약지도서 내용에 포함되어 있지 않은 것은?\n\n① 부작용\n② 진단명\n③ 저장방법\n④ 용법 ∙ 용량\n⑤ 효능 ∙ 효과",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT included in the content of medication guidance documents?\n\n① Side effects\n② Diagnosis\n③ Storage method\n④ Dosage and administration\n⑤ Efficacy and effects",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사가 처방전에 따라 조제하는 경우 정당한 사유가 없는 한 미리 확인해야 하는 의약품정보에 해당하지 않는 것은?\n\n① Minister of Food and Drug Safety이 회수 ∙ 폐기하도록 명령한 의약품 여부\n② Minister of Food and Drug Safety이 병용금기로 고시한 성분이 포함된 의약품 여부\n③ Minister of Food and Drug Safety이 신약재심사 대상으로 지정한 의약품 여부\n④ 환자에게 처방 또는 투여되고 있는 의약품과 동일한 성분의 의약품 여부\n⑤ Minister of Food and Drug Safety이 특정연령대 금기 또는 임부금기로 고시한 성분이 포함된 의약품 여부",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT information about medications that a pharmacist must verify in advance, without justifiable reason, when dispensing according to a prescription?\n\n① Whether it is a medication ordered to be recalled or disposed of by the Minister of Food and Drug Safety\n② Whether it contains ingredients that the Minister of Food and Drug Safety has announced as contraindicated for concurrent use\n③ Whether it is a medication designated by the Minister of Food and Drug Safety as subject to new drug re-evaluation\n④ Whether it is a medication with the same ingredients as those already prescribed or administered to the patient\n⑤ Whether it contains ingredients that the Minister of Food and Drug Safety has announced as contraindicated for specific age groups or pregnant women",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국에서 근무하는 약사가 판매할 목적으로 조제한 의약품의 용기에 기재를 생략할 수 있는 사항은?\n\n① 조제 연월일\n② 용법 및 용량\n③ 처방한 의료기관의 명칭\n④ 처방전에 적힌 환자의 이름\n⑤ 조제한 약국의 명칭과 소재지",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following items can be omitted from the label on a container of medicine prepared by a pharmacist working in a pharmacy for the purpose of sale?\n\n① Date of preparation\n② Dosage and administration\n③ Name of the medical institution that issued the prescription\n④ Patient's name as written on the prescription\n⑤ Name and location of the pharmacy where the medicine was prepared",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 대한약사회의 설립 목적에 해당하지 않는 것은?\n\n① 약사(藥師)의 권익 증진\n② 약사(藥師)의 자질 향상\n③ 지역사회 감염병 예방\n④ 약사(藥事)에 관한 연구\n⑤ 약사윤리(藥師倫理) 확립",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a purpose for establishing the Korean Pharmaceutical Association?\n\n① Promotion of pharmacists' rights and interests\n② Improvement of pharmacists' qualifications\n③ Prevention of infectious diseases in local communities\n④ Research on pharmaceutical affairs\n⑤ Establishment of pharmaceutical ethics",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 안전상비의약품 판매자의 등록기준에 해당하지 않는 것은?\n\n① 24시간 연중 무휴(無休) 점포를 갖출 것\n② 안전상비의약품을 안전하게 보관할 수 있는 창고를 갖출 것\n③ 안전상비의약품의 안전성 확보와 품질관리에 관한 교육을 수료할 것\n④ \"통계법\"에 따라 통계청장이 고시한 한국표준산업분류에 따른 소매업을 경영할 것\n⑤ 국제표준바코드를 이용하여 위해(危害)의약품 판매를 차단할 수 있는 시스템을 갖출 것",
        "question_text": "Question: Which of the following is NOT a registration criterion for sellers of over-the-counter drugs according to the \"Pharmaceutical Affairs Act\"?\n\n① Have a store that operates 24 hours a day, 365 days a year\n② Have a warehouse capable of safely storing over-the-counter drugs\n③ Complete education on ensuring safety and quality control of over-the-counter drugs\n④ Operate a retail business according to the Korean Standard Industrial Classification as announced by the Commissioner of Statistics Korea under the \"Statistics Act\"\n⑤ Have a system that can block the sale of harmful drugs using international standard barcodes",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품의 판매질서에 대한 설명으로 옳지 않은 것은?\n\n① 의약품 도매상은 환자에게 의약품을 직접 판매할 수 없다.\n② 의약품 제조업자는 그 종업원에게 의약품을 판매할 수 있다.\n③ 의약품 도매상은 다른 도매상에게 의약품을 판매할 수 있다.\n④ 의약품 도매상은 폐업하는 약국개설자로부터 의약품을 구입할 수 있다.\n⑤ 약국개설자는 의사가 처방한 의약품이 없는 경우 다른 약국개설자로부터 해당 의약품을 구입할 수 있다.",
        "question_text": "Question: Which of the following statements about the sales order of pharmaceuticals under the \"Pharmaceutical Affairs Act\" is incorrect?\n\n① Pharmaceutical wholesalers cannot directly sell medicines to patients.\n② Pharmaceutical manufacturers can sell medicines to their employees.\n③ Pharmaceutical wholesalers can sell medicines to other wholesalers.\n④ Pharmaceutical wholesalers can purchase medicines from pharmacy owners who are closing their business.\n⑤ Pharmacy owners can purchase medicines from other pharmacy owners if they do not have the medicine prescribed by a doctor.",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 Minister of Food and Drug Safety이 의약품특허목록에 등재하는 특허권의 대상에 해당하지 않는 것은?\n\n① 물질\n② 제형\n③ 조성물\n④ 제조방법\n⑤ 의약적 용도",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a subject of patent rights that the Minister of Food and Drug Safety registers in the list of pharmaceutical patents?\n\n① Substance\n② Dosage form\n③ Composition\n④ Manufacturing method\n⑤ Medical use",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 Minister of Food and Drug Safety으로부터 임상시험계획에 대한 승인을 받아야 하는 것은?\n\n① 판매 중인 의약외품의 임상시험\n② 판매 중인 의약품의 경제성 평가\n③ 판매 중인 의약품의 이상반응을 조사하기 위한 시험\n④ 판매 중인 의약품의 허가 범위에서 임상적인 효과를 관찰하기 위한 시험\n⑤ 판매 중인 의약품의 용법 ∙ 용량에 대한 허가사항을 변경하기 위한 시험",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following requires approval for the clinical trial plan from the Minister of Food and Drug Safety?\n\n① Clinical trial of quasi-drugs currently on the market\n② Economic evaluation of drugs currently on the market\n③ Tests to investigate adverse reactions of drugs currently on the market\n④ Tests to observe clinical effects of drugs currently on the market within the approved range\n⑤ Tests to change the approved details of dosage and administration for drugs currently on the market",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 제조업자가 낱알모음 하여 한 알씩 사용할 수 있도록 포장한 의약품의 낱알모음 포장에 기재를 생략할 수 있는 사항은?\n\n① 제조번호\n② 제품의 명칭\n③ 유효성분의 명칭\n④ 제조업자의 상호\n⑤ 유효기한 또는 사용기한",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following items can be omitted from the labeling of unit dose packaging of pharmaceuticals that are packaged individually for single-dose use by pharmaceutical manufacturers?\n\n① Lot number\n② Product name\n③ Name of active ingredient\n④ Manufacturer's trade name\n⑤ Expiration date or use-by date",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 Korea Institute of Drug Safety & Risk Management의 사업에 해당하지 않는 것은?\n\n① 의약품 부작용 피해구제사업\n② 의약품 관리종합정보센터의 운영\n③ 의약품안전정보의 수집 ∙ 분석 ∙ 평가\n④ 의약품 부작용의 인과관계 조사 ∙ 규명\n⑤ 의약품안전정보의 개발 ∙ 활용을 위한 조사 ∙ 연구",
        "question_text": "Question: Which of the following is NOT a business activity of the Korea Institute of Drug Safety & Risk Management according to the \"Pharmaceutical Affairs Act\"?\n\n① Relief services for adverse drug reactions\n② Operation of the Comprehensive Drug Management Information Center\n③ Collection, analysis, and evaluation of drug safety information\n④ Investigation and identification of causal relationships in adverse drug reactions\n⑤ Research and investigation for the development and utilization of drug safety information",
        "answer": 2
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사면허가 취소되는 경우에 해당하지 않는 것은?\n\n① 파산선고를 받은 경우\n② 피성년후견인이 된 경우\n③ 피한정후견인이 된 경우\n④ 마약중독자로 판명된 경우\n⑤ 약사(藥事)에 관한 법령을 위반하여 금고 이상의 형을 선고 받고 형 집행 중인 자",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a case where a pharmacist's license would be revoked?\n\n① In case of bankruptcy declaration\n② In case of becoming a person under adult guardianship\n③ In case of becoming a person under limited guardianship\n④ In case of being identified as a drug addict\n⑤ A person who is currently serving a sentence of imprisonment or a heavier punishment for violating laws related to pharmaceutical affairs",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류취급자에 대한 설명으로 옳지 않은 것은?\n\n① 대마재배자: 섬유 또는 종자를 채취할 목적으로 대마초를 재배하는 자\n② 마약류제조업자: 마약 또는 향정신성의약품의 제조를 업(業)으로 하는 자\n③ 마약류수출입업자: 마약 또는 향정신성의약품의 수출입을 업으로 하는 자\n④ 마약류원료사용자: 마약류가 아닌 물질 중 마약 제조에 사용되는 물질의 제조 ∙ 수출입 ∙ 매매에 종사하는 자\n⑤ 마약류소매업자: 약국개설자로서 마약류취급의료업자의 처방전에 따라 마약 또는 향정신성의약품을 조제하여 판매하는 것을 업으로 하는 자",
        "question_text": "Question: Which of the following descriptions of narcotic drug handlers under the \"Narcotics Control Act\" is incorrect?\n\n① Cannabis cultivator: A person who cultivates cannabis plants for the purpose of harvesting fiber or seeds\n② Narcotic drug manufacturer: A person who engages in the business of manufacturing narcotics or psychotropic drugs\n③ Narcotic drug importer/exporter: A person who engages in the business of importing or exporting narcotics or psychotropic drugs\n④ Narcotic raw material user: A person engaged in the manufacture, import/export, or sale of substances that are not narcotic drugs but are used in the manufacture of narcotics\n⑤ Narcotic drug retailer: A pharmacy owner who engages in the business of dispensing and selling narcotics or psychotropic drugs according to prescriptions from medical practitioners authorized to handle narcotic drugs",
        "answer": 4
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류제조업자가 자신이 제조한 향정신성의약품을 판매해서는 안 되는 자는?\n\n① 마약류도매업자\n② 마약류소매업자\n③ 마약류수출입업자\n④ 마약류취급의료업자\n⑤ 마약류취급학술연구자",
        "question_text": "Question: According to the \"Narcotics Control Act,\" to whom should a narcotic drug manufacturer not sell psychotropic drugs that they have produced?\n\n① Narcotic drug wholesaler\n② Narcotic drug retailer\n③ Narcotic drug importer/exporter\n④ Medical practitioner handling narcotic drugs\n⑤ Academic researcher handling narcotic drugs",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류소매업자가 지체 없이 해당 약국개설 등록관청에 보고해야 하는 사고마약 사유에 해당하지 않는 것은?\n\n① 파손\n② 변질 ∙ 부패\n③ 사용기한 경과\n④ 분실 또는 도난\n⑤ 재해로 인한 상실(喪失)",
        "question_text": "Question: According to the \"Narcotics Control Act,\" which of the following is NOT a reason for accidental narcotics that a narcotics retailer must report to the relevant pharmacy registration office without delay?\n\n① Damage\n② Deterioration or spoilage\n③ Expiration\n④ Loss or theft\n⑤ Loss due to disaster",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: \"National Health Promotion Act\"상 개인 또는 집단이 건강에 유익한 행위를 지속적으로 수행함으로써 건강한 상태를 유지할 수 있도록 하기 위하여 시행하는 국민건강증진 사업은?\n\n① 건강관리\n② 보건교육\n③ 영양개선\n④ 질병예방\n⑤ 생애주기별 질병관리",
        "question_text": "Question: According to the \"National Health Promotion Act,\" which of the following is a national health promotion project implemented to enable individuals or groups to maintain a healthy state by continuously performing actions beneficial to health?\n\n① Health management\n② Health education\n③ Nutrition improvement\n④ Disease prevention\n⑤ Life cycle disease management",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: \"Framework Act on Health and Medical Services\"상 이 법의 기본 이념 및 정의에 관한 내용으로 옳지 않은 것은?\n\n① 약사는 보건의료인에 포함된다.\n② 약국은 보건의료기관에 포함된다.\n③ 공공단체가 설립 ∙ 운영하는 보건의료기관은 공공보건의료기관에 포함된다.\n④ 보건의료의 형평과 효율이 조화를 이룰 수 있도록 함으로써 국민의 삶의 질 향상에 이바지한다.\n⑤ 국민의 질병 ∙ 부상에 대한 예방 ∙ 진단 ∙ 치료 ∙ 재활 및 건강증진에 대하여 보험급여를 실시함으로써 국민보건 향상에 이바지한다.",
        "question_text": "Question: Which of the following is NOT correct regarding the basic principles and definitions in the \"Framework Act on Health and Medical Services\"?\n\n① Pharmacists are included as healthcare professionals.\n② Pharmacies are included as healthcare institutions.\n③ Healthcare institutions established and operated by public organizations are included as public healthcare institutions.\n④ It contributes to improving the quality of life for citizens by ensuring a balance between equity and efficiency in healthcare.\n⑤ It contributes to improving national health by providing insurance benefits for the prevention, diagnosis, treatment, rehabilitation, and health promotion of citizens' diseases and injuries.",
        "answer": 5
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 국내에 거주하는 국민으로서 국민건강보험의 적용을 받는 가입자 또는 피부양자에 해당하지 않는 자는?\n\n① 지역가입자\n② 국가에서 상시 공무에 종사하는 사람\n③ \"Medical Benefit Act\"에 따라 의료급여를 받는 사람\n④ \"Act On The Honorable Treatment Of And Support For Persons Of Distinguished Service To The State\"에 따른 의료보호대상자 중 건강보험의 적용을 신청한 사람\n⑤ 건강보험을 적용받고 있던 중 \"The Act on the Honorable Treatment of Persons of Distinguished Service to Independence\"에 따라 의료보호 대상자가 되었으나 건강보험의 적용배제신청을 하지 않은 사람",
        "question_text": "Question: According to the \"National Health Insurance Act,\" which of the following does not correspond to a subscriber or dependent who is covered by National Health Insurance among citizens residing in Korea?\n\n① Regional subscriber\n② Person regularly engaged in public service for the state\n③ Person receiving medical benefits according to the \"Medical Benefit Act\"\n④ Person who has applied for health insurance coverage among medical protection beneficiaries under the \"Act On The Honorable Treatment Of And Support For Persons Of Distinguished Service To The State\"\n⑤ Person who became a medical protection beneficiary under \"The Act on the Honorable Treatment of Persons of Distinguished Service to Independence\" while covered by health insurance but did not apply for exclusion from health insurance coverage",
        "answer": 3
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 업무나 일상생활에 지장이 없는 질환에 대한 치료 등을 요양급여대상에서 제외하는 것을 무엇이라고 하는가?\n\n① 비급여\n② 요양비\n③ 부가급여\n④ 선별급여\n⑤ 방문요양급여",
        "question_text": "Question: According to the \"National Health Insurance Act,\" what is the term for excluding treatments for conditions that do not interfere with work or daily life from the scope of health care benefits?\n\n① Non-benefit\n② Medical expense benefit\n③ Additional benefit\n④ Selective benefit\n⑤ Home care benefit",
        "answer": 1
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: \"Regional Public Health Act\"상 지역주민의 건강증진 및 질병예방 ∙ 관리를 위한 보건소의 기능 및 업무에 해당하지 않는 것은?\n\n① 난임의 예방 및 관리\n② 의약품의 위해성 관리\n③ 감염병의 예방 및 관리\n④ 국민건강증진 및 보건교육\n⑤ 모성과 영유아의 건강유지 ∙ 증진",
        "question_text": "Question: According to the \"Regional Public Health Act,\" which of the following is NOT a function or task of public health centers for promoting health and preventing/managing diseases among local residents?\n\n① Prevention and management of infertility\n② Safety management of pharmaceuticals\n③ Prevention and management of infectious diseases\n④ National health promotion and health education\n⑤ Maintenance and promotion of maternal and infant health",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 근육 수축과 이완 과정에서 다음의 반응을 일으키는 단백질은?\n\n• 단백질 머리 부분이 액틴에 결합함\n• ATP가 단백질 머리에 결합하면 액틴에서 분리됨\n• ATP 가수분해는 단백질 입체형태 변화를 일으킴\n\n① calmodulin\n② myosin\n③ tropomyosin\n④ troponin C\n⑤ troponin T",
        "question_text": "Question: Which protein causes the following reactions during muscle contraction and relaxation?\n\n• The head portion of the protein binds to actin\n• When ATP binds to the protein head, it detaches from actin\n• ATP hydrolysis causes a conformational change in the protein\n\n① calmodulin\n② myosin\n③ tropomyosin\n④ troponin C\n⑤ troponin T",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: Michaelis-Menten 식에서 V_max를 효소의 전체 농도로 나눈 속도 상수는?\n\n① k_cat\n② K_m\n③ 1/K_m\n④ 1/V_max\n⑤ k_cat/K_m",
        "question_text": "Question: In the Michaelis-Menten equation, what is the rate constant obtained by dividing V_max by the total enzyme concentration?\n\n① k_cat\n② K_m\n③ 1/K_m\n④ 1/V_max\n⑤ k_cat/K_m",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 다음 특징을 지닌 막수송 단백질은?\n\n• 양이온의 능동수송체(active transporter)임\n• 수송 회로(transport cycle) 과정 중 ATP를 사용하여 인산화됨\n• vanadate에 의해 저해됨\n\n① ABC transporter\n② proton pump\n③ F-type ATPase\n④ P-type ATPase\n⑤ V-type ATPase",
        "question_text": "Question: Which membrane transport protein has the following characteristics?\n\n• It is an active transporter of cations\n• It is phosphorylated using ATP during the transport cycle\n• It is inhibited by vanadate\n\n① ABC transporter\n② proton pump\n③ F-type ATPase\n④ P-type ATPase\n⑤ V-type ATPase",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 효소 A 반응에 필요한 조효소는?\n\n<Data (confidential)>\n\n① biotin\n② cobalamin\n③ FADH2\n④ NADH\n⑤ pyridoxal phosphate",
        "question_text": "Question: What is the coenzyme required for enzyme A reaction?\n\n<Data (confidential)>\n\n① biotin\n② cobalamin\n③ FADH2\n④ NADH\n⑤ pyridoxal phosphate",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 다음 특징을 지닌 효소는?\n\n• 간세포 세포질세망(endoplasmic reticulum)의 내재막 단백질(integral membrane protein)임\n• 활성자리(active site)는 세포질세망의 내강에 위치함\n• 유전적 결함으로 type Ia glycogen storage disease를  일으킴\n\n① glucose 6-phosphatase\n② glycogen synthase\n③ phosphofructokinase-1\n④ phosphoglucomutase\n⑤ phosphoglycerate mutase",
        "question_text": "Question: Which enzyme has the following characteristics?\n\n• It is an integral membrane protein of the endoplasmic reticulum in liver cells\n• Its active site is located in the lumen of the endoplasmic reticulum\n• Genetic defects in this enzyme cause type Ia glycogen storage disease\n\n① glucose 6-phosphatase\n② glycogen synthase\n③ phosphofructokinase-1\n④ phosphoglucomutase\n⑤ phosphoglycerate mutase",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: Citric acid cycle에서 citrate synthase와 α-ketoglutarate dehydrogenase complex의 활성을 모두 저해하는 것은?\n\n① ADP\n② Ca2+\n③ malate\n④ oxaloacetate\n⑤ succinyl-CoA",
        "question_text": "Question: Which of the following inhibits both citrate synthase and α-ketoglutarate dehydrogenase complex activities in the citric acid cycle?\n\n① ADP\n② Ca2+\n③ malate\n④ oxaloacetate\n⑤ succinyl-CoA",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: Citric acid cycle에서 다음 반응을 촉매하는 효소 A의 경쟁적 저해제(competitive inhibitor)는?\n\n<Data (confidential)>\n\n① allopurinol\n② D-malate\n③ fluorouracil\n④ malonate\n⑤ methotrexate",
        "question_text": "Question: Which of the following is a competitive inhibitor of enzyme A that catalyzes the following reaction in the citric acid cycle?\n\n<Data (confidential)>\n\n① allopurinol\n② D-malate\n③ fluorouracil\n④ malonate\n⑤ methotrexate",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 다음 특징을 지닌 콜레스테롤 생합성 과정의 중간체는?\n\n• acetyl-CoA 3 분자의 축합 생성물\n• 케톤체 생성 과정의 공통 중간체\n• 이 중간체의 환원효소(reductase) 억제제는 고콜레스테롤 혈증의 치료제로 사용함\n\n① acetoacetyl-CoA\n② β-hydroxy-β-methylglutaryl-CoA\n③ △3-isopentenyl pyrophosphate\n④ mevalonate\n⑤ 5-phosphomevalonate",
        "question_text": "Question: Which intermediate in the cholesterol biosynthesis process has the following characteristics?\n\n• Condensation product of 3 acetyl-CoA molecules\n• Common intermediate in ketone body production\n• The inhibitor of this intermediate's reductase is used as a treatment for hypercholesterolemia\n\n① acetoacetyl-CoA\n② β-hydroxy-β-methylglutaryl-CoA\n③ △3-isopentenyl pyrophosphate\n④ mevalonate\n⑤ 5-phosphomevalonate",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: Ketogenic 아미노산은?\n\n① arginine\n② glutamine\n③ histidine\n④ lysine\n⑤ methionine",
        "question_text": "Question: Which of the following is a ketogenic amino acid?\n\n① arginine\n② glutamine\n③ histidine\n④ lysine\n⑤ methionine",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: Urea cycle 효소 결핍 치료제인 phenylbutyrate의 대사 중간체 phenylacetyl-CoA가 결합하는 아미노산은?\n\n① cysteine\n② glutamine\n③ glycine\n④ phenylalanine\n⑤ tyrosine",
        "question_text": "Question: Which amino acid does phenylacetyl-CoA, a metabolic intermediate of phenylbutyrate (a treatment for urea cycle enzyme deficiency), bind to?\n\n① cysteine\n② glutamine\n③ glycine\n④ phenylalanine\n⑤ tyrosine",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: Glycine과 arginine으로부터 합성되는 creatine을 생합성 하는 과정에서 필요한 메틸기의 공여체는?\n\n① biotin\n② homocysteine\n③ S-adenosylmethionine\n④ tetrahydrobiopterin\n⑤ valine",
        "question_text": "Question: In the biosynthesis process of creatine, which is synthesized from glycine and arginine, what is the methyl group donor?\n\n① biotin\n② homocysteine\n③ S-adenosylmethionine\n④ tetrahydrobiopterin\n⑤ valine",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 대장균 DNA 복제 과정에서 primer를 합성하는 효소는?\n\n① DnaA\n② DnaB\n③ DnaG\n④ DNA gyrase\n⑤ DNA polymerase I",
        "question_text": "Question: Which enzyme synthesizes primers during the DNA replication process in E. coli?\n\n① DnaA\n② DnaB\n③ DnaG\n④ DNA gyrase\n⑤ DNA polymerase I",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 진핵생물에서 대장균의 DnaA와 기능적으로 유사한 인자는?\n\n① Cdc10-dependent transcript 1 (CDT1)\n② cell division cycle 6 (CDC6)\n③ minichromosome maintenance (MCM) proteins\n④ origin recognition complex (ORC)\n⑤ proliferating cell nuclear antigen (PCNA)",
        "question_text": "Question: In eukaryotes, which factor is functionally similar to DnaA in E. coli?\n\n① Cdc10-dependent transcript 1 (CDT1)\n② cell division cycle 6 (CDC6)\n③ minichromosome maintenance (MCM) proteins\n④ origin recognition complex (ORC)\n⑤ proliferating cell nuclear antigen (PCNA)",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: Vibrio cholerae toxin의 생체 독성 기전은?\n\n① acetylcholine receptor 억제\n② voltage-gated Na+ channel 억제\n③ eEF2의 ADP-라이보실화에 의한 불활성화\n④ Gs 단백질의 ADP-라이보실화에 의한 cAMP 과다 생성\n⑤ Gi 단백질의 ADP-라이보실화에 의한 세포질내 칼슘 이온 농도 증가",
        "question_text": "Question: What is the biological toxicity mechanism of Vibrio cholerae toxin?\n\n① Inhibition of acetylcholine receptor\n② Inhibition of voltage-gated Na+ channel\n③ Inactivation by ADP-ribosylation of eEF2\n④ Excessive production of cAMP due to ADP-ribosylation of Gs protein\n⑤ Increase in intracellular calcium ion concentration due to ADP-ribosylation of Gi protein",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 결손되면 백색증(albinism)을 유발하는 효소는?\n\n① arginase\n② phenylalanine hydroxylase\n③ pyruvate kinase\n④ tyrosinase\n⑤ xanthine oxidase",
        "question_text": "Question: Which enzyme, when deficient, causes albinism?\n\n① arginase\n② phenylalanine hydroxylase\n③ pyruvate kinase\n④ tyrosinase\n⑤ xanthine oxidase",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 다음 특징을 지닌 효소는?\n\n• NADPH를 생성함\n• 결손되면 말라리아에 대한 저항성을 증가시킴\n• 6-amino nicotinic acid에 의해 활성이 저해됨\n\n① α-ketoglutarate dehydrogenase\n② glucose 6-phosphate dehydrogenase\n③ glyceraldehyde 3-phosphate dehydrogenase\n④ isocitrate dehydrogenase\n⑤ N 5,N 10-methylenetetrahydrofolate dehydrogenase",
        "question_text": "Question: Which enzyme has the following characteristics?\n\n• Generates NADPH\n• Its deficiency increases resistance to malaria\n• Its activity is inhibited by 6-amino nicotinic acid\n\n① α-ketoglutarate dehydrogenase\n② glucose 6-phosphate dehydrogenase\n③ glyceraldehyde 3-phosphate dehydrogenase\n④ isocitrate dehydrogenase\n⑤ N 5,N 10-methylenetetrahydrofolate dehydrogenase",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 결손되면 Tay-Sachs 환자의 뇌와 비장에서 ganglioside GM2 축적을 일으키는 효소는?\n\n① β-galactosidase\n② ganglioside neuraminidase\n③ glucocerebrosidase\n④ hexosaminidase A\n⑤ sphingomyelinase",
        "question_text": "Question: Which enzyme, when deficient, causes accumulation of ganglioside GM2 in the brain and spleen of Tay-Sachs patients?\n\n① β-galactosidase\n② ganglioside neuraminidase\n③ glucocerebrosidase\n④ hexosaminidase A\n⑤ sphingomyelinase",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 결손되면 다음의 유전질환 증상이 나타나는 효소는?\n\n• 퓨린의 과다 생산으로 uric acid의 농도가 증가됨\n• 통풍과 유사한 조직손상이 일어남\n• 강박성 자해(compulsive self-destructive) 증상이 보임\n\n① adenosine deaminase\n② dihydrofolate reductase\n③ hypoxanthine-guanine phosphoribosyltransferase\n④ thymidylate synthase\n⑤ urate oxidase",
        "question_text": "Question: Which enzyme, when deficient, results in the following genetic disorder symptoms?\n\n• Excessive production of purines leads to increased uric acid concentration\n• Tissue damage similar to gout occurs\n• Compulsive self-destructive behavior is observed\n\n① adenosine deaminase\n② dihydrofolate reductase\n③ hypoxanthine-guanine phosphoribosyltransferase\n④ thymidylate synthase\n⑤ urate oxidase",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nCitric acid cycle을 촉매하는 효소와, 이 효소의 돌연변이에 의한 glioma 유발에 관한 내용이다.\n• 효소는 산화적 탈카복실화 반응을 촉매함\n• 효소의 돌연변이에 의해 새로운 효소 활성을 획득함\n• 효소의 돌연변이에 의해 2-hydroxyglutarate가 축적됨\n\nQuestion: 위 반응을 촉매하는 효소는?\n\n① α-ketoglutarate dehydrogenase\n② citrate synthase\n③ isocitrate dehydrogenase\n④ malate dehydrogenase\n⑤ succinyl-CoA synthetase",
        "question_text": "This is about an enzyme that catalyzes the citric acid cycle and the induction of glioma due to mutations in this enzyme.\n• The enzyme catalyzes oxidative decarboxylation reactions\n• The enzyme mutation results in the acquisition of new enzyme activity\n• The enzyme mutation leads to the accumulation of 2-hydroxyglutarate\n\nQuestion: Which enzyme catalyzes the above reaction?\n\n① α-ketoglutarate dehydrogenase\n② citrate synthase\n③ isocitrate dehydrogenase\n④ malate dehydrogenase\n⑤ succinyl-CoA synthetase",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nCitric acid cycle을 촉매하는 효소와, 이 효소의 돌연변이에 의한 glioma 유발에 관한 내용이다.\n• 효소는 산화적 탈카복실화 반응을 촉매함\n• 효소의 돌연변이에 의해 새로운 효소 활성을 획득함\n• 효소의 돌연변이에 의해 2-hydroxyglutarate가 축적됨\n\nQuestion: 2-Hydroxyglutarate가 경쟁적으로 활성을 억제하는 효소는?\n\n① aconitase\n② acyl-CoA acetyltransferase\n③ alanine aminotransferase\n④ histone demethylase\n⑤ serine acetyltransferase",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThis is about an enzyme that catalyzes the citric acid cycle and the induction of glioma due to mutations in this enzyme.\n• The enzyme catalyzes oxidative decarboxylation reactions\n• A new enzyme activity is acquired due to mutations in the enzyme\n• 2-hydroxyglutarate accumulates due to mutations in the enzyme\n\nQuestion: Which enzyme is competitively inhibited by 2-Hydroxyglutarate?\n\n① aconitase\n② acyl-CoA acetyltransferase\n③ alanine aminotransferase\n④ histone demethylase\n⑤ serine acetyltransferase",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 내생포자(endospore)를 형성하는 그람 양성균은?\n\n① 탄저균(Bacillus anthracis)\n② 헤모필루스균(Haemophilus influenzae)\n③ 리스테리아균(Listeria monocytogenes)\n④ 황색포도상구균(Staphylococcus aureus)\n⑤ 돼지단독균(Erysipelothrix rhusiopathiae)",
        "question_text": "Question: Which of the following is a Gram-positive bacterium that forms endospores?\n\n① Bacillus anthracis\n② Haemophilus influenzae\n③ Listeria monocytogenes\n④ Staphylococcus aureus\n⑤ Erysipelothrix rhusiopathiae",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 게놈이 이중가닥 RNA인 바이러스는?\n\n① 로타바이러스(rotavirus)\n② 폴리오바이러스(poliovirus)\n③ 에볼라 바이러스(Ebola virus)\n④ 홍역바이러스(measles virus)\n⑤ 인플루엔자바이러스(influenza virus)",
        "question_text": "Question: Which virus has a genome consisting of double-stranded RNA?\n\n① Rotavirus\n② Poliovirus\n③ Ebola virus\n④ Measles virus\n⑤ Influenza virus",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 자신의 생존을 위해 필요한 ATP와 아미노산을 숙주 세포에게 의존하는 것은?\n\n① 대장균(Escherichia coli )\n② 수막구균(Neisseria meningitidis)\n③ 가스괴저균(Clostridium perfringens)\n④ 화농성연쇄상구균(Streptococcus pyogenes)\n⑤ 트라코마 클라미디아균(Chlamydia trachomatis)",
        "question_text": "Question: Which of the following depends on the host cell for ATP and amino acids necessary for its own survival?\n\n① Escherichia coli\n② Neisseria meningitidis\n③ Clostridium perfringens\n④ Streptococcus pyogenes\n⑤ Chlamydia trachomatis",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: Helicobacter pylori가 위(stomach)의 강한 산성 환경에서 생존하는 데 필요한 것은?\n\n① catalase\n② coagulase\n③ lipase\n④ oxidase\n⑤ urease",
        "question_text": "Question: Which of the following is necessary for Helicobacter pylori to survive in the strong acidic environment of the stomach?\n\n① catalase\n② coagulase\n③ lipase\n④ oxidase\n⑤ urease",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 뎅기열(Dengue fever)의 원인 병원체에 대한 설명으로 옳은 것은?\n\n① 비말로 전파됨\n② 역전사효소 활성을 가짐\n③ 캡시드의 형태가 나선형임\n④ 단일가닥 양성 RNA 유전체를 가짐\n⑤ 포스카네트(foscarnet)로 치료할 수 있음",
        "question_text": "Question: Which of the following statements about the causative pathogen of Dengue fever is correct?\n\n① It is transmitted through droplets\n② It possesses reverse transcriptase activity\n③ The capsid has a helical shape\n④ It has a single-stranded positive-sense RNA genome\n⑤ It can be treated with foscarnet",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 감기의 원인이 되는 바이러스로서, 상기도부 상피세포에서 주로 증식하며 당단백질이 포함된 외피(envelope)를 가지는 것은?\n\n① 노로바이러스(norovirus)\n② 에코바이러스(echovirus)\n③ 라이노바이러스(rhinovirus)\n④ 아데노바이러스(adenovirus)\n⑤ 코로나바이러스(coronavirus)",
        "question_text": "Question: Which of the following viruses is a cause of the common cold, primarily replicates in the epithelial cells of the upper respiratory tract, and has an envelope containing glycoproteins?\n\n① Norovirus\n② Echovirus\n③ Rhinovirus\n④ Adenovirus\n⑤ Coronavirus",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 바이러스는?\n\n• DNA를 유전체로 가짐\n• 신경세포에 감염된 후 잠복기에 들어갈 수 있음\n• 항원성과 병변 위치에 따라 1형과 2형의 두 종류가 존재함\n• 치료에는 아시클로버(acyclovir), 발라시클로비르(valacyclovir) 등을 사용함\n\n① 풍진바이러스(rubella virus)\n② 천연두바이러스(smallpox virus)\n③ 폴리오마바이러스(polyomavirus)\n④ 인유두종바이러스(human papillomavirus)\n⑤ 단순헤르페스바이러스(herpes simplex virus)",
        "question_text": "Question: Which virus is described by the following?\n\n• Has DNA as its genome\n• Can enter a latent period after infecting nerve cells\n• Exists in two types, Type 1 and Type 2, based on antigenicity and lesion location\n• Treatment includes the use of acyclovir and valacyclovir\n\n① Rubella virus\n② Smallpox virus\n③ Polyomavirus\n④ Human papillomavirus\n⑤ Herpes simplex virus",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 사람세포의 염색체 안으로 삽입될 수 있는 특징을 활용하여 유전자 치료(gene therapy)의 유전자 운반체로 사용하는 바이러스는?\n\n① 레트로바이러스(retrovirus)\n② 라이노바이러스(rhinovirus)\n③ 엔테로바이러스(enterovirus)\n④ 콕사키바이러스(Coxsackie virus)\n⑤ 유행귀밑샘염바이러스(mumps virus)",
        "question_text": "Question: Which virus is used as a gene carrier for gene therapy, utilizing its characteristic of being able to be inserted into human cell chromosomes?\n\n① Retrovirus\n② Rhinovirus\n③ Enterovirus\n④ Coxsackie virus\n⑤ Mumps virus",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 골수세포 내 미토콘드리아의 단백질 생합성을 저해하여 적혈구와 백혈구 등의 생성이 억제되는 범혈구감소증(pancytopenia)을 초래할 수 있는 것은?\n\n① 페니실린 G(penicillin G)\n② 폴리믹신 B(polymyxin B)\n③ 니트로푸란토인(nitrofurantoin)\n④ 클로람페니콜(chloramphenicol)\n⑤ 설파메톡사졸(sulfamethoxazole)",
        "question_text": "Question: Which of the following can cause pancytopenia by inhibiting protein synthesis in the mitochondria of bone marrow cells, thereby suppressing the production of red blood cells and white blood cells?\n\n① Penicillin G\n② Polymyxin B\n③ Nitrofurantoin\n④ Chloramphenicol\n⑤ Sulfamethoxazole",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 리팜피신(rifampicin)의 작용 타깃은?\n\n① dihydrofolate reductase\n② DNA topoisomerase II\n③ RNA polymerase\n④ thymidine kinase\n⑤ transpeptidase",
        "question_text": "Question: What is the target of action for rifampicin?\n\n① dihydrofolate reductase\n② DNA topoisomerase II\n③ RNA polymerase\n④ thymidine kinase\n⑤ transpeptidase",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 만성피부진균증의 경구 치료제로 적절한 것은?\n\n① 퀴닌(quinine)\n② 푸마길린(fumagillin)\n③ 플루시토신(flucytosine)\n④ 이트라코나졸(itraconazole)\n⑤ 암포테리신 B(amphotericin B)",
        "question_text": "Question: Which of the following is an appropriate oral treatment for chronic dermatophytosis?\n\n① Quinine\n② Fumagillin\n③ Flucytosine\n④ Itraconazole\n⑤ Amphotericin B",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 조절 T 세포(regulatory T cell) 바이오마커로서, T 세포의 성장 및 증식유지 인자의 수용체와 관련 있는 것은?\n\n① CD4\n② CD19\n③ CD25\n④ FoxP3\n⑤ GATA3",
        "question_text": "Question: Which of the following is related to the receptor for T cell growth and proliferation maintenance factor as a biomarker for regulatory T cells?\n\n① CD4\n② CD19\n③ CD25\n④ FoxP3\n⑤ GATA3",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 T 세포 발현 분자는?\n\n• 활성화된 T 세포에서 발현됨\n• T 세포의 활성화를 조절함\n• 항원제시세포(antigen presenting cell)의 B7 분자와 결합함\n\n① CD28\n② CD40\n③ CD155\n④ CTLA-4\n⑤ PD-1",
        "question_text": "Question: Which T cell expression molecule is described below?\n\n• Expressed on activated T cells\n• Regulates T cell activation\n• Binds to the B7 molecule on antigen-presenting cells\n\n① CD28\n② CD40\n③ CD155\n④ CTLA-4\n⑤ PD-1",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 형질세포형 수지상세포(plasmacytoid dendritic cell)에서 생성되어 대부분의 바이러스 감염에 대한 선천면역을 매개하는 시토카인(cytokine)은?\n\n① IFN-α\n② IL-4\n③ IL-10\n④ TGF-β\n⑤ TNF-α",
        "question_text": "Question: Which cytokine is produced by plasmacytoid dendritic cells and mediates innate immunity against most viral infections?\n\n① IFN-α\n② IL-4\n③ IL-10\n④ TGF-β\n⑤ TNF-α",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 저감작(hyposensitization) 면역치료법 적용이 가능한 과민성질환의 특징으로 옳은 것은?\n\n① IgE 항체가 작용함\n② IgM 항체가 작용함\n③ 면역복합체를 과다 형성함\n④ 투베르쿨린 반응이 양성임\n⑤ 보체가 과도하게 활성화됨",
        "question_text": "Question: Which of the following is a correct characteristic of hypersensitivity disorders that can be treated with hyposensitization immunotherapy?\n\n① IgE antibodies are involved\n② IgM antibodies are involved\n③ Excessive formation of immune complexes\n④ Positive tuberculin reaction\n⑤ Excessive activation of complement",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 이식거부반응을 치료할 때, 보체의 활성화 또는 옵소닌화를 이용하여 동종반응성(alloreactive) T 세포를 제거하기 위해 사용되는 것은?\n\n① anti-CD3 antibody\n② anti-CD40 antibody\n③ 라파마이신(rapamycin)\n④ 시클로스포린(cyclosporin)\n⑤ CTLA-4 면역글로불린(CTLA-4 Ig)",
        "question_text": "Question: When treating transplant rejection, which of the following is used to eliminate alloreactive T cells by utilizing complement activation or opsonization?\n\n① anti-CD3 antibody\n② anti-CD40 antibody\n③ rapamycin\n④ cyclosporin\n⑤ CTLA-4 immunoglobulin (CTLA-4 Ig)",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 탄수화물 항원을 단백질 수송체(carrier)에 붙여 제작하는 백신은?\n\n① 결핵 백신\n② 소아마비 백신\n③ B형 간염 백신\n④ 디프테리아 백신\n⑤ 13가 폐렴구균 백신",
        "question_text": "Question: Which vaccine is produced by attaching carbohydrate antigens to a protein carrier?\n\n① Tuberculosis vaccine\n② Polio vaccine\n③ Hepatitis B vaccine\n④ Diphtheria vaccine\n⑤ 13-valent pneumococcal conjugate vaccine",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 호중구감소증에서 호중구 수를 증가시킬 목적으로 사용하는 시토카인(cytokine)은?\n\n① G-CSF\n② IFN-γ\n③ IL-7\n④ IL-12\n⑤ IL-17",
        "question_text": "Question: Which cytokine is used to increase neutrophil count in neutropenia?\n\n① G-CSF\n② IFN-γ\n③ IL-7\n④ IL-12\n⑤ IL-17",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n오염된 수제 소시지를 먹은 사람에게 이튿날부터 시력이 나빠지고, 말초근육이 약해지고 호흡이 곤란해지는 이완성 마비증상이 나타났다.\n\nQuestion: 증상의 원인이 되는 병원균은?\n\n① 파상풍균(Clostridium tetani )\n② 백일해균(Bordetella pertussis)\n③ 세균성이질균(Shigella dysenteriae)\n④ 보툴리눔균(Clostridium botulinum )\n⑤ 디프테리아균(Corynebacterium diphtheriae)",
        "question_text": "A person who ate contaminated homemade sausage developed symptoms of flaccid paralysis starting the next day, including deteriorating vision, weakening of peripheral muscles, and difficulty breathing.\n\nQuestion: What is the pathogen causing these symptoms?\n\n① Clostridium tetani (Tetanus bacteria)\n② Bordetella pertussis (Whooping cough bacteria)\n③ Shigella dysenteriae (Bacterial dysentery bacteria)\n④ Clostridium botulinum (Botulism bacteria)\n⑤ Corynebacterium diphtheriae (Diphtheria bacteria)",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n오염된 수제 소시지를 먹은 사람에게 이튿날부터 시력이 나빠지고, 말초근육이 약해지고 호흡이 곤란해지는 이완성 마비증상이 나타났다.\n\nQuestion: 증상이 나타나게 된 독소의 작용기전은?\n\n① 타깃 세포의 E-cadherin 분해\n② 타깃 세포의 cAMP 농도 증가\n③ 타깃 세포의 아세틸콜린 방출 억제\n④ 타깃 세포의 GABA와 glycine 방출 억제\n⑤ 타깃 세포의 단백질 번역(translation) 억제",
        "question_text": "A person who ate contaminated homemade sausage developed symptoms of flaccid paralysis starting the next day, including deteriorating vision, weakening of peripheral muscles, and difficulty breathing.\n\nQuestion: What is the mechanism of action of the toxin that caused these symptoms?\n\n① Degradation of E-cadherin in target cells\n② Increase in cAMP concentration in target cells\n③ Inhibition of acetylcholine release in target cells\n④ Inhibition of GABA and glycine release in target cells\n⑤ Inhibition of protein translation in target cells",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: pKa가 3.0인 산성 약물이 경구로 투여되었을 경우, pH가 2.0인 위 내에서 약물의 이온형에 대한 비이온형의 비율은?\n\n① 0.01\n② 0.1\n③ 1\n④ 10\n⑤ 100",
        "question_text": "Question: When an acidic drug with a pKa of 3.0 is administered orally, what is the ratio of non-ionized form to ionized form of the drug in the stomach with a pH of 2.0?\n\n① 0.01\n② 0.1\n③ 1\n④ 10\n⑤ 100",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 모르핀(morphine)의 대사 반응 중에서, 모르핀보다 더 강력한 진통 효과를 나타내는 대사체의 생성반응은?\n\n① glucuronidation\n② glutathione conjugation\n③ glycine conjugation\n④ methylation\n⑤ sulfation",
        "question_text": "Question: Among the metabolic reactions of morphine, which metabolic reaction produces a metabolite that exhibits a more potent analgesic effect than morphine?\n\n① glucuronidation\n② glutathione conjugation\n③ glycine conjugation\n④ methylation\n⑤ sulfation",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 알츠하이머병에 유효한 약물과 작용기전으로 옳은 것은?\n\n① 갈란타민(galantamine) – 아세틸콜린 분비 억제\n② 프라미펙솔(pramipexole) – 아세틸콜린 수용체 활성화\n③ 베사미콜(vesamicol) – 아세틸콜린의 세포내 유입 억제\n④ 헤미콜리늄(hemicholinium) – 아세틸콜린의 소포체내 유입 억제\n⑤ 리바스티그민(rivastigmine) –콜린에스테라아제(cholinesterase) 억제",
        "question_text": "Question: Which of the following is correct regarding the drug effective for Alzheimer's disease and its mechanism of action?\n\n① Galantamine – Inhibition of acetylcholine release\n② Pramipexole – Activation of acetylcholine receptors\n③ Vesamicol – Inhibition of intracellular acetylcholine uptake\n④ Hemicholinium – Inhibition of acetylcholine uptake into vesicles\n⑤ Rivastigmine – Inhibition of cholinesterase",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 약물 – 아드레날린 수용체 – 임상용도의 연결이 옳은 것은?\n\n① 베탁솔롤(betaxolol) – β2 – 조산 방지\n② 알부테롤(albuterol) – β2 – 비충혈 제거\n③ 도부타민(dobutamine) – β1 – 좌불안증 치료\n④ 미도드린(midodrine) – α1 – 기립성저혈압 치료\n⑤ 페닐레프린(phenylephrine) – α1 – 기관지천식 치료",
        "question_text": "Question: Which of the following correctly matches the drug, adrenergic receptor, and clinical use?\n\n① Betaxolol – β2 – Prevention of premature labor\n② Albuterol – β2 – Nasal decongestion\n③ Dobutamine – β1 – Treatment of akathisia\n④ Midodrine – α1 – Treatment of orthostatic hypotension\n⑤ Phenylephrine – α1 – Treatment of bronchial asthma",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 아드레날린 수용체에 작용하는 약물은?\n\n• 상용량에서 α1 수용체 차단작용이 있음\n• 상용량에서 β 수용체 차단작용이 있음\n• 고혈압 환자의 혈압을 낮춤\n\n① 핀돌롤(pindolol)\n② 아테놀롤(atenolol)\n③ 빌란테롤(vilanterol)\n④ 독사조신(doxazosin)\n⑤ 카르베딜롤(carvedilol)",
        "question_text": "Question: Which drug acting on adrenergic receptors has the following characteristics?\n\n• Has α1 receptor blocking action at therapeutic doses\n• Has β receptor blocking action at therapeutic doses\n• Lowers blood pressure in hypertensive patients\n\n① Pindolol\n② Atenolol\n③ Vilanterol\n④ Doxazosin\n⑤ Carvedilol",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 골격근이완 약물은?\n\n• 중추신경계에 작용함\n• G 단백질 연결 수용체에 작용함\n• GABA 유사구조이며 경구투여 할 수 있음\n\n① 바클로펜(baclofen)\n② 티자니딘(tizanidine)\n③ 디아제팜(diazepam)\n④ 단트롤렌(dantrolene)\n⑤ 투보쿠라린(tubocurarine)",
        "question_text": "Question: Which of the following skeletal muscle relaxants has these characteristics?\n\n• Acts on the central nervous system\n• Acts on G protein-coupled receptors\n• Has a GABA-like structure and can be administered orally\n\n① Baclofen\n② Tizanidine\n③ Diazepam\n④ Dantrolene\n⑤ Tubocurarine",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 졸피뎀(zolpidem)이 진정효과를 나타내는 작용기전은?\n\n① GABA에 의한 K+ 유출의 증가\n② glycine에 의한 K+ 유출의 증가\n③ glutamate에 의한 K+ 유출의 증가\n④ GABA에 의한 Cl- 이온통로 개방의 증강\n⑤ glycine에 의한 Cl- 이온통로 개방의 증강",
        "question_text": "Question: What is the mechanism of action by which zolpidem exerts its sedative effect?\n\n① Increased K+ efflux by GABA\n② Increased K+ efflux by glycine\n③ Increased K+ efflux by glutamate\n④ Enhanced opening of Cl- ion channels by GABA\n⑤ Enhanced opening of Cl- ion channels by glycine",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 파킨슨병에 적용하는 약물과 작용기전으로 옳은 것은?\n\n① 톨카폰(tolcapone) – MAO-B 억제\n② 라사길린(rasagiline) – COMT 억제\n③ 팔리페리돈(paliperidone) – 도파민 전구체\n④ 카르비도파(carbidopa) – 도파민 수용체 길항\n⑤ 벤즈트로핀(benztropine) – 아세틸콜린 수용체 차단",
        "question_text": "Question: Which of the following is correct regarding the drug used for Parkinson's disease and its mechanism of action?\n\n① Tolcapone – MAO-B inhibition\n② Rasagiline – COMT inhibition\n③ Paliperidone – Dopamine precursor\n④ Carbidopa – Dopamine receptor antagonist\n⑤ Benztropine – Acetylcholine receptor blockade",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 항히스타민약에 대한 설명으로 옳은 것은?\n\n① 펙소페나딘(fexofenadine)은 위산분비 억제작용을 지닌다.\n② 독시라민(doxylamine)은 진정작용이 강하여 수면보조약으로 사용된다.\n③ 디펜히드라민(diphenhydramine)은 항정신병약의 추체외로증상을 악화시킨다.\n④ 디멘히드리네이트(dimenhydrinate)는 정신 집중이 필요한 수험생에게 선호된다.\n⑤ 세티리진(cetirizine)은 혈액뇌관문을 잘 통과하여 장거리 운전자에게는 금기이다.",
        "question_text": "Question: Which of the following statements about antihistamine drugs is correct?\n\n① Fexofenadine has a gastric acid secretion inhibitory effect.\n② Doxylamine has a strong sedative effect and is used as a sleep aid.\n③ Diphenhydramine exacerbates extrapyramidal symptoms of antipsychotic drugs.\n④ Dimenhydrinate is preferred for students who need mental concentration.\n⑤ Cetirizine crosses the blood-brain barrier easily and is contraindicated for long-distance drivers.",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 피브린용해(fibrinolysis)를 억제하는 약물은?\n\n① 헤파린(heparin)\n② 아스피린(aspirin)\n③ 플라스민(plasmin)\n④ 디쿠마롤(dicumarol)\n⑤ 아미노카프로산(aminocaproic acid)",
        "question_text": "Question: Which drug inhibits fibrinolysis?\n\n① Heparin\n② Aspirin\n③ Plasmin\n④ Dicumarol\n⑤ Aminocaproic acid",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 갑상샘항진증 환자에서 빈맥, 고혈압, 심방세동과 같은 갑상샘중독발작을 조절하기 위해 사용하는 약물은?\n\n① 캅토프릴(captopril)\n② 테라조신(terazosin)\n③ 암로디핀(amlodipine)\n④ 텔미사르탄(telmisartan)\n⑤ 프로프라놀롤(propranolol)",
        "question_text": "Question: Which drug is used to control thyroid storm symptoms such as tachycardia, hypertension, and atrial fibrillation in patients with hyperthyroidism?\n\n① Captopril\n② Terazosin\n③ Amlodipine\n④ Telmisartan\n⑤ Propranolol",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 저칼륨혈증을 동반하는 심부전 환자에게 사용하는 약물은?\n\n① 푸로세미드(furosemide)\n② 에타크린산(ethacrynic acid)\n③ 스피로노락톤(spironolactone)\n④ 아세타졸아미드(acetazolamide)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: Which drug is used for heart failure patients with hypokalemia?\n\n① Furosemide\n② Ethacrynic acid\n③ Spironolactone\n④ Acetazolamide\n⑤ Hydrochlorothiazide",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 통풍 환자에게 사용하는 약물과 작용기전으로 옳은 것은?\n\n① 콜키신(colchicine) – 요산배설 촉진\n② 알로푸리놀(allopurinol) – 요산배설 촉진\n③ 페북소스타트(febuxostat) – 요산생성 억제\n④ 인도메타신(indomethacin) – 요산생성 억제\n⑤ 프로베네시드(probenecid) – 염증반응 억제",
        "question_text": "Question: Which of the following is correct regarding the drug used for gout patients and its mechanism of action?\n\n① Colchicine – Promotes uric acid excretion\n② Allopurinol – Promotes uric acid excretion\n③ Febuxostat – Inhibits uric acid production\n④ Indomethacin – Inhibits uric acid production\n⑤ Probenecid – Inhibits inflammatory response",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 위장관질환 치료약은?\n\n• 위(stomach)의 산성용액에서 끈끈한 점성 반죽(paste)으로 변함\n• 궤양이나 미란 바닥의 양전하를 띤 단백질과 결합함\n\n① 파모티딘(famotidine)\n② 수크랄페이트(sucralfate)\n③ 란소프라졸(lansoprazole)\n④ 온단세트론(ondansetron)\n⑤ 미소프로스톨(misoprostol)",
        "question_text": "Question: Which of the following gastrointestinal disorder medications has these characteristics?\n\n• Transforms into a sticky, viscous paste in the acidic solution of the stomach\n• Binds to positively charged proteins at the base of ulcers or erosions\n\n① Famotidine\n② Sucralfate\n③ Lansoprazole\n④ Ondansetron\n⑤ Misoprostol",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 이상지질혈증을 조절하는 약물은?\n\n• 장 내 솔가장자리(intestinal brush border)에 있는 NPC1L1을 차단함\n• 담즙으로 배설된 콜레스테롤의 재흡수를 억제함\n• LDL 콜레스테롤과 피토스테롤의 혈중 수치를 감소시킴\n\n① 나이아신(niacin)\n② 에제티미브(ezetimibe)\n③ 겜피브로질(gemfibrozil)\n④ 아토르바스타틴(atorvastatin)\n⑤ 콜레스티라민(cholestyramine)",
        "question_text": "Question: Which drug regulates dyslipidemia with the following characteristics?\n\n• Blocks NPC1L1 in the intestinal brush border\n• Inhibits the reabsorption of cholesterol excreted in bile\n• Reduces blood levels of LDL cholesterol and phytosterols\n\n① Niacin\n② Ezetimibe\n③ Gemfibrozil\n④ Atorvastatin\n⑤ Cholestyramine",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 천식 치료약으로서, 지속형 β2 아드레날린 수용체 효능약은?\n\n① 살메테롤(salmeterol)\n② 테르부탈린(terbutaline)\n③ 아미노필린(aminophylline)\n④ 자피르루카스트(zafirlukast)\n⑤ 메타프로테레놀(metaproterenol)",
        "question_text": "Question: Which of the following is a long-acting β2 adrenergic receptor agonist used for asthma treatment?\n\n① Salmeterol\n② Terbutaline\n③ Aminophylline\n④ Zafirlukast\n⑤ Metaproterenol",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 사람면역결핍바이러스(HIV) 감염에 사용하는 단백분해효소 억제약인 로피나비르(lopinavir)의 생체이용률을 증가시키기 위해 병용투여 하는 약물은?\n\n① 릴피비린(rilpivirine)\n② 리토나비르(ritonavir)\n③ 네비라핀(nevirapine)\n④ 테노포비르(tenofovir)\n⑤ 에트라비린(etravirine)",
        "question_text": "Question: Which drug is co-administered to increase the bioavailability of lopinavir, a protease inhibitor used in the treatment of Human Immunodeficiency Virus (HIV) infection?\n\n① Rilpivirine\n② Ritonavir\n③ Nevirapine\n④ Tenofovir\n⑤ Etravirine",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 표피성장인자수용체(epidermal growth factor receptor, EGFR)에 결합하여 항암 효과를 나타내는 키메라 단클론항체는?\n\n① 리툭시맙(rituximab)\n② 세툭시맙(cetuximab)\n③ 데노수맙(denosumab)\n④ 인플릭시맵(infliximab)\n⑤ 에타너셉트(etanercept)",
        "question_text": "Question: Which chimeric monoclonal antibody binds to the epidermal growth factor receptor (EGFR) and exhibits an anticancer effect?\n\n① Rituximab\n② Cetuximab\n③ Denosumab\n④ Infliximab\n⑤ Etanercept",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음 그림은 흰쥐의 혈관 평활근을 적출하여 시험관에서 혈관 평활근의 수축운동을 시험한 결과이다.\nA(에피네프린, epinephrine)의 혈관 평활근 수축반응에 대한 약물 B와 약물 C의 작용을 용량-반응곡선으로 나타내었다. (단, ‘10X’는 10배 농도를 표시함)\n<Data (confidential)>\n\nQuestion: B와 C에 해당하는 약물의 예로 모두 옳은 것은?\n\n① B=요힘빈(yohimbine), C=티몰롤(timolol)\n② B=펜톨라민(phentolamine), C=프라조신(prazosin)\n③ B=펜톨라민(phentolamine), C=아트로핀(atropine)\n④ B=페녹시벤자민(phenoxybenzamine), C=아트로핀(atropine)\n⑤ B=페녹시벤자민(phenoxybenzamine), C=프라조신(prazosin)",
        "question_text": "The following figure shows the results of a test on the contraction of vascular smooth muscle conducted in vitro using isolated vascular smooth muscle from white rats.\nThe effects of drug B and drug C on the vascular smooth muscle contraction response of A (epinephrine) are represented as dose-response curves. (Note: '10X' indicates a 10-fold concentration)\n<Data (confidential)>\n\nQuestion: Which of the following is correct for examples of drugs corresponding to B and C?\n\n① B=yohimbine, C=timolol\n② B=phentolamine, C=prazosin\n③ B=phentolamine, C=atropine\n④ B=phenoxybenzamine, C=atropine\n⑤ B=phenoxybenzamine, C=prazosin",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음 그림은 흰쥐의 혈관 평활근을 적출하여 시험관에서 혈관 평활근의 수축운동을 시험한 결과이다.\nA(에피네프린, epinephrine)의 혈관 평활근 수축반응에 대한 약물 B와 약물 C의 작용을 용량-반응곡선으로 나타내었다. (단, ‘10X’는 10배 농도를 표시함)\n<Data (confidential)>\n\nQuestion: C의 작용 특성에 대한 설명으로 옳은 것은?\n\n① A와 상가작용을 나타낸다.\n② A와 상승작용을 나타낸다.\n③ A와 경쟁적으로 길항한다.\n④ A와 비경쟁적으로 길항한다.\n⑤ A의 단백결합을 증가시킨다.",
        "question_text": "The following figure shows the results of a test on the contraction of vascular smooth muscle conducted in vitro using isolated vascular smooth muscle from white rats.\nThe effects of drug B and drug C on the vascular smooth muscle contraction response of A (epinephrine) are represented as dose-response curves. (Note: '10X' indicates a 10-fold concentration)\n<Data (confidential)>\n\nQuestion: Which of the following correctly describes the action characteristics of C?\n\n① It shows an additive effect with A.\n② It shows a synergistic effect with A.\n③ It competitively antagonizes A.\n④ It non-competitively antagonizes A.\n⑤ It increases the protein binding of A.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 연간 생존출생아 1,000명당 연간 생후 365일 미만 사망아 수로 산출되며, 국가 간 의료서비스의 질을 비교하는 데에 사용되는 보건지표는?\n\n① 모성사망률\n② 모성사망비\n③ 영아사망률\n④ 신생아사망률\n⑤ 주산기사망률",
        "question_text": "Question: Which health indicator is calculated as the number of deaths of infants under 365 days old per 1,000 live births annually, and is used to compare the quality of medical services between countries?\n\n① Maternal mortality rate\n② Maternal mortality ratio\n③ Infant mortality rate\n④ Neonatal mortality rate\n⑤ Perinatal mortality rate",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 1,000명을 대상으로 한 선별검사 결과이다. 이 검사의 특이도는?\n\n(단위: 명)\n| 인구의 실제 특성 | 질병 있음 | 질병 없음 | 계 |\n|---|---|---|---|\n| 검사 결과 양성 | 90 | 45 | 135 |\n| 검사 결과 음성 | 10 | 855 | 865 |\n| 계 | 100 | 900 | 1,000 |\n\n① 10%\n② 66.7%\n③ 90%\n④ 95%\n⑤ 98.8%",
        "question_text": "Question: The following are the results of a screening test conducted on 1,000 people. What is the specificity of this test?\n\n(Unit: people)\n| Actual population characteristics | Disease present | Disease absent | Total |\n|---|---|---|---|\n| Test result positive | 90 | 45 | 135 |\n| Test result negative | 10 | 855 | 865 |\n| Total | 100 | 900 | 1,000 |\n\n① 10%\n② 66.7%\n③ 90%\n④ 95%\n⑤ 98.8%",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 대기오염물질은?\n\n• 수용성이 낮은 질식성 가스로서 폐포벽을 쉽게 투과하여 혈류로 확산됨\n• 헤모글로빈이나 시토크롬과 같은 헴단백질과 결합함\n• 메트헤모글로빈혈증(methemoglobinemia), 청색증, 경련을 유발함\n\n① CO2\n② NH3\n③ NO\n④ O3\n⑤ SO2",
        "question_text": "Question: Which of the following air pollutants is being described?\n\n• A low-solubility asphyxiant gas that easily penetrates the alveolar wall and diffuses into the bloodstream\n• Binds with heme proteins such as hemoglobin and cytochrome\n• Causes methemoglobinemia, cyanosis, and convulsions\n\n① CO2\n② NH3\n③ NO\n④ O3\n⑤ SO2",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 먹는물 정수처리법은?\n\n• 고도정수처리법의 일종임\n• 지오스민(geosmin), 페놀류 등의 악취물질과 휴민산(humic acid)과 같은 착색물질을 효과적으로 산화, 분해함\n• 트리할로메탄을 생성하지 않으나, 케톤, 알데히드 등의 부산물을 생성할 수 있음\n\n① 오존처리\n② 염소처리\n③ 폭기처리\n④ 활성탄처리\n⑤ 황산동처리(단위: 명)",
        "question_text": "Question: Which of the following describes the drinking water purification method?\n\n• It is a type of advanced water treatment method\n• Effectively oxidizes and decomposes odor-causing substances such as geosmin and phenols, and coloring substances like humic acid\n• Does not produce trihalomethanes, but may generate by-products such as ketones and aldehydes\n\n① Ozone treatment\n② Chlorine treatment\n③ Aeration treatment\n④ Activated carbon treatment\n⑤ Copper sulfate treatment (Unit: persons)",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 채취한 오수의 생물 개체수를 현미경으로 관찰한 결과이다. 이 시료의 생물학적 오염도(biological index of water pollution, BIP)는?\n\n가. 남조류: 200\n나. 규조류: 300\n다. 섬모충류: 300\n라. zooglea: 200\n\n① 20\n② 30\n③ 40\n④ 50\n⑤ 60",
        "question_text": "Question: This is the result of observing the number of biological organisms in collected sewage using a microscope. What is the biological index of water pollution (BIP) for this sample?\n\na. Blue-green algae: 200\nb. Diatoms: 300\nc. Ciliates: 300\nd. Zooglea: 200\n\n① 20\n② 30\n③ 40\n④ 50\n⑤ 60",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 온열지수는?\n\n• 냉방 설계를 위해 고안됨\n• 기동은 고려되지 않고, 기온과 기습 요인에 의해 결정됨\n• 다음 식에 의해 산출됨\n0.72(건구온도℃+습구온도℃)+40.6\n\n① 감각온도\n② 등온지수\n③ 불쾌지수\n④ 최적온도\n⑤ 카타냉각력",
        "question_text": "Question: Which of the following describes the heat index being explained?\n\n• Designed for air conditioning planning\n• Determined by temperature and humidity factors, without considering air movement\n• Calculated using the following formula:\n0.72(dry-bulb temperature℃ + wet-bulb temperature℃) + 40.6\n\n① Sensible temperature\n② Isothermal index\n③ Discomfort index\n④ Optimal temperature\n⑤ Kata cooling power",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 2상 대사반응인 포합반응(conjugation reaction)에 직접적으로 관여하는 보조인자로만 나열된 것은?\n\n① glycine, glutathione, acetyl-CoA \n② S-adenosylmethionine, benzoic acid, ornithine\n③ glucose 6-phosphate, hippuric acid, mercapturic acid\n④ cholic acid, glutamine, UDP-α-D-glucuronic acid (UDP-GA)\n⑤ ATP, bilirubin, 3’-phosphoadenosine-5’-phosphosulfate (PAPS)",
        "question_text": "Question: Which of the following lists contains only cofactors directly involved in phase II metabolism conjugation reactions?\n\n① glycine, glutathione, acetyl-CoA\n② S-adenosylmethionine, benzoic acid, ornithine\n③ glucose 6-phosphate, hippuric acid, mercapturic acid\n④ cholic acid, glutamine, UDP-α-D-glucuronic acid (UDP-GA)\n⑤ ATP, bilirubin, 3'-phosphoadenosine-5'-phosphosulfate (PAPS)",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 실험 동물에서 페노바르비탈(phenobarbital)을 전투여(pretreatment)할 경우, 사염화탄소의 간독성이 증가하는 이유는?\n\n① 사염화탄소의 대사 증가\n② 사염화탄소의 배설 감소\n③ 사염화탄소의 흡수 증가\n④ 사염화탄소의 장간순환 증가\n⑤ 사염화탄소의 간조직 내 분포 증가",
        "question_text": "Question: What is the reason for the increased hepatotoxicity of carbon tetrachloride when phenobarbital is pre-administered in experimental animals?\n\n① Increased metabolism of carbon tetrachloride\n② Decreased excretion of carbon tetrachloride\n③ Increased absorption of carbon tetrachloride\n④ Increased enterohepatic circulation of carbon tetrachloride\n⑤ Increased distribution of carbon tetrachloride in liver tissue",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 간독성 물질은?\n\n• CYP에 의해 대사 활성화됨\n• 간의 소엽 내 zone 3에 선택적으로 독성을 나타내어 중심엽성 괴사를 유발함\n• 중독 시 N-acetylcysteine을 사용할 수 있음\n\n① acetaminophen\n② allyl alcohol\n③ iron\n④ phalloidin\n⑤ vitamin A",
        "question_text": "Question: Which of the following describes the hepatotoxic substance?\n\n• Metabolically activated by CYP\n• Selectively toxic to zone 3 within the liver lobule, causing centrilobular necrosis\n• N-acetylcysteine can be used in case of poisoning\n\n① acetaminophen\n② allyl alcohol\n③ iron\n④ phalloidin\n⑤ vitamin A",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 인체위해성평가 과정 중 위해성 관리(risk management)에 해당하는 설명은?\n\n① 노출 정도, 빈도, 기간을 측정한다.\n② 용량과 반응 간의 상관관계를 파악한다.\n③ 이해당사자 간의 의사소통을 계획하고 실천한다.\n④ 유해 영향을 규명하고 그 근거의 확실성을 검증한다.\n⑤ 현재의 위해상황을 허용 수준 이하로 저감하기 위한 수단을 고려한다.",
        "question_text": "Question: Which of the following descriptions corresponds to risk management in the process of human health risk assessment?\n\n① Measure the degree, frequency, and duration of exposure.\n② Identify the correlation between dose and response.\n③ Plan and implement communication among stakeholders.\n④ Identify adverse effects and verify the certainty of their evidence.\n⑤ Consider measures to reduce the current risk situation below the acceptable level.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 다음 식으로 구하는 식품의 단백질 영양가 지표는?\n\n(체내에 보유된 질소량 / 흡수된 질소량) × 100\n• 흡수된 질소량=섭취한 질소량 – 대변으로 배설된 질소량\n• 체내에 보유된 질소량=흡수된 질소량 – 소변으로 배설된 질소량\n\n① 생물가(biological value)\n② 화학가(chemical score)\n③ 단백질가(protein score)\n④ 정단백질가(net protein utilization)\n⑤ 단백질 효율(protein efficiency ratio)",
        "question_text": "Question: Which protein nutritional value indicator for food is calculated using the following formula?\n\n(Nitrogen retained in the body / Nitrogen absorbed) × 100\n• Nitrogen absorbed = Nitrogen intake - Nitrogen excreted in feces\n• Nitrogen retained in the body = Nitrogen absorbed - Nitrogen excreted in urine\n\n① Biological value\n② Chemical score\n③ Protein score\n④ Net protein utilization\n⑤ Protein efficiency ratio",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: Fumarylacetoacetate hydrolase의 결손에 의해 신장 판코니 증후군(renal Fanconi syndrome), 진행성 간경화, 간암 등의 임상적 특징을 나타내는 선천성 아미노산 대사 이상질환은?\n\n① 티로신혈증(tyrosinemia)\n② 아르기닌혈증(argininemia)\n③ 페닐케톤뇨증(phenylketonuria)\n④ 호모시스틴뇨증(homocystinuria)\n⑤ 단풍시럽뇨병(maple syrup urine disease)",
        "question_text": "Question: Which congenital amino acid metabolic disorder is characterized by clinical features such as renal Fanconi syndrome, progressive liver cirrhosis, and liver cancer due to a deficiency of fumarylacetoacetate hydrolase?\n\n① Tyrosinemia\n② Argininemia\n③ Phenylketonuria\n④ Homocystinuria\n⑤ Maple syrup urine disease",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 옥수수를 주식으로 하는 사람들에게는 영양 결핍으로 인한 피부 증상(홍반), 소화기 증상(설사, 위염, 식욕부진), 중추신경 증상(불면, 기억손상, 인지장애)이 많이 발생한다. 이를 개선하기 위해 투여할 수 있는 영양소는?\n\n① 나이아신(niacin)\n② 토코페롤(tocopherol)\n③ 레티노산(retinoic acid)\n④ 아스코르빈산(ascorbic acid)\n⑤ 코엔자임큐10(coenzyme Q10)",
        "question_text": "Question: People who have corn as their staple food often experience nutritional deficiency symptoms such as skin symptoms (erythema), digestive symptoms (diarrhea, gastritis, loss of appetite), and central nervous system symptoms (insomnia, memory loss, cognitive impairment). Which nutrient can be administered to improve this condition?\n\n① Niacin\n② Tocopherol\n③ Retinoic acid\n④ Ascorbic acid\n⑤ Coenzyme Q10",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: 트라닐사이프로민(tranylcypromine), 페넬진(phenelzine) 또는 이소카르복사지드(isocarboxazid)를 복용하는 환자가 발효 유제품을 과량으로 섭취하면, 고혈압과 심근경색, 뇌졸중 발생 가능성이 높아진다. 이러한 증상의 원인이 되는 발효 유제품 성분은?\n\n① 티라민(tyramine)\n② 히스타민(histamine)\n③ 트립타민(tryptamine)\n④ 카다베린(cadaverine)\n⑤ 트리메틸아민(trimethylamine)",
        "question_text": "Question: Patients taking tranylcypromine, phenelzine, or isocarboxazid are at a higher risk of developing hypertension, myocardial infarction, and stroke if they consume excessive amounts of fermented dairy products. Which component in fermented dairy products is responsible for these symptoms?\n\n① Tyramine\n② Histamine\n③ Tryptamine\n④ Cadaverine\n⑤ Trimethylamine",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 유지(oil)의 불포화도를 나타내며 산패에 의해 값이 낮아지는 변질 지표는?\n\n① 산가\n② 요오드가\n③ 카보닐가\n④ 과산화물가\n⑤ thiobarbituric acid 시험가",
        "question_text": "Question: Which indicator of deterioration represents the degree of unsaturation in oils and decreases in value due to rancidity?\n\n① Acid value\n② Iodine value\n③ Carbonyl value\n④ Peroxide value\n⑤ Thiobarbituric acid test value",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 식중독의 원인균은?\n\n• 주요 감염원은 오염된 물, 돼지고기, 우유 등임\n• 가을과 겨울에 많이 발생함\n• 복통, 발열, 설사, 급성위장염, 피부 홍반, 다발성 관절염 등의 임상증상이 나타남\n• 원인균은 냉장 또는 진공포장 식품에서도 증식할 수 있음\n\n① Clostridium perfringens\n② Salmonella Typhimurium\n③ Staphylococcus aureus\n④ Vibrio vulnificus\n⑤ Yersinia enterocolitica",
        "question_text": "Question: Which of the following is the causative bacteria for the food poisoning described below?\n\n• The main sources of infection are contaminated water, pork, milk, etc.\n• It occurs frequently in autumn and winter\n• Clinical symptoms include abdominal pain, fever, diarrhea, acute gastroenteritis, skin erythema, and polyarthritis\n• The causative bacteria can grow even in refrigerated or vacuum-packed foods\n\n① Clostridium perfringens\n② Salmonella Typhimurium\n③ Staphylococcus aureus\n④ Vibrio vulnificus\n⑤ Yersinia enterocolitica",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 독성 물질은?\n\n• 맹독성 diterpene alkaloid로서 바꽃의 유독 성분임\n• Na+ channel을 활성화함\n• 주로 신경계에 작용하여 흥분, 부정맥, 호흡 곤란, 운동 마비, 심기능 마비를 초래함\n\n① aconitine\n② amanitin\n③ amygdalin\n④ atropine\n⑤ muscarine",
        "question_text": "Question: Which toxic substance is described below?\n\n• A highly toxic diterpene alkaloid, it is the poisonous component of aconite\n• Activates Na+ channels\n• Primarily affects the nervous system, causing excitement, arrhythmia, respiratory distress, motor paralysis, and cardiac failure\n\n① aconitine\n② amanitin\n③ amygdalin\n④ atropine\n⑤ muscarine",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 뿌리가 참마로, 새순이 산나물로 오인되기 쉬워 식중독의 원인이 될 수 있으며, 히오시아민(hyoscyamine), 스코폴라민(scopolamine) 등의 유독성분을 함유하고 있어 뇌흥분, 심계항진, 호흡곤란을 일으키는 유독식물은?\n\n① 바꽃\n② 소철\n③ 독미나리\n④ 가시독말풀\n⑤ 미치광이풀",
        "question_text": "Question: Which poisonous plant can cause food poisoning due to its root being easily mistaken for Chinese yam and its young shoots for wild vegetables, and contains toxic components such as hyoscyamine and scopolamine that can cause brain excitation, palpitations, and respiratory distress?\n\n① Anemone raddeana\n② Cycas revoluta\n③ Water dropwort\n④ Datura stramonium\n⑤ Scopolia japonica",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n영하의 추운 겨울날 공사 현장에서, 저장된 공사용수로 컵라면과 커피를 섭취한 근로자가 어눌한 말투, 실조, 경련 등의 증상을 보이고 있다. 검진 결과, 동맥혈 pH가 7.3이고 소변에서 옥살산염(oxalate) 결정이 검출되었다.\n\nQuestion: 중독의 원인물질로 추정할 수 있는 것은?\n\n① 벤젠\n② 메탄올\n③ 시안화칼륨\n④ 클로로포름\n⑤ 에틸렌글리콜",
        "question_text": "On a cold winter day below freezing temperature at a construction site, a worker who consumed cup noodles and coffee made with stored construction water showed symptoms such as slurred speech, ataxia, and convulsions. Upon examination, the arterial blood pH was 7.3, and oxalate crystals were detected in the urine.\n\nQuestion: What can be presumed as the causative substance of the poisoning?\n\n① Benzene\n② Methanol\n③ Potassium cyanide\n④ Chloroform\n⑤ Ethylene glycol",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n영하의 추운 겨울날 공사 현장에서, 저장된 공사용수로 컵라면과 커피를 섭취한 근로자가 어눌한 말투, 실조, 경련 등의 증상을 보이고 있다. 검진 결과, 동맥혈 pH가 7.3이고 소변에서 옥살산염(oxalate) 결정이 검출되었다.\n\nQuestion: 중독의 처치법으로 적절한 것은?\n\n① 최토와 위세척\n② 아질산아밀(amyl nitrite) 흡입\n③ 포메피졸(fomepizole) 투여와 혈액투석\n④ 특이적 처치법이 없으므로 보존적 치료에 집중\n⑤ 아트로핀(atropine)과 프랄리독심(pralidoxime) 병용투여",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nOn a cold winter day below freezing at a construction site, a worker who consumed cup noodles and coffee made with stored construction water is showing symptoms such as slurred speech, ataxia, and convulsions. Upon examination, the arterial blood pH is 7.3, and oxalate crystals are detected in the urine.\n\nQuestion: Which of the following is the appropriate treatment for this intoxication?\n\n① Emesis and gastric lavage\n② Inhalation of amyl nitrite\n③ Administration of fomepizole and hemodialysis\n④ Focus on supportive care as there is no specific treatment\n⑤ Combined administration of atropine and pralidoxime",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 결핵균 일차 감염 후 3~6주 사이에 T 세포에서 분비되어 대식세포를 활성화하는 것은?\n\n① IFN-γ\n② IL-10\n③ IL-12\n④ TGF-β\n⑤ TNF-α",
        "question_text": "Question: What is secreted by T cells between 3 to 6 weeks after primary infection with tuberculosis bacteria, activating macrophages?\n\n① IFN-γ\n② IL-10\n③ IL-12\n④ TGF-β\n⑤ TNF-α",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 토리와 폐포의 기저막 단백질에 대한 자가항체로 인해 발생하는 제2형 과민반응은?\n\n① 애디슨병(Addison’s disease)\n② 그레이브스병(Graves disease)\n③ 쇠그렌증후군(Sjögren syndrome)\n④ 디조지증후군(DiGeorge syndrome)\n⑤ 굿파스처증후군(Goodpasture’s syndrome)",
        "question_text": "Question: Which type II hypersensitivity reaction is caused by autoantibodies against basement membrane proteins in the kidneys and alveoli?\n\n① Addison's disease\n② Graves disease\n③ Sjögren syndrome\n④ DiGeorge syndrome\n⑤ Goodpasture's syndrome",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 키가 140 cm이며 한 번도 월경을 하지 않았고 이차성징이 없으며 말이 약간 어눌한 25세 여자가 있다. 복부 자기공명영상검사 결과 작고 가는 관모양으로 위축된 난소가 관찰되었다. 이 환자에서 나타날 수 있는 핵형은?\n\n① 45,X/46,XX\n② 46,XX/47,XX,+21\n③ 47,XXX\n④ 47,XXY\n⑤ 47,XX,+21",
        "question_text": "Question: There is a 25-year-old woman who is 140 cm tall, has never had a menstrual period, shows no secondary sexual characteristics, and has slightly slurred speech. An abdominal MRI scan revealed small, thin, tubular atrophied ovaries. What karyotype might be observed in this patient?\n\n① 45,X/46,XX\n② 46,XX/47,XX,+21\n③ 47,XXX\n④ 47,XXY\n⑤ 47,XX,+21",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 당뇨병이 있는 산모로부터 임신 27주 차에 태어난 조산아에서 호흡곤란이 일어나는 주요 원인은?\n\n① 미만성 폐감염\n② 혈액응고 항진\n③ 폐 상피세포의 손상\n④ 과다환기(hyperventilation)\n⑤ 허파표면활성제(pulmonary surfactant)의 결핍",
        "question_text": "Question: What is the main cause of respiratory distress in a premature infant born at 27 weeks of gestation from a mother with diabetes?\n\n① Diffuse lung infection\n② Hypercoagulability\n③ Damage to lung epithelial cells\n④ Hyperventilation\n⑤ Deficiency of pulmonary surfactant",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 혈소판 응집에 관여하는 Gp IIb-IIIa의 결핍으로 인해 출혈이 발생하는 유전질환은?\n\n① 혈우병 A(hemophilia A)\n② 폰빌레브란트병(von Willebrand disease)\n③ 그레이혈소판증후군(grey platelet syndrome)\n④ 베르나르-슐리에증후군(Bernard-Soulier syndrome)\n⑤ 글란츠만혈소판기능저하증(Glanzmann thrombasthenia)",
        "question_text": "Question: Which genetic disorder causes bleeding due to a deficiency of Gp IIb-IIIa involved in platelet aggregation?\n\n① Hemophilia A\n② von Willebrand disease\n③ Grey platelet syndrome\n④ Bernard-Soulier syndrome\n⑤ Glanzmann thrombasthenia",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 만성콩팥병을 앓고 있는 49세 남자가 쉽게 피로감을 느끼고 안색이 창백하여 혈액 검사를 받았는데 적혈구용적률이 30%이었고 적혈구의 모양과 색은 정상이었다. 이 환자에서 빈혈이 발생한 원인은?\n\n① 엽산 결핍\n② 비타민 A 결핍\n③ 헤모글로빈 S 합성 증가\n④ 거대적혈구모세포 생성 과다\n⑤ 에리트로포이에틴 생성 감소",
        "question_text": "Question: A 49-year-old man with chronic kidney disease easily feels fatigued and has a pale complexion. He underwent a blood test, which showed a hematocrit of 30%, while the shape and color of red blood cells were normal. What is the cause of anemia in this patient?\n\n① Folate deficiency\n② Vitamin A deficiency\n③ Increased hemoglobin S synthesis\n④ Excessive megaloblast production\n⑤ Decreased erythropoietin production",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 산과 합병증(obstetric complication), 심한 외상(trauma)과 연관성이 높으며 과도한 응고 활성화로 인하여 미세혈관 혈전과 출혈이 일어나는 것은?\n\n① 폰빌레브란트병(von Willebrand disease)\n② 델타저장조병(delta storage pool disease)\n③ 파종혈관내응고(disseminated intravascular coagulation)\n④ 면역저혈소판자색반(immune thrombocytopenic purpura)\n⑤ 헤파린유발저혈소판증(heparin-induced thrombocytopenia)",
        "question_text": "Question: Which condition is highly associated with obstetric complications and severe trauma, and is characterized by microvascular thrombosis and bleeding due to excessive coagulation activation?\n\n① von Willebrand disease\n② Delta storage pool disease\n③ Disseminated intravascular coagulation\n④ Immune thrombocytopenic purpura\n⑤ Heparin-induced thrombocytopenia",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 주로 유아와 소아에게 나타나는 급성괴사성혈관염으로, 고열과 발작이 나타나고 일부 환자에서는 관상동맥염으로 인한 급성심근경색이 유발되는 질환은?\n\n① 버거병(Buerger’s disease)\n② 레이노병(Raynaud’s disease)\n③ 가와사키병(Kawasaki disease)\n④ 베게너육아종증(Wegener granulomatosis)\n⑤ 처그-스트라우스증후군(Churg-Strauss syndrome)",
        "question_text": "Question: Which disease is an acute necrotizing vasculitis that primarily affects infants and young children, characterized by high fever and seizures, and in some patients can lead to acute myocardial infarction due to coronary arteritis?\n\n① Buerger's disease\n② Raynaud's disease\n③ Kawasaki disease\n④ Wegener's granulomatosis\n⑤ Churg-Strauss syndrome",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "original_text": "Question: 복부대동맥류(abdominal aortic aneurysm)를 발생시키는 주된 원인은?\n\n① 복막염(peritonitis)\n② 죽상경화증(atherosclerosis)\n③ 대동맥판협착증(aortic stenosis)\n④ 문맥고혈압(portal hypertension)\n⑤ 허파색전증(pulmonary embolism)",
        "question_text": "Question: What is the main cause of abdominal aortic aneurysm?\n\n① Peritonitis\n② Atherosclerosis\n③ Aortic stenosis\n④ Portal hypertension\n⑤ Pulmonary embolism",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "original_text": "Question: 제한성 폐질환(restrictive lung disease)의 특징은?\n\n① 폐포벽 파괴\n② 술잔세포 증식\n③ 폐사이질 섬유화\n④ α1-항트립신 결핍\n⑤ 강제폐활량에 대한 1초강제호기량의 비율(FEV1/FVC) 감소",
        "question_text": "Question: What is a characteristic of restrictive lung disease?\n\n① Destruction of alveolar walls\n② Proliferation of goblet cells\n③ Pulmonary interstitial fibrosis\n④ α1-antitrypsin deficiency\n⑤ Decreased ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC)",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "original_text": "Question: 지속적인 식도 역류와 궤양으로 식도벽 기저부까지 손상된 역류식도염에서 식도 내강이 좁아지게 되는 원인은?\n\n① 미란(erosion)\n② 위축(atrophy)\n③ 충혈(hyperemia)\n④ 이형성(dysplasia)\n⑤ 반응성섬유화(reactive fibrosis)",
        "question_text": "Question: What is the cause of narrowing of the esophageal lumen in reflux esophagitis where the esophageal wall is damaged down to the base due to persistent esophageal reflux and ulceration?\n\n① Erosion\n② Atrophy\n③ Hyperemia\n④ Dysplasia\n⑤ Reactive fibrosis",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "original_text": "Question: Helicobacter pylori 감염으로 인한 만성날문방위염(chronic antral gastritis)이 샘창자소화궤양(duodenal ulcer)으로 악화되는 주요 원인은?\n\n① 위점막 위축\n② 위산 분비 증가\n③ 비타민 B12 결핍\n④ 요소분해효소 분비 증가\n⑤ 점막연관림프조직 활성화",
        "question_text": "Question: What is the main cause of chronic antral gastritis due to Helicobacter pylori infection progressing to duodenal ulcer?\n\n① Gastric mucosal atrophy\n② Increased gastric acid secretion\n③ Vitamin B12 deficiency\n④ Increased urease secretion\n⑤ Activation of mucosa-associated lymphoid tissue",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "original_text": "Question: 5년 전 대장암 판정을 받았던 60세 남자가 황달, 허약감, 체중감소 등의 증세로 검사받은 결과 전이성 간암 판정을 받았다. 대장에서 간으로 암이 전이되는 대표적인 경로는?\n\n① 동맥성 전이\n② 림프성 전이\n③ 정맥성 전이\n④ 장간막성 전이\n⑤ 체강으로의 파종",
        "question_text": "Question: A 60-year-old man who was diagnosed with colon cancer 5 years ago was examined due to symptoms such as jaundice, weakness, and weight loss, and was diagnosed with metastatic liver cancer. What is the most representative pathway for cancer metastasis from the colon to the liver?\n\n① Arterial metastasis\n② Lymphatic metastasis\n③ Venous metastasis\n④ Mesenteric metastasis\n⑤ Dissemination to body cavities",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "original_text": "Question: Wnt 신호전달경로의 β-카테닌을 분해하는 종양억제유전자로서 돌연변이에 의해 가족성주름창자폴립증(familial colonic polyps)을 유발할 수 있는 것은?\n\n① APC\n② MYC\n③ PTEN\n④ RB\n⑤ VHL",
        "question_text": "Question: Which tumor suppressor gene that degrades β-catenin in the Wnt signaling pathway can cause familial colonic polyps due to mutations?\n\n① APC\n② MYC\n③ PTEN\n④ RB\n⑤ VHL",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "original_text": "Question: 제2형 당뇨병과 비만이 있는 27세 여자가 불규칙한 월경주기와 양쪽 난소의 대칭적 확대로 인해 불임치료를 받고 있다. 이 환자에서 나타나는 혈청 호르몬의 농도 변화로 옳은 것은?\n\n① 인슐린 감소\n② 안드로겐 감소\n③ 에스트로겐 감소\n④ 프로게스테론 증가\n⑤ 황체형성호르몬 증가",
        "question_text": "Question: A 27-year-old woman with type 2 diabetes and obesity is receiving infertility treatment due to irregular menstrual cycles and symmetrical enlargement of both ovaries. Which of the following is the correct change in serum hormone concentration in this patient?\n\n① Decreased insulin\n② Decreased androgen\n③ Decreased estrogen\n④ Increased progesterone\n⑤ Increased luteinizing hormone",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "original_text": "Question: 당뇨병의 합병증으로 발생하는 신경병증의 병인이 될 수 있는 것은?\n\n① 슈반세포 증식\n② 역행성 축삭변성\n③ 신경세포내 대식세포 침윤\n④ 말초말이집단백질22(PMP22) 이상\n⑤ 미세혈관손상성 허혈로 유발되는 신경세포 손상",
        "question_text": "Question: Which of the following can be a pathogenesis of neuropathy occurring as a complication of diabetes?\n\n① Schwann cell proliferation\n② Retrograde axonal degeneration\n③ Macrophage infiltration into nerve cells\n④ Peripheral myelin protein 22 (PMP22) abnormality\n⑤ Nerve cell damage induced by microvascular damage-related ischemia",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "original_text": "Question: 보통여드름(acne vulgaris)에 대한 설명으로 옳은 것은?\n\n① 피지샘이 막히면 악화된다.\n② 멜라닌색소량에 비례하여 발생한다.\n③ 원인균은 Cryptococcus neoformans이다.\n④ 에스트로겐 과다로 피지샘의 비대가 나타난다.\n⑤ 개방면포(open comedo)는 염증으로 진행된 상태이다.",
        "question_text": "Question: Which of the following statements about acne vulgaris is correct?\n\n① It worsens when sebaceous glands are blocked.\n② It occurs in proportion to the amount of melanin pigment.\n③ The causative organism is Cryptococcus neoformans.\n④ Excess estrogen causes sebaceous gland hypertrophy.\n⑤ Open comedones are a state of progressed inflammation.",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "original_text": "Question: 다음 환자에서 시력감소가 발생한 원인은?\n\n• 65세 남자, 지난 2년간 주변시야가 소실됨\n• 안압상승이 관찰됨\n• 시신경원반오목(optic disc cupping)이 확인됨\n\n① 망막변성(retinal degeneration)\n② 황반변성(macular degeneration)\n③ 맥락막변성(choroid degeneration)\n④ 동공확장고정(fixed pupillary dilatation)\n⑤ 각막혈관신생(corneal neovascularization)",
        "question_text": "Question: What is the cause of vision loss in the following patient?\n\n• 65-year-old male, loss of peripheral vision over the past 2 years\n• Increased intraocular pressure observed\n• Optic disc cupping confirmed\n\n① Retinal degeneration\n② Macular degeneration\n③ Choroid degeneration\n④ Fixed pupillary dilatation\n⑤ Corneal neovascularization",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n비만과 무월경 기왕력이 있는 45세 여자가 최근 3개월 동안 지속적 근육 쇠약을 호소하였다. 혈액검사 결과 코르티코트로핀분비 호르몬(corticotropin-releasing hormone) 수치 감소와 코티솔(cortisol) 수치 증가가 나타났으며, 덱사메타손(dexamethasone) 투여로도 이 두 호르몬의 수치가 개선되지 않았다.\n\nQuestion: 이 환자의 질환명은?\n\n① 애디슨병(Addison’s disease)\n② 쿠싱증후군(Cushing’s syndrome)\n③ 크롬친화세포종(pheochromocytoma)\n④ 고알도스테론혈증(hyperaldosteronism)\n⑤ 워터하우스-프리데릭센증후군(Waterhouse-Friderichsen syndrome)",
        "question_text": "A 45-year-old woman with a history of obesity and amenorrhea complained of persistent muscle weakness for the past 3 months. Blood tests showed decreased levels of corticotropin-releasing hormone (CRH) and increased levels of cortisol. Administration of dexamethasone did not improve the levels of these two hormones.\n\nQuestion: What is the name of this patient's condition?\n\n① Addison's disease\n② Cushing's syndrome\n③ Pheochromocytoma\n④ Hyperaldosteronism\n⑤ Waterhouse-Friderichsen syndrome",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n비만과 무월경 기왕력이 있는 45세 여자가 최근 3개월 동안 지속적 근육 쇠약을 호소하였다. 혈액검사 결과 코르티코트로핀분비 호르몬(corticotropin-releasing hormone) 수치 감소와 코티솔(cortisol) 수치 증가가 나타났으며, 덱사메타손(dexamethasone) 투여로도 이 두 호르몬의 수치가 개선되지 않았다.\n\nQuestion: 이 질환을 일으킨 일차적 원인이 될 수 있는 것은?\n\n① 뇌하수체샘종(pituitary adenoma)\n② 부신수질종양(adrenal medulla neoplasia)\n③ 부신피질부전(adrenocortical insufficiency)\n④ 알도스테론-생산샘종(aldosterone-producing adenoma)\n⑤ 제2형 다발내분비샘종증(multiple endocrine neoplasia, type 2)",
        "question_text": "A 45-year-old woman with a history of obesity and amenorrhea complained of persistent muscle weakness for the past 3 months. Blood tests showed decreased corticotropin-releasing hormone (CRH) levels and increased cortisol levels, which were not improved by dexamethasone administration.\n\nQuestion: What could be the primary cause of this condition?\n\n① Pituitary adenoma\n② Adrenal medulla neoplasia\n③ Adrenocortical insufficiency\n④ Aldosterone-producing adenoma\n⑤ Multiple endocrine neoplasia, type 2",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 물과 에탄올의 섞임에 관여하는 분자간 상호작용은?\n\n① 수소결합, 공유결합\n② 수소결합, 배위결합\n③ 수소결합, 반데르발스힘\n④ 공유결합, 소수성상호작용\n⑤ 공유결합, 유발쌍극자 – 유발쌍극자힘",
        "question_text": "Question: What intermolecular interactions are involved in the mixing of water and ethanol?\n\n① Hydrogen bonding, Covalent bonding\n② Hydrogen bonding, Coordinate bonding\n③ Hydrogen bonding, Van der Waals forces\n④ Covalent bonding, Hydrophobic interactions\n⑤ Covalent bonding, Induced dipole – Induced dipole forces",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 동일한 화학구조를 갖는 화합물에서 녹는점, 용해속도, X선 회절 형태 등과 같은 물리적 성질이 서로 다르게 나타나는 현상과 관련 있는 것은?\n\n① 염석\n② 고체흡착\n③ 입자침강\n④ 결정다형\n⑤ 초임계유체",
        "question_text": "Question: Which of the following is related to the phenomenon where physical properties such as melting point, dissolution rate, and X-ray diffraction patterns differ in compounds with the same chemical structure?\n\n① Salting-out\n② Solid adsorption\n③ Particle sedimentation\n④ Crystal polymorphism\n⑤ Supercritical fluid",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 이산화탄소 초임계유체에 대한 설명으로 옳은 것은?\n\n① 액체유기용매보다 점성이 높다.\n② 임계온도 미만에서 초임계유체가 형성된다.\n③ 압력을 조절하여 선택적으로 화합물을 추출할 수 있다.\n④ 기체 이산화탄소와 고체 이산화탄소의 특성을 동시에 지닌다.\n⑤ 제제화 후, 남은 이산화탄소는 실온에서 쉽게 제거되지 않는다.",
        "question_text": "Question: Which of the following statements about supercritical carbon dioxide fluid is correct?\n\n① It has higher viscosity than liquid organic solvents.\n② Supercritical fluid is formed below the critical temperature.\n③ Compounds can be selectively extracted by adjusting the pressure.\n④ It simultaneously possesses the characteristics of gaseous and solid carbon dioxide.\n⑤ After formulation, the remaining carbon dioxide is not easily removed at room temperature.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 다음은 1기압에서 고체상과 액체상을 포함하는 2성분계 약물의 상평형 그래프이다. 약물 A와 약물 B의 녹는점은 각각 68℃와 40℃이고 공융점은 20℃이다. 25℃에서 A 85%와 B 15%의 혼합물에서 관찰되는 상은? (단, 실선은 상경계선이다.)\n\n<Data (confidential)>\n\n① 고체상 A, 액체상 B\n② 액체상 A, 고체상 B\n③ A와 B의 혼합물 액체상, 고체상 A\n④ A와 B의 혼합물 액체상, 고체상 B\n⑤ A와 B의 혼합물 액체상, 고체상 A, 고체상 B",
        "question_text": "Question: The following is a phase equilibrium diagram of a two-component drug system containing solid and liquid phases at 1 atm. The melting points of drug A and drug B are 68℃ and 40℃ respectively, and the eutectic point is 20℃. What phases are observed in a mixture of 85% A and 15% B at 25℃? (Note: The solid lines represent phase boundaries.)\n\n<Data (confidential)>\n\n① Solid phase A, liquid phase B\n② Liquid phase A, solid phase B\n③ Mixed liquid phase of A and B, solid phase A\n④ Mixed liquid phase of A and B, solid phase B\n⑤ Mixed liquid phase of A and B, solid phase A, solid phase B",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 단백질 의약품에서 발생하는 물리적 변성은?\n\n① 산화\n② 응집\n③ 탈아미드\n④ 가수분해\n⑤ 베타 – 제거반응",
        "question_text": "Question: What is a physical degradation that occurs in protein pharmaceuticals?\n\n① Oxidation\n② Aggregation\n③ Deamidation\n④ Hydrolysis\n⑤ Beta-elimination reaction",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 시클로덱스트린이 약물과 내포화합물을 형성할 수 있게 하는 물리화학적 특성은?\n\n① 배위결합 능력\n② 이온교환 능력\n③ 글루코스의 생분해성\n④ 금속킬레이트 형성 능력\n⑤ 글루코스의 환형연결구조",
        "question_text": "Question: What is the physicochemical property that allows cyclodextrin to form inclusion compounds with drugs?\n\n① Coordination bonding ability\n② Ion exchange capability\n③ Biodegradability of glucose\n④ Metal chelate formation ability\n⑤ Cyclic linked structure of glucose",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 절대온도 T(K)에서 비전해질 약물 a g이 녹아 있는 수용액 1 L의 삼투압이 0.5 기압일 때, 이 약물의 분자량(g/mol)은? [단, R (L ∙ 기압/mol ∙ K)는 기체상수이다.]\n\n① aRT\n② 2aRT\n③ 5aRT\n④ aRT/5\n⑤ a/(2RT)",
        "question_text": "Question: When the osmotic pressure of 1 L of an aqueous solution containing a g of a non-electrolyte drug dissolved at absolute temperature T(K) is 0.5 atmospheres, what is the molecular weight (g/mol) of this drug? [Note: R (L ∙ atm/mol ∙ K) is the gas constant.]\n\n① aRT\n② 2aRT\n③ 5aRT\n④ aRT/5\n⑤ a/(2RT)",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 액체 분사제 A와 B의 몰비가 4 : 1이 되도록 섞어 흡입용 에어로솔제의 용기에 충전하였다. 20℃에서 순수한 A와 B의 증기압이 각각 a와 b일 때, 20℃에서 용기의 내부압력은? (단, 이 액체는 라울의 법칙을 따른다.)\n\n① a+b\n② 4a+b\n③ (a+b)/2\n④ (a+4b)/5\n⑤ (4a+b)/5",
        "question_text": "Question: Liquid propellants A and B were mixed in a molar ratio of 4:1 and filled into a container for an inhalation aerosol. If the vapor pressures of pure A and B at 20°C are a and b respectively, what is the internal pressure of the container at 20°C? (Note: This liquid follows Raoult's law.)\n\n① a+b\n② 4a+b\n③ (a+b)/2\n④ (a+4b)/5\n⑤ (4a+b)/5",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: pH 5.0 완충용액 조제에서 완충용량에 대한 설명으로 옳은 것은?\n\n① 점도는 완충용량에 영향을 준다.\n② 완충용량을 구하는 식은 디바이 – 허클식이다.\n③ 완충용량은 산과 그 짝염기의 농도합에 비례한다.\n④ 최대 완충용량을 얻기 위해 pK a 7.0인 산을 선정한다.\n⑤ 완충용량은 pH 변화량을 염기의 증가량으로 나눈 값으로 정의한다.",
        "question_text": "Question: Which of the following statements about buffer capacity in the preparation of a pH 5.0 buffer solution is correct?\n\n① Viscosity affects buffer capacity.\n② The equation for calculating buffer capacity is the Debye-Hückel equation.\n③ Buffer capacity is proportional to the sum of the concentrations of the acid and its conjugate base.\n④ To obtain maximum buffer capacity, an acid with pKa 7.0 is selected.\n⑤ Buffer capacity is defined as the change in pH divided by the increase in base.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 질산은의 염화나트륨당량이 0.33일 때, 1w/v% 질산은 용액 100 mL 등장액을 제조하기 위하여 가해야 하는 염화나트륨의 양(g)은?\n\n① 0.09\n② 0.1\n③ 0.57\n④ 0.67\n⑤ 0.9",
        "question_text": "Question: When the sodium chloride equivalent of silver nitrate is 0.33, what is the amount of sodium chloride (g) that should be added to prepare 100 mL of an isotonic solution of 1 w/v% silver nitrate solution?\n\n① 0.09\n② 0.1\n③ 0.57\n④ 0.67\n⑤ 0.9",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 25℃에서 약물 A의 물과 클로로포름에서의 분배계수(K=C oil/C water)는 10이다. 25℃에서 약물 A 55 mg을 물 50 mL과 클로로포름 50 mL의 혼합용액에 녹여 평형에 도달했을 때, 클로로포름 층에 존재하는 약물 A의 양(mg)은? (단, 두 용매의 부분섞임성은 무시한다.)\n\n① 5\n② 10\n③ 25\n④ 50\n⑤ 55",
        "question_text": "Question: At 25℃, the partition coefficient (K=C oil/C water) of drug A between water and chloroform is 10. When 55 mg of drug A is dissolved in a mixture of 50 mL of water and 50 mL of chloroform at 25℃ and reaches equilibrium, what is the amount (mg) of drug A present in the chloroform layer? (Assume that the partial miscibility of the two solvents is negligible.)\n\n① 5\n② 10\n③ 25\n④ 50\n⑤ 55",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 물질수송의 예와 그 주된 구동력(driving force)에 대한 설명으로 옳은 것은?\n\n① 삼투적 약물방출시스템의 구동력은 압력이다.\n② 전기영동에서 DNA 이동의 구동력은 압력이다.\n③ 동결건조 시 수증기의 확산에서 구동력은 전기 전위이다.\n④ 이온토포레시스를 이용한 약물전달의 구동력은 온도이다.\n⑤ 마이크로파를 이용한 물질의 추출에서 구동력은 전기 전위이다.",
        "question_text": "Question: Which of the following is correct regarding the example of material transport and its main driving force?\n\n① The driving force in osmotic drug release systems is pressure.\n② The driving force for DNA movement in electrophoresis is pressure.\n③ The driving force for water vapor diffusion during freeze-drying is electrical potential.\n④ The driving force for drug delivery using iontophoresis is temperature.\n⑤ The driving force for material extraction using microwaves is electrical potential.",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 여러 단계의 반응을 거쳐 일어나는 화학반응에서 속도결정단계는?\n\n① 반응의 최종 단계\n② 반응의 첫 번째 단계\n③ 반응속도가 가장 빠른 단계\n④ 활성화에너지가 가장 작은 단계\n⑤ 비반응속도상수가 가장 작은 단계",
        "question_text": "Question: In a chemical reaction that occurs through multiple stages, which is the rate-determining step?\n\n① The final stage of the reaction\n② The first stage of the reaction\n③ The stage with the fastest reaction rate\n④ The stage with the lowest activation energy\n⑤ The stage with the smallest non-rate constant",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 암피실린 현탁제의 보관 중 온도 변화에 따른 속도상수의 증가배수 Q10값이 3이다. 이 약품의 보관 온도를 5℃에서 25℃로 변화시켰을 때, 분해반응 속도상수의 변화배수는?\n\n① 1\n② 2\n③ 3\n④ 6\n⑤ 9",
        "question_text": "Question: The Q10 value, which represents the factor by which the rate constant increases for every 10°C rise in temperature, is 3 for an ampicillin suspension during storage. When the storage temperature of this drug is changed from 5°C to 25°C, what is the factor by which the degradation reaction rate constant changes?\n\n① 1\n② 2\n③ 3\n④ 6\n⑤ 9",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 난용성 의약품 분말을 수용성 용제에 잘 분산시키고자 습윤제를 첨가하였을 때 나타나는 효과는?\n\n① 부착일 감소\n② 접촉각 증가\n③ 용출속도 감소\n④ 퍼짐계수 증가\n⑤ 계면장력 증가",
        "question_text": "Question: What is the effect when a wetting agent is added to disperse a poorly soluble drug powder in an aqueous solvent?\n\n① Decrease in adhesion work\n② Increase in contact angle\n③ Decrease in dissolution rate\n④ Increase in spreading coefficient\n⑤ Increase in interfacial tension",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 금(Au)과 같은 무기 입자는 입자 주위에 용매층이 형성되지 않아 자발적으로 분산되지 않는다. 이러한 입자들에 특별한 처리를 통해 얻어지는 콜로이드는?\n\n① 하이드로겔\n② 회합 콜로이드\n③ 소용매성 콜로이드\n④ 양친매성 콜로이드\n⑤ 친용매성 콜로이드",
        "question_text": "Question: Inorganic particles such as gold (Au) do not spontaneously disperse because a solvent layer does not form around the particles. What type of colloid is obtained when these particles undergo special treatment?\n\n① Hydrogel\n② Association colloid\n③ Lyophobic colloid\n④ Amphiphilic colloid\n⑤ Lyophilic colloid",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n물에 대한 용해도가 낮은 고체 분말 의약품 A를 현탁제로 설계하고자 계획하였다.\n다음은 설계된 현탁제의 품질평가에서 나타난 특성과 방출실험 모식도이다.\n(가) 침전속도는 최소화되어 안정한 분산체를 형성하였다.\n(나) 현탁제를 용기에서 따를 때, 높은 점도로 인해 불편했다.\n(다) 37 ℃에서 현탁제의 용출속도는 유사 0차 반응이었다.\n(라) 모식도의 실험에서 현탁제의 용출속도는 방출속도보다 컸다.\n<Data (confidential)>\n\nQuestion: 기존 현탁화제를 대신해 선형고분자 현탁화제를 첨가하여 (나)의 특성을 개선하고자 할 때, 그 현탁화제가 갖추어야 할 성질은? (단, 다른 특성은 변화시키지 않는다.)\n\n① 항복값이 존재하여야만 한다.\n② 전단응력과 전단속도는 정비례 관계이다.\n③ 전단응력을 가하면 현탁제의 점도를 증가시킨다.\n④ 전단응력을 가하면 현탁제의 입자공극 부피를 증가시킨다.\n⑤ 전단응력을 가하면 선형고분자의 배향이 점차 흐름의 방향으로 배열한다.",
        "question_text": "A solid powder drug A with low water solubility was planned to be designed as a suspension.\nThe following are the characteristics observed in the quality evaluation of the designed suspension and a schematic diagram of the release experiment.\n(a) The sedimentation rate was minimized, forming a stable dispersion.\n(b) When pouring the suspension from the container, it was inconvenient due to high viscosity.\n(c) The dissolution rate of the suspension at 37 ℃ followed a pseudo-zero-order reaction.\n(d) In the experiment shown in the schematic diagram, the dissolution rate of the suspension was greater than the release rate.\n<Data (confidential)>\n\nQuestion: When attempting to improve the characteristic (b) by adding a linear polymer suspending agent instead of the existing suspending agent, what property should this suspending agent have? (Assume other characteristics remain unchanged.)\n\n① It must have a yield value.\n② The shear stress and shear rate are directly proportional.\n③ When shear stress is applied, it increases the viscosity of the suspension.\n④ When shear stress is applied, it increases the particle void volume of the suspension.\n⑤ When shear stress is applied, the orientation of the linear polymer gradually aligns in the direction of flow.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n물에 대한 용해도가 낮은 고체 분말 의약품 A를 현탁제로 설계하고자 계획하였다.\n다음은 설계된 현탁제의 품질평가에서 나타난 특성과 방출실험 모식도이다.\n(가) 침전속도는 최소화되어 안정한 분산체를 형성하였다.\n(나) 현탁제를 용기에서 따를 때, 높은 점도로 인해 불편했다.\n(다) 37 ℃에서 현탁제의 용출속도는 유사 0차 반응이었다.\n(라) 모식도의 실험에서 현탁제의 용출속도는 방출속도보다 컸다.\n<Data (confidential)>\n\nQuestion: (다)와 (라)에서, 반투막 안에 고체상 약물이 존재할 때 보이는 방출속도 반응차수(A)와 용출이 완료된 이후 보이는 방출속도 반응차수(B)는?\n\n(A) | (B)\n① 유사 0차 | 유사 0차\n② 유사 0차 | 1차\n③ 1차 | 유사 0차\n④ 1차 | 1차\n⑤ 2차 | 2차",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA solid powder drug A with low water solubility was planned to be designed as a suspension.\nThe following are the characteristics observed in the quality evaluation of the designed suspension and a schematic diagram of the release experiment.\n(a) The sedimentation rate was minimized, forming a stable dispersion.\n(b) When pouring the suspension from the container, it was inconvenient due to high viscosity.\n(c) The dissolution rate of the suspension at 37 ℃ followed pseudo-zero-order kinetics.\n(d) In the experiment shown in the schematic diagram, the dissolution rate of the suspension was greater than the release rate.\n<Data (confidential)>\n\nQuestion: In (c) and (d), what are the release rate reaction orders when solid drug is present inside the semipermeable membrane (A) and after dissolution is complete (B)?\n\n(A) | (B)\n① Pseudo-zero-order | Pseudo-zero-order\n② Pseudo-zero-order | First-order\n③ First-order | Pseudo-zero-order\n④ First-order | First-order\n⑤ Second-order | Second-order",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 다음 약물 중에서 전구약물(prodrug)인 것을 모두 고른 것은?\n\n<Data (confidential)> <Data (confidential)> <Data (confidential)> <Data (confidential)>\n\n① (a), (b)\n② (a), (c)\n③ (a), (d)\n④ (b), (c)\n⑤ (b), (d)",
        "question_text": "Question: Which of the following drugs are all prodrugs?\n\n<Data (confidential)> <Data (confidential)> <Data (confidential)> <Data (confidential)>\n\n① (a), (b)\n② (a), (c)\n③ (a), (d)\n④ (b), (c)\n⑤ (b), (d)",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 다음 항고혈압 약물에 대한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 키랄 탄소는 3개이다.\n② benzodiazepine 유도체이다.\n③ Na+ 채널을 선택적으로 차단한다.\n④ 3-aminophenol을 원료로 하여 제조한다.\n⑤ deacetylation된 대사체는 약리 효과를 가진다.",
        "question_text": "Question: Which of the following statements about the antihypertensive drug is correct?\n\n<Data (confidential)>\n\n① It has 3 chiral carbons.\n② It is a benzodiazepine derivative.\n③ It selectively blocks Na+ channels.\n④ It is manufactured using 3-aminophenol as a raw material.\n⑤ The deacetylated metabolite has pharmacological effects.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 페노바르비탈(phenobarbital)을 제조하기 위한 출발물질 A로 적절한 것은?\n\n<Data (confidential)>\n\n① acetone\n② benzophenone\n③ benzyl cyanide\n④ isopropyl bromide\n⑤ methyl iodide",
        "question_text": "Question: Which of the following is an appropriate starting material A for the synthesis of phenobarbital?\n\n<Data (confidential)>\n\n① acetone\n② benzophenone\n③ benzyl cyanide\n④ isopropyl bromide\n⑤ methyl iodide",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 오르리스타트(orlistat)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the intermediate A obtained in the following reaction during the synthesis process of orlistat?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 다음 합성 과정에서 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① 디아제팜(diazepam)\n② 로라제팜(lorazepam)\n③ 미다졸람(midazolam)\n④ 트리아졸람(triazolam)\n⑤ 알프라졸람(alprazolam)",
        "question_text": "Question: Which drug A is obtained from the following synthesis process?\n\n<Data (confidential)>\n\n① Diazepam\n② Lorazepam\n③ Midazolam\n④ Triazolam\n⑤ Alprazolam",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 티오트로퓸(tiotropium bromide)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the intermediate A obtained in the following reaction during the synthesis process of tiotropium bromide?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 로수바스타틴(rosuvastatin)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following is the intermediate A obtained during the synthesis process of rosuvastatin in the reaction below?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 다음 합성 과정에서 얻어지는 약물에서 A의 구조는?\n\n<Data (confidential)>\n\n① aminopyridine\n② carbamate\n③ cyanoguanidine\n④ nitroethene\n⑤ thiourea",
        "question_text": "Question: What is the structure of A in the drug obtained from the following synthesis process?\n\n<Data (confidential)>\n\n① aminopyridine\n② carbamate\n③ cyanoguanidine\n④ nitroethene\n⑤ thiourea",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 케토코나졸(ketoconazole)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following is the intermediate A obtained during the synthesis process of ketoconazole in the reaction below?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 클로람페니콜(chloramphenicol)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the intermediate A obtained in the following reaction during the synthesis process of chloramphenicol?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 다음 합성 과정에서 얻어지는 항암제 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which anticancer drug A is obtained from the following synthesis process?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 졸피뎀(zolpidem)의 대사반응에서 CYP 효소에 의해 산화가 일어나는 주된 부위는?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "question_text": "Question: What is the main site of oxidation by CYP enzymes in the metabolic reaction of zolpidem?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 다음 약물 구조의 R기를 CH3로부터 allyl로 변환하여 만든 약물이 있다. 이 약물의 아편 수용체(opioid receptor)에 대한 작용은?\n\n<Data (confidential)>\n\n① 효능작용\n② 길항작용\n③ 단백분해작용\n④ 효소 저해작용\n⑤ 이온채널 차단작용",
        "question_text": "Question: There is a drug created by changing the R group in the following drug structure from CH3 to allyl. What is the action of this drug on the opioid receptor?\n\n<Data (confidential)>\n\n① Agonist action\n② Antagonist action\n③ Proteolytic action\n④ Enzyme inhibition action\n⑤ Ion channel blocking action",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 다음 반응을 통해 얻어진 약물 A에 대한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① dihydrofolate reductase를 저해한다.\n② thymidine의 항대사물질로 작용한다.\n③ DNA의 염기와 공유결합을 형성한다.\n④ p-aminobenzoic acid와 경쟁적으로 작용한다.\n⑤ π-π stacking을 통해 DNA 염기쌍과 결합한다.",
        "question_text": "Question: Which of the following statements about drug A obtained through the reaction below is correct?\n\n<Data (confidential)>\n\n① It inhibits dihydrofolate reductase.\n② It acts as an antimetabolite of thymidine.\n③ It forms covalent bonds with DNA bases.\n④ It acts competitively with p-aminobenzoic acid.\n⑤ It binds to DNA base pairs through π-π stacking.",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 퀴놀론계 항생제에서 6번 위치에 fluoro기가 도입되어 나타나는 효과는?\n\n<Data (confidential)>\n\n① 수용성 증가로 인한 약물흡수 증가\n② 분자구조 감소로 인한 항균범위 증가\n③ 지용성 증가로 인한 세포벽 투과도 증가\n④ 수소결합 증가로 인한 킬레이션 형성 증가\n⑤ GABA 수용체 친화도 감소로 인한 CNS 부작용 감소",
        "question_text": "Question: What is the effect of introducing a fluoro group at position 6 in quinolone antibiotics?\n\n<Data (confidential)>\n\n① Increased drug absorption due to increased water solubility\n② Increased antimicrobial spectrum due to decreased molecular structure\n③ Increased cell wall permeability due to increased lipid solubility\n④ Increased chelation formation due to increased hydrogen bonding\n⑤ Decreased CNS side effects due to reduced affinity for GABA receptors",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 다음 골격의 이뇨제는 R1에 전자 끄는 치환기가 도입되고, R2에 분자의 지용성을 높이는 치환기가 도입되면 이뇨작용이 증가한다. 이러한 약물의 R1과 R2에 대한 정량적 구조-활성 상관관계를 설명하는 물리화학적 인자들로 옳게 짝지어진 것은?\n\n<Data (confidential)>\n\nR1 | R2\n① σ(+) | π(+)\n② σ(-) | π(+)\n③ σ(+) | π(-)\n④ σ(-) | Es\n⑤ Es | π(-)",
        "question_text": "Question: For the following diuretic skeleton, the diuretic effect increases when an electron-withdrawing substituent is introduced at R1, and a substituent that increases the lipophilicity of the molecule is introduced at R2. Which of the following pairs of physicochemical factors correctly describes the quantitative structure-activity relationship for R1 and R2 of such drugs?\n\n<Data (confidential)>\n\nR1 | R2\n① σ(+) | π(+)\n② σ(-) | π(+)\n③ σ(+) | π(-)\n④ σ(-) | Es\n⑤ Es | π(-)",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nAngiotensin II 수용체의 길항제인 S-8308은 angiotensin II의 아미노산 잔기들과 3가지 공통 부분(A~C)을 가진다. 이후 S-8308로부터 구조 변화를 통해 발사르탄(valsartan)이 개발되었다.\n<Data (confidential)>\n\nQuestion: S-8308의 부위(B)는 angiotensin II의 특정 아미노산 잔기를 모방한 것이다. 이에 해당하는 아미노산은?\n\n① valine\n② tyrosine\n③ isoleucine\n④ histidine\n⑤ proline",
        "question_text": "Angiotensin II receptor antagonist S-8308 has three common parts (A~C) with the amino acid residues of angiotensin II. Subsequently, valsartan was developed through structural modifications from S-8308.\n<Data (confidential)>\n\nQuestion: The site (B) of S-8308 mimics a specific amino acid residue of angiotensin II. Which amino acid corresponds to this?\n\n① valine\n② tyrosine\n③ isoleucine\n④ histidine\n⑤ proline",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nAngiotensin II 수용체의 길항제인 S-8308은 angiotensin II의 아미노산 잔기들과 3가지 공통 부분(A~C)을 가진다. 이후 S-8308로부터 구조 변화를 통해 발사르탄(valsartan)이 개발되었다.\n<Data (confidential)>\n\nQuestion: S-8308의 imidazole은 수소결합 수용자(acceptor)로서의 역할을 한다. 이 역할을 대신하는 발사르탄(valsartan)의 작용기는?\n\n① amide\n② biphenyl\n③ n-butyl\n④ carboxylic acid\n⑤ tetrazole",
        "question_text": "Angiotensin II receptor antagonist S-8308 has three common parts (A~C) with the amino acid residues of angiotensin II. Subsequently, valsartan was developed through structural modifications of S-8308.\n<Data (confidential)>\n\nQuestion: The imidazole of S-8308 acts as a hydrogen bond acceptor. Which functional group in valsartan replaces this role?\n\n① amide\n② biphenyl\n③ n-butyl\n④ carboxylic acid\n⑤ tetrazole",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 다음 수용액 중 전리도가 가장 작은 것은? (단, H2CO3의 Ka1=1.0×10^-7, NH4OH의 Kb=1.0×10^-5이다.)\n\n① 0.001 mol/L H2CO3\n② 0.001 mol/L NH4OH\n③ 0.1 mol/L H2CO3\n④ 0.1 mol/L NH4OH\n⑤ 0.1 mol/L NH4Cl",
        "question_text": "Question: Which of the following aqueous solutions has the lowest degree of ionization? (Given: Ka1 of H2CO3 = 1.0×10^-7, Kb of NH4OH = 1.0×10^-5)\n\n① 0.001 mol/L H2CO3\n② 0.001 mol/L NH4OH\n③ 0.1 mol/L H2CO3\n④ 0.1 mol/L NH4OH\n⑤ 0.1 mol/L NH4Cl",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 0.04 mol/L NH4OH 용액에 동일한 부피의 (NH4)2SO4 용액을 가했을 때, [OH-]는 1.0×10^-5 mol/L가 되었다. 이때 가한 (NH4)2SO4 용액의 농도(mol/L)는? (단, NH4OH의 Kb=1.0×10^-5이다.)\n\n① 0.01\n② 0.02\n③ 0.04\n④ 0.1\n⑤ 0.2",
        "question_text": "Question: When an equal volume of (NH4)2SO4 solution was added to a 0.04 mol/L NH4OH solution, [OH-] became 1.0×10^-5 mol/L. What is the concentration (mol/L) of the added (NH4)2SO4 solution? (Given that Kb of NH4OH = 1.0×10^-5.)\n\n① 0.01\n② 0.02\n③ 0.04\n④ 0.1\n⑤ 0.2",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: [Mg2+]가 1.0×10^-3 mol/L인 용액에 NH4OH를 넣어 [NH4OH]가 0.1 mol/L가 되도록 할 때, 이 용액에서 Mg(OH)2 침전의 생성을 방지하기 위해 넣는 NH4Cl의 필요한 최소농도(mol/L)는? (단, Mg(OH)2의 Ksp=1.0×10^-13, NH4OH의 Kb=1.0×10^-5이다.)\n\n① 0.01\n② 0.02\n③ 0.03\n④ 0.1\n⑤ 0.3",
        "question_text": "Question: What is the minimum concentration (mol/L) of NH4Cl needed to prevent the formation of Mg(OH)2 precipitate in a solution where [Mg2+] is 1.0×10^-3 mol/L and NH4OH is added to make [NH4OH] 0.1 mol/L? (Given: Ksp of Mg(OH)2 = 1.0×10^-13, Kb of NH4OH = 1.0×10^-5)\n\n① 0.01\n② 0.02\n③ 0.03\n④ 0.1\n⑤ 0.3",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 질산은 점안액에 들어 있는 질산은(AgNO3) 함량을 폴하르트(Volhard)법으로 분석할 때, 0.1 mol/L NH4SCN 100 mL에 대응하는 질산은의 mol 수는?\n\n① 0.01\n② 0.05\n③ 0.1\n④ 0.5\n⑤ 1.0",
        "question_text": "Question: When analyzing the content of silver nitrate (AgNO3) in silver nitrate eye drops using the Volhard method, what is the number of moles of silver nitrate corresponding to 100 mL of 0.1 mol/L NH4SCN?\n\n① 0.01\n② 0.05\n③ 0.1\n④ 0.5\n⑤ 1.0",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 외용소독제 요오드틴크에 들어 있는 KI 함량을 요오드산 적정법으로 분석할 때, 0.05 mol/L KIO3 1.0 mL에 대응하는 KI의 mmol 수는?\n\n① 0.025\n② 0.05\n③ 0.1\n④ 0.125\n⑤ 0.2",
        "question_text": "Question: When analyzing the KI content in iodine tincture, an external disinfectant, using the iodometric titration method, how many mmol of KI correspond to 1.0 mL of 0.05 mol/L KIO3?\n\n① 0.025\n② 0.05\n③ 0.1\n④ 0.125\n⑤ 0.2",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 다음은 구충제 성분인 피페라진시트르산염 원료의약품의 정량법이다. 0.1 mol/L 과염소산 1 mL에 대응하는 피페라진시트르산염의 양(mg)은? (단, 피페라진시트르산염의 분자량은 642이다.)\n\n<Data (confidential)>\n정량법: 이 약물 0.2 g을 정밀하게 달아 아세트산무수물 \n100 mL에 녹이고, 0.1 mol/L 과염소산으로 적정한다.\n\n① 5.35\n② 10.7\n③ 21.4\n④ 32.1\n⑤ 64.2",
        "question_text": "Question: The following is the quantitative method for piperazine citrate, an active pharmaceutical ingredient used as an anthelmintic. What is the amount (mg) of piperazine citrate corresponding to 1 mL of 0.1 mol/L perchloric acid? (Note: The molecular weight of piperazine citrate is 642.)\n\n<Data (confidential)>\nQuantitative method: Accurately weigh 0.2 g of this drug, \ndissolve it in 100 mL of acetic anhydride, and titrate with \n0.1 mol/L perchloric acid.\n\n① 5.35\n② 10.7\n③ 21.4\n④ 32.1\n⑤ 64.2",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 자외가시부스펙트럼의 특성에 대한 설명으로 옳은 것은?\n\n① 흡광도는 투광도의 역수로 나타낸다.\n② 흡수극대파장(λmax)은 층장길이에 정비례한다.\n③ 몰흡광계수(εmax)는 시료의 농도에 정비례한다.\n④ π → π* 전이의 몰흡광계수(εmax)는 σ → σ* 전이에서의 값보다 크다.\n⑤ n → π* 전이의 흡수극대파장(λmax)은 용매의 종류에 상관없이 일정하다.",
        "question_text": "Question: Which of the following statements about the characteristics of UV-visible spectroscopy is correct?\n\n① Absorbance is expressed as the reciprocal of transmittance.\n② The maximum absorption wavelength (λmax) is directly proportional to the path length.\n③ The molar absorption coefficient (εmax) is directly proportional to the sample concentration.\n④ The molar absorption coefficient (εmax) of π → π* transition is greater than that of σ → σ* transition.\n⑤ The maximum absorption wavelength (λmax) of n → π* transition is constant regardless of the type of solvent.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 미나마타병으로 입원한 환자의 소변 시료에서 수은 농도를 직접적으로 측정할 수 있는 분석법은?\n\n① 라만분광법\n② 형광광도법\n③ 적외선분광광도법\n④ 자외가시부흡광광도법\n⑤ 유도결합플라즈마분광법",
        "question_text": "Question: Which analytical method can directly measure the mercury concentration in a urine sample from a patient hospitalized with Minamata disease?\n\n① Raman spectroscopy\n② Fluorescence spectrophotometry\n③ Infrared spectrophotometry\n④ UV-visible spectrophotometry\n⑤ Inductively Coupled Plasma (ICP) spectroscopy",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 벤조산 고체시료를 적외부스펙트럼측정법의 브롬화칼륨정제법으로 측정하여 다음의 스펙트럼을 얻었다. 재분석 시 분석시료의 정확한 파수를 얻기 위한 방법은?\n\n<Data (confidential)>\n\n① 광원을 새것으로 교체한다.\n② KBr 대신 NaCl을 사용한다.\n③ 분석 스캔하는 횟수를 늘린다.\n④ KBr에 넣는 시료의 양을 줄인다.\n⑤ 측정하는 고체시료를 잘게 분쇄한다.",
        "question_text": "Question: A solid sample of benzoic acid was measured using the potassium bromide disk method of infrared spectroscopy, resulting in the following spectrum. What method should be used to obtain accurate wavenumbers of the analyte during reanalysis?\n\n<Data (confidential)>\n\n① Replace the light source with a new one.\n② Use NaCl instead of KBr.\n③ Increase the number of analytical scans.\n④ Reduce the amount of sample added to KBr.\n⑤ Finely grind the solid sample being measured.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 액체크로마토그래피의 분리기전에 대한 설명으로 옳은 것은?\n\n① 흡착크로마토그래피 – 각 성분의 이동상에 대한 흡착력 차이\n② 친화크로마토그래피 – 분리 물질의 분자량 차이에 의한 선택성\n③ 이온쌍크로마토그래피 – 이온교환수지에 대한 이온교환능의 차이\n④ 분배크로마토그래피 – 혼합성분의 액체 고정상과 이동상에 대한 용해도 차이\n⑤ 크기배제크로마토그래피– 액체 고정상과 이동상에 대한 시료 간 전기적 인력 차이",
        "question_text": "Question: Which of the following statements about the separation mechanism in liquid chromatography is correct?\n\n① Adsorption chromatography – Difference in adsorption strength of each component to the mobile phase\n② Affinity chromatography – Selectivity based on differences in molecular weight of separated substances\n③ Ion-pair chromatography – Difference in ion exchange capacity with ion exchange resin\n④ Partition chromatography – Difference in solubility of mixed components in liquid stationary phase and mobile phase\n⑤ Size exclusion chromatography – Difference in electrical attraction between samples to liquid stationary phase and mobile phase",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 크로마토그래피에서 분리성능의 파라미터 중 하나인 분리도에 영향을 주는 인자는?\n\n① 시료의 녹는점\n② 용매 재순환장치\n③ 시료 회수 용이성\n④ 고정상 입자의 크기\n⑤ 시료주입기(injector)의 종류",
        "question_text": "Question: Which factor affects the resolution, one of the parameters of separation performance in chromatography?\n\n① Melting point of the sample\n② Solvent recycling system\n③ Ease of sample recovery\n④ Size of stationary phase particles\n⑤ Type of sample injector",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 액체크로마토그래피로 분석할 때 용량인자(k′)에 대한 설명으로 옳은 것은?\n\n① 분배계수에 의해 영향을 받지 않는다.\n② k′이 작은 물질은 고정상에 머무르는 시간이 길다.\n③ 기울기 용리조건을 변화시켜 k′ 값을 변화시킬 수 없다. \n④ 효율적인 분석을 위해서 k′은 10 이상으로 클수록 좋다.\n⑤ 보정된 머무름 시간(t′)을 고정상과 상호작용이 없는 물질의 머무름 시간(to)으로 나눈 값이다.",
        "question_text": "Question: Which of the following statements about the capacity factor (k′) in liquid chromatography analysis is correct?\n\n① It is not affected by the distribution coefficient.\n② Substances with a small k′ have a longer retention time in the stationary phase.\n③ The k′ value cannot be changed by altering gradient elution conditions.\n④ For efficient analysis, k′ should be as large as possible, preferably above 10.\n⑤ It is the ratio of the adjusted retention time (t′) to the retention time of a substance that does not interact with the stationary phase (to).",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 기체크로마토그래피에 대한 설명으로 옳은 것은?\n\n① 형광 유도체화 시약은 미량분석에 유용하다.\n② 이동상은 시료분자나 고정상과 반응성이 있을수록 좋다.\n③ 굴절률 검출기는 시료의 화학구조에 제한 없이 사용될 수 있다.\n④ 개방 모세관 칼럼은 충전 칼럼에 비해 높은 분리능뿐만 아니라 분취용으로도 유용하다.\n⑤ 극성에 큰 차이가 나는 성분들의 시료를 분석할 때, 온도 프로그래밍을 통하여 분석 시간을 단축하고 피크를 예리하게 할 수 있다.",
        "question_text": "Question: Which of the following statements about gas chromatography is correct?\n\n① Fluorescent derivatization reagents are useful for trace analysis.\n② The mobile phase should be as reactive as possible with the sample molecules or stationary phase.\n③ The refractive index detector can be used without restrictions on the chemical structure of the sample.\n④ Open capillary columns are useful not only for high resolution but also for preparative purposes compared to packed columns.\n⑤ When analyzing samples with components of greatly differing polarity, temperature programming can be used to shorten analysis time and sharpen peaks.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 일산화탄소 중독으로 의심되는 환자의 혈액시료 내 일산화탄소 함량을 기체크로마토그래피로 측정하고자 할 때에 사용할 수 있는 검출기는?\n\n① 열전도도 검출기\n② 전자포획 검출기\n③ 전기화학 검출기\n④ 불꽃광도 검출기\n⑤ 증기화광산란 검출기",
        "question_text": "Question: Which detector can be used when measuring the carbon monoxide content in a blood sample of a patient suspected of carbon monoxide poisoning using gas chromatography?\n\n① Thermal conductivity detector\n② Electron capture detector\n③ Electrochemical detector\n④ Flame photometric detector\n⑤ Evaporative light scattering detector",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 원료의약품 A의 함량분석 과정 중 불확정도가 0.01 mL인 10 mL 부피측정 피펫(volumetric pipet)을 4회 사용하여 염산표준액 40 mL를 비커로 옮겼다. 비커에 있는 염산표준액의 부피에 대한 절대 불확정도(mL)는?\n\n① 0.01\n② 0.02\n③ 0.03\n④ 0.04\n⑤ 0.05",
        "question_text": "Question: During the content analysis process of the active pharmaceutical ingredient A, a 10 mL volumetric pipet with an uncertainty of 0.01 mL was used 4 times to transfer 40 mL of standard hydrochloric acid solution to a beaker. What is the absolute uncertainty (mL) of the volume of the standard hydrochloric acid solution in the beaker?\n\n① 0.01\n② 0.02\n③ 0.03\n④ 0.04\n⑤ 0.05",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 분석실험으로 얻은 측정값들의 집중경향을 나타내는 척도로 사용되는 통계 수치는?\n\n① 범위\n② 분산\n③ 최빈치\n④ 평균편차\n⑤ 상대표준편차",
        "question_text": "Question: Which statistical measure is used as a scale to represent the central tendency of measured values obtained from analytical experiments?\n\n① Range\n② Variance\n③ Mode\n④ Mean deviation\n⑤ Relative standard deviation",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n증류수 100 mL에 337 mg의 티아민염산염(분자량 337)을 녹인 다음, 층장 1 cm 셀을 사용하여 자외가시부흡광도법으로 측정하였더니 239 nm에서 최대 흡수 봉우리(peak)가 나타났고, 이 파장에서의 흡광도는 0.230이었다.\n\nQuestion: 티아민염산염의 분광광도측정법에 적용된 주요 측정 원리는?\n\n① 전자의 핵스핀\n② 분자의 진동 운동\n③ 분자의 회전 운동 \n④ 원자의 내부전자 전이\n⑤ 분자의 최외각 전자의 전이",
        "question_text": "A solution was prepared by dissolving 337 mg of thiamine hydrochloride (molecular weight 337) in 100 mL of distilled water. Using a 1 cm path length cell, the solution was measured by UV-visible spectrophotometry. The maximum absorption peak appeared at 239 nm, and the absorbance at this wavelength was 0.230.\n\nQuestion: What is the main measurement principle applied in the spectrophotometric method for thiamine hydrochloride?\n\n① Nuclear spin of electrons\n② Vibrational motion of molecules\n③ Rotational motion of molecules\n④ Internal electron transition of atoms\n⑤ Transition of outermost electrons in molecules",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n증류수 100 mL에 337 mg의 티아민염산염(분자량 337)을 녹인 다음, 층장 1 cm 셀을 사용하여 자외가시부흡광도법으로 측정하였더니 239 nm에서 최대 흡수 봉우리(peak)가 나타났고, 이 파장에서의 흡광도는 0.230이었다.\n\nQuestion: 티아민염산염의 몰흡광계수(M^-1 ∙ cm^-1)는?\n\n① 0.10\n② 2.30\n③ 4.60\n④ 23.0\n⑤ 46.0",
        "question_text": "A solution was prepared by dissolving 337 mg of thiamine hydrochloride (molecular weight 337) in 100 mL of distilled water. Using a 1 cm path length cell, the solution was measured by UV-visible spectrophotometry. The maximum absorption peak appeared at 239 nm, and the absorbance at this wavelength was 0.230.\n\nQuestion: What is the molar extinction coefficient (M^-1 ∙ cm^-1) of thiamine hydrochloride?\n\n① 0.10\n② 2.30\n③ 4.60\n④ 23.0\n⑤ 46.0",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 분체의 하우스너 비율(Hausner ratio)에 대한 설명으로 옳은 것은?\n\n① 하우스너 비율과 안식각은 서로 반비례 관계이다.\n② 겉보기부피(Vbulk)를 압축부피(Vtapped)로 나눈 값이다.\n③ 하우스너 비율이 클수록 분체의 흐름성이 개선된다.\n④ 하우스너 비율이 1.6인 분체는 우수한 흐름성을 보인다.\n⑤ 하우스너 비율이 클수록 겉보기부피와 압축부피의 차이가 작아진다.",
        "question_text": "Question: Which of the following statements about the Hausner ratio of powders is correct?\n\n① The Hausner ratio and angle of repose are inversely proportional to each other.\n② It is the value obtained by dividing the bulk volume (Vbulk) by the tapped volume (Vtapped).\n③ The higher the Hausner ratio, the better the flowability of the powder.\n④ A powder with a Hausner ratio of 1.6 shows excellent flowability.\n⑤ As the Hausner ratio increases, the difference between bulk volume and tapped volume decreases.",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 서로 반대 방향으로 회전하는 두 원반 사이의 간격에 의해 시료의 분쇄 정도가 조절되며, 고체 – 액체 혼합물의 분산이나 유화에 사용되는 것은?\n\n① colloid mill\n② Fitz mill\n③ fluid-energy mill\n④ hammer mill\n⑤ roller mill",
        "question_text": "Question: Which device is used for dispersing or emulsifying solid-liquid mixtures, where the degree of sample grinding is controlled by the gap between two discs rotating in opposite directions?\n\n① colloid mill\n② Fitz mill\n③ fluid-energy mill\n④ hammer mill\n⑤ roller mill",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 부형제 사용량을 최소화할 수 있어 약물 함량이 높으며, 밀도가 높은 펠렛의 제조에 사용되는 방법은?\n\n① 강타법\n② 롤러압축법\n③ 계면중합법\n④ 저전단과립법\n⑤ 압출구형과립법",
        "question_text": "Question: Which method is used to manufacture pellets with high drug content and high density, minimizing the use of excipients?\n\n① Slugging method\n② Roller compaction method\n③ Interfacial polymerization method\n④ Low shear granulation method\n⑤ Extrusion-spheronization method",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 젤라틴으로 만든 연질캡슐 피막이 쉽게 부서지는 것을 방지하기 위하여 가하는 첨가제는?\n\n① 광유\n② 올레산\n③ 소르비톨\n④ 세틸알코올\n⑤ 카르나우바납",
        "question_text": "Question: What additive is used to prevent the gelatin-based soft capsule shell from easily breaking?\n\n① Mineral oil\n② Oleic acid\n③ Sorbitol\n④ Cetyl alcohol\n⑤ Carnauba wax",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 빛에 민감한 약물의 안정성을 높이기 위하여 필름코팅 시 첨가하는 것은?\n\n① 포비돈\n② 산화티탄\n③ 셀라세페이트\n④ 폴리에틸렌글리콜\n⑤ 카르복시메틸셀룰로오스",
        "question_text": "Question: Which of the following is added during film coating to increase the stability of light-sensitive drugs?\n\n① Povidone\n② Titanium dioxide\n③ Cellacefate\n④ Polyethylene glycol\n⑤ Carboxymethylcellulose",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: w/o형 유제의 제조 시 유화제로 적합한 계면활성제는?\n\n① gelatin\n② polysorbate 80\n③ sodium lauryl sulfate\n④ sodium oleate\n⑤ Span 80",
        "question_text": "Question: Which surfactant is suitable as an emulsifier when manufacturing w/o type emulsions?\n\n① gelatin\n② polysorbate 80\n③ sodium lauryl sulfate\n④ sodium oleate\n⑤ Span 80",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 테스토스테론에난테이트(testosterone enanthate)의 주사제 제조에 적합한 비수성용제는?\n\n① 광유\n② 참기름\n③ 유동파라핀\n④ 링거주사액\n⑤ 클로로부탄올",
        "question_text": "Question: Which non-aqueous solvent is suitable for manufacturing an injectable preparation of testosterone enanthate?\n\n① Mineral oil\n② Sesame oil\n③ Liquid paraffin\n④ Ringer's solution\n⑤ Chlorobutanol",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 뇌종양 제거 수술 후 이식하는 카무스틴(carmustine)을 봉입한 웨이퍼의 제조에 사용하는 고분자중합체로서, 표면에서 서서히 침식되어 분해되는 것은?\n\n① polyacrylamide\n② polyanhydrides\n③ polyethyleneglycol\n④ polyvinylpyrrolidone\n⑤ poly(ethylene-vinyl acetate)",
        "question_text": "Question: Which polymer is used in the manufacture of wafers containing carmustine, implanted after brain tumor removal surgery, that slowly erodes and degrades from the surface?\n\n① polyacrylamide\n② polyanhydrides\n③ polyethyleneglycol\n④ polyvinylpyrrolidone\n⑤ poly(ethylene-vinyl acetate)",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 약물의 용출속도를 증가시킬 수 있는 정제의 조성 및 제조법에 대한 설명으로 옳은 것은?\n\n① 약물 분체의 입자크기를 증가시킨다.\n② 에틸셀룰로오스를 사용하여 코팅한다.\n③ 스테아르산마그네슘의 양을 증가시킨다.\n④ 전분글리콜산나트륨의 양을 감소시킨다.\n⑤ 포비돈으로 고체분산체를 형성하여 타정한다.",
        "question_text": "Question: Which of the following statements is correct regarding the composition and manufacturing method of tablets that can increase the dissolution rate of a drug?\n\n① Increase the particle size of the drug powder.\n② Coat the tablet using ethylcellulose.\n③ Increase the amount of magnesium stearate.\n④ Decrease the amount of sodium starch glycolate.\n⑤ Form a solid dispersion with povidone and compress into tablets.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 소장 상부에 존재하는 수송체에서만 특이적으로 흡수되는 약물의 생체이용률을 증가시킬 수 있는 정제의 설계로 적합한 것은?\n\n① 삼투압 기술을 이용한 서방출 정제\n② 서방출 마이크로캡슐을 포함하는 속붕해정\n③ 밀도를 저하시켜 물에서 부유하는 서방출 정제\n④ 약물을 이온교환수지와 결합시키고 Eudragit L100으로 코팅한 정제\n⑤ 약물을 매트릭스 기제에 포함시켜 타정한 후 쉘락으로 코팅한 정제",
        "question_text": "Question: Which tablet design is appropriate to increase the bioavailability of a drug that is specifically absorbed only by transporters present in the upper small intestine?\n\n① Extended-release tablet using osmotic technology\n② Fast-disintegrating tablet containing extended-release microcapsules\n③ Extended-release tablet that floats in water due to reduced density\n④ Tablet with drug bound to ion-exchange resin and coated with Eudragit L100\n⑤ Tablet compressed with drug included in a matrix base and coated with shellac",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 다음은 약물저장고형(reservoir) 경피흡수제의 그림이다. A~E가 가리키는 것으로 옳은 것은?\n\n<Data (confidential)>\n\nA | B | C | D | E\n① 약물저장고 | 지지체 | 조절막 | 박리지 | 점착층\n② 약물저장고 | 조절막 | 지지체 | 점착층 | 박리지\n③ 지지체 | 약물저장고 | 점착층 | 조절막 | 박리지\n④ 박리지 | 조절막 | 점착층 | 약물저장고 | 지지체\n⑤ 지지체 | 약물저장고 | 조절막 | 점착층 | 박리지",
        "question_text": "Question: The following is a diagram of a reservoir-type transdermal absorption system. Which of the following correctly identifies A to E?\n\n<Data (confidential)>\n\nA | B | C | D | E\n① Drug reservoir | Backing layer | Rate-controlling membrane | Release liner | Adhesive layer\n② Drug reservoir | Rate-controlling membrane | Backing layer | Adhesive layer | Release liner\n③ Backing layer | Drug reservoir | Adhesive layer | Rate-controlling membrane | Release liner\n④ Release liner | Rate-controlling membrane | Adhesive layer | Drug reservoir | Backing layer\n⑤ Backing layer | Drug reservoir | Rate-controlling membrane | Adhesive layer | Release liner",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 약물의 흡수와 관련된 직장의 특징에 대한 설명으로 옳은 것은?\n\n① 점액을 분비하지 않는다.\n② 소장과 비슷한 정도의 융모가 존재한다.\n③ 직장 하부로 흡수된 약물은 간문맥을 거치지 않고 전신순환계로 들어간다.\n④ 세포 간 밀착결합이 소장보다 덜 치밀하여 친수성 약물의 투과성이 높다.\n⑤ 비교반수층이 소장에서보다 더 두꺼워 분배계수가 클수록 약물의 흡수가 감소한다.",
        "question_text": "Question: Which of the following statements about the characteristics of the rectum related to drug absorption is correct?\n\n① It does not secrete mucus.\n② It has villi similar to those in the small intestine.\n③ Drugs absorbed in the lower rectum enter the systemic circulation without passing through the portal vein.\n④ The tight junctions between cells are less compact than in the small intestine, resulting in higher permeability for hydrophilic drugs.\n⑤ The unstirred water layer is thicker than in the small intestine, causing decreased absorption of drugs with higher partition coefficients.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 약물 A를 환자에게 경구투여 한 후 24시간 동안 혈액과 요를 취하여 다음과 같은 데이터를 얻었다. 약물 A의 신 클리어런스(mL/h)는? (단, 24시간 이후의 혈액과 요에서의 약물농도는 매우 낮아 무시한다.)\n\n• 24시간 동안 취한 요의 부피=1.2 L\n• 요중 약물농도=4 mg/mL\n• 혈중약물농도-시간곡선하면적(AUC)=24 mg ∙ h/mL\n\n① 50\n② 72\n③ 200\n④ 300\n⑤ 1200",
        "question_text": "Question: After orally administering drug A to a patient, blood and urine samples were collected for 24 hours, yielding the following data. What is the renal clearance (mL/h) of drug A? (Note: Drug concentrations in blood and urine after 24 hours are very low and can be ignored.)\n\n• Volume of urine collected over 24 hours = 1.2 L\n• Drug concentration in urine = 4 mg/mL\n• Area under the blood concentration-time curve (AUC) = 24 mg ∙ h/mL\n\n① 50\n② 72\n③ 200\n④ 300\n⑤ 1200",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 생물약제학적분류체계(BCS)에서 제1군에 대한 설명으로 옳은 것은?\n\n① 장관막투과는 약물흡수의 율속단계이다.\n② 낮은 용해도와 높은 막투과도를 가진다.\n③ 재현성 있는 용출패턴을 관측하기가 어렵다. \n④ 비교용출시험으로 생물학적동등성시험을 대체할 수 있는 약물을 포함한다.\n⑤ 용출속도와 생체 내 흡수 간의 상관성이 낮아 서방출 제형으로 개발하기 적합하지 않다.",
        "question_text": "Question: Which of the following statements about Class I in the Biopharmaceutics Classification System (BCS) is correct?\n\n① Intestinal membrane permeation is the rate-limiting step in drug absorption.\n② It has low solubility and high membrane permeability.\n③ It is difficult to observe reproducible dissolution patterns.\n④ It includes drugs for which bioequivalence studies can be replaced by comparative dissolution tests.\n⑤ Due to low correlation between dissolution rate and in vivo absorption, it is not suitable for developing extended-release formulations.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 만성폐쇄성폐질환으로 입원한 체중 70 kg인 환자에게 테오필린을 투여하려고 한다. 정맥주사로 부하량(loading dose)을 투여하여 처음부터 치료에 유효한 정상상태에서의 혈중농도(Css)에 도달시키고, 동시에 일정한 속도로 정맥 내 주입하여 Css를 유지하고자 한다. 테오필린은 선형 1-컴파트먼트 모델을 따르며, 이 환자에서 얻은 약동학적 파라미터가 다음과 같을 때 부하량(mg)은?\n\n• 정상상태에서의 혈중농도(Css) 10 mg/L\n• 분포용적(Vd) 0.5 L/kg \n• 전신클리어런스(CLt) 0.04 L/h/kg\n\n① 0.4\n② 0.5\n③ 28\n④ 56\n⑤ 350",
        "question_text": "Question: A patient weighing 70 kg, hospitalized with chronic obstructive pulmonary disease, is to be administered theophylline. The plan is to administer a loading dose intravenously to immediately reach the therapeutic steady-state plasma concentration (Css), and simultaneously maintain the Css by continuous intravenous infusion at a constant rate. Theophylline follows a linear one-compartment model, and given the following pharmacokinetic parameters obtained from this patient, what is the loading dose (mg)?\n\n• Steady-state plasma concentration (Css): 10 mg/L\n• Volume of distribution (Vd): 0.5 L/kg\n• Total body clearance (CLt): 0.04 L/h/kg\n\n① 0.4\n② 0.5\n③ 28\n④ 56\n⑤ 350",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 와파린을 투여받는 환자가 CYP2C9의 변이 유전형(CYP2C9*2, *3, *13 대립형질)을 가지는 경우, 이로 인한 와파린의 약물동태 변화와 임상적 대책이 순서대로 옳은 것은?\n\n① 혈중농도 증가, 유지용량 감소\n② 분포용적 감소, 유지용량 증가\n③ 소실반감기 증가, 투여간격 감소\n④ 클리어런스 증가, 투여간격 증가\n⑤ 혈중약물농도-시간곡선하면적 감소, 투여용량 증가",
        "question_text": "Question: For a patient receiving warfarin who has variant genotypes of CYP2C9 (CYP2C9*2, *3, *13 alleles), which of the following correctly describes the resulting changes in warfarin pharmacokinetics and the appropriate clinical measures, in that order?\n\n① Increased blood concentration, decreased maintenance dose\n② Decreased volume of distribution, increased maintenance dose\n③ Increased elimination half-life, decreased dosing interval\n④ Increased clearance, increased dosing interval\n⑤ Decreased area under the blood concentration-time curve, increased dosage",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n난용성 약물인 여드름 치료제 아다팔렌(adapalene)의 반고형 외용제제 A를 다음의 처방을 사용하여 개발하고자 한다. (단, 아다팔렌과 폴록사머124를 먼저 정제수에 혼화한다.)\n아다팔렌 0.3 g\n폴록사머124 0.2 g\n정제수 1.0 g\n카보머940 1.1 g\n에데트산나트륨 0.1 g\n프로필렌글리콜 4.0 g\n메틸파라벤 0.2 g\n수산화나트륨 0.2 g\n정제수 92.9 g\n----------------------------------------- 100.0 g\n\nQuestion: 위 제제처방에서 폴록사머124와 카보머940의 배합목적이 순서대로 옳은 것은?\n\n① 서방화, 유화\n② 분산화, 겔화\n③ 유동화, 겔화\n④ 서방화, 분산화\n⑤ 가용화, 유동화",
        "question_text": "A semi-solid external preparation A of adapalene, a poorly soluble acne treatment drug, is to be developed using the following formulation. (Note: Adapalene and poloxamer 124 are first mixed with purified water.)\n\nAdapalene 0.3 g\nPoloxamer 124 0.2 g\nPurified water 1.0 g\nCarbomer 940 1.1 g\nDisodium edetate 0.1 g\nPropylene glycol 4.0 g\nMethylparaben 0.2 g\nSodium hydroxide 0.2 g\nPurified water 92.9 g\n----------------------------------------- 100.0 g\n\nQuestion: What are the correct purposes of poloxamer 124 and carbomer 940 in the above formulation, in that order?\n\n① Sustained release, emulsification\n② Dispersion, gelation\n③ Fluidization, gelation\n④ Sustained release, dispersion\n⑤ Solubilization, fluidization",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n난용성 약물인 여드름 치료제 아다팔렌(adapalene)의 반고형 외용제제 A를 다음의 처방을 사용하여 개발하고자 한다. (단, 아다팔렌과 폴록사머124를 먼저 정제수에 혼화한다.)\n아다팔렌 0.3 g\n폴록사머124 0.2 g\n정제수 1.0 g\n카보머940 1.1 g\n에데트산나트륨 0.1 g\n프로필렌글리콜 4.0 g\n메틸파라벤 0.2 g\n수산화나트륨 0.2 g\n정제수 92.9 g\n----------------------------------------- 100.0 g\n\nQuestion: 제제 A에 대한 설명으로 옳은 것은?\n\n① 전형적인 틱소트로피를 나타낸다.\n② 고분자 계면활성제로 이루어진 크림제이다.\n③ 고분자가 액체에 균등하게 분포하여 단일상을 이룬다.\n④ 아주 작은 입자들의 응집체 덩어리로 이루어진 시스템이다.\n⑤ 분자량이 다른 카보머를 사용하더라도 약물방출에는 영향을 주지 않는다.",
        "question_text": "A semi-solid external preparation A of adapalene, a poorly soluble acne treatment drug, is to be developed using the following prescription. (Note: Adapalene and poloxamer 124 are first mixed with purified water.)\n\nAdapalene 0.3 g\nPoloxamer 124 0.2 g\nPurified water 1.0 g\nCarbomer 940 1.1 g\nDisodium edetate 0.1 g\nPropylene glycol 4.0 g\nMethylparaben 0.2 g\nSodium hydroxide 0.2 g\nPurified water 92.9 g\n----------------------------------------- 100.0 g\n\nQuestion: Which of the following statements about preparation A is correct?\n\n① It exhibits typical thixotropy.\n② It is a cream made of polymeric surfactants.\n③ The polymer forms a single phase, evenly distributed in the liquid.\n④ It is a system composed of agglomerated clusters of very small particles.\n⑤ Using carbomers of different molecular weights does not affect drug release.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 광감작 촉진작용이 있는 coumarin계 생약 성분은?\n\n① digitoxin\n② eugenol\n③ hypericin\n④ magnolol\n⑤ psoralen",
        "question_text": "Question: Which coumarin-based herbal ingredient has a photosensitizing effect?\n\n① digitoxin\n② eugenol\n③ hypericin\n④ magnolol\n⑤ psoralen",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: Squalene으로부터 생합성되며 dammarane 골격을 가지는 생약 성분은?\n\n① chrysophanol\n② ginsenoside Rb1\n③ hesperidin\n④ nicotine\n⑤ resveratrol",
        "question_text": "Question: Which medicinal plant component is biosynthesized from squalene and has a dammarane skeleton?\n\n① chrysophanol\n② ginsenoside Rb1\n③ hesperidin\n④ nicotine\n⑤ resveratrol",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 다음 생약에 공통으로 함유되어 있는 alkaloid는?\n\n• Belladonnae Radix\n• Daturae Folium\n• Scopoliae Rhizoma\n\n① atropine\n② berberine\n③ higenamine\n④ quinidine\n⑤ reserpine",
        "question_text": "Question: Which alkaloid is commonly contained in the following medicinal herbs?\n\n• Belladonnae Radix\n• Daturae Folium\n• Scopoliae Rhizoma\n\n① atropine\n② berberine\n③ higenamine\n④ quinidine\n⑤ reserpine",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약 성분은?\n\n• C6-C3-C6의 탄소골격을 가짐\n• Mg-HCl에 의한 정색반응으로 확인함\n• Chalcone을 거쳐 생합성됨\n\n① emodin\n② eugenol\n③ geraniin\n④ rutin\n⑤ scoparone",
        "question_text": "Question: Which of the following describes the medicinal plant component?\n\n• Has a C6-C3-C6 carbon skeleton\n• Identified by color reaction with Mg-HCl\n• Biosynthesized via chalcone\n\n① emodin\n② eugenol\n③ geraniin\n④ rutin\n⑤ scoparone",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 줄기는 네모기둥 모양이며, 잎에서 오목한 점 모양의 선린(腺鱗)을 관찰할 수 있는 꿀풀과(Labiatae) 생약은?\n\n① 대마\n② 박하\n③ 산약\n④ 천궁\n⑤ 황기",
        "question_text": "Question: Which medicinal herb from the Labiatae (Lamiaceae) family has a square-shaped stem and glandular scales that can be observed as concave dots on the leaves?\n\n① Cannabis\n② Peppermint\n③ Chinese yam\n④ Cnidium\n⑤ Astragalus root",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약은?\n\n• 생강과(科)에 속함\n• Diarylheptanoid를 함유함\n• 이담약, 방향성 건위약으로 사용함\n\n① 개자\n② 도인\n③ 백지\n④ 울금\n⑤ 치자",
        "question_text": "Question: Which of the following medicinal herbs is being described?\n\n• Belongs to the Zingiberaceae family\n• Contains diarylheptanoids\n• Used as a choleretic and aromatic stomachic\n\n① Bupleurum fruit\n② Peach kernel\n③ Angelica dahurica root\n④ Turmeric\n⑤ Gardenia fruit",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약 성분은?\n\n• 용담과(科) 생약에 함유됨\n• Secoiridoid에 속함\n• 고미건위작용을 나타냄\n\n① geniposide\n② genistein\n③ gentiopicroside\n④ matrine\n⑤ quassin",
        "question_text": "Question: Which of the following describes the medicinal plant component?\n\n• Contained in medicinal plants of the Gentianaceae family\n• Belongs to secoiridoids\n• Exhibits bitter stomachic action\n\n① geniposide\n② genistein\n③ gentiopicroside\n④ matrine\n⑤ quassin",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: Steroid계 saponin을 주성분으로 함유하는 백합과(Liliaceae) 생약은?\n\n① 길초근\n② 맥문동\n③ 사프란\n④ 오가피\n⑤ 하고초",
        "question_text": "Question: Which of the following Liliaceae (lily family) medicinal herbs contains steroid saponins as its main component?\n\n① Anemarrhena rhizome\n② Ophiopogon root\n③ Saffron\n④ Acanthopanax root bark\n⑤ Prunella spike",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약은?\n\n• 덩굴성줄기 및 뿌리줄기를 약용부위로 함\n• Sinomenine을 함유함\n• 이뇨약, 소염진통약으로 사용함\n\n① 길경\n② 당약\n③ 두충\n④ 방기\n⑤ 회향",
        "question_text": "Question: Which of the following medicinal herbs is being described?\n\n• The medicinal part is the vine stem and rhizome\n• Contains Sinomenine\n• Used as a diuretic and anti-inflammatory analgesic\n\n① Platycodon Root (Gilgyeong)\n② Chinese Angelica Root (Dangyak)\n③ Eucommia Bark (Duchung)\n④ Sinomenium Stem (Bangi)\n⑤ Fennel (Hoehyang)",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 호흡흥분 작용을 하는 alkaloid를 함유하며, 금연보조제로 사용하는 초롱꽃과(Campanulaceae) 생약은?\n\n① Cannabis Herba\n② Ephedrae Herba\n③ Hyperici Herba\n④ Lobeliae Herba \n⑤ Swertiae Herba",
        "question_text": "Question: Which herb from the Campanulaceae family contains alkaloids that stimulate respiration and is used as a smoking cessation aid?\n\n① Cannabis Herba\n② Ephedrae Herba\n③ Hyperici Herba\n④ Lobeliae Herba \n⑤ Swertiae Herba",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약 성분은?\n\n• 꼭두서니과(科) 생약에 함유됨\n• Indole alkaloid에 속함\n• 요도해면체의 말초혈관 확장작용을 나타냄\n\n① carthamin\n② colchicine\n③ ephedrine\n④ santonin\n⑤ yohimbine",
        "question_text": "Question: Which of the following describes the medicinal plant component?\n\n• Contained in medicinal plants of the Rubiaceae family\n• Belongs to indole alkaloids\n• Shows peripheral vasodilation effect on the corpus cavernosum of the urethra\n\n① carthamin\n② colchicine\n③ ephedrine\n④ santonin\n⑤ yohimbine",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약은?\n\n• 목련과(科)에 속함\n• 꽃봉오리를 약용부위로 함\n• 축농증, 코막힘, 두통 치료에 사용함\n\n① 괴화\n② 신이\n③ 정향\n④ 홍화\n⑤ 후박",
        "question_text": "Question: Which medicinal herb is described below?\n\n• Belongs to the Magnoliaceae family\n• The flower buds are used as the medicinal part\n• Used to treat sinusitis, nasal congestion, and headaches\n\n① Flos Sophorae\n② Fructus Rosae Laevigatae\n③ Flos Caryophylli\n④ Flos Carthami\n⑤ Cortex Magnoliae Officinalis",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 청열조습(淸熱燥濕), 사화해독(瀉火解毒), 퇴열제증(退熱除蒸)의 효능이 있고, 고(苦), 한(寒)의 약성(藥性)을 나타내며, 신(腎), 방광(膀胱), 대장(大腸)으로 귀경하는 청열조습약(淸熱燥濕藥)은?\n\n① 독활(獨活)\n② 마황(麻黃)\n③ 반하(半夏)\n④ 오약(烏藥)\n⑤ 황백(黃柏)",
        "question_text": "Question: Which of the following herbs has the effects of clearing heat and drying dampness (淸熱燥濕), purging fire and detoxifying (瀉火解毒), and reducing fever and eliminating steaming bone disorder (退熱除蒸)? It has bitter (苦) and cold (寒) properties, enters the Kidney (腎), Bladder (膀胱), and Large Intestine (大腸) meridians, and is classified as a heat-clearing and dampness-drying herb (淸熱燥濕藥).\n\n① Angelica pubescens (獨活, Du Huo)\n② Ephedra sinica (麻黃, Ma Huang)\n③ Pinellia ternata (半夏, Ban Xia)\n④ Lindera aggregata (烏藥, Wu Yao)\n⑤ Phellodendron amurense (黃柏, Huang Bai)",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 보혈자음(補血滋陰), 익정전수(益精塡髓)의 효능이 있으며, 감(甘), 미온(微溫)의 약성(藥性)을 가지는 보혈약(補血藥)은?\n\n① 빈랑자(檳榔子)\n② 석창포(石菖蒲)\n③ 숙지황(熟地黃)\n④ 오미자(五味子)\n⑤ 오수유(吳茱萸)",
        "question_text": "Question: Which blood-tonifying herb (補血藥) has the effects of nourishing blood and yin (補血滋陰), and benefiting essence and filling marrow (益精塡髓), with a sweet (甘) and slightly warm (微溫) medicinal property?\n\n① Areca Seed (檳榔子)\n② Acorus gramineus Rhizome (石菖蒲)\n③ Prepared Rehmannia Root (熟地黃)\n④ Schisandra Fruit (五味子)\n⑤ Evodia Fruit (吳茱萸)",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 백작약, 숙지황, 황기, 당귀, 천궁, 계지, 감초로 구성되어 있고, 조중익기(調中益氣), 양혈보허(養血補虛)의 효능이 있어, 허로(虛勞)하여 힘이 없고 팔다리가 권태로우며, 한열이 왕래하는 증상에 사용하는 한약제제는?\n\n① 사물탕(四物湯)\n② 소풍산(消風散)\n③ 쌍화탕(雙和湯)\n④ 안중산(安中散)\n⑤ 오령산(五苓散)",
        "question_text": "Question: Which herbal medicine preparation, composed of Paeonia lactiflora, Rehmannia glutinosa, Astragalus membranaceus, Angelica sinensis, Ligusticum chuanxiong, Cinnamomum cassia, and Glycyrrhiza uralensis, has the effects of regulating the middle and boosting qi (調中益氣) and nourishing blood and tonifying deficiency (養血補虛), and is used for symptoms of deficiency fatigue (虛勞) with weakness, limb fatigue, and alternating chills and fever?\n\n① Samul-tang (四物湯)\n② Sopung-san (消風散)\n③ Ssanghwa-tang (雙和湯)\n④ Anjung-san (安中散)\n⑤ Oryeong-san (五苓散)",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 자음청열(滋陰淸熱), 양혈안신(養血安神)의 효능이 있어 심계항진, 불면증, 건망증 치료에 사용하는 한약제제는?\n\n① 당귀작약산(當歸芍藥散)\n② 배농산급탕(排膿散及湯)\n③ 용담사간탕(龍膽瀉肝湯)\n④ 천왕보심단(天王補心丹)\n⑤ 황련해독탕(黃連解毒湯)",
        "question_text": "Question: Which herbal medicine preparation has the effects of nourishing yin and clearing heat (滋陰淸熱), nourishing blood and calming the spirit (養血安神), and is used to treat palpitations, insomnia, and forgetfulness?\n\n① Dangguijakyak-san (當歸芍藥散)\n② Baenong-san-geup-tang (排膿散及湯)\n③ Yongdamsagan-tang (龍膽瀉肝湯)\n④ Cheonwangbosim-dan (天王補心丹)\n⑤ Hwangryunhaedok-tang (黃連解毒湯)",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n40대의 남자가 위염, 소화불량의 증상이 있어, 조습화위(燥濕和胃), 행기제만(行氣除滿)의 효능이 있는, 다음과 같이 구성된 한약제제를 추천하였다.\n구성생약: 창출, 진피, 향부자, 지실, 곽향, 후박, 사인, 목향, 감초\n\nQuestion: 위의 사례에 해당하는 한약제제는?\n\n① 오적산(五積散)\n② 은교산(銀翹散)\n③ 삼황사심탕(三黃瀉心湯)\n④ 십전대보탕(十全大補湯)\n⑤ 향사평위산(香砂平胃散)",
        "question_text": "A man in his 40s has symptoms of gastritis and indigestion. A herbal medicine preparation with the effects of drying dampness and harmonizing the stomach (燥濕和胃), and promoting qi circulation and relieving fullness (行氣除滿) was recommended. It is composed of the following:\n\nConstituent herbs: Atractylodis Rhizoma, Citri Unshius Pericarpium, Cyperi Rhizoma, Ponciri Fructus Immaturus, Agastachis Herba, Magnoliae Cortex, Amomi Fructus, Aucklandiae Radix, Glycyrrhizae Radix et Rhizoma\n\nQuestion: Which of the following herbal medicine preparations corresponds to the above case?\n\n① Ojeok-san (五積散)\n② Eungyo-san (銀翹散)\n③ Samhwang-sasim-tang (三黃瀉心湯)\n④ Sipjeondaebo-tang (十全大補湯)\n⑤ Hyangsapyeongwi-san (香砂平胃散)",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n40대의 남자가 위염, 소화불량의 증상이 있어, 조습화위(燥濕和胃), 행기제만(行氣除滿)의 효능이 있는, 다음과 같이 구성된 한약제제를 추천하였다.\n구성생약: 창출, 진피, 향부자, 지실, 곽향, 후박, 사인, 목향, 감초\n\nQuestion: 구성생약 중에서, 부신피질호르몬 유사작용을 하는 triterpene glycoside를 함유하며, 소화성궤양 치료에 사용하는 콩과(Leguminosae) 생약은?\n\n① 감초\n② 곽향\n③ 목향\n④ 진피\n⑤ 창출",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA man in his 40s has symptoms of gastritis and indigestion. A herbal medicine preparation with the effects of drying dampness and harmonizing the stomach (燥濕和胃), and promoting qi circulation and relieving fullness (行氣除滿) was recommended, composed of the following:\nConstituent herbs: Atractylodis Rhizoma, Citri Unshius Pericarpium, Cyperi Rhizoma, Ponciri Fructus Immaturus, Agastachis Herba, Magnoliae Cortex, Amomi Fructus, Aucklandiae Radix, Glycyrrhizae Radix et Rhizoma\n\nQuestion: Among the constituent herbs, which Leguminosae herb contains triterpene glycosides that have corticosteroid-like effects and is used in the treatment of peptic ulcers?\n\n① Glycyrrhizae Radix et Rhizoma\n② Agastachis Herba\n③ Aucklandiae Radix\n④ Citri Unshius Pericarpium\n⑤ Atractylodis Rhizoma",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 55세 남자가 1개월 전 허혈성뇌졸중을 진단받고 치료 후 회복되었다. 환자의 활력징후가 다음과 같을 때 혈압조절을 위하여 적절한 약물은?\n\n[활력징후] 체온 36.4℃, 혈압 149/98 mmHg, 심박수 71회/분, 호흡수 18회/분\n\n① 아테놀롤(atenolol)\n② 페린도프릴(perindopril)\n③ 인다파미드(indapamide)\n④ 칸데사르탄(candesartan)+펠로디핀(felodipine)\n⑤ 라미프릴(ramipril)+히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: A 55-year-old man was diagnosed with ischemic stroke 1 month ago and has recovered after treatment. Given the patient's vital signs below, which medication is appropriate for blood pressure control?\n\n[Vital signs] Temperature 36.4℃, Blood pressure 149/98 mmHg, Heart rate 71 beats/min, Respiratory rate 18 breaths/min\n\n① Atenolol\n② Perindopril\n③ Indapamide\n④ Candesartan + Felodipine\n⑤ Ramipril + Hydrochlorothiazide",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 고혈압이 있는 다음 사람들 중 심뇌혈관질환의 위험인자를 가진 경우는?\n\n① 흡연력이 없는 49세 남자 \n② 복부둘레가 75 cm인 50세 여자\n③ 공복혈당이 85 mg/dL인 52세 여자\n④ 체질량지수가 21 kg/m2인 41세 남자\n⑤ 아버지가 59세에 심근경색으로 사망한 33세 남자",
        "question_text": "Question: Among the following people with hypertension, who has a risk factor for cardiovascular and cerebrovascular diseases?\n\n① A 49-year-old man with no smoking history\n② A 50-year-old woman with a waist circumference of 75 cm\n③ A 52-year-old woman with a fasting blood glucose of 85 mg/dL\n④ A 41-year-old man with a body mass index of 21 kg/m²\n⑤ A 33-year-old man whose father died of myocardial infarction at age 59",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 만성심부전이 있는 62세 여자가 다음 약물들을 안정적으로 사용 중이다. 환자의 심부전으로 인한 사망위험을  감소시키기 위해 추가해야 하는 약물은?\n\n[병력] 고혈압, 만성심부전\n[활력징후] 혈압 139/86 mmHg, 심박수 78회/분, 호흡수 19회/분\n[임상검사] Na 136 mEq/L, K 4.3 mEq/L, SCr 1.0 mg/dL, BUN 18 mg/dL, 좌심실박출률(LVEF) 33%\n[심전도검사] 정상동율동(normal sinus rhythm)\n[복용약물] 라미프릴(ramipril) 10 mg 1일 1회, 푸로세미드(furosemide) 40 mg 1일 1회\n\n① 딜티아젬(diltiazem)\n② 발사르탄(valsartan)\n③ 비소프롤롤(bisoprolol) \n④ 이바브라딘(ivabradine)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: A 62-year-old woman with chronic heart failure is stably using the following medications. Which drug should be added to reduce the risk of death from the patient's heart failure?\n\n[Medical history] Hypertension, chronic heart failure\n[Vital signs] Blood pressure 139/86 mmHg, heart rate 78 beats/min, respiratory rate 19 breaths/min\n[Clinical tests] Na 136 mEq/L, K 4.3 mEq/L, SCr 1.0 mg/dL, BUN 18 mg/dL, Left ventricular ejection fraction (LVEF) 33%\n[ECG] Normal sinus rhythm\n[Current medications] Ramipril 10 mg once daily, Furosemide 40 mg once daily\n\n① Diltiazem\n② Valsartan\n③ Bisoprolol\n④ Ivabradine\n⑤ Hydrochlorothiazide",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 만성심부전이 있는 57세 남자가 최근 2개월 동안 다른 심부전 약물들과 함께 에날라프릴(enalapril)을 안정적인 용량으로 복용 중이다. 환자의 심혈관질환으로 인한 사망과 심부전으로 인한 입원위험을 추가적으로 줄이기 위하여 에날라프릴을 다른 약으로 대체하려고 한다. 적절한 약물은?\n\n[임상검사] 좌심실박출률(LVEF) 32%, NYHA Class II\n\n① 디곡신(digoxin)\n② 푸로세미드(furosemide)\n③ 스피로노락톤(spironolactone)\n④ 사쿠비트릴/발사르탄(sacubitril/valsartan)\n⑤ 히드랄라진/이소소르비드질산염(hydralazine/isosorbide dinitrate)",
        "question_text": "Question: A 57-year-old man with chronic heart failure has been taking enalapril at a stable dose along with other heart failure medications for the past 2 months. To further reduce the risk of cardiovascular death and hospitalization due to heart failure, it is proposed to replace enalapril with another drug. What is the appropriate medication?\n\n[Clinical test] Left ventricular ejection fraction (LVEF) 32%, NYHA Class II\n\n① Digoxin\n② Furosemide\n③ Spironolactone\n④ Sacubitril/valsartan\n⑤ Hydralazine/isosorbide dinitrate",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 20갑년(pack-year)의 흡연력이 있는 37세 여자가 변이협심증을 진단받았다. 적절한 약물은?\n\n① 암로디핀(amlodipine)\n② 에날라프릴(enalapril)\n③ 비소프롤롤(bisoprolol)\n④ 클로르탈리돈(chlorthalidone)\n⑤ 스피로노락톤(spironolactone)",
        "question_text": "Question: A 37-year-old woman with a 20 pack-year smoking history has been diagnosed with variant angina. What is the appropriate medication?\n\n① Amlodipine\n② Enalapril\n③ Bisoprolol\n④ Chlorthalidone\n⑤ Spironolactone",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 비ST분절상승 심근경색을 진단받은 58세 남자가 스텐트 삽입술을 받고 다음과 같이 약물을 복용 중이다. 추가할 약물은?\n\n[병력] 고혈압, 이상지질혈증\n[활력징후] 혈압 138/88 mmHg, 심박수 59회/분\n[복용약물]\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n아토르바스타틴(atorvastatin) 80 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 2회\n아스피린(aspirin) 100 mg 1일 1회\n프라수그렐(prasugrel) 10 mg 1일 1회\n\n① 라미프릴(ramipril)\n② 라시디핀(lacidipine)\n③ 베라파밀(verapamil)\n④ 인다파미드(indapamide)\n⑤ 니트로프루시드(nitroprusside)",
        "question_text": "Question: A 58-year-old man diagnosed with non-ST-segment elevation myocardial infarction has undergone stent insertion and is currently taking the following medications. Which drug should be added?\n\n[Medical history] Hypertension, dyslipidemia\n[Vital signs] Blood pressure 138/88 mmHg, heart rate 59 beats/min\n[Current medications]\nHydrochlorothiazide 25 mg once daily\nAtorvastatin 80 mg once daily\nMetoprolol 100 mg twice daily\nAspirin 100 mg once daily\nPrasugrel 10 mg once daily\n\n① Ramipril\n② Lacidipine\n③ Verapamil\n④ Indapamide\n⑤ Nitroprusside",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 77세 남자가 ST분절상승 심근경색을 진단받고, 부하용량의 항혈소판제 투여 후 스텐트 삽입술을 받았다. 스텐트 삽입 후 최소 12개월간 지속적으로 투여해야 할 항혈전요법으로 적절한 것은?\n\n① 아스피린/디피리다몰(aspirin/dipyridamole) 25/200mg 1일 2회\n② 아스피린 100mg 1일 1회+아픽사반(apixaban) 5mg 1일 1회\n③ 아스피린 100mg 1일 1회+티카그렐러(ticagrelor) 90 mg 1일 2회\n④ 아스피린 100mg 1일 1회+실로스타졸(cilostazol) 200mg 1일 1회\n⑤ 아스피린 100mg 1일 1회+클로피도그렐(clopidogrel) 300mg 1일 1회",
        "question_text": "Question: A 77-year-old man was diagnosed with ST-segment elevation myocardial infarction and underwent stent insertion after receiving a loading dose of antiplatelet medication. Which of the following is the appropriate antithrombotic therapy to be administered continuously for at least 12 months after stent insertion?\n\n① Aspirin/dipyridamole 25/200mg twice daily\n② Aspirin 100mg once daily + apixaban 5mg once daily\n③ Aspirin 100mg once daily + ticagrelor 90mg twice daily\n④ Aspirin 100mg once daily + cilostazol 200mg once daily\n⑤ Aspirin 100mg once daily + clopidogrel 300mg once daily",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 안정협심증이 있는 52세 남자에게 최근 흉통이 자주 발생하여, 니트로글리세린(nitroglycerin) 설하정의 사용 빈도가 증가하고 있다. 임상검사 결과와 복용약물이 다음과 같을 때, 흉통 조절을 위하여 추가할 약은?\n\n[병력] 이상지질혈증, 발기부전, 안정협심증\n[활력징후] 혈압 132/84 mmHg, 심박수 57회/분\n[임상검사] 특이소견 없음\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n카르베딜롤(carvedilol) 25 mg 1일 1회\n로사르탄(losartan) 50 mg 1일 1회\n로수바스타틴(rosuvastatin) 20 mg 1일 1회\n실데나필(sildenafil) 50 mg 1일 1회, 필요시\n니트로글리세린(nitroglycerin) 0.6 mg 설하정, 필요시\n\n① 펠로디핀(felodipine) 정\n② 리시노프릴(lisinopril) 정\n③ 메토프롤롤(metoprolol) 정 \n④ 베라파밀(verapamil) 서방정\n⑤ 이소소르비드질산염(isosorbide dinitrate) 서방정",
        "question_text": "Question: A 52-year-old man with stable angina has been experiencing frequent chest pain recently, leading to increased use of sublingual nitroglycerin tablets. Given the following clinical test results and current medications, which drug should be added to control chest pain?\n\n[Medical history] Dyslipidemia, erectile dysfunction, stable angina\n[Vital signs] Blood pressure 132/84 mmHg, heart rate 57 beats/min\n[Clinical tests] No significant findings\n[Current medications]\nAspirin 100 mg once daily\nCarvedilol 25 mg once daily\nLosartan 50 mg once daily\nRosuvastatin 20 mg once daily\nSildenafil 50 mg once daily, as needed\nNitroglycerin 0.6 mg sublingual tablet, as needed\n\n① Felodipine tablet\n② Lisinopril tablet\n③ Metoprolol tablet\n④ Verapamil extended-release tablet\n⑤ Isosorbide dinitrate extended-release tablet",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 63세 남자가 허혈성뇌졸중으로 정맥내 혈전용해술을 받았다. 뇌졸중 2차 예방을 위해 아스피린을 투여하려고 한다. 정맥내 혈전용해술을 시행한 때를 기준으로 언제 투여해야 하는가?\n\n① 3시간 미만       \n② 3시간 이상 6시간 미만 \n③ 6시간 이상 12시간 미만\n④ 12시간 이상 24시간 미만\n⑤ 24시간 이상 48시간 미만",
        "question_text": "Question: A 63-year-old man received intravenous thrombolysis for ischemic stroke. Aspirin is to be administered for secondary stroke prevention. Based on the time of intravenous thrombolysis, when should it be administered?\n\n① Less than 3 hours\n② 3 hours or more but less than 6 hours\n③ 6 hours or more but less than 12 hours\n④ 12 hours or more but less than 24 hours\n⑤ 24 hours or more but less than 48 hours",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 59세 남자가 밤 9시에 텔레비전을 시청하던 중 오른쪽 팔다리에 힘도 없고 감각이 떨어지면서 주저앉았다. 병원에는 밤 10시 30분경에 도착하여 밤 11시에 급성허혈성뇌졸중을 진단받았다. 적절한 약물은?\n\n[병력] 고혈압, 이상지질혈증\n[복용약물] 암로디핀(amlodipine) 10 mg 1일 1회, 로수바스타틴(rosuvastatin) 20 mg 1일 1회\n[임상검사(응급실 도착 시)] 혈압 170/100 mmHg, SCr 0.8 mg/dL, 혈당 90 mg/dL, TC 205 mg/dL, LDL-C 117 mg/dL, 혈소판 300,000/mm3\n\n① 아스피린(aspirin)\n② 아픽사반(apixaban)\n③ 압식시맙(abciximab)\n④ 알테플라제(alteplase)\n⑤ 에녹사파린(enoxaparin)",
        "question_text": "Question: A 59-year-old man was watching television at 9 PM when he suddenly lost strength and sensation in his right arm and leg, causing him to collapse. He arrived at the hospital around 10:30 PM and was diagnosed with acute ischemic stroke at 11 PM. What is the appropriate medication?\n\n[Medical history] Hypertension, dyslipidemia\n[Current medications] Amlodipine 10 mg once daily, Rosuvastatin 20 mg once daily\n[Clinical tests (upon arrival at ER)] Blood pressure 170/100 mmHg, SCr 0.8 mg/dL, Blood glucose 90 mg/dL, TC 205 mg/dL, LDL-C 117 mg/dL, Platelets 300,000/mm3\n\n① Aspirin\n② Apixaban\n③ Abciximab\n④ Alteplase\n⑤ Enoxaparin",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 폐색전증을 진단받은 58세 남자가 헤파린(heparin) 치료를 시작한 후 지속적으로 혈소판이 감소하였다. 검사결과 헤파린 유도혈소판감소증으로 확인되어 헤파린을 중단한 후 다른 약물로 대체하고자 한다. 적절한 약물은?\n\n① 와파린(warfarin)\n② 에독사반(edoxaban)\n③ 프라수그렐(prasugrel)\n④ 티클로피딘(ticlopidine)\n⑤ 아가트로반(argatroban)",
        "question_text": "Question: A 58-year-old man diagnosed with pulmonary embolism experienced continuous decrease in platelet count after starting heparin treatment. After test results confirmed heparin-induced thrombocytopenia, heparin was discontinued and needs to be replaced with another drug. Which of the following is the appropriate drug?\n\n① Warfarin\n② Edoxaban\n③ Prasugrel\n④ Ticlopidine\n⑤ Argatroban",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n가슴 두근거림과 호흡 곤란이 있어 일상생활에 지장이 있는 68세 남자가 비판막성심방세동을 처음 진단받았다.\n\n[병력] \n이상지질혈증 일과성허혈발작\n\n[활력징후]\n혈압 130/82 mmHg, 심박수 178회/분, 호흡수 24회/분\n\n[임상검사]\n좌심실박출률(LVEF): 52%\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n프라바스타틴(pravastatin) 40 mg 1일 1회\n\nQuestion: 환자에게 심박수 조절을 위해 추가할 약으로 적절한 것은?\n\n① 딜티아젬(diltiazem) 주사제\n② 아데노신(adenosine) 주사제\n③ 플레카이니드(flecainide) 경구제\n④ 드로네다론(dronedarone) 경구제\n⑤ 니트로글리세린(nitroglycerin) 주사제",
        "question_text": "A 68-year-old man, experiencing palpitations and shortness of breath that interfere with daily activities, has been newly diagnosed with non-valvular atrial fibrillation.\n\n[Medical History]\nDyslipidemia, Transient Ischemic Attack\n\n[Vital Signs]\nBlood pressure 130/82 mmHg, Heart rate 178 beats/min, Respiratory rate 24 breaths/min\n\n[Clinical Test]\nLeft Ventricular Ejection Fraction (LVEF): 52%\n\n[Current Medications]\nAspirin 100 mg once daily\nPravastatin 40 mg once daily\n\nQuestion: Which of the following is the most appropriate medication to add for heart rate control in this patient?\n\n① Diltiazem injection\n② Adenosine injection\n③ Flecainide oral\n④ Dronedarone oral\n⑤ Nitroglycerin injection",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n가슴 두근거림과 호흡 곤란이 있어 일상생활에 지장이 있는 68세 남자가 비판막성심방세동을 처음 진단받았다.\n\n[병력] \n이상지질혈증 일과성허혈발작\n\n[활력징후]\n혈압 130/82 mmHg, 심박수 178회/분, 호흡수 24회/분\n\n[임상검사]\n좌심실박출률(LVEF): 52%\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n프라바스타틴(pravastatin) 40 mg 1일 1회\n\nQuestion: 환자에게 뇌졸중 발생을 예방하기 위한 적절한 조치는?\n\n① 현재 약물요법 유지\n② 프라수그렐(prasugrel) 추가\n③ 디피리다몰(dipyridamole) 추가\n④ 아스피린을 에녹사파린(enoxaparin)으로 변경\n⑤ 아스피린을 다비가트란에텍실레이트(dabigatran etexilate)로 변경",
        "question_text": "A 68-year-old man, experiencing palpitations and shortness of breath that interfere with his daily life, has been newly diagnosed with non-valvular atrial fibrillation.\n\n[Medical History]\nDyslipidemia, Transient Ischemic Attack\n\n[Vital Signs]\nBlood pressure 130/82 mmHg, Heart rate 178 beats/min, Respiratory rate 24 breaths/min\n\n[Clinical Test]\nLeft Ventricular Ejection Fraction (LVEF): 52%\n\n[Current Medications]\nAspirin 100 mg once daily\nPravastatin 40 mg once daily\n\nQuestion: What is the appropriate measure to prevent stroke in this patient?\n\n① Maintain current drug therapy\n② Add prasugrel\n③ Add dipyridamole\n④ Change aspirin to enoxaparin\n⑤ Change aspirin to dabigatran etexilate",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 환자의 심혈관위험도를 고려할 때, LDL-C 치료목표 수치로 적절한 것은?\n\n① < 70 mg/dL\n② < 100 mg/dL\n③ < 130 mg/dL\n④ < 160 mg/dL\n⑤ < 190 mg/dL",
        "question_text": "Question: Considering the patient's cardiovascular risk, which of the following is an appropriate LDL-C treatment target?\n\n① < 70 mg/dL\n② < 100 mg/dL\n③ < 130 mg/dL\n④ < 160 mg/dL\n⑤ < 190 mg/dL",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 환자에게 적절한 이상지질혈증 약물요법은?\n\n① 피타바스타틴(pitavastatin) 4 mg 1일 1회\n② 플루바스타틴(fluvastatin) 40 mg 1일 1회\n③ 프라바스타틴(pravastatin) 80 mg 1일 1회\n④ 로수바스타틴(rosuvastatin) 20 mg 1일 1회\n⑤ 아토르바스타틴(atorvastatin) 20 mg 1일 1회",
        "question_text": "Question: What is the appropriate drug therapy for dyslipidemia in this patient?\n\n① Pitavastatin 4 mg once daily\n② Fluvastatin 40 mg once daily\n③ Pravastatin 80 mg once daily\n④ Rosuvastatin 20 mg once daily\n⑤ Atorvastatin 20 mg once daily",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 천식을 진단받은 30세 남자가 다음 약물을 사용하고 있으나 증상이 조절되지 않고 있다. 적절한 약물요법은?\n\n[사용약물]\n저용량 부데소니드(budesonide) 흡입제 1일 1회\n살부타몰(salbutamol) 흡입제, 필요시\n\n① 티오트로퓸(tiotropium) 흡입제를 추가하여 매일 사용\n② 살부타몰 흡입제를 매일 사용으로 변경\n③ 살부타몰 흡입제 중단한 후 툴로부테롤(tulobuterol) 패치를 추가하여 매일 사용\n④ 저용량 부데소니드 흡입제를 중단한 후 포르모테롤(formoterol)/아클리디늄(aclidinium) 흡입제를 추가하여 필요시 사용\n⑤ 사용약물을 모두 중단한 후 저용량 부데소니드/포르모테롤 흡입제로 변경하여 매일 사용하며 필요시 추가",
        "question_text": "Question: A 30-year-old man diagnosed with asthma is using the following medications but his symptoms are not controlled. What is the appropriate drug therapy?\n\n[Current medications]\nLow-dose budesonide inhaler once daily\nSalbutamol inhaler as needed\n\n① Add tiotropium inhaler for daily use\n② Change salbutamol inhaler to daily use\n③ Discontinue salbutamol inhaler and add tulobuterol patch for daily use\n④ Discontinue low-dose budesonide inhaler and add formoterol/aclidinium inhaler for use as needed\n⑤ Discontinue all current medications and switch to low-dose budesonide/formoterol inhaler for daily use with additional doses as needed",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 다음 약물을 사용 중인 53세 여자의 천식 증상이 조절되지 않을 때 적절한 약물요법은?\n\n[사용약물]\n저용량 플루티카손/살메테롤(fluticasone/salmeterol) 흡입제 1일 2회\n살부타몰(salbutamol) 흡입제, 필요시\n\n① 밤부테롤(bambuterol) 정제 1일 1회 추가\n② 티오트로퓸(tiotropium) 흡입제 1일 1회 추가\n③ 오말리주맙(omalizumab) 주사제 4주마다 1회 추가\n④ 저용량 플루티카손/살메테롤 흡입제를 중간용량 1일 2회로 변경\n⑤ 저용량 플루티카손/살메테롤 흡입제를 시클레소니드(ciclesonide) 흡입제 1일 1회로 변경",
        "question_text": "Question: What is the appropriate drug therapy when asthma symptoms are not controlled in a 53-year-old woman using the following medications?\n\n[Current medications]\nLow-dose fluticasone/salmeterol inhaler twice daily\nSalbutamol inhaler as needed\n\n① Add bambuterol tablet once daily\n② Add tiotropium inhaler once daily\n③ Add omalizumab injection once every 4 weeks\n④ Change low-dose fluticasone/salmeterol inhaler to medium-dose twice daily\n⑤ Change low-dose fluticasone/salmeterol inhaler to ciclesonide inhaler once daily",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 만성폐쇄폐질환이 있는 다음 60세 남자의 초기 치료로 적절한 약물요법은?\n\n[사회력] 흡연 20갑년(pack-year), 5년 전부터 금연\n[병력] 지난 1년간 입원병력 없음\n[임상검사]\n1초간노력성호기량(FEV1) 81%\n만성폐쇄폐질환 평가검사(COPD Assessment Test) 점수: 15점\n\n① 살부타몰(salbutamol) 흡입제 필요시\n② 부데소니드(budesonide) 흡입제 1일 2회\n③ 로플루밀라스트(roflumilast) 정제 1일 1회\n④ 부데소니드 흡입제 1일 2회+살부타몰 흡입제 필요시\n⑤ 티오트로퓸(tiotropium) 흡입제 1일 1회+살부타몰 흡입제 필요시",
        "question_text": "Question: What is the appropriate initial drug therapy for the following 60-year-old male with chronic obstructive pulmonary disease (COPD)?\n\n[Social history] Smoking history of 20 pack-years, quit smoking 5 years ago\n[Medical history] No hospitalization in the past year\n[Clinical tests]\nForced Expiratory Volume in 1 second (FEV1): 81%\nCOPD Assessment Test (CAT) score: 15 points\n\n① Salbutamol inhaler as needed\n② Budesonide inhaler twice daily\n③ Roflumilast tablet once daily\n④ Budesonide inhaler twice daily + Salbutamol inhaler as needed\n⑤ Tiotropium inhaler once daily + Salbutamol inhaler as needed",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 만성폐쇄폐질환으로 다음 약물을 사용 중인 65세 남자의 증상이 조절되지 않을 때 추가해야 할 약은?\n\n[사용약물]\n인다카테롤(indacaterol) 흡입제 1일 1회\n살부타몰(salbutamol) 흡입제, 필요시\n\n① 테오필린(theophylline) 캡슐제\n② 플루티카손(fluticasone) 흡입제  \n③ 이프라트로퓸(ipratropium) 흡입제 \n④ 유메클리디늄(umeclidinium) 흡입제 \n⑤ 메틸프레드니솔론(methylprednisolone) 주사제",
        "question_text": "Question: For a 65-year-old man with chronic obstructive pulmonary disease (COPD) using the following medications, which drug should be added when symptoms are not controlled?\n\n[Current medications]\nIndacaterol inhalation, once daily\nSalbutamol inhalation, as needed\n\n① Theophylline capsule\n② Fluticasone inhalation\n③ Ipratropium inhalation\n④ Umeclidinium inhalation\n⑤ Methylprednisolone injection",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 중등도의 지속성 천식이 있어 중간용량 스테로이드 흡입제를 사용 중인 26세 여자가 알레르기비염을 진단받았다. 환자의 알레르기비염 증상을 치료하기에 적절한 약은?\n\n① 밤부테롤(bambuterol) 정제\n② 툴로부테롤(tulobuterol) 패치제\n③ 아클리디늄(aclidinium) 흡입제\n④ 프란루카스트(pranlukast) 정제\n⑤ 슈도에페드린(pseudoephedrine) 정제",
        "question_text": "Question: A 26-year-old woman with moderate persistent asthma, currently using a medium-dose inhaled steroid, has been diagnosed with allergic rhinitis. Which of the following medications is appropriate for treating the patient's allergic rhinitis symptoms?\n\n① Bambuterol tablets\n② Tulobuterol patch\n③ Aclidinium inhaler\n④ Pranlukast tablets\n⑤ Pseudoephedrine tablets",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 55세 남자가 위식도역류병으로 파모티딘(famotidine)을 6주간 복용 중이다. 증상이 조절되지 않아 약물을 변경할 때 적절한 약물은?\n\n① 바클로펜(baclofen)\n② 로페라미드(loperamide)\n③ 라모세트론(ramosetron)\n④ 란소프라졸(lansoprazole)\n⑤ 프루칼로프라이드(prucalopride)",
        "question_text": "Question: A 55-year-old man has been taking famotidine for 6 weeks for gastroesophageal reflux disease. Which of the following is an appropriate medication to switch to when symptoms are not controlled?\n\n① Baclofen\n② Loperamide\n③ Ramosetron\n④ Lansoprazole\n⑤ Prucalopride",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 5년 전 간경변증을 진단받은 58세 남자에게 간성뇌병증(hepatic encephalopathy)이 발생하였다. 락툴로오스(lactulose)를 최대용량까지 증량하였으나 충분한 효과가 없었다. 추가할 약물은?\n\n① 락티톨(lactitol)\n② 리팍시민(rifaximin)\n③ 플루마제닐(flumazenil)\n④ 메트로니다졸(metronidazole) \n⑤ 스피로노락톤(spironolactone)",
        "question_text": "Question: A 58-year-old man diagnosed with liver cirrhosis 5 years ago has developed hepatic encephalopathy. Lactulose has been increased to its maximum dose, but it has not been sufficiently effective. Which drug should be added?\n\n① Lactitol\n② Rifaximin\n③ Flumazenil\n④ Metronidazole\n⑤ Spironolactone",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 의료기관 종사자인 53세 여자가 B형간염 환자에게 사용한 주사기에 찔렸다. 이후 실시한 검사 결과는 다음과 같다. B형간염 예방을 위한 적절한 방법은?\n\n[예방접종력] B형간염백신(3회 접종 완료)\n[임상검사]\n감염원의 HBsAg 양성\n감염 노출자의 Anti-HBs < 10 mIU/mL\n\n① 약물투여 없이 경과 관찰\n② B형간염백신 투여\n③ B형간염면역글로불린 투여\n④ B형간염면역글로불린+B형간염백신 투여\n⑤ B형간염면역글로불린+엔테카비르(entecavir) 투여",
        "question_text": "Question: A 53-year-old female healthcare worker was pricked by a needle used on a hepatitis B patient. The subsequent test results are as follows. What is the appropriate method for hepatitis B prevention?\n\n[Vaccination history] Hepatitis B vaccine (3-dose series completed)\n[Clinical tests]\nSource patient's HBsAg: Positive\nExposed person's Anti-HBs < 10 mIU/mL\n\n① Observation without medication\n② Administer hepatitis B vaccine\n③ Administer hepatitis B immunoglobulin\n④ Administer hepatitis B immunoglobulin + hepatitis B vaccine\n⑤ Administer hepatitis B immunoglobulin + entecavir",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 32세 남자가 C형간염으로 치료를 시작할 예정이다. 과거에 C형간염의 치료경험이 없고 유전자형은 1b형으로 확인되었다. 적절한 초치료 약물요법은?\n\n① 글레카프레비르/피브렌타스비르(glecaprevir/pibrentasvir) 8주\n② 리바비린(ribavirin)+베시포비르(besifovir) 8주\n③ 리바비린+페그인터페론(peginterferon) 12주\n④ 소포스부비르(sofosbuvir)+페그인터페론 12주\n⑤ 소포스부비르+리바비린 24주",
        "question_text": "Question: A 32-year-old man is about to start treatment for Hepatitis C. He has no prior treatment experience for Hepatitis C, and his genotype has been confirmed as 1b. What is the appropriate initial drug therapy?\n\n① Glecaprevir/pibrentasvir for 8 weeks\n② Ribavirin + besifovir for 8 weeks\n③ Ribavirin + peginterferon for 12 weeks\n④ Sofosbuvir + peginterferon for 12 weeks\n⑤ Sofosbuvir + ribavirin for 24 weeks",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 36세 남자에게 지난 4주 동안 복통, 혈액이 섞인 묽은 변이 1일 3~4회 지속되었다. 대장내시경을 시행한 결과 공장에서 직장까지 염증이 관찰되는 경증의 궤양성대장염을 진단받았다. 적절한 약은?\n\n① 메살라진(mesalazine) 좌제 \n② 부데소니드(budesonide) 관장제\n③ 메살라진 서방정\n④ 아자티오프린(azathioprine) 정제\n⑤ 프레드니솔론(prednisolone) 정제",
        "question_text": "Question: A 36-year-old man has experienced abdominal pain and loose stools mixed with blood 3-4 times a day for the past 4 weeks. After a colonoscopy, he was diagnosed with mild ulcerative colitis with inflammation observed from the jejunum to the rectum. What is the appropriate medication?\n\n① Mesalazine suppository\n② Budesonide enema\n③ Mesalazine extended-release tablet\n④ Azathioprine tablet\n⑤ Prednisolone tablet",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n73세 여자가 위식도역류병이 있어 약을 복용 중이다. 최근 위내시경 검사를 받았고 소화성궤양이 확인되었으며 Helicobacter pylori 검사 결과 양성이었다.\n[과거 복용약물]\n클래리트로마이신(clarithromycin) 500 mg 1일 2회 (4주 전 시작하여 2주간 복용 완료)\n[복용약물]\n에스오메프라졸(esomeprazole) 20 mg 1일 1회\n\nQuestion: 환자의 Helicobacter pylori 제균요법으로 에스오메프라졸 (20 mg 1일 2회)에 추가되어야 하는 약물요법은?\n\n① 아목시실린(amoxicillin)+메트로니다졸(metronidazole)\n② 레보플록사신(levofloxacin)+아목시실린\n③ 아지트로마이신(azithromycin)+리파부틴(rifabutin)\n④ 아목시실린+아지트로마이신+메트로니다졸\n⑤ 비스무트(bismuth)+독시사이클린(doxycycline)+메트로니다졸",
        "question_text": "A 73-year-old woman is taking medication for gastroesophageal reflux disease. She recently underwent an endoscopy, which confirmed peptic ulcer, and the Helicobacter pylori test was positive.\n[Past medication]\nClarithromycin 500 mg twice daily (started 4 weeks ago and completed 2 weeks of treatment)\n[Current medication]\nEsomeprazole 20 mg once daily\n\nQuestion: What drug therapy should be added to esomeprazole (20 mg twice daily) for Helicobacter pylori eradication in this patient?\n\n① Amoxicillin + Metronidazole\n② Levofloxacin + Amoxicillin\n③ Azithromycin + Rifabutin\n④ Amoxicillin + Azithromycin + Metronidazole\n⑤ Bismuth + Doxycycline + Metronidazole",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n73세 여자가 위식도역류병이 있어 약을 복용 중이다. 최근 위내시경 검사를 받았고 소화성궤양이 확인되었으며 Helicobacter pylori 검사 결과 양성이었다.\n[과거 복용약물]\n클래리트로마이신(clarithromycin) 500 mg 1일 2회 (4주 전 시작하여 2주간 복용 완료)\n[복용약물]\n에스오메프라졸(esomeprazole) 20 mg 1일 1회\n\nQuestion: 환자가 에스오메프라졸을 장기간 복용할 때 발생 가능성이 높아지는 이상반응은?\n\n① 녹내장 \n② 파킨슨병\n③ 폐섬유증\n④ 골밀도 감소\n⑤ 뇌하수체종양",
        "question_text": "A 73-year-old woman is taking medication for gastroesophageal reflux disease. She recently underwent an endoscopy, which confirmed peptic ulcer, and the Helicobacter pylori test was positive.\n[Previously taken medication]\nClarithromycin 500 mg twice daily (started 4 weeks ago and completed 2 weeks of treatment)\n[Current medication]\nEsomeprazole 20 mg once daily\n\nQuestion: Which adverse reaction is more likely to occur with long-term use of esomeprazole in this patient?\n\n① Glaucoma\n② Parkinson's disease\n③ Pulmonary fibrosis\n④ Decreased bone density\n⑤ Pituitary tumor",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 기력이 없는 75세 남자의 임상검사와 동맥혈가스분석 검사결과는 다음과 같다. 환자의 검사결과 이상을 유발한 원인 약물로 의심되는 것은?\n\n[병력] 2형당뇨병, 고혈압, 이상지질혈증\n[혈청검사] 락트산(lactic acid) 4.0 mmol/L (참고치 < 1.0 mmol/L) \n[동맥혈가스분석 검사] pH 7.23, PaCO2 25 mmHg (참고치 35~45 mmHg) HCO3- 12 mEq/L (참고치 22~26 mEq/L) \n[복용약물] 아스피린(aspirin) 100 mg 1일 1회, 로사르탄(losartan) 50 mg 1일 1회, 암로디핀(amlodipine) 10 mg 1일 1회, 메트포르민(metformin) 1,700 mg 1일 1회, 아토르바스타틴(atorvastatin) 20 mg 1일 1회\n\n① 아스피린\n② 로사르탄\n③ 암로디핀\n④ 메트포르민\n⑤ 아토르바스타틴",
        "question_text": "Question: A 75-year-old man with low energy has the following clinical and arterial blood gas analysis results. Which of the following medications is suspected to be the cause of the patient's abnormal test results?\n\n[Medical history] Type 2 diabetes, hypertension, dyslipidemia\n[Serum test] Lactic acid 4.0 mmol/L (reference range < 1.0 mmol/L)\n[Arterial blood gas analysis] pH 7.23, PaCO2 25 mmHg (reference range 35-45 mmHg), HCO3- 12 mEq/L (reference range 22-26 mEq/L)\n[Medications] Aspirin 100 mg once daily, Losartan 50 mg once daily, Amlodipine 10 mg once daily, Metformin 1,700 mg once daily, Atorvastatin 20 mg once daily\n\n① Aspirin\n② Losartan\n③ Amlodipine\n④ Metformin\n⑤ Atorvastatin",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 67세 남자에서 심장수술 직후 소변량 감소, 구강 점막 건조, 피부긴장도 감소가 발생하였다. 이 환자의 급성신손상 예방을 위한 약물로 적절한 것은?\n\n[임상검사]\n나트륨분획배설분율(FENa): < 1%\n요삼투압: > 500 mOsm/kg\n요침전물: 없음\n\n① 테오필린(theophylline)\n② 생리식염수(0.9% NaCl)\n③ 푸로세미드(furosemide)\n④ 저용량 도파민(dopamine)\n⑤ 아세틸시스테인(acetylcysteine)",
        "question_text": "Question: A 67-year-old man experienced decreased urine output, dry oral mucosa, and decreased skin turgor immediately after cardiac surgery. Which of the following drugs is appropriate for preventing acute kidney injury in this patient?\n\n[Clinical tests]\nFractional excretion of sodium (FENa): < 1%\nUrine osmolality: > 500 mOsm/kg\nUrine sediment: None\n\n① Theophylline\n② Normal saline (0.9% NaCl)\n③ Furosemide\n④ Low-dose dopamine\n⑤ Acetylcysteine",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 70세 남자가 만성콩팥병이 있으며 투석은 하지 않는다. 검사 결과가 다음과 같을 때, 만성콩팥병으로 인한 빈혈을 관리하기 위하여 황산제일철(ferrous sulfate) 투여와 함께 필요한 조치는?\n\n[임상검사]\nSCr 2.2 mg/dL, eGFR 29 mL/min/1.73 m2\nHct 29%, Hgb 9.5 g/dL\nferritin 540 ng/mL (참고치 > 500 ng/mL)\nTSat 31% (참고치 > 30%)\n\n① 현재 약물요법 유지\n② 칼시트리올(calcitriol) 투여\n③ 수산화알루미늄(aluminium hydroxide) 투여\n④ 글루콘산제이철나트륨(sodium ferric gluconate) 투여\n⑤ 메톡시폴리에틸렌글리콜-에포에틴 베타(methoxy polyethylene glycol-epoetin beta) 투여",
        "question_text": "Question: A 70-year-old man has chronic kidney disease but is not on dialysis. Given the following test results, what measure is necessary along with ferrous sulfate administration to manage anemia due to chronic kidney disease?\n\n[Clinical tests]\nSCr 2.2 mg/dL, eGFR 29 mL/min/1.73 m2\nHct 29%, Hgb 9.5 g/dL\nferritin 540 ng/mL (reference value > 500 ng/mL)\nTSat 31% (reference value > 30%)\n\n① Maintain current drug therapy\n② Administer calcitriol\n③ Administer aluminium hydroxide\n④ Administer sodium ferric gluconate\n⑤ Administer methoxy polyethylene glycol-epoetin beta",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 만성콩팥병이 있는 68세 여자의 검사 결과가 다음과 같을 때, 이차성부갑상샘항진증 치료에 적절한 약물은?\n\n[임상검사] SCr 1.8 mg/dL, eGFR 28 mL/min/1.73 m^2, Na 142 mEq/L, K 4.8 mEq/L, Ca 8.0 mg/dL, Alb 3.0 g/dL, P 4.8 mg/dL (참고치 2.5~4.5 mg/dL), iPTH 285 pg/mL (참고치 70~110 pg/mL)\n\n① 시나칼세트(cinacalcet)\n② NPH 인슐린(insulin NPH)\n③ 파리칼시톨(paricalcitol)\n④ 폴리카르보필(polycarbophil)\n⑤ 시트르산칼륨(potassium citrate)",
        "question_text": "Question: When the test results for a 68-year-old woman with chronic kidney disease are as follows, which drug is appropriate for treating secondary hyperparathyroidism?\n\n[Clinical tests] SCr 1.8 mg/dL, eGFR 28 mL/min/1.73 m^2, Na 142 mEq/L, K 4.8 mEq/L, Ca 8.0 mg/dL, Alb 3.0 g/dL, P 4.8 mg/dL (reference range 2.5-4.5 mg/dL), iPTH 285 pg/mL (reference range 70-110 pg/mL)\n\n① Cinacalcet\n② Insulin NPH\n③ Paricalcitol\n④ Polycarbophil\n⑤ Potassium citrate",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n이상지질혈증, 만성콩팥병과 우울증이 있는 62세 남자의 복용약물과 검사 결과는 다음과 같다.\n[임상검사]\nSCr 2.1 mg/dL, eGFR 32 mL/min/1.73 m^2, Na 142 mEq/L, K 5.5 mEq/L, Ca 10.2 mg/dL, Alb 3.0 g/dL, P 6.0 mg/dL (참고치 2.5~4.5 mg/dL)\n[복용약물]\n에날라프릴(enalapril) 10 mg 1일 1회\n푸로세미드(furosemide) 40 mg 1일 1회\n로수바스타틴(rosuvastatin) 10 mg 1일 1회\n탄산칼슘(calcium carbonate) 500 mg 1일 3회\n파록세틴(paroxetine) 10 mg 1일 1회\n모사프리드(mosapride) 5 mg, 필요시\n\nQuestion: 임상검사 결과에서 나타난 혈청 칼륨 농도 이상의 원인이 될 수 있는 약물은?\n\n① 파록세틴\n② 모사프리드\n③ 에날라프릴\n④ 푸로세미드\n⑤ 로수바스타틴",
        "question_text": "A 62-year-old male with dyslipidemia, chronic kidney disease, and depression has the following medication list and test results:\n\n[Clinical Tests]\nSCr 2.1 mg/dL, eGFR 32 mL/min/1.73 m^2, Na 142 mEq/L, K 5.5 mEq/L, Ca 10.2 mg/dL, Alb 3.0 g/dL, P 6.0 mg/dL (reference range 2.5~4.5 mg/dL)\n\n[Medications]\nEnalapril 10 mg once daily\nFurosemide 40 mg once daily\nRosuvastatin 10 mg once daily\nCalcium carbonate 500 mg three times daily\nParoxetine 10 mg once daily\nMosapride 5 mg, as needed\n\nQuestion: Which medication could be the cause of the abnormal serum potassium level shown in the clinical test results?\n\n① Paroxetine\n② Mosapride\n③ Enalapril\n④ Furosemide\n⑤ Rosuvastatin",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n이상지질혈증, 만성콩팥병과 우울증이 있는 62세 남자의 복용약물과 검사 결과는 다음과 같다.\n[임상검사]\nSCr 2.1 mg/dL, eGFR 32 mL/min/1.73 m^2, Na 142 mEq/L, K 5.5 mEq/L, Ca 10.2 mg/dL, Alb 3.0 g/dL, P 6.0 mg/dL (참고치 2.5~4.5 mg/dL)\n[복용약물]\n에날라프릴(enalapril) 10 mg 1일 1회\n푸로세미드(furosemide) 40 mg 1일 1회\n로수바스타틴(rosuvastatin) 10 mg 1일 1회\n탄산칼슘(calcium carbonate) 500 mg 1일 3회\n파록세틴(paroxetine) 10 mg 1일 1회\n모사프리드(mosapride) 5 mg, 필요시\n\nQuestion: 환자의 고인산혈증을 치료하기 위한 적절한 약물요법은?\n\n① 탄산칼슘 증량\n② 세벨라머(sevelamer) 추가\n③ 폴리스티렌설폰산칼슘(calcium polystyrene sulfonate) 추가\n④ 탄산칼슘을 세벨라머로 변경\n⑤ 탄산칼슘을 폴리스티렌설폰산칼슘으로 변경",
        "question_text": "A 62-year-old male with dyslipidemia, chronic kidney disease, and depression has the following medication list and test results:\n\n[Clinical Tests]\nSCr 2.1 mg/dL, eGFR 32 mL/min/1.73 m^2, Na 142 mEq/L, K 5.5 mEq/L, Ca 10.2 mg/dL, Alb 3.0 g/dL, P 6.0 mg/dL (reference range 2.5~4.5 mg/dL)\n\n[Medications]\nEnalapril 10 mg once daily\nFurosemide 40 mg once daily\nRosuvastatin 10 mg once daily\nCalcium carbonate 500 mg three times daily\nParoxetine 10 mg once daily\nMosapride 5 mg as needed\n\nQuestion: What is the appropriate drug therapy to treat the patient's hyperphosphatemia?\n\n① Increase the dose of calcium carbonate\n② Add sevelamer\n③ Add calcium polystyrene sulfonate\n④ Change calcium carbonate to sevelamer\n⑤ Change calcium carbonate to calcium polystyrene sulfonate",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 56세 여자가 4년 전 2형당뇨병을 진단받고 메트포르민(metformin)과 리나글립틴(linagliptin)을 복용하면서 혈당을 잘 조절해 왔다. 최근 검사 결과 당화혈색소 수치가 8.2%로 상승되어 인슐린(insulin)을 추가하려 한다. 적절한 것은?\n\n① 레귤러 인슐린(regular insulin)  \n② 인슐린 글라진(insulin glargine)\n③ 인슐린 아스파트(insulin aspart)\n④ 인슐린 글루리신(insulin glulisine)\n⑤ 인슐린 라이스프로(insulin lispro)",
        "question_text": "Question: A 56-year-old woman was diagnosed with type 2 diabetes 4 years ago and has been controlling her blood sugar well by taking metformin and linagliptin. Recent test results show that her HbA1c level has increased to 8.2%, so insulin is to be added. Which of the following is appropriate?\n\n① Regular insulin\n② Insulin glargine\n③ Insulin aspart\n④ Insulin glulisine\n⑤ Insulin lispro",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 66세 남자가 1년 전에 2형당뇨병을 진단받고 메트포르민(metformin)과 인슐린(insulin)으로 치료 중이며, 식이요법을 잘 실천하고 있다. 일주일 전에 안정협심증을 진단받고, 다음 약물을 추가로 복용하기 시작하였다. 오늘 시행한 검사에서 공복혈당이 63 mg/dL로 측정되었으나, 환자는 특별한 저혈당 증상을 느끼지 못했다고 한다. 증상을 느끼지 못한 원인이 될 수 있는 약물은?\n\n[추가 복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n아테놀롤(atenolol) 50 mg 1일 1회\n라미프릴(ramipril) 10 mg 1일 1회\n로수바스타틴(rosuvastatin) 20 mg 1일 1회\n니트로글리세린(nitroglycerin) 0.6 mg 설하정, 필요시\n\n① 아스피린\n② 아테놀롤\n③ 라미프릴\n④ 로수바스타틴\n⑤ 니트로글리세린",
        "question_text": "Question: A 66-year-old man was diagnosed with type 2 diabetes a year ago and is being treated with metformin and insulin, while following a diet regimen well. A week ago, he was diagnosed with stable angina and started taking the following additional medications. Today's test showed a fasting blood glucose level of 63 mg/dL, but the patient reported not feeling any particular hypoglycemic symptoms. Which medication could be the cause of not feeling the symptoms?\n\n[Additional medications]\nAspirin 100 mg once daily\nAtenolol 50 mg once daily\nRamipril 10 mg once daily\nRosuvastatin 20 mg once daily\nNitroglycerin 0.6 mg sublingual tablet, as needed\n\n① Aspirin\n② Atenolol\n③ Ramipril\n④ Rosuvastatin\n⑤ Nitroglycerin",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 1형당뇨병으로 약물치료 중인 57세 남자가 어젯밤부터 구토, 호흡곤란과 빈맥이 발생하였다. 환자는 지난주부터 심한 독감으로 인슐린(insulin)을 잘 투여하지 않았다고 하며, 현재 의식이 저하된 상태이다. 증상 개선을 위해 생리식염수(0.9% NaCl) 투여가 시작되었다. 적절한 추가 약물은?\n\n[활력징후] 혈압 87/65 mmHg, 심박수 112회/분, 호흡수 24회/분\n[혈청검사] Na 145 mEq/L, K 5.0 mEq/L, Cl 105 mEq/L, CO2 11 mEq/L, 혈당 374 mg/dL\n[동맥혈가스분석 검사] pH 7.18, PaCO2 24 mmHg (참고치 35~45 mmHg), PaO2 88 mmHg (참고치 80~100 mmHg), HCO3- 12 mEq/L (참고치 22~26 mEq/L)\n[소변검사] 케톤체 양성\n\n① 리라글루티드(liraglutide)\n② 레귤러 인슐린(regular insulin)\n③ 인슐린 디터머(insulin detemir)\n④ 탄산수소나트륨(sodium bicarbonate)\n⑤ 폴리스티렌설폰산칼슘(calcium polystyrene sulfonate)",
        "question_text": "Question: A 57-year-old man undergoing drug treatment for Type 1 diabetes has experienced vomiting, dyspnea, and tachycardia since last night. The patient reports not having administered insulin properly for the past week due to severe flu, and is currently in a state of decreased consciousness. Saline solution (0.9% NaCl) administration has been initiated to improve symptoms. What is the appropriate additional medication?\n\n[Vital Signs] Blood pressure 87/65 mmHg, Heart rate 112 beats/min, Respiratory rate 24 breaths/min\n[Serum Test] Na 145 mEq/L, K 5.0 mEq/L, Cl 105 mEq/L, CO2 11 mEq/L, Blood glucose 374 mg/dL\n[Arterial Blood Gas Analysis] pH 7.18, PaCO2 24 mmHg (reference range 35-45 mmHg), PaO2 88 mmHg (reference range 80-100 mmHg), HCO3- 12 mEq/L (reference range 22-26 mEq/L)\n[Urine Test] Ketone bodies positive\n\n① Liraglutide\n② Regular insulin\n③ Insulin detemir\n④ Sodium bicarbonate\n⑤ Calcium polystyrene sulfonate",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 이상지질혈증, 심부전(NYHA Class III)으로 약물치료를 받고 있는 57세 남자가 2형당뇨병을 새로 진단 받았다. 환자는 30년 전부터 하루 평균 1갑의 흡연을 하고 있다. 검사결과는 다음과 같다.\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n카르베딜롤(carvedilol) 25 mg 1일 2회\n스피로노락톤(spironolactone) 25 mg 1일 1회\n아토르바스타틴(atorvastatin) 80 mg 1일 1회\n\n[활력징후]\n혈압 119/76 mmHg, 심박수 70회/분, 호흡수 18회/분, 체질량지수 30 kg/m^2\n\n[임상검사]\n공복혈당 196 mg/dL, 당화혈색소 8.6%, SCr 1.0 mg/dL, eGFR 87 mL/min/1.73m^2, TC 224 mg/dL, LDL-C 136 mg/dL, HDL-C 42 mg/dL, TG 213 mg/dL\n\nQuestion: 환자의 혈당조절을 위해 필요한 약물요법은?\n\n① 아카르보스(acarbose)\n② 글리메피리드(glimepiride)\n③ 인슐린 라이스프로(insulin lispro)\n④ 메트포르민(metformin)+엠파글리플로진(empagliflozin)\n⑤ 레파글리니드(repaglinide)+피오글리타존(pioglitazone)",
        "question_text": "A 57-year-old male, currently receiving drug treatment for hypertension, dyslipidemia, and heart failure (NYHA Class III), has been newly diagnosed with type 2 diabetes. The patient has been smoking an average of 1 pack per day for 30 years. The test results are as follows:\n\n[Current Medications]\nAspirin 100 mg once daily\nLisinopril 10 mg once daily\nCarvedilol 25 mg twice daily\nSpironolactone 25 mg once daily\nAtorvastatin 80 mg once daily\n\n[Vital Signs]\nBlood pressure 119/76 mmHg, Heart rate 70 bpm, Respiratory rate 18 breaths/min, BMI 30 kg/m^2\n\n[Clinical Tests]\nFasting blood glucose 196 mg/dL, HbA1c 8.6%, SCr 1.0 mg/dL, eGFR 87 mL/min/1.73m^2, TC 224 mg/dL, LDL-C 136 mg/dL, HDL-C 42 mg/dL, TG 213 mg/dL\n\nQuestion: What drug therapy is needed to control the patient's blood glucose?\n\n① Acarbose\n② Glimepiride\n③ Insulin lispro\n④ Metformin + Empagliflozin\n⑤ Repaglinide + Pioglitazone",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압, 이상지질혈증, 심부전(NYHA Class III)으로 약물치료를 받고 있는 57세 남자가 2형당뇨병을 새로 진단 받았다. 환자는 30년 전부터 하루 평균 1갑의 흡연을 하고 있다. 검사결과는 다음과 같다.\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n카르베딜롤(carvedilol) 25 mg 1일 2회\n스피로노락톤(spironolactone) 25 mg 1일 1회\n아토르바스타틴(atorvastatin) 80 mg 1일 1회\n\n[활력징후]\n혈압 119/76 mmHg, 심박수 70회/분, 호흡수 18회/분, 체질량지수 30 kg/m^2\n\n[임상검사]\n공복혈당 196 mg/dL, 당화혈색소 8.6%, SCr 1.0 mg/dL, eGFR 87 mL/min/1.73m^2, TC 224 mg/dL, LDL-C 136 mg/dL, HDL-C 42 mg/dL, TG 213 mg/dL\n\nQuestion: 임상검사 결과를 고려할 때, 죽상경화심혈관질환을 예방하기 위해 추가가 필요한 약물은?\n\n① 와파린(warfarin)\n② 암로디핀(amlodipine)\n③ 에제티미브(ezetimibe)\n④ 푸로세미드(furosemide)\n⑤ 겜피브로질(gemfibrozil)",
        "question_text": "A 57-year-old male, currently receiving drug treatment for hypertension, dyslipidemia, and heart failure (NYHA Class III), has been newly diagnosed with type 2 diabetes. The patient has been smoking an average of 1 pack per day for 30 years. The examination results are as follows:\n\n[Current Medications]\nAspirin 100 mg once daily\nLisinopril 10 mg once daily\nCarvedilol 25 mg twice daily\nSpironolactone 25 mg once daily\nAtorvastatin 80 mg once daily\n\n[Vital Signs]\nBlood pressure 119/76 mmHg, Heart rate 70 bpm, Respiratory rate 18 breaths/min, BMI 30 kg/m^2\n\n[Clinical Tests]\nFasting blood glucose 196 mg/dL, HbA1c 8.6%, SCr 1.0 mg/dL, eGFR 87 mL/min/1.73m^2, TC 224 mg/dL, LDL-C 136 mg/dL, HDL-C 42 mg/dL, TG 213 mg/dL\n\nQuestion: Considering the clinical test results, which additional medication is needed to prevent atherosclerotic cardiovascular disease?\n\n① Warfarin\n② Amlodipine\n③ Ezetimibe\n④ Furosemide\n⑤ Gemfibrozil",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n57세 여자가 갑상샘저하증으로 레보티록신(levothyroxine)을 복용할 예정이다. 병력과 복용약물은 다음과 같다.\n\n[병력]\n고혈압, 협심증, 이상지질혈증, 빈혈\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n로사르탄(losartan) 50 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 2회\n황산제일철(ferrous sulfate) 256 mg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n\nQuestion: 레보티록신의 체내흡수를 저하시킬 수 있어 최소 2시간 이상의 간격을 두고 복용해야 하는 약물은?\n\n① 아스피린\n② 로사르탄\n③ 메토프롤롤\n④ 황산제일철\n⑤ 아토르바스타틴",
        "question_text": "A 57-year-old woman is about to take levothyroxine for hypothyroidism. Her medical history and current medications are as follows:\n\n[Medical History]\nHypertension, Angina pectoris, Dyslipidemia, Anemia\n\n[Current Medications]\nAspirin 100 mg once daily\nLosartan 50 mg once daily\nMetoprolol 100 mg twice daily\nFerrous sulfate 256 mg once daily\nAtorvastatin 40 mg once daily\n\nQuestion: Which medication can decrease the absorption of levothyroxine and should be taken at least 2 hours apart?\n\n① Aspirin\n② Losartan\n③ Metoprolol\n④ Ferrous sulfate\n⑤ Atorvastatin",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n57세 여자가 갑상샘저하증으로 레보티록신(levothyroxine)을 복용할 예정이다. 병력과 복용약물은 다음과 같다.\n\n[병력]\n고혈압, 협심증, 이상지질혈증, 빈혈\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n로사르탄(losartan) 50 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 2회\n황산제일철(ferrous sulfate) 256 mg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n\nQuestion: 레보티록신 치료 시작 후 약효평가를 위해 갑상샘기능검사를 하는 적절한 시점은?\n\n① 5일 이내\n② 1~2주\n③ 4~8주\n④ 3~5개월\n⑤ 6개월 이후",
        "question_text": "A 57-year-old woman is about to start taking levothyroxine for hypothyroidism. Her medical history and current medications are as follows:\n\n[Medical History]\nHypertension, Angina pectoris, Dyslipidemia, Anemia\n\n[Current Medications]\nAspirin 100 mg once daily\nLosartan 50 mg once daily\nMetoprolol 100 mg twice daily\nFerrous sulfate 256 mg once daily\nAtorvastatin 40 mg once daily\n\nQuestion: What is the appropriate time to perform a thyroid function test to evaluate the effectiveness of levothyroxine treatment after starting therapy?\n\n① Within 5 days\n② 1-2 weeks\n③ 4-8 weeks\n④ 3-5 months\n⑤ After 6 months",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 42세 여자가 화장실을 자주 가고 배뇨 시 통증이 있다. 검사 결과가 다음과 같을 때 적절한 경험적 항생제는?\n\n[활력징후] 혈압 128/76 mmHg, 심박수 70회/분, 호흡수 18회/분, 체온 36.5℃\n[소변검사]\n외형: 혼탁\n비중: 1.015\npH: 8\nketones: 음성\nglucose: 음성\nleukocyte esterase: 양성\nnitrite: 양성\n세균 > 10^5 cfu/mL\n\n① 나프실린(nafcillin)\n② 리팍시민(rifaximin)\n③ 리네졸리드(linezolid)\n④ 포스포마이신(fosfomycin)\n⑤ 이미페넴/실라스타틴(imipenem/cilastatin)",
        "question_text": "Question: A 42-year-old woman frequently visits the bathroom and experiences pain during urination. Given the following test results, what is the appropriate empirical antibiotic?\n\n[Vital signs] Blood pressure 128/76 mmHg, Heart rate 70 bpm, Respiratory rate 18 breaths/min, Body temperature 36.5℃\n[Urinalysis]\nAppearance: Cloudy\nSpecific gravity: 1.015\npH: 8\nKetones: Negative\nGlucose: Negative\nLeukocyte esterase: Positive\nNitrite: Positive\nBacteria > 10^5 cfu/mL\n\n① Nafcillin\n② Rifaximin\n③ Linezolid\n④ Fosfomycin\n⑤ Imipenem/Cilastatin",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 설파제 알레르기가 있고 과거 어깨 건파열이 있었던 68세 남자가 급성신우신염 치료를 시작할 예정이다. 적절한 경험적 항생제는?\n\n① 니스타틴(nystatin)\n② 반코마이신(vancomycin)\n③ 세프트리악손(ceftriaxone)\n④ 목시플록사신(moxifloxacin)\n⑤ 트리메토프림/설파메톡사졸(trimethoprim/sulfamethoxazole)",
        "question_text": "Question: A 68-year-old man with a sulfa drug allergy and a history of shoulder tendon rupture is about to start treatment for acute pyelonephritis. What is the appropriate empirical antibiotic?\n\n① Nystatin\n② Vancomycin\n③ Ceftriaxone\n④ Moxifloxacin\n⑤ Trimethoprim/Sulfamethoxazole",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 10세 소아에게 2일 전부터 발열, 구토, 귀 통증이 발생하여 급성중이염 치료를 시작할 예정이다. 과거 페니실린 계열 항생제를 복용 후 아나필락시스가 발생했다고 한다. 적절한 경험적 항생제는?\n\n① 세포탁심(cefotaxime)\n② 겐타마이신(gentamicin)\n③ 아목시실린(amoxicillin)\n④ 시프로플록사신(ciprofloxacin)\n⑤ 클래리트로마이신(clarithromycin)",
        "question_text": "Question: A 10-year-old child has been experiencing fever, vomiting, and ear pain for 2 days, and treatment for acute otitis media is about to begin. The child reportedly experienced anaphylaxis after taking penicillin-class antibiotics in the past. What is the appropriate empirical antibiotic?\n\n① Cefotaxime\n② Gentamicin\n③ Amoxicillin\n④ Ciprofloxacin\n⑤ Clarithromycin",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 만성간질환이 있는 54세 남자에게 결핵치료를 시작할 예정이다. 적절한 약물(요법)은?\n\n[임상검사] AST 82 IU/L, ALT 94 IU/L, T.bilirubin 1.2 mg/dL, Alb 3.8 g/dL, Child-Pugh Class A\n\n① 이소니아지드(isoniazid)\n② 리팜피신(rifampicin)+에탐부톨(ethambutol)\n③ 리팜피신+피라진아미드(pyrazinamide)\n④ 이소니아지드+리팜피신+에탐부톨\n⑤ 리팜피신+에탐부톨+피라진아미드",
        "question_text": "Question: A 54-year-old man with chronic liver disease is about to start tuberculosis treatment. What is the appropriate drug (therapy)?\n\n[Clinical test results] AST 82 IU/L, ALT 94 IU/L, T.bilirubin 1.2 mg/dL, Alb 3.8 g/dL, Child-Pugh Class A\n\n① Isoniazid\n② Rifampicin + Ethambutol\n③ Rifampicin + Pyrazinamide\n④ Isoniazid + Rifampicin + Ethambutol\n⑤ Rifampicin + Ethambutol + Pyrazinamide",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 42세 남자가 사람면역결핍바이러스(human immunodeficiency virus) 감염으로 치료 중이다. 검사 결과는 다음과 같고 활동결핵의 증상이나 징후는 없다. 적절한 약물은?\n\n[임상검사]\n흉부방사선검사: 정상\n인터페론감마분비검사(interferon-gamma releasing assay): 양성\nAST 16 IU/L, ALT 20 IU/L\n\n① 베다퀼린(bedaquiline)\n② 에탐부톨(ethambutol)\n③ 카나마이신(kanamycin)\n④ 이소니아지드(isoniazid)\n⑤ 시클로세린(cycloserine)",
        "question_text": "Question: A 42-year-old man is being treated for human immunodeficiency virus (HIV) infection. The test results are as follows, and there are no symptoms or signs of active tuberculosis. What is the appropriate medication?\n\n[Clinical Tests]\nChest X-ray: Normal\nInterferon-gamma releasing assay: Positive\nAST 16 IU/L, ALT 20 IU/L\n\n① Bedaquiline\n② Ethambutol\n③ Kanamycin\n④ Isoniazid\n⑤ Cycloserine",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 추락사고로 두부 외상이 발생하여 신경외과 수술을 받은 58세 남자에게 입원 중 뇌수막염이 발생하였다. 적절한 경험적 항생제(요법)는?\n\n[약물 알레르기] 반코마이신(vancomycin): 투약 후 아나필락시스 반응\n\n① 세푸록심(cefuroxime)\n② 아즈트레오남(aztreonam)\n③ 리네졸리드(linezolid)+세페핌(cefepime)\n④ 답토마이신(daptomycin)+세폭시틴(cefoxitin)\n⑤ 암피실린(ampicillin)+세프타지딤(ceftazidime)",
        "question_text": "Question: A 58-year-old man who underwent neurosurgery due to a head injury from a fall accident developed meningitis during hospitalization. What is the appropriate empirical antibiotic (therapy)?\n\n[Drug Allergy] Vancomycin: Anaphylactic reaction after administration\n\n① Cefuroxime\n② Aztreonam\n③ Linezolid + Cefepime\n④ Daptomycin + Cefoxitin\n⑤ Ampicillin + Ceftazidime",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 47세 남자가 양쪽 엄지 발톱 모서리에 발생한 진균증 치료를 위하여 시클로피록스(ciclopirox) 외용제를 3개월간 사용 중이다. 엄지 발톱 전체로 병변이 확대되어 경구제로 변경하고자 할 때, 적절한 약물요법은?\n\n① 테르비나핀(terbinafine) 2주간 투여\n② 플루코나졸(fluconazole) 4주간 투여\n③ 포사코나졸(posaconazole) 8주간 투여\n④ 이트라코나졸(itraconazole) 12주간 투여\n⑤ 그리세오풀빈(griseofulvin) 24주간 투여",
        "question_text": "Question: A 47-year-old man has been using topical ciclopirox for 3 months to treat fungal infections on the edges of both big toenails. As the lesions have spread to the entire big toenails, he wants to switch to an oral medication. What is the appropriate drug therapy?\n\n① Administer terbinafine for 2 weeks\n② Administer fluconazole for 4 weeks\n③ Administer posaconazole for 8 weeks\n④ Administer itraconazole for 12 weeks\n⑤ Administer griseofulvin for 24 weeks",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 급성백혈병 치료를 위한 항암치료 후 아스페르길루스(Aspergillus)에 의한 폐렴을 진단받은 38세 남자가 보리코나졸(voriconazole)을 복용하고 있다. 다른 동반질환이나 복용약물은 없다. 주의하여야 할 이상반응은?\n\n① 광시증\n② 녹내장\n③ 소리공포증\n④ 횡문근융해증\n⑤ 호흡성 알칼리증",
        "question_text": "Question: A 38-year-old man diagnosed with pneumonia caused by Aspergillus following chemotherapy for acute leukemia is taking voriconazole. He has no other comorbidities or medications. Which adverse reaction should be monitored carefully?\n\n① Photopsia\n② Glaucoma\n③ Phonophobia\n④ Rhabdomyolysis\n⑤ Respiratory alkalosis",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 32세 남자가 2일 전부터 발열(38.6℃), 심한 복통, 설사가 발생하였고 천공이 동반된 충수염(appendicitis)이 확인되었다. 적절한 경험적 항생제(요법)는?\n\n[약물 알레르기] 아목시실린(amoxicillin): 30세 때 복용 후 호흡곤란을 동반한 아나필락시스 발생\n\n① 세포테탄(cefotetan)\n② 클린다마이신(clindamycin)\n③ 이미페넴/실라스타틴(imipenem/cilastatin)\n④ 피페라실린/타조박탐(piperacillin/tazobactam)\n⑤ 아즈트레오남(aztreonam)+메트로니다졸(metronidazole)",
        "question_text": "Question: A 32-year-old man has experienced fever (38.6℃), severe abdominal pain, and diarrhea for the past 2 days, and perforated appendicitis has been confirmed. What is the appropriate empirical antibiotic (therapy)?\n\n[Drug Allergy] Amoxicillin: Anaphylaxis with respiratory distress occurred after taking it at age 30\n\n① Cefotetan\n② Clindamycin\n③ Imipenem/cilastatin\n④ Piperacillin/tazobactam\n⑤ Aztreonam + Metronidazole",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n3일 전부터 발열, 기침, 객담, 호흡곤란 증상이 나타난 66세 남자가 지역사회획득폐렴을 진단받고 일반병동에 입원하였다.\n\n[병력] 고혈압, 당뇨병\n\n[활력징후] 혈압 133/82 mmHg, 심박수 72회/분, 호흡수 26회/분, 체온 39℃\n\n[혈액검사]\nBUN 23 mg/dL, SCr 1.1 mg/dL, WBC 12,200/mm3\n\n[흉부방사선검사] 폐침윤\n\n[복용약물]\n암로디핀/발사르탄(amlodipine/valsartan)\n히드로클로로티아지드(hydrochlorothiazide)\n메트포르민(metformin)\n\n[예방접종력]\n폐렴구균백신 13가(PCV13) 55세에 접종\n폐렴구균백신 23가(PPSV23) 63세에 접종\n\nQuestion: 적절한 경험적 항생제(요법)는?\n\n① 시프로플록사신(ciprofloxacin)\n② 클래리트로마이신(clarithromycin)\n③ 세프타지딤(ceftazidime)+아미카신(amikacin)\n④ 세포탁심(cefotaxime)+아지트로마이신(azithromycin)\n⑤ 반코마이신(vancomycin)+세프라딘(cephradine)+토브라마이신(tobramycin)",
        "question_text": "A 66-year-old male was admitted to the general ward with a diagnosis of community-acquired pneumonia after experiencing fever, cough, sputum, and dyspnea for 3 days.\n\n[Medical history] Hypertension, Diabetes mellitus\n\n[Vital signs] Blood pressure 133/82 mmHg, Heart rate 72 beats/min, Respiratory rate 26 breaths/min, Body temperature 39℃\n\n[Blood test]\nBUN 23 mg/dL, SCr 1.1 mg/dL, WBC 12,200/mm3\n\n[Chest X-ray] Pulmonary infiltration\n\n[Current medications]\nAmlodipine/valsartan\nHydrochlorothiazide\nMetformin\n\n[Vaccination history]\nPneumococcal vaccine 13-valent (PCV13) at age 55\nPneumococcal vaccine 23-valent (PPSV23) at age 63\n\nQuestion: What is the appropriate empirical antibiotic (therapy)?\n\n① Ciprofloxacin\n② Clarithromycin\n③ Ceftazidime + Amikacin\n④ Cefotaxime + Azithromycin\n⑤ Vancomycin + Cephradine + Tobramycin",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n3일 전부터 발열, 기침, 객담, 호흡곤란 증상이 나타난 66세 남자가 지역사회획득폐렴을 진단받고 일반병동에 입원하였다.\n\n[병력] 고혈압, 당뇨병\n\n[활력징후] 혈압 133/82 mmHg, 심박수 72회/분, 호흡수 26회/분, 체온 39℃\n\n[혈액검사]\nBUN 23 mg/dL, SCr 1.1 mg/dL, WBC 12,200/mm3\n\n[흉부방사선검사] 폐침윤\n\n[복용약물]\n암로디핀/발사르탄(amlodipine/valsartan)\n히드로클로로티아지드(hydrochlorothiazide)\n메트포르민(metformin)\n\n[예방접종력]\n폐렴구균백신 13가(PCV13) 55세에 접종\n폐렴구균백신 23가(PPSV23) 63세에 접종\n\nQuestion: 폐렴구균백신 접종 계획으로 적절한 것은?\n\n① 추가 접종 불필요\n② 입원 중 13가 추가 접종\n③ 입원 중 23가 추가 접종\n④ 68세에 13가 추가 접종\n⑤ 68세에 23가 추가 접종",
        "question_text": "A 66-year-old male who has been experiencing fever, cough, sputum, and shortness of breath for the past 3 days was diagnosed with community-acquired pneumonia and admitted to a general ward.\n\n[Medical history] Hypertension, Diabetes\n\n[Vital signs] Blood pressure 133/82 mmHg, Heart rate 72 beats/min, Respiratory rate 26 breaths/min, Body temperature 39℃\n\n[Blood test]\nBUN 23 mg/dL, SCr 1.1 mg/dL, WBC 12,200/mm3\n\n[Chest X-ray] Pulmonary infiltration\n\n[Current medications]\nAmlodipine/valsartan\nHydrochlorothiazide\nMetformin\n\n[Vaccination history]\nPneumococcal vaccine 13-valent (PCV13) administered at age 55\nPneumococcal vaccine 23-valent (PPSV23) administered at age 63\n\nQuestion: Which of the following is the appropriate plan for pneumococcal vaccination?\n\n① No additional vaccination needed\n② Additional PCV13 during hospitalization\n③ Additional PPSV23 during hospitalization\n④ Additional PCV13 at age 68\n⑤ Additional PPSV23 at age 68",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 우울증 병력이 있는 38세 여자가 편두통 치료를 위하여 졸미트립탄(zolmitriptan)을 복용하고 있다. 그러나 한 달에 3회 이상 편두통이 발생하고 이로 인해 삶의 질이 떨어지고 있다. 편두통에 대한 예방요법으로 적절한 약물은?\n\n① 베라파밀(verapamil)\n② 라모트리진(lamotrigine)\n③ 클로나제팜(clonazepam)\n④ 아미트리프틸린(amitriptyline)\n⑤ 에르고타민/카페인(ergotamine/caffeine)",
        "question_text": "Question: A 38-year-old woman with a history of depression is taking zolmitriptan for migraine treatment. However, she experiences migraines more than 3 times a month, which is affecting her quality of life. Which of the following drugs is appropriate for migraine prevention?\n\n① Verapamil\n② Lamotrigine\n③ Clonazepam\n④ Amitriptyline\n⑤ Ergotamine/Caffeine",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 72세 여자가 알츠하이머병의 치료를 위해 리바스티그민(rivastigmine) 경구제를 복용하기 시작하였다. 흔하게 발생하는 약물이상반응으로, 모니터링이 필요한 것은?\n\n① 구역\n② 그물울혈반\n③ 고칼슘혈증\n④ 출혈방광염\n⑤ 고나트륨혈증",
        "question_text": "Question: A 72-year-old woman started taking oral rivastigmine for the treatment of Alzheimer's disease. Which of the following is a common adverse drug reaction that requires monitoring?\n\n① Nausea\n② Livedo reticularis\n③ Hypercalcemia\n④ Hemorrhagic cystitis\n⑤ Hypernatremia",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 다음 약물을 3년간 복용한 52세 여자에서 골다공증이 발생하였다. 이 환자의 골다공증 유발 원인으로 의심할 수 있는 약물은?\n\n[병력] 주요우울장애, 뇌전증, 고혈압\n[복용약물] 설트랄린(sertraline) 페니토인(phenytoin) 프레가발린(pregabalin) 아리피프라졸(aripiprazole) 암로디핀(amlodipine)\n\n① 설트랄린\n② 암로디핀\n③ 페니토인\n④ 프레가발린\n⑤ 아리피프라졸",
        "question_text": "Question: A 52-year-old woman who has been taking the following medications for 3 years developed osteoporosis. Which drug can be suspected as the cause of osteoporosis in this patient?\n\n[Medical history] Major depressive disorder, Epilepsy, Hypertension\n[Medications] Sertraline, Phenytoin, Pregabalin, Aripiprazole, Amlodipine\n\n① Sertraline\n② Amlodipine\n③ Phenytoin\n④ Pregabalin\n⑤ Aripiprazole",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 양극성장애 유지치료를 위해 탄산리튬(lithium carbonate)을 복용 중인 33세 여자에게 최근 혼재성 조증삽화(manic episode with mixed features)가 발생하였다. 탄산리튬을 중단하고 대신 사용할 약물로 적절한 것은?\n\n① 클로자핀(clozapine)\n② 플루옥세틴(fluoxetine)\n③ 할로페리돌(haloperidol)\n④ 아미트리프틸린(amitriptyline)\n⑤ 발프로산나트륨(sodium valproate)",
        "question_text": "Question: A 33-year-old woman taking lithium carbonate for maintenance therapy of bipolar disorder recently experienced a manic episode with mixed features. Which of the following drugs is appropriate to use instead of discontinuing lithium carbonate?\n\n① Clozapine\n② Fluoxetine\n③ Haloperidol\n④ Amitriptyline\n⑤ Sodium valproate",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 36세 남자가 조현병으로 할로페리돌(haloperidol) 치료를 시작한 후 혀 돌출, 목 비틀림과 같은 근육긴장이상(dystonia) 증상이 발생하였다. 환자의 근육긴장이상 치료를 위하여 추가할 약물로 적절한 것은?\n\n① 나돌롤(nadolol)\n② 클로니딘(clonidine)\n③ 벤즈트로핀(benztropine)\n④ 클로르프로마진(chlorpromazine)\n⑤ 메토클로프라미드(metoclopramide)",
        "question_text": "Question: A 36-year-old man developed dystonia symptoms such as tongue protrusion and neck twisting after starting haloperidol treatment for schizophrenia. Which of the following drugs is appropriate to add for the treatment of the patient's dystonia?\n\n① Nadolol\n② Clonidine\n③ Benztropine\n④ Chlorpromazine\n⑤ Metoclopramide",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 3개월 동안 잠이 들기 어려운 증상이 있는 42세 여자가 불면증을 진단받았다. 불면증 외 다른 질환이 없다. 이 환자의 초기 치료 약물로 적절한 것은?\n\n① 벤라팍신(venlafaxine)\n② 부프로피온(bupropion)\n③ 플루옥세틴(fluoxetine)\n④ 에스조피클론(eszopiclone)\n⑤ 메틸페니데이트(methylphenidate)",
        "question_text": "Question: A 42-year-old woman who has had difficulty falling asleep for 3 months was diagnosed with insomnia. She has no other medical conditions besides insomnia. Which of the following is the most appropriate initial treatment medication for this patient?\n\n① Venlafaxine\n② Bupropion\n③ Fluoxetine\n④ Eszopiclone\n⑤ Methylphenidate",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 약물중독과 알코올남용의 병력이 있는 33세 여자가 범불안장애를 진단받아 약물치료를 시작할 예정이다. 이 환자의 범불안장애 치료약물로 적절한 것은?\n\n① 둘록세틴(duloxetine)\n② 부스피론(buspirone)\n③ 로라제팜(lorazepam)\n④ 쿠에티아핀(quetiapine)\n⑤ 히드록시진(hydroxyzine)",
        "question_text": "Question: A 33-year-old woman with a history of drug addiction and alcohol abuse has been diagnosed with generalized anxiety disorder and is about to start drug treatment. Which of the following is an appropriate medication for treating this patient's generalized anxiety disorder?\n\n① Duloxetine\n② Buspirone\n③ Lorazepam\n④ Quetiapine\n⑤ Hydroxyzine",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n62세 남자가 7년 전에 파킨슨병으로 진단되어 다음과 같은 약물을 복용하고 있다.\n\n[복용약물]\n라사길린(rasagiline) 1 mg 1일 1회, 식후 30분\n로피니롤(ropinirole) 4 mg 1일 3회, 식후 30분\n카르비도파/레보도파(carbidopa/levodopa) 25/250mg 1일 4회, 식후 30분 및 취침 전\n\nQuestion: 환자는 2주 전부터 우측 팔과 손이 떨리는 증상이 발생하였고 증상이 점점 심해진다고 한다. 이는 레보도파와 관련한 무반응(no-on response)으로 평가되었다. 적절한 조치는?\n\n① 레보도파 용량 감소\n② 돔페리돈(domperidone) 추가\n③ 카르비도파/레보도파를 공복에 복용\n④ 카르비도파/레보도파를 서방형 제제로 변경\n⑤ 카르비도파/레보도파를 고단백 식이와 함께 복용",
        "question_text": "A 62-year-old male was diagnosed with Parkinson's disease 7 years ago and is taking the following medications:\n\n[Medications]\nRasagiline 1 mg once daily, 30 minutes after meals\nRopinirole 4 mg three times daily, 30 minutes after meals\nCarbidopa/Levodopa 25/250mg four times daily, 30 minutes after meals and before bedtime\n\nQuestion: The patient reports that his right arm and hand have been trembling for the past two weeks, and the symptoms are gradually worsening. This was evaluated as a no-on response related to levodopa. What is the appropriate action?\n\n① Decrease the dose of levodopa\n② Add domperidone\n③ Take carbidopa/levodopa on an empty stomach\n④ Switch carbidopa/levodopa to an extended-release formulation\n⑤ Take carbidopa/levodopa with a high-protein diet",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n62세 남자가 7년 전에 파킨슨병으로 진단되어 다음과 같은 약물을 복용하고 있다.\n\n[복용약물]\n라사길린(rasagiline) 1 mg 1일 1회, 식후 30분\n로피니롤(ropinirole) 4 mg 1일 3회, 식후 30분\n카르비도파/레보도파(carbidopa/levodopa) 25/250mg 1일 4회, 식후 30분 및 취침 전\n\nQuestion: 환자에서 환각과 정신이상 증상이 발생하여, 라사길린과 로피니롤은 투여를 중단하고, 카르비도파/레보도파는 감량하였으나 증상이 지속되었다. 새로운 약물을 추가하고자 할 때 적절한 것은?\n\n① 아만타딘(amantadine)\n② 아토목세틴(atomoxetine)\n③ 쿠에티아핀(quetiapine)\n④ 할로페리돌(haloperidol)\n⑤ 에토숙시미드(ethosuximide)",
        "question_text": "A 62-year-old man was diagnosed with Parkinson's disease 7 years ago and is taking the following medications:\n\n[Medications]\nRasagiline 1 mg once daily, 30 minutes after meals\nRopinirole 4 mg three times daily, 30 minutes after meals\nCarbidopa/Levodopa 25/250mg four times daily, 30 minutes after meals and before bedtime\n\nQuestion: The patient developed hallucinations and psychotic symptoms. Rasagiline and ropinirole were discontinued, and carbidopa/levodopa was reduced, but the symptoms persisted. Which of the following would be the most appropriate new medication to add?\n\n① Amantadine\n② Atomoxetine\n③ Quetiapine\n④ Haloperidol\n⑤ Ethosuximide",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 특이 병력이 없는 63세 남자가 고관절 골관절염으로 나프록센(naproxen)을 복용 중이다. 위장관 출혈이 확인되어 란소프라졸(lansoprazole) 치료를 시작하였다. 나프록센을 중단한 후 대체할 적절한 약은?\n\n① 캡사이신(capsaicin) 크림\n② 이부프로펜(ibuprofen) 정\n③ 피록시캄(piroxicam) 패치\n④ 셀레콕시브(celecoxib) 캡슐\n⑤ 미소프로스톨(misoprostol) 정",
        "question_text": "Question: A 63-year-old man with no significant medical history is taking naproxen for hip osteoarthritis. Gastrointestinal bleeding is confirmed, and lansoprazole treatment is initiated. What is the appropriate medication to replace naproxen after discontinuation?\n\n① Capsaicin cream\n② Ibuprofen tablet\n③ Piroxicam patch\n④ Celecoxib capsule\n⑤ Misoprostol tablet",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 56세 여자가 류마티스관절염으로 다음 약물을 사용하던 중 심부전(NYHA Class III)을 진단받았다. 류마티스관절염 치료를 위한 적절한 약물요법은?\n\n[사용약물] 에타너셉트(etanercept) 50 mg 주 1회 피하주사, 메토트렉세이트(methotrexate) 20 mg 주 1회 경구투여, 폴산(folic acid) 1 mg 1일 1회 경구투여\n\n① 에타너셉트를 아바타셉트(abatacept)로 변경\n② 에타너셉트를 인플릭시맵(infliximab)으로 변경\n③ 에타너셉트를 아달리무맙(adalimumab)으로 변경\n④ 메토트렉세이트를 골리무맙(golimumab)으로 변경\n⑤ 메토트렉세이트를 히드록시클로로퀸(hydroxychloroquine)으로 변경",
        "question_text": "Question: A 56-year-old woman who was using the following medications for rheumatoid arthritis was diagnosed with heart failure (NYHA Class III). What is the appropriate drug therapy for treating rheumatoid arthritis?\n\n[Current medications] Etanercept 50 mg subcutaneous injection once weekly, Methotrexate 20 mg orally once weekly, Folic acid 1 mg orally once daily\n\n① Change etanercept to abatacept\n② Change etanercept to infliximab\n③ Change etanercept to adalimumab\n④ Change methotrexate to golimumab\n⑤ Change methotrexate to hydroxychloroquine",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 파제트병(Paget's disease)으로 치료 중인 57세 여자가 골다공증을 진단받았다. 환자의 골다공증 치료제로 금기인 약물은?\n\n① 티볼론(tibolone)\n② 랄록시펜(raloxifene)\n③ 데노수맙(denosumab)\n④ 알렌드론산(alendronate)\n⑤ 테리파라타이드(teriparatide)",
        "question_text": "Question: A 57-year-old woman being treated for Paget's disease has been diagnosed with osteoporosis. Which of the following drugs is contraindicated for the treatment of osteoporosis in this patient?\n\n① Tibolone\n② Raloxifene\n③ Denosumab\n④ Alendronate\n⑤ Teriparatide",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 양성전립샘비대증[전립샘 크기 27 g (참고치 15~20 g)]과 발기부전이 있는 57세 남자에게 적절한 약물요법은?\n\n① 탐스로신(tamsulosin)+타다라필(tadalafil)\n② 톨터로딘(tolterodine)+바데나필(vardenafil)\n③ 알푸조신(alfuzosin)+두타스테리드(dutasteride)\n④ 두타스테리드+실데나필(sildenafil)\n⑤ 데스모프레신(desmopressin)+타다라필",
        "question_text": "Question: What is the appropriate drug therapy for a 57-year-old man with benign prostatic hyperplasia [prostate size 27 g (reference range 15-20 g)] and erectile dysfunction?\n\n① Tamsulosin + Tadalafil\n② Tolterodine + Vardenafil\n③ Alfuzosin + Dutasteride\n④ Dutasteride + Sildenafil\n⑤ Desmopressin + Tadalafil",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n52세 여자가 얼굴 홍조와 야간 발한 증상이 있다.\n\n[병력]\n전체자궁절제술(total hysterectomy) 외 특이병력 없음\n\n[가족력] 어머니: 골다공증\n\n[활력징후]\n혈압 125/84 mmHg, 심박수 73회/분, 호흡수 18회/분\n\n[복용약물]\n칼슘/비타민D(calcium/vitamin D)\n\nQuestion: 적절한 호르몬 치료약물은?\n\n① 에스트로피페이트(estropipate)\n② 디드로게스테론(dydrogesterone)\n③ 메드록시프로게스테론(medroxyprogesterone)\n④ 에스트라디올헤미하이드레이트/디드로게스테론(estradiol hemihydrate/dydrogesterone)\n⑤ 에스트라디올발레레이트/시프로테론아세테이트(estradiol valerate/cyproterone acetate)",
        "question_text": "A 52-year-old woman presents with facial flushing and night sweats.\n\n[Medical History]\nNo significant medical history other than total hysterectomy\n\n[Family History] Mother: Osteoporosis\n\n[Vital Signs]\nBlood pressure 125/84 mmHg, Heart rate 73 beats/min, Respiratory rate 18 breaths/min\n\n[Current Medications]\nCalcium/Vitamin D\n\nQuestion: What is the appropriate hormone therapy medication?\n\n① Estropipate\n② Dydrogesterone\n③ Medroxyprogesterone\n④ Estradiol hemihydrate/Dydrogesterone\n⑤ Estradiol valerate/Cyproterone acetate",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n52세 여자가 얼굴 홍조와 야간 발한 증상이 있다.\n\n[병력]\n전체자궁절제술(total hysterectomy) 외 특이병력 없음\n\n[가족력] 어머니: 골다공증\n\n[활력징후]\n혈압 125/84 mmHg, 심박수 73회/분, 호흡수 18회/분\n\n[복용약물]\n칼슘/비타민D(calcium/vitamin D)\n\nQuestion: 호르몬 치료 3년 후 정맥혈전증이 발생하여 치료를 중지하였다. 환자의 폐경 후 증상을 개선할 적절한 약물은?\n\n① 타목시펜(tamoxifen)\n② 솔리페나신(solifenacin)\n③ 미라베그론(mirabegron)\n④ 바제독시펜(bazedoxifene)\n⑤ 에스시탈로프람(escitalopram)",
        "question_text": "A 52-year-old woman presents with facial flushing and night sweats.\n\n[Medical history]\nNo significant medical history except for total hysterectomy\n\n[Family history] Mother: Osteoporosis\n\n[Vital signs]\nBlood pressure 125/84 mmHg, Heart rate 73 beats/min, Respiratory rate 18 breaths/min\n\n[Current medications]\nCalcium/vitamin D\n\nQuestion: After 3 years of hormone therapy, treatment was discontinued due to the occurrence of venous thrombosis. Which drug is appropriate to improve the patient's postmenopausal symptoms?\n\n① Tamoxifen\n② Solifenacin\n③ Mirabegron\n④ Bazedoxifene\n⑤ Escitalopram",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 51세 여자가 4기 유방암을 진단받고 항암화학요법을 받았으나, 최근 검사에서 새로 폐 전이가 확인되었다. 적절한 약물요법은?\n\n[검사결과] 호르몬 수용체(hormone receptor, HR) 음성, 사람표피성장인자 수용체 2(human epidermal growth factor  receptor 2, HER2) 음성, gBRCA 변이 양성\n\n① 올라파립(olaparib)\n② 랄록시펜(raloxifene)\n③ 레고라페닙(regorafenib)\n④ 카페시타빈(capecitabine)+라파티닙(lapatinib) \n⑤ 도세탁셀(docetaxel)+퍼투주맙(pertuzumab)+트라스투주맙(trastuzumab)",
        "question_text": "Question: A 51-year-old woman was diagnosed with stage 4 breast cancer and received chemotherapy, but recent tests confirmed new lung metastases. What is the appropriate drug therapy?\n\n[Test results] Hormone receptor (HR) negative, Human epidermal growth factor receptor 2 (HER2) negative, gBRCA mutation positive\n\n① Olaparib\n② Raloxifene\n③ Regorafenib\n④ Capecitabine + Lapatinib\n⑤ Docetaxel + Pertuzumab + Trastuzumab",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 47세 남자가 최근 전이성 비소세포폐암(선암)을 진단받고, 펨브롤리주맙(pembrolizumab), 시스플라틴(cisplatin), 페메트렉시드(pemetrexed)로 구성된 3제 항암화학요법을 받을 예정이다. 페메트렉시드의 독성을 줄이기 위해 항암화학요법 시작 전에 투여하는 약물은?\n\n① 메스나(mesna)\n② 폴산(folic acid)\n③ 페니토인(phenytoin)\n④ 덱스라족산(dexrazoxane)\n⑤ 에리스로포이에틴(erythropoietin)",
        "question_text": "Question: A 47-year-old man was recently diagnosed with metastatic non-small cell lung cancer (adenocarcinoma) and is scheduled to receive a three-drug chemotherapy regimen consisting of pembrolizumab, cisplatin, and pemetrexed. Which drug should be administered before starting chemotherapy to reduce the toxicity of pemetrexed?\n\n① Mesna\n② Folic acid\n③ Phenytoin\n④ Dexrazoxane\n⑤ Erythropoietin",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 49세 남자가 절제가 불가능한 전이성 대장암을 진단받고, 플루오로우라실(fluorouracil), 로이코보린(leucovorin), 옥살리플라틴(oxaliplatin)으로 구성된 FOLFOX 항암화학요법을 받을 예정이다. 다른 병력은 없고, ECOG (Eastern Cooperative Oncology Group) 수행도는 1이다. 추가할 수 있는 항암제는?\n\n[검사결과]\nKRAS 변이 양성, NRAS 변이 양성, BRAF 변이 음성\n불일치복구결함/고빈도 현미부수체 불안정성(dMMR/MSI-H): 관찰 안 됨\n\n① 세툭시맙(cetuximab)\n② 베바시주맙(bevacizumab)\n③ 펨브롤리주맙(pembrolizumab)\n④ 지브-애플리버셉트(ziv-aflibercept)\n⑤ 트리플루리딘/티피라실(trifluridine/tipiracil)",
        "question_text": "Question: A 49-year-old man has been diagnosed with unresectable metastatic colorectal cancer and is scheduled to receive FOLFOX chemotherapy consisting of fluorouracil, leucovorin, and oxaliplatin. He has no other medical history, and his ECOG (Eastern Cooperative Oncology Group) performance status is 1. Which additional anticancer drug can be added?\n\n[Test Results]\nKRAS mutation positive, NRAS mutation positive, BRAF mutation negative\nMismatch repair deficiency/high microsatellite instability (dMMR/MSI-H): Not observed\n\n① Cetuximab\n② Bevacizumab\n③ Pembrolizumab\n④ Ziv-aflibercept\n⑤ Trifluridine/tipiracil",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 당뇨병이 있는 56세 여자가 3기 결장암(colon cancer)으로 결장병변 절제수술을 받았다. 환자는 평소 심한 당뇨병성 말초신경병증으로 일상생활에 어려움이 있다. 적절한 1차 보조항암화학요법은?\n\n① 카페시타빈(capecitabine)+옥살리플라틴(oxaliplatin)\n② 플루오로우라실(fluorouracil)+로이코보린(leucovorin)\n③ 플루오로우라실+로이코보린+방사선 치료\n④ 플루오로우라실+로이코보린+이리노테칸(irinotecan)\n⑤ 플루오로우라실+로이코보린+옥살리플라틴",
        "question_text": "Question: A 56-year-old woman with diabetes underwent a colonic lesion resection surgery for stage 3 colon cancer. The patient has difficulty in daily life due to severe diabetic peripheral neuropathy. What is the appropriate first-line adjuvant chemotherapy?\n\n① Capecitabine + Oxaliplatin\n② Fluorouracil + Leucovorin\n③ Fluorouracil + Leucovorin + Radiation therapy\n④ Fluorouracil + Leucovorin + Irinotecan\n⑤ Fluorouracil + Leucovorin + Oxaliplatin",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 소세포폐암을 진단받은 38세 여자가 시스플라틴(cisplatin)과 에토포시드(etoposide) 항암화학요법의 2주기 치료를 받기 위해 입원하였다. 1주기 치료 시 심한 구역구토가 있어서, 환자는 2주기 항암제 투여에 대해 매우 불안해한다. 예기성 구역구토를 예방하기 위한 적절한 약물은?\n\n① 날록손(naloxone)\n② 로라제팜(lorazepam)\n③ 아프레피탄트(aprepitant)\n④ 그라니세트론(granisetron)\n⑤ 덱사메타손(dexamethasone)",
        "question_text": "Question: A 38-year-old woman diagnosed with small cell lung cancer has been admitted for the second cycle of chemotherapy with cisplatin and etoposide. She experienced severe nausea and vomiting during the first cycle, and is very anxious about receiving the second cycle of chemotherapy. Which of the following drugs is appropriate for preventing anticipatory nausea and vomiting?\n\n① Naloxone\n② Lorazepam\n③ Aprepitant\n④ Granisetron\n⑤ Dexamethasone",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 56세 여자가 뼈로 전이된 4기 유방암을 진단받고 호르몬요법을 받고 있다. 환자는 뼈 통증에 대해 파미드론산(pamidronate) 치료를 받을 예정이다. 파미드론산 투여 전에 확인이 필요한 검사는?\n\n① 청력\n② 안압\n③ 동맥혈가스분압\n④ 혈청크레아티닌\n⑤ 1초간노력성호기량",
        "question_text": "Question: A 56-year-old woman has been diagnosed with stage 4 breast cancer with bone metastasis and is receiving hormone therapy. The patient is scheduled to receive pamidronate treatment for bone pain. Which test needs to be checked before administering pamidronate?\n\n① Hearing\n② Intraocular pressure\n③ Arterial blood gas\n④ Serum creatinine\n⑤ Forced expiratory volume in 1 second (FEV1)",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n42세 남자가 급성전골수세포백혈병(acute promyelocytic leukemia)을 진단받았다. 진단 시 혈액검사 결과는 다음과 같고, ECOG (Eastern Cooperative Oncology Group) 수행도는 1이다.\n\n[임상검사] \nWBC 42,000/mm^3, Hgb 9.4 g/dL, platelet 72,000/mm^3, SCr 1.7 mg/dL, eGFR 53 mL/min/1.73 m^2, AST 28 IU/L, ALT 32 IU/L\n\nQuestion: 관해유도요법으로 적절한 것은?\n\n① 닐로티닙(nilotinib)\n② 삼산화비소(arsenic trioxide)\n③ 시타라빈(cytarabine)+히드록시우레아(hydroxyurea)\n④ 메르캅토푸린(mercaptopurine)+다우노루비신(daunorubicin)\n⑤ 트레티노인(tretinoin)+시타라빈+다우노루비신",
        "question_text": "A 42-year-old male was diagnosed with acute promyelocytic leukemia. The blood test results at the time of diagnosis are as follows, and his ECOG (Eastern Cooperative Oncology Group) performance status is 1.\n\n[Clinical tests]\nWBC 42,000/mm^3, Hgb 9.4 g/dL, platelet 72,000/mm^3, SCr 1.7 mg/dL, eGFR 53 mL/min/1.73 m^2, AST 28 IU/L, ALT 32 IU/L\n\nQuestion: Which of the following is appropriate for induction therapy?\n\n① Nilotinib\n② Arsenic trioxide\n③ Cytarabine + Hydroxyurea\n④ Mercaptopurine + Daunorubicin\n⑤ Tretinoin + Cytarabine + Daunorubicin",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n42세 남자가 급성전골수세포백혈병(acute promyelocytic leukemia)을 진단받았다. 진단 시 혈액검사 결과는 다음과 같고, ECOG (Eastern Cooperative Oncology Group) 수행도는 1이다.\n\n[임상검사] \nWBC 42,000/mm^3, Hgb 9.4 g/dL, platelet 72,000/mm^3, SCr 1.7 mg/dL, eGFR 53 mL/min/1.73 m^2, AST 28 IU/L, ALT 32 IU/L\n\nQuestion: 관해유도요법을 앞둔 환자에게 알로푸리놀(allopurinol)이 처방되었다. 이를 통해 예방할 수 있는 것은?\n\n① 수족증후군(hand-foot syndrome)\n② 분화증후군(differentiation syndrome)\n③ 종양용해증후군(tumor lysis syndrome)\n④ 용혈요독증후군(hemolytic uremic syndrome)\n⑤ 골수형성이상증후군(myelodysplastic syndrome)",
        "question_text": "A 42-year-old male was diagnosed with acute promyelocytic leukemia. The blood test results at the time of diagnosis are as follows, and his ECOG (Eastern Cooperative Oncology Group) performance status is 1.\n\n[Clinical tests]\nWBC 42,000/mm^3, Hgb 9.4 g/dL, platelet 72,000/mm^3, SCr 1.7 mg/dL, eGFR 53 mL/min/1.73 m^2, AST 28 IU/L, ALT 32 IU/L\n\nQuestion: Allopurinol was prescribed for the patient before starting induction therapy. What can be prevented through this?\n\n① Hand-foot syndrome\n② Differentiation syndrome\n③ Tumor lysis syndrome\n④ Hemolytic uremic syndrome\n⑤ Myelodysplastic syndrome",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 중증 아토피피부염을 진단받은 19세 남자가 지난 4년간 데속시메타손(desoximetasone) 로션과 사이클로스포린(cyclosporine)을 사용해도 증상이 개선되지 않았다. 적절한 약물은?\n\n① 두필루맙(dupilumab)\n② 인플릭시맵(infliximab)\n③ 토파시티닙(tofacitinib)\n④ 토실리주맙(tocilizumab)\n⑤ 오말리주맙(omalizumab)",
        "question_text": "Question: A 19-year-old male diagnosed with severe atopic dermatitis has not shown improvement in symptoms despite using desoximetasone lotion and cyclosporine for the past 4 years. What is the appropriate medication?\n\n① Dupilumab\n② Infliximab\n③ Tofacitinib\n④ Tocilizumab\n⑤ Omalizumab",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 조절되지 않는 천식으로 흡입제를 사용 중인 67세 여자가 눈이 침침하고 시야가 흐려져 내원하였다. 검사결과 안압이 25 mmHg(정상범위 10~21 mmHg)로 개방각 녹내장으로 진단되었다. 적절한 약은?\n\n① 티몰롤(timolol) 점안제\n② 카르테올롤(carteolol) 점안제\n③ 라타노프로스트(latanoprost) 점안제\n④ 사이클로스포린(cyclosporine) 점안제\n⑤ 아프라클로니딘(apraclonidine) 점안제",
        "question_text": "Question: A 67-year-old woman using an inhaler for uncontrolled asthma visited the hospital due to blurred vision and haziness in her eyes. The examination revealed an intraocular pressure of 25 mmHg (normal range 10-21 mmHg), and she was diagnosed with open-angle glaucoma. What is the appropriate medication?\n\n① Timolol eye drops\n② Carteolol eye drops\n③ Latanoprost eye drops\n④ Cyclosporine eye drops\n⑤ Apraclonidine eye drops",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 정맥영양요법을 시작한 48세 여자에게 재주입증후군(refeeding syndrome)으로 관찰될 수 있는 혈액검사 결과는?\n\n① 저인산혈증\n② 고칼륨혈증\n③ 백혈구감소증\n④ 혈소판감소증\n⑤ 고마그네슘혈증",
        "question_text": "Question: Which of the following blood test results can be observed as a sign of refeeding syndrome in a 48-year-old woman who has started intravenous nutrition therapy?\n\n① Hypophosphatemia\n② Hyperkalemia\n③ Leukopenia\n④ Thrombocytopenia\n⑤ Hypermagnesemia",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 부적절하게 사용하는 경우 심각한 손상을 발생시킬 수 있거나 잠재적으로 높은 위험을 초래할 가능성이 있는 고위험 약물로, 처방 및 조제, 투약, 보관 등에 대한 별도의 상세한 관리 지침을 마련하여 이에 따른 정확한 관리가 필요한 약물은?\n\n① 헤파린(heparin)\n② 아미카신(amikacin)\n③ 아카르보스(acarbose)\n④ 돔페리돈(domperidone)\n⑤ 에리스로포이에틴(erythropoietin)",
        "question_text": "Question: Which of the following is a high-risk medication that can cause serious harm if used inappropriately or potentially lead to high risks, requiring accurate management according to separate detailed guidelines for prescription, dispensing, administration, and storage?\n\n① Heparin\n② Amikacin\n③ Acarbose\n④ Domperidone\n⑤ Erythropoietin",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 63세 남자가 일주일 전 정형외과 병원에서 골관절염 약물을 처방받았고, 오늘은 치과 진료 후 처방을 받아 약국에 왔다. 이 환자의 처방검토 과정에서 발견되는 문제점은?\n\n[정형외과 처방]\n| 의약품명 | 1회 투약량 | 1일 투여 횟수 | 총 투약 일수 |\n|---|---|---|---|\n| 나프록센/에스오메프라졸(naproxen /esomeprazole) 500 mg/20 mg 정 | 1 | 2 | 30 |\n\n[치과 처방]\n| 의약품명 | 1회 투약량 | 1일 투여 횟수 | 총 투약 일수 |\n|---|---|---|---|\n| 아세클로페낙(aceclofenac) 100 mg 정 | 1 | 2 | 5 |\n\n① 용량 부족\n② 부적절한 제형\n③ 투여일수 부족\n④ 효능군 중복 처방\n⑤ 약물상호작용 발생 가능성",
        "question_text": "Question: A 63-year-old man received a prescription for osteoarthritis medication from an orthopedic hospital a week ago, and today he came to the pharmacy with a prescription after a dental appointment. What is the problem identified during the prescription review process for this patient?\n\n[Orthopedic Prescription]\n| Drug Name | Dose per Administration | Frequency per Day | Total Days of Administration |\n|---|---|---|---|\n| Naproxen/Esomeprazole 500 mg/20 mg tablet | 1 | 2 | 30 |\n\n[Dental Prescription]\n| Drug Name | Dose per Administration | Frequency per Day | Total Days of Administration |\n|---|---|---|---|\n| Aceclofenac 100 mg tablet | 1 | 2 | 5 |\n\n① Insufficient dosage\n② Inappropriate formulation\n③ Insufficient duration of treatment\n④ Duplicate prescription of the same drug class\n⑤ Potential for drug interactions",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n6개월 전 신장이식을 받은 24세 여자에게 Aspergillus 감염이 발생하여 보리코나졸(voriconazole) 치료를 시작하였다. 환자의 혈액검사결과와 처방약물은 다음과 같다.\n\n[혈액검사결과]\n입원 시:\nNa 135 mEq/L\nBUN 19 mg/dL\nWBC 10.9×103/mm3\ntacrolimus 10.2 ng/mL\nK 3.8 mEq/L\nSCr 0.9 mg/dL\nplatelet 180×103/mm3\n\n입원 5일째:\nNa 133 mEq/L\nBUN 38 mg/dL\nWBC 8.2×103/mm3\ntacrolimus 17.5 ng/mL\nK 5.2 mEq/L\nSCr 2.1 mg/dL platelet 250×103/mm3\n\n[처방약물]\n| 의약품명 | 1회 투약량 | 1일 투여 횟수 | 복용 시작 시점 |\n|---|---|---|---|\n| 타크롤리무스(tacrolimus) 2 mg 정 | 1 | 2 | 입원 전부터 복용 |\n| 미코페놀레이트 모페틸(mycophenolate mofetil) 500 mg 정 2 | 2 | 입원 전부터 복용 |\n| 파모티딘(famotidine) 20 mg 정 | 1 | 2 | 입원 전부터 복용 |\n| 레바미피드(rebamipide) 100 mg 정 | 1 | 3 | 입원 전부터 복용 |\n| 데플라자코트(deflazacort) 6 mg 정 | 1 | 1 | 입원 전부터 복용 |\n| 보리코나졸(voriconazole) 200 mg 정 | 1 | 2 | 입원 1일째 복용 시작 |\n\nQuestion: 이 환자에서 발생한 약물관련문제(drug-related problem)는?\n\n① 용량 부족\n② 투여횟수 부족\n③ 동일성분 중복\n④ 낮은 복약이행도\n⑤ 약물이상반응 발생",
        "question_text": "A 24-year-old female who received a kidney transplant 6 months ago developed an Aspergillus infection, and voriconazole treatment was initiated. The patient's blood test results and prescribed medications are as follows:\n\n[Blood Test Results]\nAt admission:\nNa 135 mEq/L\nBUN 19 mg/dL\nWBC 10.9×103/mm3\ntacrolimus 10.2 ng/mL\nK 3.8 mEq/L\nSCr 0.9 mg/dL\nplatelet 180×103/mm3\n\nOn the 5th day of hospitalization:\nNa 133 mEq/L\nBUN 38 mg/dL\nWBC 8.2×103/mm3\ntacrolimus 17.5 ng/mL\nK 5.2 mEq/L\nSCr 2.1 mg/dL\nplatelet 250×103/mm3\n\n[Prescribed Medications]\n| Medication Name | Dose per Administration | Frequency per Day | Start of Administration |\n|---|---|---|---|\n| Tacrolimus 2 mg tablet | 1 | 2 | Before admission |\n| Mycophenolate mofetil 500 mg tablet | 2 | 2 | Before admission |\n| Famotidine 20 mg tablet | 1 | 2 | Before admission |\n| Rebamipide 100 mg tablet | 1 | 3 | Before admission |\n| Deflazacort 6 mg tablet | 1 | 1 | Before admission |\n| Voriconazole 200 mg tablet | 1 | 2 | Started on day 1 of admission |\n\nQuestion: What is the drug-related problem that occurred in this patient?\n\n① Insufficient dosage\n② Insufficient frequency of administration\n③ Duplication of the same ingredient\n④ Low medication adherence\n⑤ Occurrence of adverse drug reaction",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n6개월 전 신장이식을 받은 24세 여자에게 Aspergillus 감염이 발생하여 보리코나졸(voriconazole) 치료를 시작하였다. 환자의 혈액검사결과와 처방약물은 다음과 같다.\n\n[혈액검사결과]\n입원 시:\nNa 135 mEq/L\nBUN 19 mg/dL\nWBC 10.9×103/mm3\ntacrolimus 10.2 ng/mL\nK 3.8 mEq/L\nSCr 0.9 mg/dL\nplatelet 180×103/mm3\n\n입원 5일째:\nNa 133 mEq/L\nBUN 38 mg/dL\nWBC 8.2×103/mm3\ntacrolimus 17.5 ng/mL\nK 5.2 mEq/L\nSCr 2.1 mg/dL platelet 250×103/mm3\n\n[처방약물]\n| 의약품명 | 1회 투약량 | 1일 투여 횟수 | 복용 시작 시점 |\n|---|---|---|---|\n| 타크롤리무스(tacrolimus) 2 mg 정 | 1 | 2 | 입원 전부터 복용 |\n| 미코페놀레이트 모페틸(mycophenolate mofetil) 500 mg 정 2 | 2 | 입원 전부터 복용 |\n| 파모티딘(famotidine) 20 mg 정 | 1 | 2 | 입원 전부터 복용 |\n| 레바미피드(rebamipide) 100 mg 정 | 1 | 3 | 입원 전부터 복용 |\n| 데플라자코트(deflazacort) 6 mg 정 | 1 | 1 | 입원 전부터 복용 |\n| 보리코나졸(voriconazole) 200 mg 정 | 1 | 2 | 입원 1일째 복용 시작 |\n\nQuestion: 주치의가 신기능에 따른 보리코나졸의 용량을 문의하였다. 답변을 위해 참고할 3차문헌으로 적절한 것은?\n\n① DRUGDEX\n② The Lancet \n③ Annals of Pharmacotherapy\n④ Basic Skills in Interpreting Laboratory Data\n⑤ Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk",
        "question_text": "A 24-year-old woman who received a kidney transplant 6 months ago developed an Aspergillus infection, and voriconazole treatment was initiated. The patient's blood test results and prescribed medications are as follows:\n\n[Blood Test Results]\nAt admission:\nNa 135 mEq/L\nBUN 19 mg/dL\nWBC 10.9×103/mm3\ntacrolimus 10.2 ng/mL\nK 3.8 mEq/L\nSCr 0.9 mg/dL\nplatelet 180×103/mm3\n\nOn the 5th day of hospitalization:\nNa 133 mEq/L\nBUN 38 mg/dL\nWBC 8.2×103/mm3\ntacrolimus 17.5 ng/mL\nK 5.2 mEq/L\nSCr 2.1 mg/dL\nplatelet 250×103/mm3\n\n[Prescribed Medications]\n| Drug Name | Dose per Administration | Frequency per Day | Start of Administration |\n|---|---|---|---|\n| Tacrolimus 2 mg tablet | 1 | 2 | Before admission |\n| Mycophenolate mofetil 500 mg tablet | 2 | 2 | Before admission |\n| Famotidine 20 mg tablet | 1 | 2 | Before admission |\n| Rebamipide 100 mg tablet | 1 | 3 | Before admission |\n| Deflazacort 6 mg tablet | 1 | 1 | Before admission |\n| Voriconazole 200 mg tablet | 1 | 2 | Started on day 1 of admission |\n\nQuestion: The attending physician inquired about the dosage of voriconazole based on renal function. Which tertiary literature source is most appropriate to consult for the answer?\n\n① DRUGDEX\n② The Lancet \n③ Annals of Pharmacotherapy\n④ Basic Skills in Interpreting Laboratory Data\n⑤ Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 홍○○ 씨는 1월 17일 타 지역 의료기관 방문 후 교부받은 처방전 조제를 위해 1월 20일 동네 약국을 방문했으나 조제가 불가능하다는 안내를 받았다. 그 이유는?\n\n<Data (confidential)>\n\n① 질병분류기호가 누락되었다.\n② 건강보험 대상 환자가 아니다.\n③ 약국 조제가능 기간이 경과되었다. \n④ 청구를 위한 주민등록번호가 확인되지 않는다.\n⑤ 방문한 의료기관 소재 지역약국에서만 조제가 가능하다.",
        "question_text": "Question: Mr. Hong ○○ visited a local pharmacy on January 20th to fill a prescription he received from a medical institution in another region on January 17th. However, he was informed that the prescription could not be filled. What is the reason?\n\n<Data (confidential)>\n\n① The disease classification code is missing.\n② The patient is not eligible for health insurance.\n③ The pharmacy's dispensing period has expired.\n④ The resident registration number for billing cannot be verified.\n⑤ The prescription can only be filled at a local pharmacy in the area where the medical institution is located.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 4세 남아(15 kg/124 cm)가 뇌전증으로 인한 경련으로 입원치료 후 다음과 같은 퇴원처방을 받았다. 처방검토 후 약사중재가 필요한 내용은?\n\n| 처방의약품 명칭 | 1회 투약량 | 1일 투여횟수 | 총 투약일수 | 용법 |\n|---|---|---|---|---|\n| 라모트리진(lamotrigine)5 mg 츄어블정 | 0.5 | 1 | 7 | 자기 전 |\n| 레비티라세탐(levetiracetam) 500 mg XR정 | 0.33 | 2 | 7 | 12시간 마다 |\n\n① 복약이행도 개선을 위해 복용시간을 오전으로 변경한다.\n② 연령을 고려해서 라모트리진 츄어블정을 산제로 조제한다.\n③ 제형을 고려해서 레비티라세탐을 시럽제로 바꾸는 처방변경을 요청한다.\n④ 경제적 여건을 고려해서 총투약일수를 30일로 바꾸는 처방변경을 요청한다.\n⑤ 라모트리진과 레비티라세탐은 병용금기이므로 처방변경을 요청한다.",
        "question_text": "Question: A 4-year-old boy (15 kg/124 cm) was hospitalized for seizures due to epilepsy and received the following discharge prescription. After reviewing the prescription, what pharmacist intervention is necessary?\n\n| Prescribed medication | Single dose | Frequency per day | Total days of medication | Instructions |\n|---|---|---|---|---|\n| Lamotrigine 5 mg chewable tablet | 0.5 | 1 | 7 | Before bedtime |\n| Levetiracetam 500 mg XR tablet | 0.33 | 2 | 7 | Every 12 hours |\n\n① Change the administration time to morning to improve medication adherence.\n② Considering the age, prepare lamotrigine chewable tablets as a powder.\n③ Request a prescription change to switch levetiracetam to syrup form, considering the dosage form.\n④ Request a prescription change to extend the total medication period to 30 days, considering economic circumstances.\n⑤ Request a prescription change as lamotrigine and levetiracetam are contraindicated for concurrent use.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 다음 약물을 복용 중이던 환자가 입원 후 연하곤란 식이를 시작 하였다. 알약을 삼킬 수 없는 이 환자의 투약 용이성을 고려할 때 제형 변경 후 산제 조제가 필요한 약은?\n\n카르베딜롤(carvedilol) 25 mg 정 0.5정 1일 2회\n발사르탄(valsartan) 160 mg 필름코팅정 1정 1일 1회\n이소소르비드질산염(isosorbide dinitrate) 40mg 서방정 2정 1일 1회\n로수바스타틴(rosuvastatin) 5 mg OD정, 1정 1일 1회\n란소프라졸(lansoprazole) 15 mg 구강붕해정 1정 1일 1회\n\n① 카르베딜롤 25 mg 정\n② 발사르탄 160 mg 필름코팅정\n③ 이소소르비드질산염 40 mg 서방정\n④ 로수바스타틴 5 mg OD정\n⑤ 란소프라졸 15 mg 구강붕해정",
        "question_text": "Question: A patient who was taking the following medications was admitted to the hospital and started on a dysphagia diet. Considering the ease of administration for this patient who cannot swallow pills, which medication needs to be changed to a powder form for compounding?\n\nCarvedilol 25 mg tablet, 0.5 tablet twice daily\nValsartan 160 mg film-coated tablet, 1 tablet once daily\nIsosorbide dinitrate 40 mg extended-release tablet, 2 tablets once daily\nRosuvastatin 5 mg OD tablet, 1 tablet once daily\nLansoprazole 15 mg orally disintegrating tablet, 1 tablet once daily\n\n① Carvedilol 25 mg tablet\n② Valsartan 160 mg film-coated tablet\n③ Isosorbide dinitrate 40 mg extended-release tablet\n④ Rosuvastatin 5 mg OD tablet\n⑤ Lansoprazole 15 mg orally disintegrating tablet",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 기침, 코막힘 증상이 있는 환자에게 발행된 처방전을 검토하던 중, 환자가 7개월 아기에게 수유 중임을 알게 되었다. 약물선택의 적절성에 대해 의사에게 문의해야 하는 약물은?\n\n| 처방의약품 명칭 | 1회 투약량 | 1일 투여 횟수 | 총투약 일수 | 용법 |\n|---|---|---|---|---|\n| 아목시실린(amoxicillin) 500 mg 캡슐 | 1 | 3 | 3 | 8시간마다 |\n| 아세트아미노펜(acetaminophen) 500 mg 정 | 1 | 3 | 3 | 매 식후 |\n| 슈도에페드린(pseudoephedrine) 60mg 정 | 0.5 | 2 | 3 | 아침 저녁 식후 |\n| 비타민C(vitamin C) 1,000 mg 정 | 1 | 1 | 3 | 아침 식후 |\n| 생리식염수비강액 | | | 1개 | 필요시 코에 1-2회 분무 |\n\n① 비타민C\n② 아목시실린\n③ 슈도에페드린\n④ 아세트아미노펜\n⑤ 생리식염수비강액",
        "question_text": "Question: While reviewing a prescription for a patient with cough and nasal congestion symptoms, you learn that the patient is breastfeeding a 7-month-old baby. Which medication should you inquire about with the doctor regarding its appropriateness?\n\n| Prescribed Medication | Single Dose | Daily Frequency | Total Days | Instructions |\n|---|---|---|---|---|\n| Amoxicillin 500 mg capsule | 1 | 3 | 3 | Every 8 hours |\n| Acetaminophen 500 mg tablet | 1 | 3 | 3 | After each meal |\n| Pseudoephedrine 60 mg tablet | 0.5 | 2 | 3 | After breakfast and dinner |\n| Vitamin C 1,000 mg tablet | 1 | 1 | 3 | After breakfast |\n| Saline nasal spray | | | 1 bottle | 1-2 sprays in nose as needed |\n\n① Vitamin C\n② Amoxicillin\n③ Pseudoephedrine\n④ Acetaminophen\n⑤ Saline nasal spray",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 68세 남자가 다음 처방을 받았다. 처방전 내 점검사항과 관련하여 표시되는 경고알림 내용은?\n\n| 처방의약품 명칭 | 1회 투약량 | 1일 투여횟수 | 총 투약일수 |\n|---|---|---|---|\n| 심바스타틴(simvastatin) 20 mg 정 | 2 | 1 | 28 |\n| 올메사르탄(olmesartan) 20 mg 정 | 1 | 1 | 28 |\n\n① 병용금기\n② 노인주의\n③ 용량주의\n④ 효능군 중복주의\n⑤ 저함량 배수처방조제",
        "question_text": "Question: A 68-year-old man received the following prescription. What warning alert would be displayed regarding the prescription review items?\n\n| Prescribed medication name | Dosage per administration | Number of administrations per day | Total days of medication |\n|---|---|---|---|\n| Simvastatin 20 mg tablet | 2 | 1 | 28 |\n| Olmesartan 20 mg tablet | 1 | 1 | 28 |\n\n① Contraindicated combination\n② Caution for elderly\n③ Dosage caution\n④ Caution for therapeutic class duplication\n⑤ Multiple dispensing of low-dose formulations",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 58세 여자(체중 60 kg)에게 감염치료를 목적으로 겐타마이신(gentamicin) 100 mg을 8시간마다 30분간 정맥투여 하고 있다. 투여 시작 4일 후 겐타마이신에 대한 혈중약물농도 모니터링(TDM)을 시행하고자 할 때 확인해야 하는 항목은?\n\n① 전체 투약기간 동안 식이섭취 정도\n② 전일 투약도중 측정된 겐타마이신 혈중농도 \n③ 당일 투약직전 측정된 겐타마이신 혈중농도 \n④ 당일 투약종료직후 측정된 겐타마이신 혈중농도 \n⑤ 4일 전 투약도중 측정된 크레아틴키나아제(creatine kinase) 혈중농도",
        "question_text": "Question: A 58-year-old woman (weight 60 kg) is receiving gentamicin 100 mg intravenously over 30 minutes every 8 hours for infection treatment. When performing therapeutic drug monitoring (TDM) for gentamicin 4 days after starting the treatment, which of the following should be checked?\n\n① Dietary intake throughout the entire treatment period\n② Gentamicin blood concentration measured during the previous day's administration\n③ Gentamicin blood concentration measured immediately before the day's administration\n④ Gentamicin blood concentration measured immediately after the day's administration\n⑤ Creatine kinase blood concentration measured during administration 4 days ago",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n항암제 주사조제실에 다음 처방이 접수되었다. 고○○, F/58세, 168 cm/46 kg/BSA 1.6 m2\n진료과: 종양내과\n진단명: 비소세포폐암, 흉막전이 동반\n\n[처방내용]\n도세탁셀(docetaxel) 100 mg/m2, 5% 포도당(dextrose) 200 mL(희석용액)\n: 1시간 동안 정맥투여\n\nQuestion: 항암요법 처방 검토 과정에서 도세탁셀 치료 중 발생할 수 있는 체액저류 부작용 예방을 위한 전처치 약물처방이 필요함을 확인하였다. 이때 추천하는 약물은?\n\n① 만니톨(mannitol)\n② 로이코보린(leucovorin)\n③ 푸로세미드(furosemide)\n④ 덱사메타손(dexamethasone)\n⑤ 클로르페니라민(chlorpheniramine)",
        "question_text": "The following prescription was received at the chemotherapy preparation room. Ko○○, F/58 years old, 168 cm/46 kg/BSA 1.6 m2\nDepartment: Medical Oncology\nDiagnosis: Non-small cell lung cancer with pleural metastasis\n\n[Prescription]\nDocetaxel 100 mg/m2, 5% Dextrose 200 mL (diluent)\n: Intravenous infusion over 1 hour\n\nQuestion: During the review of the chemotherapy prescription, it was identified that premedication is needed to prevent fluid retention side effects that may occur during docetaxel treatment. Which drug is recommended in this case?\n\n① Mannitol\n② Leucovorin\n③ Furosemide\n④ Dexamethasone\n⑤ Chlorpheniramine",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n항암제 주사조제실에 다음 처방이 접수되었다. 고○○, F/58세, 168 cm/46 kg/BSA 1.6 m2\n진료과: 종양내과\n진단명: 비소세포폐암, 흉막전이 동반\n\n[처방내용]\n도세탁셀(docetaxel) 100 mg/m2, 5% 포도당(dextrose) 200 mL(희석용액)\n: 1시간 동안 정맥투여\n\nQuestion: 80 mg/2 mL 함량으로 시판되고 있는 도세탁셀을 사용하여 이 환자의 항암제를 조제하고자 한다. 조제 시 취해야 할 도세탁셀의 부피(mL)는?\n\n① 1 mL\n② 2 mL\n③ 4 mL\n④ 8 mL\n⑤ 16 mL",
        "question_text": "The following prescription was received at the chemotherapy preparation room. Ko ○○, F/58 years old, 168 cm/46 kg/BSA 1.6 m2\nDepartment: Medical Oncology\nDiagnosis: Non-small cell lung cancer with pleural metastasis\n\n[Prescription]\nDocetaxel 100 mg/m2, 5% Dextrose 200 mL (diluent)\n: Intravenous infusion over 1 hour\n\nQuestion: You are preparing the chemotherapy for this patient using commercially available docetaxel with a concentration of 80 mg/2 mL. What volume (mL) of docetaxel should be used in the preparation?\n\n① 1 mL\n② 2 mL\n③ 4 mL\n④ 8 mL\n⑤ 16 mL",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n위식도역류병 병력이 있는 55세 여자가 최근 골밀도 검사를 받았다. 검사결과 T-score는 -2.5(요추), -2.6(대퇴부)이다. 환자는 다음 처방을 받았다.\n| 의약품명 | 1회 투약량 | 1일 투여횟수 | 총 투약일수 |\n|---|---|---|---|\n| 리세드로네이트(risedronate) 150 mg 정 | 1 | 1 | 30 |\n| 탄산칼슘/콜레칼시페롤(calcium carbonate/cholecalciferol) 1 |250 mg/10 mg 정 | 1 | 1 | 30 |\n\nQuestion: 처방내용검토 중 처방의에게 문의가 필요한 내용은?\n\n① 리세드로네이트 연령금기\n② 리세드로네이트 용량용법\n③ 탄산칼슘/콜레칼시페롤 연령금기\n④ 탄산칼슘/콜레칼시페롤 용량용법\n⑤ 리세드로네이트와 탄산칼슘 병용금기",
        "question_text": "A 55-year-old woman with a history of gastroesophageal reflux disease recently underwent a bone density test. The test results show a T-score of -2.5 (lumbar spine) and -2.6 (femur). The patient received the following prescription:\n\n| Medication | Dosage per administration | Frequency per day | Total days of medication |\n|---|---|---|---|\n| Risedronate 150 mg tablet | 1 | 1 | 30 |\n| Calcium carbonate/cholecalciferol 1,250 mg/10 mg tablet | 1 | 1 | 30 |\n\nQuestion: Which of the following issues needs to be discussed with the prescribing physician during prescription review?\n\n① Age contraindication for risedronate\n② Dosage and administration of risedronate\n③ Age contraindication for calcium carbonate/cholecalciferol\n④ Dosage and administration of calcium carbonate/cholecalciferol\n⑤ Contraindication for concurrent use of risedronate and calcium carbonate",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n위식도역류병 병력이 있는 55세 여자가 최근 골밀도 검사를 받았다. 검사결과 T-score는 -2.5(요추), -2.6(대퇴부)이다. 환자는 다음 처방을 받았다.\n| 의약품명 | 1회 투약량 | 1일 투여횟수 | 총 투약일수 |\n|---|---|---|---|\n| 리세드로네이트(risedronate) 150 mg 정 | 1 | 1 | 30 |\n| 탄산칼슘/콜레칼시페롤(calcium carbonate/cholecalciferol) 1 |250 mg/10 mg 정 | 1 | 1 | 30 |\n\nQuestion: 이 환자에게 필요한 복약지도 내용은?\n\n① 물이 없는 경우 우유나 녹차와 함께 복용한다.\n② 리세드로네이트와 칼슘제제는 아침에 동시 복용한다.\n③ 리세드로네이트는 위장장애 예방을 위해 식후 복용한다.\n④ 구역 또는 구토감이 느껴지는 경우 즉시 복용을 중단한다.\n⑤ 리세드로네이트는 복용 후 30분간 눕지 않고 똑바른 자세를 유지한다.",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 55-year-old woman with a history of gastroesophageal reflux disease recently underwent a bone density test. The test results show a T-score of -2.5 (lumbar spine) and -2.6 (femur). The patient received the following prescription:\n| Medication | Dose per administration | Frequency per day | Total days of medication |\n|---|---|---|---|\n| Risedronate 150 mg tablet | 1 | 1 | 30 |\n| Calcium carbonate/cholecalciferol 1,250 mg/10 mg tablet | 1 | 1 | 30 |\n\nQuestion: What medication counseling is necessary for this patient?\n\n① If water is not available, take it with milk or green tea.\n② Take risedronate and calcium supplement together in the morning.\n③ Take risedronate after meals to prevent gastrointestinal disorders.\n④ If nausea or vomiting occurs, discontinue use immediately.\n⑤ After taking risedronate, maintain an upright posture and do not lie down for 30 minutes.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 산제로 조제하는 과정에서, 필요시 부형제로 유당(lactose)을 첨가할 수 있는 의약품은?\n\n① 티아민(thiamine) 정\n② 푸로세미드(furosemide) 정\n③ 이소니아지드(isoniazid) 정\n④ 아미노필린(aminophylline) 정\n⑤ 포르모테롤(formoterol) 건조시럽",
        "question_text": "Question: When preparing a powder formulation, which of the following medications can have lactose added as an excipient if necessary?\n\n① Thiamine tablet\n② Furosemide tablet\n③ Isoniazid tablet\n④ Aminophylline tablet\n⑤ Formoterol dry syrup",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 8세 소아(20 kg)에게 세프포독심(cefpodoxime)이 다음과 같이 처방되었다. 이 환아에게 처방된 세프포독심의 체중당 1일 투여량은?\n\n| 의약품명 | 1회 투약량 | 1일 투여횟수 | 총 투약일수(일) |\n|---|---|---|---|\n| 세프포독심 건조시럽 50 mg/5 mL | 6 mL | 3 | 5 |\n\n① 1.5 mg/kg/day\n② 3 mg/kg/day\n③ 6 mg/kg/day\n④ 9 mg/kg/day\n⑤ 12 mg/kg/day",
        "question_text": "Question: Cefpodoxime was prescribed as follows for an 8-year-old child (20 kg). What is the daily dose of cefpodoxime per kilogram of body weight prescribed for this child?\n\n| Medication Name | Single Dose | Frequency per Day | Total Days of Treatment |\n|---|---|---|---|\n| Cefpodoxime dry syrup 50 mg/5 mL | 6 mL | 3 | 5 |\n\n① 1.5 mg/kg/day\n② 3 mg/kg/day\n③ 6 mg/kg/day\n④ 9 mg/kg/day\n⑤ 12 mg/kg/day",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 약국에서 이중잠금장치가 있는 철제금고에 보관하여야 하며, 마약류통합관리시스템에 의해 관리되는 약물은?\n\n① 트라마돌(tramadol)\n② 피록시캄(piroxicam)\n③ 펜터민(phentermine)\n④ 타펜타돌(tapentadol)\n⑤ 알프라졸람(alprazolam)",
        "question_text": "Question: Which drug must be stored in a steel safe with a double-locking mechanism in a pharmacy and is managed through the Narcotics Integrated Management System?\n\n① Tramadol\n② Piroxicam\n③ Phentermine\n④ Tapentadol\n⑤ Alprazolam",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 주사제 조제 시, 생리식염수에만 희석해야 하는 항암제는?\n\n① 도세탁셀(docetaxel)\n② 파클리탁셀(paclitaxel)\n③ 에토포시드(etoposide)\n④ 트라스투주맙(trastuzumab)\n⑤ 플루오로우라실(fluorouracil)",
        "question_text": "Question: When preparing injectable medications, which anticancer drug should be diluted only with normal saline?\n\n① Docetaxel\n② Paclitaxel\n③ Etoposide\n④ Trastuzumab\n⑤ Fluorouracil",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 평소 안구건조증이 있는 29세 여자가 약국에 방문하여 눈이 시리고 이물감이 있다고 한다. 환자는 안구건조증 이외 안과적인 이상소견이나 병력은 없다. 약사가 이 환자에게 추천할 수 있는 일반의약품 점안액에 포함된 성분은?\n\n① 트로픽아미드(tropicamide)\n② 사이클로스포린(cyclosporine)\n③ 시클로펜톨레이트(cyclopentolate)\n④ 플루오로메톨론(fluorometholone) \n⑤ 카르복시메틸셀룰로오스나트륨(sodium carboxymethylcellulose)",
        "question_text": "Question: A 29-year-old woman with a history of dry eye syndrome visits the pharmacy complaining of eye irritation and a foreign body sensation. The patient has no other ophthalmological abnormalities or medical history besides dry eye syndrome. Which ingredient should be included in the over-the-counter eye drops that the pharmacist can recommend to this patient?\n\n① Tropicamide\n② Cyclosporine\n③ Cyclopentolate\n④ Fluorometholone\n⑤ Sodium carboxymethylcellulose",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 6세 아이(16 kg)가 30분 후 배에 승선할 예정이다. 약사가 이 아이의 배멀미 예방을 위해 추천할 수 있는 약은?\n\n① 파모티딘(famotidine) 정 \n② 로라타딘(loratadine) 시럽\n③ 디시클로민(dicyclomine) 정\n④ 스코폴라민(scopolamine) 패치\n⑤ 디멘히드리네이트(dimenhydrinate) 복합시럽",
        "question_text": "Question: A 6-year-old child (16 kg) is scheduled to board a ship in 30 minutes. Which medication can a pharmacist recommend to prevent motion sickness for this child?\n\n① Famotidine tablet\n② Loratadine syrup\n③ Dicyclomine tablet\n④ Scopolamine patch\n⑤ Dimenhydrinate combination syrup",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 전일 약국에서 임신진단테스트기를 구매한 31세 여자가 테스트결과 사진을 약사에게 보여주었다. 결과가 다음과 같을 때 적절한 상담내용은?\n\n<Data (confidential)>\n\n① 자궁내 질환이 의심됨\n② 임신진단검사 결과 음성임\n③ 임신진단검사 결과 양성임\n④ 새로운 임신진단테스트기로 다시 검사하도록 함\n⑤ 배란진단테스트기로 추가검사를 수행해야 정확한 평가가 가능함",
        "question_text": "Question: A 31-year-old woman who purchased a pregnancy test kit from the pharmacy yesterday showed the test result photo to the pharmacist. When the result is as follows, what is the appropriate counseling content?\n\n<Data (confidential)>\n\n① Intrauterine disease is suspected\n② The pregnancy test result is negative\n③ The pregnancy test result is positive\n④ Advise to retest with a new pregnancy test kit\n⑤ An accurate assessment is possible only after performing an additional test with an ovulation test kit",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 애완견을 키우는 남자가 약국을 방문하여 애완견에게 투약할 진드기 구제약을 구입하고자 한다. 적절한 약물은?\n\n① 카르프로펜(carprofen)\n② 플루랄라너(fluralaner)\n③ 이버멕틴/파모산피란텔(ivermectin/pyrantel pamoate)\n④ 목시덱틴/이미다클로프리드(moxidectin/imidacloprid)\n⑤ 페반텔/파모산피란텔/프라지콴텔(febantel/pyrantel pamoate/praziquantel)",
        "question_text": "Question: A man who owns a pet dog visits a pharmacy to purchase a tick control medication for his dog. Which of the following is the appropriate medication?\n\n① Carprofen\n② Fluralaner\n③ Ivermectin/Pyrantel pamoate\n④ Moxidectin/Imidacloprid\n⑤ Febantel/Pyrantel pamoate/Praziquantel",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 사이클로스포린(cyclosporine) 연질캡슐을 복용하는 환자에게 복약지도 할 내용은?\n\n① 오후 4시 이전에 복용함\n② 혀 위에 놓고 녹여서 복용함\n③ 복용 후 입안을 물로 잘 헹굼\n④ 운전이나 위험한 기계 조작을 피해야 함\n⑤ 자몽 주스를 섭취하면 사이클로스포린 혈중농도가 증가함",
        "question_text": "Question: What should be included in the medication counseling for a patient taking cyclosporine soft capsules?\n\n① Take before 4 PM\n② Place on the tongue and let it dissolve\n③ Rinse the mouth well with water after taking\n④ Avoid driving or operating dangerous machinery\n⑤ Grapefruit juice consumption increases cyclosporine blood concentration",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 대동맥판막협착증과 심방세동을 진단받은 31세 여자가 와파린(warfarin) 복용을 시작하게 되어 복약지도실을 방문했다. 환자에게 설명해야 하는 내용은?\n\n① 동일한 용량으로 평생 복용한다. \n② 비타민D(vitamin D) 섭취를 주의한다.\n③ 정기적인 혈액응고검사가 필수적이다. \n④ 임신 여부와 상관없이 복용할 수 있다.\n⑤ 약물효과가 나타나면 소변색이 적갈색으로 변한다.",
        "question_text": "Question: A 31-year-old woman diagnosed with aortic stenosis and atrial fibrillation visited the medication counseling room to start taking warfarin. What should be explained to the patient?\n\n① Take the same dose for life.\n② Be cautious about vitamin D intake.\n③ Regular blood coagulation tests are essential.\n④ Can be taken regardless of pregnancy status.\n⑤ When the drug takes effect, urine color changes to reddish-brown.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 허가사항 중 이상반응으로 여성형 유방 발현이 기재되어, 특히 장기간 복용하는 남자에게 이에 관한 복약지도가 필요한 약물은?\n\n① 로사르탄(losartan)\n② 아테놀롤(atenolol)\n③ 푸로세미드(furosemide)\n④ 로수바스타틴(rosuvastatin)\n⑤ 스피로노락톤(spironolactone)",
        "question_text": "Question: Which medication, listed in its approval information as having gynecomastia as a side effect, requires counseling on this matter, especially for men taking it long-term?\n\n① Losartan\n② Atenolol\n③ Furosemide\n④ Rosuvastatin\n⑤ Spironolactone",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 플루티카손(fluticasone) 디스커스 흡입제에 대한 복약지도 내용으로 적절한 것은?\n\n① 사용 기간 동안 흡입제를 냉장보관 한다.\n② 흡입기 용량표시창에 60이 표시되면 폐기한다.\n③ 흡입 시 단맛을 느끼지 못하면 한 번 더 흡입한다. \n④ 흡입 후 10초간 숨을 참은 후 서서히 코로 내쉰다.\n⑤ 약효 유지를 위해 흡입 후 물을 마시거나 입안을 헹구지 않는다.",
        "question_text": "Question: Which of the following is appropriate medication counseling for fluticasone discus inhaler?\n\n① Store the inhaler in the refrigerator during the period of use.\n② Discard the inhaler when the dose counter shows 60.\n③ If you don't taste sweetness when inhaling, take another inhalation.\n④ After inhaling, hold your breath for 10 seconds, then slowly exhale through your nose.\n⑤ To maintain the effectiveness of the medication, do not drink water or rinse your mouth after inhalation.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 반하, 복령, 후박, 생강, 자소엽으로 구성되어, 기분이 우울하고 인후, 식도부위에 이물감이 있고, 때로는 숨참, 어지러움, 구역 등을 동반하는 불안신경증이나 신경성 위염에 사용하는 한약제제는?\n\n① 가미온담탕(加味溫膽湯)\n② 반하사심탕(半夏瀉心湯)\n③ 반하후박탕(半夏厚朴湯)\n④ 보중익기탕(補中益氣湯)\n⑤ 십전대보탕(十全大補湯)",
        "question_text": "Question: Which herbal medicine preparation, composed of Pinellia ternata, Poria cocos, Magnolia officinalis, ginger, and Perilla frutescens, is used for anxiety neurosis or neurogenic gastritis accompanied by depressed mood, a feeling of something stuck in the throat or esophagus, and sometimes shortness of breath, dizziness, and nausea?\n\n① Gami-ondam-tang (Jiawei Wendan Tang)\n② Banhasasim-tang (Banxia Xiexin Tang)\n③ Banhahubak-tang (Banxia Houpo Tang)\n④ Bojungikgi-tang (Buzhong Yiqi Tang)\n⑤ Sipjeondaebo-tang (Shiquan Dabu Tang)",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 의약품 제조부서 책임자와 품질(보증)부서 책임자가 제조관리와 품질관리를 적절히 이행하기 위하여 각자 갖추어야 하는 기준서 중 공통되는 것은?\n\n① 제조지시서\n② 제품표준서\n③ 품질관리기준서\n④ 제조관리기준서\n⑤ 제조위생관리기준서",
        "question_text": "Question: Which of the following documents is common to both the head of the pharmaceutical manufacturing department and the head of the quality (assurance) department in order to properly implement manufacturing control and quality control?\n\n① Manufacturing instructions\n② Product standard document\n③ Quality control standard document\n④ Manufacturing control standard document\n⑤ Manufacturing hygiene control standard document",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 의약품 제조소의 시설 기준에서, 별개의 건물로 되어 있고 충분히 떨어져 공기의 입구와 출구가 간섭받지 아니한 상태를 의미하는 것은?\n\n① 격리\n② 구분\n③ 구획\n④ 분리\n⑤ 선별",
        "question_text": "Question: In the facility standards for pharmaceutical manufacturing sites, which term refers to separate buildings that are sufficiently distant from each other, where the air inlets and outlets do not interfere with one another?\n\n① Isolation\n② Distinction\n③ Partitioning\n④ Separation\n⑤ Sorting",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 증기멸균법으로 멸균하고자 하는 용기 내에 미생물이 초기에 108개가 존재하였는데, 이 용기를 121℃에서 15분간 멸균시켰다면 비무균확률은? (단, 주어진 멸균조건에서 해당 미생물의 D 값은 1분이다.)\n\n① 10^-7\n② 10^-8\n③ 10^-9\n④ 10^-10\n⑤ 10^-11",
        "question_text": "Question: If there were initially 10^8 microorganisms in a container to be sterilized by steam sterilization, what is the probability of non-sterility after sterilizing this container at 121°C for 15 minutes? (Note: The D-value of the microorganism under the given sterilization conditions is 1 minute.)\n\n① 10^-7\n② 10^-8\n③ 10^-9\n④ 10^-10\n⑤ 10^-11",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 재밸리데이션이 필요한 변경에 해당하는 것은?\n\n① 검체채취 방법\n② 주성분 제조원\n③ 제품의 유통경로\n④ 품질보증 책임자\n⑤ 제품의 사용상 주의사항",
        "question_text": "Question: Which of the following changes requires revalidation?\n\n① Specimen collection method\n② Active ingredient manufacturer\n③ Product distribution channel\n④ Quality assurance manager\n⑤ Precautions for product use",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 신제품 및 그 제조공정을 처음 도입할 때 적용하는 밸리데이션은?\n\n① 적격성 평가\n② 세척 밸리데이션\n③ 동시적 밸리데이션\n④ 예측적 밸리데이션\n⑤ 회고적 밸리데이션",
        "question_text": "Question: What type of validation is applied when introducing a new product and its manufacturing process for the first time?\n\n① Qualification\n② Cleaning validation\n③ Concurrent validation\n④ Prospective validation\n⑤ Retrospective validation",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 습식과립법의 공정 밸리데이션에서 과립 제조 종말점 평가에 적합한 장비는?\n\n① 암미터(ammeter)\n② 경도계(hardness tester)\n③ 용출기(dissolution tester)\n④ 마손도 측정기(friability tester) \n⑤ 시차주사열량계(differential scanning calorimetry)",
        "question_text": "Question: Which equipment is suitable for evaluating the endpoint of granule production in the process validation of wet granulation method?\n\n① Ammeter\n② Hardness tester\n③ Dissolution tester\n④ Friability tester\n⑤ Differential scanning calorimetry (DSC)",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 여과 멸균공정에 사용되는 멤브레인필터의 유효성을 검증하는 방울점시험에 대한 설명으로 옳은 것은?\n\n① 파괴적 시험이다.\n② 이동압력은 세공의 최대크기에 비례한다.\n③ 시험 종료점은 공기방울 탐지로 정해진다.\n④ 측정된 세공크기는 실측크기를 측정한 것이다.\n⑤ 이동압력은 세공을 채우는 액체의 표면장력에 반비례한다.",
        "question_text": "Question: Which of the following statements is correct regarding the bubble point test used to verify the effectiveness of membrane filters in filtration sterilization processes?\n\n① It is a destructive test.\n② The breakthrough pressure is proportional to the maximum pore size.\n③ The endpoint of the test is determined by the detection of air bubbles.\n④ The measured pore size represents the actual measured size.\n⑤ The breakthrough pressure is inversely proportional to the surface tension of the liquid filling the pores.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 의약품 분야의 각종 기준 등의 조화를 촉진하는 것을 목표로 미국, 유럽연합, 일본이 주체가 되어 설립하였고 대한민국도 정회원으로 가입한 국제기구는?\n\n① ICH\n② PDA\n③ PDG\n④ PIC/S\n⑤ SUPAC",
        "question_text": "Question: Which international organization was established with the United States, European Union, and Japan as the main participants, aiming to promote harmonization of various standards in the pharmaceutical field, and of which South Korea is also a full member?\n\n① ICH\n② PDA\n③ PDG\n④ PIC/S\n⑤ SUPAC",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 회수대상의약품등의 위해등급평가와 회수계획 공표에 대한 내용으로 옳은 것은?\n\n① 치명적 성분이 섞여 있어 3등급 위해성으로 평가하였다.\n② 포장재의 변형이 발생하여 2등급 위해성으로 평가하였다. \n③ 의약품의 유효성이 입증되지 못하여 2등급 위해성으로 평가하였다.\n④ 2등급 위해성 의약품의 회수계획을 자사의 홈페이지에 공고하였다.\n⑤ 일시적 부작용을 초래하는 의약품의 회수계획을 일간신문에 공고하였다.",
        "question_text": "Question: Which of the following statements is correct regarding the hazard classification assessment and recall plan announcement for recalled pharmaceuticals?\n\n① It was assessed as a Class 3 hazard due to the presence of a fatal ingredient.\n② It was assessed as a Class 2 hazard due to deformation of the packaging material.\n③ It was assessed as a Class 2 hazard because the efficacy of the pharmaceutical was not proven.\n④ The recall plan for a Class 2 hazard pharmaceutical was announced on the company's website.\n⑤ The recall plan for a pharmaceutical causing temporary side effects was announced in a daily newspaper.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 원자재의 품질관리에서 무균제제용 용기 및 고무마개의 세척에 대한 설명으로 옳은 것은?\n\n① 최종 세척액으로 정제수를 사용한다.\n② 세척액에 계면활성제를 사용할 수 없다.\n③ 용기에 대한 세척 밸리데이션은 생략한다.\n④ 세척 후 멸균 전까지 보관기간의 한도를 정한다.\n⑤ 용기 및 고무마개의 바이오버든을 파악할 필요는 없다.",
        "question_text": "Question: Which of the following statements is correct regarding the cleaning of containers and rubber stoppers for sterile preparations in raw material quality control?\n\n① Purified water is used as the final rinse solution.\n② Surfactants cannot be used in the cleaning solution.\n③ Cleaning validation for containers is omitted.\n④ A time limit is set for storage between cleaning and sterilization.\n⑤ It is not necessary to determine the bioburden of containers and rubber stoppers.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에 규정된 제약용수 중 25℃에서의 전도율 기준이 정제수와 동일한 것은?\n\n① 상수\n② 주사용수\n③ 멸균정제수\n④ 멸균주사용수\n⑤ 정제수(Hermetic Container 내)",
        "question_text": "Question: Among the pharmaceutical waters specified in the Korean Pharmacopoeia, which one has the same conductivity standard at 25℃ as purified water?\n\n① Tap water\n② Water for injection\n③ Sterile purified water\n④ Sterile water for injection\n⑤ Purified water (in a Hermetic Container)",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: 완제의약품의 안정성시험에서 가혹시험에 대한 설명으로 옳은 것은?\n\n① 규정된 보관조건은 40℃/75% 상대습도이다.\n② 가혹시험 결과를 토대로 의약품 유통기간을 설정한다.\n③ 검체는 원칙적으로 포장하지 않은 상태에서 시험한다.\n④ 시험빈도는 1년째는 3개월마다, 그 이후에는 6개월마다 한다.\n⑤ 가혹시험에서 현저한 변화가 생기면 중간조건에서 추가 시험한다.",
        "question_text": "Question: Which of the following statements about stress testing in stability testing of finished pharmaceutical products is correct?\n\n① The specified storage condition is 40℃/75% relative humidity.\n② The product shelf life is determined based on the results of stress testing.\n③ In principle, samples are tested in an unpackaged state.\n④ The testing frequency is every 3 months for the first year, and every 6 months thereafter.\n⑤ If significant changes occur during stress testing, additional testing is conducted under intermediate conditions.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 항생물질의 동결건조물을 무색투명한 바이알에 충전하여 분말주사제를 제조한 경우에 사용된 용기는?\n\n① Hermetic Container\n② Sealed Container\n③ Closed Container\n④ 차광용기\n⑤ 차광Hermetic Container",
        "question_text": "Question: What type of container is used when manufacturing a powder injection by filling a colorless transparent vial with freeze-dried antibiotics?\n\n① Hermetic Container\n② Sealed Container\n③ Closed Container\n④ Light-resistant Container\n⑤ Light-resistant Hermetic Container",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 의약품등의 품목허가를 위한 기준 및 시험방법에 관한 자료에서, 원료의약품인 이부프로펜과 달리 완제의약품인 이부프로펜 캡슐에만 설정되는 시험항목은?\n\n① 저장법\n② 정량법\n③ 순도시험\n④ 확인시험\n⑤ 제제균일성시험",
        "question_text": "Question: In the data on standards and test methods for item approval of pharmaceuticals, which test item is established only for the finished product ibuprofen capsules, unlike the active pharmaceutical ingredient ibuprofen?\n\n① Storage method\n② Assay method\n③ Purity test\n④ Identification test\n⑤ Uniformity of dosage units test",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: Minister of Food and Drug Safety의 출하승인을 받아야 하는 품목은?\n\n① 인슐린 주사액\n② 코로나19 백신\n③ 페니실린G칼륨\n④ 테트라사이클린염산염\n⑤ 요오드화나트륨(123I) 주사액",
        "question_text": "Question: Which of the following items requires release approval from the Minister of Food and Drug Safety?\n\n① Insulin injection\n② COVID-19 vaccine\n③ Penicillin G potassium\n④ Tetracycline hydrochloride\n⑤ Sodium iodide (123I) injection",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia의 인슐린 정량법에서 사용하는 시험동물과 측정항목에 해당하는 것은?\n\n① 토끼 – 혈당\n② 토끼 – 혈색소\n③ 흰쥐 – 혈당\n④ 흰쥐 – 혈색소\n⑤ 흰쥐 – 혈중 질소농도",
        "question_text": "Question: In the insulin quantification method of the Korean Pharmacopoeia, what is the test animal used and the measurement parameter?\n\n① Rabbit – Blood glucose\n② Rabbit – Hemoglobin\n③ White rat – Blood glucose\n④ White rat – Hemoglobin\n⑤ White rat – Blood nitrogen concentration",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 의약품 생산 현장에서 품질보증의 관리수단으로 사용되는 품질관리도이다. (s는 표준편차를 의미한다.)\n<Data (confidential)>\n\nQuestion: 이 품질관리도에서 외부한계(outer limit)로, 상부 관리 한계선(UCL) 또는 하부 관리 한계선(LCL)을 벗어나 ‘관리이탈’로 판정되는 배치의 수는?\n\n① 0\n② 1\n③ 2\n④ 3\n⑤ 5",
        "question_text": "The following is a quality control chart used as a quality assurance management tool in pharmaceutical production. (s represents standard deviation.)\n<Data (confidential)>\n\nQuestion: In this quality control chart, how many batches are determined to be \"out of control\" by exceeding the outer limits, either the Upper Control Limit (UCL) or the Lower Control Limit (LCL)?\n\n① 0\n② 1\n③ 2\n④ 3\n⑤ 5",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음은 의약품 생산 현장에서 품질보증의 관리수단으로 사용되는 품질관리도이다. (s는 표준편차를 의미한다.)\n<Data (confidential)>\n\nQuestion: 외부한계(outer limit)로써 품질규격의 상한과 하한을 설정하는 경우 배치 7번의 공정능력지수는?\n\n① 0.3\n② 0.5\n③ 1\n④ 1.5\n⑤ 2",
        "question_text": "The following is a quality control chart used as a means of quality assurance management in pharmaceutical production. (s represents standard deviation.)\n<Data (confidential)>\n\nQuestion: When setting the upper and lower limits of quality specifications as outer limits, what is the process capability index for batch number 7?\n\n① 0.3\n② 0.5\n③ 1\n④ 1.5\n⑤ 2",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: A 제약사에서 마케팅 전략 수립을 위하여 SWOT분석을 수행하였다. 현재 A 사의 내적 상황은 상대적으로 기술이 뒤떨어진 것으로 평가되나, 외적 환경은 인구의 고령화로 A 사가 판매하는 의약품의 수요가 증가할 것으로 예측된다. 이러한 분석결과에 근거하여 A 사가 취할 적절한 전략은?\n\n① SO 전략\n② WO 전략\n③ ST 전략\n④ WT 전략\n⑤ 마케팅 믹스 전략",
        "question_text": "Question: Pharmaceutical company A conducted a SWOT analysis to establish a marketing strategy. In the current internal situation, Company A is evaluated to have relatively outdated technology, but the external environment predicts an increase in demand for the medicines sold by Company A due to an aging population. Based on these analysis results, what is the appropriate strategy for Company A to adopt?\n\n① SO strategy\n② WO strategy\n③ ST strategy\n④ WT strategy\n⑤ Marketing mix strategy",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 약국의 재무 관리 시, 유동비율(current ratio)에 대한 설명으로 옳은 것은?\n\n① 포괄손익계산서를 통하여 산출한다.\n② 당좌자산과 유동부채의 비율로 나타낸다.\n③ 값이 크면 유동자산에 대한 투자가 상대적으로 낮음을 뜻한다.\n④ 값이 작으면 기한 내에 유동 부채 상환에 문제가 있음을 뜻한다.\n⑤ 약국이 얼마나 자산을 효율적으로 사용하는지 측정하는 지표이다.",
        "question_text": "Question: Which of the following statements about the current ratio in pharmacy financial management is correct?\n\n① It is calculated using the statement of comprehensive income.\n② It is expressed as the ratio of quick assets to current liabilities.\n③ A higher value indicates relatively low investment in current assets.\n④ A lower value indicates potential issues with repaying current liabilities within the due date.\n⑤ It is an indicator that measures how efficiently a pharmacy uses its assets.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 2021년 한 해 동안 A약국의 의약품 매출원가는 2억 2천만 원이다. 2021년 구매비용(당기매입)은 2억 원, 연말재고(ending inventory)는 5천만 원이면, 기초재고(beginning inventory)는 얼마인가?\n\n① 3천만 원\n② 4천만 원\n③ 5천만 원\n④ 6천만 원\n⑤ 7천만 원",
        "question_text": "Question: The cost of goods sold for pharmacy A's medications in 2021 is 220 million won. If the purchase cost (current period purchases) in 2021 is 200 million won, and the ending inventory is 50 million won, what is the beginning inventory?\n\n① 30 million won\n② 40 million won\n③ 50 million won\n④ 60 million won\n⑤ 70 million won",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 효과적인 재고관리를 위한 경제적 주문량 모형에 대한 설명으로 옳은 것은?\n\n① 주문비용을 최소화할 수 있는 1회 최적주문량을 산출한다.\n② 재고유지비를 최소화할 수 있는 1회 최적주문량을 산출한다.\n③ 총재고관리비용을 최소화할 수 있는 1회 최적주문량을 산출한다.\n④ 경제적 주문량은 재주문시점과 조달기간이 일치하는 점에서 결정된다.\n⑤ 경제적 주문량은 재고유지비와 재고부족비용이 일치하는 점에서 결정된다.",
        "question_text": "Question: Which of the following statements about the Economic Order Quantity (EOQ) model for effective inventory management is correct?\n\n① It calculates the optimal order quantity per order that minimizes ordering costs.\n② It calculates the optimal order quantity per order that minimizes inventory holding costs.\n③ It calculates the optimal order quantity per order that minimizes total inventory management costs.\n④ The economic order quantity is determined at the point where the reorder point coincides with the lead time.\n⑤ The economic order quantity is determined at the point where the inventory holding costs equal the stockout costs.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 직무 설계에 해당하는 것은?\n\n병원에서 약사가 한 가지 종류의 업무만을 반복 수행하도록 분업화하여 배치하는 경우, 생산성은 향상되나 매너리즘에 빠져 도전감이 상실된다.\n\n① 직무순환(job rotation)\n② 직무확대(job enlargement)\n③ 직무충실화(job enrichment)\n④ 과학적 관리(scientific management)\n⑤ 직무특성모형(job characteristics approach)",
        "question_text": "Question: Which of the following job design approaches is being described?\n\nIn a hospital, when pharmacists are assigned to perform only one type of task repeatedly through division of labor, productivity improves, but they may fall into mannerism and lose a sense of challenge.\n\n① Job rotation\n② Job enlargement\n③ Job enrichment\n④ Scientific management\n⑤ Job characteristics approach",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 지불보상제도는?\n\n개별 의료서비스를 각각 독립적으로 보상할 수 있어 약사의 전문서비스와 같은 새로운 서비스 도입을 촉진하는 역할을 할 수 있으나, 서비스 양과 관리운영비가 증가하는 경향이 있다.\n\n① 인두제\n② 봉급제\n③ 포괄수가제\n④ 총액예산제\n⑤ 행위별수가제",
        "question_text": "Question: Which payment system is described below?\n\nThis system can compensate for individual medical services independently, potentially promoting the introduction of new services such as pharmacists' professional services. However, it tends to increase the volume of services and management costs.\n\n① Capitation system\n② Salary system\n③ Diagnosis-Related Group (DRG) system\n④ Global budget system\n⑤ Fee-for-service system",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 우리나라 건강보장제도와 해당 제도의 관리운영기관이 옳게 연결된 것은?\n\n① 요양급여 적정성 평가 – National Health Insurance Service\n② 건강보험 관련 정책 심의 ∙ 의결 – Korea Disease Control and Prevention Agency\n③ 의약품의 보험약가 협상 – Ministry of Food and Drug Safety\n④ 의료급여 진료비 지급 및 자격관리 – Ministry of Health and Welfare\n⑤ 건강보험 의약품 보험등재 결정 – Health Insurance Review & Assessment Service",
        "question_text": "Question: Which of the following correctly matches the health care system in our country with its managing institution?\n\n① Evaluation of appropriateness of medical care benefits – National Health Insurance Service\n② Deliberation and decision on health insurance-related policies – Korea Disease Control and Prevention Agency\n③ Negotiation of insurance prices for pharmaceuticals – Ministry of Food and Drug Safety\n④ Payment of medical care expenses and eligibility management for Medical Aid – Ministry of Health and Welfare\n⑤ Decision on insurance listing of pharmaceuticals for health insurance – Health Insurance Review & Assessment Service",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 개국 약사가 처방약 조제를 할 경우 약사가 받을 수 있는 건강보험 수가로 옳은 것은?\n\n① 조제일당으로 산정한 조제기본료\n② 방문당 정액으로 산정한 약국관리료 \n③ 처방전에 기재된 약 품목수로 산정한 복약지도료\n④ 처방전에 기재된 약 품목수로 산정한 의약품관리료\n⑤ 처방전에 기재된 외용약에 대해 투약일수로 산정한 조제료",
        "question_text": "Question: Which of the following is the correct health insurance fee that a community pharmacist can receive for dispensing prescription medications?\n\n① Basic dispensing fee calculated per dispensing day\n② Pharmacy management fee calculated as a fixed amount per visit\n③ Medication counseling fee calculated based on the number of drug items listed on the prescription\n④ Medication management fee calculated based on the number of drug items listed on the prescription\n⑤ Dispensing fee for external medications calculated based on the number of days of medication supply as listed on the prescription",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 유독물질을 많이 사용하는 사업장에서 일하는 A 씨는 암보험에 가입하기 위해 여러 보험회사에 문의했으나 모두 거절당했다. 이와 같이 보험자가 고위험군을 회피하려는 경향을 설명하는 것은?\n\n① 역선택\n② 외부효과\n③ 도덕적 해이\n④ 위험군 선택\n⑤ 의약품 정보의 비대칭",
        "question_text": "Question: Mr. A, who works at a workplace that uses a lot of toxic substances, inquired with several insurance companies to purchase cancer insurance but was rejected by all of them. Which of the following explains this tendency of insurers to avoid high-risk groups?\n\n① Adverse selection\n② Externality\n③ Moral hazard\n④ Risk group selection\n⑤ Asymmetry of pharmaceutical information",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 환자의 진료에 반드시 필요하지만 채산성이 없는 의약품에 대하여 생산원가를 보전하거나 사용장려비용을 지급하는 제도는?\n\n① 선별등재제도\n② 위험분담제도\n③ 약가 재평가 제도\n④ 사용량 약가 연동제도\n⑤ 퇴장방지의약품 관리제도",
        "question_text": "Question: What is the system that compensates for production costs or provides incentives for the use of pharmaceuticals that are essential for patient care but not economically viable?\n\n① Positive list system\n② Risk sharing system\n③ Drug price re-evaluation system\n④ Price-volume agreement system\n⑤ Essential drug management system",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 의료기관이나 약국에서 처방의약품을 상한가보다 낮은 가격으로 구매할 경우 그 차액을 이익으로 취득하는 것이 허용되지 않는다. 이를 규정한 제도는?\n\n① 고시가제도\n② 선별등재제도\n③ 위험분담제도\n④ 실거래가 상환제도\n⑤ 약제비 총액 관리제도",
        "question_text": "Question: When medical institutions or pharmacies purchase prescription drugs at a price lower than the maximum price, they are not allowed to retain the difference as profit. Which system regulates this?\n\n① Official price system\n② Selective listing system\n③ Risk-sharing system\n④ Actual transaction price reimbursement system\n⑤ Total pharmaceutical expenditure management system",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 임신 중 약물 A의 복약 여부와 조산의 연관성을 조사하기 위하여 정상분만 한 산모와 조산한 산모를 모집하여, 이들의 임신 기간 동안 약물 A의 복약 여부를 조사하였다. 다음 결과표에 따르면 약물 A와 조산의 관련성에 대한 지표명과 계산식이 옳은 것은?\n\n| | 조산한 산모(명) | 정상분만 한 산모(명) |\n|---|---|---|\n| A 약물 복용 | 10 | 1,000 |\n| A 약물 복용하지 않음 | 5 | 1,500 |\n\n① 오즈비(odds ratio)=(10/15)/(1,000/2,500)\n② 오즈비(odds ratio)=(10/5)/(1,000/1,500)\n③ 상대위험도(relative risk)=(10/15)/(1,000/2,500)\n④ 상대위험도(relative risk)= (10/1,000)/(5/1,500)\n⑤ 상대위험도(relative risk)= (10/1,010)/(5/1,505)",
        "question_text": "Question: To investigate the association between taking medication A during pregnancy and preterm birth, mothers who had normal deliveries and those who had preterm births were recruited. Their medication A intake during pregnancy was examined. According to the following result table, which indicator name and calculation formula for the relationship between medication A and preterm birth are correct?\n\n| | Mothers with preterm birth (n) | Mothers with normal delivery (n) |\n|---|---|---|\n| Took medication A | 10 | 1,000 |\n| Did not take medication A | 5 | 1,500 |\n\n① Odds ratio = (10/15)/(1,000/2,500)\n② Odds ratio = (10/5)/(1,000/1,500)\n③ Relative risk = (10/15)/(1,000/2,500)\n④ Relative risk = (10/1,000)/(5/1,500)\n⑤ Relative risk = (10/1,010)/(5/1,505)",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 4개 의약품(A, B, C, D)의 경제성평가 결과가 다음 그림과 같다. 임계값이 5천만 원/QALY라고 할 때, 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 위 그림은 비용효과수용곡선(cost-effectiveness acceptability curve)이다.\n② A는 비용효과적이다.\n③ B는 비용효과적이지 않다.\n④ C는 비용최소화분석 대상이다.\n⑤ D는 비용효과적이다.",
        "question_text": "Question: The results of economic evaluation for 4 pharmaceutical products (A, B, C, D) are shown in the following figure. When the threshold value is 50 million won/QALY, which of the following statements is correct?\n\n<Data (confidential)>\n\n① The above figure is a cost-effectiveness acceptability curve.\n② A is cost-effective.\n③ B is not cost-effective.\n④ C is a subject for cost-minimization analysis.\n⑤ D is cost-effective.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 의료기관 관점에서 수행한 이상지질혈증 치료제의 경제성평가를 사회적 관점으로 변경하여 수행할 때, 추가적으로 산출해야 하는 비용 항목은?\n\n① 혈중 지질 모니터링 환자 본인부담금 \n② 이상지질혈증 치료에 수반되는 검진비용\n③ 이상지질혈증 치료를 위한 비급여 약제비\n④ 이상지질혈증 치료제의 처방전 발급을 위한 외래방문 교통비\n⑤ 이상지질혈증 합병증 치료를 위한 응급실 진료비의 보험자 부담금",
        "question_text": "Question: When changing the economic evaluation of dyslipidemia treatment from a healthcare institution perspective to a societal perspective, which additional cost item should be calculated?\n\n① Patient's out-of-pocket expenses for blood lipid monitoring\n② Examination costs associated with dyslipidemia treatment\n③ Non-reimbursed medication costs for dyslipidemia treatment\n④ Transportation costs for outpatient visits to obtain prescriptions for dyslipidemia treatment\n⑤ Insurer's share of emergency room treatment costs for dyslipidemia complications",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 30세 뇌전증환자에게 복약지도를 하는 과정에서 환자가 치료약을 잘 복용하지 않음을 알게 된 약사는 이러한 사실을 주치의에게 알려 환자 치료결과가 개선되기를 기대하였다. 이러한 약사의 행동에서 충돌하는 윤리원칙은?\n\n① 선행의 원칙 – 정의의 원칙\n② 정의의 원칙 – 피해회피의 원칙\n③ 자율성 존중 원칙 – 선행의 원칙\n④ 자율성 존중 원칙 – 정의의 원칙\n⑤ 사생활 존중 원칙 – 피해회피의 원칙",
        "question_text": "Question: During medication counseling for a 30-year-old epilepsy patient, a pharmacist learned that the patient was not taking their prescribed medication properly. The pharmacist informed the attending physician of this fact, hoping to improve the patient's treatment outcomes. Which ethical principles are in conflict in this pharmacist's action?\n\n① Principle of beneficence – Principle of justice\n② Principle of justice – Principle of non-maleficence\n③ Principle of respect for autonomy – Principle of beneficence\n④ Principle of respect for autonomy – Principle of justice\n⑤ Principle of respect for privacy – Principle of non-maleficence",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 복약이행도 측정 방법 중 간단하고 비용이 적어 임상현장에서 가장 유용한 방법이나 환자에 의해 결과가 쉽게 왜곡될 수 있는 것은?\n\n① 환자 설문\n② 환자의 증상 완화 평가\n③ 환자의 혈중 약물 농도 측정\n④ 약물소지율(medication possession ratio) 평가\n⑤ 전자투약모니터(electronic medication monitor)",
        "question_text": "Question: Among the methods for measuring medication adherence, which one is the most useful in clinical settings due to its simplicity and low cost, but can be easily distorted by patients?\n\n① Patient questionnaire\n② Assessment of patient's symptom relief\n③ Measurement of patient's blood drug concentration\n④ Evaluation of medication possession ratio\n⑤ Electronic medication monitor",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nA 지역 20세 이상 성인 중 대장암으로 사망한 사람은 총 300명이다. A 지역의 연령별 인구수와 표준인구의 연령별 대장암사망률은 다음 표와 같다.\n\n| 연령구간 | A 지역 인구수(명) | 표준인구의 대장암사망률(명/10만 명) |\n|---|---|---|\n| 20~39세 | 500 |000 | 2 |\n| 40~59세 | 800 |000 | 4 |\n| 60세 이상 | 900 |000 | 12 |\n| 계 | 2,200 |000 | - |\n\nQuestion: A 지역 20세 이상 성인의 인구 10만 명당 대장암으로 인한 기대 사망자수는?\n\n① 150명\n② 200명\n③ 250명\n④ 300명\n⑤ 350명",
        "question_text": "In region A, a total of 300 people over the age of 20 died from colorectal cancer. The population by age group in region A and the colorectal cancer mortality rate by age group in the standard population are shown in the following table.\n\n| Age Group | Population in Region A | Colorectal Cancer Mortality Rate in Standard Population (per 100,000) |\n|---|---|---|\n| 20-39 years | 500,000 | 2 |\n| 40-59 years | 800,000 | 4 |\n| 60 years and over | 900,000 | 12 |\n| Total | 2,200,000 | - |\n\nQuestion: What is the expected number of deaths due to colorectal cancer per 100,000 adults aged 20 and over in region A?\n\n① 150 people\n② 200 people\n③ 250 people\n④ 300 people\n⑤ 350 people",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nA 지역 20세 이상 성인 중 대장암으로 사망한 사람은 총 300명이다. A 지역의 연령별 인구수와 표준인구의 연령별 대장암사망률은 다음 표와 같다.\n\n| 연령구간 | A 지역 인구수(명) | 표준인구의 대장암사망률(명/10만 명) |\n|---|---|---|\n| 20~39세 | 500 |000 | 2 |\n| 40~59세 | 800 |000 | 4 |\n| 60세 이상 | 900 |000 | 12 |\n| 계 | 2,200 |000 | - |\n\nQuestion: A 지역 20세 이상 성인의 대장암 표준화사망비에 대한 설명으로 옳은 것은?\n\n① 직접표준화 방법에서 얻어지는 값이다.\n② (기대사망자수)/(관찰사망자수)로 계산한다.\n③ 값이 1보다 크므로 A 지역의 대장암 위험도는 표준인구집단보다 높다.\n④ 값이 1보다 작으므로 A 지역의 대장암 위험도는 표준인구집단보다 높다.\n⑤ 값이 1보다 작으므로 A 지역의 대장암 위험도는 표준인구집단보다 낮다.",
        "question_text": "In region A, a total of 300 adults aged 20 and over died from colorectal cancer. The population by age group in region A and the colorectal cancer mortality rate by age group in the standard population are shown in the following table.\n\n| Age Group | Population in Region A | Colorectal Cancer Mortality Rate in Standard Population (per 100,000) |\n|---|---|---|\n| 20-39 years | 500,000 | 2 |\n| 40-59 years | 800,000 | 4 |\n| 60 years and over | 900,000 | 12 |\n| Total | 2,200,000 | - |\n\nQuestion: Which of the following statements about the standardized mortality ratio for colorectal cancer among adults aged 20 and over in region A is correct?\n\n① It is a value obtained from the direct standardization method.\n② It is calculated as (expected number of deaths) / (observed number of deaths).\n③ Since the value is greater than 1, the risk of colorectal cancer in region A is higher than in the standard population.\n④ Since the value is less than 1, the risk of colorectal cancer in region A is higher than in the standard population.\n⑤ Since the value is less than 1, the risk of colorectal cancer in region A is lower than in the standard population.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 한약제제에 대한 설명으로 옳지 않은 것은?\n\n① 약국개설자는 한약제제를 개봉하여 판매할 수 있다.\n② “한약제제”란 한방원리에 따라 배합한 생약을 말한다.\n③ 약국개설자는 한약제제를 취급하는 도매상 허가를 받을 수 없다.\n④ 약사는 한약제제를 제조하는 제조소에서 제조 업무를 관리할 수 있다.\n⑤ 한약제제 품목허가를 받은 자는 약사를 두고 시판 후 안전관리를 할 수 있다.",
        "question_text": "Question: Which of the following statements about herbal medicinal preparations under the \"Pharmaceutical Affairs Act\" is incorrect?\n\n① Pharmacy owners can sell herbal medicinal preparations after opening them.\n② \"Herbal medicinal preparations\" refer to crude drugs combined according to traditional Korean medicine principles.\n③ Pharmacy owners cannot obtain a wholesale license for handling herbal medicinal preparations.\n④ Pharmacists can manage the manufacturing process in facilities that produce herbal medicinal preparations.\n⑤ Those who have obtained product approval for herbal medicinal preparations can employ pharmacists for post-marketing safety management.",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국을 개설하고자 하는 자가 등록을 위해 갖추어야 할 기준에 대한 설명으로 옳은 것은?\n\n① 조제에 필요한 기구를 갖추어야 한다.\n② 해당 지역 약사회에 미리 신고하여야 한다.\n③ 의약품을 따로 보관할 수 있는 창고를 갖추어야 한다.\n④ 개설하고자 하는 약국과 의료기관 사이에 통로가 설치되어 있어야 한다.\n⑤ \"Pharmaceutical Affairs Act\" 위반으로 개설등록이 취소된 날로부터 3개월이 된 자는 등록할 수 있다.",
        "question_text": "Question: Which of the following is the correct description of the standards that a person who wants to establish a pharmacy must meet for registration according to the \"Pharmaceutical Affairs Act\"?\n\n① They must have the necessary equipment for compounding.\n② They must notify the local pharmacists' association in advance.\n③ They must have a separate storage facility for medicines.\n④ There must be a passageway installed between the pharmacy to be established and medical institutions.\n⑤ A person whose registration was canceled due to violation of the \"Pharmaceutical Affairs Act\" can register again after 3 months from the date of cancellation.",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 복약지도서에 포함되어야 할 정보가 아닌 것은?\n\n① 저장방법\n② 원료약품의 분량\n③ 상호작용을 포함한 부작용\n④ 성상을 포함한 의약품의 명칭\n⑤ 의약품 부작용 피해구제절차 안내",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT required to be included in the medication guidance document?\n\n① Storage method\n② Quantity of raw materials\n③ Side effects, including interactions\n④ Name of the medication, including its appearance\n⑤ Information on the procedure for medication side effect relief",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 처방전과 조제기록부에 관한 내용으로 옳은 것은?\n\n① 조제기록부는 전자문서로 작성할 수 없다.\n② 약사는 환자가 처방전 사본의 발급을 요청하는 경우 이에 응하여야 한다.\n③ 약국에서 의약품을 조제하고 작성한 조제기록부는 3년 동안 보존하여야 한다.\n④ 약국에서 조제한 처방전은 의사가 발행한 날로부터 2년 동안 보존하여야 한다.\n⑤ 약사는 환자가 조제기록부의 열람을 요청하는 경우 정당한 사유 없이 이를 거부하여서는 아니 된다.",
        "question_text": "Question: Which of the following is correct regarding prescriptions and dispensing records according to the \"Pharmaceutical Affairs Act\"?\n\n① Dispensing records cannot be created as electronic documents.\n② Pharmacists must comply when patients request a copy of their prescription.\n③ Dispensing records created when dispensing medications at a pharmacy must be preserved for 3 years.\n④ Prescriptions dispensed at a pharmacy must be preserved for 2 years from the date of issuance by the doctor.\n⑤ Pharmacists must not refuse without justifiable reason when patients request to view their dispensing records.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자와 의료기관 개설자 사이의 담합행위 또는 담합의 소지가 있는 행위에 해당하지 않는 것은?\n\n① 약국개설자가 처방전을 알선해 준 의료기관 개설자에게 상품권을 주었다.\n② 약국개설자가 특정 의료기관의 처방전을 가진 자에게 약제비 10%를 할인해 주었다.\n③ 의료기관 개설자가 처방전을 가진 자에게 특정 약국에서 조제 받도록 유도하였다.\n④ 의료기관 개설자가 특정 약국에서 조제할 수 있는 기호를 적어 처방전을 발급하였다.\n⑤ 의료기관 개설자가 처방전을 가진 자에게 주변 약국들의 명칭 ∙ 소재지를 안내하였다.",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT considered a collusive act or an act that could lead to collusion between pharmacy owners and medical institution owners?\n\n① A pharmacy owner gave gift certificates to a medical institution owner who referred prescriptions.\n② A pharmacy owner offered a 10% discount on medication costs to patients with prescriptions from a specific medical institution.\n③ A medical institution owner guided patients with prescriptions to have them filled at a specific pharmacy.\n④ A medical institution owner issued prescriptions with a code indicating they should be filled at a specific pharmacy.\n⑤ A medical institution owner provided patients with prescriptions information about the names and locations of nearby pharmacies.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품을 판매하거나 판매할 목적으로 의약품을 취득할 수 없는 자는?\n\n① 한약업사\n② 의약품 도매상\n③ Korea Institute of Drug Safety & Risk Management\n④ 안전상비의약품 판매자\n⑤ Korea Orphan and Essential Drug Center",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" who is not allowed to sell or acquire drugs for the purpose of selling?\n\n① Oriental medicine pharmacist\n② Pharmaceutical wholesaler\n③ Korea Institute of Drug Safety & Risk Management\n④ Over-the-counter drug retailer\n⑤ Korea Orphan and Essential Drug Center",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 도매상 허가를 받을 수 있는 자는?\n\n① 약국개설자\n② 피한정후견인\n③ 파산선고를 받고 복권되지 아니한 자\n④ 거짓으로 약제비를 청구하여 약사면허 취소 처분을 받고 1년이 된 자\n⑤ 부정한 방법으로 도매상 허가를 받아 허가가 취소된 후",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" who can obtain a license for pharmaceutical wholesale business?\n\n① A pharmacy owner\n② A person under limited guardianship\n③ A person who has been declared bankrupt and has not been reinstated\n④ A person whose pharmacist license was revoked for fraudulent billing of pharmaceutical expenses, and one year has passed since the revocation\n⑤ A person whose wholesale license was revoked due to obtaining it through fraudulent means, after the revocation",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품의 품목허가 갱신에 대한 설명으로 옳은 것은?\n\n① 품목허가의 유효기간은 3년으로 한다.\n② 원료의약품은 유효기간을 적용하지 아니한다.\n③ 제조관리자는 의약품의 제조판매 품목허가의 갱신 업무를 철저히 하여야 한다.\n④ 재심사 대상 의약품에 대한 품목허가의 유효기간은 재심사 기간이 시작된 날부터 적용한다.\n⑤ 품목허가의 유효기간 동안 제조되지 아니한 희귀의약품에 대하여는 품목허가를 갱신받을 수 없다.",
        "question_text": "Question: Which of the following statements is correct regarding the renewal of product licenses for pharmaceuticals under the \"Pharmaceutical Affairs Act\"?\n\n① The validity period of a product license is 3 years.\n② The validity period does not apply to raw material pharmaceuticals.\n③ The manufacturing manager must thoroughly manage the renewal of manufacturing and sales product licenses for pharmaceuticals.\n④ For pharmaceuticals subject to re-examination, the validity period of the product license applies from the day the re-examination period begins.\n⑤ Orphan drugs that have not been manufactured during the validity period of the product license cannot have their license renewed.",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품특허권에 관련된 사항과 신청자가 바르게 연결된 것은?\n\n① 우선판매품목허가의 신청 – 등재특허권자\n② 의약품특허권 등재사항 삭제의 신청 – 특허청장\n③ 의약품특허권 등재사항 변경의 신청 – 특허권등재자\n④ \"Patent Act\"에 따른 특허침해 예방 청구의 소 제기 – Minister of Food and Drug Safety\n⑤ 품목허가 신청사실이 통지된 의약품의 판매금지 신청 –Minister of Health and Welfare",
        "question_text": "Question: Which of the following correctly matches the item related to pharmaceutical patent rights under the \"Pharmaceutical Affairs Act\" with the appropriate applicant?\n\n① Application for priority sales item approval – Registered patent holder\n② Application for deletion of registered pharmaceutical patent rights – Commissioner of the Korean Intellectual Property Office\n③ Application for change in registered pharmaceutical patent rights – Patent registrant\n④ Filing a lawsuit for prevention of patent infringement according to the \"Patent Act\" – Minister of Food and Drug Safety\n⑤ Application for sales prohibition of a drug for which a product approval application has been notified – Minister of Health and Welfare",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 동물용 의약품의 판매에 대한 설명으로 옳은 것은?\n\n① 약국개설자는 동물병원 개설자에게 동물용 의약품을 판매할 수 없다.\n② 약국개설자는 수의사 또는 수산질병관리사의 처방전 없이 주사용 항생물질 제제를 판매할 수 있다.\n③ 동물용 의약품을 판매하는 자는 수의사의 처방전 없이 Minister of Agriculture, Food and Rural Affairs이 정하는 도서 ∙ 벽지의 축산농가에 판매하여서는 아니 된다.\n④ 동물용 의약품을 판매하는 자는 Mayor/Do Governor가 긴급방역의 목적으로 동물용 의약품의 사용을 명령한 경우, 수의사의 처방전 없이 판매할 수 있다.\n⑤ 동물용 의약품 도매상의 허가를 받은 자는 오용 ∙ 남용으로 동물의 건강에 위해를 끼칠 우려가 있는 호르몬제를 수의사의 처방전 없이 판매할 수 있다.",
        "question_text": "Question: Which of the following statements is correct regarding the sale of veterinary medicines according to the \"Pharmaceutical Affairs Act\"?\n\n① A pharmacy owner cannot sell veterinary medicines to animal hospital owners.\n② A pharmacy owner can sell injectable antibiotic preparations without a prescription from a veterinarian or aquatic animal disease manager.\n③ Those who sell veterinary medicines must not sell to livestock farms in remote islands and mountainous areas designated by the Minister of Agriculture, Food and Rural Affairs without a veterinarian's prescription.\n④ Those who sell veterinary medicines can sell without a veterinarian's prescription when the Mayor/Do Governor orders the use of veterinary medicines for the purpose of emergency disease control.\n⑤ Those who have obtained a license for wholesale of veterinary medicines can sell hormone preparations that may harm animal health due to misuse or abuse without a veterinarian's prescription.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자가 의약품으로 인하여 발생하였다고 의심되는 유해사례로서 총리령으로 정하는 중대한 질병 ∙ 사망 사례를 알게 된 경우에 누구에게 보고하여야 하는가?\n\n① 보건소장\n② Mayor/Do Governor\n③ Commissioner of the Korea Disease Control and Prevention Agency\n④ Head of a Si/Gun/Gu\n⑤ President of Korea Institute of Drug Safety & Risk Management",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" to whom should a pharmacy owner report when they become aware of a serious illness or death case, as specified by the Prime Minister's Decree, that is suspected to have been caused by a pharmaceutical product?\n\n① Director of the Public Health Center\n② Mayor/Do Governor\n③ Commissioner of the Korea Disease Control and Prevention Agency\n④ Head of a Si/Gun/Gu\n⑤ President of Korea Institute of Drug Safety & Risk Management",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 Minister of Health and Welfare이 1년 이내의 기간을 정하여 약사 자격정지를 명할 수 있는 대상은?\n\n① 향정신성의약품에 중독된 자\n② 약국의 개설자가 될 수 없는 자에게 고용되어 약사의 업무를 한 자\n③ \"The Act on the Improvement of Mental Health and the Support for Welfare Services for Mental Patients\"에 따른 정신질환자\n④ 약사(藥事)에 관한 법령을 위반하여 금고 이상의 형을 선고받고 집행이 종료되지 아니한 자\n⑤ \"Narcotics Control Act\"을 위반하여 징역형을 선고받고 집행을 받지 아니하기로 확정되지 아니한 자",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" who can the Minister of Health and Welfare order to suspend their pharmacist license for a period of up to one year?\n\n① A person addicted to psychotropic drugs\n② A person who has been employed by someone who cannot be a pharmacy owner and has performed pharmacist duties\n③ A person with mental illness according to \"The Act on the Improvement of Mental Health and the Support for Welfare Services for Mental Patients\"\n④ A person who has been sentenced to imprisonment or a heavier punishment for violating laws related to pharmaceutical affairs and whose sentence has not been completed\n⑤ A person who has been sentenced to imprisonment for violating the \"Narcotics Control Act\" and whose sentence has not been finalized for non-execution",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류가 아닌 것은?\n\n① 칸나비스 사티바 엘(Cannabis sativa L.)의 수지\n② 에리드록실룸 코카 람(Erythroxylum coca Lam.)의 잎\n③ 소포라 야포니카 엘(Sophora japonica L.)의 꽃봉오리\n④ 파파베르 솜니페룸 엘(Papaver somniferum L.)의 열매\n⑤ 파파베르 세티게룸 디시(Papaver setigerum DC.)의 액즙이 응결된 것",
        "question_text": "Question: Which of the following is NOT classified as a narcotic under the \"Narcotics Control Act\"?\n\n① Resin of Cannabis sativa L.\n② Leaves of Erythroxylum coca Lam.\n③ Flower buds of Sophora japonica L.\n④ Fruit of Papaver somniferum L.\n⑤ Coagulated sap of Papaver setigerum DC.",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류취급자 중 지정을 받아야 자격이 얻어지는 자는?\n\n① 마약류관리자\n② 마약류제조업자\n③ 마약류도매업자\n④ 마약류취급의료업자\n⑤ 마약류취급학술연구자",
        "question_text": "Question: According to the \"Narcotics Control Act,\" which of the following narcotic drug handlers requires a designation to obtain qualification?\n\n① Narcotic drug manager\n② Narcotic drug manufacturer\n③ Narcotic drug wholesaler\n④ Narcotic drug handling medical practitioner\n⑤ Narcotic drug handling academic researcher",
        "answer": 1
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류취급의료업자가 마약 중독자에게 마약을 사용할 수 있는 경우는?\n\n① 마약류안전관리심의위원회의 심의를 거친 경우\n② 치료보호기관에서 Mayor/Do Governor의 허가를 받은 경우\n③ 중독 증상의 완화를 목적으로 마약을 투약하는 경우\n④ 중독 증상의 치료를 목적으로 마약을 기재한 처방전을 발급하는 경우\n⑤ 중독 증상의 치료를 목적으로 마약을 투약하기 위하여 제공하는 경우",
        "question_text": "Question: According to the \"Narcotics Control Act,\" in which case can a medical practitioner who handles narcotics use narcotics on a drug addict?\n\n① When it has been reviewed by the Narcotics Safety Management Review Committee\n② When permission has been obtained from the Mayor/Do Governor at a treatment and protection facility\n③ When administering narcotics for the purpose of alleviating addiction symptoms\n④ When issuing a prescription containing narcotics for the purpose of treating addiction symptoms\n⑤ When providing narcotics for the purpose of administering them to treat addiction symptoms",
        "answer": 2
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: \"National Health Promotion Act\"상 국민의 금연을 위하여 시행하는 정책에 해당하지 않는 것은?\n\n① 금연구역의 지정\n② 가향물질 함유 표시 제한\n③ 흡연자를 위한 흡연실 설치 금지\n④ 담배자동판매기에 성인인증장치 부착\n⑤ 담배갑포장지에 흡연의 폐해를 나타내는 내용의 경고그림 표시",
        "question_text": "Question: Which of the following is NOT a policy implemented for smoking cessation among citizens according to the \"National Health Promotion Act\"?\n\n① Designation of non-smoking areas\n② Restriction on labeling of flavoring substances\n③ Prohibition of installing smoking rooms for smokers\n④ Attachment of adult verification devices on cigarette vending machines\n⑤ Display of warning images showing the harmful effects of smoking on cigarette packaging",
        "answer": 3
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: \"Framework Act on Health and Medical Services\"상 보건의료인의 책임에 해당하는 것은?\n\n① 국민건강 증진에 필요한 재원을 확보하도록 노력하여야 한다.\n② 국민건강의 보호 ∙ 증진을 위하여 필요한 법적 ∙ 제도적 장치를 마련하여야 한다.\n③ 각종 국민건강 위해 요인으로부터 국민의 건강을 보호하기 위한 시책을 강구하도록 노력하여야 한다.\n④ 민간이 행하는 보건의료에 대하여 보건의료 시책상 필요하다고 인정하면 행정적 ∙ 재정적 지원을 하여야 한다.\n⑤ 국가가 관리해야 할 질병에 걸린 것으로 의심되는 대상자를 발견한 때에는 그 사실을 관계 기관에 신고하는 등 필요한 조치를 하여야 한다.",
        "question_text": "Question: According to the \"Framework Act on Health and Medical Services,\" which of the following is the responsibility of health and medical service personnel?\n\n① They should strive to secure the necessary financial resources for promoting national health.\n② They should establish necessary legal and institutional measures for the protection and promotion of national health.\n③ They should endeavor to devise measures to protect the health of the people from various factors that threaten national health.\n④ They should provide administrative and financial support to private health and medical services when deemed necessary for health and medical policies.\n⑤ When they discover a person suspected of having a disease that should be managed by the state, they should take necessary measures such as reporting the fact to the relevant authorities.",
        "answer": 5
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"의 목적에 따른 요양급여에 포함되지 않는 것은?\n\n① 예방\n② 이송\n③ 재활\n④ 단기보호\n⑤ 약제의 지급",
        "question_text": "Question: Which of the following is NOT included in the medical care benefits according to the purpose of the \"National Health Insurance Act\"?\n\n① Prevention\n② Transportation\n③ Rehabilitation\n④ Short-term care\n⑤ Provision of medications",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 건강보험 요양급여비용의 산정과 지급에 대한 설명으로 옳은 것은?\n\n① 한약제에 대한 요양급여비용은 원칙적으로 구입금액을 기준으로 산정한다.\n② 치료재료에 대한 요양급여비용은 원칙적으로 상한금액을 기준으로 산정한다.\n③ 한약제 외의 약제의 구입금액이 상한금액을 초과하는 경우에도 구입금액 전부를 약국에 상환한다.\n④ 약국의 조제료에 대하여 대한약사회와 President of National Health Insurance Service의 계약이 체결되면 그 계약은 National Health Insurance Service과 각 약국 사이에 체결된 것으로 본다.\n⑤ 약사가 아닌 자가 \"Pharmaceutical Affairs Act\"을 위반하여 약국을 개설한 사실을 수사기관의 수사 결과로 확인하더라도 그 약국이 청구한 요양급여비용의 지급을 보류할 수 없다.",
        "question_text": "Question: Which of the following statements is correct regarding the calculation and payment of health insurance benefits under the \"National Health Insurance Act\"?\n\n① The cost of herbal medicine benefits is, in principle, calculated based on the purchase price.\n② The cost of treatment materials benefits is, in principle, calculated based on the maximum price.\n③ Even if the purchase price of medications other than herbal medicines exceeds the maximum price, the entire purchase amount is reimbursed to the pharmacy.\n④ When a contract for dispensing fees is concluded between the Korean Pharmaceutical Association and the President of the National Health Insurance Service, it is considered to be a contract between the National Health Insurance Service and each pharmacy.\n⑤ Even if it is confirmed through a police investigation that a non-pharmacist has opened a pharmacy in violation of the \"Pharmaceutical Affairs Act\", the payment of health insurance benefits claimed by that pharmacy cannot be withheld.",
        "answer": 4
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: \"Regional Public Health Act\"상 보건소의 설치와 운영에 대한 설명으로 옳은 것은?\n\n① Eup/Myeon/Dong마다 1개씩 설치한다.\n② 마약류취급자 관리에 대한 업무는 수행할 수 없다.\n③ \"Medical Service Act\"에 따른 종합병원의 요건을 갖추어야 한다.\n④ 전문인력의 최소 배치 기준에 따라 약사를 두어야 한다.\n⑤ \"The Act on Special Measures for Health and Medical Services in Agricultural and Fishing Villages\"에 따라 Minister of the Interior and Safety이 설치한다.",
        "question_text": "Question: According to the \"Regional Public Health Act,\" which of the following statements about the establishment and operation of public health centers is correct?\n\n① One is established for each Eup/Myeon/Dong.\n② They cannot perform tasks related to the management of narcotic drug handlers.\n③ They must meet the requirements of a general hospital as per the \"Medical Service Act.\"\n④ They must employ pharmacists according to the minimum staffing standards for professional personnel.\n⑤ They are established by the Minister of the Interior and Safety in accordance with \"The Act on Special Measures for Health and Medical Services in Agricultural and Fishing Villages.\"",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 골격근의 수축 과정에서 ATP 가수분해가 필요한 단계는?\n\n① 액틴 섬유의 인산화\n② 트로포미오신의 이동\n③ 트로포닌 복합체의 형성\n④ 액틴 섬유의 단량체로의 해리\n⑤ 미오신 머리의 입체구조 변화",
        "question_text": "Question: In the process of skeletal muscle contraction, which step requires ATP hydrolysis?\n\n① Phosphorylation of actin filaments\n② Movement of tropomyosin\n③ Formation of troponin complex\n④ Dissociation of actin filaments into monomers\n⑤ Conformational change of myosin head",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: Michaelis-Menten 속도론을 따르는 단일 기질의 효소반응에서 다음 특징을 지닌 가역 억제제를 첨가할 경우, 효소의 겉보기 Km과 Vmax의 변화는?\n\n• 효소-기질 복합체에 결합하여 효소 활성을 억제한다.\n• 기질이 결합하지 않은 효소의 활성에는 영향을 주지 않는다.\n\n겉보기 Km | 겉보기 Vmax\n① 증가변화 | 없음\n② 증가 | 감소\n③ 감소변화 | 없음\n④ 감소 | 감소\n⑤ 변화 없음 | 감소",
        "question_text": "Question: In an enzyme reaction with a single substrate following Michaelis-Menten kinetics, what are the changes in the apparent Km and Vmax of the enzyme when adding a reversible inhibitor with the following characteristics?\n\n• It binds to the enzyme-substrate complex and inhibits enzyme activity.\n• It does not affect the activity of the enzyme without the substrate bound.\n\nApparent Km | Apparent Vmax\n① Increase | No change\n② Increase | Decrease\n③ Decrease | No change\n④ Decrease | Decrease\n⑤ No change | Decrease",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 다음 설명에 해당하는 물질은?\n\n• proteoglycan의 구성성분이다.\n• 이당류가 반복되는 구조를 지닌다.\n• 동물 조직의 세포바깥바탕질에서 볼 수 있다.\n\n① glycolipid\n② glycosaminoglycan\n③ lectin\n④ lipopolysaccharide\n⑤ peptidoglycan",
        "question_text": "Question: Which of the following substances matches this description?\n\n• It is a component of proteoglycan.\n• It has a structure of repeating disaccharides.\n• It can be found in the extracellular matrix of animal tissues.\n\n① glycolipid\n② glycosaminoglycan\n③ lectin\n④ lipopolysaccharide\n⑤ peptidoglycan",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 다음 과정을 촉매하는 효소는?\n\n<Data (confidential)>\n\n① lactate dehydrogenase\n② phosphoenolpyruvate carboxykinase\n③ phosphofructokinase-1\n④ pyruvate carboxylase\n⑤ pyruvate kinase",
        "question_text": "Question: Which enzyme catalyzes the following process?\n\n<Data (confidential)>\n\n① lactate dehydrogenase\n② phosphoenolpyruvate carboxykinase\n③ phosphofructokinase-1\n④ pyruvate carboxylase\n⑤ pyruvate kinase",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: ‘조효소’와 ‘매개하는 효소반응’이 바르게 연결된 것은?\n\n① FAD – 아미노기 전달 반응\n② coenzyme A – 메틸기 전달 반응\n③ coenzyme B12 – 아실기 전달 반응\n④ pyridoxal phosphate – 인산기 전달 반응\n⑤ thiamine pyrophosphate – 알데히드기 전달 반응",
        "question_text": "Question: Which of the following correctly matches the 'coenzyme' with the 'enzyme reaction it mediates'?\n\n① FAD – Amino group transfer reaction\n② Coenzyme A – Methyl group transfer reaction\n③ Coenzyme B12 – Acyl group transfer reaction\n④ Pyridoxal phosphate – Phosphate group transfer reaction\n⑤ Thiamine pyrophosphate – Aldehyde group transfer reaction",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 다음 효소들이 촉매하는 대사경로는?\n\n• glucose 6-phosphate dehydrogenase\n• 6-phosphogluconate dehydrogenase\n• transaldolase\n\n① 요소회로\n② 해당과정\n③ 포도당신합성\n④ 시트르산회로\n⑤ 오탄당인산경로",
        "question_text": "Question: Which metabolic pathway is catalyzed by the following enzymes?\n\n• glucose 6-phosphate dehydrogenase\n• 6-phosphogluconate dehydrogenase\n• transaldolase\n\n① Urea cycle\n② Glycolysis\n③ Gluconeogenesis\n④ Citric acid cycle\n⑤ Pentose phosphate pathway",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 다음 설명에 해당하는 단백질은?\n\n• 저혈당 시 glycogen synthase의 음성 조절자로 작용한다.\n• 고혈당 시 protein kinase B에 의해 인산화되어 활성이 억제된다.\n\n① glycogen phosphorylase a\n② glycogen synthase kinase 3\n③ insulin receptor substrate-1\n④ mitogen-activated protein kinase\n⑤ phosphoprotein phosphatase 1",
        "question_text": "Question: Which protein corresponds to the following description?\n\n• Acts as a negative regulator of glycogen synthase during hypoglycemia.\n• Its activity is inhibited by phosphorylation by protein kinase B during hyperglycemia.\n\n① glycogen phosphorylase a\n② glycogen synthase kinase 3\n③ insulin receptor substrate-1\n④ mitogen-activated protein kinase\n⑤ phosphoprotein phosphatase 1",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 사람 세포에서 지방산 생합성에 필요한 아세틸기가 미토콘드리아에서 세포질로 운반되는 형태는?\n\n① citrate\n② malate\n③ phosphoenolpyruvate\n④ propionyl-CoA\n⑤ succinyl-CoA",
        "question_text": "Question: In what form is the acetyl group, necessary for fatty acid synthesis in human cells, transported from the mitochondria to the cytoplasm?\n\n① citrate\n② malate\n③ phosphoenolpyruvate\n④ propionyl-CoA\n⑤ succinyl-CoA",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 콜레스테롤에스테르(cholesteryl ester)의 질량 구성 비율(%)이 가장 높은 지질단백질은?\n\n① 암죽미립\n② 고밀도지질단백질\n③ 중밀도지질단백질\n④ 저밀도지질단백질\n⑤ 초저밀도지질단백질",
        "question_text": "Question: Which lipoprotein has the highest mass composition ratio (%) of cholesteryl ester?\n\n① Chylomicron\n② High-density lipoprotein (HDL)\n③ Intermediate-density lipoprotein (IDL)\n④ Low-density lipoprotein (LDL)\n⑤ Very low-density lipoprotein (VLDL)",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 콜레스테롤, 비타민A, 비타민E의 생합성 과정에서 공통적으로 생성되는 중간체는?\n\n① δ-aminolevulinate\n② Δ3-isopentenyl pyrophosphate\n③ lanosterol\n④ malonate\n⑤ sphingosine",
        "question_text": "Question: What is the common intermediate produced in the biosynthesis of cholesterol, vitamin A, and vitamin E?\n\n① δ-aminolevulinate\n② Δ3-isopentenyl pyrophosphate\n③ lanosterol\n④ malonate\n⑤ sphingosine",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 핵산 생합성 과정에서 N 5,N 10-methylenetetrahydrofolate가 필요한 효소는?\n\n① dCTP deaminase\n② dUTPase\n③ nucleoside diphosphate kinase\n④ ribonucleotide reductase\n⑤ thymidylate synthase",
        "question_text": "Question: Which enzyme requires N5,N10-methylenetetrahydrofolate in the nucleic acid biosynthesis process?\n\n① dCTP deaminase\n② dUTPase\n③ nucleoside diphosphate kinase\n④ ribonucleotide reductase\n⑤ thymidylate synthase",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 진핵세포의 5.8S, 18S, 28S ribosomal RNA의 서열을 포함하는 전구 라이보소체 RNA(preribosomal RNA)를 합성하는 효소는?\n\n① RNA 중합효소 I\n② RNA 중합효소 II\n③ RNA 중합효소 III\n④ RNA 중합효소 α\n⑤ RNA 중합효소 β",
        "question_text": "Question: Which enzyme synthesizes the precursor ribosomal RNA (pre-ribosomal RNA) that includes the sequences of 5.8S, 18S, and 28S ribosomal RNA in eukaryotic cells?\n\n① RNA polymerase I\n② RNA polymerase II\n③ RNA polymerase III\n④ RNA polymerase α\n⑤ RNA polymerase β",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 타목시펜(tamoxifen)의 표적 단백질이 직접 매개하는 생화학 반응은?\n\n① DNA 복제 촉진\n② caspase-3 활성화\n③ 유전자의 전사 촉진\n④ 히스톤 단백질 분해\n⑤ protein kinase A 활성화",
        "question_text": "Question: Which biochemical reaction is directly mediated by the target protein of tamoxifen?\n\n① Promotion of DNA replication\n② Activation of caspase-3\n③ Promotion of gene transcription\n④ Degradation of histone proteins\n⑤ Activation of protein kinase A",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 세포주기에서 cyclin 단백질의 활성이 저해되는 기전은?\n\n① GDP와의 결합\n② pRb 단백질과의 결합\n③ 분자내 이황화 결합의 형성\n④ farnesylation에 의한 세포막으로의 이동\n⑤ ubiquitin 결합 후 proteasome에 의한 분해",
        "question_text": "Question: What is the mechanism by which cyclin protein activity is inhibited in the cell cycle?\n\n① Binding with GDP\n② Binding with pRb protein\n③ Formation of intramolecular disulfide bonds\n④ Translocation to the cell membrane by farnesylation\n⑤ Degradation by proteasome after ubiquitin binding",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 적혈구의 헤모글로빈(Hb)을 헤모글로빈 A1c(HbA1c)로 변환시키는 반응은?\n\n① 변광회전(mutarotation)\n② 이성질화(isomerization)\n③ 인산화(phosphorylation)\n④ 비효소적 당화(glycation)\n⑤ 효소적 당화(glycosylation)",
        "question_text": "Question: Which reaction converts hemoglobin (Hb) in red blood cells to hemoglobin A1c (HbA1c)?\n\n① Mutarotation\n② Isomerization\n③ Phosphorylation\n④ Non-enzymatic glycation\n⑤ Enzymatic glycosylation",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 다음의 증상이 나타날 때 섭취해야 하는 것은?\n\n• 탄소 개수가 홀수인 지방산의 대사 저하\n• 메틸말론산과 호모시스테인의 혈중 농도 증가\n• 거대적혈모구빈혈 발생\n\n① 비오틴\n② 티아민\n③ 나이아신\n④ 코발라민\n⑤ 피리독신",
        "question_text": "Question: Which of the following should be consumed when these symptoms appear?\n\n• Impaired metabolism of fatty acids with odd-numbered carbon atoms\n• Increased blood concentrations of methylmalonic acid and homocysteine\n• Development of megaloblastic anemia\n\n① Biotin\n② Thiamine\n③ Niacin\n④ Cobalamin\n⑤ Pyridoxine",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: Adenosine deaminase의 유전적 결핍이 있는 사람에게서 나타날 수 있는 것은?\n\n① 통풍\n② 고혈압\n③ 면역결핍\n④ 케톤산증\n⑤ 레슈-니한증후군",
        "question_text": "Question: What can be observed in individuals with a genetic deficiency of adenosine deaminase?\n\n① Gout\n② Hypertension\n③ Immunodeficiency\n④ Ketoacidosis\n⑤ Lesch-Nyhan syndrome",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 가족성고콜레스테롤혈증(familial hypercholesterolemia)에서 변이 빈도가 높은 것은?\n\n① 고밀도지질단백질 수용체 유전자\n② 저밀도지질단백질 수용체 유전자\n③ 스테롤 조절요소 결합 단백질(SREBP) 유전자\n④ SR-B1 수용체(scavenger receptor, class B type 1) 유전자\n⑤ β-하이드록시-β-메틸글루타릴-CoA 환원효소(HMG-CoA reductase) 유전자",
        "question_text": "Question: Which gene has a high mutation frequency in familial hypercholesterolemia?\n\n① High-density lipoprotein receptor gene\n② Low-density lipoprotein receptor gene\n③ Sterol regulatory element-binding protein (SREBP) gene\n④ SR-B1 receptor (scavenger receptor, class B type 1) gene\n⑤ β-hydroxy-β-methylglutaryl-CoA reductase (HMG-CoA reductase) gene",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n암 환자의 암세포에서 표피성장인자수용체(epidermal growth factor receptor, EGFR) 활성이 증가한 것을 관찰하였다.\n\nQuestion: 이 환자에서 EGFR 활성이 증가하게 된 기전으로 볼 수 있는 것은?\n\n① EGF의 세포막 통과가 촉진되었다.\n② EGFR과 β-어레스틴의 결합력이 증가하였다.\n③ EGFR의 티로신 인산화효소 활성이 증가하였다.\n④ EGF-EGFR 복합체의 세포내로의 유입이 증가하였다.\n⑤ EGF-EGFR 복합체가 특정 DNA 서열에 결합하여 유전자 전사가 활성화되었다.",
        "question_text": "An increased activity of epidermal growth factor receptor (EGFR) was observed in the cancer cells of a cancer patient.\n\nQuestion: Which of the following can be considered as the mechanism for the increased EGFR activity in this patient?\n\n① The membrane permeability of EGF was enhanced.\n② The binding affinity between EGFR and β-arrestin increased.\n③ The tyrosine kinase activity of EGFR increased.\n④ The internalization of EGF-EGFR complex into the cell increased.\n⑤ The EGF-EGFR complex bound to specific DNA sequences, activating gene transcription.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n암 환자의 암세포에서 표피성장인자수용체(epidermal growth factor receptor, EGFR) 활성이 증가한 것을 관찰하였다.\n\nQuestion: 이 환자에게 적용할 수 있는 맞춤 치료법은?\n\n① 활성형의 재조합 EGF를 투여한다.\n② caspase-3의 활성을 억제하는 약물을 투여한다.\n③ EGFR 활성을 저해하는 단일클론 항체를 투여한다.\n④ Ras 단백질의 GTPase 활성을 억제하는 약물을 투여한다.\n⑤ 인산화 효소의 ATP 결합력을 증가시키는 약물을 투여한다.",
        "question_text": "It was observed that the activity of epidermal growth factor receptor (EGFR) was increased in the cancer cells of a cancer patient.\n\nQuestion: What personalized treatment can be applied to this patient?\n\n① Administer recombinant active EGF.\n② Administer a drug that inhibits caspase-3 activity.\n③ Administer a monoclonal antibody that inhibits EGFR activity.\n④ Administer a drug that inhibits the GTPase activity of Ras protein.\n⑤ Administer a drug that increases the ATP binding capacity of phosphorylase.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 세포막의 지질구조에서 소수성 측쇄가 글리세롤과 에테르 결합(ether bond)을 이루고 있는 미생물에 관한 설명으로 옳은 것은?\n\n① 80S 리보솜을 가진다.\n② 세포벽 성분은 펩티도글리칸이다.\n③ 리팜핀(rifampin)에 감수성이 있다.\n④ 카나마이신(kanamycin)에 감수성이 있다.\n⑤ 단백질 합성 개시 아미노산은 메티오닌이다.",
        "question_text": "Question: Which of the following statements is correct about microorganisms whose cell membrane lipid structure has hydrophobic side chains forming ether bonds with glycerol?\n\n① They have 80S ribosomes.\n② The cell wall component is peptidoglycan.\n③ They are sensitive to rifampin.\n④ They are sensitive to kanamycin.\n⑤ The initiating amino acid for protein synthesis is methionine.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 한센병 원인균의 항산성염색에서 양성을 나타내게 하는 성분은?\n\n① 포린(porin)\n② 단백질 A(protein A)\n③ 마이콜산(mycolic acid)\n④ 테이코산(teichoic acid)\n⑤ N-아세틸뮤람산(N-acetylmuramic acid)",
        "question_text": "Question: Which component causes a positive result in acid-fast staining of the causative organism of Hansen's disease?\n\n① Porin\n② Protein A\n③ Mycolic acid\n④ Teichoic acid\n⑤ N-acetylmuramic acid",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 감염된 환자에서 다음과 같은 증상을 나타내는 그람양성균은?\n\n척추강직, 침흘림, 헛웃음, 호흡곤란, 후궁반장\n\n① 탄저균(Bacillus anthracis)\n② 파상풍균(Clostridium tetani )\n③ 수막염균(Neisseria meningitidis)\n④ 보툴리눔균(Clostridium botulinum )\n⑤ 화농연쇄구균(Streptococcus pyogenes)",
        "question_text": "Question: Which Gram-positive bacterium shows the following symptoms in infected patients?\n\nSpinal rigidity, drooling, risus sardonicus, respiratory distress, opisthotonos\n\n① Bacillus anthracis\n② Clostridium tetani\n③ Neisseria meningitidis\n④ Clostridium botulinum\n⑤ Streptococcus pyogenes",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: C형간염 바이러스의 RNA 의존성 RNA 중합효소를 저해하는 C형간염 치료제는?\n\n① 아데포비르(adefovir)\n② 사퀴나비르(saquinavir)\n③ 텔라프레비르(telaprevir)\n④ 소포스부비르(sofosbuvir)\n⑤ 랄테그라비르(raltegravir)",
        "question_text": "Question: Which of the following is a Hepatitis C treatment that inhibits the RNA-dependent RNA polymerase of the Hepatitis C virus?\n\n① Adefovir\n② Saquinavir\n③ Telaprevir\n④ Sofosbuvir\n⑤ Raltegravir",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 바이러스는?\n\n• DNA 바이러스이다.\n• 이 바이러스 감염은 백신으로 예방할 수 있다.\n• 이 바이러스에 의한 감염병을 치료하기 위해 라미부딘 (lamivudine)을 사용할 수 있다.\n\n① hepatitis B virus\n② human polyomavirus\n③ human papillomavirus\n④ human T-cell leukemia virus\n⑤ human immunodeficiency virus",
        "question_text": "Question: Which virus is described below?\n\n• It is a DNA virus.\n• Infection by this virus can be prevented with a vaccine.\n• Lamivudine can be used to treat the infectious disease caused by this virus.\n\n① hepatitis B virus\n② human polyomavirus\n③ human papillomavirus\n④ human T-cell leukemia virus\n⑤ human immunodeficiency virus",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 테르비나핀(terbinafine)의 표적 단백질은?\n\n① ATP 합성효소(ATP synthase)\n② 국소이성화효소(topoisomerase)\n③ RNA 중합효소(RNA polymerase)\n④ 스쿠알렌 에폭시다아제(squalene epoxidase)\n⑤ 아미노아실-tRNA 합성효소(aminoacyl-tRNA synthetase)",
        "question_text": "Question: What is the target protein of terbinafine?\n\n① ATP synthase\n② Topoisomerase\n③ RNA polymerase\n④ Squalene epoxidase\n⑤ Aminoacyl-tRNA synthetase",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 바시트라신(bacitracin)의 항미생물 작용기전은?\n\n① 전사과정에서 RNA 중합효소 억제\n② 단백질 생합성에서 리보솜 이동 억제\n③ 세포벽 생합성에서 transpeptidase 억제\n④ 세포벽 생합성에서 alanine racemase 억제\n⑤ 세포벽 생합성에서 bactoprenol pyrophosphate의 탈인산화 억제",
        "question_text": "Question: What is the antimicrobial mechanism of action of bacitracin?\n\n① Inhibition of RNA polymerase in the transcription process\n② Inhibition of ribosome translocation in protein biosynthesis\n③ Inhibition of transpeptidase in cell wall biosynthesis\n④ Inhibition of alanine racemase in cell wall biosynthesis\n⑤ Inhibition of dephosphorylation of bactoprenol pyrophosphate in cell wall biosynthesis",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 30S 리보솜 소단위를 표적으로 하여 단백질 생합성을 억제하고 살균 활성을 나타내는 항생제는?\n\n① 린코마이신(lincomycin)\n② 겐타마이신(gentamicin)\n③ 에리트로마이신(erythromycin)\n④ 스트렙토그라민(streptogramin)\n⑤ 클로람페니콜(chloramphenicol)",
        "question_text": "Question: Which antibiotic targets the 30S ribosomal subunit, inhibits protein biosynthesis, and exhibits bactericidal activity?\n\n① Lincomycin\n② Gentamicin\n③ Erythromycin\n④ Streptogramin\n⑤ Chloramphenicol",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 테트라사이클린(tetracycline)에 글리신(glycine) 유도체를 결합시킨 항생제로, 테트라사이클린 내성을 나타내는 균주에 사용되는 것은?\n\n① 독시사이클린(doxycycline)\n② 미노사이클린(minocycline)\n③ 타이제사이클린(tigecycline)\n④ 데메클로사이클린(demeclocycline)\n⑤ 옥시테트라사이클린(oxytetracycline)",
        "question_text": "Question: Which antibiotic, formed by combining a glycine derivative with tetracycline, is used against strains that show resistance to tetracycline?\n\n① Doxycycline\n② Minocycline\n③ Tigecycline\n④ Demeclocycline\n⑤ Oxytetracycline",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 케토라이드(ketolide)계 항생제로, 에리트로마이신(erythromycin)에 내성을 나타내는 폐렴연쇄구균(Streptococcus pneumoniae)에 사용되는 약물은?\n\n① 리파마이신(rifamycin)\n② 반코마이신(vancomycin)\n③ 클린다마이신(clindamycin)\n④ 텔리트로마이신(telithromycin)\n⑤ 클래리트로마이신(clarithromycin)",
        "question_text": "Question: Which drug from the ketolide class of antibiotics is used for Streptococcus pneumoniae that shows resistance to erythromycin?\n\n① Rifamycin\n② Vancomycin\n③ Clindamycin\n④ Telithromycin\n⑤ Clarithromycin",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 클로람페니콜(chloramphenicol)의 부작용인 재생불량빈혈을 해결하기 위해 니트로기를 메틸설포닐(methylsulfonyl)기로 치환한 항생제는?\n\n① 시녹사신(cinoxacin)\n② 이세파마이신(isepamicin)\n③ 피닥소마이신(fidaxomicin)\n④ 티암페니콜(thiamphenicol)\n⑤ 아지담페니콜(azidamfenicol)",
        "question_text": "Question: Which antibiotic was developed by replacing the nitro group with a methylsulfonyl group to address the aplastic anemia side effect of chloramphenicol?\n\n① Cinoxacin\n② Isepamicin\n③ Fidaxomicin\n④ Thiamphenicol\n⑤ Azidamfenicol",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: CD1d가 제시하는 당지질 항원을 인식하는 T 세포 수용체(TCR)를 가진 면역세포는?\n\n① T 세포\n② B 세포\n③ 대식세포\n④ NKT 세포\n⑤ 수지상세포",
        "question_text": "Question: Which immune cell has a T cell receptor (TCR) that recognizes glycolipid antigens presented by CD1d?\n\n① T cell\n② B cell\n③ Macrophage\n④ NKT cell\n⑤ Dendritic cell",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: C3b에 의해 옵소닌화된 면역복합체와 결합하는 적혈구 표면의 보체수용체는?\n\n① CR1\n② CR2\n③ CR3\n④ CR4\n⑤ properdin",
        "question_text": "Question: Which complement receptor on the surface of red blood cells binds to immune complexes opsonized by C3b?\n\n① CR1\n② CR2\n③ CR3\n④ CR4\n⑤ properdin",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 후기 엔도솜에서 외인성 항원 펩티드와 MHC class II 분자의 결합을 촉진하는 단백질은?\n\n① HLA-DM\n② invariant chain\n③ β2-microglobulin\n④ proteasome\n⑤ tapasin",
        "question_text": "Question: Which protein facilitates the binding of exogenous antigen peptides and MHC class II molecules in late endosomes?\n\n① HLA-DM\n② invariant chain\n③ β2-microglobulin\n④ proteasome\n⑤ tapasin",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 시상하부에 작용하여 체온을 상승시키며 간에서 급성기반응(acute phase reaction)을 유도하는 시토카인(cytokine)은?\n\n① 인터루킨-2(IL-2)\n② 인터루킨-4(IL-4)\n③ 인터페론-γ(IFN-γ)\n④ 인터루킨-10(IL-10)\n⑤ 종양괴사인자-α(TNF-α)",
        "question_text": "Question: Which cytokine acts on the hypothalamus to increase body temperature and induces acute phase reaction in the liver?\n\n① Interleukin-2 (IL-2)\n② Interleukin-4 (IL-4)\n③ Interferon-γ (IFN-γ)\n④ Interleukin-10 (IL-10)\n⑤ Tumor Necrosis Factor-α (TNF-α)",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 제1형 과민반응에 해당하는 것은?\n\n① 혈청병(serum sickness)\n② 아르투스반응(Arthus reaction)\n③ 투베르쿨린반응(tuberculin reaction)\n④ 수혈반응(blood transfusion reaction)\n⑤ 전신아나필락시스(systemic anaphylaxis)",
        "question_text": "Question: Which of the following is a Type I hypersensitivity reaction?\n\n① Serum sickness\n② Arthus reaction\n③ Tuberculin reaction\n④ Blood transfusion reaction\n⑤ Systemic anaphylaxis",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 다음 특징을 가진 시토카인(cytokine)은?\n\n• B 세포의 IgA 클래스전환(class switching)을 유도한다.\n• 이차림프조직에서 조절 T 세포(regulatory T cell)의 분화를 유도한다.\n• IL-6과 함께 작용하여, IL-17을 분비하는 CD4+ T 세포 아집단의 분화를 유도한다.\n\n① 인터페론-α(IFN-α)\n② 인터루킨-12(IL-12)\n③ 전환성장인자-β(TGF-β)\n④ 에리트로포이에틴(EPO)\n⑤ 대식세포집락자극인자(M-CSF)",
        "question_text": "Question: Which cytokine has the following characteristics?\n\n• Induces IgA class switching in B cells.\n• Promotes differentiation of regulatory T cells in secondary lymphoid tissues.\n• Acts together with IL-6 to induce differentiation of CD4+ T cell subsets that secrete IL-17.\n\n① Interferon-α (IFN-α)\n② Interleukin-12 (IL-12)\n③ Transforming growth factor-β (TGF-β)\n④ Erythropoietin (EPO)\n⑤ Macrophage colony-stimulating factor (M-CSF)",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: CD20에 결합하여 B 세포 비호지킨림프종의 치료에 사용되는 키메라 단일클론 항체의약품은?\n\n① 리툭시맙(rituximab)\n② 세툭시맙(cetuximab)\n③ 아달리무맙(adalimumab)\n④ 트라스투주맙(trastuzumab)\n⑤ 펨브롤리주맙(pembrolizumab)",
        "question_text": "Question: Which chimeric monoclonal antibody drug binds to CD20 and is used in the treatment of B-cell non-Hodgkin's lymphoma?\n\n① Rituximab\n② Cetuximab\n③ Adalimumab\n④ Trastuzumab\n⑤ Pembrolizumab",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n혈변을 동반하지 않는 심한 물설사(watery diarrhea)로 입원한 환자에게 우선적으로 수분과 전해질을 보충하였다. 설사 샘플로부터 균을 분리하여 동정한 결과, 콤마 형태의 단편모 그람음성균으로 확인되었다.\n\nQuestion: 위 사례에서 동정된 세균은?\n\n① Escherichia coli O157:H7\n② Proteus vulgaris\n③ Salmonella Typhi\n④ Shigella dysenteriae\n⑤ Vibrio cholerae",
        "question_text": "A patient was admitted to the hospital with severe watery diarrhea without bloody stools. The patient was primarily treated with fluid and electrolyte replacement. Upon isolation and identification of bacteria from the diarrheal sample, a comma-shaped, monotrichous, gram-negative bacterium was confirmed.\n\nQuestion: Which bacterium was identified in the above case?\n\n① Escherichia coli O157:H7\n② Proteus vulgaris\n③ Salmonella Typhi\n④ Shigella dysenteriae\n⑤ Vibrio cholerae",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n혈변을 동반하지 않는 심한 물설사(watery diarrhea)로 입원한 환자에게 우선적으로 수분과 전해질을 보충하였다. 설사 샘플로부터 균을 분리하여 동정한 결과, 콤마 형태의 단편모 그람음성균으로 확인되었다.\n\nQuestion: 이 균에 의한 심한 물설사의 원인 기전은?\n\n① streptolysin 생산\n② 소장 연동운동 저하\n③ 적혈구 용혈독소 생산\n④ 시가독소(Shiga toxin) 생산\n⑤ 장 상피세포에서 cAMP 증가",
        "question_text": "A patient was admitted to the hospital with severe watery diarrhea without bloody stools. The patient was primarily treated with fluid and electrolyte replacement. Upon isolation and identification of bacteria from the diarrheal sample, a comma-shaped, monotrichous, gram-negative bacterium was confirmed.\n\nQuestion: What is the mechanism causing severe watery diarrhea by this bacterium?\n\n① Production of streptolysin\n② Decreased small intestine peristalsis\n③ Production of erythrocyte hemolysin\n④ Production of Shiga toxin\n⑤ Increase of cAMP in intestinal epithelial cells",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 약물을 장기간 복용할 때, 복용 초기에 비해 같은 용량에 대한 효능이 줄어드는 경우가 있다. 이를 의미하는 용어는?\n\n① 내성(tolerance)\n② 탐닉성(addiction)\n③ 습관성(habituation)\n④ 축적작용(accumulation)\n⑤ 반응급강하현상(tachyphylaxis)",
        "question_text": "Question: When taking medication for a long period, there are cases where the efficacy of the same dose decreases compared to the initial intake. What is the term that describes this phenomenon?\n\n① Tolerance\n② Addiction\n③ Habituation\n④ Accumulation\n⑤ Tachyphylaxis",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 살충제를 살포하던 농부가 눈물과 콧물이 계속 나오고, 동공은 축소되어 있으며, 숨 쉬기가 어려운 증상을 호소한다. 이 환자의 증상을 완화할 수 있는 약물은?\n\n① 아트로핀(atropine)\n② 필로카르핀(pilocarpine)\n③ 에드로포늄(edrophonium)\n④ 아미팜프리딘(amifampridine)\n⑤ N-아세틸시스테인(N-acetylcysteine)",
        "question_text": "Question: A farmer who was spraying pesticides complains of continuous tearing and runny nose, constricted pupils, and difficulty breathing. Which drug can alleviate this patient's symptoms?\n\n① Atropine\n② Pilocarpine\n③ Edrophonium\n④ Amifampridine\n⑤ N-acetylcysteine",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 아드레날린(adrenaline)과 미라베그론(mirabegron)의 공통적인 약리작용은?\n\n① 기관지 수축\n② 배뇨근 이완\n③ 총말초저항 증가\n④ 글리코겐 분해 억제\n⑤ α-수용체의 선택적 활성화",
        "question_text": "Question: What is the common pharmacological action of adrenaline and mirabegron?\n\n① Bronchial constriction\n② Detrusor muscle relaxation\n③ Increase in total peripheral resistance\n④ Inhibition of glycogen breakdown\n⑤ Selective activation of α-receptors",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 성인 크롬친화세포종(pheochromocytoma) 환자의 높은 혈압을 조절하기 위한 초기 치료 약물은?\n\n① 클로니딘(clonidine)\n② 도부타민(dobutamine)\n③ 메토프롤롤(metoprolol)\n④ 이소프로테레놀(isoproterenol)\n⑤ 페녹시벤자민(phenoxybenzamine)",
        "question_text": "Question: What is the initial drug treatment for controlling high blood pressure in adult patients with pheochromocytoma?\n\n① Clonidine\n② Dobutamine\n③ Metoprolol\n④ Isoproterenol\n⑤ Phenoxybenzamine",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 추체외로 독성이 매우 높은 항정신병 약물은?\n\n① 클로자핀(clozapine)\n② 쿠에티아핀(quetiapine)\n③ 할로페리돌(haloperidol)\n④ 지프라시돈(ziprasidone)\n⑤ 아리피프라졸(aripiprazole)",
        "question_text": "Question: Which antipsychotic drug has a very high extrapyramidal toxicity?\n\n① Clozapine\n② Quetiapine\n③ Haloperidol\n④ Ziprasidone\n⑤ Aripiprazole",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 세로토닌의 재흡수를 선택적으로 억제하는 항우울약은?\n\n① 페넬진(phenelzine)\n② 잘레플론(zaleplon)\n③ 트라조돈(trazodone)\n④ 올란자핀(olanzapine)\n⑤ 시탈로프람(citalopram)",
        "question_text": "Question: Which antidepressant selectively inhibits the reuptake of serotonin?\n\n① Phenelzine\n② Zaleplon\n③ Trazodone\n④ Olanzapine\n⑤ Citalopram",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 파킨슨병 치료에 사용하는 D2 도파민 수용체 효능약은?\n\n① 셀레길린(selegiline)\n② 로피니롤(ropinirole)\n③ 엔타카폰(entacapone)\n④ 카르비도파(carbidopa)\n⑤ 벤즈트로핀(benztropine)",
        "question_text": "Question: Which of the following is a D2 dopamine receptor agonist used in the treatment of Parkinson's disease?\n\n① Selegiline\n② Ropinirole\n③ Entacapone\n④ Carbidopa\n⑤ Benztropine",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 수술후장폐색증(postoperative ileus) 치료에 사용하는 아편수용체 길항약은?\n\n① 수펜타닐(sufentanil)\n② 알비모판(alvimopan)\n③ 옥시코돈(oxycodone)\n④ 펜타조신(pentazocine)\n⑤ 로페라미드(loperamide)",
        "question_text": "Question: Which opioid receptor antagonist is used in the treatment of postoperative ileus?\n\n① Sufentanil\n② Alvimopan\n③ Oxycodone\n④ Pentazocine\n⑤ Loperamide",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 남성에서는 여성형유방을, 여성에서는 유즙분비를 초래할 수 있는 H2 수용체 길항약은?\n\n① 파모티딘(famotidine)\n② 시메티딘(cimetidine)\n③ 라베프라졸(rabeprazole)\n④ 수크랄페이트(sucralfate)\n⑤ 미소프로스톨(misoprostol)",
        "question_text": "Question: Which H2 receptor antagonist can cause gynecomastia in men and galactorrhea in women?\n\n① Famotidine\n② Cimetidine\n③ Rabeprazole\n④ Sucralfate\n⑤ Misoprostol",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 다음 약물들의 공통적인 작용기전은?\n\n• 아나킨라(anakinra)\n• 릴로나셉트(rilonacept)\n• 카나키누맙(canakinumab)\n\n① E-selectin 작용 차단\n② 산화질소(NO) 생성 억제\n③ 인터루킨-1(IL-1) 작용 차단\n④ 종양괴사인자-α(TNF-α) 작용 차단\n⑤ 시클로옥시게나제-2(COX-2) 작용 억제",
        "question_text": "Question: What is the common mechanism of action of the following drugs?\n\n• Anakinra\n• Rilonacept\n• Canakinumab\n\n① Blocking E-selectin action\n② Inhibition of nitric oxide (NO) production\n③ Blocking interleukin-1 (IL-1) action\n④ Blocking tumor necrosis factor-α (TNF-α) action\n⑤ Inhibition of cyclooxygenase-2 (COX-2) action",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 거대적혈모구빈혈 치료에 사용되는 약물은?\n\n① 폴산(folic acid)\n② 나이아신(niacin)\n③ 티아민(thiamine)\n④ 데페록사민(deferoxamine)\n⑤ 글루콘산제일철(ferrous gluconate)",
        "question_text": "Question: Which drug is used in the treatment of megaloblastic anemia?\n\n① Folic acid\n② Niacin\n③ Thiamine\n④ Deferoxamine\n⑤ Ferrous gluconate",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 급성관상동맥증후군 환자에게 사용하는 혈소판의 glycoprotein IIb/IIIa 수용체 차단약은?\n\n① 헤파린(heparin)\n② 와파린(warfarin)\n③ 실로스타졸(cilostazol)\n④ 티클로피딘(ticlopidine)\n⑤ 엡티피바티드(eptifibatide)",
        "question_text": "Question: Which of the following is a platelet glycoprotein IIb/IIIa receptor antagonist used in patients with acute coronary syndrome?\n\n① Heparin\n② Warfarin\n③ Cilostazol\n④ Ticlopidine\n⑤ Eptifibatide",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 강심배당체 디곡신(digoxin)의 약리작용은?\n\n① 부종 유발\n② 심근수축력 억제\n③ 방실결절 전도속도 증가\n④ Na+-H+ exchanger 활성 증가\n⑤ 심근세포 내 칼슘농도 증가",
        "question_text": "Question: What is the pharmacological action of the cardiac glycoside digoxin?\n\n① Induces edema\n② Inhibits myocardial contractility\n③ Increases atrioventricular node conduction velocity\n④ Increases Na+-H+ exchanger activity\n⑤ Increases intracellular calcium concentration in myocardial cells",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 레닌-안지오텐신(renin-angiotensin)계에 작용하는 약물과 그 약리작용을 바르게 연결한 것은?\n\n① 발사르탄(valsartan) – 레닌 분비 억제\n② 프로프라놀롤(propranolol) – 레닌 활성 억제\n③ 알리스키렌(aliskiren) – 안지오텐신 수용체 길항\n④ 에날라프릴(enalapril) – 안지오텐신 전환효소(ACE) 억제\n⑤ 올메사르탄(olmesartan) – 브라디키닌(bradykinin) 수용체 길항",
        "question_text": "Question: Which of the following correctly matches a drug acting on the renin-angiotensin system with its pharmacological action?\n\n① Valsartan – Inhibition of renin secretion\n② Propranolol – Inhibition of renin activity\n③ Aliskiren – Angiotensin receptor antagonism\n④ Enalapril – Angiotensin-converting enzyme (ACE) inhibition\n⑤ Olmesartan – Bradykinin receptor antagonism",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 유방암 환자에게 사용하는 아나스트로졸(anastrozole)의 작용기전은?\n\n① 아로마타제(aromatase) 억제\n② 5α-환원효소(5α-reductase) 억제\n③ α-글루코시다제(α-glucosidase) 억제\n④ 잔틴산화효소(xanthine oxidase) 억제\n⑤ 5-리폭시게나제(5-lipoxygenase) 억제",
        "question_text": "Question: What is the mechanism of action of anastrozole used in breast cancer patients?\n\n① Aromatase inhibition\n② 5α-reductase inhibition\n③ α-glucosidase inhibition\n④ Xanthine oxidase inhibition\n⑤ 5-lipoxygenase inhibition",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 식후 인슐린 분비를 증가시키는 glucagon-like peptide-1 (GLP-1)의 불활성화 효소인 dipeptidyl peptidase-4 (DPP-4)의 억제약은?\n\n① 메트포르민(metformin)\n② 빌다글립틴(vildagliptin)\n③ 프람린티드(pramlintide)\n④ 둘라글루티드(dulaglutide)\n⑤ 카나글리플로진(canagliflozin)",
        "question_text": "Question: Which of the following is an inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates glucagon-like peptide-1 (GLP-1) which increases postprandial insulin secretion?\n\n① Metformin\n② Vildagliptin\n③ Pramlintide\n④ Dulaglutide\n⑤ Canagliflozin",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 목시플록사신(moxifloxacin)의 작용기전은?\n\n① 단백질 합성 억제\n② DNA gyrase 억제\n③ 세포막 투과성 억제\n④ RNA 중합효소 억제\n⑤ 세포벽 transpeptidase 억제",
        "question_text": "Question: What is the mechanism of action of moxifloxacin?\n\n① Inhibition of protein synthesis\n② Inhibition of DNA gyrase\n③ Inhibition of cell membrane permeability\n④ Inhibition of RNA polymerase\n⑤ Inhibition of cell wall transpeptidase",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: T 세포의 PD-1에 결합하여 PD-1과 PD-ligand-1의 상호작용을 차단하는 약물은?\n\n① 니볼루맙(nivolumab)\n② 탈리도미드(thalidomide)\n③ 라무시루맙(ramucirumab)\n④ 레플루노미드(leflunomide)\n⑤ 파니투무맙(panitumumab)",
        "question_text": "Question: Which drug binds to PD-1 on T cells and blocks the interaction between PD-1 and PD-ligand-1?\n\n① Nivolumab\n② Thalidomide\n③ Ramucirumab\n④ Leflunomide\n⑤ Panitumumab",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n수용성 리간드(ligand)의 세포막 수용체 중에는 세포 바깥 부분의 리간드 결합 부위와 세포질 효소 부위로 구성되는 수용체 유형이 있다. 이 유형에 속하는 수용체들은 세포질 효소 부위의 활성화를 통해서 세포내 신호전달 분자들의 활성을 조절할 수 있다.\n\nQuestion: 위 사례에서 설명하는 수용체 유형에 해당하는 것은?\n\n① 인슐린 수용체\n② GABA_A 수용체\n③ 알도스테론 수용체\n④ 5-HT3 세로토닌 수용체\n⑤ EP3 프로스타글란딘 수용체",
        "question_text": "Among the cell membrane receptors for water-soluble ligands, there is a type of receptor composed of a ligand-binding site on the extracellular portion and an enzymatic domain in the cytoplasm. Receptors belonging to this type can regulate the activity of intracellular signaling molecules through the activation of their cytoplasmic enzymatic domain.\n\nQuestion: Which of the following receptors corresponds to the type described in the above case?\n\n① Insulin receptor\n② GABA_A receptor\n③ Aldosterone receptor\n④ 5-HT3 serotonin receptor\n⑤ EP3 prostaglandin receptor",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n수용성 리간드(ligand)의 세포막 수용체 중에는 세포 바깥 부분의 리간드 결합 부위와 세포질 효소 부위로 구성되는 수용체 유형이 있다. 이 유형에 속하는 수용체들은 세포질 효소 부위의 활성화를 통해서 세포내 신호전달 분자들의 활성을 조절할 수 있다.\n\nQuestion: 위 사례에서 설명하는 수용체 유형에 작용함으로써 급성 심부전 치료에 사용하는 약물은?\n\n① 밀리논(milrinone)\n② 네시리티드(nesiritide)\n③ 카르베딜롤(carvedilol)\n④ 도부타민(dobutamine)\n⑤ 푸로세미드(furosemide)",
        "question_text": "Among the cell membrane receptors for water-soluble ligands, there is a type of receptor that consists of a ligand-binding site on the extracellular portion and an enzymatic site in the cytoplasm. Receptors belonging to this type can regulate the activity of intracellular signaling molecules through the activation of the cytoplasmic enzymatic site.\n\nQuestion: Which drug is used in the treatment of acute heart failure by acting on the receptor type described in the above case?\n\n① Milrinone\n② Nesiritide\n③ Carvedilol\n④ Dobutamine\n⑤ Furosemide",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 클라미디아속 균 감염에 의해 발생하며, 환경 요인의 개선에 의해 효과적으로 예방될 수 있는 만성 감염성 안질환은?\n\n① 뎅기열\n② 백내장\n③ 황반변성\n④ 주혈흡충증\n⑤ 트라코마증",
        "question_text": "Question: Which chronic infectious eye disease is caused by Chlamydia bacteria infection and can be effectively prevented by improving environmental factors?\n\n① Dengue fever\n② Cataract\n③ Macular degeneration\n④ Schistosomiasis\n⑤ Trachoma",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 화석연료의 사용에 의해 발생하고 폐자극성이 있으며 지표면 근처에서 자외선, 산소와의 광화학 반응을 통해 광화학 옥시단트(photochemical oxidant)를 생성하는 대기오염물질은?\n\n① 불화수소\n② 황화수소\n③ 시안화수소\n④ 이산화질소\n⑤ 일산화탄소",
        "question_text": "Question: Which air pollutant is produced by the use of fossil fuels, has respiratory irritant properties, and generates photochemical oxidants through photochemical reactions with ultraviolet light and oxygen near the Earth's surface?\n\n① Hydrogen fluoride\n② Hydrogen sulfide\n③ Hydrogen cyanide\n④ Nitrogen dioxide\n⑤ Carbon monoxide",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 먹는물 정수처리 과정 중, 질소계 염소 소비 물질을 함유하는 물에 불연속점을 초과하여 염소를 주입할 때 물에 존재하는 잔류염소의 주요 화학종은?\n\n① Cl2\n② NH2Cl, HOCl\n③ NH2Cl, NHCl2\n④ NHCl2, NCl3\n⑤ NCl3, HOCl",
        "question_text": "Question: During the drinking water purification process, when chlorine is injected exceeding the breakpoint into water containing nitrogen-based chlorine-consuming substances, what are the main chemical species of residual chlorine present in the water?\n\n① Cl2\n② NH2Cl, HOCl\n③ NH2Cl, NHCl2\n④ NHCl2, NCl3\n⑤ NCl3, HOCl",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 먹는물 오염물질은?\n\n• 오염원은 지질, 광산 폐수, 공장 폐수임\n• 오염이 심할 경우 Crenothrix를 번식시켜 배관의 급수  능력을 저하시키고 수질을 악화시키며, 냄새를 발생시킴\n• 과다 섭취 시 혈색소증이 유발됨\n\n① 철\n② 구리\n③ 망간\n④ 불소\n⑤ 아연",
        "question_text": "Question: Which of the following describes the drinking water contaminant?\n\n• Sources of contamination are geological, mine wastewater, and factory wastewater\n• In severe cases of contamination, it promotes the growth of Crenothrix, reducing the water supply capacity of pipes, deteriorating water quality, and causing odors\n• Excessive intake can cause hemochromatosis\n\n① Iron\n② Copper\n③ Manganese\n④ Fluoride\n⑤ Zinc",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 심근세포의 근잔섬유(myofilament) 구성성분이며, 심근 손상에 의해 혈액 내 수준이 높아지므로 심근경색 진단에 활용되는 심장독성지표는?\n\n① troponin T\n② myoglobin\n③ endothelin-1\n④ γ-glutamyl transpeptidase\n⑤ B-type natriuretic peptide",
        "question_text": "Question: Which cardiac toxicity marker is a component of myofilaments in cardiomyocytes, and is used in the diagnosis of myocardial infarction due to its elevated levels in the blood caused by myocardial damage?\n\n① troponin T\n② myoglobin\n③ endothelin-1\n④ γ-glutamyl transpeptidase\n⑤ B-type natriuretic peptide",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 포도당 유사 구조를 가진 화합물로서, 실험동물에서 선택적으로 이자 베타세포의 손상을 유발하여 당뇨병 모델을 확립하기 위해 사용되는 것은?\n\n① 레세르핀(reserpine)\n② 리나마린(linamarin)\n③ 스피로노락톤(spironolactone)\n④ 시프로헵타딘(cyproheptadine)\n⑤ 스트렙토조토신(streptozotocin)",
        "question_text": "Question: Which compound, having a structure similar to glucose, is used to establish a diabetes model in experimental animals by selectively causing damage to pancreatic beta cells?\n\n① Reserpine\n② Linamarin\n③ Spironolactone\n④ Cyproheptadine\n⑤ Streptozotocin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 식품의 가열조리 과정에서 환원당과 아스파라긴(asparagine)의 비효소적 갈변반응(Maillard reaction)을 통해 생성되는 신경독성물질은?\n\n① acrylamide\n② benzo[a]pyrene\n③ n-hexane\n④ nitrosamine\n⑤ Trp-P-1",
        "question_text": "Question: Which neurotoxic substance is produced through the non-enzymatic browning reaction (Maillard reaction) between reducing sugars and asparagine during the heating process of food?\n\n① acrylamide\n② benzo[a]pyrene\n③ n-hexane\n④ nitrosamine\n⑤ Trp-P-1",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 어떤 유기인계 살충제의 위해성 평가를 위해 용량-반응 평가를 수행 중이다. 다음에 제시한 근거로부터 독성참고치(reference dose)를 산출하면? (단위: mg/kg/day)\n\n• 수컷 랫드에 살충제를 노출시키고 혈중 cholinesterase 활성 변화를 측정하는 2년 간의 실험에서 최소영향관찰 용량(LOAEL)은 0.3 mg/kg/day였다.\n• 불확실성계수는 최대무영향관찰용량(NOAEL) 대신 LOAEL  사용에 따른 보정(×10)과 종간 변이(×10) 및 종내 변이 (×10)에 대한 보정만을 고려하였다.\n• 조정계수 설정을 위해 고려할 만한 사항은 없었다.\n\n① 300\n② 0.3\n③ 3×10^-3\n④ 3×10^-4\n⑤ 3×10^-5",
        "question_text": "Question: A dose-response assessment is being conducted for the risk assessment of an organophosphorus insecticide. Calculate the reference dose from the evidence provided below. (Unit: mg/kg/day)\n\n• In a 2-year experiment where male rats were exposed to the insecticide and changes in blood cholinesterase activity were measured, the Lowest Observed Adverse Effect Level (LOAEL) was 0.3 mg/kg/day.\n• The uncertainty factors considered only the adjustments for using LOAEL instead of No Observed Adverse Effect Level (NOAEL) (×10), interspecies variation (×10), and intraspecies variation (×10).\n• There were no considerations for setting a modifying factor.\n\n① 300\n② 0.3\n③ 3×10^-3\n④ 3×10^-4\n⑤ 3×10^-5",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 다음은 어떤 화학물질에 대한 박테리아 복귀돌연변이 시험 내용과 그 결과이다. 이에 관한 설명으로 옳은 것은?\n\n균주 | 간 S9 분획물 첨가 여부 | |\n| | 무첨가 | 첨가 |\n|---|---|---|\n| S. Typhimurium TA98 | 음성 | 양성 |\n| S. Typhimurium TA100 | 음성 | 음성 |\n| S. Typhimurium TA1535 | 음성 | 양성 |\n| S. Typhimurium TA1537 | 음성 | 양성 |\n| E. coli WP2 uvrA | 음성 | 양성 |\n\n① 시험물질은 염색체 구조 이상을 유발한다.\n② 소핵형성 여부가 음 ∙ 양성 판단의 기준이다.\n③ 살모넬라균을 사용한 시험은 트립토판 요구성을 평가한다.\n④ 대장균을 사용한 시험은 thymidine kinase의 변이를 검출한다.\n⑤ 시험물질 자체는 변이원성이 없으나 그 대사체는 변이원성이 있다.",
        "question_text": "Question: The following is the content and results of a bacterial reverse mutation test for a certain chemical substance. Which of the following statements about this is correct?\n\nStrain | With or without liver S9 fraction | |\n| | Without | With |\n|---|---|---|\n| S. Typhimurium TA98 | Negative | Positive |\n| S. Typhimurium TA100 | Negative | Negative |\n| S. Typhimurium TA1535 | Negative | Positive |\n| S. Typhimurium TA1537 | Negative | Positive |\n| E. coli WP2 uvrA | Negative | Positive |\n\n① The test substance induces chromosomal structural abnormalities.\n② The criterion for positive or negative judgment is micronucleus formation.\n③ The test using Salmonella bacteria evaluates tryptophan auxotrophy.\n④ The test using E. coli detects mutations in thymidine kinase.\n⑤ The test substance itself is not mutagenic, but its metabolites are mutagenic.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 수은 화합물 중 메틸수은은 중추신경계에, 무기수은은 신장에 특이적으로 독성을 나타낸다. 이처럼 표적 장기가 다른 이유는?\n\n① 장간순환 여부\n② 혈장단백질 결합 차이\n③ 장기에 따른 혈류량 차이\n④ 장기에 따른 대사효소 분포 차이\n⑤ 장기에 따라 발현되는 수송체 차이",
        "question_text": "Question: Among mercury compounds, methylmercury specifically shows toxicity to the central nervous system, while inorganic mercury shows toxicity to the kidneys. What is the reason for this difference in target organs?\n\n① Presence or absence of enterohepatic circulation\n② Difference in plasma protein binding\n③ Difference in blood flow to organs\n④ Difference in distribution of metabolic enzymes among organs\n⑤ Difference in transporters expressed in different organs",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 단백질이 부패할 때 히스티딘(histidine)의 탈탄산 반응으로 생성되며, 알레르기 식중독의 원인이 되는 부패산물은?\n\n① agmatine\n② cadaverine\n③ histamine\n④ putrescine\n⑤ tyramine",
        "question_text": "Question: Which decomposition product is formed by the decarboxylation of histidine during protein putrefaction and is a cause of allergic food poisoning?\n\n① agmatine\n② cadaverine\n③ histamine\n④ putrescine\n⑤ tyramine",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 비타민은?\n\n• 노르에피네프린, 카르니틴의 생합성과 콜라겐의 삼중나선  구조 안정화를 매개함\n• 항산화제나 환원제로 작용하며, 장관에서 철분의 흡수율을  높임\n• 결핍 시에는 결합조직의 약화로 잇몸, 피하의 출혈이 유발됨\n\n① 티아민 \n② 나이아신\n③ 리보플라빈\n④ 아스코르브산\n⑤ 콜레칼시페롤",
        "question_text": "Question: Which vitamin is described below?\n\n• Mediates the biosynthesis of norepinephrine and carnitine, and stabilizes the triple-helix structure of collagen\n• Acts as an antioxidant and reducing agent, and increases iron absorption in the intestines\n• When deficient, it causes weakening of connective tissue, leading to bleeding in the gums and under the skin\n\n① Thiamine\n② Niacin\n③ Riboflavin\n④ Ascorbic acid\n⑤ Cholecalciferol",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 글루타티온 과산화효소(glutathione peroxidase)의 구성 성분으로서 항산화 작용이 있으며, 결핍되면 심근장애가 나타나는 무기질은?\n\n① 아연\n② 나트륨\n③ 셀레늄\n④ 코발트\n⑤ 몰리브덴",
        "question_text": "Question: Which mineral is a component of glutathione peroxidase, has antioxidant properties, and when deficient, can lead to myocardial disorders?\n\n① Zinc\n② Sodium\n③ Selenium\n④ Cobalt\n⑤ Molybdenum",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: 성요한풀(St. John’s wort)과 심바스타틴(simvastatin)을 병용하고 있던 환자가 성요한풀 복용을 중단할 경우 심바스타틴에 의한 횡문근융해증이 발생할 가능성이 높아진다. 그 이유는?\n\n① 장간순환 촉진\n② 위배출시간 연장\n③ 수송체 억제 회복\n④ 대사효소유도 감소\n⑤ 간문맥 혈류량 증가",
        "question_text": "Question: When a patient who has been taking St. John's wort and simvastatin concurrently discontinues St. John's wort, the risk of rhabdomyolysis caused by simvastatin increases. What is the reason for this?\n\n① Promotion of enterohepatic circulation\n② Extended gastric emptying time\n③ Recovery of transporter inhibition\n④ Decrease in metabolic enzyme induction\n⑤ Increase in portal vein blood flow",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 학교 급식에서 볶음밥과 샐러드가 제공된 후 집단 식중독이 발생하였다. 학생들은 설사와 복통을 나타냈으며, 일부는 구토 증상을 보였다. 환자의 검체에서 분리된 균은 내열성 아포를 생성하는 그람양성 간균이며, 혈액 한천 배지에서 β-용혈을 나타내었다. 식중독의 원인균은?\n\n① Bacillus cereus\n② Campylobacter jejuni\n③ Salmonella Typhimurium\n④ Staphylococcus aureus\n⑤ Yersinia enterocolitica",
        "question_text": "Question: A mass food poisoning incident occurred after fried rice and salad were served in a school cafeteria. Students experienced diarrhea and abdominal pain, with some showing symptoms of vomiting. The bacteria isolated from patient samples were gram-positive bacilli that produce heat-resistant spores and showed β-hemolysis on blood agar plates. What is the causative agent of this food poisoning?\n\n① Bacillus cereus\n② Campylobacter jejuni\n③ Salmonella Typhimurium\n④ Staphylococcus aureus\n⑤ Yersinia enterocolitica",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 바지락이나 굴 섭취로 인한 식중독의 원인물질로서 특징적으로 피하출혈반을 나타내며 간기능 저하, 토혈, 혈변 등의 증상을 유발하고 사망을 초래할 수 있는 내열성 독소는?\n\n① saxitoxin\n② surugatoxin\n③ tetramine\n④ tetrodotoxin\n⑤ venerupin",
        "question_text": "Question: Which heat-resistant toxin, known to cause food poisoning from consuming clams or oysters, characteristically presents with subcutaneous hemorrhage and can lead to symptoms such as decreased liver function, hematemesis, and melena, potentially resulting in death?\n\n① saxitoxin\n② surugatoxin\n③ tetramine\n④ tetrodotoxin\n⑤ venerupin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 독성물질은?\n\n• 알광대버섯에 함유된 환상 펩티드 구조의 독소임\n• 간에서 중심소엽괴사를 유발함\n• RNA 중합효소 II를 억제하여 세포사를 유발함\n\n① α-amanitin\n② microcystin LR\n③ muscaridine\n④ muscarine\n⑤ phalloidin",
        "question_text": "Question: Which toxic substance is described below?\n\n• It is a cyclic peptide toxin found in death cap mushrooms\n• It causes centrilobular necrosis in the liver\n• It induces cell death by inhibiting RNA polymerase II\n\n① α-amanitin\n② microcystin LR\n③ muscaridine\n④ muscarine\n⑤ phalloidin",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 식품첨가물은?\n\n• 아미노산 계열의 저칼로리 감미료로 음료, 과자, 절임류 등에 사용함\n• 구조에 페닐알라닌을 포함하고 있어 페닐케톤뇨증 환자는 섭취하지 않아야 함\n• 열에 불안정하여 제조상 가열 공정이 있는 제품에는 사용되지 않음\n\n① 아스파탐\n② 수크랄로스\n③ 사카린나트륨\n④ D-자일로오스\n⑤ 아세설팜칼륨",
        "question_text": "Question: Which food additive is described below?\n\n• A low-calorie sweetener of the amino acid family, used in beverages, snacks, pickled foods, etc.\n• Contains phenylalanine in its structure, so patients with phenylketonuria should not consume it\n• Unstable when heated, so it is not used in products that involve heating during manufacturing\n\n① Aspartame\n② Sucralose\n③ Sodium saccharin\n④ D-xylose\n⑤ Acesulfame potassium",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n[사례 1]\n• 임신 중 흡연과 저체중아 출산 간의 인과관계를 밝히기 위한 역학연구를 수행하였다.\n• 2018년부터 2020년까지 한 병원에서 출생한 신생아 중 저체중아 500명과 정상체중아 500명을 선정하고 산모의 임신 중 흡연력을 조사하였다.\n\n[사례 2]\n• 흡연과 폐암 간의 인과관계를 밝히기 위한 역학연구를 수행 중이다.\n• 2018년부터 2020년까지의 40세 이상 내원자 중, 폐암에 이환되지 않은 1,000명을 대상으로 흡연자와 비흡연자를 구분하였다.\n• 두 집단의 폐암 발생에 관한 추적조사는 2050년까지 30여 년간 이루어질 것이다.\n\nQuestion: 사례 1의 역학연구 방법은?\n\n① 단면연구\n② 무작위 임상시험\n③ 환자-대조군 연구\n④ 전향적 코호트 연구\n⑤ 후향적 코호트 연구",
        "question_text": "[Case 1]\n• An epidemiological study was conducted to determine the causal relationship between smoking during pregnancy and low birth weight.\n• 500 low birth weight infants and 500 normal weight infants born in a hospital from 2018 to 2020 were selected, and the mothers' smoking history during pregnancy was investigated.\n\n[Case 2]\n• An epidemiological study is being conducted to determine the causal relationship between smoking and lung cancer.\n• Among visitors aged 40 and over from 2018 to 2020, 1,000 individuals who were not affected by lung cancer were divided into smokers and non-smokers.\n• Follow-up studies on lung cancer incidence in both groups will be conducted for about 30 years until 2050.\n\nQuestion: What is the epidemiological research method used in Case 1?\n\n① Cross-sectional study\n② Randomized clinical trial\n③ Case-control study\n④ Prospective cohort study\n⑤ Retrospective cohort study",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n[사례 1]\n• 임신 중 흡연과 저체중아 출산 간의 인과관계를 밝히기 위한 역학연구를 수행하였다.\n• 2018년부터 2020년까지 한 병원에서 출생한 신생아 중 저체중아 500명과 정상체중아 500명을 선정하고 산모의 임신 중 흡연력을 조사하였다.\n\n[사례 2]\n• 흡연과 폐암 간의 인과관계를 밝히기 위한 역학연구를 수행 중이다.\n• 2018년부터 2020년까지의 40세 이상 내원자 중, 폐암에 이환되지 않은 1,000명을 대상으로 흡연자와 비흡연자를 구분하였다.\n• 두 집단의 폐암 발생에 관한 추적조사는 2050년까지 30여 년간 이루어질 것이다.\n\nQuestion: 사례 2와 비교하여, 사례 1과 같은 유형의 연구 방법이 가질 수 있는 일반적인 장점은?\n\n① 내적타당도가 높다.\n② 질병 발생률과 위험도의 산출이 용이하다.\n③ 연구에 소요되는 기간이 짧고 비용이 적다.\n④ 위험요인 노출에 따른 다양한 질병 발생에 대한 관찰이 가능하다.\n⑤ 위험요인의 노출에서부터 질병 발생까지의 전 과정을 관찰할 수 있다.",
        "question_text": "[Case 1]\n• An epidemiological study was conducted to determine the causal relationship between smoking during pregnancy and low birth weight.\n• 500 low birth weight infants and 500 normal weight infants born in a hospital from 2018 to 2020 were selected, and the mothers' smoking history during pregnancy was investigated.\n\n[Case 2]\n• An epidemiological study is being conducted to determine the causal relationship between smoking and lung cancer.\n• Among visitors aged 40 and over from 2018 to 2020, 1,000 individuals who were not affected by lung cancer were divided into smokers and non-smokers.\n• Follow-up studies on the incidence of lung cancer in both groups will be conducted for about 30 years until 2050.\n\nQuestion: Compared to Case 2, what is a general advantage that the type of research method used in Case 1 might have?\n\n① It has high internal validity.\n② It is easy to calculate disease incidence rates and risk factors.\n③ The research period is shorter and the cost is lower.\n④ It is possible to observe the occurrence of various diseases according to exposure to risk factors.\n⑤ The entire process from exposure to risk factors to disease occurrence can be observed.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 지속적인 유해자극에 의한 가역적 세포손상의 특징은?\n\n① 핵융해\n② 세포 종창\n③ 세포막 파괴\n④ 호산성 증가\n⑤ 미엘린상 증가",
        "question_text": "Question: What is a characteristic of reversible cell injury caused by persistent harmful stimuli?\n\n① Nuclear lysis\n② Cell swelling\n③ Cell membrane destruction\n④ Increased eosinophilia\n⑤ Increased myelin figures",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 결핵균 감염으로 인해 형성된 육아종에 관한 설명으로 옳은 것은?\n\n① 염증 부위에 발생한 양성종양\n② 낫모양 형태를 가진 세포들의 집합체\n③ 상처 수복 과정에서 형성된 일시적 육아조직\n④ 중심부 괴사를 동반한 상피모양세포들의 집합체\n⑤ 병소에 세포바깥바탕질이 과도하게 축적된 흉터종",
        "question_text": "Question: Which of the following statements about granulomas formed due to tuberculosis infection is correct?\n\n① A benign tumor occurring at the site of inflammation\n② An aggregate of sickle-shaped cells\n③ Temporary granulation tissue formed during wound healing process\n④ An aggregate of epithelioid cells with central necrosis\n⑤ A keloid with excessive accumulation of extracellular matrix at the lesion site",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 피부창상 치유의 초기단계에서 활성화되어 지혈마개(hemostatic plug)를 형성하는 세포는?\n\n① 혈소판\n② 내피세포\n③ 대식세포\n④ 비만세포\n⑤ 섬유모세포",
        "question_text": "Question: Which cell is activated in the early stages of skin wound healing to form a hemostatic plug?\n\n① Platelets\n② Endothelial cells\n③ Macrophages\n④ Mast cells\n⑤ Fibroblasts",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 다양한 종양미세환경에서 암세포가 생존할 수 있는 분자유전학적 특징은?\n\n① 숙주면역반응 활성화\n② 종양유전자의 불활성화\n③ 종양억제유전자의 활성 유지\n④ 획득돌연변이에 의한 분자진화\n⑤ 유전체 통합성(genomic integrity)의 유지",
        "question_text": "Question: What is the molecular genetic characteristic that allows cancer cells to survive in various tumor microenvironments?\n\n① Activation of host immune response\n② Inactivation of oncogenes\n③ Maintenance of tumor suppressor gene activity\n④ Molecular evolution through acquired mutations\n⑤ Maintenance of genomic integrity",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 유효혈류량 감소로 인한 저혈압에 반응하여 토리곁세포(juxtaglomerular cell)에서 분비되는 물질은?\n\n① 레닌(renin)\n② 안지오텐신(angiotensin)\n③ 알도스테론(aldosterone)\n④ 에리트로포이에틴(erythropoietin)\n⑤ 안지오텐시노겐(angiotensinogen)",
        "question_text": "Question: Which substance is secreted by juxtaglomerular cells in response to hypotension caused by a decrease in effective blood volume?\n\n① Renin\n② Angiotensin\n③ Aldosterone\n④ Erythropoietin\n⑤ Angiotensinogen",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 화학물질 또는 물리적 요인에 의해 골수 기능이 억제되어 범혈구감소증이 나타나는 것은?\n\n① 낫적혈구병\n② 지중해빈혈\n③ 철결핍빈혈\n④ 면역용혈빈혈\n⑤ 재생불량빈혈",
        "question_text": "Question: Which condition is characterized by pancytopenia due to bone marrow suppression caused by chemical substances or physical factors?\n\n① Sickle cell anemia\n② Thalassemia\n③ Iron deficiency anemia\n④ Immune hemolytic anemia\n⑤ Aplastic anemia",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 다음과 같은 증상을 보이는 질환은?\n\n• 사지 동맥과 세동맥의 심한 수축\n• 손가락이나 발가락의 간헐적 허혈 발작\n• 사지 말단에서 청색증, 감각이상과 통증 수반\n\n① 가와사키병(Kawasaki disease)\n② 타카야스동맥염(Takayasu arteritis)\n③ 레이노현상(Raynaud phenomenon)\n④ 베게너육아종증(Wegener granulomatosis)\n⑤ 처그 스트라우스증후군(Churg-Strauss syndrome)",
        "question_text": "Question: Which disease shows the following symptoms?\n\n• Severe contraction of limb arteries and arterioles\n• Intermittent ischemic attacks in fingers or toes\n• Cyanosis, paresthesia, and pain in the extremities of limbs\n\n① Kawasaki disease\n② Takayasu arteritis\n③ Raynaud phenomenon\n④ Wegener granulomatosis\n⑤ Churg-Strauss syndrome",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 흡연이나 유해 입자 흡입에 의해 발생하는 폐기종의 발병기전은?\n\n① 리파제 활성 감소\n② 아밀라제 활성 감소\n③ 뉴클레아제 활성 증가\n④ 엘라스타아제 활성 증가\n⑤ α1-안티트립신 활성 증가",
        "question_text": "Question: What is the pathogenesis of emphysema caused by smoking or inhalation of harmful particles?\n\n① Decreased lipase activity\n② Decreased amylase activity\n③ Increased nuclease activity\n④ Increased elastase activity\n⑤ Increased α1-antitrypsin activity",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "original_text": "Question: 정상식도가 바레트식도로 변할 때 식도 점막층 내 상피세포의 적응반응은?\n\n① 비대\n② 위축\n③ 화생\n④ 석회화\n⑤ 과다증식",
        "question_text": "Question: What is the adaptive response of epithelial cells in the esophageal mucosa layer when normal esophagus changes to Barrett's esophagus?\n\n① Hypertrophy\n② Atrophy\n③ Metaplasia\n④ Calcification\n⑤ Hyperplasia",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "original_text": "Question: 돌연변이에 의해 가족성샘종폴립증을 유발할 수 있는 유전자는?\n\n① APC\n② DCC\n③ KRAS\n④ TP53\n⑤ VHL",
        "question_text": "Question: Which gene can cause familial adenomatous polyposis due to mutation?\n\n① APC\n② DCC\n③ KRAS\n④ TP53\n⑤ VHL",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "original_text": "Question: 다수의 간세포가 파괴되거나 그 기능이 손상되었을 때 발생하는 간기능상실의 주요 임상 증상은?\n\n① 간뇌병증\n② 고알부민혈증\n③ 혈소판증가증\n④ 지라기능저하증\n⑤ 저에스트로겐혈증",
        "question_text": "Question: What are the main clinical symptoms of liver failure that occur when multiple hepatocytes are destroyed or their function is impaired?\n\n① Hepatic encephalopathy\n② Hyperalbuminemia\n③ Thrombocytosis\n④ Splenic hypofunction\n⑤ Hypoestrogenemia",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "original_text": "Question: 급성이자염의 발병에서 이자관 폐쇄의 직접적인 원인은?\n\n① 볼거리(mumps)\n② 혈관염(vasculitis)\n③ 쓸개돌(gallstone)\n④ 색전증(embolism)\n⑤ 혈색소증(hemochromatosis)",
        "question_text": "Question: What is the direct cause of pancreatic duct obstruction in the onset of acute pancreatitis?\n\n① Mumps\n② Vasculitis\n③ Gallstone\n④ Embolism\n⑤ Hemochromatosis",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "original_text": "Question: 요관의 폐쇄를 초래할 수 있는 양성전립샘과다형성에서 나타나는 것은?\n\n① 요 흐름의 세기 증가\n② 전립샘특이항원 결핍\n③ 5α-환원효소 작용 증가\n④ 외요도괄약근 기능 장애\n⑤ 안드로겐 호르몬 분비 감소",
        "question_text": "Question: Which of the following is associated with benign prostatic hyperplasia that can lead to ureteral obstruction?\n\n① Increased urinary flow strength\n② Prostate-specific antigen deficiency\n③ Increased 5α-reductase activity\n④ External urethral sphincter dysfunction\n⑤ Decreased androgen hormone secretion",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "original_text": "Question: 바이러스단백질 E6과 E7의 작용으로 자궁목암을 발병시키는 바이러스는?\n\n① 거대세포바이러스(CMV)\n② 사람유두종바이러스(HPV)\n③ 사람면역결핍바이러스(HIV)\n④ 엡스타인-바 바이러스(EBV)\n⑤ 단순헤르페스바이러스(HSV)",
        "question_text": "Question: Which virus causes cervical cancer through the action of viral proteins E6 and E7?\n\n① Cytomegalovirus (CMV)\n② Human Papillomavirus (HPV)\n③ Human Immunodeficiency Virus (HIV)\n④ Epstein-Barr Virus (EBV)\n⑤ Herpes Simplex Virus (HSV)",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "original_text": "Question: 자궁 바깥부위에 양성 자궁내막샘과 기질이 존재하는 질환으로, 후천적 불임의 원인이 되는 것은?\n\n① 자궁목암\n② 자궁내막암\n③ 자궁내막염\n④ 자궁내막증\n⑤ 자궁평활근종",
        "question_text": "Question: Which disease is characterized by the presence of benign endometrial glands and stroma outside the uterus and is a cause of acquired infertility?\n\n① Cervical cancer\n② Endometrial cancer\n③ Endometritis\n④ Endometriosis\n⑤ Uterine leiomyoma",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "original_text": "Question: 윤활막염을 유발하는 자가면역만성관절염의 특징적 병리소견은?\n\n① 판누스 형성\n② 골증식체 생성\n③ 연골탄력의 증가\n④ 콩팥속질이나 세뇨관의 결절 발생\n⑤ 푸린(purine) 염기 이화과정 결과물의 축적",
        "question_text": "Question: What is the characteristic pathological finding of autoimmune chronic arthritis that causes synovitis?\n\n① Formation of pannus\n② Generation of osteophytes\n③ Increase in cartilage elasticity\n④ Development of nodules in the renal medulla or tubules\n⑤ Accumulation of purine base catabolism products",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "original_text": "Question: 신경근이음부의 기능을 손상시키는 항체매개질환으로, 복시와 눈꺼풀처짐의 증상이 나타나는 자가면역질환은?\n\n① 파킨슨병\n② 다발경화증\n③ 근육퇴행위축\n④ 중증근무력증\n⑤ 길랭-바레증후군",
        "question_text": "Question: Which autoimmune disease damages the function of the neuromuscular junction and presents symptoms of diplopia and ptosis?\n\n① Parkinson's disease\n② Multiple sclerosis\n③ Muscular dystrophy\n④ Myasthenia gravis\n⑤ Guillain-Barré syndrome",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "original_text": "Question: 다음의 특징을 갖는 질환은?\n\n• 연령, 성별, 근시, 당뇨 등이 위험인자\n• 다른 눈 질환과 연관되어 발생\n• 선천적 혹은 후천적 수정체 혼탁\n\n① 각막염\n② 결막염\n③ 망막염\n④ 백내장\n⑤ 시신경유두부종",
        "question_text": "Question: Which disease has the following characteristics?\n\n• Risk factors include age, gender, myopia, diabetes, etc.\n• Occurs in association with other eye diseases\n• Congenital or acquired lens opacity\n\n① Keratitis\n② Conjunctivitis\n③ Retinitis\n④ Cataract\n⑤ Optic disc edema",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n휴식 상태에서 호흡곤란과 피로감, 특히 밤에 심해지는 발작야간호흡곤란을 호소하는 환자에게 흉부방사선 검사 결과 심장비대가 관찰되었다. 임상검사에서는 심장기능저하가 확인되었다.\n\nQuestion: 이 환자에서 나타난 발작야간호흡곤란의 기전은?\n\n① 말단 세기관지의 비가역적 팽창\n② 콩팥 관류 저하로 인한 질소혈증\n③ II형 폐포상피세포 부전으로 인한 폐 허탈\n④ 폐 모세혈관 울혈로 인한 체액의 폐포 내 축적\n⑤ 폐포와 혈관의 사이질 비후로 인한 가스교환 부전",
        "question_text": "A patient complains of dyspnea at rest and fatigue, with paroxysmal nocturnal dyspnea that worsens especially at night. A chest X-ray reveals cardiomegaly. Clinical tests confirm decreased cardiac function.\n\nQuestion: What is the mechanism of paroxysmal nocturnal dyspnea in this patient?\n\n① Irreversible dilation of terminal bronchioles\n② Azotemia due to decreased renal perfusion\n③ Pulmonary collapse due to type II alveolar epithelial cell failure\n④ Accumulation of fluid in alveoli due to pulmonary capillary congestion\n⑤ Gas exchange failure due to thickening of the interstitium between alveoli and blood vessels",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n휴식 상태에서 호흡곤란과 피로감, 특히 밤에 심해지는 발작야간호흡곤란을 호소하는 환자에게 흉부방사선 검사 결과 심장비대가 관찰되었다. 임상검사에서는 심장기능저하가 확인되었다.\n\nQuestion: 이 환자의 심장에서 프랭크-스탈링 법칙에 따른 보상기전이 장기적으로 심장비대를 악화시키는 원인은?\n\n① 심근의 수축력 감소\n② 심근 세포의 칼슘 고갈\n③ 심근의 대사 요구 증가\n④ 말초로의 혈액 공급 감소\n⑤ 심근 전도계의 기능 약화",
        "question_text": "A patient complains of dyspnea at rest and fatigue, especially worsening paroxysmal nocturnal dyspnea at night. A chest X-ray reveals cardiomegaly. Clinical tests confirm decreased cardiac function.\n\nQuestion: According to Frank-Starling's law, what is the cause of the compensatory mechanism in this patient's heart that worsens cardiomegaly in the long term?\n\n① Decreased myocardial contractility\n② Calcium depletion in myocardial cells\n③ Increased metabolic demand of the myocardium\n④ Decreased blood supply to the periphery\n⑤ Weakened function of the myocardial conduction system",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 단백질 의약품에서, 반데르발스 힘에 관한 설명으로 옳은 것은?\n\n① 펩타이드 결합에서 전자쌍을 공유한다.\n② 공유결합에 비해 높은 결합에너지를 가진다.\n③ 단백질 의약품의 3차 구조 형성에 기여한다.\n④ 단백질 의약품에서 이온 간의 상호작용이다.\n⑤ 단백질 의약품에서 이황화 결합 형성의 주된 힘이다.",
        "question_text": "Question: Regarding van der Waals forces in protein pharmaceuticals, which of the following statements is correct?\n\n① They share electron pairs in peptide bonds.\n② They have higher binding energy compared to covalent bonds.\n③ They contribute to the formation of tertiary structure in protein pharmaceuticals.\n④ They represent interactions between ions in protein pharmaceuticals.\n⑤ They are the main force in forming disulfide bonds in protein pharmaceuticals.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 항바이러스 약물인 리토나비르(ritonavir)를 경질캡슐제로 개발하여 시판하던 중, 물리적 안정성과 용출에 문제점이 발견되어 연질캡슐제로 변경해 문제를 개선하였다. 발견된 문제와 연관된 약물의 특성은?\n\n① 총괄성\n② 결정형\n③ 가성성\n④ 비전도도\n⑤ 광분해성",
        "question_text": "Question: During the marketing of ritonavir, an antiviral drug, as a hard capsule formulation, issues with physical stability and dissolution were discovered. The problem was resolved by changing to a soft capsule formulation. Which characteristic of the drug is associated with the discovered problem?\n\n① Colligativity\n② Polymorphism\n③ Pseudoplasticity\n④ Non-conductivity\n⑤ Photodegradability",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 이산화탄소를 이용한 카페인 추출이 가능한 압력과 온도 조건은? (단, CO2의 임계압력은 73기압, 임계온도는 31℃이다.)\n\n① 1기압, 25℃\n② 50기압, 25℃\n③ 50기압, 90℃\n④ 250기압, 25℃\n⑤ 250기압, 90℃",
        "question_text": "Question: What are the pressure and temperature conditions that allow for caffeine extraction using carbon dioxide? (Note: The critical pressure of CO2 is 73 atm, and the critical temperature is 31°C.)\n\n① 1 atm, 25°C\n② 50 atm, 25°C\n③ 50 atm, 90°C\n④ 250 atm, 25°C\n⑤ 250 atm, 90°C",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 1기압, 40℃에서 71.0 g의 물과 29.0 g의 페놀을 섞은 2성분계는 10.0 w/w%의 페놀을 함유하는 물층과 33.0 w/w%의 물을 함유하는 페놀층의 2개 상으로 분리된다. 이때 상층의 양(g)은? (단, 이 온도에서 페놀의 비중은 1.07이다.)\n\n① 10.0\n② 29.0\n③ 33.3\n④ 66.7\n⑤ 71.0",
        "question_text": "Question: At 1 atmosphere and 40℃, a two-component system consisting of 71.0 g of water and 29.0 g of phenol separates into two phases: a water layer containing 10.0 w/w% phenol and a phenol layer containing 33.0 w/w% water. What is the amount (g) of the upper layer? (Note: At this temperature, the specific gravity of phenol is 1.07.)\n\n① 10.0\n② 29.0\n③ 33.3\n④ 66.7\n⑤ 71.0",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 어떤 단백질 의약품 후보물질의 제제설계를 위해 의약품의 안정성 연구를 진행하던 중, pH 4.0 이하에서 이 물질의 아스파라긴 잔기가 아스파르트산 잔기로 변화되는 반응을 확인하였다. 이에 해당하는 반응은?\n\n① 탈메틸(demethylation) 반응\n② 탈아미드(deamidation) 반응\n③ 탈탄산(decarboxylation) 반응\n④ 탈수소(dehydrogenation) 반응\n⑤ N,O-acyl 이동(migration) 반응",
        "question_text": "Question: During a stability study for the formulation design of a protein drug candidate, it was observed that at pH 4.0 or lower, the asparagine residues of this substance were converted to aspartic acid residues. Which reaction corresponds to this?\n\n① Demethylation reaction\n② Deamidation reaction\n③ Decarboxylation reaction\n④ Dehydrogenation reaction\n⑤ N,O-acyl migration reaction",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 어떤 유체(fluid)의 점도를 측정하는 과정에서 전단속도를 증가시킬 때 흐름에 대한 저항이 증가하였다. 이 유체의 유동학적 특성은?\n\n① 일반적으로 항복값이 관찰된다.\n② 일반적으로 유체의 부피는 감소한다.\n③ 전단응력과 전단속도는 정비례 관계이다. \n④ 레오그램에서 상향곡선의 순간기울기[d(전단속도)/d(전단응력)]는 증가한다.\n⑤ 전단응력을 증가시킬 때 입자 주변 용매의 결핍으로 점도가 증가한다.",
        "question_text": "Question: During the process of measuring the viscosity of a fluid, when the shear rate was increased, the resistance to flow increased. What is the rheological characteristic of this fluid?\n\n① Generally, a yield value is observed.\n② Generally, the volume of the fluid decreases.\n③ The shear stress and shear rate are directly proportional.\n④ On the rheogram, the instantaneous slope [d(shear rate)/d(shear stress)] of the upward curve increases.\n⑤ When shear stress increases, viscosity increases due to solvent depletion around particles.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 1기압, 25℃에서 용액의 총괄성과 관련된 값들에 관한 설명으로 옳은 것은?\n\n① 비전해질의 반트호프인자 i 는 2이다.\n② 강전해질의 L_iso는 전해질 종류와 무관하게 동일하다.\n③ 오스몰랄농도는 몰랄농도와 반트호프인자 i 의 곱이다.\n④ 0.1 몰랄농도 염화나트륨 수용액의 삼투계수 g는 2이다.\n⑤ 0.01 mol/L와 0.02 mol/L 아세트산 수용액의 반트호프인자 i 는 같다.",
        "question_text": "Question: Which of the following statements about colligative properties of solutions at 1 atm and 25°C is correct?\n\n① The van 't Hoff factor i for non-electrolytes is 2.\n② The L_iso of strong electrolytes is the same regardless of the type of electrolyte.\n③ Osmolal concentration is the product of molal concentration and the van 't Hoff factor i.\n④ The osmotic coefficient g of a 0.1 molal sodium chloride solution is 2.\n⑤ The van 't Hoff factor i is the same for 0.01 mol/L and 0.02 mol/L acetic acid solutions.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 아세트산 수용액의 농도를 0.01 mol/L에서 0.05 mol/L로 증가시킬 때, 감소하는 것은?\n\n① 삼투압\n② 완충용량\n③ 이온강도\n④ 비전도도\n⑤ 당량전도도",
        "question_text": "Question: When increasing the concentration of acetic acid solution from 0.01 mol/L to 0.05 mol/L, which of the following decreases?\n\n① Osmotic pressure\n② Buffer capacity\n③ Ionic strength\n④ Specific conductivity\n⑤ Equivalent conductivity",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 1기압에서 디펜히드라민염산염 수용액의 어는점내림값은 0.34℃이다. 20℃에서 이 수용액의 삼투압(atm)은? (단, 디펜히드라민염산염의 L_iso값은 3.4이고, 기체상수는 R이다.)\n\n① 2.93R\n② 20.0R\n③ 29.3R \n④ 40.0R\n⑤ 293R",
        "question_text": "Question: At 1 atmosphere pressure, the freezing point depression of a diphenhydramine hydrochloride solution is 0.34℃. What is the osmotic pressure (atm) of this solution at 20℃? (Given: The L_iso value of diphenhydramine hydrochloride is 3.4, and the gas constant is R.)\n\n① 2.93R\n② 20.0R\n③ 29.3R \n④ 40.0R\n⑤ 293R",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 1% 복합비타민 주사제 200 mL를 혈액과 등장화하기 위해 필요한 염화나트륨의 양(g)은? (단, 복합비타민 주사제의 ΔT^{1%}_{f}=0.23℃, 염화나트륨의 ΔT^{1%}_{f}=0.58℃, 혈액의 ΔT^{1%}_{f}=0.52℃이다.)\n\n① 0.50\n② 0.90\n③ 1.0\n④ 1.5\n⑤ 1.8",
        "question_text": "Question: How many grams of sodium chloride are needed to make a 200 mL of 1% multivitamin injection isotonic with blood? (Given: ΔT^{1%}_{f} of the multivitamin injection = 0.23℃, ΔT^{1%}_{f} of sodium chloride = 0.58℃, ΔT^{1%}_{f} of blood = 0.52℃)\n\n① 0.50\n② 0.90\n③ 1.0\n④ 1.5\n⑤ 1.8",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 약물 A의 변형을 통해 옥탄올-물 분배계수(K = C 옥탄올 /C 물)를 증가시킬 수 있는 방법은?\n\n① 수용성염으로 제조한다.\n② 약물입자의 크기를 감소시킨다.\n③ 결정을 가용성 무정형으로 바꾼다.\n④ 치환기로 지방산 잔기를 도입한다.\n⑤ 치환기로 폴리에틸렌글리콜기를 도입한다.",
        "question_text": "Question: Which method can increase the octanol-water partition coefficient (K = C octanol / C water) of drug A through modification?\n\n① Prepare it as a water-soluble salt.\n② Decrease the particle size of the drug.\n③ Change the crystal to a soluble amorphous form.\n④ Introduce fatty acid residues as substituents.\n⑤ Introduce polyethylene glycol groups as substituents.",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 약물이 단순 확산에 의해 위장관 점막에서 흡수될 때 약물의 흡수속도가 감소하는 경우는?\n\n① 위장관 점막 두께의 증가\n② 위장관 점막 면적의 증가\n③ 장관내 약물 농도의 증가\n④ 위장관 점막에 대한 약물 확산도의 증가\n⑤ 위장관 점막에 대한 약물 분배계수의 증가",
        "question_text": "Question: In which case does the absorption rate of a drug decrease when it is absorbed through the gastrointestinal mucosa by simple diffusion?\n\n① Increase in the thickness of the gastrointestinal mucosa\n② Increase in the surface area of the gastrointestinal mucosa\n③ Increase in the drug concentration within the intestine\n④ Increase in the drug's diffusion coefficient for the gastrointestinal mucosa\n⑤ Increase in the drug's partition coefficient for the gastrointestinal mucosa",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 난용성 약물 A의 용해도는 25℃에서 0.3 g/100 mL이며, 1차 분해 반응속도상수는 5.0×10-2 month-1이다. 이 약물의 초기농도가 6.0 g/100 mL인 현탁제를 제조하였다. 이 현탁제를 25℃에서 보관할 때, 유효기간(t90%, month)은?\n\n① 2\n② 5\n③ 10\n④ 20\n⑤ 40",
        "question_text": "Question: The solubility of a poorly soluble drug A is 0.3 g/100 mL at 25℃, and its first-order degradation rate constant is 5.0×10-2 month-1. A suspension of this drug was prepared with an initial concentration of 6.0 g/100 mL. When this suspension is stored at 25℃, what is its shelf life (t90%, month)?\n\n① 2\n② 5\n③ 10\n④ 20\n⑤ 40",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 다음 표는 미토마이신C의 가수분해 반응에서 pH에 따른 속도상수의 로그값(logk obs)이다. pH 3~6에서 나타나는 촉매반응은? (단, 온도는 20℃이다.)\n\n| pH | 1 | 2 | 3 | 4 | 5 | 6 |\n|---|---|---|---|---|---|---|\n| logk obs | -2.7 | -2.9 | -3.0 | -4.0 | -5.0 | -6.0 |\n\n① 특정산촉매반응(specific acid catalysis)\n② 일반산촉매반응(general acid catalysis)\n③ 특정염기촉매반응(specific base catalysis)\n④ 일반염기촉매반응(general base catalysis)\n⑤ 자유라디칼촉매반응(free radical catalysis)",
        "question_text": "Question: The following table shows the logarithm of the rate constant (logk obs) for the hydrolysis reaction of mitomycin C at different pH values. What type of catalytic reaction is observed in the pH range of 3-6? (Note: The temperature is 20°C.)\n\n| pH | 1 | 2 | 3 | 4 | 5 | 6 |\n|---|---|---|---|---|---|---|\n| logk obs | -2.7 | -2.9 | -3.0 | -4.0 | -5.0 | -6.0 |\n\n① Specific acid catalysis\n② General acid catalysis\n③ Specific base catalysis\n④ General base catalysis\n⑤ Free radical catalysis",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 계면활성제의 친수-친유 평형비(hydrophilic lipophilic balance, HLB)에 관한 설명으로 옳은 것은?\n\n① HLB가 작을수록 친수성이 커진다.\n② 일반적으로 HLB 값이 1~3인 계면활성제는 세정제로 사용한다.\n③ 일반적으로 HLB 값이 15~18인 계면활성제는 w/o형 유제에 사용한다.\n④ 소르비탄 모노스테아레이트의 HLB가 폴리옥시에틸렌 소르비탄 모노스테아레이트의 HLB보다 크다.\n⑤ 친수성기가 폴리옥시에틸렌만으로 구성된 비이온성 양성친화제(amphiphile)에서 폴리옥시에틸렌의 질량백분율이 클수록 HLB가 크다.",
        "question_text": "Question: Which of the following statements about the Hydrophilic-Lipophilic Balance (HLB) of surfactants is correct?\n\n① The smaller the HLB, the greater the hydrophilicity.\n② Surfactants with HLB values of 1-3 are generally used as detergents.\n③ Surfactants with HLB values of 15-18 are generally used in w/o type emulsions.\n④ The HLB of sorbitan monostearate is greater than the HLB of polyoxyethylene sorbitan monostearate.\n⑤ In nonionic amphiphiles composed only of polyoxyethylene as the hydrophilic group, the higher the mass percentage of polyoxyethylene, the higher the HLB.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 구형 콜로이드 입자를 원심분리할 때 입자의 침강속도는? (단, 입자의 침강속도는 Stokes 식을 따른다.)\n\n① 매질 점도에 비례한다.\n② 입자 반경의 제곱에 비례한다.\n③ 원심분리기의 분당회전수에 반비례한다.\n④ 입자와 매질의 밀도 차이에 반비례한다.\n⑤ 회전중심에서 입자까지의 거리에 반비례한다.",
        "question_text": "Question: What is the sedimentation rate of spherical colloidal particles during centrifugation? (Note: The sedimentation rate of particles follows Stokes' equation.)\n\n① It is proportional to the viscosity of the medium.\n② It is proportional to the square of the particle radius.\n③ It is inversely proportional to the revolutions per minute of the centrifuge.\n④ It is inversely proportional to the density difference between the particle and the medium.\n⑤ It is inversely proportional to the distance from the center of rotation to the particle.",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n트레티노인(tretinoin)은 겔 제제로 제조하여 여드름이나 피부 손상에 사용한다. 25℃에서 이 약물의 물에 대한 용해도는 0.1 mg/100 mL 미만이며, logP 값은 6.3이다. (단, P = C_oil/C_water 이다.)\n<Data (confidential)>\n트레티노인\n\nQuestion: 이 약물의 용해도에 관한 설명으로 옳은 것은?\n\n① 산성 pH에서 물에 대한 용해도는 증가한다.\n② 수용성 가용화제를 넣으면 logP 값은 증가한다.\n③ 물에 에탄올을 첨가하면 약물의 용해도는 감소한다.\n④ 온도를 40℃로 높이면 물에 대한 용해도는 증가한다.\n⑤ 계면활성제 라우릴황산나트륨을 첨가하면 약물의 용해도는 감소한다.",
        "question_text": "Tretinoin is formulated as a gel preparation and used for acne or skin damage. At 25℃, the solubility of this drug in water is less than 0.1 mg/100 mL, and its logP value is 6.3. (Note: P = C_oil/C_water)\n<Data (confidential)>\nTretinoin\n\nQuestion: Which of the following statements about the solubility of this drug is correct?\n\n① The solubility in water increases at acidic pH.\n② The logP value increases when a water-soluble solubilizer is added.\n③ The solubility of the drug decreases when ethanol is added to water.\n④ The solubility in water increases when the temperature is raised to 40℃.\n⑤ The solubility of the drug decreases when the surfactant sodium lauryl sulfate is added.",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n트레티노인(tretinoin)은 겔 제제로 제조하여 여드름이나 피부 손상에 사용한다. 25℃에서 이 약물의 물에 대한 용해도는 0.1 mg/100 mL 미만이며, logP 값은 6.3이다. (단, P = C_oil/C_water 이다.)\n<Data (confidential)>\n트레티노인\n\nQuestion: 이 겔 제제가 히구치(Higuchi) 약물방출 모델을 따를 때, 옳은 것은?\n\n① 시간 t 에서 단위 면적당 방출된 약물의 양(Q )은 시간(t )에비례한다.\n② 시간 t 에서 단위 면적당 방출된 약물의 양(Q )은 시간의제곱근(t)에 반비례한다.\n③ 시간 t 에서 단위 면적당 약물방출 순간속도( dQdt )는 시간(t )에비례한다.\n④ 시간 t 에서 단위 면적당 약물방출 순간속도( dQdt )는 시간의제곱근(t)에 비례한다.\n⑤ 시간 t 에서 단위 면적당 약물방출 순간속도( dQdt )는 시간의제곱근(t)에 반비례한다.",
        "question_text": "Tretinoin is formulated as a gel preparation and used for acne or skin damage. At 25℃, the solubility of this drug in water is less than 0.1 mg/100 mL, and its logP value is 6.3. (Note: P = C_oil/C_water)\n<Data (confidential)>\nTretinoin\n\nQuestion: When this gel preparation follows the Higuchi drug release model, which of the following is correct?\n\n① The amount of drug released per unit area (Q) at time t is proportional to time (t).\n② The amount of drug released per unit area (Q) at time t is inversely proportional to the square root of time (√t).\n③ The instantaneous rate of drug release per unit area (dQ/dt) at time t is proportional to time (t).\n④ The instantaneous rate of drug release per unit area (dQ/dt) at time t is proportional to the square root of time (√t).\n⑤ The instantaneous rate of drug release per unit area (dQ/dt) at time t is inversely proportional to the square root of time (√t).",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 각 약물과 주요 대사체의 구조가 옳게 짝 지어진 것은?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following correctly pairs each drug with its major metabolite structure?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 다음 약물에서 ACE (angiotensin converting enzyme)의 Zn2+과 상호작용하는 부위는?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "question_text": "Question: Which part of the following drug interacts with the Zn2+ of ACE (angiotensin converting enzyme)?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 레보티록신(levothyroxine)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following is the intermediate A obtained during the synthesis process of levothyroxine?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 젬시타빈(gemcitabine)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following is the intermediate A obtained during the synthesis process of gemcitabine in the reaction below?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 다음 합성 과정에서 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① 메타돈(methadone)\n② 나프록센(naproxen)\n③ 디클로페낙(diclofenac)\n④ 트리아졸람(triazolam)\n⑤ 클로르프로마진(chlorpromazine)",
        "question_text": "Question: What is drug A obtained from the following synthesis process?\n\n<Data (confidential)>\n\n① Methadone\n② Naproxen\n③ Diclofenac\n④ Triazolam\n⑤ Chlorpromazine",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 바데나필(vardenafil)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which of the following is the intermediate A obtained during the synthesis process of vardenafil in the reaction below?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 살부타몰(salbutamol)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the intermediate A obtained in the following reaction during the synthesis process of salbutamol?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: A와 B를 출발물질로 사용하여 얻어지는 약물 C의 작용기전으로 옳은 것은?\n\n<Data (confidential)>\n\n① 비만세포 안정화\n② 류코트리엔 합성 억제\n③ 5-지방산화효소 저해\n④ 류코트리엔 수용체 길항\n⑤ 프로스타글란딘 합성 억제",
        "question_text": "Question: Which of the following is the correct mechanism of action for drug C obtained using A and B as starting materials?\n\n<Data (confidential)>\n\n① Mast cell stabilization\n② Inhibition of leukotriene synthesis\n③ 5-Lipoxygenase inhibition\n④ Leukotriene receptor antagonism\n⑤ Inhibition of prostaglandin synthesis",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 다음 합성 과정에서 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is drug A obtained from the following synthesis process?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: A와 B를 출발물질로 사용하여 합성되는 약물 C는?\n\n<Data (confidential)>\n\n① 발사르탄(valsartan)\n② 암브록솔(ambroxol)\n③ 디클로페낙(diclofenac)\n④ 돔페리돈(domperidone)\n⑤ 아미오다론(amiodarone)",
        "question_text": "Question: Which drug C is synthesized using A and B as starting materials?\n\n<Data (confidential)>\n\n① Valsartan\n② Ambroxol\n③ Diclofenac\n④ Domperidone\n⑤ Amiodarone",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 시프로플록사신(ciprofloxacin)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the intermediate A obtained in the following reaction during the synthesis process of ciprofloxacin?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: Arylpropanoic acid계열의 비스테로이드소염진통제는?\n\n① 설린닥(sulindac)\n② 피록시캄(piroxicam)\n③ 디클로페낙(diclofenac)\n④ 이부프로펜(ibuprofen)\n⑤ 인도메타신(indomethacin)",
        "question_text": "Question: Which of the following is an arylpropionic acid class of non-steroidal anti-inflammatory drugs?\n\n① Sulindac\n② Piroxicam\n③ Diclofenac\n④ Ibuprofen\n⑤ Indomethacin",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 위(stomach)의 강산 조건에서 spiro 형태의 중간체로 전환된 후 타깃 단백질에 비가역적으로 결합하여 작용하는 약물은?\n\n① 니페디핀(nifedipine)\n② 로라타딘(loratadine)\n③ 시메티딘(cimetidine)\n④ 오메프라졸(omeprazole)\n⑤ 프란루카스트(pranlukast)",
        "question_text": "Question: Which drug is converted into a spiro intermediate under the strongly acidic conditions of the stomach and then irreversibly binds to the target protein to exert its action?\n\n① Nifedipine\n② Loratadine\n③ Cimetidine\n④ Omeprazole\n⑤ Pranlukast",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 다음 설명에 해당하는 약물은?\n\n• 벤조디아제핀(benzodiazepine)계 항불안약물이다.\n• 다음 화합물을 합성원료로 사용한다.<Data (confidential)>\n• Polonovski 반응으로 OH기를 도입하여 합성할 수 있다.\n\n① 디아제팜(diazepam)\n② 로라제팜(lorazepam)\n③ 미다졸람(midazolam)\n④ 알프라졸람(alprazolam)\n⑤ 플루라제팜(flurazepam)",
        "question_text": "Question: Which drug corresponds to the following description?\n\n• It is a benzodiazepine class anxiolytic drug.\n• The following compound is used as a synthetic raw material: <Data (confidential)>\n• It can be synthesized by introducing an OH group through the Polonovski reaction.\n\n① Diazepam\n② Lorazepam\n③ Midazolam\n④ Alprazolam\n⑤ Flurazepam",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 다음 약물의 아드레날린 수용체와의 작용에 관한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① A: 알킬기의 크기와 활성은 상관관계 없음\n② B: NH는 생체 내에서 유리 형태(free form)로 존재함\n③ C: 수소 결합을 형성함\n④ D: 친수성 결합을 형성함\n⑤ E : 친유성 결합을 형성함",
        "question_text": "Question: Which of the following statements is correct regarding the interaction of these drugs with adrenergic receptors?\n\n<Data (confidential)>\n\n① A: There is no correlation between the size of the alkyl group and activity\n② B: NH exists in free form in the body\n③ C: Forms hydrogen bonds\n④ D: Forms hydrophilic bonds\n⑤ E: Forms lipophilic bonds",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 다음 설명에 해당하는 전신마취제는?\n\n• imidazole 구조를 가진다.\n• 간 및 혈장에 존재하는 esterase에 의해서 빠르게 불활성화 된다.\n• (R )-이성질체가 (S )-이성질체보다 효능이 우수하다.\n\n① 케타민(ketamine)\n② 엔플루란(enflurane)\n③ 프로포폴(propofol)\n④ 에토미데이트(etomidate)\n⑤ 티오펜탈나트륨(thiopental sodium)",
        "question_text": "Question: Which of the following general anesthetics matches the description below?\n\n• Has an imidazole structure.\n• Is rapidly inactivated by esterases present in the liver and plasma.\n• The (R)-isomer is more potent than the (S)-isomer.\n\n① Ketamine\n② Enflurane\n③ Propofol\n④ Etomidate\n⑤ Thiopental sodium",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n1세대 항히스타민제는 혈액뇌장벽(BBB)을 통과하여 중추신경계(CNS)에 오래 머무르며 졸음을 유발하는 부작용이 있었다. 이를 개선하고자 1세대 항히스타민제의 구조를 변형하여 부작용이 현저히 줄어든 2세대 항히스타민제를 개발하였다.\n<Data (confidential)>\n\nQuestion: BBB 통과가 어려워 졸음 유발이 적은 2세대 항히스타민제의 구조는?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "First-generation antihistamines could cross the blood-brain barrier (BBB) and remain in the central nervous system (CNS) for a long time, causing drowsiness as a side effect. To improve this, second-generation antihistamines were developed by modifying the structure of first-generation antihistamines, significantly reducing side effects.\n<Data (confidential)>\n\nQuestion: Which structure of second-generation antihistamines makes it difficult to cross the BBB and thus causes less drowsiness?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n1세대 항히스타민제는 혈액뇌장벽(BBB)을 통과하여 중추신경계(CNS)에 오래 머무르며 졸음을 유발하는 부작용이 있었다. 이를 개선하고자 1세대 항히스타민제의 구조를 변형하여 부작용이 현저히 줄어든 2세대 항히스타민제를 개발하였다.\n<Data (confidential)>\n\nQuestion: 위의 1세대 항히스타민제에서 2세대 항히스타민제로의 개발 방법을 가장 잘 설명한 것은?\n\n① 극성기의 도입\n② 극성기의 제거\n③ 고리구조의 도입\n④ 고리구조의 확장\n⑤ 입체화학의 변경",
        "question_text": "First-generation antihistamines could cross the blood-brain barrier (BBB) and remain in the central nervous system (CNS) for a long time, causing drowsiness as a side effect. To improve this, second-generation antihistamines were developed by modifying the structure of first-generation antihistamines, significantly reducing side effects.\n<Data (confidential)>\n\nQuestion: Which of the following best describes the development method from first-generation to second-generation antihistamines?\n\n① Introduction of polar groups\n② Removal of polar groups\n③ Introduction of ring structures\n④ Expansion of ring structures\n⑤ Modification of stereochemistry",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 0.3 mol의 아스피린을 물에 녹여 1 L로 하였다. 이 아스피린 용액의 [H+]가 9×10-3 mol/L일 때, 아스피린의 해리도(α)는?\n\n① 0.01\n② 0.03\n③ 0.06\n④ 0.3\n⑤ 0.6",
        "question_text": "Question: 0.3 mol of aspirin was dissolved in water to make 1 L of solution. If the [H+] of this aspirin solution is 9×10-3 mol/L, what is the degree of dissociation (α) of aspirin?\n\n① 0.01\n② 0.03\n③ 0.06\n④ 0.3\n⑤ 0.6",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 자외가시부흡광도측정법을 이용한 크로모글리크산나트륨의 확인시험을 위하여 pH 7.4인 인산염완충용액을 만들려고 한다. 적합한 시약의 조합은? (단, H3PO4의 pK 1=2.15, pK 2=7.20, pK 3=12.35)\n\n① H3PO4와 NaH2PO4\n② NaH2PO4와 Na2HPO4\n③ Na2HPO4와 Na3PO4\n④ NaOH와 Na2HPO4\n⑤ NaOH와 Na3PO4",
        "question_text": "Question: To prepare a phosphate buffer solution with pH 7.4 for the identification test of sodium cromoglycate using UV-visible spectrophotometry, which combination of reagents is appropriate? (Given: H3PO4 pK1=2.15, pK2=7.20, pK3=12.35)\n\n① H3PO4 and NaH2PO4\n② NaH2PO4 and Na2HPO4\n③ Na2HPO4 and Na3PO4\n④ NaOH and Na2HPO4\n⑤ NaOH and Na3PO4",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: 아트로핀황산염 주사액의 확인시험을 위하여 검액을 박층크로마토그래프법으로 전개시키고 나서 분리된 반점을 확인하기 위하여 드라겐도르프시액을 분무한다. 드라겐도르프시액의 화학종은?\n\n① 티오(thio) 착이온\n② 시아노(cyano) 착이온\n③ 암민(ammine) 착이온\n④ 할로게노(halogeno) 착이온\n⑤ 티오시아나토(thiocyanato) 착이온",
        "question_text": "Question: For the identification test of atropine sulfate injection, the test solution is developed using thin-layer chromatography, and then Dragendorff's reagent is sprayed to identify the separated spots. What is the chemical species in Dragendorff's reagent?\n\n① Thio complex ion\n② Cyano complex ion\n③ Ammine complex ion\n④ Halogeno complex ion\n⑤ Thiocyanato complex ion",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 건조수산화알루미늄겔을 정량할 때, 0.05 mol/L EDTA 1 mL에 대응하는 Al2O3(분자량 102)의 양(mg)은?\n\n① 2.55×10^-3\n② 5.10×10^-3\n③ 2.55\n④ 5.10\n⑤ 10.2",
        "question_text": "Question: When quantifying dried aluminum hydroxide gel, what is the amount (mg) of Al2O3 (molecular weight 102) corresponding to 1 mL of 0.05 mol/L EDTA?\n\n① 2.55×10^-3\n② 5.10×10^-3\n③ 2.55\n④ 5.10\n⑤ 10.2",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 외용소독제로 사용하는 과산화수소수(KP)를 KMnO4 표준액으로 적정할 때, 표준액의 표정에 필요한 1차 표준물질은?\n\n① Fe2(SO4)3\n② K2Cr2O7\n③ NaCl\n④ Na2CO3\n⑤ Na2C2O4",
        "question_text": "Question: When titrating hydrogen peroxide solution (KP) used as an external disinfectant with KMnO4 standard solution, what is the primary standard substance needed for standardization of the standard solution?\n\n① Fe2(SO4)3\n② K2Cr2O7\n③ NaCl\n④ Na2CO3\n⑤ Na2C2O4",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 다음과 같은 방법으로 정량하는 의약품은?\n\n이 약을 건조하여 약 0.2 g을 정밀하게 달아 물에 녹여 정확하게 100 mL로 한다. 이 액 10 mL를 정확하게 취하여 요오드병에 넣고 과요오드산칼륨시액 50 mL를 정확하게 넣어 수욕에서 15분간 가열한다. 식힌 다음 요오드화칼륨 2.5 g을 넣고 곧 요오드병에 마개를 하여 잘 흔들어 섞고 어두운 곳에 5분간 방치한 다음 유리된 요오드를 0.1 mol/L 티오황산나트륨액으로 적정한다.\n\n① 붕산\n② 페놀\n③ 살리실산\n④ D-소르비톨\n⑤ 판토텐산칼슘",
        "question_text": "Question: Which pharmaceutical product is quantified using the following method?\n\nDry this substance and accurately weigh about 0.2 g. Dissolve it in water and make up to exactly 100 mL. Accurately pipette 10 mL of this solution into an iodine flask, add exactly 50 mL of potassium periodate solution, and heat in a water bath for 15 minutes. After cooling, add 2.5 g of potassium iodide, immediately stopper the iodine flask, shake well to mix, and let stand in a dark place for 5 minutes. Then, titrate the liberated iodine with 0.1 mol/L sodium thiosulfate solution.\n\n① Boric acid\n② Phenol\n③ Salicylic acid\n④ D-Sorbitol\n⑤ Calcium pantothenate",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 디드로게스테론[E1 1% 1cm (285 nm)=845] 원료의약품 정량을 다음과 같이 실시하였다. 디드로게스테론의 함량(%)은?\n\n이 약을 건조하여 50.3 mg을 달아 메탄올에 녹여 100 mL로 한 후, 이 액 1 mL를 취하여 메탄올을 넣어 100 mL로 하였다. 이 액을 가지고 자외가시부흡광도측정법으로 285 nm에서 흡광도를 측정하였더니 0.418이었다.\n\n① 0.418/845 × 100 × 1/50.3 × 100\n② 0.418/845 × 1000 × 50.3 × 100\n③ 0.418/845 × 1000 × 1/50.3 × 100\n④ 0.418/845 × 100000 × 50.3 × 100\n⑤ 0.418/845 × 100000 × 1/50.3 × 100",
        "question_text": "Question: The quantitative analysis of dydrogesterone [E1 1% 1cm (285 nm)=845] raw material was conducted as follows. What is the content (%) of dydrogesterone?\n\n50.3 mg of the dried substance was weighed and dissolved in methanol to make 100 mL. Then, 1 mL of this solution was taken and diluted with methanol to make 100 mL. The absorbance of this solution was measured at 285 nm using UV-visible spectrophotometry, and it was found to be 0.418.\n\n① 0.418/845 × 100 × 1/50.3 × 100\n② 0.418/845 × 1000 × 50.3 × 100\n③ 0.418/845 × 1000 × 1/50.3 × 100\n④ 0.418/845 × 100000 × 50.3 × 100\n⑤ 0.418/845 × 100000 × 1/50.3 × 100",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 환산한 무수물로서 이소소르비드 5 g을 취하여 물 50 mL에 녹인 후, 20℃에서 100 mm 길이의 시료관과 나트륨 D선을 사용하여 선광도를 측정하였더니 +4.6°였다. 이소소르비드의 비선광도는?\n\n① +2.3°\n② +4.6°\n③ +23.0°\n④ +46.0°\n⑤ +92.0°",
        "question_text": "Question: 5 g of isosorbide, calculated as anhydrous, was dissolved in 50 mL of water. The optical rotation was measured at 20°C using a 100 mm sample tube and sodium D-line, and the result was +4.6°. What is the specific optical rotation of isosorbide?\n\n① +2.3°\n② +4.6°\n③ +23.0°\n④ +46.0°\n⑤ +92.0°",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 글루콘산제일철수화물에 함유되어 있는 납(Pb)을 원자흡광광도법으로 분석하고자 납표준액을 이용하여 다음의 검량선식을 구하였다. 이 의약품을 표준액과 동일한 방법으로 조제한 검액의 흡광도가 0.45였다면, 납의 농도(ppm)는?\n\n<Data (confidential)>\n\n① 0.2\n② 0.4\n③ 0.6\n④ 0.8\n⑤ 0.9",
        "question_text": "Question: Using atomic absorption spectrophotometry, lead (Pb) content in ferrous gluconate hydrate was analyzed, and the following calibration curve equation was obtained using lead standard solution. If the absorbance of the test solution prepared in the same manner as the standard solution was 0.45, what is the concentration of lead (ppm)?\n\n<Data (confidential)>\n\n① 0.2\n② 0.4\n③ 0.6\n④ 0.8\n⑤ 0.9",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 다음은 의약품 A의 예측 수소핵자기공명스펙트럼(1H-NMR)의 일부이다. 스펙트럼에서 화학적이동값 2.3~2.5 ppm에 해당하는 것은? (단, 피크 위의 숫자는 피크면적비를 나타냄)\n\n<Data (confidential)>\n\n① 인접탄소에 수소가 없는 CH3\n② 인접탄소에 수소가 1개 있는 CH2\n③ 인접탄소에 수소가 1개 있는 CH3\n④ 인접탄소에 수소가 2개 있는 CH2\n⑤ 인접탄소에 수소가 2개 있는 CH3",
        "question_text": "Question: The following is a part of the predicted proton nuclear magnetic resonance spectrum (1H-NMR) of drug A. What corresponds to the chemical shift value of 2.3~2.5 ppm in the spectrum? (Note: The numbers above the peaks represent the peak area ratio)\n\n<Data (confidential)>\n\n① CH3 with no hydrogen on the adjacent carbon\n② CH2 with one hydrogen on the adjacent carbon\n③ CH3 with one hydrogen on the adjacent carbon\n④ CH2 with two hydrogens on the adjacent carbon\n⑤ CH3 with two hydrogens on the adjacent carbon",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: '-N(CH3)3'로 표면수식된 고체 고정상을 활용하여 DNA 올리고핵산염을 분리하는 크로마토그래프법은?\n\n① 분배크로마토그래프법\n② 역상크로마토그래프법\n③ 겔투과크로마토그래프법\n④ 이온교환크로마토그래프법\n⑤ 크기배제크로마토그래프법",
        "question_text": "Question: What chromatography method is used to separate DNA oligonucleotides using a solid stationary phase surface-modified with '-N(CH3)3'?\n\n① Partition chromatography\n② Reversed-phase chromatography\n③ Gel permeation chromatography\n④ Ion-exchange chromatography\n⑤ Size-exclusion chromatography",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 항진균제 그리세오풀빈을 액체크로마토그래피(내부표준액:파라옥시벤조산부틸의 아세토니트릴용액)로 정량분석할 때, 이동상을 점도가 더 낮은 것으로 교체하였더니 분리능이 증가되었다. 그 이유는?\n\n① 이론단높이의 증가\n② 칼럼 외부의 불용공간의 감소\n③ 다통로효과에 의한 확산(eddy diffusion)의 증가\n④ 좌우세로방향 확산(longitudinal diffusion)의 증가\n⑤ 질량이동 확산(mass transfer diffusion)에 의한 분포평형 도달 시간의 감소",
        "question_text": "Question: When quantitatively analyzing the antifungal agent griseofulvin using liquid chromatography (internal standard solution: butyl paraben in acetonitrile), the resolution increased when the mobile phase was replaced with one of lower viscosity. What is the reason for this?\n\n① Increase in theoretical plate height\n② Decrease in dead volume outside the column\n③ Increase in eddy diffusion due to multipath effect\n④ Increase in longitudinal diffusion\n⑤ Decrease in time to reach distribution equilibrium due to mass transfer diffusion",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 기체크로마토그래피에 사용되는 검출기 중, 분석 대상 시료의 종류에 관계없이 사용할 수 있으며, 시료 비파괴형인 검출기는?\n\n① 열전도도 검출기\n② 전자포획 검출기\n③ 질량분석 검출기\n④ 불꽃이온화 검출기\n⑤ 주기적 방전 검출기",
        "question_text": "Question: Among the detectors used in gas chromatography, which detector can be used regardless of the type of sample being analyzed and is non-destructive to the sample?\n\n① Thermal conductivity detector\n② Electron capture detector\n③ Mass spectrometry detector\n④ Flame ionization detector\n⑤ Pulsed discharge detector",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 베타메타손, 베타메타손디프로피오네이트와 니코틴산아미드를 액체크로마토그래피로 동시에 분리분석하기 위하여 용리과정 중 이동상의 극성을 변화시키는 방법은?\n\n① 기울기 용리(gradient elution)\n② 등용매 용리(isocratic elution)\n③ 정압 용리(constant pressure elution)\n④ 등유속 용리(constant flow rate elution)\n⑤ 등온 용리(constant temperature elution)",
        "question_text": "Question: What method is used to change the polarity of the mobile phase during the elution process to simultaneously separate and analyze betamethasone, betamethasone dipropionate, and nicotinamide using liquid chromatography?\n\n① Gradient elution\n② Isocratic elution\n③ Constant pressure elution\n④ Constant flow rate elution\n⑤ Constant temperature elution",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 비이온성 소수성 의약품 a와 b가 모세관 전기영동 분석법에 의해 다음 그림과 같이 두 개의 피크로 분리되도록 하는 방법은?\n\n<Data (confidential)>\n\n① 모세관 길이를 늘인다.\n② 이동상 용액의 이온세기를 높인다.\n③ 이동상 용액의 pH가 2 이하가 되게 한다.\n④ 전기장 강도를 높여 전기영동속도를 높인다.\n⑤ 이동상 용액에 이온성 계면활성제를 임계미셀농도 이상이 되도록 넣는다.",
        "question_text": "Question: Which method allows for the separation of non-ionic hydrophobic drugs a and b into two peaks as shown in the following figure using capillary electrophoresis analysis?\n\n<Data (confidential)>\n\n① Increase the length of the capillary.\n② Increase the ionic strength of the mobile phase solution.\n③ Adjust the pH of the mobile phase solution to be below 2.\n④ Increase the electric field strength to enhance the electrophoretic velocity.\n⑤ Add an ionic surfactant to the mobile phase solution above its critical micelle concentration.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 덱사메타손 정을 액체크로마토그래피로 정량분석할 때, 동일한 시료를 동일한 방법으로 반복 시험하여 덱사메타손 함유량의 평균치와 표준편차를 얻는 방법은?\n\n① 공시험\n② 맹시험\n③ 조절시험\n④ 평행시험\n⑤ 회수시험",
        "question_text": "Question: When quantitatively analyzing dexamethasone tablets using liquid chromatography, what is the method of obtaining the average and standard deviation of dexamethasone content by repeatedly testing the same sample using the same method?\n\n① Blank test\n② Blind test\n③ Control test\n④ Parallel test\n⑤ Recovery test",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n건조한 원료의약품 A 10.0 mg을 메탄올에 녹여 정확하게 1000 mL로 하여 자외가시부흡광도 측정용 검액으로 하였다. 검액을 층장 1 cm의 셀에 넣어 흡수극대파장인 254 nm에서 메탄올을 대조로 하여 흡광도를 5회 측정하였을 때 평균 흡광도는 0.40, 표준편차는 0.01이었다.\n\nQuestion: 이 원료의약품 A의 평균 흡광도의 상대표준편차(%)는?\n\n① 0.1\n② 0.4\n③ 1.0\n④ 2.5\n⑤ 4.0",
        "question_text": "A dry active pharmaceutical ingredient A, weighing 10.0 mg, was dissolved in methanol and made up to exactly 1000 mL to prepare a test solution for UV-visible spectrophotometry. The absorbance was measured 5 times at the absorption maximum wavelength of 254 nm using a 1 cm path length cell with methanol as a blank. The average absorbance was 0.40, and the standard deviation was 0.01.\n\nQuestion: What is the relative standard deviation (%) of the average absorbance for this active pharmaceutical ingredient A?\n\n① 0.1\n② 0.4\n③ 1.0\n④ 2.5\n⑤ 4.0",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n건조한 원료의약품 A 10.0 mg을 메탄올에 녹여 정확하게 1000 mL로 하여 자외가시부흡광도 측정용 검액으로 하였다. 검액을 층장 1 cm의 셀에 넣어 흡수극대파장인 254 nm에서 메탄올을 대조로 하여 흡광도를 5회 측정하였을 때 평균 흡광도는 0.40, 표준편차는 0.01이었다.\n\nQuestion: 이 원료의약품 A의 비흡광도 E1%1 cm 는?\n\n① 0.4\n② 25\n③ 100\n④ 250\n⑤ 400",
        "question_text": "A dry active pharmaceutical ingredient A weighing 10.0 mg was dissolved in methanol and made up to exactly 1000 mL to prepare a test solution for UV-visible spectrophotometry. The absorbance was measured 5 times at the absorption maximum wavelength of 254 nm using a 1 cm path length cell with methanol as a reference. The average absorbance was 0.40 with a standard deviation of 0.01.\n\nQuestion: What is the specific absorbance E1%1 cm of this active pharmaceutical ingredient A?\n\n① 0.4\n② 25\n③ 100\n④ 250\n⑤ 400",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 여러 가지 원료 성분이 하나의 용기에서 혼합, 조립, 건조될 수 있어 공정시간을 단축할 수 있는 과립 제조법은?\n\n① 저전단과립법\n② 고전단과립법\n③ 유동층과립법\n④ 롤러압축과립법\n⑤ 압출구형과립법",
        "question_text": "Question: Which granulation method allows multiple raw ingredients to be mixed, assembled, and dried in a single container, thereby reducing processing time?\n\n① Low shear granulation\n② High shear granulation\n③ Fluid bed granulation\n④ Roller compaction granulation\n⑤ Extrusion spheronization granulation",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 수화나 침식이 일어나지 않아서, 약물을 방출하고 소화관을 통과한 후에도 모양을 유지하는 정제 매트릭스 시스템에 사용하는 서방출용 기제는?\n\n① 카보머\n② 잔탄검\n③ 알긴산나트륨\n④ 에틸셀룰로오스\n⑤ 폴리에틸렌옥사이드",
        "question_text": "Question: Which sustained-release base is used in tablet matrix systems that maintain their shape even after releasing the drug and passing through the gastrointestinal tract, without undergoing hydration or erosion?\n\n① Carbomer\n② Xanthan gum\n③ Sodium alginate\n④ Ethylcellulose\n⑤ Polyethylene oxide",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 약물을 함유한 백당 기제를 막대기에 고정시킨 형태를 띠며, 암환자의 돌발성 통증 경감을 위하여 펜타닐시트르산염 제제에 사용하는 제형은?\n\n① 박칼정\n② 추어블정\n③ 롤리폽제\n④ 유동엑스제\n⑤ 경구용젤리제",
        "question_text": "Question: Which dosage form, containing a drug in a sugar base fixed on a stick and used for fentanyl citrate preparations to relieve breakthrough pain in cancer patients, is being referred to?\n\n① Buccal tablet\n② Chewable tablet\n③ Lollipop\n④ Fluid extract\n⑤ Oral jelly",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 강한 확장력이 없어서 주로 거품을 형성하는 표면분사 용도로 사용하는 에어로솔제의 압축가스 분사제는?\n\n① 프로판\n② n-부탄\n③ 이산화탄소\n④ 디메틸에테르\n⑤ 하이드로플루오로알칸",
        "question_text": "Question: Which propellant gas in aerosol products is primarily used for surface spraying to form foam due to its lack of strong expansion power?\n\n① Propane\n② n-Butane\n③ Carbon dioxide\n④ Dimethyl ether\n⑤ Hydrofluoroalkane",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 물에 녹지 않으나 물을 흡수할 수 있어, 수용액 상태의 약물을 소수성 기제와 연합할 때 사용하는 연고기제는?\n\n① 황납\n② 실리콘\n③ 단미연고\n④ 유동파라핀\n⑤ 정제라놀린",
        "question_text": "Question: Which ointment base is insoluble in water but can absorb water, and is used when combining aqueous drug solutions with hydrophobic bases?\n\n① Yellow wax\n② Silicone\n③ Simple ointment\n④ Liquid paraffin\n⑤ Purified lanolin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 카카오지로 제조한 좌제의 융점이 높아서 체온에 의해 용융되지 않는 문제점을 개선하기 위해 가하는 것은?\n\n① 밀납\n② 파라핀\n③ 벤토나이트\n④ 함수클로랄\n⑤ 세틸에스테르왁스",
        "question_text": "Question: What can be added to improve the problem of suppositories made with cocoa butter having a high melting point and not melting at body temperature?\n\n① Beeswax\n② Paraffin\n③ Bentonite\n④ Chloral hydrate\n⑤ Cetyl ester wax",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 난용성 약물의 주사제 제조에 사용하는 계면활성제로서, 경화피마자유에 에틸렌옥사이드가 축합된 것은?\n\n① HCO-60\n② poloxamer\n③ polysorbate 80\n④ sorbitan monopalmitate\n⑤ sulfobutylether-β-cyclodextrin",
        "question_text": "Question: Which of the following surfactants, used in the preparation of injectable formulations for poorly soluble drugs, is produced by the condensation of ethylene oxide with hydrogenated castor oil?\n\n① HCO-60\n② poloxamer\n③ polysorbate 80\n④ sorbitan monopalmitate\n⑤ sulfobutylether-β-cyclodextrin",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 이식제에 관한 설명으로 옳은 것은?\n\n① 목표 치료 부위에 직접 적용해야 한다.\n② 단기방출형 이식제는 무균 처리가 필요하지 않다.\n③ 간 초회통과효과가 높은 약물에는 적용할 수 없다.\n④ 삼투압을 이용한 장기방출형 이식제 설계가 가능하다.\n⑤ polyanhydrides로 제조한 이식제는 방출 완료 후 수술로 제거해야 한다.",
        "question_text": "Question: Which of the following statements about implants is correct?\n\n① They must be applied directly to the target therapeutic site.\n② Short-acting implants do not require sterilization.\n③ They cannot be used for drugs with high hepatic first-pass effect.\n④ Long-acting implants can be designed using osmotic pressure.\n⑤ Implants made with polyanhydrides must be surgically removed after release is complete.",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 제제 설계 시 고려해야 하는 약물의 결정다형에 관한 설명으로 옳은 것은?\n\n① 약물의 결정형은 융점에 영향을 주지 않는다.\n② 결정형 약물이 무정형 약물보다 용출속도가 빠르다.\n③ 현탁제 제조 시 준안정형 약물을 우선적으로 사용한다.\n④ 결정형 변경으로 화학구조가 변화되어 용해도가 달라진다.\n⑤ 무정형 약물로 변경하여 소화관 흡수를 증진시킬 수 있다.",
        "question_text": "Question: Which of the following statements about the crystal polymorphism of drugs that should be considered in formulation design is correct?\n\n① The crystal form of a drug does not affect its melting point.\n② Crystalline drugs have a faster dissolution rate than amorphous drugs.\n③ In the preparation of suspensions, metastable forms of drugs are preferentially used.\n④ Changes in crystal form alter the chemical structure, leading to changes in solubility.\n⑤ Conversion to an amorphous form can enhance gastrointestinal absorption of a drug.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: Everted intestinal sac 기법을 사용하여 확인할 수 있는 약물의 특성은?\n\n① 용해도\n② 막투과성\n③ 분배계수\n④ 용출속도\n⑤ 해리상수",
        "question_text": "Question: Which characteristic of a drug can be confirmed using the everted intestinal sac technique?\n\n① Solubility\n② Membrane permeability\n③ Partition coefficient\n④ Dissolution rate\n⑤ Dissociation constant",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 난용성 약물의 고형제를 용출시험 할 때, 용출액에 계면활성 가용화제를 첨가하는 이유는?\n\n① 가수분해 방지\n② 싱크상태 유도\n③ 약물산화 방지\n④ 미생물오염 방지\n⑤ 복합체형성 유도",
        "question_text": "Question: What is the reason for adding a surfactant solubilizing agent to the dissolution medium when conducting a dissolution test for a solid dosage form of a poorly soluble drug?\n\n① Prevention of hydrolysis\n② Induction of sink conditions\n③ Prevention of drug oxidation\n④ Prevention of microbial contamination\n⑤ Induction of complex formation",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 다음 그림은 생체외-생체내 상관관계(IVIVC)가 높다고 알려진 약물 X를 동일량 함유하는 서로 다른 정제 A, B, C의 시간에 따른 용출률 곡선이다. ‘평균용출시간(MDT)이 가장 짧은 것’과 ‘최고혈중농도(Cmax)가 가장 높게 나타날 수 있는 것’을 순서대로 나열한 것은?\n\n<Data (confidential)>\n\n① A, A\n② A, B\n③ B, B\n④ B, C\n⑤ C, C",
        "question_text": "Question: The following figure shows the dissolution rate curves over time for different tablets A, B, and C containing the same amount of drug X, which is known to have a high in vitro-in vivo correlation (IVIVC). Which of the following correctly lists, in order, 'the one with the shortest Mean Dissolution Time (MDT)' and 'the one that could show the highest maximum plasma concentration (Cmax)'?\n\n<Data (confidential)>\n\n① A, A\n② A, B\n③ B, B\n④ B, C\n⑤ C, C",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 약물 A 10 mg을 정맥주사(iv bolus) 한 후 얻어진 투여 시점(t=0)에서의 혈중농도(C0)는 20 μg/L이었다. 이 약물의 겉보기 분포용적(L)은? (단, 약물 A는 선형 1-컴파트먼트 모델을 따른다.)\n\n① 50\n② 100\n③ 200\n④ 500\n⑤ 2000",
        "question_text": "Question: After administering a 10 mg intravenous bolus injection of drug A, the blood concentration (C0) at the time of administration (t=0) was 20 μg/L. What is the apparent volume of distribution (L) for this drug? (Note: Drug A follows a linear one-compartment model.)\n\n① 50\n② 100\n③ 200\n④ 500\n⑤ 2000",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 약물 A의 초회투여량을 정맥투여 하여 목표 유효혈중농도에 신속하게 도달시킨 후, 유지용량 50 mg을 반감기마다 정맥투여 하여 목표 유효혈중농도를 지속적으로 유지하고자 한다. 필요한 초회투여량(mg)은? (단, 약물 A는 선형 1-컴파트먼트 모델을 따른다.)\n\n① 10\n② 50\n③ 100\n④ 150\n⑤ 200",
        "question_text": "Question: After rapidly achieving the target effective blood concentration by intravenously administering the initial dose of Drug A, we want to maintain the target effective blood concentration continuously by intravenously administering a maintenance dose of 50 mg at every half-life interval. What is the required initial dose (mg)? (Note: Drug A follows a linear 1-compartment model.)\n\n① 10\n② 50\n③ 100\n④ 150\n⑤ 200",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 약물 X를 정맥으로 반복투여 한 후 얻어진 혈중농도-시간 곡선 A가 B로 변화되었다. 그 원인으로 옳은 것은? (단, 약물 X는 선형 1-컴파트먼트 모델을 따른다.)\n\n<Data (confidential)>\n\n① 반감기 증가\n② 분포용적 감소\n③ 투여용량 증가\n④ 투여간격 감소\n⑤ 클리어런스 증가",
        "question_text": "Question: After repeated intravenous administration of drug X, the blood concentration-time curve changed from A to B. What is the correct cause for this change? (Note: Drug X follows a linear one-compartment model.)\n\n<Data (confidential)>\n\n① Increase in half-life\n② Decrease in volume of distribution\n③ Increase in dosage\n④ Decrease in dosing interval\n⑤ Increase in clearance",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: OATP1B1 수송체 발현 유전자 SLCO1B1의 521T>C 유전변이가 있는 환자에서 심바스타틴의 부작용 발현율이 높은 것으로 알려져 있다. 그 이유로 옳은 것은?\n\n① 뇌세포로의 수송능력 증가로 분포용적 증가\n② 간세포로의 수송능력 저하로 혈중농도 증가\n③ 간세포로의 수송능력 증가로 독성대사체 증가\n④ 장관세포에서의 배출능력 저하로 혈중농도 증가\n⑤ 신세뇨관세포에서의 배출능력 저하로 재흡수 증가",
        "question_text": "Question: Patients with the 521T>C genetic variation in the SLCO1B1 gene, which expresses the OATP1B1 transporter, are known to have a higher incidence of side effects from simvastatin. What is the correct reason for this?\n\n① Increased distribution volume due to enhanced transport to brain cells\n② Increased blood concentration due to reduced transport to liver cells\n③ Increased toxic metabolites due to enhanced transport to liver cells\n④ Increased blood concentration due to reduced efflux from intestinal cells\n⑤ Increased reabsorption due to reduced efflux from renal tubular cells",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음의 제제 처방에 따라 소염진통 용도의 정제를 타정하고 셀라세페이트(cellacefate)로 코팅하여 경구 고형제 A를 완성하고자 한다.\n디클로페낙나트륨 50.0 mg\n유당일수화물 94.5 mg\n미결정셀룰로오스 28.0 mg\n히드록시프로필셀룰로오스 2.5 mg\n크로스카르멜로오스나트륨 20.0 mg\n스테아르산마그네슘 1.0 mg\n\nQuestion: 경구 고형제 A의 주된 특징은?\n\n① 소량의 타액으로 신속 붕해\n② 대장 미생물에 의한 약물방출\n③ 위에서 녹지 않고 소장에서 용출\n④ 소장의 소화효소에 의한 약물방출\n⑤ 위체류 연장을 통한 약물흡수 촉진",
        "question_text": "A tablet for anti-inflammatory and analgesic purposes is to be compressed according to the following formulation and coated with cellacefate to complete the oral solid dosage form A.\n\nDiclofenac sodium 50.0 mg\nLactose monohydrate 94.5 mg\nMicrocrystalline cellulose 28.0 mg\nHydroxypropyl cellulose 2.5 mg\nCroscarmellose sodium 20.0 mg\nMagnesium stearate 1.0 mg\n\nQuestion: What is the main characteristic of oral solid dosage form A?\n\n① Rapid disintegration with a small amount of saliva\n② Drug release by colonic microorganisms\n③ Not dissolving in the stomach but releasing in the small intestine\n④ Drug release by digestive enzymes in the small intestine\n⑤ Promotion of drug absorption through prolonged gastric retention",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음의 제제 처방에 따라 소염진통 용도의 정제를 타정하고 셀라세페이트(cellacefate)로 코팅하여 경구 고형제 A를 완성하고자 한다.\n디클로페낙나트륨 50.0 mg\n유당일수화물 94.5 mg\n미결정셀룰로오스 28.0 mg\n히드록시프로필셀룰로오스 2.5 mg\n크로스카르멜로오스나트륨 20.0 mg\n스테아르산마그네슘 1.0 mg\n\nQuestion: 타정 시, 일부 배치에서 구성 원료물질이 타정기의 펀치에 달라붙는 현상이 발생하였다. 이 현상의 명칭과 이를 개선하기 위해 증량이 필요한 첨가제를 옳게 짝 지은 것은?\n\n① 캡핑(capping) – 유당일수화물\n② 피킹(picking) – 스테아르산마그네슘\n③ 스플리팅(splitting) – 미결정셀룰로오스\n④ 캡핑(capping) – 크로스카르멜로오스나트륨\n⑤ 스티킹(sticking) – 크로스카르멜로오스나트륨",
        "question_text": "The following formulation is used to prepare an anti-inflammatory analgesic tablet, which is then coated with cellacefate to complete the oral solid dosage form A.\n\nDiclofenac sodium 50.0 mg\nLactose monohydrate 94.5 mg\nMicrocrystalline cellulose 28.0 mg\nHydroxypropyl cellulose 2.5 mg\nCroscarmellose sodium 20.0 mg\nMagnesium stearate 1.0 mg\n\nQuestion: During tablet compression, some batches experienced the phenomenon of constituent materials sticking to the punch of the tablet press. What is the correct name for this phenomenon, and which excipient should be increased to improve this issue?\n\n① Capping – Lactose monohydrate\n② Picking – Magnesium stearate\n③ Splitting – Microcrystalline cellulose\n④ Capping – Croscarmellose sodium\n⑤ Sticking – Croscarmellose sodium",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 트리프토판(tryptophan) 유래의 알칼로이드로서 항부정맥 작용이 있는 화합물은?\n\n① atropine\n② emetine\n③ ephedrine\n④ higenamine\n⑤ quinidine",
        "question_text": "Question: Which compound derived from tryptophan is an alkaloid with antiarrhythmic properties?\n\n① atropine\n② emetine\n③ ephedrine\n④ higenamine\n⑤ quinidine",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 화합물군은?\n\n• 페닐알라닌(phenylalanine)으로부터 생합성됨\n• emulsin에 의해 가수분해되어 HCN이 생성됨\n• 행인, 도인에 함유되어 있음\n\n① cannabinoid\n② cyanogenic glycoside\n③ diarylheptanoid\n④ glucosinolate \n⑤ resin glycoside",
        "question_text": "Question: Which group of compounds is described below?\n\n• Biosynthesized from phenylalanine\n• Hydrolyzed by emulsin to produce HCN\n• Found in bitter almonds and peach kernels\n\n① cannabinoid\n② cyanogenic glycoside\n③ diarylheptanoid\n④ glucosinolate \n⑤ resin glycoside",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia외한약(생약)규격집(KHP)에 수재된 Magnolia biondii 의 약용 부위는?\n\n① 뿌리\n② 열매\n③ 종자\n④ 꽃봉오리\n⑤ 뿌리줄기",
        "question_text": "Question: What is the medicinal part of Magnolia biondii listed in the Korean Herbal Pharmacopoeia (KHP) outside of the Korean Pharmacopoeia?\n\n① Root\n② Fruit\n③ Seed\n④ Flower bud\n⑤ Rhizome",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 소의 담낭에 생긴 결석으로, 빌리루빈(bilirubin)을 함유하는 생약은?\n\n① Bovis Calculus\n② Bufonis Venenum\n③ Galla Rhois\n④ Poria Sclerotium\n⑤ Ursi Fel",
        "question_text": "Question: Which medicinal herb contains bilirubin and is derived from gallstones formed in the gallbladder of cattle?\n\n① Bovis Calculus\n② Bufonis Venenum\n③ Galla Rhois\n④ Poria Sclerotium\n⑤ Ursi Fel",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약은?\n\n• 초롱꽃과(Campanulaceae)에 속함\n• oleanane계 saponin을 함유함\n• 진해, 거담약으로 사용함\n\n① Bupleuri Radix\n② Curcumae Radix\n③ Paeoniae Radix\n④ Platycodonis Radix\n⑤ Rehmanniae Radix",
        "question_text": "Question: Which of the following describes the medicinal herb?\n\n• Belongs to the Campanulaceae family\n• Contains oleanane-type saponins\n• Used as an antitussive and expectorant\n\n① Bupleuri Radix\n② Curcumae Radix\n③ Paeoniae Radix\n④ Platycodonis Radix\n⑤ Rehmanniae Radix",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 구릿대의 뿌리를 약용하는 생약은?\n\n① Angelicae Dahuricae Radix\n② Astragali Radix\n③ Polygoni Multiflori Radix\n④ Rehmanniae Radix Preparata\n⑤ Scutellariae Radix",
        "question_text": "Question: Which medicinal herb uses the root of Angelica gigas?\n\n① Angelicae Dahuricae Radix\n② Astragali Radix\n③ Polygoni Multiflori Radix\n④ Rehmanniae Radix Preparata\n⑤ Scutellariae Radix",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: Dianthrone 배당체와 anthraquinone 등을 함유하고, 투여량에 따라 대장성 사하제 또는 소염성 건위제로 사용하는 생약은?\n\n① Corydalis Tuber\n② Gastrodiae Rhizoma\n③ Rhei Radix et Rhizoma\n④ Scopoliae Rhizoma\n⑤ Sinomeni Caulis et Rhizoma",
        "question_text": "Question: Which crude drug contains dianthrone glycosides and anthraquinones, and is used as a large intestine laxative or anti-inflammatory stomachic depending on the dosage?\n\n① Corydalis Tuber\n② Gastrodiae Rhizoma\n③ Rhei Radix et Rhizoma\n④ Scopoliae Rhizoma\n⑤ Sinomeni Caulis et Rhizoma",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약은?\n\n• 물푸레나무과(Oleaceae)에 속함\n• 열매를 약용함\n• 항세균, 항바이러스 작용을 나타냄\n\n① 개자\n② 산초\n③ 연교\n④ 산수유\n⑤ 육두구",
        "question_text": "Question: Which of the following medicinal herbs is being described?\n\n• Belongs to the olive family (Oleaceae)\n• The fruit is used medicinally\n• Exhibits antibacterial and antiviral effects\n\n① Galla Rhois\n② Zanthoxylum fruit\n③ Forsythia fruit\n④ Cornus fruit\n⑤ Nutmeg",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 화합물은?\n\n• isoquinoline계 알칼로이드임\n• 운향과(Rutaceae)의 Phellodendron속 식물에 함유되어 있음\n• 고미건위, 정장작용을 나타냄\n\n① aconitine\n② berberine\n③ ergotamine\n④ lobeline\n⑤ reserpine",
        "question_text": "Question: Which of the following describes the compound?\n\n• It is an isoquinoline alkaloid\n• It is found in plants of the genus Phellodendron in the Rutaceae family\n• It exhibits bitter stomachic and intestinal regulating effects\n\n① aconitine\n② berberine\n③ ergotamine\n④ lobeline\n⑤ reserpine",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 섬수(蟾酥)의 bufotoxin이 속한 화합물군은?\n\n① cardiac glycoside\n② iridoid glycoside\n③ isoquinoline alkaloid\n④ steroidal alkaloid \n⑤ triterpenoidal saponin",
        "question_text": "Question: Which group of compounds does bufotoxin from toad venom (Venenum Bufonis) belong to?\n\n① cardiac glycoside\n② iridoid glycoside\n③ isoquinoline alkaloid\n④ steroidal alkaloid \n⑤ triterpenoidal saponin",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 신남산(cinnamic acid)을 함유하며, 줄기껍질을 약용하는 녹나무과(Lauraceae)의 생약은?\n\n① 두충(杜仲)\n② 육계(肉桂)\n③ 진피(陳皮)\n④ 상백피(桑白皮)\n⑤ 오가피(五加皮)뒷면 계속",
        "question_text": "Question: Which medicinal herb from the Lauraceae family contains cinnamic acid and uses the stem bark for medicinal purposes?\n\n① Eucommia bark (Du Zhong)\n② Cinnamon bark (Rou Gui)\n③ Citrus peel (Chen Pi)\n④ Mulberry root bark (Sang Bai Pi)\n⑤ Acanthopanax bark (Wu Jia Pi)\n\n(Continued on the back)",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 약용식물은?\n\n• 꿀풀과(Labiatae)에 속함\n• triterpene계열의 ursolic acid를 함유함\n• 항균, 항염증작용을 나타냄\n\n① Atropa belladonna\n② Eucommia ulmoides\n③ Prunella vulgaris var. lilacina\n④ Prunus armeniaca var. ansu\n⑤ Zizyphus jujuba var. inermis",
        "question_text": "Question: Which medicinal plant is described below?\n\n• Belongs to the Labiatae (Lamiaceae) family\n• Contains ursolic acid, a triterpene compound\n• Exhibits antibacterial and anti-inflammatory effects\n\n① Atropa belladonna\n② Eucommia ulmoides\n③ Prunella vulgaris var. lilacina\n④ Prunus armeniaca var. ansu\n⑤ Zizyphus jujuba var. inermis",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 폐에서 받아들인 자연계의 청기(淸氣)와, 비위에서 음식물을 운화(運化)하여 만들어지는 주요 성분이 결합하여 생성되는 기(氣)는?\n\n① 사기(邪氣)\n② 영기(營氣)\n③ 원기(元氣)\n④ 위기(衛氣)\n⑤ 종기(宗氣)",
        "question_text": "Question: What is the qi (氣) that is formed by combining the clear qi (淸氣) from nature absorbed by the lungs and the main components produced by the digestion and transformation of food in the spleen and stomach?\n\n① Pathogenic qi (邪氣)\n② Nutritive qi (營氣)\n③ Original qi (元氣)\n④ Defensive qi (衛氣)\n⑤ Gathering qi (宗氣)",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 육경변증(六經辨證)에서, 체표부에서 정사(正邪)가 투쟁하는 외감병(外感病)의 초기 단계에 해당하는 것은?\n\n① 태양병(太陽病)\n② 양명병(陽明病)\n③ 소양병(少陽病)\n④ 소음병(少陰病)\n⑤ 궐음병(厥陰病)",
        "question_text": "Question: In the Six-Meridian Pattern Identification (六經辨證), which of the following corresponds to the initial stage of an externally contracted disease (外感病) where there is a struggle between the healthy qi and pathogenic factors on the body surface?\n\n① Taiyang disease (太陽病)\n② Yangming disease (陽明病)\n③ Shaoyang disease (少陽病)\n④ Shaoyin disease (少陰病)\n⑤ Jueyin disease (厥陰病)",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 신(辛), 고(苦), 온(溫)의 약성(藥性)이 있으며, 산한해표(散寒解表), 거풍지통(祛風止痛)의 효능이 있는 신온해표약(辛溫解表藥)은?\n\n① 강활(羌活)\n② 대황(大黃)\n③ 원지(遠志)\n④ 택사(澤瀉)\n⑤ 황련(黃連)",
        "question_text": "Question: Which of the following is a pungent-warm exterior-releasing herb (辛溫解表藥) that has the medicinal properties (藥性) of pungent (辛), bitter (苦), and warm (溫), and the effects of dispersing cold and releasing the exterior (散寒解表) and dispelling wind and alleviating pain (祛風止痛)?\n\n① Notopterygium root (羌活, Qiang Huo)\n② Rhubarb root and rhizome (大黃, Da Huang)\n③ Polygala root (遠志, Yuan Zhi)\n④ Alisma rhizome (澤瀉, Ze Xie)\n⑤ Coptis rhizome (黃連, Huang Lian)",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 사화해독(瀉火解毒), 조습설열(燥濕泄熱), 사하(瀉下), 지혈(止血)의 효능이 있어, 얼굴색이 붉고, 흥분을 잘하며, 열로 인해 가슴이 답답한 경우나, 구취, 변비, 눈충혈, 코피 등의 증상이 있을 때에 사용하는 한약제제는?\n\n① 당귀작약산(當歸芍藥散)\n② 보중익기탕(補中益氣湯)\n③ 삼황사심탕(三黃瀉心湯)\n④ 인삼패독산(人蔘敗毒散)\n⑤ 향사평위산(香砂平胃散)",
        "question_text": "Question: Which herbal medicine preparation is used when a person has a red face, is easily excited, feels chest discomfort due to heat, and experiences symptoms such as bad breath, constipation, bloodshot eyes, and nosebleeds, due to its effects of clearing heat and detoxifying (瀉火解毒), drying dampness and purging heat (燥濕泄熱), purging downward (瀉下), and stopping bleeding (止血)?\n\n① Dangguijakyak-san (當歸芍藥散)\n② Bojungikgi-tang (補中益氣湯)\n③ Samhwangsasim-tang (三黃瀉心湯)\n④ Insampaedok-san (人蔘敗毒散)\n⑤ Hyangsapyeongwi-san (香砂平胃散)",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n회향, 인진호, 참깨의 함유 성분을 분리하고자 여러 단계의 크로마토그래피를 실시하여 3종의 화합물을 분리하였고, NMR 등의 기기 분석을 통해 다음과 같은 화합물로 확인되었다.\n• 회향에서는 phenylpropanoid계열의 anethole\n• 인진호에서는 coumarin계열의 scoparone\n• 참깨에서는 lignan계열의 sesamin\n\nQuestion: 위 사례에서 확인된 화합물들의 주된 생합성 경로는?\n\n① acetate-malonate 경로\n② amino acid 경로\n③ amino acid-mevalonate 복합경로\n④ isoprenoid 경로\n⑤ shikimate 경로",
        "question_text": "Three compounds were isolated from fennel, Artemisia capillaris, and sesame seeds using multiple stages of chromatography. Through instrumental analysis such as NMR, the following compounds were identified:\n• Anethole, a phenylpropanoid compound, from fennel\n• Scoparone, a coumarin compound, from Artemisia capillaris\n• Sesamin, a lignan compound, from sesame seeds\n\nQuestion: What is the main biosynthetic pathway for the compounds identified in the above case?\n\n① Acetate-malonate pathway\n② Amino acid pathway\n③ Amino acid-mevalonate combined pathway\n④ Isoprenoid pathway\n⑤ Shikimate pathway",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n회향, 인진호, 참깨의 함유 성분을 분리하고자 여러 단계의 크로마토그래피를 실시하여 3종의 화합물을 분리하였고, NMR 등의 기기 분석을 통해 다음과 같은 화합물로 확인되었다.\n• 회향에서는 phenylpropanoid계열의 anethole\n• 인진호에서는 coumarin계열의 scoparone\n• 참깨에서는 lignan계열의 sesamin\n\nQuestion: 위 화합물들과 같은 경로로 생합성되며 간세포 보호작용이 있는 것은?\n\n① catalpol\n② crocin\n③ dioscin\n④ gomisin A\n⑤ ophiopogonin A",
        "question_text": "Three compounds were isolated from fennel, Artemisia capillaris, and sesame seeds using multiple stages of chromatography. Through instrumental analysis such as NMR, the compounds were identified as follows:\n• Anethole, a phenylpropanoid compound from fennel\n• Scoparone, a coumarin compound from Artemisia capillaris\n• Sesamin, a lignan compound from sesame seeds\n\nQuestion: Which of the following compounds is biosynthesized through the same pathway as the above compounds and has hepatoprotective effects?\n\n① catalpol\n② crocin\n③ dioscin\n④ gomisin A\n⑤ ophiopogonin A",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 고혈압과 천식이 있는 61세 여자가 최근 안정협심증을 진단받아, 딜티아젬(diltiazem) 서방캡슐 180 mg 1일 1회를 추가로 복용할 예정이다. 이 약의 복용으로 인해 예상되는 주요 이상반응을 고려할 때 모니터링이 필요한 검사는?\n\n① 심박수\n② 유리 T4\n③ 중성지방\n④ 혈청 마그네슘\n⑤ 인터페론감마분비검사",
        "question_text": "Question: A 61-year-old woman with hypertension and asthma has recently been diagnosed with stable angina and is scheduled to additionally take diltiazem extended-release capsule 180 mg once daily. Considering the major side effects expected from taking this medication, which test requires monitoring?\n\n① Heart rate\n② Free T4\n③ Triglycerides\n④ Serum magnesium\n⑤ Interferon-gamma release assay",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 고혈압, 2형당뇨병과 통풍이 있는 58세 남자의 검사 결과와 복용약물이 다음과 같다. 혈압 조절을 위해 추가할 수 있는 약물은?\n\n[활력징후] 혈압 148/92 mmHg, 심박수 78회/분\n[임상검사] Na 141 mEq/L, K 3.5 mEq/L, BUN 18 mg/dL, SCr 1.1 mg/dL 요산 10.1 mg/dL (참고치 2.0~7.5 mg/dL), 공복혈당 112 mg/dL\n[약물 알레르기] 설폰아미드계\n[복용약물]\n메트포르민(metformin) 1,000 mg 1일 1회\n삭사글립틴(saxagliptin) 5 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n알로푸리놀(allopurinol) 100 mg 1일 1회\n\n① 베라파밀(verapamil)\n② 클로니딘(clonidine)\n③ 푸로세미드(furosemide)\n④ 칸데사르탄(candesartan)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: A 58-year-old man with hypertension, type 2 diabetes, and gout has the following test results and medications. Which drug can be added for blood pressure control?\n\n[Vital Signs] Blood pressure 148/92 mmHg, Heart rate 78 beats/min\n[Clinical Tests] Na 141 mEq/L, K 3.5 mEq/L, BUN 18 mg/dL, SCr 1.1 mg/dL, Uric acid 10.1 mg/dL (reference range 2.0-7.5 mg/dL), Fasting blood glucose 112 mg/dL\n[Drug Allergy] Sulfonamides\n[Current Medications]\nMetformin 1,000 mg once daily\nSaxagliptin 5 mg once daily\nAmlodipine 10 mg once daily\nAllopurinol 100 mg once daily\n\n① Verapamil\n② Clonidine\n③ Furosemide\n④ Candesartan\n⑤ Hydrochlorothiazide",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 심부전 치료를 위해 디곡신(digoxin)을 복용 중인 72세 여자가 1주일 전 헬리코박터필로리(Helicobacter pylori) 양성 소화성궤양과 변비를 진단받았다. 소화성궤양과 변비 치료를 위해 복용한 약물과 검사 결과가 다음과 같을 때, 디곡신 혈중농도 상승의 원인약물은?\n\n[활력징후] 혈압 124/69 mmHg, 심박수 68회/분, 호흡수 18회/분\n[임상검사] 좌심실박출률(LVEF) 37% Na 141 mEq/L, K 4.3 mEq/L, BUN 18 mg/dL, SCr 0.9 mg/dL 디곡신 혈중농도 1.7 ng/mL (1개월 전 0.9 ng/mL)\n[1주일 전 추가 약물]\n아목시실린(amoxicillin) 1,000 mg 1일 2회\n판토프라졸(pantoprazole) 40 mg 1일 2회\n클래리트로마이신(clarithromycin) 500 mg 1일 2회\n레바미피드(rebamipide) 100 mg 1일 3회\n비사코딜(bisacodyl) 5 mg 1일 1회 취침 전\n산화마그네슘(magnesium oxide) 250 mg 1일 2회\n\n① 비사코딜\n② 아목시실린\n③ 레바미피드\n④ 산화마그네슘\n⑤ 클래리트로마이신",
        "question_text": "Question: A 72-year-old woman taking digoxin for heart failure treatment was diagnosed with Helicobacter pylori-positive peptic ulcer and constipation a week ago. Given the following medications taken for peptic ulcer and constipation treatment, and the test results, which drug is the cause of the increased digoxin blood concentration?\n\n[Vital Signs] Blood pressure 124/69 mmHg, Heart rate 68 beats/min, Respiratory rate 18 breaths/min\n[Clinical Tests] Left ventricular ejection fraction (LVEF) 37%, Na 141 mEq/L, K 4.3 mEq/L, BUN 18 mg/dL, SCr 0.9 mg/dL, Digoxin blood concentration 1.7 ng/mL (0.9 ng/mL one month ago)\n[Additional medications from a week ago]\nAmoxicillin 1,000 mg twice daily\nPantoprazole 40 mg twice daily\nClarithromycin 500 mg twice daily\nRebamipide 100 mg three times daily\nBisacodyl 5 mg once daily at bedtime\nMagnesium oxide 250 mg twice daily\n\n① Bisacodyl\n② Amoxicillin\n③ Rebamipide\n④ Magnesium oxide\n⑤ Clarithromycin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 박출률감소심부전(HFrEF)이 있는 64세 남자가 다음의 약물을 복용 중이다. 최근 2개월간 체중변화는 없으나 숨차는 증상이 심해지고 일상생활에 불편감이 증가하였다. 추가할 수 있는 적절한 약물은?\n\n[병력] 고혈압, 이상지질혈증, 심근경색(10년 전 발생)\n[활력징후] 혈압 119/71 mmHg, 심박수 62회/분, 호흡수 18회/분\n[임상검사]  좌심실박출률(LVEF) 35% Na 141 mEq/L, K 4.1 mEq/L, BUN 16 mg/dL, SCr 1.1 mg/dL BNP 400 pg/mL\n[복용약물] 아스피린(aspirin) 100 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 2회\n칸데사르탄(candesartan) 32 mg 1일 1회\n푸로세미드(furosemide) 40 mg 1일 2회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n\n① 리시노프릴(lisinopril)\n② 암로디핀(amlodipine)\n③ 이바브라딘(ivabradine)\n④ 인다파미드(indapamide)\n⑤ 스피로노락톤(spironolactone)",
        "question_text": "Question: A 64-year-old man with heart failure with reduced ejection fraction (HFrEF) is taking the following medications. While there has been no change in weight over the past 2 months, his shortness of breath has worsened and discomfort in daily activities has increased. Which of the following medications would be appropriate to add?\n\n[Medical history] Hypertension, dyslipidemia, myocardial infarction (occurred 10 years ago)\n[Vital signs] Blood pressure 119/71 mmHg, heart rate 62 beats/min, respiratory rate 18 breaths/min\n[Clinical tests] Left ventricular ejection fraction (LVEF) 35%, Na 141 mEq/L, K 4.1 mEq/L, BUN 16 mg/dL, SCr 1.1 mg/dL, BNP 400 pg/mL\n[Current medications] Aspirin 100 mg once daily\nMetoprolol 100 mg twice daily\nCandesartan 32 mg once daily\nFurosemide 40 mg twice daily\nAtorvastatin 40 mg once daily\n\n① Lisinopril\n② Amlodipine\n③ Ivabradine\n④ Indapamide\n⑤ Spironolactone",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 비ST분절상승 급성관상동맥증후군(NSTE-ACS)을 진단받은 56세 남자가 스텐트 삽입술을 받았다. 스텐트 삽입술 후 아스피린과 함께 이중항혈소판요법(DAPT)에 사용할 수 있는 약물은?\n\n[병력] 고혈압, 이상지질혈증, 일과성허혈발작\n[활력징후] 혈압 130/72 mmHg, 심박수 68회/분\n[임상검사] 좌심실박출률(LVEF) 32%\n\n① 티카그렐러(ticagrelor)\n② 프라수그렐(prasugrel)\n③ 리바록사반(rivaroxaban)\n④ 디피리다몰(dipyridamole)\n⑤ 폰다파리눅스(fondaparinux)",
        "question_text": "Question: A 56-year-old man diagnosed with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) underwent stent insertion. Which drug can be used for dual antiplatelet therapy (DAPT) along with aspirin after stent insertion?\n\n[Medical history] Hypertension, dyslipidemia, transient ischemic attack\n[Vital signs] Blood pressure 130/72 mmHg, heart rate 68 beats/min\n[Clinical test] Left ventricular ejection fraction (LVEF) 32%\n\n① Ticagrelor\n② Prasugrel\n③ Rivaroxaban\n④ Dipyridamole\n⑤ Fondaparinux",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 만성폐쇄폐질환이 있는 55세 남자가 급성허혈뇌졸중 치료를 위해 알테플라제(alteplase)를 투여받았다. 현재 혈압이 200/110 mmHg일 때, 급성기 혈압 조절을 위해 적절한 약물은?\n\n① 발사르탄(valsartan)\n② 에날라프릴(enalapril)\n③ 카르베딜롤(carvedilol)\n④ 니카르디핀(nicardipine)\n⑤ 니트로프루시드(nitroprusside)",
        "question_text": "Question: A 55-year-old man with chronic obstructive pulmonary disease received alteplase for the treatment of acute ischemic stroke. When his current blood pressure is 200/110 mmHg, which drug is appropriate for acute blood pressure control?\n\n① Valsartan\n② Enalapril\n③ Carvedilol\n④ Nicardipine\n⑤ Nitroprusside",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 68세 남자가 비심인성 허혈뇌졸중의 재발을 예방하기 위해 아스피린(aspirin)을 복용한 후 심한 천식 발작이 발생하였다. 아스피린을 대체할 수 있는 적절한 약물은?\n\n① 와파린(warfarin)\n② 프라수그렐(prasugrel)\n③ 에녹사파린(enoxaparin)\n④ 리바록사반(rivaroxaban)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "Question: A 68-year-old man experienced a severe asthma attack after taking aspirin to prevent recurrence of non-cardiogenic ischemic stroke. Which of the following drugs is an appropriate alternative to aspirin?\n\n① Warfarin\n② Prasugrel\n③ Enoxaparin\n④ Rivaroxaban\n⑤ Clopidogrel",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 67세 남자가 고혈압, 2형당뇨병, 이상지질혈증의 치료를 위해 다음과 같은 약물을 복용 중이다. 최근 위장관 출혈로 의심되는 흑색변이 발생하였다. 아스피린과의 병용투여로 인한 출혈 위험을 높일 수 있는 약물은?\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n리나글립틴(linagliptin) 5 mg 1일 1회\n메트포르민(metformin) 850 mg 1일 1회\n피타바스타틴(pitavastatin) 1 mg 1일 1회\n이르베사르탄(irbesartan) 150 mg 1일 1회\n오메가3산에틸에스테르90(omega-3-acids ethyl esters 90) 2 g 1일 2회\n\n① 리나글립틴\n② 메트포르민\n③ 이르베사르탄\n④ 피타바스타틴\n⑤ 오메가3산에틸에스테르90",
        "question_text": "Question: A 67-year-old man is taking the following medications for the treatment of hypertension, type 2 diabetes, and dyslipidemia. Recently, he experienced melena, which is suspected to be gastrointestinal bleeding. Which of the following drugs can increase the risk of bleeding when used in combination with aspirin?\n\n[Medications]\nAspirin 100 mg once daily\nLinagliptin 5 mg once daily\nMetformin 850 mg once daily\nPitavastatin 1 mg once daily\nIrbesartan 150 mg once daily\nOmega-3-acids ethyl esters 90, 2 g twice daily\n\n① Linagliptin\n② Metformin\n③ Irbesartan\n④ Pitavastatin\n⑤ Omega-3-acids ethyl esters 90",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 가족성고콜레스테롤혈증이 있는 35세 남자가 이상지질혈증 치료를 위해 다음 약물을 복용 중이다. 오늘 검사 결과가 다음과 같을 때 추가할 수 있는 적절한 약물은?\n\n[임상검사]\nTC 390 mg/dL, LDL-C 300 mg/dL, HDL-C 50 mg/dL, TG 200 mg/dL\n\n[복용약물]\n에제티미브(ezetimibe) 10 mg 1일 1회\n아토르바스타틴(atorvastatin) 80 mg 1일 1회\n\n① 겜피브로질(gemfibrozil)\n② 알리로쿠맙(alirocumab)\n③ 로모소주맙(romosozumab)\n④ 콜레스티라민(cholestyramine)\n⑤ 오메가3산에틸에스테르90(omega-3-acids ethyl esters 90)",
        "question_text": "Question: A 35-year-old man with familial hypercholesterolemia is taking the following medication for the treatment of dyslipidemia. Given today's test results, what is the appropriate additional medication?\n\n[Clinical Test Results]\nTC 390 mg/dL, LDL-C 300 mg/dL, HDL-C 50 mg/dL, TG 200 mg/dL\n\n[Current Medications]\nEzetimibe 10 mg once daily\nAtorvastatin 80 mg once daily\n\n① Gemfibrozil\n② Alirocumab\n③ Romosozumab\n④ Cholestyramine\n⑤ Omega-3-acids ethyl esters 90",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 심부정맥혈전증을 치료하기 위해 에녹사파린(enoxaparin)을 사용 중인 68세 남자에게 출혈이 발생하여 항응고 효과를 역전하려고 한다. 적절한 약물은?\n\n① 비타민K(vitamin K)\n② 프로타민(protamine)\n③ 아가트로반(argatroban)\n④ 테넥테플라제(tenecteplase)\n⑤ 이다루시주맙(idarucizumab)",
        "question_text": "Question: A 68-year-old man using enoxaparin for the treatment of deep vein thrombosis experiences bleeding, and you want to reverse the anticoagulant effect. Which of the following is the appropriate drug?\n\n① Vitamin K\n② Protamine\n③ Argatroban\n④ Tenecteplase\n⑤ Idarucizumab",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 중증 궤양성대장염이 있는 58세 남자가 장절제술을 받고 중환자실에 입원하였다. 정맥혈전색전증을 예방하기 위해 적절한 약물은?\n\n[임상검사]\nNa 141 mEq/L, K 4.2 mEq/L, SCr 0.9 mg/dL, CrCl 76 mL/min\n[약물 알레르기]\n미분획헤파린(unfractionated heparin): 헤파린유도혈소판 감소증(heparin-induced thrombocytopenia, HIT)\n\n① 에독사반(edoxaban)\n② 압식시맙(abciximab)\n③ 알테플라제(alteplase)\n④ 에녹사파린(enoxaparin)\n⑤ 폰다파리눅스(fondaparinux)",
        "question_text": "Question: A 58-year-old man with severe ulcerative colitis underwent intestinal resection and was admitted to the intensive care unit. What is the appropriate medication to prevent venous thromboembolism?\n\n[Clinical tests]\nNa 141 mEq/L, K 4.2 mEq/L, SCr 0.9 mg/dL, CrCl 76 mL/min\n[Drug allergy]\nUnfractionated heparin: Heparin-induced thrombocytopenia (HIT)\n\n① Edoxaban\n② Abciximab\n③ Alteplase\n④ Enoxaparin\n⑤ Fondaparinux",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nST분절상승 심근경색을 진단받은 69세 남자가 경피적 관상동맥중재술로 재관류 치료를 받고 다음과 같이 약물을 복용 중이다.\n\n[병력] 심근경색, 고혈압\n\n[활력징후] \n혈압 129/79 mmHg, 심박수 72회/분, 호흡수 20회/분\n\n[임상검사]\nNa 140 mEq/L, K 4.2 mEq/L, BUN 12 mg/dL\nSCr 1.1 mg/dL, TC 170 mg/dL, LDL-C 72 mg/dL\nTG 180 mg/dL, HDL-C 59 mg/dL\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n리시노프릴(lisinopril) 40 mg 1일 1회\n카르베딜롤(carvedilol) 6.25 mg 1일 2회\n클로피도그렐(clopidogrel) 75 mg 1일 1회\n니트로글리세린(nitroglycerin) 설하정 0.6 mg 필요시\n\nQuestion: 이 환자에게 추가해야 할 약물은?\n\n① 암로디핀(amlodipine)\n② 로수바스타틴(rosuvastatin)\n③ 트리메타지딘(trimetazidine)\n④ 클로르탈리돈(chlorthalidone)\n⑤ 이소소르비드일질산염(isosorbide mononitrate)",
        "question_text": "A 69-year-old male diagnosed with ST-segment elevation myocardial infarction received reperfusion therapy through percutaneous coronary intervention and is currently taking the following medications.\n\n[Medical History] Myocardial infarction, Hypertension\n\n[Vital Signs]\nBlood pressure 129/79 mmHg, Heart rate 72 beats/min, Respiratory rate 20 breaths/min\n\n[Clinical Tests]\nNa 140 mEq/L, K 4.2 mEq/L, BUN 12 mg/dL\nSCr 1.1 mg/dL, TC 170 mg/dL, LDL-C 72 mg/dL\nTG 180 mg/dL, HDL-C 59 mg/dL\n\n[Current Medications]\nAspirin 100 mg once daily\nLisinopril 40 mg once daily\nCarvedilol 6.25 mg twice daily\nClopidogrel 75 mg once daily\nNitroglycerin sublingual tablet 0.6 mg as needed\n\nQuestion: Which medication should be added for this patient?\n\n① Amlodipine\n② Rosuvastatin\n③ Trimetazidine\n④ Chlorthalidone\n⑤ Isosorbide mononitrate",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nST분절상승 심근경색을 진단받은 69세 남자가 경피적 관상동맥중재술로 재관류 치료를 받고 다음과 같이 약물을 복용 중이다.\n\n[병력] 심근경색, 고혈압\n\n[활력징후] \n혈압 129/79 mmHg, 심박수 72회/분, 호흡수 20회/분\n\n[임상검사]\nNa 140 mEq/L, K 4.2 mEq/L, BUN 12 mg/dL\nSCr 1.1 mg/dL, TC 170 mg/dL, LDL-C 72 mg/dL\nTG 180 mg/dL, HDL-C 59 mg/dL\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n리시노프릴(lisinopril) 40 mg 1일 1회\n카르베딜롤(carvedilol) 6.25 mg 1일 2회\n클로피도그렐(clopidogrel) 75 mg 1일 1회\n니트로글리세린(nitroglycerin) 설하정 0.6 mg 필요시\n\nQuestion: 안정을 유지하던 환자가 최근 계단을 오를 때 흉통 발생 빈도가 증가하였다. 흉통 발생 빈도를 감소시키기 위한 적절한 조치는?\n\n① 리시노프릴의 용량 증가\n② 카르베딜롤의 용량 증가\n③ 모르핀(morphine) 추가\n④ 아픽사반(apixaban) 추가\n⑤ 니모디핀(nimodipine) 추가",
        "question_text": "A 69-year-old male diagnosed with ST-segment elevation myocardial infarction received reperfusion therapy through percutaneous coronary intervention and is currently taking the following medications.\n\n[Medical History] Myocardial infarction, Hypertension\n\n[Vital Signs]\nBlood pressure 129/79 mmHg, Heart rate 72 beats/min, Respiratory rate 20 breaths/min\n\n[Clinical Tests]\nNa 140 mEq/L, K 4.2 mEq/L, BUN 12 mg/dL\nSCr 1.1 mg/dL, TC 170 mg/dL, LDL-C 72 mg/dL\nTG 180 mg/dL, HDL-C 59 mg/dL\n\n[Medications]\nAspirin 100 mg once daily\nLisinopril 40 mg once daily\nCarvedilol 6.25 mg twice daily\nClopidogrel 75 mg once daily\nNitroglycerin sublingual tablet 0.6 mg as needed\n\nQuestion: The patient, who had been stable, recently experienced an increased frequency of chest pain when climbing stairs. What is the appropriate measure to reduce the frequency of chest pain?\n\n① Increase the dose of lisinopril\n② Increase the dose of carvedilol\n③ Add morphine\n④ Add apixaban\n⑤ Add nimodipine",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n3일 전부터 심장이 심하게 두근거리고 호흡곤란 증상이 나타난 68세 여자가 비판막성 심방세동을 진단받고, 딜티아젬(diltiazem) 주사제 치료를 시작하였다.\n\n[병력] 고혈압, 이상지질혈증\n\n[활력징후]\n혈압 122/78 mmHg, 심박수 108회/분, 산소포화도 96%\n\n[임상검사]\n심전도: 심방세동\n심초음파: 심방 내 혈전 없음\n\n[사용약물]\n딜티아젬(diltiazem)\n로수바스타틴(rosuvastatin)\n히드로클로로티아지드(hydrochlorothiazide)\n\nQuestion: 딜티아젬 주사제를 투여한 후에도 증상이 지속되어 동리듬으로 전환하기 위한 약물을 투여하려고 한다. 적절한 약물은?\n\n① 소타롤(sotalol)\n② 디곡신(digoxin)\n③ 아트로핀(atropine)\n④ 프로파페논(propafenone)\n⑤ 프로프라놀롤(propranolol)",
        "question_text": "A 68-year-old woman who has been experiencing severe heart palpitations and shortness of breath for the past 3 days was diagnosed with non-valvular atrial fibrillation and started treatment with diltiazem injection.\n\n[Medical history] Hypertension, Dyslipidemia\n\n[Vital signs]\nBlood pressure 122/78 mmHg, Heart rate 108 beats/min, Oxygen saturation 96%\n\n[Clinical tests]\nECG: Atrial fibrillation\nEchocardiogram: No thrombus in the atrium\n\n[Medications]\nDiltiazem\nRosuvastatin\nHydrochlorothiazide\n\nQuestion: The symptoms persist even after administering diltiazem injection, and now a medication is to be given to convert to sinus rhythm. Which of the following is the appropriate medication?\n\n① Sotalol\n② Digoxin\n③ Atropine\n④ Propafenone\n⑤ Propranolol",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n3일 전부터 심장이 심하게 두근거리고 호흡곤란 증상이 나타난 68세 여자가 비판막성 심방세동을 진단받고, 딜티아젬(diltiazem) 주사제 치료를 시작하였다.\n\n[병력] 고혈압, 이상지질혈증\n\n[활력징후]\n혈압 122/78 mmHg, 심박수 108회/분, 산소포화도 96%\n\n[임상검사]\n심전도: 심방세동\n심초음파: 심방 내 혈전 없음\n\n[사용약물]\n딜티아젬(diltiazem)\n로수바스타틴(rosuvastatin)\n히드로클로로티아지드(hydrochlorothiazide)\n\nQuestion: 동리듬으로 전환한 후 장기적으로 동리듬을 유지하기 위해 드로네다론(dronedarone) 투여를 시작하고자 한다. 뇌졸중 발생을 예방하기 위해 적절한 약물은?\n\n① 아스피린(aspirin)\n② 아픽사반(apixaban)\n③ 달테파린(dalteparin)\n④ 실로스타졸(cilostazol)\n⑤ 프라수그렐(prasugrel)",
        "question_text": "A 68-year-old woman who has been experiencing severe heart palpitations and shortness of breath for the past 3 days was diagnosed with non-valvular atrial fibrillation and started treatment with diltiazem injection.\n\n[Medical history] Hypertension, Dyslipidemia\n\n[Vital signs]\nBlood pressure 122/78 mmHg, Heart rate 108 beats/min, Oxygen saturation 96%\n\n[Clinical tests]\nECG: Atrial fibrillation\nEchocardiogram: No thrombus in the atrium\n\n[Medications]\nDiltiazem\nRosuvastatin\nHydrochlorothiazide\n\nQuestion: After converting to sinus rhythm, dronedarone administration is to be initiated for long-term maintenance of sinus rhythm. What is the appropriate medication to prevent stroke?\n\n① Aspirin\n② Apixaban\n③ Dalteparin\n④ Cilostazol\n⑤ Prasugrel",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 천식이 있는 15세 남자는 지난 1년간 중증 천식 악화를 2회 경험하였다. 환자는 3개월 전부터 다음과 같은 약물을 사용 중이나 ‘조절 안 됨’으로 평가되었다. 흡입제 사용방법과 치료이행도에는 문제가 없다. 적절한 조치는?\n\n[임상검사]\nIgE 190 IU/mL (참고치 0~158 IU/mL)\n피부단자검사: 집먼지진드기(+)\n1초간강제호기량(FEV1) 70% 정상예측치\n[사용약물]\n고용량 플루티카손/살메테롤(fluticasone/salmeterol) 1일 2회 흡입\n살부타몰(salbutamol) 필요시 흡입\n\n① 레슬리주맙(reslizumab) 추가\n② 오말리주맙(omalizumab) 추가\n③ 플루티카손/살메테롤을 중단하고 레슬리주맙으로 변경\n④ 플루티카손/살메테롤을 중단하고 오말리주맙으로 변경\n⑤ 플루티카손/살메테롤을 중단하고 플루티카손+티오트로퓸(tiotropium)으로 변경",
        "question_text": "Question: A 15-year-old male with asthma has experienced two severe asthma exacerbations in the past year. The patient has been using the following medications for the past 3 months but is evaluated as 'uncontrolled'. There are no issues with inhaler technique or treatment adherence. What is the appropriate action?\n\n[Clinical tests]\nIgE 190 IU/mL (reference range 0-158 IU/mL)\nSkin prick test: House dust mite (+)\nForced Expiratory Volume in 1 second (FEV1) 70% of predicted normal\n\n[Current medications]\nHigh-dose fluticasone/salmeterol inhaled twice daily\nSalbutamol inhaled as needed\n\n① Add reslizumab\n② Add omalizumab\n③ Discontinue fluticasone/salmeterol and switch to reslizumab\n④ Discontinue fluticasone/salmeterol and switch to omalizumab\n⑤ Discontinue fluticasone/salmeterol and switch to fluticasone + tiotropium",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 비만인 52세 여자가 거의 매일 천명, 숨참, 기침의 증상이 나타나고 이러한 증상으로 수면장애가 일주일에 1회 이상 있어 천식을 진단받았다. 적절한 초기 치료는?\n\n① 살부타몰(salbutamol) 흡입제 필요시 투여\n② 인다카테롤(indacaterol) 흡입제 매일 투여\n③ 몬테루카스트(montelukast) 경구제 매일 투여\n④ 저용량 부데소니드/포르모테롤(budesonide/formoterol) 흡입제 필요시 투여\n⑤ 저용량 부데소니드/포르모테롤 흡입제 매일 투여+필요시 투여",
        "question_text": "Question: A 52-year-old obese woman was diagnosed with asthma after experiencing wheezing, shortness of breath, and coughing almost daily, with sleep disturbances occurring more than once a week due to these symptoms. What is the appropriate initial treatment?\n\n① Administer salbutamol inhaler as needed\n② Administer indacaterol inhaler daily\n③ Administer oral montelukast daily\n④ Administer low-dose budesonide/formoterol inhaler as needed\n⑤ Administer low-dose budesonide/formoterol inhaler daily + as needed",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 26세 여자가 꽃가루가 날리기 시작하면서 1주 전부터 콧물, 재채기, 코가려움증의 증상이 나타났지만 직장생활을 방해할 정도는 아니다. 낮 동안 졸리지 않은 약을 원한다. 적절한 약은?\n\n① 클레마스틴(clemastine) 경구제\n② 펙소페나딘(fexofenadine) 경구제\n③ 이프라트로퓸(ipratropium) 비강분무제\n④ 슈도에페드린(pseudoephedrine) 경구제\n⑤ 옥시메타졸린(oxymetazoline) 비강분무제",
        "question_text": "Question: A 26-year-old woman has been experiencing symptoms of runny nose, sneezing, and nasal itching for 1 week since pollen started to spread, but not to the extent that it interferes with her work life. She wants a medication that doesn't cause drowsiness during the day. What is the appropriate medication?\n\n① Clemastine oral preparation\n② Fexofenadine oral preparation\n③ Ipratropium nasal spray\n④ Pseudoephedrine oral preparation\n⑤ Oxymetazoline nasal spray",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n68세 남자가 만성폐쇄폐질환 치료를 위하여 유메클리디늄/빌란테롤(umeclidinium/vilanterol) 흡입제를 사용하고 있다. 흡입제 치료에도 불구하고 호흡곤란 증상이 지속되며, 지난 1년간 급성 악화 증상이 2회 발생하였다. 흡입제 사용방법과 치료이행도에는 문제가 없다.\n\n[병력] 만성기관지염\n\n[임상검사]\n혈액검사: 백혈구 6,000/mm3, 중성구 3,300/mm3, 호산구 400/mm3\n1초간강제호기량(FEV1) 60% 정상예측치\n만성폐쇄폐질환 평가검사(COPD Assessment Test, CAT): 21점\n\nQuestion: 이 환자에게 적절한 조치는?\n\n① 테오필린(theophylline) 경구제 추가\n② 플루티카손(fluticasone) 흡입제 추가\n③ 아지트로마이신(azithromycin) 경구제 추가\n④ 유메클리디늄/빌란테롤 흡입제를 빌란테롤/플루티카손 흡입제로 변경\n⑤ 유메클리디늄/빌란테롤 흡입제를 유메클리디늄 흡입제+플루티카손 흡입제로 변경",
        "question_text": "A 68-year-old male is using umeclidinium/vilanterol inhaler for the treatment of chronic obstructive pulmonary disease (COPD). Despite the inhaler treatment, he continues to experience dyspnea, and has had two acute exacerbations in the past year. There are no issues with his inhaler technique or treatment adherence.\n\n[Medical history] Chronic bronchitis\n\n[Clinical tests]\nBlood test: White blood cells 6,000/mm3, Neutrophils 3,300/mm3, Eosinophils 400/mm3\nForced Expiratory Volume in 1 second (FEV1): 60% of predicted normal\nCOPD Assessment Test (CAT): 21 points\n\nQuestion: What is the appropriate measure for this patient?\n\n① Add oral theophylline\n② Add fluticasone inhaler\n③ Add oral azithromycin\n④ Change umeclidinium/vilanterol inhaler to vilanterol/fluticasone inhaler\n⑤ Change umeclidinium/vilanterol inhaler to umeclidinium inhaler + fluticasone inhaler",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n68세 남자가 만성폐쇄폐질환 치료를 위하여 유메클리디늄/빌란테롤(umeclidinium/vilanterol) 흡입제를 사용하고 있다. 흡입제 치료에도 불구하고 호흡곤란 증상이 지속되며, 지난 1년간 급성 악화 증상이 2회 발생하였다. 흡입제 사용방법과 치료이행도에는 문제가 없다.\n\n[병력] 만성기관지염\n\n[임상검사]\n혈액검사: 백혈구 6,000/mm3, 중성구 3,300/mm3, 호산구 400/mm3\n1초간강제호기량(FEV1) 60% 정상예측치\n만성폐쇄폐질환 평가검사(COPD Assessment Test, CAT): 21점\n\nQuestion: 위와 같은 치료에도 불구하고, 급성 악화를 경험하고, FEV1이 50% 미만으로 감소되어 로플루밀라스트(roflumilast) 투여를 시작하였다. 이 약 투여로 예상되는 주요 이상반응은?\n\n① 서맥\n② 시신경염\n③ 식욕증가\n④ 체중감소\n⑤ QTc 간격 연장",
        "question_text": "A 68-year-old male is using umeclidinium/vilanterol inhaler for the treatment of chronic obstructive pulmonary disease (COPD). Despite the inhaler treatment, he continues to experience dyspnea, and has had two acute exacerbations in the past year. There are no issues with his inhaler technique or treatment adherence.\n\n[Medical history] Chronic bronchitis\n\n[Clinical tests]\nBlood test: White blood cells 6,000/mm3, Neutrophils 3,300/mm3, Eosinophils 400/mm3\nForced Expiratory Volume in 1 second (FEV1) 60% of predicted normal\nCOPD Assessment Test (CAT): 21 points\n\nQuestion: Despite the above treatment, the patient experiences acute exacerbations, and his FEV1 decreases to less than 50%, so roflumilast treatment is initiated. What is the main adverse reaction expected from this medication?\n\n① Bradycardia\n② Optic neuritis\n③ Increased appetite\n④ Weight loss\n⑤ QTc interval prolongation",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 위궤양 병력이 있는 58세 여자에게 손가락 골관절염 증상이 지속되어 아세클로페낙(aceclofenac) 투여를 시작하려고 한다. 아세클로페낙으로 유발될 수 있는 위궤양을 예방하기 위해 적절한 약물은?\n\n① 에카베트(ecabet)\n② 비스무트(bismuth)\n③ 파모티딘(famotidine)\n④ 란소프라졸(lansoprazole)\n⑤ 메토클로프라미드(metoclopramide)",
        "question_text": "Question: A 58-year-old woman with a history of gastric ulcer is about to start taking aceclofenac for persistent finger osteoarthritis symptoms. Which of the following drugs is appropriate for preventing gastric ulcers that may be induced by aceclofenac?\n\n① Ecabet\n② Bismuth\n③ Famotidine\n④ Lansoprazole\n⑤ Metoclopramide",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 파킨슨병과 양성전립샘비대가 있는 62세 남자가 미란식도염을 치료하기 위해 레바미피드(rebamipide)를 복용 중이다. 식도염 증상이 조절되지 않아 레바미피드를 다른 약으로 변경하고자 할 때 적절한 약물은?\n\n① 베타네콜(bethanechol)\n② 테고프라잔(tegoprazan)\n③ 미소프로스톨(misoprostol)\n④ 레보설피리드(levosulpiride)\n⑤ 루비프로스톤(lubiprostone)",
        "question_text": "Question: A 62-year-old man with Parkinson's disease and benign prostatic hyperplasia is taking rebamipide to treat erosive esophagitis. When the esophagitis symptoms are not controlled and the rebamipide needs to be changed to another medication, which of the following is an appropriate drug?\n\n① Bethanechol\n② Tegoprazan\n③ Misoprostol\n④ Levosulpiride\n⑤ Lubiprostone",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 간경화증이 있는 45세 남자가 다음과 같은 약물을 복용하고 있다. 최근 복수가 증가하여 1주일간 체중이 3 kg 증가하였다. 복약이행도에는 문제가 없다. 복수를 제거하기 위한 조치로 적절한 것은?\n\n[임상검사]\n혈액검사: Na 141 mEq/L, K 5.5 mEq/L, Alb 2.4 g/dL\n소변검사: Na/K 1.3\n복수검사: Alb 0.9 g/dL\n[복용약물]\n프로프라놀롤(propranolol) 20 mg 1일 2회\n락툴로오스(lactulose) 30 mL1일 2~3회\n스피로노락톤(spironolactone) 200 mg 1일 1회\n\n① 아밀로라이드(amiloride) 10 mg 1일 1회 추가\n② 인다파미드(indapamide) 2.5 mg 1일 1회 추가\n③ 푸로세미드(furosemide) 80 mg 1일 1회 추가\n④ 스피로노락톤을 푸로세미드 80 mg 1일 1회로 변경\n⑤ 스피로노락톤을 인다파미드 2.5 mg 1일 1회로 변경",
        "question_text": "Question: A 45-year-old man with cirrhosis is taking the following medications. Recently, his ascites has increased, resulting in a 3 kg weight gain over a week. There are no issues with medication adherence. What is the appropriate measure to remove the ascites?\n\n[Clinical Tests]\nBlood test: Na 141 mEq/L, K 5.5 mEq/L, Alb 2.4 g/dL\nUrine test: Na/K 1.3\nAscites test: Alb 0.9 g/dL\n\n[Current Medications]\nPropranolol 20 mg twice daily\nLactulose 30 mL 2-3 times daily\nSpironolactone 200 mg once daily\n\n① Add amiloride 10 mg once daily\n② Add indapamide 2.5 mg once daily\n③ Add furosemide 80 mg once daily\n④ Change spironolactone to furosemide 80 mg once daily\n⑤ Change spironolactone to indapamide 2.5 mg once daily",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 간경화증이 있는 53세 남자가 자발성 세균성 복막염을 예방하기 위해 노르플록사신(norfloxacin)을 복용하고 있다. 최근 1주일간 복수가 증가하였고, 검사 결과 자발성 세균성 복막염이 진단되었을 때, 적절한 경험적 항균제는?\n\n[활력징후] 체온 38.7℃, 혈압 112/75 mmHg, 심박수 68회/분, 호흡수 18회/분\n[임상검사] 혈액검사: Alb 2.2 g/dL, 복수검사: Alb 0.9 g/dL, 다형핵백혈구(PMN) 300/mm3\n\n① 암피실린(ampicillin)\n② 세포탁심(cefotaxime)\n③ 반코마이신(vancomycin)\n④ 시프로플록사신(ciprofloxacin)\n⑤ 아지트로마이신(azithromycin)",
        "question_text": "Question: A 53-year-old man with liver cirrhosis is taking norfloxacin to prevent spontaneous bacterial peritonitis. His ascites has increased over the past week, and test results have diagnosed spontaneous bacterial peritonitis. What is the appropriate empirical antibiotic in this case?\n\n[Vital signs] Temperature 38.7°C, Blood pressure 112/75 mmHg, Heart rate 68 beats/min, Respiratory rate 18 breaths/min\n[Clinical tests] Blood test: Alb 2.2 g/dL, Ascites test: Alb 0.9 g/dL, Polymorphonuclear leukocytes (PMN) 300/mm3\n\n① Ampicillin\n② Cefotaxime\n③ Vancomycin\n④ Ciprofloxacin\n⑤ Azithromycin",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 임신을 계획하고 있는 33세 여자가 만성B형간염이 의심되어 검사를 받았다. 과거에 B형간염의 치료력이 없고 결과가 다음과 같을 때, 적절한 조치는?\n\n[임상검사] HBsAg 양성, HBeAg 양성, anti-HBe 음성, HBV DNA 32,000 IU/mL, AST 185 IU/L, ALT 220 IU/L\n\n① 약물 투여 없이 경과 관찰\n② 리바비린(ribavirin) 투여\n③ 아데포비르(adefovir) 투여\n④ 엔테카비르(entecavir) 투여\n⑤ B형간염 면역글로불린(hepatitis B immunoglobulin, HBIG) 투여",
        "question_text": "Question: A 33-year-old woman planning pregnancy was tested for suspected chronic hepatitis B. She has no history of hepatitis B treatment, and her test results are as follows. What is the appropriate course of action?\n\n[Clinical test results] HBsAg positive, HBeAg positive, anti-HBe negative, HBV DNA 32,000 IU/mL, AST 185 IU/L, ALT 220 IU/L\n\n① Observe without medication\n② Administer ribavirin\n③ Administer adefovir\n④ Administer entecavir\n⑤ Administer hepatitis B immunoglobulin (HBIG)",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n27세 남자에게 복통과 하루 4~5회 정도의 설사와 혈변이 발생하였다. 지난 2주 동안 체중이 3 kg 감소하여 현재 50 kg이고, 체온은 정상이다. 대장내시경 검사 결과 대장 점막에 염증이 있는 경증의 크론병을 진단받았고, 항문주위 누공(fistula)은 없었다.\n\n[임상검사]\n크론병활동지수(Crohn’s disease activity index, CDAI): 183점\n\n[복용약물] 로페라미드(loperamide) 2 mg 필요시\n\nQuestion: 이 환자에게 적절한 초기 치료 약물은?\n\n① 메살라진(mesalazine)\n② 토파시티닙(tofacitinib)\n③ 메트로니다졸(metronidazole)\n④ 사이클로스포린(cyclosporine)\n⑤ 메토트렉세이트(methotrexate)",
        "question_text": "A 27-year-old male experienced abdominal pain, diarrhea 4-5 times a day, and bloody stools. He lost 3 kg over the past two weeks and currently weighs 50 kg, with a normal body temperature. A colonoscopy revealed mild Crohn's disease with inflammation in the colon mucosa, and there was no perianal fistula.\n\n[Clinical test]\nCrohn's Disease Activity Index (CDAI): 183 points\n\n[Current medication] Loperamide 2 mg as needed\n\nQuestion: What is the appropriate initial treatment for this patient?\n\n① Mesalazine\n② Tofacitinib\n③ Metronidazole\n④ Cyclosporine\n⑤ Methotrexate",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n27세 남자에게 복통과 하루 4~5회 정도의 설사와 혈변이 발생하였다. 지난 2주 동안 체중이 3 kg 감소하여 현재 50 kg이고, 체온은 정상이다. 대장내시경 검사 결과 대장 점막에 염증이 있는 경증의 크론병을 진단받았고, 항문주위 누공(fistula)은 없었다.\n\n[임상검사]\n크론병활동지수(Crohn’s disease activity index, CDAI): 183점\n\n[복용약물] 로페라미드(loperamide) 2 mg 필요시\n\nQuestion: 여러 약물요법에도 증상이 지속되어 아달리무맙(adalimumab)으로 변경하였고 관해에 도달하였다. 관해를 유지하기 위해 단독요법으로 사용할 수 있는 약물은?\n\n① 메살라진\n② 아달리무맙\n③ 골리무맙(golimumab)\n④ 아자티오프린(azathioprine)\n⑤ 우스테키누맙(ustekinumab)",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 27-year-old male experienced abdominal pain, diarrhea 4-5 times a day, and bloody stools. He lost 3 kg over the past two weeks and currently weighs 50 kg, with a normal body temperature. Colonoscopy revealed mild Crohn's disease with inflammation in the colon mucosa, and there was no perianal fistula.\n\n[Clinical test]\nCrohn's Disease Activity Index (CDAI): 183 points\n\n[Medication] Loperamide 2 mg as needed\n\nQuestion: Despite various drug therapies, symptoms persisted, so treatment was changed to adalimumab, which led to remission. Which drug can be used as monotherapy to maintain remission?\n\n① Mesalazine\n② Adalimumab\n③ Golimumab\n④ Azathioprine\n⑤ Ustekinumab",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 만성콩팥병이 있는 57세 여자의 검사 결과가 다음과 같을 때, 산염기 불균형을 조절하기 위한 약물로 적절한 것은?\n\n[활력징후] 혈압 124/85 mmHg, 심박수 86회/분, 호흡수 24회/분\n[혈액검사] Na 142 mEq/L, K 5.7 mEq/L, Cl 111 mEq/L, Ca 10.4 mg/dL, P 4.5 mg/dL, Alb 3.0 g/dL, SCr 2.2 mg/dL, eGFR 23 mL/min/1.73 m2\n[동맥혈가스검사] pH 7.27, PaCO2 29 mmHg (참고치 35~45 mmHg), PaO2 88 mmHg (참고치 80~100 mmHg), HCO3- 13 mEq/L (참고치 22~26 mEq/L)\n\n① 시트르산칼륨(potassium citrate)\n② 글루콘산칼슘(calcium gluconate)\n③ 염화마그네슘(magnesium chloride)\n④ 락트산마그네슘(magnesium lactate)\n⑤ 탄산수소나트륨(sodium bicarbonate)",
        "question_text": "Question: A 57-year-old woman with chronic kidney disease has the following test results. Which drug is appropriate to regulate the acid-base imbalance?\n\n[Vital Signs] Blood pressure 124/85 mmHg, Heart rate 86 beats/min, Respiratory rate 24 breaths/min\n[Blood Test] Na 142 mEq/L, K 5.7 mEq/L, Cl 111 mEq/L, Ca 10.4 mg/dL, P 4.5 mg/dL, Alb 3.0 g/dL, SCr 2.2 mg/dL, eGFR 23 mL/min/1.73 m2\n[Arterial Blood Gas] pH 7.27, PaCO2 29 mmHg (reference range 35-45 mmHg), PaO2 88 mmHg (reference range 80-100 mmHg), HCO3- 13 mEq/L (reference range 22-26 mEq/L)\n\n① Potassium citrate\n② Calcium gluconate\n③ Magnesium chloride\n④ Magnesium lactate\n⑤ Sodium bicarbonate",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 52세 남자에게 진균감염을 치료하기 위해 암포테리신B(amphotericin B)를 투여할 예정이다. 현재 사용하는 약물은 다음과 같다. 암포테리신B와의 병용투여로 급성세뇨관괴사(acute tubular necrosis)의 위험이 증가할 수 있는 약물은?\n\n[사용약물] 졸피뎀(zolpidem) 암로디핀(amlodipine) 겐타마이신(gentamicin) 메트로니다졸(metronidazole) 아세트아미노펜(acetaminophen)\n\n① 졸피뎀\n② 암로디핀\n③ 겐타마이신\n④ 메트로니다졸\n⑤ 아세트아미노펜",
        "question_text": "Question: A 52-year-old man is scheduled to receive amphotericin B to treat a fungal infection. The medications he is currently using are as follows. Which drug, when used concurrently with amphotericin B, could increase the risk of acute tubular necrosis?\n\n[Current medications] zolpidem, amlodipine, gentamicin, metronidazole, acetaminophen\n\n① zolpidem\n② amlodipine\n③ gentamicin\n④ metronidazole\n⑤ acetaminophen",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 만성콩팥병이 있는 67세 여자에게 컴퓨터단층촬영 전에 혈관조영제로 이오헥솔(iohexol)을 투여할 예정이다. 혈관조영제에 의한 급성신손상을 예방하기 위한 약물로 적절한 것은?\n\n① 알부민(albumin)\n② 포도당(dextrose)\n③ 만니톨(mannitol)\n④ 생리식염수(0.9% NaCl)\n⑤ 저용량 도파민(dopamine)",
        "question_text": "Question: A 67-year-old woman with chronic kidney disease is scheduled to receive iohexol as a contrast agent before a computed tomography scan. Which of the following drugs is appropriate for preventing contrast-induced acute kidney injury?\n\n① Albumin\n② Dextrose\n③ Mannitol\n④ Normal saline (0.9% NaCl)\n⑤ Low-dose dopamine",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 만성콩팥병(4기)이 있는 53세 남자가 빈혈을 치료하기 위해 1개월 전부터 에포에틴 알파(epoetin alfa)를 사용하고 있다. 검사 결과가 다음과 같을 때 적절한 조치는?\n\n[임상검사]\n혈색소(Hgb) 9.7 g/dL (2주 전 9.1 g/dL, 1개월 전 8.4 g/dL)\n적혈구용적률(Hct) 29% 페리틴 85 ng/mL (참고치 >500 ng/mL)\n트랜스페린포화도(Tsat) 18% (참고치 >30%)\n\n① 에포에틴 알파의 용량 감소\n② 에포에틴 알파의 용량 증가\n③ 에포에틴 베타(epoetin beta)로 변경\n④ 황산제일철(ferrous sulfate) 경구제 추가\n⑤ 수크로스수산화제이철착염(ferric hydroxide sucrose complex) 주사제 추가",
        "question_text": "Question: A 53-year-old man with chronic kidney disease (stage 4) has been using epoetin alfa for anemia treatment for the past month. Given the following test results, what is the appropriate course of action?\n\n[Clinical Tests]\nHemoglobin (Hgb) 9.7 g/dL (9.1 g/dL 2 weeks ago, 8.4 g/dL 1 month ago)\nHematocrit (Hct) 29%\nFerritin 85 ng/mL (Reference range >500 ng/mL)\nTransferrin saturation (Tsat) 18% (Reference range >30%)\n\n① Decrease the dose of epoetin alfa\n② Increase the dose of epoetin alfa\n③ Switch to epoetin beta\n④ Add oral ferrous sulfate\n⑤ Add intravenous ferric hydroxide sucrose complex",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 고혈압과 만성콩팥병이 있는 55세 남자가 다음과 같은 약물을 복용하고 있다. 며칠 전부터 입술 저림과 양쪽 다리의 근육경련이 발생하였고, 검사 결과 혈청칼슘 농도가 감소하였다. 저칼슘혈증을 유발한 것으로 의심되는 약물은?\n\n[임상검사] Na 136 mEq/L, K 5.2 mEq/L, CO2 19 mEq/L, Ca 7.6 mg/dL, P 4.8 mg/dL, Alb 3.4 g/dL, iPTH 425 pg/mL (참고치 150~300 pg/mL)\n[복용약물]\n암로디핀(amlodipine) 10 mg 1일 1회\n이르베사르탄(irbesartan) 300 mg 1일 1회\n세벨라머(sevelamer) 800 mg 1일 3회\n시나칼세트(cinacalcet) 25 mg 1일 1회\n폴리스티렌설폰산칼슘(calcium polystyrene sulfonate) 5 g 1일 3회\n\n① 세벨라머\n② 암로디핀\n③ 시나칼세트\n④ 이르베사르탄\n⑤ 폴리스티렌설폰산칼슘",
        "question_text": "Question: A 55-year-old man with hypertension and chronic kidney disease is taking the following medications. He has been experiencing numbness in his lips and muscle cramps in both legs for the past few days, and test results show a decrease in serum calcium concentration. Which drug is suspected to have caused hypocalcemia?\n\n[Clinical tests] Na 136 mEq/L, K 5.2 mEq/L, CO2 19 mEq/L, Ca 7.6 mg/dL, P 4.8 mg/dL, Alb 3.4 g/dL, iPTH 425 pg/mL (reference range 150-300 pg/mL)\n[Medications]\nAmlodipine 10 mg once daily\nIrbesartan 300 mg once daily\nSevelamer 800 mg three times daily\nCinacalcet 25 mg once daily\nCalcium polystyrene sulfonate 5 g three times daily\n\n① Sevelamer\n② Amlodipine\n③ Cinacalcet\n④ Irbesartan\n⑤ Calcium polystyrene sulfonate",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 50세 여자가 말기콩팥병으로 신장이식을 계획하고 있다. 검사 결과에서 거부반응 발생 위험도가 낮은 것으로 나타났다. 이 환자에서 유도요법으로 고용량 메틸프레드니솔론(methylprednisolone)과 함께 사용할 약물은?\n\n① 리툭시맙(rituximab)\n② 바실릭시맙(basiliximab)\n③ 보르테조밉(bortezomib)\n④ 에쿨리주맙(eculizumab)\n⑤ 아자티오프린(azathioprine)",
        "question_text": "Question: A 50-year-old woman is planning to undergo kidney transplantation due to end-stage renal disease. Test results show that she has a low risk of rejection. Which drug should be used along with high-dose methylprednisolone as induction therapy for this patient?\n\n① Rituximab\n② Basiliximab\n③ Bortezomib\n④ Eculizumab\n⑤ Azathioprine",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 63세 남자가 3개월 전에 2형당뇨병을 진단받았고, 검사 결과와 복용약물은 다음과 같다. 추가할 약물로 적절한 것은?\n\n[병력] 안정협심증, 심부전\n[활력징후] 혈압 135/80 mmHg, 심박수 64회/분, 체질량지수 30.7 kg/m2\n[임상검사] 공복혈당 154 mg/dL, 당화혈색소 7.7%, SCr 1.0 mg/dL\n[복용약물] 메트포르민(metformin) 1,000 mg 1일 2회\n\n① 보글리보스(voglibose)\n② 삭사글립틴(saxagliptin)\n③ 글리메피리드(glimepiride)\n④ 피오글리타존(pioglitazone)\n⑤ 엠파글리플로진(empagliflozin)",
        "question_text": "Question: A 63-year-old man was diagnosed with type 2 diabetes 3 months ago. His test results and current medication are as follows. Which additional medication is most appropriate?\n\n[Medical history] Stable angina, heart failure\n[Vital signs] Blood pressure 135/80 mmHg, heart rate 64 beats/min, BMI 30.7 kg/m2\n[Clinical tests] Fasting blood glucose 154 mg/dL, HbA1c 7.7%, SCr 1.0 mg/dL\n[Current medication] Metformin 1,000 mg twice daily\n\n① Voglibose\n② Saxagliptin\n③ Glimepiride\n④ Pioglitazone\n⑤ Empagliflozin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 56세 여자가 2형당뇨병과 고혈압으로 약물 치료 중이다. 환자는 체중 증가와 주사제 사용에 대해 심한 거부감이 있다. 혈당 조절을 위해 추가할 약물은?\n\n[활력징후] 혈압 114/73 mmHg, 심박수 70회/분, 호흡수 18회/분, 체질량지수 28.0 kg/m2\n[임상검사] 공복혈당 175 mg/dL, 당화혈색소 7.4%, SCr 0.8 mg/dL, eGFR 83 mL/min/1.73 m2\n[복용약물]\n메트포르민(metformin) 850 mg 1일 3회\n암로디핀(amlodipine) 5 mg 1일 1회\n\n① 글리피지드(glipizide)\n② 시타글립틴(sitagliptin)\n③ 리라글루티드(liraglutide)\n④ 레파글리니드(repaglinide)\n⑤ 피오글리타존(pioglitazone)",
        "question_text": "Question: A 56-year-old woman is undergoing drug treatment for type 2 diabetes and hypertension. The patient has a strong aversion to weight gain and the use of injectable medications. Which drug should be added to control blood glucose?\n\n[Vital Signs] Blood pressure 114/73 mmHg, Heart rate 70 bpm, Respiratory rate 18 breaths/min, BMI 28.0 kg/m2\n[Clinical Tests] Fasting blood glucose 175 mg/dL, HbA1c 7.4%, SCr 0.8 mg/dL, eGFR 83 mL/min/1.73 m2\n[Current Medications]\nMetformin 850 mg 3 times daily\nAmlodipine 5 mg once daily\n\n① Glipizide\n② Sitagliptin\n③ Liraglutide\n④ Repaglinide\n⑤ Pioglitazone",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 2형당뇨병으로 메트포르민(metformin)과 빌다글립틴(vildagliptin)을 복용하는 49세 남자의 검사 결과가 다음과 같다. 혈당조절을 위해 주사제를 병용하고자 할 때, 적절한 약물은?\n\n[임상검사] 공복혈당 187 mg/dL, 당화혈색소 8.3%\n\n① 리라글루티드(liraglutide)\n② 둘라글루티드(dulaglutide)\n③ 인슐린디터머(insulin detemir)\n④ 인슐린글루리신(insulin glulisine)\n⑤ 릭시세나티드/인슐린글라진(lixisenatide/insulin glargine)",
        "question_text": "Question: A 49-year-old man with type 2 diabetes is taking metformin and vildagliptin. His test results are as follows. When considering adding an injectable medication for blood glucose control, which of the following is the most appropriate?\n\n[Clinical test results] Fasting blood glucose 187 mg/dL, HbA1c 8.3%\n\n① Liraglutide\n② Dulaglutide\n③ Insulin detemir\n④ Insulin glulisine\n⑤ Lixisenatide/insulin glargine",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n2형당뇨병으로 10년 전부터 경구혈당강하제를 복용하는 61세 여자가 최근 발바닥이 저리고 통증이 심해져, 검사 결과 당뇨병성 말초신경병증을 진단받았다.\n\n[병력] 2형당뇨병, 불안정협심증, 골관절염\n\n[가족력] 아버지: 갑상샘 수질암\n\n[임상검사]\n공복혈당 146 mg/dL, 당화혈색소 7.5%\nSCr 1.0 mg/dL, eGFR 68 mL/min/1.73 m2\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 2회\n라미프릴(ramipril) 10 mg 1일 1회 로수바스타틴(rosuvastatin) 20 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 2회\n나프록센(naproxen) 500 mg 1일 2회\n니트로글리세린(nitroglycerin) 설하정 0.6 mg 필요시\n\nQuestion: 당뇨병성 말초신경병증의 증상 조절을 위해 추가할 약은?\n\n① 올란자핀(olanzapine) 정제\n② 둘록세틴(duloxetine) 캡슐제\n③ 피록시캄(piroxicam) 카타플라스마제\n④ 케토프로펜(ketoprofen) 카타플라스마제\n⑤ 메토클로프라미드(metoclopramide) 정제",
        "question_text": "A 61-year-old woman who has been taking oral hypoglycemic agents for type 2 diabetes for 10 years was recently diagnosed with diabetic peripheral neuropathy after experiencing increased numbness and pain in her soles.\n\n[Medical history] Type 2 diabetes, unstable angina, osteoarthritis\n\n[Family history] Father: Medullary thyroid cancer\n\n[Clinical tests]\nFasting blood glucose 146 mg/dL, HbA1c 7.5%\nSCr 1.0 mg/dL, eGFR 68 mL/min/1.73 m2\n\n[Current medications]\nAspirin 100 mg once daily\nMetoprolol 100 mg twice daily\nRamipril 10 mg once daily\nRosuvastatin 20 mg once daily\nMetformin 1,000 mg twice daily\nNaproxen 500 mg twice daily\nNitroglycerin sublingual tablet 0.6 mg as needed\n\nQuestion: Which drug should be added to control the symptoms of diabetic peripheral neuropathy?\n\n① Olanzapine tablet\n② Duloxetine capsule\n③ Piroxicam cataplasma\n④ Ketoprofen cataplasma\n⑤ Metoclopramide tablet",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n2형당뇨병으로 10년 전부터 경구혈당강하제를 복용하는 61세 여자가 최근 발바닥이 저리고 통증이 심해져, 검사 결과 당뇨병성 말초신경병증을 진단받았다.\n\n[병력] 2형당뇨병, 불안정협심증, 골관절염\n\n[가족력] 아버지: 갑상샘 수질암\n\n[임상검사]\n공복혈당 146 mg/dL, 당화혈색소 7.5%\nSCr 1.0 mg/dL, eGFR 68 mL/min/1.73 m2\n\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n메토프롤롤(metoprolol) 100 mg 1일 2회\n라미프릴(ramipril) 10 mg 1일 1회 로수바스타틴(rosuvastatin) 20 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 2회\n나프록센(naproxen) 500 mg 1일 2회\n니트로글리세린(nitroglycerin) 설하정 0.6 mg 필요시\n\nQuestion: 혈당강하제를 추가하려 할 때, 치료적 이득이 가장 높을 것으로 기대되는 약물은?\n\n① 아카르보스(acarbose)\n② 제미글립틴(gemigliptin)\n③ 리라글루티드(liraglutide)\n④ 로베글리타존(lobeglitazone)\n⑤ 다파글리플로진(dapagliflozin)",
        "question_text": "A 61-year-old woman who has been taking oral hypoglycemic agents for type 2 diabetes for 10 years was recently diagnosed with diabetic peripheral neuropathy after experiencing increased numbness and pain in her soles.\n\n[Medical history] Type 2 diabetes, unstable angina, osteoarthritis\n\n[Family history] Father: Medullary thyroid cancer\n\n[Clinical tests]\nFasting blood glucose 146 mg/dL, HbA1c 7.5%\nSCr 1.0 mg/dL, eGFR 68 mL/min/1.73 m2\n\n[Current medications]\nAspirin 100 mg once daily\nMetoprolol 100 mg twice daily\nRamipril 10 mg once daily\nRosuvastatin 20 mg once daily\nMetformin 1,000 mg twice daily\nNaproxen 500 mg twice daily\nNitroglycerin sublingual tablet 0.6 mg as needed\n\nQuestion: When considering adding a hypoglycemic agent, which drug is expected to have the highest therapeutic benefit?\n\n① Acarbose\n② Gemigliptin\n③ Liraglutide\n④ Lobeglitazone\n⑤ Dapagliflozin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 여자에게 심계항진(145회/분), 고열(39.5℃), 구토, 탈수와 혼돈 증상이 발생하였다. 환자는 그레이브스병 치료를 위해 메티마졸(methimazole)을 복용 중이었으나 2주 전부터 약물을 복용하지 않았다. 검사 결과 갑상샘중독증을 진단받았다.\n\nQuestion: 환자에서 심계항진 증상을 신속하게 완화하기 위해 우선적으로 투여할 약물은?\n\n① 메티마졸(methimazole)\n② 카르비마졸(carbimazole)\n③ 레보티록신(levothyroxine)\n④ 프로프라놀롤(propranolol)\n⑤ 프로필티오우라실(propylthiouracil)",
        "question_text": "A 58-year-old woman presented with palpitations (145 beats/min), high fever (39.5°C), vomiting, dehydration, and confusion. The patient had been taking methimazole for Graves' disease but had not taken the medication for the past two weeks. Test results led to a diagnosis of thyrotoxicosis.\n\nQuestion: Which drug should be administered first to rapidly alleviate the patient's palpitations?\n\n① Methimazole\n② Carbimazole\n③ Levothyroxine\n④ Propranolol\n⑤ Propylthiouracil",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 여자에게 심계항진(145회/분), 고열(39.5℃), 구토, 탈수와 혼돈 증상이 발생하였다. 환자는 그레이브스병 치료를 위해 메티마졸(methimazole)을 복용 중이었으나 2주 전부터 약물을 복용하지 않았다. 검사 결과 갑상샘중독증을 진단받았다.\n\nQuestion: 이 환자의 고열 치료를 위한 적절한 약물은?\n\n① 아스피린(aspirin)\n② 트라마돌(tramadol)\n③ 셀레콕시브(celecoxib)\n④ 이부프로펜(ibuprofen)\n⑤ 아세트아미노펜(acetaminophen)",
        "question_text": "A 58-year-old woman presented with palpitations (145 beats/min), high fever (39.5°C), vomiting, dehydration, and confusion. The patient had been taking methimazole for Graves' disease but had not taken the medication for the past two weeks. Test results led to a diagnosis of thyrotoxicosis.\n\nQuestion: Which of the following drugs is appropriate for treating this patient's high fever?\n\n① Aspirin\n② Tramadol\n③ Celecoxib\n④ Ibuprofen\n⑤ Acetaminophen",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 70세 남자가 세균성 전립샘염을 치료하기 위해 시프로플록사신(ciprofloxacin)을 처방받았다. 이 환자에게 발생할 위험이 높을 것으로 예상되는 이 약의 주요 이상반응은?\n\n[병력] 건선\n[사용약물]\n프레드니솔론(prednisolone) 10 mg 1일 1회\n칼시포트리올(calcipotriol) 연고\n\n① 소변정체\n② 혈압상승\n③ 고요산혈증\n④ 건(힘줄)파열\n⑤ 여성형유방증",
        "question_text": "Question: A 70-year-old man was prescribed ciprofloxacin to treat bacterial prostatitis. Which of the following major adverse reactions of this drug is most likely to occur in this patient?\n\n[Medical history] Psoriasis\n[Medications]\nPrednisolone 10 mg once daily\nCalcipotriol ointment\n\n① Urinary retention\n② Increased blood pressure\n③ Hyperuricemia\n④ Tendon rupture\n⑤ Gynecomastia",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 8일 전 처음 도뇨관을 삽입하여 유지하고 있는 80세 여자의 요검사 결과에서 세균뇨(Escherichia coli > 105 cfu/mL)가 확인되었다. 현재 관련 증상은 없고 도뇨관을 교체하였다. 적절한 약물요법은?\n\n① 항생제 투여 없이 경과 관찰\n② 포스포마이신(fosfomycin) 3 g 단회 투여\n③ 레보플록사신(levofloxacin) 750 mg 1일 1회 5일 투여\n④ 니트로푸란토인(nitrofurantoin) 50 mg 1일 4회 7일 투여\n⑤ 시프로플록사신(ciprofloxacin) 125 mg 1일 1회 6개월 투여",
        "question_text": "Question: A urinalysis result for an 80-year-old woman who had a urinary catheter inserted for the first time 8 days ago and has been maintaining it shows bacteriuria (Escherichia coli > 105 cfu/mL). Currently, there are no related symptoms, and the catheter has been replaced. What is the appropriate drug therapy?\n\n① Observe without antibiotic administration\n② Single dose of fosfomycin 3 g\n③ Levofloxacin 750 mg once daily for 5 days\n④ Nitrofurantoin 50 mg four times daily for 7 days\n⑤ Ciprofloxacin 125 mg once daily for 6 months",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 발열(38.1℃)과 인후통이 있어 신속항원검사를 받고 급성 인두염이 확인된 11세 여자에게 아목시실린(amoxicillin)을 투여할 때 권고되는 적절한 투약기간은?\n\n[신속항원검사] A군 베타 용혈연쇄구균(group A beta-hemolytic Streptococcus)  양성\n\n① 3일\n② 5일\n③ 7일\n④ 10일\n⑤ 14일",
        "question_text": "Question: What is the recommended appropriate duration of treatment when administering amoxicillin to an 11-year-old girl with fever (38.1℃) and sore throat, who was diagnosed with acute pharyngitis after a rapid antigen test?\n\n[Rapid antigen test] Positive for group A beta-hemolytic Streptococcus\n\n① 3 days\n② 5 days\n③ 7 days\n④ 10 days\n⑤ 14 days",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 편두통, 철결핍빈혈, 위식도역류질환이 있는 34세 여자가 지역사회획득폐렴으로 입원하여 레보플록사신(levofloxacin) 경구제로 치료할 계획이다. 레보플록사신과 약물상호작용이 발생할 수 있어 충분한 시간 간격을 두고 복용해야 하는 약물은?\n\n① 수마트립탄(sumatriptan)\n② 토피라메이트(topiramate)\n③ 황산제일철(ferrous sulfate)\n④ 에스오메프라졸(esomeprazole)\n⑤ 아세트아미노펜(acetaminophen)",
        "question_text": "Question: A 34-year-old woman with migraine, iron deficiency anemia, and gastroesophageal reflux disease has been hospitalized with community-acquired pneumonia and is planned to be treated with oral levofloxacin. Which of the following drugs may interact with levofloxacin and should be taken with a sufficient time interval?\n\n① Sumatriptan\n② Topiramate\n③ Ferrous sulfate\n④ Esomeprazole\n⑤ Acetaminophen",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 59세 남자가 심근경색이 발생하여 관상동맥우회수술을 받았다. 회복하던 중, 급성호흡곤란증후군(acute respiratory distress syndrome, ARDS)이 발생해 3일 전부터 인공호흡기 치료를 받고 있다. 오늘 갑작스러운 고열 등으로 폐렴을 진단받았다. 적절한 경험적 항균요법은?\n\n[활력징후] 혈압 130/82 mmHg, 호흡수 24회/분, 체온 38.9℃\n[임상검사] SCr 0.87 mg/dL, eGFR 78 mL/min/1.73 m2\n\n① 세페핌(cefepime)+반코마이신(vancomycin)\n② 목시플록사신(moxifloxacin)+반코마이신\n③ 세페핌+목시플록사신+반코마이신\n④ 에르타페넴(ertapenem)+아미카신(amikacin)+반코마이신\n⑤ 피페라실린/타조박탐(piperacillin/tazobactam)+레보플록사신(levofloxacin)+반코마이신",
        "question_text": "Question: A 59-year-old man underwent coronary artery bypass surgery after experiencing a myocardial infarction. During recovery, he developed acute respiratory distress syndrome (ARDS) and has been on mechanical ventilation for the past 3 days. Today, he was diagnosed with pneumonia due to sudden high fever and other symptoms. What is the appropriate empirical antimicrobial therapy?\n\n[Vital signs] Blood pressure 130/82 mmHg, Respiratory rate 24 breaths/min, Body temperature 38.9℃\n[Clinical tests] SCr 0.87 mg/dL, eGFR 78 mL/min/1.73 m2\n\n① Cefepime + Vancomycin\n② Moxifloxacin + Vancomycin\n③ Cefepime + Moxifloxacin + Vancomycin\n④ Ertapenem + Amikacin + Vancomycin\n⑤ Piperacillin/Tazobactam + Levofloxacin + Vancomycin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 다제내성 결핵 치료를 받고 있는 58세 여자가 갑자기 실신하였다. 검사 결과, 심전도상에서 QTc 간격이 520 msec로 연장된 것이 확인되었다. QTc 간격 연장의 원인약물은?\n\n[사용약물] 베다퀼린(bedaquiline) 리네졸리드(linezolid) 시클로세린(cycloserine) 아미카신(amikacin) 피라진아미드(pyrazinamide)\n\n① 베다퀼린\n② 아미카신\n③ 리네졸리드\n④ 시클로세린\n⑤ 피라진아미드",
        "question_text": "Question: A 58-year-old woman receiving treatment for multidrug-resistant tuberculosis suddenly fainted. Test results showed that her QTc interval was prolonged to 520 msec on the electrocardiogram. Which drug is the likely cause of the QTc interval prolongation?\n\n[Medications used] Bedaquiline, Linezolid, Cycloserine, Amikacin, Pyrazinamide\n\n① Bedaquiline\n② Amikacin\n③ Linezolid\n④ Cycloserine\n⑤ Pyrazinamide",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 42세 남자가 중증 활동기 크론병으로 대장절제술을 받았다. 수술 후 5일째에 칸디다혈증이 의심되어 플루코나졸(fluconazole) 800 mg 부하용량 투여 후 400 mg 1일 1회 투여를 시작하였다. 플루코나졸 치료 후 5일이 지났으나, 환자의 증상이 계속 악화되었다. 적절한 조치는?\n\n[활력징후] 혈압 110/72 mmHg, 심박수 79회/분, 체온 39.2℃\n[임상검사] SCr 2.1 mg/dL (수술 전 SCr 1.0 mg/dL), CrCl 46 mL/min 혈액 미생물 검사: 효모(yeast) 형태 진균 검출, Candida krusei 동정\n\n① 플루코나졸의 용량 증가\n② 플루코나졸의 용량 감소\n③ 플루시토신(flucytosine) 추가\n④ 플루코나졸을 미카펀진(micafungin)으로 변경\n⑤ 플루코나졸을 이트라코나졸(itraconazole)로 변경",
        "question_text": "Question: A 42-year-old man underwent colectomy for severe active Crohn's disease. On the 5th day after surgery, candidemia was suspected, and fluconazole treatment was initiated with a loading dose of 800 mg followed by 400 mg once daily. After 5 days of fluconazole treatment, the patient's symptoms continued to worsen. What is the appropriate action?\n\n[Vital signs] Blood pressure 110/72 mmHg, Heart rate 79 beats/min, Body temperature 39.2℃\n[Clinical tests] SCr 2.1 mg/dL (pre-surgery SCr 1.0 mg/dL), CrCl 46 mL/min\nBlood microbiology test: Yeast-form fungi detected, Candida krusei identified\n\n① Increase the dose of fluconazole\n② Decrease the dose of fluconazole\n③ Add flucytosine\n④ Change fluconazole to micafungin\n⑤ Change fluconazole to itraconazole",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 헬리코박터필로리(Helicobacter pylori ) 양성 소화성궤양이 있는 52세 여자(체중 58 kg)에게 식도칸디다증이 발생하여 플루코나졸(fluconazole)을 투여하려 한다. 이 환자에게 플루코나졸을 상용량보다 낮추어 투여해야 하는 이유는?\n\n[복용약물] 아목시실린(amoxicillin) 클래리트로마이신(clarithromycin) 란소프라졸(lansoprazole)\n[임상검사] Na 141 mEq/L, K 4.5 mEq/L, SCr 1.6 mg/dL, CrCl 37 mL/min\n\n① 성별\n② 연령\n③ 체중\n④ 신장기능\n⑤ 아목시실린과의 상호작용",
        "question_text": "Question: A 52-year-old woman (weight 58 kg) with Helicobacter pylori-positive peptic ulcer has developed esophageal candidiasis, and fluconazole is to be administered. What is the reason for administering fluconazole at a lower dose than the usual dose for this patient?\n\n[Medications] amoxicillin, clarithromycin, lansoprazole\n[Clinical tests] Na 141 mEq/L, K 4.5 mEq/L, SCr 1.6 mg/dL, CrCl 37 mL/min\n\n① Gender\n② Age\n③ Weight\n④ Renal function\n⑤ Interaction with amoxicillin",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 35세 남자가 해외에 다녀온 후 두통, 발열, 오한, 구토, 설사, 장미 모양의 작은 발진이 발생했다. 분변에서 장티푸스균(Salmonella Typhi)이 검출되었고, 항균제 감수성 결과는 아직 나오지 않았다. 적절한 경험적 항균제는?\n\n① 콜리스틴(colistin)\n② 메로페넴(meropenem)\n③ 반코마이신(vancomycin)\n④ 메트로니다졸(metronidazole)\n⑤ 시프로플록사신(ciprofloxacin)",
        "question_text": "Question: A 35-year-old man developed headache, fever, chills, vomiting, diarrhea, and small rose-colored rashes after returning from overseas. Salmonella Typhi was detected in his stool, but the antibiotic susceptibility results are not yet available. What is the appropriate empirical antibiotic?\n\n① Colistin\n② Meropenem\n③ Vancomycin\n④ Metronidazole\n⑤ Ciprofloxacin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n극심한 두통과 구토증상이 있는 58세 남자가 세균성 뇌수막염을 진단받았다.\n\n[병력] 알코올 중독\n\n[약물 알레르기] 설폰아미드계\n\n[활력징후]\n혈압 131/82 mmHg, 심박수 79회/분, 체온 39.1℃\n\n[뇌척수액 검사]\n백혈구 2,000/mm3, 단백질 220 mg/dL\n포도당 39 mg/dL (혈중 포도당 134 mg/dL)\n뇌척수액 배양검사: 진행 중\n\nQuestion: 경험적 항균요법으로 적절한 것은?\n\n① 암피실린(ampicillin)+세포탁심(cefotaxime)\n② 세페핌(cefepime)+반코마이신(vancomycin)\n③ 세프트리악손(ceftriaxone)+반코마이신\n④ 세프트리악손+반코마이신+암피실린\n⑤ 세프트리악손+반코마이신+목시플록사신(moxifloxacin)",
        "question_text": "A 58-year-old male with severe headache and vomiting symptoms was diagnosed with bacterial meningitis.\n\n[Medical history] Alcohol addiction\n\n[Drug allergy] Sulfonamides\n\n[Vital signs]\nBlood pressure 131/82 mmHg, Heart rate 79 beats/min, Body temperature 39.1℃\n\n[Cerebrospinal fluid (CSF) test]\nWhite blood cells 2,000/mm3, Protein 220 mg/dL\nGlucose 39 mg/dL (Blood glucose 134 mg/dL)\nCSF culture test: In progress\n\nQuestion: Which of the following is the most appropriate empirical antimicrobial therapy?\n\n① Ampicillin + Cefotaxime\n② Cefepime + Vancomycin\n③ Ceftriaxone + Vancomycin\n④ Ceftriaxone + Vancomycin + Ampicillin\n⑤ Ceftriaxone + Vancomycin + Moxifloxacin",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n극심한 두통과 구토증상이 있는 58세 남자가 세균성 뇌수막염을 진단받았다.\n\n[병력] 알코올 중독\n\n[약물 알레르기] 설폰아미드계\n\n[활력징후]\n혈압 131/82 mmHg, 심박수 79회/분, 체온 39.1℃\n\n[뇌척수액 검사]\n백혈구 2,000/mm3, 단백질 220 mg/dL\n포도당 39 mg/dL (혈중 포도당 134 mg/dL)\n뇌척수액 배양검사: 진행 중\n\nQuestion: 뇌척수액 배양검사 결과는 다음과 같았다. 원인균 치료를 위해 권고되는, 효과적인 전체 항균요법 치료기간은 최소 며칠 이상인가?\n\n[뇌척수액 배양검사] Listeria monocytogenes\n\n① 3일\n② 5일\n③ 7일\n④ 10일\n⑤ 21일",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 58-year-old male with severe headache and vomiting was diagnosed with bacterial meningitis.\n\n[Medical history] Alcohol addiction\n\n[Drug allergy] Sulfonamides\n\n[Vital signs]\nBlood pressure 131/82 mmHg, Heart rate 79 beats/min, Body temperature 39.1℃\n\n[Cerebrospinal fluid (CSF) analysis]\nWhite blood cells 2,000/mm3, Protein 220 mg/dL\nGlucose 39 mg/dL (Blood glucose 134 mg/dL)\nCSF culture: In progress\n\nQuestion: The CSF culture result was as follows. What is the minimum recommended duration of effective overall antimicrobial therapy for treating the causative organism?\n\n[CSF culture result] Listeria monocytogenes\n\n① 3 days\n② 5 days\n③ 7 days\n④ 10 days\n⑤ 21 days",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 63세 여자가 고혈압, 우울증, 골관절염을 치료하기 위해 다음과 같은 약물을 복용하고 있다. 최근 편두통으로 수마트립탄(sumatriptan)을 처방받았다. 수마트립탄과의 상호작용으로 세로토닌증후군의 위험이 증가할 수 있는 약물은?\n\n[복용약물] 리시노프릴(lisinopril) 펠로디핀(felodipine) 에스시탈로프람(escitalopram) 덱시부프로펜(dexibuprofen) 오메프라졸(omeprazole)\n\n① 펠로디핀\n② 리시노프릴\n③ 오메프라졸\n④ 덱시부프로펜\n⑤ 에스시탈로프람",
        "question_text": "Question: A 63-year-old woman is taking the following medications to treat hypertension, depression, and osteoarthritis. She was recently prescribed sumatriptan for migraines. Which of the following drugs may increase the risk of serotonin syndrome due to interaction with sumatriptan?\n\n[Medications] lisinopril, felodipine, escitalopram, dexibuprofen, omeprazole\n\n① Felodipine\n② Lisinopril\n③ Omeprazole\n④ Dexibuprofen\n⑤ Escitalopram",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 76세 여자가 알츠하이머병을 치료하기 위해 도네페질(donepezil)을 복용하고 있다. 최근 지나친 의심, 환각과 함께 공격적인 행동을 보이고 있다. 적절한 약물은?\n\n① 가바펜틴(gabapentin)\n② 시탈로프람(citalopram)\n③ 쿠에티아핀(quetiapine)\n④ 미르타자핀(mirtazapine)\n⑤ 노르트립틸린(nortriptyline)",
        "question_text": "Question: A 76-year-old woman is taking donepezil to treat Alzheimer's disease. Recently, she has been showing excessive suspicion, hallucinations, and aggressive behavior. What is the appropriate medication?\n\n① Gabapentin\n② Citalopram\n③ Quetiapine\n④ Mirtazapine\n⑤ Nortriptyline",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 25세 남자가 국소발작을 치료하기 위해 발프로산(valproic acid)을 최대용량으로 복용하고 있다. 발작 조절이 충분하지 않아 약물을 추가하려 한다. 발프로산과의 상호작용을 고려할 때 상용량보다 낮추어 시작해야 하는 약물은?\n\n① 가바펜틴(gabapentin)\n② 비가바트린(vigabatrin)\n③ 프레가발린(pregabalin)\n④ 라모트리진(lamotrigine)\n⑤ 레비티라세탐(levetiracetam)",
        "question_text": "Question: A 25-year-old man is taking the maximum dose of valproic acid to treat focal seizures. As the seizure control is insufficient, an additional drug is to be added. Considering the interaction with valproic acid, which drug should be started at a lower dose than the usual dose?\n\n① Gabapentin\n② Vigabatrin\n③ Pregabalin\n④ Lamotrigine\n⑤ Levetiracetam",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 국소발작을 치료하기 위해 카르바마제핀(carbamazepine)을 복용하던 7세 남자가 최근 심한 피부발진으로 입원하였고 스티븐스-존슨증후군을 진단받았다. 카르바마제핀에 의한 스티븐스-존슨증후군 발생과 관련 있는 유전자는?\n\n① TPMT\n② BRCA1\n③ VKORC1\n④ SLCO1B1\n⑤ HLA-B*1502",
        "question_text": "Question: A 7-year-old boy who had been taking carbamazepine for the treatment of focal seizures was recently hospitalized with severe skin rash and diagnosed with Stevens-Johnson syndrome. Which gene is associated with the occurrence of Stevens-Johnson syndrome caused by carbamazepine?\n\n① TPMT\n② BRCA1\n③ VKORC1\n④ SLCO1B1\n⑤ HLA-B*1502",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 양극성장애로 탄산리튬(lithium carbonate) 300 mg을 1일 3회 복용 중인 32세 여자에게 심한 피로감, 변비, 체중증가와 생리불순 증상이 나타났다. 환자의 리튬 혈중농도가 1.6 mmol/L로 확인되었다(참고치 0.6~1.2 mmol/L). 이 약의 복용으로 인해 예상되는 주요 이상반응을 고려할 때, 확인이 필요한 검사는?\n\n① 안압\n② C-반응단백질\n③ 동맥혈가스분압\n④ 갑상샘자극호르몬\n⑤ 크레아틴키나아제",
        "question_text": "Question: A 32-year-old woman with bipolar disorder, who is taking lithium carbonate 300 mg three times daily, presents with severe fatigue, constipation, weight gain, and menstrual irregularities. The patient's serum lithium level is confirmed to be 1.6 mmol/L (reference range: 0.6-1.2 mmol/L). Considering the major side effects expected from taking this medication, which test should be performed?\n\n① Intraocular pressure\n② C-reactive protein\n③ Arterial blood gas\n④ Thyroid-stimulating hormone\n⑤ Creatine kinase",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 녹내장이 있는 58세 여자가 불면증을 치료하기 위해 멜라토닌(melatonin) 서방정을 복용했으나 여전히 잠을 자기가 어렵다. 불면증을 치료하기 위해 멜라토닌을 대체할 수 있는 적절한 약물은?\n\n① 독세핀(doxepin)\n② 졸피뎀(zolpidem)\n③ 독시라민(doxylamine)\n④ 조니사미드(zonisamide)\n⑤ 플루라제팜(flurazepam)",
        "question_text": "Question: A 58-year-old woman with glaucoma took extended-release melatonin to treat insomnia but still has difficulty falling asleep. What is an appropriate medication that can replace melatonin for treating insomnia?\n\n① Doxepin\n② Zolpidem\n③ Doxylamine\n④ Zonisamide\n⑤ Flurazepam",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 12세 여자가 주의력결핍과다행동장애(ADHD)를 치료하기 위해 메틸페니데이트(methylphenidate)를 복용하고 있다. 다른 동반질환이나 복용약물은 없다. 이 약의 복용으로 인해 예상되는 주요 이상반응을 고려할 때 모니터링이 필요한 것은?\n\n① 저혈당\n② 식욕부진\n③ 수면무호흡\n④ 갑상샘저하증\n⑤ 고중성지질혈증",
        "question_text": "Question: A 12-year-old girl is taking methylphenidate to treat Attention Deficit Hyperactivity Disorder (ADHD). She has no other comorbidities or medications. Considering the main expected adverse reactions from taking this medication, which of the following needs to be monitored?\n\n① Hypoglycemia\n② Loss of appetite\n③ Sleep apnea\n④ Hypothyroidism\n⑤ Hypertriglyceridemia",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n33세 남자가 10년 전에 조현병을 진단받고 리스페리돈(risperidone) 경구제와 아리피프라졸(aripiprazole) 경구제를 순차적으로 복용하였으나 증상이 개선되지 않았다. 환자는 아리피프라졸 경구제에 대한 복약이행도가 낮은 것으로 확인되었고, 아리피프라졸(aripiprazole monohydrate) 장기지속형 주사제로 변경하여 투여할 예정이다.\n\n[약물 알레르기] 없음\n\n[현재 복용약물] 아리피프라졸 30 mg 1일 1회 경구투여\n\nQuestion: 아리피프라졸 경구제를 아리피프라졸 장기지속형 주사제로 변경하는 방법으로 적절한 것은?\n\n① 경구제를 중단한 다음 날부터 주사제 단독 사용\n② 경구제를 중단하고 2주 후 주사제 단독 사용\n③ 경구제를 중단하고 6주 후 주사제 단독 사용\n④ 경구제와 주사제를 2주 동안 병용한 후 주사제 단독 사용\n⑤ 경구제와 주사제를 6주 동안 병용한 후 주사제 단독 사용",
        "question_text": "A 33-year-old male was diagnosed with schizophrenia 10 years ago and has sequentially taken oral risperidone and oral aripiprazole, but his symptoms have not improved. The patient was found to have low medication adherence to oral aripiprazole, and it is planned to switch to long-acting injectable aripiprazole monohydrate.\n\n[Drug allergies] None\n\n[Current medication] Aripiprazole 30 mg once daily orally\n\nQuestion: What is the appropriate method for switching from oral aripiprazole to long-acting injectable aripiprazole?\n\n① Use the injectable form alone starting the day after discontinuing the oral form\n② Use the injectable form alone 2 weeks after discontinuing the oral form\n③ Use the injectable form alone 6 weeks after discontinuing the oral form\n④ Use the oral and injectable forms concurrently for 2 weeks, then use the injectable form alone\n⑤ Use the oral and injectable forms concurrently for 6 weeks, then use the injectable form alone",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n33세 남자가 10년 전에 조현병을 진단받고 리스페리돈(risperidone) 경구제와 아리피프라졸(aripiprazole) 경구제를 순차적으로 복용하였으나 증상이 개선되지 않았다. 환자는 아리피프라졸 경구제에 대한 복약이행도가 낮은 것으로 확인되었고, 아리피프라졸(aripiprazole monohydrate) 장기지속형 주사제로 변경하여 투여할 예정이다.\n\n[약물 알레르기] 없음\n\n[현재 복용약물] 아리피프라졸 30 mg 1일 1회 경구투여\n\nQuestion: 환자가 아리피프라졸 장기지속형 주사제를 투여했음에도 불구하고 치료에 반응하지 않아 치료저항성 조현병을 진단받았다. 대체할 약물요법으로 적절한 것은?\n\n① 클로자핀(clozapine)\n② 올란자핀(olanzapine)\n③ 할로페리돌(haloperidol)\n④ 팔리페리돈(paliperidone)\n⑤ 클로자핀+할로페리돌",
        "question_text": "A 33-year-old male was diagnosed with schizophrenia 10 years ago and has sequentially taken oral risperidone and oral aripiprazole, but his symptoms have not improved. The patient was found to have low medication adherence to oral aripiprazole, and it is planned to switch to long-acting injectable aripiprazole monohydrate.\n\n[Drug allergies] None\n\n[Current medication] Aripiprazole 30 mg once daily orally\n\nQuestion: The patient was diagnosed with treatment-resistant schizophrenia after not responding to treatment despite receiving long-acting injectable aripiprazole. Which of the following is an appropriate alternative drug therapy?\n\n① Clozapine\n② Olanzapine\n③ Haloperidol\n④ Paliperidone\n⑤ Clozapine + Haloperidol",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 63세 여자가 6주 전 왼쪽 무릎 통증이 심해 시행한 검사 결과 골관절염을 진단받았다. 환자는 아세트아미노펜(acetaminophen)을 처방받아 매일 아세트아미노펜 최대용량을 복용하였지만, 통증이 크게 감소하지 않았다. 추가할 약물로 적절한 것은?\n\n[활력징후] 혈압 135/82 mmHg, 심박수 70회/분, 호흡수 21회/분, 체질량지수 28.4 kg/m2\n[임상검사] Na 145 mEq/L, K 4.8 mEq/L, CrCl 28 mL/min, AST 32 IU/L, ALT 36 IU/L\n\n① 트라마돌(tramadol)\n② 비타민D(vitamin D)\n③ 둘록세틴(duloxetine)\n④ 셀레콕시브(celecoxib)\n⑤ 디클로페낙(diclofenac)",
        "question_text": "Question: A 63-year-old woman was diagnosed with osteoarthritis after an examination 6 weeks ago due to severe left knee pain. The patient was prescribed acetaminophen and has been taking the maximum daily dose, but the pain has not significantly decreased. Which of the following is an appropriate medication to add?\n\n[Vital Signs] Blood pressure 135/82 mmHg, Heart rate 70 beats/min, Respiratory rate 21 breaths/min, Body Mass Index 28.4 kg/m2\n[Clinical Tests] Na 145 mEq/L, K 4.8 mEq/L, CrCl 28 mL/min, AST 32 IU/L, ALT 36 IU/L\n\n① Tramadol\n② Vitamin D\n③ Duloxetine\n④ Celecoxib\n⑤ Diclofenac",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 34세 여자가 양쪽 손가락마디와 손목에 통증이 있어 시행한 검사 결과 류마티스관절염을 진단받았다. 환자가 임신을 계획하고 있어 히드록시클로로퀸(hydroxychloroquine)으로 치료하고자 한다. 히드록시클로로퀸의 주요 이상반응을 고려할 때 모니터링이 필요한 검사는?\n\n① 안검사\n② 갑상샘기능검사\n③ B형간염항체검사\n④ 인터페론감마분비검사\n⑤ 위식도십이지장내시경검사",
        "question_text": "Question: A 34-year-old woman was diagnosed with rheumatoid arthritis after tests were conducted due to pain in her finger joints and wrists on both hands. As the patient is planning to get pregnant, treatment with hydroxychloroquine is being considered. Considering the major side effects of hydroxychloroquine, which test requires monitoring?\n\n① Eye examination\n② Thyroid function test\n③ Hepatitis B antibody test\n④ Interferon-gamma release assay\n⑤ Esophagogastroduodenoscopy",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 빈맥이 있는 57세 남자가 급성통풍발작이 자주 재발하여 1주 전 예방요법을 시작하였다. 환자는 어제부터 전신에 심한 근육통이 발생했다. 상호작용에 의해 근육병증의 위험을 증가시킨 것으로 의심되는 약물조합은?\n\n[임상검사]\n혈압 123/78 mmHg, 심박수 62회/분\n크레아틴키나아제 2,100 IU/L (참고치 30~200 IU/L)\n[복용약물]\n베라파밀(verapamil)\n콜키신(colchicine)\n알로푸리놀(allopurinol)\n나프록센(naproxen) 필요시\n\n① 콜키신과 베라파밀\n② 콜키신과 나프록센\n③ 콜키신과 알로푸리놀\n④ 베라파밀과 알로푸리놀\n⑤ 나프록센과 알로푸리놀",
        "question_text": "Question: A 57-year-old man with tachycardia started preventive therapy 1 week ago due to frequent recurrence of acute gout attacks. The patient has been experiencing severe muscle pain throughout his body since yesterday. Which drug combination is suspected to have increased the risk of myopathy due to drug interaction?\n\n[Clinical tests]\nBlood pressure 123/78 mmHg, Heart rate 62 beats/min\nCreatine kinase 2,100 IU/L (Reference range 30-200 IU/L)\n[Medications]\nVerapamil\nColchicine\nAllopurinol\nNaproxen as needed\n\n① Colchicine and verapamil\n② Colchicine and naproxen\n③ Colchicine and allopurinol\n④ Verapamil and allopurinol\n⑤ Naproxen and allopurinol",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 배뇨장애와 긴박뇨 증상이 있는 75세 여자가 절박요실금을 진단받았다. 환자의 증상을 개선하기 위해 투여할 약물은?\n\n① 둘록세틴(duloxetin)\n② 에스트로겐(estrogen)\n③ 벤라팍신(venlafaxine)\n④ 솔리페나신(solifenacin)\n⑤ 보툴리눔 독소 A(botulinum toxin A)",
        "question_text": "Question: A 75-year-old woman with urinary difficulties and urinary urgency symptoms has been diagnosed with urge incontinence. Which drug should be administered to improve the patient's symptoms?\n\n① Duloxetine\n② Estrogen\n③ Venlafaxine\n④ Solifenacin\n⑤ Botulinum toxin A",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n60세 남자가 최근 힘을 주어야 소변을 볼 수 있고, 빈뇨와 잔뇨감도 있다고 한다. 검사 결과 양성전립샘비대를 진단받았고, 합병증과 관련한 특이소견은 관찰되지 않았다.\n\n[임상검사] 전립샘 크기 27 mL (참고치 15~20 mL)\n\nQuestion: 이 환자의 양성전립샘비대를 치료하기 위한 적절한 약물은?\n\n① 타다라필(tadalafil)\n② 탐스로신(tamsulosin)\n③ 톨터로딘(tolterodine)\n④ 옥시부티닌(oxybutynin)\n⑤ 두타스테리드(dutasteride)",
        "question_text": "A 60-year-old man reports that he recently needs to strain to urinate, and also experiences frequent urination and a feeling of incomplete bladder emptying. Test results show a diagnosis of benign prostatic hyperplasia, with no specific findings related to complications.\n\n[Clinical test] Prostate size 27 mL (reference range 15-20 mL)\n\nQuestion: What is the appropriate medication to treat this patient's benign prostatic hyperplasia?\n\n① Tadalafil\n② Tamsulosin\n③ Tolterodine\n④ Oxybutynin\n⑤ Dutasteride",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n60세 남자가 최근 힘을 주어야 소변을 볼 수 있고, 빈뇨와 잔뇨감도 있다고 한다. 검사 결과 양성전립샘비대를 진단받았고, 합병증과 관련한 특이소견은 관찰되지 않았다.\n\n[임상검사] 전립샘 크기 27 mL (참고치 15~20 mL)\n\nQuestion: 환자는 4주 동안 처방대로 약을 복용하고 있다. 2주 전부터 밤에 자다가 소변을 보려고 깨는 횟수가 늘어 불편하다고 한다. 증상을 개선하기 위해 추가할 약물은?\n\n① 실데나필(sildenafil)\n② 페소테로딘(fesoterodine)\n③ 피나스테리드(finasteride)\n④ 레보플록사신(levofloxacin)\n⑤ 데스모프레신(desmopressin)",
        "question_text": "A 60-year-old man reports that he recently needs to strain to urinate, and also experiences frequent urination and a feeling of incomplete bladder emptying. Test results show a diagnosis of benign prostatic hyperplasia, with no specific findings related to complications.\n\n[Clinical test] Prostate size 27 mL (reference range 15-20 mL)\n\nQuestion: The patient has been taking medication as prescribed for 4 weeks. He reports that for the past 2 weeks, he has been waking up more frequently at night to urinate, which is causing discomfort. Which drug should be added to improve the symptoms?\n\n① Sildenafil\n② Fesoterodine\n③ Finasteride\n④ Levofloxacin\n⑤ Desmopressin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 이전에 건강하던 28세 남자가 급성골수세포백혈병을 진단받았다. 진단 시 양호예후군으로 확인되어, 표준용량 시타라빈(cytarabine)과 이다루비신(idarubicin)으로 관해유도요법을 받고 완전관해에 도달하였다. 현재 ECOG(Eastern Cooperative Oncology Group) 수행도는 1이다. 적절한 관해 후 치료요법은?\n\n[세포유전학적검사] t(8;21)(q22;q22.1)\n[분자학적검사] 변이 없음\n\n① 고용량 시타라빈\n② 삼산화비소(arsenic trioxide)+이다루비신\n③ 베네토클락스(venetoclax)+아자시티딘(azacitidine)\n④ 미톡산트론(mitoxantrone)+클라드리빈(cladribine)+시타라빈\n⑤ 시타라빈+다우노루비신(daunorubicin)+미도스타우린(midostaurin)",
        "question_text": "Question: A previously healthy 28-year-old man was diagnosed with acute myeloid leukemia. At diagnosis, he was identified as having a favorable prognosis and achieved complete remission after receiving induction therapy with standard-dose cytarabine and idarubicin. His current ECOG (Eastern Cooperative Oncology Group) performance status is 1. What is the appropriate post-remission therapy?\n\n[Cytogenetic test] t(8;21)(q22;q22.1)\n[Molecular test] No mutations\n\n① High-dose cytarabine\n② Arsenic trioxide + idarubicin\n③ Venetoclax + azacitidine\n④ Mitoxantrone + cladribine + cytarabine\n⑤ Cytarabine + daunorubicin + midostaurin",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 32세 여자가 만성기 만성골수세포백혈병을 진단받고, 3주 전부터 이매티닙(imatinib) 400 mg을 1일 1회 복용하였다. Bcr-abl 키나아제 도메인에 돌연변이는 없다. 오늘 혈액검사 결과, 환자의 혈구수치가 치료 전보다 현저히 감소하였다. 이매티닙의 혈액학적 독성이 의심될 때, 적절한 조치는?\n\n[혈액검사] 백혈구 3,100/mm3, 혈색소(Hgb) 9.8 g/dL, 혈소판 39,000/mm3\n\n① 이매티닙 일시 중단\n② 덱사메타손(dexamethasone) 투여\n③ 히드록시우레아(hydroxyurea) 투여\n④ 다베포에틴알파(darbepoetin alfa) 투여\n⑤ 이매티닙을 포나티닙(ponatinib)으로 변경",
        "question_text": "Question: A 32-year-old woman was diagnosed with chronic-phase chronic myeloid leukemia and has been taking imatinib 400 mg once daily for 3 weeks. There is no mutation in the Bcr-abl kinase domain. Today's blood test results show that the patient's blood cell counts have significantly decreased compared to pre-treatment levels. When hematologic toxicity of imatinib is suspected, what is the appropriate action?\n\n[Blood test] White blood cells 3,100/mm3, Hemoglobin (Hgb) 9.8 g/dL, Platelets 39,000/mm3\n\n① Temporarily discontinue imatinib\n② Administer dexamethasone\n③ Administer hydroxyurea\n④ Administer darbepoetin alfa\n⑤ Switch imatinib to ponatinib",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 이전에 건강했던 68세 여자가 호르몬수용체(hormone receptor, HR) 양성 1기 유방암을 진단받았다. 환자는 수술을 받은 후에 5년 동안 레트로졸(letrozole)을 복용할 예정이다. 이 약의 주요 이상반응을 고려할 때, 복용기간 동안 모니터링이 필요한 검사는?\n\n① 청력검사\n② 골밀도검사\n③ 대변잠혈검사\n④ 요소호기검사\n⑤ 투베르쿨린피부반응검사",
        "question_text": "Question: A previously healthy 68-year-old woman was diagnosed with hormone receptor (HR) positive stage 1 breast cancer. The patient is scheduled to take letrozole for 5 years after surgery. Considering the main adverse effects of this drug, which test should be monitored during the treatment period?\n\n① Hearing test\n② Bone density test\n③ Fecal occult blood test\n④ Urea breath test\n⑤ Tuberculin skin test",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 고혈압이 있는 63세 남자가 4기 비소세포폐암(대세포암)을 진단받았다. ECOG(Eastern Cooperative Oncology Group) 수행도는 1이다. 검사 결과가 다음과 같을 때, 적절한 1차 항암요법은?\n\n[조직검사] ALK 재배열 음성, EGFR 변이 음성, BRAF V600E 변이 양성, ROS1 재배열 음성, 그 외 관련 분자학적 검사 결과 모두 음성, PD-L1 발현율 0%\n\n① 브리가티닙(brigatinib)\n② 엔트렉티닙(entrectinib)\n③ 오시머티닙(osimertinib)\n④ 엘로티닙(erlotinib)+라무시루맙(ramucirumab)\n⑤ 다브라페닙(dabrafenib)+트라메티닙(trametinib)",
        "question_text": "Question: A 63-year-old man with hypertension has been diagnosed with stage IV non-small cell lung cancer (large cell carcinoma). His ECOG (Eastern Cooperative Oncology Group) performance status is 1. Given the following test results, what is the appropriate first-line chemotherapy?\n\n[Tissue biopsy] ALK rearrangement negative, EGFR mutation negative, BRAF V600E mutation positive, ROS1 rearrangement negative, all other relevant molecular test results negative, PD-L1 expression 0%\n\n① Brigatinib\n② Entrectinib\n③ Osimertinib\n④ Erlotinib + Ramucirumab\n⑤ Dabrafenib + Trametinib",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 3기 결장암이 있는 56세 여자가 결장병변 절제수술을 받았다. 고혈압 이외 다른 병력은 없고, ECOG(Eastern Cooperative Oncology Group) 수행도는 0이다. 수술 후 권고되는 1차 보조항암화학요법으로 적절한 것은?\n\n① 베바시주맙(bevacizumab)\n② 트리플루리딘/티피라실(trifluridine/tipiracil)\n③ 카페시타빈(capecitabine)+이리노테칸(irinotecan)\n④ 플루오로우라실(fluorouracil)+류코보린(leucovorin)+이리노테칸\n⑤ 플루오로우라실+류코보린+옥살리플라틴(oxaliplatin)",
        "question_text": "Question: A 56-year-old woman with stage III colon cancer underwent surgical resection of the colonic lesion. She has no other medical history except for hypertension, and her ECOG (Eastern Cooperative Oncology Group) performance status is 0. Which of the following is the appropriate first-line adjuvant chemotherapy recommended after surgery?\n\n① Bevacizumab\n② Trifluridine/tipiracil\n③ Capecitabine + Irinotecan\n④ Fluorouracil + Leucovorin + Irinotecan\n⑤ Fluorouracil + Leucovorin + Oxaliplatin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 53세 남자가 4기 대장암 치료를 위해 지브-애플리버셉트(ziv-aflibercept)가 포함된 항암화학요법을 받을 예정이다. 이 약의 사용으로 인해 예상되는 주요 이상반응을 고려할 때, 모니터링이 필요한 검사는?\n\n① 청력\n② 혈압\n③ 공복혈당\n④ 1초간강제호기량\n⑤ 갑상샘자극호르몬",
        "question_text": "Question: A 53-year-old man is scheduled to receive chemotherapy including ziv-aflibercept for the treatment of stage 4 colon cancer. Considering the major adverse reactions expected from the use of this drug, which test needs to be monitored?\n\n① Hearing\n② Blood pressure\n③ Fasting blood glucose\n④ Forced expiratory volume in 1 second (FEV1)\n⑤ Thyroid-stimulating hormone",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n폐경이 된 60세 여자가 4기 유방암을 진단받았다. 이상지질혈증 외에 다른 병력은 없고, 조직검사 결과는 다음과 같다.\n\n[조직검사]\n호르몬수용체(hormone receptor, HR) 음성\n사람표피성장인자수용체2(human epidermal growth factor receptor 2, HER2) 양성\n\nQuestion: 1차 항암화학요법으로 적절한 것은?\n\n① 팔보시클립(palbociclib)\n② 풀베스트란트(fulvestrant)\n③ 라파티닙(lapatinib)+엑스메스탄(exemestane)\n④ 퍼투주맙(pertuzumab)+파클리탁셀(paclitaxel)\n⑤ 퍼투주맙+트라스투주맙(trastuzumab)+도세탁셀(docetaxel)",
        "question_text": "A 60-year-old postmenopausal woman was diagnosed with stage 4 breast cancer. She has no other medical history except for dyslipidemia. The biopsy results are as follows:\n\n[Biopsy]\nHormone receptor (HR) negative\nHuman epidermal growth factor receptor 2 (HER2) positive\n\nQuestion: Which of the following is the most appropriate first-line chemotherapy?\n\n① Palbociclib\n② Fulvestrant\n③ Lapatinib + Exemestane\n④ Pertuzumab + Paclitaxel\n⑤ Pertuzumab + Trastuzumab + Docetaxel",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n폐경이 된 60세 여자가 4기 유방암을 진단받았다. 이상지질혈증 외에 다른 병력은 없고, 조직검사 결과는 다음과 같다.\n\n[조직검사]\n호르몬수용체(hormone receptor, HR) 음성\n사람표피성장인자수용체2(human epidermal growth factor receptor 2, HER2) 양성\n\nQuestion: 오늘 1차 항암화학요법을 시작하였다. 항암제 투여 전에 온단세트론(ondansetron)을 복용하였지만, 돌발성 구토가 발생하였다. 환자의 구토를 완화하기 위해 투여할 수 있는 약물은?\n\n① 바클로펜(baclofen)\n② 레바미피드(rebamipide)\n③ 미소프로스톨(misoprostol)\n④ 메토클로프라미드(metoclopramide)\n⑤ 디옥타헤드랄스멕타이트(dioctahedral smectite)",
        "question_text": "A 60-year-old postmenopausal woman was diagnosed with stage 4 breast cancer. She has no other medical history except for dyslipidemia. The results of her biopsy are as follows:\n\n[Biopsy]\nHormone receptor (HR) negative\nHuman epidermal growth factor receptor 2 (HER2) positive\n\nQuestion: The patient started her first chemotherapy session today. Despite taking ondansetron before the administration of chemotherapy drugs, she experienced breakthrough vomiting. Which of the following medications can be administered to alleviate the patient's vomiting?\n\n① Baclofen\n② Rebamipide\n③ Misoprostol\n④ Metoclopramide\n⑤ Dioctahedral smectite",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 35세 여자가 최근 얼굴에 여드름이 심해졌다. 뺨과 턱에 염증성 여드름이 10개 정도 관찰되고 결절과 흉터는 없다. 임신을 계획하고 있을 때, 적절한 약물요법은?\n\n① 아시트레틴(acitretin) 경구제\n② 독시사이클린(doxycycline) 경구제\n③ 칼시포트리올(calcipotriol) 국소제+살리실산(salicylic acid) 국소제\n④ 과산화벤조일(benzoyl peroxide) 국소제+아젤라산(azelaic acid) 국소제\n⑤ 이소트레티노인(isotretinoin) 경구제+클린다마이신(clindamycin) 국소제",
        "question_text": "Question: A 35-year-old woman has recently experienced worsening acne on her face. About 10 inflammatory acne lesions are observed on her cheeks and chin, with no nodules or scars. When she is planning to get pregnant, what is the appropriate drug therapy?\n\n① Oral acitretin\n② Oral doxycycline\n③ Topical calcipotriol + topical salicylic acid\n④ Topical benzoyl peroxide + topical azelaic acid\n⑤ Oral isotretinoin + topical clindamycin",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 56세 남자가 최근 오른쪽 눈이 뿌옇게 보이고 시력이 저하되는 증상이 나타났다. 검사 결과 안압이 25 mmHg로 개방각녹내장을 진단받았을 때, 적절한 약물요법은?\n\n① 티몰롤(timolol) 점안제 1일 2회\n② 아트로핀(atropine) 점안제 1일 3회\n③ 필로카르핀(pilocarpine) 점안제 1일 1회\n④ 타플루프로스트(tafluprost) 점안제 1일 3회\n⑤ 플루오로메톨론(fluorometholone) 점안제 1일 2회",
        "question_text": "Question: A 56-year-old man recently experienced blurred vision and decreased visual acuity in his right eye. Upon examination, his intraocular pressure was found to be 25 mmHg, and he was diagnosed with open-angle glaucoma. What is the appropriate drug therapy?\n\n① Timolol eye drops twice daily\n② Atropine eye drops three times daily\n③ Pilocarpine eye drops once daily\n④ Tafluprost eye drops three times daily\n⑤ Fluorometholone eye drops twice daily",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 정맥영양액을 조제하려고 할 때, 인(P)과의 반응으로 인한 침전물 생성 위험을 최소화 할 수 있는 칼슘제는?\n\n① 염화칼슘(calcium chloride)\n② 락트산칼슘(calcium lactate)\n③ 시트르산칼슘(calcium citrate)\n④ 아세트산칼슘(calcium acetate)\n⑤ 글루콘산칼슘(calcium gluconate)",
        "question_text": "Question: When preparing intravenous nutrition solution, which calcium preparation can minimize the risk of precipitate formation due to reaction with phosphorus (P)?\n\n① Calcium chloride\n② Calcium lactate\n③ Calcium citrate\n④ Calcium acetate\n⑤ Calcium gluconate",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 마약류통합관리시스템의 중점관리대상 의약품에 해당하는 약물은?\n\n① 프로포폴(propofol)\n② 레보도파(levodopa)\n③ 트라마돌(tramadol)\n④ 플루옥세틴(fluoxetine)\n⑤ 리스페리돈(risperidone)",
        "question_text": "Question: Which of the following drugs is considered a priority-controlled substance in the Integrated Narcotics Management System?\n\n① Propofol\n② Levodopa\n③ Tramadol\n④ Fluoxetine\n⑤ Risperidone",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 당뇨병신장병증을 동반한 2형당뇨병이 있는 65세 남자가 메트포르민(metformin) 1,000 mg 서방정을 1일 1회 복용하는 처방전을 처음으로 받았다. 이 환자의 처방전을 검토할 때 메트포르민 투여와 관련하여 확인이 필요한 임상검사는?\n\n① 당부하검사\n② 적혈구용적률\n③ 사구체여과율\n④ 젖산 탈수소효소\n⑤ 크레아틴키나아제",
        "question_text": "Question: A 65-year-old man with type 2 diabetes accompanied by diabetic nephropathy received a prescription for the first time to take metformin 1,000 mg extended-release tablet once daily. When reviewing this patient's prescription, which clinical test needs to be checked in relation to metformin administration?\n\n① Glucose tolerance test\n② Hematocrit\n③ Glomerular filtration rate\n④ Lactate dehydrogenase\n⑤ Creatine kinase",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 의료기관의 다음과 같은 약물사용평가(medication use evaluation, MUE) 업무를 수행 순서대로 나열한 것은?\n\n가. 개선방안 수립과 적용\n나. 데이터 수집과 분석\n다. 의약품사용평가 주제 선정\n라. 평가기준과 평가지표의 개발\n\n① 나 → 가 → 다 → 라\n② 나 → 다 → 라 → 가\n③ 다 → 나 → 가 → 라\n④ 다 → 라 → 나 → 가\n⑤ 라 → 나 → 가 → 다",
        "question_text": "Question: Which of the following lists the steps of medication use evaluation (MUE) in a healthcare institution in the correct order?\n\na. Develop and implement improvement strategies\nb. Collect and analyze data\nc. Select the topic for medication use evaluation\nd. Develop evaluation criteria and indicators\n\n① b → a → c → d\n② b → c → d → a\n③ c → b → a → d\n④ c → d → b → a\n⑤ d → b → a → c",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 10세 남자의 보호자가 처방전과 다음 보조기구를 가지고 와서 사용법을 문의하였다. 이 보조기구를 사용하는 약의 제형은?\n\n<Data (confidential)>\n\n① 점비액(nasal drop)\n② 비강분무제(nasal spray)\n③ 연무기 앰풀(nebulizer ampule)\n④ 건조분말흡입제(dry powder inhaler)\n⑤ 정량식흡입제(metered dose inhaler)",
        "question_text": "Question: A guardian of a 10-year-old boy brought a prescription and the following auxiliary device, asking about its usage. What is the dosage form of the medication used with this device?\n\n<Data (confidential)>\n\n① Nasal drop\n② Nasal spray\n③ Nebulizer ampule\n④ Dry powder inhaler\n⑤ Metered dose inhaler",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 68세 환자가 고혈압, 이상지질혈증, 골다공증 치료와, 관상동맥질환 예방을 위하여 다음 처방을 받았다. 투여간격과 복용시간에서 수정이 필요한 약물은?\n\n| 의약품 명칭 | 1회 투약량 | 투여 간격 | 복용 시간 |\n|---|---|---|---|\n| 암로디핀(amlodipine) 10 mg 정 | 1정 | 1일 1회 | 아침 |\n| 아스피린(aspirin) 100 mg 캡슐 | 1캡슐 | 1일 1회 | 아침 |\n| 이반드론산(ibandronate) 150 mg 정 | 1정 | 1개월에 | 1회 | 아침 공복 |\n| 아토르바스타틴(atorvastatin) 10 mg 정 | 1정 | 1일 1회 | 아침 |\n| 푸로세미드(furosemide) 40 mg 정 | 1정 | 1일 1회 | 취침전 |\n\n① 암로디핀\n② 아스피린\n③ 이반드론산\n④ 아토르바스타틴\n⑤ 푸로세미드",
        "question_text": "Question: A 68-year-old patient received the following prescription for the treatment of hypertension, dyslipidemia, osteoporosis, and prevention of coronary artery disease. Which medication needs modification in terms of dosing interval and administration time?\n\n| Medication Name | Single Dose | Dosing Interval | Administration Time |\n|---|---|---|---|\n| Amlodipine 10 mg tablet | 1 tablet | Once daily | Morning |\n| Aspirin 100 mg capsule | 1 capsule | Once daily | Morning |\n| Ibandronate 150 mg tablet | 1 tablet | Once a month | Morning on empty stomach |\n| Atorvastatin 10 mg tablet | 1 tablet | Once daily | Morning |\n| Furosemide 40 mg tablet | 1 tablet | Once daily | Before bedtime |\n\n① Amlodipine\n② Aspirin\n③ Ibandronate\n④ Atorvastatin\n⑤ Furosemide",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 와파린(warfarin)을 복용하는 환자가 다음 처방을 처음으로 받았다. 와파린과의 상호작용을 고려할 때 와파린의 용량 조절이 필요한 약물은?\n\n| 의약품 명칭 | 1회 투약량 | 1일 투여횟수 |\n| 가바펜틴(gabapentin) 100 mg | 1캡슐 | 3 |\n| 아미오다론(amiodarone) 200 mg | 1정 | 3 |\n| 알마게이트(almagate) 500 mg | 2정 | 3 |\n| 푸로세미드(furosemide) 40 mg | 1정 | 1 |\n| 스피로노락톤(spironolactone) 25 mg | 1정 | 1 |\n\n① 가바펜틴\n② 아미오다론\n③ 알마게이트\n④ 푸로세미드\n⑤ 스피로노락톤",
        "question_text": "Question: A patient taking warfarin has received the following prescription for the first time. Considering the interaction with warfarin, which drug requires dose adjustment of warfarin?\n\n| Drug Name | Dose per Administration | Frequency per Day |\n| Gabapentin 100 mg | 1 capsule | 3 |\n| Amiodarone 200 mg | 1 tablet | 3 |\n| Almagate 500 mg | 2 tablets | 3 |\n| Furosemide 40 mg | 1 tablet | 1 |\n| Spironolactone 25 mg | 1 tablet | 1 |\n\n① Gabapentin\n② Amiodarone\n③ Almagate\n④ Furosemide\n⑤ Spironolactone",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 약사는 다음 처방에 대하여 고단백질 식사와 함께 복용하는 것을 피하도록 환자에게 설명하고자 한다. 이러한 설명이 필요한 약물은?\n\n| 의약품 명칭 | 1회 투약량 | 1일 투여횟수 |\n|---|---|---|\n| 아토르바스타틴(atorvastatin) 10 mg | 1정 | 1 |\n| 클로자핀(clozapine) 200 mg | 1정 | 2 |\n| 카르바마제핀(carbamazepine) CR 200 mg | 1정 | 2 |\n| 펠로디핀(felodipine) SR 10 mg | 1정 | 1 |\n| 레보도파/카르비도파(levodopa/carbidopa) CR 200/50 mg | 1정 | 3 |\n\n① 클로자핀\n② 펠로디핀\n③ 카르바마제핀\n④ 아토르바스타틴\n⑤ 레보도파/카르비도파",
        "question_text": "Question: The pharmacist wants to explain to the patient that they should avoid taking the following prescription with a high-protein meal. Which drug requires this explanation?\n\n| Drug Name | Dosage per Administration | Frequency per Day |\n|---|---|---|\n| Atorvastatin 10 mg | 1 tablet | 1 |\n| Clozapine 200 mg | 1 tablet | 2 |\n| Carbamazepine CR 200 mg | 1 tablet | 2 |\n| Felodipine SR 10 mg | 1 tablet | 1 |\n| Levodopa/Carbidopa CR 200/50 mg | 1 tablet | 3 |\n\n① Clozapine\n② Felodipine\n③ Carbamazepine\n④ Atorvastatin\n⑤ Levodopa/Carbidopa",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 수막내투여(intrathecal administration)를 하면 치명적인 신경독성이 발생하므로, 수막내투여를 하지 않고 반드시 정맥으로만 투여해야 하는 약물은?\n\n① 시타라빈(cytarabine)\n② 빈크리스틴(vincristine)\n③ 메토트렉세이트(methotrexate)\n④ 히드로코르티손(hydrocortisone)\n⑤ 리포좀화시타라빈(liposomal cytarabine)",
        "question_text": "Question: Which drug must be administered only intravenously and never intrathecally, as intrathecal administration can cause fatal neurotoxicity?\n\n① Cytarabine\n② Vincristine\n③ Methotrexate\n④ Hydrocortisone\n⑤ Liposomal cytarabine",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n심혈관질환 가족력이 있는 60세 남자가 본태고혈압과 이상지질혈증을 치료하기 위해 다음 처방 약물을 복용하고 있다.\n\n| 의약품 명칭 | 1회 투약량 | 1일 투여횟수 |\n| 암로디핀(amlodipine) 5 mg | 1정 | 1 |\n| 발사르탄(valsartan) 40 mg | 1정 | 1 |\n| 심바스타틴(simvastatin) 40 mg | 1정 | 1 |\n| 아스피린(aspirin) 100 mg | 1정 | 1 |\n| 오메가3산에틸에스테르90(omega-3-acids ethyl esters 90) 1,000 mg | 2캡슐 | 2 |\n\nQuestion: 환자에게 심한 부비동염이 발생하여 처방된 클래리트로마이신(clarithromycin)에 대한 의약품안심서비스를 점검한 결과 병용금기 경고가 나왔다. 클래리트로마이신과 병용금기인 약물은?\n\n① 발사르탄\n② 아스피린\n③ 암로디핀\n④ 심바스타틴\n⑤ 오메가3산에틸에스테르90",
        "question_text": "A 60-year-old man with a family history of cardiovascular disease is taking the following prescribed medications to treat essential hypertension and dyslipidemia:\n\n| Medication Name | Dose per Administration | Frequency per Day |\n| Amlodipine 5 mg | 1 tablet | 1 |\n| Valsartan 40 mg | 1 tablet | 1 |\n| Simvastatin 40 mg | 1 tablet | 1 |\n| Aspirin 100 mg | 1 tablet | 1 |\n| Omega-3-acids ethyl esters 90 1,000 mg | 2 capsules | 2 |\n\nQuestion: The patient developed severe sinusitis and was prescribed clarithromycin. Upon checking the drug safety service, a contraindication warning appeared. Which of the following drugs is contraindicated with clarithromycin?\n\n① Valsartan\n② Aspirin\n③ Amlodipine\n④ Simvastatin\n⑤ Omega-3-acids ethyl esters 90",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n심혈관질환 가족력이 있는 60세 남자가 본태고혈압과 이상지질혈증을 치료하기 위해 다음 처방 약물을 복용하고 있다.\n\n| 의약품 명칭 | 1회 투약량 | 1일 투여횟수 |\n| 암로디핀(amlodipine) 5 mg | 1정 | 1 |\n| 발사르탄(valsartan) 40 mg | 1정 | 1 |\n| 심바스타틴(simvastatin) 40 mg | 1정 | 1 |\n| 아스피린(aspirin) 100 mg | 1정 | 1 |\n| 오메가3산에틸에스테르90(omega-3-acids ethyl esters 90) 1,000 mg | 2캡슐 | 2 |\n\nQuestion: 의사가 이 환자의 관상동맥질환 1차예방을 위한 항혈전요법으로 클로피도그렐(clopidogrel)의 추가 투여가 필요한지에 관하여 약사에게 문의하였다. 약사는 정보 제공을 위하여 PICO를 작성하였다. 적절히 작성된 것은?\n\n① P: 관상동맥 질환이 있는 환자\n② I : 아스피린 투여\n③ I : 클로피도그렐 투여\n④ C: 아스피린 투여\n⑤ C: 클로피도그렐 투여",
        "question_text": "A 60-year-old man with a family history of cardiovascular disease is taking the following prescribed medications to treat essential hypertension and dyslipidemia:\n\n| Medication Name | Dose per Administration | Frequency per Day |\n| Amlodipine 5 mg | 1 tablet | 1 |\n| Valsartan 40 mg | 1 tablet | 1 |\n| Simvastatin 40 mg | 1 tablet | 1 |\n| Aspirin 100 mg | 1 tablet | 1 |\n| Omega-3-acids ethyl esters 90, 1,000 mg | 2 capsules | 2 |\n\nQuestion: The doctor asked the pharmacist whether additional administration of clopidogrel is necessary for primary prevention of coronary artery disease in this patient. The pharmacist prepared a PICO to provide information. Which of the following is appropriately formulated?\n\n① P: Patients with coronary artery disease\n② I: Aspirin administration\n③ I: Clopidogrel administration\n④ C: Aspirin administration\n⑤ C: Clopidogrel administration",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 남자가 비소세포폐암 수술을 받은 후 다음 항암화학 요법을 시작하고자 한다. 환자에게 다른 동반질환은 없다.\n파클리탁셀(paclitaxel) 200 mg/m2 D1\n카르보플라틴(carboplatin) AUC6 D1\n21일마다 4주기 투여\n\nQuestion: 이 항암화학요법의 이상반응을 예방하기 위한 전처치요법에 포함될 약물은?\n\n① 메스나(mesna)\n② 폴산(folic acid)\n③ 류코보린(leucovorin)\n④ 아미포스틴(amifostine)\n⑤ 클로르페니라민(chlorpheniramine)",
        "question_text": "A 58-year-old man is about to start the following chemotherapy regimen after surgery for non-small cell lung cancer. The patient has no other comorbidities.\nPaclitaxel 200 mg/m2 D1\nCarboplatin AUC6 D1\nAdministered every 21 days for 4 cycles\n\nQuestion: Which drug should be included in the premedication regimen to prevent adverse reactions to this chemotherapy?\n\n① Mesna\n② Folic acid\n③ Leucovorin\n④ Amifostine\n⑤ Chlorpheniramine",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n58세 남자가 비소세포폐암 수술을 받은 후 다음 항암화학 요법을 시작하고자 한다. 환자에게 다른 동반질환은 없다.\n파클리탁셀(paclitaxel) 200 mg/m2 D1\n카르보플라틴(carboplatin) AUC6 D1\n21일마다 4주기 투여\n\nQuestion: 이 환자의 카르보플라틴 용량을 계산하는 데에 필요한 정보는?\n\n① 간기능\n② 사구체여과율\n③ 카르보플라틴의 분자량\n④ 카르보플라틴의 반감기\n⑤ 카르보플라틴의 분포용적",
        "question_text": "A 58-year-old male is about to start the following chemotherapy regimen after surgery for non-small cell lung cancer. The patient has no other comorbidities.\nPaclitaxel 200 mg/m2 D1\nCarboplatin AUC6 D1\nAdministered every 21 days for 4 cycles\n\nQuestion: What information is necessary to calculate the carboplatin dose for this patient?\n\n① Liver function\n② Glomerular filtration rate\n③ Molecular weight of carboplatin\n④ Half-life of carboplatin\n⑤ Volume of distribution of carboplatin",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 주사제를 조제할 때, 최종 희석할 수액으로 5% 포도당\n주사액은 사용할 수 없고 생리식염 주사액을 사용하는 약물은?\n\n① 시스플라틴(cisplatin)\n② 이리노테칸(irinotecan)\n③ 에토포시드(etoposide)\n④ 파클리탁셀(paclitaxel)\n⑤ 플루오로우라실(fluorouracil)",
        "question_text": "Question: When preparing an injectable medication, which drug cannot use 5% dextrose injection as the final dilution solution and must use normal saline injection instead?\n\n① Cisplatin\n② Irinotecan\n③ Etoposide\n④ Paclitaxel\n⑤ Fluorouracil",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 아미오다론(amiodarone)을 복용하는 75세 여자에게 체중감소, 손떨림, 설사, 더위에 민감하고 땀을 흘리는 등 이상반응 증상이 발생하였다. 이상반응 확인을 위하여 필요한 모니터링 항목은?\n\n① 혈중 백혈구 수치\n② 혈중 빌리루빈 농도\n③ 혈중 총콜레스테롤 농도\n④ 혈중 갑상샘자극호르몬 농도\n⑤ 혈중 알라닌아미노전달효소(ALT) 농도",
        "question_text": "Question: A 75-year-old woman taking amiodarone experienced adverse reactions such as weight loss, hand tremors, diarrhea, sensitivity to heat, and sweating. Which monitoring parameter is necessary to check for these adverse reactions?\n\n① Blood white blood cell count\n② Blood bilirubin concentration\n③ Blood total cholesterol concentration\n④ Blood thyroid-stimulating hormone (TSH) concentration\n⑤ Blood alanine aminotransferase (ALT) concentration",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 45세 남자에게 반코마이신(vancomycin) 1,250 mg을 정맥주입하고자 한다. 레드맨증후군 발생을 예방하는 방법은?\n\n① 24시간 간격으로 투여\n② 90분에 걸쳐 천천히 주입\n③ 주사 전 생리식염수 투여\n④ 주사 전 비타민 B12 투여\n⑤ 덱스라족산(dexrazoxane) 동시 투여",
        "question_text": "Question: A 1,250 mg dose of vancomycin is to be administered intravenously to a 45-year-old man. What is the method to prevent the occurrence of Red Man Syndrome?\n\n① Administer at 24-hour intervals\n② Infuse slowly over 90 minutes\n③ Administer normal saline before injection\n④ Administer vitamin B12 before injection\n⑤ Co-administer dexrazoxane",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: ‘의약품 등을 정상적으로 투여 또는 사용할 때 발생하는, 유해하고 의도하지 아니한 반응으로서 해당 의약품 등과의 인과관계를 배제할 수 없는 경우’를 의미하는 용어는?\n\n① 부작용\n② 이상사례\n③ 약화사고\n④ 약물이상반응\n⑤ 의약품사용과오",
        "question_text": "Question: What is the term that means 'a harmful and unintended reaction that occurs when a pharmaceutical product is administered or used normally, where a causal relationship with the pharmaceutical product cannot be ruled out'?\n\n① Side effect\n② Adverse event\n③ Drug-related accident\n④ Adverse drug reaction\n⑤ Medication error",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 안압이 잘 조절되지 않는 폐쇄각녹내장 환자가 사용할 경우, 녹내장 증상이 악화되는 이상반응이 발생할 수 있으므로, 사용을 삼가거나 사용 중 녹내장 증상 발현을 모니터링해야 하는 약은?\n\n① 트라마돌(tramadol) 정\n② 메트포르민(metformin) 정\n③ 독사조신(doxazosin) 정\n④ 톨터로딘(tolterodine) 정\n⑤ 포르모테롤(formoterol) 정",
        "question_text": "Question: Which medication should be avoided or used with careful monitoring of glaucoma symptoms in patients with poorly controlled closed-angle glaucoma, as it may worsen glaucoma symptoms as an adverse effect?\n\n① Tramadol tablets\n② Metformin tablets\n③ Doxazosin tablets\n④ Tolterodine tablets\n⑤ Formoterol tablets",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 관상동맥질환의 병력이 있는 환자가 사용할 경우 관상동맥질환 증상이 악화될 가능성이 있어 주의해야 하는 일반의약품 유효성분은?\n\n① 세티리진(cetirizine)\n② 독시라민(doxylamine)\n③ 알벤다졸(albendazole)\n④ 니푸록사지드(nifuroxazide)\n⑤ 슈도에페드린(pseudoephedrine)",
        "question_text": "Question: Which active ingredient in over-the-counter medications should be used with caution in patients with a history of coronary artery disease, as it may potentially worsen the symptoms of coronary artery disease?\n\n① Cetirizine\n② Doxylamine\n③ Albendazole\n④ Nifuroxazide\n⑤ Pseudoephedrine",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 복용 후 12시간 이내 복통이 발생할 수 있으며, 1주일 이상 복용할 경우 반동성 변비가 발생할 수 있는 약물은?\n\n① 락티톨(lactitol)\n② 비사코딜(bisacodyl)\n③ 도큐세이트(docusate)\n④ 로페라미드(loperamide)\n⑤ 차전자피(psyllium husk)",
        "question_text": "Question: Which drug can cause abdominal pain within 12 hours after ingestion and may lead to rebound constipation if taken for more than a week?\n\n① Lactitol\n② Bisacodyl\n③ Docusate\n④ Loperamide\n⑤ Psyllium husk",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 배란진단테스트기를 구매하는 고객에게 알려줄 내용은?\n\n① 반드시 아침 첫소변을 사용함\n② 피임이 주된 목적인 경우, 사용하는 것이 바람직함\n③ 예상배란 3~4일 전부터 매일 검사결과지를 모아 색 진하기를 비교해 평가함\n④ 판독선의 색이 대조선의 색보다 연해지기 시작한 날부터 3일간이 가임최적기임\n⑤ 생리기간이 불규칙한 경우, 최근 3번의 주기 중 가장 긴 주기를 기준으로 검사시작일을 정함",
        "question_text": "Question: What information should be given to customers purchasing an ovulation test kit?\n\n① Always use the first morning urine\n② It is advisable to use if the main purpose is contraception\n③ Collect test results daily starting 3-4 days before expected ovulation and compare the color intensity\n④ The 3 days starting from when the test line color begins to become lighter than the control line is the optimal fertility period\n⑤ For irregular menstrual cycles, determine the test start date based on the longest cycle among the most recent 3 cycles",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n30세 남자가 끈적이는 가래와 기침 증상이 있어 약국을 방문하였다. 환자에게 다른 동반질환은 없다.\n\nQuestion: 이 환자에게 적절한 일반의약품 유효성분은?\n\n① 피록시캄(piroxicam)\n② 알마게이트(almagate)\n③ 로페라미드(loperamide)\n④ 플루벤다졸(flubendazole)\n⑤ 구아이페네신(guaifenesin)",
        "question_text": "A 30-year-old male visited a pharmacy with symptoms of sticky phlegm and cough. The patient has no other accompanying diseases.\n\nQuestion: Which of the following active ingredients in over-the-counter medications is most appropriate for this patient?\n\n① Piroxicam\n② Almagate\n③ Loperamide\n④ Flubendazole\n⑤ Guaifenesin",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n30세 남자가 끈적이는 가래와 기침 증상이 있어 약국을 방문하였다. 환자에게 다른 동반질환은 없다.\n\nQuestion: 이 환자에게 적절한 한약제제는?\n\n① 복령음(茯笭飮)\n② 연라환(連蘿丸)\n③ 오림산(五淋散)\n④ 맥문동탕(麥門冬湯)\n⑤ 소시호탕(小柴胡湯)",
        "question_text": "A 30-year-old male visited the pharmacy with symptoms of sticky phlegm and cough. The patient has no other accompanying diseases.\n\nQuestion: Which of the following herbal preparations is appropriate for this patient?\n\n① Bokryeong-eum (Poria Decoction)\n② Yeollahwan (Coptis and Scutellaria Pill)\n③ Orim-san (Five-Dysuria Powder)\n④ Maengmundong-tang (Ophiopogon Decoction)\n⑤ Sosiho-tang (Minor Bupleurum Decoction)",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 소아 환자의 감염증 치료를 위한 아목시실린/클라불란산 함유 건조시럽을 처방에 따라 조제하여 투약하였다. 조제한 건조시럽액의 안정성을 고려할 때 권장되는 보관 조건과 보관 기간은?\n\n① 상온, 7일\n② 상온, 14일\n③ 냉장, 7일\n④ 냉장, 10일\n⑤ 냉장, 14일",
        "question_text": "Question: A dry syrup containing amoxicillin/clavulanic acid was prepared and dispensed according to the prescription for treating an infection in a pediatric patient. Considering the stability of the reconstituted dry syrup, what are the recommended storage conditions and storage period?\n\n① Room temperature, 7 days\n② Room temperature, 14 days\n③ Refrigerated, 7 days\n④ Refrigerated, 10 days\n⑤ Refrigerated, 14 days",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 스피로노락톤(spironolactone)을 복용할 남자에게 이상반응과 관련하여 설명할 내용은?\n\n① 여성형유방이 나타날 수 있음\n② 이상반응 감소를 위하여 저녁에 투여함\n③ 전해질 불균형을 해소하기 위해 저염식이를 할 수 있음\n④ 투여 초기에 소변량 및 소변 횟수가 증가하면 즉시 중단함\n⑤ 체내 칼륨 소실이 심해지므로 칼륨을 많이 함유한 식품을 섭취함",
        "question_text": "Question: What should be explained to a man who is going to take spironolactone regarding side effects?\n\n① Gynecomastia may occur\n② It is administered in the evening to reduce side effects\n③ A low-salt diet can be followed to resolve electrolyte imbalance\n④ If urine volume and frequency increase at the beginning of treatment, discontinue immediately\n⑤ Consume foods high in potassium as potassium loss in the body becomes severe",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 펜타닐(fentanyl) 패치제 처방을 받은 환자에게 약의 사용법과 관련하여 설명할 내용은?\n\n① 깨끗하고 털이 없는 건조한 피부에 붙임\n② 이상반응이 발생한 경우에는 절반을 잘라서 붙임\n③ 패치가 잘 붙지 않는 경우, 폐기하고 새것을 붙임\n④ 1매가 48시간 지속형 제제이므로 2일 간격으로 붙임\n⑤ 부착을 잊은 경우에는 생각나는 즉시 2개의 패치를 한꺼번에 붙임",
        "question_text": "Question: What should be explained to a patient who has been prescribed a fentanyl patch regarding the use of the medication?\n\n① Apply to clean, hairless, and dry skin\n② If side effects occur, cut the patch in half and apply\n③ If the patch doesn't adhere well, discard it and apply a new one\n④ As one patch is a 48-hour sustained-release preparation, apply at 2-day intervals\n⑤ If application is forgotten, immediately apply two patches at once when remembered",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 케토롤락(ketorolac)을 연속 복용할 때 이상반응을 고려하여, 케토롤락 정제의 최대 투여기간으로 권장되는 일수는?\n\n① 2일\n② 3일\n③ 5일\n④ 7일\n⑤ 10일",
        "question_text": "Question: Considering the adverse reactions when taking ketorolac continuously, what is the recommended maximum number of days for the administration of ketorolac tablets?\n\n① 2 days\n② 3 days\n③ 5 days\n④ 7 days\n⑤ 10 days",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 제형이 붕해될 때까지 뺨과 잇몸 사이에 놓고 서서히 흡수되도록 하며, 약을 빨아 먹거나, 씹거나, 삼키지 않도록 하는 약은?\n\n① 펜타닐(fentanyl) 박칼정\n② 펜타닐 설하정\n③ 비타민 발포정\n④ 트리암시놀론(triamcinolone) 부착정\n⑤ 플루르비프로펜(flurbiprofen) 트로키제",
        "question_text": "Question: Which medication is placed between the cheek and gum to be slowly absorbed until the dosage form disintegrates, and should not be sucked, chewed, or swallowed?\n\n① Fentanyl buccal tablet\n② Fentanyl sublingual tablet\n③ Vitamin effervescent tablet\n④ Triamcinolone adhesive tablet\n⑤ Flurbiprofen troche",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 다음 그림은 국제공통기술문서(CTD) 모식도이다. 모듈 4에 들어갈 내용은?\n\n<Data (confidential)>\n\n① 임상자료\n② 품질자료\n③ 비임상자료\n④ 설계기반품질고도화자료\n⑤ CMC(chemistry, manufacturing and control) 자료",
        "question_text": "Question: The following figure is a schematic diagram of the Common Technical Document (CTD). What content should be included in Module 4?\n\n<Data (confidential)>\n\n① Clinical data\n② Quality data\n③ Non-clinical data\n④ Quality by Design (QbD) data\n⑤ CMC (Chemistry, Manufacturing and Control) data",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 의약품 제조 및 품질관리기준(GMP)에서 규정하는 제품표준서에 포함되는 내용은?\n\n① 안정성시험\n② 표준품 및 시약의 관리\n③ 계측기의 규격설정 및 교정방법\n④ 작업소의 청정도 관리에 관한 사항\n⑤ 효능 ∙ 효과, 용법 ∙ 용량 및 사용상의 주의사항",
        "question_text": "Question: What is included in the product standard document as specified in the Good Manufacturing Practice (GMP) for pharmaceuticals?\n\n① Stability testing\n② Management of reference standards and reagents\n③ Specification setting and calibration methods for measuring instruments\n④ Matters related to cleanliness management of work areas\n⑤ Efficacy, effects, dosage, administration, and precautions for use",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 생산된 주사용수를 제조설비 내에 일시적으로 보존할 경우 미생물이 증식될 수 있다. 이를 방지하기 위한 방법은?\n\n① 과산화수소 첨가\n② 차아염소산 첨가\n③ 과망간산칼륨 첨가\n④ 이온교환수지 통과\n⑤ 열수 순환 시스템 적용",
        "question_text": "Question: When water for injection is temporarily stored in manufacturing equipment, microorganisms can proliferate. What method can be used to prevent this?\n\n① Adding hydrogen peroxide\n② Adding hypochlorite\n③ Adding potassium permanganate\n④ Passing through ion exchange resin\n⑤ Applying a hot water circulation system",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 의약품 제조설비에 잔류되어 있는 물질은 교차오염의 원인이 된다. 교차오염에 의한 잠재적 위험성은 의약품의 제형에 따라 차이가 있다. 잠재적 위험성이 큰 것부터 작은 것 순서로 나열된 것은?\n\n① 경피제 > 점안제 > 경구제제 > 정맥투여제제\n② 정맥투여제제 > 점안제 > 경구제제 > 경피제\n③ 정맥투여제제 > 경구제제 > 점안제 > 경피제\n④ 점안제 > 경구제제 > 정맥투여제제 > 경피제\n⑤ 점안제 > 경구제제 > 경피제 > 정맥투여제제",
        "question_text": "Question: Residual substances in pharmaceutical manufacturing equipment can cause cross-contamination. The potential risk of cross-contamination varies depending on the dosage form of the pharmaceutical. Which of the following lists the dosage forms in order from highest to lowest potential risk?\n\n① Transdermal preparations > Ophthalmic preparations > Oral preparations > Intravenous preparations\n② Intravenous preparations > Ophthalmic preparations > Oral preparations > Transdermal preparations\n③ Intravenous preparations > Oral preparations > Ophthalmic preparations > Transdermal preparations\n④ Ophthalmic preparations > Oral preparations > Intravenous preparations > Transdermal preparations\n⑤ Ophthalmic preparations > Oral preparations > Transdermal preparations > Intravenous preparations",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 여과멸균에서 사용하는 필터시스템의 완전성을 평가하는  방울점시험의 종료 시점에서 직접 측정하는 것은?\n\n① 시험액체의 이동압력\n② 시험액체의 표면장력\n③ 필터 세공의 최소크기\n④ 필터 세공의 평균크기\n⑤ 시험액체와 모세관벽의 접촉각",
        "question_text": "Question: In the bubble point test used to evaluate the integrity of the filter system in filtration sterilization, what is directly measured at the end point of the test?\n\n① Transfer pressure of the test liquid\n② Surface tension of the test liquid\n③ Minimum size of filter pores\n④ Average size of filter pores\n⑤ Contact angle between the test liquid and capillary wall",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: \"Regulation on Safety of Pharmaceuticals, etc.\"에 따라 의약품의 품목허가를 받기 위한 자료를 Ministry of Food and Drug Safety에 제출하고자 할 때 원료의약품의 기준 및 시험방법에 대한 근거자료에 포함해야 하는 자료는?\n\n① 효력시험 자료\n② 안정성에 관한 자료\n③ 순도시험에 관한 자료\n④ 단회투여독성시험 자료\n⑤ 기원 또는 발견 및 개발 경위에 관한 자료",
        "question_text": "Question: According to the \"Regulation on Safety of Pharmaceuticals, etc.,\" when submitting documents to the Ministry of Food and Drug Safety for obtaining product approval for a pharmaceutical, which of the following should be included in the supporting documents for the standards and test methods of active pharmaceutical ingredients?\n\n① Data on efficacy tests\n② Data on stability\n③ Data on purity tests\n④ Data on single-dose toxicity tests\n⑤ Data on the origin or discovery and development history",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 의약품 등의 시험방법 밸리데이션에서 확인시험을 위해 평가해야 하는 밸리데이션 파라미터는?\n\n① 특이성\n② 정확성\n③ 직선성\n④ 검출한계\n⑤ 정량한계",
        "question_text": "Question: What validation parameter should be evaluated for identification tests in the validation of test methods for pharmaceuticals and other products?\n\n① Specificity\n② Accuracy\n③ Linearity\n④ Detection limit\n⑤ Quantitation limit",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia 제12개정에 규정된 멸균주사용수에 관한 설명으로 옳은 것은?\n\n① 미생물한도시험이 필요하다.\n② 엔도톡신 규정이 정제수와 동일하다.\n③ 전도율 규정이 멸균정제수와 동일하다.\n④ 정제수를 용기에 넣고 멸균하여 제조한다.\n⑤ 주사용수를 용기에 넣고 밀봉하여 제조한다.",
        "question_text": "Question: Which of the following statements about Sterile Water for Injection, as specified in the 12th edition of the Korean Pharmacopoeia, is correct?\n\n① Microbial limit test is necessary.\n② The endotoxin specification is the same as that of purified water.\n③ The conductivity specification is the same as that of sterile purified water.\n④ It is manufactured by placing purified water in containers and sterilizing.\n⑤ It is manufactured by placing water for injection in containers and sealing.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 제약산업에서 공정분석기술(PAT)을 활용하여, 시료를 파괴하지 않으면서 실시간 분석으로 정제의 코팅 정도를 확인하는 데에 사용할 수 있는 방법은?\n\n① 모세관전기영동법\n② 시차주사열량분석법\n③ 액체크로마토그래프법\n④ 근적외부스펙트럼측정법\n⑤ 유도결합플라즈마분석법",
        "question_text": "Question: In the pharmaceutical industry, which method can be used as a Process Analytical Technology (PAT) to verify the coating level of tablets in real-time without destroying the sample?\n\n① Capillary electrophoresis\n② Differential scanning calorimetry\n③ Liquid chromatography\n④ Near-infrared spectroscopy\n⑤ Inductively coupled plasma analysis",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 정제의 제조과정에서 마손도시험이 필요한 시기는?\n\n① 원료 혼합 후\n② 과립 건조 후\n③ 과립 혼합 후\n④ 타정 후\n⑤ 코팅 후",
        "question_text": "Question: At what stage in the tablet manufacturing process is the friability test necessary?\n\n① After mixing raw materials\n② After drying granules\n③ After mixing granules\n④ After tablet compression\n⑤ After coating",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 다음은 Korean Pharmacopoeia 제12개정에 규정된 글루콘산칼슘수화물의 선광도 항이다. 글루콘산칼슘수화물의 선광도 및 측정에 관한 설명으로 옳은 것은?\n\n선광도 [α]D20: +6~+11°(건조한 다음, 0.5 g, 물, 25 mL, 가온, 식힌 다음, 100 mm)\n\n① 상온에서 측정한다.\n② 선광도시험은 한도시험이다.\n③ 측정 시 적외부의 단색광을 사용한다.\n④ 검체는 이 약의 건조감량 항의 조건으로 건조한다.\n⑤ 조건에 따라 제조한 용액의 선광도는 +6~+11°이다.",
        "question_text": "Question: The following is the optical rotation entry for calcium gluconate hydrate as specified in the 12th edition of the Korean Pharmacopoeia. Which of the following statements about the optical rotation and measurement of calcium gluconate hydrate is correct?\n\nOptical rotation [α]D20: +6 to +11° (after drying, 0.5 g, water, 25 mL, warm, cool, 100 mm)\n\n① It is measured at room temperature.\n② The optical rotation test is a limit test.\n③ Monochromatic light in the infrared region is used for measurement.\n④ The sample is dried under the conditions specified in the loss on drying section for this drug.\n⑤ The optical rotation of the solution prepared according to the conditions is +6 to +11°.",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia 제12개정에 규정된 주사제용 유리용기에 적용하는 시험은?\n\n① 수분\n② 투명성\n③ 강열잔분\n④ 급성독성\n⑤ 알칼리용출",
        "question_text": "Question: Which test is applied to glass containers for injections as specified in the 12th edition of the Korean Pharmacopoeia?\n\n① Moisture\n② Transparency\n③ Ignition residue\n④ Acute toxicity\n⑤ Alkali elution",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia 제12개정에 규정된 의약품으로 세미미크로킬달법을 적용하여 정량하는 의약품은?\n\n① 간유\n② 약용탄\n③ 건조효모\n④ 글리세린\n⑤ 아스피린",
        "question_text": "Question: According to the 12th edition of the Korean Pharmacopoeia, which of the following medicinal products is quantified using the semi-micro Kjeldahl method?\n\n① Cod-liver oil\n② Medicinal charcoal\n③ Dried yeast\n④ Glycerin\n⑤ Aspirin",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia 제12개정에 규정된 원료의약품으로 다음 성질을 가지는 것은?\n\n• 이 약은 백색으로 물에 잘 녹는다.\n• 이 약의 수용액(1 → 50) 5 mL를 취하여 과망간산칼륨시액  1방울을 떨어뜨릴 때 시액의 색은 곧 없어진다.\n\n① 카페인\n② 토코페롤\n③ 아스피린\n④ 아스코르브산\n⑤ 레티놀아세테이트",
        "question_text": "Question: Which of the following substances, listed as a raw material for pharmaceuticals in the 12th edition of the Korean Pharmacopoeia, has these properties?\n\n• This substance is white and readily soluble in water.\n• When 5 mL of an aqueous solution of this substance (1 → 50) is taken and 1 drop of potassium permanganate solution is added, the color of the solution disappears immediately.\n\n① Caffeine\n② Tocopherol\n③ Aspirin\n④ Ascorbic acid\n⑤ Retinol acetate",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 연구 대상에 대한 실험설계를 할 때, 실험자의 숙련도, 기기의 경시변화, 기온 등과 같이 실험에서 고려하지 않은 원인들이 실험결과에 미칠 수 있는 영향을 미리 차단함으로써 실험의 객관성을 유지할 수 있는 방법은?\n\n① 시료의 채취량을 줄인다.\n② 실험의 순서를 랜덤하게 한다.\n③ 인자간의 교호작용을 고려하지 않는다.\n④ 각 군당 자료의 수를 서로 다르게 한다.\n⑤ 요인으로 인한 효과에 차이가 없게 블록을 만든다.",
        "question_text": "Question: When designing an experiment for a research subject, what method can maintain the objectivity of the experiment by preemptively blocking the potential effects of unaccounted factors such as the experimenter's skill level, equipment degradation over time, and temperature on the experimental results?\n\n① Reduce the sample size.\n② Randomize the order of experiments.\n③ Disregard interactions between factors.\n④ Vary the number of data points for each group.\n⑤ Create blocks where the effects due to factors are equal.",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 어떤 의약품에 대해 특정 품질특성치의 상한과 하한이 결정되었다. 이 품질특성치의 통곗값이 어떠할 때 공정능력지수가 커지는가?\n\n① 자료수의 감소\n② 표준편차의 감소\n③ 표준편차의 증가\n④ 산술평균의 감소\n⑤ 산술평균의 증가",
        "question_text": "Question: For a certain pharmaceutical product, the upper and lower limits of a specific quality characteristic have been determined. Under which statistical condition does the process capability index increase?\n\n① Decrease in the number of data points\n② Decrease in standard deviation\n③ Increase in standard deviation\n④ Decrease in arithmetic mean\n⑤ Increase in arithmetic mean",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n모 제약회사에서 121℃에서의 D값(D 121)이 1.0분이며, Z값은 10℃인 B . stearothermophilus 균의 초기 미생물부하량(bioburden)을 103으로 하여 대용량 주사제의 멸균공정의 밸리데이션을 실시하였다. 시간에 따라 챔버의 온도를 올려 멸균하고 서서히 온도를 낮추어 가면서 치사율 곡선을 얻었으며, 이 치사율 곡선의 곡선하 면적(AUC)은 8.0분이었다.\n\nQuestion: 이 멸균공정으로 멸균하였을 때 비무균확률은?\n\n① 10^-7\n② 10^-6\n③ 10^-5\n④ 10^-4\n⑤ 10^-3",
        "question_text": "A pharmaceutical company conducted a validation of the sterilization process for large-volume parenteral products using B. stearothermophilus spores with a D-value at 121°C (D121) of 1.0 minute, a Z-value of 10°C, and an initial bioburden of 103. The chamber temperature was gradually increased for sterilization and then slowly decreased to obtain a lethality curve. The Area Under the Curve (AUC) of this lethality curve was 8.0 minutes.\n\nQuestion: What is the probability of non-sterility when sterilized using this sterilization process?\n\n① 10^-7\n② 10^-6\n③ 10^-5\n④ 10^-4\n⑤ 10^-3",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n모 제약회사에서 121℃에서의 D값(D 121)이 1.0분이며, Z값은 10℃인 B . stearothermophilus 균의 초기 미생물부하량(bioburden)을 103으로 하여 대용량 주사제의 멸균공정의 밸리데이션을 실시하였다. 시간에 따라 챔버의 온도를 올려 멸균하고 서서히 온도를 낮추어 가면서 치사율 곡선을 얻었으며, 이 치사율 곡선의 곡선하 면적(AUC)은 8.0분이었다.\n\nQuestion: 이 멸균공정과 대등한 멸균효과를 나타내는 멸균조건은?\n\n① 101℃에서 160분간 멸균\n② 110℃에서 40분간 멸균\n③ 111℃에서 80분간 멸균\n④ 120℃에서 8분간 멸균\n⑤ 131℃에서 0.4분간 멸균",
        "question_text": "A pharmaceutical company conducted a validation of the sterilization process for large-volume parenteral products using B. stearothermophilus spores with a D-value at 121°C (D121) of 1.0 minute, a Z-value of 10°C, and an initial bioburden of 103. The chamber temperature was gradually increased for sterilization and then slowly decreased to obtain a lethality curve. The area under the curve (AUC) of this lethality curve was 8.0 minutes.\n\nQuestion: Which of the following sterilization conditions would provide an equivalent sterilization effect to this process?\n\n① Sterilization at 101°C for 160 minutes\n② Sterilization at 110°C for 40 minutes\n③ Sterilization at 111°C for 80 minutes\n④ Sterilization at 120°C for 8 minutes\n⑤ Sterilization at 131°C for 0.4 minutes",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: A 약사는 보유한 현금 4억 원과 은행에서 5년 만기 상환조건으로 대출한 2억 원으로 약국점포를 5억 원에 구입하였고, 남은 현금 1억 원으로는 의약품을 구매하여 약국을 개업하였다. 약국 개업시점의 재무 상태에 관한 설명으로 옳은 것은?\n\n① 자산은 4억 원이다.\n② 자본은 6억 원이다.\n③ 유동부채는 2억 원이다.\n④ 유동자산은 1억 원이다.\n⑤ 비유동자산은 3억 원이다.",
        "question_text": "Question: A pharmacist purchased a pharmacy store for 500 million won using 400 million won of their own cash and 200 million won borrowed from a bank with a 5-year repayment term. The remaining 100 million won was used to purchase medicines to open the pharmacy. Which of the following statements is correct regarding the financial status at the time of opening the pharmacy?\n\n① The assets are 400 million won.\n② The capital is 600 million won.\n③ The current liabilities are 200 million won.\n④ The current assets are 100 million won.\n⑤ The non-current assets are 300 million won.",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: A 병원약국의 연간 수액제 수요량은 7,300병이다. 수액제 주문 시 소요되는 조달기간은 평균 5일이며, 주문비용은 2만 원이다. 수요와 조달기간의 변동에 대비한 안전재고량이 146병이라고 했을 때, 재고 부족 위험을 방지하기 위해서는 수액제 재고가 최소 몇 병 이상이 되었을 때 재주문해야 하는가? (1년은 365일로 하며, 공휴일은 고려하지 않음)\n\n① 10병\n② 50병\n③ 100병\n④ 146병\n⑤ 246병",
        "question_text": "Question: The annual demand for IV fluids at Hospital A's pharmacy is 7,300 bottles. The average procurement time when ordering IV fluids is 5 days, and the ordering cost is 20,000 won. If the safety stock to account for variations in demand and procurement time is 146 bottles, at what minimum inventory level should IV fluids be reordered to prevent the risk of stock shortage? (Assume 365 days in a year, and do not consider holidays)\n\n① 10 bottles\n② 50 bottles\n③ 100 bottles\n④ 146 bottles\n⑤ 246 bottles",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: A 약국은 2022년 1년 동안 2억 원에 해당하는 의약품을 매입하였다. 2022년 1월 1일 의약품 재고는 1억 원이었고, 당해 연도 12월 31일의 의약품 재고가 8천만 원이었다. A 약국의 매출액은 모두 의약품으로부터 발생했다고 할 때, 2022년도 A 약국의 재무제표상의 매출원가는?\n\n① 1억 8천만 원\n② 2억 원\n③ 2억 2천만 원\n④ 3억 원\n⑤ 3억 8천만 원",
        "question_text": "Question: Pharmacy A purchased medications worth 200 million won during the year 2022. The medication inventory on January 1, 2022, was 100 million won, and the medication inventory on December 31 of the same year was 80 million won. Assuming all of Pharmacy A's sales revenue came from medications, what is the cost of goods sold on Pharmacy A's financial statement for 2022?\n\n① 180 million won\n② 200 million won\n③ 220 million won\n④ 300 million won\n⑤ 380 million won",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 진료비 지불방식은?\n\n환자가 받는 의료서비스의 종류나 양에 상관없이 질병 진단명에 따라 사전에 정해진 금액을 지불하는 방식이다. 이 제도하에서 의료제공자는 가급적 비용을 절감하여 진료를 하려는 동기를 가지게 된다.\n\n① 인두제\n② 봉급제\n③ 총액예산제\n④ 포괄수가제\n⑤ 행위별수가제",
        "question_text": "Question: Which of the following describes the payment method for medical expenses?\n\nThis is a method where a predetermined amount is paid based on the diagnosis, regardless of the type or quantity of medical services received by the patient. Under this system, healthcare providers are motivated to provide care while minimizing costs as much as possible.\n\n① Capitation system\n② Salary system\n③ Global budget system\n④ Diagnosis-Related Group (DRG) system\n⑤ Fee-for-service system",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 다음의 현상을 설명하는 보건의료 시장의 특성은?\n\n항생제를 오용 ∙ 남용하면 항생제에 내성을 가진 균주가 증가하게 된다. 이러한 내성균이 많아지면 감염증 환자의 치료 시 기존 항생제의 효과가 나타나지 않는 문제가 생길 수 있다.\n\n① 역선택\n② 외부효과\n③ 도덕적 해이\n④ 공급자 유인수요\n⑤ 보건의료공급자의 공급독점",
        "question_text": "Question: Which characteristic of the healthcare market explains the following phenomenon?\n\nWhen antibiotics are misused or overused, there is an increase in antibiotic-resistant strains of bacteria. As these resistant bacteria become more prevalent, it can lead to problems where existing antibiotics may not be effective in treating patients with infectious diseases.\n\n① Adverse selection\n② Externality\n③ Moral hazard\n④ Supplier-induced demand\n⑤ Supply monopoly by healthcare providers",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 차등수가제도에 관한 설명으로 옳은 것은?\n\n① 항암제, 고영양수액제 등 무균 주사제 조제 업무에 대해 보상한다.\n② 공휴일 및 야간의 처방의약품 조제 업무에 대해 가산하여 보상한다.\n③ 약사 1인당 적정 조제건수를 초과하는 경우 조제료를 차감하여 지급한다.\n④ 소아 환자 처방의약품 조제 업무에 대해 일정 금액을 가산하여 보상한다.\n⑤ 경증질환으로 상급종합병원의 처방을 받은 경우 본인부담금을 차등 부담한다.",
        "question_text": "Question: Which of the following statements about the differential fee system is correct?\n\n① It compensates for the preparation of sterile injections such as anticancer drugs and high-nutrition fluids.\n② It provides additional compensation for dispensing prescription medications during public holidays and nighttime.\n③ It reduces the dispensing fee when the number of prescriptions exceeds the appropriate number per pharmacist.\n④ It provides additional compensation for dispensing prescription medications for pediatric patients.\n⑤ It applies differential out-of-pocket expenses for patients who receive prescriptions from tertiary hospitals for minor illnesses.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 약물감시(pharmacovigilance)에 해당하는 것은?\n\n① 시험 ∙ 검사기관을 대상으로 숙련도 평가를 실시한다.\n② 의약품 사용 중 발생한 이상사례를 수집하고 분석한다.\n③ 마약류통합관리시스템을 통해 마약류 사용 실태를 점검한다.\n④ 의약품 제조과정에서 품질기준을 준수하고 있는지를 감시한다.\n⑤ 세균백신제제 등에 대해 매 제조단위별로 품질검사를 실시한다.",
        "question_text": "Question: Which of the following corresponds to pharmacovigilance?\n\n① Conducting proficiency tests for testing and inspection agencies.\n② Collecting and analyzing adverse events that occur during drug use.\n③ Monitoring the use of narcotics through the Integrated Narcotics Management System.\n④ Supervising compliance with quality standards in the drug manufacturing process.\n⑤ Conducting quality inspections for each manufacturing batch of bacterial vaccine preparations and similar products.",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 퇴장방지의약품으로 지정될 수 있는 것은?\n\n① 고가의 희귀의약품\n② Korea Orphan and Essential Drug Center가 공급하는 자가치료용 의약품\n③ 건강보험 청구액이 높고 매년 사용량이 증가하는 의약품\n④ 국가비상상황을 대비하기 위해 필수적으로 비축 ∙ 공급해야 하는 의약품\n⑤ 저가이면서 고가의 타 약제를 대체하는 효과가 있어 비용-효과적인 측면에서 관리가 필요한 의약품",
        "question_text": "Question: Which of the following can be designated as a drug subject to supply shortage prevention measures?\n\n① Expensive rare drugs\n② Self-treatment drugs supplied by the Korea Orphan and Essential Drug Center\n③ Drugs with high health insurance claims and increasing annual usage\n④ Essential drugs that must be stockpiled and supplied in preparation for national emergencies\n⑤ Low-cost drugs that can substitute for expensive alternatives and require management from a cost-effectiveness perspective",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: National Health Insurance Service에서 약국에 장려금을 지급하는 경우는?\n\n① 약국이 청구한 구입금액이 상한금액보다 낮은 경우\n② 6개월 전과 비교하여 기대약품비 대비 실제약품비가 줄어든 경우\n③ 처방된 약과 동일 성분이면서 가격이 동일한 제품으로 대체조제한 경우\n④ 처방전을 발행한 의사의 동의를 구한 후 잘못 표시된 용량을 수정하여 조제한 경우\n⑤ 처방된 약보다 저렴하면서 생물학적동등성이 인정되지 않은 품목으로 대체조제한 경우",
        "question_text": "Question: In which case does the National Health Insurance Service provide incentives to pharmacies?\n\n① When the purchase amount claimed by the pharmacy is lower than the maximum limit\n② When the actual drug cost compared to the expected drug cost has decreased compared to 6 months ago\n③ When dispensing a substitute drug with the same ingredient and price as the prescribed medication\n④ When dispensing after correcting an incorrectly indicated dosage with the consent of the prescribing physician\n⑤ When dispensing a substitute drug that is cheaper than the prescribed medication but not recognized as bioequivalent",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 후향적 코호트연구에 비해 무작위배정 비교임상시험의 장점은?\n\n① 시간과 비용이 적게 든다.\n② 상대위험도를 구할 수 있다.\n③ 드물게 발생하는 이상사례를 관찰하기에 용이하다.\n④ 장기적으로 발생하는 결과를 관찰하기에 용이하다.\n⑤ 사전에 예상하지 못한 교란요인의 영향을 통제하기에 용이하다.",
        "question_text": "Question: What is an advantage of randomized controlled trials compared to retrospective cohort studies?\n\n① They require less time and cost.\n② They can calculate relative risk.\n③ They are suitable for observing rare adverse events.\n④ They are suitable for observing long-term outcomes.\n⑤ They are suitable for controlling the effects of unforeseen confounding factors.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 간염치료제 A의 복용과 골다공증성 골절의 연관성을 밝히기 위한 환자-대조군 연구를 설계할 경우 대조군은?\n\n① 간염치료제 A 투여군\n② 간염치료제 A 비투여군\n③ 비교대상 치료제 투여군\n④ 골다공증성 골절 발생군\n⑤ 골다공증성 골절 비발생군",
        "question_text": "Question: In designing a case-control study to determine the association between taking hepatitis treatment A and osteoporotic fractures, which of the following would be the control group?\n\n① Group receiving hepatitis treatment A\n② Group not receiving hepatitis treatment A\n③ Group receiving comparative treatment\n④ Group with osteoporotic fractures\n⑤ Group without osteoporotic fractures",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 약물관리서비스 도입 전과 후의 응급실 방문 위험을 비교한 7편의 연구[(가)~(사)]를 메타분석하여 다음과 같은 결과를 얻었다. 이에 대한 해석으로 옳은 것은? (고정효과 모형으로 분석한 결과임)\n\n| 연구 | 약물관리서비스 도입 전 총환자수 (명) | 약물관리서비스 도입 전 응급실 방문 환자수 (명) | 약물관리서비스 도입 후 총환자수 (명) | 약물관리서비스 도입 후 응급실 방문 환자수 (명) | 상대위험도 [95% 신뢰구간] |\n|---|---|---|---|---|---|\n| (가) | 151 | 47 | 161 | 40 | 0.80 [0.56, 1.14] |\n| (나) | 1,357 | 55 | 1,217 | 47 | 0.95 [0.65, 1.40] |\n| (다) | 40 | 12 | 50 | 6 | 0.40 [0.16, 0.97] |\n| (라) | 140 | 25 | 180 | 17 | 0.53 [0.30, 0.94] |\n| (마) | 1,545 | 150 | 1,240 | 103 | 0.86 [0.67, 1.09] |\n| (바) | 2,525 | 350 | 2,517 | 315 | 0.90 [0.78, 1.04] |\n| (사) | 1,050 | 88 | 987 | 68 | 0.82 [0.61, 1.11] |\n| 합 계 | 6,808 | 727 | 6,352 | 596 | 0.85 [0.76, 0.95] |\nHeterogeneity: Tau2 < 0.01, Chi2=6.57, df=6 (p=0.36): I2=9%\nTest for overall effect: Z=2.85 (p=0.004)\n\n① 개별 연구들 간의 이질성이 높다.\n② 위험도 차이에 대한 통계적 유의성이 확인된 연구는 5편이다.\n③ 통합추정치 계산에서 가장 가중치가 높게 부여된 연구는 (다)이다.\n④ 7개 연구의 결과들이 서로 일관되지 않아 정량적 합성이 바람직하지 않다.\n⑤ 메타분석 결과에 의하면 약물관리서비스 도입 후 응급실 방문 위험이 낮아진 것으로 해석된다.",
        "question_text": "Question: A meta-analysis of seven studies [(A)-(G)] comparing the risk of emergency room visits before and after the introduction of medication management services yielded the following results. Which interpretation is correct? (The results were analyzed using a fixed-effect model)\n\n| Study | Total patients before service (n) | ER visits before service (n) | Total patients after service (n) | ER visits after service (n) | Relative Risk [95% CI] |\n|---|---|---|---|---|---|\n| (A) | 151 | 47 | 161 | 40 | 0.80 [0.56, 1.14] |\n| (B) | 1,357 | 55 | 1,217 | 47 | 0.95 [0.65, 1.40] |\n| (C) | 40 | 12 | 50 | 6 | 0.40 [0.16, 0.97] |\n| (D) | 140 | 25 | 180 | 17 | 0.53 [0.30, 0.94] |\n| (E) | 1,545 | 150 | 1,240 | 103 | 0.86 [0.67, 1.09] |\n| (F) | 2,525 | 350 | 2,517 | 315 | 0.90 [0.78, 1.04] |\n| (G) | 1,050 | 88 | 987 | 68 | 0.82 [0.61, 1.11] |\n| Total | 6,808 | 727 | 6,352 | 596 | 0.85 [0.76, 0.95] |\nHeterogeneity: Tau2 < 0.01, Chi2=6.57, df=6 (p=0.36): I2=9%\nTest for overall effect: Z=2.85 (p=0.004)\n\n① The heterogeneity among individual studies is high.\n② Statistical significance in risk difference was confirmed in 5 studies.\n③ Study (C) was given the highest weight in calculating the pooled estimate.\n④ The results of the 7 studies are inconsistent, making quantitative synthesis undesirable.\n⑤ According to the meta-analysis results, the risk of emergency room visits decreased after the introduction of medication management services.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 자궁경부암 예방 백신의 비용-효과분석을 하려고 한다. 연간 할인율을 5%에서 3%로 낮추면 미접종군 대비 접종군의 점증적 비용-효과비의 변화는? (비용으로는 백신 접종 비용만 고려하고 효과는 생존연수로 평가함)\n\n① 점증적 비용-효과비에는 변함이 없다.\n② 점증적 비용이 더 높게 평가되어, 점증적 비용-효과비가 높아진다.\n③ 점증적 효과가 더 높게 평가되어, 점증적 비용-효과비가 낮아진다.\n④ 점증적 비용과 효과 모두 더 낮게 평가되나, 점증적 비용-효과비의 변화 방향은 알 수 없다.\n⑤ 점증적 비용과 효과 모두 더 높게 평가되나, 점증적 비용-효과비의 변화 방향은 알 수 없다.",
        "question_text": "Question: We are conducting a cost-effectiveness analysis of the cervical cancer prevention vaccine. What is the change in the incremental cost-effectiveness ratio (ICER) of the vaccinated group compared to the unvaccinated group when the annual discount rate is lowered from 5% to 3%? (Consider only the cost of vaccine administration for costs, and evaluate effectiveness in terms of years of survival)\n\n① There is no change in the incremental cost-effectiveness ratio.\n② The incremental cost is evaluated higher, resulting in a higher incremental cost-effectiveness ratio.\n③ The incremental effectiveness is evaluated higher, resulting in a lower incremental cost-effectiveness ratio.\n④ Both incremental cost and effectiveness are evaluated lower, but the direction of change in the incremental cost-effectiveness ratio is unknown.\n⑤ Both incremental cost and effectiveness are evaluated higher, but the direction of change in the incremental cost-effectiveness ratio is unknown.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 약 A와 B의 비용과 치료 성과는 다음 표에 제시된 바와 같다. 보험자 관점에서 분석하면, B와 비교한 A의 점증적 비용-효용비(만 원/QALY)는? (QALY=quality-adjusted life year, 할인율은 0%로 가정함)\n\n| 약 | 비용(만 원) | | | | 치료 성과 | |\n| | 보험급여 진료비 (본인부담률 | 0% 가정) | 비급여 진료비 | 교통비 (비급여), 간병비 (비급여) | 조기사망으로 인한 생산성 손실 | 수명연장 (년) | 효용 가중치 |\n|---|---|---|---|---|---|---|\n| A | 5,000 | 2,000 | 200 | 5,000 | 4 | 0.65 |\n| B | 2,000 | 1,500 | 200 | 7,000 | 3.5 | 0.6 |\n\n① 1,500\n② 1,923\n③ 3,000\n④ 6,000\n⑤ 7,000",
        "question_text": "Question: The costs and treatment outcomes of drugs A and B are presented in the following table. From the insurer's perspective, what is the incremental cost-utility ratio (10,000 won/QALY) of A compared to B? (QALY = quality-adjusted life year, assume a discount rate of 0%)\n\n| Drug | Costs (10,000 won) | | | | Treatment Outcomes | |\n| | Insured medical expenses (assuming 0% out-of-pocket) | Non-insured medical expenses | Transportation costs (non-insured), Caregiving costs (non-insured) | Productivity loss due to premature death | Life extension (years) | Utility weight |\n|---|---|---|---|---|---|---|\n| A | 5,000 | 2,000 | 200 | 5,000 | 4 | 0.65 |\n| B | 2,000 | 1,500 | 200 | 7,000 | 3.5 | 0.6 |\n\n① 1,500\n② 1,923\n③ 3,000\n④ 6,000\n⑤ 7,000",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 신약에 대한 임상시험을 수행하는 과정에서 윤리적으로 적절한 행위는?\n\n① 서면동의서에 당초 계획한 임상시험에 끝까지 참여하겠다는 약속 내용을 포함함\n② 교도소 책임자의 대표 서면동의를 받고 전체 수감자들을 임상시험에 참여시킴\n③ 임상시험 참여 시 사례비(1백만 원)를 제공한다는 내용의 대상자 모집 광고문을 나눠 줌\n④ 서면동의서에 시험약 투약으로 건강상의 피해가 발생할 경우의 보상 내용과 절차를 포함함\n⑤ 서면동의서에 과학지식 생성을 위해 임상시험 대상자 개인의 권리나 이익이 일부 침해될 수 있다는 내용을 포함함",
        "question_text": "Question: Which of the following is an ethically appropriate action when conducting clinical trials for a new drug?\n\n① Including a promise in the written consent form to participate in the clinical trial until the end as initially planned\n② Obtaining representative written consent from the prison warden and involving all inmates in the clinical trial\n③ Distributing recruitment advertisements stating that participants will receive compensation (1 million won) for participating in the clinical trial\n④ Including information and procedures for compensation in case of health damage due to the administration of the test drug in the written consent form\n⑤ Including in the written consent form that the individual rights or interests of clinical trial subjects may be partially infringed upon for the generation of scientific knowledge",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 다음 상황에서 충돌하는 윤리 원칙은?\n\n말기 암 환자인 A 씨는 개 구충제가 암 치료에 효과가 있다는 친구의 말을 듣고 구충제 구입을 위해 약국을 방문하였다. A 씨는 약사에게 구충제의 치료효과가 불확실하다는 것은 알지만 지푸라기라도 잡는 심정으로 구충제를 복용하려는 것이라고 설명하였다. 약사는 환자의 의사를 존중하여 구충제를 판매할지, 구충제 복용이 치료에 도움이 되지 않으니 의사와 상의하여 과학적 근거를 갖춘 다른 치료방법을 찾아보라고 설득할지 고민 중이다.\n\n① 자율성 존중의 원칙 – 선행의 원칙\n② 자율성 존중의 원칙 – 정의의 원칙\n③ 정의의 원칙 – 선행의 원칙\n④ 사생활 존중과 보호의 원칙 – 선행의 원칙\n⑤ 사생활 존중과 보호의 원칙 – 자율성 존중의 원칙",
        "question_text": "Question: Which ethical principles are in conflict in the following situation?\n\nMr. A, a terminal cancer patient, visited a pharmacy to purchase a dog dewormer after hearing from a friend that it might be effective in treating cancer. Mr. A explained to the pharmacist that he knows the therapeutic effect of the dewormer is uncertain, but he wants to take it as a last resort. The pharmacist is contemplating whether to respect the patient's wishes and sell the dewormer, or to persuade the patient to consult with a doctor and seek other scientifically-based treatment methods, as taking the dewormer would not be helpful for treatment.\n\n① Principle of respect for autonomy – Principle of beneficence\n② Principle of respect for autonomy – Principle of justice\n③ Principle of justice – Principle of beneficence\n④ Principle of respect for privacy and protection – Principle of beneficence\n⑤ Principle of respect for privacy and protection – Principle of respect for autonomy",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nA 약국의 2022년 12월 31일 재무제표에 기재된 일부 항목의 정보는 다음과 같다.\n• 유동자산: 80,000천 원\n• 재고자산: 50,000천 원\n• 유동부채: 20,000천 원\n• 비유동부채: 30,000천 원\n• 매출원가: 120,000천 원\n• 2022년 1월 1일 재고자산: 30,000천 원\n\nQuestion: 2022년도 A 약국 재무제표 분석으로 계산되는 유동비율은?\n\n① 0.25\n② 1\n③ 1.5\n④ 2\n⑤ 4",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThe information for some items listed in the financial statements of Pharmacy A as of December 31, 2022, is as follows:\n• Current assets: 80,000 thousand won\n• Inventory: 50,000 thousand won\n• Current liabilities: 20,000 thousand won\n• Non-current liabilities: 30,000 thousand won\n• Cost of goods sold: 120,000 thousand won\n• Inventory as of January 1, 2022: 30,000 thousand won\n\nQuestion: What is the current ratio calculated from the analysis of Pharmacy A's 2022 financial statements?\n\n① 0.25\n② 1\n③ 1.5\n④ 2\n⑤ 4",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\nA 약국의 2022년 12월 31일 재무제표에 기재된 일부 항목의 정보는 다음과 같다.\n• 유동자산: 80,000천 원\n• 재고자산: 50,000천 원\n• 유동부채: 20,000천 원\n• 비유동부채: 30,000천 원\n• 매출원가: 120,000천 원\n• 2022년 1월 1일 재고자산: 30,000천 원\n\nQuestion: 2022년도 A약국 재무제표 분석으로 계산되는 재고자산회전율은?\n\n① 1.6회\n② 2회\n③ 2.4회\n④ 3회\n⑤ 4회",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThe information for some items listed in the financial statements of Pharmacy A as of December 31, 2022, is as follows:\n• Current assets: 80,000 thousand won\n• Inventory: 50,000 thousand won\n• Current liabilities: 20,000 thousand won\n• Non-current liabilities: 30,000 thousand won\n• Cost of goods sold: 120,000 thousand won\n• Inventory as of January 1, 2022: 30,000 thousand won\n\nQuestion: What is the inventory turnover ratio calculated from the analysis of Pharmacy A's 2022 financial statements?\n\n① 1.6 times\n② 2 times\n③ 2.4 times\n④ 3 times\n⑤ 4 times",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사면허에 관한 설명으로 옳은 것은?\n\n① 면허의 기재 사항이 변경된 경우에는 면허증을 다시 교부받을 수 없다.\n② 약사국가시험에서 부정행위를 한 자는 3년간 국가시험에 응시할 수 없다.\n③ 약사는 최초로 면허를 받은 후부터 매년 취업상황 등 실태를 신고하여야 한다.\n④ 약사가 복약지도를 하지 않아 3차 위반이 된 경우 행정처분은 면허취소에 해당한다.\n⑤ 대한약사회는 면허취소 등 처분 요구에 대한 심의 ∙ 의결을 위하여 윤리위원회를 둔다.",
        "question_text": "Question: Which of the following statements about pharmacist licenses is correct according to the \"Pharmaceutical Affairs Act\"?\n\n① If the details on the license have changed, a new license cannot be reissued.\n② A person who has cheated on the National Pharmacist Examination cannot take the exam for 3 years.\n③ Pharmacists must report their employment status and other details annually, starting from when they first receive their license.\n④ If a pharmacist fails to provide medication counseling for the third time, the administrative action corresponds to license revocation.\n⑤ The Korean Pharmaceutical Association establishes an Ethics Committee to review and decide on requests for license revocation and other disciplinary actions.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국을 수리하기 위해 2022년 6월 3일부터 휴업한 후 2022년 7월 9일에 다시 열었을 때 약국개설자의 행위로 적절한 것은? (제시된 일자에서 공휴일은 고려하지 않음)\n\n① 5월 30일에 휴업 신고를 하였다.\n② 6월 14일에 휴업 신고를 하였다.\n③ 7월 4일에 재개 신고를 하였다.\n④ 7월 14일에 재개 신고를 하였다.\n⑤ 별도의 신고는 하지 않았다.",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following actions by a pharmacy owner is appropriate when the pharmacy closed for repairs from June 3, 2022, and reopened on July 9, 2022? (Do not consider public holidays in the given dates)\n\n① Reported the closure on May 30.\n② Reported the closure on June 14.\n③ Reported the reopening on July 4.\n④ Reported the reopening on July 14.\n⑤ Did not make any separate reports.",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자의 약국 관리의무 사항이 아닌 것은?\n\n① 보건위생과 관련된 사고가 없도록 종업원을 철저히 감독할 것\n② 약국에 종사하는 약사는 약사 면허증 원본을 약국 안의 보기 쉬운 곳에 게시할 것\n③ 영업 양도로 종전 약국개설자의 지위를 승계하려는 경우에는 양도일부터 7일 이내에 신고할 것\n④ 약국개설자 자신이 그 약국을 관리할 수 없는 경우에는 대신할 약사를 지정하여 약국을 관리하게 할 것\n⑤ 조제행위를 하는 “약학전공대학생”에게 “약학전공대학 실습생”의 명칭 및 성명이 함께 표시된 명찰을 달게 할 것",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a pharmacy management obligation for pharmacy owners?\n\n① Thoroughly supervise employees to prevent accidents related to public health and hygiene\n② Pharmacists working in the pharmacy should display the original pharmacist license in a visible place within the pharmacy\n③ In case of succeeding the position of the previous pharmacy owner due to business transfer, report within 7 days from the date of transfer\n④ If the pharmacy owner cannot manage the pharmacy themselves, designate another pharmacist to manage the pharmacy on their behalf\n⑤ Have \"pharmacy student interns\" who perform compounding wear a name tag displaying both the title \"Pharmacy Student Intern\" and their name",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 환자가 지정하는 대리인이 환자에 관한 조제기록부 열람을 요청하기 위해 서류를 갖추어서 약사에게 제출하고자 한다. 이때 \"Pharmaceutical Affairs Act\"상 약사가 제출받아야 하는 서류가 아닌 것은?\n\n① 환자 본인의 동의서\n② 요청인의 신분증 사본\n③ 환자 본인의 신분증 사본\n④ 요청인에게 법정대리권이 있음을 증명하는 서류\n⑤ 요청인에게 지정대리권이 있음을 증명하는 서류",
        "question_text": "Question: A designated representative of a patient wants to submit documents to a pharmacist to request access to the patient's prescription records. According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a document that the pharmacist should receive?\n\n① Consent form from the patient\n② Copy of the requester's identification\n③ Copy of the patient's identification\n④ Document proving the requester has legal representation rights\n⑤ Document proving the requester has designated representation rights",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사가 의사의 처방전 없이 조제 또는 판매할 수 있는 경우는?\n\n① 응급환자에 대한 조제\n② 의료기관 조제실제제의 조제\n③ 조울증 등으로 타인을 해칠 우려가 있는 정신질환자에 대한 조제\n④ \"Immigration Act\"에 따른 외국인 보호시설에 수용 중인 자에 대한 조제\n⑤ 감염병이 집단으로 발생할 우려가 있다고 Commissioner of the Korea Disease Control and Prevention Agency이 인정하여 경구용 감염병 예방접종약 판매",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" in which case can a pharmacist dispense or sell medication without a doctor's prescription?\n\n① Dispensing for emergency patients\n② Dispensing of preparations made in medical institution dispensaries\n③ Dispensing for mental health patients with conditions such as bipolar disorder who may pose a risk to others\n④ Dispensing for individuals detained in foreign national detention facilities as per the \"Immigration Act\"\n⑤ Selling oral infectious disease vaccination drugs when the Commissioner of the Korea Disease Control and Prevention Agency recognizes the risk of a group outbreak of an infectious disease",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 도매상이 의약품을 판매할 수 없는 대상은?\n\n① 매약상\n② 한약업사\n③ 안전상비의약품 판매자\n④ 개인 도매상인 경우 그의 4촌 친족이 개설한 약국\n⑤ 법인 도매상인 경우 해당 법인 임원의 2촌 친족이 개설한 약국",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a permitted recipient for pharmaceutical wholesalers to sell drugs to?\n\n① Over-the-counter drug retailers\n② Oriental medicine drug retailers\n③ Sellers of safe and readily available drugs\n④ In case of an individual wholesaler, a pharmacy established by their relatives within four degrees of kinship\n⑤ In case of a corporate wholesaler, a pharmacy established by relatives within two degrees of kinship of the corporation's executives",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자의 의약품 판매에 관한 설명으로 옳지 않은 것은?\n\n① 한약제제는 개봉하여 판매할 수 있다.\n② 판매하는 의약품의 가격을 의약품의 용기나 포장에 적어야 한다.\n③ 진단을 목적으로 한 건강상담을 통하여 일반의약품을 판매할 수 있다.\n④ 일반의약품을 판매할 때에 필요하다고 판단되면 복약지도를 할 수 있다.\n⑤ 의사가 처방한 의약품이 없어 긴급하게 구하려는 다른 약국개설자에게 해당 의약품을 판매할 수 있다.",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following statements about the sale of medicines by pharmacy owners is incorrect?\n\n① Traditional herbal preparations can be sold after opening.\n② The price of the medicines being sold must be written on the container or packaging of the medicine.\n③ Over-the-counter medicines can be sold through health consultations aimed at diagnosis.\n④ When selling over-the-counter medicines, medication counseling can be provided if deemed necessary.\n⑤ If a medicine prescribed by a doctor is unavailable, it can be sold to another pharmacy owner who is urgently trying to obtain it.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 품목허가 신청사실의 통지 및 판매금지에 관한 다음 설명에서 ㉠과 ㉡으로 옳은 것은?\n\n• 등재의약품의 안전성 ∙ 유효성에 관한 자료를 근거로  의약품의 품목허가를 신청한 자는 그 신청사실을 품목 허가 신청일부터 ( ㉠ ) 이내에 등재특허권자등에게  통지하여야 한다.\n• 등재특허권자등은 통지의약품의 판매금지를 신청할 수  있으며 신청을 받은 Minister of Food and Drug Safety은 등재특허권자 등이 통지받은 날부터 ( ㉡ ) 동안 판매를 금지하여야  한다.\n\n㉠ | ㉡\n① 20일 | 6개월\n② 20일 | 9개월\n③ 45일 | 6개월\n④ 45일 | 9개월\n⑤ 45일 | 11개월",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is correct for ㉠ and ㉡ regarding the notification of application for item approval and sales prohibition?\n\n• A person who applies for item approval of a drug based on safety and efficacy data of a listed drug must notify the listed patent holder, etc., of the application within ( ㉠ ) from the date of application for item approval.\n• The listed patent holder, etc., can request a sales prohibition of the notified drug, and the Minister of Food and Drug Safety who receives the request must prohibit the sale for ( ㉡ ) from the date the listed patent holder, etc., received the notification.\n\n㉠ | ㉡\n① 20 days | 6 months\n② 20 days | 9 months\n③ 45 days | 6 months\n④ 45 days | 9 months\n⑤ 45 days | 11 months",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 제조관리자의 준수사항에 해당하지 않는 것은?\n\n① 제조관리기준서, 제품표준서 등에 따라 정확히 제조할 것\n② 제조소의 시설을 위생적으로 관리하여 교차오염 등을 방지할 것\n③ 의약품의 제조판매 품목허가 ∙ 품목신고의 갱신 업무를 철저히 할 것\n④ 작업소에서 국민보건에 유해한 물질이 유출되거나 방출되지 아니하도록 할 것\n⑤ 원료 및 자재의 입고부터 완제품의 출고에 이르기까지 필요한 시험검사를 철저히 할 것",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a compliance requirement for a pharmaceutical manufacturing manager?\n\n① Manufacture accurately according to the manufacturing management standards, product standards, etc.\n② Manage the facilities of the manufacturing site hygienically to prevent cross-contamination, etc.\n③ Thoroughly manage the renewal of product licenses and notifications for manufacturing and selling pharmaceuticals\n④ Ensure that substances harmful to public health are not leaked or released from the work area\n⑤ Thoroughly conduct necessary tests and inspections from the receipt of raw materials and supplies to the shipment of finished products",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자가 수의사 또는 수산질병관리사의 처방전 없이 판매할 수 있는 동물용 의약품은?\n\n① 돼지의 분만촉진을 위한 옥시토신 주사제\n② 개의 광견병 예방을 위한 생독백신 주사제\n③ 소의 탄저병 예방을 위한 탄저생균백신 주사제\n④ 넙치의 연쇄구균증 치료를 위한 암피실린 주사제\n⑤ 고양이의 세균성 질병 치료를 위한 아미카신 주사제",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which veterinary medicine can a pharmacy owner sell without a prescription from a veterinarian or aquatic animal disease manager?\n\n① Oxytocin injection for inducing labor in pigs\n② Live attenuated vaccine injection for rabies prevention in dogs\n③ Live anthrax vaccine injection for anthrax prevention in cattle\n④ Ampicillin injection for treating streptococcosis in flatfish\n⑤ Amikacin injection for treating bacterial diseases in cats",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 부작용 피해구제에 관한 설명으로 옳은 것은?\n\n① 피해구제급여를 받으려는 사람은 National Health Insurance Service의 장에게 피해구제급여의 지급을 신청하여야 한다.\n② 의약품 부작용으로 인한 장애가 피해자의 고의로 인해 발생한 경우 피해구제급여를 지급하지 않는다.\n③ Minister of Food and Drug Safety이 정한 암질환에 사용되는 의약품의 부작용으로 인한 장애는 피해구제급여 지급대상에 해당한다.\n④ 피해구제 부담금은 의약품의 품목허가를 받은 자와 National Health Insurance Service이 판매금액과 상환금액에 비례하여 일정금액을 부담한다.\n⑤ 의약품 부작용으로 인한 사망이 \"Infectious Disease Control And Prevention Act\"에 따른 예방접종으로 인한 경우 피해구제급여 지급대상에 해당한다.",
        "question_text": "Question: Which of the following statements about the relief for adverse drug reactions under the \"Pharmaceutical Affairs Act\" is correct?\n\n① Those seeking relief benefits must apply for payment to the head of the National Health Insurance Service.\n② Relief benefits are not paid if the disability due to adverse drug reactions is caused by the victim's intentional act.\n③ Disabilities caused by adverse reactions to drugs used for cancer diseases, as determined by the Minister of Food and Drug Safety, are eligible for relief benefits.\n④ The relief contribution is paid by both the person who received product approval for the drug and the National Health Insurance Service, in proportion to the sales amount and reimbursement amount, respectively.\n⑤ Deaths due to adverse drug reactions caused by vaccinations under the \"Infectious Disease Control And Prevention Act\" are eligible for relief benefits.",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 해당 연도의 약사 연수교육을 면제받을 수 있는 자는?\n\n① 약사국가시험에 합격하여 당해 신규로 Minister of Health and Welfare의 면허를 받은 자\n② 행정기관에 근무하는 자로서 환자의 조제 관련 업무에 직접 종사하고 있는 자\n③ 휴업으로 인하여 해당 연도에 1개월 동안 조제 관련 업무에 종사하지 아니한 자\n④ 폐업으로 인하여 해당 연도에 3개월 동안 조제 관련 업무에 종사하지 아니한 자\n⑤ 해외체류로 인하여 해당 연도에 5개월 동안 조제 관련 업무에 종사하지 아니한 자",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" who can be exempted from the pharmacist continuing education for the corresponding year?\n\n① Those who have passed the national pharmacist examination and newly received a license from the Minister of Health and Welfare in that year\n② Those working in administrative agencies who are directly engaged in patient dispensing-related duties\n③ Those who have not engaged in dispensing-related duties for 1 month in the corresponding year due to temporary business closure\n④ Those who have not engaged in dispensing-related duties for 3 months in the corresponding year due to business closure\n⑤ Those who have not engaged in dispensing-related duties for 5 months in the corresponding year due to overseas stay",
        "answer": 1
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 오용하거나 남용할 우려가 심하고 의료용으로 쓰이지 아니하며 안전성이 결여되어 있는 것으로서 이를 오용하거나 남용할 경우 심한 신체적 또는 정신적 의존성을 일으키는 향정신성의약품은?\n\n① 프로포폴(propofol)\n② 클로나제팜(clonazepam)\n③ 페노바르비탈(phenobarbital)\n④ 메프로바메이트(meprobamate)\n⑤ 디메톡시브로모암페타민(dimethoxybromoamphetamine)",
        "question_text": "Question: According to the \"Narcotics Control Act,\" which psychotropic drug is highly likely to be misused or abused, is not used for medical purposes, lacks safety, and can cause severe physical or mental dependence when misused or abused?\n\n① Propofol\n② Clonazepam\n③ Phenobarbital\n④ Meprobamate\n⑤ Dimethoxybromoamphetamine (DMBA)",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류 중독자의 치료보호에 관한 설명으로 옳은 것은?\n\n① 마약류 중독자의 치료보호 기간은 24개월 이내로 한다.\n② 마약류 중독 여부의 판별검사 기간은 2개월 이내로 한다.\n③ Mayor/Do Governor는 마약류 중독자로 판명된 사람에 대하여 치료보호를 받게 할 수 있다.\n④ Minister of Food and Drug Safety은 마약류 중독자를 치료하기 위하여 치료보호기관을 설치할 수 있다.\n⑤ 마약류 중독 판별검사에 관한 사항을 심의하기 위하여 Ministry of Food and Drug Safety에 치료보호심사위원회를 둔다.",
        "question_text": "Question: Which of the following statements about the treatment and protection of drug addicts under the \"Narcotics Control Act\" is correct?\n\n① The treatment and protection period for drug addicts is limited to 24 months.\n② The period for determining drug addiction is limited to 2 months.\n③ The Mayor/Do Governor can order treatment and protection for individuals identified as drug addicts.\n④ The Minister of Food and Drug Safety can establish treatment and protection facilities to treat drug addicts.\n⑤ A Treatment and Protection Review Committee is established within the Ministry of Food and Drug Safety to deliberate on matters related to drug addiction determination tests.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류취급자가 아닌 자가 마약류를 취급할 수 있는 경우는?\n\n① 대마 재배\n② 한외마약 제조\n③ 향정신성의약품 조제\n④ 마약류취급자를 위한 마약류 운반\n⑤ 향정신성의약품을 기재한 처방전 발급",
        "question_text": "Question: According to the \"Narcotics Control Act,\" in which case can a person who is not a licensed narcotics handler deal with narcotics?\n\n① Cultivation of cannabis\n② Manufacturing of non-pharmacopoeial narcotics\n③ Compounding of psychotropic drugs\n④ Transportation of narcotics for licensed narcotics handlers\n⑤ Issuing a prescription containing psychotropic drugs",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: \"National Health Promotion Act\"상 국민건강 관리를 위한 금주 ∙ 금연 관련 규정에 관한 설명으로 옳지 않은 것은?\n\n① 담배갑포장지에는 Ordinance of the Ministry of Health and Welfare으로 정하는 금연상담전화의 전화번호를 표기하여야 한다.\n② 해당 시설 전체를 금연구역으로 지정해야 하는 시설에는 흡연자를 위한 흡연실을 설치할 수 있다.\n③ 담배갑포장지의 앞면과 뒷면에 흡연의 폐해를 나타내는 내용의 경고그림을 인쇄하여 표기하여야 한다.\n④ 주류에 관한 광고에는 음주자에게 판매촉진을 위하여 경품 및 금품을 제공한다는 내용을 표시할 수 있다.\n⑤ 주류의 광고기준 마련에 관한 사항의 자문을 위해 Minister of Health and Welfare 소속으로 음주폐해예방위원회를 둔다.",
        "question_text": "Question: Which of the following statements is NOT correct regarding the regulations on abstinence from alcohol and smoking for national health management under the \"National Health Promotion Act\"?\n\n① The telephone number for smoking cessation counseling, as determined by the Ordinance of the Ministry of Health and Welfare, must be displayed on cigarette packaging.\n\n② Smoking rooms for smokers can be installed in facilities that are required to designate the entire facility as a non-smoking area.\n\n③ Warning images depicting the harmful effects of smoking must be printed and displayed on both the front and back of cigarette packaging.\n\n④ Advertisements for alcoholic beverages can display content offering prizes and monetary rewards to promote sales to drinkers.\n\n⑤ An Alcohol Harm Prevention Committee is established under the Minister of Health and Welfare to provide consultation on matters related to establishing advertising standards for alcoholic beverages.",
        "answer": 4
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: \"Framework Act on Health and Medical Services\"상 보건의료에 관한 국민의 권리 및 의무에 관한 설명으로 옳지 않은 것은?\n\n① 보건의료인이 제안하는 정당한 보건의료서비스와 지도에 협조해야 할 의무가 있다.\n② 법령에서 정하는 바에 따라 건강을 보호 ∙ 증진하는 데에 필요한 비용을 부담하여야 할 의무가 있다.\n③ 보건의료기관에 대하여 자신의 보건의료와 관련한 기록 등의 열람을 요청할 수 있는 권리를 가진다.\n④ 보건의료와 관련하여 자신의 신체상 ∙ 건강상의 비밀과 사생활의 비밀을 침해받지 않을 권리를 가진다.\n⑤ 자신과 동일한 질병으로 진료받은 다른 환자의 의무기록 내용의 공개를 정부 및 지방자치단체에 청구할 권리를 가진다.",
        "question_text": "Question: Which of the following statements about the rights and obligations of citizens regarding health and medical services under the \"Framework Act on Health and Medical Services\" is incorrect?\n\n① They have an obligation to cooperate with legitimate health and medical services and guidance proposed by healthcare professionals.\n② They have an obligation to bear the costs necessary for protecting and promoting health in accordance with the provisions of laws and regulations.\n③ They have the right to request access to records related to their own health and medical care from healthcare institutions.\n④ They have the right not to have their physical and health-related secrets and privacy invaded in relation to health and medical care.\n⑤ They have the right to request the government and local governments to disclose the medical records of other patients who have received treatment for the same disease as themselves.",
        "answer": 5
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 비용의 일부부담에 관한 설명으로 옳은 것은?\n\n① 본인부담상한액은 가입자의 소득수준에 따른 차등을 두지 않고 산정한다.\n② 요양급여를 받은 사람이 National Health Insurance Service에 본인부담금을 직접 납부한다.\n③ Minister of Health and Welfare이 정한 희귀난치성질환을 가진 사람은 본인부담률이 경감된다.\n④ 본인일부부담금은 요양급여를 받는 자가 법에서 정한 바에 따라 부담하는 보험료의 일부를 의미한다.\n⑤ 65세 이상 환자의 원외처방을 약국에서 조제한 경우, 그 요양급여비용 총액이 일정금액을 초과할 때에는 정액의 본인부담금을 부담한다.",
        "question_text": "Question: Which of the following statements about cost-sharing under the \"National Health Insurance Act\" is correct?\n\n① The out-of-pocket maximum is calculated without differentiating based on the insured person's income level.\n② The person who received medical care directly pays the out-of-pocket expenses to the National Health Insurance Service.\n③ People with rare and intractable diseases designated by the Minister of Health and Welfare have reduced cost-sharing rates.\n④ The partial out-of-pocket payment refers to a portion of the insurance premium that the person receiving medical care pays according to the law.\n⑤ When prescriptions for patients aged 65 or older are filled at pharmacies, a fixed out-of-pocket amount is charged if the total cost of medical care exceeds a certain amount.",
        "answer": 3
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 경제성 또는 치료효과성 등이 불확실하여 그 검증을 위하여 추가적인 근거가 필요하거나, 경제성이 낮아도 가입자와 피부양자의 건강회복에 잠재적 이득이 있는 경우에 실시할 수 있는 급여의 유형은?\n\n① 부가급여\n② 선별급여\n③ 선별등재\n④ 재난적 의료비 지원\n⑤ 허가초과 사용 비급여 사용승인",
        "question_text": "Question: According to the \"National Health Insurance Act,\" what type of benefit can be provided when there is uncertainty regarding economic efficiency or therapeutic effectiveness, requiring additional evidence for verification, or when there is potential benefit for the health recovery of the insured and their dependents despite low economic efficiency?\n\n① Additional benefit\n② Selective benefit\n③ Selective listing\n④ Catastrophic health expenditure support\n⑤ Approval for off-label use as non-benefit",
        "answer": 2
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: \"Regional Public Health Act\"상 보건소에서 수행할 수 있는 기능 및 업무가 아닌 것은?\n\n① 의약품 제조업자의 폐업 신고\n② 약국개설자의 업무 개시 명령\n③ 마약류관리자의 마약류 폐기 및 조치 명령\n④ 마약류소매업자의 마약류 취급 감시 및 단속\n⑤ 약국개설자의 의약품 회수 ∙ 폐기 또는 조치 명령",
        "question_text": "Question: Which of the following is NOT a function or task that can be performed by a public health center according to the \"Regional Public Health Act\"?\n\n① Receiving closure reports from pharmaceutical manufacturers\n② Ordering pharmacy owners to commence operations\n③ Ordering narcotics managers to dispose of and take measures regarding narcotics\n④ Monitoring and cracking down on narcotics handling by retail narcotics dealers\n⑤ Ordering pharmacy owners to recall, dispose of, or take measures regarding pharmaceuticals",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 단백질은?\n\n• 나선 형태의 폴리펩티드 가닥 세 개가 감긴 코일(coiled coil) 구조를 이룸\n• 폴리펩티드 가닥에서 글리신-프롤린-히드록시프롤린 서열이 자주 반복됨\n\n① 콜라겐(collagen)\n② α-케라틴(α-keratin)\n③ 아밀로이드-β 펩티드(amyloid-β peptide)\n④ 명주 피브로인(silk fibroin)\n⑤ 헤모글로빈S(hemoglobin S)",
        "question_text": "Question: Which protein is described below?\n\n• Forms a coiled coil structure where three polypeptide strands are wound together in a helical shape\n• The sequence glycine-proline-hydroxyproline is frequently repeated in the polypeptide strands\n\n① Collagen\n② α-Keratin\n③ Amyloid-β peptide\n④ Silk fibroin\n⑤ Hemoglobin S",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 사람의 근육세포에서 일어나는 당분해 과정에서 ATP를 소모하는 효소는?\n\n① aldolase\n② enolase\n③ hexokinase\n④ phosphoglycerate kinase\n⑤ pyruvate kinase",
        "question_text": "Question: Which enzyme consumes ATP in the glycolysis process occurring in human muscle cells?\n\n① aldolase\n② enolase\n③ hexokinase\n④ phosphoglycerate kinase\n⑤ pyruvate kinase",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 식후 혈당 상승 시 인슐린의 작용에 의해 간세포에서 활성화되는 효소는?\n\n① carnitine acyltransferase I\n② glycogen phosphorylase\n③ glycogen synthase kinase 3\n④ phosphofructokinase-1\n⑤ protein kinase A",
        "question_text": "Question: Which enzyme is activated in liver cells by the action of insulin when blood glucose rises after a meal?\n\n① carnitine acyltransferase I\n② glycogen phosphorylase\n③ glycogen synthase kinase 3\n④ phosphofructokinase-1\n⑤ protein kinase A",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: Citrate synthase의 기질로서 아세틸-CoA와 반응하여 시트르산으로 전환되는 것은?\n\n① malate\n② isocitrate\n③ malonate\n④ succinate\n⑤ oxaloacetate",
        "question_text": "Question: Which of the following reacts with acetyl-CoA as a substrate for citrate synthase and is converted to citric acid?\n\n① malate\n② isocitrate\n③ malonate\n④ succinate\n⑤ oxaloacetate",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 미토콘드리아에서 전자전달계와 산화적 인산화 간의 짝풀림(uncoupling)을 일으키는 것은?\n\n① antimycin A\n② cyanide\n③ 2,4-dinitrophenol\n④ oligomycin\n⑤ rotenone",
        "question_text": "Question: Which of the following causes uncoupling between the electron transport chain and oxidative phosphorylation in mitochondria?\n\n① antimycin A\n② cyanide\n③ 2,4-dinitrophenol\n④ oligomycin\n⑤ rotenone",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 동물세포에서 n-pentadecanoic acid (C15:0) 한 분자의 β-산화가 완결되었을 때 생성되는 프로피오닐-CoA(propionyl-CoA)의 분자 수는?\n\n① 1\n② 2\n③ 3\n④ 4\n⑤ 5",
        "question_text": "Question: How many molecules of propionyl-CoA are produced when the β-oxidation of one molecule of n-pentadecanoic acid (C15:0) is completed in animal cells?\n\n① 1\n② 2\n③ 3\n④ 4\n⑤ 5",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 사람 간세포에서 지방산 생성효소(fatty acid synthase)의 촉매 반응에 필요한 것은?\n\n① FADH2\n② NADPH\n③ pyridoxal phosphate\n④ tetrahydrofolate\n⑤ thiamine pyrophosphate",
        "question_text": "Question: Which of the following is required for the catalytic reaction of fatty acid synthase in human liver cells?\n\n① FADH2\n② NADPH\n③ pyridoxal phosphate\n④ tetrahydrofolate\n⑤ thiamine pyrophosphate",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 사람 간세포에서 시트룰린(citrulline)과 결합하여 요소 생성에 사용되는 아미노산은?\n\n① 알라닌\n② 글루타민\n③ 글루탐산\n④ 아르기닌\n⑤ 아스파르트산",
        "question_text": "Question: Which amino acid combines with citrulline in human liver cells to produce urea?\n\n① Alanine\n② Glutamine\n③ Glutamic acid\n④ Arginine\n⑤ Aspartic acid",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 다음 생체 아민 생합성의 전구체는?\n\n<Data (confidential)>\n\n① 류신\n② 세린\n③ 글루탐산\n④ 히스티딘\n⑤ 트리프토판",
        "question_text": "Question: Which of the following is a precursor in the biosynthesis of biogenic amines?\n\n<Data (confidential)>\n\n① Leucine\n② Serine\n③ Glutamic acid\n④ Histidine\n⑤ Tryptophan",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 단백질의 번역후변형(posttranslational modification) 중에서 히스톤 H3의 DNA 친화력을 감소시켜 유전자 전사를 활성화할 수 있는 것은?\n\n① 세린 인산화\n② 리신 아세틸화\n③ 티로신 인산화\n④ 티로신 아데닐화\n⑤ 글루탐산 카르복실화",
        "question_text": "Question: Which of the following posttranslational modifications of proteins can activate gene transcription by reducing the DNA affinity of histone H3?\n\n① Serine phosphorylation\n② Lysine acetylation\n③ Tyrosine phosphorylation\n④ Tyrosine adenylation\n⑤ Glutamic acid carboxylation",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 다음 그림은 하나의 DNA 서열에서 서로 다른 폴리펩티드 1, 2가 생성되는 과정의 일부를 나타낸 것이다. (가) 단계에 해당하는 것은?\n\n<Data (confidential)>\n\n① 뉴클레오시드 변형\n② RNA캐핑(RNA capping)\n③ 역전사(reverse transcription)\n④ 선택적 잘라이음(alternative splicing)\n⑤ 자리-특이 재조합(site-specific recombination)",
        "question_text": "Question: The following figure shows part of the process where different polypeptides 1 and 2 are produced from a single DNA sequence. What corresponds to step (가)?\n\n<Data (confidential)>\n\n① Nucleoside modification\n② RNA capping\n③ Reverse transcription\n④ Alternative splicing\n⑤ Site-specific recombination",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 프로테아좀(proteasome)에 의해 분해되는 단백질들에서 공통적으로 나타나는 번역후변형(posttranslational modification)은?\n\n① isoprenylation\n② ubiquitination\n③ 당화(glycosylation)\n④ 인산화(phosphorylation)\n⑤ 이황화결합 형성(disulfide bond formation)",
        "question_text": "Question: Which posttranslational modification is commonly found in proteins that are degraded by the proteasome?\n\n① isoprenylation\n② ubiquitination\n③ glycosylation\n④ phosphorylation\n⑤ disulfide bond formation",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 유전자 발현을 조절하는 요인들 중에서 전사활성자(transcription activator)가 결합하는 DNA의 특정 염기서열은?\n\n① enhancer\n② initiator (Inr) sequence\n③ operator\n④ TATA box\n⑤ TerA",
        "question_text": "Question: Among the factors that regulate gene expression, what is the specific DNA sequence to which a transcription activator binds?\n\n① enhancer\n② initiator (Inr) sequence\n③ operator\n④ TATA box\n⑤ TerA",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 글루카곤에 의해 생성이 촉진되는 이차전령은?\n\n① cAMP\n② cGMP\n③ 칼슘이온\n④ 다이아실글리세롤(diacylglycerol)\n⑤ 1,4,5-삼중인산이노시톨(inositol 1,4,5-trisphosphate)",
        "question_text": "Question: Which secondary messenger is stimulated to be produced by glucagon?\n\n① cAMP\n② cGMP\n③ Calcium ion\n④ Diacylglycerol\n⑤ Inositol 1,4,5-trisphosphate",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 아미노산은?\n\n• 말초 조직에서 대사되어 아세틸-CoA 분자를 생성함\n• 대사에 필요한 효소가 결핍되면 단풍시럽뇨증(maple syrup urine disease)이 발병할 수 있음\n\n① 리신\n② 아르기닌\n③ 이소류신\n④ 히스티딘\n⑤ 페닐알라닌",
        "question_text": "Question: Which amino acid is described below?\n\n• Metabolized in peripheral tissues to produce acetyl-CoA molecules\n• Deficiency of enzymes necessary for its metabolism can lead to maple syrup urine disease\n\n① Lysine\n② Arginine\n③ Isoleucine\n④ Histidine\n⑤ Phenylalanine",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 요소 회로에 결함이 있는 환자에서는 과량의 질소가 질소 화합물 X의 형태로 축적된다. 이 환자에게 벤조산을 투여하면 다음 그림과 같이 X는 벤조산과 결합하여 배설되는 형태로 전환된다. 이 질소화합물 X는?\n\n<Data (confidential)>\n\n① 요산\n② 잔틴\n③ 글리신\n④ 우라실\n⑤ 글루타민",
        "question_text": "Question: In patients with a defective urea cycle, excess nitrogen accumulates in the form of nitrogen compound X. When benzoic acid is administered to these patients, X combines with benzoic acid and is converted into an excretable form, as shown in the following figure. What is this nitrogen compound X?\n\n<Data (confidential)>\n\n① Uric acid\n② Xanthine\n③ Glycine\n④ Uracil\n⑤ Glutamine",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 식사 후 혈장에서 대장애서 분비되어 인슐린의 분비를 촉진하는 호르몬은?\n\n① 렙틴(leptin)\n② 그렐린(ghrelin)\n③ 글루카곤(glucagon)\n④ 아디포넥틴(adiponectin)\n⑤ 글루카곤-유사 펩티드 1(GLP-1)",
        "question_text": "Question: Which hormone is secreted from the large intestine after a meal, stimulating the secretion of insulin in the plasma?\n\n① Leptin\n② Ghrelin\n③ Glucagon\n④ Adiponectin\n⑤ Glucagon-like peptide 1 (GLP-1)",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 단백질은?\n\n• DNA가 손상되면 전사인자 E2F에 결합하여 세포 분열을 억제함\n• cyclin-dependent protein kinase 2에 의해 인산화되면 E2F와의 결합능력을 상실함\n\n① caspase-3\n② cyclin E\n③ p21\n④ pRB\n⑤ PTEN",
        "question_text": "Question: Which protein is described below?\n\n• When DNA is damaged, it binds to the transcription factor E2F to inhibit cell division\n• When phosphorylated by cyclin-dependent protein kinase 2, it loses its ability to bind to E2F\n\n① caspase-3\n② cyclin E\n③ p21\n④ pRB\n⑤ PTEN",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음 그림은 콜레스테롤 생합성 과정에 관여하는 효소 Y의 억제제인 화합물 X와 효소반응 생성물인 메발론산의 구조이다.\n\n<Data (confidential)>\n\nQuestion: 효소 Y는?\n\n① acetyl-CoA acetyl transferase\n② β-hydroxy-β-methylglutaryl-CoA reductase\n③ β-hydroxy-β-methylglutaryl-CoA synthase\n④ mevalonate 5-phosphotransferase\n⑤ phosphomevalonate kinase",
        "question_text": "The following figure shows the structure of compound X, which is an inhibitor of enzyme Y involved in the cholesterol biosynthesis process, and mevalonic acid, which is the product of the enzyme reaction.\n\n<Data (confidential)>\n\nQuestion: Enzyme Y is?\n\n① acetyl-CoA acetyl transferase\n② β-hydroxy-β-methylglutaryl-CoA reductase\n③ β-hydroxy-β-methylglutaryl-CoA synthase\n④ mevalonate 5-phosphotransferase\n⑤ phosphomevalonate kinase",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n다음 그림은 콜레스테롤 생합성 과정에 관여하는 효소 Y의 억제제인 화합물 X와 효소반응 생성물인 메발론산의 구조이다.\n\n<Data (confidential)>\n\nQuestion: 화합물 X를 첨가할 경우 효소 Y의 겉보기Km과 겉보기Vmax의 변화는? (단, 효소 반응의 보조인자는 충분량을 일정하게 유지한다.)\n\n겉보기Km | 겉보기Vmax\n① 증가 | 증가\n② 변화 없음 | 감소\n③ 증가 | 변화 없음\n④ 감소 | 변화 없음\n⑤ 감소 | 감소",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThe following figure shows the structure of compound X, which is an inhibitor of enzyme Y involved in cholesterol biosynthesis, and mevalonic acid, which is the product of the enzyme reaction.\n\n<Data (confidential)>\n\nQuestion: How do the apparent Km and apparent Vmax of enzyme Y change when compound X is added? (Assume that the cofactors of the enzyme reaction are maintained at a sufficient and constant level.)\n\nApparent Km | Apparent Vmax\n① Increase | Increase\n② No change | Decrease\n③ Increase | No change\n④ Decrease | No change\n⑤ Decrease | Decrease",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 세균의 외막을 구성하는 지질다당류(lipopolysaccharide)에 관한 설명으로 옳은 것은?\n\n① 외독소로 작용한다.\n② 세균의 운동성을 부여한다.\n③ 그람양성 세균에서 관찰된다.\n④ 톨유사수용체3(TLR3)에 결합한다.\n⑤ 지질A, 중심당, O항원으로 구성된다.",
        "question_text": "Question: Which of the following statements about lipopolysaccharide, a component of the outer membrane of bacteria, is correct?\n\n① It acts as an exotoxin.\n② It provides motility to bacteria.\n③ It is observed in Gram-positive bacteria.\n④ It binds to Toll-like receptor 3 (TLR3).\n⑤ It is composed of lipid A, core oligosaccharide, and O-antigen.",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 세포벽 합성을 저해하는 항생물질에 저항성을 나타내는 미생물은?\n\n① 매독균(Treponema pallidum)\n② 임균(Neisseria gonorrhoeae)\n③ 황색포도구균(Staphylococcus aureus)\n④ 화농연쇄구균(Streptococcus pyogenes)\n⑤ 폐렴 마이코플라스마균(Mycoplasma pneumoniae)",
        "question_text": "Question: Which microorganism shows resistance to antibiotics that inhibit cell wall synthesis?\n\n① Treponema pallidum (Syphilis bacterium)\n② Neisseria gonorrhoeae (Gonorrhea bacterium)\n③ Staphylococcus aureus (Golden staph)\n④ Streptococcus pyogenes (Group A Streptococcus)\n⑤ Mycoplasma pneumoniae (Pneumonia mycoplasma)",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 트라코마(trachoma)와 성병림프육아종(lymphogranuloma venereum)의 원인체에 관한 설명으로 옳은 것은?\n\n① 그람양성 세균이다.\n② 숙주세포 내에서 증식한다.\n③ 곤충을 매개로 하여 전파된다.\n④ 망상소체(reticulate body) 형태로 감염을 일으킨다.\n⑤ 감염 치료제로 그리세오풀빈(griseofulvin)을 사용한다.",
        "question_text": "Question: Which of the following statements about the causative agents of trachoma and lymphogranuloma venereum is correct?\n\n① They are gram-positive bacteria.\n② They multiply within host cells.\n③ They are transmitted through insect vectors.\n④ They cause infection in the form of reticulate bodies.\n⑤ Griseofulvin is used as a treatment for the infection.",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 피부, 소화기, 호흡기 등에 감염을 일으키는 미생물로 부종 독소(edema toxin)와 치사독소(lethal toxin)를 생성하는 것은?\n\n① 콜레라균(Vibrio cholerae)\n② 탄저균(Bacillus anthracis)\n③ 백일해균(Bordetella pertussis)\n④ 보툴리눔균(Clostridium botulinum)\n⑤ 디프테리아균(Corynebacterium diphtheriae)",
        "question_text": "Question: Which microorganism causes infections in the skin, digestive system, and respiratory system, and produces edema toxin and lethal toxin?\n\n① Vibrio cholerae\n② Bacillus anthracis\n③ Bordetella pertussis\n④ Clostridium botulinum\n⑤ Corynebacterium diphtheriae",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 구토형 장독소와 설사형 장독소를 생성하여 식중독을 일으키는 그람양성 세균은?\n\n① Bacillus cereus\n② Clostridioides (Clostridium) difficile\n③ Enterotoxigenic Escherichia coli\n④ Salmonella enterica\n⑤ Shigella dysenteriae",
        "question_text": "Question: Which Gram-positive bacterium causes food poisoning by producing both emetic and diarrheal enterotoxins?\n\n① Bacillus cereus\n② Clostridioides (Clostridium) difficile\n③ Enterotoxigenic Escherichia coli\n④ Salmonella enterica\n⑤ Shigella dysenteriae",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 부분적으로 이중나선 구조를 지닌 환형의 DNA를 유전체로 가지며, 유전체 복제에 역전사효소가 필요한 바이러스는?\n\n① 레오바이러스(reovirus)\n② 코로나바이러스(coronavirus)\n③ A형간염바이러스(hepatitis A virus)\n④ B형간염바이러스(hepatitis B virus)\n⑤ 파라인플루엔자바이러스(parainfluenza virus)",
        "question_text": "Question: Which virus has a circular DNA genome with a partially double-stranded structure and requires reverse transcriptase for genome replication?\n\n① Reovirus\n② Coronavirus\n③ Hepatitis A virus\n④ Hepatitis B virus\n⑤ Parainfluenza virus",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 종양을 유발하는 RNA 바이러스는?\n\n① 아데노바이러스(adenovirus)\n② 폴리오마바이러스(polyomavirus)\n③ 엡스타인-바바이러스(Epstein-Barr virus)\n④ 사람유두종바이러스(human papillomavirus)\n⑤ 사람T세포림프친화바이러스(human T-cell lymphotropic virus)",
        "question_text": "Question: Which of the following is an RNA virus that causes tumors?\n\n① Adenovirus\n② Polyomavirus\n③ Epstein-Barr virus\n④ Human papillomavirus\n⑤ Human T-cell lymphotropic virus",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 질염, 요도염, 전립샘염을 일으키는 원충은?\n\n① Candida albicans\n② Treponema pallidum\n③ Trichomonas vaginalis\n④ Plasmodium falciparum\n⑤ Mycoplasma genitalium",
        "question_text": "Question: Which protozoan causes vaginitis, urethritis, and prostatitis?\n\n① Candida albicans\n② Treponema pallidum\n③ Trichomonas vaginalis\n④ Plasmodium falciparum\n⑤ Mycoplasma genitalium",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 세균이 세포벽 생합성 효소의 기질인 D-알라닌과 입체구조가 유사하여 세포벽 합성을 억제하는 것은?\n\n① 바시트라신(bacitracin)\n② 시클로세린(cycloserine)\n③ 반코마이신(vancomycin)\n④ 아즈트레오남(aztreonam)\n⑤ 포스포마이신(fosfomycin)",
        "question_text": "Question: Which of the following inhibits bacterial cell wall synthesis by having a similar stereochemistry to D-alanine, which is a substrate for cell wall synthesis enzymes?\n\n① Bacitracin\n② Cycloserine\n③ Vancomycin\n④ Aztreonam\n⑤ Fosfomycin",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 옥사페남(oxapenam)환을 가지며 베타락탐 분해효소를 비가역적으로 억제하는 약물은?\n\n① 이미페넴(imipenem)\n② 세포탁심(cefotaxime)\n③ 티카르실린(ticarcillin)\n④ 아목시실린(amoxicillin)\n⑤ 클라불란산(clavulanic acid)",
        "question_text": "Question: Which drug has an oxapenam ring and irreversibly inhibits beta-lactamase?\n\n① Imipenem\n② Cefotaxime\n③ Ticarcillin\n④ Amoxicillin\n⑤ Clavulanic acid",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 시프로플록사신(ciprofloxacin)이 작용하는 세포내 표적 효소는?\n\n① DNA 연결효소(DNA ligase)\n② DNA 자이라제(DNA gyrase)\n③ DNA 중합효소(DNA polymerase)\n④ RNA 중합효소(RNA polymerase)\n⑤ 역전사효소(reverse transcriptase)",
        "question_text": "Question: What is the intracellular target enzyme for ciprofloxacin?\n\n① DNA ligase\n② DNA gyrase\n③ DNA polymerase\n④ RNA polymerase\n⑤ Reverse transcriptase",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 미감작 B 세포의 항원 수용체로 작용하며, 분비형의 경우 오량체를 형성하여 보체를 활성화하는 항체는?\n\n① IgA\n② IgD\n③ IgE\n④ IgG\n⑤ IgM",
        "question_text": "Question: Which antibody acts as an antigen receptor on naive B cells and, in its secreted form, forms a pentamer that activates complement?\n\n① IgA\n② IgD\n③ IgE\n④ IgG\n⑤ IgM",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: MHC class II 분자에 결합한 항원 펩티드를 CD4+ 조력 T 세포에 제시하는 세포는?\n\n① 적혈구\n② 호산구\n③ 비만세포\n④ 수지상세포\n⑤ 미감작 T 세포",
        "question_text": "Question: Which cells present antigen peptides bound to MHC class II molecules to CD4+ helper T cells?\n\n① Red blood cells\n② Eosinophils\n③ Mast cells\n④ Dendritic cells\n⑤ Naive T cells",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 내인성 항원제시 경로에서 항원 펩티드를 세포질에서 소포체로 수송하는 인자는?\n\n① TAP\n② HLA-DM\n③ MHC class II\n④ 카텝신S(cathepsin S)\n⑤ 불변사슬(invariant chain)",
        "question_text": "Question: In the endogenous antigen presentation pathway, which factor transports antigen peptides from the cytosol to the endoplasmic reticulum?\n\n① TAP\n② HLA-DM\n③ MHC class II\n④ Cathepsin S\n⑤ Invariant chain",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 사이토카인(cytokine)은?\n\n• NK 세포의 세포용해 기능을 활성화함\n• CD4+ 조력 TH1 세포로 분화하도록 유도함\n• p35와 p40 폴리펩티드 사슬로 구성된 이량체임\n\n① IL-1β\n② IL-4\n③ IL-6\n④ IL-10\n⑤ IL-12",
        "question_text": "Question: Which of the following cytokines has these characteristics?\n\n• Activates the cytolytic function of NK cells\n• Induces differentiation into CD4+ helper TH1 cells\n• Is a heterodimer composed of p35 and p40 polypeptide chains\n\n① IL-1β\n② IL-4\n③ IL-6\n④ IL-10\n⑤ IL-12",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 자가면역질환은?\n\n• 신경섬유를 둘러싼 수초(myelin sheath)에 염증이 생김\n• 수초를 파괴하는 자가반응 T 세포가 존재함\n• 말단의 가벼운 마비에서부터 전신마비 또는 실명이 나타남\n\n① 그레이브스병(Graves disease)\n② 다발경화증(multiple sclerosis)\n③ 중증근무력증(myasthenia gravis)\n④ 디조지증후군(DiGeorge syndrome)\n⑤ 류마티스관절염(rheumatoid arthritis)",
        "question_text": "Question: Which autoimmune disease has the following characteristics?\n\n• Inflammation occurs in the myelin sheath surrounding nerve fibers\n• Presence of self-reactive T cells that destroy myelin\n• Symptoms range from mild paralysis of extremities to total paralysis or blindness\n\n① Graves disease\n② Multiple sclerosis\n③ Myasthenia gravis\n④ DiGeorge syndrome\n⑤ Rheumatoid arthritis",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: 백신에 첨가되는 면역보조제(adjuvant)의 기능은?\n\n① 국소적 염증 억제\n② 공동자극신호 감소\n③ 시토카인의 활성 억제\n④ 항원제시 기간의 증가\n⑤ 림프구의 세포분열 억제",
        "question_text": "Question: What is the function of adjuvants added to vaccines?\n\n① Suppression of local inflammation\n② Reduction of co-stimulatory signals\n③ Inhibition of cytokine activity\n④ Increase in the duration of antigen presentation\n⑤ Inhibition of lymphocyte cell division",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 종양괴사인자-α(TNF-α)와 결합하는 사람 단클론항체 의약품으로, 파지전사기술을 이용하여 개발된 것은?\n\n① 리툭시맙(rituximab)\n② 세툭시맙(cetuximab)\n③ 아달리무맙(adalimumab)\n④ 오말리주맙(omalizumab)\n⑤ 트라스투주맙(trastuzumab)",
        "question_text": "Question: Which of the following human monoclonal antibody drugs that binds to tumor necrosis factor-α (TNF-α) was developed using phage display technology?\n\n① Rituximab\n② Cetuximab\n③ Adalimumab\n④ Omalizumab\n⑤ Trastuzumab",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n10년 전 사람면역결핍바이러스(HIV) 양성 진단을 받은 40세 남자가 망막염 증상을 보였다. 검사 결과 CD4+ 조력 T 세포수가 혈액 µL당 200개 이하로 나타났다.\n\nQuestion: 이 환자의 HIV 감염을 치료하기 위해 단백질분해효소를 표적으로 하는 약물을 사용하고자 한다. 이 약물은?\n\n① 리바비린(ribavirin)\n② 리토나비르(ritonavir)\n③ 라미부딘(lamivudine)\n④ 지도부딘(zidovudine)\n⑤ 테노포비르(tenofovir)",
        "question_text": "A 40-year-old man diagnosed with human immunodeficiency virus (HIV) positive 10 years ago showed symptoms of retinitis. Test results revealed that his CD4+ helper T cell count was below 200 cells per µL of blood.\n\nQuestion: A drug targeting protease is to be used to treat this patient's HIV infection. This drug is:\n\n① Ribavirin\n② Ritonavir\n③ Lamivudine\n④ Zidovudine\n⑤ Tenofovir",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n10년 전 사람면역결핍바이러스(HIV) 양성 진단을 받은 40세 남자가 망막염 증상을 보였다. 검사 결과 CD4+ 조력 T 세포수가 혈액 µL당 200개 이하로 나타났다.\n\nQuestion: 검사 결과, 망막염의 원인으로 거대세포바이러스(CMV)를 확인되었다. 이 환자의 망막염 치료에 사용할 수 있는 약물은?\n\n① 자나미비르(zanamivir)\n② 아만타딘(amantadine)\n③ 텔라프레비르(telaprevir)\n④ 레디파스비르(ledipasvir)\n⑤ 간시클로비르(ganciclovir)",
        "question_text": "A 40-year-old man diagnosed with human immunodeficiency virus (HIV) positive 10 years ago showed symptoms of retinitis. Test results revealed that his CD4+ helper T cell count was below 200 cells per µL of blood.\n\nQuestion: Upon examination, cytomegalovirus (CMV) was identified as the cause of retinitis. Which of the following drugs can be used to treat this patient's retinitis?\n\n① Zanamivir\n② Amantadine\n③ Telaprevir\n④ Ledipasvir\n⑤ Ganciclovir",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 리간드와 갈합 후에 G 단백질을 활성화하여 신호전달하는 수용체는?\n\n① 인슐린 수용체\n② 티로신 수용체\n③ 아드레날린 수용체\n④ 당질코르티코이드 수용체\n⑤ 니코틴성 아세틸콜린 수용체",
        "question_text": "Question: Which receptor activates G protein after binding with a ligand to transmit signals?\n\n① Insulin receptor\n② Tyrosine receptor\n③ Adrenergic receptor\n④ Glucocorticoid receptor\n⑤ Nicotinic acetylcholine receptor",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 스테로이드핵 구조를 포함하고 있고 지용성이 커서 체내에 축적될 수 있는 약물은?\n\n① 디곡신(digoxin)\n② 코데인(codeine)\n③ 카페인(caffeine)\n④ 펜토바르비탈(pentobarbital)\n⑤ 에리트로마이신(erythromycin)",
        "question_text": "Question: Which drug contains a steroid nucleus structure and has high lipophilicity, potentially leading to accumulation in the body?\n\n① Digoxin\n② Codeine\n③ Caffeine\n④ Pentobarbital\n⑤ Erythromycin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 부교감신경계 흥분 시에 나타나는 생체 반응은?\n\n① 동공 확대\n② 배뇨근 이완\n③ 심박수 감소\n④ 위산분비 억제\n⑤ 지방분해 촉진",
        "question_text": "Question: What is the physiological response when the parasympathetic nervous system is stimulated?\n\n① Pupil dilation\n② Relaxation of the detrusor muscle\n③ Decrease in heart rate\n④ Inhibition of gastric acid secretion\n⑤ Promotion of lipolysis",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 아드레날린 β2 수용체 효능약의 약리작용은?\n\n① 혈압수축\n② 안방수 생성 억제\n③ 기관지 평활근 이완\n④ 글리코겐 분해 억제\n⑤ 방광 괄약근 수축 억제",
        "question_text": "Question: What is the pharmacological action of adrenergic β2 receptor agonists?\n\n① Vasoconstriction\n② Inhibition of aqueous humor production\n③ Bronchial smooth muscle relaxation\n④ Inhibition of glycogen breakdown\n⑤ Inhibition of bladder sphincter contraction",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: α1 소단위를 가진 GABA_A 수용체에 선택적으로 결합하여 GABA에 의한 막전위 억제작용을 강화하는 약물은?\n\n① 잘레플론(zaleplon)\n② 라멜테온(ramelteon)\n③ 부스피론(buspirone)\n④ 플루마제닐(flumazenil)\n⑤ 프로메타진(promethazine)",
        "question_text": "Question: Which drug selectively binds to GABA_A receptors with α1 subunits, enhancing the membrane potential inhibitory action of GABA?\n\n① Zaleplon\n② Ramelteon\n③ Buspirone\n④ Flumazenil\n⑤ Promethazine",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 항우울약은?\n\n• 세로토닌과 노르에피네프린의 재흡수 억제\n• 무스카린성 아세틸콜린 수용체 길항\n• 아드레날린 α1 수용체 길항\n• 히스타민 H1 수용체 길항\n\n① 벤라팍신(venlafaxine)\n② 부프로피온(bupropion)\n③ 플루옥세틴(fluoxetine)\n④ 미르타자핀(mirtazapine)\n⑤ 아미트리프틸린(amitriptyline)",
        "question_text": "Question: Which antidepressant has the following characteristics?\n\n• Inhibition of serotonin and norepinephrine reuptake\n• Muscarinic acetylcholine receptor antagonism\n• Adrenergic α1 receptor antagonism\n• Histamine H1 receptor antagonism\n\n① Venlafaxine\n② Bupropion\n③ Fluoxetine\n④ Mirtazapine\n⑤ Amitriptyline",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 전압작동 K+ 이온통로 개방약으로 신경전달물질의 유리를 억제하는 항경련약은?\n\n① 티아가빈(tiagabine)\n② 레티가빈(retigabine)\n③ 페람파넬(perampanel)\n④ 에토숙시미드(ethosuximide)\n⑤ 카르바마제핀(carbamazepine)",
        "question_text": "Question: Which anticonvulsant drug inhibits the release of neurotransmitters by acting as a voltage-gated K+ ion channel opener?\n\n① Tiagabine\n② Retigabine\n③ Perampanel\n④ Ethosuximide\n⑤ Carbamazepine",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 도파민 D3 수용체에 대하여 선택적 친화성을 보이며 경미한 파킨슨병에 단독으로 사용하는 약은?\n\n① 레보도파(levodopa)\n② 라사길린(rasagiline)\n③ 아만타딘(amantadine)\n④ 엔타카폰(entacapone)\n⑤ 프라미펙솔(pramipexole)",
        "question_text": "Question: Which drug shows selective affinity for dopamine D3 receptors and is used alone for mild Parkinson's disease?\n\n① Levodopa\n② Rasagiline\n③ Amantadine\n④ Entacapone\n⑤ Pramipexole",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 아편류 중독 시 해독제로 사용되는 순수한 오피오이드 길항약(pure opioid antagonist)은?\n\n① 코카인(cocaine)\n② 메타돈(methadone)\n③ 날트렉손(naltrexone)\n④ 메페리딘(meperidine)\n⑤ 디펜히드라민(diphenhydramine)",
        "question_text": "Question: Which of the following is a pure opioid antagonist used as an antidote in opiate overdose?\n\n① Cocaine\n② Methadone\n③ Naltrexone\n④ Meperidine\n⑤ Diphenhydramine",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 독시라민(doxylamine)에 관한 설명으로 옳은 것은?\n\n① 혈관뇌장벽을 통과하지 못한다.\n② 히스타민 H2 수용체를 억제하여 위산 분비를 억제한다.\n③ 중추신경계의 히스타민 H1 수용체를 억제하여 진정작용이 강하다.\n④ 중추신경계의 뉴로키닌(neurokinin) NK1 수용체를 억제하여 진정작용이 강하다.\n⑤ 중추신경계의 뉴로텐신(neurotensin) NTR1 수용체를 억제하여 진정작용이 강하다.",
        "question_text": "Question: Which of the following statements about doxylamine is correct?\n\n① It cannot cross the blood-brain barrier.\n② It inhibits histamine H2 receptors, thereby suppressing gastric acid secretion.\n③ It has strong sedative effects by inhibiting histamine H1 receptors in the central nervous system.\n④ It has strong sedative effects by inhibiting neurokinin NK1 receptors in the central nervous system.\n⑤ It has strong sedative effects by inhibiting neurotensin NTR1 receptors in the central nervous system.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 화학요법제를 사용하고 있는 환자에서 오심과 구토를 완화하기 위해 사용하는 세로토닌 5-HT3 수용체 길항약은?\n\n① 에메틴(emetine)\n② 올살라진(olsalazine)\n③ 드로나비놀(dronabinol)\n④ 수마트립탄(sumatriptan)\n⑤ 그라니세트론(granisetron)",
        "question_text": "Question: Which serotonin 5-HT3 receptor antagonist is used to alleviate nausea and vomiting in patients undergoing chemotherapy?\n\n① Emetine\n② Olsalazine\n③ Dronabinol\n④ Sumatriptan\n⑤ Granisetron",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 혈액응고인자 Xa를 직접적으로 억제하여 항혈전효과를 나타내는 경구용 약물은?\n\n① 와파린(warfarin)\n② 알테플라제(alteplase)\n③ 리바록사반(rivaroxaban)\n④ 바이발리루딘(bivalirudin)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "Question: Which oral medication directly inhibits blood coagulation factor Xa to produce an antithrombotic effect?\n\n① Warfarin\n② Alteplase\n③ Rivaroxaban\n④ Bivalirudin\n⑤ Clopidogrel",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 아드레날린 α1 수용체를 길항하여 고혈압과 양성전립샘 비대 치료에 사용되는 약물은?\n\n① 라베탈롤(labetalol)\n② 캅토프릴(captopril)\n③ 클로니딘(clonidine)\n④ 독사조신(doxazosin)\n⑤ 트리암테렌(triamterene)",
        "question_text": "Question: Which drug is used to treat hypertension and benign prostatic hyperplasia by antagonizing adrenergic α1 receptors?\n\n① Labetalol\n② Captopril\n③ Clonidine\n④ Doxazosin\n⑤ Triamterene",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 심근의 K+ 통로를 차단하는 부정맥 치료제로서 투약 시 주기적으로 갑상샘 기능을 감시해야 하는 약은?\n\n① 리도카인(lidocaine)\n② 베라파밀(verapamil)\n③ 아미오다론(amiodarone)\n④ 플레카이니드(flecainide)\n⑤ 드로네다론(dronedarone)",
        "question_text": "Question: Which antiarrhythmic drug that blocks K+ channels in the myocardium requires periodic monitoring of thyroid function during administration?\n\n① Lidocaine\n② Verapamil\n③ Amiodarone\n④ Flecainide\n⑤ Dronedarone",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 신장 네프론에서 Na+의 재흡수를 감소시키고 Mg2+과 Ca2+ 배설을 증가시켜, 장기간 사용하면 저마그네슘혈증을 유발할 수 있는 이뇨제는?\n\n① 푸로세미드(furosemide)\n② 아미로라이드(amiloride)\n③ 에플레레논(eplerenone)\n④ 아세타졸아미드(acetazolamide)\n⑤ 하이드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "Question: Which diuretic decreases Na+ reabsorption in the renal nephron and increases Mg2+ and Ca2+ excretion, potentially causing hypomagnesemia with long-term use?\n\n① Furosemide\n② Amiloride\n③ Eplerenone\n④ Acetazolamide\n⑤ Hydrochlorothiazide",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 에티닐에스트라디올-레보노르게스트렐(ethinylestradiol-levonorgestrel) 복합제제 투여 시 나타나는 피임 효과의 기전은?\n\n① 배란 억제\n② 자궁 수축 억제\n③ 난포 성장 억제\n④ 황체형성호르몬 분비 자극\n⑤ 자궁 내막의 혈관 형성 억제",
        "question_text": "Question: What is the mechanism of contraceptive effect when administering the ethinylestradiol-levonorgestrel combination?\n\n① Inhibition of ovulation\n② Inhibition of uterine contractions\n③ Inhibition of follicular growth\n④ Stimulation of luteinizing hormone secretion\n⑤ Inhibition of vascular formation in the endometrium",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: ATP-민감성 K+ 통로를 억제하여 인슐린 분비를 촉진하는 2형당뇨병 치료약은?\n\n① 아카르보즈(acarbose)\n② 메트포르민(metformin)\n③ 리라글루티드(liraglutide)\n④ 글리메피리드(glimepiride)\n⑤ 피오글리타존(pioglitazone)",
        "question_text": "Question: Which type 2 diabetes medication promotes insulin secretion by inhibiting ATP-sensitive K+ channels?\n\n① Acarbose\n② Metformin\n③ Liraglutide\n④ Glimepiride\n⑤ Pioglitazone",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 클린다마이신(clindamycin)의 항균 작용기전은?\n\n① 엽산 대사를 방해한다.\n② 핵산 합성을 저해한다.\n③ DNA 복제를 억제한다.\n④ 단백질 합성을 억제한다.\n⑤ 세포벽 합성을 억제한다.",
        "question_text": "Question: What is the mechanism of antimicrobial action of clindamycin?\n\n① It interferes with folate metabolism.\n② It inhibits nucleic acid synthesis.\n③ It inhibits DNA replication.\n④ It inhibits protein synthesis.\n⑤ It inhibits cell wall synthesis.",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n약물은 다양한 유형의 수용체와 결합하여 약리작용을 나타낸다. 이 중 특정 유형의 수용체는 약물이 결합하는 부위, 세포막 지질층을 1회 통과하는 소수성 연결 부위, 효소 활성 부위로 구성되어 있다. 약물이 이러한 유형의 수용체에 결합하면 수용체의 구조변화(conformational change), 이량화(dimerization), 효소의 활성화 등을 포함하는 일련의 신호전달과정을 통해 약리작용을 나타낸다.\n\nQuestion: 위에서 설명하는 수용체 유형에 해당하는 것은?\n\n① GABA_B 수용체\n② 인슐린 수용체\n③ 세로토닌 수용체\n④ 에스트로겐 수용체\n⑤ 에리트로포이에틴 수용체",
        "question_text": "Drugs exhibit their pharmacological effects by binding to various types of receptors. Among these, a specific type of receptor consists of a drug-binding site, a hydrophobic connecting region that passes through the cell membrane lipid layer once, and an enzyme active site. When a drug binds to this type of receptor, it exerts its pharmacological effect through a series of signal transduction processes, including conformational changes of the receptor, dimerization, and enzyme activation.\n\nQuestion: Which of the following receptor types corresponds to the one described above?\n\n① GABA_B receptor\n② Insulin receptor\n③ Serotonin receptor\n④ Estrogen receptor\n⑤ Erythropoietin receptor",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n약물은 다양한 유형의 수용체와 결합하여 약리작용을 나타낸다. 이 중 특정 유형의 수용체는 약물이 결합하는 부위, 세포막 지질층을 1회 통과하는 소수성 연결 부위, 효소 활성 부위로 구성되어 있다. 약물이 이러한 유형의 수용체에 결합하면 수용체의 구조변화(conformational change), 이량화(dimerization), 효소의 활성화 등을 포함하는 일련의 신호전달과정을 통해 약리작용을 나타낸다.\n\nQuestion: 사람상피성장인자수용체(human epidermal growth factor receptor, EGFR)는 위에 기술한 수용체 유형에 해당된다. EGFR의 작용을 억제하는 단클론항체로, 비소세포폐암 치료에 사용하는 약물은?\n\n① 이매티닙(imatinib)\n② 소라페닙(sorafenib)\n③ 리툭시맙(rituximab)\n④ 베바시주맙(bevacizumab)\n⑤ 네시투무맙(necitumumab)",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nDrugs exhibit pharmacological effects by binding to various types of receptors. Among these, a specific type of receptor consists of a drug-binding site, a hydrophobic connecting region that passes through the cell membrane lipid layer once, and an enzyme active site. When a drug binds to this type of receptor, it exerts its pharmacological effect through a series of signal transduction processes, including conformational changes of the receptor, dimerization, and enzyme activation.\n\nQuestion: The human epidermal growth factor receptor (EGFR) belongs to the receptor type described above. Which of the following monoclonal antibodies that inhibits EGFR action is used in the treatment of non-small cell lung cancer?\n\n① Imatinib\n② Sorafenib\n③ Rituximab\n④ Bevacizumab\n⑤ Necitumumab",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 비감염병의 2차 예방법에 해당하는 것은?\n\n① 예방접종\n② 재활치료\n③ 영양소 보충\n④ 종합건강검진\n⑤ 쾌적한 작업환경 조성",
        "question_text": "Question: Which of the following is a secondary prevention method for non-infectious diseases?\n\n① Vaccination\n② Rehabilitation therapy\n③ Nutrient supplementation\n④ Comprehensive health screening\n⑤ Creating a comfortable work environment",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 다음은 특정인구집단의 선별검사 결과이다. 이 검사의 위양성률은?\n\n(단위: 명)\n| | 인구의 실제 특성 | | 계 |\n| | 질병 있음 | 질병 없음 | |\n| 검사결과 양성 | 90 | 45 | 135 |\n| 검사결과 음성 | 10 | 855 | 865 |\n| 계 | 100 | 900 | 1,000 |\n\n① 5%\n② 10%\n③ 67%\n④ 90%\n⑤ 95%",
        "question_text": "Question: The following is the result of a screening test for a specific population. What is the false positive rate of this test?\n\n(Unit: persons)\n| | Actual Characteristics of Population | | Total |\n| | Disease Present | Disease Absent | |\n| Test Result Positive | 90 | 45 | 135 |\n| Test Result Negative | 10 | 855 | 865 |\n| Total | 100 | 900 | 1,000 |\n\n① 5%\n② 10%\n③ 67%\n④ 90%\n⑤ 95%",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 유기오염물질은?\n\n• 화학물질 제조에 광범위하게 이용됨\n• 대사활성화가 독성유발에 필수적임\n• 만성 노출 시 백혈구감소증(leukopenia), 무형성빈혈(aplastic anemia), 혈액암을 유발함\n\n① 벤젠\n② 톨루엔\n③ 클로로포름\n④ 에틸렌글리콜\n⑤ 포름알데히드",
        "question_text": "Question: Which organic pollutant is described by the following?\n\n• Widely used in chemical manufacturing\n• Metabolic activation is essential for toxicity\n• Chronic exposure causes leukopenia, aplastic anemia, and blood cancer\n\n① Benzene\n② Toluene\n③ Chloroform\n④ Ethylene glycol\n⑤ Formaldehyde",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 암석이나 토양에서 유래하는 가스상 자연방사성 물질이며, 건물의 균열 및 상하수도 주변의 틈을 통해 실내로 유입되어 장기간 노출 시 폐암을 유발하는 것은?\n\n① 라돈(radon)\n② 토륨(thorium)\n③ 우라늄(uranium)\n④ 비스무스(bismuth)\n⑤ 스트론튬(strontium)",
        "question_text": "Question: Which gaseous naturally occurring radioactive material originates from rocks and soil, enters buildings through cracks and gaps around water pipes, and can cause lung cancer with long-term exposure?\n\n① Radon\n② Thorium\n③ Uranium\n④ Bismuth\n⑤ Strontium",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 하천의 고잉 유역되는 경우 부영양화의 원인이 되어 3차 하수처리를 통해 제거하는 물질은?\n\n① 철\n② 인\n③ 시안\n④ 카드뮴\n⑤ 염소이온",
        "question_text": "Question: Which substance, when flowing into river basins, becomes a cause of eutrophication and is removed through tertiary wastewater treatment?\n\n① Iron\n② Phosphorus\n③ Cyanide\n④ Cadmium\n⑤ Chloride ion",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 황이 함유된 물속에서 잘 번식하고, 사멸 후 세포내 존재하는 황이 환원되어 황화수소를 발생시키는 세균은?\n\n① Beggiatoa 속\n② Cladothrix 속\n③ Crenothrix 속\n④ Sphaerotilus 속\n⑤ Zoogloea 속",
        "question_text": "Question: Which bacteria reproduce well in sulfur-containing water and, after death, generate hydrogen sulfide due to the reduction of sulfur present within their cells?\n\n① Genus Beggiatoa\n② Genus Cladothrix\n③ Genus Crenothrix\n④ Genus Sphaerotilus\n⑤ Genus Zoogloea",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 황이 함유된 아미노산의 결합에 의해 저해될 수 있는 2상 대사 반응은?\n\n① 인산포합(phosphorylation)\n② 글리신포합(glycine conjugation)\n③ 글루쿠론산포합(glucuronidation)\n④ 글루타민포합(glutamine conjugation)\n⑤ 글루타티온포합(glutathione conjugation)",
        "question_text": "Question: Which phase II metabolic reaction can be inhibited by the binding of sulfur-containing amino acids?\n\n① Phosphorylation\n② Glycine conjugation\n③ Glucuronidation\n④ Glutamine conjugation\n⑤ Glutathione conjugation",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 소리부딘(sorivudine)과 테가푸르(tegaful)를 병용투여 했을 때, 약물상호작용으로 인해 5-플루오로우라실(5-fluorouracil)의 혈중농도가 상승하여 사망 사고가 발생했다. 이 상호작용의 주요 원인이 되는 효소는?\n\n① N-acetyltransferase\n② dihydropyrimidine dehydrogenase\n③ flavin monooxygenase\n④ glucose-6-phosphate dehydrogenase\n⑤ methemoglobin reductase",
        "question_text": "Question: When sorivudine and tegafur were co-administered, a fatal accident occurred due to an increase in the blood concentration of 5-fluorouracil as a result of drug interaction. Which enzyme is the main cause of this interaction?\n\n① N-acetyltransferase\n② dihydropyrimidine dehydrogenase\n③ flavin monooxygenase\n④ glucose-6-phosphate dehydrogenase\n⑤ methemoglobin reductase",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 간독성물질은?\n\n• 알광대버섯 성분임\n• 굴모양혈관(sinusoid) 수송체를 통해 간세포로 흡수되어 쓸개즙정체(cholestasis)를 유발함\n• 간세포 내에서 액틴필라멘트와 결합하여 세포골격의 기능 장애를 유발함\n\n① citridin\n② muscarine\n③ phalloidin\n④ achromelin\n⑤ α-amanitin",
        "question_text": "Question: Which of the following describes the hepatotoxic substance?\n\n• It is a component of Amanita phalloides (death cap mushroom)\n• It is absorbed into hepatocytes through sinusoidal transporters and causes cholestasis\n• It binds to actin filaments within hepatocytes, causing dysfunction of the cytoskeleton\n\n① citridin\n② muscarine\n③ phalloidin\n④ achromelin\n⑤ α-amanitin",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 혈중 protoporphyrin IX 농도를 측정하여 중독 여부를 판별하는 유해 중금속은?\n\n① 납\n② 비소\n③ 카드뮴\n④ 메틸수은\n⑤ 6가 크롬",
        "question_text": "Question: Which toxic heavy metal's poisoning is determined by measuring the blood concentration of protoporphyrin IX?\n\n① Lead\n② Arsenic\n③ Cadmium\n④ Methylmercury\n⑤ Hexavalent chromium",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 아세틸콜린에스터분해효소의 활성을 비가역적으로 저해하여 호흡부전에 의한 질식을 유발할 수 있으며, 아트로핀(atropine)이나 프랄리독심(pralidoxime) 투여로 중독증상이 완화되는 농약은?\n\n① aldicarb\n② aldrin\n③ DDT\n④ parathion\n⑤ rotenone",
        "question_text": "Question: Which pesticide irreversibly inhibits acetylcholinesterase activity, potentially causing asphyxiation due to respiratory failure, and whose poisoning symptoms can be alleviated by administering atropine or pralidoxime?\n\n① aldicarb\n② aldrin\n③ DDT\n④ parathion\n⑤ rotenone",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 중국에서 분유를 섭취한 수만 명의 영아들에게 급성 신장 독성을 일으킨 원인물질로, 체내에서 cyanuric acid와 결합하여 독성이 커지는 것은?\n\n① acrylamide\n② bisphenol A\n③ dibutyl phthalate\n④ melamine\n⑤ vinyl chloride",
        "question_text": "Question: What substance caused acute renal toxicity in tens of thousands of infants who consumed milk powder in China, and becomes more toxic when combined with cyanuric acid in the body?\n\n① acrylamide\n② bisphenol A\n③ dibutyl phthalate\n④ melamine\n⑤ vinyl chloride",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 무기질은?\n\n• 메티오닌이나 시스테인 유도체 형태로 식품을 통해 섭취되어 용이하게 흡수됨\n• 과산화지질의 생성 억제 및 분해에 관여함\n• 결핍 시 심근장애가 유발됨\n\n① 철\n② 구리\n③ 망간\n④ 아연\n⑤ 셀레늄",
        "question_text": "Question: Which mineral is described below?\n\n• It is easily absorbed when consumed through food in the form of methionine or cysteine derivatives\n• It is involved in inhibiting the formation and breakdown of lipid peroxides\n• Deficiency can cause myocardial disorders\n\n① Iron\n② Copper\n③ Manganese\n④ Zinc\n⑤ Selenium",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 질환은?\n\n• ATP7B 유전자와의 돌연변이에 의해 발생됨\n• 세룰로플라스민(ceruloplasmin)이 형성되지 못하여 쓸개즙을 통한 구리 배출이 억제됨\n• 파킨슨병과 유사한 신경계 증상 및 간경화증이 유발됨\n\n① Wilson병\n② Keshan병\n③ Minamata병\n④ Cushing증후군\n⑤ Hunter-Russel증후군",
        "question_text": "Question: Which disease is described below?\n\n• Caused by mutations in the ATP7B gene\n• Ceruloplasmin formation is inhibited, leading to suppressed copper excretion through bile\n• Causes neurological symptoms similar to Parkinson's disease and liver cirrhosis\n\n① Wilson's disease\n② Keshan disease\n③ Minamata disease\n④ Cushing's syndrome\n⑤ Hunter-Russell syndrome",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 식품의 부패과정에서 대장균과 비브리오속 세균에 의해 인돌(indole), 인돌 에틸알코올(indole ethylamine) 등의 분해산물을 생성하는 아미노산은?\n\n① 티로신\n② 오르니틴\n③ 히스티딘\n④ 트리프토판\n⑤ 페닐알라닌",
        "question_text": "Question: Which amino acid produces decomposition products such as indole and indole ethylamine during food spoilage by Escherichia coli and Vibrio species bacteria?\n\n① Tyrosine\n② Ornithine\n③ Histidine\n④ Tryptophan\n⑤ Phenylalanine",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 식중독 원인독소는?\n\n• 원산지품: 열대나 아열대 지역에서 서식하는 유독어류\n• 독성기전: Na+의 투과성을 증가시킴\n• 중독 시 특이증상: 저온물체에 접촉 시 통증을 느끼는 착감작증이 발생함\n\n① ciguatoxin\n② gonyautoxin\n③ okadaic acid\n④ tetrodotoxin\n⑤ vemerupin",
        "question_text": "Question: Which of the following is the food poisoning toxin described below?\n\n• Origin: Toxic fish species inhabiting tropical or subtropical regions\n• Toxicity mechanism: Increases the permeability of Na+\n• Unique symptom during intoxication: Dysesthesia occurs, causing pain when touching cold objects\n\n① ciguatoxin\n② gonyautoxin\n③ okadaic acid\n④ tetrodotoxin\n⑤ vemerupin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 곰팡이 독소는?\n\n• Aspergillus versicolor 곰팡이의 대사산물임\n• 간에서 대사되어 생성되는 epoxide체가 DNA와 공유결합을 형성함\n• 만성 노출에 의한 중독 시 간장애를 유발함\n\n① citreoviridin\n② ochratoxin A\n③ patulin\n④ sterigmatocystin\n⑤ zearalenone",
        "question_text": "Question: Which of the following describes the fungal toxin?\n\n• It is a metabolite of Aspergillus versicolor mold\n• The epoxide form generated by metabolism in the liver forms a covalent bond with DNA\n• Chronic exposure poisoning causes liver disorders\n\n① citreoviridin\n② ochratoxin A\n③ patulin\n④ sterigmatocystin\n⑤ zearalenone",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 식품첨가물은?\n\n• 환원작용에 의해 표백작용을 나타냄\n• 식품의 보존 중 갈변 및 착색 등의 변화를 억제하는 데 이용됨\n• 미생물의 증식을 억제하여 식품의 방부 또는 발효억제 목적으로도 사용됨\n\n① 벤조산(benzoic acid)\n② 황산제일철(ferrous sulfate)\n③ 아스코르브산(ascorbic acid)\n④ 아질산나트륨(sodium nitrite)\n⑤ 아황산나트륨(sodium sulfite)",
        "question_text": "Question: Which food additive is described below?\n\n• It exhibits bleaching action through reduction\n• It is used to inhibit changes such as browning and discoloration during food preservation\n• It is also used for food preservation or fermentation inhibition by suppressing microbial growth\n\n① Benzoic acid\n② Ferrous sulfate\n③ Ascorbic acid\n④ Sodium nitrite\n⑤ Sodium sulfite",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n평소에 불충분한 식사를 하는 60대 만성 알코올중독자에게 눈의 마비, 안구진탕(nystagmus), 조화운동불능(ataxia), 뇌병증(encephalopathy)이 발생하였다. 혈액검사 결과 transketolase의 활성 저하가 관찰되었다.\n\nQuestion: 위 증상을 개선하기 위해 사용할 수 있는 것은?\n\n① 비오틴(biotin)\n② 티아민(thiamine)\n③ 비타민A(vitamin A)\n④ 판토텐산(pantothenic acid)\n⑤ 아스코르브산(ascorbic acid)",
        "question_text": "A chronic alcoholic in their 60s who typically has insufficient meals developed eye paralysis, nystagmus, ataxia, and encephalopathy. Blood tests revealed decreased transketolase activity.\n\nQuestion: Which of the following can be used to improve the above symptoms?\n\n① Biotin\n② Thiamine\n③ Vitamin A\n④ Pantothenic acid\n⑤ Ascorbic acid",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n평소에 불충분한 식사를 하는 60대 만성 알코올중독자에게 눈의 마비, 안구진탕(nystagmus), 조화운동불능(ataxia), 뇌병증(encephalopathy)이 발생하였다. 혈액검사 결과 transketolase의 활성 저하가 관찰되었다.\n\nQuestion: 이 환자의 금주를 위해 디설피람(disulfiram)을 사용하고자 한다. 이 약물이 억제하는 효소는?\n\n① alcohol dehydrogenase\n② aldehyde dehydrogenase\n③ catalase\n④ CYP2E1\n⑤ flavin monooxygenase",
        "question_text": "A chronic alcoholic in his 60s who usually has insufficient meals developed eye paralysis, nystagmus, ataxia, and encephalopathy. Blood tests showed decreased activity of transketolase.\n\nQuestion: Disulfiram is to be used to help this patient abstain from alcohol. Which enzyme does this drug inhibit?\n\n① alcohol dehydrogenase\n② aldehyde dehydrogenase\n③ catalase\n④ CYP2E1\n⑤ flavin monooxygenase",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 아라키돈산에 작용하여 프로스타글란딘류를 생성하는 효소는?\n\n① 카스파제(caspase)\n② 지질산소화효소(lipoxygenase)\n③ 인지질분해효소(phospholipase)\n④ 시클로옥시게나제(cyclooxygenase)\n⑤ 금속단백질분해효소(metalloproteinase)",
        "question_text": "Question: Which enzyme acts on arachidonic acid to produce prostaglandins?\n\n① Caspase\n② Lipoxygenase\n③ Phospholipase\n④ Cyclooxygenase\n⑤ Metalloproteinase",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 외인성 감작항원으로 활성화된 T 세포가 매개하는 지연형 과민반응에 의해 발생하는 질환은?\n\n① 1형당뇨병\n② 무형성빈혈\n③ 접촉피부염\n④ 중증근무력증\n⑤ 전신홍반루푸스",
        "question_text": "Question: Which disease is caused by delayed-type hypersensitivity mediated by T cells activated by exogenous sensitizing antigens?\n\n① Type 1 diabetes\n② Aplastic anemia\n③ Contact dermatitis\n④ Myasthenia gravis\n⑤ Systemic lupus erythematosus",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 임의 등급(grading)을 정하는 기준은?\n\n① 림프절 전이 유무\n② 암세포의 분화 정도\n③ 원발성 병변의 크기\n④ 종양의 성장확산 정도\n⑤ 다른 장기로의 전이 유무",
        "question_text": "Question: What is the criterion for determining arbitrary grading?\n\n① Presence or absence of lymph node metastasis\n② Degree of cancer cell differentiation\n③ Size of the primary lesion\n④ Extent of tumor growth and spread\n⑤ Presence or absence of metastasis to other organs",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 화학적 발암과정의 개시단계(initiation)에서 나타나는 현상은?\n\n① 약성 종양 발생\n② DNA의 영구적 손상\n③ 돌연변이 세포의 증식\n④ 돌연변이 세포의 클론 확장\n⑤ 돌연변이 세포의 추가 변이",
        "question_text": "Question: What phenomenon occurs during the initiation stage of chemical carcinogenesis?\n\n① Development of benign tumors\n② Permanent damage to DNA\n③ Proliferation of mutated cells\n④ Clonal expansion of mutated cells\n⑤ Additional mutations in mutated cells",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 부종이 발생하는 원인으로 옳은 것은?\n\n① 림프관의 폐쇄\n② 혈장 알부민의 증가\n③ 모세혈관 정수압의 감소\n④ 모세혈관 투과성의 감소\n⑤ 세뇨관 Na⁺의 분비 증가",
        "question_text": "Question: Which of the following is a correct cause of edema?\n\n① Obstruction of lymphatic vessels\n② Increase in plasma albumin\n③ Decrease in capillary hydrostatic pressure\n④ Decrease in capillary permeability\n⑤ Increase in tubular Na⁺ secretion",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 골수에서 현저한 호중구성 백혈구의 증가를 나타내며, BCR-ABL 티로신키나제 활성의 증가가 특징인 질환은?\n\n① 급성골수성백혈병(AML)\n② 만성골수성백혈병(CML)\n③ 만성림프구백혈병(CLL)\n④ 급성림프모구백혈병(ALL)\n⑤ 골수형성이상증후군(MDS)",
        "question_text": "Question: Which disease is characterized by a significant increase in neutrophilic leukocytes in the bone marrow and increased BCR-ABL tyrosine kinase activity?\n\n① Acute Myeloid Leukemia (AML)\n② Chronic Myeloid Leukemia (CML)\n③ Chronic Lymphocytic Leukemia (CLL)\n④ Acute Lymphoblastic Leukemia (ALL)\n⑤ Myelodysplastic Syndrome (MDS)",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 심박출량과 말초혈관저항 만성적으로 증가되어 있을 때 생길 수 있는 변화는?\n\n① 맥압 감소\n② 심근 위축\n③ 동맥벽 비후\n④ 혈구용적 증가\n⑤ 혈관내 지질 축적",
        "question_text": "Question: What change can occur when cardiac output and peripheral vascular resistance are chronically increased?\n\n① Decreased pulse pressure\n② Myocardial atrophy\n③ Arterial wall hypertrophy\n④ Increased blood cell volume\n⑤ Accumulation of lipids within blood vessels",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 울혈성 심장기능상실(심부전)에서 나타나는 변화는?\n\n① 심박출량 증가\n② 레닌 분비 감소\n③ 사구체 여과 증가\n④ 폐모세혈관 압력 증가\n⑤ 신장에서의 Na⁺ 재흡수 감소",
        "question_text": "Question: What changes occur in congestive heart failure?\n\n① Increased cardiac output\n② Decreased renin secretion\n③ Increased glomerular filtration\n④ Increased pulmonary capillary pressure\n⑤ Decreased Na⁺ reabsorption in the kidneys",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "original_text": "Question: 협심증에서는 보상기전으로 심장 박동이 빨라지게 된다. 이 같은 현상을 유발하는 요인은?\n\n① 심근세포의 괴사\n② 심근세포의 칼슘 고갈\n③ 심근전도계의 기능 약화\n④ 심근세포의 수축력 증가\n⑤ 심근세포 내 산소요구량 증가",
        "question_text": "Question: In angina pectoris, heart rate increases as a compensatory mechanism. What factor causes this phenomenon?\n\n① Necrosis of myocardial cells\n② Calcium depletion in myocardial cells\n③ Weakening of the myocardial conduction system\n④ Increased contractility of myocardial cells\n⑤ Increased oxygen demand within myocardial cells",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "original_text": "Question: 급성호흡곤란증후군의 발생기전으로 옳은 것은?\n\n① 섬유소세포 활성 억제\n② 표면활성제 활성 억제\n③ 폐모세혈관 투과성 감소\n④ 백혈구의 혈관외유출 감소\n⑤ 염증성 시토카인 분비 억제",
        "question_text": "Question: Which of the following is correct regarding the mechanism of acute respiratory distress syndrome?\n\n① Inhibition of fibroblast activation\n② Inhibition of surfactant activity\n③ Decrease in pulmonary capillary permeability\n④ Decrease in leukocyte extravasation\n⑤ Inhibition of inflammatory cytokine secretion",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 소화기 질환은?\n\n• 헬리코박터균(Helicobacter pylori) 감염\n• 위날문(유문)이나 샘창자 점막의 손상\n• 위산 분비의 증가와 샘창자에서 중탄산염 분비의 감소\n\n① 소화궤양\n② 메켈곁주머니\n③ 메네트리에병\n④ 가족성샘종폴립증\n⑤ 카르시노이드종양",
        "question_text": "Question: Which gastrointestinal disorder has the following characteristics?\n\n• Helicobacter pylori infection\n• Damage to the pylorus or duodenal mucosa\n• Increased gastric acid secretion and decreased bicarbonate secretion in the duodenum\n\n① Peptic ulcer\n② Meckel's diverticulum\n③ Ménétrier's disease\n④ Familial adenomatous polyposis\n⑤ Carcinoid tumor",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "original_text": "Question: 권태감, 오른쪽 상복부 통증, 황달 증상이 나타나고, 중심 정맥 부위에 지방소포의 축적, 간세포괴사, 진행성섬유화, 말로리소체와 같은 병리소견을 수반하는 간질환은?\n\n① 알코올간염\n② 길버트증후군\n③ 유전혈색소증\n④ 자가면역간염\n⑤ 간정맥혈전증",
        "question_text": "Question: Which liver disease is characterized by symptoms such as fatigue, right upper abdominal pain, jaundice, and pathological findings including accumulation of fat vesicles in the central venous area, hepatocellular necrosis, progressive fibrosis, and Mallory bodies?\n\n① Alcoholic hepatitis\n② Gilbert's syndrome\n③ Hereditary hemochromatosis\n④ Autoimmune hepatitis\n⑤ Hepatic vein thrombosis",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "original_text": "Question: 분변경구오염(fecal-oral contamination) 경로로 감염되어 급성간염을 일으키고, 감염 후 대부분의 사람에서 평생면역을 형성하며, 국내에서 상용화된 백신으로 예방 가능한 간염 바이러스 형은?\n\n① A형\n② B형\n③ C형\n④ D형\n⑤ E형",
        "question_text": "Question: Which type of hepatitis virus is transmitted through fecal-oral contamination, causes acute hepatitis, forms lifelong immunity in most people after infection, and can be prevented by a commercially available vaccine in Korea?\n\n① Type A\n② Type B\n③ Type C\n④ Type D\n⑤ Type E",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "original_text": "Question: 다음 특성을 지닌 급성질환은?\n\n• 구토, 구역, 식욕부진을 동반한 복통\n• 혈청 아밀라제(amylase), 지질분해효소(lipase) 수치 상승\n\n① 간염\n② 위염\n③ 쓸개염\n④ 이자염\n⑤ 식도염",
        "question_text": "Question: Which acute condition has the following characteristics?\n\n• Abdominal pain accompanied by vomiting, nausea, and loss of appetite\n• Elevated serum amylase and lipase levels\n\n① Hepatitis\n② Gastritis\n③ Cholecystitis\n④ Pancreatitis\n⑤ Esophagitis",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "original_text": "Question: 면역이 저하된 사람의 요로에서 세균이 오름감염(ascending infection)에 의해 유발되는 신장질환은?\n\n① 신경화증(nephrosclerosis)\n② 신우신염(pyelonephritis)\n③ 급성세뇨관괴사(acute tubular necrosis)\n④ 굿패스처증후군(Goodpasture syndrome)\n⑤ 감염후사구체신염(postinfectious glomerulonephritis)",
        "question_text": "Question: Which kidney disease is caused by ascending infection of bacteria in the urinary tract of immunocompromised individuals?\n\n① Nephrosclerosis\n② Pyelonephritis\n③ Acute tubular necrosis\n④ Goodpasture syndrome\n⑤ Postinfectious glomerulonephritis",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "original_text": "Question: 어머니, 외할머니가 모두 유방암인 가족력이 있는 20대 여자의 유방암 발생 위험도를 확인하기 위해 시행하는 유전자 돌연변이 검사의 항목은?\n\n① APC\n② BCL2\n③ BRCA1\n④ MYC\n⑤ RB1",
        "question_text": "Question: For a woman in her 20s with a family history of breast cancer in both her mother and maternal grandmother, which gene mutation test should be performed to assess her risk of developing breast cancer?\n\n① APC\n② BCL2\n③ BRCA1\n④ MYC\n⑤ RB1",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "original_text": "Question: 소세포폐암으로 진단받은 환자에서 고혈압, 부종, 달덩이 같은 얼굴, 복부 줄무늬, 멍자국 등이 관찰되었다. 이러한 증상의 원인 진단을 위해 사용할 수 있는 지표 물질은?\n\n① 알도스테론\n② 세로토닌\n③ 성장호르몬\n④ 부갑상샘호르몬\n⑤ 부신피질자극호르몬",
        "question_text": "Question: A patient diagnosed with small cell lung cancer was observed to have hypertension, edema, moon face, abdominal striae, and bruising. What indicator substance can be used to diagnose the cause of these symptoms?\n\n① Aldosterone\n② Serotonin\n③ Growth hormone\n④ Parathyroid hormone\n⑤ Adrenocorticotropic hormone",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "original_text": "Question: 혈관내피세포성장인자(VEGF) 억제제를 사용할 수 있는 안과 증상은?\n\n① 각막궤양\n② 망막감염\n③ 안구돌출\n④ 황반부종\n⑤ 망막동맥경화",
        "question_text": "Question: Which ophthalmic condition can be treated with vascular endothelial growth factor (VEGF) inhibitors?\n\n① Corneal ulcer\n② Retinal infection\n③ Exophthalmos\n④ Macular edema\n⑤ Retinal arteriosclerosis",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n심한 허리 통증으로 당질코르티코이드(glucocorticoid)와 비스테로이드소염약(NSAID)을 장기 복용하고 있던 60대 여자가 넘어져서 척추가 골절되었다. 이중에너지방사선흡수법 검사 결과 골밀도 감소가 확인되었고, 혈액 검사 결과 칼슘과 인의 농도는 정상이었다.\n\nQuestion: 이 환자에서 골밀도 감소의 병태생리기전은?\n\n① 요산염 결정 침착\n② 골모세포 활성 증가\n③ 연골세포 활성 증가\n④ 파골세포 활성 증가\n⑤ 층판뼈의 모자이크양상 재형성",
        "question_text": "A woman in her 60s, who had been taking glucocorticoids and NSAIDs long-term for severe back pain, fell and fractured her spine. A dual-energy X-ray absorptiometry (DXA) scan confirmed decreased bone density, and blood tests showed normal calcium and phosphorus levels.\n\nQuestion: What is the pathophysiological mechanism of bone density reduction in this patient?\n\n① Deposition of urate crystals\n② Increased osteoblast activity\n③ Increased chondrocyte activity\n④ Increased osteoclast activity\n⑤ Mosaic pattern remodeling of lamellar bone",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n심한 허리 통증으로 당질코르티코이드(glucocorticoid)와 비스테로이드소염약(NSAID)을 장기 복용하고 있던 60대 여자가 넘어져서 척추가 골절되었다. 이중에너지방사선흡수법 검사 결과 골밀도 감소가 확인되었고, 혈액 검사 결과 칼슘과 인의 농도는 정상이었다.\n\nQuestion: 골절 후 환자는 의사 지시에 따라 당질코르티코이드 복용을 중단하였다. 예상되는 변화는?\n\n① 면역기능 약화\n② 염증반응 감소\n③ 고혈압 위험 증가\n④ 고혈당 위험 증가\n⑤ 골다공증 위험 감소",
        "question_text": "A woman in her 60s, who had been taking glucocorticoids and NSAIDs long-term for severe back pain, fell and fractured her spine. A dual-energy X-ray absorptiometry (DXA) scan confirmed decreased bone density, while blood tests showed normal calcium and phosphorus levels.\n\nQuestion: After the fracture, the patient stopped taking glucocorticoids as instructed by her doctor. What is the expected change?\n\n① Weakened immune function\n② Decreased inflammatory response\n③ Increased risk of hypertension\n④ Increased risk of hyperglycemia\n⑤ Decreased risk of osteoporosis",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 에어로솔제의 분사제(propellant)인 기체 수소불화탄소류(hydrofluorocarbons)를 액체 상태로 용기에 충전할 수 있는 방법은?\n\n① 대기압 이하로 감압하고 상온에서 주입한다.\n② 대기압에서 상온 이상으로 가열하여 주입한다.\n③ 대기압 이상에서 비등점 미만으로 냉각하여 주입한다.\n④ 대기압 이하에서 임계온도 이상으로 가열하여 주입한다.\n⑤ 임계압력 이상에서 임계온도 이상으로 가열하여 주입한다.",
        "question_text": "Question: What is the method to fill hydrofluorocarbons, which are propellants for aerosol products, into containers in liquid state?\n\n① Depressurize below atmospheric pressure and inject at room temperature.\n② Heat above room temperature and inject at atmospheric pressure.\n③ Cool below boiling point and inject at pressure higher than atmospheric pressure.\n④ Heat above critical temperature and inject at pressure below atmospheric pressure.\n⑤ Heat above critical temperature and inject at pressure above critical pressure.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 20°C에서 각각 고체로 존재하는 리도카인과 프릴로카인을 1:1의 중량비로 섞어서 20°C에서 단일한 액체상을 형성하도록 만든 것은?\n\n① 고용체\n② 동소체\n③ 용매화물\n④ 초임계유체\n⑤ 공융혼합물",
        "question_text": "Question: What is formed when lidocaine and prilocaine, both existing as solids at 20°C, are mixed in a 1:1 weight ratio to create a single liquid phase at 20°C?\n\n① Solid solution\n② Allotrope\n③ Solvate\n④ Supercritical fluid\n⑤ Eutectic mixture",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 전해질 가교된 카르복시메틸셀룰로오스나트륨으로 이루어진 건조 하이드로겔이 물에서 팽윤할 때, 팽윤의 추진력은? (단, 물의 온도는 일정하고 하이드로겔은 반투막으로 둘러싸여 있다.)\n\n① 삼투압\n② 응집력\n③ 전단응력\n④ 표면장력\n⑤ 활성화에너지",
        "question_text": "Question: What is the driving force for swelling when a dry hydrogel composed of crosslinked sodium carboxymethylcellulose swells in water? (Note: The water temperature is constant, and the hydrogel is surrounded by a semipermeable membrane.)\n\n① Osmotic pressure\n② Cohesive force\n③ Shear stress\n④ Surface tension\n⑤ Activation energy",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 단백질의약품의 물리적 안정성 평가 시 α-helix, β-sheet 등의 2차 구조 변화를 분석할 수 있는 방법은?\n\n① 칼피셔법\n② 에드만분해법\n③ 원편광이색성 분광법\n④ 유도결합 플라즈마 분석법\n⑤ SDS를 이용한 전기영동법",
        "question_text": "Question: Which method can be used to analyze changes in secondary structures such as α-helix and β-sheet when evaluating the physical stability of protein pharmaceuticals?\n\n① Karl Fischer method\n② Edman degradation method\n③ Circular dichroism spectroscopy\n④ Inductively coupled plasma analysis\n⑤ SDS-polyacrylamide gel electrophoresis",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 약물-단백질 결합 분석에서 동적투석(dynamic dialysis)을 통해 알 수 있는 것은?\n\n① 약물의 용해도\n② 약물의 분배계수\n③ 약물의 결합부위\n④ 비결합형 약물농도\n⑤ 약물-단백질 복합체의 3차 구조",
        "question_text": "Question: What can be determined through dynamic dialysis in drug-protein binding analysis?\n\n① Solubility of the drug\n② Distribution coefficient of the drug\n③ Binding site of the drug\n④ Unbound drug concentration\n⑤ Tertiary structure of the drug-protein complex",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 히드로퀴논 분자들 간의 수소결합에 의해 형성된 새장모양 격자 안에 메탄올과 같은 작은 분자가 붙잡혀 결정화되는 착물은?\n\n① 액정(liquid crystal)\n② 클라드레트(clathrate)\n③ 동종회합(self-association)\n④ 시클로덱스트린(cyclodextrin)\n⑤ 소용매성 콜로이드(lyophobic colloid)",
        "question_text": "Question: What is the complex formed when small molecules like methanol are trapped and crystallized within a cage-like lattice formed by hydrogen bonding between hydroquinone molecules?\n\n① Liquid crystal\n② Clathrate\n③ Self-association\n④ Cyclodextrin\n⑤ Lyophobic colloid",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 인공눈물 A는 안구가 움직이지 않을 때의 점도보다 안구가 움직일 때의 점도가 더 낮아진다. 이러한 인공눈물 A의 유동학적 특성은?\n\n① 전단박화(shear thinning)\n② 뉴턴흐름(Newtonian flow)\n③ 전단후화(shear thickening)\n④ 딜레이턴트흐름(dilatant flow)\n⑤ 부틱소트로피(negative thixotropy)",
        "question_text": "Question: Artificial tear A has a lower viscosity when the eye is moving compared to when the eye is stationary. What is the rheological characteristic of this artificial tear A?\n\n① Shear thinning\n② Newtonian flow\n③ Shear thickening\n④ Dilatant flow\n⑤ Negative thixotropy",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 0.005 mol/L 아트로핀황산염(atropine sulfate) 수용액의 이온강도는 0.005 mol/L 염화나트륨 수용액의 이온강도의 몇 배인가?\n\n① 2\n② 3\n③ 4\n④ 5\n⑤ 6",
        "question_text": "Question: How many times greater is the ionic strength of a 0.005 mol/L atropine sulfate aqueous solution compared to the ionic strength of a 0.005 mol/L sodium chloride aqueous solution?\n\n① 2\n② 3\n③ 4\n④ 5\n⑤ 6",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 염산 수용액을 대기압에서 계속 분별증류하면, 액체상과 기체상에서 더 이상 조성의 변화가 없이 일정한 조성이 20.22%로 일정하게 된다. 이러한 특성을 지니는 것은?\n\n① 이량체(dimer)\n② 공결정(corystal)\n③ 용매화물(solvate)\n④ 공비혼합물(azeotropic mixture)\n⑤ 내포화합물(inclusion compound)",
        "question_text": "Question: When hydrochloric acid solution is continuously fractionally distilled at atmospheric pressure, the composition in both liquid and gas phases remains constant at 20.22% without further changes. Which of the following exhibits this characteristic?\n\n① Dimer\n② Cocrystal\n③ Solvate\n④ Azeotropic mixture\n⑤ Inclusion compound",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 어는점내림이 0.52°C인 코카인염산염 수용액의 몰농도(mol/L)는? (단, 코카인염산염의 L_iso값은 3.4이고, 몰농도와 몰랄농도의 차이는 무시한다.)\n\n① 1/100\n② 1/20\n③ 11/168\n④ 13/85\n⑤ 34/99",
        "question_text": "Question: What is the molar concentration (mol/L) of a cocaine hydrochloride solution with a freezing point depression of 0.52°C? (Note: The L_iso value of cocaine hydrochloride is 3.4, and the difference between molar concentration and molal concentration is ignored.)\n\n① 1/100\n② 1/20\n③ 11/168\n④ 13/85\n⑤ 34/99",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 프로카인염산염 1.0g과 동일한 삼투압을 나타내는 염화나트륨의 질량(g)은? (단, 프로카인염산염의 분자량은 273이고, L_iso값은 3.4이다. 염화나트륨의 화학식량은 58이고, L_iso값은 3.4이다.)\n\n① 0.17\n② 0.21\n③ 0.42\n④ 1.7\n⑤ 3.4",
        "question_text": "Question: What is the mass (g) of sodium chloride that shows the same osmotic pressure as 1.0g of procaine hydrochloride? (Note: The molecular weight of procaine hydrochloride is 273, and its L_iso value is 3.4. The formula weight of sodium chloride is 58, and its L_iso value is 3.4.)\n\n① 0.17\n② 0.21\n③ 0.42\n④ 1.7\n⑤ 3.4",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 유상(O)에서는 회합되지 않고 수상(W)에서 해리되는 약산 HA를 기름과 물의 혼합액에 분배하였을 때 겉보기 분배계수는? (단, 분배계수 = 유상에서의 농도 / 수상에서의 농도)\n\n① [A-]w / [HA]₀\n② [HA]₀ / [HA]w\n③ [HA]₀ / [A-]w\n④ [HA]₀ / ([HA]w + [A-]w)\n⑤ [A-]w / ([HA]w + [HA]o)",
        "question_text": "Question: What is the apparent distribution coefficient when a weak acid HA, which does not associate in the oil phase (O) but dissociates in the water phase (W), is distributed in a mixture of oil and water? (Note: Distribution coefficient = concentration in oil phase / concentration in water phase)\n\n① [A-]w / [HA]₀\n② [HA]₀ / [HA]w\n③ [HA]₀ / [A-]w\n④ [HA]₀ / ([HA]w + [A-]w)\n⑤ [A-]w / ([HA]w + [HA]o)",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 25°C에서 약물 A와 약물 B는 각각 1차 반응에 의해 분해된다. 약물 A의 1차 반응속도상수가 0.1×10^-5 h^-1이고, 약물 B의 1차 반응속도상수는 1×10^-5 h^-1일 때, 약물 A의 반감기는?\n\n① 약물 B의 반감기 × 0.693\n② 약물 B의 반감기 × 2\n③ 약물 B의 반감기 × 2.303\n④ 약물 B의 반감기 × 5\n⑤ 약물 B의 반감기 × 10",
        "question_text": "Question: At 25°C, drug A and drug B decompose by first-order reactions. If the first-order rate constant for drug A is 0.1×10^-5 h^-1 and the first-order rate constant for drug B is 1×10^-5 h^-1, what is the half-life of drug A?\n\n① Half-life of drug B × 0.693\n② Half-life of drug B × 2\n③ Half-life of drug B × 2.303\n④ Half-life of drug B × 5\n⑤ Half-life of drug B × 10",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 25°C에서 1차 반응에 따라 분해되는 약물의 분해 반응속도 상수는 1.05×10^-5 h^-1이다. 이 약물의 초기농도가 200 unit/mL일 때 약물의 농도가 180 unit/mL가 될 때까지 걸리는 시간 (h)은? (단, ln 200/180 = 0.105이다.)\n\n① 100\n② 1,000\n③ 10,000\n④ 100,000\n⑤ 1,000,000",
        "question_text": "Question: The decomposition rate constant of a drug that decomposes according to first-order reaction at 25°C is 1.05×10^-5 h^-1. When the initial concentration of this drug is 200 units/mL, how long (in hours) will it take for the drug concentration to reach 180 units/mL? (Note: ln 200/180 = 0.105)\n\n① 100\n② 1,000\n③ 10,000\n④ 100,000\n⑤ 1,000,000",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 교체표면에 액체방울을 떨어뜨렸을 때 접촉점에서 액체표면과 고체표면의 접촉각은 θ이다. 고체의 표면장력(γ_S), 액체의 표면장력(γ_L), 액체와 고체 사이의 계면장력(γ_LS)의 평형상태를 나타내는 관계식은?\n\n① γ_S = γ_L - γ_LS\n② γ_S = γ_LS - γ_L cosθ\n③ γ_S = γ_LS + γ_L cosθ\n④ γ_S = γ_L + γ_LS cosθ\n⑤ γ_S = γ_L - γ_LS cosθ",
        "question_text": "Question: When a liquid droplet is placed on a solid surface, the contact angle between the liquid surface and the solid surface at the point of contact is θ. What is the equation that represents the equilibrium state between the surface tension of the solid (γ_S), the surface tension of the liquid (γ_L), and the interfacial tension between the liquid and solid (γ_LS)?\n\n① γ_S = γ_L - γ_LS\n② γ_S = γ_LS - γ_L cosθ\n③ γ_S = γ_LS + γ_L cosθ\n④ γ_S = γ_L + γ_LS cosθ\n⑤ γ_S = γ_L - γ_LS cosθ",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 비이온성계면활성제 A와 B의 임계미셀농도가 각각 8.0×10^-5 mol/L와 3.0×10^-5 mol/L이다. 비이온성계면활성제 A와 B를 2:3의 몰농도비로 섞은 혼합물의 임계미셀농도 (mol/L)는? (단, 혼합물은 이상적인 혼합미셀을 형성한다.)\n\n① 5.0×10^-6\n② 4.0×10^-5\n③ 3.0×10^-5\n④ 5.0×10^-3\n⑤ 1.0×10^-2",
        "question_text": "Question: The critical micelle concentrations of non-ionic surfactants A and B are 8.0×10^-5 mol/L and 3.0×10^-5 mol/L, respectively. What is the critical micelle concentration (mol/L) of a mixture of non-ionic surfactants A and B mixed in a molar concentration ratio of 2:3? (Assume that the mixture forms ideal mixed micelles.)\n\n① 5.0×10^-6\n② 4.0×10^-5\n③ 3.0×10^-5\n④ 5.0×10^-3\n⑤ 1.0×10^-2",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "original_text": "그림은 정상상태에서의 다층 확산을 통한 약물 투과를 나타낸 모식도이다. 각 확산층에서의 약물 농도는 C1~C5이다. 정적 물확산층과 막의 두께는 각각 ha와 hm이다.\n\n<Data (confidential)>\n\nQuestion: 약물이 막을 투과하는 과정과 관련된 분배계수(K)는?\n\n① C1/C3\n② C3/C1\n③ C3/C2\n④ C5/C1\n⑤ C5/C3",
        "question_text": "The figure shows a schematic diagram of drug permeation through multi-layer diffusion at steady state. The drug concentrations in each diffusion layer are C1 to C5. The thicknesses of the static aqueous diffusion layer and the membrane are ha and hm, respectively.\n\n<Data (confidential)>\n\nQuestion: What is the partition coefficient (K) related to the process of drug permeation through the membrane?\n\n① C1/C3\n② C3/C1\n③ C3/C2\n④ C5/C1\n⑤ C5/C3",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "original_text": "그림은 정상상태에서의 다층 확산을 통한 약물 투과를 나타낸 모식도이다. 각 확산층에서의 약물 농도는 C1~C5이다. 정적 물확산층과 막의 두께는 각각 ha와 hm이다.\n\n<Data (confidential)>\n\nQuestion: 정적 물확산층을 통한 확산과정이 약물 확산의 속도결정 단계일 때, 정상상태 확산류(J)는? (단, K는 분배계수이며, Da는 정적 물확산층에서의 약물 확산계수이고, Dm은 막 내에서의 약물확산 계수이다.\n\n① Da/ha (C1-C5)\n② Da/2ha (C1-C5)\n③ KDm/hm (C1-C5)\n④ KDm/ha (C1-C5)\n⑤ KDa/2hm (C1-C5)",
        "question_text": "The figure shows a schematic diagram of drug permeation through multi-layer diffusion at steady state. The drug concentrations in each diffusion layer are C1 to C5. The thicknesses of the static aqueous diffusion layer and the membrane are ha and hm, respectively.\n\n<Data (confidential)>\n\nQuestion: When the diffusion process through the static aqueous diffusion layer is the rate-determining step for drug diffusion, what is the steady-state diffusion flux (J)? (Note: K is the partition coefficient, Da is the drug diffusion coefficient in the static aqueous diffusion layer, and Dm is the drug diffusion coefficient in the membrane.)\n\n① Da/ha (C1-C5)\n② Da/2ha (C1-C5)\n③ KDm/hm (C1-C5)\n④ KDm/ha (C1-C5)\n⑤ KDa/2hm (C1-C5)",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: Catechol-O-methyltransferase (COMT)에 의해 대사되는 구조를 가진 약물은?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which drug has a structure that is metabolized by Catechol-O-methyltransferase (COMT)?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 소화관에서 흡수가 잘되고 혈액뇌장벽을 쉽게 통과하는 알츠하이머병 치료 약물은?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which drug used for treating Alzheimer's disease is well absorbed in the gastrointestinal tract and easily crosses the blood-brain barrier?\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 정량적 구조-활성 상관관계(QSAR) 인자로서, 치환기의 소수성이 약물과 수용체의 결합에 기여하는 정도를 나타내는 것은?\n\n① σ\n② π\n③ ES\n④ MR\n⑤ Ki",
        "question_text": "Question: Which of the following quantitative structure-activity relationship (QSAR) parameters represents the degree to which the hydrophobicity of a substituent contributes to the binding between a drug and its receptor?\n\n① σ\n② π\n③ ES\n④ MR\n⑤ Ki",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 다음 변환에 사용하는 반응은?\n\n<Data (confidential)>\n\n① Ullmann 반응\n② haloform 반응\n③ Sandmeyer 반응\n④ Friedel-Crafts 반응\n⑤ Eschweiler-Clarke 반응",
        "question_text": "Question: Which reaction is used for the following transformation?\n\n<Data (confidential)>\n\n① Ullmann reaction\n② Haloform reaction\n③ Sandmeyer reaction\n④ Friedel-Crafts reaction\n⑤ Eschweiler-Clarke reaction",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 이매티닙(imatinib)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A의 중심 골격은?\n\n<Data (confidential)>\n\n① pyrazine\n② piperidine\n③ pyridazine\n④ pyrimidine\n⑤ pyrrolidine",
        "question_text": "Question: During the synthesis process of imatinib, what is the central skeleton of the intermediate A obtained from the following reaction?\n\n<Data (confidential)>\n\n① pyrazine\n② piperidine\n③ pyridazine\n④ pyrimidine\n⑤ pyrrolidine",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 다음 합성 과정에서 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① 카르비도파(carbidopa)\n② 라모트리진(lamotrigine)\n③ 옥시부티닌(oxybutynin)\n④ 아미트리프틸린(amitriptyline)\n⑤ 카르바마제핀(carbamazepine)",
        "question_text": "Question: Which drug A is obtained from the following synthesis process?\n\n<Data (confidential)>\n\n① Carbidopa\n② Lamotrigine\n③ Oxybutynin\n④ Amitriptyline\n⑤ Carbamazepine",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 다음 물질을 원료로 사용하여 제조되는 약물은?\n\n<Data (confidential)>\n\n① 와파린(warfarin)\n② 아트로핀(atropine)\n③ 딜티아젬(diltiazem)\n④ 톨라자미드(tolazamide)\n⑤ 클로피브레이트(clofibrate)",
        "question_text": "Question: Which drug is manufactured using the following substance as a raw material?\n\n<Data (confidential)>\n\n① Warfarin\n② Atropine\n③ Diltiazem\n④ Tolazamide\n⑤ Clofibrate",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "original_text": "Question: 다음 합성 과정에서 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① 살부타몰(salbutamol)\n② 옥시부티닌(oxybutynin)\n③ 프로피베린(propiverine)\n④ 이프라트로퓸(ipratropium)\n⑤ 트로픽아미드(tropicamide)",
        "question_text": "Question: Which drug A is obtained from the following synthesis process?\n\n<Data (confidential)>\n\n① Salbutamol\n② Oxybutynin\n③ Propiverine\n④ Ipratropium\n⑤ Tropicamide",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "original_text": "Question: 아미오다론(amiodarone)의 구조에서 결합 A와 B의 형성에 공통적으로 사용하는 반응은?\n\n<Data (confidential)>\n\n① Claisen condensation\n② Darzens condensation\n③ Friedel-Crafts acylation\n④ Beckmann rearrangement\n⑤ Gabriel-Colman rearrangement",
        "question_text": "Question: What reaction is commonly used in the formation of both bonds A and B in the structure of amiodarone?\n\n<Data (confidential)>\n\n① Claisen condensation\n② Darzens condensation\n③ Friedel-Crafts acylation\n④ Beckmann rearrangement\n⑤ Gabriel-Colman rearrangement",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 다음 합성 과정에서 얻어지는 약물 A는?\n\n<Data (confidential)>\n\n① 라미프릴(ramipril)\n② 딜티아젬(diltiazem)\n③ 푸로세미드(furosemide)\n④ 히드랄라진(hydralazine)\n⑤ 클로로티아지드(chlorothiazide)",
        "question_text": "Question: Which drug A is obtained from the following synthesis process?\n\n<Data (confidential)>\n\n① Ramipril\n② Diltiazem\n③ Furosemide\n④ Hydralazine\n⑤ Chlorothiazide",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 실로스타졸(cilostazol)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A의 중심 골격은?\n\n<Data (confidential)>\n\n① oxazole\n② triazole\n③ thiazole\n④ tetrazole\n⑤ imidazole",
        "question_text": "Question: In the synthesis process of cilostazol, what is the central skeleton of the intermediate A obtained from the following reaction?\n\n<Data (confidential)>\n\n① oxazole\n② triazole\n③ thiazole\n④ tetrazole\n⑤ imidazole",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 오메프라졸(omeprazole)의 합성 과정 중 다음 반응에서 얻어지는 중간체 A는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: Which intermediate A is obtained from the following reaction during the synthesis process of omeprazole?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 다음 골격을 포함하는 약물은?\n\n<Data (confidential)>\n\n① 졸피뎀(zolpidem)\n② 디아제팜(diazepam)\n③ 타목시펜(tamoxifen)\n④ 돔페리돈(domperidone)\n⑤ 메트로니다졸(metronidazole)",
        "question_text": "Question: Which of the following drugs includes this skeleton?\n\n<Data (confidential)>\n\n① Zolpidem\n② Diazepam\n③ Tamoxifen\n④ Domperidone\n⑤ Metronidazole",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 칼슘채널차단제인 니페디핀(nifedipine)에 관한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 분자는 대칭 구조를 지닌다.\n② 1번 위치의 질소에 치환기가 도입되면 저해활성은 증가된다.\n③ 3번 위치의 에스터가 니트로기로 치환되어도 저해활성은 유지된다.\n④ 4번 위치의 페닐 고리가 dihydropyridine과 같은 평면에 있다.\n⑤ dihydropyridine의 piperidine 고리로 환원되어도 저해활성은 유지된다.",
        "question_text": "Question: Which of the following statements about nifedipine, a calcium channel blocker, is correct?\n\n① The molecule has a symmetrical structure.\n② The inhibitory activity increases when a substituent is introduced at the nitrogen in position 1.\n③ The inhibitory activity is maintained even when the ester at position 3 is replaced with a nitro group.\n④ The phenyl ring at position 4 is in the same plane as the dihydropyridine.\n⑤ The inhibitory activity is maintained even when the dihydropyridine ring is reduced to a piperidine ring.",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: Phenylisopropylamine계 약물의 중추신경 흥분작용에 대한 구조-활성 상관관계에 관한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① (a): hydroxy기가 도입되면 효능이 증가한다.\n② (b): N-알킬화로 3차 아민이 되면 효능이 증가한다.\n③ (c): (S)-이성질체가 (R)-이성질체보다 효능이 크다.\n④ (d): methyl기가 제거되면 작용시간이 길어진다.\n⑤ (e): hydroxy기가 도입되면 효능이 증가한다.",
        "question_text": "Question: Which of the following statements is correct regarding the structure-activity relationship of phenylisopropylamine derivatives on central nervous system stimulation?\n\n<Data (confidential)>\n\n① (a): The introduction of a hydroxy group increases potency.\n② (b): N-alkylation to form a tertiary amine increases potency.\n③ (c): The (S)-isomer has greater potency than the (R)-isomer.\n④ (d): Removal of the methyl group prolongs the duration of action.\n⑤ (e): The introduction of a hydroxy group increases potency.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 혈소판의 P2Y12 퓨린성 수용체와 결합하는 클로피도그렐(clopidogrel)의 활성형 대사체는?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "question_text": "Question: What is the active metabolite of clopidogrel that binds to the P2Y12 purinergic receptor of platelets?\n\n<Data (confidential)>\n\n① <Data (confidential)>\n② <Data (confidential)>\n③ <Data (confidential)>\n④ <Data (confidential)>\n⑤ <Data (confidential)>",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n• 5-플루오로우라실(5-fluorouracil)은 체내에서 5-fluorodeoxyuridine monophosphate (5-F-dUMP)로 대사된다.\n• 5-F-dUMP는 N5,N10-methylenetetrahydrofolate, thymidylate synthase와 함께 삼중착제를 형성하여 thymidylate synthase의 기능을 비가역적으로 저해한다.\n\n<Data (confidential)>\n\nQuestion: 5-F-dUMP 구조 내에서 thymidylate synthase와의 공유결합을 형성하는 부위는?\n\n① (a)\n② (b)\n③ (c)\n④ (d)\n⑤ (e)",
        "question_text": "• 5-fluorouracil is metabolized in the body to 5-fluorodeoxyuridine monophosphate (5-F-dUMP).\n• 5-F-dUMP forms a ternary complex with N5,N10-methylenetetrahydrofolate and thymidylate synthase, irreversibly inhibiting the function of thymidylate synthase.\n\n<Data (confidential)>\n\nQuestion: Which site in the 5-F-dUMP structure forms a covalent bond with thymidylate synthase?\n\n① (a)\n② (b)\n③ (c)\n④ (d)\n⑤ (e)",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n• 5-플루오로우라실(5-fluorouracil)은 체내에서 5-fluorodeoxyuridine monophosphate (5-F-dUMP)로 대사된다.\n• 5-F-dUMP는 N5,N10-methylenetetrahydrofolate, thymidylate synthase와 함께 삼중착제를 형성하여 thymidylate synthase의 기능을 비가역적으로 저해한다.\n\n<Data (confidential)>\n\nQuestion: 5-F-dUMP로부터 생성된 삼중착체가 thymidylate synthase 효소의 기능을 비가역적으로 저해하는 기전은?\n\n① 제거반응 억제\n② 산화반응 억제\n③ 가수분해 억제\n④ 축합반응 억제\n⑤ 환원반응 억제",
        "question_text": "• 5-fluorouracil is metabolized in the body to 5-fluorodeoxyuridine monophosphate (5-F-dUMP).\n• 5-F-dUMP forms a ternary complex with N5,N10-methylenetetrahydrofolate and thymidylate synthase, irreversibly inhibiting the function of thymidylate synthase.\n\n<Data (confidential)>\n\nQuestion: What is the mechanism by which the ternary complex formed from 5-F-dUMP irreversibly inhibits the function of the thymidylate synthase enzyme?\n\n① Inhibition of elimination reaction\n② Inhibition of oxidation reaction\n③ Inhibition of hydrolysis\n④ Inhibition of condensation reaction\n⑤ Inhibition of reduction reaction",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: L-이소류신 원료의약품의 등전점(pI)은 25 ℃에서 6.0이다. 이때 pKa_1이 2.40이면, pKa_2는?\n\n① 3.6\n② 4.8\n③ 6.4\n④ 8.4\n⑤ 9.6",
        "question_text": "Question: The isoelectric point (pI) of L-isoleucine raw material is 6.0 at 25 ℃. If pKa_1 is 2.40, what is pKa_2?\n\n① 3.6\n② 4.8\n③ 6.4\n④ 8.4\n⑤ 9.6",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 0.1 mol/L 인도메타신(indomethacin) 검액 20 mL에 0.2 mol/L 수산화나트륨액 4 mL를 적가한 용액의 pH는? (단, 인도메타신의 pKa = 3.8이다.)\n\n<Data (confidential)>\n\n① 3.8\n② 3.8 + log 1/2\n③ 3.8 + log 1/1.5\n④ 3.8 + log 1.5\n⑤ 3.8 + log 2",
        "question_text": "Question: What is the pH of a solution obtained by adding 4 mL of 0.2 mol/L sodium hydroxide solution to 20 mL of 0.1 mol/L indomethacin test solution? (Note: The pKa of indomethacin is 3.8.)\n\n<Data (confidential)>\n\n① 3.8\n② 3.8 + log 1/2\n③ 3.8 + log 1/1.5\n④ 3.8 + log 1.5\n⑤ 3.8 + log 2",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: 점안제 성분인 AgNO3 0.060 mol의 Na2S2O3 0.32 mol을 넣고 물에 녹여 1 L로 하였다. 이 용액 중, Ag⁺의 농도(mol/L)는? (단, [Ag(S2O3)2]3-의 Kf = 1.0×10^21)\n\n① 6.7×10^-25\n② 3.0×10^-23\n③ 6.7×10^-22\n④ 1.5×10^-21\n⑤ 3.0×10^-21",
        "question_text": "Question: 0.060 mol of AgNO3 and 0.32 mol of Na2S2O3, which are ingredients of an eye drop, were dissolved in water to make 1 L of solution. What is the concentration (mol/L) of Ag⁺ in this solution? (Given: Kf of [Ag(S2O3)2]3- = 1.0×10^21)\n\n① 6.7×10^-25\n② 3.0×10^-23\n③ 6.7×10^-22\n④ 1.5×10^-21\n⑤ 3.0×10^-21",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: 다음은 외용살균제인 묽은요오드 틴크 중 요오드화칼륨을 Korean Pharmacopoeia에 따라 정량하는 방법의 일부이다. 이때 종말점 확인을 위해 사용하는 물질은?\n\n이 약 10 mL를 정확하게 취하여 요오드병에 넣고 물 20 mL와 염산 50 mL를 넣은 후, 0.05 mol/L 요오드산칼륨(KIO3)액으로 적정한다.\n\n① 메탄올\n② 전분시액\n③ NN 지시약\n④ 클로르포름\n⑤ 에리오크롬블랙 T(EBT)",
        "question_text": "Question: The following is part of the method for quantifying potassium iodide in Dilute Iodine Tincture, an external antiseptic, according to the Korean Pharmacopoeia. What substance is used to confirm the endpoint?\n\nAccurately measure 10 mL of this solution and place it in an iodine flask, add 20 mL of water and 50 mL of hydrochloric acid, then titrate with 0.05 mol/L potassium iodate (KIO3) solution.\n\n① Methanol\n② Starch solution\n③ NN indicator\n④ Chloroform\n⑤ Eriochrome Black T (EBT)",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 소독제로 사용되는 페놀수(phenolated water)를 Korean Pharmacopoeia에 따라 정량할 때 사용하는 적정 표준액 순차적으로 옳게 나열한 것은?\n\n① Br2 – KBr\n② KBrO3 – KBr\n③ Br2 – Na2S2O3\n④ KBr – Na2S2O3\n⑤ KBrO3 – Na2S2O3",
        "question_text": "Question: When quantifying phenolated water used as a disinfectant according to the Korean Pharmacopoeia, which of the following correctly lists the titration standard solutions in sequential order?\n\n① Br2 – KBr\n② KBrO3 – KBr\n③ Br2 – Na2S2O3\n④ KBr – Na2S2O3\n⑤ KBrO3 – Na2S2O3",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 이소니아지드(isoniazid, 분자량 137.1) 원료의약품을 Korean Pharmacopoeia 정량법에 따라 다음과 같이 분석하였다. 이소니아지드의 양(mg)은?\n\n이 약을 정확하게 달아 아세트산(100) 50 mL 및 아세트산탈수물 10 mL를 넣어 0.1 mol/L 과염소산으로 종말점까지 적정하여 10.5 mL가 소비되었다. 같은 방법으로 공시험하였을 때, 0.1 mol/L 과염소산 0.5 mL가 소비되었다.\n\n<Data (confidential)>\n\n① 46.70\n② 68.55\n③ 137.1\n④ 274.2\n⑤ 411.3",
        "question_text": "Question: The raw material isoniazid (molecular weight 137.1) was analyzed according to the Korean Pharmacopoeia assay method as follows. What is the amount of isoniazid (mg)?\n\nAn accurately weighed sample of this drug was dissolved in 50 mL of acetic acid (100) and 10 mL of acetic anhydride, then titrated with 0.1 mol/L perchloric acid to the endpoint, consuming 10.5 mL. When a blank test was performed using the same method, 0.5 mL of 0.1 mol/L perchloric acid was consumed.\n\n<Data (confidential)>\n\n① 46.70\n② 68.55\n③ 137.1\n④ 274.2\n⑤ 411.3",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 히드로코르티손아세테이트 함유 제제를 메탄올에 녹여 정확히 1,000 mL로 하여 검액으로 하였다. 이 검액을 층장 1 cm 셀에 넣고 242 nm에서 흡광도를 측정하였더니 0.790 이었다. 242 nm에서 히드로코르티손아세테이트의 비흡광도 (E 1% 1cm)가 395일 때, 검액 중의 히드로코르티손아세테이트의 양(mg)은?\n\n① 2.00\n② 5.00\n③ 10.0\n④ 20.0\n⑤ 40.0",
        "question_text": "Question: A preparation containing hydrocortisone acetate was dissolved in methanol and made up to exactly 1,000 mL to prepare the test solution. When this test solution was placed in a 1 cm cell and its absorbance was measured at 242 nm, it was 0.790. If the specific absorbance (E 1% 1cm) of hydrocortisone acetate at 242 nm is 395, what is the amount of hydrocortisone acetate (mg) in the test solution?\n\n① 2.00\n② 5.00\n③ 10.0\n④ 20.0\n⑤ 40.0",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: Lambert-Beer 법칙에 관한 설명으로 옳은 것은?\n\n① 몰흡광계수는 검액의 농도에 비례한다.\n② 흡광측정파장(λ_max)에서 몰흡광계수가 가장 작다.\n③ 이 법칙은 농도가 높은 콜로이드 용액에 적용하기 적합하다.\n④ 검액의 농도가 증가할수록 투과광의 강도가 비례하여 커진다.\n⑤ 빛이 셀을 통과한 투과 길이가 길어질수록 흡광도는 비례하여 커진다.",
        "question_text": "Question: Which of the following statements about Lambert-Beer's Law is correct?\n\n① The molar absorption coefficient is proportional to the concentration of the sample solution.\n② The molar absorption coefficient is smallest at the maximum absorption wavelength (λ_max).\n③ This law is suitable for application to colloidal solutions with high concentrations.\n④ As the concentration of the sample solution increases, the intensity of transmitted light increases proportionally.\n⑤ As the path length of light passing through the cell increases, the absorbance increases proportionally.",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 에페네프린의 선광도를 다음의 Korean Pharmacopoeia 조건으로 측정할 때, 기준 범위에 부합하는 선광도(α)는?\n\n[α] 20 D: -50.0 ~ -53.5° (건조한 다음 1 g, 1 mol/L 염산시액, 25 mL, 100 mm)\n\n① -2.5°\n② -2.0°\n③ -1.5°\n④ -1.0°\n⑤ -0.5°",
        "question_text": "Question: When measuring the optical rotation of epinephrine under the following Korean Pharmacopoeia conditions, which optical rotation (α) meets the standard range?\n\n[α] 20 D: -50.0 to -53.5° (1 g after drying, 1 mol/L hydrochloric acid solution, 25 mL, 100 mm)\n\n① -2.5°\n② -2.0°\n③ -1.5°\n④ -1.0°\n⑤ -0.5°",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 적외부스펙트럼측정법에 관한 설명으로 옳은 것은?\n\n① 4,000 ~ 1,300 cm^-1 영역을 지문영역으로 구분한다.\n② C-C 결합보다 C=C 결합에 의한 진동수가 더 크다.\n③ 거울상 이성질체는 스펙트럼이 서로 다르게 나타난다.\n④ 탄소에 결합한 원자의 질량이 증가하면, 진동수는 커진다.\n⑤ 동일 관능기에서 신축진동의 진동수가 변각진동의 진동수보다 작다.",
        "question_text": "Question: Which of the following statements about infrared spectroscopy is correct?\n\n① The region between 4,000 and 1,300 cm^-1 is classified as the fingerprint region.\n② The vibration frequency of C=C bonds is greater than that of C-C bonds.\n③ Enantiomers show different spectra.\n④ As the mass of atoms bonded to carbon increases, the vibration frequency increases.\n⑤ In the same functional group, the frequency of stretching vibration is smaller than that of bending vibration.",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 이부프로펜(ibuprofen)의 수소 핵자기공명스펙트럼(1H-NMR, 400 MHz, CDCl3)에서 밑줄 친 수소의 피크가 갈라지는 개수는?\n\n<Data (confidential)>\n\n① 1\n② 2\n③ 3\n④ 5\n⑤ 7",
        "question_text": "Question: In the proton nuclear magnetic resonance spectrum (1H-NMR, 400 MHz, CDCl3) of ibuprofen, how many peaks does the underlined hydrogen split into?\n\n<Data (confidential)>\n\n① 1\n② 2\n③ 3\n④ 5\n⑤ 7",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 특정 항체를 공유결합 시킨 고정상 사용하여 혼합시료 중에서 이 항체와 결합하는 단백질만을 분리할 수 있는 크로마토그래피 분리 기작은?\n\n① 고정상에 대한 친화성의 차이\n② 이동상에 대한 확산 정도의 차이\n③ 이동상에 대한 이온화 정도의 차이\n④ 고정상에 대한 전기적 인력의 차이\n⑤ 유사고정상 미셀에 대한 친화력의 차이",
        "question_text": "Question: What is the chromatographic separation mechanism that can isolate only the proteins that bind to a specific antibody from a mixed sample using a stationary phase with the antibody covalently attached?\n\n① Difference in affinity for the stationary phase\n② Difference in the degree of diffusion in the mobile phase\n③ Difference in the degree of ionization in the mobile phase\n④ Difference in electrical attraction to the stationary phase\n⑤ Difference in affinity for pseudo-stationary phase micelles",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 소혈청알부민(67,000 Da), β-락토글로불린(18,400 Da), 사이토크롬 c(12,400 Da)가 섞여 있는 혼합시료를 분리하기 위해 사용하는 크기배체크로마토그래피의 주요 분리 기작은?\n\n① 시료와 고정상의 비가역적인 결합력 차이에 의해 분리된다.\n② 고정상 표면에 형성된 전기 이중층에 대한 분배 차이에 의해 분리된다.\n③ 고정상으로 충전된 겔의 공극(pore)에 대한 침투성 차이에 의해 분리된다.\n④ 고정상에 대하여 전하를 띤 성분들의 전기적 인력 차이에 의해 분리된다.\n⑤ 시료와 고정상의 소수성 결합력 차이와 온도변화에 따른 증기압 차이에 의해 분리된다.",
        "question_text": "Question: What is the main separation mechanism of size exclusion chromatography used to separate a mixed sample containing human serum albumin (67,000 Da), β-lactoglobulin (18,400 Da), and cytochrome c (12,400 Da)?\n\n① Separation occurs due to differences in irreversible binding forces between the sample and the stationary phase.\n② Separation occurs due to differences in distribution with respect to the electrical double layer formed on the surface of the stationary phase.\n③ Separation occurs due to differences in penetrability into the pores of the gel packed as the stationary phase.\n④ Separation occurs due to differences in electrical attraction of charged components to the stationary phase.\n⑤ Separation occurs due to differences in hydrophobic binding forces between the sample and the stationary phase, and differences in vapor pressure with temperature changes.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: 순상 액체크로마토그래피에 사용하는 다음의 이동상 중에 중에서, 용매강도가 가장 큰 것은?\n\n① 메탄올\n② n-헥산\n③ 클로로포름\n④ 디에틸에테르\n⑤ 에틸아세테이트",
        "question_text": "Question: Among the following mobile phases used in normal-phase liquid chromatography, which one has the highest solvent strength?\n\n① Methanol\n② n-Hexane\n③ Chloroform\n④ Diethyl ether\n⑤ Ethyl acetate",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 분석오차에 관한 설명으로 옳은 것은?\n\n① 계통오차의 크기는 불확정도로 나타낸다.\n② 공시험은 우연오차를 제거하는 수단이다.\n③ 계통오차는 일정한 방향과 크기를 갖는다.\n④ 절대오차가 클수록 측정치의 정확도가 낮아진다.\n⑤ 우연오차는 오차의 원인을 규명할 수 있는 오차이다.",
        "question_text": "Question: Which of the following statements about analytical errors is correct?\n\n① The magnitude of systematic error is expressed as uncertainty.\n② A blank test is a means to eliminate random error.\n③ Systematic error has a consistent direction and magnitude.\n④ The larger the absolute error, the lower the accuracy of the measurement.\n⑤ Random error is an error for which the cause can be identified.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 구아야줄렌 원료의약품의 함량 분석을 위하여, 자외가시부흡광도측정법으로 구아야줄렌 표준품의 흡광도를 측정하였다. 흡광도로부터 검량선을 구하는 내용에 관한 설명으로 옳은 것은?\n\n① 최소제곱법을 이용하여 구한다.\n② 수직편차의 합은 양수이다.\n③ 수직편차의 제곱합을 최대화하는 직선을 구한다.\n④ y값의 오차에 비해 x값의 오차가 크다고 가정한다.\n⑤ 상관계수가 0에 가까울수록 측정치들이 직선에 밀집된다.",
        "question_text": "Question: To analyze the content of guaiazulene as an active pharmaceutical ingredient, the absorbance of guaiazulene standard was measured using UV-visible spectrophotometry. Which of the following statements is correct regarding the method of obtaining a calibration curve from the absorbance?\n\n① It is obtained using the method of least squares.\n② The sum of vertical deviations is positive.\n③ It finds a line that maximizes the sum of squared vertical deviations.\n④ It assumes that the error in x-values is larger compared to the error in y-values.\n⑤ As the correlation coefficient approaches 0, the measured values cluster closer to the line.",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n펜토바르비탈나트륨 캡슐 시 펜토바르비탈나트륨의 함량을 측정하기 위하여 Korean Pharmacopoeia의 기체크로마토그래프법에 따라 시험하였을 때, n-트리코산과 펜토바르비탈 피크의 유지시간은 각각 5.2분, 5.6분이며, 기준선에서의 피크폭은 둘 다 0.080분이었다.\n\n[표준 조건의 일부]\n내부표준액: n-트리코산의 클로로포름용액(4 → 10000)\n검출기: 불꽃이온화검출기\n\nQuestion: n-트리코산과 펜토바르비탈 피크의 분리도는?\n\n① 0.25\n② 5.0\n③ 33\n④ 65\n⑤ 70",
        "question_text": "When testing the content of pentobarbital sodium in pentobarbital sodium capsules according to the gas chromatography method of the Korean Pharmacopoeia, the retention times of n-tricosane and pentobarbital peaks were 5.2 minutes and 5.6 minutes, respectively, and the peak widths at the baseline were both 0.080 minutes.\n\n[Part of the standard conditions]\nInternal standard solution: Chloroform solution of n-tricosane (4 → 10000)\nDetector: Flame ionization detector\n\nQuestion: What is the resolution between the n-tricosane and pentobarbital peaks?\n\n① 0.25\n② 5.0\n③ 33\n④ 65\n⑤ 70",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n펜토바르비탈나트륨 캡슐 시 펜토바르비탈나트륨의 함량을 측정하기 위하여 Korean Pharmacopoeia의 기체크로마토그래프법에 따라 시험하였을 때, n-트리코산과 펜토바르비탈 피크의 유지시간은 각각 5.2분, 5.6분이며, 기준선에서의 피크폭은 둘 다 0.080분이었다.\n\n[표준 조건의 일부]\n내부표준액: n-트리코산의 클로로포름용액(4 → 10000)\n검출기: 불꽃이온화검출기\n\nQuestion: 사용한 검출기에 관한 설명으로 옳은 것은?\n\n① 불활성기체에 민감한 감응을 나타낸다.\n② 연소될 때 이온을 생성하는 물질에 감응한다.\n③ 신호 크기는 시료의 탄소 원자 수에 반비례한다.\n④ 검출한계가 열전도도 검출기보다 100배 정도로 크다.\n⑤ 유기화합물이 연소될 때 생성되는 수분의 반응에 근거한다.",
        "question_text": "When testing the content of pentobarbital sodium in pentobarbital sodium capsules according to the gas chromatography method in the Korean Pharmacopoeia, the retention times of n-tricosane and pentobarbital peaks were 5.2 minutes and 5.6 minutes, respectively, and the peak widths at the baseline were both 0.080 minutes.\n\n[Part of the standard conditions]\nInternal standard solution: Chloroform solution of n-tricosane (4 → 10000)\nDetector: Flame ionization detector\n\nQuestion: Which of the following statements about the detector used is correct?\n\n① It shows sensitive response to inert gases.\n② It responds to substances that produce ions when burned.\n③ The signal size is inversely proportional to the number of carbon atoms in the sample.\n④ The detection limit is about 100 times larger than that of a thermal conductivity detector.\n⑤ It is based on the reaction of water produced when organic compounds are burned.",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 전기적 저항을 이용하여 분립체 입자의 동체적구상당경을 측정하는 방법은?\n\n① 광산란법\n② 쿨터계수기법\n③ 광자상관분광법\n④ 투과전자현미경법\n⑤ 주사전자현미경법",
        "question_text": "Question: Which method uses electrical resistance to measure the equivalent spherical diameter of particulate matter?\n\n① Light scattering method\n② Coulter counter method\n③ Photon correlation spectroscopy\n④ Transmission electron microscopy\n⑤ Scanning electron microscopy",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 지용성 비타민과 유동엑스제와 같은 액체 약물을 분말화하여 정제를 제조할 때, 액체 약물을 흡착시키는 데 사용하는 첨가제는?\n\n① 글리세롤\n② 에틸셀룰로오스\n③ 프로필렌글리콜\n④ 폴리소르베이트 80\n⑤ 콜로이드성 이산화규소",
        "question_text": "Question: When manufacturing tablets by powdering liquid drugs such as fat-soluble vitamins and fluid extracts, which additive is used to absorb the liquid drugs?\n\n① Glycerol\n② Ethylcellulose\n③ Propylene glycol\n④ Polysorbate 80\n⑤ Colloidal silicon dioxide",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 다음은 로터리식 정제기의 압축 기구의 일부를 나타내는 모식도이다. 정제의 중량을 조절하는 곳은?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "question_text": "Question: The following is a schematic diagram showing part of the compression mechanism of a rotary tablet press. Which part controls the weight of the tablet?\n\n<Data (confidential)>\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 현탁제 제조 과정에서 난용성 약물 입자를 초기에 신속하게 물에 분산시키는 방법으로 적합한 것은?\n\n① 매질의 점도를 증가시킨다.\n② 침강용적이 1이 되도록 침강시킨다.\n③ 점가제를 함유하지 않은 물에 혼합한다.\n④ 친수-친유 균형(HLB)값이 7~9인 계면활성제를 사용한다.\n⑤ 약물입자의 전하와 반대되는 전하를 지닌 물질을 가한다.",
        "question_text": "Question: Which method is appropriate for rapidly dispersing poorly soluble drug particles in water during the initial stage of suspension preparation?\n\n① Increase the viscosity of the medium.\n② Allow sedimentation until the sedimentation volume becomes 1.\n③ Mix with water that does not contain a suspending agent.\n④ Use a surfactant with a hydrophilic-lipophilic balance (HLB) value of 7-9.\n⑤ Add a substance with an opposite charge to that of the drug particles.",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 다음은 Korean Pharmacopoeia에 수재된 연고기제의 조성이다. 이 연고기제에 관한 설명으로 옳은 것은?\n\n백납\t50 g\n세스퀴올레산소르비탄\t20 g\n백색바셀린\t적당량\n전제량\t1000 g\n\n① 친수바셀린이다.\n② 물로 씻어내기 쉽다.\n③ 물을 흡수하여 w/o형 유제를 형성할 수 있다.\n④ 세스퀴올레산소르비탄은 항산화 목적으로 사용된다.\n⑤ 양모로부터 추출한 성분을 함유하여 알레르기를 유발할 수 있다.",
        "question_text": "Question: The following is the composition of an ointment base listed in the Korean Pharmacopoeia. Which statement about this ointment base is correct?\n\nWhite beeswax\t50 g\nSorbitan sesquioleate\t20 g\nWhite petrolatum\tAppropriate amount\nTotal amount\t1000 g\n\n① It is hydrophilic petrolatum.\n② It is easily washed off with water.\n③ It can absorb water to form a w/o type emulsion.\n④ Sorbitan sesquioleate is used for antioxidant purposes.\n⑤ It may cause allergies due to containing components extracted from wool.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 양이온성 약물이나 앙이온성 첨가제와 정전기적 상호작용을 일으킬 수 있어 배합 시 주의가 필요한 겔화제는?\n\n① 포비돈(povidone)\n② 아라비아고무(acacia)\n③ 히프로멜로오스(hypromellose)\n④ 메틸셀룰로오스(methylcellulose)\n⑤ 히드록시프로필셀룰로오스(hydroxypropylcellulose)",
        "question_text": "Question: Which gelling agent requires caution when combining with cationic drugs or anionic additives due to potential electrostatic interactions?\n\n① Povidone\n② Acacia\n③ Hypromellose\n④ Methylcellulose\n⑤ Hydroxypropylcellulose",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 난용성 약물을 고분자 담체 내에 분산시켜 용출률을 높이고자 할 때, 고분자 담체로 적합한 물질은?\n\n① povidone\n② ethylcellulose\n③ polydimethylsiloxane\n④ poly(lactide-co-glycolide)\n⑤ poly(ethylene-vinyl acetate)",
        "question_text": "Question: When dispersing a poorly soluble drug in a polymer carrier to increase its dissolution rate, which of the following is an appropriate polymer carrier?\n\n① povidone\n② ethylcellulose\n③ polydimethylsiloxane\n④ poly(lactide-co-glycolide)\n⑤ poly(ethylene-vinyl acetate)",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 침출 제제는?\n\n• 보통 조말한 한 생약을 냉침, 온침 또는 퍼콜레이션법으로 침출한다.\n• 침출액을 여과하고 적당한 방법으로 농축 또는 건조 한다.\n• 분쇄할 수 있는 덩어리, 입상(粒狀) 또는 분말로 할 수 있다.\n\n① 전제\n② 침제\n③ 엑스제\n④ 틴크제\n⑤ 유동엑스제",
        "question_text": "Question: Which of the following describes an extract preparation?\n\n• Usually, a coarsely powdered crude drug is extracted by cold maceration, hot maceration, or percolation method.\n• The extract is filtered and concentrated or dried by an appropriate method.\n• It can be made into grindable lumps, granules, or powder.\n\n① Decoction\n② Infusion\n③ Extract\n④ Tincture\n⑤ Fluidextract",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 난용성인 약산성 약물 분말로부터 약물 용출속도가 증가되는 경우는?\n\n① 분말의 입자크기를 증가시켰을 때\n② 용출시험액의 pH를 감소시켰을 때\n③ 용출시험액의 부피를 증가시켰을 때\n④ 용출실험에서 교반속도를 감소시켰을 때\n⑤ 분말의 결정형이 준안정형에서 안정형으로 변화되었을 때",
        "question_text": "Question: In which case does the dissolution rate increase for a poorly soluble, weakly acidic drug powder?\n\n① When the particle size of the powder is increased\n② When the pH of the dissolution medium is decreased\n③ When the volume of the dissolution medium is increased\n④ When the stirring speed in the dissolution experiment is decreased\n⑤ When the crystal form of the powder changes from metastable to stable form",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 위장관을 통과하면서 지속적으로 서서히 약물을 방출하는 서방정으로 제제화하기에 적합한 약물은?\n\n① 친수성 단백질 약물\n② 위장관에서 소화효소에 의해 분해되는 약물\n③ 위장관 전제에 걸쳐 흡수속도가 균일한 약물\n④ 위장관 약물배출펌프(efflux pump) 기질인 약물\n⑤ 투여용량이 높아 삼키기 어려울 정도로 정제가 커질 우려가 있는 약물",
        "question_text": "Question: Which drug is suitable for formulation as a sustained-release tablet that continuously releases the drug slowly as it passes through the gastrointestinal tract?\n\n① Hydrophilic protein drugs\n② Drugs that are degraded by digestive enzymes in the gastrointestinal tract\n③ Drugs with uniform absorption rates throughout the entire gastrointestinal tract\n④ Drugs that are substrates of gastrointestinal efflux pumps\n⑤ Drugs with high dosages that may result in tablets too large to swallow comfortably",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: 이온토포레시스(iontophoresis)에 관한 설명으로 옳은 것은?\n\n① 피부에 초음파를 가하여 준다.\n② 양이온으로 해리된 약물의 피부투과를 촉진한다.\n③ 레이저광을 이용하여 피부에 미세구멍을 뚫는다.\n④ 각질층 두께에 해당되는 미세바늘을 피부에 삽입한다.\n⑤ 각질층에 일시적으로 공극을 만들어서 약물의 피부투과를 촉진한다.",
        "question_text": "Question: Which of the following statements about iontophoresis is correct?\n\n① It applies ultrasound to the skin.\n② It promotes skin penetration of drugs dissociated into cations.\n③ It uses laser light to create micropores in the skin.\n④ It inserts microneedles into the skin corresponding to the thickness of the stratum corneum.\n⑤ It creates temporary pores in the stratum corneum to promote drug penetration through the skin.",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: 소화관을 통한 약물 흡수에 관한 설명으로 옳은 것은?\n\n① 수송체를 매개하여 흡수되는 경우 pH-분배가설이 성립한다.\n② 막투과도가 높은 약물은 흡수부위 혈류속도의 영향을 받지 않는다.\n③ 소화관 막표면에 존재하는 다량의 뮤신은 약물 흡수를 증가시킨다.\n④ 소화관 막표면에 존재하는 비교반수층은 지용성이 높은 약물의 흡수를 저해한다.\n⑤ 소장에서 흡수가 용이한 약물은 위배출시간이 길수록 최고 혈중농도도달시간이 짧아진다.",
        "question_text": "Question: Which of the following statements about drug absorption through the gastrointestinal tract is correct?\n\n① The pH-partition hypothesis applies when absorption is mediated by transporters.\n② Drugs with high membrane permeability are not affected by blood flow rate at the absorption site.\n③ The large amount of mucin present on the gastrointestinal membrane surface increases drug absorption.\n④ The unstirred water layer on the gastrointestinal membrane surface inhibits the absorption of highly lipophilic drugs.\n⑤ For drugs easily absorbed in the small intestine, a longer gastric emptying time results in a shorter time to reach maximum blood concentration.",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 약물의 조직분포에 영향을 주는 인자에 관한 설명으로 옳은 것은?\n\n① 조직 세포막 투과에 농동수송계는 관여하지 않는다.\n② 모세혈관벽의 투과성은 조직의 종류에 상관없이 유사하다.\n③ 혈장단백질의 결합은 조직으로의 약물 이행속도를 감소시킨다.\n④ 조직으로 유입되는 혈류량이 높을수록 조직분포는 감소한다.\n⑤ 조직의 산성인지질 함량이 높을수록 염기성 약물의 분포는 감소한다.",
        "question_text": "Question: Which of the following statements about factors affecting tissue distribution of drugs is correct?\n\n① Active transport systems are not involved in tissue cell membrane permeation.\n② The permeability of capillary walls is similar regardless of the type of tissue.\n③ Binding to plasma proteins decreases the rate of drug transfer to tissues.\n④ The higher the blood flow to a tissue, the lower the tissue distribution.\n⑤ The higher the acidic phospholipid content of a tissue, the lower the distribution of basic drugs.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 약물의 신배설 과정에 관한 설명으로 옳은 것은?\n\n① 세뇨관에서 약물 분비는 수송체를 매개로 한다.\n② 사구체 여과는 약물 분자량의 영향을 받지 않는다.\n③ 혈장단백질의 결합률이 높을수록 신배설 속도가 증가한다.\n④ 소변이 산성으로 되면 약염기성 약물의 재흡수가 급격히 증가한다.\n⑤ 글루쿠론산 포합체는 미대사체에 비해 세뇨관에서의 재흡수가 용이하다.",
        "question_text": "Question: Which of the following statements about the renal excretion process of drugs is correct?\n\n① Drug secretion in the renal tubules is mediated by transporters.\n② Glomerular filtration is not affected by the molecular weight of drugs.\n③ The higher the plasma protein binding rate, the faster the renal excretion rate.\n④ When urine becomes acidic, the reabsorption of weakly basic drugs increases dramatically.\n⑤ Glucuronide conjugates are more easily reabsorbed in the renal tubules compared to unmetabolized drugs.",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 선형 1-컴파트먼트 모델을 따르는 약물 A의 약동학 정보는 다음과 같다. 약물 A를 100 mg을 정맥주사 하였을 때 소변으로 배설되는 약물 A의 총량(mg)은?\n\n• CL(전신클리어런스)=10 L/h\n• CLr(신클리어런스)=7.5 L/h\n\n① 0.75\n② 7.5\n③ 10\n④ 75\n⑤ 100",
        "question_text": "Question: The pharmacokinetic information for drug A, which follows a linear 1-compartment model, is as follows. What is the total amount (mg) of drug A excreted in urine when 100 mg of drug A is administered intravenously?\n\n• CL (systemic clearance) = 10 L/h\n• CLr (renal clearance) = 7.5 L/h\n\n① 0.75\n② 7.5\n③ 10\n④ 75\n⑤ 100",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 선형 1-컴파트먼트 모델을 따른 약물을 경구로 반복투여 하여 얻어지는 정상상태 혈중농도는 단회 경구투여 하여 얻어지는 혈중농도보다 축적률(R)만큼 더 증가한다. 축적률(R)을 결정하는 주된 약동학 파라미터는? (단, 흡수속도상수(ka) > 소실속도상수(k)이고, 반복투여에서 앞서 투여된 약물은 다음 투여 전에 흡수가 완료되는 것으로 가정한다).\n\n① 추출률(E)\n② 분포용적(Vd)\n③ 생체이용율(F)\n④ 소실속도상수(k)\n⑤ 흡수속도상수(ka)",
        "question_text": "Question: For a drug following a linear one-compartment model, the steady-state blood concentration obtained from repeated oral administration is higher than the blood concentration obtained from a single oral dose by a factor called the accumulation ratio (R). What is the main pharmacokinetic parameter that determines the accumulation ratio (R)? (Assume that the absorption rate constant (ka) > elimination rate constant (k), and in repeated dosing, the previously administered drug is completely absorbed before the next dose is given).\n\n① Extraction ratio (E)\n② Volume of distribution (Vd)\n③ Bioavailability (F)\n④ Elimination rate constant (k)\n⑤ Absorption rate constant (ka)",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n에틸셀룰로오스를 유기용매에 용해시킨 유계 코팅액을 사용한 코팅 과정에서 환경오염, 비용, 안전성 문제가 발생하였다. 이를 해결하기 위해 다음과 같은 조성의 새로운 코팅액을 사용하고자 한다.\n\n• 에틸셀룰로오스(ethylcellulose) 17%\n• 디부틸세바케이트(dibutyl sebacate) 4%\n• 올레산(oleic acid) 2%\n• 콜로이드성 이산화규소(fumed silica) 2%\n• 물(암모니아 0.8~1.0% 함유) 75%\n\nQuestion: 디부틸세바케이트의 역할은?\n\n① 코팅막의 형성 촉진\n② 코팅막의 분해 방지\n③ 코팅막의 경도 증가\n④ 코팅막의 색상 부여\n⑤ 미생물 발육 억제",
        "question_text": "A problem with environmental pollution, cost, and safety occurred during the coating process using an oil-based coating solution in which ethylcellulose was dissolved in an organic solvent. To solve this, a new coating solution with the following composition is proposed:\n\n• Ethylcellulose 17%\n• Dibutyl sebacate 4%\n• Oleic acid 2%\n• Fumed silica 2%\n• Water (containing 0.8-1.0% ammonia) 75%\n\nQuestion: What is the role of dibutyl sebacate?\n\n① Promoting the formation of the coating film\n② Preventing the degradation of the coating film\n③ Increasing the hardness of the coating film\n④ Providing color to the coating film\n⑤ Inhibiting microbial growth",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n에틸셀룰로오스를 유기용매에 용해시킨 유계 코팅액을 사용한 코팅 과정에서 환경오염, 비용, 안전성 문제가 발생하였다. 이를 해결하기 위해 다음과 같은 조성의 새로운 코팅액을 사용하고자 한다.\n\n• 에틸셀룰로오스(ethylcellulose) 17%\n• 디부틸세바케이트(dibutyl sebacate) 4%\n• 올레산(oleic acid) 2%\n• 콜로이드성 이산화규소(fumed silica) 2%\n• 물(암모니아 0.8~1.0% 함유) 75%\n\nQuestion: 새로운 코팅액과 이를 이용한 정제의 코팅에 관한 설명으로 옳은 것은?\n\n① 정전기를 이용한 코팅법에 사용한다.\n② 장용성 코팅에 적합한 조성을 지닌다.\n③ 다층 압축코팅법에서 코팅효율을 높이기 위해 사용한다.\n④ 팬코팅법에 사용될 수 있는 유사유탁(pseudolatex) 분산액이다.\n⑤ 분무응고법에 사용할 때 열을 사용하지 않아도 코팅막 형성이 가능한 장점이 있다.",
        "question_text": "During the coating process using an oil-based coating solution where ethylcellulose was dissolved in organic solvents, issues with environmental pollution, cost, and safety arose. To address these problems, a new coating solution with the following composition is proposed:\n\n• Ethylcellulose 17%\n• Dibutyl sebacate 4%\n• Oleic acid 2%\n• Fumed silica 2%\n• Water (containing 0.8-1.0% ammonia) 75%\n\nQuestion: Which of the following statements about the new coating solution and its use in tablet coating is correct?\n\n① It is used in electrostatic coating methods.\n② It has a composition suitable for enteric coating.\n③ It is used to increase coating efficiency in multilayer compression coating.\n④ It is a pseudolatex dispersion that can be used in pan coating methods.\n⑤ When used in spray congealing, it has the advantage of forming a coating film without the need for heat.",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: 생약에서 geranyl pyrophosphate (GPP)를 전구체로 하여 생합성되는 화합물은?\n\n① emodin\n② schisandrin A\n③ kuwanon G\n④ humulone\n⑤ geniposide",
        "question_text": "Question: Which compound is biosynthesized in medicinal plants using geranyl pyrophosphate (GPP) as a precursor?\n\n① emodin\n② schisandrin A\n③ kuwanon G\n④ humulone\n⑤ geniposide",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 화합물군은?\n\n• α-아미노산으로부터 생합성됨\n• 가수분해되어 isothiocyanate류 화합물이 생성됨\n• 신미성 물질임\n\n① cannabinoid\n② capsaicinoid\n③ cardiac glycoside\n④ cyanogenic glycoside\n⑤ glucosinolate",
        "question_text": "Question: Which group of compounds is described below?\n\n• Biosynthesized from α-amino acids\n• Hydrolysis produces isothiocyanate compounds\n• Has a pungent taste\n\n① cannabinoid\n② capsaicinoid\n③ cardiac glycoside\n④ cyanogenic glycoside\n⑤ glucosinolate",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 당귀(當歸)에 함유 성분인 decursin이 속한 화합물군은?\n\n① coumarin\n② anthraquinone\n③ flavonoid\n④ lignan\n⑤ saponin",
        "question_text": "Question: Which group of compounds does decursin, a component found in Angelica gigas (Korean angelica), belong to?\n\n① coumarin\n② anthraquinone\n③ flavonoid\n④ lignan\n⑤ saponin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 생약은?\n\n• 기원식물은 Papaveraceae에 속함\n• phenanthrene계 알칼로이드를 함유함\n• 진통, 진해, 진경약으로 사용함\n\n① 목향(木香)\n② 울금(鬱金)\n③ 홍화(紅花)\n④ 오배자(五倍子)\n⑤ 아편가루(阿片末)",
        "question_text": "Question: Which of the following describes the medicinal herb?\n\n• The source plant belongs to Papaveraceae\n• Contains phenanthrene alkaloids\n• Used as an analgesic, antitussive, and antispasmodic\n\n① Aucklandia root (木香)\n② Turmeric root (鬱金)\n③ Safflower (紅花)\n④ Chinese gall (五倍子)\n⑤ Opium powder (阿片末)",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 배당체의 당부분이 glucuronic acid인 감미물질은?\n\n① carthamin\n② glycyrrhizin\n③ limonin\n④ phyllodulcin\n⑤ quassin",
        "question_text": "Question: Which sweetening substance has glucuronic acid as the sugar part of its glycoside?\n\n① carthamin\n② glycyrrhizin\n③ limonin\n④ phyllodulcin\n⑤ quassin",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: 인도사목(印度蛇木)에 함유되어 있는 화합물로, 혈압강하, 진정작용이 있는 인돌(indole) 알칼로이드는?\n\n① aconitine\n② atropine\n③ emetine\n④ higenamine\n⑤ reserpine",
        "question_text": "Question: Which indole alkaloid, contained in Rauwolfia serpentina, has blood pressure-lowering and sedative effects?\n\n① aconitine\n② atropine\n③ emetine\n④ higenamine\n⑤ reserpine",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: 스테로이드 호르몬을 합성하는 데에 원료로 사용되는 화합물을 함유하는 생약은?\n\n① Colchici Semen\n② Coptidis Rhizoma\n③ Crataegi Fructus\n④ Dioscoreae Rhizoma\n⑤ Lycii Fructus",
        "question_text": "Question: Which medicinal herb contains a compound used as a raw material in the synthesis of steroid hormones?\n\n① Colchici Semen\n② Coptidis Rhizoma\n③ Crataegi Fructus\n④ Dioscoreae Rhizoma\n⑤ Lycii Fructus",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: 다음 화합물들이 공통으로 나타내는 약리작용은?\n\nbarbaloin pharbitin sennoside A\n\n① 사하작용\n② 강심작용\n③ 진경작용\n④ 진통작용\n⑤ 진해작용",
        "question_text": "Question: What is the common pharmacological action exhibited by the following compounds?\n\nbarbaloin pharbitin sennoside A\n\n① Laxative action\n② Cardiotonic action\n③ Antispasmodic action\n④ Analgesic action\n⑤ Antitussive action",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: 채 익기 전의 열매를 약용하는 생약은?\n\n① 개자(芥子)\n② 산초(山椒)\n③ 행인(杏仁)\n④ 회향(茴香)\n⑤ 후추(胡椒)",
        "question_text": "Question: Which medicinal herb uses unripe fruit for medicinal purposes?\n\n① Mustard seed (Sinapis semen)\n② Sichuan pepper (Zanthoxyli fructus)\n③ Apricot kernel (Armeniacae semen)\n④ Fennel (Foeniculi fructus)\n⑤ Black pepper (Piperis nigri fructus)",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: 진피(陳皮)과 지실(枳實)에 공통으로 함유되어 있는 플라보노이드는?\n\n① allicin\n② capillarin\n③ digitoxin\n④ hesperidin\n⑤ sinigrin",
        "question_text": "Question: Which flavonoid is commonly found in both Citrus Peel (Chenpi) and Immature Trifoliate Orange Fruit (Zhishi)?\n\n① allicin\n② capillarin\n③ digitoxin\n④ hesperidin\n⑤ sinigrin",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: 가수분해에 의해 ellagic acid를 생성하는 화합물로, 정장·지사작용을 나타내는 것은?\n\n① geraniin\n② catechin\n③ icariin\n④ sinomenine\n⑤ theaflavin",
        "question_text": "Question: Which compound produces ellagic acid through hydrolysis and exhibits intestinal regulating and antidiarrheal effects?\n\n① geraniin\n② catechin\n③ icariin\n④ sinomenine\n⑤ theaflavin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "original_text": "Question: 에페드린류를 함유한 생약은?\n\n① 대마(大麻)\n② 대황(大黃)\n③ 황백(黃柏)\n④ 백굴(白朮)\n⑤ 마황(麻黃)",
        "question_text": "Question: Which herbal medicine contains ephedrine-like compounds?\n\n① Cannabis (大麻)\n② Rhubarb (大黃)\n③ Phellodendron bark (黃柏)\n④ Atractylodes rhizome (白朮)\n⑤ Ephedra (麻黃)",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "original_text": "Question: 정(精)을 저장하며, 발육·성숙·골생성을 주관하고, 귀와 이음(二陰)에 개규(開竅)하며, 방광과 표리관계인 것은?\n\n① 간장(肝臟)\n② 비장(脾臟)\n③ 폐장(肺臟)\n④ 심장(心臟)\n⑤ 신장(腎臟)",
        "question_text": "Question: Which organ stores essence (jing), governs growth, maturation, and bone formation, opens into the ears and two yin, and has an interior-exterior relationship with the bladder?\n\n① Liver (肝臟)\n② Spleen (脾臟)\n③ Lung (肺臟)\n④ Heart (心臟)\n⑤ Kidney (腎臟)",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "original_text": "Question: 다음에서 설명하는 기(氣)의 생리기능은?\n\n• 기(氣)와 운동으로 발생하는 각종 변화와, 체내에서 일어나는 각종 대사활동을 의미함\n• 이 기능으로 인하여 체내의 정(精), 혈(血), 진액(津液)이 신진대사를 하거나, 상호 전화(轉化)함\n\n① 고섭작용(固攝作用)\n② 기작작용(氣化作用)\n③ 방어작용(防禦作用)\n④ 온후작용(溫煦作用)\n⑤ 추동작용(推動作用)",
        "question_text": "Question: Which of the following describes the physiological function of qi (气)?\n\n• It refers to various changes caused by qi and movement, and various metabolic activities occurring within the body\n• This function enables the essence (精), blood (血), and body fluids (津液) within the body to undergo metabolism or mutual transformation\n\n① Consolidation and astringent function (固攝作用)\n② Qi transformation function (氣化作用)\n③ Defensive function (防禦作用)\n④ Warming function (溫煦作用)\n⑤ Promoting function (推動作用)",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "original_text": "Question: 혈활거어(活血祛瘀), 윤장통변(潤腸通便)의 효능이 있으며, 고(苦), 감(甘), 평(平)의 약성(藥性)을 지닌 활혈조경지통약(活血調經止痛藥)은?\n\n① 도인(桃仁)\n② 백지(白芷)\n③ 부자(附子)\n④ 시호(柴胡)\n⑤ 황금(黃芩)",
        "question_text": "Question: Which of the following is a blood-activating, menstruation-regulating, and pain-relieving herb (活血調經止痛藥) that has the effects of activating blood circulation and removing blood stasis (活血祛瘀), moistening the intestines and promoting bowel movement (潤腸通便), and possesses bitter (苦), sweet (甘), and neutral (平) medicinal properties?\n\n① Peach kernel (桃仁)\n② Angelica dahurica root (白芷)\n③ Prepared aconite root (附子)\n④ Bupleurum root (柴胡)\n⑤ Baical skullcap root (黃芩)",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "original_text": "Question: 신온해표(辛溫解表), 생진서근(生津舒筋)의 효능이 있어, 목통미와 어깨 결림, 두통이 있고, 땀이 나지 않는 증상에 사용되는 한약제제는?\n\n① 갈근탕(葛根湯)\n② 사물탕(四物湯)\n③ 쌍화탕(雙和湯)\n④ 안중산(安中散)\n⑤ 오적산(五積散)",
        "question_text": "Question: Which herbal medicine preparation has the effects of dispersing cold through pungent warmth (辛溫解表) and generating body fluids and relaxing tendons (生津舒筋), and is used for symptoms such as stiff neck and shoulders, headache, and absence of sweating?\n\n① Galgeun-tang (Ge Gen Tang, 葛根湯)\n② Samul-tang (Si Wu Tang, 四物湯)\n③ Ssanghwa-tang (Shuang Hua Tang, 雙和湯)\n④ Anjung-san (An Zhong San, 安中散)\n⑤ Ojeok-san (Wu Ji San, 五積散)",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n단삼, 박하, 개똥쑥, 은행잎, 하고초의 함유 성분을 용매추출 및 크로마토그래피를 이용하여 분리하고, 기기분석을 통해 다음 화합물들을 확인하였다.\n\n• 단삼: tanshinone I\n• 박하: (-)-menthol\n• 개똥쑥: artemisinin\n• 은행잎: ginkgolide A\n• 하고초: ursolic acid\n\nQuestion: 위에서 확인한 화합물들의 주된 생합성 경로는?\n\n① amino acid 경로\n② isoprenoid 경로\n③ shikimate 경로\n④ amino acid-polyketide 복합경로\n⑤ polyketide-shikimate 복합경로",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThe components of Salvia miltiorrhiza (Danshen), peppermint, Artemisia annua (Sweet wormwood), ginkgo leaves, and Prunella vulgaris (Self-heal) were separated using solvent extraction and chromatography, and the following compounds were identified through instrumental analysis.\n\n• Salvia miltiorrhiza: tanshinone I\n• Peppermint: (-)-menthol\n• Artemisia annua: artemisinin\n• Ginkgo leaves: ginkgolide A\n• Prunella vulgaris: ursolic acid\n\nQuestion: What is the main biosynthetic pathway for the compounds identified above?\n\n① Amino acid pathway\n② Isoprenoid pathway\n③ Shikimate pathway\n④ Amino acid-polyketide hybrid pathway\n⑤ Polyketide-shikimate hybrid pathway",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n단삼, 박하, 개똥쑥, 은행잎, 하고초의 함유 성분을 용매추출 및 크로마토그래피를 이용하여 분리하고, 기기분석을 통해 다음 화합물들을 확인하였다.\n\n• 단삼: tanshinone I\n• 박하: (-)-menthol\n• 개똥쑥: artemisinin\n• 은행잎: ginkgolide A\n• 하고초: ursolic acid\n\nQuestion: 위에서 확인한 화합물 중에서 기본골격의 탄소수가 α-santonin과 같은 것은?\n\n① artemisinin\n② ginkgolide A\n③ (-)-menthol\n④ tanshinone I\n⑤ ursolic acid",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nThe components of Salvia miltiorrhiza (Danshen), peppermint, Artemisia annua (Sweet wormwood), ginkgo leaves, and Prunella vulgaris (Self-heal) were separated using solvent extraction and chromatography, and the following compounds were identified through instrumental analysis.\n\n• Salvia miltiorrhiza: tanshinone I\n• Peppermint: (-)-menthol\n• Artemisia annua: artemisinin\n• Ginkgo leaves: ginkgolide A\n• Prunella vulgaris: ursolic acid\n\nQuestion: Among the compounds identified above, which one has the same number of carbon atoms in its basic skeleton as α-santonin?\n\n① artemisinin\n② ginkgolide A\n③ (-)-menthol\n④ tanshinone I\n⑤ ursolic acid",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 이상지질혈증과 심한 만성변비가 있는 67세 여자가 고혈압을 진단받았다. 혈압 조절을 위한 적절한 약물요법은?\n\n[활력징후]\n혈압 162/127 mmHg, 심박수 75회/분, 체질량지수 27 kg/m^2\n[사회력] 흡연 20갑년(pack-year)\n[가족력]\n부: 50세에 심근경색으로 사망\n모: 87세 생존(2형당뇨병)\n[복용약물]\n심바스타틴(simvastatin) 20 mg 1일 1회\n락툴로오스(lactulose) 15 mL 1일 3회\n\n① 라미프릴(ramipril)\n② 히드로클로로티아지드(hydrochlorothiazide)\n③ 베라파밀(verapamil)+발사르탄(valsartan)\n④ 칸데사르탄(candesartan)+레르카니디핀(lercanidipine)\n⑤ 히드랄라진(hydralazine)+이소소르비드이질산염(isosorbide dinitrate)",
        "question_text": "Question: A 67-year-old woman with dyslipidemia and severe chronic constipation has been diagnosed with hypertension. What is the appropriate drug therapy for blood pressure control?\n\n[Vital Signs]\nBlood pressure 162/127 mmHg, Heart rate 75 beats/min, BMI 27 kg/m^2\n[Social History] Smoking 20 pack-years\n[Family History]\nFather: Died of myocardial infarction at age 50\nMother: Alive at 87 (Type 2 diabetes)\n[Current Medications]\nSimvastatin 20 mg once daily\nLactulose 15 mL three times daily\n\n① Ramipril\n② Hydrochlorothiazide\n③ Verapamil + Valsartan\n④ Candesartan + Lercanidipine\n⑤ Hydralazine + Isosorbide dinitrate",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 59세 여자가 규칙적으로 약물을 복용함에도 불구하고 숨이 차는 증상으로 일상생활이 불편하다. 최근 2개월간 체중변화나 생활습관의 변화는 없다. 심부전으로 인한 입원위험 감소와 심혈관질환으로 인한 사망위험 감소를 위해 추가할 약물은?\n\n[병력] 박출률감소심부전(HFrEF)\n[활력징후]\n혈압 139/85 mmHg, 심박수 68회/분, 호흡수 20회/분\n[임상검사]\nNa 134 mEq/L, K 4.4 mEq/L, Cl 98 mEq/L\neGFR 68 mL/min/1.73m^2, 좌심실박출률(LVEF) 33 %\n[복용약물]\n비스프로롤(bisoprolol) 10 mg 1일 1회\n푸로세미드(furosemide) 40 mg 1일 1회\n스피로노락톤(spironolactone) 25 mg 1일 1회\n사쿠비트릴/발사르탄(sacubitril/valsartan) 200 mg 1일 2회\n\n① 디곡신(digoxin)\n② 베라파밀(verapamil)\n③ 이바브라딘(ivabradine)\n④ 히드랄라진(hydralazine)\n⑤ 엠파글리플로진(empagliflozin)",
        "question_text": "Question: A 59-year-old woman finds daily life uncomfortable due to shortness of breath despite taking medication regularly. There have been no changes in weight or lifestyle habits over the past 2 months. Which drug should be added to reduce the risk of hospitalization due to heart failure and the risk of death from cardiovascular disease?\n\n[Medical history] Heart failure with reduced ejection fraction (HFrEF)\n[Vital signs]\nBlood pressure 139/85 mmHg, Heart rate 68 beats/min, Respiratory rate 20 breaths/min\n[Clinical tests]\nNa 134 mEq/L, K 4.4 mEq/L, Cl 98 mEq/L\neGFR 68 mL/min/1.73m^2, Left ventricular ejection fraction (LVEF) 33%\n[Current medications]\nBisoprolol 10 mg once daily\nFurosemide 40 mg once daily\nSpironolactone 25 mg once daily\nSacubitril/valsartan 200 mg twice daily\n\n① Digoxin\n② Verapamil\n③ Ivabradine\n④ Hydralazine\n⑤ Empagliflozin",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "original_text": "Question: 박출률감소심부전(HFrEF)이 있는 57세 남자가 현재 에날라프릴(enalapril)을 복용하고 있다. 에날라프릴을 중단하고 사쿠비트릴/발사르탄(sacubitril/valsartan)으로 변경하려고 한다. 에날라프릴을 마지막으로 복용한 시점으로부터 사쿠비트릴/발사르탄을 최초로 투여할 시점은?\n\n① 즉시\n② 6시간 후\n③ 12시간 후\n④ 24시간 후\n⑤ 36시간 후",
        "question_text": "Question: A 57-year-old man with heart failure with reduced ejection fraction (HFrEF) is currently taking enalapril. The plan is to discontinue enalapril and switch to sacubitril/valsartan. From the time of the last dose of enalapril, when should the first dose of sacubitril/valsartan be administered?\n\n① Immediately\n② After 6 hours\n③ After 12 hours\n④ After 24 hours\n⑤ After 36 hours",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "original_text": "Question: 이상지질혈증이 있는 62세 남자가 ST분절상승 심근경색을 진단받았다. 경피관상동맥중재술(PCI) 시행이 2시간 이내에는 불가능하여, 혈전용해제로 재관류치료를 시행할 계획이다. 이에 보조적 항혈소판제 중 하나로 클로피도그렐(clopidogrel)을 투여하려고 한다. 클로피도그렐의 적절한 부하용량은?\n\n① 60 mg\n② 75 mg\n③ 180 mg\n④ 300 mg\n⑤ 600 mg",
        "question_text": "Question: A 62-year-old man with dyslipidemia has been diagnosed with ST-segment elevation myocardial infarction. Percutaneous coronary intervention (PCI) is not possible within 2 hours, so reperfusion therapy with a thrombolytic agent is planned. Clopidogrel is to be administered as one of the adjunctive antiplatelet agents. What is the appropriate loading dose of clopidogrel?\n\n① 60 mg\n② 75 mg\n③ 180 mg\n④ 300 mg\n⑤ 600 mg",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 비ST분절상승 급성관상동맥증후군(NSTE-ACS)을 진단받은 62세 여자가 보존적치료전략(ischemia-guided strategy)에 기반한 약물치료를 받고 있다. 추가해야 할 약물은?\n\n[병력] 이상지질혈증, 위식도역류병\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n판토프라졸(pantoprazole) 40 mg 1일 1회\n비소프로롤(bisoprolol) 10 mg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n이소소르비드이질산염(isosorbide dinitrate) 20 mg 1일 3회\n니트로글리세린(nitroglycerin) 설하정 0.6 mg 필요시\n\n① 티로피반(tirofiban)\n② 압식시맙(abciximab)\n③ 알테플라제(alteplase)\n④ 프라수그렐(prasugrel)\n⑤ 클로피도그렐(clopidogrel)",
        "question_text": "Question: A 62-year-old woman diagnosed with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is receiving drug therapy based on a conservative treatment strategy (ischemia-guided strategy). Which medication should be added?\n\n[Medical history] Dyslipidemia, Gastroesophageal reflux disease\n[Current medications]\nAspirin 100 mg once daily\nPantoprazole 40 mg once daily\nBisoprolol 10 mg once daily\nAtorvastatin 40 mg once daily\nIsosorbide dinitrate 20 mg three times daily\nNitroglycerin 0.6 mg sublingual tablet as needed\n\n① Tirofiban\n② Abciximab\n③ Alteplase\n④ Prasugrel\n⑤ Clopidogrel",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 평소 건강하던 40세 남자가 갑작스러운 흉통이 발생하여 검사받은 결과 변형협심증(variant angina)을 진단받았다. 딜티아젬(diltiazem)을 복용하였으나 증상이 충분히 개선되지 않는다. 적절한 추가약물은?\n\n① 나돌롤(nadolol)\n② 암로디핀(amlodipine)\n③ 수마트립탄(sumatriptan)\n④ 프로프라놀롤(propranolol)\n⑤ 이소소르비드이질산염(isosorbide dinitrate)",
        "question_text": "Question: A previously healthy 40-year-old man experienced sudden chest pain and was diagnosed with variant angina after examination. He took diltiazem, but his symptoms did not improve sufficiently. What is the appropriate additional medication?\n\n① Nadolol\n② Amlodipine\n③ Sumatriptan\n④ Propranolol\n⑤ Isosorbide dinitrate",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: 51세 남자가 어지럼증 증상과 팔다리의 감각 저하가 있어 검사받은 결과, 경증의 비심장성색전성뇌졸중(National Institute of Health Stroke Scale 2점)을 진단받았다. 혈전용해술은 시행하지 않았다. 뇌졸중의 조기 재발을 예방하기 위한 약물요법은?\n\n① 티로피반(tirofiban)\n② 압식시맙(abciximab)\n③ 프라수그렐(prasugrel)\n④ 아스피린(aspirin)+클로피도그렐(clopidogrel)\n⑤ 아스피린/디피리다몰(aspirin/dipyridamole)+클로피도그렐",
        "question_text": "Question: A 51-year-old man was examined for symptoms of dizziness and decreased sensation in his limbs. He was diagnosed with mild non-cardioembolic stroke (National Institute of Health Stroke Scale score of 2). Thrombolytic therapy was not performed. What is the appropriate drug therapy to prevent early recurrence of stroke?\n\n① Tirofiban\n② Abciximab\n③ Prasugrel\n④ Aspirin + Clopidogrel\n⑤ Aspirin/Dipyridamole + Clopidogrel",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 65세 남자가 오늘 아침에 몸의 중심을 잡지 못하고 말을 어눌하게 하여 검사받은 결과 급성허혈뇌졸증을 진단받았다. 우선적으로 투여할 약물은?\n\n[경과기록]\n08:15 구음장애, 중심을 잡지 못하고 몸이 휘청임\n09:50 응급실 도착, 의식 없음\n10:15 급성허혈뇌졸증 진단\n현재 시간 10:30\n[활력징후]\n혈압 225/130 mmHg, 심박수 115회/분, 호흡수 23회/분\n[임상검사]\n백혈구 4,200/mm^3, 혈소판 215,000/mm^3\n혈색소(Hgb) 12.3 g/dl, 적혈구용적률(Hct) 38.5 %\n\n① 헤파린(heparin)\n② 라베타롤(labetalol)\n③ 딜티아젬(diltiazem)\n④ 알테플라제(alteplase)\n⑤ 니트로글리세린(nitroglycerin)",
        "question_text": "Question: A 65-year-old man was unable to maintain his balance and spoke inarticulately this morning. After examination, he was diagnosed with acute ischemic stroke. Which drug should be administered as a priority?\n\n[Progress Notes]\n08:15 Dysarthria, inability to maintain balance, and staggering\n09:50 Arrived at the emergency room, unconscious\n10:15 Diagnosed with acute ischemic stroke\nCurrent time 10:30\n[Vital Signs]\nBlood pressure 225/130 mmHg, Heart rate 115 beats/min, Respiratory rate 23 breaths/min\n[Clinical Tests]\nWhite blood cells 4,200/mm^3, Platelets 215,000/mm^3\nHemoglobin (Hgb) 12.3 g/dl, Hematocrit (Hct) 38.5%\n\n① Heparin\n② Labetalol\n③ Diltiazem\n④ Alteplase\n⑤ Nitroglycerin",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 건선이 있는 50세 남자가 이상지질혈증을 진단받았다. 검사 결과와 사용약물이 다음과 같을 때 추가할 약물요법은?\n\n[사회력] 흡연 10갑년(pack-year)\n[임상검사]\n혈압 118/82 mmHg, 공복혈당 106 mg/dL\nAST 25 IU/L, ALT 27 IU/L\nTC 220 mg/dL, LDL-C 156 mg/dL, TG 128 mg/dL, HDL-C 38 mg/dL\n[사용약물]\n메토트렉세이트(methotrexate) 15 mg 주 1회\n사이클로스포린(cyclosporine) 100 mg 1일 2회\n폴산(folic acid) 1 mg 1일 1회\n칼시포트리올(calcipotriol) 연고 1일 2회\n\n① 로바스타틴(lovastatin) 20 mg 1일 1회\n② 심바스타틴(simvastatin) 40 mg 1일 1회\n③ 피타바스타틴(pitavastatin) 4 mg 1일 1회\n④ 프라바스타틴(pravastatin) 10 mg 1일 1회\n⑤ 로수바스타틴(rosuvastatin) 10 mg 1일 1회",
        "question_text": "Question: A 50-year-old man with psoriasis has been diagnosed with dyslipidemia. Given the following test results and current medications, what additional drug therapy should be prescribed?\n\n[Social history] Smoking history of 10 pack-years\n[Clinical tests]\nBlood pressure 118/82 mmHg, Fasting blood glucose 106 mg/dL\nAST 25 IU/L, ALT 27 IU/L\nTC 220 mg/dL, LDL-C 156 mg/dL, TG 128 mg/dL, HDL-C 38 mg/dL\n[Current medications]\nMethotrexate 15 mg once weekly\nCyclosporine 100 mg twice daily\nFolic acid 1 mg once daily\nCalcipotriol ointment twice daily\n\n① Lovastatin 20 mg once daily\n② Simvastatin 40 mg once daily\n③ Pitavastatin 4 mg once daily\n④ Pravastatin 10 mg once daily\n⑤ Rosuvastatin 10 mg once daily",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 77세 남자가 폐색전증을 진단받고 다비가트란 에텍실레이트(dabigatran etexilate) 복용을 시작하였다고 한다. 현재 복용약물 중 다비가트란의 출혈 이상반응 위험을 높일 수 있는 약물은?\n\n[병력]\n고혈압, 이상지질혈증, 주요우울장애\n[복용약물]\n페린도프릴(perindopril)\n인다파미드(indapamide)\n베라파밀(verapamil)\n로수바스타틴(rosuvastatin)\n성요한풀(St. John's wort)\n\n① 베라파밀\n② 성요한풀\n③ 인다파미드\n④ 페린도프릴\n⑤ 로수바스타틴",
        "question_text": "Question: A 77-year-old man was diagnosed with pulmonary embolism and started taking dabigatran etexilate. Which of the current medications can increase the risk of bleeding adverse reactions of dabigatran?\n\n[Medical History]\nHypertension, Dyslipidemia, Major Depressive Disorder\n[Current Medications]\nPerindopril\nIndapamide\nVerapamil\nRosuvastatin\nSt. John's wort\n\n① Verapamil\n② St. John's wort\n③ Indapamide\n④ Perindopril\n⑤ Rosuvastatin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 임신 18주 차인 39세 임부가 왼쪽 종아리에 발생한 심부정맥혈전증으로 입원하였다. 항혈전요법으로 적절한 약물은?\n\n[활력징후]\n혈압 124/75 mmHg, 심박수 72회/분\n[임상검사]\n혈색소(Hgb) 12.5 g/dl, 적혈구용적률(Hct) 39 %\n혈소판 275,000/mm^3\n크레아티닌청소율(CLcr) 64 mL/min\n\n① 와파린(warfarin)\n② 아스피린(aspirin)\n③ 달테파린(dalteparin)\n④ 에독사반(edoxaban)\n⑤ 아가트로반(argatroban)",
        "question_text": "Question: A 39-year-old pregnant woman at 18 weeks of gestation has been hospitalized for deep vein thrombosis in her left calf. Which of the following drugs is appropriate for antithrombotic therapy?\n\n[Vital Signs]\nBlood pressure 124/75 mmHg, Heart rate 72 beats/min\n[Clinical Tests]\nHemoglobin (Hgb) 12.5 g/dl, Hematocrit (Hct) 39%\nPlatelets 275,000/mm^3\nCreatinine clearance (CLcr) 64 mL/min\n\n① Warfarin\n② Aspirin\n③ Dalteparin\n④ Edoxaban\n⑤ Argatroban",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n당뇨병신장병증과 양성전립선비대가 있는 72세 남자가 일주일 전에 고혈압과 이상지질혈증을 새로 진단받고 다음 약물을 복용 중이다. 검사결과는 다음과 같고 다른 특이 소견은 없다.\n\n[활력징후]\n(오늘)\n혈압 130/82 mmHg, 심박수 72회/분\n[임상검사]\n(일주일 전)\nNa 141 mEq/L, K 4.3 mEq/L\nSCr 1.4 mg/dL, eGFR 53 mL/min/1.73m^2\nTC 290 mg/dL, LDL-C 195 mg/dL, TG 240 mg/dL, HDL-C 47 mg/dL\n소변 알부민대비크레아티닌비(ACR) 50 mg/g\n(오늘)\nNa 143 mEq/L, K 4.6 mEq/L\nSCr 1.9 mg/dL, eGFR 37 mL/min/1.73m^2\n[복용약물]\n탐스로신(tamsulosin) 0.2 mg 1일 1회\n테네리글립틴(teneligliptin) 20 mg 1일 1회\n피오글리타존(pioglitazone) 15 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n아토르바스타틴(atorvastatin) 80 mg 1일 1회\n\nQuestion: 복용약물 중 혈청 크레아티닌 상승의 원인으로 의심되는 약물은?\n\n① 탐스로신\n② 리시노프릴\n③ 테네리글립틴\n④ 피오글리타존\n⑤ 아토르바스타틴",
        "question_text": "A 72-year-old man with diabetic nephropathy and benign prostatic hyperplasia was newly diagnosed with hypertension and dyslipidemia a week ago and is currently taking the following medications. The test results are as follows, and there are no other significant findings.\n\n[Vital Signs]\n(Today)\nBlood pressure 130/82 mmHg, Heart rate 72 beats/min\n[Clinical Tests]\n(One week ago)\nNa 141 mEq/L, K 4.3 mEq/L\nSCr 1.4 mg/dL, eGFR 53 mL/min/1.73m^2\nTC 290 mg/dL, LDL-C 195 mg/dL, TG 240 mg/dL, HDL-C 47 mg/dL\nUrine albumin-to-creatinine ratio (ACR) 50 mg/g\n(Today)\nNa 143 mEq/L, K 4.6 mEq/L\nSCr 1.9 mg/dL, eGFR 37 mL/min/1.73m^2\n[Medications]\nTamsulosin 0.2 mg once daily\nTeneligliptin 20 mg once daily\nPioglitazone 15 mg once daily\nLisinopril 10 mg once daily\nAtorvastatin 80 mg once daily\n\nQuestion: Which medication among those being taken is suspected to be the cause of the increase in serum creatinine?\n\n① Tamsulosin\n② Lisinopril\n③ Teneligliptin\n④ Pioglitazone\n⑤ Atorvastatin",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n당뇨병신장병증과 양성전립선비대가 있는 72세 남자가 일주일 전에 고혈압과 이상지질혈증을 새로 진단받고 다음 약물을 복용 중이다. 검사결과는 다음과 같고 다른 특이 소견은 없다.\n\n[활력징후]\n(오늘)\n혈압 130/82 mmHg, 심박수 72회/분\n[임상검사]\n(일주일 전)\nNa 141 mEq/L, K 4.3 mEq/L\nSCr 1.4 mg/dL, eGFR 53 mL/min/1.73m^2\nTC 290 mg/dL, LDL-C 195 mg/dL, TG 240 mg/dL, HDL-C 47 mg/dL\n소변 알부민대비크레아티닌비(ACR) 50 mg/g\n(오늘)\nNa 143 mEq/L, K 4.6 mEq/L\nSCr 1.9 mg/dL, eGFR 37 mL/min/1.73m^2\n[복용약물]\n탐스로신(tamsulosin) 0.2 mg 1일 1회\n테네리글립틴(teneligliptin) 20 mg 1일 1회\n피오글리타존(pioglitazone) 15 mg 1일 1회\n리시노프릴(lisinopril) 10 mg 1일 1회\n아토르바스타틴(atorvastatin) 80 mg 1일 1회\n\nQuestion: 혈청 크레아티닌 상승 문제가 해결된 후 3개월째에 시행한 공복 지질검사 결과는 다음과 같다. 다른 특이 소견은 없다. 환자는 운동과 식이요법을 잘 실천하고 약물도 잘 복용하고 있다. 이 환자의 혈중 콜레스테롤 조절을 위한 적절한 치료 계획은?\n\n[지질검사]\nTC 197 mg/dL, LDL-C 110 mg/dL, TG 195 mg/dL\nHDL-C 48 mg/dL\n\n① 현재의 약물요법 유지\n② 에제티미브(ezetimibe) 추가\n③ 알리로쿠맙(alirocumab) 추가\n④ 아토르바스타틴을 에볼로쿠맙(evolocumab)으로 변경\n⑤ 아토르바스타틴을 페노피브레이트(fenofibrate)로 변경",
        "question_text": "A 72-year-old male with diabetic nephropathy and benign prostatic hyperplasia was newly diagnosed with hypertension and dyslipidemia a week ago and is currently taking the following medications. The test results are as follows, with no other significant findings.\n\n[Vital Signs]\n(Today)\nBlood pressure 130/82 mmHg, Heart rate 72 bpm\n[Clinical Tests]\n(One week ago)\nNa 141 mEq/L, K 4.3 mEq/L\nSCr 1.4 mg/dL, eGFR 53 mL/min/1.73m^2\nTC 290 mg/dL, LDL-C 195 mg/dL, TG 240 mg/dL, HDL-C 47 mg/dL\nUrine albumin-to-creatinine ratio (ACR) 50 mg/g\n(Today)\nNa 143 mEq/L, K 4.6 mEq/L\nSCr 1.9 mg/dL, eGFR 37 mL/min/1.73m^2\n[Medications]\nTamsulosin 0.2 mg once daily\nTeneligliptin 20 mg once daily\nPioglitazone 15 mg once daily\nLisinopril 10 mg once daily\nAtorvastatin 80 mg once daily\n\nQuestion: The fasting lipid test results at 3 months after resolving the serum creatinine elevation issue are as follows. There are no other significant findings. The patient is adhering well to exercise and dietary recommendations and is taking medications as prescribed. What is the appropriate treatment plan for managing this patient's blood cholesterol levels?\n\n[Lipid Test]\nTC 197 mg/dL, LDL-C 110 mg/dL, TG 195 mg/dL\nHDL-C 48 mg/dL\n\n① Maintain current drug therapy\n② Add ezetimibe\n③ Add alirocumab\n④ Change atorvastatin to evolocumab\n⑤ Change atorvastatin to fenofibrate",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n68세 남자가 최근 심장이 두근거리고 피로감과 활동 시 숨차는 증상이 있어 검사받은 결과 비판막성 심방세동을 진단받았다.\n\n[병력] 심부전\n[활력징후]\n혈압 138/80 mmHg, 심박수 104회/분, 호흡수 22회/분\n[임상검사]\n심전도: 심방세동\n심초음파: 심방 내 혈전 없음\n좌심실박출률(LVEF) 35 %\n[복용약물]\n라미프릴(ramipril) 10 mg 1일 1회\n푸로세미드(furosemide) 20 mg 1일 2회\n\nQuestion: 심박수 조절을 위한 적절한 약물은?\n\n① 소타롤(sotalol)\n② 베라파밀(verapamil)\n③ 메토프로롤(metoprolol)\n④ 니카르디핀(nicardipine)\n⑤ 스피로노락톤(spironolactone)",
        "question_text": "A 68-year-old male was recently diagnosed with non-valvular atrial fibrillation after experiencing heart palpitations, fatigue, and shortness of breath during activity.\n\n[Medical history] Heart failure\n[Vital signs]\nBlood pressure 138/80 mmHg, Heart rate 104 beats/min, Respiratory rate 22 breaths/min\n[Clinical tests]\nECG: Atrial fibrillation\nEchocardiogram: No thrombus in atrium\nLeft ventricular ejection fraction (LVEF) 35%\n[Current medications]\nRamipril 10 mg once daily\nFurosemide 20 mg twice daily\n\nQuestion: What is the appropriate medication for heart rate control?\n\n① Sotalol\n② Verapamil\n③ Metoprolol\n④ Nicardipine\n⑤ Spironolactone",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n68세 남자가 최근 심장이 두근거리고 피로감과 활동 시 숨차는 증상이 있어 검사받은 결과 비판막성 심방세동을 진단받았다.\n\n[병력] 심부전\n[활력징후]\n혈압 138/80 mmHg, 심박수 104회/분, 호흡수 22회/분\n[임상검사]\n심전도: 심방세동\n심초음파: 심방 내 혈전 없음\n좌심실박출률(LVEF) 35 %\n[복용약물]\n라미프릴(ramipril) 10 mg 1일 1회\n푸로세미드(furosemide) 20 mg 1일 2회\n\nQuestion: 약물치료로 심박수는 조절되었고, 항응고치료도 시작하였지만 여전히 두근거림 증상이 있다. 동리듬으로 전환하고자 할 때 적절한 약물은?\n\n① 딜티아젬(diltiazem)\n② 이바브라딘(ivabradine)\n③ 아미오다론(amiodarone)\n④ 프로파페논(propafenone)\n⑤ 드로네다론(dronedarone)",
        "question_text": "A 68-year-old male was recently diagnosed with non-valvular atrial fibrillation after experiencing heart palpitations, fatigue, and shortness of breath during activity.\n\n[Medical history] Heart failure\n[Vital signs]\nBlood pressure 138/80 mmHg, Heart rate 104 beats/min, Respiratory rate 22 breaths/min\n[Clinical tests]\nECG: Atrial fibrillation\nEchocardiogram: No thrombus in atrium\nLeft ventricular ejection fraction (LVEF) 35%\n[Current medications]\nRamipril 10 mg once daily\nFurosemide 20 mg twice daily\n\nQuestion: The heart rate has been controlled with drug therapy, and anticoagulation therapy has been initiated, but the patient still experiences palpitations. Which of the following drugs is appropriate for converting to sinus rhythm?\n\n① Diltiazem\n② Ivabradine\n③ Amiodarone\n④ Propafenone\n⑤ Dronedarone",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "original_text": "Question: 천식이 있는 24세 남자가 지난 3개월 동안 천식증상이 잘 조절되지 않고, 중등의 천식악화가 두 차례 발생하였다. 환자는 처방대로 약물을 사용하고 있고, 검사결과는 다음과 같다. 적절한 약물요법 계획은?\n\n[임상검사]\n혈액검사: IgE 82 IU/mL (참고치 0~158 IU/mL)\n백혈구 6,000/mm^3, 중성구 3,800/mm^3, 호산구 540/mm^3\n피부반응검사: 음성\n1초간강제호기량(FEV1) 65 % 정상예측치\n[사용약물]\n고용량 플루티카손/살메테롤(fluticasone/salmeterol) 1일 2회 흡입\n살부타몰(salbutamol) 필요시 흡입\n\n① 메폴리주맙(mepolizumab) 추가\n② 갈카네주맙(galcanezumab) 추가\n③ 플루티카손/살메테롤을 메폴리주맙으로 변경\n④ 플루티카손/살메테롤을 갈카네주맙으로 변경\n⑤ 플루티카손/살메테롤을 피하면역요법으로 변경",
        "question_text": "Question: A 24-year-old male with asthma has had poorly controlled asthma symptoms for the past 3 months, with two moderate asthma exacerbations. The patient is using medications as prescribed, and the test results are as follows. What is the appropriate drug therapy plan?\n\n[Clinical Tests]\nBlood test: IgE 82 IU/mL (reference range 0-158 IU/mL)\nWhite blood cells 6,000/mm^3, neutrophils 3,800/mm^3, eosinophils 540/mm^3\nSkin reaction test: Negative\nForced Expiratory Volume in 1 second (FEV1) 65% of predicted normal value\n\n[Current Medications]\nHigh-dose fluticasone/salmeterol inhaled twice daily\nSalbutamol inhaled as needed\n\n① Add mepolizumab\n② Add galcanezumab\n③ Change fluticasone/salmeterol to mepolizumab\n④ Change fluticasone/salmeterol to galcanezumab\n⑤ Change fluticasone/salmeterol to subcutaneous immunotherapy",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "original_text": "Question: 알레르기천식이 있는 28세 여자가 고용량 부데소니드/포르모테롤(budesonide/formoterol)을 사용하여도 천식악화가 자주 발생한다. 오말리주맙(omalizumab)을 추가하려고 할 때 용량을 결정하기 위해 확인해야 하는 항목은?\n\n① 호산구\n② 혈청 크레아티닌(SCr)\n③ 1초간강제호기량(FEV1)\n④ 혈청 면역글로불린E(IgE)\n⑤ 알라닌아미노기전달효소(ALT)",
        "question_text": "Question: A 28-year-old woman with allergic asthma experiences frequent asthma exacerbations despite using high-dose budesonide/formoterol. When considering adding omalizumab, which parameter should be checked to determine the dosage?\n\n① Eosinophils\n② Serum Creatinine (SCr)\n③ Forced Expiratory Volume in 1 second (FEV1)\n④ Serum Immunoglobulin E (IgE)\n⑤ Alanine Aminotransferase (ALT)",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 만성폐쇄폐질환이 있는 66세 남자가 기침과 호흡곤란 증상이 급격히 악화되었다. 환자는 이전에 급성악화 증상을 경험한 적이 없고, 흡입제 사용방법과 치료이행도에도 문제가 없다. 오늘 시행한 검사결과는 다음과 같고, 화농성 가래가 관찰되었다. 급성악화 치료를 위해 경구 스테로이드와 함께 투여할 적절한 약은?\n\n[사회력] 흡연 26갑년(pack-year), 1년 전부터 금연\n[임상검사]\n1초간강제호기량(FEV1) 55 % 정상예측치\n만성폐쇄폐질환 평가검사(COPD Assessment Test) 점수: 21점\n[사용약물] 빌란테롤/우메클리디늄(vilanterol/umeclidinium) 1일 1회, 1회 1번 흡입\n\n① 인디카테롤(indacaterol) 흡입제\n② 시클레소니드(ciclesonide) 흡입제\n③ 몬테루카스트(montelukast) 경구제\n④ 로플루밀라스트(roflumilast) 경구제\n⑤ 아지트로마이신(azithromycin) 경구제",
        "question_text": "Question: A 66-year-old man with chronic obstructive pulmonary disease (COPD) experienced a sudden worsening of cough and dyspnea symptoms. The patient has never experienced acute exacerbation symptoms before, and there are no issues with inhaler use method or treatment adherence. Today's test results are as follows, and purulent sputum was observed. What is the appropriate medication to be administered along with oral steroids for the treatment of acute exacerbation?\n\n[Social history] Smoking history of 26 pack-years, quit smoking 1 year ago\n[Clinical tests]\nForced Expiratory Volume in 1 second (FEV1) 55% of predicted normal\nCOPD Assessment Test (CAT) score: 21 points\n[Current medication] Vilanterol/umeclidinium, once daily, 1 inhalation per dose\n\n① Indacaterol inhaler\n② Ciclesonide inhaler\n③ Montelukast oral tablet\n④ Roflumilast oral tablet\n⑤ Azithromycin oral tablet",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 만성폐쇄폐질환이 있는 69세 남자의 호흡곤란 증상이 적절하게 조절되지 않는다. 환자의 검사결과와 사용약물은 다음과 같다. 적절한 약물요법 계획은?\n\n[임상검사]\n1초간강제호기량(FEV1) 60 % 정상예측치\n만성폐쇄폐질환 평가검사(COPD Assessment Test) 점수: 18점\n[사용약물] 아클리디늄(aclidinium) 1일 2회, 1회 1번 흡입\n\n① 플루티카손(fluticasone) 흡입제 추가\n② 로플루밀라스트(roflumilast) 경구제 추가\n③ 아지트로마이신(azithromycin) 경구제 추가\n④ 아클리디늄 흡입제를 포르모테롤/아클리디늄(formoterol/aclidinium)으로 변경\n⑤ 아클리디늄 흡입제를 베클로메타손/포르모테롤(beclomethasone/formoterol)로 변경",
        "question_text": "Question: A 69-year-old male with chronic obstructive pulmonary disease (COPD) has inadequately controlled dyspnea symptoms. The patient's test results and current medication are as follows. What is the appropriate drug therapy plan?\n\n[Clinical tests]\nForced Expiratory Volume in 1 second (FEV1): 60% of predicted normal value\nCOPD Assessment Test (CAT) score: 18 points\n[Current medication] Aclidinium, twice daily, 1 inhalation per dose\n\n① Add fluticasone inhaler\n② Add oral roflumilast\n③ Add oral azithromycin\n④ Change aclidinium inhaler to formoterol/aclidinium\n⑤ Change aclidinium inhaler to beclomethasone/formoterol",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 알레르기비염이 있는 32세 남자가 플루티카손(fluticasone) 비강분무제를 사용하고 있다. 며칠 전부터 꽃가루로 인해 콧물, 재채기가 심해져서 일상생활이 불편하고 코막힘은 없다. 적절한 약물요법 계획은?\n\n① 에바스틴(ebastine) 경구제 추가\n② 슈도에페드린(pseudoephedrine) 경구제 추가\n③ 자일로메타졸린(xylometazoline) 비강분무제 추가\n④ 플루티카손 비강분무제를 프린루카스트(pranlukast) 경구제로 변경\n⑤ 플루티카손 비강분무제를 이프라트로퓸(ipratropium) 비강분무제로 변경",
        "question_text": "Question: A 32-year-old man with allergic rhinitis is using fluticasone nasal spray. For the past few days, due to pollen, his runny nose and sneezing have worsened, making daily life uncomfortable, but there is no nasal congestion. What is the appropriate drug therapy plan?\n\n① Add oral ebastine\n② Add oral pseudoephedrine\n③ Add xylometazoline nasal spray\n④ Change fluticasone nasal spray to oral pranlukast\n⑤ Change fluticasone nasal spray to ipratropium nasal spray",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 55세 여자가 상부 복통이 있어 시행한 위내시경 검사결과, 비출혈성 소화성궤양을 진단받았다. 헬리코박터균(Helicobacter pylori) 양성이 확인되어 다음 약물로 제균치료를 할 계획이다. 적절한 치료 기간은?\n\n[약물알레르기]\n페니실린(penicillin): 아나필락시스\n[복용약물]\n비스무스(bismuth)\n란소프라졸(lansoprazole)\n테트라사이클린(tetracycline)\n메트로니다졸(metronidazole)\n\n① 3일\n② 5일\n③ 7일\n④ 14일\n⑤ 28일",
        "question_text": "Question: A 55-year-old woman with upper abdominal pain was diagnosed with non-bleeding peptic ulcer through an endoscopy. Helicobacter pylori was confirmed positive, and eradication therapy is planned with the following drugs. What is the appropriate duration of treatment?\n\n[Drug Allergy]\nPenicillin: Anaphylaxis\n[Medications]\nBismuth\nLansoprazole\nTetracycline\nMetronidazole\n\n① 3 days\n② 5 days\n③ 7 days\n④ 14 days\n⑤ 28 days",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 위식도역류병이 있는 67세 여자가 사용할 때, 하부식도괄약근압을 저하시켜 위식도역류병을 악화시킬 수 있는 약물은?\n\n① 바클로펜(baclofen)\n② 이토프리드(itopride)\n③ 베타네콜(bethanechol)\n④ 테오필린(theophylline)\n⑤ 메토프롤롤(metoprolol)",
        "question_text": "Question: Which of the following drugs can worsen gastroesophageal reflux disease (GERD) in a 67-year-old woman with GERD by decreasing lower esophageal sphincter pressure when used?\n\n① Baclofen\n② Itopride\n③ Bethanechol\n④ Theophylline\n⑤ Metoprolol",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 간경화증이 있는 47세 남자가 최근 복수증가, 발열(38.7°C), 복통 증상으로 검사를 받았다. 검사결과 자발세균성복막염이 의심되어 세포탁심(cefotaxime)을 투여할 계획이다. 환자의 신손상 예방 및 사망위험 감소를 위해 세포탁심과 함께 투여할 수 있는 약물은?\n\n[임상검사]\nSCr 1.8 mg/dL, BUN 38 mg/dL, Alb 2.0 g/dL\n[복수천자검사]\nAlb 0.9 g/dL, 다형핵백혈구(PMN) 290/mm^3\n[복수 및 혈액 배양검사] 진행 중\n\n① 알부민(albumin)\n② 락툴로오스(lactulose)\n③ 겐타마이신(gentamicin)\n④ 프로프라놀롤(propranolol)\n⑤ 테를리프레신(terlipressin)",
        "question_text": "Question: A 47-year-old man with liver cirrhosis recently underwent tests due to symptoms of increased ascites, fever (38.7°C), and abdominal pain. The test results suggest spontaneous bacterial peritonitis, and a plan to administer cefotaxime has been made. Which drug can be administered along with cefotaxime to prevent renal damage and reduce the risk of mortality in this patient?\n\n[Clinical tests]\nSCr 1.8 mg/dL, BUN 38 mg/dL, Alb 2.0 g/dL\n[Paracentesis test]\nAlb 0.9 g/dL, Polymorphonuclear leukocytes (PMN) 290/mm^3\n[Ascites and blood culture tests] In progress\n\n① Albumin\n② Lactulose\n③ Gentamicin\n④ Propranolol\n⑤ Terlipressin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 만성변비가 있는 68세 여자가 다음과 같은 약물을 복용 중이다. 배변 빈도와 배변 시 불편감이 개선되지 않을 때, 추가할 약물은?\n\n[병력] 과민대장증후군, 파킨슨병\n[복용약물]\n차전자피(psylium husk) 6개월 전부터 필요시 복용\n락툴로오스(lactulose) 3개월 전부터 복용\n카르비도파/레보도파(carbidopa/levodopa) 2년 전부터 복용\n\n① 독세핀(doxepin)\n② 라모세트론(ramosetron)\n③ 트리메부틴(trimethbutine)\n④ 프루칼로프라이드(prucalopride)\n⑤ 메토클로프라미드(metoclopramide)",
        "question_text": "Question: A 68-year-old woman with chronic constipation is taking the following medications. Which drug should be added if the frequency of bowel movements and discomfort during defecation do not improve?\n\n[Medical history] Irritable bowel syndrome, Parkinson's disease\n[Current medications]\nPsyllium husk: taken as needed for 6 months\nLactulose: taken for 3 months\nCarbidopa/levodopa: taken for 2 years\n\n① Doxepin\n② Ramosetron\n③ Trimebutine\n④ Prucalopride\n⑤ Metoclopramide",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 중등도의 활동성 광범위 궤양대장염이 있는 23세 남자가 최근 출혈성 설사 빈도가 증가하고 복통이 심해져 5일 전부터 프레드니솔론(prednisolone)을 복용 중이다. 관해에 도달하지 못하여 약물치료를 변경하고자 할 때, 적절한 약물요법은?\n\n① 부데소니드(budesonide) 관장제\n② 타크로리무스(tacrolimus) 경구제\n③ 메토트렉세이트(methotrexate) 경구제\n④ 베돌리주맙(vedolizumab) 주사제+도파시티닙(tofacitinib) 경구제\n⑤ 인플릭시맙(infliximab) 주사제+아자티오프린(azathioprine) 경구제",
        "question_text": "Question: A 23-year-old male with moderate active extensive ulcerative colitis has been taking prednisolone for 5 days due to increased frequency of bloody diarrhea and worsening abdominal pain. If the treatment needs to be changed because remission has not been achieved, what is the appropriate drug therapy?\n\n① Budesonide enema\n② Oral tacrolimus\n③ Oral methotrexate\n④ Vedolizumab injection + oral tofacitinib\n⑤ Infliximab injection + oral azathioprine",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n보상간경화증(compensated cirrhosis)이 있는 50세 남자가 C형간염을 진단받았다. 임상검사 결과는 다음과 같다.\n\n[임상검사]\nHCV RNA 950,000 IU/mL\nHCV 유전자형 1b, NS5A 내성 유전자형 음성\nanti-HAV 양성, HBsAg 음성, anti-HBs 음성, anti-HBc 양성\n\nQuestion: 적절한 초기 치료 약물요법은?\n\n① 글레카프레비르/피브렌타스비르(glecaprevir/pibrentasvir) 4주\n② 소포스부비르(sofosbuvir)+리바비린(ribavirin) 8주\n③ 소포스부비르/벨파타스비르(sofosbuvir/velpatasvir) 12주\n④ 테노포비르(tenofovir)+베시포비르(besifovir) 16주\n⑤ 엔테카비르(entecavir)+레디파스비르/소포스부비르(ledipasvir/sofosbuvir) 24주",
        "question_text": "A 50-year-old man with compensated cirrhosis has been diagnosed with hepatitis C. The clinical test results are as follows:\n\n[Clinical Tests]\nHCV RNA 950,000 IU/mL\nHCV genotype 1b, NS5A resistance genotype negative\nanti-HAV positive, HBsAg negative, anti-HBs negative, anti-HBc positive\n\nQuestion: What is the appropriate initial drug therapy?\n\n① Glecaprevir/pibrentasvir for 4 weeks\n② Sofosbuvir + ribavirin for 8 weeks\n③ Sofosbuvir/velpatasvir for 12 weeks\n④ Tenofovir + besifovir for 16 weeks\n⑤ Entecavir + ledipasvir/sofosbuvir for 24 weeks",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n보상간경화증(compensated cirrhosis)이 있는 50세 남자가 C형간염을 진단받았다. 임상검사 결과는 다음과 같다.\n\n[임상검사]\nHCV RNA 950,000 IU/mL\nHCV 유전자형 1b, NS5A 내성 유전자형 음성\nanti-HAV 양성, HBsAg 음성, anti-HBs 음성, anti-HBc 양성\n\nQuestion: 환자는 최근 B형간염의 감염원이 노출된 적이 없다. B형간염 임상시험 결과에 따른 적절한 조치는?\n\n① 예방요법 불필요\n② B형간염백신 접종\n③ 인터페론베타(interferon beta) 피하주사 투여\n④ B형간염면역글로불린(hepatitis B immunoglobulin) 정맥주사 투여\n⑤ B형간염백신 접종+B형간염면역글로불린 정맥주사 투여",
        "question_text": "A 50-year-old man with compensated cirrhosis has been diagnosed with hepatitis C. The clinical test results are as follows:\n\n[Clinical Tests]\nHCV RNA 950,000 IU/mL\nHCV genotype 1b, NS5A resistance genotype negative\nanti-HAV positive, HBsAg negative, anti-HBs negative, anti-HBc positive\n\nQuestion: The patient has not been recently exposed to any source of hepatitis B infection. Based on the hepatitis B clinical test results, what is the appropriate course of action?\n\n① No preventive measures necessary\n② Administer hepatitis B vaccine\n③ Administer subcutaneous injection of interferon beta\n④ Administer intravenous injection of hepatitis B immunoglobulin\n⑤ Administer hepatitis B vaccine + intravenous injection of hepatitis B immunoglobulin",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 57세 여자가 신장기원요붕증(nephrogenic diabetes insipidus)으로 인한 고나트륨혈증을 진단받았다. 복용하던 탄산리튬(lithium carbonate)을 중단하고 5% 포도당액을 정맥투여 하였다. 적절한 추가약물은?\n\n[병력] 양극성장애\n[임상검사]\nNa 152 mEq/L, K 4.2 mEq/L, BUN 15 mg/dL, SCr 1.1 mg/dL\n혈장삼투압 312 mOsm/kg (참고치 275~300 mOsm/kg)\n소변삼투압 98 mOsm/kg (참고치 250~900 mOsm/kg)\n소변량 4,500 mL/24시간 (참고치 800~2,000 mL/24시간)\n리튬 혈중농도 1.4 mEq/L (참고치 0.6~1.2 mEq/L)\n[복용약물] 탄산리튬 600 mg 1일 2회\n\n① 톨밥탄(tolvaptan)\n② 리시노프릴(lisinopril)\n③ 푸로세미드(furosemide)\n④ 아미로라이드(amiloride)\n⑤ 폴리스티렌설폰산칼슘(calcium polystyrene sulfonate)",
        "question_text": "Question: A 57-year-old woman was diagnosed with hypernatremia due to nephrogenic diabetes insipidus. The lithium carbonate she had been taking was discontinued, and 5% glucose solution was administered intravenously. What is the appropriate additional medication?\n\n[Medical history] Bipolar disorder\n[Clinical tests]\nNa 152 mEq/L, K 4.2 mEq/L, BUN 15 mg/dL, SCr 1.1 mg/dL\nPlasma osmolality 312 mOsm/kg (reference range 275-300 mOsm/kg)\nUrine osmolality 98 mOsm/kg (reference range 250-900 mOsm/kg)\nUrine output 4,500 mL/24 hours (reference range 800-2,000 mL/24 hours)\nSerum lithium concentration 1.4 mEq/L (reference range 0.6-1.2 mEq/L)\n[Current medication] Lithium carbonate 600 mg twice daily\n\n① Tolvaptan\n② Lisinopril\n③ Furosemide\n④ Amiloride\n⑤ Calcium polystyrene sulfonate",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 고혈압, 2형당뇨병, 이상지질혈증이 있는 57세 남자가 다음 약물을 복용하고 있다. 환자는 오늘 만성콩팥병을 진단받았고, 검사결과는 다음과 같다. 용량을 감량해야 하는 약물은?\n\n[활력징후]\n혈압 138/88 mmHg, 심박수 72회/분, 호흡수 19회/분\n[임상검사]\nBUN 33 mg/dL, SCr 1.9 mg/dL, eGFR 40 mL/min/1.73m^2\n당화혈색소 6.4 %\nTC 160 mg/dL, LDL-C 90 mg/dL, TG 150 mg/dL, HDL-C 40 mg/dL\n[복용약물]\n로사르탄(losartan) 100 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n삭사글립틴(saxagliptin) 5 mg 1일 1회\n로베글리타존(lobeglitazone) 0.5 mg 1일 1회\n로수바스타틴(rosuvastatin) 5 mg 1일 1회\n\n① 로사르탄\n② 삭사글립틴\n③ 로베글리타존\n④ 로수바스타틴\n⑤ 히드로클로로티아지드",
        "question_text": "Question: A 57-year-old man with hypertension, type 2 diabetes, and dyslipidemia is taking the following medications. The patient was diagnosed with chronic kidney disease today, and the test results are as follows. Which medication should have its dosage reduced?\n\n[Vital Signs]\nBlood pressure 138/88 mmHg, Heart rate 72 beats/min, Respiratory rate 19 breaths/min\n[Clinical Tests]\nBUN 33 mg/dL, SCr 1.9 mg/dL, eGFR 40 mL/min/1.73m^2\nHbA1c 6.4%\nTC 160 mg/dL, LDL-C 90 mg/dL, TG 150 mg/dL, HDL-C 40 mg/dL\n[Medications]\nLosartan 100 mg once daily\nHydrochlorothiazide 25 mg once daily\nSaxagliptin 5 mg once daily\nLobeglitazone 0.5 mg once daily\nRosuvastatin 5 mg once daily\n\n① Losartan\n② Saxagliptin\n③ Lobeglitazone\n④ Rosuvastatin\n⑤ Hydrochlorothiazide",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: 만성콩팥병이 있는 64세 남자가 3개월 전 빈혈을 진단받고 황산제일철(ferrous sulfate)를 복용해 왔다. 최근 심한 속쓰림으로 제산제를 복용하여도 증상이 좋아지지 않아 철분제 복용을 중단하였다. 오늘 시행한 검사결과가 다음과 같을 때 적절한 조치는?\n\n[임상검사]\nBUN 48 mg/dL, SCr 2.9 mg/dL\n혈색소(Hgb) 9.8 g/dL (3개월 전 9.4 g/dL)\n적혈구용적률(Hct) 31 % (3개월 전 27 %)\n페리틴 74 ng/mL (목표치 >500 ng/mL)\n트랜스페린포화도(Tsat) 16 % (목표치 >30 %)\n\n① 적혈구 수혈\n② 테스토스테론(testosterone) 투여\n③ 철수크로오즈(iron sucrose) 투여\n④ 에포에틴 알파(epoetin alfa) 투여\n⑤ L-카르니틴(L-carnitine)+비타민C(vitamin C) 투여",
        "question_text": "Question: A 64-year-old man with chronic kidney disease was diagnosed with anemia 3 months ago and has been taking ferrous sulfate. Recently, he stopped taking the iron supplement due to severe heartburn that did not improve even with antacids. Given the following test results from today, what is the appropriate course of action?\n\n[Clinical Tests]\nBUN 48 mg/dL, SCr 2.9 mg/dL\nHemoglobin (Hgb) 9.8 g/dL (9.4 g/dL 3 months ago)\nHematocrit (Hct) 31% (27% 3 months ago)\nFerritin 74 ng/mL (target >500 ng/mL)\nTransferrin saturation (Tsat) 16% (target >30%)\n\n① Red blood cell transfusion\n② Testosterone administration\n③ Iron sucrose administration\n④ Epoetin alfa administration\n⑤ L-carnitine + Vitamin C administration",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 45세 남자가 한 달 전 동생으로부터 신장을 이식받았다. 며칠 전부터 소변량이 급격히 감소하고 이식부위에 통증이 지속되고 있다. 이식거부반응이 의심되어 시행한 검사에서 공여자특이항체(donor-specific antibody)가 음성이다. 이식거부반응 치료에 적절한 약물은?\n\n① 리툭시맙(rituximab)\n② 미조리빈(mizoribine)\n③ 바실릭시맙(basiliximab)\n④ 토실리주맙(tocilizumab)\n⑤ 메틸프레드니솔론(methylprednisolone)",
        "question_text": "Question: A 45-year-old man received a kidney transplant from his younger sibling a month ago. For the past few days, he has experienced a rapid decrease in urine output and persistent pain at the transplant site. Suspecting transplant rejection, a test was conducted, and the donor-specific antibody was found to be negative. Which drug is appropriate for treating transplant rejection?\n\n① Rituximab\n② Mizoribine\n③ Basiliximab\n④ Tocilizumab\n⑤ Methylprednisolone",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n만성콩팥병이 있는 52세 남자가 일주일 전부터 발이 심하게 붓고, 체중이 늘었다. 검사결과와 복용약물은 다음과 같다.\n\n[활력징후]\n혈압 142/88 mmHg, 심박수 72회/분, 호흡수 19회/분, 체중 74 kg (일주일 전 71 kg)\n[임상검사]\nSCr 2.8 mg/dL, eGFR 24 mL/min/1.73m^2\nNa 144 mEq/L, K 5.0 mEq/L, CO2 19 mEq/L\nCa 7.4 mg/dL, P 6.1 mg/dL, Alb 3.4 g/dL\niPTH 185 pg/mL (참고치 70~110 pg/mL)\n소변 알부민대비크레아티닌비(ACR) 122 mg/g\n[신체검사] 오목부종(pitting edema) (2+/2+)\n[복용약물]\n텔미사르탄(telmisartan) 40 mg 1일 1회\n\nQuestion: 환자의 증상을 개선하기 위해 추가할 약물은?\n\n① 만니톨(mannitol)\n② 라미프릴(ramipril)\n③ 푸로세미드(furosemide)\n④ 스피로노락톤(spironolactone)\n⑤ 히드로클로로티아지드(hydrochlorothiazide)",
        "question_text": "A 52-year-old man with chronic kidney disease has experienced severe swelling in his feet and weight gain for the past week. His test results and current medications are as follows:\n\n[Vital Signs]\nBlood pressure 142/88 mmHg, Heart rate 72 beats/min, Respiratory rate 19 breaths/min, Weight 74 kg (71 kg a week ago)\n[Clinical Tests]\nSCr 2.8 mg/dL, eGFR 24 mL/min/1.73m^2\nNa 144 mEq/L, K 5.0 mEq/L, CO2 19 mEq/L\nCa 7.4 mg/dL, P 6.1 mg/dL, Alb 3.4 g/dL\niPTH 185 pg/mL (reference range 70-110 pg/mL)\nUrine albumin-to-creatinine ratio (ACR) 122 mg/g\n[Physical Examination] Pitting edema (2+/2+)\n[Current Medication]\nTelmisartan 40 mg once daily\n\nQuestion: Which medication should be added to improve the patient's symptoms?\n\n① Mannitol\n② Ramipril\n③ Furosemide\n④ Spironolactone\n⑤ Hydrochlorothiazide",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n만성콩팥병이 있는 52세 남자가 일주일 전부터 발이 심하게 붓고, 체중이 늘었다. 검사결과와 복용약물은 다음과 같다.\n\n[활력징후]\n혈압 142/88 mmHg, 심박수 72회/분, 호흡수 19회/분, 체중 74 kg (일주일 전 71 kg)\n[임상검사]\nSCr 2.8 mg/dL, eGFR 24 mL/min/1.73m^2\nNa 144 mEq/L, K 5.0 mEq/L, CO2 19 mEq/L\nCa 7.4 mg/dL, P 6.1 mg/dL, Alb 3.4 g/dL\niPTH 185 pg/mL (참고치 70~110 pg/mL)\n소변 알부민대비크레아티닌비(ACR) 122 mg/g\n[신체검사] 오목부종(pitting edema) (2+/2+)\n[복용약물]\n텔미사르탄(telmisartan) 40 mg 1일 1회\n\nQuestion: 고인산혈증을 치료하기 위한 적절한 약물은?\n\n① 세벨라머(sevelamer)\n② 칼시트리올(calcitriol)\n③ 탄산칼슘(calcium carbonate)\n④ 탄산란탄(lanthanum carbonate)\n⑤ 수산화마그네슘(magnesium hydroxide)",
        "question_text": "A 52-year-old man with chronic kidney disease has experienced severe swelling in his feet and weight gain for the past week. His test results and current medications are as follows:\n\n[Vital Signs]\nBlood pressure 142/88 mmHg, Heart rate 72 beats/min, Respiratory rate 19 breaths/min, Weight 74 kg (71 kg a week ago)\n\n[Clinical Tests]\nSCr 2.8 mg/dL, eGFR 24 mL/min/1.73m^2\nNa 144 mEq/L, K 5.0 mEq/L, CO2 19 mEq/L\nCa 7.4 mg/dL, P 6.1 mg/dL, Alb 3.4 g/dL\niPTH 185 pg/mL (reference range 70-110 pg/mL)\nUrine albumin-to-creatinine ratio (ACR) 122 mg/g\n\n[Physical Examination] Pitting edema (2+/2+)\n\n[Current Medication]\nTelmisartan 40 mg once daily\n\nQuestion: Which of the following is the most appropriate medication to treat hyperphosphatemia?\n\n① Sevelamer\n② Calcitriol\n③ Calcium carbonate\n④ Lanthanum carbonate\n⑤ Magnesium hydroxide",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 불안정협심증, 2형당뇨병이 있는 57세 여자의 검사결과가 다음과 같다. 당뇨병 관리를 위한 적절한 약물요법 계획은?\n\n[활력징후]\n혈압 124/73 mmHg, 심박수 69회/분, 체질량지수 30.7 kg/m^2\n[임상검사]\n공복혈당 167 mg/dL, 당화혈색소 7.3 %\nSCr 0.9 mg/dL, eGFR 73 mL/min/1.73m^2\n[복용약물]\n아스피린(aspirin) 100 mg 1일 1회\n메트로프로롤(metoprolol) 100 mg 1일 2회\n리시노프릴(lisinopril) 10 mg 1일 1회\n로수바스타틴(rosuvastatin) 20 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 2회\n글리메피리드(glimepiride) 4 mg 1일 1회\n니트로글리세린(nitroglycerin) 설하정 0.6 mg 필요시\n\n① 메트포르민 증량\n② 아카르보스(acarbose) 추가\n③ 둘라글루타이드(dulaglutide) 추가\n④ 메트포르민을 나테글리니드(nateglinide)로 변경\n⑤ 메트포르민을 에르투글리플로진(ertugliflozin)로 변경",
        "question_text": "Question: A 57-year-old woman with unstable angina and type 2 diabetes has the following test results. What is the appropriate drug therapy plan for managing her diabetes?\n\n[Vital Signs]\nBlood pressure 124/73 mmHg, Heart rate 69 beats/min, Body Mass Index 30.7 kg/m^2\n[Clinical Tests]\nFasting blood glucose 167 mg/dL, HbA1c 7.3%\nSCr 0.9 mg/dL, eGFR 73 mL/min/1.73m^2\n[Current Medications]\nAspirin 100 mg once daily\nMetoprolol 100 mg twice daily\nLisinopril 10 mg once daily\nRosuvastatin 20 mg once daily\nMetformin 1,000 mg twice daily\nGlimepiride 4 mg once daily\nNitroglycerin sublingual tablet 0.6 mg as needed\n\n① Increase metformin dose\n② Add acarbose\n③ Add dulaglutide\n④ Change metformin to nateglinide\n⑤ Change metformin to ertugliflozin",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: 1형당뇨병이 있는 25세 남자가 인슐린을 사용 중이다. 환자는 규칙적으로 식사하고 건강한 생활습관을 실천하고 있다. 지난 3일 동안 연속혈당측정(continuous glucose monitoring) 결과가 다음과 같을 때 적절한 조치는?\n\n[활력징후]\n혈압 118/79 mmHg, 심박수 67회/분, 호흡수 19회/분, 체온 36.5°C, 체중 80 kg\n[임상검사]\n당화혈색소 6.4 %\n평균혈당\n저녁 식전 112 mg/dL, 저녁 식후 2시간 174 mg/dL, 취침 전 128 mg/dL, 새벽 3시 92 mg/dL, 아침 식전 63 mg/dL, 점심 식전 108 mg/dL\n[복용약물]\n인슐린라이스프로(insulin lispro) 10 IU 1일 3회 식사 15분 전\n인슐린글라진(insulin glargine) 42 IU 1일 1회 아침\n\n① 현재의 약물요법 유지\n② 인슐린글라진의 용량 감소\n③ 인슐린라이스프로의 아침 용량 증가\n④ 인슐린라이스프로의 저녁 용량 증가\n⑤ 인슐린글라진의 투여시간을 취침 전으로 변경",
        "question_text": "Question: A 25-year-old male with Type 1 diabetes is using insulin. The patient maintains regular meals and practices a healthy lifestyle. Given the following continuous glucose monitoring results for the past 3 days, what is the appropriate action?\n\n[Vital Signs]\nBlood pressure 118/79 mmHg, Heart rate 67 bpm, Respiratory rate 19 breaths/min, Temperature 36.5°C, Weight 80 kg\n[Clinical Tests]\nHbA1c 6.4%\nAverage blood glucose\nPre-dinner 112 mg/dL, 2 hours post-dinner 174 mg/dL, Before bedtime 128 mg/dL, 3 AM 92 mg/dL, Pre-breakfast 63 mg/dL, Pre-lunch 108 mg/dL\n[Medications]\nInsulin lispro 10 IU three times daily, 15 minutes before meals\nInsulin glargine 42 IU once daily in the morning\n\n① Maintain current medication regimen\n② Decrease the dose of insulin glargine\n③ Increase the morning dose of insulin lispro\n④ Increase the evening dose of insulin lispro\n⑤ Change the administration time of insulin glargine to bedtime",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: 53세 남자가 고혈압, 2형당뇨병, 이상지질혈증, 만성콩팥병으로 약물치료 중이다. 검사결과가 다음과 같을 때, 당뇨병 관리를 위한 적절한 추가 약물은?\n\n[활력징후]\n(오늘) 혈압 121/78 mmHg, 심박수 69회/분\n[임상검사]\n(3개월 전)\n공복혈당 118 mg/dL, 당화혈색소 6.5 %\nSCr 1.5 mg/dL, eGFR 53 mL/min/1.73m^2\nTC 167 mg/dL, LDL-C 77 mg/dL, TG 200 mg/dL, HDL-C 49 mg/dL\n(오늘)\n공복혈당 137 mg/dL, 당화혈색소 6.8 %\nSCr 1.7 mg/dL, eGFR 44 mL/min/1.73m^2\nTC 160 mg/dL, LDL-C 65 mg/dL, TG 195 mg/dL, HDL-C 48 mg/dL\n[요검사]\n(3개월 전) 알부민대크레아티닌비(ACR) 13 mg/g\n(오늘) ACR 45 mg/g\n[복용약물]\n글리메피리드(glimepiride) 2 mg 1일 1회\n텔미사르탄(telmisartan) 40 mg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n\n① 보글리보스(voglibose)\n② 메트포르민(metformin)\n③ 레파글리니드(repaglinide)\n④ 로베글리타존(lobeglitazone)\n⑤ 다파글리플로진(dapagliflozin)",
        "question_text": "Question: A 53-year-old man is undergoing drug treatment for hypertension, type 2 diabetes, dyslipidemia, and chronic kidney disease. Given the following test results, what is the appropriate additional medication for diabetes management?\n\n[Vital Signs]\n(Today) Blood pressure 121/78 mmHg, Heart rate 69 bpm\n[Clinical Tests]\n(3 months ago)\nFasting blood glucose 118 mg/dL, HbA1c 6.5%\nSCr 1.5 mg/dL, eGFR 53 mL/min/1.73m^2\nTC 167 mg/dL, LDL-C 77 mg/dL, TG 200 mg/dL, HDL-C 49 mg/dL\n(Today)\nFasting blood glucose 137 mg/dL, HbA1c 6.8%\nSCr 1.7 mg/dL, eGFR 44 mL/min/1.73m^2\nTC 160 mg/dL, LDL-C 65 mg/dL, TG 195 mg/dL, HDL-C 48 mg/dL\n[Urinalysis]\n(3 months ago) Albumin-to-Creatinine Ratio (ACR) 13 mg/g\n(Today) ACR 45 mg/g\n[Current Medications]\nGlimepiride 2 mg once daily\nTelmisartan 40 mg once daily\nAtorvastatin 40 mg once daily\n\n① Voglibose\n② Metformin\n③ Repaglinide\n④ Lobeglitazone\n⑤ Dapagliflozin",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n72세 여자가 고혈압, 2형당뇨병, 이상지질혈증에 대해 약물치료 중이다. 복용약물과 검사결과는 다음과 같다.\n\n[활력징후]\n(오늘)\n혈압 118/72 mmHg, 심박수 68회/분\n키 160 cm, 체중 65 kg (1개월 전에 비해 4 kg 증가)\n[임상검사]\n(1년 전)\n공복혈당 120 mg/dL, 당화혈색소 6.5 %\nBNP 97 pg/mL\n좌심실박출률(LVEF) 55 %\n(오늘)\n공복혈당 103 mg/dL, 당화혈색소 6.1 %\nBNP 187 pg/mL\nLVEF 40 %\n[복용약물]\n리시노프릴(lisinopril) 10 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 2회\n피오글리타존(pioglitazone) 15 mg 1일 1회\n아토르바스타틴(atorvastatin) 20 mg 1일 1회\n\nQuestion: 환자의 체중 증가와 오늘 시행한 임상검사상 이상소견의 원인이 될 수 있는 약물은?\n\n① 리시노프릴\n② 메트포르민\n③ 피오글리타존\n④ 아토르바스타틴\n⑤ 히드로클로로티아지드",
        "question_text": "A 72-year-old woman is undergoing drug therapy for hypertension, type 2 diabetes, and dyslipidemia. Her medications and test results are as follows:\n\n[Vital Signs]\n(Today)\nBlood pressure 118/72 mmHg, Heart rate 68 beats/min\nHeight 160 cm, Weight 65 kg (4 kg increase compared to 1 month ago)\n\n[Clinical Tests]\n(1 year ago)\nFasting blood glucose 120 mg/dL, HbA1c 6.5%\nBNP 97 pg/mL\nLeft ventricular ejection fraction (LVEF) 55%\n\n(Today)\nFasting blood glucose 103 mg/dL, HbA1c 6.1%\nBNP 187 pg/mL\nLVEF 40%\n\n[Medications]\nLisinopril 10 mg once daily\nHydrochlorothiazide 25 mg once daily\nMetformin 1,000 mg twice daily\nPioglitazone 15 mg once daily\nAtorvastatin 20 mg once daily\n\nQuestion: Which medication could be the cause of the patient's weight gain and abnormal findings in today's clinical tests?\n\n① Lisinopril\n② Metformin\n③ Pioglitazone\n④ Atorvastatin\n⑤ Hydrochlorothiazide",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n72세 여자가 고혈압, 2형당뇨병, 이상지질혈증에 대해 약물치료 중이다. 복용약물과 검사결과는 다음과 같다.\n\n[활력징후]\n(오늘)\n혈압 118/72 mmHg, 심박수 68회/분\n키 160 cm, 체중 65 kg (1개월 전에 비해 4 kg 증가)\n[임상검사]\n(1년 전)\n공복혈당 120 mg/dL, 당화혈색소 6.5 %\nBNP 97 pg/mL\n좌심실박출률(LVEF) 55 %\n(오늘)\n공복혈당 103 mg/dL, 당화혈색소 6.1 %\nBNP 187 pg/mL\nLVEF 40 %\n[복용약물]\n리시노프릴(lisinopril) 10 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n메트포르민(metformin) 1,000 mg 1일 2회\n피오글리타존(pioglitazone) 15 mg 1일 1회\n아토르바스타틴(atorvastatin) 20 mg 1일 1회\n\nQuestion: 환자는 최근 지속적으로 오심, 구토를 동반한 위마비 증상이 있다. 검사결과, 당뇨병 자율신경병증을 진단받았다. 이 증상을 조절하기 위한 적절한 약물은?\n\n① 베타네콜(bethanechol)\n② 돔페리돈(domperidone)\n③ 옥트레오티드(octreotide)\n④ 미소프로스톨(misoprostol)\n⑤ 메트로니다졸(metronidazole)",
        "question_text": "A 72-year-old woman is undergoing drug therapy for hypertension, type 2 diabetes, and dyslipidemia. Her medications and test results are as follows:\n\n[Vital Signs]\n(Today)\nBlood pressure 118/72 mmHg, Heart rate 68 bpm\nHeight 160 cm, Weight 65 kg (4 kg increase compared to 1 month ago)\n\n[Clinical Tests]\n(1 year ago)\nFasting blood glucose 120 mg/dL, HbA1c 6.5%\nBNP 97 pg/mL\nLeft ventricular ejection fraction (LVEF) 55%\n\n(Today)\nFasting blood glucose 103 mg/dL, HbA1c 6.1%\nBNP 187 pg/mL\nLVEF 40%\n\n[Medications]\nLisinopril 10 mg once daily\nHydrochlorothiazide 25 mg once daily\nMetformin 1,000 mg twice daily\nPioglitazone 15 mg once daily\nAtorvastatin 20 mg once daily\n\nQuestion: The patient has recently been experiencing persistent nausea, vomiting, and gastroparesis symptoms. After examination, she was diagnosed with diabetic autonomic neuropathy. Which of the following drugs is most appropriate to control these symptoms?\n\n① Bethanechol\n② Domperidone\n③ Octreotide\n④ Misoprostol\n⑤ Metronidazole",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n46세 여자가 한 달 전 그레이브스병을 진단받고 다음과 같은 약물을 복용 중이다.\n\n[활력징후]\n혈압 125/77 mmHg, 심박수 78회/분, 호흡수 21회/분\n[임상검사]\n유리 T4 3.1 ng/dL (참고치 0.8~2.7 ng/dL)\nTSH 0.3 mIU/L (참고치 0.5~4.7 mIU/L)\nAST 27 IU/L, ALT 29 IU/L\n[복용약물]\n메티마졸(methimazole) 10 mg 1일 3회\n프로프라놀롤(propranolol) 20 mg 1일 4회\n\nQuestion: 환자는 여전히 불안 증상이 있어 업무를 수행하는 데 어려움이 있다. 증상을 신속하게 완화하기 위해 추가할 약물은?\n\n① 디아제팜(diazepam)\n② 부프로피온(bupropion)\n③ 프레가발린(pregabalin)\n④ 리스페리돈(risperidone)\n⑤ 이미프라민(imipramine)",
        "question_text": "A 46-year-old woman was diagnosed with Graves' disease a month ago and is currently taking the following medications.\n\n[Vital Signs]\nBlood pressure 125/77 mmHg, Heart rate 78 beats/min, Respiratory rate 21 breaths/min\n[Clinical Tests]\nFree T4 3.1 ng/dL (Reference range 0.8-2.7 ng/dL)\nTSH 0.3 mIU/L (Reference range 0.5-4.7 mIU/L)\nAST 27 IU/L, ALT 29 IU/L\n[Medications]\nMethimazole 10 mg 3 times daily\nPropranolol 20 mg 4 times daily\n\nQuestion: The patient still experiences anxiety symptoms, making it difficult to perform her work. Which drug should be added to quickly alleviate the symptoms?\n\n① Diazepam\n② Bupropion\n③ Pregabalin\n④ Risperidone\n⑤ Imipramine",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n46세 여자가 한 달 전 그레이브스병을 진단받고 다음과 같은 약물을 복용 중이다.\n\n[활력징후]\n혈압 125/77 mmHg, 심박수 78회/분, 호흡수 21회/분\n[임상검사]\n유리 T4 3.1 ng/dL (참고치 0.8~2.7 ng/dL)\nTSH 0.3 mIU/L (참고치 0.5~4.7 mIU/L)\nAST 27 IU/L, ALT 29 IU/L\n[복용약물]\n메티마졸(methimazole) 10 mg 1일 3회\n프로프라놀롤(propranolol) 20 mg 1일 4회\n\nQuestion: 메티마졸을 복용하고 두 달 뒤에 환자에게 고열과 인후통이 발생하였다. 메티마졸에 의한 이상반응인지 확인하기 위해 필요한 검사는?\n\n① 전혈구수\n② 동맥혈기체분석\n③ 1초간강제호기량\n④ 부갑상샘호르몬 농도\n⑤ 인터페론감마방출검사",
        "question_text": "A 46-year-old woman was diagnosed with Graves' disease a month ago and is currently taking the following medications.\n\n[Vital Signs]\nBlood pressure 125/77 mmHg, Heart rate 78 beats/min, Respiratory rate 21 breaths/min\n[Clinical Tests]\nFree T4 3.1 ng/dL (Reference range 0.8~2.7 ng/dL)\nTSH 0.3 mIU/L (Reference range 0.5~4.7 mIU/L)\nAST 27 IU/L, ALT 29 IU/L\n[Medications]\nMethimazole 10 mg 3 times a day\nPropranolol 20 mg 4 times a day\n\nQuestion: Two months after taking methimazole, the patient developed high fever and sore throat. Which test is necessary to confirm if this is an adverse reaction to methimazole?\n\n① Complete blood count\n② Arterial blood gas analysis\n③ Forced expiratory volume in 1 second\n④ Parathyroid hormone level\n⑤ Interferon-gamma release assay",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: 경증의 급성 세균전립선염을 진단받은 68세 남자에게 시프로플록사신(ciprofloxacin)을 투여할 예정이다. 적절한 투여 기간은?\n\n① 3일\n② 5일\n③ 10일\n④ 28일\n⑤ 56일",
        "question_text": "Question: A 68-year-old man diagnosed with mild acute bacterial prostatitis is to be administered ciprofloxacin. What is the appropriate duration of treatment?\n\n① 3 days\n② 5 days\n③ 10 days\n④ 28 days\n⑤ 56 days",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 임신 10주 차인 37세 임부가 무증상세균뇨를 진단받았다. 환자는 과거에 아목시실린(amoxicillin)을 복용한 후 지연과민반응으로 경미한 발진을 경험하였다. 무증상세균뇨 치료에 적절한 항생제는?\n\n① 세팔렉신(cefalexin)\n② 암피실린(ampicillin)\n③ 독시사이클린(doxycycline)\n④ 레보플록사신(levofloxacin)\n⑤ 설파메톡사졸/트리메토프림(sulfamethoxazole/trimethoprim)",
        "question_text": "Question: A 37-year-old woman in her 10th week of pregnancy has been diagnosed with asymptomatic bacteriuria. The patient has previously experienced a mild rash as a delayed hypersensitivity reaction after taking amoxicillin. Which antibiotic is appropriate for treating asymptomatic bacteriuria?\n\n① Cefalexin\n② Ampicillin\n③ Doxycycline\n④ Levofloxacin\n⑤ Sulfamethoxazole/Trimethoprim",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 46세 여자가 급성 세균부비동염을 진단받았다. 약물알레르기 과거력은 없다. 적절한 약물은?\n\n① 아목시실린(amoxicillin)\n② 세포독심(cefpodoxime)\n③ 독시사이클린(doxycycline)\n④ 시프로플록사신(ciprofloxacin)\n⑤ 클래리트로마이신(clarithromycin)",
        "question_text": "Question: A 46-year-old woman has been diagnosed with acute bacterial sinusitis. She has no history of drug allergies. What is the appropriate medication?\n\n① Amoxicillin\n② Cefpodoxime\n③ Doxycycline\n④ Ciprofloxacin\n⑤ Clarithromycin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "original_text": "Question: 68세 여자가 폐결핵을 진단받아 약물치료를 시작하였으나 한 달 후 간독성이 발생하여 모든 복용약물을 중단하였다. 약물치료 중단 3주 후에 실시한 임상검사 결과에 따라 치료를 다시 시작하려고 한다. 이때 사용을 피해야 하는 약물은?\n\n[임상검사]\n(약물치료 시작 전) AST 30 IU/L, ALT 34 IU/L\n(약물치료 시작 한 달 후) AST 1,250 IU/L, ALT 1,320 IU/L\n(약물치료 중단 3주 후) AST 50 IU/L, ALT 56 IU/L\n[중단한 복용약물]\n피리독신(pyridoxine) 50 mg 1일 1회\n리팜피신(rifampicin) 600 mg 1일 1회\n에탐부톨(ethambutol) 800 mg 1일 1회\n이소니아지드(isoniazid) 300 mg 1일 1회\n피라진아미드(pyrazinamide) 1,000 mg 1일 1회\n\n① 피리독신\n② 리팜피신\n③ 에탐부톨\n④ 이소니아지드\n⑤ 피라진아미드",
        "question_text": "Question: A 68-year-old woman was diagnosed with pulmonary tuberculosis and started drug treatment. However, after one month, she developed hepatotoxicity and discontinued all medications. Based on the clinical test results conducted three weeks after stopping the treatment, they are planning to restart the therapy. Which drug should be avoided at this time?\n\n[Clinical Tests]\n(Before starting drug treatment) AST 30 IU/L, ALT 34 IU/L\n(One month after starting drug treatment) AST 1,250 IU/L, ALT 1,320 IU/L\n(Three weeks after stopping drug treatment) AST 50 IU/L, ALT 56 IU/L\n\n[Discontinued Medications]\nPyridoxine 50 mg once daily\nRifampicin 600 mg once daily\nEthambutol 800 mg once daily\nIsoniazid 300 mg once daily\nPyrazinamide 1,000 mg once daily\n\n① Pyridoxine\n② Rifampicin\n③ Ethambutol\n④ Isoniazid\n⑤ Pyrazinamide",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "original_text": "Question: 극심한 두통과 구토 증상이 있는 54세 남자에게 세균수막염 치료를 시작하려고 한다. 수막염으로 인한 신경학적 합병증의 발생을 감소하기 위해 항생제 치료 전에 투여할 약물은?\n\n[활력징후]\n혈압 122/78 mmHg, 심박수 68회/분, 체온 39.1°C\n[임상검사]\n백혈구 18,000/mm^3, 포도당 134 mg/dL\n[뇌척수액검사]\n백혈구 2,000/mm^3, 단백질 220 mg/dL, 포도당 39 mg/dL\n[미생물 배양검사] 진행 중\n\n① 둘록세틴(duloxetine)\n② 피리독신(pyridoxine)\n③ 올란자핀(olanzapine)\n④ 덱사메타손(dexamethasone)\n⑤ 플루드로코르티손(fludrocortisone)",
        "question_text": "Question: A 54-year-old man with severe headache and vomiting symptoms is about to start treatment for bacterial meningitis. Which drug should be administered before antibiotic treatment to reduce the occurrence of neurological complications due to meningitis?\n\n[Vital Signs]\nBlood pressure 122/78 mmHg, Heart rate 68 beats/min, Body temperature 39.1°C\n[Clinical Tests]\nWhite blood cells 18,000/mm^3, Glucose 134 mg/dL\n[Cerebrospinal Fluid Test]\nWhite blood cells 2,000/mm^3, Protein 220 mg/dL, Glucose 39 mg/dL\n[Microbial Culture Test] In progress\n\n① Duloxetine\n② Pyridoxine\n③ Olanzapine\n④ Dexamethasone\n⑤ Fludrocortisone",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: 생후 5일째인 신생아에게 세균감염이 발생하였을 때, 적절한 경험적 항균요법은?\n\n[활력징후]\n혈압 72/40 mmHg, 심박수 158회/분, 체온 38.7℃\n[혈액검사]\n백혈구 31,000/mm^3, 포도당 110 mg/dL\n[뇌척수액검사]\n백혈구 2,000/mm^3, 단백질 120 mg/dL, 포도당 20 mg/dL\n미생물 배양검사: 진행 중\n\n① 타이wp사이클린(tigecycline)\n② 설파메톡사졸/트리메토프림(sulfamethoxazole/trimethoprim)\n③ 암피실린(ampicillin)+세포탁심(cefotaxime)\n④ 반코마이신(vancomycin)+메트로니다졸(metronidazole)\n⑤ 세폭시틴(cefoxitin)+시프로플록사신(ciprofloxacin)",
        "question_text": "Question: What is the appropriate empirical antimicrobial therapy for a 5-day-old newborn with a bacterial infection?\n\n[Vital Signs]\nBlood pressure 72/40 mmHg, Heart rate 158 beats/min, Temperature 38.7°C\n[Blood Test]\nWhite blood cells 31,000/mm^3, Glucose 110 mg/dL\n[Cerebrospinal Fluid Test]\nWhite blood cells 2,000/mm^3, Protein 120 mg/dL, Glucose 20 mg/dL\nMicrobial culture test: In progress\n\n① Tigecycline\n② Sulfamethoxazole/Trimethoprim\n③ Ampicillin + Cefotaxime\n④ Vancomycin + Metronidazole\n⑤ Cefoxitin + Ciprofloxacin",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 41세 남자의 팔에 가려움을 동반한 붉은색 반점이 생겨 백선 치료를 시작하려고 한다. 가려움은 심하지 않고 화끈거림이나 진물도 없다. 적절한 초기 치료약은?\n\n① 무피로신(mupirocin) 크림\n② 아다팔렌(adapalene) 크림\n③ 테르비나핀(terbinafine) 크림\n④ 메트로니다졸(metronidazole) 젤\n⑤ 히드로코르티손(hydrocortisone) 로션",
        "question_text": "Question: A 41-year-old man has developed red spots with itching on his arm and is about to start treatment for tinea. The itching is not severe, and there is no burning sensation or discharge. What is the appropriate initial treatment?\n\n① Mupirocin cream\n② Adapalene cream\n③ Terbinafine cream\n④ Metronidazole gel\n⑤ Hydrocortisone lotion",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 폐 아스페르길루스증을 진단받은 52세 여자에게 주사용 암포테리신B(amphotericin B deoxycholate)를 투여 시, 신장기능과 함께 모니터링해야 하는 약물 이상반응은?\n\n① 탈모\n② 치은염\n③ 건 파열\n④ 대장천공\n⑤ 저칼륨혈증",
        "question_text": "Question: When administering injectable amphotericin B (amphotericin B deoxycholate) to a 52-year-old woman diagnosed with pulmonary aspergillosis, which adverse drug reaction should be monitored along with renal function?\n\n① Alopecia\n② Gingivitis\n③ Tendon rupture\n④ Colon perforation\n⑤ Hypokalemia",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 담석증이 있는 48세 남자가 경증의 급성 지역사회획득담낭염을 진단받았다. 적절한 경험적 항균요법은?\n\n[약물알레르기] 알려진 바 없음\n[임상검사] 체온 38.5℃, 백혈구 12,000/mm^3\n\n① 나프실린(nafcillin) 정맥주사\n② 세포탁심(cefotaxime) 정맥주사\n③ 메트로니다졸(metronidazole) 경구제\n④ 암피실린(ampicillin) 정맥주사+답토마이신(daptomycin) 정맥주사\n⑤ 반코마이신(vancomycin) 정맥주사+클린다마이신(clindamycin) 경구제",
        "question_text": "Question: A 48-year-old man with cholelithiasis has been diagnosed with mild acute community-acquired cholecystitis. What is the appropriate empirical antimicrobial therapy?\n\n[Drug Allergy] None known\n[Clinical Tests] Body temperature 38.5°C, WBC 12,000/mm^3\n\n① Nafcillin intravenous injection\n② Cefotaxime intravenous injection\n③ Metronidazole oral administration\n④ Ampicillin intravenous injection + Daptomycin intravenous injection\n⑤ Vancomycin intravenous injection + Clindamycin oral administration",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n67세 남자가 교통사고로 병원에 입원하였다. 산소포화도와 혈압이 갑작스럽게 떨어져 10일 전부터 중환자실에서 환기치료(ventilation therapy)를 받고 있다. 오늘 고열과 백혈구증가가 발생하여 흉부방사선검사를 받은 결과 기계환기관련폐렴(ventilator-associated pneumonia)을 진단받았다. 임상검사 결과는 다음과 같다.\n\n[병력] 고혈압, 이상지질혈증, 만성폐쇄폐질환, 주요우울장애\n[활력징후]\n혈압 151/96 mmHg, 심박수 110회/분, 체온 39℃\n[임상검사]\nNa 141 mEq/L, K 4.8 mEq/L, BUN 31 mg/dL, SCr 1.2 mg/dL\n백혈구 18,500/mm^3, 혈소판 250,000/mm^3\n[가래배양검사] 진행 중\n[흉부방사선검사] 폐침윤\n[약물알레르기] 알려진 바 없음\n[사용약물]\n리시노프릴(lisinopril) 40 mg 1일 1회\n티오트로퓸(tiotropium) 22.5 μg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n에스시탈로프람(escitalopram) 10 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n\nQuestion: 적절한 경험적 항균요법은?\n\n① 피페라실린/타조박탐(piperacillin/tazobactam)\n② 세페핌(cefepime)+레보플록사신(levofloxacin)\n③ 세페핌+시프로플록사신(ciprofloxacin)+반코마이신(vancomycin)\n④ 피페라실린/타조박탐+반코마이신\n⑤ 레보플록사신+토브라마이신(tobramycin)+반코마이신",
        "question_text": "A 67-year-old male was hospitalized due to a traffic accident. His oxygen saturation and blood pressure suddenly dropped, and he has been receiving ventilation therapy in the intensive care unit for the past 10 days. Today, he developed a high fever and an increase in white blood cell count. After a chest X-ray, he was diagnosed with ventilator-associated pneumonia. The clinical test results are as follows:\n\n[Medical history] Hypertension, dyslipidemia, chronic obstructive pulmonary disease, major depressive disorder\n[Vital signs]\nBlood pressure 151/96 mmHg, Heart rate 110 beats/min, Body temperature 39℃\n[Clinical tests]\nNa 141 mEq/L, K 4.8 mEq/L, BUN 31 mg/dL, SCr 1.2 mg/dL\nWhite blood cells 18,500/mm^3, Platelets 250,000/mm^3\n[Sputum culture test] In progress\n[Chest X-ray] Pulmonary infiltration\n[Drug allergies] None known\n[Current medications]\nLisinopril 40 mg once daily\nTiotropium 22.5 μg once daily\nAtorvastatin 40 mg once daily\nEscitalopram 10 mg once daily\nHydrochlorothiazide 25 mg once daily\n\nQuestion: What is the appropriate empirical antimicrobial therapy?\n\n① Piperacillin/tazobactam\n② Cefepime + Levofloxacin\n③ Cefepime + Ciprofloxacin + Vancomycin\n④ Piperacillin/tazobactam + Vancomycin\n⑤ Levofloxacin + Tobramycin + Vancomycin",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n67세 남자가 교통사고로 병원에 입원하였다. 산소포화도와 혈압이 갑작스럽게 떨어져 10일 전부터 중환자실에서 환기치료(ventilation therapy)를 받고 있다. 오늘 고열과 백혈구증가가 발생하여 흉부방사선검사를 받은 결과 기계환기관련폐렴(ventilator-associated pneumonia)을 진단받았다. 임상검사 결과는 다음과 같다.\n\n[병력] 고혈압, 이상지질혈증, 만성폐쇄폐질환, 주요우울장애\n[활력징후]\n혈압 151/96 mmHg, 심박수 110회/분, 체온 39℃\n[임상검사]\nNa 141 mEq/L, K 4.8 mEq/L, BUN 31 mg/dL, SCr 1.2 mg/dL\n백혈구 18,500/mm^3, 혈소판 250,000/mm^3\n[가래배양검사] 진행 중\n[흉부방사선검사] 폐침윤\n[약물알레르기] 알려진 바 없음\n[사용약물]\n리시노프릴(lisinopril) 40 mg 1일 1회\n티오트로퓸(tiotropium) 22.5 μg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n에스시탈로프람(escitalopram) 10 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n\nQuestion: 가래배양검사에서 메티실린내성황색포도알균(MRSA)이 검출되어 경험적 항균요법을 리네졸리드(linezolid) 단독요법으로 변경하고자 한다. 리네졸리드와 병용 시 상호작용이 발생할 수 있는 약물은?\n\n① 리시노프릴\n② 티오트로퓸\n③ 아토르바스타틴\n④ 에스시탈로프람\n⑤ 히드로클로로티아지드",
        "question_text": "A 67-year-old male was hospitalized due to a traffic accident. His oxygen saturation and blood pressure suddenly dropped, and he has been receiving ventilation therapy in the intensive care unit for 10 days. Today, he developed a high fever and increased white blood cell count. After a chest X-ray, he was diagnosed with ventilator-associated pneumonia. The clinical test results are as follows:\n\n[Medical history] Hypertension, dyslipidemia, chronic obstructive pulmonary disease, major depressive disorder\n[Vital signs]\nBlood pressure 151/96 mmHg, Heart rate 110 beats/min, Body temperature 39℃\n[Clinical tests]\nNa 141 mEq/L, K 4.8 mEq/L, BUN 31 mg/dL, SCr 1.2 mg/dL\nWhite blood cells 18,500/mm^3, Platelets 250,000/mm^3\n[Sputum culture test] In progress\n[Chest X-ray] Pulmonary infiltration\n[Drug allergies] None known\n[Current medications]\nLisinopril 40 mg once daily\nTiotropium 22.5 μg once daily\nAtorvastatin 40 mg once daily\nEscitalopram 10 mg once daily\nHydrochlorothiazide 25 mg once daily\n\nQuestion: Methicillin-resistant Staphylococcus aureus (MRSA) was detected in the sputum culture test, and the empirical antibiotic therapy is to be changed to linezolid monotherapy. Which drug may have an interaction when used concurrently with linezolid?\n\n① Lisinopril\n② Tiotropium\n③ Atorvastatin\n④ Escitalopram\n⑤ Hydrochlorothiazide",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 협심증과 조절되지 않는 고혈압이 있는 55세 여자가 경증의 편두통으로 약물을 복용할 예정이다. 편두통 치료약물로 적절한 것은?\n\n① 나프록센(naproxen)\n② 졸미트립탄(zolmitriptan)\n③ 덱사메타손(dexamethasone)\n④ 메토클로프라미드(metoclopramide)\n⑤ 에르고타민/카페인(ergotamine/caffeine)",
        "question_text": "Question: A 55-year-old woman with angina and uncontrolled hypertension is planning to take medication for mild migraine. Which of the following is an appropriate medication for migraine treatment?\n\n① Naproxen\n② Zolmitriptan\n③ Dexamethasone\n④ Metoclopramide\n⑤ Ergotamine/Caffeine",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 만성편두통이 있는 32세 여자가 다음과 같은 약물을 복용함에도 편두통이 빈번하게 재발한다. 편두통 외 다른 병력은 없다. 현재 복용하고 있는 편두통 예방약물을 중단하고 다른 예방 약물로 변경하려고 할 때 적절한 것은?\n\n[약물알레르기]\n설폰아미드계\n[6개월 전 복용약물]\n알모트립탄(almotriptan) 필요시\n발프로산(valproic acid)\n[현재 복용약물]\n알모트립탄 필요시\n프로프라놀롤(propranolol)\n에티닐에스트라디올/게스토덴(ethinylestradiol/gestodene)\n\n① 라스미디탄(lasmiditan)\n② 레슬리주맙(reslizumab)\n③ 조니사미드(zonisamide)\n④ 토피라메이트(topiramate)\n⑤ 프레마네주맙(fremanezumab)",
        "question_text": "Question: A 32-year-old woman with chronic migraine experiences frequent recurrences despite taking the following medications. She has no other medical history besides migraines. When discontinuing the current migraine preventive medication and switching to another preventive medication, which of the following is appropriate?\n\n[Drug Allergy]\nSulfonamides\n[Medications taken 6 months ago]\nAlmotriptan (as needed)\nValproic acid\n[Current medications]\nAlmotriptan (as needed)\nPropranolol\nEthinylestradiol/gestodene\n\n① Lasmiditan\n② Reslizumab\n③ Zonisamide\n④ Topiramate\n⑤ Fremanezumab",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 72세 남자가 알츠하이머병으로 도네페질(donepezil)을 복용하였으나 인지장애가 더욱 심해졌다. 고혈압, 당뇨병, 이상지질혈증, 말초신경병증이 있어 라미프릴(ramipril), 메트포르민(metformin), 시타글립틴(sitagliptin), 로수바스타틴(rosuvastatin), 아미트리프틸린(amitriptyline)을 복용하고 있다. 인지기능 악화와 관련 있는 약물은?\n\n① 라미프릴\n② 메트포르민\n③ 시타글립틴\n④ 로수바스타틴\n⑤ 아미트리프틸린",
        "question_text": "Question: A 72-year-old man took donepezil for Alzheimer's disease, but his cognitive impairment worsened. He has hypertension, diabetes, dyslipidemia, and peripheral neuropathy, and is taking ramipril, metformin, sitagliptin, rosuvastatin, and amitriptyline. Which drug is associated with the worsening of cognitive function?\n\n① Ramipril\n② Metformin\n③ Sitagliptin\n④ Rosuvastatin\n⑤ Amitriptyline",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 75세 남자가 파킨슨병으로 카르비도파/레보도파(carbidopa/levodopa)를 최대용량으로 복용 중이다. 최근 들어 약물을 복용한 후기 전에 약효 소실(wearing-off)에 의한 증상을 보이고 있다. 추가할 수 있는 약물은?\n\n① 도파민(dopamine)\n② 아만타딘(amantadine)\n③ 엔타카폰(entacapone)\n④ 벤세라지드(benserazide)\n⑤ 벤즈트로핀(benztropine)",
        "question_text": "Question: A 75-year-old man is taking carbidopa/levodopa at the maximum dose for Parkinson's disease. Recently, he has been showing symptoms due to wearing-off before the end of each dose. Which drug can be added?\n\n① Dopamine\n② Amantadine\n③ Entacapone\n④ Benserazide\n⑤ Benztropine",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 35세 남자가 주요우울장애를 치료하기 위해 파록세틴(paroxetine)을 복용하고 있다. 이상반응으로 성기능장애가 발생하여 부프로피온(bupropion)으로 변경하려 한다. 부프로피온을 사용하기 전에 확인이 필요한 금기병력은?\n\n① 발작\n② 천식\n③ 무과립구증\n④ 아토피피부염\n⑤ 이상지질혈증",
        "question_text": "Question: A 35-year-old man is taking paroxetine to treat major depressive disorder. Due to sexual dysfunction as a side effect, he wants to switch to bupropion. Which contraindicated medical history needs to be checked before using bupropion?\n\n① Seizures\n② Asthma\n③ Agranulocytosis\n④ Atopic dermatitis\n⑤ Dyslipidemia",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 조현병을 진단받은 21세 남자가 올란자핀(olanzapine)을 복용하고 있다. 모니터링이 필요한 약물이상반응은?\n\n① 감상샘염\n② 체중감소\n③ 고칼슘혈증\n④ 그물울혈반\n⑤ 고중성지방혈증",
        "question_text": "Question: A 21-year-old male diagnosed with schizophrenia is taking olanzapine. Which adverse drug reaction needs to be monitored?\n\n① Sialadenitis\n② Weight loss\n③ Hypercalcemia\n④ Livedo reticularis\n⑤ Hypertriglyceridemia",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 43세 여자가 2개월 전에 주요우울장애를 진단받고 플루옥세틴(fluoxetine)을 복용하기 시작하였다. 우울 증상은 개선되었으나 지속적으로 불면증이 나타나고 있다. 적절한 약물요법은?\n\n① 트라조돈(trazodone) 추가\n② 벤라팍신(venlafaxine) 추가\n③ 플루옥세틴을 설트랄린(sertraline)으로 변경\n④ 플루옥세틴을 보티옥세틴(vortioxetine)으로 변경\n⑤ 플루옥세틴을 에스시탈로프람(escitalopram)으로 변경",
        "question_text": "Question: A 43-year-old woman was diagnosed with major depressive disorder 2 months ago and started taking fluoxetine. While her depressive symptoms have improved, she continues to experience insomnia. What is the appropriate drug therapy?\n\n① Add trazodone\n② Add venlafaxine\n③ Switch fluoxetine to sertraline\n④ Switch fluoxetine to vortioxetine\n⑤ Switch fluoxetine to escitalopram",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n13세 여아(키 160 cm, 체중 47 kg)가 최근 갑작스러운 행동 정지가 약 30초 동안 발생하고 의식이 소실되는 증상이 반복적으로 나타나 검사받은 결과 소발작(absence seizure)을 진단받았다. 알러지 약물알레르기는 없다.\n\nQuestion: 소발작을 치료하기 위한 약물로 적절한 것은?\n\n① 페니토인(phenytoin)\n② 비가바트린(vigabatrin)\n③ 브리바라세탐(brivaracetam)\n④ 에토숙시미드(ethosuximide)\n⑤ 카르바마제핀(carbamazepine)",
        "question_text": "A 13-year-old girl (height 160 cm, weight 47 kg) has recently been experiencing sudden behavioral arrests lasting about 30 seconds with loss of consciousness, occurring repeatedly. After examination, she was diagnosed with absence seizures. She has no known drug allergies.\n\nQuestion: Which of the following drugs is appropriate for treating absence seizures?\n\n① Phenytoin\n② Vigabatrin\n③ Brivaracetam\n④ Ethosuximide\n⑤ Carbamazepine",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n13세 여아(키 160 cm, 체중 47 kg)가 최근 갑작스러운 행동 정지가 약 30초 동안 발생하고 의식이 소실되는 증상이 반복적으로 나타나 검사받은 결과 소발작(absence seizure)을 진단받았다. 알러지 약물알레르기는 없다.\n\nQuestion: 2년 후 환자는 1형양극성장애를 진단받았고, 탄산리튬(lithium carbonate)을 복용 중이다. 우울삽화 재발을 예방하기 위해 유지요법으로 약물을 추가하려 한다. 적절한 것은?\n\n① 클로바잠(clobazam)\n② 가바펜틴(gabapentin)\n③ 라모트리진(lamotrigine)\n④ 토피라메이트(topiramate)\n⑤ 에스리카르바제핀(eslicarbazepine)",
        "question_text": "A 13-year-old girl (height 160 cm, weight 47 kg) was recently diagnosed with absence seizures after experiencing sudden behavioral arrests lasting about 30 seconds and repeated loss of consciousness. She has no known drug allergies.\n\nQuestion: Two years later, the patient was diagnosed with bipolar I disorder and is currently taking lithium carbonate. An additional medication is being considered as maintenance therapy to prevent the recurrence of depressive episodes. Which of the following is the most appropriate?\n\n① Clobazam\n② Gabapentin\n③ Lamotrigine\n④ Topiramate\n⑤ Eslicarbazepine",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: 64세 여자가 2주 전 골관절염을 진단받고, 나프록센(naproxen) 복용을 시작하였다. 나프록센과 함께 복용할 때 위장관출혈 위험을 증가시킬 수 있는 약물은?\n\n[병력]\n골관절염, 고혈압, 이상지질혈증, 주요우울장애\n[복용약물]\n나프록센 500 mg 1일 2회\n파록세틴(paroxetine) 20 mg 1일 1회\n암로디핀(amlodipine) 10 mg 1일 1회\n이르베사르탄(irbesartan) 150 mg 1일 1회\n히드로클로로티아지드(hydrochlorothiazide) 25 mg 1일 1회\n아토르바스타틴(atorvastatin) 40 mg 1일 1회\n\n① 파록세틴\n② 암로디핀\n③ 이르베사르탄\n④ 히드로클로로티아지드\n⑤ 아토르바스타틴",
        "question_text": "Question: A 64-year-old woman was diagnosed with osteoarthritis 2 weeks ago and started taking naproxen. Which drug can increase the risk of gastrointestinal bleeding when taken together with naproxen?\n\n[Medical History]\nOsteoarthritis, hypertension, dyslipidemia, major depressive disorder\n[Medications]\nNaproxen 500 mg twice daily\nParoxetine 20 mg once daily\nAmlodipine 10 mg once daily\nIrbesartan 150 mg once daily\nHydrochlorothiazide 25 mg once daily\nAtorvastatin 40 mg once daily\n\n① Paroxetine\n② Amlodipine\n③ Irbesartan\n④ Hydrochlorothiazide\n⑤ Atorvastatin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "original_text": "Question: 41세 여자가 루마티스관절염을 진단받고 아달리무맙(adalimumab)을 사용 중이나 치료 목표를 달성하지 못하였다. 환자의 선호도를 고려하여 경구제로 변경하고자 할 때, 이 환자에게 적절한 약물은?\n\n① 세리티닙(ceritinib)\n② 보수틴립(bosutinib)\n③ 다사티닙(dasatinib)\n④ 브리그티닙(brigatinib)\n⑤ 바리시티닙(baricitinib)",
        "question_text": "Question: A 41-year-old woman diagnosed with rheumatoid arthritis has been using adalimumab but has not achieved the treatment goal. When considering changing to an oral medication based on the patient's preference, which of the following drugs is appropriate for this patient?\n\n① Ceritinib\n② Bosutinib\n③ Dasatinib\n④ Brigatinib\n⑤ Baricitinib",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "original_text": "Question: 55세 남자가 급성 통풍발작이 발생하여 콜키신(colchicine) 약물요법을 시작하려고 한다. 다른 통풍질환은 없다. 적절한 약물치료 계획은?\n\n① 0.6 mg 1일 투여\n② 1.8 mg 1일 투여\n③ 1.2 mg 투여, 1시간 후 0.6 mg 투여\n④ 0.6 mg 투여, 6시간 후 0.6 mg 투여\n⑤ 1.2 mg 투여, 12시간 후 0.6 mg 투여",
        "question_text": "Question: A 55-year-old man has experienced an acute gout attack and is about to start colchicine drug therapy. He has no other gout-related conditions. What is the appropriate drug treatment plan?\n\n① Administer 0.6 mg once daily\n② Administer 1.8 mg once daily\n③ Administer 1.2 mg, followed by 0.6 mg after 1 hour\n④ Administer 0.6 mg, followed by 0.6 mg after 6 hours\n⑤ Administer 1.2 mg, followed by 0.6 mg after 12 hours",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: 72세 여자가 빈뇨, 절박뇨의 증상으로 검사를 받은 결과 요실금을 진단받았다. 환자의 사용약물 중 요실금의 증상을 악화시킬 수 있는 약물은?\n\n[병력]\n알츠하이머병, 골다공증, 골관절염\n[사용약물]\n도네페질(donepezil) 10 mg 1일 1회\n비타민D(vitamin D) 400 IU 1일 1회\n탄산칼슘(calcium carbonate) 500 mg 1일 3회\n리세드론산(risedronic acid) 150 mg 월 1회\n아세클로페낙(aceclofenac) 100 mg 1일 1회\n트리암시놀론(triamcinolone) 관절강내 주사\n\n① 도네페질\n② 비타민D\n③ 리세드론산\n④ 아세클로페낙\n⑤ 트리암시놀론",
        "question_text": "Question: A 72-year-old woman was diagnosed with urinary incontinence after being examined for symptoms of frequent urination and urge incontinence. Which of the medications the patient is using could potentially worsen the symptoms of urinary incontinence?\n\n[Medical History]\nAlzheimer's disease, osteoporosis, osteoarthritis\n\n[Current Medications]\nDonepezil 10 mg once daily\nVitamin D 400 IU once daily\nCalcium carbonate 500 mg three times daily\nRisedronic acid 150 mg once monthly\nAceclofenac 100 mg once daily\nTriamcinolone intra-articular injection\n\n① Donepezil\n② Vitamin D\n③ Risedronic acid\n④ Aceclofenac\n⑤ Triamcinolone",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n63세 여자가 최근 골다공증을 진단받았다. 검사결과와 복용약물은 다음과 같다.\n\n[병력] 고혈압, 이상지질혈증, 2형당뇨병, 말초신경병증, 만성콩팥병\n[임상검사]\n크레아티닌청소율(CLcr) 20 mL/min\n골밀도검사: T-score -3.3(요추), -2.8(고관절)\n[복용약물]\n발사르탄(valsartan) 160 mg 1일 1회\n로수바스타틴(rosuvastatin) 10 mg 1일 1회\n프레가발린(pregabalin) 50 mg 1일 1회\n카르바마제핀(carbamazepine) 100 mg 1일 2회\n글리피지드(glipizide) 2.5 mg 1일 1회\n칼슘/비타민D(calcium/vitamin D) 500 mg/1,000 IU 1일 1회\n\nQuestion: 골밀도 감소의 위험을 증가시킬 수 있는 약물은?\n\n① 발사르탄\n② 로수바스타틴\n③ 프레가발린\n④ 카르바마제핀\n⑤ 글리피지드",
        "question_text": "A 63-year-old woman was recently diagnosed with osteoporosis. Her test results and current medications are as follows:\n\n[Medical History] Hypertension, dyslipidemia, type 2 diabetes, peripheral neuropathy, chronic kidney disease\n[Clinical Tests]\nCreatinine clearance (CLcr) 20 mL/min\nBone density test: T-score -3.3 (lumbar spine), -2.8 (hip)\n[Current Medications]\nValsartan 160 mg once daily\nRosuvastatin 10 mg once daily\nPregabalin 50 mg once daily\nCarbamazepine 100 mg twice daily\nGlipizide 2.5 mg once daily\nCalcium/Vitamin D 500 mg/1,000 IU once daily\n\nQuestion: Which medication can increase the risk of bone density reduction?\n\n① Valsartan\n② Rosuvastatin\n③ Pregabalin\n④ Carbamazepine\n⑤ Glipizide",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n63세 여자가 최근 골다공증을 진단받았다. 검사결과와 복용약물은 다음과 같다.\n\n[병력] 고혈압, 이상지질혈증, 2형당뇨병, 말초신경병증, 만성콩팥병\n[임상검사]\n크레아티닌청소율(CLcr) 20 mL/min\n골밀도검사: T-score -3.3(요추), -2.8(고관절)\n[복용약물]\n발사르탄(valsartan) 160 mg 1일 1회\n로수바스타틴(rosuvastatin) 10 mg 1일 1회\n프레가발린(pregabalin) 50 mg 1일 1회\n카르바마제핀(carbamazepine) 100 mg 1일 2회\n글리피지드(glipizide) 2.5 mg 1일 1회\n칼슘/비타민D(calcium/vitamin D) 500 mg/1,000 IU 1일 1회\n\nQuestion: 이 환자의 골다공증 치료를 위한 적절한 약물은?\n\n① 랄록시펜(raloxifene)\n② 데노수맙(denosumab)\n③ 두필루맙(dupilumab)\n④ 에스트로겐(estrogen)\n⑤ 이반드론산(ibandronic acid)",
        "question_text": "A 63-year-old woman was recently diagnosed with osteoporosis. Her test results and current medications are as follows:\n\n[Medical History] Hypertension, dyslipidemia, type 2 diabetes, peripheral neuropathy, chronic kidney disease\n[Clinical Tests]\nCreatinine clearance (CLcr) 20 mL/min\nBone density test: T-score -3.3 (lumbar spine), -2.8 (hip)\n[Current Medications]\nValsartan 160 mg once daily\nRosuvastatin 10 mg once daily\nPregabalin 50 mg once daily\nCarbamazepine 100 mg twice daily\nGlipizide 2.5 mg once daily\nCalcium/Vitamin D 500 mg/1,000 IU once daily\n\nQuestion: What is the most appropriate medication for treating this patient's osteoporosis?\n\n① Raloxifene\n② Denosumab\n③ Dupilumab\n④ Estrogen\n⑤ Ibandronic acid",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: 50세 여자가 3기 유방암이 재발하여 다음과 같은 약물을 2주기를 투여받았다. 3주기 약물요법을 시작하기 전에 심장 독성과 관련하여 총누적 투여량 확인이 필요한 약물은?\n\n[약물요법]\n독소루비신(doxorubicin) 60 mg/m^2/일 정맥투여 제1일\n시클로포스파미드(cyclophosphamide) 600 mg/m^2/일 정맥투여 제1일\n파클리탁셀(paclitaxel) 175 mg/m^2/일 정맥투여 제1일\n아프레피탄트(aprepitant) 125 mg 경구투여 제1일, 80 mg 경구투여 제2~3일\n팔로노세트론(palonosetron) 0.25 mg 정맥투여 제1일\n덱사메타손(dexamethasone) 12 mg 정맥투여 제1일, 8 mg 경구투여 제2~4일\n\n① 덱사메타손\n② 독소루비신\n③ 파클리탁셀\n④ 아프레피탄트\n⑤ 시클로포스파미드",
        "question_text": "Question: A 50-year-old woman with recurrent stage 3 breast cancer received two cycles of the following drug regimen. Which drug requires monitoring of the total cumulative dose for cardiac toxicity before starting the third cycle of chemotherapy?\n\n[Drug Regimen]\nDoxorubicin 60 mg/m^2/day IV on Day 1\nCyclophosphamide 600 mg/m^2/day IV on Day 1\nPaclitaxel 175 mg/m^2/day IV on Day 1\nAprepitant 125 mg PO on Day 1, 80 mg PO on Days 2-3\nPalonosetron 0.25 mg IV on Day 1\nDexamethasone 12 mg IV on Day 1, 8 mg PO on Days 2-4\n\n① Dexamethasone\n② Doxorubicin\n③ Paclitaxel\n④ Aprepitant\n⑤ Cyclophosphamide",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: 폐경이 된 65세 여자가 1기 유방암을 진단받았다. 조직검사 결과는 다음과 같고, ECOG(Eastern Cooperative Oncology Group) 수행능도는 0이다. 심부정맥혈전증 치료를 위해 와파린(warfarin)을 복용 중이며 그 외에 다른 병력은 없다. 수술 후 내분비 단독 요법을 시행하고자 할 때 적절한 약물은?\n\n[조직검사]\n호르몬수용체(hormone receptor, HR) 양성\n사람표피성장인자수용체2(human epidermal growth factor receptor 2, HER2) 음성\n\n① 알펠리십(alpelisib)\n② 타목시펜(tamoxifen)\n③ 풀베스트란트(fulvestrant)\n④ 아나스트로졸(anastrozole)\n⑤ 트라스투주맙(trastuzumab)",
        "question_text": "Question: A 65-year-old postmenopausal woman has been diagnosed with stage 1 breast cancer. The biopsy results are as follows, and her ECOG (Eastern Cooperative Oncology Group) performance status is 0. She is currently taking warfarin for deep vein thrombosis treatment and has no other medical history. What is the appropriate drug for endocrine monotherapy after surgery?\n\n[Biopsy results]\nHormone receptor (HR) positive\nHuman epidermal growth factor receptor 2 (HER2) negative\n\n① Alpelisib\n② Tamoxifen\n③ Fulvestrant\n④ Anastrozole\n⑤ Trastuzumab",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: 4기 비소세포폐암을 진단받은 60세 남자에게 알렉티닙(alectinib)을 투여하려고 할 때, 투여 전에 양성을 확인해야 할 검사는?\n\n① ALK 변이\n② BRAF 변이\n③ EGFR 변이\n④ NTRK 변이\n⑤ PD-L1 발현",
        "question_text": "Question: For a 60-year-old man diagnosed with stage 4 non-small cell lung cancer, when planning to administer alectinib, which test should be confirmed positive before administration?\n\n① ALK mutation\n② BRAF mutation\n③ EGFR mutation\n④ NTRK mutation\n⑤ PD-L1 expression",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: 기저질환이 없는 53세 남자가 확장병기 소세포폐암을 진단받았다. 뇌 전이는 없고, ECOG(Eastern Cooperative Oncology Group) 수행도는 1이다. 적절한 1차 항암요법은?\n\n① 아파티닙(afatinib)\n② 라무시루맙(ramucirumab)\n③ 시스플라틴(cisplatin)+이포스파미드(ifosfamide)\n④ 젬시타빈(gemcitabine)+비노렐빈(vinorelbine)+더발루맙(durvalumab)\n⑤ 카르보플라틴(carboplatin)+에토포시드(etoposide)+아테졸리주맙(atezolizumab)",
        "question_text": "Question: A 53-year-old man with no underlying diseases has been diagnosed with extensive-stage small cell lung cancer. There is no brain metastasis, and his ECOG (Eastern Cooperative Oncology Group) performance status is 1. What is the appropriate first-line chemotherapy?\n\n① Afatinib\n② Ramucirumab\n③ Cisplatin + Ifosfamide\n④ Gemcitabine + Vinorelbine + Durvalumab\n⑤ Carboplatin + Etoposide + Atezolizumab",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: 36세 남자가 4기 결장암 치료를 위해 3주 간격으로 다음 약물을 투여받고 있다. 환자는 오늘 손바닥과 발바닥이 붓고 통증이 있다고 하였고, 손발증후군을 진단받았다. 손발증후군을 유발했을 가능성이 높은 약물은?\n\n[복용약물]\n카페시타빈(capecitabine)\n옥살리플라틴(oxaliplatin)\n베바시주맙(bevacizumab)\n온단세트론(ondansetron)\n덱사메타손(dexamethasone)\n\n① 카페시타빈\n② 옥살리플라틴\n③ 베바시주맙\n④ 온단세트론\n⑤ 덱사메타손",
        "question_text": "Question: A 36-year-old man is receiving the following drugs every 3 weeks for the treatment of stage 4 colon cancer. Today, the patient reported swelling and pain in his palms and soles, and was diagnosed with hand-foot syndrome. Which drug is most likely to have caused the hand-foot syndrome?\n\n[Medications]\nCapecitabine\nOxaliplatin\nBevacizumab\nOndansetron\nDexamethasone\n\n① Capecitabine\n② Oxaliplatin\n③ Bevacizumab\n④ Ondansetron\n⑤ Dexamethasone",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: 67세 여자가 간과 폐로 전이되어 수술이 불가능한 4기 대장암을 진단받았다. 현재 ECOG(Eastern Cooperative Oncology Group) 수행도는 1이다. 유전자검사 결과가 다음과 같은 때, 적절한 1차 항암요법은?\n\n[유전자검사]\nKRAS 변이 음성, NRAS 변이 음성, BRAF 변이 음성, HER2 음성\ndMMR/MSI-H(유전적불일치복구결함/고빈도-현미부수체 불안정성)\n\n① 레고라페닙(regorafenib)\n② 펨브롤리주맙(pembrolizumab)\n③ 지브-애플리버셉트(ziv-aflibercept)\n④ 트리플루리딘/티피라실(trifluridine/tipiracil)\n⑤ 퍼투주맙(pertuzumab)+트라스투주맙(trastuzumab)",
        "question_text": "Question: A 67-year-old woman has been diagnosed with stage 4 colon cancer that has metastasized to the liver and lungs, making surgery impossible. Her current ECOG (Eastern Cooperative Oncology Group) performance status is 1. Given the following genetic test results, what is the appropriate first-line chemotherapy?\n\n[Genetic Test Results]\nKRAS mutation negative, NRAS mutation negative, BRAF mutation negative, HER2 negative\ndMMR/MSI-H (deficient mismatch repair/high microsatellite instability)\n\n① Regorafenib\n② Pembrolizumab\n③ Ziv-aflibercept\n④ Trifluridine/tipiracil\n⑤ Pertuzumab + Trastuzumab",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n기저질환이 없는 55세 남자가 급성골수성백혈병(AML)을 진단받았다. 세포유전학적 검사 결과 CD33 양성의 양호예후군으로 확인되었다. 현재 ECOG(Eastern Cooperative Oncology Group) 수행도는 1이다.\n\nQuestion: 적절한 관해유도요법은?\n\n① 고용량 시타라빈(cytarabine)\n② 고용량 시타라빈+이다루비신(daunorubicin)\n③ 표준용량 시타라빈+아자시티딘(azacitidine)\n④ 고용량 시타라빈+젬투주맵오조가마이신(gemtuzumab ozogamicin)\n⑤ 표준용량 시타라빈+다우노루비신(daunorubicin)+젬투주맵오조가마이신",
        "question_text": "A 55-year-old man with no underlying diseases was diagnosed with acute myeloid leukemia (AML). Cytogenetic testing confirmed CD33-positive favorable-risk group. His current ECOG (Eastern Cooperative Oncology Group) performance status is 1.\n\nQuestion: What is the appropriate induction therapy?\n\n① High-dose cytarabine\n② High-dose cytarabine + daunorubicin\n③ Standard-dose cytarabine + azacitidine\n④ High-dose cytarabine + gemtuzumab ozogamicin\n⑤ Standard-dose cytarabine + daunorubicin + gemtuzumab ozogamicin",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n기저질환이 없는 55세 남자가 급성골수성백혈병(AML)을 진단받았다. 세포유전학적 검사 결과 CD33 양성의 양호예후군으로 확인되었다. 현재 ECOG(Eastern Cooperative Oncology Group) 수행도는 1이다.\n\nQuestion: 환자는 관해유도요법으로 관해에 도달하였다. 관해 후 치료요법으로 고용량 시타라빈을 포함한 항암화학요법을 받을 예정이다. 시타라빈의 이상반응을 예방하기 위해 투여가 필요한 약은?\n\n① 메스나(mesna) 주사제\n② 로이코보린(leucovorin) 경구제\n③ 덱스라족산(dexrazoxane) 주사제\n④ 타플루프로스트(tafluprost) 점안제\n⑤ 덱사메타손(dexamethasone) 점안제",
        "question_text": "A 55-year-old man with no underlying diseases was diagnosed with acute myeloid leukemia (AML). Cytogenetic testing confirmed it as a CD33-positive favorable prognosis group. His current ECOG (Eastern Cooperative Oncology Group) performance status is 1.\n\nQuestion: The patient achieved remission with induction therapy. He is scheduled to receive chemotherapy including high-dose cytarabine as post-remission therapy. Which drug should be administered to prevent side effects of cytarabine?\n\n① Mesna injection\n② Oral leucovorin\n③ Dexrazoxane injection\n④ Tafluprost eye drops\n⑤ Dexamethasone eye drops",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: 20세 여자가 아토피피부염을 진단받고 중증도(Class 4) 외용 스테로이드를 사용 중이다. 팔의 접히는 부위와 얼굴의 병변은 개선되었지만 손과 팔에 태선화된 부위가 낮지 않고 있어 이 부위에 단기간 적용하기에 적절한 약물은?\n\n① 히드로코르티손(hydrocortisone) 1% 로션\n② 히드로코르티손 2.5% 로션\n③ 트리암시놀론아세토니드(triamcinolone acetonide) 0.1% 크림\n④ 클로베타솔프로피오네이트(clobetasol propionate) 0.05% 연고\n⑤ 프레드니솔론발레로아세테이트(prednisolone valerate acetate) 0.3% 크림",
        "question_text": "Question: A 20-year-old woman has been diagnosed with atopic dermatitis and is using a moderate-strength (Class 4) topical steroid. While the lesions on the flexural areas of the arms and face have improved, the lichenified areas on the hands and arms have not subsided. Which of the following drugs is most appropriate for short-term application to these areas?\n\n① Hydrocortisone 1% lotion\n② Hydrocortisone 2.5% lotion\n③ Triamcinolone acetonide 0.1% cream\n④ Clobetasol propionate 0.05% ointment\n⑤ Prednisolone valerate acetate 0.3% cream",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: 60세 여자가 녹내장과 만성폐쇄폐질환으로 약물치료 중이다. 안압이 잘 조절되지 않아 선택적 베타차단제를 추가하고자 할 때 적절한 점안제는?\n\n[사용약물]\n브리모니딘(brimonidine) 점안제 1일 3회\n라타노프로스트(latanoprost) 점안제 1일 1회\n살부타몰(salbutamol) 흡입제 필요시\n\n① 티몰롤(timolol)\n② 베탁솔롤(betaxolol)\n③ 카르테올롤(carteolol)\n④ 니프라딜롤(nipradilol)\n⑤ 레보부놀롤(levobunolol)",
        "question_text": "Question: A 60-year-old woman is undergoing drug treatment for glaucoma and chronic obstructive pulmonary disease. Her intraocular pressure is not well controlled, and a selective beta-blocker is to be added. Which eye drop is appropriate?\n\n[Current medications]\nBrimonidine eye drops 3 times daily\nLatanoprost eye drops once daily\nSalbutamol inhaler as needed\n\n① Timolol\n② Betaxolol\n③ Carteolol\n④ Nipradilol\n⑤ Levobunolol",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: 폐렴으로 중환자실에 입원 중인 67세 남자가 프로포폴(propofol)을 투여받고 있다. 환자는 완전정맥영양을 투여받고 있으며 1일 총열량요구량은 2,000 kcal이다. 이 중 600 kcal을 지질로 투여하고자 할 때 20% 정맥용 지질유제의 부피는? (단, 환자에게 투여 중인 프로포폴은 1일 181.8 mL로 200 kcal의 지질에 해당한다.)\n\n① 100 mL\n② 200 mL\n③ 300 mL\n④ 400 mL\n⑤ 500 mL",
        "question_text": "Question: A 67-year-old male patient is admitted to the ICU with pneumonia and is receiving propofol. The patient is on total parenteral nutrition with a daily total caloric requirement of 2,000 kcal. If 600 kcal is to be administered as lipids, what is the volume of 20% intravenous lipid emulsion needed? (Note: The propofol currently being administered to the patient is 181.8 mL per day, which corresponds to 200 kcal of lipids.)\n\n① 100 mL\n② 200 mL\n③ 300 mL\n④ 400 mL\n⑤ 500 mL",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "original_text": "Question: 의무기록에 기슬된 약어 중 '호흡곤란 또는 숨참'의 의미에 해당하는 것은?\n\n① NKDA\n② PMH\n③ ROS\n④ SOB\n⑤ WNL",
        "question_text": "Question: Which of the following abbreviations used in medical records means \"shortness of breath or difficulty breathing\"?\n\n① NKDA\n② PMH\n③ ROS\n④ SOB\n⑤ WNL",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "original_text": "Question: 지난달에 승인된 아토피피부염 치료제 A와 기존 치료제 B의 효과와 안전성을 비교한 정보를 찾으려고 한다. 최신의 무작위대조임상시험(RCT)에 대한 초록과 서지 정보를 검색하는 데 적절한 의약정보원은?\n\n① MEDLINE\n② DrugBank\n③ Drug Interaction Facts\n④ Drug Information Handbook\n⑤ Applied Therapeutics: The Clinical Use of Drugs",
        "question_text": "Question: You want to find information comparing the efficacy and safety of atopic dermatitis treatment A, which was approved last month, with existing treatment B. Which of the following medical information sources is appropriate for searching abstracts and bibliographic information on the latest randomized controlled trials (RCTs)?\n\n① MEDLINE\n② DrugBank\n③ Drug Interaction Facts\n④ Drug Information Handbook\n⑤ Applied Therapeutics: The Clinical Use of Drugs",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압과 당뇨병이 있는 51세 남자가 3일 전부터 열이 나면서 온옴에 붉은 자국이 생겼다고 응급실에 왔다. 발가락 통증이 자주 재발하여 1개월 전부터 통풍 예방요법을 받고 있다. 유전자 검사 결과 HLA-B*5801 맞섬유전자(allele) 형성을 확인하였다. 당화혈색소는 6.2 %이고 다른 특이소견은 없다. 복용약물은 다음과 같다.\n\n| 의약품명 | 1회 투약량 | 1일 투여횟수 | 복용시작시점 |\n|---|---|---|---|\n| 암로디핀(amlodipine) 5 mg 정 | 1 | 1 | 2년 전 |\n| 메트포르민(metformin) 500 mg 정 | 1 | 2 | 1년 전 |\n| 알로푸리놀(allopurinol) 100 mg 정 | 1 | 1 | 1개월 전 |\n| 아세트아미노펜(acetaminophen) 500 mg 정 | 1 | 3 | 3일 전 |\n\nQuestion: 이 환자의 주요호소증상(chief complaint)은?\n\n① 고혈압\n② 발가락 통증\n③ HLA-B*5801 양성\n④ 당뇨병수치 6.2%\n⑤ 온몸의 붉은 자국",
        "question_text": "Read the following case and choose the most appropriate answer for each question.\n\nA 51-year-old man with hypertension and diabetes came to the emergency room complaining of fever and red marks all over his body for the past 3 days. He has been receiving gout prophylaxis for a month due to frequent recurrence of toe pain. Genetic testing confirmed the presence of the HLA-B*5801 allele. His glycated hemoglobin is 6.2%, and there are no other significant findings. His current medications are as follows:\n\n| Drug name | Dose per administration | Frequency per day | Start date |\n|---|---|---|---|\n| Amlodipine 5 mg tablet | 1 | 1 | 2 years ago |\n| Metformin 500 mg tablet | 1 | 2 | 1 year ago |\n| Allopurinol 100 mg tablet | 1 | 1 | 1 month ago |\n| Acetaminophen 500 mg tablet | 1 | 3 | 3 days ago |\n\nQuestion: What is this patient's chief complaint?\n\n① Hypertension\n② Toe pain\n③ HLA-B*5801 positive\n④ Diabetes level of 6.2%\n⑤ Red marks all over the body",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n고혈압과 당뇨병이 있는 51세 남자가 3일 전부터 열이 나면서 온옴에 붉은 자국이 생겼다고 응급실에 왔다. 발가락 통증이 자주 재발하여 1개월 전부터 통풍 예방요법을 받고 있다. 유전자 검사 결과 HLA-B*5801 맞섬유전자(allele) 형성을 확인하였다. 당화혈색소는 6.2 %이고 다른 특이소견은 없다. 복용약물은 다음과 같다.\n\n| 의약품명 | 1회 투약량 | 1일 투여횟수 | 복용시작시점 |\n|---|---|---|---|\n| 암로디핀(amlodipine) 5 mg 정 | 1 | 1 | 2년 전 |\n| 메트포르민(metformin) 500 mg 정 | 1 | 2 | 1년 전 |\n| 알로푸리놀(allopurinol) 100 mg 정 | 1 | 1 | 1개월 전 |\n| 아세트아미노펜(acetaminophen) 500 mg 정 | 1 | 3 | 3일 전 |\n\nQuestion: 이 환자의 약물관련문제(drug-related problem)에 해당하는 것은?\n\n① 암로디핀 용량 과다\n② 메트포르민 용량 부족\n③ 알로푸리놀 약물이상반응\n④ 아세트아미노펜 약물이상반응\n⑤ 암로디핀과 알로푸리놀의 약물상호작용",
        "question_text": "A 51-year-old man with hypertension and diabetes came to the emergency room complaining of fever and red marks all over his body for the past 3 days. He has been receiving gout prevention therapy for a month due to frequent recurrence of toe pain. Genetic testing confirmed the formation of the HLA-B*5801 allele. His glycated hemoglobin is 6.2%, and there are no other significant findings. His current medications are as follows:\n\n| Drug name | Dose per administration | Frequency per day | Start of medication |\n|---|---|---|---|\n| Amlodipine 5 mg tablet | 1 | 1 | 2 years ago |\n| Metformin 500 mg tablet | 1 | 2 | 1 year ago |\n| Allopurinol 100 mg tablet | 1 | 1 | 1 month ago |\n| Acetaminophen 500 mg tablet | 1 | 3 | 3 days ago |\n\nQuestion: Which of the following is the drug-related problem for this patient?\n\n① Excessive dose of amlodipine\n② Insufficient dose of metformin\n③ Adverse drug reaction to allopurinol\n④ Adverse drug reaction to acetaminophen\n⑤ Drug interaction between amlodipine and allopurinol",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "original_text": "Question: 다음과 같은 처방전에 기입해야 하는 항목 중, 환자가 요구할 경우 생략할 수 있는 것은?\n\n처방전\n[]건강보험 []의료급여 []산업재해보험 []자동차보험 []기타\n\n요양기관기호\n발급 연월일 및 번호\n환자 성명\n환자 주민등록번호\n의료기관 명칭\n의료기관 전화번호\n의료기관 팩스번호\n\n질병분류기호\n처방 의료인의 성명\n면허종류\n면허번호\n\n| 처방 의약품의 명칭 및 코드 | 1회 투약량 | 1일 투여횟수 | 총 투약일수 | 본인 부담률 구분코드 | 용법 |\n\n주사제 처방명세\n조제 시 참고사항\n본임부담 구분기호\n사용기간\n\n① 정보본류기호\n② 의료기관형명\n③ 처방전 사용기간\n④ 환자 주민등록번호\n⑤ 처방전 발급 연월일",
        "question_text": "Question: Among the items that should be filled in on the following prescription, which one can be omitted if requested by the patient?\n\nPrescription\n[]Health Insurance []Medical Aid []Industrial Accident Insurance []Auto Insurance []Other\n\nHealthcare Institution Code\nDate of Issue and Number\nPatient Name\nPatient Resident Registration Number\nMedical Institution Name\nMedical Institution Phone Number\nMedical Institution Fax Number\n\nDisease Classification Code\nPrescribing Medical Professional's Name\nLicense Type\nLicense Number\n\n| Prescribed Medication Name and Code | Single Dose | Daily Frequency | Total Days of Medication | Patient Copayment Classification Code | Usage Instructions |\n\nInjection Prescription Details\nNotes for Dispensing\nPatient Copayment Classification Symbol\nPeriod of Use\n\n① Disease Classification Code\n② Medical Institution Name\n③ Prescription Period of Use\n④ Patient Resident Registration Number\n⑤ Prescription Issue Date",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "original_text": "Question: 정제를 삼킬 수 없는 환자에게 투여하려고 할 때, 흡습성으로 인해 제형을 변경하거나 복용 직전에 분쇄해야 하는 약은?\n\n① 독사조신(doxazosin) XL정\n② 옥시코돈(oxycodone) SR정\n③ 오메프라졸(omeprazole) 정\n④ 알렌드론산(alendronate) 정\n⑤ 아목시실린/클라불란산(amoxicillin/clavulanic acid) 정",
        "question_text": "Question: Which of the following medications should have its formulation changed or be crushed immediately before administration due to hygroscopicity when administering to a patient who cannot swallow tablets?\n\n① Doxazosin XL tablet\n② Oxycodone SR tablet\n③ Omeprazole tablet\n④ Alendronate tablet\n⑤ Amoxicillin/clavulanic acid tablet",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "original_text": "Question: Beers Criteria를 기준으로 할 때, 신기능이 정상인 70세 환자에게 잠재적으로 부적절한 약(potentially inappropriate medication)?\n\n① 콜키신(colchicine) 정\n② 케토롤락(ketorolac) 정\n③ 리라글루타이드(liraglutide) 주\n④ 클로피도그렐(clopidogrel) 정\n⑤ 니페디핀 오로스(nifedipine OROS) 정",
        "question_text": "Question: According to the Beers Criteria, which of the following is a potentially inappropriate medication for a 70-year-old patient with normal renal function?\n\n① Colchicine tablet\n② Ketorolac tablet\n③ Liraglutide injection\n④ Clopidogrel tablet\n⑤ Nifedipine OROS tablet",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "original_text": "Question: 37세 여자가 고혈압으로 칸데사르탄(candesartan) 16 mg을 1일 1회 복용 중이다. 임신을 계획 중이라면 적절한 약물은?\n\n① 칸데사르탄 유지\n② 칸데사르탄을 라미프릴(ramipril)로 변경\n③ 칸데사르탄을 아테놀롤(atenolol)로 변경\n④ 칸데사르탄을 니페디핀(nifedipine)으로 변경\n⑤ 칸데사르탄을 히드로클로로티아지드(hydrochlorothiazide)로 변경",
        "question_text": "Question: A 37-year-old woman is taking candesartan 16 mg once daily for hypertension. If she is planning to become pregnant, which medication is appropriate?\n\n① Maintain candesartan\n② Change candesartan to ramipril\n③ Change candesartan to atenolol\n④ Change candesartan to nifedipine\n⑤ Change candesartan to hydrochlorothiazide",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "original_text": "Question: 72세 남자 입원 시 확인된 크레아티닌청소율이 50 mL/min으로, 입원 전 70 mL/min보다 감소하였다. 입원 전 복용약물은 다음과 같다. 현재 신기능을 고려할 때 용량 조절이 필요한 약물은?\n\n[복용약물]\n아세트아미노펜/트라마돌(acetaminophen/tramadol) 325/37.5 mg 정 1정 1일 2회\n프레가발린(pregabalin) 75 mg 캡슐 1캡슐 1일 2회\n에페리손(eperisone) 50 mg 정 1정 1일 2회\n모사프리드(mosapride) 5 mg 정 1정 1일 2회\n팩수프라잔(fexuprazan) 40 mg 정 1정 1일 1회\n\n① 아세트아미노펜/트라마돌\n② 프레가발린\n③ 에페리손\n④ 모사프리드\n⑤ 팩수프라잔",
        "question_text": "Question: A 72-year-old male patient's creatinine clearance was confirmed to be 50 mL/min upon admission, which is lower than the 70 mL/min before hospitalization. The medications taken before admission are as follows. Considering the current renal function, which medication requires dose adjustment?\n\n[Medications]\nAcetaminophen/tramadol 325/37.5 mg tablet, 1 tablet twice daily\nPregabalin 75 mg capsule, 1 capsule twice daily\nEperisone 50 mg tablet, 1 tablet twice daily\nMosapride 5 mg tablet, 1 tablet twice daily\nFexuprazan 40 mg tablet, 1 tablet once daily\n\n① Acetaminophen/tramadol\n② Pregabalin\n③ Eperisone\n④ Mosapride\n⑤ Fexuprazan",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "original_text": "Question: 여드름 치료제를 복용 중이고 페니실린 알레르기가 있는 23세 남자가 오늘 치과 진료 후 처방전을 받았다. 처방내역은 다음과 같다. 이 환자의 처방전 과정에서 발생되는 문제점은?\n\n[피부과 처방]\n| 의약품명 | 1회 투약량 | 1일 투약량 | 총 투약일수 |\n|---|---|---|---|\n| 이소트레티노인(isotretinoin) 10 mg 캡슐 | 2 | 2 | 30 |\n[치과 처방]\n| 의약품명 | 1회 투약량 | 1일 투약량 | 총 투약일수 |\n|---|---|---|---|\n| 독시사이클린(doxycycline) 100 mg 정 | 1 | 2 | 3 |\n\n① 농소근 중복 처방\n② 병용 금기 약물 사용\n③ 독시사이클린 용량 부족\n④ 독시사이클린 투여횟수 부족\n⑤ 독시사이클린의 부적절한 체형",
        "question_text": "Question: A 23-year-old male who is currently taking acne medication and has a penicillin allergy received a prescription after a dental appointment today. The prescription details are as follows. What is the problem that occurs in the prescription process for this patient?\n\n[Dermatology Prescription]\n| Medication Name | Dose per Administration | Daily Dose | Total Days of Administration |\n|---|---|---|---|\n| Isotretinoin 10 mg capsule | 2 | 2 | 30 |\n\n[Dental Prescription]\n| Medication Name | Dose per Administration | Daily Dose | Total Days of Administration |\n|---|---|---|---|\n| Doxycycline 100 mg tablet | 1 | 2 | 3 |\n\n① Duplicate prescription of tetracyclines\n② Use of contraindicated drugs in combination\n③ Insufficient dosage of doxycycline\n④ Insufficient frequency of doxycycline administration\n⑤ Inappropriate formulation of doxycycline",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": false,
        "original_text": "Question: 60세 남자가 병원획득폐렴으로 반코마이신(vancomycin)을 3일째 투여받고 있다. 액체배지 미량희석법(broth microdilution)으로 추정한, 메티실린저항성황생성포도상구균(MRSA)에 대한 반코마이신의 최대억제농도(MIC)가 1 mg/L일 때, 이 환자에게 적절한 반코마이신의 AUC_{0-24} (mg·h/L)는?\n\n① 100\n② 150\n③ 200\n④ 300\n⑤ 400",
        "question_text": "Question: A 60-year-old man has been receiving vancomycin for 3 days for hospital-acquired pneumonia. When the minimum inhibitory concentration (MIC) of vancomycin against methicillin-resistant Staphylococcus aureus (MRSA), estimated by broth microdilution method, is 1 mg/L, what is the appropriate AUC_{0-24} (mg·h/L) of vancomycin for this patient?\n\n① 100\n② 150\n③ 200\n④ 300\n⑤ 400",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": false,
        "original_text": "Question: 몸무게가 10 kg인 1세 여아에 대한 다음 처방에 따라 의약품을 조제하려고 한다. 이에 취하여야 할 건조시럽 분말의 중량은?\n\n• 클래리트로마이신(clarithromycin) 1정 7.5 mg/kg, 1일 2회, 12시간 간격, 5일 복용\n[참고] 클래리트로마이신 건조시럽 정보\n– 함량: 125 mg/5 mL\n– 100 mL 병에 들어 있는 건조시럽 분말의 중량: 70 g\n\n① 10.5 g\n② 14 g\n③ 21 g\n④ 30 g\n⑤ 42 g",
        "question_text": "Question: You are preparing medication according to the following prescription for a 1-year-old female patient weighing 10 kg. What should be the weight of the dry syrup powder to be used?\n\n• Clarithromycin 7.5 mg/kg per dose, twice daily, at 12-hour intervals, for 5 days\n[Reference] Information on clarithromycin dry syrup\n– Concentration: 125 mg/5 mL\n– Weight of dry syrup powder in a 100 mL bottle: 70 g\n\n① 10.5 g\n② 14 g\n③ 21 g\n④ 30 g\n⑤ 42 g",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "original_text": "Question: 완전정맥영양(total parenteral nutrition)을 무균조제 할 때, 개별 전해질 제제를 이용하여 혼합하려고 한다. 침전생성을 최소화하기 위한 전해질 주입 순서는?\n\n① 인산이수소칼륨 → 염화칼륨 → 글루콘산칼슘 → 염화나트륨 → 황산마그네슘\n② 인산이수소칼륨 → 염화나트륨 → 염화칼륨 → 황산마그네슘 → 글루콘산칼슘\n③ 염화나트륨 → 염화칼륨 → 글루콘산칼슘 → 황산마그네슘 → 인산이수소칼륨\n④ 염화나트륨 → 염화칼륨 → 글루콘산칼슘 → 인산이수소칼륨 → 황산마그네슘\n⑤ 글루콘산칼슘 → 인산이수소칼륨 → 염화나트륨 → 염화칼륨 → 황산마그네슘",
        "question_text": "Question: When preparing total parenteral nutrition under aseptic conditions, individual electrolyte preparations are to be mixed. What is the order of electrolyte addition that minimizes precipitation?\n\n① Potassium dihydrogen phosphate → Potassium chloride → Calcium gluconate → Sodium chloride → Magnesium sulfate\n② Potassium dihydrogen phosphate → Sodium chloride → Potassium chloride → Magnesium sulfate → Calcium gluconate\n③ Sodium chloride → Potassium chloride → Calcium gluconate → Magnesium sulfate → Potassium dihydrogen phosphate\n④ Sodium chloride → Potassium chloride → Calcium gluconate → Potassium dihydrogen phosphate → Magnesium sulfate\n⑤ Calcium gluconate → Potassium dihydrogen phosphate → Sodium chloride → Potassium chloride → Magnesium sulfate",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "original_text": "Question: 시스플라틴(cisplatin) 130 mg 정맥주사 처방전의 처방검토 및 조제감사 과정에서 약사가 확인한 사항이 바른 것은?\n\n① Calvert 공식을 이용하여 투여량이 계산됨\n② 심장독성 예방을 위해 누적용량을 확인함\n③ 희석액으로 5 % 포도당 주사액이 사용됨\n④ '수막내투여'라는 문구가 적인 라벨이 부착됨\n⑤ 고위험군에 사용하는 항구토예방요법이 처방됨",
        "question_text": "Question: Which of the following is correct regarding what a pharmacist confirmed during the prescription review and dispensing audit process for a 130 mg intravenous cisplatin prescription?\n\n① The dosage is calculated using the Calvert formula\n② The cumulative dose is checked to prevent cardiac toxicity\n③ 5% dextrose injection is used as the diluent\n④ A label with the phrase 'For intrathecal use' is attached\n⑤ Antiemetic prophylaxis for high-risk groups is prescribed",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "original_text": "Question: 비가바트린(vigabatrin)을 처방받은 6세 소아 환자에게 주기적으로 모니터링해야 하는 항목은?\n\n① 시력\n② 청력\n③ 혈당\n④ 혈소판\n⑤ 빌리루빈",
        "question_text": "Question: Which of the following should be periodically monitored in a 6-year-old pediatric patient prescribed vigabatrin?\n\n① Vision\n② Hearing\n③ Blood glucose\n④ Platelets\n⑤ Bilirubin",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n57세 여자가 고혈압, 이상지질혈증, 위염으로 진료받고 다음의 처방전을 가지고 약국에 왔다. 환자는 파킨슨병으로 로피니롤(roprinol)을 복용 중이다.\n\n| 의약품명 | 1회 투약량 | 1일 투여횟수 | 총 투약일수 |\n|---|---|---|---|\n| 페린도프릴(perindopril) 4 mg 정 | 1 | 1 | 30 |\n| 아토르바스타틴(atorvastatin) 10 mg 정 | 1 | 1 | 30 |\n| 히드로클로로티아지드(hydrochlorothiazide) 25 mg 정 | 0.5 | 1 | 30 |\n| 파모티딘(famotidine) 20 mg 정 | 1 | 2 | 5 |\n| 메토클로프라미드(metoclopramide) 3.84 mg 정 | 1 | 2 | 5 |\n\nQuestion: 처방검토 결과, 파킨슨병 운동 증상을 약화시킬 가능성이 있어 약사의 중재가 필요한 약물은?\n\n① 파모티딘\n② 페린도프릴\n③ 아토르바스타틴\n④ 메토클로프라미드\n⑤ 히드로클로로티아지드",
        "question_text": "A 57-year-old woman came to the pharmacy with the following prescription after being treated for hypertension, dyslipidemia, and gastritis. The patient is currently taking ropinirole for Parkinson's disease.\n\n| Medication Name | Dose per Administration | Frequency per Day | Total Days of Treatment |\n|---|---|---|---|\n| Perindopril 4 mg tablet | 1 | 1 | 30 |\n| Atorvastatin 10 mg tablet | 1 | 1 | 30 |\n| Hydrochlorothiazide 25 mg tablet | 0.5 | 1 | 30 |\n| Famotidine 20 mg tablet | 1 | 2 | 5 |\n| Metoclopramide 3.84 mg tablet | 1 | 2 | 5 |\n\nQuestion: Based on the prescription review, which medication requires pharmacist intervention due to its potential to exacerbate Parkinson's disease motor symptoms?\n\n① Famotidine\n② Perindopril\n③ Atorvastatin\n④ Metoclopramide\n⑤ Hydrochlorothiazide",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n57세 여자가 고혈압, 이상지질혈증, 위염으로 진료받고 다음의 처방전을 가지고 약국에 왔다. 환자는 파킨슨병으로 로피니롤(roprinol)을 복용 중이다.\n\n| 의약품명 | 1회 투약량 | 1일 투여횟수 | 총 투약일수 |\n|---|---|---|---|\n| 페린도프릴(perindopril) 4 mg 정 | 1 | 1 | 30 |\n| 아토르바스타틴(atorvastatin) 10 mg 정 | 1 | 1 | 30 |\n| 히드로클로로티아지드(hydrochlorothiazide) 25 mg 정 | 0.5 | 1 | 30 |\n| 파모티딘(famotidine) 20 mg 정 | 1 | 2 | 5 |\n| 메토클로프라미드(metoclopramide) 3.84 mg 정 | 1 | 2 | 5 |\n\nQuestion: 이 환자가 위 처방약을 복용한 후부터 지속적인 마른기침이 발생하였다. 환자는 의사 지시에 따라 페린도프릴 복용을 중단한 후 마른기침이 호전되었다. 재투여에 대한 정보는 없고 다른 관련 질병은 의심되지 않는다. 약물이상사례 인과성평가를 WHO-UMC 방법으로 수행한 판정 결과는?\n\n① 상당히 확실함(probable)\n② 가능함(possible)\n③ 가능성 적음(unlikely)\n④ 평가곤란(conditional)\n⑤ 평가불가(unassessable)",
        "question_text": "A 57-year-old woman came to the pharmacy with the following prescription after being treated for hypertension, dyslipidemia, and gastritis. The patient is taking ropinirole for Parkinson's disease.\n\n| Medication Name | Dose per Administration | Frequency per Day | Total Days of Treatment |\n|---|---|---|---|\n| Perindopril 4 mg tablet | 1 | 1 | 30 |\n| Atorvastatin 10 mg tablet | 1 | 1 | 30 |\n| Hydrochlorothiazide 25 mg tablet | 0.5 | 1 | 30 |\n| Famotidine 20 mg tablet | 1 | 2 | 5 |\n| Metoclopramide 3.84 mg tablet | 1 | 2 | 5 |\n\nQuestion: The patient developed persistent dry cough after taking the prescribed medications above. Following the doctor's instructions, the patient stopped taking perindopril, and the dry cough improved. There is no information about re-administration, and no other related diseases are suspected. What is the result of the causality assessment for this adverse drug reaction using the WHO-UMC method?\n\n① Probable\n② Possible\n③ Unlikely\n④ Conditional\n⑤ Unassessable",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "original_text": "Question: 수분을 흡수하여 팽창함으로써 배변을 촉진하는 하제로, 복용 후 충분한 양의 물을 마시도록 복약지도 해야 하는 약물은?\n\n① 락티톨(lactitol)\n② 비사코딜(bisacodyl)\n③ 락툴로오스(lactulose)\n④ 도큐세이트(docusate)\n⑤ 차전자피(psyllium husk)",
        "question_text": "Question: Which of the following laxatives promotes bowel movement by absorbing water and expanding, and requires patient counseling to drink sufficient water after taking it?\n\n① Lactitol\n② Bisacodyl\n③ Lactulose\n④ Docusate\n⑤ Psyllium husk",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "original_text": "Question: 생후 15개월 된 딸이 있는 부부가 구충제를 위해 약국을 방문하였다. 온 가족이 함께 복용할 수 있는 구충제는?\n\n① 티니다졸(tinidazole)\n② 알벤다졸(albendazole)\n③ 플루벤다졸(flubendazole)\n④ 케토코나졸(ketoconazole)\n⑤ 메트로니다졸(metronidazole)",
        "question_text": "Question: A couple with a 15-month-old daughter visited a pharmacy for an anthelmintic medication. Which anthelmintic can be taken by the whole family?\n\n① Tinidazole\n② Albendazole\n③ Flubendazole\n④ Ketoconazole\n⑤ Metronidazole",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "original_text": "Question: 개읜ㄴㄴㄴ 관련 염증과 통증을 완화할 목적으로 투여하고자 할 때, 3일간 투여가 결정되며, 지속적인 투여가 필요한 경우에도 3일 연속 투여 후 최소 4일간 휴약기간을 갖도록 투여지도 해야 하는 약물은?\n\n① 카르프로펜(carprofen)\n② 마로피탄트(maropitant)\n③ 톨페남산(tolfenamic acid)\n④ 아세트아미노펜(acetaminophen)\n⑤ 메토클로프라미드(metoclopramide)",
        "question_text": "Question: When administering a drug to alleviate inflammation and pain related to [개읜ㄴㄴㄴ], it is decided to administer for 3 days, and even if continuous administration is necessary, which drug should be instructed to have a minimum 4-day rest period after 3 consecutive days of administration?\n\n① Carprofen\n② Maropitant\n③ Tolfenamic acid\n④ Acetaminophen\n⑤ Metoclopramide\n\nNote: The term [개읜ㄴㄴㄴ] in the original question appears to be a typo or an incomplete word, so it has been left as is in the translation.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "original_text": "Question: 부프레노르핀(buprenorphine) 10 μg/h 패치(patch)의 적절한 사용 방법은?\n\n① 매일 교체\n② 격일로 교체\n③ 3일마다 교체\n④ 5일마다 교체\n⑤ 7일마다 교체",
        "question_text": "Question: What is the appropriate usage method for a buprenorphine 10 μg/h patch?\n\n① Replace daily\n② Replace every other day\n③ Replace every 3 days\n④ Replace every 5 days\n⑤ Replace every 7 days",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "original_text": "Question: 발기부전 치료 목적의 타다라필(tadalafil)과 병용금기인 약물은?\n\n① 딜티아젬(diltiazem)\n② 탐스로신(tamsulosin)\n③ 카르베딜롤(carvedilol)\n④ 두타스테리드(dutasteride)\n⑤ 이소소르비드이질산염(isosorbide dinitrate)",
        "question_text": "Question: Which drug is contraindicated for use with tadalafil, used for treating erectile dysfunction?\n\n① Diltiazem\n② Tamsulosin\n③ Carvedilol\n④ Dutasteride\n⑤ Isosorbide dinitrate",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "original_text": "Question: 20세 여자에게 적절한 응급피임약은?\n\n① 레트로졸(letrozole)\n② 메게스트롤(megestrol)\n③ 울리프리스탈(ulipristal)\n④ 에티닐에스트라디올(ethinylestradiol)\n⑤ 메드록시프로게스테론(medroxyprogesterone)",
        "question_text": "Question: What is the appropriate emergency contraceptive for a 20-year-old woman?\n\n① Letrozole\n② Megestrol\n③ Ulipristal\n④ Ethinylestradiol\n⑤ Medroxyprogesterone",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "original_text": "Question: 다음 그림과 같은 단일 일회용 주사제의 사용에 관한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 팔의 상부 외측에서 흡수율이 가장 높다.\n② 한 번 개봉하여 사용한 제품은 2주가 경과되면 폐기한다.\n③ 용량표시창에 설정된 숫자는 주입이 끝난 후에도 유지된다.\n④ 주사부위를 집어 올린 상태에서 주삿바늘을 30° 각도로 주사한다.\n⑤ 주삿바늘을 피부에 찌르고 주입버튼을 누른 채 10까지 천천히 세고 난 후 뺀다.",
        "question_text": "Question: Which of the following statements is correct regarding the use of a single-use disposable injection device as shown in the figure?\n\n<Data (confidential)>\n\n① The absorption rate is highest in the upper outer part of the arm.\n② A product that has been opened and used once should be discarded after 2 weeks.\n③ The number set in the dose display window remains unchanged even after the injection is completed.\n④ The injection is administered at a 30° angle while pinching the injection site.\n⑤ After inserting the needle into the skin, press the injection button, count slowly to 10, and then remove the needle.",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "original_text": "Question: 다음 그림과 같은 흡입기의 사용에 관한 설명으로 옳은 것은?\n\n<Data (confidential)>\n\n① 사용 전에 충분히 흔들어 준다.\n② 흡입력이 약한 소아에게 사용하기 적합하다.\n③ 흡입 후 캡슐에 약이 남아 있으면 흡입을 반복한다.\n④ 천천히 깊게 숨을 들이마시는 동시에 버튼을 누른다.\n⑤ 흡입할 때 캡슐이 회전하는 소리가 들리면 잘못 흡입한 것이다.",
        "question_text": "Question: Which of the following statements is correct regarding the use of the inhaler shown in the figure?\n\n<Data (confidential)>\n\n① Shake well before use.\n② It is suitable for use in children with weak inhalation strength.\n③ If medication remains in the capsule after inhalation, repeat the inhalation.\n④ Press the button while slowly and deeply inhaling.\n⑤ If you hear the capsule rotating during inhalation, it means you are inhaling incorrectly.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n45세 여자가 전날부터 시작된 물설사 증상으로 약국을 방문하였다. 열이 없으며, 다른 동반질환도 없다.\n\nQuestion: 이 환자에게 적절한 일반의약품의 주요성분은?\n\n① 세티리진(cetirizine)\n② 로라타딘(loratadine)\n③ 알마게이트(almagate)\n④ 테르비나핀(terbinafine)\n⑤ 디옥타헤드랄스멕타이트(dioctahedral smectite)",
        "question_text": "A 45-year-old woman visited the pharmacy with symptoms of watery diarrhea that started the day before. She has no fever and no other accompanying conditions.\n\nQuestion: What is the main ingredient of the appropriate over-the-counter medication for this patient?\n\n① Cetirizine\n② Loratadine\n③ Almagate\n④ Terbinafine\n⑤ Dioctahedral smectite",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n45세 여자가 전날부터 시작된 물설사 증상으로 약국을 방문하였다. 열이 없으며, 다른 동반질환도 없다.\n\nQuestion: 이 환자에게 적절한 한약제제는?\n\n① 삼소음(參蘇飮)\n② 오령산(五笭散)\n③ 대청룡탕(大靑龍湯)\n④ 당귀수산(當歸鬚散)\n⑤ 거풍지보단(祛風至寶丹)",
        "question_text": "A 45-year-old woman visited the pharmacy with symptoms of watery diarrhea that started the day before. She has no fever and no other accompanying conditions.\n\nQuestion: Which of the following herbal preparations is appropriate for this patient?\n\n① Samsoeum (參蘇飮)\n② Oryeong-san (五笭散)\n③ Daecheongryong-tang (大靑龍湯)\n④ Danggwisoo-san (當歸鬚散)\n⑤ Geopungjibodan (祛風至寶丹)",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "original_text": "Question: 청정구역의 청정작업실과 청정공기장치 모니터링에 관한 설명으로 옳은 것은?\n\n① 오염도는 A등급 구역보다 B등급 구역이 높다.\n② D등급 구역에서는 무균조작을 통해 제품을 충전할 수 있다.\n③ 부유균 측정 시 콘택트 플레이트(contact plate)법을 활용한다.\n④ 오염도가 높은 구역의 양압 유지를 통해 주변 구역의 청정도를 유지할 수 있다.\n⑤ 표면균은 측정 장소에서 평판배지를 일정 시간 개방하고 낙하된 미생물을 배양하여 측정한다.",
        "question_text": "Question: Which of the following statements is correct regarding the monitoring of clean rooms and clean air devices in clean areas?\n\n① The contamination level is higher in Grade B areas than in Grade A areas.\n② Products can be filled through aseptic manipulation in Grade D areas.\n③ The contact plate method is used for measuring airborne microorganisms.\n④ The cleanliness of surrounding areas can be maintained by keeping high-contamination areas under positive pressure.\n⑤ Surface microorganisms are measured by exposing agar plates at the measurement site for a certain period and culturing the fallen microorganisms.",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "original_text": "Question: 제조용수공급시스템 및 공기조화장치시스템의 적격성을 검증하고 문서화하는 밸리데이션은?\n\n① 공정 밸리데이션\n② 세척 밸리데이션\n③ 시험방법 밸리데이션\n④ 제조지원설비 밸리데이션\n⑤ 컴퓨터시스템 밸리데이션",
        "question_text": "Question: What validation involves verifying and documenting the qualification of manufacturing water supply systems and air conditioning systems?\n\n① Process validation\n② Cleaning validation\n③ Test method validation\n④ Manufacturing support equipment validation\n⑤ Computer system validation",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia 의약품 각조에 수재되어 있는 다음 의약품 중, 공정 밸리데이션에 관점에서 중요도 순위가 가장 높은 의약품은?\n\n① 에녹사신 정(enoxacin tablets)\n② 노르에티스테론 정(norethisterone tablets)\n③ 네오마이신황산염 연고(neomycin sulfate ointment)\n④ 네오마이신B황산염 첩부제(neomycin B sulfate plaster)\n⑤ 겐타마이신황산염 안연고(gentamicin sulfate ophthalmic ointment)",
        "question_text": "Question: Among the following pharmaceutical products listed in the Korean Pharmacopoeia, which one has the highest priority in terms of process validation?\n\n① Enoxacin tablets\n② Norethisterone tablets\n③ Neomycin sulfate ointment\n④ Neomycin B sulfate plaster\n⑤ Gentamicin sulfate ophthalmic ointment",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "original_text": "Question: 무균 밸리데이션에서 D값에 관한 설명으로 옳은 것은?\n\n① 가열멸균 공정에서 온도에 따라 달라진다.\n② 가스멸균 공정에서 멸균 시간에 따라 달라진다.\n③ 미생물이 노출된 표면의 재질에 영향을 받지 않는다.\n④ 방사선멸균 공정에서 방사선량에 영향을 받지 않는다.\n⑤ 생물학적 지표로 사용된 미생물의 종류에 영향을 받지 않는다.",
        "question_text": "Question: Which of the following statements about the D-value in sterile validation is correct?\n\n① It varies with temperature in the heat sterilization process.\n② It varies with sterilization time in the gas sterilization process.\n③ It is not affected by the material of the surface to which microorganisms are exposed.\n④ It is not affected by the radiation dose in the radiation sterilization process.\n⑤ It is not affected by the type of microorganism used as a biological indicator.",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "original_text": "Question: 무균여과를 위하여 필터의 유효성을 점검하는 완전성 시험(integrity test)에 관한 설명으로 옳은 것은?\n\n① 방울점시험에서 확산시험은 비파괴시험이다.\n② 필터 제조사에서 실시하는 세균유지시험은 비파괴시험이다.\n③ 방울점시험에서 멤브레인 내의 기공 크기가 클수록 방울점 압력이 높다.\n④ 방울점시험에서 명시된 압력보다 방울점 압력이 낮으면 필터의 손상이 없음을 의미한다.\n⑤ 필터의 공극률이 일정하다면 방울점 압력은 필터의 형태(disk type 또는 cartridge type)에 영향을 받지 않는다.",
        "question_text": "Question: Which of the following statements about the integrity test for checking the effectiveness of filters for sterile filtration is correct?\n\n① In the bubble point test, the diffusion test is a non-destructive test.\n② The bacterial retention test conducted by the filter manufacturer is a non-destructive test.\n③ In the bubble point test, the larger the pore size within the membrane, the higher the bubble point pressure.\n④ In the bubble point test, if the bubble point pressure is lower than the specified pressure, it means there is no damage to the filter.\n⑤ If the porosity of the filter is constant, the bubble point pressure is not affected by the filter shape (disk type or cartridge type).",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "original_text": "Question: 생산현장에서 품질보증 평가기준으로 사용하는 관리수단으로서 제품의 품질을 일정한 수준으로 관리하기 위하여 생산공장에서 제품 시료를 분석한 결과를 주기적으로 도시한 것은?\n\n① 특성요인도\n② 품질관리도\n③ 히스토그램\n④ 상자수염그림\n⑤ 제조공정 흔들도",
        "question_text": "Question: Which of the following is a control measure used as a quality assurance evaluation criterion in production sites, where the results of product sample analyses from the production plant are periodically plotted to maintain product quality at a consistent level?\n\n① Cause-and-effect diagram\n② Quality control chart\n③ Histogram\n④ Box-and-whisker plot\n⑤ Manufacturing process variability chart",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "original_text": "Question: 변경관리, 연간품질평가 등에서 도출된 문제점을 개선하는 출발점이 되며, 정기적으로 그 개선 효과를 검증하도록 하는 품질경영시스템(QMS)의 요소는?\n\n① 감사\n② 교육\n③ 일탈\n④ 시정 및 예방조치\n⑤ 소비자 불만 조사",
        "question_text": "Question: Which element of the Quality Management System (QMS) serves as the starting point for improving issues identified through change management and annual quality assessments, and regularly verifies the effectiveness of these improvements?\n\n① Audit\n② Training\n③ Deviation\n④ Corrective and Preventive Action\n⑤ Consumer Complaint Investigation",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에서 규정하는 수성주사제를 제조할 때에 쓰이는 주사용수에 적용하는 시험항목은?\n\n① 실용량시험\n② 엔도톡신시험\n③ 미생물한도시험\n④ 불용성이물시험\n⑤ 불용성미립자시험",
        "question_text": "Question: Which of the following test items is applied to water for injection used in the manufacture of aqueous injections as specified in the Korean Pharmacopoeia?\n\n① Deliverable volume test\n② Endotoxin test\n③ Microbial limit test\n④ Insoluble particulate matter test\n⑤ Insoluble particulate test",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에서 규정하는 금속성이물시험을 적용하는 제제는?\n\n① 점안제\n② 주사제\n③ 안연고제\n④ 반고형제제\n⑤ 에어로솔제",
        "question_text": "Question: Which of the following dosage forms is subject to the test for metallic particles as specified in the Korean Pharmacopoeia?\n\n① Ophthalmic solutions\n② Injections\n③ Ophthalmic ointments\n④ Semi-solid preparations\n⑤ Aerosols",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에서 덱스트란 40의 품질관리를 위한 시험방법의 일부분이다. 이 시험법은?\n\n• 기니피그 4마리를 써서 제1일째, 제3일째, 제5일째에 검액을 복강내에 주사한다. 따로 대조로서 같은 수의 기니피그에 말혈청을 복강내에 주사한다.\n• 제5일째에 2마리, 제22일째에 나머지 2마리에, 검액을 주사한 기니피그에게는 검액을 정맥내에 주사하고, 같은 방법으로 말혈청을 주사한 기니피그에게는 말혈청을 정맥내에 주사한다.\n\n① 소화력시험\n② 안전성시험\n③ 제산력시험\n④ 항원성시험\n⑤ 히스타민시험",
        "question_text": "Question: This is part of the test method for quality control of Dextran 40 in the Korean Pharmacopoeia. What is this test method?\n\n• Using 4 guinea pigs, inject the test solution intraperitoneally on the 1st, 3rd, and 5th days. Separately, as a control, inject horse serum intraperitoneally into the same number of guinea pigs.\n• On the 5th day for 2 guinea pigs and on the 22nd day for the remaining 2 guinea pigs, intravenously inject the test solution to the guinea pigs that received the test solution, and intravenously inject horse serum to the guinea pigs that received horse serum in the same manner.\n\n① Digestive power test\n② Safety test\n③ Acid-neutralizing capacity test\n④ Antigenicity test\n⑤ Histamine test",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "original_text": "Question: 항원의 건조감량을 측정하기 위해서는 생약을 항량이 될 때까지 건조한다. 항량은 따로 규정이 없는 한 계속하여 1시간 더 건조할 때 전후의 칭량차 백분율(%)로 판정한다. 생약의 경우 항량으로 간주하기 위해서는 칭량자가 전회 측정한 건조물 질량의 최대 몇 % 이하이어야 하는가?\n\n① 0.25\n② 0.50\n③ 0.75\n④ 1.00\n⑤ 2.00",
        "question_text": "Question: To measure the loss on drying of a crude drug, it is dried until it reaches constant weight. Unless otherwise specified, constant weight is determined by the percentage difference in weight before and after an additional hour of drying. For crude drugs, what is the maximum percentage difference allowed from the previous measurement for the weight to be considered constant?\n\n① 0.25\n② 0.50\n③ 0.75\n④ 1.00\n⑤ 2.00",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "original_text": "Question: 따로 규정이 없는 한 Korean Pharmacopoeia에서 정한 제제의 보존 온도로 허용되는 최대온도(℃)는?\n\n① 15\n② 20\n③ 25\n④ 30\n⑤ 40",
        "question_text": "Question: Unless otherwise specified, what is the maximum allowable temperature (℃) for storing preparations as defined by the Korean Pharmacopoeia?\n\n① 15\n② 20\n③ 25\n④ 30\n⑤ 40",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia에서 에틸렌디아민테트라아세트산이나트륨액으로 적정하여 정량하는 의약품은?\n\n① 아스피린\n② 이소니아지드\n③ 티아민염산염\n④ 글루콘산칼슘수화물\n⑤ 퀴닌염산염수화물",
        "question_text": "Question: Which of the following pharmaceutical products is quantified by titration with ethylenediaminetetraacetic acid disodium solution according to the Korean Pharmacopoeia?\n\n① Aspirin\n② Isoniazid\n③ Thiamine hydrochloride\n④ Calcium gluconate hydrate\n⑤ Quinine hydrochloride hydrate",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "original_text": "Question: Korean Pharmacopoeia 수재 '에탄올'은 에탄올 95.1~96.9 vol%를 함유한다. 에탄올 함량을 측정하는 방법은?\n\n① 비중측정법\n② 점도측정법\n③ 선광도측정법\n④ 증발잔류물측정법\n⑤ 자외가시부흡광도측정법",
        "question_text": "Question: The 'Ethanol' listed in the Korean Pharmacopoeia contains 95.1-96.9 vol% of ethanol. What is the method for measuring the ethanol content?\n\n① Specific gravity measurement method\n② Viscosity measurement method\n③ Optical rotation measurement method\n④ Evaporation residue measurement method\n⑤ UV-visible spectrophotometry method",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "original_text": "Question: 실험단위의 실험순서를 난수생성기를 이용하여 결정하며, 실험자의 숙련도나 기온 등과 같이 실험에서 고려하지 않은 원인들이 실험결과에 끼칠 수 있는 영향을 미리 차단함으로써 실험의 객관성을 유지할 수 있게 하기 위한 실험계획의 기본 원리는?\n\n① 반복(replication)\n② 랜덤화(randomization)\n③ 블록화(blocking)\n④ 최적화(optimization)\n⑤ 심플렉스(simplex)",
        "question_text": "Question: What is the basic principle of experimental design that determines the order of experimental units using a random number generator, and maintains the objectivity of the experiment by preemptively blocking potential influences on experimental results from factors not considered in the experiment, such as the experimenter's skill level or temperature?\n\n① Replication\n② Randomization\n③ Blocking\n④ Optimization\n⑤ Simplex",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "original_text": "Question: 어떤 제품의 생산공장에서 품질의 특성을 분석한 결과, 그림과 같은 분포를 보였다. 이 품질에 대한 공정능력지수(process capability index, Cpk)는? (단, USL은 규격의 상한을, LSL은 규격의 하한을 나타낸다.)\n\n<Data (confidential)>\n\n① 0.67\n② 1.33\n③ 1.50\n④ 2.17\n⑤ 3.00",
        "question_text": "Question: In a production plant for a certain product, analysis of quality characteristics showed a distribution as illustrated in the figure. What is the process capability index (Cpk) for this quality? (Note: USL represents the upper specification limit, and LSL represents the lower specification limit.)\n\n<Data (confidential)>\n\n① 0.67\n② 1.33\n③ 1.50\n④ 2.17\n⑤ 3.00",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n의약품등등시험기준에 따르면, 코팅제제/비코팅제제의 첨가제별 변경 수준은 다음 표와 같다.\n\n| 첨가제의 배합 목적과 성분 | 함유율의 차(%)\n| | B 수준 | C 수준 | D 수준 |\n|---|---|---|---|\n| 붕해제 - 전분 | 3.0 | 6.0 | 9.0 |\n| 붕해제 - 기타 | 1.0 | 2.0 | 3.0 |\n| 결합제 | 0.50 | 1.0 | 1.5 |\n| 활택제, 광택제 - 스테아르산 및 그 염류 | 0.25 | 0.50 | 0.75 |\n| 활택제, 광택제 - 기타 | 1.0 | 2.0 | 3.0 |\n| 부형제 | 5.0 | 1.0 | 15 |\n(단, 첨가제 및 처방약의 변경은 A 수준이며, B, C, D 순으로 변경 수준이 높다)\n\nK 제약회사는 아세트아미노펜 650 mg 서방성 필름코팅정 제조공정에서 나정 중의 처방을 다음과 같이 변경하고자 한다.\n\n| 원료성분 | 매정당 함량(mg) | | 함량(%) | |\n| | 변경 전 | 변경 후 | 변경 전 | 변경 후 | \n|---|---|---|---|---|\n| 아세트아미노펜 | 650 | 650 | 76.5 | 76.5 |\n| 히프로멜로오스 | 80 | 80 | 94.4 | 94.4 |\n| 폴리에틸렌옥시드 | 80 | 80 | 94.4 | 94.4 |\n| 유당수화물 | 35 | 33 | 4.1 | 3.9 |\n| 스테아르산마그네슘 | 5 | 7 | 0.6 | 0.8 |\n| 합계 | 850 | 850 | 100.0 | 100.0 |\n\nQuestion: K 제약회사가 변경하고자 하는 변경 수준은?\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "question_text": "According to the Pharmaceutical Equivalence Test Standards, the levels of change for excipients in coated/uncoated formulations are as follows:\n\n| Purpose and component of excipient | Difference in content (%)\n| | Level B | Level C | Level D |\n|---|---|---|---|\n| Disintegrant - Starch | 3.0 | 6.0 | 9.0 |\n| Disintegrant - Others | 1.0 | 2.0 | 3.0 |\n| Binder | 0.50 | 1.0 | 1.5 |\n| Lubricant, Glidant - Stearic acid and its salts | 0.25 | 0.50 | 0.75 |\n| Lubricant, Glidant - Others | 1.0 | 2.0 | 3.0 |\n| Diluent | 5.0 | 1.0 | 15 |\n(Note: Changes in excipients and prescription drugs are Level A, and the level of change increases in the order of B, C, D)\n\nPharmaceutical company K wants to change the formulation of the uncoated tablet in the manufacturing process of acetaminophen 650 mg extended-release film-coated tablets as follows:\n\n| Ingredient | Content per tablet (mg) | | Content (%) | |\n| | Before change | After change | Before change | After change | \n|---|---|---|---|---|\n| Acetaminophen | 650 | 650 | 76.5 | 76.5 |\n| Hypromellose | 80 | 80 | 94.4 | 94.4 |\n| Polyethylene oxide | 80 | 80 | 94.4 | 94.4 |\n| Lactose hydrate | 35 | 33 | 4.1 | 3.9 |\n| Magnesium stearate | 5 | 7 | 0.6 | 0.8 |\n| Total | 850 | 850 | 100.0 | 100.0 |\n\nQuestion: What is the level of change that Pharmaceutical company K wants to make?\n\n① A\n② B\n③ C\n④ D\n⑤ E",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n의약품등등시험기준에 따르면, 코팅제제/비코팅제제의 첨가제별 변경 수준은 다음 표와 같다.\n\n| 첨가제의 배합 목적과 성분 | 함유율의 차(%)\n| | B 수준 | C 수준 | D 수준 |\n|---|---|---|---|\n| 붕해제 - 전분 | 3.0 | 6.0 | 9.0 |\n| 붕해제 - 기타 | 1.0 | 2.0 | 3.0 |\n| 결합제 | 0.50 | 1.0 | 1.5 |\n| 활택제, 광택제 - 스테아르산 및 그 염류 | 0.25 | 0.50 | 0.75 |\n| 활택제, 광택제 - 기타 | 1.0 | 2.0 | 3.0 |\n| 부형제 | 5.0 | 1.0 | 15 |\n(단, 첨가제 및 처방약의 변경은 A 수준이며, B, C, D 순으로 변경 수준이 높다)\n\nK 제약회사는 아세트아미노펜 650 mg 서방성 필름코팅정 제조공정에서 나정 중의 처방을 다음과 같이 변경하고자 한다.\n\n| 원료성분 | 매정당 함량(mg) | | 함량(%) | |\n| | 변경 전 | 변경 후 | 변경 전 | 변경 후 | \n|---|---|---|---|---|\n| 아세트아미노펜 | 650 | 650 | 76.5 | 76.5 |\n| 히프로멜로오스 | 80 | 80 | 94.4 | 94.4 |\n| 폴리에틸렌옥시드 | 80 | 80 | 94.4 | 94.4 |\n| 유당수화물 | 35 | 33 | 4.1 | 3.9 |\n| 스테아르산마그네슘 | 5 | 7 | 0.6 | 0.8 |\n| 합계 | 850 | 850 | 100.0 | 100.0 |\n\nQuestion: 위와 같이 변경하고자 할 때 관할기관에 제출해야 하는 시험 자료는?\n\n① 비교붕해시험\n② 비교용출시험\n③ 비교투과시험\n④ 비교용해도시험\n⑤ 생물학적동등성시험",
        "question_text": "According to the Pharmaceutical Equivalence Test Standards, the levels of change for excipients in coated/uncoated preparations are as follows:\n\n| Purpose and component of excipient | Difference in content (%)\n| | Level B | Level C | Level D |\n|---|---|---|---|\n| Disintegrant - Starch | 3.0 | 6.0 | 9.0 |\n| Disintegrant - Others | 1.0 | 2.0 | 3.0 |\n| Binder | 0.50 | 1.0 | 1.5 |\n| Lubricant, Glidant - Stearic acid and its salts | 0.25 | 0.50 | 0.75 |\n| Lubricant, Glidant - Others | 1.0 | 2.0 | 3.0 |\n| Diluent | 5.0 | 1.0 | 15 |\n(Note: Changes in excipients and prescription drugs are Level A, and the level of change increases in the order of B, C, D)\n\nK Pharmaceutical Company wants to change the formulation of the uncoated tablet in the manufacturing process of acetaminophen 650 mg extended-release film-coated tablets as follows:\n\n| Ingredient | Content per tablet (mg) | | Content (%) | |\n| | Before change | After change | Before change | After change | \n|---|---|---|---|---|\n| Acetaminophen | 650 | 650 | 76.5 | 76.5 |\n| Hypromellose | 80 | 80 | 94.4 | 94.4 |\n| Polyethylene oxide | 80 | 80 | 94.4 | 94.4 |\n| Lactose hydrate | 35 | 33 | 4.1 | 3.9 |\n| Magnesium stearate | 5 | 7 | 0.6 | 0.8 |\n| Total | 850 | 850 | 100.0 | 100.0 |\n\nQuestion: What test data should be submitted to the relevant authority when making such changes?\n\n① Comparative disintegration test\n② Comparative dissolution test\n③ Comparative permeation test\n④ Comparative solubility test\n⑤ Bioequivalence test",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "original_text": "Question: A 제약회사는 마케팅 전략을 수립하기 위해 대내외 환경에 대해 SWOT 분석을 수행하였다. SWOT 분석에 따라 수립한 전략으로 옳은 것은?\n\n① WT 전략: 회사가 가진 강점을 활용하여 시장의 기회를 창출함\n② ST 전략: 회사가 가진 강점을 활용하여 시장의 위협을 최소화함\n③ SO 전략: 회사가 가진 취약점을 보완하여 시장의 기회를 활용함\n④ WO 전략: 회사가 가진 취약점을 보완하여 시장의 위협을 최소화함\n⑤ OT 전략: 회사가 가진 취약점과 강점 간의 적절한 균형점을 찾음",
        "question_text": "Question: Pharmaceutical company A conducted a SWOT analysis of internal and external environments to establish a marketing strategy. Which of the following is the correct strategy formulated according to the SWOT analysis?\n\n① WT strategy: Utilize the company's strengths to create market opportunities\n② ST strategy: Utilize the company's strengths to minimize market threats\n③ SO strategy: Complement the company's weaknesses to take advantage of market opportunities\n④ WO strategy: Complement the company's weaknesses to minimize market threats\n⑤ OT strategy: Find an appropriate balance between the company's weaknesses and strengths",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "original_text": "Question: 투자자와 채권자로부터 조달된 자금이 얼마나 효율적으로 이용되는지를 나타내는 제약기업의 경영성과 지표는?\n\n① 당좌비율\n② 매출총이익률\n③ 총자산이익률\n④ 매출채권회전율\n⑤ 재고자산회전율",
        "question_text": "Question: Which financial performance indicator of a pharmaceutical company shows how efficiently the funds raised from investors and creditors are being utilized?\n\n① Quick ratio\n② Gross profit margin\n③ Return on assets (ROA)\n④ Accounts receivable turnover ratio\n⑤ Inventory turnover ratio",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "original_text": "Question: 약국의 재무상태표에 관한 설명으로 옳은 것은?\n\n① 이익잉여금은 자본에 포함하지 않는다.\n② 특정 기간의 매출액을 제시한다.\n③ 특정 기간의 영업비용을 제시한다.\n④ 특정 기간의 순이익 규모를 제시한다.\n⑤ 특정 시점의 자본과 부채 규모를 제시한다.",
        "question_text": "Question: Which of the following statements about a pharmacy's balance sheet is correct?\n\n① Retained earnings are not included in capital.\n② It presents sales revenue for a specific period.\n③ It presents operating expenses for a specific period.\n④ It presents the amount of net profit for a specific period.\n⑤ It presents the amount of capital and liabilities at a specific point in time.",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "original_text": "Question: 약국의 재무제표에서 감가상각을 적용해야 하는 것은?\n\n① 종업원 인건비\n② 금융기관 대출금\n③ 의약품 구입 비용\n④ 약 봉투 구입 비용\n⑤ 자동정제포장기 구입 비용",
        "question_text": "Question: Which of the following should be subject to depreciation in a pharmacy's financial statements?\n\n① Employee wages\n② Bank loans\n③ Cost of purchasing medicines\n④ Cost of purchasing medicine envelopes\n⑤ Cost of purchasing an automatic tablet packaging machine",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "original_text": "Question: A 약국은 항생제 B를 연간 1,000병 사용한다. 항생제 B의 가격은 병당 10,000원이며, 재고유지비용은 병당 가격의 10%이다. 1회 주문비용은 5,000원, 주문한 약품이 배달될 때까지 소요되는 조달기간은 5일이다. 경제적 주문량 모형에 따른 항생제 B의 최적 1회 주문량은?\n\n① 10병\n② 20병\n③ 50병\n④ 100병\n⑤ 200병",
        "question_text": "Question: Pharmacy A uses 1,000 bottles of antibiotic B annually. The price of antibiotic B is 10,000 won per bottle, and the inventory holding cost is 10% of the price per bottle. The ordering cost is 5,000 won per order, and the lead time for delivery of ordered medication is 5 days. According to the Economic Order Quantity (EOQ) model, what is the optimal order quantity for antibiotic B?\n\n① 10 bottles\n② 20 bottles\n③ 50 bottles\n④ 100 bottles\n⑤ 200 bottles",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "original_text": "Question: 대한민국 국민건강보험제도에 관한 설명으로 옳은 것은?\n\n① 건강보험 보장범위는 가입자가 선택할 수 있다.\n② 의료서비스 이용이 많은 개인은 보험료 납부액이 더 많다.\n③ 가입자는 지불한 보험료 액수와 상관없이 동일한 보장을 받는다.\n④ 보험료 납부액은 가입자의 과거 병력을 고려하여 책정할 수 있다.\n⑤ 대한민국 국민은 본인의 희망에 따라 국민건강보험을 탈퇴할 수 있다.",
        "question_text": "Question: Which of the following statements about the National Health Insurance system in South Korea is correct?\n\n① The coverage scope of health insurance can be chosen by the insured.\n② Individuals who use more medical services pay higher insurance premiums.\n③ Insured individuals receive the same coverage regardless of the amount of insurance premiums paid.\n④ Insurance premium amounts can be determined by considering the insured's medical history.\n⑤ South Korean citizens can opt out of the National Health Insurance system if they wish.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "original_text": "Question: 건강보험에서 본인부담액의 연간 총액이 개인별 상한액을 넘는 경우 그 초과액을 납부자가 부담하는 본인부담금 제도는?\n\n① 정률제\n② 정액제\n③ 급여상한제\n④ 본인부담상한제\n⑤ 일정액공제제(deductible)",
        "question_text": "Question: In health insurance, what is the system called where the insured person pays the excess amount when the annual total of out-of-pocket expenses exceeds the individual limit?\n\n① Proportional system\n② Fixed amount system\n③ Benefit ceiling system\n④ Out-of-pocket maximum system\n⑤ Deductible system",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "original_text": "Question: 대한민국 국민건강보험에서 보장하는 보건의료서비스는?\n\n① 친자확인 진단\n② 발기부전 치료\n③ 주사제 무균조제\n④ 대상포진 예방백신 접종\n⑤ 의료 개선 목적 치료과정",
        "question_text": "Question: Which of the following healthcare services is covered by the National Health Insurance of the Republic of Korea?\n\n① Paternity test diagnosis\n② Erectile dysfunction treatment\n③ Aseptic preparation of injectable medications\n④ Shingles (herpes zoster) vaccination\n⑤ Medical treatment for improvement purposes",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "original_text": "Question: 신약 허가 신청 자료의 국제조화를 도모하기 위해 허가심사 당국에 제출하는 국제공통양식은?\n\n① Common Technical Document (CTD)\n② Investigational New Drug Application (IND)\n③ Pharmaceutical Inspection Cooperation Scheme (PIC/S)\n④ Periodic Safety Update Reports (PSUR)\n⑤ Post Marketing Surveillance (PMS)",
        "question_text": "Question: What is the international common format submitted to regulatory authorities to promote international harmonization of new drug approval application data?\n\n① Common Technical Document (CTD)\n② Investigational New Drug Application (IND)\n③ Pharmaceutical Inspection Cooperation Scheme (PIC/S)\n④ Periodic Safety Update Reports (PSUR)\n⑤ Post Marketing Surveillance (PMS)",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "original_text": "Question: 국내에서 허가되지 않았으나 자기치료용으로 수입이 필요한 의약품을 공급하는 기관은?\n\n① Korean Center for Regulatory Science\n② Regional Pharmacovigilance Center\n③ Korea Institute of Drug Safety & Risk Management\n④ Integrated Drug Information System\n⑤ Korea Orphan and Essential Drug Center",
        "question_text": "Question: Which institution supplies medications that are not approved domestically but need to be imported for self-treatment purposes?\n\n① Korean Center for Regulatory Science\n② Regional Pharmacovigilance Center\n③ Korea Institute of Drug Safety & Risk Management\n④ Integrated Drug Information System\n⑤ Korea Orphan and Essential Drug Center",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "original_text": "Question: 신약 A는 대체 치료법이 없는 고가 항암제이고, 효능 ∙ 효과나 보험 재정 영향 등에 대한 불확실성 때문에 급여대상에 포함되지 못했다. 이 의약품에 대한 환자 접근성을 높이기 위하여, 보험자가 제약사로부터 환급받는 등의 조건으로 급여할 수 있는 제도는?\n\n① 위험분담제\n② 참조가격제\n③ 의약품 위해관리제\n④ 사용량–약가 연동제\n⑤ 약품비 총액 관리제",
        "question_text": "Question: New drug A is an expensive anticancer drug with no alternative treatment, and it was not included in the reimbursement list due to uncertainties about its efficacy and effects, as well as its impact on insurance finances. What system allows for reimbursement under conditions such as the insurer receiving a refund from the pharmaceutical company in order to increase patient access to this drug?\n\n① Risk-sharing agreement\n② Reference pricing system\n③ Drug risk management system\n④ Volume-price linkage system\n⑤ Total drug expenditure management system",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "original_text": "Question: 체계적 문헌고찰에서 문헌검색의 특이도(specifity)를 높이는 방법은?\n\n① 절단검색어 사용\n② 포괄적 검색어 사용\n③ OR 불리언연산자 사용\n④ 검색제한 필터(filter) 사용\n⑤ 유의어 또는 대안어를 검색어에 포함",
        "question_text": "Question: Which method increases the specificity of literature search in a systematic literature review?\n\n① Using truncated search terms\n② Using comprehensive search terms\n③ Using the OR Boolean operator\n④ Using search limitation filters\n⑤ Including synonyms or alternative terms in the search",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "original_text": "Question: 항우울제 A를 1년간 투약한 환자에서 삶의 질 가중치는 0.70이고, 항우울제 B를 1년간 투약한 환자에서 삶의 질 가중치는 0.90이다. 항우울제 A 대비 항우울제 B의 질보정수명 증분(incremental quality-adjusted life years)은?\n\n① 0.2\n② 0.7\n③ 0.8\n④ 0.9\n⑤ 1.6",
        "question_text": "Question: The quality of life weight for a patient taking antidepressant A for one year is 0.70, and the quality of life weight for a patient taking antidepressant B for one year is 0.90. What is the incremental quality-adjusted life years of antidepressant B compared to antidepressant A?\n\n① 0.2\n② 0.7\n③ 0.8\n④ 0.9\n⑤ 1.6",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "original_text": "Question: 여러 선행연구에서 신약 A의 치료효과는 10~50%로 나타났다. 신약의 비용-효과 평가 시 치료효과의 불확실성이 점증적 비용효과비에 미치는 영향을 평가하는 방법은?\n\n① 치료비용의 평균값을 사용한 분석\n② 치료효과의 평균값을 사용한 분석\n③ 치료효과를 화폐단위로 변경한 분석\n④ 치료효과의 하한값과 상한값을 사용한 비교 분석\n⑤ 치료비용의 하한값과 상한값을 사용한 비교 분석",
        "question_text": "Question: Several previous studies have shown that the therapeutic effect of new drug A ranges from 10% to 50%. When evaluating the cost-effectiveness of a new drug, what method is used to assess the impact of uncertainty in therapeutic effect on the incremental cost-effectiveness ratio?\n\n① Analysis using the average value of treatment costs\n② Analysis using the average value of therapeutic effects\n③ Analysis with therapeutic effects converted to monetary units\n④ Comparative analysis using the lower and upper limits of therapeutic effects\n⑤ Comparative analysis using the lower and upper limits of treatment costs",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "original_text": "Question: 약사의 윤리적 행동 원칙 중 정의의 원칙과 관련된 것은?\n\n① 환자 개인정보의 보호\n② 환자와 신뢰 관계 형성\n③ 환자 개인 이익의 최대화\n④ 환정된 의료자원의 환자 간 분배\n⑤ 환자와 환자보조자의 의견 최대한 반영",
        "question_text": "Question: Which of the following is related to the principle of justice among the ethical principles of pharmacists?\n\n① Protection of patient's personal information\n② Building trust relationships with patients\n③ Maximizing individual patient benefits\n④ Distribution of limited medical resources among patients\n⑤ Maximizing consideration of opinions from patients and their caregivers",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "original_text": "Question: A 약사는 처방전에 적힌 의약품의 재고가 없어서 환자에게 대체조제를 원하는지 또는 다른 약국을 가고자 하는지 물었다. A 약사의 행동과 관련한 윤리원칙은?\n\n① 선행의 원칙\n② 피해 회피의 원칙\n③ 자율성 존중의 원칙\n④ 이해상충 회피의 원칙\n⑤ 사생활 존중과 보호의 원칙",
        "question_text": "Question: Pharmacist A asked the patient whether they wanted a substitute medication or preferred to go to another pharmacy because the prescribed medication was out of stock. What ethical principle is related to Pharmacist A's action?\n\n① Principle of beneficence\n② Principle of non-maleficence\n③ Principle of respect for autonomy\n④ Principle of avoiding conflicts of interest\n⑤ Principle of respect for and protection of privacy",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n류마티스치료제 A와 실험군과의 이상사례 발생의 연관성을 확인하기 위하여 환자-대조군 연구를 수행하여 다음 결과를 얻었다.\n\n| | 환자군: 심혈관계 이상사례 발생군(n=25, 명) | 대조군: 심혈관계 이상사례 미발생군(n=48, 명) |\n|---|---|---|\n| 류마티스치료제 A 복용한 적 있음 | 5 | 8 |\n| 류마티스치료제 A 복용한 적 없음 | 20 | 40 |\n\nQuestion: 류마티스치료제 A와 심혈관계 이상사례의 연관성에 대한 오즈비(odds ratio)는?\n\n① 0.13\n② 0.80\n③ 1.00\n④ 1.20\n⑤ 1.25",
        "question_text": "A case-control study was conducted to determine the association between rheumatoid arthritis treatment A and the occurrence of adverse events in the experimental group. The following results were obtained:\n\n| | Case group: Cardiovascular adverse event occurrence (n=25, persons) | Control group: No cardiovascular adverse event occurrence (n=48, persons) |\n|---|---|---|\n| Have taken rheumatoid arthritis treatment A | 5 | 8 |\n| Have never taken rheumatoid arthritis treatment A | 20 | 40 |\n\nQuestion: What is the odds ratio for the association between rheumatoid arthritis treatment A and cardiovascular adverse events?\n\n① 0.13\n② 0.80\n③ 1.00\n④ 1.20\n⑤ 1.25",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "original_text": "다음 사례를 읽고 각 문제에 적합한 답을 고르시오.\n\n류마티스치료제 A와 실험군과의 이상사례 발생의 연관성을 확인하기 위하여 환자-대조군 연구를 수행하여 다음 결과를 얻었다.\n\n| | 환자군: 심혈관계 이상사례 발생군(n=25, 명) | 대조군: 심혈관계 이상사례 미발생군(n=48, 명) |\n|---|---|---|\n| 류마티스치료제 A 복용한 적 있음 | 5 | 8 |\n| 류마티스치료제 A 복용한 적 없음 | 20 | 40 |\n\nQuestion: 류마티스치료제 A와 심혈관계 이상사례 발생의 연관성에 대해 후속 연구를 수행하고자 할 때 위 연구보다 타당성을 높일 수 있는 연구 설계는?\n\n① 전향적 코호트 연구\n② 사례보고(case report)\n③ 설문지를 이용한 단면연구\n④ 사례군연구(case series study)\n⑤ 건강보험자료를 이용한 단면연구",
        "question_text": "A case-control study was conducted to determine the association between rheumatoid arthritis drug A and the occurrence of adverse events in the experimental group. The following results were obtained:\n\n| | Case group: Cardiovascular adverse event occurrence (n=25, persons) | Control group: No cardiovascular adverse event occurrence (n=48, persons) |\n|---|---|---|\n| Have taken rheumatoid arthritis drug A | 5 | 8 |\n| Have never taken rheumatoid arthritis drug A | 20 | 40 |\n\nQuestion: When planning to conduct a follow-up study on the association between rheumatoid arthritis drug A and the occurrence of cardiovascular adverse events, which research design would increase the validity compared to the above study?\n\n① Prospective cohort study\n② Case report\n③ Cross-sectional study using questionnaires\n④ Case series study\n⑤ Cross-sectional study using health insurance data",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 '약사(藥事)'의 범위에 해당하는 것은?\n\n① 붕대 보관\n② 혈당측정기 판매\n③ 비만치료제 수출\n④ 코로나19–독감 진단시약 제조\n⑤ 세포배양액을 함유한 화장품 수입",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following falls within the scope of 'pharmaceutical affairs (藥事)'?\n\n① Storage of bandages\n② Sale of blood glucose meters\n③ Export of obesity treatment drugs\n④ Manufacturing of COVID-19–influenza diagnostic reagents\n⑤ Import of cosmetics containing cell culture media",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 서울특별시 강남구에 약국을 개설한 자가 약국의 관리를 위해 준수할 사항이 아닌 것은?\n\n① 약국개설등록증을 원본을 해당 약국 안의 보기 쉬운 곳에 게시하여야 한다.\n② 약국을 관리할 약사를 지정하고자 하는 경우에는 Mayor of Gangnam District의 승인을 받아야 한다.\n③ 의약품 사용과 관련하여 부작용이 발생한 경우에는 필요한 안전대책을 강구하여야 한다.\n④ 3개월 동안 휴업하고자 하는 경우에는 휴업 날부터 7일 이내에 Mayor of Gangnam District에게 신고하여야 한다.\n⑤ 약국의 소재지를 변경하고자 하는 경우에는 변경하려는 날의 3일 전까지 변경등록을 신청하여야 한다.",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT a requirement that a person who has opened a pharmacy in Gangnam-gu, Seoul, must comply with for the management of the pharmacy?\n\n① The original pharmacy establishment registration certificate must be displayed in a visible place inside the pharmacy.\n② If designating a pharmacist to manage the pharmacy, approval must be obtained from the Mayor of Gangnam District.\n③ In case of side effects related to the use of pharmaceuticals, necessary safety measures must be devised.\n④ If intending to close the pharmacy for 3 months, it must be reported to the Mayor of Gangnam District within 7 days from the date of closure.\n⑤ If intending to change the location of the pharmacy, an application for change registration must be submitted at least 3 days before the intended date of change.",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자와 의료기관 개설자에게 금지되는 담합행위나 담합의 소지가 있는 행위에 해당하지 않는 것은?\n\n① 약국개설자가 직접 의료기관 개설자에게 처방전 알선의 대가로 노무를 제공하는 행위\n② 약국개설자가 제3자를 통하여 다른 약국개설자로부터 처방전 알선의 대가로 편익을 받는 행위\n③ 약국개설자가 \"National Health Insurance Act\"에 따른 요양급여비용에 대한 의료기관 개설자의 심사청구업무를 관리하는 행위\n④ 의료기관 개설자가 처방전 소지자의 요구에 따라 특정 약국개설자에게 컴퓨터통신을 이용하여 처방전을 전송하는 행위\n⑤ 의사회 분회가 약사회 분회에 제공한 처방의약품 목록에 포함되어 있는 의약품과 같은 성분의 다른 품목을 반복하여 처방한 처방전에 따라 약사가 조제하는 행위",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT considered a collusive practice or an act that could lead to collusion, prohibited for pharmacy owners and medical institution founders?\n\n① A pharmacy owner directly providing labor to a medical institution founder in exchange for prescription referrals\n② A pharmacy owner receiving benefits through a third party from another pharmacy owner in exchange for prescription referrals\n③ A pharmacy owner managing the review and claim process for medical care benefits of a medical institution founder in accordance with the \"National Health Insurance Act\"\n④ A medical institution founder transmitting prescriptions via computer network to a specific pharmacy owner at the request of the prescription holder\n⑤ A pharmacist dispensing medications based on prescriptions that repeatedly prescribe different items with the same ingredients as those included in the list of prescribed medications provided by a branch of the medical association to a branch of the pharmaceutical association",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 조제 및 판매에 관한 설명으로 옳지 않은 것은?\n\n① 약사는 Korea Orphan and Essential Drug Center에 설치된 조제실에서 조제할 수 있다.\n② 약품을 전공하는 대학의 학생은 약사의 지시 ∙ 감독을 받아 사회봉사활동을 위해 조제할 수 있다.\n③ 약국개설자는 의료기관이 없는 지역에서 성인기준 5일 분량의 전문의약품을 처방전 없이 판매할 수 있다.\n④ 의료기관의 조제실에서 조제업무에 종사하는 약사는 처방전 교부된 환자를 위해 조제하여서는 아니 된다.\n⑤ 감염병이 집단으로 발생할 경우가 있다고 Commissioner of the Korea Disease Control and Prevention Agency이 인정한 경우에는 약사는 경구용 감염병 예방접종약을 처방전 없이 판매할 수 있다.",
        "question_text": "Question: Which of the following statements regarding the preparation and sale of pharmaceuticals under the \"Pharmaceutical Affairs Act\" is incorrect?\n\n① Pharmacists can prepare medications in the dispensary set up at the Korea Orphan and Essential Drug Center.\n② University students majoring in pharmacy can prepare medications for social service activities under the instruction and supervision of a pharmacist.\n③ Pharmacy owners can sell prescription drugs without a prescription for up to 5 days' supply for adults in areas without medical institutions.\n④ Pharmacists working in the dispensary of medical institutions must not prepare medications for patients who have been issued prescriptions.\n⑤ In cases where the Commissioner of the Korea Disease Control and Prevention Agency recognizes the potential for an infectious disease outbreak, pharmacists can sell oral vaccines for infectious diseases without a prescription.",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약사가 판매할 목적으로 조제한 약제의 용기 또는 포장에 반드시 적어야 하는 사항에 해당하지 않는 것은?\n\n① 조제량\n② 조제 연월일\n③ 조제자의 이름\n④ 처방전에 적힌 용법 및 용량\n⑤ 조제한 약국의 명칭과 소재지",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT required to be written on the container or packaging of a medication prepared by a pharmacist for the purpose of sale?\n\n① Quantity prepared\n② Date of preparation\n③ Name of the preparer\n④ Dosage and administration as written on the prescription\n⑤ Name and location of the pharmacy where it was prepared",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 판매에 관한 설명으로 옳은 것은?\n\n① 약국개설자는 일반의약품을 도매할 수 있다.\n② 의약품 도매상은 그의 남동생이 개설한 약국에 한약제제를 판매할 수 있다.\n③ 약국개설자는 일반의약품의 용기나 포장에 의약품의 가격을 표시해서는 아니 된다.\n④ 약국개설자는 \"Veterinarians Act\"에 따른 동물병원 개설자에게 의약품을 판매할 수 있다.\n⑤ 약국개설자는 Minister of Health and Welfare의 승인을 받은 경우에는 약국 이외의 장소에서 의약품을 판매할 수 있다.",
        "question_text": "Question: Which of the following statements is correct regarding the sale of pharmaceuticals according to the \"Pharmaceutical Affairs Act\"?\n\n① A pharmacy owner can wholesale over-the-counter drugs.\n② A pharmaceutical wholesaler can sell herbal medicine preparations to a pharmacy opened by his younger brother.\n③ A pharmacy owner must not display the price of over-the-counter drugs on their containers or packaging.\n④ A pharmacy owner can sell pharmaceuticals to animal hospital owners established under the \"Veterinarians Act\".\n⑤ A pharmacy owner can sell pharmaceuticals outside the pharmacy if approved by the Minister of Health and Welfare.",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 약국개설자가 의약품을 개봉하여 판매할 수 없는 경우는?\n\n① 감기약제제가 한약제제를 개봉하여 판매\n② 의사의 처방전에 따라 일반의약품 조제 ∙ 판매\n③ 의사의 처방전에 따라 항생제를 조제 ∙ 판매\n④ 연구기관에 근무하고 있는 수의사에게 전문의약품 판매\n⑤ 치과의사가 처방한 의약품이 없어 이를 긴급하게 구입하려는 다른 약국개설자에게 해당 의약품 판매",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" in which case is a pharmacy owner not allowed to open and sell medicines?\n\n① Opening and selling herbal medicine preparations as cold medicine\n② Dispensing and selling over-the-counter drugs according to a doctor's prescription\n③ Dispensing and selling antibiotics according to a doctor's prescription\n④ Selling prescription drugs to a veterinarian working at a research institution\n⑤ Selling medicines to another pharmacy owner who urgently needs to purchase them due to a shortage of drugs prescribed by a dentist",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 신약에 대한 임상시험 계획서에 포함되어야 할 사항이 아닌 것은?\n\n① 개발계획\n② 시험모집단\n③ 시험의 제목\n④ 시험 절차 및 평가\n⑤ 윤리적 고려사항 및 행정적 절차",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following is NOT required to be included in a clinical trial protocol for a new drug?\n\n① Development plan\n② Study population\n③ Title of the study\n④ Study procedures and evaluation\n⑤ Ethical considerations and administrative procedures",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 품목허가를 받은 의약품에 관한 특허권을 등재받은 자와 등재특허권자등에게 의약품의 품목허가 신청 사실을 통지하여야 하는 자가 Minister of Food and Drug Safety에게 신청할 수 있는 자는? (단, 신청 전에 해당 등재의약품에 대한 특허의 무효심판을 청구하였음)\n\n① 특허목록 공개\n② 우선판매품목허가\n③ 특허 권리범위 확인심판\n④ 동일의약품에 대한 판매금지\n⑤ 통지의약품 판매금지의 영향평가",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" who can apply to the Minister of Food and Drug Safety among those who must notify the patent registrant and the registered patent holder, etc., about the application for marketing authorization of a pharmaceutical product? (Note: The applicant has filed for a patent invalidation trial for the listed drug before applying)\n\n① Disclosure of patent list\n② Priority sale item authorization\n③ Patent scope confirmation trial\n④ Sales prohibition of identical drugs\n⑤ Impact assessment of sales prohibition for notified drugs",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 서울특별시 강남구에 약국을 개설한 자가 수의사의 처방전 없이 판매하여서는 안 되는 동물용 의약품은? (단, 긴급방역의 목적으로 동물용 의약품의 사용을 명령한 경우는 제외)\n\n① 마취를 위한 아세프로마진 주사제\n② 이뇨 촉진을 위한 퓨로세미드 주사제\n③ 혈액응고 억제를 위한 헤파린 주사제\n④ 유즙분비 촉진을 위한 옥시토신 주사제\n⑤ 일본뇌염 예방을 위한 생바이러스백신 주사제",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" which of the following veterinary medicines should not be sold without a veterinarian's prescription by a person who has opened a pharmacy in Gangnam-gu, Seoul? (Excluding cases where the use of veterinary medicines is ordered for the purpose of emergency quarantine)\n\n① Acepromazine injection for anesthesia\n② Furosemide injection for promoting diuresis\n③ Heparin injection for inhibiting blood coagulation\n④ Oxytocin injection for promoting milk secretion\n⑤ Live virus vaccine injection for preventing Japanese encephalitis",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 의약품 제조업자의 의약품 광고가 허용되는 경우는?\n\n① 진통제 의료의약품의 공영방송 광고\n② 의약품의 효능을 의사가 보증하는 광고\n③ 의약품의 효능을 암시하는 사진을 사용하는 광고\n④ 사람유두종바이러스 감염증 예방 백신의 라디오 광고\n⑤ 전문의약품의 명칭과 효능에 관하여 품목허가 신청과 동시에 게재하는 의약전문지 광고",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" in which case is advertising of pharmaceuticals by drug manufacturers allowed?\n\n① TV advertising of analgesic prescription drugs on public broadcasting\n② Advertising where a doctor guarantees the efficacy of a drug\n③ Advertising using photos that imply the efficacy of a drug\n④ Radio advertising of vaccines for the prevention of human papillomavirus infection\n⑤ Advertising in medical journals about the name and efficacy of prescription drugs, published simultaneously with the application for product approval",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "original_text": "Question: \"Pharmaceutical Affairs Act\"상 대한약사회장이나 대한약사회의 윤리위원회의 심의 ∙ 의결을 거쳐 Minister of Health and Welfare에게 해당 약사의 면허취소 처분을 요구할 수 있는 경우는?\n\n① 대마 중독자에 해당하는 경우\n② 피한정후견인에 해당하는 경우\n③ 거짓 또는 과대 광고행위를 한 경우\n④ 무자격자에게 의약품을 조제 ∙ 판매하도록 하는 행위를 한 경우\n⑤ 본인부담금의 일부를 면제하는 방법으로 처방전을 가진 자를 자신의 약국으로 유인하는 행위를 한 경우",
        "question_text": "Question: According to the \"Pharmaceutical Affairs Act,\" in which case can the president of the Korean Pharmaceutical Association or the Ethics Committee of the Korean Pharmaceutical Association request the Minister of Health and Welfare to revoke the license of a pharmacist after deliberation and resolution?\n\n① When the pharmacist is a cannabis addict\n② When the pharmacist is under limited guardianship\n③ When the pharmacist engages in false or exaggerated advertising\n④ When the pharmacist allows unqualified individuals to dispense or sell medications\n⑤ When the pharmacist attracts prescription holders to their pharmacy by exempting part of the patient's co-payment",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 다음의 의약품을 제조할 수 있는 자는?\n\n1정(600 mg)당\n디히드로코데인타르타르산염(dihydrocodeine tartrate) 5 mg\n클로르페니라민말레산염(chlorpheniramine maleate) 1.5 mg\nDL-메틸에페드린염산염(DL-methylephedrine hydrochloride) 17.5 mg\n구아이페네신(guaifenesin) 50 mg\n\n① 마약류관리자\n② 마약류도매업자\n③ 원료물질취급자\n④ 마약류수출입업자\n⑤ 마약류원료사용자",
        "question_text": "Question: According to the \"Narcotics Control Act,\" who is authorized to manufacture the following pharmaceutical product?\n\nPer tablet (600 mg)\nDihydrocodeine tartrate 5 mg\nChlorpheniramine maleate 1.5 mg\nDL-Methylephedrine hydrochloride 17.5 mg\nGuaifenesin 50 mg\n\n① Narcotics manager\n② Narcotics wholesaler\n③ Raw material handler\n④ Narcotics importer/exporter\n⑤ Narcotics raw material user",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 마약류의 저장 규정에 위반되는 경우는?\n\n① 업무시간 후 프로포폴 주사제를 다른 전문의약품과 함께 저장한다.\n② 이중으로 잠금장치가 설치된 철제금고에 모르핀 주사제를 저장한다.\n③ 마약류를 취급하는 자의 업소 안에 펜타닐 박칼정의 저장 장소를 설치한다.\n④ 마약류소매업자가 원활한 조제를 목적으로 업무시간 중 조제대에 졸피뎀 정제를 비치한다.\n⑤ 대마초를 반출 ∙ 반입하는 경우를 제외하고는 대마초의 저장장소에 잠금장치를 설치하여 다른 사람의 출입을 제한하는 조치를 취한다.",
        "question_text": "Question: Which of the following cases violates the storage regulations for narcotic drugs under the \"Narcotics Control Act\"?\n\n① Storing propofol injections with other prescription drugs after business hours.\n② Storing morphine injections in a steel safe with double locks.\n③ Installing a storage place for fentanyl buccal tablets within the premises of a person handling narcotic drugs.\n④ A narcotic drug retailer keeping zolpidem tablets at the dispensing counter during business hours for smooth dispensing.\n⑤ Installing locks on the storage place for cannabis to restrict access by others, except when cannabis is being taken out or brought in.",
        "answer": 1
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "original_text": "Question: \"Narcotics Control Act\"상 의약품소매업자의 마약류 판매에 관한 설명으로 옳은 것은?\n\n① 2군 임시마약류는 처방전에 따라 판매할 수 있다.\n② 마약을 기재한 처방전에 따라 조제한 후 처방전을 5년간 보존하여야 한다.\n③ 마약의 유효기한이 경과한 경우 약국 개설 등록관청에 지체 없이 보고하여야 한다.\n④ \"The Framework Act on Electronic Documents and Transactions\"에 따른 전자거래를 통하여 향정신성의약품을 판매할 수 있다.\n⑤ 동물 대상 향정신성의약품을 조제한 경우 Minister of Food and Drug Safety에게 보고하여야 한다.",
        "question_text": "Question: Which of the following statements is correct regarding the sale of narcotics by pharmaceutical retailers according to the \"Narcotics Control Act\"?\n\n① Temporary narcotics in Group 2 can be sold according to a prescription.\n② After dispensing narcotics based on a prescription, the prescription must be preserved for 5 years.\n③ If the expiration date of narcotics has passed, it must be reported to the pharmacy registration office without delay.\n④ Psychotropic drugs can be sold through electronic transactions in accordance with \"The Framework Act on Electronic Documents and Transactions\".\n⑤ When psychotropic drugs are dispensed for animals, it must be reported to the Minister of Food and Drug Safety.",
        "answer": 5
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "original_text": "Question: \"National Health Promotion Act\"의 정의상 개인 또는 집단이 균형된 식생활을 통하여 건강을 개선시키는 것은?\n\n① 건강관리\n② 식품위생\n③ 영양개선\n④ 질병예방\n⑤ 신체활동장려",
        "question_text": "Question: According to the definition in the \"National Health Promotion Act,\" what is it called when an individual or group improves their health through a balanced diet?\n\n① Health management\n② Food hygiene\n③ Nutrition improvement\n④ Disease prevention\n⑤ Physical activity promotion",
        "answer": 3
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "original_text": "Question: \"Framework Act on Health and Medical Services\"의 정의에 관한 규정의 내용으로 옳지 않은 것은?\n\n① 약국은 보건의료기관에 포함된다.\n② 사립학교가 설립 ∙ 운영하는 종합병원은 공공보건의료기관에 포함된다.\n③ 보건의료와 관련하여 영상으로 표현된 자료는 보건의료정보에 포함된다.\n④ 지방자치단체가 국민의 건강을 보호 ∙ 증진하기 위하여 행하는 모든 활동은 보건의료에 포함된다.\n⑤ 약사가 국민의 건강을 보호 ∙ 증진하기 위하여 행하는 모든 활동은 보건의료서비스에 포함된다.",
        "question_text": "Question: Which of the following statements is NOT correct regarding the definitions in the \"Framework Act on Health and Medical Services\"?\n\n① Pharmacies are included in healthcare institutions.\n② General hospitals established and operated by private schools are included in public healthcare institutions.\n③ Visual data related to healthcare is included in healthcare information.\n④ All activities carried out by local governments to protect and promote public health are included in healthcare.\n⑤ All activities carried out by pharmacists to protect and promote public health are included in healthcare services.",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 건강보험의 보장자는?\n\n① Ministry of Health and Welfare\n② National Health Insurance Service\n③ Health Insurance Review & Assessment Service\n④ Health Insurance Dispute Mediation Committee\n⑤ Health Insurance Policy Deliberation Committee",
        "question_text": "Question: According to the \"National Health Insurance Act,\" who is the guarantor of health insurance?\n\n① Ministry of Health and Welfare\n② National Health Insurance Service\n③ Health Insurance Review & Assessment Service\n④ Health Insurance Dispute Mediation Committee\n⑤ Health Insurance Policy Deliberation Committee",
        "answer": 2
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "original_text": "Question: \"National Health Insurance Act\"상 약제에 대한 요양급여비용의 결정 및 산정에 관한 설명으로 옳은 것은?\n\n① 한약의 요양급여비용은 구입금액을 기준으로 산정한다.\n② 한약외 외의 약제 요양급여비용은 상한금액을 기준으로 산정한다.\n③ Minister of Health and Welfare이 비급여대상으로 정한 것을 제외한 일체의 약제가 요양급여대상이 된다.\n④ 약제의 제조업자등은 약제에 대하여 Minister of Health and Welfare에게 요양급여대상 여부의 결정을 신청할 수 있다.\n⑤ \"Pharmaceutical Affairs Act\"상 경제적 이익등 제공의 금지를 위반한 약제에 대하여는 요양급여비용 상한약의 100분의 50을 감액하여야 한다.",
        "question_text": "Question: Which of the following statements is correct regarding the determination and calculation of health care benefit costs for medications under the \"National Health Insurance Act\"?\n\n① The health care benefit costs for herbal medicines are calculated based on the purchase price.\n② The health care benefit costs for medications other than herbal medicines are calculated based on the maximum amount.\n③ All medications, except those designated as non-reimbursable by the Minister of Health and Welfare, are subject to health care benefits.\n④ Manufacturers of medications can apply to the Minister of Health and Welfare for a determination on whether their medication is eligible for health care benefits.\n⑤ For medications that violate the prohibition on providing economic benefits under the \"Pharmaceutical Affairs Act\", the maximum reimbursement amount for health care benefit costs should be reduced by 50 percent.",
        "answer": 4
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "original_text": "Question: \"Regional Public Health Act\"상 보건소에서 수행할 수 있는 기능 및 업무가 아닌 것은?\n\n① 약국 개설등록 수리\n② 의약품 도매상 허가\n③ 마약류 통합정보 제공\n④ 마약류관리자의 마약류 취급 감시\n⑤ 의료기관 조제실제제의 제조 품목 신고 수리",
        "question_text": "Question: According to the \"Regional Public Health Act,\" which of the following is NOT a function or task that can be performed by a public health center?\n\n① Accepting pharmacy establishment registrations\n② Licensing pharmaceutical wholesalers\n③ Providing integrated information on narcotics\n④ Monitoring the handling of narcotics by narcotics managers\n⑤ Accepting reports on the manufacturing items of in-house preparations in medical institutions",
        "answer": 3
    }
]